<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="0" size="13" family="Times" color="#000000"/>
	<fontspec id="1" size="11" family="Times" color="#000000"/>
	<fontspec id="2" size="16" family="Times" color="#000000"/>
	<fontspec id="3" size="14" family="Times" color="#000000"/>
	<fontspec id="4" size="14" family="Times" color="#000000"/>
	<fontspec id="5" size="13" family="Times" color="#000000"/>
	<fontspec id="6" size="13" family="Times" color="#000000"/>
<text top="814" left="1127" width="10" height="17" font="0">1 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="54" left="459" width="274" height="21" font="2"><b>2015 SVT Guideline Data Supplements </b></text>
<text top="75" left="594" width="4" height="21" font="2"><b> </b></text>
<text top="95" left="537" width="118" height="19" font="3"><b>Table of Contents </b></text>
<text top="114" left="594" width="4" height="21" font="2"><b> </b></text>
<text top="135" left="54" width="1079" height="17" font="0">Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of Clinical Presentation and Differential Diagnosis Based on Symptoms – Section 2.3.1 ........ 2</text>
<text top="134" left="1133" width="4" height="18" font="4"> </text>
<text top="152" left="54" width="1079" height="17" font="0">Data Supplement 2. Randomized Trials Comparing Principles of Acute and Chronic Therapy – Section 2.4 ................................................................................................................. 7</text>
<text top="151" left="1133" width="4" height="18" font="4"> </text>
<text top="170" left="54" width="1079" height="17" font="0">Data Supplement 3. Nonrandomized Trials, Observational Studies, and/or Registries of Principles of Acute and Chronic Therapy – Section 2.4 ...................................................... 17</text>
<text top="168" left="1133" width="4" height="18" font="4"> </text>
<text top="187" left="54" width="1079" height="17" font="0">Data Supplement 4. Randomized Trials Comparing Sinus Tachyarrhythmias – Section 3 ............................................................................................................................................ 25</text>
<text top="186" left="1133" width="4" height="18" font="4"> </text>
<text top="204" left="54" width="1079" height="17" font="0">Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Sinus Tachyarrhythmias – Section 3 ................................................................................... 27</text>
<text top="203" left="1133" width="4" height="18" font="4"> </text>
<text top="222" left="54" width="1079" height="17" font="0">Data Supplement 6. Nonrandomized Trials, Observational Studies, and/or Registries of Focal Atrial Tachycardia – Section 4.1 ............................................................................... 32</text>
<text top="220" left="1133" width="4" height="18" font="4"> </text>
<text top="239" left="54" width="1079" height="17" font="0">Data Supplement 7. Randomized Trials Comparing Multifocal Atrial Tachycardia – Section 4.2 ................................................................................................................................ 36</text>
<text top="238" left="1133" width="4" height="18" font="4"> </text>
<text top="256" left="54" width="1079" height="17" font="0">Data Supplement 8. Nonrandomized Trials, Observational Studies, and/or Registries of Multifocal Atrial Tachycardia – Section 4.2 ....................................................................... 37</text>
<text top="255" left="1133" width="4" height="18" font="4"> </text>
<text top="273" left="54" width="1079" height="17" font="0">Data Supplement 9. Randomized Trials Comparing Atrioventricular Nodal Re-Entrant Tachycardia – Section 5 ........................................................................................................ 38</text>
<text top="272" left="1133" width="4" height="18" font="4"> </text>
<text top="291" left="54" width="1079" height="17" font="0">Data Supplement 10. Nonrandomized Trials, Observational Studies, and/or Registries of Atrioventricular Nodal Re-Entrant Tachycardia – Section 5 ............................................. 56</text>
<text top="289" left="1133" width="4" height="18" font="4"> </text>
<text top="308" left="54" width="1079" height="17" font="0">Data Supplement 11.  Randomized Trials Comparing Manifest and Concealed Accessory Pathways – Section 6.1 ..................................................................................................... 64</text>
<text top="306" left="1133" width="4" height="18" font="4"> </text>
<text top="325" left="54" width="1079" height="17" font="0">Data Supplement 12. Nonrandomized Trials, Observations Studies, and/or Registires of Manifest and Concealed Accessory Pathways – Section 6.1 .............................................. 65</text>
<text top="324" left="1133" width="4" height="18" font="4"> </text>
<text top="342" left="54" width="1079" height="17" font="0">Data Supplement 13. Summary of Included Studies – ERC Report (Section 6.2) .......................................................................................................................................................... 70</text>
<text top="341" left="1133" width="4" height="18" font="4"> </text>
<text top="359" left="54" width="1079" height="17" font="0">Data Supplement 14. Comparators and Outcomes – ERC Report (Section 6.2) ............................................................................................................................................................. 72</text>
<text top="358" left="1133" width="4" height="18" font="4"> </text>
<text top="377" left="54" width="1079" height="17" font="0">Data Supplement 15. Quality Assesment of Included Studies – ERC Report (Section 6.2) ........................................................................................................................................... 75</text>
<text top="375" left="1133" width="4" height="18" font="4"> </text>
<text top="394" left="54" width="1079" height="17" font="0">Data Supplement 16. Randomized Trials Comparing Atrial Flutter – Section 7 ............................................................................................................................................................ 76</text>
<text top="393" left="1133" width="4" height="18" font="4"> </text>
<text top="411" left="54" width="1079" height="17" font="0">Data Supplement 17. Nonrandomized Trials, Observational Studies, and/or Registries of Atrial Flutter – Section 7 ................................................................................................... 94</text>
<text top="410" left="1133" width="4" height="18" font="4"> </text>
<text top="429" left="54" width="1079" height="17" font="0">Data Supplement 18. Randomized Trials for Junctional Tachycardia – Section 8 ......................................................................................................................................................... 98</text>
<text top="427" left="1133" width="4" height="18" font="4"> </text>
<text top="446" left="54" width="1079" height="17" font="0">Data Supplement 19. Nonrandomized Trials, Observational Studies, and/or Registries of Junctional Tachycardia – Section 8 ................................................................................... 98</text>
<text top="445" left="1133" width="4" height="18" font="4"> </text>
<text top="463" left="54" width="1079" height="17" font="0">Data Supplement 20. Nonrandomized Trials, Observational Studies, and/or Registries of Special Populations – Section 9 ....................................................................................... 101</text>
<text top="462" left="1133" width="4" height="18" font="4"> </text>
<text top="480" left="54" width="1079" height="17" font="0">Data Supplement 21. Randomized Trials Comparing Special Populations – Section 9 ............................................................................................................................................... 121</text>
<text top="479" left="1133" width="4" height="18" font="4"> </text>
<text top="498" left="54" width="1079" height="17" font="0">Data Supplement 22. Nonrandomized Trials, Observational Studies, and/or Registries of Quality-of-Life Considerations – Section 10 ...................................................................  122</text>
<text top="496" left="1133" width="4" height="18" font="4"> </text>
<text top="515" left="54" width="1079" height="17" font="0">Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of Cost Effectiveness – Section 11 ...................................................................................... 126</text>
<text top="513" left="1133" width="4" height="18" font="4"> </text>
<text top="532" left="54" width="1079" height="17" font="0">Appendix 1. Acute Drug Therapy for SVT, Intravenous Administration* ................................................................................................................................................................... 131</text>
<text top="531" left="1133" width="4" height="18" font="4"> </text>
<text top="549" left="54" width="1079" height="17" font="0">Appendix 2. Ongoing Drug Therapy for SVT, Oral Administration* .......................................................................................................................................................................... 134</text>
<text top="548" left="1133" width="4" height="18" font="4"> </text>
<text top="566" left="54" width="1079" height="17" font="0">Appendix 3. Success and Complication Rates for Ablation of SVT* ........................................................................................................................................................................... 139</text>
<text top="565" left="1133" width="4" height="18" font="4"> </text>
<text top="584" left="54" width="1079" height="17" font="0">References ........................................................................................................................................................................................................................ <b>Error! Bookmark not defined.</b></text>
<text top="585" left="1133" width="4" height="16" font="4"> </text>
<text top="601" left="54" width="4" height="17" font="0"> </text>
<text top="619" left="54" width="274" height="20" font="2"><b>Methodology and Evidence Review </b></text>
<text top="639" left="54" width="1080" height="17" font="0">The recommendations listed in this guideline are, whenever possible, evidence based. An extensive evidence review was conducted in April 2014 that included literature published </text>
<text top="656" left="54" width="1040" height="17" font="0">through September 2014. Other selected references published through May 2015 were incorporated by the writing committee. Literature included was derived from research </text>
<text top="673" left="54" width="1078" height="17" font="0">involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, </text>
<text top="691" left="54" width="1064" height="17" font="0">and other selected databases relevant to this guideline. The relevant search terms and data are included in Data Supplement evidence tables. Key search words included but were </text>
<text top="708" left="54" width="1057" height="17" font="0">not limited to the following<i>: ablation therapy (catheter and radiofrequency; fast and slow pathway), accessory pathway (manifest and concealed), antiarrhythmic drugs, atrial </i></text>
<text top="728" left="54" width="1084" height="14" font="6"><i>fibrillation, atrial tachycardia, atrioventricular nodal reentrant (reentry, reciprocating) tachycardia, atrioventricular reentrant (reentry, reciprocating) tachycardia, beta blockers, </i></text>
<text top="746" left="54" width="1068" height="14" font="6"><i>calcium channel blockers, cardiac imaging, cardioversion, cost effectiveness, cryotherapy, echocardiography, elderly (aged and older), focal atrial tachycardia, Holter monitor, </i></text>
<text top="763" left="54" width="1048" height="14" font="6"><i>inappropriate sinus tachycardia, junctional tachycardia, multifocal atrial tachycardia, paroxysmal supraventricular tachycardia, permanent form of junctional reciprocating </i></text>
<text top="780" left="54" width="1023" height="14" font="6"><i>tachycardia, pre-excitation, pregnancy, quality of life, sinoatrial node, sinus node reentry, sinus tachycardia, supraventricular tachycardia, supraventricular arrhythmia, </i></text>
<text top="797" left="54" width="659" height="14" font="6"><i>tachycardia, tachyarrhythmia, vagal maneuvers (Valsalva maneuver), </i>and<i> Wolff-Parkinson-White syndrome</i>. </text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="7" size="14" family="Times" color="#0000ff"/>
	<fontspec id="8" size="11" family="Times" color="#0000ff"/>
	<fontspec id="9" size="11" family="Times" color="#ff0000"/>
	<fontspec id="10" size="7" family="Times" color="#000000"/>
<text top="814" left="1127" width="10" height="17" font="0">2 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="63" left="54" width="151" height="19" font="3"><b>DataSupplement1.</b></text>
<text top="63" left="205" width="921" height="19" font="7"><b>NonrandomizedTrials,ObservationalStudies,and/orRegistriesofClinicalPresentationandDifferentialDiagnosisBased</b></text>
<text top="82" left="54" width="207" height="19" font="7"><b>onSymptoms – Section 2.3.1</b></text>
<text top="83" left="261" width="4" height="18" font="3"><b> </b></text>
<text top="102" left="84" width="38" height="17" font="5"><b>Study </b></text>
<text top="120" left="59" width="88" height="17" font="5"><b>Name, Author, </b></text>
<text top="137" left="88" width="30" height="17" font="5"><b>Year </b></text>
<text top="102" left="168" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="120" left="183" width="44" height="17" font="5"><b>Design </b></text>
<text top="102" left="262" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="102" left="368" width="165" height="17" font="5"><b>Inclusion/Exclusion Criteria </b></text>
<text top="102" left="571" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="102" left="743" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="102" left="956" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="155" left="54" width="63" height="15" font="1">Sganzerla P </text>
<text top="170" left="54" width="31" height="15" font="1">1989  </text>
<text top="186" left="54" width="17" height="15" font="1">(1) </text>
<text top="201" left="54" width="43" height="15" font="8">2702964</text>
<text top="201" left="97" width="3" height="15" font="1"> </text>
<text top="155" left="165" width="64" height="15" font="1">Prospective, </text>
<text top="170" left="165" width="79" height="15" font="1">nonrandomized </text>
<text top="155" left="257" width="15" height="15" font="1">16 </text>
<text top="170" left="257" width="41" height="15" font="1">AVNRT </text>
<text top="155" left="344" width="59" height="15" font="1">All AVNRT  </text>
<text top="155" left="569" width="64" height="15" font="1">Relationship </text>
<text top="170" left="569" width="48" height="15" font="1">between  </text>
<text top="186" left="569" width="72" height="15" font="1">hemodynamic </text>
<text top="201" left="569" width="101" height="15" font="1">changes associated </text>
<text top="217" left="569" width="104" height="15" font="1">w/ artificially induced </text>
<text top="232" left="569" width="101" height="15" font="1">arrhythmias and the </text>
<text top="248" left="569" width="101" height="15" font="1">EP properties of the </text>
<text top="263" left="569" width="85" height="15" font="1">related AV nodal </text>
<text top="279" left="569" width="38" height="15" font="1">reentry </text>
<text top="294" left="569" width="3" height="15" font="1"> </text>
<text top="155" left="691" width="144" height="15" font="1">Group 1 AVNRT w/ short RP </text>
<text top="170" left="691" width="143" height="15" font="1">Group 2 AVNRT  w/ long RP </text>
<text top="186" left="691" width="185" height="15" font="1">No significant difference between the </text>
<text top="201" left="691" width="187" height="15" font="1">CLs of the two types of SVT (329 and </text>
<text top="217" left="691" width="53" height="15" font="1">330-8 ms) </text>
<text top="232" left="691" width="206" height="15" font="1">Atypical SVT differed from the typical one </text>
<text top="248" left="691" width="200" height="15" font="1">by a significantly smaller initial decrease </text>
<text top="263" left="691" width="178" height="15" font="1">and a more rapid recovery of BP. In </text>
<text top="279" left="691" width="175" height="15" font="1">group 1, cardiac output and arterial </text>
<text top="294" left="691" width="202" height="15" font="1">pressure were lower in SVR higher and   </text>
<text top="310" left="691" width="58" height="15" font="1">PAP equal. </text>
<text top="325" left="691" width="3" height="15" font="1"> </text>
<text top="341" left="691" width="197" height="15" font="1">Contraction on a closed valve may be a </text>
<text top="356" left="691" width="188" height="15" font="1">factor resulting in impaired pulmonary </text>
<text top="372" left="691" width="182" height="15" font="1">drainage leading to neural factors w/ </text>
<text top="387" left="691" width="119" height="15" font="1">reduced cardiac output. </text>
<text top="155" left="910" width="191" height="15" font="1">The induction of typical SVT (long AH) </text>
<text top="170" left="910" width="223" height="15" font="1">caused a marked initial fall in systemic BP w/ </text>
<text top="186" left="910" width="198" height="15" font="1">only a partial recovery, leading to stable </text>
<text top="201" left="910" width="218" height="15" font="1">hypotension and reduction of cardiac output </text>
<text top="217" left="910" width="225" height="15" font="1">owing to a decrease in stroke volume. On the </text>
<text top="232" left="910" width="199" height="15" font="1">contrary, in comparison to sinus rhythm, </text>
<text top="248" left="910" width="209" height="15" font="1">during the atypical SVT (long HA) a lesser </text>
<text top="263" left="910" width="201" height="15" font="1">degree of initial hypotension, a complete </text>
<text top="279" left="910" width="216" height="15" font="1">recovery of BP and no significant change in </text>
<text top="294" left="910" width="217" height="15" font="1">cardiac output were observed. The different </text>
<text top="310" left="910" width="204" height="15" font="1">hemodynamic response between the two </text>
<text top="325" left="910" width="183" height="15" font="1">types of SVT took place w/ the same </text>
<text top="341" left="910" width="212" height="15" font="1">increase in heart rate indicating that rate is </text>
<text top="356" left="910" width="210" height="15" font="1">not involved per se in the genesis of these </text>
<text top="372" left="910" width="105" height="15" font="1">circulatory changes.  </text>
<text top="387" left="910" width="221" height="15" font="1">Simultaneous contraction more symptomatic </text>
<text top="403" left="910" width="55" height="15" font="1">for people. </text>
<text top="403" left="966" width="3" height="15" font="9"> </text>
<text top="419" left="54" width="65" height="15" font="1">Bhandari AK </text>
<text top="434" left="54" width="28" height="15" font="1">1992 </text>
<text top="450" left="54" width="17" height="15" font="1">(2) </text>
<text top="465" left="54" width="43" height="15" font="8">1636582</text>
<text top="465" left="97" width="3" height="15" font="1"> </text>
<text top="419" left="165" width="61" height="15" font="1">Prospective </text>
<text top="434" left="165" width="30" height="15" font="1">study </text>
<text top="419" left="257" width="63" height="15" font="1">115 pts who </text>
<text top="434" left="257" width="69" height="15" font="1">were enrolled </text>
<text top="450" left="257" width="21" height="15" font="1">in a </text>
<text top="465" left="257" width="57" height="15" font="1">multicenter </text>
<text top="481" left="257" width="70" height="15" font="1">clinical trial of </text>
<text top="496" left="257" width="50" height="15" font="1">flecainide </text>
<text top="419" left="344" width="129" height="15" font="1">Pts w/ SVT or AF or both, </text>
<text top="434" left="344" width="62" height="15" font="1">49 had SVT </text>
<text top="419" left="569" width="97" height="15" font="1">Determine whether </text>
<text top="434" left="569" width="75" height="15" font="1">sx recorded w/ </text>
<text top="450" left="569" width="78" height="15" font="1">transtelephonic </text>
<text top="465" left="569" width="107" height="15" font="1">monitoring correlated </text>
<text top="481" left="569" width="69" height="15" font="1">w/ SVT or AF </text>
<text top="419" left="691" width="167" height="15" font="1">Among 49 pts w/ PSVT, 62.7% of </text>
<text top="434" left="691" width="188" height="15" font="1">symptomatic calls were associated w/ </text>
<text top="451" left="691" width="194" height="15" font="1">ECG-documented PSVT as compared </text>
<text top="467" left="691" width="205" height="15" font="1">w/ 6.6% of asymptomatic calls (p&lt;0.001). </text>
<text top="483" left="691" width="3" height="15" font="1"> </text>
<text top="419" left="910" width="202" height="15" font="1">The sensitivity of a symptomatic call was </text>
<text top="434" left="910" width="73" height="15" font="1">91% for PSVT </text>
<text top="450" left="910" width="3" height="15" font="1"> </text>
<text top="513" left="54" width="52" height="15" font="1">Leitch JW </text>
<text top="528" left="54" width="31" height="15" font="1">1992  </text>
<text top="543" left="54" width="17" height="15" font="1">(3) </text>
<text top="559" left="54" width="43" height="15" font="8">1537103</text>
<text top="559" left="97" width="3" height="15" font="1"> </text>
<text top="513" left="165" width="64" height="15" font="1">Prospective, </text>
<text top="528" left="165" width="79" height="15" font="1">nonrandomized </text>
<text top="513" left="257" width="30" height="15" font="1">N=22 </text>
<text top="513" left="344" width="72" height="15" font="1">22 pts w/ SVT </text>
<text top="528" left="344" width="56" height="15" font="1">AVNRT 13 </text>
<text top="543" left="344" width="42" height="15" font="1">AVRT 8 </text>
<text top="559" left="344" width="26" height="15" font="1">AT 1 </text>
<text top="574" left="344" width="3" height="15" font="1"> </text>
<text top="590" left="344" width="109" height="15" font="1">11 had a h/o syncope </text>
<text top="513" left="569" width="59" height="15" font="1">Explore the </text>
<text top="529" left="569" width="72" height="15" font="1">mechanism of </text>
<text top="545" left="569" width="103" height="15" font="1">syncope during SVT </text>
<text top="561" left="569" width="3" height="15" font="1"> </text>
<text top="513" left="691" width="105" height="15" font="1">Lowest BP found in 1</text>
<text top="513" left="795" width="6" height="10" font="10">st</text>
<text top="513" left="801" width="39" height="15" font="1"> 10 sec </text>
<text top="528" left="691" width="204" height="15" font="1">Compensated BP w/in 60 sec w/ minimal </text>
<text top="543" left="691" width="68" height="15" font="1">change in CL </text>
<text top="559" left="691" width="172" height="15" font="1">shorter and BP lower w/ upright tilt </text>
<text top="574" left="691" width="190" height="15" font="1">Comparison of the 7 pts w/ and the 15 </text>
<text top="590" left="691" width="183" height="15" font="1">pts w/o syncope. The only significant </text>
<text top="605" left="691" width="197" height="15" font="1">differences occurred in the extent of BP </text>
<text top="621" left="691" width="206" height="15" font="1">decrease during tachycardia (decrease in </text>
<text top="636" left="691" width="197" height="15" font="1">mean BP, 70±4 compared w/ 45+5 mm </text>
<text top="652" left="691" width="179" height="15" font="1">Hg; p=0.01) and in the frequency w/ </text>
<text top="667" left="691" width="196" height="15" font="1">which syncope occurred during passive </text>
<text top="683" left="691" width="182" height="15" font="1">tilt testing in sinus rhythm. The CL of </text>
<text top="698" left="691" width="197" height="15" font="1">tachycardia, in fact, tended to be longer </text>
<text top="715" left="691" width="199" height="15" font="1">in pts w/ syncope (311±10 compared w/ </text>
<text top="731" left="691" width="124" height="15" font="1">290±+11 msec, p=0.27). </text>
<text top="513" left="910" width="203" height="15" font="1">Syncope is associated w/ vasodepressor </text>
<text top="528" left="910" width="217" height="15" font="1">mechanism and is not directly related to the </text>
<text top="543" left="910" width="77" height="15" font="1">tachycardia CL </text>
<text top="747" left="54" width="40" height="15" font="1">Lee SH </text>
<text top="763" left="54" width="31" height="15" font="1">1995  </text>
<text top="778" left="54" width="17" height="15" font="1">(4) </text>
<text top="794" left="54" width="43" height="15" font="8">7572623</text>
<text top="794" left="97" width="3" height="15" font="1"> </text>
<text top="747" left="165" width="71" height="15" font="1">Retrospective </text>
<text top="763" left="165" width="35" height="15" font="1">review </text>
<text top="747" left="257" width="21" height="15" font="1">207 </text>
<text top="763" left="257" width="61" height="15" font="1">consecutive </text>
<text top="778" left="257" width="50" height="15" font="1">pts w/ h/o </text>
<text top="794" left="257" width="25" height="15" font="1">SVT </text>
<text top="747" left="344" width="112" height="15" font="1">107 pts AP mediated,  </text>
<text top="763" left="344" width="91" height="15" font="1">100 pts w/ AVNRT</text>
<text top="763" left="436" width="3" height="15" font="9"> </text>
<text top="747" left="569" width="102" height="15" font="1">Determine effects of </text>
<text top="763" left="569" width="95" height="15" font="1">pregnancy on SVT </text>
<text top="747" left="691" width="180" height="15" font="1">3.9% experienced first onset of SVT </text>
<text top="763" left="691" width="199" height="15" font="1">during pregnancy. Sx were exacerbated </text>
<text top="778" left="691" width="171" height="15" font="1">in 22% of pts w/ tachycardia in the </text>
<text top="794" left="691" width="186" height="15" font="1">pregnant and non-pregnant periods.   </text>
<text top="747" left="910" width="223" height="15" font="1">Pregnancy exacerbates SVT in some but not </text>
<text top="763" left="910" width="38" height="15" font="1">all pts.  </text>
<text top="778" left="910" width="3" height="15" font="1"> </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="11" size="11" family="Times" color="#ffffff"/>
	<fontspec id="12" size="11" family="Times" color="#1a1718"/>
<text top="814" left="1127" width="10" height="17" font="0">3 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="43" height="15" font="1">Drago F </text>
<text top="70" left="54" width="31" height="15" font="1">1996  </text>
<text top="86" left="54" width="17" height="15" font="1">(5) </text>
<text top="101" left="54" width="43" height="15" font="8">8701888</text>
<text top="101" left="97" width="3" height="15" font="1"> </text>
<text top="55" left="165" width="64" height="15" font="1">Prospective, </text>
<text top="70" left="165" width="79" height="15" font="1">nonrandomized </text>
<text top="55" left="257" width="36" height="15" font="1">N = 22 </text>
<text top="70" left="257" width="42" height="15" font="1">children </text>
<text top="55" left="344" width="211" height="15" font="1">Ventriculoatrial interval &lt;70 msec in 11 pts </text>
<text top="70" left="344" width="100" height="15" font="1">and &gt;70 msec in 11 </text>
<text top="86" left="344" width="3" height="15" font="1"> </text>
<text top="55" left="569" width="105" height="15" font="1">The aim of this study </text>
<text top="70" left="569" width="98" height="15" font="1">was to evaluate, by </text>
<text top="86" left="569" width="29" height="15" font="1">using </text>
<text top="101" left="569" width="85" height="15" font="1">transesophageal </text>
<text top="117" left="569" width="84" height="15" font="1">atrial pacing and </text>
<text top="132" left="569" width="107" height="15" font="1">recording, the clinical </text>
<text top="147" left="569" width="95" height="15" font="1">and EP features of </text>
<text top="163" left="569" width="103" height="15" font="1">reciprocating SVT at </text>
<text top="178" left="569" width="77" height="15" font="1">rest and during </text>
<text top="194" left="569" width="78" height="15" font="1">exercise and to </text>
<text top="210" left="569" width="107" height="15" font="1">determine the factors </text>
<text top="225" left="569" width="94" height="15" font="1">related to syncope </text>
<text top="240" left="569" width="58" height="15" font="1">during high </text>
<text top="256" left="569" width="83" height="15" font="1">adrenergic tone. </text>
<text top="271" left="569" width="3" height="15" font="1"> </text>
<text top="55" left="691" width="141" height="15" font="1">Group A = SVT, palpitations </text>
<text top="70" left="691" width="148" height="15" font="1">Group B = SVT near syncope </text>
<text top="86" left="691" width="190" height="15" font="1">Induced SVT via esoph pacing in both </text>
<text top="101" left="691" width="40" height="15" font="1">groups. </text>
<text top="117" left="691" width="3" height="15" font="1"> </text>
<text top="55" left="910" width="213" height="15" font="1">AVRT faster when induced during exercise </text>
<text top="70" left="910" width="215" height="15" font="1">Rate of SVT unrelated to sx of pre-syncope </text>
<text top="288" left="54" width="43" height="15" font="1">Goyal R </text>
<text top="303" left="54" width="31" height="15" font="1">1996  </text>
<text top="319" left="54" width="17" height="15" font="1">(6) </text>
<text top="334" left="54" width="43" height="15" font="8">8831363</text>
<text top="334" left="97" width="3" height="15" font="1"> </text>
<text top="350" left="54" width="78" height="15" font="11">1996;132:765-7</text>
<text top="350" left="132" width="3" height="15" font="1"> </text>
<text top="365" left="54" width="3" height="15" font="1"> </text>
<text top="288" left="165" width="135" height="15" font="1">Observational 519 </text>
<text top="288" left="279" width="24" height="15" font="1"> </text>
<text top="303" left="257" width="62" height="15" font="1">231 AVNRT </text>
<text top="319" left="257" width="54" height="15" font="1">288 AVRT </text>
<text top="334" left="257" width="3" height="15" font="1"> </text>
<text top="288" left="344" width="86" height="15" font="1">AVNRT or AVRT </text>
<text top="288" left="569" width="97" height="15" font="1">Assessment of age </text>
<text top="303" left="569" width="43" height="15" font="1">of onset </text>
<text top="288" left="691" width="197" height="15" font="1">The mean age of sx onset was 32±18 y </text>
<text top="303" left="691" width="205" height="15" font="1">for AVNRT and 23±14 y for AP-mediated </text>
<text top="319" left="691" width="172" height="15" font="1">tachycardia. A significantly greater </text>
<text top="334" left="691" width="206" height="15" font="1">proportion of pts w/ AVNRT had the initial </text>
<text top="350" left="691" width="185" height="15" font="1">onset of sxs after the age of 20 y (AV </text>
<text top="365" left="691" width="190" height="15" font="1">nodal reen- trant tachycardia, 67% vs. </text>
<text top="381" left="691" width="97" height="15" font="1">AP, 41% (p&lt;0.001) </text>
<text top="288" left="910" width="220" height="15" font="1">There is a different mean age of sx onset for </text>
<text top="303" left="910" width="224" height="15" font="1">pts w/ AVNRT and AP-mediated tachycardia. </text>
<text top="319" left="910" width="3" height="15" font="1"> </text>
<text top="397" left="54" width="34" height="15" font="1">Abe H </text>
<text top="412" left="54" width="28" height="15" font="1">1997 </text>
<text top="428" left="54" width="17" height="15" font="1">(7) </text>
<text top="443" left="54" width="43" height="15" font="8">9392809</text>
<text top="443" left="97" width="3" height="15" font="1"> </text>
<text top="397" left="165" width="61" height="15" font="1">Prospective </text>
<text top="412" left="165" width="74" height="15" font="1">study of pts w/ </text>
<text top="428" left="165" width="28" height="15" font="1">SVT  </text>
<text top="397" left="257" width="30" height="15" font="1">N=32 </text>
<text top="412" left="257" width="3" height="15" font="1"> </text>
<text top="428" left="257" width="56" height="15" font="1">13 AVNRT </text>
<text top="443" left="257" width="67" height="15" font="1">4 atrial flutter </text>
<text top="459" left="257" width="48" height="15" font="1">15 AVRT </text>
<text top="474" left="257" width="3" height="15" font="1"> </text>
<text top="397" left="344" width="141" height="15" font="1">32 consecutive pts w/ PSVT </text>
<text top="397" left="569" width="102" height="15" font="1">Hypothesis was that </text>
<text top="412" left="569" width="104" height="15" font="1">pts w/ AVNRT would </text>
<text top="428" left="569" width="82" height="15" font="1">have more sx of </text>
<text top="443" left="569" width="98" height="15" font="1">diuresis because of </text>
<text top="459" left="569" width="105" height="15" font="1">higher right pressure </text>
<text top="397" left="691" width="198" height="15" font="1">Increased diuresis in 12/13 (92%) of pts </text>
<text top="412" left="691" width="191" height="15" font="1">w/ AVNRT; 2/15 (13%) AVRT; and 1/4 </text>
<text top="428" left="691" width="171" height="15" font="1">atrial flutter w/ 2:1 AV conduction.  </text>
<text top="443" left="691" width="3" height="15" font="1"> </text>
<text top="459" left="691" width="172" height="15" font="1">Measured right atrial pressure and </text>
<text top="474" left="691" width="143" height="15" font="1">plasma ANP in 14 of 32 pts.  </text>
<text top="490" left="691" width="203" height="15" font="1">RA pressure higher in AVNRT compared </text>
<text top="505" left="691" width="173" height="15" font="1">to the other tachycardias (16 vs. 5; </text>
<text top="521" left="691" width="202" height="15" font="1">p&lt;0.01) and ANP levels also higher (215 </text>
<text top="536" left="691" width="86" height="15" font="1">vs. 63; p&lt;0.001)  </text>
<text top="397" left="910" width="223" height="15" font="12">Sx of diuresis more common w/ AVNRT. The </text>
<text top="412" left="910" width="178" height="15" font="12">higher secretion of ANP may be the </text>
<text top="428" left="910" width="183" height="15" font="12">mechanism because there is a linear </text>
<text top="443" left="910" width="225" height="15" font="12">relationship between plasma ANP  levels and </text>
<text top="459" left="910" width="76" height="15" font="12">atrial pressure  </text>
<text top="552" left="54" width="70" height="15" font="1">Lessmeier TJ </text>
<text top="568" left="54" width="31" height="15" font="1">1997  </text>
<text top="583" left="54" width="17" height="15" font="1">(8) </text>
<text top="599" left="54" width="43" height="15" font="8">9066458</text>
<text top="599" left="97" width="3" height="15" font="1"> </text>
<text top="552" left="165" width="71" height="15" font="1">Retrospective </text>
<text top="568" left="165" width="36" height="15" font="1">survey </text>
<text top="552" left="257" width="21" height="15" font="1">119 </text>
<text top="568" left="257" width="61" height="15" font="1">consecutive </text>
<text top="583" left="257" width="18" height="15" font="1">pts </text>
<text top="552" left="344" width="127" height="15" font="1">Limited to AVRT, AVNRT </text>
<text top="552" left="569" width="74" height="15" font="1">Systematically </text>
<text top="568" left="569" width="63" height="15" font="1">evaluate the </text>
<text top="583" left="569" width="98" height="15" font="1">potential for SVT to </text>
<text top="599" left="569" width="74" height="15" font="1">simulate panic </text>
<text top="614" left="569" width="43" height="15" font="1">disorder </text>
<text top="552" left="691" width="188" height="15" font="1">Criteria for panic disorder per DSM-IV </text>
<text top="568" left="691" width="199" height="15" font="1">were fulfilled in 67%. SVT unrecognized </text>
<text top="583" left="691" width="175" height="15" font="1">after initial medical evaluation in 59 </text>
<text top="599" left="691" width="146" height="15" font="1">(55%) including 41% of 32 w/ </text>
<text top="614" left="691" width="201" height="15" font="1">preexcitation. Physicians attributed sx to </text>
<text top="630" left="691" width="186" height="15" font="1">panic, anxiety orstress in 32 of the 59 </text>
<text top="645" left="691" width="39" height="15" font="1">(54%).  </text>
<text top="661" left="691" width="182" height="15" font="1">SVT unrecognized a median of 3.3 y </text>
<text top="676" left="691" width="178" height="15" font="1">Women more likely to be labeled w/ </text>
<text top="692" left="691" width="187" height="15" font="1">panic than men (65% vs. 32% p&lt;0.04 </text>
<text top="707" left="691" width="192" height="15" font="1">SVT diagnosed in 6  (9%) of  64 pts w/ </text>
<text top="723" left="691" width="174" height="15" font="1">Holters and 8 (47%) of 17 w/ event </text>
<text top="738" left="691" width="99" height="15" font="1">monitors  (p=0.001) </text>
<text top="552" left="910" width="196" height="15" font="1">SVT can mimic panic disorders and the </text>
<text top="568" left="910" width="213" height="15" font="1">diagnosis is often delayed by inappropriate </text>
<text top="583" left="910" width="193" height="15" font="1">rhythm detection techniques or missed </text>
<text top="599" left="910" width="193" height="15" font="1">preexcitation. Unrecognized SVT often </text>
<text top="615" left="910" width="173" height="15" font="1">attributed to psychiatric conditions. </text>
<text top="630" left="910" width="207" height="15" font="1">Perhaps misdiagnosis happens in women </text>
<text top="645" left="910" width="191" height="15" font="1">more often due to miscategorization of </text>
<text top="661" left="910" width="94" height="15" font="1">“feeling” in survey  </text>
<text top="755" left="54" width="60" height="15" font="1">Kalusche D </text>
<text top="770" left="54" width="31" height="15" font="1">1998  </text>
<text top="786" left="54" width="17" height="15" font="1">(9) </text>
<text top="755" left="165" width="135" height="15" font="1">Observational 395 </text>
<text top="755" left="279" width="33" height="15" font="1">pt </text>
<text top="755" left="291" width="35" height="15" font="1">w/ </text>
<text top="770" left="257" width="41" height="15" font="1">AVNRT </text>
<text top="786" left="257" width="73" height="15" font="1">85 were &gt;65 y </text>
<text top="755" left="344" width="92" height="15" font="1">Limited to AVNRT </text>
<text top="770" left="344" width="3" height="15" font="9"> </text>
<text top="755" left="569" width="97" height="15" font="1">Main objective was </text>
<text top="770" left="569" width="101" height="15" font="1">to analyze risks and </text>
<text top="786" left="569" width="63" height="15" font="1">outcomes of </text>
<text top="755" left="691" width="204" height="15" font="1">Elderly patents (mean 70.4 y) more often </text>
<text top="770" left="691" width="194" height="15" font="1">had syncope or presyncope w/ AVNRT </text>
<text top="786" left="691" width="188" height="15" font="1">(43.2% vs. 29.8%; P=0.05); had more </text>
<text top="755" left="910" width="203" height="15" font="1">Elderly pts have more sxs, ER visits, and </text>
<text top="770" left="910" width="221" height="15" font="1">hospitalizations despite slower tachycardias. </text>
<text top="786" left="910" width="204" height="15" font="1">(Outcomes of ablation were no different.) </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1127" width="10" height="17" font="0">4 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="43" height="15" font="8">9812187</text>
<text top="55" left="97" width="3" height="15" font="1"> </text>
<text top="55" left="569" width="87" height="15" font="1">ablation, but they </text>
<text top="70" left="569" width="93" height="15" font="1">also characterized </text>
<text top="86" left="569" width="74" height="15" font="1">presenting sxs </text>
<text top="55" left="691" width="158" height="15" font="1">hospitalizations and emergency </text>
<text top="70" left="691" width="183" height="15" font="1">department visits because of their sx </text>
<text top="86" left="691" width="193" height="15" font="1">56.8 vs. 39.5% p,0.05 even though the </text>
<text top="101" left="691" width="204" height="15" font="1">CL was longer in the elderly (368 vs. 325 </text>
<text top="117" left="691" width="90" height="15" font="1">msec; P=0.0001)  </text>
<text top="133" left="54" width="69" height="15" font="1">Orejarena LA </text>
<text top="148" left="54" width="31" height="15" font="1">1998  </text>
<text top="164" left="54" width="23" height="15" font="1">(10) </text>
<text top="179" left="54" width="43" height="15" font="8">9426034</text>
<text top="179" left="97" width="3" height="15" font="1"> </text>
<text top="195" left="54" width="3" height="15" font="1"> </text>
<text top="133" left="165" width="55" height="15" font="1">Population </text>
<text top="148" left="165" width="71" height="15" font="1">epidemiologic </text>
<text top="164" left="165" width="46" height="15" font="1">research </text>
<text top="133" left="257" width="50" height="15" font="1">Screened </text>
<text top="148" left="257" width="37" height="15" font="1">50,000 </text>
<text top="164" left="257" width="3" height="15" font="1"> </text>
<text top="179" left="257" width="48" height="15" font="1">Identified </text>
<text top="195" left="257" width="69" height="15" font="1">1,763 w/ SVT </text>
<text top="133" left="344" width="83" height="15" font="1">Limited to PSVT </text>
<text top="148" left="344" width="186" height="15" font="1">Standard ECG criteria for PSVT were </text>
<text top="164" left="344" width="207" height="15" font="1">employed: 1) paroxysmal, 2) normal QRS </text>
<text top="179" left="344" width="180" height="15" font="1">complex configuration or preexisting </text>
<text top="195" left="344" width="175" height="15" font="1">bundle branch block, 3) variation in </text>
<text top="210" left="344" width="189" height="15" font="1">successive RR intervals ≤40 msec, 4) </text>
<text top="226" left="344" width="201" height="15" font="1">ventricular rate 120 bpm, 5) no evidence </text>
<text top="241" left="344" width="210" height="15" font="1">of AV dissociation, and 6) no identifiable P </text>
<text top="257" left="344" width="210" height="15" font="1">waves preceding the QRS complex during </text>
<text top="272" left="344" width="66" height="15" font="1">tachycardia.  </text>
<text top="288" left="344" width="3" height="15" font="1"> </text>
<text top="133" left="569" width="78" height="15" font="1">The aim was to </text>
<text top="148" left="569" width="71" height="15" font="1">determine the </text>
<text top="164" left="569" width="90" height="15" font="1">epidemiology and </text>
<text top="179" left="569" width="97" height="15" font="1">clinical significance </text>
<text top="195" left="569" width="74" height="15" font="1">of PSVT in the </text>
<text top="210" left="569" width="100" height="15" font="1">general population.  </text>
<text top="226" left="569" width="3" height="15" font="1"> </text>
<text top="133" left="691" width="200" height="15" font="1">The prevalence was 2.25/1,000 persons </text>
<text top="148" left="691" width="171" height="15" font="1">and the incidence was 35/100,000 </text>
<text top="164" left="691" width="136" height="15" font="1">person-ys (95% CI: 23-47). </text>
<text top="179" left="691" width="174" height="15" font="1">Those w/ lone PSVT were younger </text>
<text top="195" left="691" width="181" height="15" font="1">(mean 37 vs. 69 y; p&lt;0.0002), had a </text>
<text top="210" left="691" width="186" height="15" font="1">faster PSVT heart rate (mean 186 vs. </text>
<text top="226" left="691" width="179" height="15" font="1">155 bpm; p&lt;0.0006) and were more </text>
<text top="241" left="691" width="160" height="15" font="1">likely to have their condition first </text>
<text top="257" left="691" width="180" height="15" font="1">documented in the emergency room </text>
<text top="272" left="691" width="195" height="15" font="1">(69% vs. 30%; p&lt;0.0377). The onset of </text>
<text top="288" left="691" width="201" height="15" font="1">sxs occurred during the childbearing y in </text>
<text top="303" left="691" width="198" height="15" font="1">58% of females w/ lone PSVT vs. 9% of </text>
<text top="319" left="691" width="165" height="15" font="1">females w/ other cardio- vascular </text>
<text top="334" left="691" width="101" height="15" font="1">disease (p&lt;0.0272). </text>
<text top="350" left="691" width="203" height="15" font="1">21 incident pts (64%) had sxsconcordant </text>
<text top="365" left="691" width="136" height="15" font="1">w/ PSVT before initial ECG </text>
<text top="381" left="691" width="79" height="15" font="1">documentation. </text>
<text top="396" left="691" width="199" height="15" font="1">The probability of recurrence by the end </text>
<text top="412" left="691" width="176" height="15" font="1">of y 2 of f/u was 0.20 (95% CI: 0.06-</text>
<text top="427" left="691" width="170" height="15" font="1">0.35). There were no predictors of </text>
<text top="443" left="691" width="193" height="15" font="1">recurrence. For pts w/ a recurrence, all </text>
<text top="458" left="691" width="203" height="15" font="1">except one had their first recurrence w/in </text>
<text top="474" left="691" width="161" height="15" font="1">12 mo of diagnosis and one had </text>
<text top="489" left="691" width="175" height="15" font="1">hemodynamic instability. 5 pts died </text>
<text top="505" left="691" width="149" height="15" font="1">during f/u, none due to PSVT  </text>
<text top="133" left="910" width="196" height="15" font="1">Approximately 89,000 new cases/y and </text>
<text top="148" left="910" width="197" height="15" font="1">570,000 persons w/ PSVT in the United </text>
<text top="164" left="910" width="41" height="15" font="1">States.  </text>
<text top="179" left="910" width="3" height="15" font="1"> </text>
<text top="521" left="54" width="55" height="15" font="1">Erdogan A </text>
<text top="536" left="54" width="31" height="15" font="1">2001  </text>
<text top="552" left="54" width="23" height="15" font="1">(11) </text>
<text top="567" left="54" width="49" height="15" font="8">11785371</text>
<text top="567" left="103" width="3" height="15" font="1"> </text>
<text top="521" left="165" width="72" height="15" font="1">Cohort survey </text>
<text top="521" left="257" width="63" height="15" font="1">748 pts who </text>
<text top="536" left="257" width="55" height="15" font="1">underwent </text>
<text top="552" left="257" width="42" height="15" font="1">ablation </text>
<text top="567" left="257" width="68" height="15" font="1">responded to </text>
<text top="583" left="257" width="45" height="15" font="1">a survey </text>
<text top="521" left="344" width="92" height="15" font="1">Limited to AVNRT </text>
<text top="521" left="569" width="102" height="15" font="1">Analyze the medical </text>
<text top="536" left="569" width="91" height="15" font="1">h/o pts w/ AVNRT </text>
<text top="521" left="691" width="198" height="15" font="1">Interval from onset of sx to ablation was </text>
<text top="536" left="691" width="200" height="15" font="1">4.1 +/- 1.5 y. Mean age 55.4 female and </text>
<text top="552" left="691" width="168" height="15" font="1">58.7 males. Only 6% had SHD. In </text>
<text top="567" left="691" width="206" height="15" font="1">females AVNRT appeared after age 50 in </text>
<text top="583" left="691" width="198" height="15" font="1">16% and &lt;age 20 in 18%. Women were </text>
<text top="598" left="691" width="193" height="15" font="1">more symptomatic. Women were more </text>
<text top="614" left="691" width="180" height="15" font="1">likely to delay ablation (average 7 y) </text>
<text top="629" left="691" width="170" height="15" font="1">(unknown whether this was due to </text>
<text top="645" left="691" width="172" height="15" font="1">personal preference or bias due to </text>
<text top="660" left="691" width="65" height="15" font="1">advice given)</text>
<text top="660" left="756" width="3" height="15" font="9"> </text>
<text top="521" left="910" width="212" height="15" font="1">High rate of pt w/ AVNRT begin in an older </text>
<text top="536" left="910" width="60" height="15" font="1">stage of life </text>
<text top="552" left="910" width="3" height="15" font="1"> </text>
<text top="676" left="54" width="81" height="15" font="1">Fitzsimmons PJ </text>
<text top="692" left="54" width="31" height="15" font="1">2001  </text>
<text top="707" left="54" width="23" height="15" font="1">(12) </text>
<text top="723" left="54" width="49" height="15" font="8">11526369</text>
<text top="723" left="103" width="3" height="15" font="1"> </text>
<text top="676" left="165" width="71" height="15" font="1">Retrospective </text>
<text top="692" left="165" width="35" height="15" font="1">review </text>
<text top="676" left="257" width="63" height="15" font="1">238 aviators </text>
<text top="676" left="344" width="137" height="15" font="1">Focused on manifest WPW </text>
<text top="692" left="344" width="3" height="15" font="9"> </text>
<text top="676" left="569" width="92" height="15" font="1">Report the natural </text>
<text top="692" left="569" width="71" height="15" font="1">h/o WPW in a </text>
<text top="707" left="569" width="80" height="15" font="1">nontertiary care </text>
<text top="723" left="569" width="89" height="15" font="1">population for the </text>
<text top="738" left="569" width="105" height="15" font="1">development of SCD </text>
<text top="754" left="569" width="46" height="15" font="1">and SVT </text>
<text top="676" left="691" width="105" height="15" font="1">232 males, 6 women </text>
<text top="692" left="691" width="115" height="15" font="1">median age 35 (17-56) </text>
<text top="707" left="691" width="197" height="15" font="1">11.7% had sx suggestive of SVT. 1 had </text>
<text top="723" left="691" width="178" height="15" font="1">syncope and 12 had near syncope.  </text>
<text top="738" left="691" width="3" height="15" font="1"> </text>
<text top="754" left="691" width="198" height="15" font="1">During f/u SVT occurred in 20.6%. SCD </text>
<text top="769" left="691" width="63" height="15" font="1">in 1 (0.02%) </text>
<text top="676" left="910" width="207" height="15" font="1">Incidence of SVT is 1% per pt y. SCD risk </text>
<text top="692" left="910" width="20" height="15" font="1">low </text>
<text top="786" left="54" width="65" height="15" font="1">Hamdan MH </text>
<text top="786" left="165" width="61" height="15" font="1">Prospective </text>
<text top="786" left="257" width="22" height="15" font="1">112 </text>
<text top="786" left="344" width="117" height="15" font="1">112 pts w/ pacemakers </text>
<text top="786" left="569" width="89" height="15" font="1">Examine effect of </text>
<text top="786" left="691" width="419" height="15" font="1">Decrease in BP greatest w/ simultaneous  SNA  increases during all pacing modes </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1127" width="10" height="17" font="0">5 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="31" height="15" font="1">2001  </text>
<text top="70" left="54" width="23" height="15" font="1">(13) </text>
<text top="86" left="54" width="49" height="15" font="8">11136692</text>
<text top="86" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="165" width="793" height="15" font="1">analysis atrial </text>
<text top="55" left="596" width="394" height="15" font="1">timing </text>
<text top="55" left="629" width="395" height="15" font="1">during </text>
<text top="70" left="569" width="50" height="15" font="1">simulated </text>
<text top="86" left="569" width="75" height="15" font="1">tachycardia on </text>
<text top="101" left="569" width="94" height="15" font="1">hemodynamic and </text>
<text top="117" left="569" width="91" height="15" font="1">neural responses. </text>
<text top="55" left="691" width="187" height="15" font="1">pacing, less w/ short RP, and least w/ </text>
<text top="70" left="691" width="43" height="15" font="1">long RP </text>
<text top="86" left="691" width="185" height="15" font="1">Increase in CVP followed same trend </text>
<text top="101" left="691" width="192" height="15" font="1">SNA% increased w/ all three, but most </text>
<text top="117" left="691" width="186" height="15" font="1">pronounced w/ simultaneous AV  and </text>
<text top="132" left="691" width="87" height="15" font="1">most w/ short RP </text>
<text top="147" left="691" width="3" height="15" font="1"> </text>
<text top="163" left="691" width="172" height="15" font="1">Arterial baroreflex  SNA correlated </text>
<text top="178" left="691" width="138" height="15" font="1">modestly w/ change in CVP </text>
<text top="55" left="910" width="223" height="15" font="1">Decrease in BP and pulse pressure, which is </text>
<text top="70" left="910" width="191" height="15" font="1">directly related to the tachycardia rate, </text>
<text top="86" left="910" width="214" height="15" font="1">cardiac function, and AV synchrony. At any </text>
<text top="101" left="910" width="204" height="15" font="1">given rate, the timing of atrial systole has </text>
<text top="117" left="910" width="190" height="15" font="1">been shown to alter the hemodynamic </text>
<text top="132" left="910" width="52" height="15" font="1">response. </text>
<text top="147" left="910" width="3" height="15" font="1"> </text>
<text top="195" left="54" width="49" height="15" font="1">Razavi M </text>
<text top="210" left="54" width="31" height="15" font="1">2005  </text>
<text top="226" left="54" width="23" height="15" font="1">(14) </text>
<text top="241" left="54" width="49" height="15" font="8">16191112</text>
<text top="241" left="103" width="3" height="15" font="1"> </text>
<text top="257" left="54" width="3" height="15" font="1"> </text>
<text top="195" left="165" width="143" height="15" font="1">Observational N=17 </text>
<text top="195" left="344" width="41" height="15" font="1">AVNRT </text>
<text top="195" left="569" width="96" height="15" font="1">Change in BP over </text>
<text top="210" left="569" width="24" height="15" font="1">time </text>
<text top="195" left="691" width="201" height="15" font="1">BP decreased immediately after AVNRT </text>
<text top="210" left="691" width="199" height="15" font="1">initiation, w/ gradual recovery during the </text>
<text top="226" left="691" width="187" height="15" font="1">first 30 sec from 71.9±16.5 mm Hg to </text>
<text top="241" left="691" width="198" height="15" font="1">86±13.8 mm Hg, p&lt;0.01. When upright, </text>
<text top="257" left="691" width="188" height="15" font="1">the mean BP time course was similar, </text>
<text top="272" left="691" width="187" height="15" font="1">but mean BP recovery during AVNRT </text>
<text top="288" left="691" width="58" height="15" font="1">was slower </text>
<text top="195" left="910" width="223" height="15" font="1">A short AV interval is associated w/ a greater </text>
<text top="210" left="910" width="170" height="15" font="1">mean BP decrease at the onset of </text>
<text top="226" left="910" width="225" height="15" font="1">tachycardia. These observations may explain </text>
<text top="241" left="910" width="204" height="15" font="1">clinical sxs immediately after the onset of </text>
<text top="257" left="910" width="41" height="15" font="1">AVNRT </text>
<text top="272" left="910" width="3" height="15" font="1"> </text>
<text top="304" left="54" width="68" height="15" font="1">Walfidsson U </text>
<text top="319" left="54" width="31" height="15" font="1">2005  </text>
<text top="335" left="54" width="23" height="15" font="1">(15) </text>
<text top="350" left="54" width="49" height="15" font="8">15733177</text>
<text top="350" left="103" width="3" height="15" font="1"> </text>
<text top="304" left="165" width="68" height="15" font="1">Survey of pts </text>
<text top="319" left="165" width="58" height="15" font="1">referred for </text>
<text top="335" left="165" width="42" height="15" font="1">ablation </text>
<text top="304" left="257" width="40" height="15" font="1">301 pts </text>
<text top="319" left="257" width="54" height="15" font="1">226 active </text>
<text top="335" left="257" width="36" height="15" font="1">drivers </text>
<text top="304" left="344" width="146" height="15" font="1">Limited to AVRT and AVNRT </text>
<text top="304" left="569" width="103" height="15" font="1">Evaluate the sx in pt </text>
<text top="319" left="569" width="96" height="15" font="1">w/ SVT and impact </text>
<text top="335" left="569" width="51" height="15" font="1">on driving </text>
<text top="304" left="691" width="170" height="15" font="1">In 226 active drivers, fatigue 77%, </text>
<text top="319" left="691" width="190" height="15" font="1">dizziness 47%, diaphoresis 52%, near </text>
<text top="335" left="691" width="205" height="15" font="1">syncope 50%, and syncope14% reported </text>
<text top="350" left="691" width="196" height="15" font="1">w/ SVT. Women had more sxs for each </text>
<text top="366" left="691" width="52" height="15" font="1">category.  </text>
<text top="381" left="691" width="199" height="15" font="1">57% experienced SVT while driving and </text>
<text top="397" left="691" width="186" height="15" font="1">42% had to stop because of it (during </text>
<text top="412" left="691" width="73" height="15" font="1">that episode).  </text>
<text top="428" left="691" width="187" height="15" font="1">24 pts considered SVT an obstacle to </text>
<text top="443" left="691" width="42" height="15" font="1">driving.  </text>
<text top="304" left="910" width="201" height="15" font="1">SVT is frequent while driving and can be </text>
<text top="319" left="910" width="200" height="15" font="1">associated w/ near syncope or syncope. </text>
<text top="335" left="910" width="212" height="15" font="1">Women seemed to have worse sxs. Pts w/ </text>
<text top="350" left="910" width="195" height="15" font="1">near syncope or syncope more likely to </text>
<text top="366" left="910" width="177" height="15" font="1">consider SVT an obstacle to driving </text>
<text top="460" left="54" width="43" height="15" font="1">Drago F </text>
<text top="475" left="54" width="31" height="15" font="1">2006  </text>
<text top="491" left="54" width="23" height="15" font="1">(16) </text>
<text top="506" left="54" width="49" height="15" font="8">16835801</text>
<text top="506" left="103" width="3" height="15" font="1"> </text>
<text top="460" left="165" width="71" height="15" font="1">Observational </text>
<text top="460" left="257" width="57" height="15" font="1">62 children </text>
<text top="460" left="344" width="98" height="15" font="1">Limited to AVNRT.  </text>
<text top="460" left="569" width="97" height="15" font="1">Determine whether </text>
<text top="475" left="569" width="96" height="15" font="1">severity of sxs was </text>
<text top="491" left="569" width="67" height="15" font="1">related to EP </text>
<text top="506" left="569" width="74" height="15" font="1">characteristics </text>
<text top="460" left="691" width="199" height="15" font="1">When pts w/ severe sxs were compared </text>
<text top="475" left="691" width="166" height="15" font="1">to those w/ mild sxs there was no </text>
<text top="491" left="691" width="194" height="15" font="1">difference in inducibility, CL of AVNRT, </text>
<text top="506" left="691" width="161" height="15" font="1">or the ERPs of the fast and slow </text>
<text top="522" left="691" width="53" height="15" font="1">pathways  </text>
<text top="460" left="910" width="203" height="15" font="1">The severity of sxs was not related to EP </text>
<text top="475" left="910" width="80" height="15" font="1">characteristics.  </text>
<text top="491" left="910" width="221" height="15" font="1">-Although this study focused on children, the </text>
<text top="506" left="910" width="198" height="15" font="1">results are probably applicable to adults </text>
<text top="522" left="910" width="3" height="15" font="1"> </text>
<text top="538" left="54" width="50" height="15" font="1">Gonzalez-</text>
<text top="553" left="54" width="59" height="15" font="1">Torrecilla E </text>
<text top="569" left="54" width="31" height="15" font="1">2009  </text>
<text top="584" left="54" width="23" height="15" font="1">(17) </text>
<text top="600" left="54" width="49" height="15" font="8">19539146</text>
<text top="600" left="103" width="3" height="15" font="1"> </text>
<text top="615" left="54" width="3" height="15" font="1"> </text>
<text top="538" left="165" width="61" height="15" font="1">Prospective </text>
<text top="553" left="165" width="43" height="15" font="1">analysis </text>
<text top="538" left="257" width="21" height="15" font="1">370 </text>
<text top="553" left="257" width="61" height="15" font="1">consecutive </text>
<text top="569" left="257" width="41" height="15" font="1">pts who </text>
<text top="584" left="257" width="73" height="15" font="1">underwent EP </text>
<text top="600" left="257" width="30" height="15" font="1">study </text>
<text top="538" left="344" width="125" height="15" font="1">AVRNT 262 (23 atypical) </text>
<text top="553" left="344" width="48" height="15" font="1">ORT 108 </text>
<text top="569" left="344" width="3" height="15" font="1"> </text>
<text top="584" left="344" width="159" height="15" font="1">Excluded manifest preexcitation </text>
<text top="538" left="569" width="57" height="15" font="1">Assess the </text>
<text top="553" left="569" width="64" height="15" font="1">independent </text>
<text top="569" left="569" width="53" height="15" font="1">predictive  </text>
<text top="584" left="569" width="91" height="15" font="1">contribution to the </text>
<text top="600" left="569" width="76" height="15" font="1">ECG of clinical </text>
<text top="615" left="569" width="60" height="15" font="1">variables to </text>
<text top="631" left="569" width="86" height="15" font="1">distinguish major </text>
<text top="646" left="569" width="68" height="15" font="1">forms of SVT </text>
<text top="538" left="691" width="101" height="15" font="1">370 consecutive pts </text>
<text top="553" left="691" width="171" height="15" font="1">ECG interpreted by 2 independent </text>
<text top="569" left="691" width="52" height="15" font="1">observers </text>
<text top="584" left="691" width="191" height="15" font="1">AVNRT more likely to be female, older </text>
<text top="600" left="691" width="93" height="15" font="1">age of onset (&gt;30) </text>
<text top="615" left="691" width="206" height="15" font="1">Correct ECG interpretation more frequent </text>
<text top="631" left="691" width="94" height="15" font="1">in the AVRT group </text>
<text top="646" left="691" width="3" height="15" font="1"> </text>
<text top="662" left="691" width="166" height="15" font="1">Rapid pounding in the neck more </text>
<text top="677" left="691" width="175" height="15" font="1">common w/ AVNRT (51% vs. 25%) </text>
<text top="538" left="910" width="209" height="15" font="12">Age at the onset of sxs, sensation of rapid </text>
<text top="553" left="910" width="177" height="15" font="12">regular pounding in the neck during </text>
<text top="569" left="910" width="202" height="15" font="12">tachycardia, and female sex are the only </text>
<text top="584" left="910" width="133" height="15" font="12">significant clinical variables</text>
<text top="584" left="1043" width="3" height="15" font="1"> </text>
<text top="600" left="910" width="3" height="15" font="1"> </text>
<text top="693" left="54" width="52" height="15" font="1">Laurent G </text>
<text top="709" left="54" width="31" height="15" font="1">2009  </text>
<text top="724" left="54" width="23" height="15" font="1">(18) </text>
<text top="740" left="54" width="49" height="15" font="8">18775049</text>
<text top="740" left="103" width="3" height="15" font="1"> </text>
<text top="693" left="165" width="72" height="15" font="1">Mechanism of </text>
<text top="709" left="165" width="69" height="15" font="1">sx in SVT not </text>
<text top="724" left="165" width="61" height="15" font="1">understood. </text>
<text top="740" left="165" width="79" height="15" font="1">They evaluated </text>
<text top="755" left="165" width="50" height="15" font="1">VA timing </text>
<text top="693" left="257" width="38" height="15" font="1">Survey </text>
<text top="709" left="257" width="66" height="15" font="1">included 152 </text>
<text top="724" left="257" width="73" height="15" font="1">pts w/ AVNRT </text>
<text top="740" left="257" width="51" height="15" font="1">and 80 w/ </text>
<text top="755" left="257" width="33" height="15" font="1">AVRT </text>
<text top="771" left="257" width="3" height="15" font="1"> </text>
<text top="786" left="257" width="74" height="15" font="1">Hemodynamic </text>
<text top="693" left="344" width="155" height="15" font="1">326 pts w/ a variety of clinically </text>
<text top="709" left="344" width="176" height="15" font="1">documented tachycardias (AVNRT, </text>
<text top="724" left="344" width="197" height="15" font="1">AVRT, VT, atrial flutter, AF completed a </text>
<text top="740" left="344" width="182" height="15" font="1">brief self-administered questionnaire </text>
<text top="755" left="344" width="201" height="15" font="1">regarding the occurrence of 5 sxs: “neck </text>
<text top="771" left="344" width="199" height="15" font="1">pounding,” chest pounding, palpitations, </text>
<text top="786" left="344" width="205" height="15" font="1">“shirt flapping,” and dizziness. This paper </text>
<text top="693" left="569" width="97" height="15" font="1">Measured left atrial </text>
<text top="709" left="569" width="80" height="15" font="1">pressure during </text>
<text top="724" left="569" width="104" height="15" font="1">AVRT and simulated </text>
<text top="740" left="569" width="95" height="15" font="1">AVRT and AVNRT </text>
<text top="755" left="569" width="78" height="15" font="1">by the timing of </text>
<text top="771" left="569" width="100" height="15" font="1">pacing the atria and </text>
<text top="786" left="569" width="56" height="15" font="1">ventricles.  </text>
<text top="693" left="691" width="206" height="15" font="1">Sx of “shirt flapping” and “neck pounding” </text>
<text top="709" left="691" width="187" height="15" font="1">occur more frequently in AVNRT. Left </text>
<text top="724" left="691" width="170" height="15" font="1">atrial contractions during AV valve </text>
<text top="740" left="691" width="196" height="15" font="1">closure increase left atrial pressure and </text>
<text top="755" left="691" width="164" height="15" font="1">may explain the differences in sx </text>
<text top="771" left="691" width="193" height="15" font="1">between AVNRT and AVRT. Other sxs </text>
<text top="786" left="691" width="191" height="15" font="1">were about the same (chest pounding, </text>
<text top="693" left="910" width="193" height="15" font="1">The sx of “shirt flapping” appears to be </text>
<text top="709" left="910" width="213" height="15" font="1">associated w/ pulsatile reversed flow in the </text>
<text top="724" left="910" width="220" height="15" font="1">pulmonary veins due to left atrial contraction </text>
<text top="740" left="910" width="214" height="15" font="1">against closed MV and is more common w/ </text>
<text top="755" left="910" width="41" height="15" font="1">AVNRT </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1127" width="10" height="17" font="0">6 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="678" left="54" width="1044" height="15" font="1">AF indicates atrial fibrillation; AP, accessory pathway; ANP, atrial natriuretic peptide; AT, atrial tachycardia; AV, atrioventricular; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant </text>
<text top="693" left="54" width="1070" height="15" font="1">tachycardia; AT, atrial tachycardia; BP, blood pressure; bpm, beats per minute; CL, cycle length; CVP, central venous pressure; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-IV; ECG, echocardiogram; </text>
<text top="709" left="54" width="1076" height="15" font="1">EP, electrophysiological; ERP, effective refractory period; f/u, follow up; h/o, history of; MV, ??; ORT, orthodromic reentrant tachycardia; PAP, pulmonary arterial pressure; PSVT, paroxysmal supraventricular tachycardia; </text>
<text top="724" left="54" width="1080" height="15" font="1">pt, patient; QOL, quality of life; RA, right arterial; SCD, sudden cardiac death; SF-36, Short-Form (36) Healt Survey; SHD, structural heart disease; SNA, sympathetic nerve activity; SVR, systemic valvular resistance; SVT, </text>
<text top="740" left="54" width="1079" height="15" font="1">supraventricular tachycardia; sx, symptom; sx, symptom; U22 questionnaire, Umea 22 Arrhythmia Questions; VA, ventricular arrhythmia; VT, ventricular tachycardia; w/, with; and WPW, Wolff-Parkinson-White syndrome.  </text>
<text top="755" left="54" width="9" height="15" font="1">   </text>
<text top="781" left="54" width="4" height="18" font="3"><b> </b></text>
<text top="55" left="257" width="69" height="15" font="1">studies on 18 </text>
<text top="70" left="257" width="68" height="15" font="1">w/ AVRT and </text>
<text top="86" left="257" width="41" height="15" font="1">AVNRT </text>
<text top="55" left="344" width="89" height="15" font="1">focuses on AVRT </text>
<text top="70" left="344" width="3" height="15" font="1"> </text>
<text top="55" left="691" width="114" height="15" font="1">palpitations, dizziness) </text>
<text top="70" left="691" width="3" height="15" font="1"> </text>
<text top="86" left="691" width="177" height="15" font="1">Arterial pressures were significantly </text>
<text top="101" left="691" width="175" height="15" font="1">lower and left atrial pressures were </text>
<text top="117" left="691" width="196" height="15" font="1">significantly higher during native AVRT, </text>
<text top="132" left="691" width="197" height="15" font="1">simulated AVRT and AVNRT compared </text>
<text top="147" left="691" width="168" height="15" font="1">w/ sinus rhythm. Simulated AVRT </text>
<text top="163" left="691" width="200" height="15" font="1">created similar hemodynamic conditions </text>
<text top="178" left="691" width="196" height="15" font="1">as seen during native AVRT. Simulated </text>
<text top="194" left="691" width="202" height="15" font="1">AVNRT produced significantly higher left </text>
<text top="209" left="691" width="184" height="15" font="1">atrial pressure (peak and mean) than </text>
<text top="225" left="691" width="86" height="15" font="1">simulated AVRT. </text>
<text top="241" left="54" width="72" height="15" font="1">Walfridsson U </text>
<text top="257" left="54" width="31" height="15" font="1">2009  </text>
<text top="272" left="54" width="23" height="15" font="1">(19) </text>
<text top="288" left="54" width="49" height="15" font="8">19702600</text>
<text top="288" left="103" width="3" height="15" font="1"> </text>
<text top="241" left="165" width="62" height="15" font="1">QOL survey </text>
<text top="241" left="257" width="56" height="15" font="1">97 AVNRT </text>
<text top="257" left="257" width="48" height="15" font="1">79 AVRT </text>
<text top="241" left="344" width="188" height="15" font="1">Focused on pts w/ AVRT and AVNRT </text>
<text top="241" left="569" width="62" height="15" font="1">QOL scores </text>
<text top="241" left="691" width="167" height="15" font="1">QOL scores were lower for pts w/ </text>
<text top="257" left="691" width="205" height="15" font="1">AVNRT compared to AVRT. Scores were </text>
<text top="272" left="691" width="204" height="15" font="1">affected by occurrence more than once a </text>
<text top="288" left="691" width="201" height="15" font="1">mo, arrhythmia duration, and whether sx </text>
<text top="303" left="691" width="185" height="15" font="1">occurred not only during exercise but </text>
<text top="319" left="691" width="63" height="15" font="1">also at rest.  </text>
<text top="241" left="910" width="211" height="15" font="1">The main conclusion was that QOL scores </text>
<text top="257" left="910" width="100" height="15" font="1">may direct therapy.  </text>
<text top="335" left="54" width="46" height="15" font="1">Kesek M </text>
<text top="350" left="54" width="31" height="15" font="1">2011  </text>
<text top="366" left="54" width="23" height="15" font="1">(20) </text>
<text top="381" left="54" width="49" height="15" font="8">21077786</text>
<text top="381" left="103" width="3" height="15" font="1"> </text>
<text top="335" left="165" width="76" height="15" font="1">Assessment of </text>
<text top="350" left="165" width="78" height="15" font="1">the U22 survey </text>
<text top="366" left="165" width="72" height="15" font="1">for clinical sxs </text>
<text top="381" left="165" width="56" height="15" font="1">before and </text>
<text top="397" left="165" width="67" height="15" font="1">after ablation </text>
<text top="335" left="257" width="63" height="15" font="1">156 pts who </text>
<text top="350" left="257" width="55" height="15" font="1">underwent </text>
<text top="366" left="257" width="54" height="15" font="1">ablation of </text>
<text top="381" left="257" width="25" height="15" font="1">SVT </text>
<text top="335" left="344" width="95" height="15" font="1">AVNRT and AVRT </text>
<text top="335" left="569" width="62" height="15" font="1">QOL scores </text>
<text top="335" left="691" width="192" height="15" font="1">Mean age 43.9 AVNRT vs. 57.1 AVRT </text>
<text top="350" left="691" width="170" height="15" font="1">Men 65% AVRT and 38% AVNRT </text>
<text top="366" left="691" width="191" height="15" font="1">71% took medications prior to ablation </text>
<text top="335" left="910" width="210" height="15" font="1">QOL scores using either the U22 or SF-36 </text>
<text top="350" left="910" width="122" height="15" font="1">improved after ablation.  </text>
<text top="366" left="910" width="3" height="15" font="1"> </text>
<text top="413" left="54" width="37" height="15" font="1">Cain N </text>
<text top="429" left="54" width="28" height="15" font="1">2013 </text>
<text top="444" left="54" width="23" height="15" font="1">(21) </text>
<text top="460" left="54" width="49" height="15" font="8">23827401</text>
<text top="460" left="103" width="3" height="15" font="1"> </text>
<text top="413" left="165" width="71" height="15" font="1">Retrospective </text>
<text top="429" left="165" width="35" height="15" font="1">review </text>
<text top="413" left="257" width="43" height="15" font="1">446 pts  </text>
<text top="413" left="344" width="163" height="15" font="1">Pts &lt;21 w/ WPW (median age of </text>
<text top="429" left="344" width="91" height="15" font="1">diagnosis was 7y) </text>
<text top="413" left="569" width="49" height="15" font="1">Modes of </text>
<text top="429" left="569" width="64" height="15" font="1">presentation </text>
<text top="413" left="691" width="181" height="15" font="1">Modes of presentation included SVT </text>
<text top="429" left="691" width="184" height="15" font="1">(38%), palpitations (22%), chest pain </text>
<text top="444" left="691" width="199" height="15" font="1">(5%), syncope (4%), AF (0.4%), sudden </text>
<text top="460" left="691" width="182" height="15" font="1">death (0.2%), and incidental findings </text>
<text top="475" left="691" width="183" height="15" font="1">(26%); data were unavailable in 4%   </text>
<text top="491" left="691" width="3" height="15" font="1"> </text>
<text top="413" left="910" width="183" height="15" font="1">64% had sxs at presentation, and an </text>
<text top="429" left="910" width="202" height="15" font="1">additional 20% developed sxs during f/u. </text>
<text top="444" left="910" width="212" height="15" font="1">There were 6 sudden deaths (1.3%), w/ an </text>
<text top="460" left="910" width="217" height="15" font="1">overall incidence of 1.1 per 1,000 pt-y in pts </text>
<text top="475" left="910" width="197" height="15" font="1">w/ structurally normal hearts and 27 per </text>
<text top="491" left="910" width="225" height="15" font="1">1,000 pt-y in pts w/ associated heart disease. </text>
<text top="506" left="910" width="185" height="15" font="1">Although this was a pediatric study, it </text>
<text top="522" left="910" width="212" height="15" font="1">provides historical data that we can expect </text>
<text top="537" left="910" width="96" height="15" font="1">adults to describe.  </text>
<text top="553" left="54" width="58" height="15" font="1">Maryniak A </text>
<text top="569" left="54" width="31" height="15" font="1">2013  </text>
<text top="584" left="54" width="23" height="15" font="1">(22) </text>
<text top="600" left="54" width="49" height="15" font="8">23129107</text>
<text top="600" left="103" width="3" height="15" font="1"> </text>
<text top="553" left="165" width="71" height="15" font="1">Retrospective </text>
<text top="569" left="165" width="43" height="15" font="1">analysis </text>
<text top="553" left="257" width="22" height="15" font="1">113 </text>
<text top="553" left="344" width="145" height="15" font="1">AVRT or AVNRT pts (9-13 y) </text>
<text top="553" left="569" width="99" height="15" font="1">Evaluated cognitive </text>
<text top="569" left="569" width="73" height="15" font="1">and emotional </text>
<text top="584" left="569" width="87" height="15" font="1">development in a </text>
<text top="600" left="569" width="107" height="15" font="1">group of children and </text>
<text top="615" left="569" width="76" height="15" font="1">adolescents w/ </text>
<text top="631" left="569" width="98" height="15" font="1">AVRT and AVNRT. </text>
<text top="646" left="569" width="3" height="15" font="1"> </text>
<text top="553" left="691" width="94" height="15" font="1">Mean age AVRT 8 </text>
<text top="569" left="691" width="111" height="15" font="1">Meant age AVNRT 11 </text>
<text top="584" left="691" width="203" height="15" font="1">32% had hx syncope, more frequently w/ </text>
<text top="600" left="691" width="157" height="15" font="1">AVRT (37.5% vs. 24%; p=0.16) </text>
<text top="615" left="691" width="190" height="15" font="1">Deficiencies in cognitive function were </text>
<text top="631" left="691" width="52" height="15" font="1">prevalent. </text>
<text top="646" left="691" width="148" height="15" font="1">Anxiety levels increase w/ the </text>
<text top="662" left="691" width="100" height="15" font="1">appearance of sxs.  </text>
<text top="553" left="910" width="204" height="15" font="1">Both AVRT and AVNRT in childhood and </text>
<text top="569" left="910" width="218" height="15" font="1">adolescence can have a negative impact on </text>
<text top="584" left="910" width="208" height="15" font="1">cognitive and emotional development. Pts </text>
<text top="600" left="910" width="207" height="15" font="1">experiencing AVRT in the first y of life are </text>
<text top="615" left="910" width="217" height="15" font="1">likely to exhibit particularly severe deficits in </text>
<text top="631" left="910" width="185" height="15" font="1">cognitive function, including memory. </text>
<text top="646" left="910" width="3" height="15" font="1"> </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="13" size="13" family="Times" color="#000000"/>
<text top="814" left="1127" width="10" height="17" font="0">7 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="143" height="18" font="3"><b>Data Supplement 2. </b></text>
<text top="55" left="197" width="616" height="18" font="7"><b>Randomized Trials Comparing Principles of Acute and Chronic Therapy – Section 2.4  </b></text>
<text top="74" left="60" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="58" width="40" height="17" font="5"><b>Name, </b></text>
<text top="108" left="55" width="47" height="17" font="5"><b>Author, </b></text>
<text top="125" left="64" width="30" height="17" font="5"><b>Year </b></text>
<text top="74" left="119" width="42" height="17" font="5"><b>Aim of </b></text>
<text top="91" left="121" width="38" height="17" font="5"><b>Study </b></text>
<text top="74" left="182" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="185" width="32" height="17" font="5"><b>Type </b></text>
<text top="108" left="183" width="36" height="17" font="5"><b>(Size, </b></text>
<text top="125" left="193" width="16" height="17" font="5"><b>N) </b></text>
<text top="74" left="256" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="238" width="74" height="17" font="5"><b>Intervention </b></text>
<text top="108" left="245" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="74" left="344" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="326" width="73" height="17" font="5"><b>Comparator </b></text>
<text top="108" left="333" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="74" left="490" width="83" height="17" font="5"><b>Pt Population </b></text>
<text top="74" left="756" width="64" height="17" font="5"><b>Endpoints </b></text>
<text top="74" left="933" width="109" height="17" font="5"><b>P Values, OR: HR: </b></text>
<text top="91" left="945" width="85" height="17" font="5"><b>RR: &amp; 95% CI: </b></text>
<text top="74" left="1081" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="1066" width="69" height="17" font="5"><b>Limitations </b></text>
<text top="108" left="1068" width="64" height="17" font="5"><b>&amp; Adverse </b></text>
<text top="125" left="1078" width="44" height="17" font="5"><b>Events </b></text>
<text top="143" left="67" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="138" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="199" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="273" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="361" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="419" width="104" height="17" font="13"><i><b>Inclusion Criteria </b></i></text>
<text top="143" left="542" width="108" height="17" font="13"><i><b>Exclusion Criteria </b></i></text>
<text top="143" left="676" width="49" height="17" font="13"><i><b>Primary </b></i></text>
<text top="161" left="672" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="178" left="672" width="58" height="17" font="13"><i><b>(efficacy) </b></i></text>
<text top="195" left="664" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="143" left="771" width="40" height="17" font="13"><i><b>Safety </b></i></text>
<text top="161" left="763" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="178" left="755" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="143" left="846" width="70" height="17" font="13"><i><b>Secondary  </b></i></text>
<text top="161" left="851" width="67" height="17" font="13"><i><b>Endpoint    </b></i></text>
<text top="178" left="867" width="25" height="17" font="13"><i><b>and </b></i></text>
<text top="195" left="855" width="48" height="17" font="13"><i><b>Results </b></i></text>
<text top="143" left="986" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="1098" width="3" height="17" font="5"><b> </b></text>
<text top="213" left="54" width="42" height="15" font="1">Mauritso</text>
<text top="228" left="54" width="9" height="15" font="1">n </text>
<text top="244" left="54" width="31" height="15" font="1">1982  </text>
<text top="259" left="54" width="23" height="15" font="1">(23) </text>
<text top="275" left="54" width="43" height="15" font="8">7065555</text>
<text top="275" left="97" width="3" height="15" font="1"> </text>
<text top="213" left="116" width="42" height="15" font="1">Effective</text>
<text top="228" left="116" width="26" height="15" font="1">ness </text>
<text top="244" left="116" width="21" height="15" font="1">and </text>
<text top="259" left="116" width="45" height="15" font="1">safety of </text>
<text top="275" left="116" width="21" height="15" font="1">oral </text>
<text top="290" left="116" width="43" height="15" font="1">verapam</text>
<text top="306" left="116" width="8" height="15" font="1">il </text>
<text top="213" left="177" width="159" height="15" font="1">11 Verapamil </text>
<text top="213" left="290" width="67" height="15" font="1">240 </text>
<text top="228" left="238" width="71" height="15" font="1">mg/d followed </text>
<text top="244" left="238" width="67" height="15" font="1">by 480 mg/d  </text>
<text top="259" left="238" width="35" height="15" font="1">(n=11) </text>
<text top="213" left="325" width="199" height="15" font="1">Placebo Symptomatic </text>
<text top="213" left="480" width="80" height="15" font="1">PSVT, </text>
<text top="228" left="413" width="86" height="15" font="1">≥2 episodes/mo, </text>
<text top="244" left="413" width="102" height="15" font="1">ascertained by ECG </text>
<text top="259" left="413" width="3" height="15" font="1"> </text>
<text top="275" left="413" width="41" height="15" font="1">AVNRT </text>
<text top="290" left="413" width="29" height="15" font="1">(n=7) </text>
<text top="306" left="413" width="3" height="15" font="1"> </text>
<text top="321" left="413" width="33" height="15" font="1">AVRT </text>
<text top="337" left="413" width="110" height="15" font="1">(n=2 w/ WPW, n=3 w/ </text>
<text top="352" left="413" width="75" height="15" font="1">concealed AP) </text>
<text top="368" left="413" width="3" height="15" font="1"> </text>
<text top="383" left="413" width="3" height="15" font="1"> </text>
<text top="213" left="541" width="65" height="15" font="1">CHF, severe </text>
<text top="228" left="541" width="69" height="15" font="1">hypertension, </text>
<text top="244" left="541" width="105" height="15" font="1">hypotension, VHD or </text>
<text top="259" left="541" width="97" height="15" font="1">CHD, renal/hepatic </text>
<text top="275" left="541" width="82" height="15" font="1">failure, SSS, AV </text>
<text top="290" left="541" width="93" height="15" font="1">block, atrial flutter, </text>
<text top="306" left="541" width="52" height="15" font="1">AF, AADs </text>
<text top="213" left="663" width="58" height="15" font="1">Episodes/d </text>
<text top="228" left="663" width="70" height="15" font="1">(diary, Holter) </text>
<text top="244" left="663" width="53" height="15" font="1">Verapamil </text>
<text top="259" left="663" width="63" height="15" font="1">0.1±0.1 ,0.3 </text>
<text top="275" left="663" width="26" height="15" font="1">±0.5 </text>
<text top="290" left="663" width="43" height="15" font="1">Placebo </text>
<text top="306" left="663" width="63" height="15" font="1">0.3±0.3 ,0.7 </text>
<text top="321" left="663" width="26" height="15" font="1">±0.7 </text>
<text top="337" left="663" width="3" height="15" font="1"> </text>
<text top="352" left="663" width="73" height="15" font="1">Duration(min)  </text>
<text top="368" left="663" width="70" height="15" font="1">(diary, Holter) </text>
<text top="383" left="663" width="53" height="15" font="1">Verapamil </text>
<text top="399" left="663" width="49" height="15" font="1">3±3 ,1±2 </text>
<text top="414" left="663" width="72" height="15" font="1">Placebo 27±5 </text>
<text top="430" left="663" width="44" height="15" font="1">,67±111 </text>
<text top="445" left="663" width="3" height="15" font="1"> </text>
<text top="213" left="751" width="75" height="15" font="1">Minor AEs in 6 </text>
<text top="228" left="751" width="33" height="15" font="1">pts on </text>
<text top="244" left="751" width="51" height="15" font="1">verapamil </text>
<text top="259" left="751" width="3" height="15" font="1"> </text>
<text top="275" left="751" width="80" height="15" font="1">5 pts required a </text>
<text top="290" left="751" width="52" height="15" font="1">total of 35 </text>
<text top="306" left="751" width="74" height="15" font="1">cardioversions </text>
<text top="321" left="751" width="66" height="15" font="1">for sustained </text>
<text top="337" left="751" width="72" height="15" font="1">tachycardia, 2 </text>
<text top="352" left="751" width="34" height="15" font="1">during </text>
<text top="368" left="751" width="69" height="15" font="1">verapamil, 33 </text>
<text top="383" left="751" width="76" height="15" font="1">during placebo </text>
<text top="399" left="751" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="414" left="751" width="3" height="15" font="1"> </text>
<text top="430" left="751" width="67" height="15" font="1">Programmed </text>
<text top="445" left="751" width="47" height="15" font="1">electrical </text>
<text top="461" left="751" width="56" height="15" font="1">stimulation </text>
<text top="476" left="751" width="66" height="15" font="1">performed at </text>
<text top="492" left="751" width="76" height="15" font="1">end of study to </text>
<text top="507" left="751" width="36" height="15" font="1">induce </text>
<text top="523" left="751" width="63" height="15" font="1">tachycardia. </text>
<text top="538" left="751" width="41" height="15" font="1">Caused </text>
<text top="554" left="751" width="50" height="15" font="1">sustained </text>
<text top="569" left="751" width="81" height="15" font="1">tachycardia in 9 </text>
<text top="585" left="751" width="69" height="15" font="1">on placebo, 2 </text>
<text top="600" left="751" width="66" height="15" font="1">on verapamil </text>
<text top="616" left="751" width="48" height="15" font="1">(p&lt;0.01)  </text>
<text top="213" left="845" width="22" height="15" font="1">N/A </text>
<text top="213" left="926" width="93" height="15" font="1">p&lt;0.05 for primary </text>
<text top="228" left="926" width="51" height="15" font="1">endpoints </text>
<text top="213" left="1063" width="24" height="15" font="1">Oral </text>
<text top="228" left="1063" width="51" height="15" font="1">verapamil </text>
<text top="244" left="1063" width="45" height="15" font="1">safe and </text>
<text top="259" left="1063" width="47" height="15" font="1">effective. </text>
<text top="275" left="1063" width="3" height="15" font="1"> </text>
<text top="290" left="1063" width="69" height="15" font="1">Small sample </text>
<text top="306" left="1063" width="26" height="15" font="1">size. </text>
<text top="321" left="1063" width="3" height="15" font="1"> </text>
<text top="337" left="1063" width="73" height="15" font="1">Unclear which </text>
<text top="352" left="1063" width="62" height="15" font="1">pt withdrew, </text>
<text top="368" left="1063" width="73" height="15" font="1">so numbers of </text>
<text top="383" left="1063" width="58" height="15" font="1">AVNRT vs. </text>
<text top="399" left="1063" width="72" height="15" font="1">AVRT may be </text>
<text top="414" left="1063" width="69" height="15" font="1">similar (i.e., 6 </text>
<text top="430" left="1063" width="36" height="15" font="1">vs. 5).  </text>
<text top="632" left="54" width="40" height="15" font="1">Winnifor</text>
<text top="647" left="54" width="9" height="15" font="1">d </text>
<text top="663" left="54" width="28" height="15" font="1">1984 </text>
<text top="678" left="54" width="23" height="15" font="1">(24) </text>
<text top="694" left="54" width="43" height="15" font="8">6388299</text>
<text top="694" left="97" width="3" height="15" font="1"> </text>
<text top="632" left="116" width="44" height="15" font="1">Effect of </text>
<text top="647" left="116" width="18" height="15" font="1">AV </text>
<text top="663" left="116" width="30" height="15" font="1">nodal </text>
<text top="678" left="116" width="44" height="15" font="1">blockers </text>
<text top="694" left="116" width="41" height="15" font="1">for long-</text>
<text top="709" left="116" width="25" height="15" font="1">term </text>
<text top="725" left="116" width="40" height="15" font="1">therapy </text>
<text top="740" left="116" width="44" height="15" font="1">of PSVT </text>
<text top="632" left="177" width="15" height="15" font="1">11 </text>
<text top="647" left="177" width="3" height="15" font="1"> </text>
<text top="632" left="238" width="58" height="15" font="1">One mo of: </text>
<text top="647" left="238" width="3" height="15" font="1"> </text>
<text top="663" left="238" width="71" height="15" font="1">Digoxin 0.375 </text>
<text top="678" left="238" width="28" height="15" font="1">mg/d </text>
<text top="694" left="238" width="3" height="15" font="1"> </text>
<text top="709" left="238" width="60" height="15" font="1">Propranolol </text>
<text top="725" left="238" width="49" height="15" font="1">240 mg/d </text>
<text top="740" left="238" width="3" height="15" font="1"> </text>
<text top="756" left="238" width="74" height="15" font="1">Verapamil 480 </text>
<text top="771" left="238" width="28" height="15" font="1">mg/d </text>
<text top="632" left="325" width="32" height="15" font="1">Direct </text>
<text top="647" left="325" width="60" height="15" font="1">comparison </text>
<text top="663" left="325" width="71" height="15" font="1">between all 3, </text>
<text top="678" left="325" width="52" height="15" font="1">w/ 1 wk of </text>
<text top="694" left="325" width="42" height="15" font="1">placebo </text>
<text top="709" left="325" width="44" height="15" font="1">washout </text>
<text top="632" left="413" width="102" height="15" font="1">Symptomatic PSVT, </text>
<text top="647" left="413" width="86" height="15" font="1">≥2 episodes/mo, </text>
<text top="663" left="413" width="102" height="15" font="1">ascertained by ECG </text>
<text top="632" left="541" width="87" height="15" font="1">ECG evidence of </text>
<text top="647" left="541" width="66" height="15" font="1">preexcitation </text>
<text top="632" left="663" width="70" height="15" font="1">Episodes and </text>
<text top="647" left="663" width="43" height="15" font="1">duration </text>
<text top="663" left="663" width="64" height="15" font="1">(ascertained </text>
<text top="678" left="663" width="63" height="15" font="1">by diary and </text>
<text top="694" left="663" width="61" height="15" font="1">weekly 24 h </text>
<text top="709" left="663" width="39" height="15" font="1">Holter), </text>
<text top="725" left="663" width="42" height="15" font="1">adverse </text>
<text top="740" left="663" width="71" height="15" font="1">effects, SDCs </text>
<text top="756" left="663" width="65" height="15" font="1">of each drug </text>
<text top="771" left="663" width="3" height="15" font="1"> </text>
<text top="787" left="663" width="65" height="15" font="1">Episodes/wk </text>
<text top="632" left="751" width="47" height="15" font="1">Mild side </text>
<text top="647" left="751" width="72" height="15" font="1">effects in 3/11 </text>
<text top="663" left="751" width="70" height="15" font="1">pts w/ digoxin </text>
<text top="678" left="751" width="21" height="15" font="1">and </text>
<text top="694" left="751" width="61" height="15" font="1">propranolol, </text>
<text top="709" left="751" width="60" height="15" font="1">and 5/11 w/ </text>
<text top="725" left="751" width="69" height="15" font="1">verapamil. All </text>
<text top="740" left="751" width="55" height="15" font="1">SDCs w/in </text>
<text top="756" left="751" width="37" height="15" font="1">normal </text>
<text top="771" left="751" width="50" height="15" font="1">reference </text>
<text top="787" left="751" width="34" height="15" font="1">range. </text>
<text top="632" left="845" width="25" height="15" font="1"> N/A </text>
<text top="632" left="926" width="34" height="15" font="1"> p=NS </text>
<text top="632" left="1063" width="26" height="15" font="1">Only </text>
<text top="647" left="1063" width="73" height="15" font="1">verapamil had </text>
<text top="663" left="1063" width="66" height="15" font="1">been studied </text>
<text top="678" left="1063" width="63" height="15" font="1">in RCT prior </text>
<text top="694" left="1063" width="73" height="15" font="1">to this (above) </text>
<text top="709" left="1063" width="65" height="15" font="1">and given its </text>
<text top="725" left="1063" width="37" height="15" font="1">proven </text>
<text top="740" left="1063" width="44" height="15" font="1">efficacy, </text>
<text top="756" left="1063" width="73" height="15" font="1">authors felt no </text>
<text top="771" left="1063" width="44" height="15" font="1">need for </text>
<text top="787" left="1063" width="48" height="15" font="1">placebo.  </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1127" width="10" height="17" font="0">8 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="70" height="15" font="1">(diary, Holter) </text>
<text top="70" left="663" width="40" height="15" font="1">Digoxin </text>
<text top="86" left="663" width="44" height="15" font="1">2.3±3.1, </text>
<text top="101" left="663" width="41" height="15" font="1">1.9±2.9 </text>
<text top="117" left="663" width="60" height="15" font="1">Propranolol </text>
<text top="132" left="663" width="41" height="15" font="1">1.5±2.3 </text>
<text top="147" left="663" width="44" height="15" font="1">,0.2±0.6 </text>
<text top="163" left="663" width="53" height="15" font="1">Verapamil </text>
<text top="178" left="663" width="63" height="15" font="1">2.9±5.7 ,0.6 </text>
<text top="194" left="663" width="26" height="15" font="1">±1.6 </text>
<text top="210" left="663" width="3" height="15" font="1"> </text>
<text top="225" left="663" width="73" height="15" font="1">Duration(min)  </text>
<text top="240" left="663" width="70" height="15" font="1">(diary, Holter) </text>
<text top="256" left="663" width="40" height="15" font="1">Digoxin </text>
<text top="271" left="663" width="44" height="15" font="1">75±164, </text>
<text top="287" left="663" width="41" height="15" font="1">47±157 </text>
<text top="302" left="663" width="60" height="15" font="1">Propranolol </text>
<text top="318" left="663" width="67" height="15" font="1">60±112 ,1±1 </text>
<text top="333" left="663" width="53" height="15" font="1">Verapamil </text>
<text top="349" left="663" width="67" height="15" font="1">56±148 ,1±1 </text>
<text top="55" left="1063" width="3" height="15" font="1"> </text>
<text top="70" left="1063" width="63" height="15" font="1">Small series </text>
<text top="86" left="1063" width="33" height="15" font="1">of pts. </text>
<text top="101" left="1063" width="41" height="15" font="1">Unclear </text>
<text top="117" left="1063" width="72" height="15" font="1">mechanism of </text>
<text top="132" left="1063" width="32" height="15" font="1">PSVT </text>
<text top="147" left="1063" width="44" height="15" font="1">(authors </text>
<text top="163" left="1063" width="65" height="15" font="1">speculate all </text>
<text top="178" left="1063" width="73" height="15" font="1">pts w/ AVRNT </text>
<text top="194" left="1063" width="34" height="15" font="1">or oral </text>
<text top="209" left="1063" width="58" height="15" font="1">rehydration </text>
<text top="225" left="1063" width="54" height="15" font="1">therapy w/ </text>
<text top="240" left="1063" width="53" height="15" font="1">concealed </text>
<text top="256" left="1063" width="63" height="15" font="1">conduction.  </text>
<text top="365" left="54" width="41" height="15" font="1">Anderso</text>
<text top="381" left="54" width="9" height="15" font="1">n </text>
<text top="396" left="54" width="31" height="15" font="1">1986  </text>
<text top="412" left="54" width="23" height="15" font="1">(25) </text>
<text top="427" left="54" width="43" height="15" font="8">2868645</text>
<text top="427" left="97" width="3" height="15" font="1"> </text>
<text top="443" left="54" width="3" height="15" font="1"> </text>
<text top="458" left="54" width="3" height="15" font="1"> </text>
<text top="365" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="381" left="116" width="12" height="15" font="1">of </text>
<text top="396" left="116" width="41" height="15" font="1">esmolol </text>
<text top="412" left="116" width="12" height="15" font="1">in </text>
<text top="427" left="116" width="44" height="15" font="1">treatmen</text>
<text top="443" left="116" width="18" height="15" font="1">t of </text>
<text top="458" left="116" width="32" height="15" font="1">PSVT </text>
<text top="365" left="177" width="15" height="15" font="1">71 </text>
<text top="381" left="177" width="3" height="15" font="1"> </text>
<text top="396" left="177" width="44" height="15" font="1">Multicent</text>
<text top="412" left="177" width="16" height="15" font="1">er, </text>
<text top="427" left="177" width="37" height="15" font="1">double-</text>
<text top="443" left="177" width="29" height="15" font="1">blind, </text>
<text top="458" left="177" width="34" height="15" font="1">partial-</text>
<text top="474" left="177" width="44" height="15" font="1">crossove</text>
<text top="489" left="177" width="36" height="15" font="1">r study </text>
<text top="365" left="238" width="42" height="15" font="1">Esmolol </text>
<text top="381" left="238" width="35" height="15" font="1">(n=36) </text>
<text top="365" left="325" width="43" height="15" font="1">Placebo </text>
<text top="381" left="325" width="35" height="15" font="1">(n=35) </text>
<text top="365" left="413" width="86" height="15" font="1"> “SVT” (HR&gt;120) </text>
<text top="381" left="413" width="3" height="15" font="1"> </text>
<text top="396" left="413" width="107" height="15" font="1">Note: AVNRT in 18% </text>
<text top="412" left="413" width="56" height="15" font="1">of subjects </text>
<text top="365" left="541" width="82" height="15" font="1">VHD, AV block,  </text>
<text top="381" left="541" width="81" height="15" font="1">SSS, significant </text>
<text top="396" left="541" width="54" height="15" font="1">electrolyte </text>
<text top="412" left="541" width="63" height="15" font="1">abnormality, </text>
<text top="427" left="541" width="104" height="15" font="1">precluding treatment </text>
<text top="443" left="541" width="89" height="15" font="1">w/ beta blockade, </text>
<text top="458" left="541" width="48" height="15" font="1">bronchial </text>
<text top="474" left="541" width="97" height="15" font="1">asthma, ventricular </text>
<text top="489" left="541" width="107" height="15" font="1">arrhythmias requiring </text>
<text top="505" left="541" width="68" height="15" font="1">drug therapy, </text>
<text top="520" left="541" width="95" height="15" font="1">cardiogenic shock, </text>
<text top="535" left="541" width="96" height="15" font="1">CHF (NYHA III-IV), </text>
<text top="551" left="541" width="79" height="15" font="1">renal or hepatic </text>
<text top="567" left="541" width="100" height="15" font="1">dysfunction, drug or </text>
<text top="582" left="541" width="78" height="15" font="1">alcohol abuse,  </text>
<text top="597" left="541" width="69" height="15" font="1">on other beta-</text>
<text top="613" left="541" width="100" height="15" font="1">adrenergic blockers </text>
<text top="628" left="541" width="95" height="15" font="1">or calcium channel </text>
<text top="644" left="541" width="87" height="15" font="1">blockers w/in two </text>
<text top="659" left="541" width="89" height="15" font="1">half-lives of study </text>
<text top="675" left="541" width="28" height="15" font="1">entry </text>
<text top="690" left="541" width="3" height="15" font="1"> </text>
<text top="365" left="663" width="62" height="15" font="1">Therapeutic </text>
<text top="381" left="663" width="52" height="15" font="1">response: </text>
<text top="396" left="663" width="33" height="15" font="1">≥20% </text>
<text top="412" left="663" width="60" height="15" font="1">reduction in </text>
<text top="427" left="663" width="66" height="15" font="1">HR, HR&lt;100 </text>
<text top="443" left="663" width="41" height="15" font="1">bpm, or </text>
<text top="458" left="663" width="69" height="15" font="1">conversion to </text>
<text top="474" left="663" width="30" height="15" font="1">NSR. </text>
<text top="489" left="663" width="3" height="15" font="1"> </text>
<text top="505" left="663" width="62" height="15" font="1">Therapeutic </text>
<text top="520" left="663" width="61" height="15" font="1">response to </text>
<text top="535" left="663" width="41" height="15" font="1">esmolol </text>
<text top="551" left="663" width="52" height="15" font="1">during the </text>
<text top="567" left="663" width="28" height="15" font="1">initial </text>
<text top="582" left="663" width="50" height="15" font="1">treatment </text>
<text top="597" left="663" width="66" height="15" font="1">period (72%) </text>
<text top="613" left="663" width="65" height="15" font="1">similar when </text>
<text top="628" left="663" width="64" height="15" font="1">esmolol was </text>
<text top="644" left="663" width="54" height="15" font="1">given as a </text>
<text top="659" left="663" width="70" height="15" font="1">second agent </text>
<text top="675" left="663" width="3" height="15" font="1"> </text>
<text top="690" left="663" width="53" height="15" font="1">4 pts (6%) </text>
<text top="706" left="663" width="64" height="15" font="1">converted to </text>
<text top="721" left="663" width="26" height="15" font="1">NSR </text>
<text top="737" left="663" width="3" height="15" font="1"> </text>
<text top="752" left="663" width="56" height="15" font="1">In the 80% </text>
<text top="768" left="663" width="58" height="15" font="1">therapeutic </text>
<text top="783" left="663" width="69" height="15" font="1">response lost </text>
<text top="365" left="751" width="65" height="15" font="1">Hypotension </text>
<text top="381" left="751" width="77" height="15" font="1">which occurred </text>
<text top="396" left="751" width="49" height="15" font="1">in12% on </text>
<text top="412" left="751" width="77" height="15" font="1">esmolol, 2% w/ </text>
<text top="427" left="751" width="45" height="15" font="1">placebo. </text>
<text top="365" left="845" width="22" height="15" font="1">N/A </text>
<text top="365" left="926" width="31" height="15" font="1">p=NS </text>
<text top="365" left="1063" width="62" height="15" font="1">Rapid onset </text>
<text top="381" left="1063" width="62" height="15" font="1">and short of </text>
<text top="396" left="1063" width="45" height="15" font="1">action of </text>
<text top="412" left="1063" width="66" height="15" font="1">esmolol offer </text>
<text top="427" left="1063" width="71" height="15" font="1">safe, effective </text>
<text top="443" left="1063" width="56" height="15" font="1">therapy for </text>
<text top="458" left="1063" width="30" height="15" font="1">acute </text>
<text top="474" left="1063" width="62" height="15" font="1">treatment of </text>
<text top="489" left="1063" width="67" height="15" font="1">pts w/ PSVT. </text>
<text top="505" left="1063" width="69" height="15" font="1">Low numbers </text>
<text top="520" left="1063" width="44" height="15" font="1">of pts w/ </text>
<text top="535" left="1063" width="44" height="15" font="1">AVNRT. </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1127" width="10" height="17" font="0">9 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="59" height="15" font="1">w/in 30 min </text>
<text top="70" left="663" width="46" height="15" font="1">following </text>
<text top="86" left="663" width="68" height="15" font="1">discontinuatio</text>
<text top="101" left="663" width="63" height="15" font="1">n of esmolol </text>
<text top="117" left="663" width="41" height="15" font="1">infusion </text>
<text top="133" left="54" width="49" height="15" font="1">Henthorn </text>
<text top="148" left="54" width="31" height="15" font="1">1991  </text>
<text top="164" left="54" width="23" height="15" font="1">(26) </text>
<text top="179" left="54" width="43" height="15" font="8">1898640</text>
<text top="179" left="97" width="3" height="15" font="1"> </text>
<text top="133" left="116" width="44" height="15" font="1">Flecainid</text>
<text top="148" left="116" width="25" height="15" font="1">e for </text>
<text top="164" left="116" width="44" height="15" font="1">treatmen</text>
<text top="179" left="116" width="18" height="15" font="1">t of </text>
<text top="195" left="116" width="36" height="15" font="1">sympto</text>
<text top="210" left="116" width="29" height="15" font="1">matic </text>
<text top="226" left="116" width="32" height="15" font="1">PSVT </text>
<text top="241" left="116" width="20" height="15" font="1">(≥2 </text>
<text top="257" left="116" width="44" height="15" font="1">episodes</text>
<text top="272" left="116" width="7" height="15" font="1">) </text>
<text top="288" left="116" width="3" height="15" font="1"> </text>
<text top="133" left="177" width="15" height="15" font="1">34 </text>
<text top="148" left="177" width="3" height="15" font="1"> </text>
<text top="164" left="177" width="26" height="15" font="1">8-wk </text>
<text top="179" left="177" width="44" height="15" font="1">crossove</text>
<text top="195" left="177" width="36" height="15" font="1">r (after </text>
<text top="210" left="177" width="22" height="15" font="1">four </text>
<text top="226" left="177" width="47" height="15" font="1">episodes </text>
<text top="241" left="177" width="44" height="15" font="1">of PSVT </text>
<text top="257" left="177" width="47" height="15" font="1">or end of </text>
<text top="272" left="177" width="44" height="15" font="1">treatmen</text>
<text top="288" left="177" width="44" height="15" font="1">t period) </text>
<text top="303" left="177" width="3" height="15" font="1"> </text>
<text top="319" left="177" width="3" height="15" font="1"> </text>
<text top="133" left="238" width="57" height="15" font="1"> Flecainide </text>
<text top="148" left="238" width="35" height="15" font="1">(n=34) </text>
<text top="164" left="238" width="3" height="15" font="1"> </text>
<text top="133" left="325" width="43" height="15" font="1">Placebo </text>
<text top="148" left="325" width="35" height="15" font="1">(n=34) </text>
<text top="164" left="325" width="3" height="15" font="1"> </text>
<text top="179" left="325" width="3" height="15" font="1"> </text>
<text top="133" left="413" width="35" height="15" font="1">PSVT  </text>
<text top="148" left="413" width="3" height="15" font="1"> </text>
<text top="133" left="541" width="102" height="15" font="1">Syncope, angina, or </text>
<text top="148" left="541" width="89" height="15" font="1">transient cerebral </text>
<text top="164" left="541" width="108" height="15" font="1">events during PSVT,  </text>
<text top="179" left="541" width="76" height="15" font="1">second or third </text>
<text top="195" left="541" width="97" height="15" font="1">degree AV block or </text>
<text top="210" left="541" width="98" height="15" font="1">had CHF (NYHA III-</text>
<text top="226" left="541" width="23" height="15" font="1">IV)   </text>
<text top="133" left="663" width="73" height="15" font="1">Freedom from </text>
<text top="148" left="663" width="65" height="15" font="1">symptomatic </text>
<text top="164" left="663" width="72" height="15" font="1">PSVT at 60 d: </text>
<text top="179" left="663" width="61" height="15" font="1">79% events </text>
<text top="195" left="663" width="42" height="15" font="1">vs. 15% </text>
<text top="210" left="663" width="54" height="15" font="1"> (p&lt;0.001) </text>
<text top="226" left="663" width="3" height="15" font="1"> </text>
<text top="241" left="663" width="53" height="15" font="1">Flecainide </text>
<text top="257" left="663" width="37" height="15" font="1">slowed </text>
<text top="272" left="663" width="65" height="15" font="1">symptomatic </text>
<text top="288" left="663" width="63" height="15" font="1">PSVT HR to </text>
<text top="303" left="663" width="66" height="15" font="1">143±12 bpm </text>
<text top="319" left="663" width="70" height="15" font="1">from 178 ±12 </text>
<text top="334" left="663" width="69" height="15" font="1">on placebo in </text>
<text top="350" left="663" width="72" height="15" font="1">7 pts who had </text>
<text top="365" left="663" width="66" height="15" font="1">events in the </text>
<text top="381" left="663" width="63" height="15" font="1">placebo and </text>
<text top="396" left="663" width="50" height="15" font="1">flecainide </text>
<text top="412" left="663" width="50" height="15" font="1">treatment </text>
<text top="427" left="663" width="39" height="15" font="1">phases </text>
<text top="443" left="663" width="45" height="15" font="1">(p&lt;0.02) </text>
<text top="133" left="751" width="62" height="15" font="1">Significantly </text>
<text top="148" left="751" width="52" height="15" font="1">more side </text>
<text top="164" left="751" width="50" height="15" font="1">effects w/ </text>
<text top="179" left="751" width="50" height="15" font="1">flecainide </text>
<text top="195" left="751" width="45" height="15" font="1">(p&lt;0.05) </text>
<text top="133" left="845" width="53" height="15" font="1">Flecainide </text>
<text top="148" left="845" width="62" height="15" font="1">vs. placebo: </text>
<text top="164" left="845" width="3" height="15" font="1"> </text>
<text top="179" left="845" width="63" height="15" font="1">Recurrence: </text>
<text top="195" left="845" width="42" height="15" font="1">8/34 vs. </text>
<text top="210" left="845" width="31" height="15" font="1">29/34 </text>
<text top="226" left="845" width="54" height="15" font="1">(p&lt;0.001). </text>
<text top="241" left="845" width="3" height="15" font="1"> </text>
<text top="257" left="845" width="63" height="15" font="1">Median time </text>
<text top="272" left="845" width="66" height="15" font="1">to first event: </text>
<text top="288" left="845" width="57" height="15" font="1">55 vs. 11 d </text>
<text top="303" left="845" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="319" left="845" width="3" height="15" font="1"> </text>
<text top="334" left="845" width="39" height="15" font="1">Median </text>
<text top="350" left="845" width="39" height="15" font="1">interval </text>
<text top="365" left="845" width="45" height="15" font="1">between </text>
<text top="381" left="845" width="51" height="15" font="1">episodes  </text>
<text top="396" left="845" width="64" height="15" font="1">&gt;55 vs. 12 d </text>
<text top="412" left="845" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="133" left="926" width="25" height="15" font="1"> N/A </text>
<text top="133" left="1063" width="40" height="15" font="1">Despite </text>
<text top="148" left="1063" width="63" height="15" font="1">participation </text>
<text top="164" left="1063" width="69" height="15" font="1">of 19 medical </text>
<text top="179" left="1063" width="66" height="15" font="1">centers, only </text>
<text top="195" left="1063" width="33" height="15" font="1">34 pts </text>
<text top="210" left="1063" width="57" height="15" font="1">completed  </text>
<text top="226" left="1063" width="73" height="15" font="1">entire protocol </text>
<text top="241" left="1063" width="67" height="15" font="1">and provided </text>
<text top="257" left="1063" width="56" height="15" font="1">analyzable </text>
<text top="272" left="1063" width="28" height="15" font="1">data. </text>
<text top="288" left="1063" width="3" height="15" font="1"> </text>
<text top="303" left="1063" width="33" height="15" font="1">All pts </text>
<text top="319" left="1063" width="46" height="15" font="1">tolerated </text>
<text top="334" left="1063" width="53" height="15" font="1">flecainide, </text>
<text top="350" left="1063" width="37" height="15" font="1">limiting </text>
<text top="365" left="1063" width="68" height="15" font="1">generalizabilit</text>
<text top="381" left="1063" width="12" height="15" font="1">y. </text>
<text top="396" left="1063" width="3" height="15" font="1"> </text>
<text top="412" left="1063" width="71" height="15" font="1">Transtelephon</text>
<text top="427" left="1063" width="66" height="15" font="1">ic monitoring </text>
<text top="443" left="1063" width="45" height="15" font="1">does not </text>
<text top="458" left="1063" width="37" height="15" font="1">permit  </text>
<text top="474" left="1063" width="62" height="15" font="1">assessment </text>
<text top="489" left="1063" width="12" height="15" font="1">of </text>
<text top="505" left="1063" width="68" height="15" font="1">proarrhythmia</text>
<text top="520" left="1063" width="6" height="15" font="1">. </text>
<text top="535" left="1063" width="3" height="15" font="1"> </text>
<text top="551" left="1063" width="39" height="15" font="1">6/34 w/ </text>
<text top="567" left="1063" width="44" height="15" font="1">AVNRT, </text>
<text top="582" left="1063" width="67" height="15" font="1">confirmed by </text>
<text top="597" left="1063" width="72" height="15" font="1">EP study, and </text>
<text top="613" left="1063" width="45" height="15" font="1">18/34 w/ </text>
<text top="628" left="1063" width="47" height="15" font="1">unknown </text>
<text top="644" left="1063" width="63" height="15" font="1">mechanism. </text>
<text top="660" left="54" width="41" height="15" font="1">Pritchett</text>
<text top="676" left="54" width="31" height="15" font="1">1991  </text>
<text top="691" left="54" width="23" height="15" font="1">(27) </text>
<text top="707" left="54" width="46" height="15" font="8">1899432 </text>
<text top="707" left="100" width="3" height="15" font="1"> </text>
<text top="660" left="116" width="30" height="15" font="1">Dose-</text>
<text top="676" left="116" width="39" height="15" font="1">respons</text>
<text top="691" left="116" width="9" height="15" font="1">e </text>
<text top="707" left="116" width="41" height="15" font="1">efficacy </text>
<text top="722" left="116" width="12" height="15" font="1">of </text>
<text top="738" left="116" width="41" height="15" font="1">flecainid</text>
<text top="753" left="116" width="21" height="15" font="1">e in </text>
<text top="769" left="116" width="39" height="15" font="1">patents </text>
<text top="784" left="116" width="14" height="15" font="1">w/ </text>
<text top="660" left="177" width="160" height="15" font="1">42 Flecainide </text>
<text top="676" left="238" width="41" height="15" font="1">given in </text>
<text top="691" left="238" width="53" height="15" font="1">ascending </text>
<text top="707" left="238" width="29" height="15" font="1">order </text>
<text top="722" left="238" width="67" height="15" font="1">(255010</text>
<text top="738" left="238" width="59" height="15" font="1">0150 mg </text>
<text top="753" left="238" width="22" height="15" font="1">bid) </text>
<text top="769" left="238" width="3" height="15" font="1"> </text>
<text top="784" left="238" width="32" height="15" font="1">PSVT </text>
<text top="660" left="325" width="43" height="15" font="1">Placebo </text>
<text top="676" left="325" width="55" height="15" font="1">inserted at </text>
<text top="691" left="325" width="41" height="15" font="1">random </text>
<text top="707" left="325" width="73" height="15" font="1">(alternating w/ </text>
<text top="722" left="325" width="66" height="15" font="1">flecainide) at </text>
<text top="738" left="325" width="69" height="15" font="1">30 d intervals </text>
<text top="660" left="413" width="76" height="15" font="1">PSVT, PAF, or </text>
<text top="676" left="413" width="87" height="15" font="1">paroxysmal atrial </text>
<text top="691" left="413" width="31" height="15" font="1">flutter </text>
<text top="660" left="541" width="102" height="15" font="1">Syncope, angina, or </text>
<text top="676" left="541" width="89" height="15" font="1">transient cerebral </text>
<text top="691" left="541" width="108" height="15" font="1">events during PSVT,  </text>
<text top="707" left="541" width="76" height="15" font="1">second or third </text>
<text top="722" left="541" width="97" height="15" font="1">degree AV block or </text>
<text top="738" left="541" width="98" height="15" font="1">had CHF (NYHA III-</text>
<text top="753" left="541" width="26" height="15" font="1">IV)  . </text>
<text top="660" left="663" width="71" height="15" font="1">Among 14 pts </text>
<text top="676" left="663" width="55" height="15" font="1">in Group 1 </text>
<text top="691" left="663" width="63" height="15" font="1">(PSVT) who </text>
<text top="707" left="663" width="60" height="15" font="1">qualified for </text>
<text top="722" left="663" width="41" height="15" font="1">efficacy </text>
<text top="738" left="663" width="55" height="15" font="1">analysis, 4 </text>
<text top="753" left="663" width="70" height="15" font="1">(29%) had no </text>
<text top="769" left="663" width="60" height="15" font="1">tachycardia </text>
<text top="784" left="663" width="61" height="15" font="1">while taking </text>
<text top="660" left="751" width="59" height="15" font="1">Noncardiac </text>
<text top="676" left="751" width="42" height="15" font="1">adverse </text>
<text top="691" left="751" width="63" height="15" font="1">experiences </text>
<text top="707" left="751" width="66" height="15" font="1">were leading </text>
<text top="722" left="751" width="45" height="15" font="1">cause of </text>
<text top="738" left="751" width="53" height="15" font="1">premature </text>
<text top="753" left="751" width="30" height="15" font="1">study </text>
<text top="769" left="751" width="77" height="15" font="1">discontinuation </text>
<text top="784" left="751" width="34" height="15" font="1">during </text>
<text top="660" left="845" width="22" height="15" font="1">N/A </text>
<text top="660" left="926" width="22" height="15" font="1">N/A </text>
<text top="660" left="1063" width="69" height="15" font="1">Small sample </text>
<text top="676" left="1063" width="53" height="15" font="1">size, short </text>
<text top="691" left="1063" width="50" height="15" font="1">treatment </text>
<text top="707" left="1063" width="40" height="15" font="1">period.  </text>
<text top="722" left="1063" width="3" height="15" font="1"> </text>
<text top="738" left="1063" width="3" height="15" font="1"> </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">10 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="35" height="15" font="1">PSVT, </text>
<text top="70" left="116" width="28" height="15" font="1">PAF, </text>
<text top="86" left="116" width="39" height="15" font="1">paroxys</text>
<text top="101" left="116" width="21" height="15" font="1">mal </text>
<text top="117" left="116" width="27" height="15" font="1">atrial </text>
<text top="132" left="116" width="31" height="15" font="1">flutter </text>
<text top="55" left="238" width="68" height="15" font="1">(n=14, Group </text>
<text top="70" left="238" width="13" height="15" font="1">1) </text>
<text top="86" left="238" width="3" height="15" font="1"> </text>
<text top="101" left="238" width="37" height="15" font="1">PAF or </text>
<text top="117" left="238" width="60" height="15" font="1">parosysmal </text>
<text top="132" left="238" width="58" height="15" font="1">atrial flutter </text>
<text top="147" left="238" width="68" height="15" font="1">(n=28, Group </text>
<text top="163" left="238" width="13" height="15" font="1">2) </text>
<text top="55" left="663" width="48" height="15" font="1">placebo.  </text>
<text top="70" left="663" width="3" height="15" font="1"> </text>
<text top="86" left="663" width="72" height="15" font="1">Number w/ no </text>
<text top="101" left="663" width="60" height="15" font="1">tachycardia </text>
<text top="117" left="663" width="65" height="15" font="1">increased w/ </text>
<text top="132" left="663" width="68" height="15" font="1">progressively </text>
<text top="147" left="663" width="31" height="15" font="1">larger </text>
<text top="163" left="663" width="50" height="15" font="1">flecainide </text>
<text top="178" left="663" width="68" height="15" font="1">doses; w/ the </text>
<text top="194" left="663" width="68" height="15" font="1">150 mg twice </text>
<text top="210" left="663" width="71" height="15" font="1">daily dose, 12 </text>
<text top="225" left="663" width="60" height="15" font="1">(86%) of 14 </text>
<text top="240" left="663" width="55" height="15" font="1">pts had no </text>
<text top="256" left="663" width="60" height="15" font="1">tachycardia </text>
<text top="271" left="663" width="57" height="15" font="1">(p&lt;0.01 for </text>
<text top="287" left="663" width="36" height="15" font="1">overall </text>
<text top="302" left="663" width="57" height="15" font="1">differences </text>
<text top="318" left="663" width="51" height="15" font="1">among all </text>
<text top="333" left="663" width="62" height="15" font="1">treatments). </text>
<text top="55" left="751" width="50" height="15" font="1">flecainide </text>
<text top="70" left="751" width="50" height="15" font="1">treatment </text>
<text top="86" left="751" width="70" height="15" font="1">periods (5 pts </text>
<text top="101" left="751" width="76" height="15" font="1">in Group 1 and </text>
<text top="117" left="751" width="73" height="15" font="1">6 pts in Group </text>
<text top="132" left="751" width="16" height="15" font="1">2). </text>
<text top="350" left="54" width="44" height="15" font="1">Pritchett </text>
<text top="365" left="54" width="31" height="15" font="1">1991  </text>
<text top="381" left="54" width="23" height="15" font="1">(28) </text>
<text top="396" left="54" width="43" height="15" font="8">2001087</text>
<text top="396" left="97" width="3" height="15" font="1"> </text>
<text top="350" left="116" width="24" height="15" font="1">Oral </text>
<text top="365" left="116" width="44" height="15" font="1">propafen</text>
<text top="381" left="116" width="34" height="15" font="1">one to </text>
<text top="396" left="116" width="40" height="15" font="1">prevent </text>
<text top="412" left="116" width="36" height="15" font="1">sympto</text>
<text top="427" left="116" width="29" height="15" font="1">matic </text>
<text top="443" left="116" width="32" height="15" font="1">PSVT </text>
<text top="458" left="116" width="3" height="15" font="1"> </text>
<text top="474" left="116" width="44" height="15" font="1">Randomi</text>
<text top="489" left="116" width="24" height="15" font="1">zed, </text>
<text top="505" left="116" width="37" height="15" font="1">double-</text>
<text top="520" left="116" width="29" height="15" font="1">blind, </text>
<text top="535" left="116" width="42" height="15" font="1">placebo-</text>
<text top="551" left="116" width="42" height="15" font="1">controlle</text>
<text top="567" left="116" width="12" height="15" font="1">d, </text>
<text top="582" left="116" width="44" height="15" font="1">crossove</text>
<text top="597" left="116" width="43" height="15" font="1">r phase, </text>
<text top="613" left="116" width="41" height="15" font="1">w/ each </text>
<text top="628" left="116" width="44" height="15" font="1">treatmen</text>
<text top="644" left="116" width="40" height="15" font="1">t period </text>
<text top="659" left="116" width="35" height="15" font="1">lasting </text>
<text top="675" left="116" width="43" height="15" font="1">up to 60 </text>
<text top="690" left="116" width="12" height="15" font="1">d. </text>
<text top="350" left="177" width="15" height="15" font="1">23 </text>
<text top="365" left="177" width="3" height="15" font="1"> </text>
<text top="381" left="177" width="3" height="15" font="1"> </text>
<text top="350" left="238" width="66" height="15" font="1">Propafenone </text>
<text top="365" left="238" width="35" height="15" font="1">(n=23) </text>
<text top="350" left="325" width="43" height="15" font="1">Placebo </text>
<text top="365" left="325" width="35" height="15" font="1">(n=23) </text>
<text top="350" left="413" width="32" height="15" font="1">PSVT </text>
<text top="365" left="413" width="35" height="15" font="1">(n=14) </text>
<text top="381" left="413" width="6" height="15" font="1">  </text>
<text top="396" left="413" width="25" height="15" font="1">PAF </text>
<text top="412" left="413" width="29" height="15" font="1">(n=9) </text>
<text top="350" left="541" width="71" height="15" font="1">Angina during </text>
<text top="365" left="541" width="63" height="15" font="1">tachycardia, </text>
<text top="381" left="541" width="95" height="15" font="1">pulmonary edema, </text>
<text top="396" left="541" width="54" height="15" font="1">neurologic </text>
<text top="412" left="541" width="26" height="15" font="1">sxs.  </text>
<text top="427" left="541" width="88" height="15" font="1">PAF w/ WPW, on </text>
<text top="443" left="541" width="31" height="15" font="1">AADs </text>
<text top="350" left="663" width="69" height="15" font="1">Compared w/ </text>
<text top="365" left="663" width="45" height="15" font="1">placebo, </text>
<text top="381" left="663" width="65" height="15" font="1">propafenone </text>
<text top="396" left="663" width="54" height="15" font="1">caused an </text>
<text top="412" left="663" width="57" height="15" font="1">increase in </text>
<text top="427" left="663" width="57" height="15" font="1">time to first </text>
<text top="443" left="663" width="68" height="15" font="1">recurrence of </text>
<text top="458" left="663" width="55" height="15" font="1">arrhythmia </text>
<text top="474" left="663" width="51" height="15" font="1">(p=0.004) </text>
<text top="489" left="663" width="3" height="15" font="1"> </text>
<text top="505" left="663" width="35" height="15" font="1">PSVT: </text>
<text top="520" left="663" width="37" height="15" font="1">p=0.03 </text>
<text top="535" left="663" width="3" height="15" font="1"> </text>
<text top="551" left="663" width="28" height="15" font="1">PAF: </text>
<text top="567" left="663" width="37" height="15" font="1">p=0.06 </text>
<text top="582" left="663" width="6" height="15" font="1">. </text>
<text top="350" left="751" width="65" height="15" font="1">Cardiac AEs </text>
<text top="365" left="751" width="81" height="15" font="1">occurred only in </text>
<text top="381" left="751" width="57" height="15" font="1">pts w/ PAF </text>
<text top="396" left="751" width="58" height="15" font="1">(9/11): 2 w/ </text>
<text top="412" left="751" width="52" height="15" font="1">prolonged </text>
<text top="427" left="751" width="74" height="15" font="1">episode of AF, </text>
<text top="443" left="751" width="81" height="15" font="1">1 w/ atrial flutter </text>
<text top="458" left="751" width="54" height="15" font="1">w/ a mean </text>
<text top="474" left="751" width="54" height="15" font="1">ventricular </text>
<text top="489" left="751" width="81" height="15" font="1">rate of 263 bpm </text>
<text top="505" left="751" width="76" height="15" font="1">recorded using </text>
<text top="520" left="751" width="70" height="15" font="1">the telephone </text>
<text top="535" left="751" width="43" height="15" font="1">monitor. </text>
<text top="350" left="845" width="53" height="15" font="1">HR during </text>
<text top="365" left="845" width="65" height="15" font="1">recurrences, </text>
<text top="381" left="845" width="40" height="15" font="1">and not </text>
<text top="396" left="845" width="57" height="15" font="1">statistically </text>
<text top="412" left="845" width="43" height="15" font="1">different </text>
<text top="427" left="845" width="45" height="15" font="1">between </text>
<text top="443" left="845" width="65" height="15" font="1">propafenone </text>
<text top="458" left="845" width="63" height="15" font="1">and placebo </text>
<text top="350" left="926" width="22" height="15" font="1">N/A </text>
<text top="350" left="1063" width="66" height="15" font="1">Propafenone </text>
<text top="365" left="1063" width="67" height="15" font="1">efficacious in </text>
<text top="381" left="1063" width="72" height="15" font="1">treating PSVT </text>
<text top="396" left="1063" width="49" height="15" font="1">and PAF. </text>
<text top="412" left="1063" width="3" height="15" font="1"> </text>
<text top="427" left="1063" width="31" height="15" font="1">Major </text>
<text top="443" left="1063" width="58" height="15" font="1">limitation in </text>
<text top="458" left="1063" width="62" height="15" font="1">not knowing </text>
<text top="474" left="1063" width="71" height="15" font="1">how many pts </text>
<text top="489" left="1063" width="68" height="15" font="1">had AVNRT.  </text>
<text top="505" left="1063" width="6" height="15" font="1">. </text>
<text top="707" left="54" width="41" height="15" font="1">Anderso</text>
<text top="722" left="54" width="9" height="15" font="1">n </text>
<text top="738" left="54" width="31" height="15" font="1">1994  </text>
<text top="753" left="54" width="23" height="15" font="1">(29) </text>
<text top="769" left="54" width="46" height="15" font="8">8074041 </text>
<text top="769" left="100" width="3" height="15" font="1"> </text>
<text top="784" left="54" width="3" height="15" font="1"> </text>
<text top="707" left="116" width="28" height="15" font="1">Long-</text>
<text top="722" left="116" width="25" height="15" font="1">term </text>
<text top="738" left="116" width="41" height="15" font="1">efficacy </text>
<text top="753" left="116" width="12" height="15" font="1">of </text>
<text top="769" left="116" width="41" height="15" font="1">flecainid</text>
<text top="784" left="116" width="29" height="15" font="1">e (≥6 </text>
<text top="707" left="177" width="138" height="15" font="1">49 PSVT </text>
<text top="722" left="238" width="35" height="15" font="1">(n=21) </text>
<text top="738" left="238" width="3" height="15" font="1"> </text>
<text top="753" left="238" width="25" height="15" font="1">PAF </text>
<text top="769" left="238" width="35" height="15" font="1">(n=28) </text>
<text top="784" left="238" width="3" height="15" font="1"> </text>
<text top="707" left="325" width="43" height="15" font="1">Placebo </text>
<text top="707" left="413" width="96" height="15" font="1">Pts enrolled from 3 </text>
<text top="722" left="413" width="63" height="15" font="1">prior studies </text>
<text top="738" left="413" width="107" height="15" font="1">evaluating short-term </text>
<text top="753" left="413" width="94" height="15" font="1">flecainide efficacy  </text>
<text top="707" left="541" width="102" height="15" font="1">Syncope, angina, or </text>
<text top="722" left="541" width="89" height="15" font="1">transient cerebral </text>
<text top="738" left="541" width="108" height="15" font="1">events during PSVT,  </text>
<text top="753" left="541" width="76" height="15" font="1">second or third </text>
<text top="769" left="541" width="97" height="15" font="1">degree AV block or </text>
<text top="784" left="541" width="98" height="15" font="1">had CHF (NYHA III-</text>
<text top="707" left="663" width="58" height="15" font="1">-Number of </text>
<text top="722" left="663" width="38" height="15" font="1">pts w/o </text>
<text top="738" left="663" width="38" height="15" font="1">attacks </text>
<text top="753" left="663" width="65" height="15" font="1">-Time to first </text>
<text top="769" left="663" width="33" height="15" font="1">attack </text>
<text top="784" left="663" width="43" height="15" font="1">-Interval </text>
<text top="707" left="751" width="29" height="15" font="1">No pt </text>
<text top="722" left="751" width="63" height="15" font="1">experienced </text>
<text top="738" left="751" width="74" height="15" font="1">proarrhythmia, </text>
<text top="753" left="751" width="55" height="15" font="1">MI, or died </text>
<text top="769" left="751" width="73" height="15" font="1">during chronic </text>
<text top="784" left="751" width="73" height="15" font="1">efficacy study. </text>
<text top="707" left="845" width="22" height="15" font="1">N/A </text>
<text top="707" left="926" width="22" height="15" font="1">N/A </text>
<text top="707" left="1063" width="47" height="15" font="1">Supports </text>
<text top="722" left="1063" width="66" height="15" font="1">flecainide for </text>
<text top="738" left="1063" width="39" height="15" font="1">chronic </text>
<text top="753" left="1063" width="52" height="15" font="1">therapy of </text>
<text top="769" left="1063" width="35" height="15" font="1">PSVT. </text>
<text top="784" left="1063" width="3" height="15" font="1"> </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">11 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="846" height="15" font="1">mo) IV) </text>
<text top="55" left="559" width="406" height="15" font="1"> </text>
<text top="55" left="562" width="3" height="15" font="1"> </text>
<text top="55" left="663" width="45" height="15" font="1">between </text>
<text top="70" left="663" width="38" height="15" font="1">attacks </text>
<text top="86" left="663" width="48" height="15" font="1">-Average </text>
<text top="101" left="663" width="64" height="15" font="1">frequency of </text>
<text top="117" left="663" width="41" height="15" font="1">attacks, </text>
<text top="132" left="663" width="60" height="15" font="1">-Ventricular </text>
<text top="147" left="663" width="56" height="15" font="1">rate during </text>
<text top="163" left="663" width="41" height="15" font="1">attacks. </text>
<text top="178" left="663" width="3" height="15" font="1"> </text>
<text top="194" left="663" width="53" height="15" font="1">PSVT pts: </text>
<text top="210" left="663" width="3" height="15" font="1"> </text>
<text top="225" left="663" width="71" height="15" font="1">Of 17 efficacy </text>
<text top="240" left="663" width="71" height="15" font="1">evaluable pts, </text>
<text top="256" left="663" width="69" height="15" font="1">14 (82%) had </text>
<text top="271" left="663" width="40" height="15" font="1">no SVT </text>
<text top="287" left="663" width="72" height="15" font="1">attacks during </text>
<text top="302" left="663" width="57" height="15" font="1">the chronic </text>
<text top="318" left="663" width="70" height="15" font="1">efficacy study </text>
<text top="333" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="349" left="663" width="71" height="15" font="1">4 (24%) w/ no </text>
<text top="364" left="663" width="72" height="15" font="1">attacks during </text>
<text top="380" left="663" width="42" height="15" font="1">placebo </text>
<text top="395" left="663" width="52" height="15" font="1">therapy at </text>
<text top="411" left="663" width="44" height="15" font="1">baseline </text>
<text top="426" left="663" width="54" height="15" font="1">(p=0.013). </text>
<text top="442" left="663" width="3" height="15" font="1"> </text>
<text top="457" left="663" width="61" height="15" font="1">Time to first </text>
<text top="473" left="663" width="55" height="15" font="1">arrhythmia </text>
<text top="488" left="663" width="54" height="15" font="1">attack and </text>
<text top="504" left="663" width="69" height="15" font="1">time between </text>
<text top="519" left="663" width="38" height="15" font="1">attacks </text>
<text top="535" left="663" width="51" height="15" font="1">increased </text>
<text top="550" left="663" width="73" height="15" font="1">during chronic </text>
<text top="566" left="663" width="54" height="15" font="1">therapy w/ </text>
<text top="581" left="663" width="50" height="15" font="1">flecainide </text>
<text top="597" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="612" left="663" width="42" height="15" font="1">placebo </text>
<text top="628" left="663" width="50" height="15" font="1">treatment </text>
<text top="643" left="663" width="69" height="15" font="1">(p=0.008 and </text>
<text top="659" left="663" width="46" height="15" font="1">p=0.012, </text>
<text top="674" left="663" width="65" height="15" font="1">respectively) </text>
<text top="690" left="663" width="3" height="15" font="1"> </text>
<text top="705" left="663" width="44" height="15" font="1">Rates of </text>
<text top="721" left="663" width="60" height="15" font="1">attack/d not </text>
<text top="736" left="663" width="60" height="15" font="1">significantly </text>
<text top="752" left="663" width="43" height="15" font="1">different </text>
<text top="767" left="663" width="51" height="15" font="1">(p=0.130) </text>
<text top="783" left="663" width="3" height="15" font="1"> </text>
<text top="55" left="1063" width="31" height="15" font="1">Small </text>
<text top="70" left="1063" width="58" height="15" font="1">numbers of </text>
<text top="86" left="1063" width="67" height="15" font="1">pts w/ PSVT, </text>
<text top="101" left="1063" width="72" height="15" font="1">and PSVT not </text>
<text top="117" left="1063" width="57" height="15" font="1">specifically </text>
<text top="132" left="1063" width="42" height="15" font="1">defined. </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="14" size="11" family="Times" color="#0a0905"/>
<text top="814" left="1120" width="17" height="17" font="0">12 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="67" height="15" font="1">No PSVT pts </text>
<text top="70" left="663" width="68" height="15" font="1">w/ ventricular </text>
<text top="86" left="663" width="61" height="15" font="1">arrhythmias </text>
<text top="102" left="54" width="44" height="15" font="1">Chimient</text>
<text top="117" left="54" width="6" height="15" font="1">i </text>
<text top="133" left="54" width="31" height="15" font="1">1995  </text>
<text top="148" left="54" width="23" height="15" font="1">(30) </text>
<text top="164" left="54" width="43" height="15" font="8">8682031</text>
<text top="164" left="97" width="3" height="15" font="1"> </text>
<text top="179" left="54" width="3" height="15" font="1"> </text>
<text top="195" left="54" width="3" height="15" font="1"> </text>
<text top="102" left="116" width="39" height="15" font="1">Compar</text>
<text top="117" left="116" width="28" height="15" font="1">e the </text>
<text top="133" left="116" width="25" height="15" font="1">long-</text>
<text top="148" left="116" width="25" height="15" font="1">term </text>
<text top="164" left="116" width="45" height="15" font="1">safety of </text>
<text top="179" left="116" width="41" height="15" font="1">flecainid</text>
<text top="195" left="116" width="31" height="15" font="1">e and </text>
<text top="210" left="116" width="44" height="15" font="1">propafen</text>
<text top="226" left="116" width="22" height="15" font="1">one </text>
<text top="102" left="177" width="22" height="15" font="1">335 </text>
<text top="117" left="177" width="3" height="15" font="1"> </text>
<text top="133" left="177" width="3" height="15" font="1"> </text>
<text top="102" left="238" width="28" height="15" font="1">SVT: </text>
<text top="117" left="238" width="71" height="15" font="1">flecainide 100 </text>
<text top="133" left="238" width="63" height="15" font="1">mg (n = 72)  </text>
<text top="148" left="238" width="3" height="15" font="1"> </text>
<text top="164" left="238" width="28" height="15" font="1">PAF: </text>
<text top="179" left="238" width="71" height="15" font="1">flecainide 200 </text>
<text top="195" left="238" width="63" height="15" font="1">mg (n = 97)  </text>
<text top="102" left="325" width="28" height="15" font="1">SVT: </text>
<text top="117" left="325" width="65" height="15" font="1">propafenone </text>
<text top="133" left="325" width="40" height="15" font="1">450 mg </text>
<text top="148" left="325" width="35" height="15" font="1">(n=63) </text>
<text top="164" left="325" width="3" height="15" font="1"> </text>
<text top="179" left="325" width="28" height="15" font="1">PAF: </text>
<text top="195" left="325" width="65" height="15" font="1">propafenone </text>
<text top="210" left="325" width="40" height="15" font="1">450 mg </text>
<text top="226" left="325" width="45" height="15" font="1">(n=103). </text>
<text top="102" left="413" width="25" height="15" font="1">SVT </text>
<text top="117" left="413" width="41" height="15" font="1">(n=135) </text>
<text top="133" left="413" width="3" height="15" font="1"> </text>
<text top="148" left="413" width="25" height="15" font="1">PAF </text>
<text top="164" left="413" width="41" height="15" font="1">(n=200) </text>
<text top="179" left="413" width="3" height="15" font="1"> </text>
<text top="195" left="413" width="3" height="15" font="1"> </text>
<text top="102" left="541" width="83" height="15" font="1">LVEF &lt;35%, AV </text>
<text top="117" left="541" width="87" height="15" font="1">block, QRS &gt;140 </text>
<text top="133" left="541" width="61" height="15" font="1">msec, SSS, </text>
<text top="148" left="541" width="68" height="15" font="1">persistent AF </text>
<text top="164" left="541" width="106" height="15" font="1">(episodes &gt;72 h), VT </text>
<text top="179" left="541" width="100" height="15" font="1">(episodes &gt;30 sec), </text>
<text top="195" left="541" width="63" height="15" font="1">NYHA III-IV, </text>
<text top="210" left="541" width="74" height="15" font="1">ischemic heart </text>
<text top="226" left="541" width="108" height="15" font="1">disease, hypertrophic </text>
<text top="241" left="541" width="84" height="15" font="1">cardiomyopathy, </text>
<text top="257" left="541" width="107" height="15" font="1">hypotension, valvular </text>
<text top="272" left="541" width="44" height="15" font="1">disease, </text>
<text top="288" left="541" width="66" height="15" font="1">renal/hepatic </text>
<text top="303" left="541" width="103" height="15" font="1">insufficiency, thyroid </text>
<text top="319" left="541" width="76" height="15" font="1">disease, AADs </text>
<text top="102" left="663" width="63" height="15" font="1">ITT analysis </text>
<text top="117" left="663" width="69" height="15" font="1">(probability of </text>
<text top="133" left="663" width="58" height="15" font="1">12 mo safe </text>
<text top="148" left="663" width="66" height="15" font="1">and effective </text>
<text top="164" left="663" width="15" height="15" font="1">tx) </text>
<text top="179" left="663" width="35" height="15" font="1">PSVT: </text>
<text top="195" left="663" width="41" height="15" font="1">93% for </text>
<text top="210" left="663" width="71" height="15" font="1">flecainide and </text>
<text top="226" left="663" width="41" height="15" font="1">86% for </text>
<text top="241" left="663" width="65" height="15" font="1">propafenone </text>
<text top="257" left="663" width="45" height="15" font="1">(p=0.24) </text>
<text top="272" left="663" width="3" height="15" font="1"> </text>
<text top="288" left="663" width="28" height="15" font="1">PAF: </text>
<text top="303" left="663" width="41" height="15" font="1">77% for </text>
<text top="319" left="663" width="71" height="15" font="1">flecainide and </text>
<text top="334" left="663" width="41" height="15" font="1">75% for </text>
<text top="350" left="663" width="65" height="15" font="1">propafenone </text>
<text top="365" left="663" width="45" height="15" font="1">(p=0.72) </text>
<text top="102" left="751" width="49" height="15" font="1">12 pts on </text>
<text top="117" left="751" width="50" height="15" font="1">flecainide </text>
<text top="133" left="751" width="60" height="15" font="1">reported 16 </text>
<text top="148" left="751" width="77" height="15" font="1">cardiac AEs, of </text>
<text top="164" left="751" width="42" height="15" font="1">whom 6 </text>
<text top="179" left="751" width="65" height="15" font="1">discontinued </text>
<text top="195" left="751" width="74" height="15" font="1">the treatment.  </text>
<text top="210" left="751" width="3" height="15" font="1"> </text>
<text top="226" left="751" width="74" height="15" font="1">7 propafenone </text>
<text top="241" left="751" width="49" height="15" font="1">pts had 8 </text>
<text top="257" left="751" width="77" height="15" font="1">cardiac AEs, of </text>
<text top="272" left="751" width="42" height="15" font="1">whom 5 </text>
<text top="288" left="751" width="65" height="15" font="1">discontinued </text>
<text top="303" left="751" width="71" height="15" font="1">the treatment. </text>
<text top="319" left="751" width="69" height="15" font="1">(1 case of VT </text>
<text top="334" left="751" width="81" height="15" font="1">on propafenone </text>
<text top="350" left="751" width="3" height="15" font="1"> </text>
<text top="365" left="751" width="71" height="15" font="1">2 cases of AF </text>
<text top="381" left="751" width="42" height="15" font="1">w/ rapid </text>
<text top="396" left="751" width="54" height="15" font="1">ventricular </text>
<text top="412" left="751" width="64" height="15" font="1">response on </text>
<text top="427" left="751" width="50" height="15" font="1">flecainide </text>
<text top="102" left="845" width="22" height="15" font="1">N/A </text>
<text top="102" left="926" width="22" height="15" font="1">N/A </text>
<text top="102" left="1063" width="26" height="15" font="1">Both </text>
<text top="117" left="1063" width="71" height="15" font="1">flecainide and </text>
<text top="133" left="1063" width="65" height="15" font="1">propafenone </text>
<text top="148" left="1063" width="63" height="15" font="1">were safe in </text>
<text top="164" left="1063" width="68" height="15" font="1">the long-term </text>
<text top="179" left="1063" width="62" height="15" font="1">treatment of </text>
<text top="195" left="1063" width="67" height="15" font="1">pts w/ PSVT. </text>
<text top="210" left="1063" width="3" height="15" font="1"> </text>
<text top="226" left="1063" width="73" height="15" font="1">Only one-third </text>
<text top="241" left="1063" width="52" height="15" font="1">of pts had </text>
<text top="257" left="1063" width="31" height="15" font="1">SVT.  </text>
<text top="443" left="54" width="18" height="15" font="1">UK </text>
<text top="459" left="54" width="45" height="15" font="1">Propafen</text>
<text top="474" left="54" width="21" height="15" font="1">one </text>
<text top="490" left="54" width="32" height="15" font="1">PSVT </text>
<text top="505" left="54" width="31" height="15" font="1">Study </text>
<text top="521" left="54" width="34" height="15" font="1">Group </text>
<text top="536" left="54" width="31" height="15" font="1">1995  </text>
<text top="552" left="54" width="23" height="15" font="1">(31) </text>
<text top="567" left="54" width="43" height="15" font="8">7586356</text>
<text top="567" left="97" width="3" height="15" font="1"> </text>
<text top="443" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="459" left="116" width="21" height="15" font="1">and </text>
<text top="474" left="116" width="44" height="15" font="1">tolerabilit</text>
<text top="490" left="116" width="21" height="15" font="1">y of </text>
<text top="505" left="116" width="44" height="15" font="1">propafen</text>
<text top="521" left="116" width="34" height="15" font="1">one at </text>
<text top="536" left="116" width="40" height="15" font="1">600 mg </text>
<text top="552" left="116" width="43" height="15" font="1">and 900 </text>
<text top="567" left="116" width="44" height="15" font="1">mg daily </text>
<text top="583" left="116" width="33" height="15" font="1">doses </text>
<text top="598" left="116" width="33" height="15" font="1">(given </text>
<text top="614" left="116" width="25" height="15" font="1">bid). </text>
<text top="629" left="116" width="3" height="15" font="1"> </text>
<text top="645" left="116" width="9" height="15" font="1">2 </text>
<text top="660" left="116" width="44" height="15" font="1">consecut</text>
<text top="676" left="116" width="17" height="15" font="1">ive </text>
<text top="691" left="116" width="44" height="15" font="1">crossove</text>
<text top="707" left="116" width="46" height="15" font="1">r periods </text>
<text top="443" left="177" width="22" height="15" font="1">100 </text>
<text top="459" left="177" width="3" height="15" font="1"> </text>
<text top="474" left="177" width="3" height="15" font="1"> </text>
<text top="443" left="238" width="66" height="15" font="1">Propafenone </text>
<text top="459" left="238" width="58" height="15" font="1">300 mg bid </text>
<text top="474" left="238" width="3" height="15" font="1"> </text>
<text top="490" left="238" width="66" height="15" font="1">Propafenone </text>
<text top="505" left="238" width="55" height="15" font="1">300 mg tid </text>
<text top="443" left="325" width="120" height="15" font="1">Placebo PSVT </text>
<text top="459" left="413" width="39" height="15" font="1">(n=52)  </text>
<text top="474" left="413" width="3" height="15" font="1"> </text>
<text top="490" left="413" width="25" height="15" font="1">PAF </text>
<text top="505" left="413" width="39" height="15" font="1">(n=48)  </text>
<text top="521" left="413" width="3" height="15" font="1"> </text>
<text top="536" left="413" width="92" height="15" font="1">75 pts in low-dose </text>
<text top="552" left="413" width="36" height="15" font="1">phase: </text>
<text top="567" left="413" width="90" height="15" font="1">45 PSVT, 30 PAF </text>
<text top="583" left="413" width="3" height="15" font="1"> </text>
<text top="598" left="413" width="97" height="15" font="1">59 pts advanced to </text>
<text top="614" left="413" width="88" height="15" font="1">high-dose phase: </text>
<text top="629" left="413" width="93" height="15" font="1">34 PSVT, 25 PAF  </text>
<text top="645" left="413" width="3" height="15" font="1"> </text>
<text top="660" left="413" width="82" height="15" font="1">≥2 symptomatic </text>
<text top="676" left="413" width="62" height="15" font="1">episodes by </text>
<text top="691" left="413" width="78" height="15" font="1">transtelephonic </text>
<text top="707" left="413" width="52" height="15" font="1">monitoring</text>
<text top="707" left="465" width="6" height="15" font="14">  </text>
<text top="722" left="413" width="3" height="15" font="1"> </text>
<text top="443" left="541" width="46" height="15" font="1">PSVT w/ </text>
<text top="459" left="541" width="72" height="15" font="1">hemodynamic </text>
<text top="474" left="541" width="78" height="15" font="1">collapse, LVEF </text>
<text top="490" left="541" width="98" height="15" font="1">≤25%, recent MI or </text>
<text top="505" left="541" width="84" height="15" font="1">unstable angina; </text>
<text top="521" left="541" width="103" height="15" font="1">hepatic/renal failure, </text>
<text top="536" left="541" width="78" height="15" font="1">SSS, AV block, </text>
<text top="552" left="541" width="101" height="15" font="1">AADs, female pts of </text>
<text top="567" left="541" width="63" height="15" font="1">childbearing </text>
<text top="583" left="541" width="86" height="15" font="1">potential, COPD, </text>
<text top="598" left="541" width="95" height="15" font="1">myasthenia gravis. </text>
<text top="443" left="663" width="60" height="15" font="1">Placebo vs. </text>
<text top="459" left="663" width="68" height="15" font="1">propafenone: </text>
<text top="474" left="663" width="3" height="15" font="1"> </text>
<text top="490" left="663" width="55" height="15" font="1">PSVT, low-</text>
<text top="505" left="663" width="30" height="15" font="1">dose: </text>
<text top="521" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="536" left="663" width="69" height="15" font="1">recurrence or </text>
<text top="552" left="663" width="18" height="15" font="1">AE </text>
<text top="567" left="663" width="69" height="15" font="1">RR: 6.8 (95% </text>
<text top="583" left="663" width="67" height="15" font="1">CI: 2.2-21.2;  </text>
<text top="598" left="663" width="53" height="15" font="1">p&lt;0.001),  </text>
<text top="614" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="629" left="663" width="56" height="15" font="1">recurrence </text>
<text top="645" left="663" width="69" height="15" font="1">RR: 7.4 (95% </text>
<text top="660" left="663" width="64" height="15" font="1">CI: 2.3-23.3, </text>
<text top="676" left="663" width="50" height="15" font="1">p&lt;0.001). </text>
<text top="691" left="663" width="3" height="15" font="1"> </text>
<text top="707" left="663" width="60" height="15" font="1">PSVT, high-</text>
<text top="722" left="663" width="30" height="15" font="1">dose: </text>
<text top="738" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="753" left="663" width="69" height="15" font="1">recurrence or </text>
<text top="769" left="663" width="18" height="15" font="1">AE </text>
<text top="784" left="663" width="69" height="15" font="1">RR: 2.2 (95% </text>
<text top="443" left="751" width="46" height="15" font="1">More pts </text>
<text top="459" left="751" width="63" height="15" font="1">experienced </text>
<text top="474" left="751" width="52" height="15" font="1">more AEs </text>
<text top="490" left="751" width="34" height="15" font="1">during </text>
<text top="505" left="751" width="65" height="15" font="1">propafenone </text>
<text top="521" left="751" width="72" height="15" font="1">(900 mg &gt;600 </text>
<text top="536" left="751" width="52" height="15" font="1">mg). Most </text>
<text top="552" left="751" width="45" height="15" font="1">common </text>
<text top="567" left="751" width="78" height="15" font="1">adverse events </text>
<text top="583" left="751" width="66" height="15" font="1">during PSVT </text>
<text top="598" left="751" width="46" height="15" font="1">and PAF </text>
<text top="614" left="751" width="64" height="15" font="1">groups were </text>
<text top="629" left="751" width="68" height="15" font="1">related to the </text>
<text top="645" left="751" width="77" height="15" font="1">gastrointestinal </text>
<text top="660" left="751" width="21" height="15" font="1">and </text>
<text top="676" left="751" width="75" height="15" font="1">neuropsychiatri</text>
<text top="691" left="751" width="55" height="15" font="1">c systems. </text>
<text top="707" left="751" width="74" height="15" font="1">Total numbers </text>
<text top="722" left="751" width="55" height="15" font="1">of adverse </text>
<text top="738" left="751" width="51" height="15" font="1">events on </text>
<text top="753" left="751" width="65" height="15" font="1">propafenone </text>
<text top="769" left="751" width="79" height="15" font="1">were 46 and 56 </text>
<text top="784" left="751" width="77" height="15" font="1">in the low-dose </text>
<text top="443" left="845" width="63" height="15" font="1">1 episode of </text>
<text top="459" left="845" width="26" height="15" font="1">wide-</text>
<text top="474" left="845" width="44" height="15" font="1">complex </text>
<text top="490" left="845" width="60" height="15" font="1">tachycardia </text>
<text top="505" left="845" width="23" height="15" font="1">was </text>
<text top="521" left="845" width="64" height="15" font="1">documented </text>
<text top="536" left="845" width="34" height="15" font="1">during </text>
<text top="552" left="845" width="65" height="15" font="1">propafenone </text>
<text top="567" left="845" width="40" height="15" font="1">therapy </text>
<text top="443" left="926" width="119" height="15" font="1">Propafenone at 600 mg </text>
<text top="459" left="926" width="99" height="15" font="1">is effective and well </text>
<text top="474" left="926" width="118" height="15" font="1">tolerated. A larger dose </text>
<text top="490" left="926" width="119" height="15" font="1">of 900 mg causes more </text>
<text top="505" left="926" width="109" height="15" font="1">AEs but may be more </text>
<text top="521" left="926" width="110" height="15" font="1">effective in those who </text>
<text top="536" left="926" width="69" height="15" font="1">can tolerate it </text>
<text top="443" left="1063" width="55" height="15" font="1">Sequential </text>
<text top="459" left="1063" width="58" height="15" font="1">design (not </text>
<text top="474" left="1063" width="61" height="15" font="1">randomized </text>
<text top="490" left="1063" width="73" height="15" font="1">after low-dose </text>
<text top="505" left="1063" width="52" height="15" font="1">phase) so </text>
<text top="521" left="1063" width="65" height="15" font="1">population is </text>
<text top="536" left="1063" width="18" height="15" font="1">not </text>
<text top="552" left="1063" width="69" height="15" font="1">generalizable </text>
<text top="567" left="1063" width="52" height="15" font="1">at 900 mg </text>
<text top="583" left="1063" width="33" height="15" font="1">dose.  </text>
<text top="598" left="1063" width="3" height="15" font="1"> </text>
<text top="614" left="1063" width="66" height="15" font="1">Not powered </text>
<text top="629" left="1063" width="64" height="15" font="1">for mortality. </text>
<text top="645" left="1063" width="3" height="15" font="1"> </text>
<text top="660" left="1063" width="72" height="15" font="1">Limited in that </text>
<text top="676" left="1063" width="38" height="15" font="1">PSVTs </text>
<text top="691" left="1063" width="44" height="15" font="1">included </text>
<text top="707" left="1063" width="64" height="15" font="1">AVNRT, AT, </text>
<text top="722" left="1063" width="49" height="15" font="1">or AVRT. </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="15" size="11" family="Times" color="#2d2d2d"/>
<text top="814" left="1120" width="17" height="17" font="0">13 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="58" height="15" font="1">CI: 0.9-5.3, </text>
<text top="70" left="663" width="38" height="15" font="1">p=NS); </text>
<text top="86" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="101" left="663" width="56" height="15" font="1">recurrence </text>
<text top="117" left="663" width="69" height="15" font="1">RR: 15.0 (95: </text>
<text top="132" left="663" width="61" height="15" font="1">CI: 2.0-113, </text>
<text top="147" left="663" width="53" height="15" font="1">p=0.009).  </text>
<text top="163" left="663" width="3" height="15" font="1"> </text>
<text top="55" left="751" width="73" height="15" font="1">and high-dose </text>
<text top="70" left="751" width="63" height="15" font="1">PSVT group </text>
<text top="86" left="751" width="74" height="15" font="1">and 67 and 74 </text>
<text top="101" left="751" width="77" height="15" font="1">in the low-dose </text>
<text top="117" left="751" width="73" height="15" font="1">and high-dose </text>
<text top="132" left="751" width="65" height="15" font="1">PAF groups, </text>
<text top="147" left="751" width="65" height="15" font="1">respectively. </text>
<text top="179" left="54" width="36" height="15" font="1">Dorian </text>
<text top="195" left="54" width="31" height="15" font="1">1996  </text>
<text top="210" left="54" width="23" height="15" font="1">(32) </text>
<text top="226" left="54" width="46" height="15" font="8">8607397 </text>
<text top="179" left="116" width="39" height="15" font="1">Compar</text>
<text top="195" left="116" width="31" height="15" font="1">e oral </text>
<text top="210" left="116" width="41" height="15" font="1">flecainid</text>
<text top="226" left="116" width="21" height="15" font="1">e to </text>
<text top="241" left="116" width="43" height="15" font="1">verapam</text>
<text top="257" left="116" width="20" height="15" font="1">il in </text>
<text top="272" left="116" width="39" height="15" font="1">preventi</text>
<text top="288" left="116" width="47" height="15" font="1">ng PSVT </text>
<text top="303" left="116" width="41" height="15" font="1">recurren</text>
<text top="319" left="116" width="15" height="15" font="1">ce </text>
<text top="179" left="177" width="39" height="15" font="1">121 pts </text>
<text top="195" left="177" width="28" height="15" font="1">at 32 </text>
<text top="210" left="177" width="26" height="15" font="1">sites </text>
<text top="179" left="238" width="53" height="15" font="1">Flecainide </text>
<text top="195" left="238" width="73" height="15" font="1">(n=63) (50 mg </text>
<text top="210" left="238" width="69" height="15" font="1">bid increased </text>
<text top="226" left="238" width="70" height="15" font="1">to max of 300 </text>
<text top="241" left="238" width="31" height="15" font="1">mg/d) </text>
<text top="257" left="238" width="3" height="15" font="1"> </text>
<text top="272" left="238" width="73" height="15" font="1">AVNRT(n=17) </text>
<text top="288" left="238" width="59" height="15" font="1">AVRT(n=6) </text>
<text top="303" left="238" width="61" height="15" font="1">Unspecified </text>
<text top="319" left="238" width="35" height="15" font="1">(n=40) </text>
<text top="179" left="325" width="53" height="15" font="1">Verapamil </text>
<text top="195" left="325" width="73" height="15" font="1">(n=58) (80 mg </text>
<text top="210" left="325" width="66" height="15" font="1">tid increased </text>
<text top="226" left="325" width="70" height="15" font="1">to max of 480 </text>
<text top="241" left="325" width="31" height="15" font="1">mg/d) </text>
<text top="257" left="325" width="3" height="15" font="1"> </text>
<text top="272" left="325" width="73" height="15" font="1">AVNRT(n=10) </text>
<text top="288" left="325" width="59" height="15" font="1">AVRT(n=7) </text>
<text top="303" left="325" width="61" height="15" font="1">Unspecified </text>
<text top="319" left="325" width="35" height="15" font="1">(n=41) </text>
<text top="179" left="413" width="81" height="15" font="1">PSVT, requiring </text>
<text top="195" left="413" width="99" height="15" font="1">therapy, majority w/ </text>
<text top="210" left="413" width="92" height="15" font="1">≥2 attacks per mo </text>
<text top="226" left="413" width="3" height="15" font="1"> </text>
<text top="241" left="413" width="41" height="15" font="1">AVNRT </text>
<text top="257" left="413" width="33" height="15" font="1">AVRT </text>
<text top="272" left="413" width="111" height="15" font="1">Unspecified PSVT but </text>
<text top="288" left="413" width="113" height="15" font="1">w/ clinical diagnosis of </text>
<text top="303" left="413" width="32" height="15" font="1">PSVT </text>
<text top="179" left="541" width="108" height="15" font="1">Coexisting PAF, prior </text>
<text top="195" left="541" width="102" height="15" font="1">MI/UA, NYHA Class </text>
<text top="210" left="541" width="79" height="15" font="1">III-IV, AV block, </text>
<text top="226" left="541" width="100" height="15" font="1">preexcitation, AADs </text>
<text top="179" left="663" width="52" height="15" font="1">86% of all </text>
<text top="195" left="663" width="50" height="15" font="1">flecainide </text>
<text top="210" left="663" width="52" height="15" font="1">73% of all </text>
<text top="226" left="663" width="64" height="15" font="1">verapamil pt-</text>
<text top="241" left="663" width="64" height="15" font="1">mo occurred </text>
<text top="257" left="663" width="66" height="15" font="1">w/ 0-1 attack </text>
<text top="272" left="663" width="3" height="15" font="1"> </text>
<text top="288" left="663" width="66" height="15" font="1">19 (30%) pts </text>
<text top="303" left="663" width="65" height="15" font="1">on flecainide </text>
<text top="319" left="663" width="68" height="15" font="1">vs. 7 (13% of </text>
<text top="334" left="663" width="51" height="15" font="1">verapamil </text>
<text top="350" left="663" width="73" height="15" font="1">completed the </text>
<text top="365" left="663" width="65" height="15" font="1">trial (&gt;270 d) </text>
<text top="381" left="663" width="20" height="15" font="1">w/o </text>
<text top="396" left="663" width="65" height="15" font="1">symptomatic </text>
<text top="412" left="663" width="57" height="15" font="1">attacks (p= </text>
<text top="427" left="663" width="34" height="15" font="1">0.026) </text>
<text top="443" left="663" width="3" height="15" font="1"> </text>
<text top="458" left="663" width="60" height="15" font="1">f/u 8.1 ±5.1 </text>
<text top="474" left="663" width="34" height="15" font="1">mo for </text>
<text top="489" left="663" width="71" height="15" font="1">flecainide and </text>
<text top="505" left="663" width="63" height="15" font="1">7.5± 5.4 mo </text>
<text top="520" left="663" width="65" height="15" font="1">w/ verapamil </text>
<text top="179" left="751" width="38" height="15" font="1">19% of </text>
<text top="195" left="751" width="81" height="15" font="1">flecainide group </text>
<text top="210" left="751" width="42" height="15" font="1">vs. 24% </text>
<text top="226" left="751" width="51" height="15" font="1">verapamil </text>
<text top="241" left="751" width="65" height="15" font="1">discontinued </text>
<text top="257" left="751" width="76" height="15" font="1">due to adverse </text>
<text top="272" left="751" width="77" height="15" font="1">effects (p=NS). </text>
<text top="288" left="751" width="3" height="15" font="1"> </text>
<text top="303" left="751" width="72" height="15" font="1">Most common </text>
<text top="319" left="751" width="70" height="15" font="1">sx: flecainide: </text>
<text top="334" left="751" width="52" height="15" font="1">dizziness, </text>
<text top="350" left="751" width="73" height="15" font="1">concentration, </text>
<text top="365" left="751" width="72" height="15" font="1">sleep, nausea </text>
<text top="381" left="751" width="3" height="15" font="1"> </text>
<text top="396" left="751" width="56" height="15" font="1">Verapamil: </text>
<text top="412" left="751" width="48" height="15" font="1">dyspnea, </text>
<text top="427" left="751" width="71" height="15" font="1">fatigue, HF sx </text>
<text top="179" left="845" width="22" height="15" font="1">N/A </text>
<text top="179" left="926" width="104" height="15" font="1">These agents confer </text>
<text top="195" left="926" width="111" height="15" font="1">potential benefit in pts </text>
<text top="210" left="926" width="117" height="15" font="1">who are not candidates </text>
<text top="226" left="926" width="41" height="15" font="1">for RFA </text>
<text top="179" left="1063" width="22" height="15" font="1">N/A </text>
<text top="536" left="54" width="46" height="15" font="1">Wanless </text>
<text top="552" left="54" width="28" height="15" font="1">1997 </text>
<text top="567" left="54" width="23" height="15" font="1">(33) </text>
<text top="583" left="54" width="43" height="15" font="8">9124166</text>
<text top="583" left="97" width="3" height="15" font="1"> </text>
<text top="536" left="116" width="37" height="15" font="1">Sotalol </text>
<text top="552" left="116" width="12" height="15" font="1">in </text>
<text top="567" left="116" width="44" height="15" font="1">treatmen</text>
<text top="583" left="116" width="18" height="15" font="1">t of </text>
<text top="598" left="116" width="32" height="15" font="1">PSVT </text>
<text top="536" left="177" width="25" height="15" font="1">126  </text>
<text top="536" left="238" width="71" height="15" font="1">Sotalol 80 mg </text>
<text top="552" left="238" width="35" height="15" font="1">(n=35) </text>
<text top="567" left="238" width="73" height="15" font="1">AVNRT (23%) </text>
<text top="583" left="238" width="3" height="15" font="1"> </text>
<text top="598" left="238" width="59" height="15" font="1">Sotalol 160 </text>
<text top="614" left="238" width="18" height="15" font="1">mg </text>
<text top="629" left="238" width="35" height="15" font="1">(n=46) </text>
<text top="645" left="238" width="73" height="15" font="1">AVNRT (22%) </text>
<text top="536" left="325" width="43" height="15" font="1">Placebo </text>
<text top="552" left="325" width="35" height="15" font="1">(n=45) </text>
<text top="567" left="325" width="73" height="15" font="1">AVNRT (24%) </text>
<text top="536" left="413" width="52" height="15" font="1">Recurrent </text>
<text top="552" left="413" width="97" height="15" font="1">symptomatic PSVT </text>
<text top="567" left="413" width="80" height="15" font="1">were eligible for </text>
<text top="583" left="413" width="61" height="15" font="1">enrollment.  </text>
<text top="598" left="413" width="3" height="15" font="1"> </text>
<text top="614" left="413" width="41" height="15" font="1">AVNRT </text>
<text top="629" left="413" width="25" height="15" font="1">PAF </text>
<text top="645" left="413" width="88" height="15" font="1">Paroxysmal atrial </text>
<text top="660" left="413" width="31" height="15" font="1">flutter </text>
<text top="676" left="413" width="33" height="15" font="1">AVRT </text>
<text top="691" left="413" width="81" height="15" font="1">Paroxysmal AT  </text>
<text top="536" left="541" width="84" height="15" font="1">Decompensated </text>
<text top="552" left="541" width="71" height="15" font="1">CHF, asthma, </text>
<text top="567" left="541" width="95" height="15" font="1">chronic obstructive </text>
<text top="583" left="541" width="85" height="15" font="1">airways disease, </text>
<text top="598" left="541" width="89" height="15" font="1">second degree or </text>
<text top="614" left="541" width="80" height="15" font="1">third degree AV </text>
<text top="629" left="541" width="101" height="15" font="1">block, recent MI (&lt;1 </text>
<text top="645" left="541" width="105" height="15" font="1">mo), recent coronary </text>
<text top="660" left="541" width="95" height="15" font="1">artery bypass graft </text>
<text top="676" left="541" width="84" height="15" font="1">surgery (&lt;2 mo), </text>
<text top="691" left="541" width="81" height="15" font="1">unstable angina </text>
<text top="707" left="541" width="106" height="15" font="1">pectoris, bradycardia </text>
<text top="722" left="541" width="85" height="15" font="1">(&lt;50 bpm), SSS, </text>
<text top="738" left="541" width="76" height="15" font="1">prolonged QTc </text>
<text top="753" left="541" width="101" height="15" font="1">interval (&gt;0.45 sec), </text>
<text top="769" left="541" width="46" height="15" font="1">systemic </text>
<text top="784" left="541" width="66" height="15" font="1">hypertension </text>
<text top="536" left="663" width="40" height="15" font="1">Time to </text>
<text top="552" left="663" width="68" height="15" font="1">recurrence of </text>
<text top="567" left="663" width="55" height="15" font="1">PSVT was </text>
<text top="583" left="663" width="23" height="15" font="1">less </text>
<text top="598" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="614" left="663" width="71" height="15" font="1">placebo when </text>
<text top="629" left="663" width="47" height="15" font="1">receiving </text>
<text top="645" left="663" width="69" height="15" font="1">sotalol 80 mg </text>
<text top="660" left="663" width="66" height="15" font="1">(p=0.04) and </text>
<text top="676" left="663" width="57" height="15" font="1">sotalol 160 </text>
<text top="691" left="663" width="18" height="15" font="1">mg </text>
<text top="707" left="663" width="63" height="15" font="1">(p=0.0009).  </text>
<text top="722" left="663" width="3" height="15" font="1"> </text>
<text top="738" left="663" width="18" height="15" font="1">On </text>
<text top="753" left="663" width="64" height="15" font="1">subanalysis, </text>
<text top="769" left="663" width="58" height="15" font="1">sotalol was </text>
<text top="784" left="663" width="63" height="15" font="1">shown to be </text>
<text top="536" left="751" width="57" height="15" font="15">No deaths, </text>
<text top="552" left="751" width="44" height="15" font="15">cases of </text>
<text top="567" left="751" width="54" height="15" font="15">ventricular </text>
<text top="583" left="751" width="68" height="15" font="15">proarrhythmia</text>
<text top="583" left="819" width="6" height="15" font="1">, </text>
<text top="598" left="751" width="29" height="15" font="1">CHF. </text>
<text top="614" left="751" width="66" height="15" font="1">Treatment of </text>
<text top="629" left="751" width="65" height="15" font="1">pts receiving </text>
<text top="645" left="751" width="62" height="15" font="1">sotalol were </text>
<text top="660" left="751" width="65" height="15" font="1">discontinued </text>
<text top="676" left="751" width="57" height="15" font="1">because of </text>
<text top="691" left="751" width="59" height="15" font="1">typical beta </text>
<text top="707" left="751" width="62" height="15" font="1">blocker side </text>
<text top="722" left="751" width="39" height="15" font="1">effects, </text>
<text top="738" left="751" width="47" height="15" font="1">including </text>
<text top="753" left="751" width="64" height="15" font="1">bradycardia, </text>
<text top="769" left="751" width="70" height="15" font="1">dyspnea, and </text>
<text top="784" left="751" width="39" height="15" font="1">fatigue. </text>
<text top="536" left="845" width="22" height="15" font="1">N/A </text>
<text top="536" left="926" width="22" height="15" font="1">N/A </text>
<text top="536" left="1063" width="37" height="15" font="1">Sotalol </text>
<text top="552" left="1063" width="67" height="15" font="1">efficacious in </text>
<text top="567" left="1063" width="18" height="15" font="1">the </text>
<text top="583" left="1063" width="71" height="15" font="1">prophylaxis of </text>
<text top="598" left="1063" width="38" height="15" font="1">PSVT.  </text>
<text top="614" left="1063" width="3" height="15" font="1"> </text>
<text top="629" left="1063" width="66" height="15" font="1">Study limited </text>
<text top="645" left="1063" width="34" height="15" font="1">due to </text>
<text top="660" left="1063" width="58" height="15" font="1">grouping of </text>
<text top="676" left="1063" width="41" height="15" font="1">PSVTs. </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">14 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="541" width="93" height="15" font="1">(diastolic BP &gt;115 </text>
<text top="70" left="541" width="99" height="15" font="1">mm Hg), electrolyte </text>
<text top="86" left="541" width="85" height="15" font="1">imbalance, AADs</text>
<text top="86" left="626" width="3" height="15" font="14"> </text>
<text top="55" left="663" width="75" height="15" font="1">effective in the </text>
<text top="70" left="663" width="71" height="15" font="1">prophylaxis of </text>
<text top="86" left="663" width="49" height="15" font="1">both PAF </text>
<text top="101" left="663" width="66" height="15" font="1">(p=0.03) and </text>
<text top="117" left="663" width="60" height="15" font="1">paroxysmal </text>
<text top="132" left="663" width="47" height="15" font="1">reentrant </text>
<text top="147" left="663" width="61" height="15" font="1">arrhythmias </text>
<text top="163" left="663" width="60" height="15" font="1">(p=0.0003). </text>
<text top="179" left="54" width="21" height="15" font="1">Lim </text>
<text top="195" left="54" width="31" height="15" font="1">1998  </text>
<text top="210" left="54" width="23" height="15" font="1">(34) </text>
<text top="226" left="54" width="43" height="15" font="8">9437338</text>
<text top="226" left="97" width="3" height="15" font="1"> </text>
<text top="179" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="195" left="116" width="45" height="15" font="1">of VM or </text>
<text top="210" left="116" width="40" height="15" font="1">CSM to </text>
<text top="226" left="116" width="40" height="15" font="1">terminat</text>
<text top="241" left="116" width="45" height="15" font="1">e SVT in </text>
<text top="257" left="116" width="37" height="15" font="1">the ED </text>
<text top="179" left="177" width="39" height="15" font="1">N=148  </text>
<text top="195" left="177" width="44" height="15" font="1">Randomi</text>
<text top="210" left="177" width="33" height="15" font="1">zed to </text>
<text top="226" left="177" width="40" height="15" font="1">VM first </text>
<text top="241" left="177" width="36" height="15" font="1">(62) or </text>
<text top="257" left="177" width="28" height="15" font="1">CSM </text>
<text top="272" left="177" width="47" height="15" font="1">first (86), </text>
<text top="288" left="177" width="25" height="15" font="1">then </text>
<text top="303" left="177" width="42" height="15" font="1">crossed-</text>
<text top="319" left="177" width="37" height="15" font="1">over to </text>
<text top="334" left="177" width="28" height="15" font="1">other </text>
<text top="350" left="177" width="40" height="15" font="1">therapy </text>
<text top="365" left="177" width="29" height="15" font="1">if first </text>
<text top="381" left="177" width="18" height="15" font="1">not </text>
<text top="396" left="177" width="44" height="15" font="1">effective </text>
<text top="179" left="238" width="70" height="15" font="1">VM (blow into </text>
<text top="195" left="238" width="73" height="15" font="1">mouthpiece to </text>
<text top="210" left="238" width="57" height="15" font="1">achieve 40 </text>
<text top="226" left="238" width="60" height="15" font="1">mm Hg and </text>
<text top="241" left="238" width="66" height="15" font="1">sustain for at </text>
<text top="257" left="238" width="66" height="15" font="1">least 30 sec) </text>
<text top="179" left="325" width="28" height="15" font="1">CSM </text>
<text top="195" left="325" width="65" height="15" font="1">(randomized </text>
<text top="210" left="325" width="64" height="15" font="1">first to left or </text>
<text top="226" left="325" width="49" height="15" font="1">then right </text>
<text top="241" left="325" width="31" height="15" font="1">CSM) </text>
<text top="179" left="413" width="102" height="15" font="1"> 10 y of age or older </text>
<text top="179" left="541" width="82" height="15" font="1">ECG w/ obvious </text>
<text top="195" left="541" width="91" height="15" font="1">atrial flutter, AF or </text>
<text top="210" left="541" width="92" height="15" font="1">sinus tachycardia, </text>
<text top="226" left="541" width="89" height="15" font="1">hemodynamically </text>
<text top="241" left="541" width="95" height="15" font="1">unstable (including </text>
<text top="257" left="541" width="68" height="15" font="1">poor cerebral </text>
<text top="272" left="541" width="107" height="15" font="1">perfusion, pulmonary </text>
<text top="288" left="541" width="95" height="15" font="1">edema or unstable </text>
<text top="303" left="541" width="76" height="15" font="1">angina). Pts w/ </text>
<text top="319" left="541" width="102" height="15" font="1">contraindications for </text>
<text top="334" left="541" width="102" height="15" font="1">CSM (h/o TIA, CVA, </text>
<text top="350" left="541" width="65" height="15" font="1">carotid bruit) </text>
<text top="179" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="195" left="663" width="18" height="15" font="1">SR </text>
<text top="179" left="751" width="60" height="15" font="1">No adverse </text>
<text top="195" left="751" width="74" height="15" font="1">events directly </text>
<text top="210" left="751" width="69" height="15" font="1">related to VM </text>
<text top="226" left="751" width="80" height="15" font="1">or CSM. One pt </text>
<text top="241" left="751" width="77" height="15" font="1">was diagnosed </text>
<text top="257" left="751" width="77" height="15" font="1">w/ non-Q wave </text>
<text top="272" left="751" width="45" height="15" font="1">MI. 4 pts </text>
<text top="288" left="751" width="61" height="15" font="1">admitted for </text>
<text top="303" left="751" width="69" height="15" font="1">other medical </text>
<text top="319" left="751" width="73" height="15" font="1">problems (HF, </text>
<text top="334" left="751" width="62" height="15" font="1">pneumonia) </text>
<text top="179" left="845" width="22" height="15" font="1">N/A </text>
<text top="179" left="926" width="93" height="15" font="1">62 VM first, 19.4% </text>
<text top="195" left="926" width="60" height="15" font="1">conversion; </text>
<text top="210" left="926" width="107" height="15" font="1">86 CSMc first, 10.5% </text>
<text top="226" left="926" width="57" height="15" font="1">conversion </text>
<text top="241" left="926" width="99" height="15" font="1">Crossover: to CSM, </text>
<text top="257" left="926" width="116" height="15" font="1">14.0% conversion, and </text>
<text top="272" left="926" width="80" height="15" font="1">to VM w/ 16.9% </text>
<text top="288" left="926" width="57" height="15" font="1">conversion </text>
<text top="303" left="926" width="106" height="15" font="1">Total conversion rate </text>
<text top="319" left="926" width="122" height="15" font="1">(VM and CSM, including </text>
<text top="334" left="926" width="101" height="15" font="1">cross-overs): 27.7% </text>
<text top="350" left="926" width="3" height="15" font="1"> </text>
<text top="365" left="926" width="121" height="15" font="1">No difference in efficacy </text>
<text top="381" left="926" width="114" height="15" font="1">between VM and CSM </text>
<text top="396" left="926" width="3" height="15" font="1"> </text>
<text top="412" left="926" width="104" height="15" font="1">VM more effective in </text>
<text top="427" left="926" width="84" height="15" font="1">men, CSM more </text>
<text top="443" left="926" width="102" height="15" font="1">effective in older pts </text>
<text top="458" left="926" width="3" height="15" font="1"> </text>
<text top="474" left="926" width="119" height="15" font="1">Recurrences w/in 2 h; 3 </text>
<text top="489" left="926" width="90" height="15" font="1">VM pts, 1 CSM pt </text>
<text top="179" left="1063" width="22" height="15" font="1">N/A </text>
<text top="505" left="54" width="44" height="15" font="1">Gupta A </text>
<text top="521" left="54" width="31" height="15" font="1">1999  </text>
<text top="536" left="54" width="23" height="15" font="1">(35) </text>
<text top="552" left="54" width="43" height="15" font="8">1077868</text>
<text top="567" left="54" width="9" height="15" font="8">9 </text>
<text top="505" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="521" left="116" width="26" height="15" font="1">of IV </text>
<text top="536" left="116" width="47" height="15" font="1">diltiazem </text>
<text top="552" left="116" width="17" height="15" font="1">vs. </text>
<text top="567" left="116" width="41" height="15" font="1">esmolol </text>
<text top="583" left="116" width="16" height="15" font="1">for </text>
<text top="598" left="116" width="42" height="15" font="1">terminati</text>
<text top="614" left="116" width="47" height="15" font="1">ng PSVT </text>
<text top="505" left="177" width="30" height="15" font="1">N=32 </text>
<text top="521" left="177" width="33" height="15" font="1">(study </text>
<text top="536" left="177" width="40" height="15" font="1">terminat</text>
<text top="552" left="177" width="15" height="15" font="1">ed </text>
<text top="567" left="177" width="44" height="15" font="1">prematur</text>
<text top="583" left="177" width="39" height="15" font="1">ely due </text>
<text top="598" left="177" width="12" height="15" font="1">to </text>
<text top="614" left="177" width="42" height="15" font="1">superiori</text>
<text top="629" left="177" width="24" height="15" font="1">ty of </text>
<text top="645" left="177" width="44" height="15" font="1">diltiazem</text>
<text top="660" left="177" width="7" height="15" font="1">) </text>
<text top="676" left="177" width="3" height="15" font="1"> </text>
<text top="691" left="177" width="44" height="15" font="1">Prospect</text>
<text top="707" left="177" width="17" height="15" font="1">ive </text>
<text top="722" left="177" width="40" height="15" font="1">randomi</text>
<text top="738" left="177" width="21" height="15" font="1">zed </text>
<text top="753" left="177" width="44" height="15" font="1">crossove</text>
<text top="769" left="177" width="38" height="15" font="1">r, open-</text>
<text top="784" left="177" width="39" height="15" font="1">labeled </text>
<text top="505" left="238" width="61" height="15" font="1">Esmolol 0.5 </text>
<text top="521" left="238" width="73" height="15" font="1">mg/kg twice in </text>
<text top="536" left="238" width="69" height="15" font="1">5 min interval </text>
<text top="505" left="325" width="73" height="15" font="1">Diltiazem 0.25 </text>
<text top="521" left="325" width="73" height="15" font="1">mg/kg twice in </text>
<text top="536" left="325" width="69" height="15" font="1">5 min interval </text>
<text top="505" left="413" width="25" height="15" font="1">SVT </text>
<text top="521" left="413" width="90" height="15" font="1">Hemodynamically </text>
<text top="536" left="413" width="80" height="15" font="1">tolerated in ICU </text>
<text top="505" left="541" width="107" height="15" font="1">SHD; AT, AF or atrial </text>
<text top="521" left="541" width="78" height="15" font="1">flutter excluded </text>
<text top="505" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="521" left="663" width="18" height="15" font="1">SR </text>
<text top="505" left="751" width="22" height="15" font="1">N/A </text>
<text top="505" left="845" width="22" height="15" font="1">N/A </text>
<text top="505" left="926" width="104" height="15" font="1">Diltiazem terminated </text>
<text top="521" left="926" width="117" height="15" font="1">SVT in all 16 pts where </text>
<text top="536" left="926" width="69" height="15" font="1">was first drug </text>
<text top="552" left="926" width="122" height="15" font="1">Esmolol terminated 4/16 </text>
<text top="567" left="926" width="117" height="15" font="1">(p&lt;0.001 c/w diltiazem) </text>
<text top="583" left="926" width="90" height="15" font="1">and other 12 then </text>
<text top="598" left="926" width="117" height="15" font="1">terminated by diltiazem </text>
<text top="614" left="926" width="90" height="15" font="1">(total for diltiazem </text>
<text top="629" left="926" width="34" height="15" font="1">28/28) </text>
<text top="645" left="926" width="67" height="15" font="1">Of the 28 pts </text>
<text top="660" left="926" width="117" height="15" font="1">responding to diltiazem </text>
<text top="676" left="926" width="98" height="15" font="1">a second dose was </text>
<text top="691" left="926" width="70" height="15" font="1">needed in 13. </text>
<text top="707" left="926" width="3" height="15" font="1"> </text>
<text top="722" left="926" width="117" height="15" font="1">All 32 pts subsequently </text>
<text top="738" left="926" width="121" height="15" font="1">underwent EP study; 17 </text>
<text top="753" left="926" width="126" height="15" font="1">w/ AVNRT, 15 w/ AVRT.  </text>
<text top="769" left="926" width="102" height="15" font="1">Diltiazem: first bolus </text>
<text top="784" left="926" width="102" height="15" font="1">converted 5/9 pts w/ </text>
<text top="505" left="1063" width="55" height="15" font="1">Small trial, </text>
<text top="521" left="1063" width="55" height="15" font="1">terminated </text>
<text top="536" left="1063" width="61" height="15" font="1">early due to </text>
<text top="552" left="1063" width="66" height="15" font="1">superiority of </text>
<text top="567" left="1063" width="50" height="15" font="1">diltiazem. </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">15 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="926" width="98" height="15" font="1">AVNRT, and 0/7 w/ </text>
<text top="70" left="926" width="90" height="15" font="1">AVRT (p&lt;0.0001) </text>
<text top="86" left="926" width="84" height="15" font="1">Esmolol: equally </text>
<text top="101" left="926" width="100" height="15" font="1">ineffective for either </text>
<text top="117" left="926" width="119" height="15" font="1">tachycardia mechanism </text>
<text top="133" left="54" width="34" height="15" font="1">Alboni </text>
<text top="148" left="54" width="31" height="15" font="1">2001  </text>
<text top="164" left="54" width="23" height="15" font="1">(36) </text>
<text top="179" left="54" width="43" height="15" font="8">1121697</text>
<text top="195" left="54" width="6" height="15" font="8">7</text>
<text top="195" left="60" width="3" height="15" font="1"> </text>
<text top="210" left="54" width="3" height="15" font="1"> </text>
<text top="226" left="54" width="3" height="15" font="1"> </text>
<text top="133" left="116" width="42" height="15" font="1">Effective</text>
<text top="148" left="116" width="39" height="15" font="1">ness of </text>
<text top="164" left="116" width="21" height="15" font="1">self-</text>
<text top="179" left="116" width="41" height="15" font="1">administ</text>
<text top="195" left="116" width="25" height="15" font="1">ered </text>
<text top="210" left="116" width="41" height="15" font="1">flecianid</text>
<text top="226" left="116" width="22" height="15" font="1">e or </text>
<text top="241" left="116" width="44" height="15" font="1">diltiazem</text>
<text top="257" left="116" width="41" height="15" font="1">/propran</text>
<text top="272" left="116" width="33" height="15" font="1">olol to </text>
<text top="288" left="116" width="40" height="15" font="1">terminat</text>
<text top="303" left="116" width="34" height="15" font="1">e SVT </text>
<text top="133" left="177" width="44" height="15" font="1">Randomi</text>
<text top="148" left="177" width="33" height="15" font="1">zed to </text>
<text top="164" left="177" width="45" height="15" font="1">placebo, </text>
<text top="179" left="177" width="41" height="15" font="1">flecainid</text>
<text top="195" left="177" width="22" height="15" font="1">e (3 </text>
<text top="210" left="177" width="40" height="15" font="1">mg/kg), </text>
<text top="226" left="177" width="40" height="15" font="1">120 mg </text>
<text top="241" left="177" width="44" height="15" font="1">diltiazem</text>
<text top="257" left="177" width="37" height="15" font="1">/80 mg </text>
<text top="272" left="177" width="44" height="15" font="1">proprano</text>
<text top="288" left="177" width="39" height="15" font="1">lol on 3 </text>
<text top="303" left="177" width="43" height="15" font="1">different </text>
<text top="319" left="177" width="25" height="15" font="1">d for </text>
<text top="334" left="177" width="39" height="15" font="1">each pt </text>
<text top="350" left="177" width="30" height="15" font="1">N=33 </text>
<text top="365" left="177" width="19" height="15" font="1">(37 </text>
<text top="381" left="177" width="46" height="15" font="1">enrolled) </text>
<text top="133" left="238" width="66" height="15" font="1">Flecainide (3 </text>
<text top="148" left="238" width="71" height="15" font="1">mg/kg) or 120 </text>
<text top="164" left="238" width="65" height="15" font="1">mg diltiazem </text>
<text top="179" left="238" width="48" height="15" font="1">w/ 80 mg </text>
<text top="195" left="238" width="58" height="15" font="1">propranolol </text>
<text top="133" left="325" width="223" height="15" font="1">Placebo Hemodynamically </text>
<text top="148" left="413" width="92" height="15" font="1">tolerated and long-</text>
<text top="164" left="413" width="111" height="15" font="1">lasting SVT confirmed </text>
<text top="179" left="413" width="90" height="15" font="1">by EP study to be </text>
<text top="195" left="413" width="104" height="15" font="1">reentrant (AVNRT or </text>
<text top="210" left="413" width="36" height="15" font="1">AVRT) </text>
<text top="226" left="413" width="74" height="15" font="1">Age 18-75, ≤5 </text>
<text top="241" left="413" width="56" height="15" font="1">episodes/y </text>
<text top="133" left="541" width="100" height="15" font="1">Preexcitation, CAD, </text>
<text top="148" left="541" width="78" height="15" font="1">sinus &lt;50 bpm, </text>
<text top="164" left="541" width="96" height="15" font="1">LVEF &lt;50% or HF, </text>
<text top="179" left="541" width="102" height="15" font="1">recent MI, or stroke, </text>
<text top="195" left="541" width="93" height="15" font="1">need for long term </text>
<text top="210" left="541" width="107" height="15" font="1">beta blocker, calcium </text>
<text top="226" left="541" width="84" height="15" font="1">channel blocker, </text>
<text top="241" left="541" width="108" height="15" font="1">digoxin or AAD or h/o </text>
<text top="257" left="541" width="108" height="15" font="1">sustained atrial or VT </text>
<text top="133" left="663" width="59" height="15" font="1">Conversion </text>
<text top="148" left="663" width="69" height="15" font="1">w/in 2 h: 52% </text>
<text top="164" left="663" width="70" height="15" font="1">placebo, 61% </text>
<text top="179" left="663" width="53" height="15" font="1">flecainide, </text>
<text top="195" left="663" width="25" height="15" font="1">94% </text>
<text top="210" left="663" width="69" height="15" font="1">diltiazem/prop</text>
<text top="226" left="663" width="36" height="15" font="1">ranolol </text>
<text top="241" left="663" width="54" height="15" font="1">(p&lt;0.001). </text>
<text top="257" left="663" width="59" height="15" font="1">Conversion </text>
<text top="272" left="663" width="45" height="15" font="1">faster w/ </text>
<text top="288" left="663" width="69" height="15" font="1">diltiazem/prop</text>
<text top="303" left="663" width="36" height="15" font="1">ranolol </text>
<text top="319" left="663" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="334" left="663" width="3" height="15" font="1"> </text>
<text top="133" left="751" width="68" height="15" font="1">Hypotension, </text>
<text top="148" left="751" width="61" height="15" font="1">bradycardia </text>
<text top="133" left="845" width="62" height="15" font="1">Over 17±12 </text>
<text top="148" left="845" width="18" height="15" font="1">mo </text>
<text top="164" left="845" width="50" height="15" font="1">treatment </text>
<text top="179" left="845" width="61" height="15" font="1">success f/u  </text>
<text top="195" left="845" width="28" height="15" font="1">(SVT </text>
<text top="210" left="845" width="67" height="15" font="1">terminated in </text>
<text top="226" left="845" width="65" height="15" font="1">&lt;2 h) in 81% </text>
<text top="241" left="845" width="28" height="15" font="1">of 26 </text>
<text top="257" left="845" width="63" height="15" font="1">diltiazem/pro</text>
<text top="272" left="845" width="60" height="15" font="1">panolol pts, </text>
<text top="288" left="845" width="47" height="15" font="1">80% of 5 </text>
<text top="303" left="845" width="68" height="15" font="1">flecainide pts </text>
<text top="319" left="845" width="61" height="15" font="1">% pts going </text>
<text top="334" left="845" width="53" height="15" font="1">to ED was </text>
<text top="350" left="845" width="48" height="15" font="1">9% down </text>
<text top="365" left="845" width="57" height="15" font="1">from 100% </text>
<text top="381" left="845" width="46" height="15" font="1">of prior y </text>
<text top="396" left="845" width="57" height="15" font="1">(p&lt;0.0001) </text>
<text top="412" left="845" width="3" height="15" font="1"> </text>
<text top="133" left="926" width="82" height="15" font="1">Adverse events: </text>
<text top="148" left="926" width="84" height="15" font="1">hypotension in 1 </text>
<text top="164" left="926" width="104" height="15" font="1">placebo, 2 flecainide </text>
<text top="179" left="926" width="31" height="15" font="1">and 1 </text>
<text top="195" left="926" width="105" height="15" font="1">diltiazem/propranolol </text>
<text top="210" left="926" width="102" height="15" font="1">pts; 3 had sinus &lt;50 </text>
<text top="226" left="926" width="37" height="15" font="1">bpm (3 </text>
<text top="241" left="926" width="118" height="15" font="1">diltiazem/propranolol, 1 </text>
<text top="257" left="926" width="54" height="15" font="1">flecainide) </text>
<text top="272" left="926" width="114" height="15" font="1">1 diltiazem/propranolol </text>
<text top="288" left="926" width="78" height="15" font="1">pt had syncope </text>
<text top="303" left="926" width="3" height="15" font="1"> </text>
<text top="319" left="926" width="119" height="15" font="1">5 pts ultimately referred </text>
<text top="334" left="926" width="58" height="15" font="1">for ablation </text>
<text top="133" left="1063" width="58" height="15" font="1">Unknown if </text>
<text top="148" left="1063" width="63" height="15" font="1">outpt events </text>
<text top="164" left="1063" width="60" height="15" font="1">that pts self-</text>
<text top="179" left="1063" width="65" height="15" font="1">treated were </text>
<text top="195" left="1063" width="61" height="15" font="1">indeed SVT </text>
<text top="210" left="1063" width="58" height="15" font="1">and time to </text>
<text top="226" left="1063" width="57" height="15" font="1">conversion </text>
<text top="241" left="1063" width="50" height="15" font="1">assessed </text>
<text top="257" left="1063" width="60" height="15" font="1">subjectively </text>
<text top="272" left="1063" width="27" height="15" font="1">by pt </text>
<text top="288" left="1063" width="3" height="15" font="1"> </text>
<text top="303" left="1063" width="30" height="15" font="1">Outpt </text>
<text top="319" left="1063" width="68" height="15" font="1">management </text>
<text top="334" left="1063" width="55" height="15" font="1">was not w/ </text>
<text top="350" left="1063" width="42" height="15" font="1">placebo </text>
<text top="428" left="54" width="44" height="15" font="1">Tendera </text>
<text top="443" left="54" width="31" height="15" font="1">2001  </text>
<text top="459" left="54" width="23" height="15" font="1">(37) </text>
<text top="474" left="54" width="43" height="15" font="8">1143166</text>
<text top="490" left="54" width="6" height="15" font="8">3</text>
<text top="490" left="60" width="3" height="15" font="1"> </text>
<text top="428" left="116" width="42" height="15" font="1">Compari</text>
<text top="443" left="116" width="33" height="15" font="1">son of </text>
<text top="459" left="116" width="47" height="15" font="1">dofetilide </text>
<text top="474" left="116" width="12" height="15" font="1">to </text>
<text top="490" left="116" width="44" height="15" font="1">propafen</text>
<text top="505" left="116" width="43" height="15" font="1">one and </text>
<text top="521" left="116" width="42" height="15" font="1">placebo </text>
<text top="536" left="116" width="30" height="15" font="1">in the </text>
<text top="552" left="116" width="39" height="15" font="1">preventi</text>
<text top="567" left="116" width="28" height="15" font="1">on of </text>
<text top="583" left="116" width="32" height="15" font="1">PSVT </text>
<text top="428" left="177" width="149" height="15" font="1">122 Dofetilide </text>
<text top="428" left="287" width="42" height="15" font="1"> </text>
<text top="443" left="238" width="35" height="15" font="1">(n=40) </text>
<text top="459" left="238" width="3" height="15" font="1"> </text>
<text top="474" left="238" width="66" height="15" font="1">Propafenone </text>
<text top="490" left="238" width="35" height="15" font="1">(n=41) </text>
<text top="428" left="325" width="43" height="15" font="1">Placebo </text>
<text top="443" left="325" width="35" height="15" font="1">(n=41) </text>
<text top="428" left="413" width="113" height="15" font="1">18-75 y w/ ≥1 episode </text>
<text top="443" left="413" width="93" height="15" font="1">of PSVT w/in 6 wk </text>
<text top="459" left="413" width="106" height="15" font="1">documented by ECG </text>
<text top="428" left="541" width="100" height="15" font="1">Pulmonary disease, </text>
<text top="443" left="541" width="95" height="15" font="1">myasthenia gravis, </text>
<text top="459" left="541" width="105" height="15" font="1">bundle branch block, </text>
<text top="474" left="541" width="97" height="15" font="1">resting bradycardia </text>
<text top="490" left="541" width="107" height="15" font="1">(&lt;50 bpm), AV block, </text>
<text top="505" left="541" width="98" height="15" font="1">prolonged QTc, MI, </text>
<text top="521" left="541" width="84" height="15" font="1">unstable angina, </text>
<text top="536" left="541" width="107" height="15" font="1">recent sudden death, </text>
<text top="552" left="541" width="63" height="15" font="1">hematologic </text>
<text top="567" left="541" width="69" height="15" font="1">/hepatic/renal </text>
<text top="583" left="541" width="41" height="15" font="1">disease </text>
<text top="428" left="663" width="66" height="15" font="1">After 6 mo of </text>
<text top="443" left="663" width="71" height="15" font="1">treatment, pts </text>
<text top="459" left="663" width="33" height="15" font="1">taking </text>
<text top="474" left="663" width="50" height="15" font="1">dofetilide, </text>
<text top="490" left="663" width="68" height="15" font="1">propafenone, </text>
<text top="505" left="663" width="63" height="15" font="1">and placebo </text>
<text top="521" left="663" width="59" height="15" font="1">had a 50%, </text>
<text top="536" left="663" width="69" height="15" font="1">54%, and 6% </text>
<text top="552" left="663" width="57" height="15" font="1">probability, </text>
<text top="567" left="663" width="65" height="15" font="1">respectively, </text>
<text top="583" left="663" width="64" height="15" font="1">of remaining </text>
<text top="598" left="663" width="34" height="15" font="1">free of </text>
<text top="614" left="663" width="60" height="15" font="1">episodes of </text>
<text top="629" left="663" width="32" height="15" font="1">PSVT </text>
<text top="645" left="663" width="63" height="15" font="1">(p&lt;0.001 for </text>
<text top="660" left="663" width="72" height="15" font="1">both dofetilide </text>
<text top="676" left="663" width="21" height="15" font="1">and </text>
<text top="691" left="663" width="65" height="15" font="1">propafenone </text>
<text top="707" left="663" width="66" height="15" font="1">vs. placebo). </text>
<text top="722" left="663" width="3" height="15" font="1"> </text>
<text top="738" left="663" width="59" height="15" font="1">The hazard </text>
<text top="753" left="663" width="41" height="15" font="1">ratio for </text>
<text top="769" left="663" width="65" height="15" font="1">dofetilide vs. </text>
<text top="784" left="663" width="65" height="15" font="1">placebo was </text>
<text top="428" left="751" width="61" height="15" font="1">19 of 40 pts </text>
<text top="443" left="751" width="70" height="15" font="1">(48%) treated </text>
<text top="459" left="751" width="61" height="15" font="1">w/ dofetilide </text>
<text top="474" left="751" width="65" height="15" font="1">and 21 of 41 </text>
<text top="490" left="751" width="70" height="15" font="1">(51%) treated </text>
<text top="505" left="751" width="79" height="15" font="1">w/ propafenone </text>
<text top="521" left="751" width="60" height="15" font="1">reported no </text>
<text top="536" left="751" width="30" height="15" font="1">AEs.  </text>
<text top="552" left="751" width="3" height="15" font="1"> </text>
<text top="567" left="751" width="69" height="15" font="1">No significant </text>
<text top="583" left="751" width="57" height="15" font="1">differences </text>
<text top="598" left="751" width="58" height="15" font="1">were noted </text>
<text top="614" left="751" width="54" height="15" font="1">between 3 </text>
<text top="629" left="751" width="49" height="15" font="1">groups in </text>
<text top="645" left="751" width="62" height="15" font="1">incidence of </text>
<text top="660" left="751" width="50" height="15" font="1">treatment-</text>
<text top="676" left="751" width="79" height="15" font="1">related adverse </text>
<text top="691" left="751" width="63" height="15" font="1">events or all-</text>
<text top="707" left="751" width="75" height="15" font="1">cause adverse </text>
<text top="722" left="751" width="77" height="15" font="1">events (p=0.73 </text>
<text top="738" left="751" width="62" height="15" font="1">and p=0.74, </text>
<text top="753" left="751" width="68" height="15" font="1">respectively). </text>
<text top="428" left="845" width="28" height="15" font="1">Total </text>
<text top="443" left="845" width="53" height="15" font="1">number of </text>
<text top="459" left="845" width="47" height="15" font="1">episodes </text>
<text top="474" left="845" width="49" height="15" font="1">occurring </text>
<text top="490" left="845" width="34" height="15" font="1">during </text>
<text top="505" left="845" width="53" height="15" font="1">treatment, </text>
<text top="521" left="845" width="67" height="15" font="1">and type and </text>
<text top="536" left="845" width="64" height="15" font="1">frequency of </text>
<text top="552" left="845" width="53" height="15" font="1">sxs during </text>
<text top="567" left="845" width="60" height="15" font="1">episodes of </text>
<text top="583" left="845" width="66" height="15" font="1">PSVT before </text>
<text top="598" left="845" width="55" height="15" font="1">and during </text>
<text top="614" left="845" width="50" height="15" font="1">treatment </text>
<text top="629" left="845" width="3" height="15" font="1"> </text>
<text top="645" left="845" width="68" height="15" font="1">Frequency of </text>
<text top="660" left="845" width="47" height="15" font="1">episodes </text>
<text top="676" left="845" width="59" height="15" font="1">lower in pts </text>
<text top="691" left="845" width="52" height="15" font="1">treated w/ </text>
<text top="707" left="845" width="60" height="15" font="1">dofetilide or </text>
<text top="722" left="845" width="65" height="15" font="1">propafenone </text>
<text top="738" left="845" width="65" height="15" font="1">thancompare</text>
<text top="753" left="845" width="66" height="15" font="1">d to placebo. </text>
<text top="769" left="845" width="33" height="15" font="1">Active </text>
<text top="784" left="845" width="68" height="15" font="1">treatment did </text>
<text top="428" left="926" width="22" height="15" font="1">N/A </text>
<text top="428" left="1063" width="73" height="15" font="1">Dofetilide is at </text>
<text top="443" left="1063" width="65" height="15" font="1">least as safe </text>
<text top="459" left="1063" width="66" height="15" font="1">and effective </text>
<text top="474" left="1063" width="15" height="15" font="1">as </text>
<text top="490" left="1063" width="65" height="15" font="1">propafenone </text>
<text top="505" left="1063" width="30" height="15" font="1">as an </text>
<text top="521" left="1063" width="54" height="15" font="1">alternative </text>
<text top="536" left="1063" width="58" height="15" font="1">therapeutic </text>
<text top="552" left="1063" width="68" height="15" font="1">option for the </text>
<text top="567" left="1063" width="62" height="15" font="1">treatment of </text>
<text top="583" left="1063" width="67" height="15" font="1">pts w/ PSVT. </text>
<text top="598" left="1063" width="3" height="15" font="1"> </text>
<text top="614" left="1063" width="72" height="15" font="1">Limited in that </text>
<text top="629" left="1063" width="56" height="15" font="1">PSVTs not </text>
<text top="645" left="1063" width="50" height="15" font="1">specified. </text>
<text top="660" left="1063" width="3" height="15" font="1"> </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">16 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="71" height="15" font="1">0.33 (95% CI: </text>
<text top="70" left="663" width="57" height="15" font="1">0.18-0.61), </text>
<text top="86" left="663" width="40" height="15" font="1">and the </text>
<text top="101" left="663" width="61" height="15" font="1">hazard ratio </text>
<text top="117" left="663" width="16" height="15" font="1">for </text>
<text top="132" left="663" width="65" height="15" font="1">propafenone </text>
<text top="147" left="663" width="59" height="15" font="1">vs. placebo </text>
<text top="163" left="663" width="47" height="15" font="1">was 0.27 </text>
<text top="178" left="663" width="71" height="15" font="1">(95% CI: 0.14-</text>
<text top="194" left="663" width="31" height="15" font="1">0.51). </text>
<text top="210" left="663" width="3" height="15" font="1"> </text>
<text top="225" left="663" width="48" height="15" font="1">Of 40 pts </text>
<text top="240" left="663" width="52" height="15" font="1">treated w/ </text>
<text top="256" left="663" width="69" height="15" font="1">dofetilide and </text>
<text top="271" left="663" width="68" height="15" font="1">propafenone, </text>
<text top="287" left="663" width="69" height="15" font="1">23 (58%) and </text>
<text top="302" left="663" width="69" height="15" font="1">25 (61%) had </text>
<text top="318" left="663" width="62" height="15" font="1">no recurring </text>
<text top="333" left="663" width="35" height="15" font="1">PSVT, </text>
<text top="349" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="364" left="663" width="60" height="15" font="1">16 (39%) in </text>
<text top="380" left="663" width="42" height="15" font="1">placebo </text>
<text top="395" left="663" width="34" height="15" font="1">group. </text>
<text top="55" left="845" width="43" height="15" font="1">not alter </text>
<text top="70" left="845" width="57" height="15" font="1">distribution </text>
<text top="86" left="845" width="66" height="15" font="1">of sxs during </text>
<text top="101" left="845" width="30" height="15" font="1">a first </text>
<text top="117" left="845" width="54" height="15" font="1">episode of </text>
<text top="132" left="845" width="35" height="15" font="1">PSVT. </text>
<text top="412" left="54" width="21" height="15" font="1">Lim </text>
<text top="427" left="54" width="31" height="15" font="1">2009  </text>
<text top="443" left="54" width="23" height="15" font="1">(38) </text>
<text top="458" left="54" width="43" height="15" font="8">1926136</text>
<text top="474" left="54" width="6" height="15" font="8">7</text>
<text top="474" left="60" width="3" height="15" font="1"> </text>
<text top="412" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="427" left="116" width="21" height="15" font="1">and </text>
<text top="443" left="116" width="45" height="15" font="1">safety of </text>
<text top="458" left="116" width="25" height="15" font="1">slow </text>
<text top="474" left="116" width="41" height="15" font="1">infusion </text>
<text top="489" left="116" width="12" height="15" font="1">of </text>
<text top="505" left="116" width="41" height="15" font="1">calcium </text>
<text top="520" left="116" width="42" height="15" font="1">channel </text>
<text top="535" left="116" width="47" height="15" font="1">blockade </text>
<text top="551" left="116" width="17" height="15" font="1">vs. </text>
<text top="567" left="116" width="39" height="15" font="1">adenosi</text>
<text top="582" left="116" width="45" height="15" font="1">ne in the </text>
<text top="597" left="116" width="18" height="15" font="1">ED </text>
<text top="613" left="116" width="33" height="15" font="1">(RCT) </text>
<text top="412" left="177" width="39" height="15" font="1"> N=206 </text>
<text top="412" left="238" width="68" height="15" font="1">Slow infusion </text>
<text top="427" left="238" width="53" height="15" font="1">of calcium </text>
<text top="443" left="238" width="42" height="15" font="1">channel </text>
<text top="458" left="238" width="42" height="15" font="1">blocker: </text>
<text top="474" left="238" width="60" height="15" font="1">verapamil 1 </text>
<text top="489" left="238" width="67" height="15" font="1">mg/min to 20 </text>
<text top="505" left="238" width="58" height="15" font="1">mg total, or </text>
<text top="520" left="238" width="65" height="15" font="1">diltiazem 2.5 </text>
<text top="535" left="238" width="67" height="15" font="1">mg/min to 50 </text>
<text top="551" left="238" width="43" height="15" font="1">mg total </text>
<text top="567" left="238" width="3" height="15" font="1"> </text>
<text top="582" left="238" width="39" height="15" font="1">If failed </text>
<text top="597" left="238" width="41" height="15" font="1">calcium </text>
<text top="613" left="238" width="42" height="15" font="1">channel </text>
<text top="628" left="238" width="63" height="15" font="1">blocker then </text>
<text top="644" left="238" width="29" height="15" font="1">given </text>
<text top="659" left="238" width="54" height="15" font="1">adenosine </text>
<text top="412" left="325" width="68" height="15" font="1">Adenosine (6 </text>
<text top="427" left="325" width="62" height="15" font="1">mg followed </text>
<text top="443" left="325" width="67" height="15" font="1">by 12 mg if 6 </text>
<text top="458" left="325" width="18" height="15" font="1">mg </text>
<text top="474" left="325" width="74" height="15" font="1">ineffective) vs. </text>
<text top="489" left="325" width="67" height="15" font="1">(If adenosine </text>
<text top="505" left="325" width="53" height="15" font="1">ineffective </text>
<text top="520" left="325" width="59" height="15" font="1">after 12 mg </text>
<text top="535" left="325" width="69" height="15" font="1">they received </text>
<text top="551" left="325" width="50" height="15" font="1">a calcium </text>
<text top="567" left="325" width="42" height="15" font="1">channel </text>
<text top="582" left="325" width="39" height="15" font="1">blocker </text>
<text top="597" left="325" width="45" height="15" font="1">infusion) </text>
<text top="412" left="413" width="102" height="15" font="1">10 y of age or older, </text>
<text top="427" left="413" width="110" height="15" font="1">SVT not converted by </text>
<text top="443" left="413" width="82" height="15" font="1">vagal maneuver </text>
<text top="412" left="541" width="89" height="15" font="1">Impaired cerebral </text>
<text top="427" left="541" width="52" height="15" font="1">perfusion, </text>
<text top="443" left="541" width="60" height="15" font="1">subsequent </text>
<text top="458" left="541" width="84" height="15" font="1">diagnosis of non-</text>
<text top="474" left="541" width="65" height="15" font="1">SVT rhythm, </text>
<text top="489" left="541" width="55" height="15" font="1">pregnancy </text>
<text top="412" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="427" left="663" width="18" height="15" font="1">SR </text>
<text top="412" left="751" width="65" height="15" font="1">Hypotension </text>
<text top="427" left="751" width="3" height="15" font="1"> </text>
<text top="443" left="751" width="58" height="15" font="1">One pt that </text>
<text top="458" left="751" width="45" height="15" font="1">received </text>
<text top="474" left="751" width="41" height="15" font="1">calcium </text>
<text top="489" left="751" width="81" height="15" font="1">channel blocker </text>
<text top="505" left="751" width="42" height="15" font="1">became </text>
<text top="520" left="751" width="62" height="15" font="1">hypotensive </text>
<text top="412" left="845" width="22" height="15" font="1">N/A </text>
<text top="412" left="926" width="84" height="15" font="1">102 pts received </text>
<text top="427" left="926" width="121" height="15" font="1">calcium channel blocker </text>
<text top="443" left="926" width="111" height="15" font="1">and 98% converted to </text>
<text top="458" left="926" width="79" height="15" font="1">SR, 104 pts got </text>
<text top="474" left="926" width="114" height="15" font="1">adenosine, conversion </text>
<text top="489" left="926" width="108" height="15" font="1">was 86.5% (p=0.002) </text>
<text top="505" left="926" width="108" height="15" font="1">BP dropped by -13.0/-</text>
<text top="520" left="926" width="117" height="15" font="1">8.1 verapamil and -7.0/-</text>
<text top="535" left="926" width="84" height="15" font="1">9.4 for diltiazem. </text>
<text top="551" left="926" width="3" height="15" font="1"> </text>
<text top="567" left="926" width="119" height="15" font="1">Recurrences w/in 2 h: 1 </text>
<text top="582" left="926" width="111" height="15" font="1">pt w/ diltiazem, 2 from </text>
<text top="597" left="926" width="86" height="15" font="1">adenosine group </text>
<text top="613" left="926" width="3" height="15" font="1"> </text>
<text top="628" left="926" width="103" height="15" font="1">One pt that received </text>
<text top="644" left="926" width="121" height="15" font="1">calcium channel blocker </text>
<text top="659" left="926" width="105" height="15" font="1">became hypotensive </text>
<text top="412" left="1063" width="68" height="15" font="1">Slow infusion </text>
<text top="427" left="1063" width="63" height="15" font="1">of verapamil </text>
<text top="443" left="1063" width="60" height="15" font="1">or diltiazem </text>
<text top="458" left="1063" width="67" height="15" font="1">was effective </text>
<text top="474" left="1063" width="44" height="15" font="1">and well </text>
<text top="489" left="1063" width="70" height="15" font="1">tolerated. Fall </text>
<text top="505" left="1063" width="29" height="15" font="1">in BP </text>
<text top="520" left="1063" width="49" height="15" font="1">transient. </text>
<text top="535" left="1063" width="3" height="15" font="1"> </text>
<text top="551" left="1063" width="65" height="15" font="1">Unclear how </text>
<text top="567" left="1063" width="48" height="15" font="1">many pts </text>
<text top="582" left="1063" width="27" height="15" font="1">were </text>
<text top="597" left="1063" width="73" height="15" font="1">excluded from </text>
<text top="613" left="1063" width="67" height="15" font="1">analysis as a </text>
<text top="628" left="1063" width="47" height="15" font="1">non-SVT </text>
<text top="644" left="1063" width="60" height="15" font="1">rhythm was </text>
<text top="659" left="1063" width="72" height="15" font="1">then identified </text>
<text top="675" left="1063" width="71" height="15" font="1">– how did this </text>
<text top="690" left="1063" width="58" height="15" font="1">cohort fair? </text>
<text top="707" left="54" width="31" height="15" font="1">Smith </text>
<text top="722" left="54" width="31" height="15" font="1">2013  </text>
<text top="738" left="54" width="23" height="15" font="1">(39) </text>
<text top="753" left="54" width="43" height="15" font="8">2354357</text>
<text top="769" left="54" width="6" height="15" font="8">8</text>
<text top="769" left="60" width="3" height="15" font="1"> </text>
<text top="707" left="116" width="39" height="15" font="1">Determi</text>
<text top="722" left="116" width="15" height="15" font="1">ne </text>
<text top="738" left="116" width="41" height="15" font="1">effective</text>
<text top="753" left="116" width="39" height="15" font="1">ness of </text>
<text top="769" left="116" width="32" height="15" font="1">VM to </text>
<text top="784" left="116" width="40" height="15" font="1">terminat</text>
<text top="707" left="177" width="39" height="15" font="1">Review </text>
<text top="722" left="177" width="21" height="15" font="1">of 3 </text>
<text top="738" left="177" width="47" height="15" font="1">RCTs: 1) </text>
<text top="753" left="177" width="45" height="15" font="1">Mehta D </text>
<text top="769" left="177" width="28" height="15" font="1">1988 </text>
<text top="784" left="177" width="39" height="15" font="1">(40); 2) </text>
<text top="707" left="238" width="197" height="15" font="1">N/A N/A N/A </text>
<text top="707" left="541" width="22" height="15" font="1">N/A </text>
<text top="707" left="663" width="65" height="15" font="1">Reversion to </text>
<text top="722" left="663" width="18" height="15" font="1">SR </text>
<text top="707" left="751" width="77" height="15" font="1">Cardiovascular </text>
<text top="722" left="751" width="68" height="15" font="1">effects of VM </text>
<text top="738" left="751" width="69" height="15" font="1">(hypotension, </text>
<text top="753" left="751" width="68" height="15" font="1">bradycardia), </text>
<text top="769" left="751" width="70" height="15" font="1">mortality from </text>
<text top="784" left="751" width="74" height="15" font="1">VM, frequency </text>
<text top="707" left="845" width="49" height="15" font="1">Failure to </text>
<text top="722" left="845" width="62" height="15" font="1">revert to SR </text>
<text top="738" left="845" width="59" height="15" font="1">followed by </text>
<text top="753" left="845" width="28" height="15" font="1">other </text>
<text top="769" left="845" width="52" height="15" font="1">therapies  </text>
<text top="707" left="926" width="119" height="15" font="1">Reversion success was </text>
<text top="722" left="926" width="121" height="15" font="1">54.3% (19/35) in Mehta, </text>
<text top="738" left="926" width="116" height="15" font="1">45.9% (61/133) in Wen </text>
<text top="753" left="926" width="89" height="15" font="1">and 19.4% in Lim </text>
<text top="769" left="926" width="38" height="15" font="1">(12/62) </text>
<text top="784" left="926" width="3" height="15" font="1"> </text>
<text top="707" left="1063" width="58" height="15" font="1">Speculated </text>
<text top="722" left="1063" width="73" height="15" font="1">that difference </text>
<text top="738" left="1063" width="68" height="15" font="1">in conversion </text>
<text top="753" left="1063" width="67" height="15" font="1">rates may be </text>
<text top="769" left="1063" width="70" height="15" font="1">due to setting </text>
<text top="784" left="1063" width="57" height="15" font="1">(ED vs. EP </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">17 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="34" height="15" font="1">e SVT </text>
<text top="55" left="177" width="44" height="15" font="1">Wen ZC </text>
<text top="70" left="177" width="28" height="15" font="1">1998 </text>
<text top="86" left="177" width="39" height="15" font="1">(41); 3) </text>
<text top="101" left="177" width="21" height="15" font="1">Lim </text>
<text top="117" left="177" width="28" height="15" font="1">1998 </text>
<text top="132" left="177" width="26" height="15" font="1">(34). </text>
<text top="147" left="177" width="3" height="15" font="1"> </text>
<text top="163" left="177" width="34" height="15" font="1">Mehta </text>
<text top="178" left="177" width="47" height="15" font="1">and Wen </text>
<text top="194" left="177" width="38" height="15" font="1">studies </text>
<text top="210" left="177" width="39" height="15" font="1">were in </text>
<text top="225" left="177" width="27" height="15" font="1">a lab </text>
<text top="240" left="177" width="39" height="15" font="1">setting, </text>
<text top="256" left="177" width="33" height="15" font="1">Lim in </text>
<text top="271" left="177" width="18" height="15" font="1">ED </text>
<text top="287" left="177" width="36" height="15" font="1">setting </text>
<text top="55" left="751" width="75" height="15" font="1">and severity of </text>
<text top="70" left="751" width="78" height="15" font="1">adverse events </text>
<text top="86" left="751" width="45" height="15" font="1">from VM </text>
<text top="55" left="926" width="117" height="15" font="1">Heterogeneity between </text>
<text top="70" left="926" width="102" height="15" font="1">studies precluded  a </text>
<text top="86" left="926" width="116" height="15" font="1">meta analysis; adverse </text>
<text top="101" left="926" width="98" height="15" font="1">effects not reported </text>
<text top="55" left="1063" width="22" height="15" font="1">lab) </text>
<text top="303" left="54" width="1075" height="15" font="1">AAD indicates antiarrhythmic drug;  AE, adverse event; AF, atrial fibrillation; AP, accessory pathway; AT, atrial tachycardia; AV, atrioventricular; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular </text>
<text top="319" left="54" width="1056" height="15" font="1">reentrant tachycardia; bid, two times per day; bpm, beats per minute; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CSM, carotid </text>
<text top="334" left="54" width="1063" height="15" font="1">sinus massage; CVA, cerebral vascular accident; c/w, consistent with; ECG, electrocardiogram; ED, emergency department; EP, electrophysiological; f/u, follow up; HF, heart failure; h/o, history of; HR, heart rate; ICU, </text>
<text top="350" left="54" width="1069" height="15" font="1">intensive care unit; ITT, insulin tolerance test; IV, intravenous; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, not applicable; NS, not significant; NSR, normal sinus rhythm; NYHA, New York Heart </text>
<text top="365" left="54" width="1011" height="15" font="1">Association; PAF, paroxysmal atrial fibrillation; PSVT, paroxysmal supraventricular tachycardia; pt, patient; RCT, randomized controlled trial; RFA, radiofrequency ablation; RR, relative risk; SDC, serum drug </text>
<text top="381" left="54" width="1047" height="15" font="1">concentration; SHD, structural heart disease; SR, sinus rhythm; SSS, sick sinus syndrome; SVT, supraventricular tachycardia; sx, symptom; TIA, transient ischemic attack; tid, three times per day; tx, treatment; UA, </text>
<text top="396" left="54" width="826" height="15" font="1">unstable angina; VHD, valvular heart disease; VM, Valsalva maneuver; VT, ventricular tachycardia; w/, with; w/o, without; and WPW, Wolff-Parkinson-White syndrome.   </text>
<text top="412" left="54" width="3" height="15" font="1"> </text>
<text top="437" left="54" width="143" height="18" font="3"><b>Data Supplement 3. </b></text>
<text top="437" left="197" width="862" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Principles of Acute and Chronic Therapy – Section 2.4 </b></text>
<text top="437" left="1059" width="4" height="18" font="3"><b> </b></text>
<text top="456" left="83" width="38" height="17" font="5"><b>Study </b></text>
<text top="473" left="58" width="88" height="17" font="5"><b>Name, Author, </b></text>
<text top="490" left="87" width="30" height="17" font="5"><b>Year </b></text>
<text top="456" left="203" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="473" left="217" width="44" height="17" font="5"><b>Design </b></text>
<text top="456" left="338" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="456" left="437" width="119" height="17" font="5"><b>Inclusion/Exclusion </b></text>
<text top="473" left="473" width="46" height="17" font="5"><b>Criteria </b></text>
<text top="456" left="637" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="456" left="829" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="456" left="980" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="508" left="54" width="47" height="15" font="1">Waxman </text>
<text top="524" left="54" width="31" height="15" font="1">1980  </text>
<text top="539" left="54" width="23" height="15" font="1">(42) </text>
<text top="555" left="54" width="43" height="15" font="8">7416025</text>
<text top="555" left="97" width="3" height="15" font="1"> </text>
<text top="508" left="163" width="147" height="15" font="1">Prospective cohort consisting </text>
<text top="524" left="163" width="146" height="15" font="1">of 33 pts in ED (group A) and </text>
<text top="539" left="163" width="152" height="15" font="1">35 pts during EP study (Group </text>
<text top="555" left="163" width="146" height="15" font="1">B) to assess SVT termination </text>
<text top="570" left="163" width="151" height="15" font="1">using a protocol of successive </text>
<text top="586" left="163" width="143" height="15" font="1">vagal interventions until SVT </text>
<text top="601" left="163" width="140" height="15" font="1">terminated: a) L/R CSP (1-5 </text>
<text top="617" left="163" width="152" height="15" font="1">sec) b) multiple unilateral CSP </text>
<text top="632" left="163" width="152" height="15" font="1">c) edrophonium IV followed by </text>
<text top="648" left="163" width="137" height="15" font="1">CSP d)Valsalva (10 sec) e) </text>
<text top="663" left="163" width="140" height="15" font="1">edrophonium IV followed by </text>
<text top="679" left="163" width="130" height="15" font="1">Valsalva f) phenylephrine  </text>
<text top="694" left="163" width="3" height="15" font="1"> </text>
<text top="508" left="329" width="30" height="15" font="1">N=68 </text>
<text top="524" left="329" width="64" height="15" font="1">(33 Group A-</text>
<text top="539" left="329" width="71" height="15" font="1">ED, 38 Group </text>
<text top="555" left="329" width="65" height="15" font="1">B- EP study) </text>
<text top="508" left="426" width="114" height="15" font="1">SVT (AVNRT or AVRT </text>
<text top="524" left="426" width="133" height="15" font="1">(orthodromic). Overt WPW </text>
<text top="539" left="426" width="47" height="15" font="1">included. </text>
<text top="508" left="579" width="92" height="15" font="1">Termination to SR </text>
<text top="508" left="813" width="107" height="15" font="1">In all 68 pts SVT was </text>
<text top="524" left="813" width="129" height="15" font="1">terminated. 6 pts required </text>
<text top="539" left="813" width="76" height="15" font="1">phenylephrine. </text>
<text top="555" left="813" width="3" height="15" font="1"> </text>
<text top="570" left="813" width="116" height="15" font="1">No complications. Post </text>
<text top="586" left="813" width="119" height="15" font="1">termination pauses was </text>
<text top="601" left="813" width="68" height="15" font="1">1683± 66 ms </text>
<text top="617" left="813" width="3" height="15" font="1"> </text>
<text top="632" left="813" width="130" height="15" font="1">In group B (EP study) pts, </text>
<text top="648" left="813" width="100" height="15" font="1">repeated trials were </text>
<text top="663" left="813" width="128" height="15" font="1">performed w/ overall 92% </text>
<text top="679" left="813" width="116" height="15" font="1">success in termination. </text>
<text top="508" left="959" width="161" height="15" font="1">Data not broken down by group. </text>
<text top="524" left="959" width="173" height="15" font="1">However, text describes that 30/33 </text>
<text top="539" left="959" width="164" height="15" font="1">group A pts terminated SVT by a </text>
<text top="555" left="959" width="168" height="15" font="1">maneuver up to and including (e). </text>
<text top="710" left="54" width="56" height="15" font="1">Rankin AC </text>
<text top="726" left="54" width="31" height="15" font="1">1989  </text>
<text top="741" left="54" width="23" height="15" font="1">(43) </text>
<text top="757" left="54" width="43" height="15" font="8">2789911</text>
<text top="757" left="97" width="3" height="15" font="1"> </text>
<text top="710" left="163" width="103" height="15" font="1">Cohort administered </text>
<text top="726" left="163" width="101" height="15" font="1">adenosine for either </text>
<text top="741" left="163" width="139" height="15" font="1">spontaneous tachycardia or </text>
<text top="757" left="163" width="42" height="15" font="1">induced </text>
<text top="710" left="329" width="73" height="15" font="1">N=64 of which </text>
<text top="726" left="329" width="55" height="15" font="1">54 pts had </text>
<text top="741" left="329" width="66" height="15" font="1">spontaneous </text>
<text top="757" left="329" width="81" height="15" font="1">tachycardia and </text>
<text top="772" left="329" width="72" height="15" font="1">15 induced by </text>
<text top="788" left="329" width="66" height="15" font="1">programmed </text>
<text top="710" left="426" width="132" height="15" font="1">Spontaneous and induced </text>
<text top="726" left="426" width="129" height="15" font="1">tachycardia in 16-79 y old </text>
<text top="741" left="426" width="18" height="15" font="1">pts </text>
<text top="710" left="579" width="220" height="15" font="1">Termination to SR and diagnostic efficacy to </text>
<text top="726" left="579" width="156" height="15" font="1">identify atrial flutter or AT or VT </text>
<text top="710" left="813" width="126" height="15" font="1">Adenosine terminated 46 </text>
<text top="726" left="813" width="124" height="15" font="1">of 48 episodes of narrow </text>
<text top="741" left="813" width="74" height="15" font="1">complex tachy </text>
<text top="757" left="813" width="3" height="15" font="1"> </text>
<text top="772" left="813" width="96" height="15" font="1">Other tachycardias </text>
<text top="788" left="813" width="108" height="15" font="1">treated included wide </text>
<text top="710" left="959" width="140" height="15" font="1">Adenosine effective for both </text>
<text top="726" left="959" width="164" height="15" font="1">diagnosis and treatment. Of note </text>
<text top="741" left="959" width="154" height="15" font="1">administration in wide complex </text>
<text top="757" left="959" width="138" height="15" font="1">tachycardia was safe. Early </text>
<text top="772" left="959" width="173" height="15" font="1">recurrences of arrhythmias seen in </text>
<text top="788" left="959" width="28" height="15" font="1">35%. </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">18 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="329" width="56" height="15" font="1">stimulation </text>
<text top="55" left="813" width="88" height="15" font="1">complex (24 pts), </text>
<text top="70" left="813" width="3" height="15" font="1"> </text>
<text top="86" left="813" width="106" height="15" font="1">Side effects: dysnea, </text>
<text top="101" left="813" width="101" height="15" font="1">chest pain, flushing, </text>
<text top="117" left="813" width="114" height="15" font="1">headache. No adverse </text>
<text top="132" left="813" width="108" height="15" font="1">hemodynamic effects </text>
<text top="147" left="813" width="3" height="15" font="1"> </text>
<text top="163" left="813" width="116" height="15" font="1">High rate of recurrence </text>
<text top="178" left="813" width="26" height="15" font="1">(1/3) </text>
<text top="195" left="54" width="35" height="15" font="1">Cairns </text>
<text top="210" left="54" width="31" height="15" font="1">1991  </text>
<text top="226" left="54" width="23" height="15" font="1">(44) </text>
<text top="241" left="54" width="46" height="15" font="8">2064090 </text>
<text top="195" left="163" width="105" height="15" font="1">Observational cohort </text>
<text top="210" left="163" width="3" height="15" font="1"> </text>
<text top="226" left="163" width="137" height="15" font="1">Adenosine to convert SR in </text>
<text top="241" left="163" width="54" height="15" font="1">ED setting </text>
<text top="195" left="329" width="30" height="15" font="1">N=23 </text>
<text top="195" left="426" width="132" height="15" font="1">16 y or older presenting to </text>
<text top="210" left="426" width="136" height="15" font="1">ED in an 8 mo study period </text>
<text top="226" left="426" width="114" height="15" font="1">w/ sustained SVT, rate </text>
<text top="241" left="426" width="53" height="15" font="1">&gt;140 bpm </text>
<text top="257" left="426" width="3" height="15" font="1"> </text>
<text top="272" left="426" width="119" height="15" font="1">Exclusion: severe CHF, </text>
<text top="288" left="426" width="130" height="15" font="1">unstable angina, acute MI </text>
<text top="303" left="426" width="117" height="15" font="1">by ECG, hemodynamic </text>
<text top="319" left="426" width="115" height="15" font="1">compromise. Excluded </text>
<text top="334" left="426" width="119" height="15" font="1">sinus tachycardia, atrial </text>
<text top="350" left="426" width="127" height="15" font="1">flutter, AF, QRS &gt;140 ms </text>
<text top="195" left="579" width="90" height="15" font="1">Conversion to SR </text>
<text top="195" left="813" width="106" height="15" font="1">2 pts after adenosine </text>
<text top="210" left="813" width="116" height="15" font="1">identified as not having </text>
<text top="226" left="813" width="89" height="15" font="1">SVT (a fluter, VT) </text>
<text top="241" left="813" width="127" height="15" font="1">24 episodes of SVT in 21 </text>
<text top="257" left="813" width="87" height="15" font="1">pts of which 96% </text>
<text top="272" left="813" width="120" height="15" font="1">converted w/ adenosine </text>
<text top="288" left="813" width="113" height="15" font="1">(mean dose 10±6 mg) </text>
<text top="303" left="813" width="118" height="15" font="1">SVT recurred in 57% of </text>
<text top="319" left="813" width="97" height="15" font="1">episodes and other </text>
<text top="334" left="813" width="128" height="15" font="1">antiarrhythmic drugs then </text>
<text top="350" left="813" width="109" height="15" font="1">used to maintain SR.  </text>
<text top="365" left="813" width="3" height="15" font="1"> </text>
<text top="381" left="813" width="124" height="15" font="1">Adverse effects: 3 pts w/ </text>
<text top="396" left="813" width="105" height="15" font="1">chest pain, one pt w/ </text>
<text top="412" left="813" width="121" height="15" font="1">dyspnea but no adverse </text>
<text top="427" left="813" width="46" height="15" font="1">outcome </text>
<text top="195" left="959" width="143" height="15" font="1">Adenosine highly effective in </text>
<text top="210" left="959" width="156" height="15" font="1">converted SVT but recurrences </text>
<text top="226" left="959" width="44" height="15" font="1">frequent </text>
<text top="443" left="54" width="44" height="15" font="1">McCabe </text>
<text top="459" left="54" width="31" height="15" font="1">1992  </text>
<text top="474" left="54" width="23" height="15" font="1">(45) </text>
<text top="490" left="54" width="43" height="15" font="8">1554170</text>
<text top="490" left="97" width="3" height="15" font="1"> </text>
<text top="443" left="163" width="95" height="15" font="1">Prospective cohort </text>
<text top="459" left="163" width="3" height="15" font="1"> </text>
<text top="474" left="163" width="148" height="15" font="1">Adenosine 6 mg , then 12 mg </text>
<text top="490" left="163" width="92" height="15" font="1">if ineffective, and 3</text>
<text top="490" left="255" width="7" height="10" font="10">rd</text>
<text top="490" left="262" width="42" height="15" font="1"> dose of </text>
<text top="505" left="163" width="115" height="15" font="1">12 mg if still ineffective </text>
<text top="443" left="329" width="33" height="15" font="1">N=37, </text>
<text top="459" left="329" width="57" height="15" font="1">prehospital </text>
<text top="474" left="329" width="36" height="15" font="1">setting </text>
<text top="443" left="426" width="106" height="15" font="1">18 y or older, w/ SVT </text>
<text top="459" left="426" width="122" height="15" font="1">assessed by paramedic, </text>
<text top="474" left="426" width="120" height="15" font="1">QRS &lt;120 ms, rate 150-</text>
<text top="490" left="426" width="46" height="15" font="1">250 bpm </text>
<text top="505" left="426" width="3" height="15" font="1"> </text>
<text top="521" left="426" width="132" height="15" font="1">Exclusion: hypersensitivity </text>
<text top="536" left="426" width="136" height="15" font="1">to adenosine or in extremis </text>
<text top="443" left="579" width="90" height="15" font="1">Conversion to SR </text>
<text top="443" left="813" width="117" height="15" font="1">26/37 in SVT (non-SVT </text>
<text top="459" left="813" width="108" height="15" font="1">rhythms were 5 AF, 4 </text>
<text top="474" left="813" width="89" height="15" font="1">sinus tach, 2 VT). </text>
<text top="490" left="813" width="127" height="15" font="1">23/26 (88%) converted to </text>
<text top="505" left="813" width="18" height="15" font="1">SR </text>
<text top="521" left="813" width="3" height="15" font="1"> </text>
<text top="536" left="813" width="108" height="15" font="1">11 pts hypotensive at </text>
<text top="552" left="813" width="122" height="15" font="1">presentation in SVT and </text>
<text top="567" left="813" width="103" height="15" font="1">became stable upon </text>
<text top="583" left="813" width="57" height="15" font="1">conversion </text>
<text top="598" left="813" width="3" height="15" font="1"> </text>
<text top="614" left="813" width="114" height="15" font="1">9 pts had WCT and no </text>
<text top="629" left="813" width="72" height="15" font="1">hemodynamic </text>
<text top="645" left="813" width="132" height="15" font="1">compromise w/ adenosine </text>
<text top="443" left="959" width="123" height="15" font="1">Small prospective series </text>
<text top="661" left="54" width="47" height="15" font="1">Gausche </text>
<text top="676" left="54" width="31" height="15" font="1">1994  </text>
<text top="692" left="54" width="23" height="15" font="1">(46) </text>
<text top="707" left="54" width="43" height="15" font="8">8037382</text>
<text top="707" left="97" width="3" height="15" font="1"> </text>
<text top="661" left="163" width="95" height="15" font="1">Prospective cohort </text>
<text top="676" left="163" width="3" height="15" font="1"> </text>
<text top="692" left="163" width="132" height="15" font="1">Adenosine 12 mg as initial </text>
<text top="707" left="163" width="131" height="15" font="1">dose, followed in  2 min of </text>
<text top="723" left="163" width="99" height="15" font="1">another 12 mg if no </text>
<text top="738" left="163" width="57" height="15" font="1">conversion </text>
<text top="661" left="329" width="75" height="15" font="1">N=129, 106 w/ </text>
<text top="676" left="329" width="81" height="15" font="1">before and after </text>
<text top="692" left="329" width="30" height="15" font="1">strips </text>
<text top="707" left="329" width="3" height="15" font="1"> </text>
<text top="723" left="329" width="58" height="15" font="1">Prehospital </text>
<text top="738" left="329" width="36" height="15" font="1">setting </text>
<text top="661" left="426" width="106" height="15" font="1">18 y or older, w/ SVT </text>
<text top="676" left="426" width="122" height="15" font="1">assessed by paramedic. </text>
<text top="692" left="426" width="138" height="15" font="1">QRS &lt;120 msec, rate &gt;140 </text>
<text top="707" left="426" width="28" height="15" font="1">bpm. </text>
<text top="723" left="426" width="3" height="15" font="1"> </text>
<text top="738" left="426" width="111" height="15" font="1">Exclusion: pregnancy, </text>
<text top="754" left="426" width="91" height="15" font="1">hypersensitivity to </text>
<text top="769" left="426" width="121" height="15" font="1">adenosine, sbp &lt;80 mm </text>
<text top="785" left="426" width="127" height="15" font="1">Hg, or on carbamazepine </text>
<text top="661" left="579" width="90" height="15" font="1">Conversion to SR </text>
<text top="661" left="813" width="116" height="15" font="1">84/106 had SVT (AF in </text>
<text top="676" left="813" width="129" height="15" font="1">13, ST in 5, atrial flutter in </text>
<text top="692" left="813" width="108" height="15" font="1">2, and VT in 2 cases) </text>
<text top="707" left="813" width="3" height="15" font="1"> </text>
<text top="723" left="813" width="113" height="15" font="1">71/84 converted to SR </text>
<text top="738" left="813" width="103" height="15" font="1">(85%) and 4 needed </text>
<text top="754" left="813" width="100" height="15" font="1">second 12 mg dose </text>
<text top="769" left="813" width="3" height="15" font="1"> </text>
<text top="785" left="813" width="115" height="15" font="1">Adverse effects:  chest </text>
<text top="661" left="959" width="157" height="15" font="1">Adenosine safe and effective in </text>
<text top="676" left="959" width="96" height="15" font="1">prehospital setting. </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">19 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="426" width="79" height="15" font="1">or dipyridamole </text>
<text top="55" left="813" width="111" height="15" font="1">pain (12), flushing (3), </text>
<text top="70" left="813" width="117" height="15" font="1">shortness of breath (2), </text>
<text top="86" left="813" width="117" height="15" font="1">nausea (1), anxiety (1), </text>
<text top="101" left="813" width="120" height="15" font="1">dizziness (1), headache </text>
<text top="117" left="813" width="17" height="15" font="1">(1) </text>
<text top="133" left="54" width="42" height="15" font="1">Madsen </text>
<text top="148" left="54" width="31" height="15" font="1">1995  </text>
<text top="164" left="54" width="23" height="15" font="1">(47) </text>
<text top="179" left="54" width="43" height="15" font="8">7741343</text>
<text top="179" left="97" width="3" height="15" font="1"> </text>
<text top="133" left="163" width="144" height="15" font="1">Nonrandomized, prospective </text>
<text top="148" left="163" width="109" height="15" font="1">12 mo chart review of </text>
<text top="164" left="163" width="141" height="15" font="1">adenosine w/ comparison to </text>
<text top="179" left="163" width="147" height="15" font="1">historical cohort that received </text>
<text top="195" left="163" width="51" height="15" font="1">verapamil </text>
<text top="210" left="163" width="3" height="15" font="1"> </text>
<text top="226" left="163" width="132" height="15" font="1">Pre-hospital setting (EMS) </text>
<text top="241" left="163" width="3" height="15" font="1"> </text>
<text top="257" left="163" width="148" height="15" font="1">Verapamil up to 2 IV doses of </text>
<text top="272" left="163" width="139" height="15" font="1">2.5 mg and 5 mg, or up to 2 </text>
<text top="288" left="163" width="133" height="15" font="1">doses of adenosine , 6 mg </text>
<text top="303" left="163" width="55" height="15" font="1">and 12 mg </text>
<text top="133" left="329" width="30" height="15" font="1">N=73 </text>
<text top="133" left="426" width="114" height="15" font="1">Age &gt;14 w/ paramedic </text>
<text top="148" left="426" width="111" height="15" font="1">assessment of narrow </text>
<text top="164" left="426" width="135" height="15" font="1">complex tachycardia (QRS </text>
<text top="179" left="426" width="125" height="15" font="1">&lt;120, rate 160-240 bpm) </text>
<text top="195" left="426" width="3" height="15" font="1"> </text>
<text top="210" left="426" width="133" height="15" font="1">3/1990-2/1991 (verapamil) </text>
<text top="226" left="426" width="96" height="15" font="1">and 3/1991-2/1992 </text>
<text top="241" left="426" width="62" height="15" font="1">(adenosine) </text>
<text top="257" left="426" width="3" height="15" font="1"> </text>
<text top="272" left="426" width="130" height="15" font="1">Pts had to be regarded as </text>
<text top="288" left="426" width="130" height="15" font="1">stable and first underwent </text>
<text top="303" left="426" width="82" height="15" font="1">Valsalva prior to </text>
<text top="319" left="426" width="135" height="15" font="1">administration of verapamil </text>
<text top="334" left="426" width="109" height="15" font="1">or adenosine by base </text>
<text top="350" left="426" width="127" height="15" font="1">hospital physician’s order </text>
<text top="133" left="579" width="90" height="15" font="1">Conversion to SR </text>
<text top="148" left="579" width="3" height="15" font="1"> </text>
<text top="164" left="579" width="191" height="15" font="1">Also incidentally analyzed rate of ECG </text>
<text top="179" left="579" width="217" height="15" font="1">misinterpretation by EMS and base hospital </text>
<text top="195" left="579" width="49" height="15" font="1">physician </text>
<text top="133" left="813" width="131" height="15" font="1">Verapamil given to 17 pts, </text>
<text top="148" left="813" width="129" height="15" font="1">of which 6 on subsequent </text>
<text top="164" left="813" width="130" height="15" font="1">review by cardiologist had </text>
<text top="179" left="813" width="122" height="15" font="1">AF, attach or sinus tach. </text>
<text top="195" left="813" width="125" height="15" font="1">7/11 pts converted to SR </text>
<text top="210" left="813" width="108" height="15" font="1">(64%). Side effects in </text>
<text top="226" left="813" width="112" height="15" font="1">5/17 pts (hypotension, </text>
<text top="241" left="813" width="71" height="15" font="1">NSVT, PACs) </text>
<text top="257" left="813" width="3" height="15" font="1"> </text>
<text top="272" left="813" width="116" height="15" font="1">Adenosine: given to 64 </text>
<text top="288" left="813" width="113" height="15" font="1">pts, strips available for </text>
<text top="303" left="813" width="132" height="15" font="1">review in 56 pts. 24 pts on </text>
<text top="319" left="813" width="110" height="15" font="1">subsequent review by </text>
<text top="334" left="813" width="101" height="15" font="1">cardiologist had AF, </text>
<text top="350" left="813" width="119" height="15" font="1">attach, sinus tach, atrial </text>
<text top="365" left="813" width="130" height="15" font="1">flutter or VT. Of remaining </text>
<text top="381" left="813" width="116" height="15" font="1">32 w/ true SVT that got </text>
<text top="396" left="813" width="82" height="15" font="1">adenosine, 78% </text>
<text top="412" left="813" width="111" height="15" font="1">converted to SR. Side </text>
<text top="427" left="813" width="125" height="15" font="1">effects: ventricular ectoic </text>
<text top="443" left="813" width="46" height="15" font="1">activity, 1</text>
<text top="443" left="859" width="6" height="10" font="10">st</text>
<text top="443" left="865" width="22" height="15" font="1"> or 2</text>
<text top="443" left="887" width="8" height="10" font="10">nd</text>
<text top="443" left="896" width="41" height="15" font="1"> degree </text>
<text top="458" left="813" width="99" height="15" font="1">AV block of &lt;1 min, </text>
<text top="474" left="813" width="129" height="15" font="1">asystole (2-10 sec), chest </text>
<text top="489" left="813" width="71" height="15" font="1">pain, flushing, </text>
<text top="505" left="813" width="79" height="15" font="1">bronchospasm) </text>
<text top="520" left="813" width="3" height="15" font="1"> </text>
<text top="535" left="813" width="123" height="15" font="1">Overall misinterpretation </text>
<text top="551" left="813" width="116" height="15" font="1">of the ECG occurred in </text>
<text top="567" left="813" width="49" height="15" font="1">30/73 pts </text>
<text top="582" left="813" width="81" height="15" font="1">No difference in </text>
<text top="597" left="813" width="129" height="15" font="1">conversion rates between </text>
<text top="613" left="813" width="127" height="15" font="1">verapamil and adenosine </text>
<text top="133" left="959" width="158" height="15" font="1">Misinterpretation of the ECG by </text>
<text top="148" left="959" width="150" height="15" font="1">paramedics and base hospital </text>
<text top="164" left="959" width="121" height="15" font="1">physician was common. </text>
<text top="179" left="959" width="3" height="15" font="1"> </text>
<text top="195" left="959" width="177" height="15" font="1">But serious adverse events unlikely </text>
<text top="210" left="959" width="141" height="15" font="1">– no reported hemodynamic </text>
<text top="226" left="959" width="132" height="15" font="1">collapse from intervention. </text>
<text top="241" left="959" width="3" height="15" font="1"> </text>
<text top="257" left="959" width="172" height="15" font="1">Conversion to SR by adenosine or </text>
<text top="272" left="959" width="150" height="15" font="1">verapamil similar (about 70%) </text>
<text top="629" left="54" width="32" height="15" font="1">Brady </text>
<text top="645" left="54" width="28" height="15" font="1">1996 </text>
<text top="660" left="54" width="23" height="15" font="1">(48) </text>
<text top="676" left="54" width="46" height="15" font="8">8727628 </text>
<text top="691" left="54" width="3" height="15" font="1"> </text>
<text top="629" left="163" width="144" height="15" font="1">Nonrandomized, prospective </text>
<text top="645" left="163" width="121" height="15" font="1">cohort w/ comparison to </text>
<text top="660" left="163" width="81" height="15" font="1">historical cohort </text>
<text top="676" left="163" width="3" height="15" font="1"> </text>
<text top="691" left="163" width="129" height="15" font="1">Comparison of adenosine </text>
<text top="707" left="163" width="113" height="15" font="1">(prospective cohort) to </text>
<text top="722" left="163" width="139" height="15" font="1">verapamil (historical cohort) </text>
<text top="629" left="329" width="39" height="15" font="1">N=211  </text>
<text top="645" left="329" width="3" height="15" font="1"> </text>
<text top="629" left="426" width="132" height="15" font="1">Inclusion criteria: any age, </text>
<text top="645" left="426" width="124" height="15" font="1">narrow QRS tachycardia </text>
<text top="660" left="426" width="118" height="15" font="1">(120-300 bpm), or wide </text>
<text top="676" left="426" width="120" height="15" font="1">complex (120-300 bpm) </text>
<text top="691" left="426" width="132" height="15" font="1">who had received 2 doses </text>
<text top="707" left="426" width="107" height="15" font="1">of lidocaine, palpable </text>
<text top="722" left="426" width="90" height="15" font="1">pulse, IV in place. </text>
<text top="738" left="426" width="3" height="15" font="1"> </text>
<text top="753" left="426" width="133" height="15" font="1">Exclusion: drug sensitivity, </text>
<text top="769" left="426" width="111" height="15" font="1">cardiac arrest, trauma </text>
<text top="784" left="426" width="118" height="15" font="1">etiology, for adenosine: </text>
<text top="629" left="579" width="90" height="15" font="1">Conversion to SR </text>
<text top="629" left="813" width="126" height="15" font="1">Adenosine: 87 of 105 pts </text>
<text top="645" left="813" width="98" height="15" font="1">received drug, 69% </text>
<text top="660" left="813" width="83" height="15" font="1">converted to SR </text>
<text top="676" left="813" width="3" height="15" font="1"> </text>
<text top="691" left="813" width="123" height="15" font="1">Verapamil: 52 of 106 pts </text>
<text top="707" left="813" width="98" height="15" font="1">received drug, 88% </text>
<text top="722" left="813" width="121" height="15" font="1">converted to SR (p=0.1) </text>
<text top="738" left="813" width="3" height="15" font="1"> </text>
<text top="753" left="813" width="82" height="15" font="1">Adverse events: </text>
<text top="769" left="813" width="118" height="15" font="1">adenosine: 4 pts (chest </text>
<text top="784" left="813" width="127" height="15" font="1">pain, dyspnea, prolonged </text>
<text top="629" left="959" width="153" height="15" font="1">Adenosine and verapamil both </text>
<text top="645" left="959" width="176" height="15" font="1">effective in out of hospital setting to </text>
<text top="660" left="959" width="70" height="15" font="1">convert SVT.  </text>
<text top="676" left="959" width="3" height="15" font="1"> </text>
<text top="691" left="959" width="146" height="15" font="1">Rhythms were still commonly </text>
<text top="707" left="959" width="106" height="15" font="1">misidentified by EMS </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="16" size="11" family="Times" color="#000000"/>
<text top="814" left="1120" width="17" height="17" font="0">20 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="426" width="119" height="15" font="1">prior cardiac transplant, </text>
<text top="70" left="426" width="64" height="15" font="1">treatment w/ </text>
<text top="86" left="426" width="92" height="15" font="1">carbamazepine or </text>
<text top="101" left="426" width="66" height="15" font="1">dipyridamole </text>
<text top="117" left="426" width="3" height="15" font="1"> </text>
<text top="132" left="426" width="121" height="15" font="1">Exclusion for verapamil: </text>
<text top="147" left="426" width="101" height="15" font="1">sbp &lt;90, pulmonary </text>
<text top="163" left="426" width="119" height="15" font="1">edema, LV dysfunction, </text>
<text top="178" left="426" width="74" height="15" font="1">age &lt;2 y, WCT</text>
<text top="179" left="500" width="2" height="10" font="10"> </text>
<text top="55" left="813" width="55" height="15" font="1">brady, VT) </text>
<text top="70" left="813" width="3" height="15" font="1"> </text>
<text top="86" left="813" width="83" height="15" font="1">Verapamil: 4 pts </text>
<text top="101" left="813" width="129" height="15" font="1">(hypotension, VT, VF) – 2 </text>
<text top="117" left="813" width="84" height="15" font="1">pts had received </text>
<text top="132" left="813" width="117" height="15" font="1">verapamil for WCT and </text>
<text top="147" left="813" width="118" height="15" font="1">both had hemodynamic </text>
<text top="163" left="813" width="44" height="15" font="1">collapse </text>
<text top="178" left="813" width="3" height="15" font="1"> </text>
<text top="194" left="813" width="81" height="15" font="1">Noted that EMS </text>
<text top="209" left="813" width="127" height="15" font="1">commonly misinterpreted </text>
<text top="225" left="813" width="129" height="15" font="1">non-SVT rhythms as SVT </text>
<text top="240" left="813" width="112" height="15" font="1">(including AF, ST, VT) </text>
<text top="257" left="54" width="31" height="15" font="1">Luber </text>
<text top="272" left="54" width="28" height="15" font="1">2001 </text>
<text top="288" left="54" width="23" height="15" font="1">(49) </text>
<text top="303" left="54" width="49" height="15" font="8">11146016</text>
<text top="303" left="103" width="3" height="15" font="1"> </text>
<text top="257" left="163" width="105" height="15" font="1">Observational cohort </text>
<text top="272" left="163" width="137" height="15" font="1">(retrospective chart review) </text>
<text top="288" left="163" width="3" height="15" font="1"> </text>
<text top="303" left="163" width="137" height="15" font="1">Outcomes of pts treated for </text>
<text top="319" left="163" width="104" height="15" font="1">SVT in ED, including </text>
<text top="334" left="163" width="140" height="15" font="1">recurrence rates, from 1993-</text>
<text top="350" left="163" width="28" height="15" font="1">1996 </text>
<text top="257" left="329" width="197" height="15" font="1">N=111 Narrow </text>
<text top="257" left="465" width="105" height="15" font="1">complex </text>
<text top="272" left="426" width="118" height="15" font="1">tachycardia (QRS &lt;120 </text>
<text top="288" left="426" width="132" height="15" font="1">ms), no P waves, rate 120-</text>
<text top="303" left="426" width="49" height="15" font="1">300 bpm. </text>
<text top="319" left="426" width="125" height="15" font="1">1993-1996, single center </text>
<text top="257" left="579" width="97" height="15" font="1">Recurrence of SVT </text>
<text top="272" left="579" width="3" height="15" font="1"> </text>
<text top="288" left="579" width="215" height="15" font="1">Descriptive percentages of therapies given, </text>
<text top="303" left="579" width="85" height="15" font="1">pt demographics </text>
<text top="257" left="813" width="85" height="15" font="1">Therapies given: </text>
<text top="272" left="813" width="90" height="15" font="1">adenosine (41%), </text>
<text top="288" left="813" width="124" height="15" font="1">Valsalva (22%), Calcium </text>
<text top="303" left="813" width="116" height="15" font="1">channel blocker (14%), </text>
<text top="319" left="813" width="98" height="15" font="1">beta blockers (4%), </text>
<text top="334" left="813" width="98" height="15" font="1">cardioversion (1%). </text>
<text top="350" left="813" width="3" height="15" font="1"> </text>
<text top="365" left="813" width="123" height="15" font="1">79 pts (71%) discharged </text>
<text top="381" left="813" width="130" height="15" font="1">from ED, mean age of 49, </text>
<text top="396" left="813" width="116" height="15" font="1">mean ED stay of 3.8 h, </text>
<text top="412" left="813" width="117" height="15" font="1">and 3 pts had recurrent </text>
<text top="427" left="813" width="72" height="15" font="1">SVT w/in 24 h </text>
<text top="443" left="813" width="3" height="15" font="1"> </text>
<text top="458" left="813" width="124" height="15" font="1">32 pts (29%) admitted to </text>
<text top="474" left="813" width="124" height="15" font="1">hospital, mean age 65, 6 </text>
<text top="489" left="813" width="119" height="15" font="1">pts (19%) had recurrent </text>
<text top="505" left="813" width="99" height="15" font="1">SVT in the hospital. </text>
<text top="520" left="813" width="3" height="15" font="1"> </text>
<text top="535" left="813" width="109" height="15" font="1">SVT recurrence more </text>
<text top="551" left="813" width="103" height="15" font="1">likely in admitted pts </text>
<text top="567" left="813" width="93" height="15" font="1">(p&lt;0.05), older pts </text>
<text top="582" left="813" width="115" height="15" font="1">(p&lt;0.01) or h/o cardiac </text>
<text top="597" left="813" width="86" height="15" font="1">disease (p&lt;0.01) </text>
<text top="257" left="959" width="142" height="15" font="1">Largely a descriptive paper.  </text>
<text top="614" left="54" width="37" height="15" font="1">Roth A </text>
<text top="629" left="54" width="28" height="15" font="1">2003 </text>
<text top="645" left="54" width="23" height="15" font="1">(50) </text>
<text top="660" left="54" width="52" height="15" font="8">12586276 </text>
<text top="676" left="54" width="3" height="15" font="1"> </text>
<text top="614" left="163" width="124" height="15" font="1">Prospective cohort study </text>
<text top="614" left="329" width="15" height="15" font="1">84 </text>
<text top="614" left="426" width="57" height="15" font="1">PSVT 77% </text>
<text top="629" left="426" width="42" height="15" font="1">AF 23% </text>
<text top="645" left="426" width="3" height="15" font="1"> </text>
<text top="660" left="426" width="3" height="15" font="1"> </text>
<text top="614" left="579" width="199" height="15" font="1">Effectiveness of DC cardioversion in pts </text>
<text top="629" left="579" width="190" height="15" font="1">who did not respond promptly to vagal </text>
<text top="645" left="579" width="198" height="15" font="1">maneuvers that were tried first and then </text>
<text top="660" left="579" width="215" height="15" font="1">tried again after intravenously administered </text>
<text top="676" left="579" width="191" height="15" font="1">medical treatment w/ 1 of the following </text>
<text top="691" left="579" width="168" height="15" font="1">intravenously administered drugs: </text>
<text top="707" left="579" width="184" height="15" font="1">adenosine,verapamil, digoxin, and/or </text>
<text top="722" left="579" width="76" height="15" font="1">procainamide.  </text>
<text top="738" left="579" width="3" height="15" font="1"> </text>
<text top="753" left="579" width="178" height="15" font="1">All study pts were hemodynamically </text>
<text top="769" left="579" width="162" height="15" font="1">compromised but did not require </text>
<text top="784" left="579" width="153" height="15" font="1">cardiopulmonary resuscitation. </text>
<text top="614" left="813" width="130" height="15" font="1">DC cardioversion resulted </text>
<text top="629" left="813" width="120" height="15" font="1">in successful converson </text>
<text top="645" left="813" width="122" height="15" font="1">to sinus rhythm in all pts </text>
<text top="660" left="813" width="94" height="15" font="1">after 103 electrical </text>
<text top="676" left="813" width="119" height="15" font="1">attempts, using 118±69 </text>
<text top="691" left="813" width="41" height="15" font="1">Joules.  </text>
<text top="707" left="813" width="3" height="15" font="1"> </text>
<text top="722" left="813" width="123" height="15" font="1">No complications; all but </text>
<text top="738" left="813" width="131" height="15" font="1">1 pt (w/ pulmonary edema </text>
<text top="753" left="813" width="117" height="15" font="1">and cardiogenic shock) </text>
<text top="769" left="813" width="124" height="15" font="1">discharged alive w/in 7 d </text>
<text top="784" left="813" width="92" height="15" font="1">of hospitalization.  </text>
<text top="614" left="959" width="173" height="15" font="1">Use of DC cardioversion to restore </text>
<text top="629" left="959" width="156" height="15" font="1">sinus rhythm can be safely and </text>
<text top="645" left="959" width="132" height="15" font="1">efficaciously applied in the </text>
<text top="660" left="959" width="165" height="15" font="1">prehospital setting in pts who are </text>
<text top="676" left="959" width="177" height="15" font="1">hemodynamically compromised but </text>
<text top="691" left="959" width="156" height="15" font="1">do not require cardiopulmonary </text>
<text top="707" left="959" width="68" height="15" font="1">resuscitation.<b> </b></text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">21 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="579" width="3" height="15" font="1"> </text>
<text top="71" left="54" width="425" height="15" font="1">Chronic therapy of SVT (exclude WPW and preexcitation, but include if concealed AP) </text>
<text top="87" left="54" width="46" height="15" font="1">Neuss H </text>
<text top="102" left="54" width="31" height="15" font="1">1988  </text>
<text top="118" left="54" width="23" height="15" font="1">(51) </text>
<text top="134" left="54" width="43" height="15" font="8">3136637</text>
<text top="134" left="97" width="3" height="15" font="1"> </text>
<text top="87" left="163" width="144" height="15" font="1">Open label trial of chronic po </text>
<text top="102" left="163" width="152" height="15" font="1">flecainide to pts that first given </text>
<text top="118" left="163" width="124" height="15" font="1">IV dose in EP lab. Pts w/ </text>
<text top="134" left="163" width="146" height="15" font="1">WPW (concealed or overt) or </text>
<text top="149" left="163" width="44" height="15" font="1">AVNRT. </text>
<text top="87" left="329" width="84" height="15" font="1">63 pts (47 WPW </text>
<text top="102" left="329" width="53" height="15" font="1">of which 8 </text>
<text top="118" left="329" width="72" height="15" font="1">concealed, 36 </text>
<text top="134" left="329" width="58" height="15" font="1">w/ AVNRT) </text>
<text top="149" left="329" width="71" height="15" font="1">Mean f/u 22.8 </text>
<text top="165" left="329" width="18" height="15" font="1">mo </text>
<text top="87" left="426" width="133" height="15" font="1">WPW (overt or concealed) </text>
<text top="102" left="426" width="109" height="15" font="1">or AVNRT, previously </text>
<text top="118" left="426" width="124" height="15" font="1">refractory or intolerant to </text>
<text top="134" left="426" width="135" height="15" font="1">other antiarrhythmic drugs, </text>
<text top="149" left="426" width="89" height="15" font="1">verapamil or beta </text>
<text top="165" left="426" width="51" height="15" font="1">blockade) </text>
<text top="180" left="426" width="127" height="15" font="1">IV flecainide given during </text>
<text top="195" left="426" width="126" height="15" font="1">SVT induced at EP study </text>
<text top="211" left="426" width="102" height="15" font="1">(100 mg over 5 min) </text>
<text top="87" left="579" width="199" height="15" font="1">Drug efficacy and tolerance based upon </text>
<text top="102" left="579" width="27" height="15" font="1">diary </text>
<text top="118" left="579" width="3" height="15" font="1"> </text>
<text top="134" left="579" width="201" height="15" font="1">EP study also repeated while on therapy </text>
<text top="87" left="813" width="103" height="15" font="1">In AVNRT pts (31) – </text>
<text top="102" left="813" width="119" height="15" font="1">mean observation of 23 </text>
<text top="118" left="813" width="129" height="15" font="1">mo, mean flecainide dose </text>
<text top="134" left="813" width="124" height="15" font="1">257 mg/d, effective in 20 </text>
<text top="149" left="813" width="130" height="15" font="1">pts and reduced episodes </text>
<text top="164" left="813" width="126" height="15" font="1">in 4 other pts. Worsening </text>
<text top="180" left="813" width="119" height="15" font="1">of attacks seen in 2 pts. </text>
<text top="195" left="813" width="3" height="15" font="1"> </text>
<text top="211" left="813" width="117" height="15" font="1">Adverse effects: visual, </text>
<text top="226" left="813" width="121" height="15" font="1">nervousness, dizziness, </text>
<text top="242" left="813" width="104" height="15" font="1">taste, hallucinations, </text>
<text top="257" left="813" width="91" height="15" font="1">vomiting. Therapy </text>
<text top="273" left="813" width="104" height="15" font="1">discontinued in 3 pts </text>
<text top="288" left="813" width="79" height="15" font="1">(AVNRT group) </text>
<text top="87" left="959" width="155" height="15" font="1">Flecainide effective in reducing </text>
<text top="102" left="959" width="178" height="15" font="1">subjective episodes – among pts w/ </text>
<text top="118" left="959" width="174" height="15" font="1">AVNRT was effective in 20/31 pts.  </text>
<text top="305" left="54" width="58" height="15" font="1">Cockrell JL </text>
<text top="320" left="54" width="31" height="15" font="1">1991  </text>
<text top="336" left="54" width="23" height="15" font="1">(52) </text>
<text top="351" left="54" width="43" height="15" font="8">1898629</text>
<text top="351" left="97" width="3" height="15" font="1"> </text>
<text top="305" left="163" width="145" height="15" font="1">Open-label, uncontrolled trial </text>
<text top="320" left="163" width="115" height="15" font="1">of long term efficacy of </text>
<text top="336" left="163" width="50" height="15" font="1">flecainide </text>
<text top="305" left="329" width="36" height="15" font="1">63 pts. </text>
<text top="320" left="329" width="80" height="15" font="1">mean f/u 24 mo </text>
<text top="305" left="426" width="103" height="15" font="1">All pts w/ AV reentry </text>
<text top="305" left="579" width="138" height="15" font="1">Drug efficacy and tolerance </text>
<text top="305" left="813" width="119" height="15" font="1">Flecainide prevented or </text>
<text top="320" left="813" width="118" height="15" font="1">slowed AVRT in 44 pts. </text>
<text top="336" left="813" width="119" height="15" font="1">who were then followed </text>
<text top="351" left="813" width="99" height="15" font="1">and 33 (75%) w/ no </text>
<text top="367" left="813" width="117" height="15" font="1">adverse effects. Isuprel </text>
<text top="382" left="813" width="112" height="15" font="1">reversed the effects in </text>
<text top="398" left="813" width="124" height="15" font="1">11/21 pts.  Overall, 33 of </text>
<text top="413" left="813" width="122" height="15" font="1">63 pts responded to and </text>
<text top="429" left="813" width="114" height="15" font="1">tolerated flecainide. 11 </text>
<text top="444" left="813" width="94" height="15" font="1">pts stopped due to </text>
<text top="460" left="813" width="81" height="15" font="1">adverse effects. </text>
<text top="305" left="959" width="159" height="15" font="1">Flecainide moderately helpful in </text>
<text top="320" left="959" width="132" height="15" font="1">about 50% of pts over 2 y. </text>
<text top="476" left="54" width="70" height="15" font="1">Jackman WM </text>
<text top="491" left="54" width="28" height="15" font="1">1992 </text>
<text top="507" left="54" width="23" height="15" font="1">(53) </text>
<text top="522" left="54" width="46" height="15" font="8">1620170 </text>
<text top="522" left="100" width="3" height="15" font="1"> </text>
<text top="538" left="54" width="3" height="17" font="0"> </text>
<text top="476" left="163" width="130" height="15" font="1">Prospective observational </text>
<text top="491" left="163" width="34" height="15" font="1">cohort </text>
<text top="476" left="329" width="246" height="15" font="1">80 Symptomatic </text>
<text top="476" left="493" width="122" height="15" font="1">AVNRT </text>
<text top="491" left="426" width="122" height="15" font="1">undergoing RFA of slow-</text>
<text top="507" left="426" width="44" height="15" font="1">pathway </text>
<text top="476" left="579" width="190" height="15" font="1">Successful ablation w/ intact AV nodal </text>
<text top="491" left="579" width="188" height="15" font="1">conduction, guided by atrial slow-path </text>
<text top="507" left="579" width="51" height="15" font="1">potentials </text>
<text top="476" left="813" width="88" height="15" font="1">RFA abolished or </text>
<text top="491" left="813" width="115" height="15" font="1">modified slow-pathway </text>
<text top="507" left="813" width="117" height="15" font="1">conduction in 78/80 pts </text>
<text top="522" left="813" width="128" height="15" font="1">w/o affecting normal AVN </text>
<text top="538" left="813" width="111" height="15" font="1">conduction. Mean (+/- </text>
<text top="553" left="813" width="113" height="15" font="1">SD) f/u of 15.5 mo w/o </text>
<text top="569" left="813" width="62" height="15" font="1">recurrence.  </text>
<text top="476" left="959" width="165" height="15" font="1">Early report of success of RFA of </text>
<text top="491" left="959" width="158" height="15" font="1">slow-path conduction guided by </text>
<text top="507" left="959" width="166" height="15" font="1">atrial slow-path potentials—led to </text>
<text top="522" left="959" width="142" height="15" font="1">slow-pathway ablation being </text>
<text top="538" left="959" width="138" height="15" font="1">preferred method. Provided </text>
<text top="553" left="959" width="159" height="15" font="1">evidence that atrial insertions of </text>
<text top="569" left="959" width="176" height="15" font="1">fast and slow path are anatomically </text>
<text top="584" left="959" width="41" height="15" font="1">distinct. </text>
<text top="600" left="54" width="64" height="15" font="1">Gambhir DS </text>
<text top="616" left="54" width="28" height="15" font="1">1996 </text>
<text top="631" left="54" width="23" height="15" font="1">(54) </text>
<text top="647" left="54" width="49" height="15" font="8">8682552  </text>
<text top="662" left="54" width="3" height="15" font="1"> </text>
<text top="600" left="163" width="124" height="15" font="1">Prospective cohort study </text>
<text top="600" left="329" width="9" height="15" font="1">9 </text>
<text top="600" left="426" width="112" height="15" font="1">All pts w/ symptomatic </text>
<text top="616" left="426" width="91" height="15" font="1">AVNRT, recurrent </text>
<text top="631" left="426" width="127" height="15" font="1">palpitations for 2-12 y EP </text>
<text top="647" left="426" width="100" height="15" font="1">study performed, IV </text>
<text top="662" left="426" width="108" height="15" font="1">amiodarone then oral </text>
<text top="678" left="426" width="126" height="15" font="1">therapy subsequently EP </text>
<text top="693" left="426" width="123" height="15" font="1">study repeated 1.5-3 mo </text>
<text top="709" left="426" width="25" height="15" font="1">later </text>
<text top="600" left="579" width="205" height="15" font="1">No pts reported sxs of tachycardia during </text>
<text top="616" left="579" width="181" height="15" font="1">mean f/u of 65 d on oral amiodarone </text>
<text top="631" left="579" width="3" height="15" font="1"> </text>
<text top="647" left="579" width="219" height="15" font="1">IV amiodarone terminated AVNRT in 7/9 pts </text>
<text top="662" left="579" width="219" height="15" font="1">(retrograde FP in 4/7 and anterograde SP in </text>
<text top="678" left="579" width="22" height="15" font="1">3/7) </text>
<text top="693" left="579" width="3" height="15" font="1"> </text>
<text top="709" left="579" width="197" height="15" font="1">Not inducible on PES after oral therapy, </text>
<text top="724" left="579" width="218" height="15" font="1">largely to due to prolonging refractoriness in </text>
<text top="740" left="579" width="181" height="15" font="1">atrium and ventricle, and depressing </text>
<text top="755" left="579" width="115" height="15" font="1">conduction through FP </text>
<text top="600" left="813" width="111" height="15" font="1">No pts reported sxs of </text>
<text top="616" left="813" width="124" height="15" font="1">tachycardia during mean </text>
<text top="631" left="813" width="89" height="15" font="1">f/u of 65 d on oral </text>
<text top="647" left="813" width="62" height="15" font="1">amiodarone </text>
<text top="662" left="813" width="3" height="15" font="1"> </text>
<text top="678" left="813" width="130" height="15" font="1">IV amiodarone terminated </text>
<text top="693" left="813" width="89" height="15" font="1">AVNRT in 7/9 pts </text>
<text top="709" left="813" width="127" height="15" font="1">(retrograde FP in 4/7 and </text>
<text top="724" left="813" width="115" height="15" font="1">anterograde SP in 3/7) </text>
<text top="740" left="813" width="3" height="15" font="1"> </text>
<text top="755" left="813" width="108" height="15" font="1">Not inducible on PES </text>
<text top="771" left="813" width="126" height="15" font="1">after oral therapy, largely </text>
<text top="786" left="813" width="101" height="15" font="1">to due to prolonging </text>
<text top="600" left="959" width="143" height="15" font="1">Small series of pts, but all w/ </text>
<text top="616" left="959" width="41" height="15" font="1">AVNRT </text>
<text top="631" left="959" width="3" height="15" font="1"> </text>
<text top="647" left="959" width="151" height="15" font="1">Oral therapy w/ amiodarone is </text>
<text top="662" left="959" width="162" height="15" font="1">effective in suppressing AVNRT. </text>
<text top="678" left="959" width="3" height="15" font="1"> </text>
<text top="693" left="959" width="172" height="15" font="1">IV amiodarone is effective in acute </text>
<text top="709" left="959" width="43" height="15" font="1">therapy. </text>
<text top="724" left="959" width="3" height="15" font="1"> </text>
<text top="740" left="959" width="91" height="15" font="1">EP study efficacy. </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">22 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="813" width="116" height="15" font="1">refractoriness in atrium </text>
<text top="70" left="813" width="90" height="15" font="1">and ventricle, and </text>
<text top="86" left="813" width="114" height="15" font="1">depressing conduction </text>
<text top="101" left="813" width="58" height="15" font="1">through FP </text>
<text top="117" left="54" width="52" height="15" font="1">Spector P </text>
<text top="133" left="54" width="28" height="15" font="1">2009 </text>
<text top="148" left="54" width="23" height="15" font="1">(55) </text>
<text top="164" left="54" width="55" height="15" font="8">19699343  </text>
<text top="164" left="109" width="3" height="15" font="1"> </text>
<text top="117" left="163" width="142" height="15" font="1">Systematic review and meta-</text>
<text top="133" left="163" width="151" height="15" font="1">analysis to evaluate the safety </text>
<text top="148" left="163" width="112" height="15" font="1">and efficacy of RFA of </text>
<text top="164" left="163" width="135" height="15" font="1">AVNRT, AP-mediated, and </text>
<text top="179" left="163" width="61" height="15" font="1">atrial flutter. </text>
<text top="117" left="329" width="82" height="15" font="1">For AVNRT and </text>
<text top="133" left="329" width="70" height="15" font="1">AP-mediated: </text>
<text top="148" left="329" width="55" height="15" font="1">39 primary </text>
<text top="164" left="329" width="68" height="15" font="1">studies w/ 49 </text>
<text top="179" left="329" width="78" height="15" font="1">treatment arms </text>
<text top="195" left="329" width="63" height="15" font="1">in 7,693 pts. </text>
<text top="117" left="426" width="128" height="15" font="1">Previous reviews or meta-</text>
<text top="133" left="426" width="134" height="15" font="1">analyses; animal or in vitro </text>
<text top="148" left="426" width="134" height="15" font="1">studies; subjects aged &lt;18 </text>
<text top="164" left="426" width="126" height="15" font="1">y or mixed populations of </text>
<text top="179" left="426" width="135" height="15" font="1">which &gt;15% were pediatric </text>
<text top="195" left="426" width="133" height="15" font="1">pts; f/u of &lt;7 d; not studies </text>
<text top="210" left="426" width="132" height="15" font="1">of RFA; alternative energy </text>
<text top="226" left="426" width="130" height="15" font="1">sources used for ablation; </text>
<text top="241" left="426" width="115" height="15" font="1">AV junction ablation w/ </text>
<text top="257" left="426" width="124" height="15" font="1">pacemaker implantation; </text>
<text top="272" left="426" width="127" height="15" font="1">&lt;40 pts per arrhythmia or </text>
<text top="288" left="426" width="96" height="15" font="1">ablation technique; </text>
<text top="303" left="426" width="128" height="15" font="1">published only in abstract </text>
<text top="319" left="426" width="113" height="15" font="1">form; published before </text>
<text top="334" left="426" width="114" height="15" font="1">1990; and published in </text>
<text top="350" left="426" width="107" height="15" font="1">languages other than </text>
<text top="365" left="426" width="129" height="15" font="1">English, Spanish, French, </text>
<text top="381" left="426" width="103" height="15" font="1">Italian, German, and </text>
<text top="396" left="426" width="63" height="15" font="1">Portuguese. </text>
<text top="117" left="579" width="161" height="15" font="1">SVT (AVNRT and AP-mediated) </text>
<text top="133" left="579" width="3" height="15" font="1"> </text>
<text top="148" left="579" width="200" height="15" font="1">Single- and multiple-procedure success, </text>
<text top="164" left="579" width="194" height="15" font="1">arrhythmia recurrence, repeat ablation, </text>
<text top="179" left="579" width="134" height="15" font="1">adverse events, and death </text>
<text top="195" left="579" width="3" height="15" font="1"> </text>
<text top="210" left="579" width="6" height="15" font="1">  </text>
<text top="117" left="813" width="87" height="15" font="1">Single-procedure </text>
<text top="133" left="813" width="84" height="15" font="1">success: 93.2%  </text>
<text top="148" left="813" width="113" height="15" font="1">(95% CI 90.8-95.5%).  </text>
<text top="164" left="813" width="3" height="15" font="1"> </text>
<text top="179" left="813" width="95" height="15" font="1">Multiple-procedure </text>
<text top="195" left="813" width="81" height="15" font="1">success: 94.6% </text>
<text top="210" left="813" width="103" height="15" font="1">(95% CI 92.4- 96.9). </text>
<text top="226" left="813" width="3" height="15" font="1"> </text>
<text top="241" left="813" width="126" height="15" font="1">Post-ablation arrhythmia: </text>
<text top="257" left="813" width="32" height="15" font="1">5.6%  </text>
<text top="272" left="813" width="100" height="15" font="1">(95% CI 4.1-7.2%).  </text>
<text top="288" left="813" width="3" height="15" font="1"> </text>
<text top="303" left="813" width="112" height="15" font="1">Repeat ablation: 6.5% </text>
<text top="319" left="813" width="94" height="15" font="1">(95% CI 4.7-8.3%) </text>
<text top="334" left="813" width="3" height="15" font="1"> </text>
<text top="350" left="813" width="125" height="15" font="1">All-cause mortality: 0.1% </text>
<text top="365" left="813" width="3" height="15" font="1"> </text>
<text top="381" left="813" width="114" height="15" font="1">Adverse events: 2.9%  </text>
<text top="117" left="959" width="149" height="15" font="1">First meta-analysis of RFA for </text>
<text top="133" left="959" width="157" height="15" font="1">AVNRT, AVRT (AP-mediated).  </text>
<text top="148" left="959" width="3" height="15" font="1"> </text>
<text top="164" left="959" width="164" height="15" font="1">Demonstrates high efficacy rates </text>
<text top="179" left="959" width="154" height="15" font="1">and low rates of complications. </text>
<text top="412" left="54" width="54" height="15" font="1">Bohnen M </text>
<text top="428" left="54" width="28" height="15" font="1">2011 </text>
<text top="443" left="54" width="23" height="15" font="1">(56) </text>
<text top="459" left="54" width="49" height="15" font="8">21699857</text>
<text top="459" left="103" width="3" height="15" font="1"> </text>
<text top="412" left="163" width="130" height="15" font="1">Prospective observational </text>
<text top="428" left="163" width="103" height="15" font="1">cohort, single center </text>
<text top="443" left="163" width="140" height="15" font="1">Incidence and predictors for </text>
<text top="459" left="163" width="113" height="15" font="1">major complications of </text>
<text top="474" left="163" width="88" height="15" font="1">catheter ablation  </text>
<text top="412" left="329" width="28" height="15" font="1">1676 </text>
<text top="428" left="329" width="62" height="15" font="1">procedures  </text>
<text top="412" left="426" width="134" height="15" font="1">All pts undergoing ablation </text>
<text top="428" left="426" width="136" height="15" font="1">in a 2 y period (2009-2011) </text>
<text top="443" left="426" width="134" height="15" font="1">at a high volume center for </text>
<text top="459" left="426" width="109" height="15" font="1">variety of arrhythmias </text>
<text top="474" left="426" width="129" height="15" font="1">(SVT, AF, VT due to SHD </text>
<text top="490" left="426" width="66" height="15" font="1">or idiopathic) </text>
<text top="412" left="579" width="196" height="15" font="1">Complications assessed over 30 d post-</text>
<text top="428" left="579" width="56" height="15" font="1">procedure. </text>
<text top="412" left="813" width="94" height="15" font="1">524 SVT ablations </text>
<text top="428" left="813" width="128" height="15" font="1">performed of which major </text>
<text top="443" left="813" width="130" height="15" font="1">complications (total 0.8%) </text>
<text top="459" left="813" width="100" height="15" font="1">included perforation </text>
<text top="474" left="813" width="120" height="15" font="1">(n=1), pseudoaneurysm </text>
<text top="490" left="813" width="118" height="15" font="1">(groin, n=2), pulmonary </text>
<text top="505" left="813" width="124" height="15" font="1">edema (1). No instances </text>
<text top="521" left="813" width="107" height="15" font="1">of conduction system </text>
<text top="536" left="813" width="46" height="15" font="1">damage  </text>
<text top="412" left="959" width="161" height="15" font="1">Total major complication rate for </text>
<text top="428" left="959" width="149" height="15" font="1">SVT ablation below 1% in this </text>
<text top="443" left="959" width="163" height="15" font="1">contemporary prospective study. </text>
<text top="552" left="54" width="131" height="15" font="1">Outcomes (Registry Data) </text>
<text top="569" left="54" width="60" height="15" font="1">Hindricks G </text>
<text top="584" left="54" width="28" height="15" font="1">1993 </text>
<text top="600" left="54" width="23" height="15" font="1">(57) </text>
<text top="615" left="54" width="46" height="15" font="8">8131762 </text>
<text top="615" left="100" width="3" height="15" font="1"> </text>
<text top="569" left="163" width="95" height="15" font="1">Prospective cohort </text>
<text top="569" left="329" width="28" height="15" font="1">4398 </text>
<text top="569" left="426" width="116" height="15" font="1">AT/atrial flutter (n=141, </text>
<text top="584" left="426" width="32" height="15" font="1">3.2%) </text>
<text top="600" left="426" width="102" height="15" font="1">AVJ (n=900, 20.5%) </text>
<text top="615" left="426" width="120" height="15" font="1">AVNRT (n=815, 18.5%) </text>
<text top="631" left="426" width="127" height="15" font="1">AVRT: (n = 2222, 50.5%) </text>
<text top="646" left="426" width="93" height="15" font="1">VT (n=320, 7.3%). </text>
<text top="569" left="579" width="133" height="15" font="1">Incidence of complications </text>
<text top="569" left="813" width="130" height="15" font="1">Complications occurred in </text>
<text top="584" left="813" width="111" height="15" font="1">223 pts (5.1%) overall </text>
<text top="600" left="813" width="3" height="15" font="1"> </text>
<text top="615" left="813" width="106" height="15" font="1">AT/atrial flutter: 5.0% </text>
<text top="631" left="813" width="55" height="15" font="1">AVJ: 3.2% </text>
<text top="646" left="813" width="72" height="15" font="1">AVNRT: 8.0% </text>
<text top="662" left="813" width="64" height="15" font="1">AVRT: 4.4% </text>
<text top="677" left="813" width="49" height="15" font="1">VT: 7.5% </text>
<text top="693" left="813" width="3" height="15" font="1"> </text>
<text top="708" left="813" width="112" height="15" font="1">Complications more in </text>
<text top="724" left="813" width="130" height="15" font="1">AVNRT RFA compared to </text>
<text top="739" left="813" width="96" height="15" font="1">AVJ or AP ablation </text>
<text top="755" left="813" width="54" height="15" font="1">(p&lt;0.001)  </text>
<text top="770" left="813" width="3" height="15" font="1"> </text>
<text top="786" left="813" width="130" height="15" font="1">Complications more in VT </text>
<text top="569" left="959" width="178" height="15" font="1">Early report showing high incidence </text>
<text top="584" left="959" width="148" height="15" font="1">of complications after AVNRT </text>
<text top="600" left="959" width="45" height="15" font="1">ablation. </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">23 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="813" width="88" height="15" font="1">compared to AVJ </text>
<text top="70" left="813" width="126" height="15" font="1">(p&lt;0.002) or AP (p&lt;0.02) </text>
<text top="86" left="54" width="60" height="15" font="1">Hindricks G </text>
<text top="102" left="54" width="28" height="15" font="1">1996 </text>
<text top="117" left="54" width="23" height="15" font="1">(58) </text>
<text top="133" left="54" width="46" height="15" font="8">8682135 </text>
<text top="133" left="100" width="3" height="15" font="1"> </text>
<text top="86" left="163" width="95" height="15" font="1">Prospective cohort </text>
<text top="86" left="329" width="28" height="15" font="1">4463 </text>
<text top="86" left="426" width="82" height="15" font="1">AVNRT (n=880) </text>
<text top="86" left="579" width="110" height="15" font="1">Incidence of AV block </text>
<text top="86" left="813" width="126" height="15" font="1">AV block (4/ 880, 4.7%).  </text>
<text top="102" left="813" width="3" height="15" font="1"> </text>
<text top="117" left="813" width="113" height="15" font="1">AV block higher in fast </text>
<text top="133" left="813" width="130" height="15" font="1">pathway ablation (19/361, </text>
<text top="148" left="813" width="75" height="15" font="1">5.3%, p&lt;0.05)  </text>
<text top="164" left="813" width="3" height="15" font="1"> </text>
<text top="179" left="813" width="129" height="15" font="1">6.3% in centers w/ limited </text>
<text top="195" left="813" width="121" height="15" font="1">experience in RFA (≤30 </text>
<text top="210" left="813" width="124" height="15" font="1">pts treated, p&lt;0.05), and </text>
<text top="226" left="813" width="96" height="15" font="1">higher in these low-</text>
<text top="241" left="813" width="119" height="15" font="1">volume centers for both </text>
<text top="257" left="813" width="112" height="15" font="1">slow and fast pathway </text>
<text top="272" left="813" width="86" height="15" font="1">ablation (p&lt;0.05) </text>
<text top="86" left="959" width="173" height="15" font="1">Early report showing 5% incidence </text>
<text top="102" left="959" width="169" height="15" font="1">of AV block after RFA for AVNRT, </text>
<text top="117" left="959" width="135" height="15" font="1">and higher w/ fast pathway </text>
<text top="133" left="959" width="45" height="15" font="1">ablation. </text>
<text top="288" left="54" width="50" height="15" font="1">Calkins H </text>
<text top="304" left="54" width="28" height="15" font="1">1999 </text>
<text top="319" left="54" width="23" height="15" font="1">(59) </text>
<text top="335" left="54" width="46" height="15" font="8">9892593 </text>
<text top="335" left="100" width="3" height="15" font="1"> </text>
<text top="288" left="163" width="95" height="15" font="1">Prospective cohort </text>
<text top="288" left="329" width="28" height="15" font="1">1050 </text>
<text top="304" left="329" width="57" height="15" font="1">(previously </text>
<text top="319" left="329" width="79" height="15" font="1">enrolled in RFA </text>
<text top="335" left="329" width="61" height="15" font="1">clinical trial) </text>
<text top="288" left="426" width="138" height="15" font="1">RFA of AVNRT, AP, or AVJ </text>
<text top="304" left="426" width="3" height="15" font="1"> </text>
<text top="319" left="426" width="82" height="15" font="1">AVNRT (n=373) </text>
<text top="335" left="426" width="59" height="15" font="1">AP (n=500) </text>
<text top="350" left="426" width="65" height="15" font="1">AVJ (n=121) </text>
<text top="366" left="426" width="3" height="15" font="1"> </text>
<text top="288" left="579" width="216" height="15" font="1">Efficacy and safety of RFA w/ long-term f/u. </text>
<text top="304" left="579" width="3" height="15" font="1"> </text>
<text top="319" left="579" width="3" height="15" font="1"> </text>
<text top="288" left="813" width="84" height="15" font="1">Overall success: </text>
<text top="304" left="813" width="25" height="15" font="1">95% </text>
<text top="319" left="813" width="94" height="15" font="1">Overall recurrence </text>
<text top="335" left="813" width="19" height="15" font="1">6% </text>
<text top="350" left="813" width="3" height="15" font="1"> </text>
<text top="366" left="813" width="48" height="15" font="1">Success: </text>
<text top="381" left="813" width="69" height="15" font="1">AVNRT: 97% </text>
<text top="397" left="813" width="46" height="15" font="1">AP: 93% </text>
<text top="412" left="813" width="58" height="15" font="1">AVJ: 100% </text>
<text top="428" left="813" width="3" height="15" font="1"> </text>
<text top="443" left="813" width="63" height="15" font="1">Recurrence: </text>
<text top="459" left="813" width="63" height="15" font="1">AVNRT: 5% </text>
<text top="474" left="813" width="40" height="15" font="1">AP: 8% </text>
<text top="490" left="813" width="46" height="15" font="1">AVJ: 2% </text>
<text top="505" left="813" width="3" height="15" font="1"> </text>
<text top="521" left="813" width="111" height="15" font="1">Predictors of success: </text>
<text top="536" left="813" width="44" height="15" font="1">-AVNRT </text>
<text top="552" left="813" width="116" height="15" font="1">OR: 3.94 (95%CI: 1.93-</text>
<text top="567" left="813" width="81" height="15" font="1">8.04; p=0.0002) </text>
<text top="583" left="813" width="87" height="15" font="1">-Left free wall AP </text>
<text top="598" left="813" width="119" height="15" font="1">OR: 3.09 (95% CI: 1.46-</text>
<text top="614" left="813" width="81" height="15" font="1">6.53; p=0.0003) </text>
<text top="629" left="813" width="116" height="15" font="1">-Experience of ablation </text>
<text top="645" left="813" width="81" height="15" font="1">center (&gt;39 pts) </text>
<text top="660" left="813" width="122" height="15" font="1">OR: 2.39 (95% CI: 1.21- </text>
<text top="676" left="813" width="78" height="15" font="1">4.71;  p=0.012) </text>
<text top="691" left="813" width="3" height="15" font="1"> </text>
<text top="707" left="813" width="90" height="15" font="1">Joint predictors of </text>
<text top="722" left="813" width="48" height="15" font="1">mortality: </text>
<text top="738" left="813" width="72" height="15" font="1">-EF (p=0.003) </text>
<text top="753" left="813" width="81" height="15" font="1">-SHD (p=0.016) </text>
<text top="769" left="813" width="120" height="15" font="1">-AVJ ablation (p=0.048) </text>
<text top="288" left="959" width="178" height="15" font="1">Shows RFA is a favorable option w/ </text>
<text top="304" left="959" width="144" height="15" font="1">low risk of complications and </text>
<text top="319" left="959" width="168" height="15" font="1">recurrence, and identifies pts who </text>
<text top="335" left="959" width="161" height="15" font="1">are at risk. Per-protocol analysis </text>
<text top="785" left="54" width="245" height="15" font="1">Cheng Comparison </text>
<text top="785" left="226" width="86" height="15" font="1">of </text>
<text top="785" left="238" width="232" height="15" font="1">cost Symptomatic </text>
<text top="785" left="426" width="28" height="15" font="1">RFA: </text>
<text top="785" left="579" width="105" height="15" font="1">Perspective: societal </text>
<text top="785" left="813" width="118" height="15" font="1">W/ monthly episodes of </text>
<text top="785" left="959" width="160" height="15" font="1">RDA improves quality of life and </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="17" size="11" family="Times" color="#000000"/>
<text top="814" left="1120" width="17" height="17" font="0">24 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="28" height="15" font="1">2000 </text>
<text top="70" left="54" width="23" height="15" font="1">(60) </text>
<text top="86" left="54" width="49" height="15" font="8">11103056</text>
<text top="86" left="103" width="3" height="15" font="17"><i> </i></text>
<text top="55" left="163" width="119" height="15" font="1">effectiveness of RFA w/ </text>
<text top="70" left="163" width="121" height="15" font="1">medical management of </text>
<text top="86" left="163" width="32" height="15" font="1">PSVT </text>
<text top="55" left="329" width="50" height="15" font="1">pts w/ 4.6 </text>
<text top="70" left="329" width="66" height="15" font="1">unscheduled </text>
<text top="86" left="329" width="52" height="15" font="1">visits/y for </text>
<text top="101" left="329" width="84" height="15" font="1">arrhythmia while </text>
<text top="117" left="329" width="65" height="15" font="1">on long-term </text>
<text top="132" left="329" width="65" height="15" font="1">drug therapy </text>
<text top="55" left="426" width="110" height="15" font="1">Estimated population: </text>
<text top="70" left="426" width="69" height="15" font="1">AVNRT: 65% </text>
<text top="86" left="426" width="121" height="15" font="1">AVRT w/ concealed AP: </text>
<text top="101" left="426" width="25" height="15" font="1">30% </text>
<text top="117" left="426" width="3" height="15" font="1"> </text>
<text top="132" left="426" width="95" height="15" font="1">Efficacy estimates: </text>
<text top="147" left="426" width="69" height="15" font="1">AVNRT: 97% </text>
<text top="163" left="426" width="121" height="15" font="1">AVRT w/ concealed AP: </text>
<text top="178" left="426" width="25" height="15" font="1">93% </text>
<text top="194" left="426" width="3" height="15" font="1"> </text>
<text top="209" left="426" width="114" height="15" font="1">Recurrence estimates: </text>
<text top="225" left="426" width="63" height="15" font="1">AVNRT: 5% </text>
<text top="240" left="426" width="121" height="15" font="1">AVRT w/ concealed AP: </text>
<text top="256" left="426" width="19" height="15" font="1">8% </text>
<text top="271" left="426" width="3" height="15" font="1"> </text>
<text top="287" left="426" width="96" height="15" font="1">Drug efficacy: 60% </text>
<text top="55" left="579" width="3" height="15" font="1"> </text>
<text top="70" left="579" width="221" height="15" font="1">Outcomes: costs (office visit, annual drug rx, </text>
<text top="86" left="579" width="204" height="15" font="1">EP study, RFA, PPM, PPM replacement) </text>
<text top="101" left="579" width="33" height="15" font="1">QALY </text>
<text top="117" left="579" width="52" height="15" font="1">Life-years </text>
<text top="132" left="579" width="167" height="15" font="1">Marginal cost-effectiveness ratios </text>
<text top="147" left="579" width="3" height="15" font="9"> </text>
<text top="55" left="813" width="132" height="15" font="1">PSVT, RFA most effective </text>
<text top="70" left="813" width="101" height="15" font="1">and least expensive </text>
<text top="86" left="813" width="33" height="15" font="1">option </text>
<text top="101" left="813" width="3" height="15" font="1"> </text>
<text top="117" left="813" width="106" height="15" font="1">RFA reduced lifetime </text>
<text top="132" left="813" width="123" height="15" font="1">medical expenditures by </text>
<text top="147" left="813" width="109" height="15" font="1">$27,940 compared w/ </text>
<text top="163" left="813" width="125" height="15" font="1">long-term pharmacologic </text>
<text top="178" left="813" width="40" height="15" font="1">therapy </text>
<text top="194" left="813" width="3" height="15" font="1"> </text>
<text top="210" left="813" width="74" height="15" font="1">Lifetime costs: </text>
<text top="225" left="813" width="31" height="15" font="1">RFA:  </text>
<text top="240" left="813" width="43" height="15" font="1">$61,880 </text>
<text top="256" left="813" width="94" height="15" font="1">Long-term drug rx: </text>
<text top="271" left="813" width="43" height="15" font="1">$89,820 </text>
<text top="287" left="813" width="86" height="15" font="1">Episodic drug rx: </text>
<text top="302" left="813" width="49" height="15" font="1">$143,530 </text>
<text top="318" left="813" width="3" height="15" font="1"> </text>
<text top="333" left="813" width="109" height="15" font="1">RFA improved quality-</text>
<text top="349" left="813" width="121" height="15" font="1">adjusted life expectancy </text>
<text top="364" left="813" width="81" height="15" font="1">by 3.10 QALYs. </text>
<text top="55" left="959" width="173" height="15" font="1">reduces costs when treating highly </text>
<text top="70" left="959" width="86" height="15" font="1">symptomatic pts. </text>
<text top="86" left="959" width="3" height="15" font="1"> </text>
<text top="101" left="959" width="155" height="15" font="1">Effects in less symptomatic not </text>
<text top="117" left="959" width="38" height="15" font="1">studies </text>
<text top="381" left="54" width="80" height="15" font="1">Scheinman MM </text>
<text top="396" left="54" width="28" height="15" font="1">2000 </text>
<text top="412" left="54" width="23" height="15" font="1">(61) </text>
<text top="427" left="54" width="52" height="15" font="8">10879389 </text>
<text top="427" left="106" width="3" height="15" font="1"> </text>
<text top="381" left="163" width="124" height="15" font="1">Prospective cohort study </text>
<text top="396" left="163" width="87" height="15" font="1">(NASPE registry) </text>
<text top="381" left="329" width="31" height="15" font="1">3,357 </text>
<text top="381" left="426" width="120" height="15" font="1">Ablation of AVNRT, AP, </text>
<text top="396" left="426" width="131" height="15" font="1">AVJ, atrial flutter, AT, IST, </text>
<text top="412" left="426" width="87" height="15" font="1">VT, idiopathic VT </text>
<text top="427" left="426" width="3" height="15" font="1"> </text>
<text top="443" left="426" width="129" height="15" font="1">AVNRT (n=1,197 [35.6%) </text>
<text top="458" left="426" width="65" height="15" font="1">AVJ (n=646) </text>
<text top="474" left="426" width="59" height="15" font="1">AP (n=654) </text>
<text top="489" left="426" width="59" height="15" font="1">AT (n=216) </text>
<text top="505" left="426" width="101" height="15" font="1">Atrial flutter (n=447) </text>
<text top="520" left="426" width="56" height="15" font="1">IST (n=40) </text>
<text top="381" left="579" width="216" height="15" font="1">Efficacy and safety of RFA w/ long-term f/u. </text>
<text top="396" left="579" width="3" height="15" font="1"> </text>
<text top="412" left="579" width="3" height="15" font="1"> </text>
<text top="427" left="579" width="3" height="15" font="1"> </text>
<text top="381" left="813" width="41" height="15" font="1">AVNRT </text>
<text top="396" left="813" width="82" height="15" font="1">Success: 96.1% </text>
<text top="412" left="813" width="95" height="15" font="1">Complications: 2% </text>
<text top="427" left="813" width="3" height="15" font="1"> </text>
<text top="443" left="813" width="30" height="15" font="1">AVJ:  </text>
<text top="458" left="813" width="73" height="15" font="1">Success: 96% </text>
<text top="474" left="813" width="109" height="15" font="1">Complications: 25 pts </text>
<text top="489" left="813" width="89" height="15" font="1">Recurrence:3.5% </text>
<text top="505" left="813" width="3" height="15" font="1"> </text>
<text top="520" left="813" width="21" height="15" font="1">AP: </text>
<text top="535" left="813" width="89" height="15" font="1">Success: 94-96% </text>
<text top="551" left="813" width="109" height="15" font="1">Complications: 31 pts </text>
<text top="567" left="813" width="24" height="15" font="1">total </text>
<text top="582" left="813" width="92" height="15" font="1">Recurrence: 4.6% </text>
<text top="597" left="813" width="3" height="15" font="1"> </text>
<text top="613" left="813" width="20" height="15" font="1">AT: </text>
<text top="628" left="813" width="89" height="15" font="1">Success: 51-79% </text>
<text top="644" left="813" width="106" height="15" font="1">Complications:5 total </text>
<text top="659" left="813" width="95" height="15" font="1">Recurrence:15.2% </text>
<text top="675" left="813" width="3" height="15" font="1"> </text>
<text top="690" left="813" width="62" height="15" font="1">Atrial flutter: </text>
<text top="706" left="813" width="73" height="15" font="1">Success: 86% </text>
<text top="721" left="813" width="106" height="15" font="1">Complications:12 pts </text>
<text top="737" left="813" width="95" height="15" font="1">Recurrence:14.7% </text>
<text top="752" left="813" width="3" height="15" font="1"> </text>
<text top="768" left="813" width="23" height="15" font="1">IST: </text>
<text top="783" left="813" width="73" height="15" font="1">Success: 71% </text>
<text top="381" left="959" width="166" height="15" font="1">Large series reporting success of </text>
<text top="396" left="959" width="148" height="15" font="1">RFA, and stratification by age </text>
<text top="412" left="959" width="171" height="15" font="1">group confirms safety and efficacy </text>
<text top="427" left="959" width="171" height="15" font="1">in elderly pts, as well as by type of </text>
<text top="443" left="959" width="163" height="15" font="1">facility (teaching vs. community). </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">25 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="813" width="100" height="15" font="1">Complications:2 pts </text>
<text top="70" left="813" width="85" height="15" font="1">Recurrence:10% </text>
<text top="86" left="54" width="1059" height="15" font="1">AF, atrial fibrillation; AT, atrial tachycardia; AP, accessory pathway; AV, atrioventricular; AVJ, atrioventricular junction; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; </text>
<text top="102" left="54" width="1076" height="15" font="1">bpm, beats per minute; CHF, congestive heart failure; CI, confidence interval; CSP, carotid sinus pressure; DC, direct current; ECG, electrocardiogram; ED, emergency department; EF, ejection fraction; EMS, emergency </text>
<text top="117" left="54" width="1049" height="15" font="1">medical services; EP, electrophysiological; FP, fast pathway; f/u, follow up; h/o, history of; IST, inappropriate sinus tachycardia; IV, intravenous; LV, left ventricular; MI, myocardial infarction; NASPE, North American </text>
<text top="133" left="54" width="1072" height="15" font="1">Society of Pacing and Electrophysiology; NSVT, non-sustained ventricular tachycardia; OR, odds ratio; PAC, premature atrial complex; PES, programmed electrical stimulation; PPM, prosthesis-patient mismatch; PSVT, </text>
<text top="148" left="54" width="1081" height="15" font="1">paroxysmal supraventricular tachycardia; pt, patient; QALY, quality-adjusted life year; RFA, radiofrequency ablation; rx, prescription; sbp, systolic blood pressure; SD, standard deviation; SHD, structural heart disease; SP, </text>
<text top="164" left="54" width="1057" height="15" font="1">slow pathway; SR, sinus rhythm; ST, sinus tachycardia; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia; WCT, wide complex tachycardia; w/, with; and WPW, Wolff-Parkinson-</text>
<text top="179" left="54" width="92" height="15" font="1">White syndrome.   </text>
<text top="195" left="54" width="3" height="15" font="1"> </text>
<text top="220" left="54" width="143" height="18" font="3"><b>Data Supplement 4. </b></text>
<text top="220" left="197" width="487" height="18" font="7"><b>Randomized Trials Comparing Sinus Tachyarrhythmias – Section 3  </b></text>
<text top="239" left="60" width="38" height="17" font="5"><b>Study </b></text>
<text top="256" left="58" width="40" height="17" font="5"><b>Name, </b></text>
<text top="273" left="55" width="47" height="17" font="5"><b>Author, </b></text>
<text top="291" left="64" width="30" height="17" font="5"><b>Year </b></text>
<text top="239" left="119" width="42" height="17" font="5"><b>Aim of </b></text>
<text top="256" left="121" width="38" height="17" font="5"><b>Study </b></text>
<text top="239" left="182" width="38" height="17" font="5"><b>Study </b></text>
<text top="256" left="185" width="32" height="17" font="5"><b>Type </b></text>
<text top="273" left="183" width="36" height="17" font="5"><b>(Size, </b></text>
<text top="291" left="193" width="16" height="17" font="5"><b>N) </b></text>
<text top="239" left="256" width="38" height="17" font="5"><b>Study </b></text>
<text top="256" left="238" width="74" height="17" font="5"><b>Intervention </b></text>
<text top="273" left="245" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="239" left="344" width="38" height="17" font="5"><b>Study </b></text>
<text top="256" left="326" width="73" height="17" font="5"><b>Comparator </b></text>
<text top="273" left="333" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="239" left="490" width="83" height="17" font="5"><b>Pt Population </b></text>
<text top="239" left="756" width="64" height="17" font="5"><b>Endpoints </b></text>
<text top="239" left="933" width="109" height="17" font="5"><b>P Values, OR: HR: </b></text>
<text top="256" left="945" width="85" height="17" font="5"><b>RR: &amp; 95% CI: </b></text>
<text top="239" left="1081" width="38" height="17" font="5"><b>Study </b></text>
<text top="256" left="1066" width="69" height="17" font="5"><b>Limitations </b></text>
<text top="273" left="1068" width="64" height="17" font="5"><b>&amp; Adverse </b></text>
<text top="291" left="1078" width="44" height="17" font="5"><b>Events </b></text>
<text top="309" left="67" width="3" height="17" font="5"><b> </b></text>
<text top="309" left="138" width="3" height="17" font="5"><b> </b></text>
<text top="309" left="199" width="3" height="17" font="5"><b> </b></text>
<text top="309" left="273" width="3" height="17" font="5"><b> </b></text>
<text top="309" left="361" width="3" height="17" font="5"><b> </b></text>
<text top="309" left="419" width="104" height="17" font="13"><i><b>Inclusion Criteria </b></i></text>
<text top="309" left="542" width="108" height="17" font="13"><i><b>Exclusion Criteria </b></i></text>
<text top="309" left="676" width="49" height="17" font="13"><i><b>Primary </b></i></text>
<text top="326" left="672" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="343" left="672" width="58" height="17" font="13"><i><b>(efficacy) </b></i></text>
<text top="360" left="664" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="309" left="771" width="40" height="17" font="13"><i><b>Safety </b></i></text>
<text top="326" left="763" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="343" left="755" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="309" left="846" width="70" height="17" font="13"><i><b>Secondary  </b></i></text>
<text top="326" left="851" width="67" height="17" font="13"><i><b>Endpoint    </b></i></text>
<text top="343" left="867" width="25" height="17" font="13"><i><b>and </b></i></text>
<text top="360" left="855" width="48" height="17" font="13"><i><b>Results </b></i></text>
<text top="309" left="986" width="3" height="17" font="5"><b> </b></text>
<text top="309" left="1098" width="3" height="17" font="5"><b> </b></text>
<text top="378" left="54" width="40" height="15" font="1">BEAUTI</text>
<text top="394" left="54" width="24" height="15" font="1">FUL </text>
<text top="409" left="54" width="28" height="15" font="1">2008 </text>
<text top="425" left="54" width="23" height="15" font="1">(62) </text>
<text top="440" left="54" width="43" height="15" font="8">1875708</text>
<text top="456" left="54" width="6" height="15" font="8">8</text>
<text top="456" left="60" width="3" height="15" font="1"> </text>
<text top="378" left="116" width="16" height="15" font="1">To </text>
<text top="394" left="116" width="43" height="15" font="1">determin</text>
<text top="409" left="116" width="37" height="15" font="1">e if HR </text>
<text top="425" left="116" width="44" height="15" font="1">lowering </text>
<text top="440" left="116" width="14" height="15" font="1">w/ </text>
<text top="456" left="116" width="39" height="15" font="1">ivabradi</text>
<text top="471" left="116" width="15" height="15" font="1">ne </text>
<text top="487" left="116" width="42" height="15" font="1">reduces </text>
<text top="502" left="116" width="42" height="15" font="1">cardiova</text>
<text top="518" left="116" width="33" height="15" font="1">scular </text>
<text top="533" left="116" width="31" height="15" font="1">death </text>
<text top="549" left="116" width="21" height="15" font="1">and </text>
<text top="564" left="116" width="39" height="15" font="1">morbidit</text>
<text top="579" left="116" width="38" height="15" font="1">y in pts </text>
<text top="595" left="116" width="14" height="15" font="1">w/ </text>
<text top="610" left="116" width="46" height="15" font="1">coronary </text>
<text top="626" left="116" width="41" height="15" font="1">disease </text>
<text top="642" left="116" width="38" height="15" font="1">and LV </text>
<text top="657" left="116" width="39" height="15" font="1">systolic </text>
<text top="672" left="116" width="44" height="15" font="1">dysfuncti</text>
<text top="688" left="116" width="15" height="15" font="1">on </text>
<text top="378" left="177" width="44" height="15" font="1">Randomi</text>
<text top="394" left="177" width="24" height="15" font="1">zed, </text>
<text top="409" left="177" width="36" height="15" font="1">double </text>
<text top="425" left="177" width="26" height="15" font="1">blind </text>
<text top="440" left="177" width="42" height="15" font="1">placebo </text>
<text top="456" left="177" width="42" height="15" font="1">controlle</text>
<text top="471" left="177" width="12" height="15" font="1">d, </text>
<text top="487" left="177" width="39" height="15" font="1">parallel </text>
<text top="502" left="177" width="34" height="15" font="1">group. </text>
<text top="518" left="177" width="44" height="15" font="1">Multicent</text>
<text top="533" left="177" width="13" height="15" font="1">er </text>
<text top="549" left="177" width="37" height="15" font="1">10,917 </text>
<text top="564" left="177" width="18" height="15" font="1">pts </text>
<text top="579" left="177" width="45" height="15" font="1">enrolled. </text>
<text top="595" left="177" width="45" height="15" font="1">Intention </text>
<text top="610" left="177" width="37" height="15" font="1">to treat </text>
<text top="626" left="177" width="43" height="15" font="1">analysis </text>
<text top="378" left="238" width="64" height="15" font="1">Ivabradine 5 </text>
<text top="394" left="238" width="70" height="15" font="1">mg increased </text>
<text top="409" left="238" width="67" height="15" font="1">to 7.5 mg bid </text>
<text top="378" left="325" width="181" height="15" font="1">Placebo Coronary </text>
<text top="378" left="462" width="76" height="15" font="1">artery </text>
<text top="394" left="413" width="107" height="15" font="1">disease, LVEF &lt;40% </text>
<text top="409" left="413" width="93" height="15" font="1">Age ≥55, or ≥18 if </text>
<text top="425" left="413" width="41" height="15" font="1">diabetic </text>
<text top="440" left="413" width="109" height="15" font="1">Sinus rhythm, HR≥60 </text>
<text top="456" left="413" width="25" height="15" font="1">bpm </text>
<text top="471" left="413" width="97" height="15" font="1">Angina and HF sxs </text>
<text top="487" left="413" width="110" height="15" font="1">stable over 3 mo prior </text>
<text top="502" left="413" width="115" height="15" font="1">to enrollment on stable </text>
<text top="518" left="413" width="111" height="15" font="1">doses of at least 1 mo </text>
<text top="533" left="413" width="77" height="15" font="1">of conventional </text>
<text top="549" left="413" width="84" height="15" font="1">medical therapy  </text>
<text top="378" left="541" width="74" height="15" font="1">MI or coronary </text>
<text top="394" left="541" width="86" height="15" font="1">revascularization </text>
<text top="409" left="541" width="76" height="15" font="1">w/in prior 6 mo </text>
<text top="425" left="541" width="102" height="15" font="1">Stroke/TIA in prior 3 </text>
<text top="440" left="541" width="18" height="15" font="1">mo </text>
<text top="456" left="541" width="94" height="15" font="1">Pacemaker or ICD </text>
<text top="471" left="541" width="69" height="15" font="1">VHD needing </text>
<text top="487" left="541" width="81" height="15" font="1">surgery w/in 3 y </text>
<text top="502" left="541" width="108" height="15" font="1">Sick sinus syndrome, </text>
<text top="518" left="541" width="93" height="15" font="1">long QT, complete </text>
<text top="533" left="541" width="60" height="15" font="1">heart block, </text>
<text top="549" left="541" width="92" height="15" font="1">uncontrolled HTN, </text>
<text top="564" left="541" width="47" height="15" font="1">NYHA IV </text>
<text top="580" left="541" width="107" height="15" font="1">Other medications w/ </text>
<text top="595" left="541" width="89" height="15" font="1">strong CYP P450 </text>
<text top="610" left="541" width="70" height="15" font="1">3A4 inhibition </text>
<text top="378" left="663" width="68" height="15" font="1">Composite of </text>
<text top="394" left="663" width="74" height="15" font="1">cardiovascular </text>
<text top="409" left="663" width="34" height="15" font="1">death, </text>
<text top="425" left="663" width="41" height="15" font="1">hospital </text>
<text top="440" left="663" width="69" height="15" font="1">admission for </text>
<text top="456" left="663" width="49" height="15" font="1">acute MI, </text>
<text top="471" left="663" width="41" height="15" font="1">hospital </text>
<text top="487" left="663" width="69" height="15" font="1">admission for </text>
<text top="502" left="663" width="66" height="15" font="1">new onset or </text>
<text top="518" left="663" width="71" height="15" font="1">worsening HF </text>
<text top="378" left="751" width="22" height="15" font="1">N/A </text>
<text top="378" left="845" width="45" height="15" font="1">Mortality </text>
<text top="394" left="845" width="3" height="15" font="1"> </text>
<text top="409" left="845" width="41" height="15" font="1">Cardiac </text>
<text top="425" left="845" width="53" height="15" font="1">death (MI, </text>
<text top="440" left="845" width="55" height="15" font="1">HF, due to </text>
<text top="456" left="845" width="39" height="15" font="1">cardiac </text>
<text top="471" left="845" width="53" height="15" font="1">procedure </text>
<text top="487" left="845" width="3" height="15" font="1"> </text>
<text top="502" left="845" width="64" height="15" font="1">Cardiovascul</text>
<text top="518" left="845" width="44" height="15" font="1">ar death </text>
<text top="533" left="845" width="3" height="15" font="1"> </text>
<text top="549" left="845" width="43" height="15" font="1">Hospital </text>
<text top="564" left="845" width="46" height="15" font="1">admit for </text>
<text top="579" left="845" width="59" height="15" font="1">acute MI or </text>
<text top="595" left="845" width="45" height="15" font="1">unstable </text>
<text top="610" left="845" width="36" height="15" font="1">angina </text>
<text top="626" left="845" width="3" height="15" font="1"> </text>
<text top="642" left="845" width="49" height="15" font="1">Coronary </text>
<text top="657" left="845" width="59" height="15" font="1">revasculariz</text>
<text top="672" left="845" width="27" height="15" font="1">ation </text>
<text top="688" left="845" width="3" height="15" font="1"> </text>
<text top="703" left="845" width="43" height="15" font="1">Hospital </text>
<text top="719" left="845" width="64" height="15" font="1">admit for HF </text>
<text top="734" left="845" width="43" height="15" font="1">Hospital </text>
<text top="750" left="845" width="46" height="15" font="1">admit for </text>
<text top="765" left="845" width="46" height="15" font="1">acute MI </text>
<text top="781" left="845" width="3" height="15" font="1"> </text>
<text top="378" left="926" width="92" height="15" font="1">Median f/u 19 mo. </text>
<text top="394" left="926" width="95" height="15" font="1">Baseline mean HR </text>
<text top="409" left="926" width="117" height="15" font="1">71.6±9.9 bpm, lowered </text>
<text top="425" left="926" width="116" height="15" font="1">at 12 mo by 6 bpm and </text>
<text top="440" left="926" width="95" height="15" font="1">by 5 bpm at 24 mo </text>
<text top="456" left="926" width="107" height="15" font="1">corrected for placebo </text>
<text top="471" left="926" width="3" height="15" font="1"> </text>
<text top="487" left="926" width="87" height="15" font="1">Primary endpoint </text>
<text top="502" left="926" width="73" height="15" font="1">unchanged by </text>
<text top="518" left="926" width="54" height="15" font="1">ivabradine </text>
<text top="533" left="926" width="123" height="15" font="1">For pts w/ HR of 70 bpm </text>
<text top="549" left="926" width="104" height="15" font="1">or higher, ivabradine </text>
<text top="564" left="926" width="85" height="15" font="1">reduced admit to </text>
<text top="580" left="926" width="103" height="15" font="1">hospital for fatal and </text>
<text top="595" left="926" width="82" height="15" font="1">non fatal MI and </text>
<text top="610" left="926" width="46" height="15" font="1">coronary </text>
<text top="626" left="926" width="86" height="15" font="1">revascularization </text>
<text top="642" left="926" width="113" height="15" font="1">(secondary endpoints) </text>
<text top="657" left="926" width="92" height="15" font="1">87% were on beta </text>
<text top="672" left="926" width="44" height="15" font="1">blockers </text>
<text top="688" left="926" width="3" height="15" font="1"> </text>
<text top="703" left="926" width="119" height="15" font="1">No difference in serious </text>
<text top="719" left="926" width="123" height="15" font="1">adverse events between </text>
<text top="734" left="926" width="69" height="15" font="1">pts treated w/ </text>
<text top="750" left="926" width="109" height="15" font="1">ivabradine or placebo </text>
<text top="378" left="1063" width="52" height="15" font="1">Heart rate </text>
<text top="394" left="1063" width="67" height="15" font="1">reduction not </text>
<text top="409" left="1063" width="56" height="15" font="1">a specified </text>
<text top="425" left="1063" width="58" height="15" font="1">endpoint of </text>
<text top="440" left="1063" width="42" height="15" font="1">the trial, </text>
<text top="456" left="1063" width="48" height="15" font="1">though is </text>
<text top="471" left="1063" width="47" height="15" font="1">reported. </text>
<text top="487" left="1063" width="3" height="15" font="1"> </text>
<text top="502" left="1063" width="56" height="15" font="1">Not an IST </text>
<text top="518" left="1063" width="73" height="15" font="1">population but </text>
<text top="533" left="1063" width="48" height="15" font="1">trial does </text>
<text top="549" left="1063" width="65" height="15" font="1">demonstrate </text>
<text top="564" left="1063" width="45" height="15" font="1">safety of </text>
<text top="580" left="1063" width="66" height="15" font="1">ivabradine in </text>
<text top="595" left="1063" width="54" height="15" font="1">a high risk </text>
<text top="610" left="1063" width="66" height="15" font="1">population in </text>
<text top="626" left="1063" width="40" height="15" font="1">a large, </text>
<text top="642" left="1063" width="64" height="15" font="1">randomized, </text>
<text top="657" left="1063" width="42" height="15" font="1">placebo </text>
<text top="672" left="1063" width="72" height="15" font="1">controlled trial </text>
<text top="688" left="1063" width="3" height="15" font="1"> </text>
<text top="703" left="1063" width="52" height="15" font="1">Heart rate </text>
<text top="719" left="1063" width="49" height="15" font="1">reduction </text>
<text top="734" left="1063" width="58" height="15" font="1">modest but </text>
<text top="750" left="1063" width="73" height="15" font="1">baseline heart </text>
<text top="765" left="1063" width="47" height="15" font="1">rates are </text>
<text top="781" left="1063" width="29" height="15" font="1">lower </text>
<text top="796" left="1063" width="65" height="15" font="1">compared to </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">26 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="1063" width="36" height="15" font="1">an IST </text>
<text top="70" left="1063" width="57" height="15" font="1">population. </text>
<text top="86" left="54" width="35" height="15" font="1">SHIFT </text>
<text top="102" left="54" width="28" height="15" font="1">2010 </text>
<text top="117" left="54" width="23" height="15" font="1">(63) </text>
<text top="133" left="54" width="43" height="15" font="8">2080150</text>
<text top="148" left="54" width="6" height="15" font="8">0</text>
<text top="148" left="60" width="3" height="15" font="1"> </text>
<text top="86" left="116" width="16" height="15" font="1">To </text>
<text top="102" left="116" width="43" height="15" font="1">determin</text>
<text top="117" left="116" width="37" height="15" font="1">e if HR </text>
<text top="133" left="116" width="44" height="15" font="1">lowering </text>
<text top="148" left="116" width="14" height="15" font="1">w/ </text>
<text top="164" left="116" width="39" height="15" font="1">ivabradi</text>
<text top="179" left="116" width="15" height="15" font="1">ne </text>
<text top="195" left="116" width="39" height="15" font="1">improve</text>
<text top="210" left="116" width="9" height="15" font="1">s </text>
<text top="226" left="116" width="42" height="15" font="1">outcome</text>
<text top="241" left="116" width="38" height="15" font="1">s in HF </text>
<text top="86" left="177" width="44" height="15" font="1">Randomi</text>
<text top="102" left="177" width="24" height="15" font="1">zed, </text>
<text top="117" left="177" width="37" height="15" font="1">double-</text>
<text top="133" left="177" width="29" height="15" font="1">blind, </text>
<text top="148" left="177" width="42" height="15" font="1">placebo-</text>
<text top="164" left="177" width="42" height="15" font="1">controlle</text>
<text top="179" left="177" width="12" height="15" font="1">d, </text>
<text top="195" left="177" width="39" height="15" font="1">parallel-</text>
<text top="210" left="177" width="34" height="15" font="1">group. </text>
<text top="226" left="177" width="44" height="15" font="1">Multicent</text>
<text top="241" left="177" width="34" height="15" font="1">er trial </text>
<text top="257" left="177" width="21" height="15" font="1">that </text>
<text top="272" left="177" width="42" height="15" font="1">enrolled </text>
<text top="288" left="177" width="28" height="15" font="1">6558 </text>
<text top="303" left="177" width="21" height="15" font="1">pts. </text>
<text top="86" left="238" width="65" height="15" font="1">Ivabradine 5-</text>
<text top="102" left="238" width="55" height="15" font="1">7.5 mg bid </text>
<text top="86" left="325" width="43" height="15" font="1">Placebo </text>
<text top="86" left="413" width="100" height="15" font="1">Age ≥18 in sinus w/ </text>
<text top="102" left="413" width="90" height="15" font="1">resting HR of ≥70 </text>
<text top="117" left="413" width="97" height="15" font="1">Stable HF sxs over </text>
<text top="133" left="413" width="51" height="15" font="1">prior 4 wk </text>
<text top="148" left="413" width="114" height="15" font="1">Prior hospital admit for </text>
<text top="164" left="413" width="108" height="15" font="1">HF in previous 12 mo </text>
<text top="179" left="413" width="63" height="15" font="1">LVEF ≤35% </text>
<text top="195" left="413" width="99" height="15" font="1">On optimum, stable </text>
<text top="210" left="413" width="106" height="15" font="1">medical therapy over </text>
<text top="226" left="413" width="51" height="15" font="1">prior 4 wk </text>
<text top="86" left="541" width="27" height="15" font="1">CHD </text>
<text top="102" left="541" width="77" height="15" font="1">Primary severe </text>
<text top="117" left="541" width="82" height="15" font="1">valvular disease </text>
<text top="133" left="541" width="95" height="15" font="1">Recent MI (&lt;2 mo) </text>
<text top="148" left="541" width="95" height="15" font="1">Pacing for ≥40%/d </text>
<text top="164" left="541" width="75" height="15" font="1">AF/atrial flutter </text>
<text top="179" left="541" width="67" height="15" font="1">Symptomatic </text>
<text top="195" left="541" width="63" height="15" font="1">hypotension </text>
<text top="210" left="541" width="3" height="15" font="1"> </text>
<text top="226" left="541" width="90" height="15" font="1">Pts not allowed to </text>
<text top="241" left="541" width="61" height="15" font="1">receive non-</text>
<text top="257" left="541" width="78" height="15" font="1">dihydropyridine </text>
<text top="272" left="541" width="82" height="15" font="1">calcium channel </text>
<text top="288" left="541" width="98" height="15" font="1">blocker, class I anti-</text>
<text top="303" left="541" width="101" height="15" font="1">arrhythmic or strong </text>
<text top="319" left="541" width="100" height="15" font="1">inhibitor of CYP3A4 </text>
<text top="86" left="663" width="68" height="15" font="1">Composite of </text>
<text top="102" left="663" width="74" height="15" font="1">cardiovascular </text>
<text top="117" left="663" width="44" height="15" font="1">death or </text>
<text top="133" left="663" width="41" height="15" font="1">hospital </text>
<text top="148" left="663" width="69" height="15" font="1">admission for </text>
<text top="164" left="663" width="74" height="15" font="1">worsening HF. </text>
<text top="179" left="663" width="58" height="15" font="1">Intention to </text>
<text top="195" left="663" width="68" height="15" font="1">treat analysis </text>
<text top="86" left="751" width="22" height="15" font="1">N/A </text>
<text top="86" left="845" width="56" height="15" font="1">Composite </text>
<text top="102" left="845" width="61" height="15" font="1">cardiovascul</text>
<text top="117" left="845" width="57" height="15" font="1">ar death or </text>
<text top="133" left="845" width="41" height="15" font="1">hospital </text>
<text top="148" left="845" width="46" height="15" font="1">admit for </text>
<text top="164" left="845" width="53" height="15" font="1">worsening </text>
<text top="179" left="845" width="50" height="15" font="1">HF in pts  </text>
<text top="195" left="845" width="60" height="15" font="1">receiving at </text>
<text top="210" left="845" width="64" height="15" font="1">least 50% of </text>
<text top="226" left="845" width="57" height="15" font="1">target daily </text>
<text top="241" left="845" width="64" height="15" font="1">dose of beta </text>
<text top="257" left="845" width="39" height="15" font="1">blocker </text>
<text top="272" left="845" width="58" height="15" font="1">(metoprolol </text>
<text top="288" left="845" width="58" height="15" font="1">target dose </text>
<text top="303" left="845" width="62" height="15" font="1">= 150 mg/d) </text>
<text top="319" left="845" width="3" height="15" font="1"> </text>
<text top="334" left="845" width="48" height="15" font="1">All cause </text>
<text top="350" left="845" width="31" height="15" font="1">death </text>
<text top="365" left="845" width="3" height="15" font="1"> </text>
<text top="381" left="845" width="41" height="15" font="1">Any CV </text>
<text top="396" left="845" width="31" height="15" font="1">death </text>
<text top="412" left="845" width="3" height="15" font="1"> </text>
<text top="427" left="845" width="43" height="15" font="1">Hospital </text>
<text top="443" left="845" width="58" height="15" font="1">admit (any) </text>
<text top="458" left="845" width="3" height="15" font="1"> </text>
<text top="474" left="845" width="60" height="15" font="1">CV hospital </text>
<text top="489" left="845" width="30" height="15" font="1">admit </text>
<text top="505" left="845" width="3" height="15" font="1"> </text>
<text top="520" left="845" width="58" height="15" font="1">Death from </text>
<text top="535" left="845" width="18" height="15" font="1">HF </text>
<text top="551" left="845" width="3" height="15" font="1"> </text>
<text top="567" left="845" width="56" height="15" font="1">Composite </text>
<text top="582" left="845" width="65" height="15" font="1">of CV death, </text>
<text top="597" left="845" width="41" height="15" font="1">hospital </text>
<text top="613" left="845" width="46" height="15" font="1">admit for </text>
<text top="628" left="845" width="53" height="15" font="1">worsening </text>
<text top="644" left="845" width="62" height="15" font="1">HF, hospital </text>
<text top="659" left="845" width="46" height="15" font="1">admit for </text>
<text top="675" left="845" width="62" height="15" font="1">non-fatal MI </text>
<text top="86" left="926" width="104" height="15" font="1">Median f/u 22.9 mo.  </text>
<text top="102" left="926" width="111" height="15" font="1">HR at 28 d decreased </text>
<text top="117" left="926" width="105" height="15" font="1">by 15.4±10.7 bpm in </text>
<text top="133" left="926" width="118" height="15" font="1">ivabradine c/w baseline </text>
<text top="148" left="926" width="104" height="15" font="1">and by 10.9 (CI 10.4-</text>
<text top="164" left="926" width="117" height="15" font="1">11.4) bpm c/w placebo. </text>
<text top="179" left="926" width="102" height="15" font="1">At 1 y, HR reduction </text>
<text top="195" left="926" width="100" height="15" font="1">was 9.1 (CI 8.5-9.7) </text>
<text top="210" left="926" width="123" height="15" font="1">bpm c/w placebo, and at </text>
<text top="226" left="926" width="106" height="15" font="1">study end 8.1 (CI 7.5-</text>
<text top="241" left="926" width="108" height="15" font="1">8.7) bpm c/w placebo </text>
<text top="257" left="926" width="3" height="15" font="1"> </text>
<text top="272" left="926" width="87" height="15" font="1">Primary endpoint </text>
<text top="288" left="926" width="92" height="15" font="1">reached in 24% of </text>
<text top="303" left="926" width="107" height="15" font="1">ivabradine group and </text>
<text top="319" left="926" width="79" height="15" font="1">29% of placebo </text>
<text top="334" left="926" width="108" height="15" font="1">(p&lt;0.0001), driven by </text>
<text top="350" left="926" width="105" height="15" font="1">difference in hospital </text>
<text top="365" left="926" width="108" height="15" font="1">admission for HF and </text>
<text top="381" left="926" width="89" height="15" font="1">death due to HF.  </text>
<text top="396" left="926" width="115" height="15" font="1">Fewer serious adverse </text>
<text top="412" left="926" width="101" height="15" font="1">events in ivabradine </text>
<text top="427" left="926" width="117" height="15" font="1">group (p=0.025). 5% of </text>
<text top="443" left="926" width="87" height="15" font="1">ibabradine pts w/ </text>
<text top="458" left="926" width="65" height="15" font="1">symptomatic </text>
<text top="474" left="926" width="113" height="15" font="1">bradycardia compared </text>
<text top="489" left="926" width="86" height="15" font="1">to 1% of placebo </text>
<text top="505" left="926" width="117" height="15" font="1">(p&lt;0.0001). Visual side </text>
<text top="520" left="926" width="118" height="15" font="1">effects (phosphenes) in </text>
<text top="535" left="926" width="117" height="15" font="1">3% of ivabradine group </text>
<text top="551" left="926" width="90" height="15" font="1">vs. 1% of placebo </text>
<text top="567" left="926" width="57" height="15" font="1">(p&lt;0.0001) </text>
<text top="86" left="1063" width="52" height="15" font="1">Heart rate </text>
<text top="102" left="1063" width="67" height="15" font="1">reduction not </text>
<text top="117" left="1063" width="56" height="15" font="1">a specified </text>
<text top="133" left="1063" width="58" height="15" font="1">endpoint of </text>
<text top="148" left="1063" width="42" height="15" font="1">the trial, </text>
<text top="164" left="1063" width="48" height="15" font="1">though is </text>
<text top="179" left="1063" width="47" height="15" font="1">reported. </text>
<text top="195" left="1063" width="3" height="15" font="1"> </text>
<text top="210" left="1063" width="56" height="15" font="1">Not an IST </text>
<text top="226" left="1063" width="73" height="15" font="1">population but </text>
<text top="241" left="1063" width="48" height="15" font="1">trial does </text>
<text top="257" left="1063" width="65" height="15" font="1">demonstrate </text>
<text top="272" left="1063" width="45" height="15" font="1">safety of </text>
<text top="288" left="1063" width="66" height="15" font="1">ivabradine in </text>
<text top="303" left="1063" width="54" height="15" font="1">a high risk </text>
<text top="319" left="1063" width="66" height="15" font="1">population in </text>
<text top="334" left="1063" width="40" height="15" font="1">a large, </text>
<text top="350" left="1063" width="64" height="15" font="1">randomized, </text>
<text top="365" left="1063" width="42" height="15" font="1">placebo </text>
<text top="381" left="1063" width="72" height="15" font="1">controlled trial </text>
<text top="396" left="1063" width="3" height="15" font="1"> </text>
<text top="412" left="1063" width="68" height="15" font="1">HR reduction </text>
<text top="427" left="1063" width="58" height="15" font="1">modest but </text>
<text top="443" left="1063" width="73" height="15" font="1">baseline heart </text>
<text top="458" left="1063" width="47" height="15" font="1">rates are </text>
<text top="474" left="1063" width="29" height="15" font="1">lower </text>
<text top="489" left="1063" width="65" height="15" font="1">compared to </text>
<text top="505" left="1063" width="36" height="15" font="1">an IST </text>
<text top="520" left="1063" width="57" height="15" font="1">population. </text>
<text top="691" left="54" width="45" height="15" font="1">Cappato </text>
<text top="707" left="54" width="11" height="15" font="1">R </text>
<text top="722" left="54" width="28" height="15" font="1">2012 </text>
<text top="738" left="54" width="23" height="15" font="1">(64) </text>
<text top="753" left="54" width="43" height="15" font="8">2298155</text>
<text top="769" left="54" width="6" height="15" font="8">5</text>
<text top="769" left="60" width="3" height="15" font="1"> </text>
<text top="691" left="116" width="16" height="15" font="1">To </text>
<text top="707" left="116" width="43" height="15" font="1">determin</text>
<text top="722" left="116" width="28" height="15" font="1">e the </text>
<text top="738" left="116" width="41" height="15" font="1">effective</text>
<text top="753" left="116" width="39" height="15" font="1">ness of </text>
<text top="769" left="116" width="39" height="15" font="1">ivabradi</text>
<text top="784" left="116" width="28" height="15" font="1">ne to </text>
<text top="691" left="177" width="38" height="15" font="1">Double </text>
<text top="707" left="177" width="29" height="15" font="1">blind, </text>
<text top="722" left="177" width="40" height="15" font="1">randomi</text>
<text top="738" left="177" width="24" height="15" font="1">zed, </text>
<text top="753" left="177" width="42" height="15" font="1">placebo </text>
<text top="769" left="177" width="42" height="15" font="1">controlle</text>
<text top="784" left="177" width="9" height="15" font="1">d </text>
<text top="691" left="238" width="55" height="15" font="1">Ivabradine </text>
<text top="707" left="238" width="60" height="15" font="1">(2.5-7.5 mg </text>
<text top="722" left="238" width="74" height="15" font="1">twice daily) for </text>
<text top="738" left="238" width="69" height="15" font="1">6 wk then 7 d </text>
<text top="753" left="238" width="69" height="15" font="1">washout then </text>
<text top="769" left="238" width="63" height="15" font="1">crossover to </text>
<text top="784" left="238" width="67" height="15" font="1">placebo for 6 </text>
<text top="691" left="325" width="68" height="15" font="1">Placebo for 6 </text>
<text top="707" left="325" width="60" height="15" font="1">wk then 7 d </text>
<text top="722" left="325" width="69" height="15" font="1">washout then </text>
<text top="738" left="325" width="63" height="15" font="1">crossover to </text>
<text top="753" left="325" width="70" height="15" font="1">ivabradine for </text>
<text top="769" left="325" width="61" height="15" font="1">6 wk (n = 9) </text>
<text top="691" left="413" width="97" height="15" font="1">Mean resting dtime </text>
<text top="707" left="413" width="102" height="15" font="1">HR &gt;95 on Holter or </text>
<text top="722" left="413" width="112" height="15" font="1">&gt;25 bpm symptomatic </text>
<text top="738" left="413" width="113" height="15" font="1">rise in HR from supine </text>
<text top="753" left="413" width="82" height="15" font="1">to standing or in </text>
<text top="769" left="413" width="94" height="15" font="1">response to stress </text>
<text top="691" left="541" width="82" height="15" font="1">Underlying SHD </text>
<text top="707" left="541" width="66" height="15" font="1">(excluded by </text>
<text top="722" left="541" width="89" height="15" font="1">echocardiogram), </text>
<text top="738" left="541" width="82" height="15" font="1">SVT, orthostatic </text>
<text top="753" left="541" width="66" height="15" font="1">hypotension, </text>
<text top="769" left="541" width="101" height="15" font="1">compensatory sinus </text>
<text top="784" left="541" width="78" height="15" font="1">tachycardia, on </text>
<text top="691" left="663" width="67" height="15" font="1">Sx resolution </text>
<text top="707" left="663" width="49" height="15" font="1">from 7 sx </text>
<text top="722" left="663" width="50" height="15" font="1">indicators </text>
<text top="691" left="751" width="22" height="15" font="1">N/A </text>
<text top="691" left="845" width="19" height="15" font="1">HR </text>
<text top="707" left="845" width="65" height="15" font="1">measuremen</text>
<text top="722" left="845" width="40" height="15" font="1">ts (rest, </text>
<text top="738" left="845" width="51" height="15" font="1">exercise), </text>
<text top="753" left="845" width="44" height="15" font="1">exercise </text>
<text top="769" left="845" width="44" height="15" font="1">capacity </text>
<text top="691" left="926" width="104" height="15" font="1">Ivabradine: &gt;70% sx </text>
<text top="707" left="926" width="109" height="15" font="1">elimination (RR: 0.25; </text>
<text top="722" left="926" width="95" height="15" font="1">95% CI: 0.18-0.34; </text>
<text top="738" left="926" width="115" height="15" font="1">p&lt;0.001), resting heart </text>
<text top="753" left="926" width="119" height="15" font="1">rate reduced (p=0.011), </text>
<text top="769" left="926" width="98" height="15" font="1">and during exertion </text>
<text top="784" left="926" width="123" height="15" font="1">(p=0.001) and increased </text>
<text top="691" left="1063" width="57" height="15" font="1">Duration of </text>
<text top="707" left="1063" width="68" height="15" font="1">therapy short </text>
<text top="722" left="1063" width="66" height="15" font="1">(6 wk), some </text>
<text top="738" left="1063" width="54" height="15" font="1">pts did not </text>
<text top="753" left="1063" width="74" height="15" font="1">improve in sxs </text>
<text top="769" left="1063" width="67" height="15" font="1">despite heart </text>
<text top="784" left="1063" width="22" height="15" font="1">rate </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">27 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="37" height="15" font="1">reduce </text>
<text top="70" left="116" width="41" height="15" font="1">sxs due </text>
<text top="86" left="116" width="33" height="15" font="1">to IST </text>
<text top="55" left="177" width="44" height="15" font="1">crossove</text>
<text top="70" left="177" width="10" height="15" font="1">r  </text>
<text top="86" left="177" width="46" height="15" font="1">(N = 21)  </text>
<text top="55" left="238" width="61" height="15" font="1">wk (n = 10)  </text>
<text top="55" left="541" width="73" height="15" font="1">antiarrhythmic </text>
<text top="70" left="541" width="84" height="15" font="1">therapy, renal or </text>
<text top="86" left="541" width="105" height="15" font="1">hepatic insufficiency, </text>
<text top="101" left="541" width="70" height="15" font="1">on inhibitor of </text>
<text top="117" left="541" width="46" height="15" font="1">CYP3A4 </text>
<text top="55" left="926" width="109" height="15" font="1">exercise performance </text>
<text top="55" left="1063" width="57" height="15" font="1">reductions. </text>
<text top="70" left="1063" width="53" height="15" font="1">Long term </text>
<text top="86" left="1063" width="68" height="15" font="1">effectiveness </text>
<text top="101" left="1063" width="73" height="15" font="1">and safety not </text>
<text top="117" left="1063" width="42" height="15" font="1">studied. </text>
<text top="133" left="54" width="1057" height="15" font="1">AF indicates atrial fibrillation; bid, two times per day; bpm indicates beats per min; CI, confidence interval; CPY3A4, cytochrome p450 3A4; CV, cardiovascular; c/w, consistent with; f/u, follow up; HF, heart failure; HR, </text>
<text top="148" left="54" width="1054" height="15" font="1">heart rate; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; IAST, inappropriate sinus tachycardia; N/A, not available; pt, patient; RR, relative risk; SHD, structural heart disease; sx, </text>
<text top="164" left="54" width="270" height="15" font="1">symptom; TIA, transient ischemic attack; and w/, with.  </text>
<text top="179" left="54" width="3" height="15" font="1"> </text>
<text top="205" left="54" width="143" height="18" font="3"><b>Data Supplement 5. </b></text>
<text top="205" left="197" width="729" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Sinus Tachyarrhythmias – Section 3</b></text>
<text top="205" left="926" width="4" height="18" font="3"><b> </b></text>
<text top="224" left="68" width="38" height="17" font="5"><b>Study </b></text>
<text top="241" left="66" width="40" height="17" font="5"><b>Name, </b></text>
<text top="258" left="63" width="47" height="17" font="5"><b>Author, </b></text>
<text top="275" left="71" width="30" height="17" font="5"><b>Year </b></text>
<text top="224" left="135" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="241" left="149" width="44" height="17" font="5"><b>Design </b></text>
<text top="224" left="230" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="224" left="346" width="165" height="17" font="5"><b>Inclusion/Exclusion Criteria </b></text>
<text top="224" left="562" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="224" left="746" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="224" left="960" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="293" left="54" width="38" height="15" font="1">Lee RJ </text>
<text top="308" left="54" width="28" height="15" font="1">1995 </text>
<text top="324" left="54" width="23" height="15" font="1">(65) </text>
<text top="340" left="54" width="43" height="15" font="8">7586260</text>
<text top="340" left="97" width="3" height="15" font="1"> </text>
<text top="293" left="131" width="61" height="15" font="1">Prospective </text>
<text top="308" left="131" width="69" height="15" font="1">observational </text>
<text top="293" left="224" width="66" height="15" font="1">16 pts (12 w/ </text>
<text top="308" left="224" width="26" height="15" font="1">SAN </text>
<text top="324" left="224" width="62" height="15" font="1">modification </text>
<text top="340" left="224" width="71" height="15" font="1">and 4 w/ SAN </text>
<text top="355" left="224" width="46" height="15" font="1">ablation) </text>
<text top="293" left="315" width="221" height="15" font="1">Symptomatic, medically refractory pts w/ IST </text>
<text top="308" left="315" width="126" height="15" font="1">undergoing RFA enrolled </text>
<text top="324" left="315" width="3" height="15" font="1"> </text>
<text top="340" left="315" width="60" height="15" font="1">Procedure:  </text>
<text top="355" left="315" width="181" height="15" font="1">- Activation mapping (point-by-point) </text>
<text top="371" left="315" width="179" height="15" font="1">- Mapping guided by fluoroscopy or  </text>
<text top="386" left="315" width="122" height="15" font="1">  ICE (to visualize crista) </text>
<text top="401" left="315" width="74" height="15" font="1">- Isoproterenol </text>
<text top="417" left="315" width="3" height="15" font="1"> </text>
<text top="432" left="315" width="49" height="15" font="1">F/u tests: </text>
<text top="448" left="315" width="191" height="15" font="1">- Autonomic blockade (intrinsic HR) w/ </text>
<text top="463" left="315" width="192" height="15" font="1">propranolol + atropine before and after </text>
<text top="479" left="315" width="45" height="15" font="1">ablation  </text>
<text top="494" left="315" width="31" height="15" font="1">- ETT </text>
<text top="510" left="315" width="39" height="15" font="1">- Holter </text>
<text top="293" left="554" width="103" height="15" font="1">Procedural success: </text>
<text top="308" left="554" width="103" height="15" font="1">SAN modification: at </text>
<text top="324" left="554" width="112" height="15" font="1">least 25% reduction in </text>
<text top="340" left="554" width="109" height="15" font="1">sinus HR under same </text>
<text top="355" left="554" width="65" height="15" font="1">conditions of </text>
<text top="371" left="554" width="116" height="15" font="1">catecholamine infusion </text>
<text top="386" left="554" width="103" height="15" font="1">w/ either retention of </text>
<text top="401" left="554" width="112" height="15" font="1">normal P wave axis or </text>
<text top="417" left="554" width="86" height="15" font="1">low atrial escape </text>
<text top="432" left="554" width="3" height="15" font="1"> </text>
<text top="448" left="554" width="98" height="15" font="1">Total SAN ablation: </text>
<text top="463" left="554" width="111" height="15" font="1">reduction in HR &gt;50% </text>
<text top="479" left="554" width="105" height="15" font="1">of tachycardia HR w/ </text>
<text top="494" left="554" width="89" height="15" font="1">junctional escape </text>
<text top="293" left="688" width="122" height="15" font="1">Mean f/u = 20.5±0.4 mo </text>
<text top="308" left="688" width="91" height="15" font="1">SAN modification: </text>
<text top="324" left="688" width="194" height="15" font="1">- Procedural success 12/12 (100%) pts </text>
<text top="340" left="688" width="192" height="15" font="1">- 2 recurrences during F/U 7.1±1.7 mo </text>
<text top="355" left="688" width="3" height="15" font="1"> </text>
<text top="371" left="688" width="98" height="15" font="1">Total SAN ablation: </text>
<text top="386" left="688" width="182" height="15" font="1">- Procedural success 4/4 (100%) pts </text>
<text top="401" left="688" width="119" height="15" font="1">- No recurrences at F/U </text>
<text top="417" left="688" width="3" height="15" font="1"> </text>
<text top="432" left="688" width="76" height="15" font="1">Complications: </text>
<text top="448" left="688" width="206" height="15" font="1">- 2 pts PPM (both had total SAN ablation) </text>
<text top="463" left="688" width="218" height="15" font="1">- 1 pt transient right diaphragmatic paralysis </text>
<text top="479" left="688" width="151" height="15" font="1">- 1 pt transient SVC syndrome </text>
<text top="293" left="920" width="204" height="15" font="1">- SAN modification is feasible and should </text>
<text top="308" left="920" width="202" height="15" font="1">be considered as alternative to complete </text>
<text top="324" left="920" width="211" height="15" font="1">AV junction ablation in pts w/ disabling sxs </text>
<text top="340" left="920" width="215" height="15" font="1">of IST that is refractory to medical therapy.  </text>
<text top="355" left="920" width="204" height="15" font="1">-SAN modification may be aided by ICE.  </text>
<text top="526" left="54" width="57" height="15" font="1">Rakovec P </text>
<text top="542" left="54" width="28" height="15" font="1">2009 </text>
<text top="557" left="54" width="23" height="15" font="1">(66) </text>
<text top="573" left="54" width="49" height="15" font="8">19998013</text>
<text top="573" left="103" width="3" height="15" font="1"> </text>
<text top="526" left="131" width="72" height="15" font="1">Consecutively </text>
<text top="542" left="131" width="71" height="15" font="1">treated cohort </text>
<text top="526" left="224" width="15" height="15" font="1">13 </text>
<text top="526" left="315" width="155" height="15" font="1">Resting HR on ECG &gt;100 bpm </text>
<text top="542" left="315" width="209" height="15" font="1">Normal thyroid function, SHD excluded by </text>
<text top="557" left="315" width="82" height="15" font="1">echocardiogram </text>
<text top="526" left="554" width="111" height="15" font="1">Evaluation at baseline </text>
<text top="542" left="554" width="117" height="15" font="1">(ECG, Holter) and after </text>
<text top="557" left="554" width="111" height="15" font="1">2 wk on ivabradine 15 </text>
<text top="573" left="554" width="102" height="15" font="1">mg/d (repeat Holter) </text>
<text top="588" left="554" width="3" height="15" font="1"> </text>
<text top="526" left="688" width="184" height="15" font="1">11 women, 2 men, mean age 42±8 y </text>
<text top="542" left="688" width="191" height="15" font="1">7/13 were pretreated w/ beta blockers. </text>
<text top="557" left="688" width="177" height="15" font="1">Mean HR decreased from 94±10 to </text>
<text top="573" left="688" width="212" height="15" font="1">74.6±5.2 bpm w/ ivabradine (12 pts whose </text>
<text top="588" left="688" width="206" height="15" font="1">prior therapy could be discontinued or did </text>
<text top="604" left="688" width="210" height="15" font="1">not have prior therapy drug therapy). In 10 </text>
<text top="619" left="688" width="181" height="15" font="1">pts where min and max HR could be </text>
<text top="635" left="688" width="203" height="15" font="1">determined, the max HR decreased from </text>
<text top="650" left="688" width="199" height="15" font="1">150.3±13.4 bpm to 120.6± 9.8 bpm and </text>
<text top="666" left="688" width="180" height="15" font="1">min HR decreased from 66.7±9.6 to </text>
<text top="681" left="688" width="51" height="15" font="1">54.8±6.9. </text>
<text top="697" left="688" width="203" height="15" font="1">P&lt;0.001 for all HR comparisons (paired t </text>
<text top="712" left="688" width="33" height="15" font="1">tests). </text>
<text top="728" left="688" width="214" height="15" font="1">One pt on metoprolol 300 mg/d switched to </text>
<text top="743" left="688" width="217" height="15" font="1">15 mg of ivabradine and decrease of 4 bpm </text>
<text top="759" left="688" width="34" height="15" font="1">noted. </text>
<text top="774" left="688" width="3" height="15" font="1"> </text>
<text top="526" left="920" width="198" height="15" font="1">Limitation – small cohort, no meaningful </text>
<text top="542" left="920" width="195" height="15" font="1">comparisons to beta blockade could be </text>
<text top="557" left="920" width="34" height="15" font="1">made. </text>
<text top="790" left="54" width="35" height="15" font="1">Calo L </text>
<text top="790" left="131" width="64" height="15" font="1">Prospective, </text>
<text top="790" left="224" width="15" height="15" font="1">18 </text>
<text top="790" left="315" width="140" height="15" font="1">Inclusion: Symptomatic IST, </text>
<text top="790" left="554" width="98" height="15" font="1">Stress test ECG for </text>
<text top="790" left="688" width="207" height="15" font="1">Mean and maximal HR on Holter reduced </text>
<text top="790" left="920" width="198" height="15" font="1">Ivabradine lowers HR and improves sxs </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">28 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="28" height="15" font="1">2010 </text>
<text top="70" left="54" width="23" height="15" font="1">(67) </text>
<text top="86" left="54" width="49" height="15" font="8">20621618</text>
<text top="86" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="131" width="79" height="15" font="1">nonrandomized </text>
<text top="70" left="131" width="69" height="15" font="1">consecutively </text>
<text top="86" left="131" width="76" height="15" font="1">enrolled cohort </text>
<text top="55" left="315" width="221" height="15" font="1">Exclusion: secondary causes of tachycardia, </text>
<text top="70" left="315" width="170" height="15" font="1">SHD (echocardiogram performed) </text>
<text top="86" left="315" width="192" height="15" font="1">Beta blockers and non-dihydropyridine </text>
<text top="101" left="315" width="217" height="15" font="1">calcium channel blockers interrupted before </text>
<text top="117" left="315" width="30" height="15" font="1">study </text>
<text top="55" left="554" width="89" height="15" font="1">evaluation of sxs, </text>
<text top="70" left="554" width="101" height="15" font="1">maximal load, basal </text>
<text top="86" left="554" width="88" height="15" font="1">HR, maximal HR. </text>
<text top="101" left="554" width="100" height="15" font="1">Evaluation of stress </text>
<text top="117" left="554" width="106" height="15" font="1">ECG and 24-h Holter </text>
<text top="132" left="554" width="100" height="15" font="1">made at baseline, 3 </text>
<text top="147" left="554" width="49" height="15" font="1">mo, 6 mo </text>
<text top="163" left="554" width="3" height="15" font="1"> </text>
<text top="178" left="554" width="71" height="15" font="1">Pts treated w/ </text>
<text top="194" left="554" width="119" height="15" font="1">ivabradine 5 mg-7.5 mg </text>
<text top="210" left="554" width="54" height="15" font="1">twice daily </text>
<text top="55" left="688" width="171" height="15" font="1">compared to baseline at 3 or 6 mo </text>
<text top="70" left="688" width="205" height="15" font="1">(p&lt;0.001) and at 6 mo compared to 3 mo </text>
<text top="86" left="688" width="45" height="15" font="1">(p=0.02) </text>
<text top="101" left="688" width="194" height="15" font="1">Resting and Maximal HR on stress test </text>
<text top="117" left="688" width="207" height="15" font="1">reduced and increased achieved maximal </text>
<text top="132" left="688" width="24" height="15" font="1">load </text>
<text top="55" left="920" width="77" height="15" font="1">over 3 to 6 mo. </text>
<text top="70" left="920" width="3" height="15" font="1"> </text>
<text top="86" left="920" width="209" height="15" font="1">Limitation – non-randomized, small cohort </text>
<text top="101" left="920" width="3" height="15" font="1"> </text>
<text top="117" left="920" width="3" height="15" font="1"> </text>
<text top="226" left="54" width="61" height="15" font="1">Kaplinsky E </text>
<text top="241" left="54" width="28" height="15" font="1">2010 </text>
<text top="257" left="54" width="23" height="15" font="1">(68) </text>
<text top="272" left="54" width="49" height="15" font="8">20544616</text>
<text top="272" left="103" width="3" height="15" font="1"> </text>
<text top="226" left="131" width="64" height="15" font="1">Prospective, </text>
<text top="241" left="131" width="69" height="15" font="1">observational </text>
<text top="257" left="131" width="34" height="15" font="1">cohort </text>
<text top="226" left="224" width="214" height="15" font="1">4 Resting </text>
<text top="226" left="356" width="101" height="15" font="1">HR </text>
<text top="226" left="375" width="145" height="15" font="1">≥100, mean HR ≥90 on 24-h </text>
<text top="241" left="315" width="33" height="15" font="1">Holter </text>
<text top="257" left="315" width="3" height="15" font="1"> </text>
<text top="272" left="315" width="206" height="15" font="1">Also noted: not previously treated w/ beta </text>
<text top="288" left="315" width="208" height="15" font="1">blocker or verapamil. SHD and secondary </text>
<text top="303" left="315" width="158" height="15" font="1">causes of tachycardia excluded </text>
<text top="226" left="554" width="114" height="15" font="1">Evaluation at baseline, </text>
<text top="241" left="554" width="109" height="15" font="1">wk 1, 2, 3 and 4 and 2</text>
<text top="242" left="663" width="8" height="10" font="10">nd</text>
<text top="241" left="671" width="3" height="15" font="1"> </text>
<text top="257" left="554" width="28" height="15" font="1">and 3</text>
<text top="257" left="582" width="7" height="10" font="10">rd</text>
<text top="257" left="589" width="69" height="15" font="1"> mo. At 3 mo, </text>
<text top="272" left="554" width="108" height="15" font="1">Holter, ETT and QOL </text>
<text top="288" left="554" width="69" height="15" font="1">questionnaire </text>
<text top="303" left="554" width="57" height="15" font="1">performed. </text>
<text top="319" left="554" width="117" height="15" font="1">Ivabradine initiated at 5 </text>
<text top="334" left="554" width="103" height="15" font="1">mg bid, increased to </text>
<text top="350" left="554" width="101" height="15" font="1">7.5 mg bid after first </text>
<text top="365" left="554" width="20" height="15" font="1">wk. </text>
<text top="226" left="688" width="190" height="15" font="1">Ivabradine decreased resting HR from </text>
<text top="241" left="688" width="210" height="15" font="1">mean of 106.5±3 at baseline to 88.5 ±2 at </text>
<text top="257" left="688" width="201" height="15" font="1">wk 1 and 77 ±3 by wk 2 and 73.7 ±13 at </text>
<text top="272" left="688" width="196" height="15" font="1">mo 3. Holter monitor determined mean, </text>
<text top="288" left="688" width="210" height="15" font="1">max and minimum HR also reduced by 15-</text>
<text top="303" left="688" width="205" height="15" font="1">24% compared to baseline, exercise time </text>
<text top="319" left="688" width="135" height="15" font="1">increased, QOL improved.  </text>
<text top="334" left="688" width="3" height="15" font="1"> </text>
<text top="226" left="920" width="117" height="15" font="1">Limitation- small cohort </text>
<text top="381" left="54" width="60" height="15" font="1">Zellerhoff S </text>
<text top="397" left="54" width="28" height="15" font="1">2010 </text>
<text top="412" left="54" width="23" height="15" font="1">(69) </text>
<text top="428" left="54" width="49" height="15" font="8">20859616</text>
<text top="428" left="103" width="3" height="15" font="1"> </text>
<text top="381" left="131" width="61" height="15" font="1">Prospective </text>
<text top="397" left="131" width="69" height="15" font="1">observational </text>
<text top="412" left="131" width="34" height="15" font="1">cohort </text>
<text top="381" left="224" width="15" height="15" font="1">10 </text>
<text top="381" left="315" width="188" height="15" font="1">Pts had failed or refused conventional </text>
<text top="397" left="315" width="192" height="15" font="1">therapy (beta blocker, calcium channel </text>
<text top="412" left="315" width="120" height="15" font="1">blocker, class IC AAD).  </text>
<text top="428" left="315" width="210" height="15" font="1">Blood count, electrolytes and TSH normal. </text>
<text top="443" left="315" width="77" height="15" font="1">SHD excluded. </text>
<text top="459" left="315" width="224" height="15" font="1">EP study performed in 3 pts to exclude SVT.  </text>
<text top="474" left="315" width="208" height="15" font="1">One pt w/ prior ablation of sinus node and </text>
<text top="490" left="315" width="217" height="15" font="1">pacemaker and another pt w/ prior ablation. </text>
<text top="381" left="554" width="120" height="15" font="1">Ivabradine 5 mg-7.5 mg </text>
<text top="397" left="554" width="110" height="15" font="1">bid, w/ additional beta </text>
<text top="412" left="554" width="118" height="15" font="1">blocker therapy in 3 pts </text>
<text top="428" left="554" width="110" height="15" font="1">and monotherapy in 7 </text>
<text top="443" left="554" width="21" height="15" font="1">pts. </text>
<text top="459" left="554" width="3" height="15" font="1"> </text>
<text top="474" left="554" width="114" height="15" font="1">72-h Holter at baseline </text>
<text top="490" left="554" width="114" height="15" font="1">and during therapy. Sx </text>
<text top="505" left="554" width="116" height="15" font="1">assessment performed </text>
<text top="521" left="554" width="109" height="15" font="1">by telephone at mean </text>
<text top="536" left="554" width="75" height="15" font="1">f/u of 16±9 mo </text>
<text top="381" left="688" width="193" height="15" font="1">Ivabradine reduced max and mean HR </text>
<text top="397" left="688" width="188" height="15" font="1">(baseline, max heart = 176±45, mean </text>
<text top="412" left="688" width="197" height="15" font="1">84±11. On ivabradine max HR was 137 </text>
<text top="428" left="688" width="212" height="15" font="1">±36 and mean 74±8 bpm, p&lt;0.05. Min HR </text>
<text top="443" left="688" width="124" height="15" font="1">not significantly changed </text>
<text top="459" left="688" width="215" height="15" font="1">Of 8 pts contacted on followup at 16±9 mo, </text>
<text top="474" left="688" width="184" height="15" font="1">sxs improved in 3 pts and completely </text>
<text top="490" left="688" width="87" height="15" font="1">resolved in 5 pts. </text>
<text top="381" left="920" width="122" height="15" font="1">Limitation – small cohort </text>
<text top="552" left="54" width="44" height="15" font="1">Benezet-</text>
<text top="568" left="54" width="62" height="15" font="1">Mazuecos J </text>
<text top="583" left="54" width="31" height="15" font="1">2013  </text>
<text top="599" left="54" width="23" height="15" font="1">(70) </text>
<text top="614" left="54" width="49" height="15" font="8">23510001</text>
<text top="614" left="103" width="3" height="15" font="1"> </text>
<text top="552" left="131" width="23" height="15" font="1">Non </text>
<text top="568" left="131" width="61" height="15" font="1">randomized </text>
<text top="583" left="131" width="68" height="15" font="1">prospectively </text>
<text top="599" left="131" width="76" height="15" font="1">enrolled cohort </text>
<text top="552" left="224" width="15" height="15" font="1">24 </text>
<text top="552" left="315" width="221" height="15" font="1">Inclusion: symptomatic pts diagnosed w/ IST </text>
<text top="568" left="315" width="217" height="15" font="1">at single institution (2009-2012) IST defined </text>
<text top="583" left="315" width="183" height="15" font="1">as resting dtime HR &gt;100; excessive </text>
<text top="599" left="315" width="204" height="15" font="1">increase in HR w/ activity. Two Holters to </text>
<text top="614" left="315" width="60" height="15" font="1">confirm IST </text>
<text top="630" left="315" width="212" height="15" font="1">Exclusion: secondary cause of tachycardia </text>
<text top="552" left="554" width="119" height="15" font="1">Comparison of baseline </text>
<text top="568" left="554" width="86" height="15" font="1">to 6 mo of mean, </text>
<text top="583" left="554" width="110" height="15" font="1">minimal, and maximal </text>
<text top="599" left="554" width="111" height="15" font="1">HR on Holter, and sxs </text>
<text top="614" left="554" width="98" height="15" font="1">assessed by SF-36 </text>
<text top="630" left="554" width="73" height="15" font="1">Health Survey </text>
<text top="645" left="554" width="3" height="15" font="1"> </text>
<text top="661" left="554" width="69" height="15" font="1">(Secondary – </text>
<text top="676" left="554" width="114" height="15" font="1">assessment at 1 y and </text>
<text top="692" left="554" width="119" height="15" font="1">asked to stop treatment </text>
<text top="707" left="554" width="91" height="15" font="1">and reevaluate by </text>
<text top="723" left="554" width="86" height="15" font="1">Holter after 1 mo </text>
<text top="738" left="554" width="48" height="15" font="1">washout) </text>
<text top="754" left="554" width="3" height="15" font="1"> </text>
<text top="769" left="554" width="71" height="15" font="1">Pts treated w/ </text>
<text top="785" left="554" width="119" height="15" font="1">ivabradine 5 mg-7.5 mg </text>
<text top="552" left="688" width="185" height="15" font="1">At 6 mo, maximal HR, mean HR, and </text>
<text top="568" left="688" width="215" height="15" font="1">minimal HR reduced (p&lt;0.05). SF-36 mean </text>
<text top="583" left="688" width="199" height="15" font="1">score improved on ivabradine (p&lt;0.001) </text>
<text top="599" left="688" width="3" height="15" font="1"> </text>
<text top="614" left="688" width="217" height="15" font="1">At 1 y 10 pts accepted to stop ivabradine w/ </text>
<text top="630" left="688" width="174" height="15" font="1">2 pts continued to have IST criteria </text>
<text top="552" left="920" width="201" height="15" font="1">At 6 mo ivabradine improved HR indices </text>
<text top="568" left="920" width="216" height="15" font="1">and sxs. Stopping ivabradine at 1 y showed </text>
<text top="583" left="920" width="214" height="15" font="1">HR continued to be in normal range in 8/10 </text>
<text top="599" left="920" width="21" height="15" font="1">pts. </text>
<text top="614" left="920" width="3" height="15" font="1"> </text>
<text top="630" left="920" width="211" height="15" font="1">Limitation – non randomized, small cohort. </text>
<text top="645" left="920" width="193" height="15" font="1">Unclear given that pts that stopped the </text>
<text top="661" left="920" width="199" height="15" font="1">drug at 1 y no longer met criteria for IST </text>
<text top="676" left="920" width="212" height="15" font="1">that cohort itself may have consisted of pts </text>
<text top="692" left="920" width="211" height="15" font="1">w/ milder forms of IST or did not truly have </text>
<text top="707" left="920" width="23" height="15" font="1">IST. </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">29 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="554" width="18" height="15" font="1">bid </text>
<text top="71" left="54" width="56" height="15" font="1">Ptaszynski </text>
<text top="86" left="54" width="10" height="15" font="1">P </text>
<text top="102" left="54" width="31" height="15" font="1">2013  </text>
<text top="117" left="54" width="23" height="15" font="1">(71) </text>
<text top="133" left="54" width="49" height="15" font="8">22772053</text>
<text top="133" left="103" width="3" height="15" font="1"> </text>
<text top="71" left="131" width="67" height="15" font="1">Prospective,  </text>
<text top="86" left="131" width="79" height="15" font="1">nonrandomized </text>
<text top="102" left="131" width="34" height="15" font="1">cohort </text>
<text top="71" left="224" width="15" height="15" font="1">20 </text>
<text top="86" left="224" width="59" height="15" font="1">(pts treated </text>
<text top="102" left="224" width="35" height="15" font="1">first w/ </text>
<text top="117" left="224" width="71" height="15" font="1">metoprolol for </text>
<text top="133" left="224" width="53" height="15" font="1">4 wk, then </text>
<text top="148" left="224" width="70" height="15" font="1">ivabradine for </text>
<text top="164" left="224" width="30" height="15" font="1">4 wk) </text>
<text top="71" left="315" width="192" height="15" font="1">resting HR&gt;100, or mean HR &gt;90 bpm </text>
<text top="86" left="315" width="92" height="15" font="1">during 24-h Holter </text>
<text top="102" left="315" width="218" height="15" font="1">Antiarrhythmic therapy discontinued at least </text>
<text top="117" left="315" width="51" height="15" font="1">4 wk prior </text>
<text top="133" left="315" width="218" height="15" font="1">Secondary causes for tachycardia and SHD </text>
<text top="148" left="315" width="74" height="15" font="1">were excluded </text>
<text top="71" left="554" width="104" height="15" font="1">Aim: Evaluate safety </text>
<text top="86" left="554" width="75" height="15" font="1">and efficacy of </text>
<text top="102" left="554" width="119" height="15" font="1">ivabradine compared to </text>
<text top="117" left="554" width="55" height="15" font="1">metoprolol </text>
<text top="133" left="554" width="3" height="15" font="1"> </text>
<text top="71" left="688" width="176" height="15" font="1">Mean and resting HR lower w/ both </text>
<text top="86" left="688" width="195" height="15" font="1">metoprolol and ivabradine compared to </text>
<text top="102" left="688" width="95" height="15" font="1">baseline (p&lt;0.001) </text>
<text top="117" left="688" width="218" height="15" font="1">Exercise capacity (METS) on ETT improved </text>
<text top="133" left="688" width="169" height="15" font="1">w/ both metoprolol and ivabradine </text>
<text top="148" left="688" width="160" height="15" font="1">compared to baseline (p&lt;0.001) </text>
<text top="164" left="688" width="213" height="15" font="1">Sxs reduced more w/ ivabradine compared </text>
<text top="179" left="688" width="112" height="15" font="1">to metoprolol (p&lt;0.05) </text>
<text top="195" left="688" width="212" height="15" font="1">70% treated w/ ivabradine were free of sxs </text>
<text top="210" left="688" width="69" height="15" font="1">related to IST </text>
<text top="226" left="688" width="202" height="15" font="1">Side effects: Metoprolol – hypotension in </text>
<text top="241" left="688" width="209" height="15" font="1">30%, asymptomatic sinus bradycardia (40-</text>
<text top="257" left="688" width="81" height="15" font="1">50 bpm) in 25% </text>
<text top="71" left="920" width="199" height="15" font="1">Ivabradine and metoprolol both reduced </text>
<text top="86" left="920" width="176" height="15" font="1">HR. Ivabradine better tolerated and </text>
<text top="102" left="920" width="152" height="15" font="1">improved sxs to greater extent </text>
<text top="117" left="920" width="3" height="15" font="1"> </text>
<text top="133" left="920" width="201" height="15" font="1">Limitation – short term (4 wk therapy per </text>
<text top="148" left="920" width="150" height="15" font="1">treatment), small sample size, </text>
<text top="164" left="920" width="213" height="15" font="1">nonrandomized w/o crossover; no washout </text>
<text top="179" left="920" width="110" height="15" font="1">period between drugs </text>
<text top="273" left="54" width="56" height="15" font="1">Ptaszynski </text>
<text top="288" left="54" width="10" height="15" font="1">P </text>
<text top="304" left="54" width="31" height="15" font="1">2013  </text>
<text top="319" left="54" width="23" height="15" font="1">(72) </text>
<text top="335" left="54" width="49" height="15" font="8">23078130</text>
<text top="335" left="103" width="3" height="15" font="1"> </text>
<text top="273" left="131" width="64" height="15" font="1">Prospective, </text>
<text top="288" left="131" width="79" height="15" font="1">nonrandomized </text>
<text top="304" left="131" width="34" height="15" font="1">cohort </text>
<text top="273" left="224" width="15" height="15" font="1">14 </text>
<text top="273" left="315" width="205" height="15" font="1">Inclusion: IST w/ resting HR ±100 bpm in </text>
<text top="288" left="315" width="216" height="15" font="1">sitting position and average HR ±90 bpm in </text>
<text top="304" left="315" width="187" height="15" font="1">24-h Holter, following successful slow </text>
<text top="319" left="315" width="210" height="15" font="1">pathway ablation for AVNRT. Pts had also </text>
<text top="335" left="315" width="187" height="15" font="1">received at least 3 mo of beta blocker </text>
<text top="350" left="315" width="40" height="15" font="1">therapy </text>
<text top="366" left="315" width="212" height="15" font="1">Exclusion: secondary cause of tachycardia </text>
<text top="381" left="315" width="48" height="15" font="1">and SHD </text>
<text top="273" left="554" width="114" height="15" font="1">Evaluation at baseline, </text>
<text top="288" left="554" width="89" height="15" font="1">1 mo and 2 mo of </text>
<text top="304" left="554" width="108" height="15" font="1">therapy w/ ivabradine </text>
<text top="319" left="554" width="97" height="15" font="1">(5 mg -7.5 mg bid). </text>
<text top="335" left="554" width="96" height="15" font="1">Resting ECG, 24-h </text>
<text top="350" left="554" width="97" height="15" font="1">Holter to determine </text>
<text top="366" left="554" width="73" height="15" font="1">resting, mean, </text>
<text top="381" left="554" width="95" height="15" font="1">maximum HR, and </text>
<text top="397" left="554" width="103" height="15" font="1">evaluation of rhythm </text>
<text top="412" left="554" width="58" height="15" font="1">from Holter </text>
<text top="428" left="554" width="111" height="15" font="1">corresponding to sxs.  </text>
<text top="443" left="554" width="90" height="15" font="1">ETT performed at </text>
<text top="459" left="554" width="104" height="15" font="1">baseline, 4 wk and 8 </text>
<text top="474" left="554" width="19" height="15" font="1">wk  </text>
<text top="490" left="554" width="84" height="15" font="1">Questionnaire to </text>
<text top="505" left="554" width="116" height="15" font="1">assess sxs  before and </text>
<text top="521" left="554" width="96" height="15" font="1">after 30 and 60 d – </text>
<text top="536" left="554" width="64" height="15" font="1">EHRA score </text>
<text top="273" left="688" width="203" height="15" font="1">Mean resting HR at 30 and 60 d reduced </text>
<text top="288" left="688" width="160" height="15" font="1">compared to baseline (p&lt;0.001) </text>
<text top="304" left="688" width="217" height="15" font="1">24-h Holter w/ reduced mean and mean HR </text>
<text top="319" left="688" width="154" height="15" font="1">during daily activity (p&lt;0.001).  </text>
<text top="335" left="688" width="205" height="15" font="1">Improved exercise capacity w/ ivabradine </text>
<text top="350" left="688" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="366" left="688" width="218" height="15" font="1">Reduced sxs w/ no severe sxs in any pts by </text>
<text top="381" left="688" width="28" height="15" font="1">2 mo </text>
<text top="273" left="920" width="204" height="15" font="1">At 2 mo severe sxs were eliminated in all </text>
<text top="288" left="920" width="21" height="15" font="1">pts. </text>
<text top="304" left="920" width="3" height="15" font="1"> </text>
<text top="319" left="920" width="207" height="15" font="1">Limitation – No long term data for efficacy </text>
<text top="335" left="920" width="87" height="15" font="1">or if IST resolved </text>
<text top="552" left="54" width="56" height="15" font="1">Ptaszynski </text>
<text top="568" left="54" width="10" height="15" font="1">P </text>
<text top="583" left="54" width="31" height="15" font="1">2013  </text>
<text top="599" left="54" width="23" height="15" font="1">(73) </text>
<text top="614" left="54" width="49" height="15" font="8">23426376</text>
<text top="614" left="103" width="3" height="15" font="1"> </text>
<text top="552" left="131" width="64" height="15" font="1">Prospective, </text>
<text top="568" left="131" width="69" height="15" font="1">observational </text>
<text top="583" left="131" width="34" height="15" font="1">cohort </text>
<text top="552" left="224" width="15" height="15" font="1">20 </text>
<text top="552" left="315" width="205" height="15" font="1">Inclusion: IST w/ resting HR ≥100 bpm in </text>
<text top="568" left="315" width="216" height="15" font="1">sitting position and average HR ≥90 bpm in </text>
<text top="583" left="315" width="209" height="15" font="1">24-h Holter. Pts previously treated w/ beta </text>
<text top="599" left="315" width="205" height="15" font="1">blockers or verapamil w/o effect or poorly </text>
<text top="614" left="315" width="46" height="15" font="1">tolerated </text>
<text top="630" left="315" width="212" height="15" font="1">Exclusion: secondary cause of tachycardia </text>
<text top="645" left="315" width="220" height="15" font="1">and SHD; postural orthostatic tachycardia or </text>
<text top="661" left="315" width="130" height="15" font="1">h/o orthostatic intolerance </text>
<text top="552" left="554" width="104" height="15" font="1">Received metoprolol </text>
<text top="568" left="554" width="115" height="15" font="1">succinate 47.5 mg - 95 </text>
<text top="583" left="554" width="110" height="15" font="1">mg daily for first 4 wk, </text>
<text top="599" left="554" width="113" height="15" font="1">then ivabradine added </text>
<text top="615" left="554" width="97" height="15" font="1">5 mg- 7.5 mg twice </text>
<text top="630" left="554" width="118" height="15" font="1">daily for additional 4 wk </text>
<text top="645" left="554" width="110" height="15" font="1">(combination therapy) </text>
<text top="661" left="554" width="3" height="15" font="1"> </text>
<text top="676" left="554" width="78" height="15" font="1">Holter and ETT </text>
<text top="692" left="554" width="110" height="15" font="1">performed baseline, 4 </text>
<text top="707" left="554" width="70" height="15" font="1">wk, and 8 wk. </text>
<text top="723" left="554" width="3" height="15" font="1"> </text>
<text top="738" left="554" width="86" height="15" font="1">Sxs assessed by </text>
<text top="754" left="554" width="107" height="15" font="1">questionnaire (EHRA </text>
<text top="769" left="554" width="34" height="15" font="1">score) </text>
<text top="785" left="554" width="3" height="15" font="1"> </text>
<text top="552" left="688" width="205" height="15" font="1">Resting HR:  baseline 114.4±7.5, at 4 wk </text>
<text top="568" left="688" width="188" height="15" font="1">97.3 ±14.4 and 8 wk 90.5 ±13.3 bpm, </text>
<text top="583" left="688" width="48" height="15" font="1">P&lt;0.001. </text>
<text top="599" left="688" width="6" height="15" font="1">  </text>
<text top="614" left="688" width="204" height="15" font="1">Mean and maximal HR on Holter monitor </text>
<text top="630" left="688" width="167" height="15" font="1">also lower in combination therapy </text>
<text top="645" left="688" width="153" height="15" font="1">compared to either baseline or </text>
<text top="661" left="688" width="209" height="15" font="1">monotherapy w/ beta blockade (P&lt;0.001). </text>
<text top="676" left="688" width="3" height="15" font="1"> </text>
<text top="692" left="688" width="167" height="15" font="1">Exercise capacity also increased. </text>
<text top="707" left="688" width="3" height="15" font="1"> </text>
<text top="723" left="688" width="191" height="15" font="1">After 1 mo of combined therapy no pts </text>
<text top="738" left="688" width="121" height="15" font="1">reported IST related sxs </text>
<text top="552" left="920" width="149" height="15" font="1">Limitation – no long term data </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">30 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="554" width="3" height="15" font="1"> </text>
<text top="71" left="54" width="46" height="15" font="1">Kang KT </text>
<text top="86" left="54" width="28" height="15" font="1">2014 </text>
<text top="102" left="54" width="23" height="15" font="1">(74) </text>
<text top="117" left="54" width="49" height="15" font="8">25015944</text>
<text top="117" left="103" width="3" height="15" font="1"> </text>
<text top="71" left="131" width="71" height="15" font="1">Retrospective </text>
<text top="86" left="131" width="63" height="15" font="1">chart review </text>
<text top="102" left="131" width="64" height="15" font="1">(10 pediatric </text>
<text top="117" left="131" width="43" height="15" font="1">centers) </text>
<text top="71" left="224" width="39" height="15" font="1">249 pts </text>
<text top="71" left="315" width="213" height="15" font="1">Pediatric patient with focal AT (median age </text>
<text top="86" left="315" width="202" height="15" font="1">at diagnosis: 7.2 y), diagnosed based on </text>
<text top="102" left="315" width="199" height="15" font="1">ECG, 24-h Holter, or event monitor data </text>
<text top="117" left="315" width="127" height="15" font="1">consistent w/ EP criteria.  </text>
<text top="133" left="315" width="3" height="15" font="1"> </text>
<text top="148" left="315" width="219" height="15" font="1">168 pts received antiarrhythmic medications </text>
<text top="164" left="315" width="194" height="15" font="1">(44 different medication combinations), </text>
<text top="179" left="315" width="224" height="15" font="1">including 154 pts as initial therapy and 14 pts </text>
<text top="195" left="315" width="187" height="15" font="1">after initial management with catheter </text>
<text top="210" left="315" width="222" height="15" font="1">ablation. Median duration of first-line therapy </text>
<text top="226" left="315" width="54" height="15" font="1">was 89 d.  </text>
<text top="71" left="554" width="96" height="15" font="1">Characterization of </text>
<text top="86" left="554" width="105" height="15" font="1">current management </text>
<text top="102" left="554" width="111" height="15" font="1">strategies for focal AT </text>
<text top="117" left="554" width="54" height="15" font="1">in children </text>
<text top="133" left="554" width="3" height="15" font="1"> </text>
<text top="71" left="688" width="199" height="15" font="1">Resolution of focal AT in 89% (including </text>
<text top="86" left="688" width="181" height="15" font="1">spontaneous resolution w/o catheter </text>
<text top="102" left="688" width="86" height="15" font="1">ablation in 34%). </text>
<text top="117" left="688" width="210" height="15" font="1">-antiarrhythmic medications used for initial </text>
<text top="133" left="688" width="214" height="15" font="1">therapy with control of focal AT in 72% (BB </text>
<text top="148" left="688" width="180" height="15" font="1">were most common, 53%, and most </text>
<text top="164" left="688" width="210" height="15" font="1">effective, 42%). 34% of the 154 pts w/ first-</text>
<text top="179" left="688" width="186" height="15" font="1">line therapy along achieved complete </text>
<text top="195" left="688" width="202" height="15" font="1">suppression or rate control of focal AT. 9 </text>
<text top="210" left="688" width="212" height="15" font="1">pts had serious AE while on antiarrhythmic </text>
<text top="226" left="688" width="65" height="15" font="1">medications. </text>
<text top="241" left="688" width="211" height="15" font="1">-catheter ablation successful in 109 of 134 </text>
<text top="257" left="688" width="57" height="15" font="1">pts (81%).  </text>
<text top="272" left="688" width="210" height="15" font="1">-53 of 72 pts (74%) presenting at age &lt;3 y </text>
<text top="288" left="688" width="205" height="15" font="1">had spontaneous resolution (including 50 </text>
<text top="303" left="688" width="196" height="15" font="1">pts aged &lt;1 y). Spontaneous resolution </text>
<text top="319" left="688" width="155" height="15" font="1">observed in 18 of 129 pts &gt;5 y. </text>
<text top="334" left="688" width="214" height="15" font="1">-Cardiomyopathy observed in 28%. 80% of </text>
<text top="350" left="688" width="187" height="15" font="1">pts with cardiomyopathy had focal AT </text>
<text top="365" left="688" width="108" height="15" font="1">resolution at last f/u.   </text>
<text top="381" left="688" width="3" height="15" font="1"> </text>
<text top="396" left="688" width="146" height="15" font="1">Lower recurrence rates when </text>
<text top="412" left="688" width="202" height="15" font="1">electroanatomic mapping techniques are </text>
<text top="427" left="688" width="212" height="15" font="1">used vs. conventional mapping techniques </text>
<text top="443" left="688" width="122" height="15" font="1">(16% vs. 35%; p=0.02).  </text>
<text top="71" left="920" width="209" height="15" font="1">Focal AT is managed successfully in most </text>
<text top="86" left="920" width="196" height="15" font="1">children. Many pts control focal AT with </text>
<text top="102" left="920" width="207" height="15" font="1">medications, but catheter ablation is used </text>
<text top="117" left="920" width="167" height="15" font="1">for most pts and successful for all </text>
<text top="133" left="920" width="200" height="15" font="1">ages.Spontaeous resolution is common, </text>
<text top="148" left="920" width="215" height="15" font="1">emphasizing delayed ablation in this group. </text>
<text top="164" left="920" width="3" height="15" font="1"> </text>
<text top="179" left="920" width="59" height="15" font="1">Limitations: </text>
<text top="195" left="920" width="203" height="15" font="1">-retrospective study, variable f/u duration </text>
<text top="210" left="920" width="173" height="15" font="1">(median 2.1 y) and available data.  </text>
<text top="459" left="54" width="61" height="15" font="1">Case series </text>
<text top="475" left="54" width="57" height="15" font="1">Callans DJ </text>
<text top="491" left="54" width="28" height="15" font="1">1999 </text>
<text top="506" left="54" width="23" height="15" font="1">(75) </text>
<text top="522" left="54" width="49" height="15" font="8">10334440</text>
<text top="522" left="103" width="3" height="15" font="1"> </text>
<text top="537" left="54" width="3" height="15" font="1"> </text>
<text top="475" left="131" width="61" height="15" font="1">Case series </text>
<text top="475" left="224" width="33" height="15" font="1">10 pts </text>
<text top="491" left="224" width="19" height="15" font="1">(13 </text>
<text top="506" left="224" width="62" height="15" font="1">procedures) </text>
<text top="475" left="315" width="221" height="15" font="1">Symptomatic, drug refractory pts referred for </text>
<text top="491" left="315" width="58" height="15" font="1">RFA of IST </text>
<text top="506" left="315" width="3" height="15" font="1"> </text>
<text top="522" left="315" width="57" height="15" font="1">Procedure: </text>
<text top="537" left="315" width="186" height="15" font="1">- Primarily anatomic-based using ICE </text>
<text top="552" left="315" width="204" height="15" font="1">guidance, but also activation mapping for </text>
<text top="568" left="315" width="150" height="15" font="1">confirmation (point-by-point or </text>
<text top="583" left="315" width="129" height="15" font="1">electroanatomic w/ Carto) </text>
<text top="599" left="315" width="116" height="15" font="1">- Isoproterenol infusion </text>
<text top="475" left="554" width="116" height="15" font="1">Procedural success: - - </text>
<text top="491" left="554" width="111" height="15" font="1">Abrupt decrease (≥30 </text>
<text top="506" left="554" width="91" height="15" font="1">bpm) in sinus rate </text>
<text top="522" left="554" width="84" height="15" font="1">during RF lesion </text>
<text top="537" left="554" width="41" height="15" font="1">delivery </text>
<text top="552" left="554" width="110" height="15" font="1">- Sudden appearance </text>
<text top="568" left="554" width="115" height="15" font="1">of superiorly directed p </text>
<text top="583" left="554" width="90" height="15" font="1">wave morphology </text>
<text top="599" left="554" width="111" height="15" font="1">(negative P in lead III) </text>
<text top="615" left="554" width="110" height="15" font="1">- Persistence of these </text>
<text top="630" left="554" width="82" height="15" font="1">features despite </text>
<text top="645" left="554" width="104" height="15" font="1">isoproterenol up to 4 </text>
<text top="661" left="554" width="115" height="15" font="1">mcg/min for at least 30 </text>
<text top="676" left="554" width="108" height="15" font="1">min following final RF </text>
<text top="692" left="554" width="32" height="15" font="1">lesion </text>
<text top="707" left="554" width="3" height="15" font="1"> </text>
<text top="475" left="688" width="177" height="15" font="1">11/13 (85%) procedures successful </text>
<text top="491" left="688" width="3" height="15" font="1"> </text>
<text top="506" left="688" width="210" height="15" font="1">Local circumferential swelling w/ reduction </text>
<text top="522" left="688" width="216" height="15" font="1">in diameter of SVC-RA junction to 12.6±3.3 </text>
<text top="537" left="688" width="155" height="15" font="1">mm (24% reduction, p=0.0001) </text>
<text top="552" left="688" width="3" height="15" font="1"> </text>
<text top="568" left="688" width="117" height="15" font="1">Complications – “none” </text>
<text top="583" left="688" width="216" height="15" font="1">- Reduction in diameter of SVC-RA junction </text>
<text top="599" left="688" width="218" height="15" font="1">by ≥30% compared w/ baseline observed in </text>
<text top="615" left="688" width="192" height="15" font="1">5 pts; no pts had clinical signs for SVC </text>
<text top="630" left="688" width="55" height="15" font="1">syndrome. </text>
<text top="645" left="688" width="163" height="15" font="1">- Small adherent thrombi in 4 pts </text>
<text top="661" left="688" width="194" height="15" font="1">- 1 pt ppm (after complete SN ablation) </text>
<text top="676" left="688" width="3" height="15" font="1"> </text>
<text top="475" left="920" width="66" height="15" font="1">Conclusions: </text>
<text top="491" left="920" width="188" height="15" font="1">- RFA for IST can cause considerable </text>
<text top="506" left="920" width="220" height="15" font="1">swelling and narrowing of SVC-RA junction.  </text>
<text top="522" left="920" width="173" height="15" font="1">- ICE might be useful in preventing </text>
<text top="537" left="920" width="213" height="15" font="1">excessive tissue swelling that could lead to </text>
<text top="552" left="920" width="73" height="15" font="1">complications. </text>
<text top="568" left="920" width="3" height="15" font="1"> </text>
<text top="724" left="54" width="43" height="15" font="1">Man KC </text>
<text top="739" left="54" width="28" height="15" font="1">2000 </text>
<text top="755" left="54" width="23" height="15" font="1">(76) </text>
<text top="770" left="54" width="49" height="15" font="8">10676693</text>
<text top="770" left="103" width="3" height="15" font="1"> </text>
<text top="724" left="131" width="61" height="15" font="1">Case series </text>
<text top="724" left="224" width="33" height="15" font="1">29 pts </text>
<text top="724" left="315" width="210" height="15" font="1">Consecutive, drug refractory, symptomatic </text>
<text top="739" left="315" width="154" height="15" font="1">pts who underwent RFA of IST </text>
<text top="755" left="315" width="3" height="15" font="1"> </text>
<text top="770" left="315" width="60" height="15" font="1">Procedure:  </text>
<text top="786" left="315" width="181" height="15" font="1">- Activation mapping (point-by-point) </text>
<text top="724" left="554" width="103" height="15" font="1">Procedural success: </text>
<text top="739" left="554" width="109" height="15" font="1">Reduction of baseline </text>
<text top="755" left="554" width="113" height="15" font="1">sinus rate to &lt;90 bpm, </text>
<text top="770" left="554" width="107" height="15" font="1">and a 20% or greater </text>
<text top="786" left="554" width="111" height="15" font="1">reduction in sinus rate </text>
<text top="724" left="688" width="181" height="15" font="1">Procedural success 22/29 (76%) pts </text>
<text top="739" left="688" width="201" height="15" font="1">Sxs due to IST recurred in 6/22 (27%) at </text>
<text top="755" left="688" width="97" height="15" font="1">mean f/u 4.4±3 mo </text>
<text top="770" left="688" width="149" height="15" font="1">Additional procedures in 3 pts </text>
<text top="786" left="688" width="3" height="15" font="1"> </text>
<text top="724" left="920" width="204" height="15" font="1">RFA is at best only modestly effective for </text>
<text top="739" left="920" width="107" height="15" font="1">managing pts w/ IST. </text>
<text top="755" left="920" width="3" height="15" font="1"> </text>
<text top="770" left="920" width="3" height="15" font="1"> </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">31 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="315" width="180" height="15" font="1">- Isoproterenol infusion 1-2 mcg/min </text>
<text top="55" left="554" width="87" height="15" font="1">during infusion of </text>
<text top="70" left="554" width="70" height="15" font="1">isoproterenol. </text>
<text top="86" left="554" width="3" height="15" font="1"> </text>
<text top="55" left="688" width="212" height="15" font="1">Overall success 19/29 (66%) pts over long-</text>
<text top="70" left="688" width="25" height="15" font="1">term </text>
<text top="86" left="688" width="3" height="15" font="1"> </text>
<text top="101" left="688" width="153" height="15" font="1">Complications in 2/29 (7%) pts </text>
<text top="117" left="688" width="178" height="15" font="1">- Sinus pauses/near-syncope (ppm) </text>
<text top="132" left="688" width="171" height="15" font="1">- Paralysis of right hemidiaphragm </text>
<text top="148" left="54" width="56" height="15" font="1">Marrouche </text>
<text top="164" left="54" width="18" height="15" font="1">NF </text>
<text top="179" left="54" width="31" height="15" font="1">2002  </text>
<text top="195" left="54" width="23" height="15" font="1">(77) </text>
<text top="210" left="54" width="49" height="15" font="8">11897449</text>
<text top="210" left="103" width="3" height="15" font="1"> </text>
<text top="148" left="131" width="61" height="15" font="1">Case series </text>
<text top="148" left="224" width="33" height="15" font="1">39 pts </text>
<text top="148" left="315" width="55" height="15" font="1">Inclusions: </text>
<text top="164" left="315" width="203" height="15" font="1">“Debilitating” IST (no prior drugs in 6 pts) </text>
<text top="179" left="315" width="3" height="15" font="1"> </text>
<text top="195" left="315" width="59" height="15" font="1">Exclusions: </text>
<text top="210" left="315" width="225" height="15" font="1">- Prior sinoatrial node ablation at other center </text>
<text top="226" left="315" width="50" height="15" font="1">- F/u &lt;2 y </text>
<text top="241" left="315" width="40" height="15" font="1">- POTS </text>
<text top="257" left="315" width="3" height="15" font="1"> </text>
<text top="272" left="315" width="60" height="15" font="1">Procedure:  </text>
<text top="288" left="315" width="223" height="15" font="1">- Mapping at baseline and after isoproterenol </text>
<text top="303" left="315" width="91" height="15" font="1">(or aminophylline) </text>
<text top="319" left="315" width="161" height="15" font="1">- Earliest site of activation by 3D </text>
<text top="334" left="315" width="170" height="15" font="1">electroanatomic mapping targeted </text>
<text top="350" left="315" width="204" height="15" font="1">- Autonomic testing (10 pts w/ resting HR </text>
<text top="365" left="315" width="208" height="15" font="1">&gt;100) - tested response to esmolol before </text>
<text top="381" left="315" width="45" height="15" font="1">ablation  </text>
<text top="396" left="315" width="154" height="15" font="1">- ETT before and after ablation </text>
<text top="412" left="315" width="103" height="15" font="1">- ICE to verify crista  </text>
<text top="148" left="554" width="103" height="15" font="1">Procedural success: </text>
<text top="164" left="554" width="98" height="15" font="1">HR drop below 120 </text>
<text top="179" left="554" width="59" height="15" font="1">bmp during </text>
<text top="195" left="554" width="76" height="15" font="1">isoproterenol 2 </text>
<text top="210" left="554" width="100" height="15" font="1">mcg/min alone or in </text>
<text top="226" left="554" width="77" height="15" font="1">combination w/ </text>
<text top="241" left="554" width="71" height="15" font="1">aminophylline </text>
<text top="257" left="554" width="3" height="15" font="1"> </text>
<text top="272" left="554" width="65" height="15" font="1">(Look for SN </text>
<text top="288" left="554" width="97" height="15" font="1">acceleration during </text>
<text top="303" left="554" width="70" height="15" font="1">RFA delivery) </text>
<text top="319" left="554" width="3" height="15" font="1"> </text>
<text top="334" left="554" width="78" height="15" font="1">When endpoint </text>
<text top="350" left="554" width="75" height="15" font="1">achieved, then </text>
<text top="365" left="554" width="104" height="15" font="1">recreated 3D map of </text>
<text top="381" left="554" width="18" height="15" font="1">RA </text>
<text top="396" left="554" width="3" height="15" font="1"> </text>
<text top="412" left="554" width="119" height="15" font="1">Observe for recovery of </text>
<text top="427" left="554" width="99" height="15" font="1">HR for 45 to 60 min </text>
<text top="443" left="554" width="87" height="15" font="1">after last ablation </text>
<text top="148" left="688" width="210" height="15" font="1">Sinoatrial node successfully modified in all </text>
<text top="164" left="688" width="57" height="15" font="1">pts (100%) </text>
<text top="179" left="688" width="218" height="15" font="1">Drop in mean HR from 99 ±14 bpm to 72±8 </text>
<text top="195" left="688" width="65" height="15" font="1">bpm, p&lt;0.01 </text>
<text top="210" left="688" width="182" height="15" font="1">Shift in caudal activation along crista </text>
<text top="226" left="688" width="159" height="15" font="1">terminalis on 3D map was more </text>
<text top="241" left="688" width="212" height="15" font="1">pronounced after RFA than during esmolol </text>
<text top="257" left="688" width="169" height="15" font="1">(23 ±11 mm vs. 7±5 mm, p&lt;0.05) </text>
<text top="272" left="688" width="209" height="15" font="1">No pt underwent ppm after mean f/u 32±9 </text>
<text top="288" left="688" width="22" height="15" font="1">mo. </text>
<text top="303" left="688" width="207" height="15" font="1">21% of pts experienced recurrence of IST </text>
<text top="319" left="688" width="164" height="15" font="1">and were successfully re-ablated </text>
<text top="334" left="688" width="3" height="15" font="1"> </text>
<text top="350" left="688" width="79" height="15" font="1">Complications:  </text>
<text top="365" left="688" width="194" height="15" font="1">SVC syndrome (1 pt), requiring dilation </text>
<text top="148" left="920" width="201" height="15" font="1">3D mapping provides an effective tool to </text>
<text top="164" left="920" width="210" height="15" font="1">monitor and guide RFA for IST. (Seems to </text>
<text top="179" left="920" width="208" height="15" font="1">eliminate excessive destruction of SN and </text>
<text top="195" left="920" width="196" height="15" font="1">reduce or eliminate risk of complete SN </text>
<text top="210" left="920" width="49" height="15" font="1">ablation.) </text>
<text top="226" left="920" width="176" height="15" font="1">Difference in caudal shift seen after </text>
<text top="241" left="920" width="184" height="15" font="1">esmolol and following sinoatrial node </text>
<text top="257" left="920" width="186" height="15" font="1">modification suggests that adrenergic </text>
<text top="272" left="920" width="210" height="15" font="1">hypersensitivity is not the only mechanism </text>
<text top="288" left="920" width="99" height="15" font="1">responsible for IST. </text>
<text top="303" left="920" width="3" height="15" font="1"> </text>
<text top="319" left="920" width="3" height="15" font="1"> </text>
<text top="459" left="54" width="29" height="15" font="1">Lin D </text>
<text top="474" left="54" width="31" height="15" font="1">2007  </text>
<text top="490" left="54" width="23" height="15" font="1">(78) </text>
<text top="505" left="54" width="49" height="15" font="8">17338721</text>
<text top="505" left="103" width="3" height="15" font="1"> </text>
<text top="521" left="54" width="3" height="15" font="1"> </text>
<text top="459" left="131" width="61" height="15" font="1">Case series </text>
<text top="459" left="224" width="27" height="15" font="1">7 pts </text>
<text top="459" left="315" width="219" height="15" font="1">Medically refractory IST referred for ablation </text>
<text top="474" left="315" width="3" height="15" font="1"> </text>
<text top="490" left="315" width="57" height="15" font="1">Procedure: </text>
<text top="505" left="315" width="180" height="15" font="1">- Non-contact mapping (Endocardial </text>
<text top="521" left="315" width="213" height="15" font="1">Solutions, Ensite array, 4 mm Chilli Cooled </text>
<text top="536" left="315" width="88" height="15" font="1">Ablation system)  </text>
<text top="552" left="315" width="145" height="15" font="1">- Isoproterenol 1-10 mcg/min </text>
<text top="567" left="315" width="215" height="15" font="1">- Intrinsic HR evaluated w/ BB and atropine </text>
<text top="459" left="554" width="112" height="15" font="1">Endpoint: Decrease in </text>
<text top="474" left="554" width="79" height="15" font="1">HR of ≥25% off </text>
<text top="490" left="554" width="89" height="15" font="1">isoproterenol and </text>
<text top="505" left="554" width="117" height="15" font="1">associated change in P </text>
<text top="521" left="554" width="114" height="15" font="1">wave morphology in III </text>
<text top="536" left="554" width="112" height="15" font="1">and AVF from positive </text>
<text top="552" left="554" width="97" height="15" font="1">to a flat or negative </text>
<text top="567" left="554" width="96" height="15" font="1">defection c/w more </text>
<text top="583" left="554" width="70" height="15" font="1">inferior origin  </text>
<text top="459" left="688" width="134" height="15" font="1">Procedural success: 100% </text>
<text top="474" left="688" width="3" height="15" font="1"> </text>
<text top="490" left="688" width="191" height="15" font="1">Complications: 1 pt ppm (symptomatic </text>
<text top="505" left="688" width="207" height="15" font="1">junctional bradycardia requiring ppm 2 wk </text>
<text top="521" left="688" width="205" height="15" font="1">after procedure) – but also had prior RFA </text>
<text top="459" left="920" width="193" height="15" font="1">Non-contact mapping in conjunction w/ </text>
<text top="474" left="920" width="207" height="15" font="1">saline-cooled ablation for SN modification </text>
<text top="490" left="920" width="179" height="15" font="1">may provide effective HR control for </text>
<text top="505" left="920" width="86" height="15" font="1">treatment of IST. </text>
<text top="521" left="920" width="3" height="15" font="1"> </text>
<text top="536" left="920" width="3" height="15" font="1"> </text>
<text top="599" left="54" width="58" height="15" font="1">Frankel DS </text>
<text top="614" left="54" width="31" height="15" font="1">2012  </text>
<text top="630" left="54" width="23" height="15" font="1">(79) </text>
<text top="645" left="54" width="49" height="15" font="8">22471900</text>
<text top="645" left="103" width="3" height="15" font="1"> </text>
<text top="599" left="131" width="61" height="15" font="1">Case series </text>
<text top="599" left="224" width="33" height="15" font="1">33 pts </text>
<text top="599" left="315" width="210" height="15" font="1">Consecutive, drug refractory, symptomatic </text>
<text top="614" left="315" width="3" height="15" font="1"> </text>
<text top="630" left="315" width="60" height="15" font="1">Procedure:  </text>
<text top="645" left="315" width="223" height="15" font="1">- Evolved from anatomic approach using ICE </text>
<text top="661" left="315" width="185" height="15" font="1">to EP approach using multi-electrode </text>
<text top="676" left="315" width="188" height="15" font="1">mapping (St. Jude Ensite or Biosense </text>
<text top="692" left="315" width="48" height="15" font="1">Webster) </text>
<text top="707" left="315" width="74" height="15" font="1">- Isoproterenol </text>
<text top="599" left="554" width="105" height="15" font="1">Procedural endpoint: </text>
<text top="614" left="554" width="113" height="15" font="1">- Decrease of &gt;25% in </text>
<text top="630" left="554" width="112" height="15" font="1">resting HR, w/ blunted </text>
<text top="645" left="554" width="80" height="15" font="1">HR response to </text>
<text top="661" left="554" width="112" height="15" font="1">isoproterenol and shift </text>
<text top="676" left="554" width="113" height="15" font="1">of P wave morphology </text>
<text top="692" left="554" width="109" height="15" font="1">from positive to flat or </text>
<text top="707" left="554" width="120" height="15" font="1">negative in leads III and </text>
<text top="723" left="554" width="28" height="15" font="1">AVF  </text>
<text top="738" left="554" width="116" height="15" font="1">- Cranial to caudal shift </text>
<text top="754" left="554" width="102" height="15" font="1">in site of earliest RA </text>
<text top="769" left="554" width="114" height="15" font="1">activation pre and post </text>
<text top="785" left="554" width="111" height="15" font="1">SAN modification was </text>
<text top="599" left="688" width="69" height="15" font="1">F/u 2.0±1.5 y </text>
<text top="614" left="688" width="100" height="15" font="1">- 18% recurrent IST </text>
<text top="630" left="688" width="210" height="15" font="1">- 27% developed non-IST tachyarrhythmia </text>
<text top="645" left="688" width="212" height="15" font="1">(42% had non-IST arrhythmia prior to SAN </text>
<text top="661" left="688" width="66" height="15" font="1">modification) </text>
<text top="676" left="688" width="3" height="15" font="1"> </text>
<text top="692" left="688" width="204" height="15" font="1">2 deaths (unrelated) during long-term f/u: </text>
<text top="707" left="688" width="92" height="15" font="1">- 1 mechanical fall </text>
<text top="723" left="688" width="205" height="15" font="1">- 1 pulseless electrical activity (end-stage </text>
<text top="738" left="688" width="85" height="15" font="1">cardiomyopathy) </text>
<text top="754" left="688" width="3" height="15" font="1"> </text>
<text top="769" left="688" width="133" height="15" font="1">Complications (long-term): </text>
<text top="785" left="688" width="194" height="15" font="1">12% required ppm for SAN dysfunction </text>
<text top="599" left="920" width="208" height="15" font="1">Non-IST tachyarrhythmias are common in </text>
<text top="615" left="920" width="159" height="15" font="1">pts w/ IST before and after SAN </text>
<text top="630" left="920" width="209" height="15" font="1">modification, and are often responsible for </text>
<text top="645" left="920" width="72" height="15" font="1">sxs during f/u. </text>
<text top="661" left="920" width="3" height="15" font="1"> </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">32 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="554" width="82" height="15" font="1">measured using </text>
<text top="70" left="554" width="112" height="15" font="1">mapping system (later </text>
<text top="86" left="554" width="12" height="15" font="1">y) </text>
<text top="55" left="688" width="3" height="15" font="1"> </text>
<text top="102" left="54" width="52" height="15" font="1">Takemoto </text>
<text top="117" left="54" width="12" height="15" font="1">M </text>
<text top="133" left="54" width="31" height="15" font="1">2012  </text>
<text top="148" left="54" width="23" height="15" font="1">(80) </text>
<text top="164" left="54" width="49" height="15" font="8">22333369</text>
<text top="164" left="103" width="3" height="15" font="1"> </text>
<text top="102" left="131" width="61" height="15" font="1">Case series </text>
<text top="102" left="224" width="27" height="15" font="1">6 pts </text>
<text top="102" left="315" width="212" height="15" font="1">Consecutive, drug refractory, “debilitating”  </text>
<text top="117" left="315" width="3" height="15" font="1"> </text>
<text top="133" left="315" width="57" height="15" font="1">Procedure: </text>
<text top="148" left="315" width="200" height="15" font="1">- Non-contact mapping (St. Jude Ensite) </text>
<text top="164" left="315" width="208" height="15" font="1">- Break-out sites also identified as earliest </text>
<text top="179" left="315" width="194" height="15" font="1">sites that showed rS pattern w/ sudden </text>
<text top="195" left="315" width="189" height="15" font="1">increase in peak negative potential on </text>
<text top="210" left="315" width="161" height="15" font="1">noncontact unipolar electrogram </text>
<text top="226" left="315" width="138" height="15" font="1">- Isoproterenol 2-5 mcg/min </text>
<text top="102" left="554" width="105" height="15" font="1">Procedural endpoint: </text>
<text top="117" left="554" width="108" height="15" font="1">When break-out sites </text>
<text top="133" left="554" width="111" height="15" font="1">observed at heart rate </text>
<text top="148" left="554" width="114" height="15" font="1">&gt;100 bpm moved from </text>
<text top="164" left="554" width="114" height="15" font="1">the tall P wave zone to </text>
<text top="179" left="554" width="95" height="15" font="1">the normal P wave </text>
<text top="195" left="554" width="100" height="15" font="1">zone, w/ and w/o IV </text>
<text top="210" left="554" width="67" height="15" font="1">isoproterenol </text>
<text top="226" left="554" width="3" height="15" font="1"> </text>
<text top="102" left="688" width="68" height="15" font="1">F/U 29±2 mo </text>
<text top="117" left="688" width="157" height="15" font="1">Procedural success 6/6 (100%) </text>
<text top="133" left="688" width="113" height="15" font="1">1 y F/U: 0 recurrences </text>
<text top="148" left="688" width="201" height="15" font="1">1 ½ y: 1/6 pts had recurrence of IST and </text>
<text top="164" left="688" width="172" height="15" font="1">underwent repeat RFA w/ success </text>
<text top="179" left="688" width="215" height="15" font="1">Also showed improvement of HR on Holter, </text>
<text top="195" left="688" width="189" height="15" font="1">BNP, NYHA functional class, exercise </text>
<text top="210" left="688" width="204" height="15" font="1">tolerance, and time to achieve HR of 130 </text>
<text top="226" left="688" width="131" height="15" font="1">bpm on ETT post-ablation </text>
<text top="241" left="688" width="3" height="15" font="1"> </text>
<text top="257" left="688" width="3" height="15" font="1"> </text>
<text top="272" left="688" width="103" height="15" font="1">Complications: none </text>
<text top="102" left="920" width="216" height="15" font="1">Non-contact mapping can be used to safely </text>
<text top="117" left="920" width="122" height="15" font="1">and effectively treat IST. </text>
<text top="288" left="54" width="55" height="15" font="1">Huang HD </text>
<text top="304" left="54" width="28" height="15" font="1">2013 </text>
<text top="319" left="54" width="23" height="15" font="1">(81) </text>
<text top="335" left="54" width="49" height="15" font="8">23313383</text>
<text top="335" left="103" width="3" height="15" font="1"> </text>
<text top="350" left="54" width="3" height="15" font="1"> </text>
<text top="288" left="131" width="61" height="15" font="1">Case report </text>
<text top="304" left="131" width="68" height="15" font="1">using stellate </text>
<text top="319" left="131" width="74" height="15" font="1">ganglion block </text>
<text top="288" left="224" width="9" height="15" font="1">1 </text>
<text top="288" left="315" width="185" height="15" font="1">34 y old woman previously treated w/ </text>
<text top="304" left="315" width="173" height="15" font="1">verapamil, beta blockers, clonidine </text>
<text top="319" left="315" width="202" height="15" font="1">Baseline mean HR (Holter) 104 bpm. Tilt </text>
<text top="335" left="315" width="212" height="15" font="1">table hr increased from 86 to 104 bpm at 2 </text>
<text top="350" left="315" width="65" height="15" font="1">min (70 deg) </text>
<text top="366" left="315" width="217" height="15" font="1">Stellate ganglion block performed (transient </text>
<text top="381" left="315" width="213" height="15" font="1">Horner syndrome) (right, then left 2 d later) </text>
<text top="288" left="554" width="92" height="15" font="1">Following bilateral </text>
<text top="304" left="554" width="115" height="15" font="1">stellate ganglion block, </text>
<text top="319" left="554" width="109" height="15" font="1">Holter w/ mean HR of </text>
<text top="335" left="554" width="43" height="15" font="1">73 bpm. </text>
<text top="350" left="554" width="94" height="15" font="1">Last f/u at 4 mo w/ </text>
<text top="366" left="554" width="111" height="15" font="1">resting HR of 87 bpm. </text>
<text top="288" left="688" width="207" height="15" font="1">Following bilateral stellate ganglion block, </text>
<text top="304" left="688" width="152" height="15" font="1">Holter w/ mean HR of 73 bpm. </text>
<text top="319" left="688" width="204" height="15" font="1">Last f/u at 4 mo w/ resting HR of 87 bpm. </text>
<text top="288" left="920" width="201" height="15" font="1">Mechanisms for lasting effect unclear as </text>
<text top="304" left="920" width="212" height="15" font="1">anesthetic agent used has half-life of 4-5 h </text>
<text top="398" left="54" width="1076" height="15" font="1">AAD indicates antiarrhythmic drug; AVNRT, atrioventricular nodal reentrant tachycardia; bid, two times per day; BNP, B-type natriuretic peptide; bpm indicates beats per min; c/w, consistent with; ECG, electrocardiogram; </text>
<text top="413" left="54" width="1068" height="15" font="1">EHRA, European Heart Rhythm Association; EP, electrophysiological; ETT, exercise tolerance test; f/u, follow up; h/o, history of; HR, heart rate; ICE, intracardiac echocardiography; IST, inappropriate sinus tachycardia; </text>
<text top="429" left="54" width="1005" height="15" font="1">IV, intravenous; METS, metabolic equivalents; NYHA, New York Heart Association; POTS, postural orthostatic tachycardia syndrome; PPM, prosthesis-patient mismatch; pt, patient; QOL, quality of life; RF, </text>
<text top="444" left="54" width="1055" height="15" font="1">radiofrequency; RFA, radiofrequency ablation; SF, short form; SHD, structural heart disease; SN, sinus node; SVC, superior vena cava; SVC-RA, superior vena cava-right atrial; SVT, supraventricular tachycardia; sx, </text>
<text top="460" left="54" width="180" height="15" font="1">symptom; w/, with; and w/o, without. </text>
<text top="475" left="54" width="3" height="15" font="1"> </text>
<text top="500" left="54" width="143" height="18" font="3"><b>Data Supplement 6. </b></text>
<text top="500" left="197" width="749" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Focal Atrial Tachycardia – Section 4.1 </b></text>
<text top="500" left="946" width="4" height="18" font="3"><b> </b></text>
<text top="519" left="65" width="38" height="17" font="5"><b>Study </b></text>
<text top="537" left="63" width="40" height="17" font="5"><b>Name, </b></text>
<text top="554" left="60" width="47" height="17" font="5"><b>Author, </b></text>
<text top="571" left="68" width="30" height="17" font="5"><b>Year </b></text>
<text top="519" left="127" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="537" left="142" width="44" height="17" font="5"><b>Design </b></text>
<text top="519" left="227" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="519" left="345" width="165" height="17" font="5"><b>Inclusion/Exclusion Criteria </b></text>
<text top="519" left="554" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="519" left="733" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="519" left="952" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="589" left="54" width="56" height="15" font="1">Gillette PC </text>
<text top="604" left="54" width="31" height="15" font="1">1977  </text>
<text top="620" left="54" width="23" height="15" font="1">(82) </text>
<text top="635" left="54" width="37" height="15" font="8">902384</text>
<text top="635" left="91" width="3" height="15" font="1"> </text>
<text top="651" left="54" width="3" height="15" font="1"> </text>
<text top="589" left="126" width="71" height="15" font="1">Observational </text>
<text top="589" left="215" width="86" height="15" font="1">7 children (6 wks </text>
<text top="604" left="215" width="68" height="15" font="1">to 9 y of age) </text>
<text top="589" left="318" width="199" height="15" font="1">Sustained automatic AT taken to EP lab </text>
<text top="589" left="549" width="67" height="15" font="1">Programmed </text>
<text top="604" left="549" width="103" height="15" font="1">stimulation and drug </text>
<text top="620" left="549" width="36" height="15" font="1">testing </text>
<text top="589" left="677" width="195" height="15" font="1">1 responded to digoxin, 3 responded to </text>
<text top="604" left="677" width="121" height="15" font="1">propranolol and digoxin; </text>
<text top="620" left="677" width="196" height="15" font="1">diphenylhydantoin in one and reserpine </text>
<text top="635" left="677" width="18" height="15" font="1">in1 </text>
<text top="589" left="904" width="171" height="15" font="1">Newborn and pediatric population  </text>
<text top="667" left="54" width="46" height="15" font="1">Creamer </text>
<text top="683" left="54" width="16" height="15" font="1">JE </text>
<text top="698" left="54" width="31" height="15" font="1">1985  </text>
<text top="713" left="54" width="23" height="15" font="1">(83) </text>
<text top="729" left="54" width="43" height="15" font="8">3966957</text>
<text top="729" left="97" width="3" height="15" font="1"> </text>
<text top="667" left="126" width="61" height="15" font="1">Case report </text>
<text top="667" left="215" width="84" height="15" font="1">3 (23, 33 and 57 </text>
<text top="683" left="215" width="88" height="15" font="1">y of age, all man) </text>
<text top="667" left="318" width="135" height="15" font="1">Symptomatic persistent AT </text>
<text top="667" left="549" width="98" height="15" font="1">Acute (IV) and long </text>
<text top="683" left="549" width="103" height="15" font="1">term (oral) response </text>
<text top="698" left="549" width="62" height="15" font="1">to flecainide </text>
<text top="667" left="677" width="210" height="15" font="1">All responded acutely and on long term f/u </text>
<text top="683" left="677" width="83" height="15" font="1">from 3 mo to 3 y </text>
<text top="667" left="904" width="195" height="15" font="1">Case report demonstrating flecainide is </text>
<text top="683" left="904" width="177" height="15" font="1">effective in focal AT in selected pts. </text>
<text top="745" left="54" width="52" height="15" font="1">Kunze KP </text>
<text top="761" left="54" width="28" height="15" font="1">1986 </text>
<text top="776" left="54" width="23" height="15" font="1">(84) </text>
<text top="792" left="54" width="43" height="15" font="8">3082957</text>
<text top="792" left="97" width="3" height="15" font="1"> </text>
<text top="745" left="126" width="71" height="15" font="1">Observational </text>
<text top="745" left="215" width="83" height="15" font="1">5 pts (mean age </text>
<text top="761" left="215" width="19" height="15" font="1">37) </text>
<text top="745" left="318" width="200" height="15" font="1">Chronic symptomatic ectopic AT failed 4 </text>
<text top="761" left="318" width="178" height="15" font="1">other antiarrhythmic drugs including </text>
<text top="776" left="318" width="134" height="15" font="1">amiodarone and verapamil </text>
<text top="745" left="549" width="114" height="15" font="1">Assess acute and long </text>
<text top="761" left="549" width="90" height="15" font="1">term outcomes w/ </text>
<text top="776" left="549" width="72" height="15" font="1">encainide and </text>
<text top="792" left="549" width="90" height="15" font="1">flecainide therapy </text>
<text top="745" left="677" width="213" height="15" font="1">4/5 pts had complete suppression of AT by </text>
<text top="761" left="677" width="213" height="15" font="1">encainide and 1/5 had significant reduction </text>
<text top="776" left="677" width="183" height="15" font="1">at a mean f/u of 8 mo. 3/5 pts did not </text>
<text top="792" left="677" width="213" height="15" font="1">tolerate encainide. These pts responded to </text>
<text top="745" left="904" width="225" height="15" font="1">One of the more  comprehensive mechanism-</text>
<text top="761" left="904" width="193" height="15" font="1">based investigation in human subjects. </text>
<text top="776" left="904" width="232" height="15" font="1">Differentiation of mechanisms is based on best </text>
<text top="792" left="904" width="231" height="15" font="1">established criteria although overlaps between </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">33 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="677" width="150" height="15" font="1">flecainide w/o any side effects </text>
<text top="55" left="904" width="229" height="15" font="1">reentry and trigger are present; drug response </text>
<text top="70" left="904" width="212" height="15" font="1">was not specific. It is not apparent whether </text>
<text top="86" left="904" width="217" height="15" font="1">these were micro- or macro-reentry circuits. </text>
<text top="101" left="904" width="197" height="15" font="1">Ablation targeted the earliest activation, </text>
<text top="117" left="904" width="128" height="15" font="1">suggesting micro-reentry. </text>
<text top="133" left="54" width="41" height="15" font="1">Lucet V </text>
<text top="148" left="54" width="28" height="15" font="1">1987 </text>
<text top="164" left="54" width="23" height="15" font="1">(85) </text>
<text top="179" left="54" width="43" height="15" font="8">3122689</text>
<text top="179" left="97" width="3" height="15" font="1"> </text>
<text top="133" left="126" width="123" height="15" font="1">Observational 30 </text>
<text top="133" left="230" width="63" height="15" font="1">children, </text>
<text top="133" left="275" width="40" height="15" font="1">age </text>
<text top="148" left="215" width="64" height="15" font="1">3 mo to 20 y </text>
<text top="133" left="318" width="206" height="15" font="1">All pts treated w/ propafenone for a mean </text>
<text top="148" left="318" width="80" height="15" font="1">period of 14 mo </text>
<text top="133" left="549" width="105" height="15" font="1">Clinical outcomes on </text>
<text top="148" left="549" width="105" height="15" font="1">propafenone therapy </text>
<text top="133" left="677" width="199" height="15" font="1">Study cohorts: chronic AT (8), junctional </text>
<text top="148" left="677" width="210" height="15" font="1">arrhythmia (9), ventricular arrhythmia (13). </text>
<text top="164" left="677" width="188" height="15" font="1">Propafeone was “more effective” than </text>
<text top="179" left="677" width="207" height="15" font="1">amiodarone in 3 pts w/ chronic AT and as </text>
<text top="195" left="677" width="206" height="15" font="1">effective as amiodarone in 2. Side effects </text>
<text top="210" left="677" width="204" height="15" font="1">were present in 27%, although “generally </text>
<text top="226" left="677" width="75" height="15" font="1">well tolerated”. </text>
<text top="133" left="904" width="224" height="15" font="1">There is significant limitation of the study due </text>
<text top="148" left="904" width="230" height="15" font="1">to the observational nature of the study design </text>
<text top="164" left="904" width="161" height="15" font="1">and mix of different arrhythmias. </text>
<text top="242" left="54" width="52" height="15" font="1">Mehta AV </text>
<text top="257" left="54" width="28" height="15" font="1">1988 </text>
<text top="273" left="54" width="23" height="15" font="1">(86) </text>
<text top="288" left="54" width="43" height="15" font="8">3339178</text>
<text top="288" left="97" width="3" height="15" font="1"> </text>
<text top="242" left="126" width="71" height="15" font="1">Observational </text>
<text top="242" left="215" width="73" height="15" font="1">10 infants and </text>
<text top="257" left="215" width="84" height="15" font="1">children; median </text>
<text top="273" left="215" width="84" height="15" font="1">age 6 mo, range </text>
<text top="288" left="215" width="86" height="15" font="1">from new born to </text>
<text top="304" left="215" width="27" height="15" font="1">7.5 y </text>
<text top="242" left="318" width="159" height="15" font="1">Met ECG critieria for ectopic AT </text>
<text top="242" left="549" width="102" height="15" font="1">Acute and long term </text>
<text top="257" left="549" width="70" height="15" font="1">response to a </text>
<text top="273" left="549" width="89" height="15" font="1">sequence of drug </text>
<text top="288" left="549" width="75" height="15" font="1">testing. One pt </text>
<text top="304" left="549" width="96" height="15" font="1">underwent surgical </text>
<text top="319" left="549" width="79" height="15" font="1">ablation; one pt </text>
<text top="335" left="549" width="98" height="15" font="1">underwent catheter </text>
<text top="350" left="549" width="42" height="15" font="1">ablation </text>
<text top="242" left="677" width="199" height="15" font="1">Digoxin did not suppress any AT but did </text>
<text top="257" left="677" width="212" height="15" font="1">slow the ventricular rate by 5-20% in 8 pts. </text>
<text top="273" left="677" width="168" height="15" font="1">IV propranolol was effective in AT </text>
<text top="288" left="677" width="194" height="15" font="1">suppression in 3/5 pts; oral propranolol </text>
<text top="304" left="677" width="177" height="15" font="1">was effective in 2/5. Class Ia and Ib </text>
<text top="319" left="677" width="210" height="15" font="1">antiarrhythmic agents were not effective in </text>
<text top="335" left="677" width="171" height="15" font="1">AT suppression and worsened the </text>
<text top="350" left="677" width="177" height="15" font="1">ventricular rate. IV amiodarone was </text>
<text top="366" left="677" width="200" height="15" font="1">effective in 3 /4 pts and oral amiodarone </text>
<text top="381" left="677" width="202" height="15" font="1">was effective in one pt. During f/u (10-28 </text>
<text top="397" left="677" width="193" height="15" font="1">mo), AT resolved in 4 pts and was well </text>
<text top="412" left="677" width="200" height="15" font="1">controlled in 4 pts. Surgical and catheter </text>
<text top="428" left="677" width="196" height="15" font="1">ablation was each performed in one pts </text>
<text top="242" left="904" width="220" height="15" font="1">This small study was conducted in new born </text>
<text top="257" left="904" width="121" height="15" font="1">and very young children </text>
<text top="444" left="54" width="3" height="15" font="1"> </text>
<text top="444" left="126" width="3" height="15" font="1"> </text>
<text top="444" left="215" width="3" height="15" font="1"> </text>
<text top="444" left="318" width="3" height="15" font="1"> </text>
<text top="444" left="549" width="3" height="15" font="1"> </text>
<text top="444" left="677" width="3" height="15" font="1"> </text>
<text top="444" left="904" width="3" height="15" font="1"> </text>
<text top="460" left="54" width="53" height="15" font="1">Colloridi V </text>
<text top="476" left="54" width="28" height="15" font="1">1992 </text>
<text top="491" left="54" width="23" height="15" font="1">(87) </text>
<text top="507" left="54" width="43" height="15" font="8">1729843</text>
<text top="507" left="97" width="3" height="15" font="1"> </text>
<text top="460" left="126" width="58" height="15" font="1">Case study </text>
<text top="460" left="215" width="72" height="15" font="1">5 pediatric pts </text>
<text top="460" left="318" width="179" height="15" font="1">Ectopic AT was met by ECG criteria </text>
<text top="460" left="549" width="101" height="15" font="1">Pts failed a mean of </text>
<text top="476" left="549" width="59" height="15" font="1">three drugs </text>
<text top="460" left="677" width="187" height="15" font="1">Sotalol was added to digoxin; AT was </text>
<text top="476" left="677" width="113" height="15" font="1">suppressed in all 5 pts </text>
<text top="460" left="904" width="214" height="15" font="1">A small case series study showing effect of </text>
<text top="476" left="904" width="142" height="15" font="1">sotalol on AT in pediatric pts </text>
<text top="523" left="54" width="21" height="15" font="1">von </text>
<text top="539" left="54" width="54" height="15" font="1">Bernuth G </text>
<text top="554" left="54" width="28" height="15" font="1">1992 </text>
<text top="569" left="54" width="23" height="15" font="1">(88) </text>
<text top="585" left="54" width="43" height="15" font="8">1396817</text>
<text top="585" left="97" width="3" height="15" font="1"> </text>
<text top="523" left="126" width="71" height="15" font="1">Observational </text>
<text top="523" left="215" width="73" height="15" font="1">21 infants and </text>
<text top="539" left="215" width="45" height="15" font="1">children  </text>
<text top="523" left="318" width="203" height="15" font="1">Automatic AT was documented by Holter </text>
<text top="539" left="318" width="183" height="15" font="1">and ECG; 12 were incessant, 7 were </text>
<text top="554" left="318" width="200" height="15" font="1">repetitive, 2 were undefined; 16/21 were </text>
<text top="569" left="318" width="65" height="15" font="1">symptomatic </text>
<text top="523" left="549" width="112" height="15" font="1">All pts were treated w/ </text>
<text top="539" left="549" width="92" height="15" font="1">1-8 antiarrhythmic </text>
<text top="554" left="549" width="87" height="15" font="1">drugs (median 3) </text>
<text top="523" left="677" width="201" height="15" font="1">Amiodarone was most effective followed </text>
<text top="539" left="677" width="160" height="15" font="1">by class Ic drugs: flecainide and </text>
<text top="554" left="677" width="207" height="15" font="1">propafenone. During a median f/u of 2.5 y </text>
<text top="569" left="677" width="185" height="15" font="1">(range from 4 mo to 21 y), 12 were in </text>
<text top="585" left="677" width="206" height="15" font="1">sinus rhythm, 5 were w/o any drugs. Nine </text>
<text top="600" left="677" width="200" height="15" font="1">pts were still on antiarrhythmic drugs; all </text>
<text top="616" left="677" width="142" height="15" font="1">were intermittent except one </text>
<text top="523" left="904" width="204" height="15" font="1">Small observational study in the pediatric </text>
<text top="539" left="904" width="54" height="15" font="1">population </text>
<text top="632" left="54" width="47" height="15" font="1">Chen SA </text>
<text top="648" left="54" width="28" height="15" font="1">1994 </text>
<text top="663" left="54" width="23" height="15" font="1">(89) </text>
<text top="679" left="54" width="43" height="15" font="8">8087935</text>
<text top="679" left="97" width="3" height="15" font="1"> </text>
<text top="632" left="126" width="170" height="15" font="1">Observational   36 (57+/-13 y of </text>
<text top="648" left="215" width="25" height="15" font="1">age) </text>
<text top="632" left="318" width="194" height="15" font="1">Sustained AT referred to the EP lab for </text>
<text top="648" left="318" width="42" height="15" font="1">ablation </text>
<text top="632" left="549" width="67" height="15" font="1">Programmed </text>
<text top="648" left="549" width="84" height="15" font="1">stimulation, drug </text>
<text top="663" left="549" width="87" height="15" font="1">testing, Valsalva, </text>
<text top="679" left="549" width="81" height="15" font="1">monophasic AP </text>
<text top="694" left="549" width="113" height="15" font="1">recording and ablation </text>
<text top="710" left="549" width="67" height="15" font="1">to assess AT </text>
<text top="725" left="549" width="65" height="15" font="1">mechanisms </text>
<text top="632" left="677" width="120" height="15" font="1">20/36 had reentrant AT, </text>
<text top="648" left="677" width="105" height="15" font="1">9/36 triggered (DAD) </text>
<text top="663" left="677" width="76" height="15" font="1">7/36 automatic </text>
<text top="679" left="677" width="161" height="15" font="1">Immediate success 40/41 (98%) </text>
<text top="694" left="677" width="184" height="15" font="1">Recurrence 2/40 (5%) in 18 mons f/u </text>
<text top="710" left="677" width="158" height="15" font="1">2 failed RF, both were triggered </text>
<text top="632" left="904" width="198" height="15" font="1">One of the earlier  more comprehensive </text>
<text top="648" left="904" width="207" height="15" font="1">mechanism-based investigation in human </text>
<text top="663" left="904" width="207" height="15" font="1">subjects. Differentiation of mechanisms is </text>
<text top="679" left="904" width="213" height="15" font="1">based on best established criteria although </text>
<text top="694" left="904" width="202" height="15" font="1">overlaps between reentry and trigger are </text>
<text top="710" left="904" width="221" height="15" font="1">present; drug response was not specific. It is </text>
<text top="725" left="904" width="212" height="15" font="1">not apparent whether these were micro- or </text>
<text top="741" left="904" width="218" height="15" font="1">macro-reentry circuits. Ablation targeted the </text>
<text top="756" left="904" width="220" height="15" font="1">earliest activation, suggesting micro-reentry. </text>
<text top="772" left="54" width="55" height="15" font="1">Engelstein </text>
<text top="788" left="54" width="18" height="15" font="1">ED </text>
<text top="772" left="126" width="71" height="15" font="1">Observational </text>
<text top="772" left="215" width="36" height="15" font="1">27 pts  </text>
<text top="788" left="215" width="86" height="15" font="1">Automatic (7 pts, </text>
<text top="772" left="318" width="193" height="15" font="1">Pts were referred for electrophysiology </text>
<text top="788" left="318" width="203" height="15" font="1">study (25 pts; 17 for symptomatic SVT, 7 </text>
<text top="772" left="549" width="72" height="15" font="1">Mechanism of </text>
<text top="788" left="549" width="82" height="15" font="1">tachycardia was </text>
<text top="772" left="677" width="181" height="15" font="1">Adenosine terminated all sinus node </text>
<text top="788" left="677" width="173" height="15" font="1">reentry tachycardia (6/6), triggered </text>
<text top="772" left="904" width="212" height="15" font="1">These earlier observations established our </text>
<text top="788" left="904" width="233" height="15" font="1">current understanding of potential mechanisms </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">34 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="28" height="15" font="1">1994 </text>
<text top="70" left="54" width="23" height="15" font="14">(90) </text>
<text top="86" left="54" width="43" height="15" font="8">8205677</text>
<text top="86" left="97" width="3" height="15" font="14"> </text>
<text top="55" left="215" width="72" height="15" font="1">age 34+/- 18); </text>
<text top="70" left="215" width="57" height="15" font="1">sinus node </text>
<text top="86" left="215" width="71" height="15" font="1">reentry (6 pts, </text>
<text top="101" left="215" width="72" height="15" font="1">age 58+/- 16); </text>
<text top="117" left="215" width="71" height="15" font="1">atrial flutter (8 </text>
<text top="132" left="215" width="87" height="15" font="1">pts, age 62+/- 8); </text>
<text top="147" left="215" width="90" height="15" font="1">intra-atrial reentry </text>
<text top="163" left="215" width="87" height="15" font="1">(5 pts, age 70 +/- </text>
<text top="178" left="215" width="66" height="15" font="1">8 ); triggered </text>
<text top="194" left="215" width="88" height="15" font="1">tachycardia (1 pt, </text>
<text top="210" left="215" width="41" height="15" font="1">age 79) </text>
<text top="55" left="318" width="204" height="15" font="1">for VT, 1 for syncope) or cardioversion (2 </text>
<text top="70" left="318" width="94" height="15" font="1">pts w/ atrial flutter) </text>
<text top="55" left="549" width="86" height="15" font="1">confirmed during </text>
<text top="70" left="549" width="89" height="15" font="1">electrophysiology </text>
<text top="86" left="549" width="101" height="15" font="1">study.  Response to </text>
<text top="101" left="549" width="77" height="15" font="1">adenosine was </text>
<text top="117" left="549" width="113" height="15" font="1">assessed according to </text>
<text top="132" left="549" width="106" height="15" font="1">EP study determined </text>
<text top="147" left="549" width="65" height="15" font="1">mechanisms </text>
<text top="55" left="677" width="198" height="15" font="1">tachycardia (1/1). Adenosine transiently </text>
<text top="70" left="677" width="206" height="15" font="1">suppressed automatic AT (7/7); it had not </text>
<text top="86" left="677" width="181" height="15" font="1">effect on reentry tachycardia (13/13) </text>
<text top="55" left="904" width="190" height="15" font="1">of AT and drug effects as predicted by </text>
<text top="70" left="904" width="122" height="15" font="1">underlying mechanisms. </text>
<text top="226" left="54" width="51" height="15" font="1">Heusch A </text>
<text top="241" left="54" width="28" height="15" font="1">1994 </text>
<text top="257" left="54" width="23" height="15" font="1">(91) </text>
<text top="272" left="54" width="43" height="15" font="8">7527342</text>
<text top="272" left="97" width="3" height="15" font="1"> </text>
<text top="226" left="126" width="123" height="15" font="1">Observational 72 </text>
<text top="226" left="230" width="63" height="15" font="1">children, </text>
<text top="241" left="215" width="75" height="15" font="1">mean age was </text>
<text top="257" left="215" width="79" height="15" font="1">34 mo (range 0-</text>
<text top="272" left="215" width="25" height="15" font="1">192) </text>
<text top="226" left="318" width="180" height="15" font="1">All pts were treated w/ propafenone  </text>
<text top="226" left="549" width="80" height="15" font="1">AT or junctional </text>
<text top="241" left="549" width="98" height="15" font="1">tachycardia were in </text>
<text top="257" left="549" width="84" height="15" font="1">10/72 pts (14%). </text>
<text top="272" left="549" width="92" height="15" font="1">Other arrhythmias </text>
<text top="288" left="549" width="112" height="15" font="1">including AV reentrant </text>
<text top="303" left="549" width="100" height="15" font="1">tachycardia (32 pts, </text>
<text top="319" left="549" width="109" height="15" font="1">44%), atrial flutter (16 </text>
<text top="334" left="549" width="80" height="15" font="1">pts, 22%), atrial </text>
<text top="350" left="549" width="110" height="15" font="1">reentry tachycardia (3 </text>
<text top="365" left="549" width="65" height="15" font="1">pts, 4%) and </text>
<text top="381" left="549" width="54" height="15" font="1">ventricular </text>
<text top="396" left="549" width="101" height="15" font="1">arrhythmias (11 pts, </text>
<text top="412" left="549" width="32" height="15" font="1">16%). </text>
<text top="226" left="677" width="199" height="15" font="1">Propafenone was effective in controlling </text>
<text top="241" left="677" width="199" height="15" font="1">atrial or junctional ectopic tachycardia in </text>
<text top="257" left="677" width="196" height="15" font="1">83%. Of the entire study cohorts, better </text>
<text top="272" left="677" width="207" height="15" font="1">outcomes were observed in pts w/ normal </text>
<text top="288" left="677" width="203" height="15" font="1">hearts and in whom onset of arrhythmias </text>
<text top="303" left="677" width="73" height="15" font="1">was pre-natal. </text>
<text top="226" left="904" width="218" height="15" font="1">A mix of many different arrhythmias renders </text>
<text top="241" left="904" width="208" height="15" font="1">interpretation of results difficult. The study </text>
<text top="257" left="904" width="188" height="15" font="1">population is young children, many w/ </text>
<text top="272" left="904" width="135" height="15" font="1">congenital heart conditions </text>
<text top="428" left="54" width="50" height="15" font="1">Janousek </text>
<text top="443" left="54" width="9" height="15" font="1">J </text>
<text top="459" left="54" width="31" height="15" font="1">1998  </text>
<text top="474" left="54" width="23" height="15" font="1">(92) </text>
<text top="490" left="54" width="43" height="15" font="8">9605053</text>
<text top="490" left="97" width="3" height="15" font="1"> </text>
<text top="428" left="126" width="54" height="15" font="1">European, </text>
<text top="443" left="126" width="66" height="15" font="1">retrospective </text>
<text top="459" left="126" width="21" height="15" font="1">and </text>
<text top="474" left="126" width="57" height="15" font="1">multicenter </text>
<text top="490" left="126" width="30" height="15" font="1">study </text>
<text top="428" left="215" width="79" height="15" font="1">722 infants and </text>
<text top="443" left="215" width="82" height="15" font="1">children from 27 </text>
<text top="459" left="215" width="51" height="15" font="1">European </text>
<text top="474" left="215" width="39" height="15" font="1">centers </text>
<text top="490" left="215" width="76" height="15" font="1">coordinated by </text>
<text top="505" left="215" width="62" height="15" font="1">the Working </text>
<text top="521" left="215" width="49" height="15" font="1">Group on </text>
<text top="536" left="215" width="46" height="15" font="1">Pediatric </text>
<text top="552" left="215" width="84" height="15" font="1">Arrhythmias and </text>
<text top="567" left="215" width="90" height="15" font="1">Electrophysiology </text>
<text top="583" left="215" width="31" height="15" font="1">of the </text>
<text top="598" left="215" width="72" height="15" font="1">Association of </text>
<text top="614" left="215" width="51" height="15" font="1">European </text>
<text top="629" left="215" width="46" height="15" font="1">Pediatric </text>
<text top="645" left="215" width="61" height="15" font="1">Cardiologist </text>
<text top="428" left="318" width="199" height="15" font="1">All pts were treated w/ oral propafenone </text>
<text top="428" left="549" width="86" height="15" font="1">Safety outcomes </text>
<text top="428" left="677" width="194" height="15" font="1">Ectopic AT was in 66/722 study cohort. </text>
<text top="443" left="677" width="208" height="15" font="1">Other arrhythmias included reentrant SVT </text>
<text top="459" left="677" width="205" height="15" font="1">(388), junctional ectopic tachycardia (39), </text>
<text top="474" left="677" width="191" height="15" font="1">atrial flutter (21), ventricular premature </text>
<text top="490" left="677" width="204" height="15" font="1">complexes (140), VT (78) and other (39). </text>
<text top="505" left="677" width="174" height="15" font="1">249/722 had SHD. Adverse events </text>
<text top="521" left="677" width="180" height="15" font="1">included sinus node dysfunction (4), </text>
<text top="536" left="677" width="150" height="15" font="1">complete heart block (2), SVT </text>
<text top="552" left="677" width="205" height="15" font="1">proarrhythmia (2), accelerated ventricular </text>
<text top="567" left="677" width="188" height="15" font="1">rate during atrial flutter (1), ventricular </text>
<text top="583" left="677" width="207" height="15" font="1">arrhythmias (5), unexplained syncope (1). </text>
<text top="598" left="677" width="205" height="15" font="1">Cardiac arrest occurred in 6 (0.6%, 2 had </text>
<text top="614" left="677" width="95" height="15" font="1">WPW, 3 had SHD) </text>
<text top="428" left="904" width="225" height="15" font="1">A large retrospective multicenter study on the </text>
<text top="443" left="904" width="185" height="15" font="1">safety of propafenone in the pediatric </text>
<text top="459" left="904" width="60" height="15" font="1">population.  </text>
<text top="661" left="54" width="58" height="15" font="1">Kalman JM </text>
<text top="676" left="54" width="31" height="15" font="1">1998  </text>
<text top="692" left="54" width="23" height="15" font="1">(93) </text>
<text top="707" left="54" width="43" height="15" font="8">9462592</text>
<text top="707" left="97" width="3" height="15" font="1"> </text>
<text top="661" left="126" width="71" height="15" font="1">Observational </text>
<text top="661" left="215" width="70" height="15" font="1">23 pts, 27 RA </text>
<text top="676" left="215" width="60" height="15" font="1">tachycardia </text>
<text top="661" left="318" width="171" height="15" font="1">17 female, age 41 +/- 14 y; h/o AT </text>
<text top="676" left="318" width="212" height="15" font="1">suspected from RA; point to point mapping </text>
<text top="692" left="318" width="151" height="15" font="1">w/ 5 mm tip steerable catheter </text>
<text top="661" left="549" width="109" height="15" font="1">ICE localization of AT </text>
<text top="676" left="549" width="97" height="15" font="1">origin; outcomes of </text>
<text top="692" left="549" width="25" height="15" font="1">RFA </text>
<text top="661" left="677" width="197" height="15" font="1">23/27 localized to RA; 4 were from right </text>
<text top="676" left="677" width="178" height="15" font="1">superior pulmonary vein; other sites </text>
<text top="692" left="677" width="202" height="15" font="1">include posterior septum, coronary sinus </text>
<text top="707" left="677" width="192" height="15" font="1">os, RAA; 18/27 (67%) were on the CT; </text>
<text top="723" left="677" width="177" height="15" font="1">26/27 successful ablation (96%); all </text>
<text top="738" left="677" width="88" height="15" font="1">visualized by ICE </text>
<text top="661" left="904" width="210" height="15" font="1">Visual confirmation by ICE of ablation site; </text>
<text top="676" left="904" width="226" height="15" font="1">high prevalence of AT originating from cristae </text>
<text top="692" left="904" width="50" height="15" font="1">terminalis </text>
<text top="755" left="54" width="53" height="15" font="1">Markowitz </text>
<text top="770" left="54" width="20" height="15" font="1">SM </text>
<text top="786" left="54" width="28" height="15" font="1">1999 </text>
<text top="755" left="126" width="71" height="15" font="1">Observational </text>
<text top="755" left="215" width="74" height="15" font="1">30 pts (age 55 </text>
<text top="770" left="215" width="44" height="15" font="1">+/- 18 y) </text>
<text top="755" left="318" width="197" height="15" font="1">Referred to EP study for evaluation and </text>
<text top="770" left="318" width="122" height="15" font="1">treatment of tachycardia </text>
<text top="755" left="549" width="100" height="15" font="1">Assess response to </text>
<text top="770" left="549" width="105" height="15" font="1">adenosine according </text>
<text top="786" left="549" width="60" height="15" font="1">to EP study </text>
<text top="755" left="677" width="207" height="15" font="1">Adenosine terminated 14/17 focal AT and </text>
<text top="770" left="677" width="191" height="15" font="1">transiently suppressed the other 3 pts. </text>
<text top="786" left="677" width="211" height="15" font="1">Only 1/13 macrorenetrant tachycardia was </text>
<text top="755" left="904" width="233" height="15" font="1">This study highlighted the challenges remain in </text>
<text top="770" left="904" width="231" height="15" font="1">differentiating automatic vs. triggered focal AT. </text>
<text top="786" left="904" width="201" height="15" font="1">The proportion of focal AT terminated by </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">35 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="23" height="15" font="1">(94) </text>
<text top="70" left="54" width="49" height="15" font="8">10355690</text>
<text top="70" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="549" width="58" height="15" font="1">determined </text>
<text top="70" left="549" width="65" height="15" font="1">mechanisms </text>
<text top="55" left="677" width="207" height="15" font="1">terminated by adenosine. The termination </text>
<text top="70" left="677" width="185" height="15" font="1">occurred in the slow of conduction w/ </text>
<text top="86" left="677" width="178" height="15" font="1">decrementing properties. Verapamil </text>
<text top="101" left="677" width="212" height="15" font="1">terminated all of the focal ATs when tested </text>
<text top="55" left="904" width="199" height="15" font="1">adenosine (presumably due to triggered </text>
<text top="70" left="904" width="231" height="15" font="1">activity) is significantly different from the report </text>
<text top="86" left="904" width="205" height="15" font="1">from Englestein 1994, from the same lab. </text>
<text top="117" left="54" width="54" height="15" font="1">Morton JB </text>
<text top="133" left="54" width="28" height="15" font="1">2001 </text>
<text top="148" left="54" width="23" height="15" font="1">(95) </text>
<text top="164" left="54" width="49" height="15" font="8">11405398</text>
<text top="164" left="103" width="3" height="15" font="1"> </text>
<text top="117" left="126" width="71" height="15" font="1">Observational </text>
<text top="117" left="215" width="68" height="15" font="1">9 pts from 64 </text>
<text top="133" left="215" width="79" height="15" font="1">consecutive pts </text>
<text top="148" left="215" width="80" height="15" font="1">underwent RFA </text>
<text top="164" left="215" width="52" height="15" font="1">for RA AT </text>
<text top="117" left="318" width="201" height="15" font="1">6 male, 50 +/- 20 y; AT from CT; point to </text>
<text top="133" left="318" width="119" height="15" font="1">point steerable catheter </text>
<text top="117" left="549" width="67" height="15" font="1">Mapping and </text>
<text top="133" left="549" width="100" height="15" font="1">localization of AT to </text>
<text top="148" left="549" width="18" height="15" font="1">CT </text>
<text top="117" left="677" width="198" height="15" font="1">34/67 (51%) from CT; 8 (12%) from CS; </text>
<text top="133" left="677" width="198" height="15" font="1">10 (15%) para-Hisian; 9 (13%) from TA. </text>
<text top="148" left="677" width="201" height="15" font="1">8/9 were successfully ablated; 1 was not </text>
<text top="164" left="677" width="47" height="15" font="1">inducible </text>
<text top="117" left="904" width="171" height="15" font="1">AT originating from CT is common </text>
<text top="180" left="54" width="53" height="15" font="1">Kistler PM </text>
<text top="195" left="54" width="28" height="15" font="1">2003 </text>
<text top="211" left="54" width="23" height="15" font="1">(96) </text>
<text top="226" left="54" width="49" height="15" font="8">12821250</text>
<text top="226" left="103" width="3" height="15" font="1"> </text>
<text top="180" left="126" width="117" height="15" font="1">Observational 7 </text>
<text top="180" left="224" width="39" height="15" font="1">pts/ </text>
<text top="180" left="245" width="40" height="15" font="1">172 </text>
<text top="195" left="215" width="79" height="15" font="1">consecutive pts </text>
<text top="211" left="215" width="58" height="15" font="1">w/ focal AT </text>
<text top="180" left="318" width="114" height="15" font="1">AT from mitral annulus </text>
<text top="195" left="318" width="113" height="15" font="1">Point to point mapping </text>
<text top="180" left="549" width="109" height="15" font="1">Mapping and ablation </text>
<text top="195" left="549" width="95" height="15" font="1">need to make note </text>
<text top="211" left="549" width="103" height="15" font="1">how they figured out </text>
<text top="226" left="549" width="103" height="15" font="1">where it was coming </text>
<text top="242" left="549" width="25" height="15" font="1">from </text>
<text top="180" left="677" width="183" height="15" font="1">All mapped to left fibrous trigone and </text>
<text top="195" left="677" width="173" height="15" font="1">mitral-aortic continuity; P wave low </text>
<text top="211" left="677" width="194" height="15" font="1">amplitude in precordial leads, biphasic, </text>
<text top="226" left="677" width="178" height="15" font="1">negative followed by positive; 100% </text>
<text top="242" left="677" width="65" height="15" font="1">success rate </text>
<text top="180" left="904" width="180" height="15" font="1">Mitral annular origin is less common </text>
<text top="258" left="54" width="53" height="15" font="1">Kistler PM </text>
<text top="274" left="54" width="28" height="15" font="1">2003 </text>
<text top="289" left="54" width="23" height="15" font="1">(97) </text>
<text top="305" left="54" width="49" height="15" font="8">14557361</text>
<text top="305" left="103" width="3" height="15" font="1"> </text>
<text top="258" left="126" width="71" height="15" font="1">Observational </text>
<text top="258" left="215" width="86" height="15" font="1">27 pts w/ 28 ATs </text>
<text top="258" left="318" width="215" height="15" font="1">AT from pulmonary veins; 39 +/- 16 y; point </text>
<text top="274" left="318" width="165" height="15" font="1">to point mapping w/ or w/o Lasso </text>
<text top="258" left="549" width="109" height="15" font="1">Mapping and ablation </text>
<text top="258" left="677" width="186" height="15" font="1">Right superior pumonlary vein 11, left </text>
<text top="274" left="677" width="194" height="15" font="1">superior pulmonary vein 11, left inferior </text>
<text top="289" left="677" width="207" height="15" font="1">pulmonary vein 5, right inferior pulmonary </text>
<text top="305" left="677" width="212" height="15" font="1">vein 1; 26/28 were ostia; 100% successful; </text>
<text top="320" left="677" width="180" height="15" font="1">4 recurrence; 25/28 were focal; 3/28 </text>
<text top="336" left="677" width="54" height="15" font="1">segmental </text>
<text top="258" left="904" width="205" height="15" font="1">28/172 consecutive focal ATs (16%) from </text>
<text top="274" left="904" width="227" height="15" font="1">pulmonary vein; high success rate; majority at </text>
<text top="289" left="904" width="26" height="15" font="1">ostia </text>
<text top="352" left="54" width="50" height="15" font="1">Gonzalez </text>
<text top="367" left="54" width="20" height="15" font="1">MD </text>
<text top="383" left="54" width="31" height="15" font="1">2004  </text>
<text top="398" left="54" width="23" height="15" font="1">(98) </text>
<text top="414" left="54" width="49" height="15" font="8">15533857</text>
<text top="414" left="103" width="3" height="15" font="1"> </text>
<text top="352" left="126" width="123" height="15" font="1">Observational 10 </text>
<text top="352" left="230" width="51" height="15" font="1">pts/35 </text>
<text top="367" left="215" width="79" height="15" font="1">consecutive pts </text>
<text top="383" left="215" width="33" height="15" font="1">(28%) </text>
<text top="352" left="318" width="153" height="15" font="1">AT from mitral-aortic continuity </text>
<text top="352" left="549" width="109" height="15" font="1">Mapping and ablation </text>
<text top="352" left="677" width="213" height="15" font="1">Tachycardia CL 340 msec +/- 56; local e-P </text>
<text top="367" left="677" width="175" height="15" font="1">– 44 msec +/- 14; 100% successful </text>
<text top="352" left="904" width="227" height="15" font="1">Provided a brief discussion on mouse embryo </text>
<text top="367" left="904" width="229" height="15" font="1">and the specialized conduction system in near </text>
<text top="383" left="904" width="163" height="15" font="1">the mitral-aortic continuity region </text>
<text top="430" left="54" width="53" height="15" font="1">Kistler PM </text>
<text top="446" left="54" width="28" height="15" font="1">2005 </text>
<text top="461" left="54" width="23" height="15" font="1">(99) </text>
<text top="477" left="54" width="49" height="15" font="8">15862424</text>
<text top="477" left="103" width="3" height="15" font="1"> </text>
<text top="430" left="126" width="71" height="15" font="1">Observational </text>
<text top="430" left="215" width="85" height="15" font="1">13 pts (of 193 w/ </text>
<text top="446" left="215" width="47" height="15" font="1">focal AT) </text>
<text top="430" left="318" width="188" height="15" font="1">7 female; 41 +/- 6 y; AT from tricuspid </text>
<text top="446" left="318" width="182" height="15" font="1">annulus (TA); point to point mapping </text>
<text top="430" left="549" width="67" height="15" font="1">Mapping and </text>
<text top="446" left="549" width="100" height="15" font="1">localization of AT to </text>
<text top="461" left="549" width="17" height="15" font="1">TA </text>
<text top="430" left="677" width="180" height="15" font="1">Negative p wave in all inferior leads; </text>
<text top="446" left="677" width="194" height="15" font="1">negative or isoelectric in V1, positive in </text>
<text top="461" left="677" width="169" height="15" font="1">avL; 11/13 successfully ablated; 2 </text>
<text top="477" left="677" width="185" height="15" font="1">noninducible; no recurrence in 25 mo </text>
<text top="430" left="904" width="210" height="15" font="1">13/ 193 (6.7%) of all AT are from coronary </text>
<text top="446" left="904" width="50" height="15" font="1">sinus os.  </text>
<text top="493" left="54" width="46" height="15" font="1">Eidher U </text>
<text top="508" left="54" width="28" height="15" font="1">2006 </text>
<text top="524" left="54" width="29" height="15" font="1">(100) </text>
<text top="539" left="54" width="49" height="15" font="8">16650262</text>
<text top="539" left="103" width="3" height="15" font="1"> </text>
<text top="493" left="126" width="71" height="15" font="1">Observational </text>
<text top="493" left="215" width="52" height="15" font="1">38 pts, 49 </text>
<text top="508" left="215" width="77" height="15" font="1">episodes of AT </text>
<text top="493" left="318" width="207" height="15" font="1">“monomorphic” AT, excluded typical atrial </text>
<text top="508" left="318" width="217" height="15" font="1">flutter and AF; likely included macro-reentry </text>
<text top="524" left="318" width="71" height="15" font="1">atypical flutter </text>
<text top="493" left="549" width="110" height="15" font="1">Ibutilide conversion to </text>
<text top="508" left="549" width="114" height="15" font="1">SR in the acute setting </text>
<text top="493" left="677" width="129" height="15" font="1">19/49 (38.8%) conversion </text>
<text top="493" left="904" width="222" height="15" font="1">Inclusion does not differentiate focal AT from </text>
<text top="508" left="904" width="221" height="15" font="1">macro-reentry AT; conversion rate appear to </text>
<text top="524" left="904" width="169" height="15" font="1">be lower than atrial flutter and AF. </text>
<text top="555" left="54" width="52" height="15" font="1">Ouyang F </text>
<text top="571" left="54" width="28" height="15" font="1">2006 </text>
<text top="587" left="54" width="29" height="15" font="1">(101) </text>
<text top="602" left="54" width="49" height="15" font="8">16814658</text>
<text top="602" left="103" width="3" height="15" font="1"> </text>
<text top="555" left="126" width="71" height="15" font="1">Observational </text>
<text top="555" left="215" width="69" height="15" font="1">9 pts; 6 failed </text>
<text top="571" left="215" width="74" height="15" font="1">previous “para-</text>
<text top="587" left="215" width="82" height="15" font="1">Hisian” ablation; </text>
<text top="602" left="215" width="46" height="15" font="1">6 female </text>
<text top="555" left="318" width="44" height="15" font="1">NCC AT </text>
<text top="555" left="549" width="108" height="15" font="1">Location and ablation </text>
<text top="555" left="677" width="199" height="15" font="1">Local egram preceded His local A by 12 </text>
<text top="571" left="677" width="195" height="15" font="1">msec; no H on the ablation catheter; all </text>
<text top="587" left="677" width="196" height="15" font="1">ablation was successful w/o recurrence </text>
<text top="602" left="677" width="136" height="15" font="1">Age 54 +/- 12, range 32-66 </text>
<text top="555" left="904" width="196" height="15" font="1">One of the earlier observational studies </text>
<text top="571" left="904" width="231" height="15" font="1">reported AT localized to NCC and successfully </text>
<text top="587" left="904" width="218" height="15" font="1">ablated; highlights mapping NCC early if AT </text>
<text top="602" left="904" width="103" height="15" font="1">appears para-Hisian </text>
<text top="618" left="54" width="42" height="15" font="1">Roberts-</text>
<text top="634" left="54" width="49" height="15" font="1">Thomson </text>
<text top="649" left="54" width="18" height="15" font="1">KC </text>
<text top="665" left="54" width="31" height="15" font="1">2007  </text>
<text top="680" left="54" width="29" height="15" font="1">(102) </text>
<text top="696" left="54" width="49" height="15" font="8">17286568</text>
<text top="696" left="103" width="3" height="15" font="1"> </text>
<text top="618" left="126" width="71" height="15" font="1">Observational </text>
<text top="618" left="215" width="85" height="15" font="1">10 pts (of 261 w/ </text>
<text top="634" left="215" width="47" height="15" font="1">focal AT) </text>
<text top="618" left="318" width="215" height="15" font="1">9 male, 39 =+/- 20 y; AT from RAA; point to </text>
<text top="634" left="318" width="189" height="15" font="1">point mapping w/ 4 mm tip deflectable </text>
<text top="649" left="318" width="43" height="15" font="1">catheter </text>
<text top="618" left="549" width="67" height="15" font="1">Mapping and </text>
<text top="634" left="549" width="96" height="15" font="1">localization to RAA </text>
<text top="618" left="677" width="199" height="15" font="1">P wave negative in V1; low amplitude or </text>
<text top="634" left="677" width="195" height="15" font="1">positive in inferior leads; acute success </text>
<text top="649" left="677" width="140" height="15" font="1">rate in 100%, no recurrence </text>
<text top="618" left="904" width="195" height="15" font="1">RAA AT is less common 10/261 (3.8%) </text>
<text top="712" left="54" width="38" height="15" font="1">Medi C </text>
<text top="727" left="54" width="28" height="15" font="1">2009 </text>
<text top="743" left="54" width="29" height="15" font="1">(103) </text>
<text top="758" left="54" width="49" height="15" font="8">19422986</text>
<text top="758" left="103" width="3" height="15" font="1"> </text>
<text top="712" left="126" width="65" height="15" font="1">Case control </text>
<text top="712" left="215" width="47" height="15" font="1">30 pts w/ </text>
<text top="727" left="215" width="88" height="15" font="1">cardriomyopathy  </text>
<text top="743" left="215" width="59" height="15" font="1">vs. 301 w/o </text>
<text top="758" left="215" width="81" height="15" font="1">cardiomyopathy </text>
<text top="712" left="318" width="140" height="15" font="1">AT induced cardiomyopathy </text>
<text top="712" left="549" width="110" height="15" font="1">Outcome assessment </text>
<text top="712" left="677" width="172" height="15" font="1">AT induced caridomyopathy 10% ( </text>
<text top="727" left="677" width="208" height="15" font="1">30/301); incessant, younger (39 +/- 22 vs. </text>
<text top="743" left="677" width="191" height="15" font="1">51 +/- 17, 60% males vs. 38%), longer </text>
<text top="758" left="677" width="207" height="15" font="1">tachycardia CL (502 msec vs. 402 msec); </text>
<text top="774" left="677" width="152" height="15" font="1">LVEF was restored in 97% pts </text>
<text top="712" left="904" width="211" height="15" font="1">Prevalence of AT induced cardiomyopathy </text>
<text top="727" left="904" width="224" height="15" font="1">10% in all AT pts; RFA is highly successful in </text>
<text top="743" left="904" width="68" height="15" font="1">restore LVEF </text>
<text top="790" left="54" width="28" height="15" font="1">Liu X </text>
<text top="790" left="126" width="65" height="15" font="1">Case control </text>
<text top="790" left="215" width="63" height="15" font="1">13 study pts </text>
<text top="790" left="318" width="124" height="15" font="1">AT origination from NCC </text>
<text top="790" left="549" width="71" height="15" font="1">Local e-gram, </text>
<text top="790" left="677" width="193" height="15" font="1">Wide initial activation patter in the right </text>
<text top="790" left="904" width="209" height="15" font="1">Presence of “para-Hisian AT” should raise </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="18" size="11" family="Times" color="#323232"/>
<text top="814" left="1120" width="17" height="17" font="0">36 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="28" height="15" font="1">2010 </text>
<text top="70" left="54" width="29" height="15" font="1">(104) </text>
<text top="86" left="54" width="49" height="15" font="8">20797494</text>
<text top="86" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="215" width="61" height="15" font="1">15 PAF/PVI </text>
<text top="70" left="215" width="40" height="15" font="1">25 PAF </text>
<text top="55" left="549" width="104" height="15" font="1">activation sequence, </text>
<text top="70" left="549" width="90" height="15" font="1">electroanatomical </text>
<text top="86" left="549" width="99" height="15" font="1">mapping, histology, </text>
<text top="101" left="549" width="61" height="15" font="1">and P-wave </text>
<text top="117" left="549" width="61" height="15" font="1">morphology </text>
<text top="55" left="677" width="182" height="15" font="1">atrium (RA), left atrium (LA) from the </text>
<text top="70" left="677" width="204" height="15" font="1">parahistian area; earliest activation in the </text>
<text top="86" left="677" width="196" height="15" font="1">NCC; no atrial myocardium in the NCC; </text>
<text top="101" left="677" width="211" height="15" font="1">NCC was adjacent to the atrial para-septal </text>
<text top="117" left="677" width="32" height="15" font="1">tissue </text>
<text top="55" left="904" width="226" height="15" font="1">awareness of close anatomical relationship to </text>
<text top="70" left="904" width="168" height="15" font="1">atrial –paraseptal tissue and NCC </text>
<text top="86" left="904" width="218" height="15" font="1">Early mapping and ablation in the NCC may </text>
<text top="101" left="904" width="188" height="15" font="1">increase ablation success and reduce </text>
<text top="117" left="904" width="70" height="15" font="1">complications </text>
<text top="132" left="904" width="204" height="15" font="1">P wave morphology may not differentiate </text>
<text top="147" left="904" width="218" height="15" font="1">NCC-AT from left atrial or RA paraseptal AT </text>
<text top="164" left="54" width="57" height="15" font="1">Biviano AB </text>
<text top="179" left="54" width="31" height="15" font="1">2012  </text>
<text top="195" left="54" width="29" height="15" font="1">(105) </text>
<text top="210" left="54" width="49" height="15" font="8">21967474</text>
<text top="210" left="103" width="3" height="15" font="1"> </text>
<text top="164" left="126" width="126" height="15" font="1">Observational 24, </text>
<text top="164" left="234" width="33" height="15" font="1">14 </text>
<text top="164" left="249" width="58" height="15" font="1">female, </text>
<text top="179" left="215" width="66" height="15" font="1">age 48+/- 18 </text>
<text top="164" left="318" width="172" height="15" font="1">Focal left atrial AT; no prior h/o AF </text>
<text top="164" left="549" width="94" height="15" font="1">Location and short </text>
<text top="179" left="549" width="113" height="15" font="1">term ablation outcome </text>
<text top="164" left="677" width="213" height="15" font="1">CL 347 msec (190-510 msec); CS, septum </text>
<text top="179" left="677" width="207" height="15" font="1">(5), free wall, MVA, roof, LAA, ligament of </text>
<text top="195" left="677" width="101" height="15" font="1">Marshall and PV (6) </text>
<text top="210" left="677" width="151" height="15" font="1">Immediate success 19/22 ATs </text>
<text top="164" left="904" width="227" height="15" font="1">A good observational study on the distribution </text>
<text top="179" left="904" width="190" height="15" font="1">of left atrial AT location; contemporary </text>
<text top="195" left="904" width="222" height="15" font="1">techniques; no major complications; success </text>
<text top="210" left="904" width="165" height="15" font="1">rate is consistent w/ the literature </text>
<text top="226" left="54" width="47" height="15" font="1">de Loma-</text>
<text top="242" left="54" width="46" height="15" font="1">Osorio A </text>
<text top="257" left="54" width="28" height="15" font="1">2013 </text>
<text top="273" left="54" width="29" height="15" font="1">(106) </text>
<text top="288" left="54" width="49" height="15" font="8">24774111</text>
<text top="288" left="103" width="3" height="15" font="1"> </text>
<text top="226" left="126" width="43" height="15" font="1">Spanish </text>
<text top="242" left="126" width="65" height="15" font="1">registry from </text>
<text top="257" left="126" width="58" height="15" font="1">74 centers, </text>
<text top="273" left="126" width="48" height="15" font="1">voluntary </text>
<text top="226" left="215" width="68" height="15" font="1">333 of 11042 </text>
<text top="242" left="215" width="85" height="15" font="1">procedures (3%) </text>
<text top="226" left="318" width="203" height="15" font="1">Registry included all ablation procedures </text>
<text top="242" left="318" width="53" height="15" font="1">from 2012 </text>
<text top="226" left="549" width="94" height="15" font="1">Ablation outcomes </text>
<text top="226" left="677" width="203" height="15" font="1">Acute success rate 284/333 (85.3%); RA </text>
<text top="242" left="677" width="186" height="15" font="1">61%, 36% in LA; complications 7/333 </text>
<text top="257" left="677" width="174" height="15" font="1">(2.1%), 1 permanent pacemaker, 2 </text>
<text top="273" left="677" width="153" height="15" font="1">vascular, 4 pericardial effusion </text>
<text top="226" left="904" width="165" height="15" font="1">One of the few national registries </text>
<text top="305" left="54" width="42" height="15" font="1">Mano H </text>
<text top="320" left="54" width="28" height="15" font="1">2013 </text>
<text top="336" left="54" width="29" height="15" font="1">(107) </text>
<text top="351" left="54" width="49" height="15" font="8">23595943</text>
<text top="351" left="103" width="3" height="15" font="1"> </text>
<text top="305" left="126" width="65" height="15" font="1">Case control </text>
<text top="305" left="215" width="81" height="15" font="1">6 study cohorts, </text>
<text top="320" left="215" width="57" height="15" font="1">12 controls </text>
<text top="305" left="318" width="185" height="15" font="1">Anatomical substrate for NCC-AT vs. </text>
<text top="320" left="318" width="41" height="15" font="1">AVNRT </text>
<text top="305" left="549" width="97" height="15" font="1">Comparing P wave </text>
<text top="320" left="549" width="68" height="15" font="1">duration, PQ, </text>
<text top="336" left="549" width="105" height="15" font="1">intracardiac intervals </text>
<text top="351" left="549" width="93" height="15" font="1">and local anatomy </text>
<text top="367" left="549" width="111" height="15" font="1">between NCC-AT and </text>
<text top="382" left="549" width="41" height="15" font="1">AVNRT </text>
<text top="305" left="677" width="189" height="15" font="1">P wave duration, PQ and AH intervals </text>
<text top="320" left="677" width="203" height="15" font="1">were longer in NCC-AT than AVNRT; AS </text>
<text top="336" left="677" width="176" height="15" font="1">(aortic roof to IVS angle) angle was </text>
<text top="351" left="677" width="141" height="15" font="1">steeper and IVS was thicker </text>
<text top="305" left="904" width="226" height="15" font="1">Interesting details, but not sure how useful for </text>
<text top="320" left="904" width="78" height="15" font="1">clinical practice </text>
<text top="398" left="54" width="995" height="15" font="1">AF indicates atrial fibrillation; AP, accessory pathway; AT, atrial tachycardia; AV, atrioventricular; AVNRT, atrioventricular nodal reentrant tachycardia; CL, cycle length; CT, crista terminalis; DAD, delayed </text>
<text top="414" left="54" width="1033" height="15" font="1">afterdepolarizations; ECG, electrocardiogram; EP, electrophysiological; f/u, follow up; h/o, history of; ICE, intracardiac echocardiography; IV, intravenous; IVS, intraventricular septum; LA, left atrial; LAA, left atrial </text>
<text top="429" left="54" width="1058" height="15" font="1">appendage; LVEF, left ventricular ejection fraction; MVA, mitral valve area; NCC, non-coronary cusp; pt, patient; PV, pulmonary vein; RA, right atrial; RF, radiofrequency; RFA, radiofrequency ablation; SHD, structural </text>
<text top="445" left="54" width="810" height="15" font="1">heart disease; SR, sinus rhythm; SVT, supraventricular tachycardia; VT, ventricular tachycardia; w/, with; w/o, without; and WPW, Wolff-Parkinson-White syndrome.   </text>
<text top="460" left="54" width="3" height="15" font="1"> </text>
<text top="486" left="54" width="143" height="18" font="3"><b>Data Supplement 7. </b></text>
<text top="486" left="197" width="538" height="18" font="7"><b>Randomized Trials Comparing Multifocal Atrial Tachycardia – Section 4.2  </b></text>
<text top="505" left="60" width="38" height="17" font="5"><b>Study </b></text>
<text top="522" left="58" width="40" height="17" font="5"><b>Name, </b></text>
<text top="539" left="55" width="47" height="17" font="5"><b>Author, </b></text>
<text top="556" left="64" width="30" height="17" font="5"><b>Year </b></text>
<text top="505" left="119" width="42" height="17" font="5"><b>Aim of </b></text>
<text top="522" left="121" width="38" height="17" font="5"><b>Study </b></text>
<text top="505" left="182" width="38" height="17" font="5"><b>Study </b></text>
<text top="522" left="185" width="32" height="17" font="5"><b>Type </b></text>
<text top="539" left="183" width="36" height="17" font="5"><b>(Size, </b></text>
<text top="556" left="193" width="16" height="17" font="5"><b>N) </b></text>
<text top="505" left="256" width="38" height="17" font="5"><b>Study </b></text>
<text top="522" left="238" width="74" height="17" font="5"><b>Intervention </b></text>
<text top="539" left="245" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="505" left="344" width="38" height="17" font="5"><b>Study </b></text>
<text top="522" left="326" width="73" height="17" font="5"><b>Comparator </b></text>
<text top="539" left="333" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="505" left="490" width="83" height="17" font="5"><b>Pt Population </b></text>
<text top="505" left="756" width="64" height="17" font="5"><b>Endpoints </b></text>
<text top="505" left="933" width="109" height="17" font="5"><b>P Values, OR: HR: </b></text>
<text top="522" left="945" width="85" height="17" font="5"><b>RR: &amp; 95% CI: </b></text>
<text top="505" left="1081" width="38" height="17" font="5"><b>Study </b></text>
<text top="522" left="1066" width="69" height="17" font="5"><b>Limitations </b></text>
<text top="539" left="1068" width="64" height="17" font="5"><b>&amp; Adverse </b></text>
<text top="556" left="1078" width="44" height="17" font="5"><b>Events </b></text>
<text top="574" left="67" width="3" height="17" font="5"><b> </b></text>
<text top="574" left="138" width="3" height="17" font="5"><b> </b></text>
<text top="574" left="199" width="3" height="17" font="5"><b> </b></text>
<text top="574" left="273" width="3" height="17" font="5"><b> </b></text>
<text top="574" left="361" width="3" height="17" font="5"><b> </b></text>
<text top="574" left="419" width="104" height="17" font="13"><i><b>Inclusion Criteria </b></i></text>
<text top="574" left="542" width="108" height="17" font="13"><i><b>Exclusion Criteria </b></i></text>
<text top="574" left="676" width="49" height="17" font="13"><i><b>Primary </b></i></text>
<text top="592" left="672" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="609" left="672" width="58" height="17" font="13"><i><b>(efficacy) </b></i></text>
<text top="626" left="664" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="574" left="771" width="40" height="17" font="13"><i><b>Safety </b></i></text>
<text top="592" left="763" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="609" left="755" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="574" left="846" width="70" height="17" font="13"><i><b>Secondary  </b></i></text>
<text top="592" left="851" width="67" height="17" font="13"><i><b>Endpoint    </b></i></text>
<text top="609" left="867" width="25" height="17" font="13"><i><b>and </b></i></text>
<text top="626" left="855" width="48" height="17" font="13"><i><b>Results </b></i></text>
<text top="574" left="986" width="3" height="17" font="5"><b> </b></text>
<text top="574" left="1098" width="3" height="17" font="5"><b> </b></text>
<text top="644" left="54" width="46" height="15" font="1">Arsura E </text>
<text top="659" left="54" width="28" height="15" font="1">1989 </text>
<text top="675" left="54" width="29" height="15" font="1">(108) </text>
<text top="690" left="54" width="43" height="15" font="8">3052051</text>
<text top="690" left="97" width="3" height="15" font="1"> </text>
<text top="706" left="54" width="6" height="15" font="1">  </text>
<text top="644" left="116" width="16" height="15" font="1">To </text>
<text top="659" left="116" width="43" height="15" font="1">determin</text>
<text top="675" left="116" width="9" height="15" font="1">e </text>
<text top="690" left="116" width="41" height="15" font="1">efficacy </text>
<text top="706" left="116" width="12" height="15" font="1">of </text>
<text top="721" left="116" width="43" height="15" font="1">verapam</text>
<text top="737" left="116" width="11" height="15" font="1">il, </text>
<text top="752" left="116" width="43" height="15" font="1">metoprol</text>
<text top="768" left="116" width="24" height="15" font="1">ol or </text>
<text top="783" left="116" width="42" height="15" font="1">placebo </text>
<text top="644" left="177" width="44" height="15" font="1">Randomi</text>
<text top="659" left="177" width="24" height="15" font="1">zed, </text>
<text top="675" left="177" width="37" height="15" font="1">double-</text>
<text top="690" left="177" width="29" height="15" font="1">blind, </text>
<text top="706" left="177" width="42" height="15" font="1">placebo-</text>
<text top="721" left="177" width="42" height="15" font="1">controlle</text>
<text top="737" left="177" width="39" height="15" font="1">d study </text>
<text top="752" left="177" width="12" height="15" font="1">of </text>
<text top="768" left="177" width="43" height="15" font="1">verapam</text>
<text top="783" left="177" width="29" height="15" font="1">il and </text>
<text top="644" left="238" width="27" height="15" font="1">9 pts </text>
<text top="659" left="238" width="63" height="15" font="1">verapamil, 9 </text>
<text top="675" left="238" width="73" height="15" font="1">pts metoprolol </text>
<text top="644" left="325" width="63" height="15" font="1">10 pts given </text>
<text top="659" left="325" width="73" height="15" font="1">placebo (2 pts </text>
<text top="675" left="325" width="71" height="15" font="1">given placebo </text>
<text top="690" left="325" width="70" height="15" font="1">on both days) </text>
<text top="644" left="413" width="98" height="15" font="1">MAT diagnosed via </text>
<text top="659" left="413" width="33" height="15" font="1">ECG.  </text>
<text top="644" left="541" width="55" height="15" font="1">Reversible </text>
<text top="659" left="541" width="98" height="15" font="1">precipitants of MAT </text>
<text top="675" left="541" width="102" height="15" font="1">(hypoxia, electrolyte </text>
<text top="690" left="541" width="72" height="15" font="1">abnormalities, </text>
<text top="706" left="541" width="89" height="15" font="1">anemia, acidosis, </text>
<text top="721" left="541" width="106" height="15" font="1">and serum digoxin or </text>
<text top="737" left="541" width="94" height="15" font="1">theophylline levels </text>
<text top="752" left="541" width="97" height="15" font="1">outside therapeutic </text>
<text top="768" left="541" width="102" height="15" font="1">range) – if corrected </text>
<text top="783" left="541" width="97" height="15" font="1">and pt continued to </text>
<text top="644" left="663" width="71" height="15" font="18">Conversion to </text>
<text top="659" left="663" width="69" height="15" font="18">sinus rhythm, </text>
<text top="675" left="663" width="59" height="15" font="18">a decline in </text>
<text top="690" left="663" width="73" height="15" font="18">the ventricular </text>
<text top="706" left="663" width="70" height="15" font="18">rate of ≥15%, </text>
<text top="721" left="663" width="63" height="15" font="18">or decline in </text>
<text top="737" left="663" width="54" height="15" font="18">ventricular </text>
<text top="752" left="663" width="62" height="15" font="18">rate to &lt;100 </text>
<text top="768" left="663" width="25" height="15" font="18">bpm </text>
<text top="783" left="663" width="3" height="15" font="1"> </text>
<text top="644" left="751" width="22" height="15" font="1">N/A </text>
<text top="644" left="845" width="39" height="15" font="1">Repeat </text>
<text top="659" left="845" width="43" height="15" font="1">physical </text>
<text top="675" left="845" width="52" height="15" font="1">exam and </text>
<text top="690" left="845" width="67" height="15" font="1">arterial blood </text>
<text top="706" left="845" width="62" height="15" font="1">gas values.  </text>
<text top="644" left="926" width="114" height="15" font="18">2/10 (20%); 4/9 (44%); </text>
<text top="659" left="926" width="101" height="15" font="18">8/9 (89%) showed a </text>
<text top="675" left="926" width="106" height="15" font="18">response to placebo, </text>
<text top="690" left="926" width="67" height="15" font="18">verapamil, or </text>
<text top="706" left="926" width="116" height="15" font="18">metoprolol, respectively</text>
<text top="706" left="1042" width="3" height="15" font="1"> </text>
<text top="721" left="926" width="83" height="15" font="18">Mean slowing of </text>
<text top="737" left="926" width="121" height="15" font="18">ventricular rate was 3.4, </text>
<text top="752" left="926" width="94" height="15" font="18">7.3, and 24.5% for </text>
<text top="768" left="926" width="121" height="15" font="18">placebo, verapamil, and </text>
<text top="783" left="926" width="119" height="15" font="18">metoprolol, respectively </text>
<text top="644" left="1063" width="55" height="15" font="18">Metoprolol </text>
<text top="659" left="1063" width="71" height="15" font="18">appears more </text>
<text top="675" left="1063" width="69" height="15" font="18">effective than </text>
<text top="690" left="1063" width="63" height="15" font="18">verapamil in </text>
<text top="706" left="1063" width="70" height="15" font="18">treating MAT. </text>
<text top="721" left="1063" width="68" height="15" font="18">Caution must </text>
<text top="737" left="1063" width="66" height="15" font="18">be exercised </text>
<text top="752" left="1063" width="58" height="15" font="18">in selecting </text>
<text top="768" left="1063" width="15" height="15" font="18">pts</text>
<text top="768" left="1078" width="3" height="15" font="1"> </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">37 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="38" height="15" font="1">in MAT </text>
<text top="55" left="177" width="43" height="15" font="1">metoprol</text>
<text top="70" left="177" width="23" height="15" font="1">ol in </text>
<text top="86" left="177" width="44" height="15" font="1">treatmen</text>
<text top="101" left="177" width="18" height="15" font="1">t of </text>
<text top="117" left="177" width="45" height="15" font="1">MAT; 13 </text>
<text top="132" left="177" width="31" height="15" font="1">pts (4 </text>
<text top="147" left="177" width="39" height="15" font="1">male, 9 </text>
<text top="163" left="177" width="40" height="15" font="1">female) </text>
<text top="55" left="541" width="93" height="15" font="1">have MAT, able to </text>
<text top="70" left="541" width="60" height="15" font="1">participate.  </text>
<text top="86" left="541" width="3" height="15" font="1"> </text>
<text top="101" left="541" width="104" height="15" font="1">CHF; SBP &lt;100 mm </text>
<text top="117" left="541" width="99" height="15" font="1">Hg; bronchospasm; </text>
<text top="132" left="541" width="103" height="15" font="1">h/o greater than first-</text>
<text top="147" left="541" width="98" height="15" font="1">degree heart block; </text>
<text top="163" left="541" width="90" height="15" font="1">bifascicular block; </text>
<text top="178" left="541" width="94" height="15" font="1">altered sinus node </text>
<text top="194" left="541" width="45" height="15" font="1">function; </text>
<text top="210" left="541" width="91" height="15" font="1">hypersensitivity to </text>
<text top="225" left="541" width="106" height="15" font="1">either age; estimated </text>
<text top="240" left="541" width="99" height="15" font="1">survival time &lt;72 h; </text>
<text top="256" left="541" width="94" height="15" font="1">use of either study </text>
<text top="271" left="541" width="105" height="15" font="1">agent w/in preceding </text>
<text top="287" left="541" width="25" height="15" font="1">72 h </text>
<text top="302" left="541" width="3" height="15" font="1"> </text>
<text top="55" left="926" width="112" height="15" font="18">(p&lt;0.01 for metoprolol </text>
<text top="70" left="926" width="66" height="15" font="18">vs. placebo). </text>
<text top="70" left="992" width="3" height="15" font="1"> </text>
<text top="86" left="926" width="96" height="15" font="18">Five pts who had a </text>
<text top="101" left="926" width="116" height="15" font="18">response to metoprolol </text>
<text top="117" left="926" width="100" height="15" font="18">had failed to have a </text>
<text top="132" left="926" width="112" height="15" font="18">response to verapamil.</text>
<text top="132" left="1038" width="3" height="15" font="1"> </text>
<text top="319" left="54" width="42" height="15" font="1">McCord </text>
<text top="334" left="54" width="19" height="15" font="1">JK  </text>
<text top="350" left="54" width="28" height="15" font="1">1998 </text>
<text top="365" left="54" width="29" height="15" font="1">(109) </text>
<text top="381" left="54" width="43" height="15" font="8">9462615</text>
<text top="381" left="97" width="3" height="15" font="1"> </text>
<text top="396" left="54" width="3" height="15" font="1"> </text>
<text top="319" left="116" width="16" height="15" font="1">To </text>
<text top="334" left="116" width="38" height="15" font="1">assess </text>
<text top="350" left="116" width="39" height="15" font="1">the use </text>
<text top="365" left="116" width="44" height="15" font="1">of IV Mg </text>
<text top="381" left="116" width="42" height="15" font="1">for MAT </text>
<text top="396" left="116" width="44" height="15" font="1">in pts w/ </text>
<text top="412" left="116" width="35" height="15" font="1">COPD </text>
<text top="319" left="177" width="44" height="15" font="1">Randomi</text>
<text top="334" left="177" width="39" height="15" font="1">zed; 14 </text>
<text top="350" left="177" width="18" height="15" font="1">pts </text>
<text top="319" left="238" width="72" height="15" font="1">9 pts received </text>
<text top="334" left="238" width="68" height="15" font="1">2 grams over </text>
<text top="350" left="238" width="67" height="15" font="1">5 min and 10 </text>
<text top="365" left="238" width="52" height="15" font="1">g over 5 h </text>
<text top="381" left="238" width="3" height="15" font="1"> </text>
<text top="319" left="325" width="72" height="15" font="1">5 pts received </text>
<text top="334" left="325" width="43" height="15" font="1">Placebo </text>
<text top="350" left="325" width="3" height="15" font="1"> </text>
<text top="319" left="413" width="90" height="15" font="1">Pts w/ COPD and </text>
<text top="334" left="413" width="26" height="15" font="1">MAT </text>
<text top="319" left="541" width="78" height="15" font="1">Cr ≥2.0 mg/dL, </text>
<text top="334" left="541" width="83" height="15" font="1">intolerance to IV </text>
<text top="350" left="541" width="41" height="15" font="1">infusion </text>
<text top="319" left="663" width="41" height="15" font="1">Rhythm </text>
<text top="334" left="663" width="74" height="15" font="1">assessment at </text>
<text top="350" left="663" width="18" height="15" font="1">5 h </text>
<text top="365" left="663" width="71" height="15" font="1">Pts treated w/ </text>
<text top="381" left="663" width="60" height="15" font="1">magnesium </text>
<text top="396" left="663" width="71" height="15" font="1">had a slowing </text>
<text top="412" left="663" width="63" height="15" font="1">of heart rate </text>
<text top="427" left="663" width="74" height="15" font="1">from 130 to 99 </text>
<text top="443" left="663" width="70" height="15" font="1">beats per min </text>
<text top="458" left="663" width="62" height="15" font="1">Placebo- no </text>
<text top="474" left="663" width="68" height="15" font="1">effect on HR. </text>
<text top="489" left="663" width="73" height="15" font="1">NSR at end of </text>
<text top="505" left="663" width="71" height="15" font="1">infusion in 7/9 </text>
<text top="520" left="663" width="70" height="15" font="1">treated w/ Mg </text>
<text top="535" left="663" width="50" height="15" font="1">vs. 1/5 w/ </text>
<text top="551" left="663" width="45" height="15" font="1">placebo. </text>
<text top="319" left="751" width="22" height="15" font="1">N/A </text>
<text top="319" left="845" width="22" height="15" font="1">N/A </text>
<text top="319" left="926" width="22" height="15" font="1">N/A </text>
<text top="319" left="1063" width="57" height="15" font="1">Caregivers </text>
<text top="334" left="1063" width="60" height="15" font="1">not blinded. </text>
<text top="350" left="1063" width="69" height="15" font="1">Small sample </text>
<text top="365" left="1063" width="61" height="15" font="1">size with no </text>
<text top="381" left="1063" width="74" height="15" font="1">control group.  </text>
<text top="567" left="54" width="1073" height="15" font="1">BP indicates blood pressure; CI, confidence interval; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; Cr, creatinine; ECG, electrocardiogram; HR, heart rate; IV, intravenous; MAT, multifocal </text>
<text top="583" left="54" width="577" height="15" font="1">atrial tachycardia; N/A, not applicable; OR, odds ratio; pt, patient; RR, relative risk; and SBP, systolic blood pressure.  </text>
<text top="608" left="54" width="143" height="18" font="3"><b>Data Supplement 8. </b></text>
<text top="608" left="197" width="784" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Multifocal Atrial Tachycardia – Section 4.2 </b></text>
<text top="608" left="981" width="4" height="18" font="3"><b> </b></text>
<text top="627" left="68" width="38" height="17" font="5"><b>Study </b></text>
<text top="644" left="66" width="40" height="17" font="5"><b>Name, </b></text>
<text top="662" left="63" width="47" height="17" font="5"><b>Author, </b></text>
<text top="679" left="71" width="30" height="17" font="5"><b>Year </b></text>
<text top="627" left="133" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="644" left="148" width="44" height="17" font="5"><b>Design </b></text>
<text top="627" left="227" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="627" left="343" width="165" height="17" font="5"><b>Inclusion/Exclusion Criteria </b></text>
<text top="627" left="559" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="627" left="743" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="627" left="959" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="697" left="54" width="40" height="15" font="1">Iseri LT </text>
<text top="712" left="54" width="28" height="15" font="1">1985 </text>
<text top="728" left="54" width="29" height="15" font="1">(110) </text>
<text top="743" left="54" width="43" height="15" font="8">4050650</text>
<text top="743" left="97" width="3" height="15" font="1"> </text>
<text top="697" left="131" width="71" height="15" font="1">Observational </text>
<text top="697" left="221" width="9" height="15" font="1">8 </text>
<text top="697" left="312" width="221" height="15" font="1">8 pts w/ MAT received 7-12 Gm IV mag over </text>
<text top="712" left="312" width="18" height="15" font="1">5 h </text>
<text top="697" left="551" width="26" height="15" font="1">NSR </text>
<text top="697" left="685" width="21" height="15" font="1">N/A </text>
<text top="697" left="917" width="205" height="15" font="1">MAT was successfully converted to sinus </text>
<text top="712" left="917" width="204" height="15" font="1">rhythm or sinus tachycardia in seven pts. </text>
<text top="728" left="917" width="212" height="15" font="1">MAT rhythm (at slow rate) persisted in one </text>
<text top="743" left="917" width="15" height="15" font="1">pt. </text>
<text top="759" left="54" width="57" height="15" font="1">Hazard PB </text>
<text top="775" left="54" width="28" height="15" font="1">1987 </text>
<text top="790" left="54" width="29" height="15" font="1">(111) </text>
<text top="759" left="131" width="74" height="15" font="1">Observational, </text>
<text top="775" left="131" width="32" height="15" font="1">active </text>
<text top="790" left="131" width="64" height="15" font="1">treatment w/ </text>
<text top="759" left="221" width="15" height="15" font="1">25 </text>
<text top="759" left="312" width="219" height="15" font="1">25 pts w/ MAT that was complicating severe </text>
<text top="775" left="312" width="119" height="15" font="1">cardiopulmonary illness </text>
<text top="759" left="551" width="111" height="15" font="1">Observed its effect on </text>
<text top="775" left="551" width="112" height="15" font="1">heart rate and rhythm, </text>
<text top="790" left="551" width="109" height="15" font="1">BP, and arterial blood </text>
<text top="759" left="685" width="180" height="15" font="1">All pts showed slowing of heart rate, </text>
<text top="775" left="685" width="175" height="15" font="1">averaging 54.0±4.0 bpm (p&lt;0.001) </text>
<text top="790" left="685" width="3" height="15" font="1"> </text>
<text top="759" left="917" width="220" height="15" font="1">Metoprolol is effective in the management of </text>
<text top="775" left="917" width="26" height="15" font="1">MAT.</text>
<text top="775" left="943" width="3" height="15" font="18"> </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">38 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="43" height="15" font="8">3792010</text>
<text top="55" left="97" width="6" height="15" font="1">  </text>
<text top="70" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="131" width="444" height="15" font="1">metoprolol gase</text>
<text top="55" left="575" width="3" height="15" font="18"> </text>
<text top="55" left="685" width="188" height="15" font="1">pH and PaCO2 were unaltered; mean </text>
<text top="70" left="685" width="176" height="15" font="1">PaO2 increased by 12.2 +/- 5.8 torr </text>
<text top="86" left="685" width="41" height="15" font="1">(p&lt;0.05)</text>
<text top="86" left="726" width="3" height="15" font="18"> </text>
<text top="102" left="54" width="991" height="15" font="1">B indicates blood pressure; bpm, beats per minute; MAT, multifocal atrial tachycardia; N/A, not applicable; NSR, normal sinus rhythm; PaCO2, partial pressure of carbon dioxide; pt, patient; and w/, with.  </text>
<text top="117" left="54" width="3" height="15" font="1"> </text>
<text top="143" left="54" width="143" height="18" font="3"><b>Data Supplement 9. </b></text>
<text top="143" left="197" width="649" height="18" font="7"><b>Randomized Trials Comparing Atrioventricular Nodal Re-Entrant Tachycardia – Section 5 </b></text>
<text top="143" left="846" width="4" height="18" font="3"><b> </b></text>
<text top="162" left="60" width="38" height="17" font="5"><b>Study </b></text>
<text top="179" left="58" width="40" height="17" font="5"><b>Name, </b></text>
<text top="196" left="55" width="47" height="17" font="5"><b>Author, </b></text>
<text top="213" left="64" width="30" height="17" font="5"><b>Year </b></text>
<text top="162" left="119" width="42" height="17" font="5"><b>Aim of </b></text>
<text top="179" left="121" width="38" height="17" font="5"><b>Study </b></text>
<text top="162" left="182" width="38" height="17" font="5"><b>Study </b></text>
<text top="179" left="185" width="32" height="17" font="5"><b>Type </b></text>
<text top="196" left="183" width="36" height="17" font="5"><b>(Size, </b></text>
<text top="213" left="193" width="16" height="17" font="5"><b>N) </b></text>
<text top="162" left="256" width="38" height="17" font="5"><b>Study </b></text>
<text top="179" left="238" width="74" height="17" font="5"><b>Intervention </b></text>
<text top="196" left="245" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="162" left="344" width="38" height="17" font="5"><b>Study </b></text>
<text top="179" left="326" width="73" height="17" font="5"><b>Comparator </b></text>
<text top="196" left="333" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="162" left="490" width="83" height="17" font="5"><b>Pt Population </b></text>
<text top="162" left="756" width="64" height="17" font="5"><b>Endpoints </b></text>
<text top="162" left="933" width="109" height="17" font="5"><b>P Values, OR: HR: </b></text>
<text top="179" left="945" width="85" height="17" font="5"><b>RR: &amp; 95% CI: </b></text>
<text top="162" left="1081" width="38" height="17" font="5"><b>Study </b></text>
<text top="179" left="1066" width="69" height="17" font="5"><b>Limitations </b></text>
<text top="196" left="1068" width="64" height="17" font="5"><b>&amp; Adverse </b></text>
<text top="213" left="1078" width="44" height="17" font="5"><b>Events </b></text>
<text top="231" left="67" width="3" height="17" font="5"><b> </b></text>
<text top="231" left="138" width="3" height="17" font="5"><b> </b></text>
<text top="231" left="199" width="3" height="17" font="5"><b> </b></text>
<text top="231" left="273" width="3" height="17" font="5"><b> </b></text>
<text top="231" left="361" width="3" height="17" font="5"><b> </b></text>
<text top="231" left="419" width="104" height="17" font="13"><i><b>Inclusion Criteria </b></i></text>
<text top="231" left="542" width="108" height="17" font="13"><i><b>Exclusion Criteria </b></i></text>
<text top="231" left="676" width="49" height="17" font="13"><i><b>Primary </b></i></text>
<text top="248" left="672" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="266" left="672" width="58" height="17" font="13"><i><b>(efficacy) </b></i></text>
<text top="283" left="664" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="231" left="771" width="40" height="17" font="13"><i><b>Safety </b></i></text>
<text top="248" left="763" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="266" left="755" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="231" left="846" width="70" height="17" font="13"><i><b>Secondary  </b></i></text>
<text top="248" left="851" width="67" height="17" font="13"><i><b>Endpoint    </b></i></text>
<text top="266" left="867" width="25" height="17" font="13"><i><b>and </b></i></text>
<text top="283" left="855" width="48" height="17" font="13"><i><b>Results </b></i></text>
<text top="231" left="986" width="3" height="17" font="5"><b> </b></text>
<text top="231" left="1098" width="3" height="17" font="5"><b> </b></text>
<text top="301" left="54" width="129" height="15" font="1">Pharmacological Therapy </text>
<text top="321" left="54" width="47" height="15" font="1">Waxman </text>
<text top="336" left="54" width="17" height="15" font="1">HL </text>
<text top="352" left="54" width="28" height="15" font="1">1981 </text>
<text top="367" left="54" width="29" height="15" font="1">(112) </text>
<text top="382" left="54" width="46" height="15" font="8">7447203 </text>
<text top="398" left="54" width="3" height="15" font="1"> </text>
<text top="321" left="116" width="42" height="15" font="1">Effective</text>
<text top="336" left="116" width="42" height="15" font="1">ness  of </text>
<text top="352" left="116" width="14" height="15" font="1">IV </text>
<text top="367" left="116" width="43" height="15" font="1">verapam</text>
<text top="382" left="116" width="8" height="15" font="1">il </text>
<text top="321" left="177" width="140" height="15" font="1">50 Group </text>
<text top="321" left="271" width="55" height="15" font="1">1 </text>
<text top="336" left="238" width="67" height="15" font="1">(n=20) w/ AF </text>
<text top="352" left="238" width="44" height="15" font="1">or flutter </text>
<text top="367" left="238" width="3" height="15" font="1"> </text>
<text top="382" left="238" width="43" height="15" font="1">Group 2 </text>
<text top="398" left="238" width="35" height="15" font="1">(n=30) </text>
<text top="414" left="238" width="32" height="15" font="1">PSVT </text>
<text top="429" left="238" width="65" height="15" font="1">(AVNRT in 8 </text>
<text top="444" left="238" width="28" height="15" font="1">pts),  </text>
<text top="321" left="325" width="186" height="15" font="1">N/A PSVT </text>
<text top="321" left="445" width="80" height="15" font="1">w/ </text>
<text top="321" left="459" width="48" height="15" font="1">AF, atrial </text>
<text top="336" left="413" width="66" height="15" font="1">flutter, PSVT </text>
<text top="321" left="541" width="22" height="15" font="1">N/A </text>
<text top="321" left="663" width="51" height="15" font="1">Control of </text>
<text top="336" left="663" width="54" height="15" font="1">ventricular </text>
<text top="352" left="663" width="60" height="15" font="1">response in </text>
<text top="367" left="663" width="44" height="15" font="1">group 1, </text>
<text top="382" left="663" width="68" height="15" font="1">restoration of </text>
<text top="398" left="663" width="66" height="15" font="1">sinus rhythm </text>
<text top="414" left="663" width="52" height="15" font="1">in group 2 </text>
<text top="429" left="663" width="3" height="15" font="1"> </text>
<text top="444" left="663" width="55" height="15" font="1">In Group 1 </text>
<text top="460" left="663" width="47" height="15" font="1">low-dose </text>
<text top="475" left="663" width="51" height="15" font="1">verapamil </text>
<text top="491" left="663" width="68" height="15" font="1">(0.075 mg/kg </text>
<text top="506" left="663" width="66" height="15" font="1">body weight) </text>
<text top="522" left="663" width="73" height="15" font="1">decreased the </text>
<text top="537" left="663" width="31" height="15" font="1">mean </text>
<text top="553" left="663" width="54" height="15" font="1">ventricular </text>
<text top="568" left="663" width="69" height="15" font="1">rate from 146 </text>
<text top="584" left="663" width="58" height="15" font="1">to 114 bpm </text>
<text top="599" left="663" width="45" height="15" font="1">(p&lt;0.01) </text>
<text top="615" left="663" width="74" height="15" font="1">compared to a </text>
<text top="630" left="663" width="61" height="15" font="1">decrease of </text>
<text top="646" left="663" width="55" height="15" font="1">145 to 132 </text>
<text top="661" left="663" width="69" height="15" font="1">bpm (p&lt;0.01) </text>
<text top="677" left="663" width="70" height="15" font="1">after placebo. </text>
<text top="692" left="663" width="3" height="15" font="1"> </text>
<text top="708" left="663" width="58" height="15" font="1">In Group 2, </text>
<text top="723" left="663" width="49" height="15" font="1">14/29 pts </text>
<text top="739" left="663" width="64" height="15" font="1">converted to </text>
<text top="754" left="663" width="66" height="15" font="1">sinus rhythm </text>
<text top="770" left="663" width="73" height="15" font="1">after low-dose </text>
<text top="785" left="663" width="54" height="15" font="1">verapamil, </text>
<text top="321" left="751" width="22" height="15" font="1">N/A </text>
<text top="321" left="845" width="22" height="15" font="1">N/A </text>
<text top="321" left="926" width="22" height="15" font="1">N/A </text>
<text top="321" left="1063" width="53" height="15" font="1">Verapamil </text>
<text top="336" left="1063" width="56" height="15" font="1">results in a </text>
<text top="352" left="1063" width="44" height="15" font="1">clinically </text>
<text top="367" left="1063" width="52" height="15" font="1">significant </text>
<text top="382" left="1063" width="71" height="15" font="1">slowing of the </text>
<text top="398" left="1063" width="54" height="15" font="1">ventricular </text>
<text top="414" left="1063" width="60" height="15" font="1">response in </text>
<text top="429" left="1063" width="57" height="15" font="1">AF or atrial </text>
<text top="444" left="1063" width="63" height="15" font="1">flutter and is </text>
<text top="460" left="1063" width="55" height="15" font="1">superior to </text>
<text top="475" left="1063" width="58" height="15" font="1">placebo for </text>
<text top="491" left="1063" width="69" height="15" font="1">conversion of </text>
<text top="506" left="1063" width="73" height="15" font="1">PSVT to sinus </text>
<text top="522" left="1063" width="37" height="15" font="1">rhythm </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">39 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="50" height="15" font="1">9/15 after </text>
<text top="70" left="663" width="52" height="15" font="1">high-dose </text>
<text top="86" left="663" width="51" height="15" font="1">verapamil </text>
<text top="101" left="663" width="68" height="15" font="1">(0.15 mg/kg), </text>
<text top="117" left="663" width="71" height="15" font="1">and 1/24 after </text>
<text top="132" left="663" width="42" height="15" font="1">placebo </text>
<text top="147" left="663" width="48" height="15" font="1">(p&lt;0.01). </text>
<text top="164" left="54" width="42" height="15" font="1">Mauritso</text>
<text top="179" left="54" width="28" height="15" font="1">n DR </text>
<text top="195" left="54" width="28" height="15" font="1">1982 </text>
<text top="210" left="54" width="23" height="15" font="1">(23) </text>
<text top="226" left="54" width="46" height="15" font="8">7065555 </text>
<text top="241" left="54" width="3" height="15" font="1"> </text>
<text top="164" left="116" width="42" height="15" font="1">Effective</text>
<text top="179" left="116" width="26" height="15" font="1">ness </text>
<text top="195" left="116" width="21" height="15" font="1">and </text>
<text top="210" left="116" width="45" height="15" font="1">safety of </text>
<text top="226" left="116" width="21" height="15" font="1">oral </text>
<text top="241" left="116" width="43" height="15" font="1">verapam</text>
<text top="257" left="116" width="8" height="15" font="1">il </text>
<text top="164" left="177" width="159" height="15" font="1">11 Verapamil </text>
<text top="164" left="290" width="67" height="15" font="1">240 </text>
<text top="179" left="238" width="71" height="15" font="1">mg/d followed </text>
<text top="195" left="238" width="67" height="15" font="1">by 480 mg/d  </text>
<text top="210" left="238" width="35" height="15" font="1">(n=11) </text>
<text top="164" left="325" width="199" height="15" font="1">Placebo Symptomatic </text>
<text top="164" left="480" width="80" height="15" font="1">PSVT, </text>
<text top="179" left="413" width="86" height="15" font="1">≥2 episodes/mo, </text>
<text top="195" left="413" width="102" height="15" font="1">ascertained by ECG </text>
<text top="210" left="413" width="3" height="15" font="1"> </text>
<text top="226" left="413" width="41" height="15" font="1">AVNRT </text>
<text top="241" left="413" width="29" height="15" font="1">(n=7) </text>
<text top="257" left="413" width="3" height="15" font="1"> </text>
<text top="272" left="413" width="33" height="15" font="1">AVRT </text>
<text top="288" left="413" width="110" height="15" font="1">(n=2 w/ WPW, n=3 w/ </text>
<text top="303" left="413" width="75" height="15" font="1">concealed AP) </text>
<text top="319" left="413" width="3" height="15" font="1"> </text>
<text top="334" left="413" width="3" height="15" font="1"> </text>
<text top="164" left="541" width="65" height="15" font="1">CHF, severe </text>
<text top="179" left="541" width="69" height="15" font="1">hypertension, </text>
<text top="195" left="541" width="105" height="15" font="1">hypotension, VHD or </text>
<text top="210" left="541" width="97" height="15" font="1">CHD, renal/hepatic </text>
<text top="226" left="541" width="82" height="15" font="1">failure, SSS, AV </text>
<text top="241" left="541" width="93" height="15" font="1">block, atrial flutter, </text>
<text top="257" left="541" width="52" height="15" font="1">AF, AADs </text>
<text top="164" left="663" width="65" height="15" font="1">Episodes/wk </text>
<text top="179" left="663" width="70" height="15" font="1">(diary, Holter) </text>
<text top="195" left="663" width="53" height="15" font="1">Verapamil </text>
<text top="210" left="663" width="63" height="15" font="1">0.1±0.1 ,0.3 </text>
<text top="226" left="663" width="26" height="15" font="1">±0.5 </text>
<text top="241" left="663" width="43" height="15" font="1">Placebo </text>
<text top="257" left="663" width="63" height="15" font="1">0.3±0.3 ,0.7 </text>
<text top="272" left="663" width="26" height="15" font="1">±0.7 </text>
<text top="288" left="663" width="3" height="15" font="1"> </text>
<text top="303" left="663" width="76" height="15" font="1">Duration (min)  </text>
<text top="319" left="663" width="70" height="15" font="1">(diary, Holter) </text>
<text top="334" left="663" width="53" height="15" font="1">Verapamil </text>
<text top="350" left="663" width="49" height="15" font="1">3±3 ,1±2 </text>
<text top="365" left="663" width="72" height="15" font="1">Placebo 27±5 </text>
<text top="381" left="663" width="44" height="15" font="1">,67±111 </text>
<text top="396" left="663" width="3" height="15" font="1"> </text>
<text top="164" left="751" width="75" height="15" font="1">Minor AEs in 6 </text>
<text top="179" left="751" width="33" height="15" font="1">pts on </text>
<text top="195" left="751" width="51" height="15" font="1">verapamil </text>
<text top="210" left="751" width="3" height="15" font="1"> </text>
<text top="226" left="751" width="80" height="15" font="1">5 pts required a </text>
<text top="241" left="751" width="52" height="15" font="1">total of 35 </text>
<text top="257" left="751" width="74" height="15" font="1">cardioversions </text>
<text top="272" left="751" width="66" height="15" font="1">for sustained </text>
<text top="288" left="751" width="72" height="15" font="1">tachycardia, 2 </text>
<text top="303" left="751" width="34" height="15" font="1">during </text>
<text top="319" left="751" width="69" height="15" font="1">verapamil, 33 </text>
<text top="334" left="751" width="76" height="15" font="1">during placebo </text>
<text top="350" left="751" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="365" left="751" width="3" height="15" font="1"> </text>
<text top="381" left="751" width="79" height="15" font="1">PES performed </text>
<text top="396" left="751" width="76" height="15" font="1">at end of study </text>
<text top="412" left="751" width="48" height="15" font="1">to induce </text>
<text top="427" left="751" width="63" height="15" font="1">tachycardia. </text>
<text top="443" left="751" width="41" height="15" font="1">Caused </text>
<text top="458" left="751" width="50" height="15" font="1">sustained </text>
<text top="474" left="751" width="81" height="15" font="1">tachycardia in 9 </text>
<text top="489" left="751" width="69" height="15" font="1">on placebo, 2 </text>
<text top="505" left="751" width="66" height="15" font="1">on verapamil </text>
<text top="520" left="751" width="48" height="15" font="1">(p&lt;0.01)  </text>
<text top="164" left="845" width="22" height="15" font="1">N/A </text>
<text top="164" left="926" width="93" height="15" font="1">p&lt;0.05 for primary </text>
<text top="179" left="926" width="46" height="15" font="1">endpoint </text>
<text top="164" left="1063" width="24" height="15" font="1">Oral </text>
<text top="179" left="1063" width="51" height="15" font="1">verapamil </text>
<text top="195" left="1063" width="45" height="15" font="1">safe and </text>
<text top="210" left="1063" width="47" height="15" font="1">effective. </text>
<text top="226" left="1063" width="3" height="15" font="1"> </text>
<text top="241" left="1063" width="69" height="15" font="1">Small sample </text>
<text top="257" left="1063" width="26" height="15" font="1">size. </text>
<text top="272" left="1063" width="3" height="15" font="1"> </text>
<text top="288" left="1063" width="73" height="15" font="1">Unclear which </text>
<text top="303" left="1063" width="62" height="15" font="1">pt withdrew, </text>
<text top="319" left="1063" width="73" height="15" font="1">so numbers of </text>
<text top="334" left="1063" width="58" height="15" font="1">AVNRT vs. </text>
<text top="350" left="1063" width="72" height="15" font="1">AVRT may be </text>
<text top="365" left="1063" width="69" height="15" font="1">similar (i.e., 6 </text>
<text top="381" left="1063" width="36" height="15" font="1">vs. 5).  </text>
<text top="536" left="54" width="40" height="15" font="1">Winnifor</text>
<text top="552" left="54" width="30" height="15" font="1">d MD </text>
<text top="567" left="54" width="28" height="15" font="1">1984 </text>
<text top="583" left="54" width="23" height="15" font="1">(24) </text>
<text top="598" left="54" width="43" height="15" font="8">6388299</text>
<text top="598" left="97" width="3" height="15" font="1"> </text>
<text top="614" left="54" width="3" height="15" font="1"> </text>
<text top="536" left="116" width="44" height="15" font="1">Effect of </text>
<text top="552" left="116" width="18" height="15" font="1">AV </text>
<text top="567" left="116" width="30" height="15" font="1">nodal </text>
<text top="583" left="116" width="44" height="15" font="1">blockers </text>
<text top="598" left="116" width="41" height="15" font="1">for long-</text>
<text top="614" left="116" width="25" height="15" font="1">term </text>
<text top="629" left="116" width="40" height="15" font="1">therapy </text>
<text top="645" left="116" width="44" height="15" font="1">of PSVT </text>
<text top="536" left="177" width="15" height="15" font="1">11 </text>
<text top="552" left="177" width="3" height="15" font="1"> </text>
<text top="536" left="238" width="58" height="15" font="1">One mo of: </text>
<text top="552" left="238" width="3" height="15" font="1"> </text>
<text top="567" left="238" width="71" height="15" font="1">Digoxin 0.375 </text>
<text top="583" left="238" width="28" height="15" font="1">mg/d </text>
<text top="598" left="238" width="3" height="15" font="1"> </text>
<text top="614" left="238" width="60" height="15" font="1">Propranolol </text>
<text top="629" left="238" width="49" height="15" font="1">240 mg/d </text>
<text top="645" left="238" width="3" height="15" font="1"> </text>
<text top="660" left="238" width="74" height="15" font="1">Verapamil 480 </text>
<text top="676" left="238" width="28" height="15" font="1">mg/d </text>
<text top="536" left="325" width="32" height="15" font="1">Direct </text>
<text top="552" left="325" width="60" height="15" font="1">comparison </text>
<text top="567" left="325" width="71" height="15" font="1">between all 3, </text>
<text top="583" left="325" width="65" height="15" font="1">w/ one wk of </text>
<text top="598" left="325" width="42" height="15" font="1">placebo </text>
<text top="614" left="325" width="44" height="15" font="1">washout </text>
<text top="536" left="413" width="102" height="15" font="1">Symptomatic PSVT, </text>
<text top="552" left="413" width="86" height="15" font="1">≥2 episodes/mo, </text>
<text top="567" left="413" width="102" height="15" font="1">ascertained by ECG </text>
<text top="536" left="541" width="87" height="15" font="1">ECG evidence of </text>
<text top="552" left="541" width="66" height="15" font="1">preexcitation </text>
<text top="536" left="663" width="70" height="15" font="1">Episodes and </text>
<text top="552" left="663" width="43" height="15" font="1">duration </text>
<text top="567" left="663" width="64" height="15" font="1">(ascertained </text>
<text top="583" left="663" width="63" height="15" font="1">by diary and </text>
<text top="598" left="663" width="62" height="15" font="1">weekly 24-h </text>
<text top="614" left="663" width="39" height="15" font="1">Holter), </text>
<text top="629" left="663" width="42" height="15" font="1">adverse </text>
<text top="645" left="663" width="71" height="15" font="1">effects, SDCs </text>
<text top="660" left="663" width="65" height="15" font="1">of each drug </text>
<text top="676" left="663" width="3" height="15" font="1"> </text>
<text top="691" left="663" width="65" height="15" font="1">Episodes/wk </text>
<text top="707" left="663" width="70" height="15" font="1">(diary, Holter) </text>
<text top="722" left="663" width="40" height="15" font="1">Digoxin </text>
<text top="738" left="663" width="44" height="15" font="1">2.3±3.1, </text>
<text top="753" left="663" width="41" height="15" font="1">1.9±2.9 </text>
<text top="769" left="663" width="60" height="15" font="1">Propranolol </text>
<text top="784" left="663" width="44" height="15" font="1">1.5±2.3, </text>
<text top="536" left="751" width="47" height="15" font="1">Mild side </text>
<text top="552" left="751" width="72" height="15" font="1">effects in 3/11 </text>
<text top="567" left="751" width="70" height="15" font="1">pts w/ digoxin </text>
<text top="583" left="751" width="21" height="15" font="1">and </text>
<text top="598" left="751" width="61" height="15" font="1">propranolol, </text>
<text top="614" left="751" width="60" height="15" font="1">and 5/11 w/ </text>
<text top="629" left="751" width="69" height="15" font="1">verapamil. All </text>
<text top="645" left="751" width="55" height="15" font="1">SDCs w/in </text>
<text top="660" left="751" width="37" height="15" font="1">normal </text>
<text top="676" left="751" width="50" height="15" font="1">reference </text>
<text top="691" left="751" width="34" height="15" font="1">range. </text>
<text top="536" left="845" width="25" height="15" font="1"> N/A </text>
<text top="536" left="926" width="34" height="15" font="1"> p=NS </text>
<text top="536" left="1063" width="26" height="15" font="1">Only </text>
<text top="552" left="1063" width="73" height="15" font="1">verapamil had </text>
<text top="567" left="1063" width="66" height="15" font="1">been studied </text>
<text top="583" left="1063" width="63" height="15" font="1">in RCT prior </text>
<text top="598" left="1063" width="33" height="15" font="1">to this </text>
<text top="614" left="1063" width="65" height="15" font="1">(above), and </text>
<text top="629" left="1063" width="44" height="15" font="1">given its </text>
<text top="645" left="1063" width="37" height="15" font="1">proven </text>
<text top="660" left="1063" width="44" height="15" font="1">efficacy, </text>
<text top="676" left="1063" width="73" height="15" font="1">authors felt no </text>
<text top="691" left="1063" width="44" height="15" font="1">need for </text>
<text top="707" left="1063" width="48" height="15" font="1">placebo.  </text>
<text top="722" left="1063" width="3" height="15" font="1"> </text>
<text top="738" left="1063" width="63" height="15" font="1">Small series </text>
<text top="753" left="1063" width="33" height="15" font="1">of pts. </text>
<text top="769" left="1063" width="41" height="15" font="1">Unclear </text>
<text top="784" left="1063" width="72" height="15" font="1">mechanism of </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">40 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="41" height="15" font="1">0.2±0.6 </text>
<text top="70" left="663" width="53" height="15" font="1">Verapamil </text>
<text top="86" left="663" width="44" height="15" font="1">2.9±5.7, </text>
<text top="101" left="663" width="41" height="15" font="1">0.6±1.6 </text>
<text top="117" left="663" width="3" height="15" font="1"> </text>
<text top="132" left="663" width="76" height="15" font="1">Duration (min)  </text>
<text top="147" left="663" width="70" height="15" font="1">(diary, Holter) </text>
<text top="163" left="663" width="40" height="15" font="1">Digoxin </text>
<text top="178" left="663" width="44" height="15" font="1">75±164, </text>
<text top="194" left="663" width="41" height="15" font="1">47±157 </text>
<text top="210" left="663" width="60" height="15" font="1">Propranolol </text>
<text top="225" left="663" width="67" height="15" font="1">60±112, 1±1 </text>
<text top="240" left="663" width="53" height="15" font="1">Verapamil </text>
<text top="256" left="663" width="67" height="15" font="1">56±148, 1±1 </text>
<text top="55" left="1063" width="32" height="15" font="1">PSVT </text>
<text top="70" left="1063" width="44" height="15" font="1">(authors </text>
<text top="86" left="1063" width="65" height="15" font="1">speculate all </text>
<text top="101" left="1063" width="73" height="15" font="1">pts w/ AVRNT </text>
<text top="117" left="1063" width="53" height="15" font="1">or ORT w/ </text>
<text top="132" left="1063" width="53" height="15" font="1">concealed </text>
<text top="147" left="1063" width="63" height="15" font="1">conduction.  </text>
<text top="272" left="54" width="39" height="15" font="1">Yeh SJ </text>
<text top="288" left="54" width="28" height="15" font="1">1984 </text>
<text top="303" left="54" width="29" height="15" font="1">(113) </text>
<text top="319" left="54" width="46" height="15" font="8">3964710 </text>
<text top="319" left="100" width="3" height="15" font="1"> </text>
<text top="272" left="116" width="44" height="15" font="1">Effect of </text>
<text top="288" left="116" width="47" height="15" font="1">diltiazem </text>
<text top="303" left="116" width="21" height="15" font="1">and </text>
<text top="319" left="116" width="44" height="15" font="1">proprano</text>
<text top="334" left="116" width="29" height="15" font="1">lol as </text>
<text top="350" left="116" width="29" height="15" font="1">pill-in-</text>
<text top="365" left="116" width="19" height="15" font="1">the-</text>
<text top="381" left="116" width="36" height="15" font="1">pocket </text>
<text top="272" left="177" width="171" height="15" font="1">15 Combination </text>
<text top="288" left="238" width="68" height="15" font="1">diltiazem 120 </text>
<text top="303" left="238" width="71" height="15" font="1">mg/propranolo</text>
<text top="319" left="238" width="63" height="15" font="1">l 160 mg vs. </text>
<text top="334" left="238" width="47" height="15" font="1">placebos </text>
<text top="272" left="325" width="32" height="15" font="1">Direct </text>
<text top="288" left="325" width="60" height="15" font="1">comparison </text>
<text top="303" left="325" width="25" height="15" font="1">on 2 </text>
<text top="319" left="325" width="71" height="15" font="1">consecutive d </text>
<text top="272" left="413" width="79" height="15" font="1">Inducible PSVT </text>
<text top="288" left="413" width="3" height="15" font="1"> </text>
<text top="303" left="413" width="68" height="15" font="1">AVRT (n=13) </text>
<text top="319" left="413" width="70" height="15" font="1">AVNRT (n=2) </text>
<text top="272" left="541" width="22" height="15" font="1">N/A </text>
<text top="272" left="663" width="58" height="15" font="1">W/ placebo </text>
<text top="288" left="663" width="65" height="15" font="1">PSVT lasted </text>
<text top="303" left="663" width="74" height="15" font="1">164±89 min; 4 </text>
<text top="319" left="663" width="39" height="15" font="1">pts had </text>
<text top="334" left="663" width="66" height="15" font="1">spontaneous </text>
<text top="350" left="663" width="63" height="15" font="1">conversion.  </text>
<text top="365" left="663" width="3" height="15" font="1"> </text>
<text top="381" left="663" width="63" height="15" font="1">W/ diltiazem </text>
<text top="396" left="663" width="21" height="15" font="1">and </text>
<text top="412" left="663" width="58" height="15" font="1">propranolol </text>
<text top="427" left="663" width="65" height="15" font="1">PSVT lasted </text>
<text top="443" left="663" width="56" height="15" font="1">39±49 min </text>
<text top="458" left="663" width="63" height="15" font="1">(p&lt;.001). 14 </text>
<text top="474" left="663" width="39" height="15" font="1">pts had </text>
<text top="489" left="663" width="66" height="15" font="1">spontaneous </text>
<text top="505" left="663" width="68" height="15" font="1">conversion in </text>
<text top="520" left="663" width="71" height="15" font="1">an average of </text>
<text top="535" left="663" width="65" height="15" font="1">27 ±15 min.  </text>
<text top="551" left="663" width="3" height="15" font="1"> </text>
<text top="567" left="663" width="60" height="15" font="1">None of the </text>
<text top="582" left="663" width="55" height="15" font="1">14 pts had </text>
<text top="597" left="663" width="47" height="15" font="1">electrical </text>
<text top="613" left="663" width="69" height="15" font="1">reinduction of </text>
<text top="628" left="663" width="50" height="15" font="1">sustained </text>
<text top="644" left="663" width="57" height="15" font="1">PSVT after </text>
<text top="659" left="663" width="60" height="15" font="1">conversion. </text>
<text top="675" left="663" width="3" height="15" font="1"> </text>
<text top="690" left="663" width="69" height="15" font="1">Outpatient f/u </text>
<text top="706" left="663" width="45" height="15" font="1">w/ 50/51 </text>
<text top="721" left="663" width="69" height="15" font="1">conversion of </text>
<text top="737" left="663" width="55" height="15" font="1">PSVT w/in </text>
<text top="752" left="663" width="75" height="15" font="1">21±16 min, f/u </text>
<text top="768" left="663" width="55" height="15" font="1">of 5.6 mo.  </text>
<text top="272" left="751" width="73" height="15" font="1">The heart rate </text>
<text top="288" left="751" width="58" height="15" font="1">was 87±16 </text>
<text top="303" left="751" width="81" height="15" font="1">bpm before and </text>
<text top="319" left="751" width="72" height="15" font="1">59±10 bpm at </text>
<text top="334" left="751" width="61" height="15" font="1">90 min after </text>
<text top="350" left="751" width="68" height="15" font="1">diltiazem and </text>
<text top="365" left="751" width="58" height="15" font="1">propranolol </text>
<text top="381" left="751" width="57" height="15" font="1">(p&lt;0.001).  </text>
<text top="396" left="751" width="3" height="15" font="1"> </text>
<text top="412" left="751" width="61" height="15" font="1">The systolic </text>
<text top="427" left="751" width="65" height="15" font="1">and diastolic </text>
<text top="443" left="751" width="52" height="15" font="1">pressures </text>
<text top="458" left="751" width="30" height="15" font="1">were, </text>
<text top="474" left="751" width="65" height="15" font="1">respectively, </text>
<text top="489" left="751" width="63" height="15" font="1">111±11 and </text>
<text top="505" left="751" width="57" height="15" font="1">77±10 mm </text>
<text top="520" left="751" width="73" height="15" font="1">Hg before and </text>
<text top="535" left="751" width="81" height="15" font="1">88 + 9 and 66 + </text>
<text top="551" left="751" width="73" height="15" font="1">9 mm Hg after </text>
<text top="567" left="751" width="68" height="15" font="1">diltiazem and </text>
<text top="582" left="751" width="58" height="15" font="1">propranolol </text>
<text top="598" left="751" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="272" left="845" width="22" height="15" font="1">N/A </text>
<text top="272" left="926" width="22" height="15" font="1">N/A </text>
<text top="272" left="1063" width="73" height="15" font="1">Single dose of </text>
<text top="288" left="1063" width="69" height="15" font="1">diltiazem/prop</text>
<text top="303" left="1063" width="36" height="15" font="1">ranolol </text>
<text top="319" left="1063" width="55" height="15" font="1">terminated </text>
<text top="334" left="1063" width="62" height="15" font="1">acute PSVT </text>
<text top="350" left="1063" width="3" height="15" font="1"> </text>
<text top="365" left="1063" width="73" height="15" font="1">Limited due to </text>
<text top="381" left="1063" width="47" height="15" font="1">EP study </text>
<text top="396" left="1063" width="62" height="15" font="1">efficacy and </text>
<text top="412" left="1063" width="66" height="15" font="1">low numbers </text>
<text top="427" left="1063" width="74" height="15" font="1">of AVNRT pts. </text>
<text top="443" left="1063" width="62" height="15" font="1">Not placebo </text>
<text top="458" left="1063" width="57" height="15" font="1">controlled.  </text>
<text top="784" left="54" width="41" height="15" font="1">Anderso</text>
<text top="784" left="116" width="87" height="15" font="1">Efficacy </text>
<text top="784" left="177" width="323" height="15" font="1">71 Esmolol Placebo  “SVT” (HR&gt;120) </text>
<text top="784" left="541" width="82" height="15" font="1">VHD, AV block,  </text>
<text top="784" left="663" width="204" height="15" font="1">Therapeutic Hypotension  N/A </text>
<text top="784" left="926" width="31" height="15" font="1">p=NS </text>
<text top="784" left="1063" width="62" height="15" font="1">Rapid onset </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">41 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="20" height="15" font="1">n S </text>
<text top="70" left="54" width="28" height="15" font="1">1986 </text>
<text top="86" left="54" width="23" height="15" font="1">(25) </text>
<text top="101" left="54" width="43" height="15" font="8">2868645</text>
<text top="101" left="97" width="3" height="15" font="1"> </text>
<text top="117" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="116" width="12" height="15" font="1">of </text>
<text top="70" left="116" width="41" height="15" font="1">esmolol </text>
<text top="86" left="116" width="12" height="15" font="1">in </text>
<text top="101" left="116" width="44" height="15" font="1">treatmen</text>
<text top="117" left="116" width="18" height="15" font="1">t of </text>
<text top="132" left="116" width="32" height="15" font="1">PSVT </text>
<text top="55" left="177" width="3" height="15" font="1"> </text>
<text top="70" left="177" width="44" height="15" font="1">Multicent</text>
<text top="86" left="177" width="16" height="15" font="1">er, </text>
<text top="101" left="177" width="37" height="15" font="1">double-</text>
<text top="117" left="177" width="29" height="15" font="1">blind, </text>
<text top="132" left="177" width="34" height="15" font="1">partial-</text>
<text top="147" left="177" width="44" height="15" font="1">crossove</text>
<text top="163" left="177" width="36" height="15" font="1">r study </text>
<text top="55" left="238" width="179" height="15" font="1">(n=36) (n=35)  </text>
<text top="70" left="413" width="107" height="15" font="1">Note: AVNRT in 18% </text>
<text top="86" left="413" width="56" height="15" font="1">of subjects </text>
<text top="55" left="541" width="81" height="15" font="1">SSS, significant </text>
<text top="70" left="541" width="54" height="15" font="1">electrolyte </text>
<text top="86" left="541" width="63" height="15" font="1">abnormality, </text>
<text top="101" left="541" width="104" height="15" font="1">precluding treatment </text>
<text top="117" left="541" width="89" height="15" font="1">w/ beta blockade, </text>
<text top="132" left="541" width="48" height="15" font="1">bronchial </text>
<text top="147" left="541" width="97" height="15" font="1">asthma, ventricular </text>
<text top="163" left="541" width="107" height="15" font="1">arrhythmias requiring </text>
<text top="178" left="541" width="68" height="15" font="1">drug therapy, </text>
<text top="194" left="541" width="95" height="15" font="1">cardiogenic shock, </text>
<text top="209" left="541" width="96" height="15" font="1">CHF (NYHA III-IV), </text>
<text top="225" left="541" width="79" height="15" font="1">renal or hepatic </text>
<text top="240" left="541" width="100" height="15" font="1">dysfunction, drug or </text>
<text top="256" left="541" width="78" height="15" font="1">alcohol abuse,  </text>
<text top="271" left="541" width="69" height="15" font="1">on other beta-</text>
<text top="287" left="541" width="100" height="15" font="1">adrenergic blockers </text>
<text top="302" left="541" width="95" height="15" font="1">or calcium channel </text>
<text top="318" left="541" width="87" height="15" font="1">blockers w/in two </text>
<text top="333" left="541" width="89" height="15" font="1">half-lives of study </text>
<text top="349" left="541" width="28" height="15" font="1">entry </text>
<text top="364" left="541" width="3" height="15" font="1"> </text>
<text top="55" left="663" width="52" height="15" font="1">response: </text>
<text top="70" left="663" width="33" height="15" font="1">≥20% </text>
<text top="86" left="663" width="60" height="15" font="1">reduction in </text>
<text top="101" left="663" width="66" height="15" font="1">HR, HR&lt;100 </text>
<text top="117" left="663" width="41" height="15" font="1">bpm, or </text>
<text top="132" left="663" width="69" height="15" font="1">conversion to </text>
<text top="147" left="663" width="30" height="15" font="1">NSR. </text>
<text top="163" left="663" width="3" height="15" font="1"> </text>
<text top="178" left="663" width="62" height="15" font="1">Therapeutic </text>
<text top="194" left="663" width="61" height="15" font="1">response to </text>
<text top="210" left="663" width="41" height="15" font="1">esmolol </text>
<text top="225" left="663" width="52" height="15" font="1">during the </text>
<text top="240" left="663" width="28" height="15" font="1">initial </text>
<text top="256" left="663" width="50" height="15" font="1">treatment </text>
<text top="271" left="663" width="66" height="15" font="1">period (72%) </text>
<text top="287" left="663" width="65" height="15" font="1">similar when </text>
<text top="302" left="663" width="64" height="15" font="1">esmolol was </text>
<text top="318" left="663" width="54" height="15" font="1">given as a </text>
<text top="333" left="663" width="70" height="15" font="1">second agent </text>
<text top="349" left="663" width="3" height="15" font="1"> </text>
<text top="364" left="663" width="53" height="15" font="1">4 pts (6%) </text>
<text top="380" left="663" width="64" height="15" font="1">converted to </text>
<text top="395" left="663" width="26" height="15" font="1">NSR </text>
<text top="411" left="663" width="3" height="15" font="1"> </text>
<text top="426" left="663" width="56" height="15" font="1">In the 80% </text>
<text top="442" left="663" width="58" height="15" font="1">therapeutic </text>
<text top="457" left="663" width="69" height="15" font="1">response lost </text>
<text top="473" left="663" width="59" height="15" font="1">w/in 30 min </text>
<text top="488" left="663" width="46" height="15" font="1">following </text>
<text top="504" left="663" width="68" height="15" font="1">discontinuatio</text>
<text top="519" left="663" width="63" height="15" font="1">n of esmolol </text>
<text top="535" left="663" width="41" height="15" font="1">infusion </text>
<text top="55" left="751" width="77" height="15" font="1">which occurred </text>
<text top="70" left="751" width="49" height="15" font="1">in12% on </text>
<text top="86" left="751" width="77" height="15" font="1">esmolol, 2% w/ </text>
<text top="101" left="751" width="45" height="15" font="1">placebo. </text>
<text top="55" left="1063" width="62" height="15" font="1">and short of </text>
<text top="70" left="1063" width="45" height="15" font="1">action of </text>
<text top="86" left="1063" width="66" height="15" font="1">esmolol offer </text>
<text top="101" left="1063" width="71" height="15" font="1">safe, effective </text>
<text top="117" left="1063" width="56" height="15" font="1">therapy for </text>
<text top="132" left="1063" width="30" height="15" font="1">acute </text>
<text top="148" left="1063" width="62" height="15" font="1">treatment of </text>
<text top="163" left="1063" width="67" height="15" font="1">pts w/ PSVT. </text>
<text top="178" left="1063" width="69" height="15" font="1">Low numbers </text>
<text top="194" left="1063" width="44" height="15" font="1">of pts w/ </text>
<text top="210" left="1063" width="44" height="15" font="1">AVNRT. </text>
<text top="551" left="54" width="49" height="15" font="1">*DiMarco </text>
<text top="567" left="54" width="16" height="15" font="1">JP </text>
<text top="582" left="54" width="28" height="15" font="1">1990 </text>
<text top="597" left="54" width="29" height="15" font="1">(114) </text>
<text top="613" left="54" width="43" height="15" font="8">2193560</text>
<text top="613" left="97" width="3" height="15" font="1"> </text>
<text top="551" left="116" width="46" height="15" font="1">Evaluate </text>
<text top="567" left="116" width="27" height="15" font="1">dose </text>
<text top="582" left="116" width="39" height="15" font="1">respons</text>
<text top="597" left="116" width="30" height="15" font="1">es of  </text>
<text top="613" left="116" width="39" height="15" font="1">adenosi</text>
<text top="628" left="116" width="27" height="15" font="1">ne in </text>
<text top="644" left="116" width="42" height="15" font="1">terminati</text>
<text top="659" left="116" width="47" height="15" font="1">ng PSVT </text>
<text top="551" left="177" width="46" height="15" font="1">359 total </text>
<text top="567" left="177" width="36" height="15" font="1">in both </text>
<text top="582" left="177" width="39" height="15" font="1">protocol</text>
<text top="597" left="177" width="9" height="15" font="1">s </text>
<text top="613" left="177" width="41" height="15" font="1">(n=201) </text>
<text top="628" left="177" width="3" height="15" font="1"> </text>
<text top="551" left="238" width="69" height="15" font="1">Sequential IV </text>
<text top="567" left="238" width="74" height="15" font="1">bolus doses of </text>
<text top="582" left="238" width="70" height="15" font="1">adenosine (3, </text>
<text top="597" left="238" width="65" height="15" font="1">6, 9, 12 mg)  </text>
<text top="613" left="238" width="41" height="15" font="1">(n=137) </text>
<text top="628" left="238" width="3" height="15" font="1"> </text>
<text top="551" left="325" width="34" height="15" font="1">Saline </text>
<text top="567" left="325" width="42" height="15" font="1">placebo </text>
<text top="582" left="325" width="35" height="15" font="1">(n=64) </text>
<text top="551" left="413" width="32" height="15" font="1">PSVT </text>
<text top="551" left="541" width="67" height="15" font="1">Severe CHF, </text>
<text top="567" left="541" width="84" height="15" font="1">unstable angina, </text>
<text top="582" left="541" width="89" height="15" font="1">recent MI, severe </text>
<text top="597" left="541" width="41" height="15" font="1">valvular </text>
<text top="613" left="541" width="68" height="15" font="1">regurgitation, </text>
<text top="628" left="541" width="99" height="15" font="1">intracardiac shunts, </text>
<text top="644" left="541" width="104" height="15" font="1">sleep apnea, current </text>
<text top="659" left="541" width="90" height="15" font="1">methylxanthine or </text>
<text top="675" left="541" width="87" height="15" font="1">dipyridamole use </text>
<text top="551" left="663" width="55" height="15" font="1">Adenosine </text>
<text top="567" left="663" width="59" height="15" font="1">terminated  </text>
<text top="582" left="663" width="30" height="15" font="1">acute </text>
<text top="597" left="663" width="60" height="15" font="1">episodes of </text>
<text top="613" left="663" width="52" height="15" font="1">PSVT, vs. </text>
<text top="628" left="663" width="48" height="15" font="1">placebo:  </text>
<text top="644" left="663" width="65" height="15" font="1">3 mg: 35.2% </text>
<text top="659" left="663" width="45" height="15" font="1">vs. 8.9% </text>
<text top="675" left="663" width="62" height="15" font="1">6 mg 62.3% </text>
<text top="690" left="663" width="52" height="15" font="1">vs. 10.7% </text>
<text top="706" left="663" width="65" height="15" font="1">9 mg: 80.2% </text>
<text top="721" left="663" width="52" height="15" font="1">vs. 14.3% </text>
<text top="737" left="663" width="74" height="15" font="1">12 mg: 91.4%  </text>
<text top="752" left="663" width="52" height="15" font="1">vs. 16.1% </text>
<text top="768" left="663" width="3" height="15" font="1"> </text>
<text top="551" left="751" width="55" height="15" font="1">Adenosine </text>
<text top="567" left="751" width="65" height="15" font="1">caused mild, </text>
<text top="582" left="751" width="69" height="15" font="1">transient side </text>
<text top="597" left="751" width="73" height="15" font="1">effects in 36% </text>
<text top="613" left="751" width="78" height="15" font="1">of pts (flushing, </text>
<text top="628" left="751" width="30" height="15" font="1">chest </text>
<text top="644" left="751" width="73" height="15" font="1">pain/pressure, </text>
<text top="659" left="751" width="66" height="15" font="1">hypotension, </text>
<text top="675" left="751" width="49" height="15" font="1">dyspnea) </text>
<text top="551" left="845" width="22" height="15" font="1">N/A </text>
<text top="551" left="926" width="53" height="15" font="1"> p&lt;0.0001 </text>
<text top="551" left="1063" width="38" height="15" font="1">Overall </text>
<text top="567" left="1063" width="53" height="15" font="1">efficacy of </text>
<text top="582" left="1063" width="54" height="15" font="1">adenosine </text>
<text top="597" left="1063" width="27" height="15" font="1">high, </text>
<text top="613" left="1063" width="66" height="15" font="1">especially w/ </text>
<text top="628" left="1063" width="53" height="15" font="1">increasing </text>
<text top="644" left="1063" width="33" height="15" font="1">doses </text>
<text top="784" left="54" width="101" height="15" font="1">*DiMarco  Compar</text>
<text top="784" left="177" width="108" height="15" font="1">359 total  6-12 mg  </text>
<text top="784" left="325" width="59" height="15" font="1">5-7.5 mg of </text>
<text top="784" left="413" width="35" height="15" font="1"> PSVT </text>
<text top="784" left="541" width="67" height="15" font="1">Severe CHF, </text>
<text top="784" left="663" width="58" height="15" font="1">Cumulative </text>
<text top="784" left="751" width="55" height="15" font="1">Adenosine </text>
<text top="784" left="845" width="25" height="15" font="1"> N/A </text>
<text top="784" left="926" width="22" height="15" font="1">N/A </text>
<text top="784" left="1063" width="38" height="15" font="1">Overall </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">42 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="16" height="15" font="1">JP </text>
<text top="70" left="54" width="28" height="15" font="1">1990 </text>
<text top="86" left="54" width="32" height="15" font="1">(114)  </text>
<text top="101" left="54" width="46" height="15" font="8">2193560 </text>
<text top="55" left="116" width="9" height="15" font="1">e </text>
<text top="70" left="116" width="39" height="15" font="1">adenosi</text>
<text top="86" left="116" width="28" height="15" font="1">ne to </text>
<text top="101" left="116" width="43" height="15" font="1">verapam</text>
<text top="117" left="116" width="23" height="15" font="1">il in  </text>
<text top="132" left="116" width="42" height="15" font="1">terminati</text>
<text top="147" left="116" width="47" height="15" font="1">ng PSVT </text>
<text top="55" left="177" width="36" height="15" font="1">in both </text>
<text top="70" left="177" width="39" height="15" font="1">protocol</text>
<text top="86" left="177" width="9" height="15" font="1">s </text>
<text top="101" left="177" width="41" height="15" font="1">(n=158) </text>
<text top="55" left="238" width="57" height="15" font="1">adenosine  </text>
<text top="70" left="238" width="35" height="15" font="1">(n=77) </text>
<text top="86" left="238" width="3" height="15" font="1"> </text>
<text top="55" left="325" width="54" height="15" font="1">verapamil. </text>
<text top="70" left="325" width="35" height="15" font="1">(n=81) </text>
<text top="55" left="541" width="84" height="15" font="1">unstable angina, </text>
<text top="70" left="541" width="89" height="15" font="1">recent MI, severe </text>
<text top="86" left="541" width="41" height="15" font="1">valvular </text>
<text top="101" left="541" width="68" height="15" font="1">regurgitation, </text>
<text top="117" left="541" width="99" height="15" font="1">intracardiac shunts, </text>
<text top="132" left="541" width="104" height="15" font="1">sleep apnea, current </text>
<text top="147" left="541" width="90" height="15" font="1">methylxanthine or </text>
<text top="163" left="541" width="87" height="15" font="1">dipyridamole use </text>
<text top="55" left="663" width="49" height="15" font="1">response </text>
<text top="70" left="663" width="31" height="15" font="1">rates  </text>
<text top="86" left="663" width="59" height="15" font="1">Adenosine: </text>
<text top="101" left="663" width="55" height="15" font="1">6 mg: 57.4 </text>
<text top="117" left="663" width="75" height="15" font="1">12 mg: 93.4%  </text>
<text top="132" left="663" width="3" height="15" font="1"> </text>
<text top="147" left="663" width="56" height="15" font="1">Verapamil: </text>
<text top="163" left="663" width="68" height="15" font="1">5 mg: 81.3%  </text>
<text top="178" left="663" width="43" height="15" font="1">7.5 mg:  </text>
<text top="194" left="663" width="34" height="15" font="1">91.4% </text>
<text top="55" left="751" width="65" height="15" font="1">caused mild, </text>
<text top="70" left="751" width="69" height="15" font="1">transient side </text>
<text top="86" left="751" width="73" height="15" font="1">effects in 36% </text>
<text top="101" left="751" width="30" height="15" font="1">of pts </text>
<text top="55" left="1063" width="53" height="15" font="1">efficacy of </text>
<text top="70" left="1063" width="65" height="15" font="1">adenosine is </text>
<text top="86" left="1063" width="47" height="15" font="1">similar to </text>
<text top="101" left="1063" width="73" height="15" font="1">verapamil, but </text>
<text top="117" left="1063" width="43" height="15" font="1">onset of </text>
<text top="132" left="1063" width="72" height="15" font="1">action is more </text>
<text top="147" left="1063" width="31" height="15" font="1">rapid. </text>
<text top="210" left="54" width="49" height="15" font="1">Henthorn </text>
<text top="226" left="54" width="22" height="15" font="1">RW </text>
<text top="241" left="54" width="28" height="15" font="1">1991 </text>
<text top="257" left="54" width="23" height="15" font="1">(26) </text>
<text top="272" left="54" width="46" height="15" font="8">1898640 </text>
<text top="288" left="54" width="3" height="15" font="1"> </text>
<text top="303" left="54" width="3" height="15" font="1"> </text>
<text top="210" left="116" width="44" height="15" font="1">Flecainid</text>
<text top="226" left="116" width="25" height="15" font="1">e for </text>
<text top="241" left="116" width="44" height="15" font="1">treatmen</text>
<text top="257" left="116" width="18" height="15" font="1">t of </text>
<text top="272" left="116" width="36" height="15" font="1">sympto</text>
<text top="288" left="116" width="29" height="15" font="1">matic </text>
<text top="303" left="116" width="32" height="15" font="1">PSVT </text>
<text top="319" left="116" width="20" height="15" font="1">(≥2 </text>
<text top="334" left="116" width="44" height="15" font="1">episodes</text>
<text top="350" left="116" width="7" height="15" font="1">) </text>
<text top="365" left="116" width="3" height="15" font="1"> </text>
<text top="210" left="177" width="15" height="15" font="1">34 </text>
<text top="226" left="177" width="3" height="15" font="1"> </text>
<text top="241" left="177" width="26" height="15" font="1">8-wk </text>
<text top="257" left="177" width="44" height="15" font="1">crossove</text>
<text top="272" left="177" width="36" height="15" font="1">r (after </text>
<text top="288" left="177" width="22" height="15" font="1">four </text>
<text top="303" left="177" width="47" height="15" font="1">episodes </text>
<text top="319" left="177" width="44" height="15" font="1">of PSVT </text>
<text top="334" left="177" width="47" height="15" font="1">or end of </text>
<text top="350" left="177" width="44" height="15" font="1">treatmen</text>
<text top="365" left="177" width="44" height="15" font="1">t period) </text>
<text top="381" left="177" width="3" height="15" font="1"> </text>
<text top="396" left="177" width="3" height="15" font="1"> </text>
<text top="210" left="238" width="57" height="15" font="1"> Flecainide </text>
<text top="226" left="238" width="35" height="15" font="1">(n=34) </text>
<text top="241" left="238" width="3" height="15" font="1"> </text>
<text top="210" left="325" width="43" height="15" font="1">Placebo </text>
<text top="226" left="325" width="35" height="15" font="1">(n=34) </text>
<text top="241" left="325" width="3" height="15" font="1"> </text>
<text top="257" left="325" width="3" height="15" font="1"> </text>
<text top="210" left="413" width="35" height="15" font="1">PSVT  </text>
<text top="226" left="413" width="3" height="15" font="1"> </text>
<text top="210" left="541" width="102" height="15" font="1">Syncope, angina, or </text>
<text top="226" left="541" width="89" height="15" font="1">transient cerebral </text>
<text top="241" left="541" width="108" height="15" font="1">events during PSVT,  </text>
<text top="257" left="541" width="76" height="15" font="1">second or third </text>
<text top="272" left="541" width="97" height="15" font="1">degree AV block or </text>
<text top="288" left="541" width="98" height="15" font="1">had CHF (NYHA III-</text>
<text top="303" left="541" width="23" height="15" font="1">IV)   </text>
<text top="210" left="663" width="73" height="15" font="1">Freedom from </text>
<text top="226" left="663" width="65" height="15" font="1">symptomatic </text>
<text top="241" left="663" width="72" height="15" font="1">PSVT at 60 d: </text>
<text top="257" left="663" width="61" height="15" font="1">79% events </text>
<text top="272" left="663" width="42" height="15" font="1">vs. 15% </text>
<text top="288" left="663" width="54" height="15" font="1"> (p&lt;0.001) </text>
<text top="303" left="663" width="3" height="15" font="1"> </text>
<text top="319" left="663" width="53" height="15" font="1">Flecainide </text>
<text top="334" left="663" width="37" height="15" font="1">slowed </text>
<text top="350" left="663" width="65" height="15" font="1">symptomatic </text>
<text top="365" left="663" width="63" height="15" font="1">PSVT HR to </text>
<text top="381" left="663" width="66" height="15" font="1">143±12 bpm </text>
<text top="396" left="663" width="70" height="15" font="1">from 178 ±12 </text>
<text top="412" left="663" width="69" height="15" font="1">on placebo in </text>
<text top="427" left="663" width="72" height="15" font="1">7 pts who had </text>
<text top="443" left="663" width="66" height="15" font="1">events in the </text>
<text top="458" left="663" width="63" height="15" font="1">placebo and </text>
<text top="474" left="663" width="50" height="15" font="1">flecainide </text>
<text top="489" left="663" width="50" height="15" font="1">treatment </text>
<text top="505" left="663" width="39" height="15" font="1">phases </text>
<text top="520" left="663" width="45" height="15" font="1">(p&lt;0.02) </text>
<text top="210" left="751" width="62" height="15" font="1">Significantly </text>
<text top="226" left="751" width="52" height="15" font="1">more side </text>
<text top="241" left="751" width="50" height="15" font="1">effects w/ </text>
<text top="257" left="751" width="50" height="15" font="1">flecainide </text>
<text top="272" left="751" width="45" height="15" font="1">(p&lt;0.05) </text>
<text top="210" left="845" width="53" height="15" font="1">Flecainide </text>
<text top="226" left="845" width="62" height="15" font="1">vs. placebo: </text>
<text top="241" left="845" width="3" height="15" font="1"> </text>
<text top="257" left="845" width="63" height="15" font="1">Recurrence: </text>
<text top="272" left="845" width="42" height="15" font="1">8/34 vs. </text>
<text top="288" left="845" width="31" height="15" font="1">29/34 </text>
<text top="303" left="845" width="54" height="15" font="1">(p&lt;0.001). </text>
<text top="319" left="845" width="3" height="15" font="1"> </text>
<text top="334" left="845" width="63" height="15" font="1">Median time </text>
<text top="350" left="845" width="66" height="15" font="1">to first event: </text>
<text top="365" left="845" width="57" height="15" font="1">55 vs. 11 d </text>
<text top="381" left="845" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="396" left="845" width="3" height="15" font="1"> </text>
<text top="412" left="845" width="39" height="15" font="1">Median </text>
<text top="427" left="845" width="39" height="15" font="1">interval </text>
<text top="443" left="845" width="45" height="15" font="1">between </text>
<text top="458" left="845" width="51" height="15" font="1">episodes  </text>
<text top="474" left="845" width="58" height="15" font="1">&gt;55 vs. 12  </text>
<text top="489" left="845" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="210" left="926" width="22" height="15" font="1">N/A </text>
<text top="210" left="1063" width="40" height="15" font="1">Despite </text>
<text top="226" left="1063" width="63" height="15" font="1">participation </text>
<text top="241" left="1063" width="69" height="15" font="1">of 19 medical </text>
<text top="257" left="1063" width="66" height="15" font="1">centers, only </text>
<text top="272" left="1063" width="33" height="15" font="1">34 pts </text>
<text top="288" left="1063" width="57" height="15" font="1">completed  </text>
<text top="303" left="1063" width="73" height="15" font="1">entire protocol </text>
<text top="319" left="1063" width="67" height="15" font="1">and provided </text>
<text top="334" left="1063" width="56" height="15" font="1">analyzable </text>
<text top="350" left="1063" width="28" height="15" font="1">data. </text>
<text top="365" left="1063" width="3" height="15" font="1"> </text>
<text top="381" left="1063" width="33" height="15" font="1">All pts </text>
<text top="396" left="1063" width="46" height="15" font="1">tolerated </text>
<text top="412" left="1063" width="53" height="15" font="1">flecainide, </text>
<text top="427" left="1063" width="37" height="15" font="1">limiting </text>
<text top="443" left="1063" width="68" height="15" font="1">generalizabilit</text>
<text top="458" left="1063" width="12" height="15" font="1">y. </text>
<text top="474" left="1063" width="3" height="15" font="1"> </text>
<text top="489" left="1063" width="71" height="15" font="1">Transtelephon</text>
<text top="505" left="1063" width="66" height="15" font="1">ic monitoring </text>
<text top="520" left="1063" width="45" height="15" font="1">does not </text>
<text top="535" left="1063" width="34" height="15" font="1">permit </text>
<text top="551" left="1063" width="62" height="15" font="1">assessment </text>
<text top="567" left="1063" width="12" height="15" font="1">of </text>
<text top="582" left="1063" width="71" height="15" font="1">proarrhythmia </text>
<text top="597" left="1063" width="3" height="15" font="1"> </text>
<text top="613" left="1063" width="39" height="15" font="1">6/34 w/ </text>
<text top="628" left="1063" width="44" height="15" font="1">AVNRT, </text>
<text top="644" left="1063" width="67" height="15" font="1">confirmed by </text>
<text top="659" left="1063" width="72" height="15" font="1">EP study, and </text>
<text top="675" left="1063" width="45" height="15" font="1">18/34 w/ </text>
<text top="690" left="1063" width="47" height="15" font="1">unknown </text>
<text top="706" left="1063" width="63" height="15" font="1">mechanism. </text>
<text top="722" left="54" width="44" height="15" font="1">Pritchett </text>
<text top="738" left="54" width="17" height="15" font="1">EL </text>
<text top="753" left="54" width="28" height="15" font="1">1991 </text>
<text top="769" left="54" width="23" height="15" font="1">(27) </text>
<text top="784" left="54" width="49" height="15" font="8">1899432  </text>
<text top="722" left="116" width="30" height="15" font="1">Dose-</text>
<text top="738" left="116" width="39" height="15" font="1">respons</text>
<text top="753" left="116" width="9" height="15" font="1">e </text>
<text top="769" left="116" width="41" height="15" font="1">efficacy </text>
<text top="784" left="116" width="12" height="15" font="1">of </text>
<text top="722" left="177" width="160" height="15" font="1">42 Flecainide </text>
<text top="738" left="238" width="41" height="15" font="1">given in </text>
<text top="753" left="238" width="53" height="15" font="1">ascending </text>
<text top="769" left="238" width="29" height="15" font="1">order </text>
<text top="784" left="238" width="67" height="15" font="1">(255010</text>
<text top="722" left="325" width="43" height="15" font="1">Placebo </text>
<text top="738" left="325" width="55" height="15" font="1">inserted at </text>
<text top="753" left="325" width="41" height="15" font="1">random </text>
<text top="769" left="325" width="73" height="15" font="1">(alternating w/ </text>
<text top="784" left="325" width="66" height="15" font="1">flecainide) at </text>
<text top="722" left="413" width="76" height="15" font="1">PSVT, PAF, or </text>
<text top="738" left="413" width="87" height="15" font="1">paroxysmal atrial </text>
<text top="753" left="413" width="31" height="15" font="1">flutter </text>
<text top="722" left="541" width="102" height="15" font="1">Syncope, angina, or </text>
<text top="738" left="541" width="89" height="15" font="1">transient cerebral </text>
<text top="753" left="541" width="108" height="15" font="1">events during PSVT,  </text>
<text top="769" left="541" width="76" height="15" font="1">second or third </text>
<text top="784" left="541" width="97" height="15" font="1">degree AV block or </text>
<text top="722" left="663" width="71" height="15" font="1">Among 14 pts </text>
<text top="738" left="663" width="55" height="15" font="1">in Group 1 </text>
<text top="753" left="663" width="68" height="15" font="1">who qualified </text>
<text top="769" left="663" width="57" height="15" font="1">for efficacy </text>
<text top="784" left="663" width="55" height="15" font="1">analysis, 4 </text>
<text top="722" left="751" width="59" height="15" font="1">Noncardiac </text>
<text top="738" left="751" width="42" height="15" font="1">adverse </text>
<text top="753" left="751" width="63" height="15" font="1">experiences </text>
<text top="769" left="751" width="66" height="15" font="1">were leading </text>
<text top="784" left="751" width="45" height="15" font="1">cause of </text>
<text top="722" left="845" width="22" height="15" font="1">N/A </text>
<text top="722" left="926" width="22" height="15" font="1">N/A </text>
<text top="722" left="1063" width="69" height="15" font="1">Small sample </text>
<text top="738" left="1063" width="53" height="15" font="1">size, short </text>
<text top="753" left="1063" width="50" height="15" font="1">treatment </text>
<text top="769" left="1063" width="40" height="15" font="1">period.  </text>
<text top="784" left="1063" width="3" height="15" font="1"> </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">43 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="103" height="15" font="1"> flecainid</text>
<text top="70" left="116" width="21" height="15" font="1">e in </text>
<text top="86" left="116" width="39" height="15" font="1">patents </text>
<text top="101" left="116" width="14" height="15" font="1">w/ </text>
<text top="117" left="116" width="35" height="15" font="1">PSVT, </text>
<text top="132" left="116" width="28" height="15" font="1">PAF, </text>
<text top="147" left="116" width="39" height="15" font="1">paroxys</text>
<text top="163" left="116" width="21" height="15" font="1">mal </text>
<text top="178" left="116" width="27" height="15" font="1">atrial </text>
<text top="194" left="116" width="31" height="15" font="1">flutter </text>
<text top="55" left="238" width="66" height="15" font="1">01150 mg </text>
<text top="70" left="238" width="58" height="15" font="1">twice daily) </text>
<text top="86" left="238" width="3" height="15" font="1"> </text>
<text top="101" left="238" width="32" height="15" font="1">PSVT </text>
<text top="117" left="238" width="68" height="15" font="1">(n=14, Group </text>
<text top="132" left="238" width="13" height="15" font="1">1) </text>
<text top="147" left="238" width="3" height="15" font="1"> </text>
<text top="163" left="238" width="37" height="15" font="1">PAF or </text>
<text top="178" left="238" width="60" height="15" font="1">parosysmal </text>
<text top="194" left="238" width="58" height="15" font="1">atrial flutter </text>
<text top="210" left="238" width="68" height="15" font="1">(n=28, Group </text>
<text top="225" left="238" width="13" height="15" font="1">2) </text>
<text top="55" left="325" width="69" height="15" font="1">30 d intervals </text>
<text top="55" left="541" width="98" height="15" font="1">had CHF (NYHA III-</text>
<text top="70" left="541" width="26" height="15" font="1">IV)  . </text>
<text top="55" left="663" width="70" height="15" font="1">(29%) had no </text>
<text top="70" left="663" width="60" height="15" font="1">tachycardia </text>
<text top="86" left="663" width="61" height="15" font="1">while taking </text>
<text top="101" left="663" width="48" height="15" font="1">placebo.  </text>
<text top="117" left="663" width="3" height="15" font="1"> </text>
<text top="132" left="663" width="72" height="15" font="1">Number w/ no </text>
<text top="147" left="663" width="60" height="15" font="1">tachycardia </text>
<text top="163" left="663" width="65" height="15" font="1">increased w/ </text>
<text top="178" left="663" width="68" height="15" font="1">progressively </text>
<text top="194" left="663" width="31" height="15" font="1">larger </text>
<text top="210" left="663" width="50" height="15" font="1">flecainide </text>
<text top="225" left="663" width="68" height="15" font="1">doses; w/ the </text>
<text top="240" left="663" width="68" height="15" font="1">150 mg twice </text>
<text top="256" left="663" width="71" height="15" font="1">daily dose, 12 </text>
<text top="271" left="663" width="60" height="15" font="1">(86%) of 14 </text>
<text top="287" left="663" width="55" height="15" font="1">pts had no </text>
<text top="302" left="663" width="60" height="15" font="1">tachycardia </text>
<text top="318" left="663" width="57" height="15" font="1">(p&lt;0.01 for </text>
<text top="333" left="663" width="36" height="15" font="1">overall </text>
<text top="349" left="663" width="57" height="15" font="1">differences </text>
<text top="364" left="663" width="51" height="15" font="1">among all </text>
<text top="380" left="663" width="62" height="15" font="1">treatments). </text>
<text top="55" left="751" width="53" height="15" font="1">premature </text>
<text top="70" left="751" width="30" height="15" font="1">study </text>
<text top="86" left="751" width="77" height="15" font="1">discontinuation </text>
<text top="101" left="751" width="34" height="15" font="1">during </text>
<text top="117" left="751" width="50" height="15" font="1">flecainide </text>
<text top="132" left="751" width="50" height="15" font="1">treatment </text>
<text top="147" left="751" width="70" height="15" font="1">periods (5 pts </text>
<text top="163" left="751" width="76" height="15" font="1">in Group 1 and </text>
<text top="178" left="751" width="73" height="15" font="1">6 pts in Group </text>
<text top="194" left="751" width="17" height="15" font="1">2). </text>
<text top="55" left="1063" width="3" height="15" font="1"> </text>
<text top="396" left="54" width="44" height="15" font="1">Pritchett </text>
<text top="412" left="54" width="17" height="15" font="1">EL </text>
<text top="427" left="54" width="28" height="15" font="1">1991 </text>
<text top="443" left="54" width="23" height="15" font="1">(28) </text>
<text top="458" left="54" width="46" height="15" font="8">2001087 </text>
<text top="396" left="116" width="24" height="15" font="1">Oral </text>
<text top="412" left="116" width="44" height="15" font="1">propafen</text>
<text top="427" left="116" width="34" height="15" font="1">one to </text>
<text top="443" left="116" width="40" height="15" font="1">prevent </text>
<text top="458" left="116" width="36" height="15" font="1">sympto</text>
<text top="474" left="116" width="29" height="15" font="1">matic </text>
<text top="489" left="116" width="32" height="15" font="1">PSVT </text>
<text top="505" left="116" width="3" height="15" font="1"> </text>
<text top="520" left="116" width="44" height="15" font="1">Randomi</text>
<text top="535" left="116" width="24" height="15" font="1">zed, </text>
<text top="551" left="116" width="37" height="15" font="1">double-</text>
<text top="567" left="116" width="29" height="15" font="1">blind, </text>
<text top="582" left="116" width="42" height="15" font="1">placebo-</text>
<text top="597" left="116" width="42" height="15" font="1">controlle</text>
<text top="613" left="116" width="12" height="15" font="1">d, </text>
<text top="628" left="116" width="44" height="15" font="1">crossove</text>
<text top="644" left="116" width="43" height="15" font="1">r phase, </text>
<text top="659" left="116" width="41" height="15" font="1">w/ each </text>
<text top="675" left="116" width="44" height="15" font="1">treatmen</text>
<text top="690" left="116" width="40" height="15" font="1">t period </text>
<text top="706" left="116" width="35" height="15" font="1">lasting </text>
<text top="721" left="116" width="43" height="15" font="1">up to 60 </text>
<text top="737" left="116" width="12" height="15" font="1">d. </text>
<text top="396" left="177" width="15" height="15" font="1">23 </text>
<text top="412" left="177" width="3" height="15" font="1"> </text>
<text top="427" left="177" width="3" height="15" font="1"> </text>
<text top="396" left="238" width="66" height="15" font="1">Propafenone </text>
<text top="412" left="238" width="35" height="15" font="1">(n=23) </text>
<text top="396" left="325" width="43" height="15" font="1">Placebo </text>
<text top="412" left="325" width="35" height="15" font="1">(n=23) </text>
<text top="396" left="413" width="32" height="15" font="1">PSVT </text>
<text top="412" left="413" width="35" height="15" font="1">(n=14) </text>
<text top="427" left="413" width="6" height="15" font="1">  </text>
<text top="443" left="413" width="25" height="15" font="1">PAF </text>
<text top="458" left="413" width="29" height="15" font="1">(n=9) </text>
<text top="396" left="541" width="71" height="15" font="1">Angina during </text>
<text top="412" left="541" width="63" height="15" font="1">tachycardia, </text>
<text top="427" left="541" width="95" height="15" font="1">pulmonary edema, </text>
<text top="443" left="541" width="54" height="15" font="1">neurologic </text>
<text top="458" left="541" width="26" height="15" font="1">sxs.  </text>
<text top="474" left="541" width="70" height="15" font="1">PAF w/ WPW </text>
<text top="489" left="541" width="102" height="15" font="1">syndrome, on AADs </text>
<text top="396" left="663" width="69" height="15" font="1">Compared w/ </text>
<text top="412" left="663" width="45" height="15" font="1">placebo, </text>
<text top="427" left="663" width="65" height="15" font="1">propafenone </text>
<text top="443" left="663" width="54" height="15" font="1">caused an </text>
<text top="458" left="663" width="57" height="15" font="1">increase in </text>
<text top="474" left="663" width="57" height="15" font="1">time to first </text>
<text top="489" left="663" width="68" height="15" font="1">recurrence of </text>
<text top="505" left="663" width="55" height="15" font="1">arrhythmia </text>
<text top="520" left="663" width="51" height="15" font="1">(p=0.004) </text>
<text top="535" left="663" width="3" height="15" font="1"> </text>
<text top="551" left="663" width="35" height="15" font="1">PSVT: </text>
<text top="567" left="663" width="37" height="15" font="1">p=0.03 </text>
<text top="582" left="663" width="3" height="15" font="1"> </text>
<text top="597" left="663" width="28" height="15" font="1">PAF: </text>
<text top="613" left="663" width="37" height="15" font="1">p=0.06 </text>
<text top="628" left="663" width="6" height="15" font="1">. </text>
<text top="396" left="751" width="65" height="15" font="1">Cardiac AEs </text>
<text top="412" left="751" width="81" height="15" font="1">occurred only in </text>
<text top="427" left="751" width="57" height="15" font="1">pts w/ PAF </text>
<text top="443" left="751" width="58" height="15" font="1">(9/11): 2 w/ </text>
<text top="458" left="751" width="52" height="15" font="1">prolonged </text>
<text top="474" left="751" width="74" height="15" font="1">episode of AF, </text>
<text top="489" left="751" width="81" height="15" font="1">1 w/ atrial flutter </text>
<text top="505" left="751" width="54" height="15" font="1">w/ a mean </text>
<text top="520" left="751" width="54" height="15" font="1">ventricular </text>
<text top="535" left="751" width="81" height="15" font="1">rate of 263 bpm </text>
<text top="551" left="751" width="76" height="15" font="1">recorded using </text>
<text top="567" left="751" width="70" height="15" font="1">the telephone </text>
<text top="582" left="751" width="43" height="15" font="1">monitor. </text>
<text top="396" left="845" width="22" height="15" font="1">N/A </text>
<text top="396" left="926" width="22" height="15" font="1">N/A </text>
<text top="396" left="1063" width="66" height="15" font="1">Propafenone </text>
<text top="412" left="1063" width="67" height="15" font="1">efficacious in </text>
<text top="427" left="1063" width="72" height="15" font="1">treating PSVT </text>
<text top="443" left="1063" width="49" height="15" font="1">and PAF. </text>
<text top="458" left="1063" width="3" height="15" font="1"> </text>
<text top="474" left="1063" width="31" height="15" font="1">Major </text>
<text top="489" left="1063" width="58" height="15" font="1">limitation in </text>
<text top="505" left="1063" width="62" height="15" font="1">not knowing </text>
<text top="520" left="1063" width="71" height="15" font="1">how many pts </text>
<text top="535" left="1063" width="68" height="15" font="1">had AVNRT.  </text>
<text top="551" left="1063" width="6" height="15" font="1">. </text>
<text top="753" left="54" width="45" height="15" font="1">Doughert</text>
<text top="769" left="54" width="27" height="15" font="1">y AH </text>
<text top="784" left="54" width="28" height="15" font="1">1992 </text>
<text top="753" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="769" left="116" width="21" height="15" font="1">and </text>
<text top="784" left="116" width="45" height="15" font="1">safety of </text>
<text top="753" left="177" width="15" height="15" font="1">87 </text>
<text top="769" left="177" width="3" height="15" font="1"> </text>
<text top="784" left="177" width="41" height="15" font="1">AVNRT </text>
<text top="753" left="238" width="49" height="15" font="1">Diltiazem </text>
<text top="769" left="238" width="3" height="15" font="1"> </text>
<text top="784" left="238" width="3" height="15" font="1"> </text>
<text top="753" left="325" width="43" height="15" font="1">Placebo </text>
<text top="753" left="413" width="106" height="15" font="1">Induction of PSVT w/ </text>
<text top="769" left="413" width="72" height="15" font="1">PES, required </text>
<text top="784" left="413" width="105" height="15" font="1">to have a rate of 120 </text>
<text top="753" left="541" width="69" height="15" font="1">Pts w/ severe </text>
<text top="769" left="541" width="84" height="15" font="1">congestive heart </text>
<text top="784" left="541" width="93" height="15" font="1">failure, sinus node </text>
<text top="753" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="769" left="663" width="66" height="15" font="1">sinus rhythm </text>
<text top="784" left="663" width="67" height="15" font="1">occurred in 4 </text>
<text top="753" left="751" width="22" height="15" font="1">N/A </text>
<text top="753" left="845" width="27" height="15" font="1">Most </text>
<text top="769" left="845" width="44" height="15" font="1">frequent </text>
<text top="784" left="845" width="42" height="15" font="1">adverse </text>
<text top="753" left="926" width="22" height="15" font="1">N/A </text>
<text top="753" left="1063" width="72" height="15" font="1">IV diltiazem in </text>
<text top="769" left="1063" width="73" height="15" font="1">doses of 0.15, </text>
<text top="784" left="1063" width="71" height="15" font="1">0.25 and 0.45 </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">44 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="29" height="15" font="1">(115) </text>
<text top="70" left="54" width="46" height="15" font="8">1510006 </text>
<text top="55" left="116" width="14" height="15" font="1">IV </text>
<text top="70" left="116" width="47" height="15" font="1">diltiazem </text>
<text top="55" left="177" width="35" height="15" font="1">(n=25) </text>
<text top="70" left="177" width="33" height="15" font="1">AVRT </text>
<text top="86" left="177" width="35" height="15" font="1">(n=60) </text>
<text top="101" left="177" width="46" height="15" font="1">AT (n=2) </text>
<text top="117" left="177" width="3" height="15" font="1"> </text>
<text top="55" left="413" width="110" height="15" font="1">bpm and to persist for </text>
<text top="70" left="413" width="46" height="15" font="1">115 min. </text>
<text top="55" left="541" width="62" height="15" font="1">dysfunction, </text>
<text top="70" left="541" width="58" height="15" font="1">pregnancy, </text>
<text top="86" left="541" width="57" height="15" font="1">myocardial </text>
<text top="101" left="541" width="97" height="15" font="1">infarction w/in 2 wk </text>
<text top="117" left="541" width="58" height="15" font="1">of study, or </text>
<text top="132" left="541" width="92" height="15" font="1">hypotension (SBP </text>
<text top="147" left="541" width="64" height="15" font="1">&lt;90 mm Hg) </text>
<text top="55" left="663" width="45" height="15" font="1">of 14 pts </text>
<text top="70" left="663" width="71" height="15" font="1">(29%) w/ 0.05 </text>
<text top="86" left="663" width="46" height="15" font="1">mg/kg of </text>
<text top="101" left="663" width="65" height="15" font="1">diltiazem, 16 </text>
<text top="117" left="663" width="74" height="15" font="1">of 19 (84%) w/ </text>
<text top="132" left="663" width="61" height="15" font="1">0.15 mg/kg, </text>
<text top="147" left="663" width="43" height="15" font="1">13 of 13 </text>
<text top="163" left="663" width="53" height="15" font="1">(100%) w/ </text>
<text top="178" left="663" width="61" height="15" font="1">0.25 mg/kg, </text>
<text top="194" left="663" width="65" height="15" font="1">and 14 of 17 </text>
<text top="210" left="663" width="71" height="15" font="1">(82%) w/ 0.45 </text>
<text top="225" left="663" width="33" height="15" font="1">mg/kg </text>
<text top="240" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="256" left="663" width="70" height="15" font="1">6 of 24 (25%) </text>
<text top="271" left="663" width="52" height="15" font="1">treated w/ </text>
<text top="287" left="663" width="48" height="15" font="1">placebo.  </text>
<text top="302" left="663" width="3" height="15" font="1"> </text>
<text top="318" left="663" width="59" height="15" font="1">Conversion </text>
<text top="333" left="663" width="39" height="15" font="1">rates in </text>
<text top="349" left="663" width="37" height="15" font="1">groups </text>
<text top="364" left="663" width="47" height="15" font="1">receiving </text>
<text top="380" left="663" width="70" height="15" font="1">doses of 0.15 </text>
<text top="395" left="663" width="70" height="15" font="1">to 0.45 mg/kg </text>
<text top="411" left="663" width="59" height="15" font="1">of diltiazem </text>
<text top="426" left="663" width="70" height="15" font="1">were superior </text>
<text top="442" left="663" width="64" height="15" font="1">to that in the </text>
<text top="457" left="663" width="73" height="15" font="1">placebo group </text>
<text top="473" left="663" width="57" height="15" font="1">(p&lt;0.001).  </text>
<text top="488" left="663" width="3" height="15" font="1"> </text>
<text top="504" left="663" width="40" height="15" font="1">Time to </text>
<text top="519" left="663" width="57" height="15" font="1">conversion </text>
<text top="535" left="663" width="64" height="15" font="1">was 3.0±2.6 </text>
<text top="550" left="663" width="33" height="15" font="1">min in </text>
<text top="566" left="663" width="58" height="15" font="1">responding </text>
<text top="581" left="663" width="65" height="15" font="1">diltiazem pts </text>
<text top="597" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="612" left="663" width="74" height="15" font="1">5.9±6.1 min in </text>
<text top="628" left="663" width="58" height="15" font="1">responding </text>
<text top="643" left="663" width="57" height="15" font="1">control pts. </text>
<text top="55" left="845" width="61" height="15" font="1">response to </text>
<text top="70" left="845" width="47" height="15" font="1">diltiazem </text>
<text top="86" left="845" width="23" height="15" font="1">was </text>
<text top="101" left="845" width="63" height="15" font="1">hypotension </text>
<text top="117" left="845" width="65" height="15" font="1">(7 of 63 pts); </text>
<text top="132" left="845" width="48" height="15" font="1">however, </text>
<text top="148" left="845" width="50" height="15" font="1">only 4 pts </text>
<text top="163" left="845" width="41" height="15" font="1">had sxs </text>
<text top="178" left="845" width="49" height="15" font="1">related to </text>
<text top="194" left="845" width="66" height="15" font="1">hypotension. </text>
<text top="55" left="1063" width="44" height="15" font="1">mg/kg is </text>
<text top="70" left="1063" width="66" height="15" font="1">effective and </text>
<text top="86" left="1063" width="70" height="15" font="1">safe for acute </text>
<text top="101" left="1063" width="68" height="15" font="1">management </text>
<text top="117" left="1063" width="47" height="15" font="1">of PSVT. </text>
<text top="659" left="54" width="41" height="15" font="1">Anderso</text>
<text top="675" left="54" width="24" height="15" font="1">n JL </text>
<text top="690" left="54" width="28" height="15" font="1">1994 </text>
<text top="706" left="54" width="23" height="15" font="1">(29) </text>
<text top="721" left="54" width="49" height="15" font="8">8074041  </text>
<text top="737" left="54" width="3" height="15" font="1"> </text>
<text top="659" left="116" width="28" height="15" font="1">Long-</text>
<text top="675" left="116" width="25" height="15" font="1">term </text>
<text top="690" left="116" width="41" height="15" font="1">efficacy </text>
<text top="706" left="116" width="12" height="15" font="1">of </text>
<text top="721" left="116" width="41" height="15" font="1">flecainid</text>
<text top="737" left="116" width="29" height="15" font="1">e (≥6 </text>
<text top="752" left="116" width="22" height="15" font="1">mo) </text>
<text top="659" left="177" width="15" height="15" font="1">49 </text>
<text top="675" left="177" width="3" height="15" font="1"> </text>
<text top="690" left="177" width="32" height="15" font="1">PSVT </text>
<text top="706" left="177" width="35" height="15" font="1">(n=21) </text>
<text top="721" left="177" width="3" height="15" font="1"> </text>
<text top="737" left="177" width="25" height="15" font="1">PAF </text>
<text top="752" left="177" width="35" height="15" font="1">(n=28) </text>
<text top="768" left="177" width="3" height="15" font="1"> </text>
<text top="659" left="238" width="54" height="15" font="1">Flecainide </text>
<text top="675" left="238" width="3" height="15" font="1"> </text>
<text top="690" left="238" width="3" height="15" font="1"> </text>
<text top="659" left="325" width="43" height="15" font="1">Placebo </text>
<text top="659" left="413" width="96" height="15" font="1">Pts enrolled from 3 </text>
<text top="675" left="413" width="63" height="15" font="1">prior studies </text>
<text top="690" left="413" width="107" height="15" font="1">evaluating short-term </text>
<text top="706" left="413" width="103" height="15" font="1">flecainide efficacy (2 </text>
<text top="721" left="413" width="101" height="15" font="1">above, Pritchett and </text>
<text top="737" left="413" width="78" height="15" font="1">Henthorn—one </text>
<text top="752" left="413" width="110" height="15" font="1">[Anderson, 1989]) not </text>
<text top="768" left="413" width="103" height="15" font="1">tabulated above due </text>
<text top="783" left="413" width="61" height="15" font="1">to PAF-only </text>
<text top="659" left="541" width="102" height="15" font="1">Syncope, angina, or </text>
<text top="675" left="541" width="89" height="15" font="1">transient cerebral </text>
<text top="690" left="541" width="108" height="15" font="1">events during PSVT,  </text>
<text top="706" left="541" width="76" height="15" font="1">second or third </text>
<text top="721" left="541" width="97" height="15" font="1">degree AV block or </text>
<text top="737" left="541" width="98" height="15" font="1">had CHF (NYHA III-</text>
<text top="752" left="541" width="23" height="15" font="1">IV)   </text>
<text top="659" left="663" width="58" height="15" font="1">-Number of </text>
<text top="675" left="663" width="38" height="15" font="1">pts w/o </text>
<text top="690" left="663" width="38" height="15" font="1">attacks </text>
<text top="706" left="663" width="65" height="15" font="1">-Time to first </text>
<text top="721" left="663" width="33" height="15" font="1">attack </text>
<text top="737" left="663" width="43" height="15" font="1">-Interval </text>
<text top="752" left="663" width="45" height="15" font="1">between </text>
<text top="768" left="663" width="38" height="15" font="1">attacks </text>
<text top="783" left="663" width="48" height="15" font="1">-Average </text>
<text top="659" left="751" width="29" height="15" font="1">No pt </text>
<text top="675" left="751" width="63" height="15" font="1">experienced </text>
<text top="690" left="751" width="74" height="15" font="1">proarrhythmia, </text>
<text top="706" left="751" width="55" height="15" font="1">MI, or died </text>
<text top="721" left="751" width="73" height="15" font="1">during chronic </text>
<text top="737" left="751" width="73" height="15" font="1">efficacy study. </text>
<text top="659" left="845" width="22" height="15" font="1">N/A </text>
<text top="659" left="926" width="22" height="15" font="1">N/A </text>
<text top="659" left="1063" width="47" height="15" font="1">Supports </text>
<text top="675" left="1063" width="66" height="15" font="1">flecainide for </text>
<text top="690" left="1063" width="39" height="15" font="1">chronic </text>
<text top="706" left="1063" width="52" height="15" font="1">therapy of </text>
<text top="721" left="1063" width="35" height="15" font="1">PSVT. </text>
<text top="737" left="1063" width="3" height="15" font="1"> </text>
<text top="752" left="1063" width="31" height="15" font="1">Small </text>
<text top="768" left="1063" width="58" height="15" font="1">numbers of </text>
<text top="783" left="1063" width="67" height="15" font="1">pts w/ PSVT, </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">45 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="413" width="58" height="15" font="1">population) </text>
<text top="55" left="663" width="64" height="15" font="1">frequency of </text>
<text top="70" left="663" width="41" height="15" font="1">attacks, </text>
<text top="86" left="663" width="60" height="15" font="1">-Ventricular </text>
<text top="101" left="663" width="56" height="15" font="1">rate during </text>
<text top="117" left="663" width="41" height="15" font="1">attacks. </text>
<text top="132" left="663" width="3" height="15" font="1"> </text>
<text top="147" left="663" width="53" height="15" font="1">PSVT pts: </text>
<text top="163" left="663" width="3" height="15" font="1"> </text>
<text top="178" left="663" width="71" height="15" font="1">Of 17 efficacy </text>
<text top="194" left="663" width="71" height="15" font="1">evaluable pts, </text>
<text top="210" left="663" width="69" height="15" font="1">14 (82%) had </text>
<text top="225" left="663" width="40" height="15" font="1">no SVT </text>
<text top="240" left="663" width="72" height="15" font="1">attacks during </text>
<text top="256" left="663" width="57" height="15" font="1">the chronic </text>
<text top="271" left="663" width="70" height="15" font="1">efficacy study </text>
<text top="287" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="302" left="663" width="71" height="15" font="1">4 (24%) w/ no </text>
<text top="318" left="663" width="72" height="15" font="1">attacks during </text>
<text top="333" left="663" width="42" height="15" font="1">placebo </text>
<text top="349" left="663" width="52" height="15" font="1">therapy at </text>
<text top="364" left="663" width="44" height="15" font="1">baseline </text>
<text top="380" left="663" width="54" height="15" font="1">(p=0.013). </text>
<text top="395" left="663" width="3" height="15" font="1"> </text>
<text top="411" left="663" width="61" height="15" font="1">Time to first </text>
<text top="426" left="663" width="55" height="15" font="1">arrhythmia </text>
<text top="442" left="663" width="54" height="15" font="1">attack and </text>
<text top="457" left="663" width="69" height="15" font="1">time between </text>
<text top="473" left="663" width="38" height="15" font="1">attacks </text>
<text top="488" left="663" width="51" height="15" font="1">increased </text>
<text top="504" left="663" width="73" height="15" font="1">during chronic </text>
<text top="519" left="663" width="54" height="15" font="1">therapy w/ </text>
<text top="535" left="663" width="50" height="15" font="1">flecainide </text>
<text top="550" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="566" left="663" width="42" height="15" font="1">placebo </text>
<text top="581" left="663" width="50" height="15" font="1">treatment </text>
<text top="597" left="663" width="69" height="15" font="1">(p=0.008 and </text>
<text top="612" left="663" width="46" height="15" font="1">p=0.012, </text>
<text top="628" left="663" width="65" height="15" font="1">respectively) </text>
<text top="643" left="663" width="3" height="15" font="1"> </text>
<text top="659" left="663" width="44" height="15" font="1">Rates of </text>
<text top="674" left="663" width="60" height="15" font="1">attack/d not </text>
<text top="690" left="663" width="60" height="15" font="1">significantly </text>
<text top="705" left="663" width="43" height="15" font="1">different </text>
<text top="721" left="663" width="51" height="15" font="1">(p=0.130) </text>
<text top="736" left="663" width="3" height="15" font="1"> </text>
<text top="752" left="663" width="67" height="15" font="1">No PSVT pts </text>
<text top="767" left="663" width="68" height="15" font="1">w/ ventricular </text>
<text top="783" left="663" width="61" height="15" font="1">arrhythmias </text>
<text top="55" left="1063" width="72" height="15" font="1">and PSVT not </text>
<text top="70" left="1063" width="57" height="15" font="1">specifically </text>
<text top="86" left="1063" width="42" height="15" font="1">defined. </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">46 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="44" height="15" font="1">Chimient</text>
<text top="70" left="54" width="18" height="15" font="1">i M </text>
<text top="86" left="54" width="28" height="15" font="1">1995 </text>
<text top="101" left="54" width="23" height="15" font="1">(30) </text>
<text top="117" left="54" width="46" height="15" font="8">8682031 </text>
<text top="132" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="116" width="39" height="15" font="1">Compar</text>
<text top="70" left="116" width="28" height="15" font="1">e the </text>
<text top="86" left="116" width="25" height="15" font="1">long-</text>
<text top="101" left="116" width="25" height="15" font="1">term </text>
<text top="117" left="116" width="45" height="15" font="1">safety of </text>
<text top="132" left="116" width="41" height="15" font="1">flecainid</text>
<text top="147" left="116" width="31" height="15" font="1">e and </text>
<text top="163" left="116" width="44" height="15" font="1">propafen</text>
<text top="178" left="116" width="22" height="15" font="1">one </text>
<text top="55" left="177" width="22" height="15" font="1">335 </text>
<text top="70" left="177" width="3" height="15" font="1"> </text>
<text top="86" left="177" width="3" height="15" font="1"> </text>
<text top="55" left="238" width="44" height="15" font="1">AVNRT: </text>
<text top="70" left="238" width="71" height="15" font="1">flecainide 100 </text>
<text top="86" left="238" width="63" height="15" font="1">mg (n = 72)  </text>
<text top="101" left="238" width="3" height="15" font="1"> </text>
<text top="117" left="238" width="28" height="15" font="1">PAF: </text>
<text top="132" left="238" width="71" height="15" font="1">flecainide 200 </text>
<text top="147" left="238" width="63" height="15" font="1">mg (n = 97)  </text>
<text top="55" left="325" width="44" height="15" font="1">AVNRT: </text>
<text top="70" left="325" width="65" height="15" font="1">propafenone </text>
<text top="86" left="325" width="40" height="15" font="1">450 mg </text>
<text top="101" left="325" width="35" height="15" font="1">(n=63) </text>
<text top="117" left="325" width="3" height="15" font="1"> </text>
<text top="132" left="325" width="28" height="15" font="1">PAF: </text>
<text top="147" left="325" width="65" height="15" font="1">propafenone </text>
<text top="163" left="325" width="40" height="15" font="1">450 mg </text>
<text top="178" left="325" width="45" height="15" font="1">(n=103). </text>
<text top="55" left="413" width="25" height="15" font="1">PAF </text>
<text top="70" left="413" width="39" height="15" font="1">(n-200) </text>
<text top="86" left="413" width="3" height="15" font="1"> </text>
<text top="101" left="413" width="41" height="15" font="1">AVNRT </text>
<text top="117" left="413" width="41" height="15" font="1">(n=135) </text>
<text top="55" left="541" width="83" height="15" font="1">LVEF &lt;35%, AV </text>
<text top="70" left="541" width="87" height="15" font="1">block, QRS &gt;140 </text>
<text top="86" left="541" width="61" height="15" font="1">msec, SSS, </text>
<text top="101" left="541" width="68" height="15" font="1">persistent AF </text>
<text top="117" left="541" width="106" height="15" font="1">(episodes &gt;72 h), VT </text>
<text top="132" left="541" width="100" height="15" font="1">(episodes &gt;30 sec), </text>
<text top="147" left="541" width="63" height="15" font="1">NYHA III-IV, </text>
<text top="163" left="541" width="74" height="15" font="1">ischemic heart </text>
<text top="178" left="541" width="108" height="15" font="1">disease, hypertrophic </text>
<text top="194" left="541" width="84" height="15" font="1">cardiomyopathy, </text>
<text top="210" left="541" width="107" height="15" font="1">hypotension, valvular </text>
<text top="225" left="541" width="44" height="15" font="1">disease, </text>
<text top="240" left="541" width="66" height="15" font="1">renal/hepatic </text>
<text top="256" left="541" width="103" height="15" font="1">insufficiency, thyroid </text>
<text top="271" left="541" width="76" height="15" font="1">disease, AADs </text>
<text top="55" left="663" width="63" height="15" font="1">ITT analysis </text>
<text top="70" left="663" width="35" height="15" font="1">PSVT: </text>
<text top="86" left="663" width="41" height="15" font="1">93% for </text>
<text top="101" left="663" width="71" height="15" font="1">flecainide and </text>
<text top="117" left="663" width="41" height="15" font="1">86% for </text>
<text top="132" left="663" width="65" height="15" font="1">propafenone </text>
<text top="147" left="663" width="45" height="15" font="1">(p=0.24) </text>
<text top="163" left="663" width="3" height="15" font="1"> </text>
<text top="178" left="663" width="28" height="15" font="1">PAF: </text>
<text top="194" left="663" width="41" height="15" font="1">77% for </text>
<text top="210" left="663" width="71" height="15" font="1">flecainide and </text>
<text top="225" left="663" width="41" height="15" font="1">75% for </text>
<text top="240" left="663" width="65" height="15" font="1">propafenone </text>
<text top="256" left="663" width="45" height="15" font="1">(p=0.72) </text>
<text top="55" left="751" width="49" height="15" font="1">12 pts on </text>
<text top="70" left="751" width="50" height="15" font="1">flecainide </text>
<text top="86" left="751" width="60" height="15" font="1">reported 16 </text>
<text top="101" left="751" width="77" height="15" font="1">cardiac AEs, of </text>
<text top="117" left="751" width="49" height="15" font="1">whom six </text>
<text top="132" left="751" width="65" height="15" font="1">discontinued </text>
<text top="147" left="751" width="74" height="15" font="1">the treatment.  </text>
<text top="163" left="751" width="3" height="15" font="1"> </text>
<text top="178" left="751" width="74" height="15" font="1">7 propafenone </text>
<text top="194" left="751" width="49" height="15" font="1">pts had 8 </text>
<text top="210" left="751" width="77" height="15" font="1">cardiac AEs, of </text>
<text top="225" left="751" width="42" height="15" font="1">whom 5 </text>
<text top="240" left="751" width="65" height="15" font="1">discontinued </text>
<text top="256" left="751" width="71" height="15" font="1">the treatment. </text>
<text top="271" left="751" width="69" height="15" font="1">(1 case of VT </text>
<text top="287" left="751" width="81" height="15" font="1">on propafenone </text>
<text top="302" left="751" width="3" height="15" font="1"> </text>
<text top="318" left="751" width="71" height="15" font="1">2 cases of AF </text>
<text top="333" left="751" width="42" height="15" font="1">w/ rapid </text>
<text top="349" left="751" width="54" height="15" font="1">ventricular </text>
<text top="364" left="751" width="64" height="15" font="1">response on </text>
<text top="380" left="751" width="50" height="15" font="1">flecainide </text>
<text top="55" left="845" width="22" height="15" font="1">N/A </text>
<text top="55" left="926" width="22" height="15" font="1">N/A </text>
<text top="55" left="1063" width="26" height="15" font="1">Both </text>
<text top="70" left="1063" width="71" height="15" font="1">flecainide and </text>
<text top="86" left="1063" width="65" height="15" font="1">propafenone </text>
<text top="101" left="1063" width="63" height="15" font="1">were safe in </text>
<text top="117" left="1063" width="68" height="15" font="1">the long-term </text>
<text top="132" left="1063" width="62" height="15" font="1">treatment of </text>
<text top="147" left="1063" width="67" height="15" font="1">pts w/ PSVT. </text>
<text top="163" left="1063" width="3" height="15" font="1"> </text>
<text top="178" left="1063" width="72" height="15" font="1">Limited in that </text>
<text top="194" left="1063" width="70" height="15" font="1">only one-third </text>
<text top="210" left="1063" width="44" height="15" font="1">of pts w/ </text>
<text top="225" left="1063" width="47" height="15" font="1">AVNRT.  </text>
<text top="396" left="54" width="18" height="15" font="1">UK </text>
<text top="412" left="54" width="45" height="15" font="1">Propafen</text>
<text top="427" left="54" width="21" height="15" font="1">one </text>
<text top="443" left="54" width="32" height="15" font="1">PSVT </text>
<text top="458" left="54" width="31" height="15" font="1">Study </text>
<text top="474" left="54" width="34" height="15" font="1">Group </text>
<text top="489" left="54" width="28" height="15" font="1">1995 </text>
<text top="505" left="54" width="23" height="15" font="1">(31) </text>
<text top="520" left="54" width="46" height="15" font="8">7586356 </text>
<text top="535" left="54" width="3" height="15" font="1"> </text>
<text top="396" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="412" left="116" width="21" height="15" font="1">and </text>
<text top="427" left="116" width="44" height="15" font="1">tolerabilit</text>
<text top="443" left="116" width="21" height="15" font="1">y of </text>
<text top="458" left="116" width="44" height="15" font="1">propafen</text>
<text top="474" left="116" width="34" height="15" font="1">one at </text>
<text top="489" left="116" width="43" height="15" font="1">600 and </text>
<text top="505" left="116" width="40" height="15" font="1">900 mg </text>
<text top="520" left="116" width="26" height="15" font="1">daily </text>
<text top="535" left="116" width="33" height="15" font="1">doses </text>
<text top="551" left="116" width="33" height="15" font="1">(given </text>
<text top="567" left="116" width="28" height="15" font="1">twice </text>
<text top="582" left="116" width="33" height="15" font="1">daily). </text>
<text top="597" left="116" width="3" height="15" font="1"> </text>
<text top="613" left="116" width="9" height="15" font="1">2 </text>
<text top="628" left="116" width="44" height="15" font="1">consecut</text>
<text top="644" left="116" width="17" height="15" font="1">ive </text>
<text top="659" left="116" width="44" height="15" font="1">crossove</text>
<text top="675" left="116" width="46" height="15" font="1">r periods </text>
<text top="396" left="177" width="22" height="15" font="1">100 </text>
<text top="412" left="177" width="3" height="15" font="1"> </text>
<text top="427" left="177" width="3" height="15" font="1"> </text>
<text top="396" left="238" width="66" height="15" font="1">Propafenone </text>
<text top="412" left="238" width="58" height="15" font="1">300 mg bid </text>
<text top="427" left="238" width="3" height="15" font="1"> </text>
<text top="443" left="238" width="66" height="15" font="1">Propafenone </text>
<text top="458" left="238" width="55" height="15" font="1">300 mg tid </text>
<text top="396" left="325" width="120" height="15" font="1">Placebo PSVT </text>
<text top="412" left="413" width="39" height="15" font="1">(n=52)  </text>
<text top="427" left="413" width="3" height="15" font="1"> </text>
<text top="443" left="413" width="25" height="15" font="1">PAF </text>
<text top="458" left="413" width="39" height="15" font="1">(n=48)  </text>
<text top="474" left="413" width="3" height="15" font="1"> </text>
<text top="489" left="413" width="92" height="15" font="1">75 pts in low-dose </text>
<text top="505" left="413" width="36" height="15" font="1">phase: </text>
<text top="520" left="413" width="90" height="15" font="1">45 PSVT, 30 PAF </text>
<text top="535" left="413" width="3" height="15" font="1"> </text>
<text top="551" left="413" width="97" height="15" font="1">59 pts advanced to </text>
<text top="567" left="413" width="88" height="15" font="1">high-dose phase: </text>
<text top="582" left="413" width="93" height="15" font="1">34 PSVT, 25 PAF  </text>
<text top="597" left="413" width="3" height="15" font="1"> </text>
<text top="613" left="413" width="82" height="15" font="1">≥2 symptomatic </text>
<text top="628" left="413" width="62" height="15" font="1">episodes by </text>
<text top="644" left="413" width="78" height="15" font="1">transtelephonic </text>
<text top="659" left="413" width="52" height="15" font="1">monitoring</text>
<text top="659" left="465" width="6" height="15" font="14">  </text>
<text top="675" left="413" width="3" height="15" font="1"> </text>
<text top="396" left="541" width="46" height="15" font="14">PSVT w/ </text>
<text top="412" left="541" width="72" height="15" font="14">hemodynamic </text>
<text top="427" left="541" width="78" height="15" font="14">collapse, LVEF </text>
<text top="443" left="541" width="98" height="15" font="14">≤25%, recent MI or </text>
<text top="458" left="541" width="84" height="15" font="14">unstable angina; </text>
<text top="474" left="541" width="103" height="15" font="14">hepatic/renal failure, </text>
<text top="489" left="541" width="78" height="15" font="14">SSS, AV block, </text>
<text top="505" left="541" width="101" height="15" font="14">AADs, female pts of </text>
<text top="520" left="541" width="63" height="15" font="14">childbearing </text>
<text top="535" left="541" width="86" height="15" font="14">potential, COPD, </text>
<text top="551" left="541" width="92" height="15" font="14">myasthenia gravis.</text>
<text top="551" left="634" width="3" height="15" font="1"> </text>
<text top="396" left="663" width="60" height="15" font="1">Placebo vs. </text>
<text top="412" left="663" width="68" height="15" font="1">propafenone: </text>
<text top="427" left="663" width="3" height="15" font="1"> </text>
<text top="443" left="663" width="72" height="15" font="1">Relative risks, </text>
<text top="458" left="663" width="55" height="15" font="1">PSVT, low-</text>
<text top="474" left="663" width="30" height="15" font="1">dose: </text>
<text top="489" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="505" left="663" width="69" height="15" font="1">recurrence or </text>
<text top="520" left="663" width="18" height="15" font="1">AE </text>
<text top="535" left="663" width="65" height="15" font="1">6.8 (95% CI: </text>
<text top="551" left="663" width="47" height="15" font="1">2.2-21.2; </text>
<text top="567" left="663" width="47" height="15" font="1">p&lt;0.001) </text>
<text top="582" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="598" left="663" width="56" height="15" font="1">recurrence </text>
<text top="613" left="663" width="65" height="15" font="1">7.4 (95% CI: </text>
<text top="628" left="663" width="47" height="15" font="1">2.3-23.3; </text>
<text top="644" left="663" width="47" height="15" font="1">p&lt;0.001) </text>
<text top="659" left="663" width="3" height="15" font="1"> </text>
<text top="675" left="663" width="72" height="15" font="1">Relative risks, </text>
<text top="690" left="663" width="60" height="15" font="1">PSVT, high-</text>
<text top="706" left="663" width="30" height="15" font="1">dose: </text>
<text top="721" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="737" left="663" width="69" height="15" font="1">recurrence or </text>
<text top="752" left="663" width="18" height="15" font="1">AE </text>
<text top="768" left="663" width="65" height="15" font="1">2.2 (95% CI: </text>
<text top="783" left="663" width="41" height="15" font="1">0.9-5.3; </text>
<text top="396" left="751" width="46" height="15" font="14">More pts </text>
<text top="412" left="751" width="63" height="15" font="14">experienced </text>
<text top="427" left="751" width="71" height="15" font="14">more adverse </text>
<text top="443" left="751" width="69" height="15" font="14">events during </text>
<text top="458" left="751" width="65" height="15" font="14">propafenone </text>
<text top="474" left="751" width="69" height="15" font="14">(900 mg&gt;600 </text>
<text top="489" left="751" width="52" height="15" font="14">mg). Most </text>
<text top="505" left="751" width="45" height="15" font="14">common </text>
<text top="520" left="751" width="78" height="15" font="14">adverse events </text>
<text top="535" left="751" width="66" height="15" font="14">during PSVT </text>
<text top="551" left="751" width="46" height="15" font="14">and PAF </text>
<text top="567" left="751" width="64" height="15" font="14">groups were </text>
<text top="582" left="751" width="68" height="15" font="14">related to the </text>
<text top="598" left="751" width="77" height="15" font="14">gastrointestinal </text>
<text top="613" left="751" width="21" height="15" font="14">and </text>
<text top="628" left="751" width="75" height="15" font="14">neuropsychiatri</text>
<text top="644" left="751" width="55" height="15" font="14">c systems. </text>
<text top="659" left="751" width="74" height="15" font="14">Total numbers </text>
<text top="675" left="751" width="55" height="15" font="14">of adverse </text>
<text top="690" left="751" width="51" height="15" font="14">events on </text>
<text top="706" left="751" width="65" height="15" font="14">propafenone </text>
<text top="721" left="751" width="79" height="15" font="14">were 46 and 56 </text>
<text top="737" left="751" width="77" height="15" font="14">in the low-dose </text>
<text top="752" left="751" width="73" height="15" font="14">and high-dose </text>
<text top="768" left="751" width="63" height="15" font="14">PSVT group </text>
<text top="783" left="751" width="74" height="15" font="14">and 67 and 74 </text>
<text top="396" left="845" width="63" height="15" font="1">1 episode of </text>
<text top="412" left="845" width="26" height="15" font="1">wide-</text>
<text top="427" left="845" width="44" height="15" font="1">complex </text>
<text top="443" left="845" width="60" height="15" font="1">tachycardia </text>
<text top="458" left="845" width="23" height="15" font="1">was </text>
<text top="474" left="845" width="64" height="15" font="1">documented </text>
<text top="489" left="845" width="34" height="15" font="1">during </text>
<text top="505" left="845" width="65" height="15" font="1">propafenone </text>
<text top="520" left="845" width="40" height="15" font="1">therapy </text>
<text top="396" left="926" width="22" height="15" font="1">N/A </text>
<text top="396" left="1063" width="66" height="15" font="1">Propafenone </text>
<text top="412" left="1063" width="63" height="15" font="1">at 600 mg is </text>
<text top="427" left="1063" width="66" height="15" font="1">effective and </text>
<text top="443" left="1063" width="71" height="15" font="1">well tolerated. </text>
<text top="458" left="1063" width="69" height="15" font="1">A larger dose </text>
<text top="474" left="1063" width="52" height="15" font="1">of 900 mg </text>
<text top="489" left="1063" width="66" height="15" font="1">causes more </text>
<text top="505" left="1063" width="42" height="15" font="1">adverse </text>
<text top="520" left="1063" width="54" height="15" font="1">effects but </text>
<text top="535" left="1063" width="68" height="15" font="1">may be more </text>
<text top="551" left="1063" width="56" height="15" font="1">effective in </text>
<text top="567" left="1063" width="53" height="15" font="1">those who </text>
<text top="582" left="1063" width="73" height="15" font="1">can tolerate it. </text>
<text top="597" left="1063" width="3" height="15" font="1"> </text>
<text top="613" left="1063" width="55" height="15" font="1">Sequential </text>
<text top="628" left="1063" width="58" height="15" font="1">design (not </text>
<text top="644" left="1063" width="61" height="15" font="1">randomized </text>
<text top="659" left="1063" width="73" height="15" font="1">after low-dose </text>
<text top="675" left="1063" width="52" height="15" font="1">phase) so </text>
<text top="690" left="1063" width="65" height="15" font="1">population is </text>
<text top="706" left="1063" width="18" height="15" font="1">not </text>
<text top="721" left="1063" width="69" height="15" font="1">generalizable </text>
<text top="737" left="1063" width="52" height="15" font="1">at 900 mg </text>
<text top="752" left="1063" width="33" height="15" font="1">dose.  </text>
<text top="768" left="1063" width="3" height="15" font="1"> </text>
<text top="783" left="1063" width="66" height="15" font="1">Not powered </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">47 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="35" height="15" font="1">p=NS) </text>
<text top="70" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="86" left="663" width="56" height="15" font="1">recurrence </text>
<text top="101" left="663" width="71" height="15" font="1">15.0 (95% CI: </text>
<text top="117" left="663" width="44" height="15" font="1">2.0-113; </text>
<text top="132" left="663" width="47" height="15" font="1">p=0.009) </text>
<text top="147" left="663" width="3" height="15" font="1"> </text>
<text top="55" left="751" width="77" height="15" font="14">in the low-dose </text>
<text top="70" left="751" width="73" height="15" font="14">and high-dose </text>
<text top="86" left="751" width="65" height="15" font="14">PAF groups, </text>
<text top="101" left="751" width="61" height="15" font="14">respectively.</text>
<text top="101" left="812" width="3" height="15" font="1"> </text>
<text top="55" left="1063" width="64" height="15" font="1">for mortality. </text>
<text top="70" left="1063" width="3" height="15" font="1"> </text>
<text top="86" left="1063" width="72" height="15" font="1">Limited in that </text>
<text top="101" left="1063" width="38" height="15" font="1">PSVTs </text>
<text top="117" left="1063" width="44" height="15" font="1">included </text>
<text top="132" left="1063" width="64" height="15" font="1">AVNRT, AT, </text>
<text top="147" left="1063" width="49" height="15" font="1">or AVRT. </text>
<text top="164" left="54" width="46" height="15" font="1">Wanless </text>
<text top="179" left="54" width="18" height="15" font="1">RS </text>
<text top="195" left="54" width="28" height="15" font="1">1997 </text>
<text top="210" left="54" width="23" height="15" font="1">(33) </text>
<text top="226" left="54" width="49" height="15" font="8">9124166  </text>
<text top="241" left="54" width="3" height="15" font="1"> </text>
<text top="164" left="116" width="37" height="15" font="1">Sotalol </text>
<text top="179" left="116" width="12" height="15" font="1">in </text>
<text top="195" left="116" width="44" height="15" font="1">treatmen</text>
<text top="210" left="116" width="18" height="15" font="1">t of </text>
<text top="226" left="116" width="32" height="15" font="1">PSVT </text>
<text top="164" left="177" width="25" height="15" font="1">126  </text>
<text top="164" left="238" width="71" height="15" font="1">Sotalol 80 mg </text>
<text top="179" left="238" width="35" height="15" font="1">(n=35) </text>
<text top="195" left="238" width="73" height="15" font="1">AVNRT (23%) </text>
<text top="210" left="238" width="3" height="15" font="1"> </text>
<text top="226" left="238" width="59" height="15" font="1">Sotalol 160 </text>
<text top="241" left="238" width="18" height="15" font="1">mg </text>
<text top="257" left="238" width="35" height="15" font="1">(n=46) </text>
<text top="272" left="238" width="73" height="15" font="1">AVNRT (22%) </text>
<text top="164" left="325" width="43" height="15" font="1">Placebo </text>
<text top="179" left="325" width="35" height="15" font="1">(n=45) </text>
<text top="195" left="325" width="73" height="15" font="1">AVNRT (24%) </text>
<text top="164" left="413" width="52" height="15" font="1">Recurrent </text>
<text top="179" left="413" width="97" height="15" font="1">symptomatic PSVT </text>
<text top="195" left="413" width="80" height="15" font="1">were eligible for </text>
<text top="210" left="413" width="61" height="15" font="1">enrollment.  </text>
<text top="226" left="413" width="3" height="15" font="1"> </text>
<text top="241" left="413" width="41" height="15" font="1">AVNRT </text>
<text top="257" left="413" width="25" height="15" font="1">PAF </text>
<text top="272" left="413" width="88" height="15" font="1">Paroxysmal atrial </text>
<text top="288" left="413" width="31" height="15" font="1">flutter </text>
<text top="303" left="413" width="33" height="15" font="1">AVRT </text>
<text top="319" left="413" width="81" height="15" font="1">Paroxysmal AT  </text>
<text top="164" left="541" width="84" height="15" font="1">Decompensated </text>
<text top="179" left="541" width="71" height="15" font="1">CHF, asthma, </text>
<text top="195" left="541" width="95" height="15" font="1">chronic obstructive </text>
<text top="210" left="541" width="85" height="15" font="1">airways disease, </text>
<text top="226" left="541" width="89" height="15" font="1">second degree or </text>
<text top="241" left="541" width="80" height="15" font="1">third degree AV </text>
<text top="257" left="541" width="66" height="15" font="1">block, recent </text>
<text top="272" left="541" width="105" height="15" font="1">myocardial infarction </text>
<text top="288" left="541" width="78" height="15" font="1">(&lt;1 mo), recent </text>
<text top="303" left="541" width="78" height="15" font="1">coronary artery </text>
<text top="319" left="541" width="103" height="15" font="1">bypass graft surgery </text>
<text top="334" left="541" width="89" height="15" font="1">(&lt;2 mo), unstable </text>
<text top="350" left="541" width="81" height="15" font="1">angina pectoris, </text>
<text top="365" left="541" width="86" height="15" font="1">bradycardia (&lt;50 </text>
<text top="381" left="541" width="60" height="15" font="1">bpm), SSS, </text>
<text top="396" left="541" width="76" height="15" font="1">prolonged QTc </text>
<text top="412" left="541" width="101" height="15" font="1">interval (&gt;0.45 sec), </text>
<text top="427" left="541" width="46" height="15" font="1">systemic </text>
<text top="443" left="541" width="66" height="15" font="1">hypertension </text>
<text top="458" left="541" width="93" height="15" font="1">(diastolic pressure </text>
<text top="474" left="541" width="74" height="15" font="1">&gt;115 mm Hg), </text>
<text top="489" left="541" width="53" height="15" font="1">electrolyte </text>
<text top="505" left="541" width="85" height="15" font="1">imbalance, AADs</text>
<text top="505" left="626" width="3" height="15" font="14"> </text>
<text top="164" left="663" width="40" height="15" font="1">Time to </text>
<text top="179" left="663" width="68" height="15" font="1">recurrence of </text>
<text top="195" left="663" width="55" height="15" font="1">PSVT was </text>
<text top="210" left="663" width="23" height="15" font="1">less </text>
<text top="226" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="241" left="663" width="71" height="15" font="1">placebo when </text>
<text top="257" left="663" width="47" height="15" font="1">receiving </text>
<text top="272" left="663" width="69" height="15" font="1">sotalol 80 mg </text>
<text top="288" left="663" width="66" height="15" font="1">(p=0.04) and </text>
<text top="303" left="663" width="57" height="15" font="1">sotalol 160 </text>
<text top="319" left="663" width="18" height="15" font="1">mg </text>
<text top="334" left="663" width="63" height="15" font="1">(p=0.0009).  </text>
<text top="350" left="663" width="3" height="15" font="1"> </text>
<text top="365" left="663" width="18" height="15" font="1">On </text>
<text top="381" left="663" width="64" height="15" font="1">subanalysis, </text>
<text top="396" left="663" width="58" height="15" font="1">sotalol was </text>
<text top="412" left="663" width="63" height="15" font="1">shown to be </text>
<text top="427" left="663" width="75" height="15" font="1">effective in the </text>
<text top="443" left="663" width="71" height="15" font="1">prophylaxis of </text>
<text top="458" left="663" width="49" height="15" font="1">both PAF </text>
<text top="474" left="663" width="69" height="15" font="1">(p=0.03)  and </text>
<text top="489" left="663" width="60" height="15" font="1">paroxysmal </text>
<text top="505" left="663" width="47" height="15" font="1">reentrant </text>
<text top="520" left="663" width="61" height="15" font="1">arrhythmias </text>
<text top="536" left="663" width="60" height="15" font="1">(p=0.0003). </text>
<text top="164" left="751" width="57" height="15" font="15">No deaths, </text>
<text top="179" left="751" width="44" height="15" font="15">cases of </text>
<text top="195" left="751" width="54" height="15" font="15">ventricular </text>
<text top="210" left="751" width="68" height="15" font="15">proarrhythmia</text>
<text top="210" left="819" width="6" height="15" font="1">, </text>
<text top="226" left="751" width="29" height="15" font="1">CHF. </text>
<text top="241" left="751" width="66" height="15" font="1">Treatment of </text>
<text top="257" left="751" width="65" height="15" font="1">pts receiving </text>
<text top="272" left="751" width="62" height="15" font="1">sotalol were </text>
<text top="288" left="751" width="65" height="15" font="1">discontinued </text>
<text top="303" left="751" width="57" height="15" font="1">because of </text>
<text top="319" left="751" width="76" height="15" font="1">typical BB side </text>
<text top="334" left="751" width="39" height="15" font="1">effects, </text>
<text top="350" left="751" width="47" height="15" font="1">including </text>
<text top="365" left="751" width="64" height="15" font="1">bradycardia, </text>
<text top="381" left="751" width="70" height="15" font="1">dyspnea, and </text>
<text top="396" left="751" width="39" height="15" font="1">fatigue. </text>
<text top="164" left="845" width="22" height="15" font="1">N/A </text>
<text top="164" left="926" width="22" height="15" font="1">N/A </text>
<text top="164" left="1063" width="37" height="15" font="1">Sotalol </text>
<text top="179" left="1063" width="67" height="15" font="1">efficacious in </text>
<text top="195" left="1063" width="18" height="15" font="1">the </text>
<text top="210" left="1063" width="71" height="15" font="1">prophylaxis of </text>
<text top="226" left="1063" width="38" height="15" font="1">PSVT.  </text>
<text top="241" left="1063" width="3" height="15" font="1"> </text>
<text top="257" left="1063" width="66" height="15" font="1">Study limited </text>
<text top="272" left="1063" width="34" height="15" font="1">due to </text>
<text top="288" left="1063" width="58" height="15" font="1">grouping of </text>
<text top="303" left="1063" width="41" height="15" font="1">PSVTs. </text>
<text top="552" left="54" width="47" height="15" font="1">Gupta A  </text>
<text top="567" left="54" width="28" height="15" font="1">1999 </text>
<text top="583" left="54" width="23" height="15" font="1">(35) </text>
<text top="598" left="54" width="43" height="15" font="8">1077868</text>
<text top="614" left="54" width="6" height="15" font="8">9</text>
<text top="614" left="60" width="3" height="15" font="1"> </text>
<text top="552" left="116" width="14" height="15" font="1">IV </text>
<text top="567" left="116" width="47" height="15" font="1">diltiazem </text>
<text top="583" left="116" width="21" height="15" font="1">and </text>
<text top="598" left="116" width="41" height="15" font="1">esmolol </text>
<text top="614" left="116" width="42" height="15" font="1">in acute </text>
<text top="629" left="116" width="40" height="15" font="1">therapy </text>
<text top="645" left="116" width="44" height="15" font="1">of PSVT </text>
<text top="552" left="177" width="15" height="15" font="1">32 </text>
<text top="567" left="177" width="40" height="15" font="1">(initially </text>
<text top="583" left="177" width="15" height="15" font="1">50 </text>
<text top="598" left="177" width="45" height="15" font="1">enrolled, </text>
<text top="614" left="177" width="39" height="15" font="1">but trial </text>
<text top="629" left="177" width="42" height="15" font="1">stopped </text>
<text top="645" left="177" width="31" height="15" font="1">early) </text>
<text top="552" left="238" width="71" height="15" font="1">Hemodynamic</text>
<text top="567" left="238" width="66" height="15" font="1">ally tolerated </text>
<text top="583" left="238" width="32" height="15" font="1">PSVT </text>
<text top="552" left="325" width="22" height="15" font="1">N/A </text>
<text top="552" left="413" width="110" height="15" font="1">Two sequential doses </text>
<text top="567" left="413" width="104" height="15" font="1">w/ a 5 min interval of </text>
<text top="583" left="413" width="83" height="15" font="1">either drug were </text>
<text top="598" left="413" width="101" height="15" font="1">administered before </text>
<text top="614" left="413" width="103" height="15" font="1">crossover. Diltiazem </text>
<text top="629" left="413" width="113" height="15" font="1">was given in a dose of </text>
<text top="645" left="413" width="104" height="15" font="1">0.25 mg/kg while the </text>
<text top="660" left="413" width="109" height="15" font="1">esmolol dose was 0.5 </text>
<text top="676" left="413" width="36" height="15" font="1">mg/kg. </text>
<text top="552" left="541" width="22" height="15" font="1">N/A </text>
<text top="552" left="663" width="49" height="15" font="1">Diltiazem </text>
<text top="567" left="663" width="55" height="15" font="1">terminated </text>
<text top="583" left="663" width="58" height="15" font="1">PSVT in all </text>
<text top="598" left="663" width="63" height="15" font="1">the 16 pts in </text>
<text top="614" left="663" width="64" height="15" font="1">whom it was </text>
<text top="629" left="663" width="63" height="15" font="1">given as the </text>
<text top="645" left="663" width="71" height="15" font="1">first drug. The </text>
<text top="660" left="663" width="74" height="15" font="1">12 pts who did </text>
<text top="676" left="663" width="74" height="15" font="1">not respond to </text>
<text top="691" left="663" width="68" height="15" font="1">esmolol were </text>
<text top="707" left="663" width="23" height="15" font="1">also </text>
<text top="722" left="663" width="52" height="15" font="1">effectively </text>
<text top="738" left="663" width="52" height="15" font="1">treated w/ </text>
<text top="753" left="663" width="53" height="15" font="1">diltiazem.  </text>
<text top="769" left="663" width="3" height="15" font="1"> </text>
<text top="784" left="663" width="49" height="15" font="1">28/28 pts </text>
<text top="552" left="751" width="69" height="15" font="1">No significant </text>
<text top="567" left="751" width="78" height="15" font="1">adverse effects </text>
<text top="583" left="751" width="57" height="15" font="1">were seen. </text>
<text top="552" left="845" width="22" height="15" font="1">N/A </text>
<text top="552" left="926" width="22" height="15" font="1">N/A </text>
<text top="552" left="1063" width="71" height="15" font="1">IV diltiazem is </text>
<text top="567" left="1063" width="32" height="15" font="1">highly </text>
<text top="583" left="1063" width="66" height="15" font="1">effective and </text>
<text top="598" left="1063" width="40" height="15" font="1">safe for </text>
<text top="614" left="1063" width="58" height="15" font="1">terminating </text>
<text top="629" left="1063" width="67" height="15" font="1">PSVT. When </text>
<text top="645" left="1063" width="69" height="15" font="1">the first bolus </text>
<text top="660" left="1063" width="67" height="15" font="1">is ineffective, </text>
<text top="676" left="1063" width="57" height="15" font="1">the second </text>
<text top="691" left="1063" width="59" height="15" font="1">bolus given </text>
<text top="707" left="1063" width="55" height="15" font="1">after 5 min </text>
<text top="722" left="1063" width="37" height="15" font="1">usually </text>
<text top="738" left="1063" width="53" height="15" font="1">succeeds. </text>
<text top="753" left="1063" width="73" height="15" font="1">Esmolol in the </text>
<text top="769" left="1063" width="58" height="15" font="1">dose of 0.5 </text>
<text top="784" left="1063" width="54" height="15" font="1">mg/kg has </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">48 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="68" height="15" font="1">responded to </text>
<text top="70" left="663" width="47" height="15" font="1">diltiazem </text>
<text top="86" left="663" width="52" height="15" font="1">while only </text>
<text top="101" left="663" width="42" height="15" font="1">4/16 pts </text>
<text top="117" left="663" width="68" height="15" font="1">responded to </text>
<text top="132" left="663" width="41" height="15" font="1">esmolol </text>
<text top="147" left="663" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="163" left="663" width="3" height="15" font="1"> </text>
<text top="178" left="663" width="67" height="15" font="1">Of the 28 pts </text>
<text top="194" left="663" width="23" height="15" font="1">who </text>
<text top="210" left="663" width="68" height="15" font="1">responded to </text>
<text top="225" left="663" width="61" height="15" font="1">diltiazem, in </text>
<text top="240" left="663" width="52" height="15" font="1">13 pts the </text>
<text top="256" left="663" width="68" height="15" font="1">second bolus </text>
<text top="271" left="663" width="59" height="15" font="1">of diltiazem </text>
<text top="287" left="663" width="64" height="15" font="1">worked after </text>
<text top="302" left="663" width="61" height="15" font="1">the first one </text>
<text top="318" left="663" width="54" height="15" font="1">had failed. </text>
<text top="55" left="1063" width="66" height="15" font="1">poor efficacy </text>
<text top="70" left="1063" width="74" height="15" font="1">for terminating </text>
<text top="86" left="1063" width="62" height="15" font="1">PSVT, even </text>
<text top="101" left="1063" width="39" height="15" font="1">when 2 </text>
<text top="117" left="1063" width="60" height="15" font="1">boluses are </text>
<text top="132" left="1063" width="69" height="15" font="1">administered. </text>
<text top="334" left="54" width="44" height="15" font="1">Alboni P </text>
<text top="350" left="54" width="28" height="15" font="1">2001 </text>
<text top="365" left="54" width="23" height="15" font="1">(36) </text>
<text top="381" left="54" width="43" height="15" font="8">1121697</text>
<text top="396" left="54" width="9" height="15" font="8">7 </text>
<text top="412" left="54" width="3" height="15" font="1"> </text>
<text top="334" left="116" width="31" height="15" font="1">Pill-in-</text>
<text top="350" left="116" width="19" height="15" font="1">the-</text>
<text top="365" left="116" width="36" height="15" font="1">pocket </text>
<text top="381" left="116" width="40" height="15" font="1">approac</text>
<text top="396" left="116" width="21" height="15" font="1">h to </text>
<text top="412" left="116" width="40" height="15" font="1">manage</text>
<text top="427" left="116" width="40" height="15" font="1">ment of </text>
<text top="443" left="116" width="35" height="15" font="1">PSVT, </text>
<text top="458" left="116" width="23" height="15" font="1">well-</text>
<text top="474" left="116" width="46" height="15" font="1">tolerated </text>
<text top="334" left="177" width="160" height="15" font="1">33 Flecainide </text>
<text top="350" left="238" width="35" height="15" font="1">(n=33) </text>
<text top="365" left="238" width="3" height="15" font="1"> </text>
<text top="381" left="238" width="3" height="15" font="1"> </text>
<text top="396" left="238" width="52" height="15" font="1">Diltiazem/ </text>
<text top="412" left="238" width="58" height="15" font="1">propranolol </text>
<text top="427" left="238" width="35" height="15" font="1">(n=33) </text>
<text top="334" left="325" width="43" height="15" font="1">Placebo </text>
<text top="350" left="325" width="35" height="15" font="1">(n=33) </text>
<text top="334" left="413" width="95" height="15" font="14">AVNRT and AVRT </text>
<text top="350" left="413" width="114" height="15" font="14">confirmed by EP study </text>
<text top="365" left="413" width="3" height="15" font="14"> </text>
<text top="381" left="413" width="110" height="15" font="14">Well-tolerated (no sxs </text>
<text top="396" left="413" width="108" height="15" font="14">of dyspnea, syncope, </text>
<text top="412" left="413" width="79" height="15" font="14">presyncope, no </text>
<text top="427" left="413" width="113" height="15" font="14">interference w/ normal </text>
<text top="443" left="413" width="46" height="15" font="14">activities </text>
<text top="458" left="413" width="3" height="15" font="14"> </text>
<text top="474" left="413" width="73" height="15" font="14">Infrequent (≤5 </text>
<text top="489" left="413" width="109" height="15" font="14">episodes/y) w/ ≥1 ED </text>
<text top="505" left="413" width="31" height="15" font="14">visit/y </text>
<text top="520" left="413" width="3" height="15" font="14"> </text>
<text top="535" left="413" width="111" height="15" font="14">PSVT documented by </text>
<text top="551" left="413" width="27" height="15" font="14">ECG </text>
<text top="334" left="541" width="100" height="15" font="14">Preexcitation, CAD, </text>
<text top="350" left="541" width="97" height="15" font="14">resting bradycardia </text>
<text top="365" left="541" width="80" height="15" font="14">&lt;50 bpm, LVEF </text>
<text top="381" left="541" width="74" height="15" font="14">&lt;50%, h/o HF, </text>
<text top="396" left="541" width="80" height="15" font="14">severe “general </text>
<text top="412" left="541" width="103" height="15" font="14">diseases,” recent MI </text>
<text top="427" left="541" width="72" height="15" font="14">or CVA, acute </text>
<text top="443" left="541" width="81" height="15" font="14">illness, need for </text>
<text top="458" left="541" width="103" height="15" font="14">AADs, h/o sustained </text>
<text top="474" left="541" width="81" height="15" font="14">atrial/ventricular </text>
<text top="489" left="541" width="87" height="15" font="14">tachyarrhythmias </text>
<text top="334" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="350" left="663" width="66" height="15" font="1">sinus rhythm </text>
<text top="365" left="663" width="69" height="15" font="1">occurred w/in </text>
<text top="381" left="663" width="61" height="15" font="1">2 h  in 52%, </text>
<text top="396" left="663" width="50" height="15" font="1">61%, and </text>
<text top="412" left="663" width="71" height="15" font="1">94% of pts on </text>
<text top="427" left="663" width="45" height="15" font="1">placebo, </text>
<text top="443" left="663" width="71" height="15" font="1">flecainide and </text>
<text top="458" left="663" width="50" height="15" font="1">diltiazem/ </text>
<text top="474" left="663" width="61" height="15" font="1">propranolol, </text>
<text top="489" left="663" width="61" height="15" font="1">respectively </text>
<text top="505" left="663" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="520" left="663" width="3" height="15" font="1"> </text>
<text top="535" left="663" width="22" height="15" font="1">The </text>
<text top="551" left="663" width="57" height="15" font="1">conversion </text>
<text top="567" left="663" width="47" height="15" font="1">time was </text>
<text top="582" left="663" width="63" height="15" font="1">shorter after </text>
<text top="598" left="663" width="50" height="15" font="1">diltiazem/ </text>
<text top="613" left="663" width="61" height="15" font="1">propranolol  </text>
<text top="628" left="663" width="63" height="15" font="1">(32±22 min) </text>
<text top="644" left="663" width="50" height="15" font="1">than after </text>
<text top="659" left="663" width="42" height="15" font="1">placebo </text>
<text top="675" left="663" width="63" height="15" font="1">(77±42 min, </text>
<text top="690" left="663" width="60" height="15" font="1">p&lt;0.001) or </text>
<text top="706" left="663" width="50" height="15" font="1">flecainide </text>
<text top="721" left="663" width="66" height="15" font="1">(74± 37 min, </text>
<text top="737" left="663" width="50" height="15" font="1">p&lt;0.001). </text>
<text top="752" left="663" width="3" height="15" font="1"> </text>
<text top="768" left="663" width="33" height="15" font="1">26 pts </text>
<text top="783" left="663" width="73" height="15" font="1">discharged on </text>
<text top="334" left="751" width="57" height="15" font="1">Four pts (1 </text>
<text top="350" left="751" width="54" height="15" font="1">placebo, 1 </text>
<text top="365" left="751" width="50" height="15" font="1">diltiazem/ </text>
<text top="381" left="751" width="61" height="15" font="1">propranolol, </text>
<text top="396" left="751" width="31" height="15" font="1">and 2 </text>
<text top="412" left="751" width="75" height="15" font="1">flecainide) had </text>
<text top="427" left="751" width="63" height="15" font="1">hypotension </text>
<text top="443" left="751" width="57" height="15" font="1">and four (3 </text>
<text top="458" left="751" width="50" height="15" font="1">diltiazem/ </text>
<text top="474" left="751" width="80" height="15" font="1">propranolol and </text>
<text top="489" left="751" width="72" height="15" font="1">1 flecainide) a </text>
<text top="505" left="751" width="73" height="15" font="1">sinus rate &lt;50 </text>
<text top="520" left="751" width="71" height="15" font="1">bpm following </text>
<text top="536" left="751" width="25" height="15" font="1">SVT </text>
<text top="551" left="751" width="58" height="15" font="1">interruption </text>
<text top="334" left="845" width="22" height="15" font="1">N/A </text>
<text top="334" left="926" width="22" height="15" font="1">N/A </text>
<text top="334" left="1063" width="65" height="15" font="1">Use of these </text>
<text top="350" left="1063" width="47" height="15" font="1">agents is </text>
<text top="365" left="1063" width="67" height="15" font="1">efficacious in </text>
<text top="381" left="1063" width="73" height="15" font="1">acute therapy, </text>
<text top="396" left="1063" width="51" height="15" font="1">both w/ in-</text>
<text top="412" left="1063" width="63" height="15" font="1">hospital and </text>
<text top="427" left="1063" width="71" height="15" font="1">outpt therapy. </text>
<text top="443" left="1063" width="73" height="15" font="1">However, only </text>
<text top="458" left="1063" width="36" height="15" font="1">4/5 pts </text>
<text top="474" left="1063" width="73" height="15" font="1">discharged on </text>
<text top="489" left="1063" width="53" height="15" font="1">flecainide. </text>
<text top="505" left="1063" width="73" height="15" font="1">Complications </text>
<text top="520" left="1063" width="69" height="15" font="1">not trivial and </text>
<text top="535" left="1063" width="52" height="15" font="1">all pts pre-</text>
<text top="551" left="1063" width="65" height="15" font="1">tested w/ EP </text>
<text top="567" left="1063" width="36" height="15" font="1">study.  </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">49 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="50" height="15" font="1">diltiazem/ </text>
<text top="70" left="663" width="58" height="15" font="1">propranolol </text>
<text top="86" left="663" width="46" height="15" font="1">and 5 on </text>
<text top="101" left="663" width="53" height="15" font="1">flecainide. </text>
<text top="117" left="663" width="71" height="15" font="1">During 17±12 </text>
<text top="132" left="663" width="37" height="15" font="1">mo f/u, </text>
<text top="147" left="663" width="50" height="15" font="1">treatment </text>
<text top="163" left="663" width="66" height="15" font="1">successful in </text>
<text top="178" left="663" width="38" height="15" font="1">81% of </text>
<text top="194" left="663" width="50" height="15" font="1">diltiazem/ </text>
<text top="210" left="663" width="58" height="15" font="1">propranolol </text>
<text top="225" left="663" width="51" height="15" font="1">pts and in </text>
<text top="240" left="663" width="38" height="15" font="1">80% of </text>
<text top="256" left="663" width="68" height="15" font="1">flecainide pts </text>
<text top="271" left="663" width="36" height="15" font="1">(all the </text>
<text top="287" left="663" width="55" height="15" font="1">arrhythmic </text>
<text top="302" left="663" width="74" height="15" font="1">episodes were </text>
<text top="318" left="663" width="56" height="15" font="1">interrupted </text>
<text top="333" left="663" width="73" height="15" font="1">out-of-hospital </text>
<text top="349" left="663" width="60" height="15" font="1">w/in 2 h). In </text>
<text top="364" left="663" width="73" height="15" font="1">remaining pts, </text>
<text top="380" left="663" width="42" height="15" font="1">a failure </text>
<text top="395" left="663" width="46" height="15" font="1">occurred </text>
<text top="411" left="663" width="50" height="15" font="1">during ≥1 </text>
<text top="426" left="663" width="47" height="15" font="1">episodes </text>
<text top="442" left="663" width="57" height="15" font="1">because of </text>
<text top="457" left="663" width="25" height="15" font="1">drug </text>
<text top="473" left="663" width="68" height="15" font="1">ineffectivenes</text>
<text top="488" left="663" width="47" height="15" font="1">s or drug </text>
<text top="504" left="663" width="69" height="15" font="1">unavailability. </text>
<text top="519" left="663" width="3" height="15" font="1"> </text>
<text top="535" left="663" width="73" height="15" font="1">During f/u, the </text>
<text top="550" left="663" width="71" height="15" font="1">percentage of </text>
<text top="566" left="663" width="68" height="15" font="1">pts calling for </text>
<text top="581" left="663" width="58" height="15" font="1">emergency </text>
<text top="597" left="663" width="28" height="15" font="1">room </text>
<text top="612" left="663" width="55" height="15" font="1">assistance </text>
<text top="628" left="663" width="23" height="15" font="1">was </text>
<text top="643" left="663" width="60" height="15" font="1">significantly </text>
<text top="659" left="663" width="58" height="15" font="1">reduced as </text>
<text top="674" left="663" width="65" height="15" font="1">compared to </text>
<text top="690" left="663" width="61" height="15" font="1">the y before </text>
<text top="705" left="663" width="55" height="15" font="1">enrollment </text>
<text top="721" left="663" width="74" height="15" font="1">(9% vs. 100%, </text>
<text top="736" left="663" width="56" height="15" font="1">p&lt;0.0001). </text>
<text top="752" left="54" width="44" height="15" font="1">Tendera </text>
<text top="768" left="54" width="12" height="15" font="1">M </text>
<text top="783" left="54" width="28" height="15" font="1">2001 </text>
<text top="752" left="116" width="42" height="15" font="1">Compari</text>
<text top="768" left="116" width="33" height="15" font="1">son of </text>
<text top="783" left="116" width="47" height="15" font="1">dofetilide </text>
<text top="752" left="177" width="149" height="15" font="1">122 Dofetilide </text>
<text top="752" left="287" width="42" height="15" font="1"> </text>
<text top="768" left="238" width="35" height="15" font="1">(n=40) </text>
<text top="783" left="238" width="3" height="15" font="1"> </text>
<text top="752" left="325" width="43" height="15" font="1">Placebo </text>
<text top="768" left="325" width="35" height="15" font="1">(n=41) </text>
<text top="752" left="413" width="113" height="15" font="14">18-75 y w/ ≥1 episode </text>
<text top="768" left="413" width="93" height="15" font="14">of PSVT w/in 6 wk </text>
<text top="783" left="413" width="103" height="15" font="14">documented by ECG</text>
<text top="783" left="516" width="3" height="15" font="1"> </text>
<text top="752" left="541" width="100" height="15" font="14">Pulmonary disease, </text>
<text top="768" left="541" width="95" height="15" font="14">myasthenia gravis, </text>
<text top="783" left="541" width="64" height="15" font="14">BBB, resting </text>
<text top="752" left="663" width="66" height="15" font="1">After 6 mo of </text>
<text top="768" left="663" width="71" height="15" font="1">treatment, pts </text>
<text top="783" left="663" width="33" height="15" font="1">taking </text>
<text top="752" left="751" width="61" height="15" font="1">19 of 40 pts </text>
<text top="768" left="751" width="70" height="15" font="1">(48%) treated </text>
<text top="783" left="751" width="61" height="15" font="1">w/ dofetilide </text>
<text top="752" left="845" width="22" height="15" font="1">N/A </text>
<text top="752" left="926" width="22" height="15" font="1">N/A </text>
<text top="752" left="1063" width="73" height="15" font="1">Dofetilide is at </text>
<text top="768" left="1063" width="65" height="15" font="1">least as safe </text>
<text top="783" left="1063" width="66" height="15" font="1">and effective </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">50 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="23" height="15" font="1">(37) </text>
<text top="70" left="54" width="43" height="15" font="8">1143166</text>
<text top="86" left="54" width="12" height="15" font="8">3  </text>
<text top="55" left="116" width="12" height="15" font="1">to </text>
<text top="70" left="116" width="44" height="15" font="1">propafen</text>
<text top="86" left="116" width="43" height="15" font="1">one and </text>
<text top="101" left="116" width="42" height="15" font="1">placebo </text>
<text top="117" left="116" width="30" height="15" font="1">in the </text>
<text top="132" left="116" width="39" height="15" font="1">preventi</text>
<text top="147" left="116" width="28" height="15" font="1">on of </text>
<text top="163" left="116" width="32" height="15" font="1">PSVT </text>
<text top="55" left="238" width="66" height="15" font="1">Propafenone </text>
<text top="70" left="238" width="35" height="15" font="1">(n=41) </text>
<text top="55" left="541" width="86" height="15" font="14">bradycardia (&lt;50 </text>
<text top="70" left="541" width="81" height="15" font="14">bpm), AV block, </text>
<text top="86" left="541" width="98" height="15" font="14">prolonged QTc, MI, </text>
<text top="101" left="541" width="84" height="15" font="14">unstable angina, </text>
<text top="117" left="541" width="107" height="15" font="14">recent sudden death, </text>
<text top="132" left="541" width="63" height="15" font="14">hematologic </text>
<text top="147" left="541" width="69" height="15" font="14">/hepatic/renal </text>
<text top="163" left="541" width="41" height="15" font="14">disease </text>
<text top="55" left="663" width="50" height="15" font="1">dofetilide, </text>
<text top="70" left="663" width="68" height="15" font="1">propafenone, </text>
<text top="86" left="663" width="63" height="15" font="1">and placebo </text>
<text top="101" left="663" width="59" height="15" font="1">had a 50%, </text>
<text top="117" left="663" width="69" height="15" font="1">54%, and 6% </text>
<text top="132" left="663" width="57" height="15" font="1">probability, </text>
<text top="147" left="663" width="65" height="15" font="1">respectively, </text>
<text top="163" left="663" width="64" height="15" font="1">of remaining </text>
<text top="178" left="663" width="34" height="15" font="1">free of </text>
<text top="194" left="663" width="60" height="15" font="1">episodes of </text>
<text top="210" left="663" width="73" height="15" font="1">PSVT (p&lt;.001 </text>
<text top="225" left="663" width="41" height="15" font="1">for both </text>
<text top="240" left="663" width="69" height="15" font="1">dofetilide and </text>
<text top="256" left="663" width="65" height="15" font="1">propafenone </text>
<text top="271" left="663" width="66" height="15" font="1">vs. placebo). </text>
<text top="287" left="663" width="3" height="15" font="1"> </text>
<text top="302" left="663" width="59" height="15" font="1">The hazard </text>
<text top="318" left="663" width="41" height="15" font="1">ratio for </text>
<text top="333" left="663" width="65" height="15" font="1">dofetilide vs. </text>
<text top="349" left="663" width="65" height="15" font="1">placebo was </text>
<text top="364" left="663" width="71" height="15" font="1">0.33 (95% CI: </text>
<text top="380" left="663" width="57" height="15" font="1">0.18-0.61), </text>
<text top="395" left="663" width="40" height="15" font="1">and the </text>
<text top="411" left="663" width="61" height="15" font="1">hazard ratio </text>
<text top="426" left="663" width="16" height="15" font="1">for </text>
<text top="442" left="663" width="65" height="15" font="1">propafenone </text>
<text top="457" left="663" width="59" height="15" font="1">vs. placebo </text>
<text top="473" left="663" width="47" height="15" font="1">was 0.27 </text>
<text top="488" left="663" width="71" height="15" font="1">(95% CI: 0.14-</text>
<text top="504" left="663" width="31" height="15" font="1">0.51). </text>
<text top="519" left="663" width="3" height="15" font="1"> </text>
<text top="535" left="663" width="48" height="15" font="1">Of 40 pts </text>
<text top="550" left="663" width="52" height="15" font="1">treated w/ </text>
<text top="566" left="663" width="69" height="15" font="1">dofetilide and </text>
<text top="581" left="663" width="68" height="15" font="1">propafenone, </text>
<text top="597" left="663" width="69" height="15" font="1">23 (58%) and </text>
<text top="612" left="663" width="69" height="15" font="1">25 (61%) had </text>
<text top="628" left="663" width="62" height="15" font="1">no recurring </text>
<text top="643" left="663" width="35" height="15" font="1">PSVT, </text>
<text top="659" left="663" width="66" height="15" font="1">compared w/ </text>
<text top="674" left="663" width="60" height="15" font="1">16 (39%) in </text>
<text top="690" left="663" width="42" height="15" font="1">placebo </text>
<text top="705" left="663" width="34" height="15" font="1">group. </text>
<text top="55" left="751" width="65" height="15" font="1">and 21 of 41 </text>
<text top="70" left="751" width="70" height="15" font="1">(51%) treated </text>
<text top="86" left="751" width="79" height="15" font="1">w/ propafenone </text>
<text top="101" left="751" width="60" height="15" font="1">reported no </text>
<text top="117" left="751" width="84" height="15" font="1">adverse events.  </text>
<text top="132" left="751" width="3" height="15" font="1"> </text>
<text top="147" left="751" width="69" height="15" font="1">No significant </text>
<text top="163" left="751" width="57" height="15" font="1">differences </text>
<text top="178" left="751" width="58" height="15" font="1">were noted </text>
<text top="194" left="751" width="54" height="15" font="1">between 3 </text>
<text top="209" left="751" width="49" height="15" font="1">groups in </text>
<text top="225" left="751" width="62" height="15" font="1">incidence of </text>
<text top="240" left="751" width="50" height="15" font="1">treatment-</text>
<text top="256" left="751" width="79" height="15" font="1">related adverse </text>
<text top="271" left="751" width="63" height="15" font="1">events or all-</text>
<text top="287" left="751" width="75" height="15" font="1">cause adverse </text>
<text top="302" left="751" width="77" height="15" font="1">events (p=0.73 </text>
<text top="318" left="751" width="62" height="15" font="1">and p=0.74, </text>
<text top="333" left="751" width="68" height="15" font="1">respectively). </text>
<text top="55" left="1063" width="15" height="15" font="1">as </text>
<text top="70" left="1063" width="65" height="15" font="1">propafenone </text>
<text top="86" left="1063" width="30" height="15" font="1">as an </text>
<text top="101" left="1063" width="54" height="15" font="1">alternative </text>
<text top="117" left="1063" width="58" height="15" font="1">therapeutic </text>
<text top="132" left="1063" width="68" height="15" font="1">option for the </text>
<text top="147" left="1063" width="62" height="15" font="1">treatment of </text>
<text top="163" left="1063" width="67" height="15" font="1">pts w/ PSVT. </text>
<text top="178" left="1063" width="3" height="15" font="1"> </text>
<text top="194" left="1063" width="72" height="15" font="1">Limited in that </text>
<text top="210" left="1063" width="56" height="15" font="1">PSVTs not </text>
<text top="225" left="1063" width="50" height="15" font="1">specified. </text>
<text top="240" left="1063" width="3" height="15" font="1"> </text>
<text top="721" left="54" width="287" height="15" font="1">Catheter Therapy (including cyroablation vs. RFA studies) </text>
<text top="741" left="54" width="40" height="15" font="1">Langber</text>
<text top="757" left="54" width="23" height="15" font="1">g JJ </text>
<text top="772" left="54" width="28" height="15" font="1">1993 </text>
<text top="788" left="54" width="29" height="15" font="1">(116) </text>
<text top="741" left="116" width="44" height="15" font="1">Slow vs. </text>
<text top="757" left="116" width="45" height="15" font="1">fast path </text>
<text top="772" left="116" width="42" height="15" font="1">ablation </text>
<text top="788" left="116" width="16" height="15" font="1">for </text>
<text top="741" left="177" width="18" height="15" font="1"> 50 </text>
<text top="741" left="238" width="42" height="15" font="1">Anterior </text>
<text top="757" left="238" width="35" height="15" font="1">(n=22) </text>
<text top="772" left="238" width="61" height="15" font="1">Up to 1 h or </text>
<text top="788" left="238" width="33" height="15" font="1">10 RF </text>
<text top="741" left="325" width="47" height="15" font="1">Posterior </text>
<text top="757" left="325" width="35" height="15" font="1">(n=28) </text>
<text top="772" left="325" width="3" height="15" font="1"> </text>
<text top="788" left="325" width="61" height="15" font="1">Up to 1 h or </text>
<text top="741" left="413" width="47" height="15" font="1"> AVNRT  </text>
<text top="741" left="541" width="63" height="15" font="1">None stated </text>
<text top="741" left="663" width="41" height="15" font="1">Primary </text>
<text top="757" left="663" width="74" height="15" font="1">success rates, </text>
<text top="772" left="663" width="58" height="15" font="1">anterior vs. </text>
<text top="788" left="663" width="46" height="15" font="1">posterior </text>
<text top="741" left="751" width="50" height="15" font="1">One pt w/ </text>
<text top="757" left="751" width="67" height="15" font="1">RBBB during </text>
<text top="772" left="751" width="56" height="15" font="1">an anterior </text>
<text top="788" left="751" width="32" height="15" font="1">lesion </text>
<text top="741" left="845" width="25" height="15" font="1"> N/A </text>
<text top="741" left="926" width="22" height="15" font="1">N/A </text>
<text top="741" left="1063" width="47" height="15" font="1">Posterior </text>
<text top="757" left="1063" width="57" height="15" font="1">(slow path) </text>
<text top="772" left="1063" width="61" height="15" font="1">approach to </text>
<text top="788" left="1063" width="18" height="15" font="1">RF </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">51 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="43" height="15" font="8">8491010</text>
<text top="55" left="97" width="3" height="15" font="1"> </text>
<text top="70" left="54" width="3" height="15" font="1"> </text>
<text top="86" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="116" width="264" height="15" font="1">AVNRT applications </text>
<text top="70" left="238" width="34" height="15" font="1">before </text>
<text top="86" left="238" width="54" height="15" font="1">alternative </text>
<text top="101" left="238" width="51" height="15" font="1">technique </text>
<text top="55" left="325" width="33" height="15" font="1">10 RF </text>
<text top="70" left="325" width="61" height="15" font="1">applications </text>
<text top="86" left="325" width="34" height="15" font="1">before </text>
<text top="101" left="325" width="54" height="15" font="1">alternative </text>
<text top="117" left="325" width="54" height="15" font="1">technique  </text>
<text top="55" left="663" width="74" height="15" font="1">(55% vs. 68%, </text>
<text top="70" left="663" width="35" height="15" font="1">p=NS) </text>
<text top="86" left="663" width="3" height="15" font="1"> </text>
<text top="101" left="663" width="57" height="15" font="1">All pts who </text>
<text top="117" left="663" width="58" height="15" font="1">failed initial </text>
<text top="132" left="663" width="49" height="15" font="1">approach </text>
<text top="147" left="663" width="27" height="15" font="1">were </text>
<text top="163" left="663" width="63" height="15" font="1">successfully </text>
<text top="178" left="663" width="52" height="15" font="1">treated by </text>
<text top="194" left="663" width="54" height="15" font="1">alternative </text>
<text top="210" left="663" width="71" height="15" font="1">technique w/o </text>
<text top="225" left="663" width="57" height="15" font="1">developing </text>
<text top="240" left="663" width="74" height="15" font="1">high-grade AV </text>
<text top="256" left="663" width="29" height="15" font="1">block </text>
<text top="55" left="751" width="50" height="15" font="1">One pt w/ </text>
<text top="70" left="751" width="66" height="15" font="1">complete AV </text>
<text top="86" left="751" width="77" height="15" font="1">block complete </text>
<text top="101" left="751" width="80" height="15" font="1">during posterior </text>
<text top="117" left="751" width="32" height="15" font="1">lesion </text>
<text top="55" left="1063" width="62" height="15" font="1">modification </text>
<text top="70" left="1063" width="69" height="15" font="1">of AV node is </text>
<text top="86" left="1063" width="74" height="15" font="1">as effective as </text>
<text top="101" left="1063" width="59" height="15" font="1">the anterior </text>
<text top="117" left="1063" width="53" height="15" font="1">(fast path) </text>
<text top="132" left="1063" width="74" height="15" font="1">approach, and </text>
<text top="147" left="1063" width="25" height="15" font="1">both </text>
<text top="163" left="1063" width="57" height="15" font="1">techniques </text>
<text top="178" left="1063" width="70" height="15" font="1">associated w/ </text>
<text top="194" left="1063" width="62" height="15" font="1">a low risk of </text>
<text top="210" left="1063" width="73" height="15" font="1">complications. </text>
<text top="225" left="1063" width="3" height="15" font="1"> </text>
<text top="240" left="1063" width="72" height="15" font="1">Limiting to 1 h </text>
<text top="256" left="1063" width="74" height="15" font="1">or 10 attempts </text>
<text top="271" left="1063" width="24" height="15" font="1">may </text>
<text top="287" left="1063" width="73" height="15" font="1">underestimate </text>
<text top="302" left="1063" width="74" height="15" font="1">success rates. </text>
<text top="319" left="54" width="42" height="15" font="1">Kalbfleis</text>
<text top="334" left="54" width="31" height="15" font="1">ch SJ </text>
<text top="350" left="54" width="28" height="15" font="1">1994 </text>
<text top="365" left="54" width="29" height="15" font="1">(117) </text>
<text top="381" left="54" width="43" height="15" font="8">8113557</text>
<text top="381" left="97" width="3" height="15" font="1"> </text>
<text top="396" left="54" width="3" height="15" font="1"> </text>
<text top="412" left="54" width="3" height="15" font="1"> </text>
<text top="319" left="116" width="42" height="15" font="1">Compari</text>
<text top="334" left="116" width="36" height="15" font="1">son of  </text>
<text top="350" left="116" width="39" height="15" font="1">anatomi</text>
<text top="365" left="116" width="26" height="15" font="1">c vs. </text>
<text top="381" left="116" width="28" height="15" font="1">EGM </text>
<text top="396" left="116" width="45" height="15" font="1">mapping </text>
<text top="412" left="116" width="16" height="15" font="1">for </text>
<text top="427" left="116" width="41" height="15" font="1">AVNRT </text>
<text top="443" left="116" width="42" height="15" font="1">ablation </text>
<text top="458" left="116" width="29" height="15" font="1">(slow </text>
<text top="474" left="116" width="28" height="15" font="1">path) </text>
<text top="489" left="116" width="3" height="15" font="1"> </text>
<text top="319" left="177" width="15" height="15" font="1">50 </text>
<text top="319" left="238" width="49" height="15" font="1">Anatomic </text>
<text top="334" left="238" width="35" height="15" font="1">(n=25) </text>
<text top="350" left="238" width="71" height="15" font="1">sequential RF </text>
<text top="365" left="238" width="37" height="15" font="1">energy </text>
<text top="381" left="238" width="61" height="15" font="1">applications </text>
<text top="396" left="238" width="50" height="15" font="1">(up to 12) </text>
<text top="412" left="238" width="48" height="15" font="1">delivered </text>
<text top="427" left="238" width="74" height="15" font="1">along tricuspid </text>
<text top="443" left="238" width="67" height="15" font="1">annulus from </text>
<text top="458" left="238" width="57" height="15" font="1">level of the </text>
<text top="474" left="238" width="46" height="15" font="1">coronary </text>
<text top="489" left="238" width="65" height="15" font="1">sinus ostium </text>
<text top="505" left="238" width="71" height="15" font="1">to His bundle  </text>
<text top="319" left="325" width="74" height="15" font="1">EGM mapping </text>
<text top="334" left="325" width="38" height="15" font="1">(n= 25) </text>
<text top="350" left="325" width="3" height="15" font="1"> </text>
<text top="365" left="325" width="61" height="15" font="1">Target sites </text>
<text top="381" left="325" width="30" height="15" font="1">along </text>
<text top="396" left="325" width="73" height="15" font="1">posteromedial </text>
<text top="412" left="325" width="44" height="15" font="1">tricuspid </text>
<text top="427" left="325" width="67" height="15" font="1">annulus near </text>
<text top="443" left="325" width="46" height="15" font="1">coronary </text>
<text top="458" left="325" width="68" height="15" font="1">sinus ostium  </text>
<text top="319" left="413" width="41" height="15" font="1">AVNRT </text>
<text top="319" left="541" width="66" height="15" font="1"> None stated </text>
<text top="319" left="663" width="66" height="15" font="1">Anatomic vs. </text>
<text top="334" left="663" width="49" height="15" font="1">mapping: </text>
<text top="350" left="663" width="73" height="15" font="1">Effective in 84 </text>
<text top="365" left="663" width="52" height="15" font="1">vs. 100%  </text>
<text top="381" left="663" width="38" height="15" font="1">(p=0.1) </text>
<text top="396" left="663" width="3" height="15" font="1"> </text>
<text top="412" left="663" width="39" height="15" font="1">4 w/ an </text>
<text top="427" left="663" width="53" height="15" font="1">ineffective </text>
<text top="443" left="663" width="48" height="15" font="1">anatomic </text>
<text top="458" left="663" width="71" height="15" font="1">approach had </text>
<text top="474" left="663" width="64" height="15" font="1">a successful </text>
<text top="489" left="663" width="60" height="15" font="1">outcome w/ </text>
<text top="505" left="663" width="45" height="15" font="1">mapping </text>
<text top="520" left="663" width="49" height="15" font="1">approach </text>
<text top="319" left="751" width="22" height="15" font="1">N/A </text>
<text top="319" left="845" width="63" height="15" font="1">ITT analysis </text>
<text top="334" left="845" width="63" height="15" font="1">Mapping vs. </text>
<text top="350" left="845" width="54" height="15" font="1">anatomic:  </text>
<text top="365" left="845" width="3" height="15" font="1"> </text>
<text top="381" left="845" width="28" height="15" font="1">Time </text>
<text top="396" left="845" width="60" height="15" font="1">required for </text>
<text top="412" left="845" width="45" height="15" font="1">ablation: </text>
<text top="427" left="845" width="56" height="15" font="1">(28±21 vs. </text>
<text top="443" left="845" width="59" height="15" font="1">31±31 min, </text>
<text top="458" left="845" width="38" height="15" font="1">p=0.7)  </text>
<text top="474" left="845" width="3" height="15" font="1"> </text>
<text top="489" left="845" width="57" height="15" font="1">Duration of </text>
<text top="505" left="845" width="66" height="15" font="1">fluoroscopy:  </text>
<text top="520" left="845" width="56" height="15" font="1">(27±20 vs. </text>
<text top="535" left="845" width="59" height="15" font="1">27±18 min, </text>
<text top="551" left="845" width="38" height="15" font="1">p=0.9)  </text>
<text top="567" left="845" width="3" height="15" font="1"> </text>
<text top="582" left="845" width="31" height="15" font="1">Mean </text>
<text top="597" left="845" width="53" height="15" font="1">number of </text>
<text top="613" left="845" width="18" height="15" font="1">RF </text>
<text top="628" left="845" width="65" height="15" font="1">applications: </text>
<text top="644" left="845" width="62" height="15" font="1">(6.3±3.9 vs. </text>
<text top="659" left="845" width="44" height="15" font="1">7.2±8.0, </text>
<text top="675" left="845" width="35" height="15" font="1">p=0.6) </text>
<text top="319" left="926" width="22" height="15" font="1">N/A </text>
<text top="319" left="1063" width="70" height="15" font="1">The anatomic </text>
<text top="334" left="1063" width="67" height="15" font="1">and mapping </text>
<text top="350" left="1063" width="61" height="15" font="1">approaches </text>
<text top="365" left="1063" width="70" height="15" font="1">for ablation of </text>
<text top="381" left="1063" width="61" height="15" font="1">the slow AV </text>
<text top="396" left="1063" width="30" height="15" font="1">nodal </text>
<text top="412" left="1063" width="63" height="15" font="1">pathway are </text>
<text top="427" left="1063" width="73" height="15" font="1">comparable in </text>
<text top="443" left="1063" width="62" height="15" font="1">efficacy and </text>
<text top="458" left="1063" width="49" height="15" font="1">duration.  </text>
<text top="474" left="1063" width="3" height="15" font="1"> </text>
<text top="489" left="1063" width="70" height="15" font="1">Generalizabilit</text>
<text top="505" left="1063" width="68" height="15" font="1">y limited, and </text>
<text top="520" left="1063" width="53" height="15" font="1">applicable </text>
<text top="535" left="1063" width="36" height="15" font="1">only to </text>
<text top="551" left="1063" width="51" height="15" font="1">technique </text>
<text top="567" left="1063" width="51" height="15" font="1">described </text>
<text top="582" left="1063" width="68" height="15" font="1">(e.g., authors </text>
<text top="597" left="1063" width="39" height="15" font="1">cite not </text>
<text top="613" left="1063" width="69" height="15" font="1">applicable for </text>
<text top="628" left="1063" width="52" height="15" font="1">expanded </text>
<text top="644" left="1063" width="48" height="15" font="1">anatomic </text>
<text top="659" left="1063" width="62" height="15" font="1">approach or </text>
<text top="675" left="1063" width="44" height="15" font="1">an EGM </text>
<text top="690" left="1063" width="45" height="15" font="1">mapping </text>
<text top="706" left="1063" width="71" height="15" font="1">approach that </text>
<text top="721" left="1063" width="62" height="15" font="1">required the </text>
<text top="737" left="1063" width="70" height="15" font="1">presence of a </text>
<text top="752" left="1063" width="69" height="15" font="1">slow pathway </text>
<text top="768" left="1063" width="52" height="15" font="1">potential). </text>
<text top="783" left="1063" width="3" height="15" font="1"> </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">52 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="1063" width="73" height="15" font="1">Small sample; </text>
<text top="70" left="1063" width="66" height="15" font="1">probability of </text>
<text top="86" left="1063" width="57" height="15" font="1">detecting a </text>
<text top="101" left="1063" width="25" height="15" font="1">20% </text>
<text top="117" left="1063" width="63" height="15" font="1">difference in </text>
<text top="132" left="1063" width="41" height="15" font="1">efficacy </text>
<text top="147" left="1063" width="65" height="15" font="1">between two </text>
<text top="163" left="1063" width="57" height="15" font="1">techniques </text>
<text top="178" left="1063" width="51" height="15" font="1">only 0.67. </text>
<text top="195" left="54" width="44" height="15" font="1">Kopelma</text>
<text top="210" left="54" width="28" height="15" font="1">n HA </text>
<text top="226" left="54" width="28" height="15" font="1">2003 </text>
<text top="241" left="54" width="29" height="15" font="1">(118) </text>
<text top="257" left="54" width="43" height="15" font="8">1263364</text>
<text top="272" left="54" width="6" height="15" font="8">2</text>
<text top="272" left="60" width="3" height="15" font="1"> </text>
<text top="288" left="54" width="3" height="15" font="1"> </text>
<text top="195" left="116" width="42" height="15" font="1">Efficienc</text>
<text top="210" left="116" width="21" height="15" font="1">y of </text>
<text top="226" left="116" width="41" height="15" font="1">conventi</text>
<text top="241" left="116" width="24" height="15" font="1">onal </text>
<text top="257" left="116" width="39" height="15" font="1">fluorosc</text>
<text top="272" left="116" width="45" height="15" font="1">opic and </text>
<text top="288" left="116" width="39" height="15" font="1">electroa</text>
<text top="303" left="116" width="42" height="15" font="1">natomic </text>
<text top="319" left="116" width="45" height="15" font="1">mapping </text>
<text top="334" left="116" width="42" height="15" font="1">(CARTO</text>
<text top="350" left="116" width="18" height="15" font="1">) in </text>
<text top="365" left="116" width="39" height="15" font="1">guiding </text>
<text top="381" left="116" width="43" height="15" font="1">catheter </text>
<text top="396" left="116" width="42" height="15" font="1">ablation </text>
<text top="412" left="116" width="12" height="15" font="1">of </text>
<text top="427" left="116" width="41" height="15" font="1">AVNRT </text>
<text top="195" left="177" width="18" height="15" font="1"> 20 </text>
<text top="195" left="238" width="71" height="15" font="1">Electroanatom</text>
<text top="210" left="238" width="57" height="15" font="1">ic mapping </text>
<text top="226" left="238" width="35" height="15" font="1">(n=10) </text>
<text top="195" left="325" width="66" height="15" font="1">Fluoroscopic </text>
<text top="210" left="325" width="49" height="15" font="1">mapping  </text>
<text top="226" left="325" width="35" height="15" font="1">(n=10) </text>
<text top="195" left="413" width="44" height="15" font="1"> AVNRT </text>
<text top="195" left="541" width="66" height="15" font="1"> None stated </text>
<text top="195" left="663" width="71" height="15" font="1">Electroanatom</text>
<text top="210" left="663" width="28" height="15" font="1">ic vs. </text>
<text top="226" left="663" width="63" height="15" font="1">fluoroscopy: </text>
<text top="241" left="663" width="3" height="15" font="1"> </text>
<text top="257" left="663" width="66" height="15" font="1">Fluoroscopic </text>
<text top="272" left="663" width="46" height="15" font="1">duration: </text>
<text top="288" left="663" width="65" height="15" font="1">12.6±6.8 vs. </text>
<text top="303" left="663" width="53" height="15" font="1">35.9±18.3 </text>
<text top="319" left="663" width="67" height="15" font="1">min, p&lt;0.001 </text>
<text top="334" left="663" width="3" height="15" font="1"> </text>
<text top="350" left="663" width="66" height="15" font="1">Fluoroscopic </text>
<text top="365" left="663" width="49" height="15" font="1">exposure </text>
<text top="381" left="663" width="62" height="15" font="1">(0.7±0.5 vs. </text>
<text top="396" left="663" width="65" height="15" font="1">9.6±5.0 min; </text>
<text top="412" left="663" width="43" height="15" font="1">p&lt;0.001 </text>
<text top="427" left="663" width="3" height="15" font="1"> </text>
<text top="443" left="663" width="28" height="15" font="1">Total </text>
<text top="458" left="663" width="53" height="15" font="1">procedure </text>
<text top="474" left="663" width="27" height="15" font="1">time: </text>
<text top="489" left="663" width="71" height="15" font="1">83.6±23.6 vs. </text>
<text top="505" left="663" width="75" height="15" font="1">114±19.3 min, </text>
<text top="520" left="663" width="47" height="15" font="1">p=0.008  </text>
<text top="535" left="663" width="3" height="15" font="1"> </text>
<text top="551" left="663" width="28" height="15" font="1">Total </text>
<text top="567" left="663" width="62" height="15" font="1">fluoroscopic </text>
<text top="582" left="663" width="52" height="15" font="1">exposure: </text>
<text top="597" left="663" width="59" height="15" font="1">4.2±1.4 vs. </text>
<text top="613" left="663" width="51" height="15" font="1">15.9±-6.4 </text>
<text top="628" left="663" width="67" height="15" font="1">min, p&lt;0.001 </text>
<text top="644" left="663" width="3" height="15" font="1"> </text>
<text top="659" left="663" width="73" height="15" font="1">Number of RF </text>
<text top="675" left="663" width="65" height="15" font="1">applications: </text>
<text top="690" left="663" width="59" height="15" font="1">2.7±1.6 vs. </text>
<text top="706" left="663" width="35" height="15" font="1">5±2.8, </text>
<text top="721" left="663" width="46" height="15" font="1">p=0.018, </text>
<text top="737" left="663" width="3" height="15" font="1"> </text>
<text top="752" left="663" width="57" height="15" font="1">Duration of </text>
<text top="768" left="663" width="21" height="15" font="1">RF: </text>
<text top="783" left="663" width="66" height="15" font="1">165.3±181.6 </text>
<text top="195" left="751" width="60" height="15" font="1">No acute or </text>
<text top="210" left="751" width="50" height="15" font="1">long-term </text>
<text top="226" left="751" width="63" height="15" font="1">8.9±2.2 mo) </text>
<text top="241" left="751" width="70" height="15" font="1">complications </text>
<text top="257" left="751" width="68" height="15" font="1">or arrhythmia </text>
<text top="272" left="751" width="68" height="15" font="1">recurrence in </text>
<text top="288" left="751" width="62" height="15" font="1">either group </text>
<text top="303" left="751" width="3" height="15" font="1"> </text>
<text top="319" left="751" width="3" height="15" font="1"> </text>
<text top="195" left="845" width="22" height="15" font="1">N/A </text>
<text top="195" left="926" width="22" height="15" font="1">N/A </text>
<text top="195" left="1063" width="62" height="15" font="1">Electroanato</text>
<text top="210" left="1063" width="66" height="15" font="1">mic mapping </text>
<text top="226" left="1063" width="31" height="15" font="1">offers </text>
<text top="241" left="1063" width="60" height="15" font="1">significantly </text>
<text top="257" left="1063" width="37" height="15" font="1">shorter </text>
<text top="272" left="1063" width="53" height="15" font="1">procedure </text>
<text top="288" left="1063" width="21" height="15" font="1">and </text>
<text top="303" left="1063" width="60" height="15" font="1">fluoroscopy </text>
<text top="319" left="1063" width="32" height="15" font="1">times, </text>
<text top="334" left="1063" width="70" height="15" font="1">improving the </text>
<text top="350" left="1063" width="61" height="15" font="1">efficiency of </text>
<text top="365" left="1063" width="71" height="15" font="1">the procedure </text>
<text top="381" left="1063" width="67" height="15" font="1">and reducing </text>
<text top="396" left="1063" width="30" height="15" font="1">X-ray </text>
<text top="412" left="1063" width="52" height="15" font="1">exposure. </text>
<text top="427" left="1063" width="3" height="15" font="1"> </text>
<text top="443" left="1063" width="69" height="15" font="1">Small sample </text>
<text top="458" left="1063" width="64" height="15" font="1">size, curious </text>
<text top="474" left="1063" width="58" height="15" font="1">lack of side </text>
<text top="489" left="1063" width="39" height="15" font="1">effects. </text>
<text top="505" left="1063" width="3" height="15" font="1"> </text>
<text top="520" left="1063" width="63" height="15" font="1">Cost higher  </text>
<text top="535" left="1063" width="14" height="15" font="1">w/ </text>
<text top="551" left="1063" width="70" height="15" font="1">electroanatom</text>
<text top="567" left="1063" width="65" height="15" font="1">ical mapping </text>
<text top="582" left="1063" width="65" height="15" font="1">catheter, but </text>
<text top="597" left="1063" width="28" height="15" font="1">likely </text>
<text top="613" left="1063" width="45" height="15" font="1">offset by </text>
<text top="628" left="1063" width="61" height="15" font="1">potential for </text>
<text top="644" left="1063" width="49" height="15" font="1">improved </text>
<text top="659" left="1063" width="65" height="15" font="1">efficiency, pt </text>
<text top="675" left="1063" width="56" height="15" font="1">throughput </text>
<text top="690" left="1063" width="51" height="15" font="1">and X-ray </text>
<text top="706" left="1063" width="74" height="15" font="1">exposure from </text>
<text top="721" left="1063" width="66" height="15" font="1">reductions in </text>
<text top="737" left="1063" width="53" height="15" font="1">procedure </text>
<text top="752" left="1063" width="21" height="15" font="1">and </text>
<text top="768" left="1063" width="60" height="15" font="1">fluoroscopy </text>
<text top="783" left="1063" width="33" height="15" font="1">times. </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">53 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="74" height="15" font="1">vs. 341±177.7 </text>
<text top="70" left="663" width="67" height="15" font="1">sec, p=0.013 </text>
<text top="86" left="663" width="3" height="15" font="1"> </text>
<text top="101" left="663" width="65" height="15" font="1">Total energy </text>
<text top="117" left="663" width="44" height="15" font="1">delivery: </text>
<text top="132" left="663" width="65" height="15" font="1">24.3±3.1 vs. </text>
<text top="147" left="663" width="47" height="15" font="1">28.7±4.5 </text>
<text top="163" left="663" width="32" height="15" font="1">watts, </text>
<text top="178" left="663" width="43" height="15" font="1">p=0.042 </text>
<text top="195" left="54" width="44" height="15" font="1">Kimman </text>
<text top="210" left="54" width="19" height="15" font="1">GP </text>
<text top="226" left="54" width="28" height="15" font="1">2004 </text>
<text top="241" left="54" width="29" height="15" font="1">(119) </text>
<text top="257" left="54" width="43" height="15" font="8">1558964</text>
<text top="272" left="54" width="6" height="15" font="8">1</text>
<text top="272" left="60" width="3" height="15" font="1"> </text>
<text top="288" left="54" width="3" height="15" font="1"> </text>
<text top="303" left="54" width="3" height="15" font="1"> </text>
<text top="195" left="116" width="36" height="15" font="1">CA vs. </text>
<text top="210" left="116" width="25" height="15" font="1">RFA </text>
<text top="195" left="177" width="18" height="15" font="1"> 63 </text>
<text top="210" left="177" width="3" height="15" font="1"> </text>
<text top="195" left="238" width="57" height="15" font="1"> CA (n=30) </text>
<text top="195" left="325" width="61" height="15" font="1">RFA (n=33) </text>
<text top="195" left="413" width="44" height="15" font="1"> AVNRT </text>
<text top="195" left="541" width="66" height="15" font="1"> None stated </text>
<text top="195" left="663" width="57" height="15" font="1">Procedural </text>
<text top="210" left="663" width="43" height="15" font="1">success </text>
<text top="226" left="663" width="59" height="15" font="1">achieved in </text>
<text top="241" left="663" width="72" height="15" font="1">91% RFA and </text>
<text top="257" left="663" width="44" height="15" font="1">93% CA </text>
<text top="272" left="663" width="6" height="15" font="1">  </text>
<text top="195" left="751" width="22" height="15" font="1">N/A </text>
<text top="195" left="845" width="39" height="15" font="1">Median </text>
<text top="210" left="845" width="53" height="15" font="1">number of </text>
<text top="226" left="845" width="18" height="15" font="1">CA </text>
<text top="241" left="845" width="61" height="15" font="1">applications </text>
<text top="257" left="845" width="54" height="15" font="1">lower than </text>
<text top="272" left="845" width="25" height="15" font="1">RFA </text>
<text top="288" left="845" width="51" height="15" font="1">(p&lt;0.005) </text>
<text top="303" left="845" width="3" height="15" font="1"> </text>
<text top="319" left="845" width="26" height="15" font="1">Both </text>
<text top="334" left="845" width="60" height="15" font="1">fluoroscopy </text>
<text top="350" left="845" width="21" height="15" font="1">and </text>
<text top="365" left="845" width="55" height="15" font="1">procedural </text>
<text top="381" left="845" width="57" height="15" font="1">times were </text>
<text top="396" left="845" width="61" height="15" font="1">comparable </text>
<text top="195" left="926" width="22" height="15" font="1">N/A </text>
<text top="195" left="1063" width="67" height="15" font="1">CA useful for </text>
<text top="210" left="1063" width="62" height="15" font="1">treatment of </text>
<text top="226" left="1063" width="70" height="15" font="1">tachyarrhythm</text>
<text top="241" left="1063" width="61" height="15" font="1">ias near the </text>
<text top="257" left="1063" width="63" height="15" font="1">compact AV </text>
<text top="272" left="1063" width="31" height="15" font="1">node. </text>
<text top="288" left="1063" width="3" height="15" font="1"> </text>
<text top="303" left="1063" width="68" height="15" font="1">Questionable </text>
<text top="319" left="1063" width="65" height="15" font="1">whether lack </text>
<text top="334" left="1063" width="62" height="15" font="1">of junctional </text>
<text top="350" left="1063" width="48" height="15" font="1">rhythm is </text>
<text top="365" left="1063" width="60" height="15" font="1">seen w/ CA </text>
<text top="381" left="1063" width="56" height="15" font="1">makes this </text>
<text top="396" left="1063" width="49" height="15" font="1">approach </text>
<text top="412" left="1063" width="52" height="15" font="1">safer than </text>
<text top="427" left="1063" width="43" height="15" font="1">RFA, as </text>
<text top="443" left="1063" width="40" height="15" font="1">authors </text>
<text top="458" left="1063" width="41" height="15" font="1">remark. </text>
<text top="474" left="54" width="42" height="15" font="1">Zrenner </text>
<text top="490" left="54" width="10" height="15" font="1">B </text>
<text top="505" left="54" width="28" height="15" font="1">2004 </text>
<text top="521" left="54" width="29" height="15" font="1">(120) </text>
<text top="536" left="54" width="43" height="15" font="8">1558964</text>
<text top="552" left="54" width="6" height="15" font="8">0</text>
<text top="552" left="60" width="3" height="15" font="1"> </text>
<text top="567" left="54" width="3" height="15" font="1"> </text>
<text top="474" left="116" width="36" height="15" font="1">CA vs. </text>
<text top="490" left="116" width="41" height="15" font="1">RFA for </text>
<text top="505" left="116" width="41" height="15" font="1">AVNRT </text>
<text top="474" left="177" width="22" height="15" font="1">200 </text>
<text top="474" left="238" width="60" height="15" font="1">CA (n=100) </text>
<text top="474" left="325" width="67" height="15" font="1">RFA (n=100) </text>
<text top="474" left="413" width="41" height="15" font="1">AVNRT </text>
<text top="474" left="541" width="22" height="15" font="1">N/A </text>
<text top="474" left="663" width="58" height="15" font="1">Cumulative </text>
<text top="490" left="663" width="62" height="15" font="1">incidence of </text>
<text top="505" left="663" width="40" height="15" font="1">primary </text>
<text top="521" left="663" width="58" height="15" font="1">endpoint (a </text>
<text top="536" left="663" width="63" height="15" font="1">combination </text>
<text top="552" left="663" width="68" height="15" font="1">of procedural </text>
<text top="567" left="663" width="36" height="15" font="1">failure, </text>
<text top="583" left="663" width="56" height="15" font="1">permanent </text>
<text top="598" left="663" width="66" height="15" font="1">complete AV </text>
<text top="614" left="663" width="50" height="15" font="1">block and </text>
<text top="629" left="663" width="41" height="15" font="1">AVNRT </text>
<text top="645" left="663" width="60" height="15" font="1">recurrence) </text>
<text top="660" left="663" width="64" height="15" font="1">higher in the </text>
<text top="676" left="663" width="53" height="15" font="1">CA group, </text>
<text top="691" left="663" width="37" height="15" font="1">p=0.03 </text>
<text top="474" left="751" width="67" height="15" font="1">Transient AV </text>
<text top="490" left="751" width="52" height="15" font="1">block was </text>
<text top="505" left="751" width="76" height="15" font="1">encountered in </text>
<text top="521" left="751" width="73" height="15" font="1">18% pts in the </text>
<text top="536" left="751" width="71" height="15" font="1">CA group and </text>
<text top="552" left="751" width="34" height="15" font="1">in 8%  </text>
<text top="567" left="751" width="61" height="15" font="1">in RF group </text>
<text top="583" left="751" width="48" height="15" font="1">(p&lt;0.04)  </text>
<text top="598" left="751" width="3" height="15" font="1"> </text>
<text top="614" left="751" width="75" height="15" font="1">21 episodes of </text>
<text top="629" left="751" width="63" height="15" font="1">transient AV </text>
<text top="645" left="751" width="77" height="15" font="1">block occurring </text>
<text top="660" left="751" width="34" height="15" font="1">during </text>
<text top="676" left="751" width="79" height="15" font="1">cryomapping (n </text>
<text top="691" left="751" width="76" height="15" font="1">= 4) or CA (n = </text>
<text top="707" left="751" width="50" height="15" font="1">17) and 8 </text>
<text top="722" left="751" width="81" height="15" font="1">episodes during </text>
<text top="738" left="751" width="18" height="15" font="1">RF </text>
<text top="753" left="751" width="65" height="15" font="1">applications. </text>
<text top="769" left="751" width="78" height="15" font="1">The duration of </text>
<text top="784" left="751" width="63" height="15" font="1">transient AV </text>
<text top="474" left="845" width="57" height="15" font="1">Procedural </text>
<text top="490" left="845" width="43" height="15" font="1">success </text>
<text top="505" left="845" width="54" height="15" font="1">defined as </text>
<text top="521" left="845" width="56" height="15" font="1">elimination </text>
<text top="536" left="845" width="37" height="15" font="1">of slow </text>
<text top="552" left="845" width="57" height="15" font="1">pathway or </text>
<text top="567" left="845" width="64" height="15" font="1">noninducibilit</text>
<text top="583" left="845" width="61" height="15" font="1">y of AVNRT </text>
<text top="598" left="845" width="3" height="15" font="1"> </text>
<text top="614" left="845" width="61" height="15" font="1">CA vs. RFA </text>
<text top="629" left="845" width="68" height="15" font="1">97% vs. 98% </text>
<text top="645" left="845" width="3" height="15" font="1"> </text>
<text top="474" left="926" width="22" height="15" font="1">N/A </text>
<text top="474" left="1063" width="52" height="15" font="1">Early pilot </text>
<text top="490" left="1063" width="54" height="15" font="1">study (first </text>
<text top="505" left="1063" width="60" height="15" font="1">prospective </text>
<text top="521" left="1063" width="61" height="15" font="1">randomized </text>
<text top="536" left="1063" width="65" height="15" font="1">investigation </text>
<text top="552" left="1063" width="55" height="15" font="1">comparing </text>
<text top="567" left="1063" width="70" height="15" font="1">CA w/ RFA of </text>
<text top="583" left="1063" width="44" height="15" font="1">AVNRT) </text>
<text top="598" left="1063" width="62" height="15" font="1">showing CA </text>
<text top="614" left="1063" width="70" height="15" font="1">associated w/ </text>
<text top="629" left="1063" width="70" height="15" font="1">a comparable </text>
<text top="645" left="1063" width="73" height="15" font="1">acute success </text>
<text top="660" left="1063" width="50" height="15" font="1">rate but a </text>
<text top="676" left="1063" width="34" height="15" font="1">higher </text>
<text top="691" left="1063" width="56" height="15" font="1">recurrence </text>
<text top="707" left="1063" width="37" height="15" font="1">rate as </text>
<text top="722" left="1063" width="66" height="15" font="1">compared w/ </text>
<text top="738" left="1063" width="69" height="15" font="1">RFA in pts w/ </text>
<text top="753" left="1063" width="44" height="15" font="1">AVNRT. </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">54 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="751" width="66" height="15" font="1">block ranged </text>
<text top="70" left="751" width="77" height="15" font="1">from 2-420 s in </text>
<text top="86" left="751" width="71" height="15" font="1">CA group and </text>
<text top="101" left="751" width="77" height="15" font="1">from 2-180 s in </text>
<text top="117" left="751" width="49" height="15" font="1">RF group </text>
<text top="133" left="54" width="49" height="15" font="1">Kardos A </text>
<text top="148" left="54" width="28" height="15" font="1">2007 </text>
<text top="164" left="54" width="29" height="15" font="1">(121) </text>
<text top="179" left="54" width="43" height="15" font="8">1821412</text>
<text top="195" left="54" width="6" height="15" font="8">4</text>
<text top="195" left="60" width="3" height="15" font="1"> </text>
<text top="210" left="54" width="3" height="15" font="1"> </text>
<text top="226" left="54" width="3" height="15" font="1"> </text>
<text top="133" left="116" width="43" height="15" font="1">Test the </text>
<text top="148" left="116" width="40" height="15" font="1">feasibilit</text>
<text top="164" left="116" width="21" height="15" font="1">y of </text>
<text top="179" left="116" width="42" height="15" font="1">cryomap</text>
<text top="195" left="116" width="24" height="15" font="1">ping </text>
<text top="210" left="116" width="34" height="15" font="1">during </text>
<text top="226" left="116" width="41" height="15" font="1">AVNRT </text>
<text top="241" left="116" width="21" height="15" font="1">and </text>
<text top="257" left="116" width="33" height="15" font="1">AVRT </text>
<text top="272" left="116" width="3" height="15" font="1"> </text>
<text top="288" left="116" width="29" height="15" font="1">Note: </text>
<text top="303" left="116" width="42" height="15" font="1">ablation </text>
<text top="319" left="116" width="44" height="15" font="1">performe</text>
<text top="334" left="116" width="41" height="15" font="1">d only if </text>
<text top="350" left="116" width="42" height="15" font="1">cryomap</text>
<text top="365" left="116" width="24" height="15" font="1">ping </text>
<text top="381" left="116" width="40" height="15" font="1">terminat</text>
<text top="396" left="116" width="34" height="15" font="1">ed the </text>
<text top="412" left="116" width="42" height="15" font="1">tachycar</text>
<text top="427" left="116" width="38" height="15" font="1">dia w/o </text>
<text top="443" left="116" width="43" height="15" font="1">prolonga</text>
<text top="458" left="116" width="33" height="15" font="1">tion of </text>
<text top="474" left="116" width="18" height="15" font="1">AV </text>
<text top="489" left="116" width="41" height="15" font="1">conducti</text>
<text top="505" left="116" width="15" height="15" font="1">on </text>
<text top="133" left="177" width="15" height="15" font="1">30 </text>
<text top="148" left="177" width="3" height="15" font="1"> </text>
<text top="164" left="177" width="41" height="15" font="1">AVNRT </text>
<text top="179" left="177" width="28" height="15" font="1">n=17 </text>
<text top="195" left="177" width="3" height="15" font="1"> </text>
<text top="210" left="177" width="33" height="15" font="1">AVRT </text>
<text top="226" left="177" width="31" height="15" font="1">n=13  </text>
<text top="241" left="177" width="3" height="15" font="1"> </text>
<text top="257" left="177" width="44" height="15" font="1">Randomi</text>
<text top="272" left="177" width="46" height="15" font="1">zed after </text>
<text top="288" left="177" width="27" height="15" font="1">dx of </text>
<text top="303" left="177" width="45" height="15" font="1">AVRT or </text>
<text top="319" left="177" width="41" height="15" font="1">AVNRT </text>
<text top="334" left="177" width="31" height="15" font="1">made </text>
<text top="350" left="177" width="3" height="15" font="1"> </text>
<text top="365" left="177" width="46" height="15" font="1">9 APS in </text>
<text top="381" left="177" width="42" height="15" font="1">CA, 4 in </text>
<text top="396" left="177" width="18" height="15" font="1">RF </text>
<text top="133" left="238" width="60" height="15" font="1"> CA (n=13 ) </text>
<text top="133" left="325" width="61" height="15" font="1">RFA (n=17) </text>
<text top="133" left="413" width="100" height="15" font="1">AVNRT or AVRT w/ </text>
<text top="148" left="413" width="108" height="15" font="1">anteroseptal pathway </text>
<text top="133" left="541" width="56" height="15" font="1">AVRT w/ a </text>
<text top="148" left="541" width="91" height="15" font="1">posteroseptal, left-</text>
<text top="164" left="541" width="92" height="15" font="1">sided, or right free </text>
<text top="179" left="541" width="40" height="15" font="1">wall AP </text>
<text top="133" left="663" width="61" height="15" font="1">CA vs. RFA </text>
<text top="148" left="663" width="3" height="15" font="1"> </text>
<text top="164" left="663" width="68" height="15" font="1">Overall acute </text>
<text top="179" left="663" width="68" height="15" font="1">success rate: </text>
<text top="195" left="663" width="70" height="15" font="1">85 vs. 82.4%, </text>
<text top="210" left="663" width="37" height="15" font="1">p=0.43 </text>
<text top="226" left="663" width="3" height="15" font="1"> </text>
<text top="241" left="663" width="3" height="15" font="1"> </text>
<text top="133" left="751" width="70" height="15" font="1">CA: in one pt, </text>
<text top="148" left="751" width="60" height="15" font="1">ablation not </text>
<text top="164" left="751" width="52" height="15" font="1">attempted </text>
<text top="179" left="751" width="75" height="15" font="1">because of AV </text>
<text top="195" left="751" width="64" height="15" font="1">prolongation </text>
<text top="210" left="751" width="3" height="15" font="1"> </text>
<text top="226" left="751" width="81" height="15" font="1">RFA: two pts w/ </text>
<text top="241" left="751" width="53" height="15" font="1">temporary </text>
<text top="257" left="751" width="77" height="15" font="1">second-degree </text>
<text top="272" left="751" width="50" height="15" font="1">AV block  </text>
<text top="133" left="845" width="61" height="15" font="1">CA vs. RFA </text>
<text top="148" left="845" width="3" height="15" font="1"> </text>
<text top="164" left="845" width="53" height="15" font="1">Long-term </text>
<text top="179" left="845" width="65" height="15" font="1">success rate </text>
<text top="195" left="845" width="57" height="15" font="1">(12 mo f/u) </text>
<text top="210" left="845" width="35" height="15" font="1">similar </text>
<text top="226" left="845" width="63" height="15" font="1">between the </text>
<text top="241" left="845" width="57" height="15" font="1">two groups </text>
<text top="257" left="845" width="3" height="15" font="1"> </text>
<text top="272" left="845" width="63" height="15" font="1">Fluoroscopy </text>
<text top="288" left="845" width="40" height="15" font="1">and the </text>
<text top="303" left="845" width="53" height="15" font="1">procedure </text>
<text top="319" left="845" width="59" height="15" font="1">time similar </text>
<text top="334" left="845" width="62" height="15" font="1">(p=0.37 and </text>
<text top="350" left="845" width="40" height="15" font="1">p=0.14, </text>
<text top="365" left="845" width="62" height="15" font="1">respectively)</text>
<text top="381" left="845" width="9" height="15" font="1">.  </text>
<text top="396" left="845" width="3" height="15" font="1"> </text>
<text top="412" left="845" width="31" height="15" font="1">Mean </text>
<text top="427" left="845" width="53" height="15" font="1">number of </text>
<text top="443" left="845" width="68" height="15" font="1">applications:  </text>
<text top="458" left="845" width="62" height="15" font="1">2 (1-6) vs. 7 </text>
<text top="474" left="845" width="36" height="15" font="1">(1-41), </text>
<text top="489" left="845" width="43" height="15" font="1">p=0.002 </text>
<text top="133" left="926" width="22" height="15" font="1">N/A </text>
<text top="133" left="1063" width="66" height="15" font="1">First study to </text>
<text top="148" left="1063" width="59" height="15" font="1">assess ICE </text>
<text top="164" left="1063" width="45" height="15" font="1">mapping </text>
<text top="179" left="1063" width="36" height="15" font="1">guided </text>
<text top="195" left="1063" width="63" height="15" font="1">ablation in a </text>
<text top="210" left="1063" width="60" height="15" font="1">prospective </text>
<text top="226" left="1063" width="61" height="15" font="1">randomized </text>
<text top="241" left="1063" width="46" height="15" font="1">method.  </text>
<text top="257" left="1063" width="3" height="15" font="1"> </text>
<text top="272" left="1063" width="69" height="15" font="1">Cryomapping </text>
<text top="288" left="1063" width="50" height="15" font="1">a feasible </text>
<text top="303" left="1063" width="52" height="15" font="1">method to </text>
<text top="319" left="1063" width="52" height="15" font="1">determine </text>
<text top="334" left="1063" width="71" height="15" font="1">exact location </text>
<text top="350" left="1063" width="69" height="15" font="1">of APs and of </text>
<text top="365" left="1063" width="69" height="15" font="1">slow pathway </text>
<text top="381" left="1063" width="34" height="15" font="1">during </text>
<text top="396" left="1063" width="63" height="15" font="1">tachycardia. </text>
<text top="412" left="1063" width="3" height="15" font="1"> </text>
<text top="427" left="1063" width="69" height="15" font="1">Cryomapping </text>
<text top="443" left="1063" width="53" height="15" font="1">performed </text>
<text top="458" left="1063" width="34" height="15" font="1">during </text>
<text top="474" left="1063" width="60" height="15" font="1">tachycardia </text>
<text top="489" left="1063" width="61" height="15" font="1">causes less </text>
<text top="505" left="1063" width="42" height="15" font="1">ablation </text>
<text top="520" left="1063" width="58" height="15" font="1">lesions w/o </text>
<text top="535" left="1063" width="53" height="15" font="1">increasing </text>
<text top="551" left="1063" width="53" height="15" font="1">procedure </text>
<text top="567" left="1063" width="21" height="15" font="1">and </text>
<text top="582" left="1063" width="60" height="15" font="1">fluoroscopy </text>
<text top="597" left="1063" width="33" height="15" font="1">times. </text>
<text top="613" left="1063" width="3" height="15" font="1"> </text>
<text top="628" left="1063" width="64" height="15" font="1">Pediatric pts </text>
<text top="644" left="1063" width="59" height="15" font="1">eligible and </text>
<text top="659" left="1063" width="48" height="15" font="1">pts in CA </text>
<text top="675" left="1063" width="31" height="15" font="1">group </text>
<text top="690" left="1063" width="43" height="15" font="1">younger </text>
<text top="706" left="1063" width="65" height="15" font="1">(median age </text>
<text top="721" left="1063" width="58" height="15" font="1">20 vs. 44).  </text>
<text top="737" left="1063" width="3" height="15" font="1"> </text>
<text top="752" left="1063" width="57" height="15" font="1">No control, </text>
<text top="768" left="1063" width="67" height="15" font="1">and arguably </text>
<text top="783" left="1063" width="65" height="15" font="1">2 groups not </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="19" size="11" family="Times" color="#181818"/>
<text top="814" left="1120" width="17" height="17" font="0">55 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="1063" width="61" height="15" font="1">comparable </text>
<text top="70" left="1063" width="63" height="15" font="1">because RF </text>
<text top="86" left="1063" width="42" height="15" font="1">not safe </text>
<text top="101" left="1063" width="34" height="15" font="1">during </text>
<text top="117" left="1063" width="60" height="15" font="1">tachycardia </text>
<text top="132" left="1063" width="29" height="15" font="1">when </text>
<text top="147" left="1063" width="49" height="15" font="1">substrate </text>
<text top="163" left="1063" width="64" height="15" font="1">located near </text>
<text top="178" left="1063" width="52" height="15" font="1">AV node.  </text>
<text top="194" left="1063" width="3" height="15" font="1"> </text>
<text top="210" left="1063" width="47" height="15" font="1">LocaLisa </text>
<text top="225" left="1063" width="65" height="15" font="1">system used </text>
<text top="240" left="1063" width="69" height="15" font="1">in CA and RF </text>
<text top="256" left="1063" width="64" height="15" font="1">groups, thus </text>
<text top="271" left="1063" width="51" height="15" font="1">improving </text>
<text top="287" left="1063" width="65" height="15" font="1">performance </text>
<text top="302" left="1063" width="20" height="15" font="1">c/w </text>
<text top="318" left="1063" width="73" height="15" font="1">“conventional” </text>
<text top="333" left="1063" width="31" height="15" font="1">RFA.  </text>
<text top="350" left="54" width="39" height="15" font="1">CRYAN</text>
<text top="365" left="54" width="46" height="15" font="1">O Study  </text>
<text top="381" left="54" width="31" height="15" font="1">2010  </text>
<text top="396" left="54" width="29" height="15" font="1">(122) </text>
<text top="412" left="54" width="43" height="15" font="8">2109843</text>
<text top="427" left="54" width="6" height="15" font="8">5</text>
<text top="427" left="60" width="6" height="15" font="1">  </text>
<text top="443" left="54" width="3" height="15" font="1"> </text>
<text top="458" left="54" width="3" height="15" font="1"> </text>
<text top="350" left="116" width="36" height="15" font="1">CA vs. </text>
<text top="365" left="116" width="41" height="15" font="1">RFA for </text>
<text top="381" left="116" width="41" height="15" font="1">AVNRT </text>
<text top="350" left="177" width="22" height="15" font="1">509 </text>
<text top="365" left="177" width="3" height="15" font="1"> </text>
<text top="350" left="238" width="63" height="15" font="1"> CA (n=251) </text>
<text top="350" left="325" width="70" height="15" font="1"> RFA (n=258) </text>
<text top="350" left="413" width="44" height="15" font="1"> AVNRT </text>
<text top="350" left="541" width="23" height="15" font="1">Prior</text>
<text top="350" left="565" width="47" height="15" font="19"> AVNRT  </text>
<text top="365" left="541" width="100" height="15" font="19">ablation  CHD, prior </text>
<text top="381" left="541" width="58" height="15" font="19">pacemaker </text>
<text top="396" left="541" width="66" height="15" font="19">implantation, </text>
<text top="412" left="541" width="79" height="15" font="19">pregnancy, and </text>
<text top="427" left="541" width="84" height="15" font="19">inability to follow </text>
<text top="443" left="541" width="69" height="15" font="19">study protocol</text>
<text top="443" left="610" width="3" height="15" font="1"> </text>
<text top="350" left="663" width="55" height="15" font="1">Immediate </text>
<text top="365" left="663" width="42" height="15" font="1">ablation </text>
<text top="381" left="663" width="36" height="15" font="1">failure, </text>
<text top="396" left="663" width="74" height="15" font="1">permanent AV </text>
<text top="412" left="663" width="53" height="15" font="1">block, and </text>
<text top="427" left="663" width="41" height="15" font="1">AVNRT </text>
<text top="443" left="663" width="56" height="15" font="1">recurrence </text>
<text top="458" left="663" width="71" height="15" font="1">during a 6-mo </text>
<text top="474" left="663" width="19" height="15" font="1">f/u  </text>
<text top="489" left="663" width="3" height="15" font="1"> </text>
<text top="505" left="663" width="61" height="15" font="1">CA vs. RFA </text>
<text top="520" left="663" width="52" height="15" font="1">12.6% vs. </text>
<text top="535" left="663" width="31" height="15" font="1">6.3%, </text>
<text top="551" left="663" width="47" height="15" font="1">p=0.018) </text>
<text top="567" left="663" width="3" height="15" font="1"> </text>
<text top="582" left="663" width="55" height="15" font="1">Immediate </text>
<text top="597" left="663" width="42" height="15" font="1">ablation </text>
<text top="613" left="663" width="46" height="15" font="1">success: </text>
<text top="628" left="663" width="52" height="15" font="1">96.8% vs. </text>
<text top="644" left="663" width="69" height="15" font="1">98.4%, p=NS </text>
<text top="659" left="663" width="3" height="15" font="1"> </text>
<text top="675" left="663" width="57" height="15" font="1">Permanent </text>
<text top="690" left="663" width="50" height="15" font="1">AV block: </text>
<text top="706" left="663" width="71" height="15" font="1"> 0% vs. 0.4%, </text>
<text top="721" left="663" width="31" height="15" font="1">p=NS </text>
<text top="737" left="663" width="3" height="15" font="1"> </text>
<text top="752" left="663" width="41" height="15" font="1">AVNRT </text>
<text top="768" left="663" width="59" height="15" font="1">recurrence: </text>
<text top="783" left="663" width="45" height="15" font="1">9.4% vs. </text>
<text top="350" left="751" width="72" height="15" font="1">N/A (AV block </text>
<text top="365" left="751" width="52" height="15" font="1">in primary </text>
<text top="381" left="751" width="49" height="15" font="1">endpoint) </text>
<text top="350" left="845" width="64" height="15" font="1">CA vs. RFA. </text>
<text top="365" left="845" width="3" height="15" font="1"> </text>
<text top="381" left="845" width="54" height="15" font="1">Procedure </text>
<text top="396" left="845" width="43" height="15" font="1">duration </text>
<text top="412" left="845" width="62" height="15" font="1">(138±54 vs. </text>
<text top="427" left="845" width="65" height="15" font="1">123±48 min, </text>
<text top="443" left="845" width="56" height="15" font="1">p=0.0012)  </text>
<text top="458" left="845" width="3" height="15" font="1"> </text>
<text top="474" left="845" width="37" height="15" font="1">Device </text>
<text top="489" left="845" width="52" height="15" font="1">problems: </text>
<text top="505" left="845" width="63" height="15" font="1">13 vs. 2 pts, </text>
<text top="520" left="845" width="50" height="15" font="1">p=0.033)  </text>
<text top="535" left="845" width="3" height="15" font="1"> </text>
<text top="551" left="845" width="25" height="15" font="1">Pain </text>
<text top="567" left="845" width="55" height="15" font="1">perception </text>
<text top="582" left="845" width="60" height="15" font="1">lower in the </text>
<text top="597" left="845" width="63" height="15" font="1">cryoablation </text>
<text top="613" left="845" width="34" height="15" font="1">group. </text>
<text top="628" left="845" width="43" height="15" font="1">p&lt;0.001 </text>
<text top="350" left="926" width="22" height="15" font="1">N/A </text>
<text top="350" left="1063" width="34" height="15" font="1">CA for </text>
<text top="365" left="1063" width="66" height="15" font="1">AVNRT is as </text>
<text top="381" left="1063" width="59" height="15" font="1">effective as </text>
<text top="396" left="1063" width="50" height="15" font="1">RFA over </text>
<text top="412" left="1063" width="71" height="15" font="1">short term but </text>
<text top="427" left="1063" width="70" height="15" font="1">associated w/ </text>
<text top="443" left="1063" width="34" height="15" font="1">higher </text>
<text top="458" left="1063" width="56" height="15" font="1">recurrence </text>
<text top="474" left="1063" width="63" height="15" font="1">rate at 6-mo </text>
<text top="489" left="1063" width="22" height="15" font="1">f/u.  </text>
<text top="505" left="1063" width="3" height="15" font="1"> </text>
<text top="520" left="1063" width="37" height="15" font="1">Risk of </text>
<text top="535" left="1063" width="74" height="15" font="1">permanent AV </text>
<text top="551" left="1063" width="56" height="15" font="1">block does </text>
<text top="567" left="1063" width="46" height="15" font="1">not differ </text>
<text top="582" left="1063" width="60" height="15" font="1">significantly </text>
<text top="597" left="1063" width="63" height="15" font="1">between CA </text>
<text top="613" left="1063" width="53" height="15" font="1">and RFA.  </text>
<text top="628" left="1063" width="3" height="15" font="1"> </text>
<text top="644" left="1063" width="46" height="15" font="1">Potential </text>
<text top="659" left="1063" width="73" height="15" font="1">benefits of CA </text>
<text top="675" left="1063" width="51" height="15" font="1">relative to </text>
<text top="690" left="1063" width="42" height="15" font="1">ablation </text>
<text top="706" left="1063" width="54" height="15" font="1">safety and </text>
<text top="721" left="1063" width="24" height="15" font="1">pain </text>
<text top="737" left="1063" width="55" height="15" font="1">perception </text>
<text top="752" left="1063" width="45" height="15" font="1">offset by </text>
<text top="768" left="1063" width="34" height="15" font="1">longer </text>
<text top="783" left="1063" width="53" height="15" font="1">procedure </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">56 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="31" height="15" font="1">4.4%; </text>
<text top="70" left="663" width="45" height="15" font="1">P=0.029 </text>
<text top="55" left="1063" width="61" height="15" font="1">times, more </text>
<text top="70" left="1063" width="35" height="15" font="1">device </text>
<text top="86" left="1063" width="73" height="15" font="1">problems, and </text>
<text top="101" left="1063" width="33" height="15" font="1">a high </text>
<text top="117" left="1063" width="56" height="15" font="1">recurrence </text>
<text top="132" left="1063" width="25" height="15" font="1">rate. </text>
<text top="148" left="54" width="45" height="15" font="1">Rodrigue</text>
<text top="164" left="54" width="44" height="15" font="1">z-Entem </text>
<text top="179" left="54" width="15" height="15" font="1">FJ </text>
<text top="195" left="54" width="28" height="15" font="1">2013 </text>
<text top="210" left="54" width="29" height="15" font="1">(123) </text>
<text top="226" left="54" width="43" height="15" font="8">2308032</text>
<text top="241" left="54" width="6" height="15" font="8">6</text>
<text top="241" left="60" width="3" height="15" font="1"> </text>
<text top="257" left="54" width="3" height="15" font="1"> </text>
<text top="148" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="164" left="116" width="31" height="15" font="1">of CA </text>
<text top="179" left="116" width="42" height="15" font="1">vs. RFA </text>
<text top="148" left="177" width="22" height="15" font="1">119 </text>
<text top="148" left="238" width="57" height="15" font="1"> CA (n=60) </text>
<text top="148" left="325" width="64" height="15" font="1"> RFA (n=59) </text>
<text top="148" left="413" width="44" height="15" font="1"> AVNRT </text>
<text top="148" left="541" width="22" height="15" font="1">N/A </text>
<text top="148" left="663" width="31" height="15" font="1">Acute </text>
<text top="164" left="663" width="55" height="15" font="1">procedural </text>
<text top="179" left="663" width="43" height="15" font="1">success </text>
<text top="195" left="663" width="59" height="15" font="1">achieved in </text>
<text top="210" left="663" width="44" height="15" font="1">98% CA </text>
<text top="226" left="663" width="68" height="15" font="1">group and 59 </text>
<text top="241" left="663" width="68" height="15" font="1">100% in RFA </text>
<text top="257" left="663" width="31" height="15" font="1">group </text>
<text top="148" left="751" width="73" height="15" font="1">One pt in RFA </text>
<text top="164" left="751" width="31" height="15" font="1">group </text>
<text top="179" left="751" width="55" height="15" font="1">underwent </text>
<text top="195" left="751" width="66" height="15" font="1">complete AV </text>
<text top="210" left="751" width="50" height="15" font="1">block and </text>
<text top="226" left="751" width="58" height="15" font="1">pacemaker </text>
<text top="241" left="751" width="66" height="15" font="1">implantation  </text>
<text top="148" left="845" width="61" height="15" font="1">CA vs. RFA </text>
<text top="164" left="845" width="3" height="15" font="1"> </text>
<text top="179" left="845" width="67" height="15" font="1">Over a mean </text>
<text top="195" left="845" width="61" height="15" font="1">f/u period of </text>
<text top="210" left="845" width="43" height="15" font="1">256.6 d, </text>
<text top="226" left="845" width="60" height="15" font="1">there was a </text>
<text top="241" left="845" width="52" height="15" font="1">significant </text>
<text top="257" left="845" width="63" height="15" font="1">difference in </text>
<text top="272" left="845" width="41" height="15" font="1">AVNRT </text>
<text top="288" left="845" width="56" height="15" font="1">recurrence </text>
<text top="303" left="845" width="68" height="15" font="1">(15 vs. 3.4%, </text>
<text top="319" left="845" width="44" height="15" font="1">p=0.03). </text>
<text top="148" left="926" width="22" height="15" font="1">N/A </text>
<text top="148" left="1063" width="71" height="15" font="1">CA of AVNRT </text>
<text top="164" left="1063" width="65" height="15" font="1">is a clinically </text>
<text top="179" left="1063" width="44" height="15" font="1">effective </text>
<text top="195" left="1063" width="66" height="15" font="1">alternative to </text>
<text top="210" left="1063" width="63" height="15" font="1">RF ablation, </text>
<text top="226" left="1063" width="61" height="15" font="1">w/ excellent </text>
<text top="241" left="1063" width="73" height="15" font="1">acute success </text>
<text top="257" left="1063" width="28" height="15" font="1">rate.  </text>
<text top="272" left="1063" width="3" height="15" font="1"> </text>
<text top="288" left="1063" width="50" height="15" font="1">Despite a </text>
<text top="303" left="1063" width="71" height="15" font="1">slightly higher </text>
<text top="319" left="1063" width="35" height="15" font="1">rate of </text>
<text top="334" left="1063" width="56" height="15" font="1">recurrence </text>
<text top="350" left="1063" width="58" height="15" font="1">during long-</text>
<text top="365" left="1063" width="62" height="15" font="1">term f/u, CA </text>
<text top="381" left="1063" width="39" height="15" font="1">may be </text>
<text top="396" left="1063" width="57" height="15" font="1">considered </text>
<text top="412" left="1063" width="42" height="15" font="1">first-line </text>
<text top="427" left="1063" width="52" height="15" font="1">approach, </text>
<text top="443" left="1063" width="63" height="15" font="1">especially in </text>
<text top="458" left="1063" width="43" height="15" font="1">younger </text>
<text top="474" left="1063" width="43" height="15" font="1">people.  </text>
<text top="490" left="54" width="184" height="15" font="16"><b>*</b>Two protocols tested in same study.<b> </b></text>
<text top="505" left="54" width="1067" height="15" font="1">AAD indicates antiarrhythmic drug;  AE, adverse effect; AF, atrial fibrillation; AP, accessory pathway; APS, acute procedureal success; AT, atrial tachycardia; AV, atrioventricular; AVNRT, atrioventricular nodal reentrant </text>
<text top="521" left="54" width="1081" height="15" font="1">tachycardia; AVRT, atrioventricular reentrant tachycardia; BBB, bundle branch block; bid, two times per day; bpm indicates beats per min; CA, cryoablation; CAD, coronary artery disease; CHF, congestive heart failure; CI, </text>
<text top="536" left="54" width="1082" height="15" font="1">confidence interval; COPD, chronic obstructive pulmonary disease; CVA, cerebral vascular accident; c/w, consistent with; ECG, electrocardiogram; ED, emergency department; EGM, electrogram; EP, electrophysiological; </text>
<text top="552" left="54" width="1028" height="15" font="1">f/u, follow up; HF, heart failure; h/o, history of; HR, heart rate; ICE, intracardiac echocardiography; ITT, intention to treat; IV, intravenous; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, not </text>
<text top="567" left="54" width="1055" height="15" font="1">applicable; NS, not significant; NSR, normal sinus rhythm; NYHA, New York Heart Association; ORT, orthodromic reciprocating tachycardia; PAF, paroxysmal atrial fibrillation; PES, programmed electrical stimulation; </text>
<text top="583" left="54" width="1081" height="15" font="1">PSVT, paroxysmal supraventricular tachycardia; pt, patient; RBBB, right bundle branch block; RCT, randomized controlled trial; RF, radiofrequency; RFA, radiofrequency ablation; sbp, systolic blood pressure; SDC, serum </text>
<text top="598" left="54" width="1067" height="15" font="1">drug concentration; SSS, sick sinus syndrome; SVT, supraventricular tachycardia; sx, symptom; tid, three times per day; VHD, valvular heart disease; VT, ventricular tachycardia; w/, with;  w/o, without; and WPW, Wolff-</text>
<text top="614" left="54" width="148" height="15" font="1">Parkinson-White syndrome.    </text>
<text top="639" left="54" width="151" height="18" font="3"><b>Data Supplement 10. </b></text>
<text top="639" left="205" width="895" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Atrioventricular Nodal Re-Entrant Tachycardia – Section 5</b></text>
<text top="639" left="1100" width="8" height="18" font="3"><b>  </b></text>
<text top="658" left="71" width="38" height="17" font="5"><b>Study </b></text>
<text top="675" left="70" width="40" height="17" font="5"><b>Name, </b></text>
<text top="693" left="66" width="47" height="17" font="5"><b>Author, </b></text>
<text top="710" left="75" width="30" height="17" font="5"><b>Year </b></text>
<text top="658" left="150" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="675" left="165" width="44" height="17" font="5"><b>Design </b></text>
<text top="658" left="259" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="658" left="375" width="165" height="17" font="5"><b>Inclusion/Exclusion Criteria </b></text>
<text top="658" left="610" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="658" left="800" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="658" left="978" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="728" left="54" width="161" height="15" font="1">Vagal Maneuvers/Cardioversion </text>
<text top="744" left="54" width="45" height="15" font="1">Mehta D </text>
<text top="759" left="54" width="28" height="15" font="1">1988 </text>
<text top="775" left="54" width="23" height="15" font="1">(40) </text>
<text top="790" left="54" width="49" height="15" font="8">2897005  </text>
<text top="744" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="759" left="139" width="94" height="15" font="1">study comparing 4 </text>
<text top="775" left="139" width="90" height="15" font="1">vagal maneuvers: </text>
<text top="790" left="139" width="73" height="15" font="1">right CSM, left </text>
<text top="744" left="248" width="15" height="15" font="1">35 </text>
<text top="744" left="349" width="76" height="15" font="1">AVNRT (n=11) </text>
<text top="759" left="349" width="68" height="15" font="1">AVRT (n=24) </text>
<text top="775" left="349" width="3" height="15" font="1"> </text>
<text top="790" left="349" width="160" height="15" font="1">EP study to induce SVT by PES </text>
<text top="744" left="579" width="143" height="15" font="1">Termination of at least 2 of 3 </text>
<text top="759" left="579" width="126" height="15" font="1">episodes of induced SVT </text>
<text top="744" left="761" width="144" height="15" font="1">Vagal maneuvers terminated </text>
<text top="759" left="761" width="119" height="15" font="1">tachycardia in 22 (63%) </text>
<text top="775" left="761" width="21" height="15" font="1">pts. </text>
<text top="790" left="761" width="3" height="15" font="1"> </text>
<text top="744" left="955" width="146" height="15" font="1">Valsalva most effective vagal </text>
<text top="759" left="955" width="164" height="15" font="1">maneuver for terminating PSVT.  </text>
<text top="775" left="955" width="3" height="15" font="1"> </text>
<text top="790" left="955" width="156" height="15" font="1">Limited in that study conducted </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">57 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="3" height="15" font="8"> </text>
<text top="70" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="139" width="55" height="15" font="1">CSM, face </text>
<text top="70" left="139" width="66" height="15" font="1">immersion in </text>
<text top="86" left="139" width="78" height="15" font="1">water, Valsalva </text>
<text top="101" left="139" width="52" height="15" font="1">maneuver </text>
<text top="55" left="349" width="3" height="15" font="1"> </text>
<text top="70" left="349" width="172" height="15" font="1">Excluded AADs taken 72 h prior to </text>
<text top="86" left="349" width="207" height="15" font="1">admission (amiodarone stopped prior to 3 </text>
<text top="101" left="349" width="159" height="15" font="1">mo), no AADs during admission </text>
<text top="55" left="761" width="103" height="15" font="1">Valsalva maneuvers </text>
<text top="70" left="761" width="169" height="15" font="1">in supine position in 19 pts (54%), </text>
<text top="86" left="761" width="175" height="15" font="1">right CSM in 6 (17%), left CSM in 2 </text>
<text top="101" left="761" width="150" height="15" font="1">(5%), and face immersion in 6 </text>
<text top="117" left="761" width="157" height="15" font="1">(17%). (p&lt;0.001 for difference). </text>
<text top="132" left="761" width="3" height="15" font="1"> </text>
<text top="147" left="761" width="173" height="15" font="1">Vagal maneuvers more effective in </text>
<text top="163" left="761" width="176" height="15" font="1">pts w/ AVRT than AVNRT (79% vs. </text>
<text top="178" left="761" width="72" height="15" font="1">27%, p&lt;0.01)  </text>
<text top="194" left="761" width="3" height="15" font="1"> </text>
<text top="209" left="761" width="66" height="15" font="1">Pts w/ AVRT </text>
<text top="225" left="761" width="161" height="15" font="1">terminated by a vagal maneuver </text>
<text top="240" left="761" width="87" height="15" font="1">were significantly </text>
<text top="256" left="761" width="163" height="15" font="1">younger (p&lt;0.001) than those w/ </text>
<text top="271" left="761" width="177" height="15" font="1">AVRT who did not respond to vagal </text>
<text top="287" left="761" width="174" height="15" font="1">maneuver; no such age difference  </text>
<text top="302" left="761" width="82" height="15" font="1">seen w/ AVNRT </text>
<text top="55" left="955" width="84" height="15" font="1">during EP study. </text>
<text top="319" left="54" width="44" height="15" font="1">Wen ZC </text>
<text top="334" left="54" width="28" height="15" font="1">1998 </text>
<text top="350" left="54" width="23" height="15" font="1">(41) </text>
<text top="365" left="54" width="46" height="15" font="8">9851958 </text>
<text top="381" left="54" width="3" height="15" font="1"> </text>
<text top="319" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="334" left="139" width="30" height="15" font="1">study </text>
<text top="319" left="248" width="22" height="15" font="1">133 </text>
<text top="319" left="349" width="71" height="15" font="1">AVRT (n=85)  </text>
<text top="334" left="349" width="76" height="15" font="1">AVNRT (n=48) </text>
<text top="350" left="349" width="3" height="15" font="1"> </text>
<text top="365" left="349" width="167" height="15" font="1">EP study to induce PSVT by PES </text>
<text top="381" left="349" width="3" height="15" font="1"> </text>
<text top="396" left="349" width="194" height="15" font="1">Excluded atrial flutter, AF organic heart </text>
<text top="412" left="349" width="175" height="15" font="1">disease or other systemic diseases </text>
<text top="427" left="349" width="189" height="15" font="1">involving the autonomic function (e.g., </text>
<text top="443" left="349" width="215" height="15" font="1">diabetes), those who could not blow into an </text>
<text top="458" left="349" width="212" height="15" font="1">aneroid manometer to maintain a pressure </text>
<text top="474" left="349" width="187" height="15" font="1">of 35 mm Hg for 20 sec, and those w/ </text>
<text top="489" left="349" width="156" height="15" font="1">unstable hemodynamics during </text>
<text top="505" left="349" width="63" height="15" font="1">tachycardia. </text>
<text top="319" left="579" width="106" height="15" font="1">Termination of PSVT </text>
<text top="319" left="761" width="173" height="15" font="1">Vagal maneuvers more effective in </text>
<text top="334" left="761" width="175" height="15" font="1">terminating AVRT than AVNRT (53 </text>
<text top="350" left="761" width="93" height="15" font="1">vs. 33%, p&lt;0.05).  </text>
<text top="365" left="761" width="3" height="15" font="1"> </text>
<text top="381" left="761" width="131" height="15" font="1">AVNRT: vagal maneuvers </text>
<text top="396" left="761" width="180" height="15" font="1">terminated tachycardia in antegrade </text>
<text top="412" left="761" width="127" height="15" font="1">slow pathway (14%) or in </text>
<text top="427" left="761" width="158" height="15" font="1">retrograde fast pathway (19%).  </text>
<text top="443" left="761" width="3" height="15" font="1"> </text>
<text top="458" left="761" width="162" height="15" font="1">Baroreflex sensitivity was poorer </text>
<text top="474" left="761" width="157" height="15" font="1">but isoproterenol sensitivity test </text>
<text top="489" left="761" width="119" height="15" font="1">better in pts w/ AVNRT. </text>
<text top="319" left="955" width="180" height="15" font="1">Vagal maneuvers effective, more so </text>
<text top="334" left="955" width="55" height="15" font="1">for AVRT.  </text>
<text top="350" left="955" width="3" height="15" font="1"> </text>
<text top="365" left="955" width="156" height="15" font="1">Limited in that study conducted </text>
<text top="381" left="955" width="84" height="15" font="1">during EP study. </text>
<text top="521" left="54" width="37" height="15" font="1">Roth A </text>
<text top="536" left="54" width="28" height="15" font="1">2003 </text>
<text top="552" left="54" width="23" height="15" font="1">(50) </text>
<text top="567" left="54" width="52" height="15" font="8">12586276 </text>
<text top="583" left="54" width="3" height="15" font="1"> </text>
<text top="521" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="536" left="139" width="30" height="15" font="1">study </text>
<text top="521" left="248" width="219" height="15" font="1">84 PSVT </text>
<text top="521" left="381" width="25" height="15" font="1">77% </text>
<text top="536" left="349" width="42" height="15" font="1">AF 23% </text>
<text top="552" left="349" width="3" height="15" font="1"> </text>
<text top="567" left="349" width="3" height="15" font="1"> </text>
<text top="521" left="579" width="100" height="15" font="1">Effectiveness of DC </text>
<text top="536" left="579" width="158" height="15" font="1">cardioversion in pts who did not </text>
<text top="552" left="579" width="130" height="15" font="1">respond promptly to vagal </text>
<text top="567" left="579" width="152" height="15" font="1">maneuvers that were tried first </text>
<text top="583" left="579" width="126" height="15" font="1">and then tried again after </text>
<text top="598" left="579" width="135" height="15" font="1">intravenously administered </text>
<text top="614" left="579" width="145" height="15" font="1">medical treatment w/ 1 of the </text>
<text top="629" left="579" width="121" height="15" font="1">following intraveneously </text>
<text top="645" left="579" width="158" height="15" font="1">administered drugs: adenosine, </text>
<text top="660" left="579" width="130" height="15" font="1">verapamil, digoxin, and/or </text>
<text top="676" left="579" width="76" height="15" font="1">procainamide.  </text>
<text top="691" left="579" width="3" height="15" font="1"> </text>
<text top="707" left="579" width="90" height="15" font="1">All study pts were </text>
<text top="722" left="579" width="158" height="15" font="1">hemodynamically compromised </text>
<text top="738" left="579" width="92" height="15" font="1">but did not require </text>
<text top="753" left="579" width="153" height="15" font="1">cardiopulmonary resuscitation. </text>
<text top="521" left="761" width="142" height="15" font="1">DC cardioversion resulted in </text>
<text top="536" left="761" width="150" height="15" font="1">successful converson to sinus </text>
<text top="552" left="761" width="174" height="15" font="1">rhythm in all pts after 103 electrical </text>
<text top="567" left="761" width="161" height="15" font="1">attempts, using 118±69 Joules.  </text>
<text top="583" left="761" width="3" height="15" font="1"> </text>
<text top="598" left="761" width="175" height="15" font="1">No complications; all but one pt (w/ </text>
<text top="614" left="761" width="173" height="15" font="1">pulmonary edema and cardiogenic </text>
<text top="629" left="761" width="172" height="15" font="1">shock) discharged alive w/in 7 d of </text>
<text top="645" left="761" width="79" height="15" font="1">hospitalization.  </text>
<text top="521" left="955" width="173" height="15" font="1">Use of DC cardioversion to restore </text>
<text top="536" left="955" width="156" height="15" font="1">sinus rhythm can be safely and </text>
<text top="552" left="955" width="132" height="15" font="1">efficaciously applied in the </text>
<text top="567" left="955" width="165" height="15" font="1">prehospital setting in pts who are </text>
<text top="583" left="955" width="177" height="15" font="1">hemodynamically compromised but </text>
<text top="598" left="955" width="156" height="15" font="1">do not require cardiopulmonary </text>
<text top="614" left="955" width="68" height="15" font="1">resuscitation. </text>
<text top="769" left="54" width="129" height="15" font="1">Pharmacological Therapy </text>
<text top="786" left="54" width="161" height="15" font="1">Rinkenberger Prospective </text>
<text top="786" left="200" width="79" height="15" font="1">cohort 28 </text>
<text top="786" left="349" width="70" height="15" font="1">AVNRT (n=6) </text>
<text top="786" left="579" width="151" height="15" font="1">Effect of IV and oral verapamil </text>
<text top="786" left="761" width="172" height="15" font="1">IV verapamil terminated AVNRT in </text>
<text top="786" left="954" width="151" height="15" font="1">IV verapamil effective in acute </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">58 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="17" height="15" font="1">RL </text>
<text top="70" left="54" width="28" height="15" font="1">1980 </text>
<text top="86" left="54" width="29" height="15" font="1">(124) </text>
<text top="101" left="54" width="46" height="15" font="8">7418184 </text>
<text top="101" left="100" width="3" height="15" font="1"> </text>
<text top="55" left="139" width="30" height="15" font="1">study </text>
<text top="55" left="349" width="62" height="15" font="1">AVRT (n=6) </text>
<text top="70" left="349" width="98" height="15" font="1">AF/atrial flutter (15) </text>
<text top="86" left="349" width="43" height="15" font="1">AT(n=3) </text>
<text top="55" left="761" width="41" height="15" font="1">all 6 pts </text>
<text top="70" left="761" width="3" height="15" font="1"> </text>
<text top="86" left="761" width="178" height="15" font="1">Oral verapamil given to 19/28 pts, 7 </text>
<text top="101" left="761" width="168" height="15" font="1">reported improvement in sxs after </text>
<text top="117" left="761" width="164" height="15" font="1">19 mo f/u (shorter frequency and </text>
<text top="132" left="761" width="84" height="15" font="1">shorter duration) </text>
<text top="55" left="955" width="162" height="15" font="1">termination, while oral verapamil </text>
<text top="70" left="955" width="114" height="15" font="1">has selective efficacy.  </text>
<text top="148" left="54" width="34" height="15" font="1">Das G </text>
<text top="164" left="54" width="28" height="15" font="1">1988 </text>
<text top="179" left="54" width="29" height="15" font="1">(125) </text>
<text top="195" left="54" width="46" height="15" font="8">2905710 </text>
<text top="195" left="100" width="3" height="15" font="1"> </text>
<text top="210" left="54" width="3" height="15" font="8"> </text>
<text top="210" left="57" width="3" height="15" font="1"> </text>
<text top="148" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="164" left="139" width="30" height="15" font="1">study </text>
<text top="148" left="248" width="22" height="15" font="1">113 </text>
<text top="148" left="349" width="123" height="15" font="1">Pts w/ PSVT (HR &gt;100). </text>
<text top="148" left="579" width="153" height="15" font="1">Efficacy and safety of esmolol. </text>
<text top="164" left="579" width="148" height="15" font="1">Also investigated feasibility of </text>
<text top="179" left="579" width="156" height="15" font="1">transferring pts from esmolol to </text>
<text top="195" left="579" width="154" height="15" font="1">alternate oral AADs w/o loss of </text>
<text top="210" left="579" width="109" height="15" font="1">therapeutic response. </text>
<text top="148" left="761" width="153" height="15" font="1">95 (84%) achieved therapeutic </text>
<text top="164" left="761" width="175" height="15" font="1">response (reduction in heart rate of </text>
<text top="179" left="761" width="177" height="15" font="1">15% or more or conversion to sinus </text>
<text top="195" left="761" width="174" height="15" font="1">rhythm). 93% achieved therapeutic </text>
<text top="210" left="761" width="169" height="15" font="1">response at esmolol doses of 200 </text>
<text top="226" left="761" width="142" height="15" font="1">micrograms/kg/min or lower. </text>
<text top="241" left="761" width="3" height="15" font="1"> </text>
<text top="257" left="761" width="170" height="15" font="1">(88%) pts successfully transferred </text>
<text top="272" left="761" width="68" height="15" font="1">to oral AADs. </text>
<text top="288" left="761" width="3" height="15" font="1"> </text>
<text top="303" left="761" width="143" height="15" font="1">Most frequent adverse effect </text>
<text top="319" left="761" width="153" height="15" font="1">observed during the study was </text>
<text top="334" left="761" width="179" height="15" font="1">hypotension, which resolved quickly </text>
<text top="350" left="761" width="63" height="15" font="1">(16±14 min) </text>
<text top="148" left="955" width="179" height="15" font="1">Esmolol effective in HR reduction or </text>
<text top="164" left="955" width="172" height="15" font="1">convertion to NSR, and majority of </text>
<text top="179" left="955" width="173" height="15" font="1">pts successfully treated w/ esmolol </text>
<text top="195" left="955" width="142" height="15" font="1">can be safely and effectively </text>
<text top="210" left="955" width="125" height="15" font="1">transferred to oral AADs. </text>
<text top="366" left="54" width="56" height="15" font="1">Rankin AC </text>
<text top="381" left="54" width="28" height="15" font="1">1989 </text>
<text top="397" left="54" width="23" height="15" font="1">(43) </text>
<text top="412" left="54" width="46" height="15" font="8">2789911 </text>
<text top="412" left="100" width="3" height="15" font="1"> </text>
<text top="366" left="139" width="66" height="15" font="1">Cohort study </text>
<text top="366" left="248" width="15" height="15" font="1">64 </text>
<text top="366" left="349" width="166" height="15" font="1">94 episodes of sustained, regular </text>
<text top="381" left="349" width="185" height="15" font="1">tachycardia; 40 pts w/ 64 episodes of </text>
<text top="397" left="349" width="208" height="15" font="1">narrow complex tachycardia (9 induced at </text>
<text top="412" left="349" width="51" height="15" font="1">EP study) </text>
<text top="366" left="579" width="122" height="15" font="1">Efficacy of IV adenosine </text>
<text top="366" left="761" width="176" height="15" font="1">Adenosine restored sinus rhythm in </text>
<text top="381" left="761" width="153" height="15" font="1">25 pts 46/48 pts) w/ “junctional </text>
<text top="397" left="761" width="159" height="15" font="1">tachycardia,” found to be due to </text>
<text top="412" left="761" width="86" height="15" font="1">AVRT or AVNRT </text>
<text top="366" left="955" width="160" height="15" font="1">Not specific for AVNRT (defined </text>
<text top="381" left="955" width="163" height="15" font="1">AVRT and AVNRT as “junctional </text>
<text top="397" left="955" width="63" height="15" font="1">tachycardia” </text>
<text top="429" left="54" width="60" height="15" font="1">Amsterdam </text>
<text top="444" left="54" width="18" height="15" font="1">EA </text>
<text top="460" left="54" width="28" height="15" font="1">1991 </text>
<text top="475" left="54" width="29" height="15" font="1">(126) </text>
<text top="491" left="54" width="46" height="15" font="8">1880230 </text>
<text top="491" left="100" width="3" height="15" font="1"> </text>
<text top="506" left="54" width="3" height="15" font="8"> </text>
<text top="506" left="57" width="3" height="15" font="1"> </text>
<text top="429" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="444" left="139" width="30" height="15" font="1">study </text>
<text top="429" left="248" width="15" height="15" font="1">16 </text>
<text top="429" left="349" width="53" height="15" font="1">AF (n=11) </text>
<text top="444" left="349" width="88" height="15" font="1">Atrial flutter (n=2) </text>
<text top="460" left="349" width="61" height="15" font="1">PSVT (n=2) </text>
<text top="475" left="349" width="59" height="15" font="1">MAT (n=1)  </text>
<text top="429" left="579" width="152" height="15" font="1">In 13 responders (81%), mean </text>
<text top="444" left="579" width="156" height="15" font="1">ventricular rate decreased from </text>
<text top="460" left="579" width="143" height="15" font="1">134±6 to 106±7 bpm 10 min </text>
<text top="475" left="579" width="152" height="15" font="1">after metoprolol administration </text>
<text top="491" left="579" width="167" height="15" font="1">and controlled for 40-320 min w/o </text>
<text top="506" left="579" width="81" height="15" font="1">further therapy.  </text>
<text top="522" left="579" width="3" height="15" font="1"> </text>
<text top="537" left="579" width="152" height="15" font="1">Metoprolol reduced ventricular </text>
<text top="552" left="579" width="156" height="15" font="1">rate by &gt;15% in 11 (69%) of 16 </text>
<text top="568" left="579" width="155" height="15" font="1">pts, including 9 (82%) of 11 pts </text>
<text top="583" left="579" width="157" height="15" font="1">w/ AF. In one w/ AF and one w/ </text>
<text top="599" left="579" width="134" height="15" font="1">PSVT, ventricular rate was </text>
<text top="615" left="579" width="90" height="15" font="1">reduced by &gt;12% </text>
<text top="429" left="761" width="169" height="15" font="1">Hypotension, occurring in five pts, </text>
<text top="444" left="761" width="165" height="15" font="1">was the most frequent side effect </text>
<text top="460" left="761" width="144" height="15" font="1">but was transient and readily </text>
<text top="475" left="761" width="52" height="15" font="1">managed. </text>
<text top="429" left="955" width="169" height="15" font="1">Metoprolol was rapidly effective in </text>
<text top="444" left="955" width="151" height="15" font="1">controlling ventricular rate in a </text>
<text top="460" left="955" width="168" height="15" font="1">majority of pts w/ supraventricular </text>
<text top="475" left="955" width="170" height="15" font="1">tachyarrhythmias. Limited data for </text>
<text top="491" left="955" width="44" height="15" font="1">AVNRT. </text>
<text top="631" left="54" width="53" height="15" font="1">Cairns CB </text>
<text top="646" left="54" width="28" height="15" font="1">1991 </text>
<text top="662" left="54" width="23" height="15" font="1">(44) </text>
<text top="677" left="54" width="46" height="15" font="8">2064090 </text>
<text top="677" left="100" width="3" height="15" font="1"> </text>
<text top="693" left="54" width="3" height="15" font="1"> </text>
<text top="631" left="139" width="71" height="15" font="1">Observational </text>
<text top="646" left="139" width="34" height="15" font="1">cohort </text>
<text top="662" left="139" width="3" height="15" font="1"> </text>
<text top="677" left="139" width="3" height="15" font="1"> </text>
<text top="631" left="248" width="246" height="15" font="1">23 Conversion </text>
<text top="631" left="408" width="98" height="15" font="1">to </text>
<text top="631" left="420" width="19" height="15" font="1">SR </text>
<text top="646" left="349" width="3" height="15" font="1"> </text>
<text top="662" left="349" width="205" height="15" font="1">16 y or older presenting to ED in an 8 mo </text>
<text top="677" left="349" width="206" height="15" font="1">study period w/ sustained SVT, rate &gt;140 </text>
<text top="693" left="349" width="25" height="15" font="1">bpm </text>
<text top="708" left="349" width="3" height="15" font="1"> </text>
<text top="724" left="349" width="203" height="15" font="1">Exclusion: severe CHF, unstable angina, </text>
<text top="739" left="349" width="162" height="15" font="1">acute MI by ECG, hemodynamic </text>
<text top="755" left="349" width="207" height="15" font="1">compromise. Excluded sinus tachycardia, </text>
<text top="770" left="349" width="154" height="15" font="1">atrial flutter, AF, QRS &gt;140 ms </text>
<text top="631" left="579" width="156" height="15" font="1">Adenosine to convert SR in ED </text>
<text top="646" left="579" width="36" height="15" font="1">setting </text>
<text top="631" left="761" width="169" height="15" font="1">2 pts after adenosine identified as </text>
<text top="646" left="761" width="164" height="15" font="1">not having SVT (atrial flutter, VT) </text>
<text top="662" left="761" width="157" height="15" font="1">24 episodes of SVT in 21 pts of </text>
<text top="677" left="761" width="176" height="15" font="1">which 96% converted w/ adenosine </text>
<text top="693" left="761" width="113" height="15" font="1">(mean dose 10±6 mg) </text>
<text top="708" left="761" width="166" height="15" font="1">SVT recurred in 57% of episodes </text>
<text top="724" left="761" width="178" height="15" font="1">and other antiarrhythmic drugs then </text>
<text top="739" left="761" width="109" height="15" font="1">used to maintain SR.  </text>
<text top="755" left="761" width="3" height="15" font="1"> </text>
<text top="770" left="761" width="180" height="15" font="1">Adverse effects: 3 pts w/ chest pain, </text>
<text top="786" left="761" width="169" height="15" font="1">one pt w/ dyspnea but no adverse </text>
<text top="631" left="955" width="143" height="15" font="1">Adenosine highly effective in </text>
<text top="646" left="955" width="156" height="15" font="1">converted SVT but recurrences </text>
<text top="662" left="955" width="44" height="15" font="1">frequent </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">59 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="761" width="46" height="15" font="1">outcome </text>
<text top="71" left="54" width="44" height="15" font="1">Musto B </text>
<text top="86" left="54" width="28" height="15" font="1">1992 </text>
<text top="102" left="54" width="29" height="15" font="1">(127) </text>
<text top="117" left="54" width="46" height="15" font="8">1615792 </text>
<text top="117" left="100" width="3" height="15" font="1"> </text>
<text top="71" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="86" left="139" width="30" height="15" font="1">study </text>
<text top="71" left="248" width="19" height="15" font="1">35  </text>
<text top="86" left="248" width="3" height="15" font="1"> </text>
<text top="102" left="248" width="82" height="15" font="1">9 pts w/ AVNRT </text>
<text top="117" left="248" width="61" height="15" font="1">(Age 10-23) </text>
<text top="71" left="349" width="208" height="15" font="1">Recurrent PSVT documented by ECG; no </text>
<text top="86" left="349" width="188" height="15" font="1">h/o VT or AF, well-tolerated PSVT not </text>
<text top="102" left="349" width="89" height="15" font="1">induced by stress </text>
<text top="117" left="349" width="3" height="15" font="1"> </text>
<text top="133" left="349" width="208" height="15" font="1">9 total pts w/ AVNRT, remainder w/ AVRT </text>
<text top="71" left="579" width="121" height="15" font="1">Termination of PSVT by </text>
<text top="86" left="579" width="53" height="15" font="1">flecainide. </text>
<text top="71" left="761" width="124" height="15" font="1">PSVT terminated in 6/9.  </text>
<text top="86" left="761" width="3" height="15" font="1"> </text>
<text top="71" left="955" width="172" height="15" font="1">Pts prescreened w/ EP study. Non-</text>
<text top="86" left="955" width="150" height="15" font="1">randomized study, and limited </text>
<text top="102" left="955" width="132" height="15" font="1">number of pts w/ AVNRT.  </text>
<text top="149" left="54" width="64" height="15" font="1">Gambhir DS </text>
<text top="164" left="54" width="28" height="15" font="1">1995 </text>
<text top="180" left="54" width="29" height="15" font="1">(128) </text>
<text top="195" left="54" width="46" height="15" font="8">7558090 </text>
<text top="195" left="100" width="3" height="15" font="1"> </text>
<text top="211" left="54" width="3" height="15" font="1"> </text>
<text top="149" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="164" left="139" width="30" height="15" font="1">study </text>
<text top="149" left="248" width="15" height="15" font="1">26 </text>
<text top="149" left="349" width="195" height="15" font="1">All pts w/ symptomatic PSVT, recurrent </text>
<text top="164" left="349" width="109" height="15" font="1">palpitations for 1-13 y </text>
<text top="180" left="349" width="197" height="15" font="1">EP study performed, IV flecainide given </text>
<text top="195" left="349" width="192" height="15" font="1">and then EP study repeated 20-30 min </text>
<text top="211" left="349" width="102" height="15" font="1">later w/ IV flecainide </text>
<text top="149" left="579" width="161" height="15" font="1">Effective in terminating all pts w/ </text>
<text top="164" left="579" width="121" height="15" font="1">AVNRT, 11/12 w/ AVRT </text>
<text top="180" left="579" width="3" height="15" font="1"> </text>
<text top="195" left="579" width="157" height="15" font="1">Time to termination both similar </text>
<text top="211" left="579" width="167" height="15" font="1">(146±70 vs. 149±29 sec, AVNRT </text>
<text top="226" left="579" width="53" height="15" font="1">vs. AVRT) </text>
<text top="242" left="579" width="3" height="15" font="1"> </text>
<text top="257" left="579" width="157" height="15" font="1">AVNRT reinducible in one pt w/ </text>
<text top="273" left="579" width="121" height="15" font="1">AVNRT, 4 pts w/ AVRT  </text>
<text top="288" left="579" width="3" height="15" font="1"> </text>
<text top="304" left="579" width="118" height="15" font="1">Selective depression of </text>
<text top="319" left="579" width="77" height="15" font="1">retrograde limb </text>
<text top="149" left="761" width="22" height="15" font="1">N/A </text>
<text top="149" left="955" width="169" height="15" font="1">IV flecainide effective and safe for </text>
<text top="164" left="955" width="152" height="15" font="1">acute episodes of AVNRT and </text>
<text top="180" left="955" width="33" height="15" font="1">AVRT </text>
<text top="195" left="955" width="3" height="15" font="1"> </text>
<text top="211" left="955" width="144" height="15" font="1">Oral therapy presumed to be </text>
<text top="226" left="955" width="176" height="15" font="1">effective given effects in preventing </text>
<text top="242" left="955" width="67" height="15" font="1">reinducibility. </text>
<text top="257" left="955" width="3" height="15" font="1"> </text>
<text top="273" left="955" width="91" height="15" font="1">EP study efficacy. </text>
<text top="336" left="54" width="64" height="15" font="1">Gambhir DS </text>
<text top="351" left="54" width="28" height="15" font="1">1996 </text>
<text top="367" left="54" width="23" height="15" font="1">(54) </text>
<text top="382" left="54" width="49" height="15" font="8">8682552  </text>
<text top="398" left="54" width="3" height="15" font="1"> </text>
<text top="336" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="351" left="139" width="30" height="15" font="1">study </text>
<text top="336" left="248" width="9" height="15" font="1">9 </text>
<text top="336" left="349" width="204" height="15" font="1">All pts w/ symptomatic AVNRT, recurrent </text>
<text top="351" left="349" width="213" height="15" font="1">palpitations for 2-12 y EP study performed, </text>
<text top="367" left="349" width="161" height="15" font="1">IV amiodarone then oral therapy </text>
<text top="382" left="349" width="209" height="15" font="1">subsequently EP study repeated 1.5-3 mo </text>
<text top="398" left="349" width="25" height="15" font="1">later </text>
<text top="336" left="579" width="111" height="15" font="1">No pts reported sxs of </text>
<text top="351" left="579" width="167" height="15" font="1">tachycardia during mean f/u of 65 </text>
<text top="367" left="579" width="108" height="15" font="1">d on oral amiodarone </text>
<text top="382" left="579" width="3" height="15" font="1"> </text>
<text top="398" left="579" width="130" height="15" font="1">IV amiodarone terminated </text>
<text top="413" left="579" width="163" height="15" font="1">AVNRT in 7/9 pts (retrograde FP </text>
<text top="429" left="579" width="166" height="15" font="1">in 4/7 and anterograde SP in 3/7) </text>
<text top="444" left="579" width="3" height="15" font="1"> </text>
<text top="460" left="579" width="154" height="15" font="1">Not inducible on PES after oral </text>
<text top="475" left="579" width="125" height="15" font="1">therapy, largely to due to </text>
<text top="491" left="579" width="137" height="15" font="1">prolonging refractoriness in </text>
<text top="506" left="579" width="124" height="15" font="1">atrium and ventricle, and </text>
<text top="522" left="579" width="154" height="15" font="1">depressing conduction through </text>
<text top="537" left="579" width="17" height="15" font="1">FP </text>
<text top="336" left="761" width="22" height="15" font="1">N/A </text>
<text top="336" left="955" width="143" height="15" font="1">Small series of pts, but all w/ </text>
<text top="351" left="955" width="41" height="15" font="1">AVNRT </text>
<text top="367" left="955" width="3" height="15" font="1"> </text>
<text top="382" left="955" width="151" height="15" font="1">Oral therapy w/ amiodarone is </text>
<text top="398" left="955" width="162" height="15" font="1">effective in suppressing AVNRT. </text>
<text top="413" left="955" width="3" height="15" font="1"> </text>
<text top="429" left="955" width="172" height="15" font="1">IV amiodarone is effective in acute </text>
<text top="444" left="955" width="43" height="15" font="1">therapy. </text>
<text top="460" left="955" width="3" height="15" font="1"> </text>
<text top="475" left="955" width="91" height="15" font="1">EP study efficacy. </text>
<text top="553" left="54" width="54" height="15" font="1">Glatter KA </text>
<text top="569" left="54" width="28" height="15" font="1">1999 </text>
<text top="584" left="54" width="29" height="15" font="1">(129) </text>
<text top="600" left="54" width="55" height="15" font="8">10051297  </text>
<text top="615" left="54" width="3" height="15" font="1"> </text>
<text top="553" left="139" width="71" height="15" font="1">Retrospective </text>
<text top="569" left="139" width="63" height="15" font="1">cohort study </text>
<text top="553" left="248" width="22" height="15" font="1">229 </text>
<text top="553" left="349" width="113" height="15" font="1">PSVT during EP study </text>
<text top="569" left="349" width="3" height="15" font="1"> </text>
<text top="584" left="349" width="68" height="15" font="1">AVRT (n=59) </text>
<text top="600" left="349" width="117" height="15" font="1">Typical  AVNRT (n=82) </text>
<text top="615" left="349" width="121" height="15" font="1">Artypical AVNRT (n=13) </text>
<text top="631" left="349" width="66" height="15" font="1">PJRT (n=12) </text>
<text top="646" left="349" width="53" height="15" font="1">AT (n=53) </text>
<text top="662" left="349" width="56" height="15" font="1">IST (n=10) </text>
<text top="553" left="579" width="153" height="15" font="1">Determining the mechanism of </text>
<text top="569" left="579" width="149" height="15" font="1">PSVT w/ adenosine response </text>
<text top="553" left="761" width="144" height="15" font="1">Adenosine of limited value in </text>
<text top="569" left="761" width="165" height="15" font="1">determining mechanism of PSVT </text>
<text top="584" left="761" width="3" height="15" font="1"> </text>
<text top="600" left="761" width="155" height="15" font="1">100% of pts w/ AVNRT, AVRT, </text>
<text top="615" left="761" width="137" height="15" font="1">atypical AVNRT, and PJRT </text>
<text top="631" left="761" width="124" height="15" font="1">terminated w/ adenosine </text>
<text top="553" left="955" width="22" height="15" font="1">N/A </text>
<text top="678" left="54" width="43" height="15" font="1">Ablation </text>
<text top="694" left="54" width="70" height="15" font="1">Jackman WM </text>
<text top="710" left="54" width="28" height="15" font="1">1992 </text>
<text top="725" left="54" width="23" height="15" font="1">(53) </text>
<text top="741" left="54" width="46" height="15" font="8">1620170 </text>
<text top="741" left="100" width="3" height="15" font="1"> </text>
<text top="756" left="54" width="3" height="17" font="0"> </text>
<text top="694" left="139" width="61" height="15" font="1">Prospective </text>
<text top="710" left="139" width="69" height="15" font="1">observational </text>
<text top="725" left="139" width="34" height="15" font="1">cohort </text>
<text top="694" left="248" width="15" height="15" font="1">80 </text>
<text top="694" left="349" width="204" height="15" font="1">Symptomatic AVNRT undergoing RFA of </text>
<text top="710" left="349" width="70" height="15" font="1">slow-pathway </text>
<text top="694" left="579" width="160" height="15" font="1">Successful ablation w/ intact AV </text>
<text top="710" left="579" width="168" height="15" font="1">nodal conduction, guided by atrial </text>
<text top="725" left="579" width="101" height="15" font="1">slow-path potentials </text>
<text top="694" left="761" width="159" height="15" font="1">RFA abolished or modified slow-</text>
<text top="710" left="761" width="161" height="15" font="1">pathway conduction in 78/80 pts </text>
<text top="725" left="761" width="128" height="15" font="1">w/o affecting normal AVN </text>
<text top="741" left="761" width="176" height="15" font="1">conduction. Mean (±SD) f/u of 15.5 </text>
<text top="756" left="761" width="101" height="15" font="1">mo w/o recurrence.  </text>
<text top="694" left="955" width="165" height="15" font="1">Early report of success of RFA of </text>
<text top="710" left="955" width="158" height="15" font="1">slow-path conduction guided by </text>
<text top="725" left="955" width="166" height="15" font="1">atrial slow-path potentials—led to </text>
<text top="741" left="955" width="142" height="15" font="1">slow-pathway ablation being </text>
<text top="756" left="955" width="138" height="15" font="1">preferred method. Provided </text>
<text top="772" left="955" width="180" height="15" font="1">evidence that atrial insertions of fast </text>
<text top="787" left="955" width="155" height="15" font="1">and slow path are anatomically </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">60 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="955" width="41" height="15" font="1">distinct. </text>
<text top="71" left="54" width="42" height="15" font="1">Kay GN </text>
<text top="86" left="54" width="28" height="15" font="1">1992 </text>
<text top="102" left="54" width="29" height="15" font="1">(130) </text>
<text top="117" left="54" width="46" height="15" font="8">1572026 </text>
<text top="117" left="100" width="3" height="15" font="1"> </text>
<text top="71" left="139" width="61" height="15" font="1">Prospective </text>
<text top="86" left="139" width="69" height="15" font="1">observational </text>
<text top="102" left="139" width="34" height="15" font="1">cohort </text>
<text top="71" left="248" width="18" height="15" font="1">34  </text>
<text top="71" left="349" width="149" height="15" font="1">Slow pathway ablation (n=30) </text>
<text top="86" left="349" width="140" height="15" font="1">Fast pathway ablation (n=4) </text>
<text top="102" left="349" width="3" height="15" font="1"> </text>
<text top="117" left="349" width="3" height="15" font="1"> </text>
<text top="71" left="579" width="154" height="15" font="1">Antegrade conduction over the </text>
<text top="86" left="579" width="156" height="15" font="1">fast pathway remained intact in </text>
<text top="102" left="579" width="127" height="15" font="1">all 30 pts after successful </text>
<text top="117" left="579" width="157" height="15" font="1">selective slow pathway ablation </text>
<text top="133" left="579" width="3" height="15" font="1"> </text>
<text top="148" left="579" width="127" height="15" font="1">There was no statistically </text>
<text top="164" left="579" width="166" height="15" font="1">significant change in the atrio-His </text>
<text top="179" left="579" width="160" height="15" font="1">interval (68.5±21.8 msec before </text>
<text top="195" left="579" width="130" height="15" font="1">and 69.6±23.9 msec after </text>
<text top="210" left="579" width="165" height="15" font="1">ablation) or AV Wenckebach rate </text>
<text top="226" left="579" width="150" height="15" font="1">(167±27 beats per min before </text>
<text top="241" left="579" width="158" height="15" font="1">and 178±50 beats per min after </text>
<text top="257" left="579" width="166" height="15" font="1">ablation) after slow path ablation  </text>
<text top="71" left="761" width="179" height="15" font="1">3 complications in two pts, including </text>
<text top="86" left="761" width="161" height="15" font="1">an episode of pulmonary edema </text>
<text top="102" left="761" width="119" height="15" font="1">and the development of </text>
<text top="117" left="761" width="180" height="15" font="1">spontaneous AV Wenckebach block </text>
<text top="133" left="761" width="159" height="15" font="1">during sleep in one pt after slow </text>
<text top="148" left="761" width="147" height="15" font="1">pathway ablation and the late </text>
<text top="164" left="761" width="174" height="15" font="1">development of complete AV block </text>
<text top="179" left="761" width="155" height="15" font="1">in another pt after fast pathway </text>
<text top="195" left="761" width="175" height="15" font="1">ablation. Over a mean f/u period of </text>
<text top="210" left="761" width="178" height="15" font="1">322±73 d, AVNRT recurred in three </text>
<text top="226" left="761" width="170" height="15" font="1">pts, all of whom were successfully </text>
<text top="241" left="761" width="145" height="15" font="1">treated w/ a second ablation. </text>
<text top="71" left="955" width="171" height="15" font="1">Early report suggesting benefits of </text>
<text top="86" left="955" width="157" height="15" font="1">slow pathway ablation over fast </text>
<text top="102" left="955" width="92" height="15" font="1">pathway ablation.  </text>
<text top="273" left="54" width="45" height="15" font="1">Bogun F </text>
<text top="288" left="54" width="31" height="15" font="1">1996  </text>
<text top="304" left="54" width="29" height="15" font="1">(131) </text>
<text top="319" left="54" width="46" height="15" font="8">8837581 </text>
<text top="319" left="100" width="3" height="15" font="1"> </text>
<text top="273" left="139" width="61" height="15" font="1">Prospective </text>
<text top="288" left="139" width="69" height="15" font="1">observational </text>
<text top="304" left="139" width="34" height="15" font="1">cohort </text>
<text top="273" left="248" width="23" height="15" font="1">7 w/ </text>
<text top="288" left="248" width="65" height="15" font="1">noninducible </text>
<text top="304" left="248" width="41" height="15" font="1">AVNRT </text>
<text top="319" left="248" width="82" height="15" font="1">compared w/ 34 </text>
<text top="335" left="248" width="61" height="15" font="1">w/ inducible </text>
<text top="350" left="248" width="38" height="15" font="1">AVNRT</text>
<text top="350" left="285" width="3" height="15" font="9"> </text>
<text top="273" left="349" width="210" height="15" font="1">Spontaneous but noninducible AVNRT (w/ </text>
<text top="288" left="349" width="199" height="15" font="1">evidence of dual AV nodal physiology at </text>
<text top="304" left="349" width="54" height="15" font="1">EP study)  </text>
<text top="273" left="579" width="145" height="15" font="1">All evidence of dual AV node </text>
<text top="288" left="579" width="154" height="15" font="1">pathways was eliminated in six </text>
<text top="304" left="579" width="167" height="15" font="1">pts, and dual AV node physiology </text>
<text top="319" left="579" width="141" height="15" font="1">remained present in one pt.  </text>
<text top="335" left="579" width="3" height="15" font="1"> </text>
<text top="350" left="579" width="137" height="15" font="1">During a mean f/u period of </text>
<text top="366" left="579" width="160" height="15" font="1">15±10 mo (range 8 to 27), no pt </text>
<text top="381" left="579" width="164" height="15" font="1">had a recurrence of symptomatic </text>
<text top="397" left="579" width="160" height="15" font="1">tachycardia (success rate 95%). </text>
<text top="273" left="761" width="22" height="15" font="1">N/A </text>
<text top="273" left="955" width="153" height="15" font="1">Slow pathway ablation may be </text>
<text top="288" left="955" width="121" height="15" font="1">clinically useful in pts w/ </text>
<text top="304" left="955" width="180" height="15" font="1">documented but noninducible PSVT </text>
<text top="319" left="955" width="180" height="15" font="1">who have evidence of dual AV node </text>
<text top="335" left="955" width="50" height="15" font="1">pathways </text>
<text top="350" left="955" width="3" height="15" font="1"> </text>
<text top="366" left="955" width="157" height="15" font="1">First recommendation that slow </text>
<text top="381" left="955" width="178" height="15" font="1">pathway ablation be indicated in pts </text>
<text top="397" left="955" width="169" height="15" font="1">w/ spontaneous PSVT w/ dual AV </text>
<text top="412" left="955" width="167" height="15" font="1">node physiology but noninducible </text>
<text top="428" left="955" width="97" height="15" font="1">PSVT in EP study.  </text>
<text top="443" left="955" width="3" height="15" font="1"> </text>
<text top="459" left="955" width="95" height="15" font="1">Small sample size. </text>
<text top="475" left="54" width="47" height="15" font="1">D’Este D </text>
<text top="491" left="54" width="28" height="15" font="1">2005 </text>
<text top="506" left="54" width="29" height="15" font="1">(132) </text>
<text top="522" left="54" width="52" height="15" font="8">16814416 </text>
<text top="522" left="106" width="3" height="15" font="1"> </text>
<text top="475" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="491" left="139" width="30" height="15" font="1">study </text>
<text top="475" left="248" width="15" height="15" font="1">93 </text>
<text top="475" left="349" width="201" height="15" font="1">Pts w/ AVNRT prospectively followed for </text>
<text top="491" left="349" width="177" height="15" font="1">mean 13.2 y, compare outcomes of </text>
<text top="506" left="349" width="194" height="15" font="1">ablation (n=18) vs. AADs (n=24) vs. no </text>
<text top="522" left="349" width="75" height="15" font="1">therapy (n=38) </text>
<text top="537" left="349" width="3" height="15" font="1"> </text>
<text top="552" left="349" width="210" height="15" font="1">AADs: flecainide, propafenone, verapamil, </text>
<text top="568" left="349" width="130" height="15" font="1">sotalol, atenolol, diltiazem </text>
<text top="475" left="579" width="140" height="15" font="1">At f/u, asymptomatic for 3 y: </text>
<text top="491" left="579" width="77" height="15" font="1">Ablation: 100% </text>
<text top="506" left="579" width="69" height="15" font="1">AADs: 60.8% </text>
<text top="522" left="579" width="95" height="15" font="1">No therapy: 44.7% </text>
<text top="537" left="579" width="3" height="15" font="1"> </text>
<text top="552" left="579" width="135" height="15" font="1">Untreated pts who became </text>
<text top="568" left="579" width="140" height="15" font="1">asymptomatic had a shorter </text>
<text top="583" left="579" width="162" height="15" font="1">duration of sxs before enrolment </text>
<text top="599" left="579" width="156" height="15" font="1">(3.7±1.5 vs. 7.1±3.6 y, p&lt;0.05) </text>
<text top="615" left="579" width="145" height="15" font="1">and a shorter mean length of </text>
<text top="630" left="579" width="152" height="15" font="1">tachycardia episodes (3.8±2.4 </text>
<text top="645" left="579" width="160" height="15" font="1">vs. 42.6±17.8 min, p&lt;0.02) than </text>
<text top="661" left="579" width="128" height="15" font="1">pts from same group who </text>
<text top="676" left="579" width="114" height="15" font="1">remained symptomatic </text>
<text top="475" left="761" width="118" height="15" font="1">3 pts died, 10 lost to f/u </text>
<text top="475" left="955" width="119" height="15" font="1">During a long-term f/u a </text>
<text top="491" left="955" width="169" height="15" font="1">considerable number of untreated </text>
<text top="506" left="955" width="115" height="15" font="1">pts w/ AVNRT become </text>
<text top="522" left="955" width="74" height="15" font="1">asymptomatic. </text>
<text top="537" left="955" width="3" height="15" font="1"> </text>
<text top="552" left="955" width="177" height="15" font="1">Suggests that pts w/ infrequent and </text>
<text top="568" left="955" width="179" height="15" font="1">minor sxs may be able to be treated </text>
<text top="583" left="955" width="168" height="15" font="1">conservatively (i.e., no ablation or </text>
<text top="599" left="955" width="34" height="15" font="1">AADs. </text>
<text top="615" left="955" width="3" height="15" font="1"> </text>
<text top="630" left="955" width="182" height="15" font="1">Study directly evaluates AVNRT and </text>
<text top="645" left="955" width="167" height="15" font="1">suggests efficacy of ablation over </text>
<text top="661" left="955" width="34" height="15" font="1">AADs. </text>
<text top="676" left="955" width="3" height="15" font="1"> </text>
<text top="692" left="955" width="165" height="15" font="1">Limitations that the results are sx </text>
<text top="707" left="955" width="36" height="15" font="1">based. </text>
<text top="724" left="54" width="52" height="15" font="1">Spector P </text>
<text top="739" left="54" width="28" height="15" font="1">2009 </text>
<text top="755" left="54" width="23" height="15" font="1">(55) </text>
<text top="770" left="54" width="55" height="15" font="8">19699343  </text>
<text top="770" left="109" width="3" height="15" font="1"> </text>
<text top="724" left="139" width="92" height="15" font="1">Systematic review </text>
<text top="739" left="139" width="93" height="15" font="1">and meta-analysis </text>
<text top="755" left="139" width="76" height="15" font="1">to evaluate the </text>
<text top="770" left="139" width="95" height="15" font="1">safety and efficacy </text>
<text top="786" left="139" width="94" height="15" font="1">of RFA of AVNRT, </text>
<text top="724" left="248" width="82" height="15" font="1">For AVNRT and </text>
<text top="739" left="248" width="86" height="15" font="1">AP-mediated: 39 </text>
<text top="755" left="248" width="78" height="15" font="1">primary studies </text>
<text top="770" left="248" width="79" height="15" font="1">w/ 49 treatment </text>
<text top="786" left="248" width="88" height="15" font="1">arms in 7,693 pts </text>
<text top="724" left="349" width="213" height="15" font="1">Previous reviews or meta-analyses; animal </text>
<text top="739" left="349" width="205" height="15" font="1">or in vitro studies; subjects aged &lt;18 y or </text>
<text top="755" left="349" width="195" height="15" font="1">mixed populations of which &gt;15% were </text>
<text top="770" left="349" width="190" height="15" font="1">pediatric pts; f/u of &lt;7 d; not studies of </text>
<text top="786" left="349" width="204" height="15" font="1">RFA; alternative energy sources used for </text>
<text top="724" left="579" width="161" height="15" font="1">SVT (AVNRT and AP-mediated) </text>
<text top="739" left="579" width="3" height="15" font="1"> </text>
<text top="755" left="579" width="154" height="15" font="1">Single- and multiple-procedure </text>
<text top="770" left="579" width="160" height="15" font="1">success, arrhythmia recurrence, </text>
<text top="786" left="579" width="161" height="15" font="1">repeat ablation, adverse events, </text>
<text top="724" left="761" width="171" height="15" font="1">Single-procedure success: 93.2%  </text>
<text top="739" left="761" width="116" height="15" font="1">(95% CI: 90.8-95.5%).  </text>
<text top="755" left="761" width="3" height="15" font="1"> </text>
<text top="770" left="761" width="175" height="15" font="1">Multiple-procedure success: 94.6% </text>
<text top="786" left="761" width="106" height="15" font="1">(95% CI: 92.4- 96.9). </text>
<text top="724" left="955" width="149" height="15" font="1">First meta-analysis of RFA for </text>
<text top="739" left="955" width="157" height="15" font="1">AVNRT, AVRT (AP-mediated).  </text>
<text top="755" left="955" width="3" height="15" font="1"> </text>
<text top="770" left="955" width="164" height="15" font="1">Demonstrates high efficacy rates </text>
<text top="786" left="955" width="154" height="15" font="1">and low rates of complications. </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">61 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="139" width="92" height="15" font="1">AP-mediated, and </text>
<text top="70" left="139" width="61" height="15" font="1">atrial flutter. </text>
<text top="55" left="349" width="160" height="15" font="1">ablation; AV junction ablation w/ </text>
<text top="70" left="349" width="182" height="15" font="1">pacemaker implantation; &lt;40 pts per </text>
<text top="86" left="349" width="215" height="15" font="1">arrhythmia or ablation technique; published </text>
<text top="101" left="349" width="191" height="15" font="1">only in abstract form; published before </text>
<text top="117" left="349" width="197" height="15" font="1">1990; and published in languages other </text>
<text top="132" left="349" width="189" height="15" font="1">than English, Spanish, French, Italian, </text>
<text top="147" left="349" width="130" height="15" font="1">German, and Portuguese. </text>
<text top="55" left="579" width="52" height="15" font="1">and death </text>
<text top="70" left="579" width="3" height="15" font="1"> </text>
<text top="86" left="579" width="6" height="15" font="1">  </text>
<text top="55" left="761" width="3" height="15" font="1"> </text>
<text top="70" left="761" width="158" height="15" font="1">Post-ablation arrhythmia: 5.6%  </text>
<text top="86" left="761" width="103" height="15" font="1">(95% CI: 4.1-7.2%).  </text>
<text top="101" left="761" width="3" height="15" font="1"> </text>
<text top="117" left="761" width="177" height="15" font="1">Repeat ablation: 6.5% (95% C:I 4.7-</text>
<text top="132" left="761" width="32" height="15" font="1">8.3%) </text>
<text top="147" left="761" width="3" height="15" font="1"> </text>
<text top="163" left="761" width="125" height="15" font="1">All-cause mortality: 0.1% </text>
<text top="178" left="761" width="3" height="15" font="1"> </text>
<text top="194" left="761" width="114" height="15" font="1">Adverse events: 2.9%  </text>
<text top="210" left="54" width="131" height="15" font="1">Outcomes (Registry Data) </text>
<text top="226" left="54" width="60" height="15" font="1">Hindricks G </text>
<text top="242" left="54" width="28" height="15" font="1">1993 </text>
<text top="257" left="54" width="23" height="15" font="1">(57) </text>
<text top="273" left="54" width="46" height="15" font="8">8131762 </text>
<text top="273" left="100" width="3" height="15" font="1"> </text>
<text top="226" left="139" width="137" height="15" font="1">Prospective cohort  4398 </text>
<text top="226" left="349" width="148" height="15" font="1">AT/atrial flutter (n=141, 3.2%) </text>
<text top="242" left="349" width="102" height="15" font="1">AVJ (n=900, 20.5%) </text>
<text top="257" left="349" width="120" height="15" font="1">AVNRT (n=815, 18.5%) </text>
<text top="273" left="349" width="127" height="15" font="1">AVRT: (n = 2222, 50.5%) </text>
<text top="288" left="349" width="93" height="15" font="1">VT (n=320, 7.3%). </text>
<text top="226" left="579" width="133" height="15" font="1">Incidence of complications </text>
<text top="226" left="761" width="170" height="15" font="1">Complications occurred in 223 pts </text>
<text top="242" left="761" width="71" height="15" font="1">(5.1%) overall </text>
<text top="257" left="761" width="3" height="15" font="1"> </text>
<text top="273" left="761" width="106" height="15" font="1">AT/atrial flutter: 5.0% </text>
<text top="288" left="761" width="55" height="15" font="1">AVJ: 3.2% </text>
<text top="304" left="761" width="72" height="15" font="1">AVNRT: 8.0% </text>
<text top="319" left="761" width="64" height="15" font="1">AVRT: 4.4% </text>
<text top="335" left="761" width="49" height="15" font="1">VT: 7.5% </text>
<text top="350" left="761" width="3" height="15" font="1"> </text>
<text top="366" left="761" width="178" height="15" font="1">Complications more in AVNRT RFA </text>
<text top="381" left="761" width="161" height="15" font="1">compared to AVJ or AP ablation </text>
<text top="397" left="761" width="54" height="15" font="1">(p&lt;0.001)  </text>
<text top="412" left="761" width="3" height="15" font="1"> </text>
<text top="428" left="761" width="130" height="15" font="1">Complications more in VT </text>
<text top="443" left="761" width="169" height="15" font="1">compared to AVJ (p&lt;0.002) or AP </text>
<text top="459" left="761" width="45" height="15" font="1">(p&lt;0.02) </text>
<text top="226" left="955" width="178" height="15" font="1">Early report showing high incidence </text>
<text top="242" left="955" width="148" height="15" font="1">of complications after AVNRT </text>
<text top="257" left="955" width="45" height="15" font="1">ablation. </text>
<text top="475" left="54" width="60" height="15" font="1">Hindricks G </text>
<text top="491" left="54" width="28" height="15" font="1">1996 </text>
<text top="506" left="54" width="23" height="15" font="1">(58) </text>
<text top="522" left="54" width="46" height="15" font="8">8682135 </text>
<text top="522" left="100" width="3" height="15" font="1"> </text>
<text top="475" left="139" width="137" height="15" font="1">Prospective cohort  4463 </text>
<text top="475" left="349" width="82" height="15" font="1">AVNRT (n=880) </text>
<text top="475" left="579" width="110" height="15" font="1">Incidence of AV block </text>
<text top="475" left="761" width="126" height="15" font="1">AV block (4/ 880, 4.7%).  </text>
<text top="491" left="761" width="3" height="15" font="1"> </text>
<text top="506" left="761" width="157" height="15" font="1">AV block higher in fast pathway </text>
<text top="522" left="761" width="161" height="15" font="1">ablation (19/361, 5.3%, p&lt;0.05)  </text>
<text top="537" left="761" width="3" height="15" font="1"> </text>
<text top="552" left="761" width="129" height="15" font="1">6.3% in centers w/ limited </text>
<text top="568" left="761" width="179" height="15" font="1">experience in RFA (≤30 pts treated, </text>
<text top="583" left="761" width="161" height="15" font="1">p&lt;0.05), and higher in these low-</text>
<text top="599" left="761" width="165" height="15" font="1">volume centers for both slow and </text>
<text top="615" left="761" width="152" height="15" font="1">fast pathway ablation (p&lt;0.05) </text>
<text top="475" left="955" width="173" height="15" font="1">Early report showing 5% incidence </text>
<text top="491" left="955" width="169" height="15" font="1">of AV block after RFA for AVNRT, </text>
<text top="506" left="955" width="180" height="15" font="1">and higher w/ fast pathway ablation. </text>
<text top="631" left="54" width="50" height="15" font="1">Calkins H </text>
<text top="646" left="54" width="28" height="15" font="1">1999 </text>
<text top="662" left="54" width="23" height="15" font="1">(59) </text>
<text top="677" left="54" width="46" height="15" font="8">9892593 </text>
<text top="677" left="100" width="3" height="15" font="1"> </text>
<text top="631" left="139" width="137" height="15" font="1">Prospective cohort  1050 </text>
<text top="646" left="248" width="57" height="15" font="1">(previously </text>
<text top="662" left="248" width="79" height="15" font="1">enrolled in RFA </text>
<text top="677" left="248" width="61" height="15" font="1">clinical trial) </text>
<text top="631" left="349" width="138" height="15" font="1">RFA of AVNRT, AP, or AVJ </text>
<text top="646" left="349" width="3" height="15" font="1"> </text>
<text top="662" left="349" width="82" height="15" font="1">AVNRT (n=373) </text>
<text top="677" left="349" width="59" height="15" font="1">AP (n=500) </text>
<text top="693" left="349" width="65" height="15" font="1">AVJ (n=121) </text>
<text top="708" left="349" width="3" height="15" font="1"> </text>
<text top="631" left="579" width="148" height="15" font="1">Efficacy and safety of RFA w/ </text>
<text top="646" left="579" width="68" height="15" font="1">long-term f/u. </text>
<text top="662" left="579" width="3" height="15" font="1"> </text>
<text top="677" left="579" width="3" height="15" font="1"> </text>
<text top="631" left="761" width="84" height="15" font="1">Overall success: </text>
<text top="646" left="761" width="25" height="15" font="1">95% </text>
<text top="662" left="761" width="94" height="15" font="1">Overall recurrence </text>
<text top="677" left="761" width="19" height="15" font="1">6% </text>
<text top="693" left="761" width="3" height="15" font="1"> </text>
<text top="708" left="761" width="48" height="15" font="1">Success: </text>
<text top="724" left="761" width="69" height="15" font="1">AVNRT: 97% </text>
<text top="739" left="761" width="46" height="15" font="1">AP: 93% </text>
<text top="755" left="761" width="58" height="15" font="1">AVJ: 100% </text>
<text top="770" left="761" width="3" height="15" font="1"> </text>
<text top="786" left="761" width="63" height="15" font="1">Recurrence: </text>
<text top="631" left="955" width="178" height="15" font="1">Shows RFA is a favorable option w/ </text>
<text top="646" left="955" width="144" height="15" font="1">low risk of complications and </text>
<text top="662" left="955" width="168" height="15" font="1">recurrence, and identifies pts who </text>
<text top="677" left="955" width="161" height="15" font="1">are at risk. Per-protocol analysis </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">62 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="761" width="63" height="15" font="1">AVNRT: 5% </text>
<text top="70" left="761" width="40" height="15" font="1">AP: 8% </text>
<text top="86" left="761" width="46" height="15" font="1">AVJ: 2% </text>
<text top="101" left="761" width="3" height="15" font="1"> </text>
<text top="117" left="761" width="111" height="15" font="1">Predictors of success: </text>
<text top="132" left="761" width="44" height="15" font="1">-AVNRT </text>
<text top="147" left="761" width="146" height="15" font="1">OR: 3.94 (95% CI: 1.93-8.04; </text>
<text top="163" left="761" width="53" height="15" font="1">p=0.0002) </text>
<text top="178" left="761" width="87" height="15" font="1">-Left free wall AP </text>
<text top="194" left="761" width="146" height="15" font="1">OR: 3.09 (95% CI: 1.46-6.53; </text>
<text top="209" left="761" width="53" height="15" font="1">p=0.0003) </text>
<text top="225" left="761" width="176" height="15" font="1">-Experience of ablation center (&gt;39 </text>
<text top="240" left="761" width="22" height="15" font="1">pts) </text>
<text top="256" left="761" width="146" height="15" font="1">OR: 2.39 (95% CI: 1.21-4.71; </text>
<text top="271" left="761" width="47" height="15" font="1">p=0.012) </text>
<text top="287" left="761" width="3" height="15" font="1"> </text>
<text top="302" left="761" width="138" height="15" font="1">Joint predictors of mortality: </text>
<text top="318" left="761" width="72" height="15" font="1">-EF (p=0.003) </text>
<text top="333" left="761" width="81" height="15" font="1">-SHD (p=0.016) </text>
<text top="349" left="761" width="120" height="15" font="1">-AVJ ablation (p=0.048) </text>
<text top="365" left="54" width="58" height="15" font="1">Scheinman </text>
<text top="381" left="54" width="22" height="15" font="1">MM </text>
<text top="396" left="54" width="28" height="15" font="1">2000 </text>
<text top="412" left="54" width="23" height="15" font="1">(61) </text>
<text top="427" left="54" width="52" height="15" font="8">10879389 </text>
<text top="427" left="106" width="3" height="15" font="1"> </text>
<text top="365" left="139" width="95" height="15" font="1">Prospective cohort </text>
<text top="381" left="139" width="30" height="15" font="1">study </text>
<text top="396" left="139" width="87" height="15" font="1">(NASPE registry) </text>
<text top="365" left="248" width="31" height="15" font="1">3,357 </text>
<text top="365" left="349" width="207" height="15" font="1">Ablation of AVNRT, AP, AVJ, atrial flutter, </text>
<text top="381" left="349" width="131" height="15" font="1">AT, IST, VT, idiopathic VT </text>
<text top="396" left="349" width="3" height="15" font="1"> </text>
<text top="412" left="349" width="129" height="15" font="1">AVNRT (n=1,197 [35.6%) </text>
<text top="427" left="349" width="65" height="15" font="1">AVJ (n=646) </text>
<text top="443" left="349" width="59" height="15" font="1">AP (n=654) </text>
<text top="458" left="349" width="59" height="15" font="1">AT (n=216) </text>
<text top="474" left="349" width="101" height="15" font="1">Atrial flutter (n=447) </text>
<text top="489" left="349" width="56" height="15" font="1">IST (n=40) </text>
<text top="365" left="579" width="148" height="15" font="1">Efficacy and safety of RFA w/ </text>
<text top="381" left="579" width="68" height="15" font="1">long-term f/u. </text>
<text top="396" left="579" width="3" height="15" font="1"> </text>
<text top="412" left="579" width="3" height="15" font="1"> </text>
<text top="427" left="579" width="3" height="15" font="1"> </text>
<text top="365" left="761" width="41" height="15" font="1">AVNRT </text>
<text top="381" left="761" width="82" height="15" font="1">Success: 96.1% </text>
<text top="396" left="761" width="95" height="15" font="1">Complications: 2% </text>
<text top="412" left="761" width="3" height="15" font="1"> </text>
<text top="427" left="761" width="30" height="15" font="1">AVJ:  </text>
<text top="443" left="761" width="73" height="15" font="1">Success: 96% </text>
<text top="458" left="761" width="109" height="15" font="1">Complications: 25 pts </text>
<text top="474" left="761" width="92" height="15" font="1">Recurrence: 3.5% </text>
<text top="489" left="761" width="3" height="15" font="1"> </text>
<text top="505" left="761" width="21" height="15" font="1">AP: </text>
<text top="520" left="761" width="89" height="15" font="1">Success: 94-96% </text>
<text top="535" left="761" width="133" height="15" font="1">Complications: 31 pts total </text>
<text top="551" left="761" width="92" height="15" font="1">Recurrence: 4.6% </text>
<text top="567" left="761" width="3" height="15" font="1"> </text>
<text top="582" left="761" width="20" height="15" font="1">AT: </text>
<text top="597" left="761" width="89" height="15" font="1">Success: 51-79% </text>
<text top="613" left="761" width="109" height="15" font="1">Complications: 5 total </text>
<text top="628" left="761" width="98" height="15" font="1">Recurrence: 15.2% </text>
<text top="644" left="761" width="3" height="15" font="1"> </text>
<text top="659" left="761" width="62" height="15" font="1">Atrial flutter: </text>
<text top="675" left="761" width="73" height="15" font="1">Success: 86% </text>
<text top="690" left="761" width="109" height="15" font="1">Complications: 12 pts </text>
<text top="706" left="761" width="98" height="15" font="1">Recurrence: 14.7% </text>
<text top="721" left="761" width="3" height="15" font="1"> </text>
<text top="737" left="761" width="23" height="15" font="1">IST: </text>
<text top="752" left="761" width="73" height="15" font="1">Success: 71% </text>
<text top="768" left="761" width="103" height="15" font="1">Complications: 2 pts </text>
<text top="783" left="761" width="89" height="15" font="1">Recurrence: 10% </text>
<text top="365" left="955" width="166" height="15" font="1">Large series reporting success of </text>
<text top="381" left="955" width="180" height="15" font="1">RFA, and stratification by age group </text>
<text top="396" left="955" width="151" height="15" font="1">confirms safety and efficacy in </text>
<text top="412" left="955" width="159" height="15" font="1">elderly pts, as well as by type of </text>
<text top="427" left="955" width="163" height="15" font="1">facility (teaching vs. community). </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">63 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="143" height="15" font="1">Special Ablation Techniques </text>
<text top="71" left="54" width="66" height="15" font="1">Friedman PL </text>
<text top="86" left="54" width="28" height="15" font="1">2004 </text>
<text top="102" left="54" width="29" height="15" font="1">(133) </text>
<text top="117" left="54" width="55" height="15" font="8">15851143  </text>
<text top="117" left="109" width="3" height="15" font="1"> </text>
<text top="71" left="139" width="57" height="15" font="1">Multicenter </text>
<text top="86" left="139" width="89" height="15" font="1">prospective study </text>
<text top="71" left="248" width="22" height="15" font="1">157 </text>
<text top="86" left="248" width="62" height="15" font="1">(166 initially </text>
<text top="102" left="248" width="46" height="15" font="1">enrolled) </text>
<text top="71" left="349" width="82" height="15" font="1">AVNRT (n=101) </text>
<text top="86" left="349" width="68" height="15" font="1">AVRT (n=44) </text>
<text top="102" left="349" width="53" height="15" font="1">AF (n=12) </text>
<text top="71" left="579" width="166" height="15" font="1">Efficacy of cryomapping/ablation  </text>
<text top="71" left="761" width="135" height="15" font="1">Acute success overall 83% </text>
<text top="86" left="761" width="3" height="15" font="1"> </text>
<text top="102" left="761" width="151" height="15" font="1">Success in AVNRT 91%, 69% </text>
<text top="117" left="761" width="154" height="15" font="1">AVRT and 67% AVJ (p&lt;0.001) </text>
<text top="133" left="761" width="3" height="15" font="1"> </text>
<text top="148" left="761" width="66" height="15" font="1">Per-protocol: </text>
<text top="164" left="761" width="167" height="15" font="1">Success in AVNRT 93%, 77% for </text>
<text top="179" left="761" width="119" height="15" font="1">AVRT and 67% for AVJ </text>
<text top="195" left="761" width="3" height="15" font="1"> </text>
<text top="210" left="761" width="175" height="15" font="1">Long-term success after 6 mo 91% </text>
<text top="226" left="761" width="121" height="15" font="1">overall, 94% for AVNRT </text>
<text top="241" left="761" width="3" height="15" font="1"> </text>
<text top="257" left="761" width="179" height="15" font="1">Cryomapping successfully identified </text>
<text top="272" left="761" width="149" height="15" font="1">ablation targets in 64% of pts, </text>
<text top="288" left="761" width="165" height="15" font="1">effects completely reversible w/in </text>
<text top="303" left="761" width="137" height="15" font="1">minutes in 94% of attempts </text>
<text top="71" left="955" width="138" height="15" font="1">Acute success lower for CA </text>
<text top="86" left="955" width="175" height="15" font="1">compared to studies in RFA, but w/ </text>
<text top="102" left="955" width="180" height="15" font="1">no difference in long-term outcomes </text>
<text top="117" left="955" width="127" height="15" font="1">or arrhythmia recurrence. </text>
<text top="133" left="955" width="3" height="15" font="1"> </text>
<text top="148" left="955" width="143" height="15" font="1">Later reports show improved </text>
<text top="164" left="955" width="46" height="15" font="1">success. </text>
<text top="319" left="54" width="50" height="15" font="1">de Sisti A </text>
<text top="335" left="54" width="28" height="15" font="1">2011 </text>
<text top="350" left="54" width="29" height="15" font="1">(134) </text>
<text top="366" left="54" width="52" height="15" font="8">22017562 </text>
<text top="366" left="106" width="3" height="15" font="1"> </text>
<text top="319" left="139" width="92" height="15" font="1">Systematic review </text>
<text top="319" left="248" width="68" height="15" font="1">22 studies w/ </text>
<text top="335" left="248" width="49" height="15" font="1">2,654 pts </text>
<text top="319" left="349" width="212" height="15" font="1">Cryoablation for AVNRT compared to RFA </text>
<text top="319" left="579" width="152" height="15" font="1">Overall success 95% (95% CI: </text>
<text top="335" left="579" width="145" height="15" font="1">85-99%), but recurrence rate </text>
<text top="350" left="579" width="138" height="15" font="1">11% (95% CI: 2-20%). RFA </text>
<text top="366" left="579" width="170" height="15" font="1">recurrence rate reported at 3-5%.  </text>
<text top="319" left="761" width="22" height="15" font="1">N/A </text>
<text top="319" left="955" width="176" height="15" font="1">Cryoablation effective and safe, but </text>
<text top="335" left="955" width="156" height="15" font="1">lower long-term clinical efficacy </text>
<text top="350" left="955" width="96" height="15" font="1">compared to RFA.  </text>
<text top="382" left="54" width="63" height="15" font="1">Hanninen M </text>
<text top="398" left="54" width="28" height="15" font="1">2013 </text>
<text top="413" left="54" width="29" height="15" font="1">(135) </text>
<text top="429" left="54" width="55" height="15" font="8">24016223  </text>
<text top="429" left="109" width="3" height="15" font="1"> </text>
<text top="382" left="139" width="92" height="15" font="1">Systematic review </text>
<text top="398" left="139" width="93" height="15" font="1">and meta-analysis </text>
<text top="382" left="248" width="66" height="15" font="1">14 studies (5 </text>
<text top="398" left="248" width="87" height="15" font="1">RCTs), 5,617 pts </text>
<text top="413" left="248" width="76" height="15" font="1">(1990-2012). 3 </text>
<text top="429" left="248" width="83" height="15" font="1">studies pediatric </text>
<text top="382" left="349" width="205" height="15" font="1">Pts w/ AVNRT treated w/ cryoablation vs. </text>
<text top="398" left="349" width="58" height="15" font="1">RFA (81%) </text>
<text top="382" left="579" width="158" height="15" font="1">AVNRT recurrence (&gt;2 mo post </text>
<text top="398" left="579" width="141" height="15" font="1">procedure; acute procedural </text>
<text top="413" left="579" width="148" height="15" font="1">failure and AV block requiring </text>
<text top="429" left="579" width="36" height="15" font="1">pacing </text>
<text top="382" left="761" width="164" height="15" font="1">Acute failure w/ cryoablation was </text>
<text top="398" left="761" width="174" height="15" font="1">nonsignificantly slightly higher than </text>
<text top="413" left="761" width="137" height="15" font="1">w/ RFA (RR: 1.44; p=0.12). </text>
<text top="429" left="761" width="157" height="15" font="1">Long-term recurrence higher w/ </text>
<text top="444" left="761" width="173" height="15" font="1">cryoablation (RR: 3.66; p=0.0002)  </text>
<text top="460" left="761" width="3" height="15" font="1"> </text>
<text top="475" left="761" width="169" height="15" font="1">RFA associated w/ permanent AV </text>
<text top="491" left="761" width="150" height="15" font="1">block in 0.75% of pts, none w/ </text>
<text top="506" left="761" width="110" height="15" font="1">cryoablation (p=0.01). </text>
<text top="382" left="955" width="152" height="15" font="1">Although late-recurrence more </text>
<text top="398" left="955" width="161" height="15" font="1">common w/ cryoablation than w/ </text>
<text top="413" left="955" width="168" height="15" font="1">RFA, avoidance of permanent AV </text>
<text top="429" left="955" width="116" height="15" font="1">block is advantageous  </text>
<text top="522" left="54" width="66" height="15" font="1">Santangeli P </text>
<text top="538" left="54" width="28" height="15" font="1">2014 </text>
<text top="553" left="54" width="29" height="15" font="1">(136) </text>
<text top="569" left="54" width="52" height="15" font="8">24293174 </text>
<text top="569" left="106" width="3" height="15" font="1"> </text>
<text top="522" left="139" width="92" height="15" font="1">Systematic review </text>
<text top="538" left="139" width="93" height="15" font="1">and meta-analysis </text>
<text top="522" left="248" width="66" height="15" font="1">14 studies (9 </text>
<text top="538" left="248" width="87" height="15" font="1">observational) w/ </text>
<text top="553" left="248" width="81" height="15" font="1">2,340 pts (1980-</text>
<text top="569" left="248" width="31" height="15" font="1">2013) </text>
<text top="522" left="349" width="194" height="15" font="1">Pts w/ AVNRT treated w/ CA (54%) vs. </text>
<text top="538" left="349" width="58" height="15" font="1">RFA (46%) </text>
<text top="522" left="579" width="157" height="15" font="1">Successful ablation, procedural </text>
<text top="538" left="579" width="114" height="15" font="1">time, fluoroscopy time, </text>
<text top="553" left="579" width="70" height="15" font="1">complications </text>
<text top="522" left="761" width="171" height="15" font="1">Acute success in 88% w/ RFA, vs. </text>
<text top="538" left="761" width="151" height="15" font="1">83% treated w/ CA (OR: 0.72; </text>
<text top="553" left="761" width="41" height="15" font="1">p=0.16) </text>
<text top="569" left="761" width="3" height="15" font="1"> </text>
<text top="584" left="761" width="157" height="15" font="1">RFA associated w/ shorter total </text>
<text top="600" left="761" width="149" height="15" font="1">procedure time (p=0.004), but </text>
<text top="615" left="761" width="155" height="15" font="1">slightly longer fluoroscopy time </text>
<text top="631" left="761" width="57" height="15" font="1">(p=0.002).  </text>
<text top="646" left="761" width="3" height="15" font="1"> </text>
<text top="662" left="761" width="162" height="15" font="1">Permanent AV block occurred in </text>
<text top="677" left="761" width="165" height="15" font="1">0.9% RF case, none in CA cases </text>
<text top="693" left="761" width="107" height="15" font="1">(OR: 3.60; p=0.035).  </text>
<text top="708" left="761" width="3" height="15" font="1"> </text>
<text top="724" left="761" width="160" height="15" font="1">Freedom from recurrent AVNRT </text>
<text top="739" left="761" width="160" height="15" font="1">(10.5 mo median f/u) 97% in RF </text>
<text top="755" left="761" width="163" height="15" font="1">group vs. 90.9% in the CA group </text>
<text top="770" left="761" width="107" height="15" font="1">(OR: 0.40; p&lt; 0.001). </text>
<text top="522" left="955" width="172" height="15" font="1">RF significantly reduces the risk of </text>
<text top="538" left="955" width="161" height="15" font="1">long-term arrhythmia recurrence </text>
<text top="553" left="955" width="160" height="15" font="1">compared to cryoablation, but is </text>
<text top="569" left="955" width="146" height="15" font="1">associated w/ a higher risk of </text>
<text top="584" left="955" width="175" height="15" font="1">permanent AV block. No significant </text>
<text top="600" left="955" width="143" height="15" font="1">difference in acute success.  </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">64 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="54" left="54" width="1039" height="15" font="1">AAD indicates antiarrhythmic drug;  AF, atrial fibrillation; AP, accessory pathway; AT, atrial tachycardia; AV, atrioventricular; AVJ, atrioventricular junction; AVN, atrioventricular node; AVNRT, atrioventricular nodal </text>
<text top="69" left="54" width="1056" height="15" font="1">reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; bpm, beats per min; CA, cryoablation; CHF, congestive heart failure; CSM, carotid sinus massage; DC, direct current; ECG, electrocardiogram; ED, </text>
<text top="85" left="54" width="1055" height="15" font="1">emergency department; EF, ejection fraction; EP, electrophysiological; FP, fast pathway; f/u, follow up; HR, heart rate; IST, inappropriate sinus tachycardia; IV, intravenous; MAT, multifocal atrial tachycardia; N/A, not </text>
<text top="100" left="54" width="1024" height="15" font="1">applicable; NASPE, North American Society of Pacing and Electrophysiology; OR, odds ratio; PES, programmed electrical stimulation; PJRT, permanent junctional reciprocating tachycardia; PSVT, paroxysmal </text>
<text top="116" left="54" width="1076" height="15" font="1">supraventricular tachycardia; pt, patient; RFA, radiofrequency ablation; RR, relative risk; SD, standard deviation; SHD, structural heart disease; SP, slow pathway; SR, sinus rhythm; SVT, supraventricular tachycardia; sx, </text>
<text top="131" left="54" width="320" height="15" font="1">symptom; VT, ventricular tachycardia; w/, with;  and w/o, without. </text>
<text top="147" left="54" width="3" height="15" font="1"> </text>
<text top="172" left="54" width="155" height="18" font="3"><b>Data Supplement 11.  </b></text>
<text top="172" left="209" width="634" height="18" font="7"><b>Randomized Trials Comparing Manifest and Concealed Accessory Pathways – Section 6.1</b></text>
<text top="172" left="843" width="4" height="18" font="3"><b> </b></text>
<text top="191" left="60" width="38" height="17" font="5"><b>Study </b></text>
<text top="208" left="58" width="40" height="17" font="5"><b>Name, </b></text>
<text top="226" left="55" width="47" height="17" font="5"><b>Author, </b></text>
<text top="243" left="64" width="30" height="17" font="5"><b>Year </b></text>
<text top="191" left="119" width="42" height="17" font="5"><b>Aim of </b></text>
<text top="208" left="121" width="38" height="17" font="5"><b>Study </b></text>
<text top="191" left="182" width="38" height="17" font="5"><b>Study </b></text>
<text top="208" left="185" width="32" height="17" font="5"><b>Type </b></text>
<text top="226" left="183" width="36" height="17" font="5"><b>(Size, </b></text>
<text top="243" left="193" width="16" height="17" font="5"><b>N) </b></text>
<text top="191" left="256" width="38" height="17" font="5"><b>Study </b></text>
<text top="208" left="238" width="74" height="17" font="5"><b>Intervention </b></text>
<text top="226" left="245" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="191" left="344" width="38" height="17" font="5"><b>Study </b></text>
<text top="208" left="326" width="73" height="17" font="5"><b>Comparator </b></text>
<text top="226" left="333" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="191" left="490" width="83" height="17" font="5"><b>Pt Population </b></text>
<text top="191" left="756" width="64" height="17" font="5"><b>Endpoints </b></text>
<text top="191" left="933" width="109" height="17" font="5"><b>P Values, OR: HR: </b></text>
<text top="208" left="945" width="85" height="17" font="5"><b>RR: &amp; 95% CI: </b></text>
<text top="191" left="1081" width="38" height="17" font="5"><b>Study </b></text>
<text top="208" left="1066" width="69" height="17" font="5"><b>Limitations </b></text>
<text top="226" left="1068" width="64" height="17" font="5"><b>&amp; Adverse </b></text>
<text top="243" left="1078" width="44" height="17" font="5"><b>Events </b></text>
<text top="261" left="67" width="3" height="17" font="5"><b> </b></text>
<text top="261" left="138" width="3" height="17" font="5"><b> </b></text>
<text top="261" left="199" width="3" height="17" font="5"><b> </b></text>
<text top="261" left="273" width="3" height="17" font="5"><b> </b></text>
<text top="261" left="361" width="3" height="17" font="5"><b> </b></text>
<text top="261" left="419" width="104" height="17" font="13"><i><b>Inclusion Criteria </b></i></text>
<text top="261" left="542" width="108" height="17" font="13"><i><b>Exclusion Criteria </b></i></text>
<text top="261" left="676" width="49" height="17" font="13"><i><b>Primary </b></i></text>
<text top="278" left="672" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="295" left="672" width="58" height="17" font="13"><i><b>(efficacy) </b></i></text>
<text top="312" left="664" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="261" left="771" width="40" height="17" font="13"><i><b>Safety </b></i></text>
<text top="278" left="763" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="295" left="755" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="261" left="846" width="70" height="17" font="13"><i><b>Secondary  </b></i></text>
<text top="278" left="851" width="67" height="17" font="13"><i><b>Endpoint    </b></i></text>
<text top="295" left="867" width="25" height="17" font="13"><i><b>and </b></i></text>
<text top="312" left="855" width="48" height="17" font="13"><i><b>Results </b></i></text>
<text top="261" left="986" width="3" height="17" font="5"><b> </b></text>
<text top="261" left="1098" width="3" height="17" font="5"><b> </b></text>
<text top="330" left="54" width="49" height="15" font="1">Henthorn </text>
<text top="346" left="54" width="22" height="15" font="1">RW </text>
<text top="361" left="54" width="31" height="15" font="1">1991  </text>
<text top="377" left="54" width="23" height="15" font="1">(26) </text>
<text top="392" left="54" width="46" height="15" font="8">1898640 </text>
<text top="392" left="100" width="3" height="15" font="1"> </text>
<text top="330" left="116" width="38" height="15" font="1">Double </text>
<text top="346" left="116" width="26" height="15" font="1">blind </text>
<text top="361" left="116" width="42" height="15" font="1">placebo </text>
<text top="377" left="116" width="42" height="15" font="1">controlle</text>
<text top="392" left="116" width="9" height="15" font="1">d </text>
<text top="408" left="116" width="44" height="15" font="1">crossove</text>
<text top="423" left="116" width="40" height="15" font="1">r trial of </text>
<text top="439" left="116" width="41" height="15" font="1">flecainid</text>
<text top="454" left="116" width="9" height="15" font="1">e </text>
<text top="330" left="177" width="33" height="15" font="1">34 pts </text>
<text top="346" left="177" width="3" height="15" font="1"> </text>
<text top="330" left="238" width="41" height="15" font="1">8 wk on </text>
<text top="346" left="238" width="50" height="15" font="1">flecainide </text>
<text top="330" left="325" width="41" height="15" font="1">8 wk on </text>
<text top="346" left="325" width="42" height="15" font="1">placebo </text>
<text top="330" left="413" width="62" height="15" font="1">13 w/ AVRT </text>
<text top="346" left="413" width="64" height="15" font="1">7 w/ AVNRT </text>
<text top="361" left="413" width="41" height="15" font="1">3 w/ AT </text>
<text top="377" left="413" width="60" height="15" font="1">28 unknown</text>
<text top="377" left="473" width="2" height="10" font="10"> </text>
<text top="330" left="541" width="88" height="15" font="1">Syncopy, angina, </text>
<text top="346" left="541" width="97" height="15" font="1">and/or neurological </text>
<text top="361" left="541" width="53" height="15" font="1">sxs during </text>
<text top="377" left="541" width="103" height="15" font="1">tachycardia. Second </text>
<text top="392" left="541" width="93" height="15" font="1">or third degree AV </text>
<text top="408" left="541" width="92" height="15" font="1">block. NYHA CHF </text>
<text top="423" left="541" width="57" height="15" font="1">class III, IV </text>
<text top="330" left="663" width="53" height="15" font="1">Flecainide </text>
<text top="346" left="663" width="55" height="15" font="1">superior to </text>
<text top="361" left="663" width="45" height="15" font="1">placebo. </text>
<text top="377" left="663" width="53" height="15" font="1">Flecainide </text>
<text top="392" left="663" width="70" height="15" font="1">associated w/ </text>
<text top="408" left="663" width="69" height="15" font="1">79% freedom </text>
<text top="423" left="663" width="57" height="15" font="1">from PSVT </text>
<text top="439" left="663" width="63" height="15" font="1">and placebo </text>
<text top="454" left="663" width="72" height="15" font="1">15% p&lt;0.001. </text>
<text top="470" left="663" width="63" height="15" font="1">Median time </text>
<text top="485" left="663" width="18" height="15" font="1">to 1</text>
<text top="486" left="681" width="6" height="10" font="10">st</text>
<text top="485" left="687" width="35" height="15" font="1"> PSVT </text>
<text top="501" left="663" width="36" height="15" font="1">11 d in </text>
<text top="516" left="663" width="73" height="15" font="1">placebo group </text>
<text top="532" left="663" width="58" height="15" font="1">and 55 d in </text>
<text top="547" left="663" width="50" height="15" font="1">flecainide </text>
<text top="562" left="663" width="37" height="15" font="1">group.  </text>
<text top="578" left="663" width="53" height="15" font="1">Flecainide </text>
<text top="594" left="663" width="69" height="15" font="1">slowed PSVT </text>
<text top="609" left="663" width="53" height="15" font="1">to 143±12 </text>
<text top="624" left="663" width="50" height="15" font="1">bpm from </text>
<text top="640" left="663" width="66" height="15" font="1">178±12 bpm </text>
<text top="655" left="663" width="63" height="15" font="1">on placebo.  </text>
<text top="330" left="751" width="64" height="15" font="1">Side effects: </text>
<text top="346" left="751" width="67" height="15" font="1">flec 63% and </text>
<text top="361" left="751" width="70" height="15" font="1">placebo 36%. </text>
<text top="377" left="751" width="34" height="15" font="1">All not </text>
<text top="392" left="751" width="55" height="15" font="1">significant. </text>
<text top="330" left="845" width="53" height="15" font="1">Flecainide </text>
<text top="346" left="845" width="45" height="15" font="1">was well </text>
<text top="361" left="845" width="49" height="15" font="1">tolerated. </text>
<text top="330" left="926" width="109" height="15" font="1">Flecainide associated </text>
<text top="346" left="926" width="108" height="15" font="1">w/ 79% freedom from </text>
<text top="361" left="926" width="120" height="15" font="1">PSVT and placebo 15% </text>
<text top="377" left="926" width="122" height="15" font="1">p&lt;0.001. Median time to </text>
<text top="392" left="926" width="6" height="15" font="1">1</text>
<text top="393" left="932" width="6" height="10" font="10">st</text>
<text top="392" left="938" width="71" height="15" font="1"> PSVT 11 d in </text>
<text top="408" left="926" width="119" height="15" font="1">placebo group and 55 d </text>
<text top="423" left="926" width="99" height="15" font="1">in flecainide group.  </text>
<text top="439" left="926" width="123" height="15" font="1">Flecainide slowed PSVT </text>
<text top="454" left="926" width="103" height="15" font="1">to 143±12 bpm from </text>
<text top="470" left="926" width="81" height="15" font="1">178±12 bpm on </text>
<text top="485" left="926" width="121" height="15" font="1">placebo. Side effects on </text>
<text top="501" left="926" width="109" height="15" font="1">flec 63% and placebo </text>
<text top="516" left="926" width="118" height="15" font="1">36%. All not significant. </text>
<text top="330" left="1063" width="65" height="15" font="1">Study period </text>
<text top="346" left="1063" width="47" height="15" font="1">was brief </text>
<text top="672" left="54" width="44" height="15" font="1">Pritchett </text>
<text top="687" left="54" width="20" height="15" font="1">EL  </text>
<text top="703" left="54" width="28" height="15" font="1">1991 </text>
<text top="718" left="54" width="23" height="15" font="1">(28) </text>
<text top="734" left="54" width="46" height="15" font="8">2001087 </text>
<text top="734" left="100" width="3" height="15" font="1"> </text>
<text top="672" left="116" width="38" height="15" font="1">Double </text>
<text top="687" left="116" width="26" height="15" font="1">blind </text>
<text top="703" left="116" width="42" height="15" font="1">placebo </text>
<text top="718" left="116" width="42" height="15" font="1">controlle</text>
<text top="734" left="116" width="9" height="15" font="1">d </text>
<text top="749" left="116" width="44" height="15" font="1">crossove</text>
<text top="765" left="116" width="40" height="15" font="1">r trial of </text>
<text top="780" left="116" width="44" height="15" font="1">propafen</text>
<text top="796" left="116" width="22" height="15" font="1">one </text>
<text top="672" left="177" width="33" height="15" font="1">33 pts </text>
<text top="687" left="177" width="3" height="15" font="1"> </text>
<text top="672" left="238" width="40" height="15" font="1">60 d on </text>
<text top="687" left="238" width="65" height="15" font="1">propafenone </text>
<text top="672" left="325" width="40" height="15" font="1">60 d on </text>
<text top="687" left="325" width="65" height="15" font="1">propafenone </text>
<text top="672" left="413" width="101" height="15" font="1">16 pts w/ PSVT and </text>
<text top="687" left="413" width="105" height="15" font="1">17 w/ PAF. Not clear </text>
<text top="703" left="413" width="68" height="15" font="1">number of AP</text>
<text top="703" left="481" width="2" height="10" font="10"> </text>
<text top="672" left="541" width="101" height="15" font="1">NYHA class III or IV </text>
<text top="687" left="541" width="99" height="15" font="1">HF. Second or third </text>
<text top="703" left="541" width="87" height="15" font="1">degree AV block. </text>
<text top="718" left="541" width="81" height="15" font="1">Sxs of syncope, </text>
<text top="734" left="541" width="102" height="15" font="1">angina, neurological </text>
<text top="749" left="541" width="69" height="15" font="1">events during </text>
<text top="765" left="541" width="63" height="15" font="1">tachycardia. </text>
<text top="672" left="663" width="73" height="15" font="1">Well-designed </text>
<text top="687" left="663" width="73" height="15" font="1">study showing </text>
<text top="703" left="663" width="65" height="15" font="1">propafenone </text>
<text top="718" left="663" width="55" height="15" font="1">superior to </text>
<text top="734" left="663" width="48" height="15" font="1">placebo.  </text>
<text top="749" left="663" width="66" height="15" font="1">Propafenone </text>
<text top="765" left="663" width="71" height="15" font="1">prolonged the </text>
<text top="780" left="663" width="56" height="15" font="1">recurrence </text>
<text top="796" left="663" width="35" height="15" font="1">rate of </text>
<text top="672" left="751" width="79" height="15" font="1">No serious side </text>
<text top="687" left="751" width="36" height="15" font="1">effects </text>
<text top="672" left="845" width="22" height="15" font="1">N/A </text>
<text top="672" left="926" width="117" height="15" font="1">Time to first recurrence </text>
<text top="687" left="926" width="87" height="15" font="1">prolonged for the </text>
<text top="703" left="926" width="100" height="15" font="1">propafenone group, </text>
<text top="718" left="926" width="46" height="15" font="1">p=0.004. </text>
<text top="672" left="1063" width="52" height="15" font="1">The study </text>
<text top="687" left="1063" width="69" height="15" font="1">was brief and </text>
<text top="703" left="1063" width="69" height="15" font="1">not clear how </text>
<text top="718" left="1063" width="66" height="15" font="1">many AP pts </text>
<text top="734" left="1063" width="45" height="15" font="1">studied.  </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">65 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="55" height="15" font="1">arrhythmia </text>
<text top="70" left="663" width="69" height="15" font="1">and was 20% </text>
<text top="86" left="663" width="74" height="15" font="1">the recurrence </text>
<text top="101" left="663" width="35" height="15" font="1">rate of </text>
<text top="117" left="663" width="45" height="15" font="1">placebo. </text>
<text top="133" left="54" width="18" height="15" font="1">UK </text>
<text top="148" left="54" width="45" height="15" font="1">Propafen</text>
<text top="164" left="54" width="21" height="15" font="1">one </text>
<text top="179" left="54" width="31" height="15" font="1">Study </text>
<text top="195" left="54" width="34" height="15" font="1">Group </text>
<text top="210" left="54" width="28" height="15" font="1">1995 </text>
<text top="226" left="54" width="23" height="15" font="1">(31) </text>
<text top="241" left="54" width="46" height="15" font="8">7586356 </text>
<text top="241" left="100" width="3" height="15" font="1"> </text>
<text top="133" left="116" width="38" height="15" font="1">Double </text>
<text top="148" left="116" width="29" height="15" font="1">blind, </text>
<text top="164" left="116" width="42" height="15" font="1">placebo </text>
<text top="179" left="116" width="42" height="15" font="1">controlle</text>
<text top="195" left="116" width="39" height="15" font="1">d study </text>
<text top="210" left="116" width="12" height="15" font="1">of </text>
<text top="226" left="116" width="44" height="15" font="1">propafen</text>
<text top="241" left="116" width="22" height="15" font="1">one </text>
<text top="133" left="177" width="40" height="15" font="1">100 pts </text>
<text top="148" left="177" width="3" height="15" font="1"> </text>
<text top="133" left="238" width="152" height="15" font="1">Propafenone Placebo </text>
<text top="133" left="413" width="53" height="15" font="1">PSVT </text>
<text top="133" left="445" width="37" height="15" font="1">52 </text>
<text top="133" left="460" width="18" height="15" font="1">pts </text>
<text top="148" left="413" width="51" height="15" font="1">AF 48 pts </text>
<text top="164" left="413" width="103" height="15" font="1">Unclear if any AP pts</text>
<text top="164" left="516" width="2" height="10" font="10"> </text>
<text top="133" left="541" width="105" height="15" font="1">Documented second </text>
<text top="148" left="541" width="93" height="15" font="1">or third degree AV </text>
<text top="164" left="541" width="102" height="15" font="1">block. Class III or IV </text>
<text top="179" left="541" width="102" height="15" font="1">HF. Sxs of syncope, </text>
<text top="195" left="541" width="73" height="15" font="1">angina, during </text>
<text top="210" left="541" width="60" height="15" font="1">tachycardia </text>
<text top="133" left="663" width="57" height="15" font="1">Arrhythmia </text>
<text top="148" left="663" width="59" height="15" font="1">recurrence. </text>
<text top="164" left="663" width="63" height="15" font="1">Relative risk </text>
<text top="179" left="663" width="62" height="15" font="1">of treatment </text>
<text top="195" left="663" width="49" height="15" font="1">failure for </text>
<text top="210" left="663" width="42" height="15" font="1">placebo </text>
<text top="226" left="663" width="65" height="15" font="1">compared to </text>
<text top="241" left="663" width="65" height="15" font="1">propafenone </text>
<text top="257" left="663" width="70" height="15" font="1">was 6.8 (95% </text>
<text top="272" left="663" width="64" height="15" font="1">CI: 2.2-21.2; </text>
<text top="288" left="663" width="46" height="15" font="1">p&lt;0.001; </text>
<text top="303" left="663" width="48" height="15" font="1">n=45) for </text>
<text top="319" left="663" width="72" height="15" font="1">PSVT and 6.0 </text>
<text top="334" left="663" width="65" height="15" font="1">(95% CI: 1.8-</text>
<text top="350" left="663" width="28" height="15" font="1">20.0; </text>
<text top="365" left="663" width="63" height="15" font="1">p=0.004) for </text>
<text top="381" left="663" width="23" height="15" font="1">AF.  </text>
<text top="133" left="751" width="78" height="15" font="1">One episode of </text>
<text top="148" left="751" width="53" height="15" font="1">wide QRS </text>
<text top="164" left="751" width="39" height="15" font="1">tachy.   </text>
<text top="133" left="845" width="20" height="15" font="1">Not </text>
<text top="148" left="845" width="53" height="15" font="1">applicable </text>
<text top="133" left="926" width="76" height="15" font="1">Relative risk of </text>
<text top="148" left="926" width="99" height="15" font="1">treatment failure for </text>
<text top="164" left="926" width="106" height="15" font="1">placebo compared to </text>
<text top="179" left="926" width="106" height="15" font="1">propafenone was 6.8 </text>
<text top="195" left="926" width="93" height="15" font="1">(95% CI: 2.2-21.2; </text>
<text top="210" left="926" width="94" height="15" font="1">p&lt;0.001; n=45) for </text>
<text top="226" left="926" width="118" height="15" font="1">PSVT and 6.0 (95% CI: </text>
<text top="241" left="926" width="110" height="15" font="1">1.8-20.0; p=0.004) for </text>
<text top="257" left="926" width="20" height="15" font="1">AF. </text>
<text top="133" left="1063" width="73" height="15" font="1">Unusual study </text>
<text top="148" left="1063" width="39" height="15" font="1">design. </text>
<text top="397" left="54" width="46" height="15" font="1">Dorian P </text>
<text top="412" left="54" width="28" height="15" font="1">1996 </text>
<text top="428" left="54" width="23" height="15" font="1">(32) </text>
<text top="443" left="54" width="43" height="15" font="8">8607397</text>
<text top="443" left="97" width="3" height="15" font="1"> </text>
<text top="397" left="116" width="44" height="15" font="1">Randomi</text>
<text top="412" left="116" width="21" height="15" font="1">zed </text>
<text top="428" left="116" width="44" height="15" font="1">multicent</text>
<text top="443" left="116" width="42" height="15" font="1">er study </text>
<text top="459" left="116" width="12" height="15" font="1">of </text>
<text top="474" left="116" width="43" height="15" font="1">verapam</text>
<text top="490" left="116" width="25" height="15" font="1">il vs. </text>
<text top="505" left="116" width="41" height="15" font="1">flecainid</text>
<text top="521" left="116" width="25" height="15" font="1">e for </text>
<text top="536" left="116" width="44" height="15" font="1">treatmen</text>
<text top="552" left="116" width="18" height="15" font="1">t of </text>
<text top="567" left="116" width="32" height="15" font="1">PSVT </text>
<text top="397" left="177" width="40" height="15" font="1">121 pts </text>
<text top="397" left="238" width="53" height="15" font="1">Verapamil </text>
<text top="397" left="325" width="54" height="15" font="1">Flecainide </text>
<text top="397" left="413" width="98" height="15" font="1">63 pts on flecainide </text>
<text top="412" left="413" width="94" height="15" font="1">and 58 verapamil.  </text>
<text top="428" left="413" width="105" height="15" font="1">Followed for 8.1±5.1 </text>
<text top="443" left="413" width="84" height="15" font="1">and 7.5±5.4 mo, </text>
<text top="459" left="413" width="65" height="15" font="1">respectively. </text>
<text top="397" left="541" width="108" height="15" font="1">Prior AF, atrial flutter, </text>
<text top="412" left="541" width="108" height="15" font="1">myocardial infarction, </text>
<text top="428" left="541" width="87" height="15" font="1">unstable angina.  </text>
<text top="443" left="541" width="103" height="15" font="1">NYHA Class III or IV </text>
<text top="459" left="541" width="107" height="15" font="1">CHF. Second or third </text>
<text top="474" left="541" width="87" height="15" font="1">degree AV block. </text>
<text top="397" left="663" width="38" height="15" font="1">86% of </text>
<text top="412" left="663" width="63" height="15" font="1">flecainide pt-</text>
<text top="428" left="663" width="65" height="15" font="1">mo and 73% </text>
<text top="443" left="663" width="63" height="15" font="1">of verapamil </text>
<text top="459" left="663" width="73" height="15" font="1">pt-mos w/ 0 or </text>
<text top="474" left="663" width="63" height="15" font="1">1 episode of </text>
<text top="490" left="663" width="41" height="15" font="1">PSVT.   </text>
<text top="397" left="751" width="22" height="15" font="1">N/A </text>
<text top="397" left="845" width="22" height="15" font="1">N/A </text>
<text top="397" left="926" width="112" height="15" font="1">30% on flecainide and </text>
<text top="412" left="926" width="119" height="15" font="1">13% on verapamil were </text>
<text top="428" left="926" width="117" height="15" font="1">free of PSVT (p=0.026) </text>
<text top="397" left="1063" width="53" height="15" font="1">Flecainide </text>
<text top="412" left="1063" width="73" height="15" font="1">and verapamil </text>
<text top="428" left="1063" width="27" height="15" font="1">were </text>
<text top="443" left="1063" width="58" height="15" font="1">moderately </text>
<text top="459" left="1063" width="60" height="15" font="1">effective for </text>
<text top="474" left="1063" width="73" height="15" font="1">the prevention </text>
<text top="490" left="1063" width="47" height="15" font="1">of PSVT. </text>
<text top="583" left="54" width="1057" height="15" font="1">AF indicates atrial fibrillation; AP, accessory pathway; AT, atrial tachycardia; AV, atrioventricular; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; bpm, beats per min; </text>
<text top="599" left="54" width="1053" height="15" font="1">CHF, congestive heart failure; CI, confidence interval; HF, heart failure; N/A, not applicable; NYHA, New York Heart Association; PAF, paroxysmal atrial fibrillation; PSVT, paroxysmal supraventricular tachycardia; pt, </text>
<text top="614" left="54" width="172" height="15" font="1">patient; sx, symptom; and w/, with. </text>
<text top="630" left="54" width="3" height="15" font="1"> </text>
<text top="655" left="54" width="151" height="18" font="3"><b>Data Supplement 12. </b></text>
<text top="655" left="205" width="882" height="18" font="7"><b>Nonrandomized Trials, Observations Studies, and/or Registires of Manifest and Concealed Accessory Pathways – Section 6.1 </b></text>
<text top="655" left="1087" width="4" height="18" font="3"><b> </b></text>
<text top="674" left="80" width="38" height="17" font="5"><b>Study </b></text>
<text top="692" left="55" width="88" height="17" font="5"><b>Name, Author, </b></text>
<text top="709" left="84" width="30" height="17" font="5"><b>Year </b></text>
<text top="674" left="174" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="692" left="188" width="44" height="17" font="5"><b>Design </b></text>
<text top="674" left="284" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="674" left="373" width="289" height="17" font="5"><b>Inclusion/Exclusion Criteria  Primary Endpoint </b></text>
<text top="674" left="752" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="674" left="972" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="727" left="54" width="330" height="15" font="1">Risk Stratification of Symptomatic Patients with Manifest Pathways </text>
<text top="743" left="54" width="45" height="15" font="1">Klein GJ </text>
<text top="758" left="54" width="28" height="15" font="1">1979 </text>
<text top="774" left="54" width="29" height="15" font="1">(137) </text>
<text top="789" left="54" width="37" height="15" font="8">492252</text>
<text top="789" left="91" width="3" height="15" font="1"> </text>
<text top="743" left="156" width="101" height="15" font="1">Observational study </text>
<text top="758" left="156" width="97" height="15" font="1">of pts w/ WPW and </text>
<text top="774" left="156" width="17" height="15" font="1">VF </text>
<text top="743" left="277" width="15" height="15" font="1">25 </text>
<text top="743" left="369" width="160" height="15" font="1">25 WPW pts w/ VF compared to </text>
<text top="758" left="369" width="53" height="15" font="1">73 pts w/o </text>
<text top="743" left="556" width="75" height="15" font="1">Comparing EP </text>
<text top="758" left="556" width="41" height="15" font="1">findings </text>
<text top="743" left="675" width="228" height="15" font="1">Pts w/ WPW and VF had higher prevalence of </text>
<text top="758" left="675" width="251" height="15" font="1">AVRT (14/25 vs. 18/73, p=0.004) and multiple APs </text>
<text top="774" left="675" width="245" height="15" font="1">(5/25 vs. 4/73; p=0.012).  The shortest preexcited </text>
<text top="789" left="675" width="225" height="15" font="1">RR was less in VF pts (mean RR 180 vs. 240 </text>
<text top="743" left="943" width="194" height="15" font="1">WPW pts w/ h/o VF had more rapid AF </text>
<text top="758" left="943" width="181" height="15" font="1">(mean RR 180 msec) and increased </text>
<text top="774" left="943" width="188" height="15" font="1">prevalence of AVRT and multiple APs </text>
<text top="789" left="943" width="104" height="15" font="1">compared to control. </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">66 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="675" width="248" height="15" font="1">msec; p&lt;0.0001) as was the mean RR (mean 269 </text>
<text top="70" left="675" width="128" height="15" font="1">vs. 340 msec; p&lt;0.0001). </text>
<text top="86" left="54" width="42" height="15" font="1">Rinne E </text>
<text top="102" left="54" width="28" height="15" font="1">1987 </text>
<text top="117" left="54" width="29" height="15" font="1">(138) </text>
<text top="133" left="54" width="46" height="15" font="8">3630940 </text>
<text top="133" left="100" width="3" height="15" font="1"> </text>
<text top="86" left="156" width="101" height="15" font="1">Observational study </text>
<text top="102" left="156" width="108" height="15" font="1">of clinical vs. induced </text>
<text top="117" left="156" width="42" height="15" font="1">rhythms </text>
<text top="86" left="277" width="25" height="15" font="1">126  </text>
<text top="86" left="369" width="276" height="15" font="1">WPW pts w/ clinical AVRT and AF   Relation between </text>
<text top="102" left="556" width="100" height="15" font="1">clinical and induced </text>
<text top="117" left="556" width="61" height="15" font="1">arrhythmias </text>
<text top="86" left="675" width="234" height="15" font="1">The shortest RR of clinical AF compared w/ the </text>
<text top="102" left="675" width="236" height="15" font="1">induced AF (r=0.72; p&lt;0.00001). AVRT CL was </text>
<text top="117" left="675" width="245" height="15" font="1">similar (r=0.79; p&lt;0.00001). 41% of pts w/ clinical </text>
<text top="133" left="675" width="253" height="15" font="1">AVRT had AF induced w/ shortest RR &lt;250 msec.  </text>
<text top="86" left="943" width="154" height="15" font="1">There was good reproducibility </text>
<text top="102" left="943" width="183" height="15" font="1">between clinical and induced AF and </text>
<text top="117" left="943" width="188" height="15" font="1">AVRT. Clinical AVRT pts were at high </text>
<text top="133" left="943" width="144" height="15" font="1">risk for rapid AF at EP study. </text>
<text top="149" left="54" width="63" height="15" font="1">Sharma AD  </text>
<text top="164" left="54" width="28" height="15" font="1">1987 </text>
<text top="180" left="54" width="29" height="15" font="1">(139) </text>
<text top="195" left="54" width="46" height="15" font="8">3598007 </text>
<text top="195" left="100" width="3" height="15" font="1"> </text>
<text top="149" left="156" width="101" height="15" font="1">Observational study </text>
<text top="164" left="156" width="55" height="15" font="1">comparing </text>
<text top="180" left="156" width="101" height="15" font="1">noninvasive and EP </text>
<text top="195" left="156" width="30" height="15" font="1">study </text>
<text top="149" left="277" width="15" height="15" font="1">67 </text>
<text top="149" left="369" width="164" height="15" font="1">WPW pts w/ noninvasive and EP </text>
<text top="164" left="369" width="36" height="15" font="1">testing </text>
<text top="149" left="556" width="98" height="15" font="1">Comparing findings </text>
<text top="164" left="556" width="100" height="15" font="1">of noninvasive tests </text>
<text top="180" left="556" width="69" height="15" font="1">and EP tests. </text>
<text top="149" left="675" width="249" height="15" font="1">EP study (AF w/ shortest RR&lt;250 msec) identified </text>
<text top="165" left="675" width="232" height="15" font="1">7/9 pts w/ clinical VF. Continuous preexcitation </text>
<text top="180" left="675" width="236" height="15" font="1">during exercise testing had a sensitivity of 80%, </text>
<text top="195" left="675" width="230" height="15" font="1">specificity of 28.6% and predictive accuracy of </text>
<text top="211" left="675" width="38" height="15" font="1">11.8%. </text>
<text top="149" left="943" width="175" height="15" font="1">EP testing was more accurate than </text>
<text top="165" left="943" width="192" height="15" font="1">stress testing in predicting WPW pts at </text>
<text top="180" left="943" width="169" height="15" font="1">risk for VF. Stess testing had high </text>
<text top="195" left="943" width="54" height="15" font="1">sensitivity. </text>
<text top="227" left="54" width="39" height="15" font="1">Gaita F </text>
<text top="243" left="54" width="28" height="15" font="1">1989 </text>
<text top="258" left="54" width="29" height="15" font="1">(140) </text>
<text top="274" left="54" width="46" height="15" font="8">2773792 </text>
<text top="274" left="100" width="3" height="15" font="1"> </text>
<text top="227" left="156" width="101" height="15" font="1">Observational study </text>
<text top="243" left="156" width="72" height="15" font="1">of accuracy of </text>
<text top="258" left="156" width="88" height="15" font="1">noninvasive tests </text>
<text top="227" left="277" width="15" height="15" font="1">65 </text>
<text top="227" left="369" width="166" height="15" font="1">Consecutive WPW pts studied w/ </text>
<text top="243" left="369" width="162" height="15" font="1">procainamide, stress testing and </text>
<text top="258" left="369" width="171" height="15" font="1">EP. 15 pts were asymptomatic; 50 </text>
<text top="274" left="369" width="44" height="15" font="1">had sxs. </text>
<text top="227" left="556" width="75" height="15" font="1">Comparison of </text>
<text top="243" left="556" width="100" height="15" font="1">noninvasive tests to </text>
<text top="258" left="556" width="62" height="15" font="1">EP findings. </text>
<text top="227" left="675" width="242" height="15" font="1">24 pts had high risk AF (shortest RR &lt;250 msec, </text>
<text top="243" left="675" width="252" height="15" font="1">AP ERP&lt;250 msec). Persistence of the delta wave </text>
<text top="258" left="675" width="238" height="15" font="1">during stress testing has a sens of 96%, spec of </text>
<text top="274" left="675" width="240" height="15" font="1">17% to identify high-risk pts (PPV 40% and NPV </text>
<text top="289" left="675" width="35" height="15" font="1">88%).  </text>
<text top="227" left="943" width="192" height="15" font="1">Stress tests and IV procainamide tests </text>
<text top="243" left="943" width="186" height="15" font="1">had good sensitivity and NPV but low </text>
<text top="258" left="943" width="191" height="15" font="1">specificity and PPV for identifying high </text>
<text top="274" left="943" width="69" height="15" font="1">risk WPW pts </text>
<text top="305" left="54" width="65" height="15" font="1">Beckman KJ </text>
<text top="321" left="54" width="28" height="15" font="1">1990 </text>
<text top="336" left="54" width="29" height="15" font="1">(141) </text>
<text top="352" left="54" width="46" height="15" font="8">2303633 </text>
<text top="352" left="100" width="3" height="15" font="1"> </text>
<text top="305" left="156" width="101" height="15" font="1">Observational study </text>
<text top="321" left="156" width="103" height="15" font="1">of ability of EP study </text>
<text top="336" left="156" width="103" height="15" font="1">to predict arrhythmic </text>
<text top="352" left="156" width="36" height="15" font="1">events </text>
<text top="305" left="277" width="200" height="15" font="1">42 WPW </text>
<text top="305" left="400" width="131" height="15" font="1">pts w/ no sxs up to clinical </text>
<text top="321" left="369" width="56" height="15" font="1">AVRT/AF.  </text>
<text top="305" left="556" width="80" height="15" font="1">Assessing if EP </text>
<text top="321" left="556" width="90" height="15" font="1">findings predicted </text>
<text top="336" left="556" width="72" height="15" font="1">clinical events </text>
<text top="305" left="675" width="209" height="15" font="1">During a f/u of 7.5±4.9 y, showed the only </text>
<text top="321" left="675" width="251" height="15" font="1">variables that correlated w/ subsequent arrhythmia </text>
<text top="336" left="675" width="252" height="15" font="1">were h/o documented arrhythmias before EP study </text>
<text top="352" left="675" width="253" height="15" font="1">(p&lt;0.01) and inducible AVRT at EP study (p&lt;0.05). </text>
<text top="305" left="943" width="144" height="15" font="1">H/o arrhythmia and inducible </text>
<text top="321" left="943" width="191" height="15" font="1">arrhythmia predict subsequent events. </text>
<text top="368" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="384" left="54" width="28" height="15" font="1">2012 </text>
<text top="399" left="54" width="29" height="15" font="1">(142) </text>
<text top="415" left="54" width="52" height="15" font="8">22215859 </text>
<text top="415" left="106" width="3" height="15" font="1"> </text>
<text top="368" left="156" width="101" height="15" font="1">Observational study </text>
<text top="384" left="156" width="73" height="15" font="1">identifying risk </text>
<text top="399" left="156" width="48" height="15" font="1">factors in </text>
<text top="415" left="156" width="97" height="15" font="1">symptomatic WPW </text>
<text top="430" left="156" width="18" height="15" font="1">pts </text>
<text top="368" left="277" width="25" height="15" font="1">369  </text>
<text top="368" left="369" width="143" height="15" font="1">WPW pts followed to assess </text>
<text top="384" left="369" width="159" height="15" font="1">predictive factors from EP study </text>
<text top="368" left="556" width="65" height="15" font="1">Evaluate the </text>
<text top="384" left="556" width="64" height="15" font="1">predictors of </text>
<text top="399" left="556" width="94" height="15" font="1">malignant rhythms </text>
<text top="368" left="675" width="210" height="15" font="1">Mean f/u 42.1±10 mo. 29 pts w/ malignant </text>
<text top="384" left="675" width="226" height="15" font="1">arrhythmias, 168 asymptomatic on f/u, 172 w/ </text>
<text top="399" left="675" width="254" height="15" font="1">AVRT/AF. Malignant arrhythmia pts had shorter AP </text>
<text top="415" left="675" width="254" height="15" font="1">ERP (p&lt;0.001), AVRT triggering AF (p&lt;0.001), and </text>
<text top="430" left="675" width="68" height="15" font="1">multiple APs. </text>
<text top="368" left="943" width="178" height="15" font="1">Short AP ERP, AVRT triggering AF, </text>
<text top="384" left="943" width="155" height="15" font="1">were independent predictors of </text>
<text top="399" left="943" width="115" height="15" font="1">malignant arrhythmias. </text>
<text top="446" left="54" width="45" height="15" font="1">Spar DS </text>
<text top="462" left="54" width="28" height="15" font="1">2012 </text>
<text top="477" left="54" width="29" height="15" font="1">(143) </text>
<text top="493" left="54" width="52" height="15" font="8">22221954 </text>
<text top="493" left="106" width="3" height="15" font="1"> </text>
<text top="446" left="156" width="101" height="15" font="1">Observational study </text>
<text top="462" left="156" width="71" height="15" font="1">of the utility of </text>
<text top="477" left="156" width="83" height="15" font="1">exercise testing  </text>
<text top="446" left="277" width="78" height="15" font="1">76 pediatric pts </text>
<text top="462" left="277" width="37" height="15" font="1">&lt;22 y.  </text>
<text top="446" left="369" width="147" height="15" font="1">WPW pts w/ exercise and EP </text>
<text top="462" left="369" width="36" height="15" font="1">testing </text>
<text top="446" left="556" width="102" height="15" font="1">Exercise test results </text>
<text top="462" left="556" width="82" height="15" font="1">compared to EP </text>
<text top="477" left="556" width="41" height="15" font="1">findings </text>
<text top="446" left="675" width="247" height="15" font="1">11 pts w/ sudden loss of delta, 18 gradual, and 47 </text>
<text top="462" left="675" width="202" height="15" font="1">no loss during exercise. Of pts w/ 1:1 AP </text>
<text top="477" left="675" width="250" height="15" font="1">conduction &lt;270 msec, none in sudden loss group </text>
<text top="493" left="675" width="246" height="15" font="1">and 18 in no loss group. Pts in gradual loss group </text>
<text top="508" left="675" width="173" height="15" font="1">more likely to have a left sided AP. </text>
<text top="446" left="943" width="173" height="15" font="1">Pts w/ sudden loss of preexcitation </text>
<text top="462" left="943" width="152" height="15" font="1">during exercise had longer 1:1 </text>
<text top="477" left="943" width="185" height="15" font="1">conduction when the AP blocked and </text>
<text top="493" left="943" width="189" height="15" font="1">none had 1:1 over the AP &lt;270 msec. </text>
<text top="524" left="54" width="50" height="15" font="1">Wackel P </text>
<text top="540" left="54" width="28" height="15" font="1">2012 </text>
<text top="555" left="54" width="29" height="15" font="1">(144) </text>
<text top="571" left="54" width="52" height="15" font="8">22978820 </text>
<text top="571" left="106" width="3" height="15" font="1"> </text>
<text top="524" left="156" width="101" height="15" font="1">Observational study </text>
<text top="540" left="156" width="89" height="15" font="1">of long term f/u of </text>
<text top="555" left="156" width="88" height="15" font="1">noninvasive tests </text>
<text top="524" left="277" width="78" height="15" font="1">24 pediatric pts </text>
<text top="540" left="277" width="30" height="15" font="1">&lt;22 y </text>
<text top="524" left="369" width="156" height="15" font="1">WPW pts w/ Holter, stress test, </text>
<text top="540" left="369" width="66" height="15" font="1">ECG and EP </text>
<text top="524" left="556" width="84" height="15" font="1">Noninvasive test </text>
<text top="540" left="556" width="100" height="15" font="1">results compared to </text>
<text top="555" left="556" width="59" height="15" font="1">EP findings </text>
<text top="525" left="675" width="234" height="15" font="1">24 pts w/ at least one noninvasive test showing </text>
<text top="540" left="675" width="226" height="15" font="1">loss of preexcitation. 2 of the 24 had rapid AP </text>
<text top="555" left="675" width="208" height="15" font="1">conduction (1:1 over AP &lt;260 msec). The </text>
<text top="571" left="675" width="250" height="15" font="1">noninvasive tests had a PPV of 92% and a NPV of </text>
<text top="587" left="675" width="242" height="15" font="1">31%. 16 of 24 had loss of delta during stress test </text>
<text top="602" left="675" width="231" height="15" font="1">and none of those had rapid conduction at EP. </text>
<text top="525" left="943" width="137" height="15" font="1">Small study showed loss of </text>
<text top="540" left="943" width="161" height="15" font="1">preexcitation during noninvasive </text>
<text top="555" left="943" width="188" height="15" font="1">testing had a high PPV and specificity </text>
<text top="571" left="943" width="174" height="15" font="1">for slow AP conduction during EP.  </text>
<text top="618" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="634" left="54" width="28" height="15" font="1">2014 </text>
<text top="649" left="54" width="29" height="15" font="1">(145) </text>
<text top="665" left="54" width="49" height="15" font="8">25052405</text>
<text top="665" left="103" width="6" height="15" font="1">  </text>
<text top="680" left="54" width="3" height="15" font="1"> </text>
<text top="618" left="156" width="93" height="15" font="1">Prospective single </text>
<text top="634" left="156" width="85" height="15" font="1">center registry of </text>
<text top="649" left="156" width="52" height="15" font="1">WPW pts  </text>
<text top="618" left="277" width="46" height="15" font="1">2169 pts </text>
<text top="618" left="369" width="119" height="15" font="1">All pts w/ a manifest AP </text>
<text top="634" left="369" width="130" height="15" font="1">underwent EP study±RF.  </text>
<text top="649" left="369" width="65" height="15" font="1">Followed 8 y </text>
<text top="618" left="556" width="97" height="15" font="1">Both asymptomatic </text>
<text top="634" left="556" width="105" height="15" font="1">and symptomatic pts </text>
<text top="649" left="556" width="81" height="15" font="1">studied at EP to </text>
<text top="665" left="556" width="95" height="15" font="1">identify risk factors </text>
<text top="680" left="556" width="33" height="15" font="1">for VF </text>
<text top="618" left="675" width="244" height="15" font="1">1001 pts (550 asymptomatic) did not undergo RF </text>
<text top="634" left="675" width="244" height="15" font="1">and 1168 (550 asymptomatic) underwent RF. F/u </text>
<text top="649" left="675" width="233" height="15" font="1">of 8 y. VF occurred in 1.5% of the no-RF group </text>
<text top="665" left="675" width="232" height="15" font="1">(mean age 11 y) and no VF occurred in the RF </text>
<text top="680" left="675" width="242" height="15" font="1">treated group (p&lt;0.001). VF was associated w/ a </text>
<text top="696" left="675" width="238" height="15" font="1">short ERP of the AP w/ an optimal cut-off of 240 </text>
<text top="711" left="675" width="249" height="15" font="1">msec (p&lt;0.001) and AVRT initiating AF (p&lt;0.001). </text>
<text top="618" left="943" width="180" height="15" font="1">Large single center registry showing </text>
<text top="634" left="943" width="169" height="15" font="1">that EP findings identified pts w/ a </text>
<text top="649" left="943" width="193" height="15" font="1">manifest AP at high risk for VF and the </text>
<text top="665" left="943" width="156" height="15" font="1">risk was eliminated w/ ablation. </text>
<text top="727" left="54" width="85" height="15" font="1">Acute Treatment </text>
<text top="744" left="54" width="55" height="15" font="1">Sellers TD </text>
<text top="759" left="54" width="28" height="15" font="1">1977 </text>
<text top="775" left="54" width="29" height="15" font="1">(146) </text>
<text top="790" left="54" width="37" height="15" font="8">872319</text>
<text top="790" left="91" width="3" height="15" font="1"> </text>
<text top="744" left="156" width="105" height="15" font="1">Acute EP study of IV </text>
<text top="759" left="156" width="91" height="15" font="1">digitalis effects on </text>
<text top="775" left="156" width="60" height="15" font="1">AF in WPW </text>
<text top="744" left="277" width="33" height="15" font="1">21 pts </text>
<text top="744" left="369" width="156" height="15" font="1">WPW pts w/ AF induced during </text>
<text top="759" left="369" width="152" height="15" font="1">EP study and given IV digitalis </text>
<text top="744" left="556" width="79" height="15" font="1">Safety for AF in </text>
<text top="759" left="556" width="31" height="15" font="1">WPW </text>
<text top="744" left="675" width="203" height="15" font="1">Digitalis shortened the CL of the shortest </text>
<text top="759" left="675" width="250" height="15" font="1">preexcited RR in 6/21 pts increased the CL in 7/21 </text>
<text top="775" left="675" width="226" height="15" font="1">pts and had no effect in 5/21. Digitalis directly </text>
<text top="790" left="675" width="242" height="15" font="1">related to onset of AF degenerating to VF in 9/21 </text>
<text top="744" left="943" width="190" height="15" font="1">This study is old but highlights the risk </text>
<text top="759" left="943" width="145" height="15" font="1">of digitalis in WPW pts w/ AF </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">67 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="675" width="254" height="15" font="1">pts.  Each of these 9 had a shortest RR &lt;230 msec </text>
<text top="70" left="675" width="98" height="15" font="1">during AF baseline. </text>
<text top="86" left="54" width="55" height="15" font="1">Sellers TD </text>
<text top="102" left="54" width="28" height="15" font="1">1977 </text>
<text top="117" left="54" width="29" height="15" font="1">(147) </text>
<text top="133" left="54" width="37" height="15" font="8">830205</text>
<text top="133" left="91" width="3" height="15" font="1"> </text>
<text top="148" left="54" width="3" height="15" font="1"> </text>
<text top="86" left="156" width="97" height="15" font="1">Single center study </text>
<text top="102" left="156" width="95" height="15" font="1">of IV procainamide </text>
<text top="117" left="156" width="81" height="15" font="1">and quinidine in </text>
<text top="133" left="156" width="102" height="15" font="1">WPS pts w/ induced </text>
<text top="86" left="277" width="33" height="15" font="1">33 pts </text>
<text top="86" left="369" width="141" height="15" font="1">All pts w/ a manifest AP and </text>
<text top="102" left="369" width="59" height="15" font="1">induced AF </text>
<text top="86" left="556" width="83" height="15" font="1">IV procainamide </text>
<text top="102" left="556" width="89" height="15" font="1">studied to assess </text>
<text top="117" left="556" width="51" height="15" font="1">effects on </text>
<text top="133" left="556" width="90" height="15" font="1">conduction during </text>
<text top="148" left="556" width="17" height="15" font="1">AF </text>
<text top="86" left="675" width="215" height="15" font="1">IV procainamide prolonged the shortest RR </text>
<text top="102" left="675" width="252" height="15" font="1">between preexcited complexes during AF by 20-70 </text>
<text top="117" left="675" width="220" height="15" font="1">msec in 15 of 21 pts and no change in 6 pts. </text>
<text top="86" left="943" width="154" height="15" font="1">IV procainamide prolonged the </text>
<text top="102" left="943" width="161" height="15" font="1">shortest RR between preexcited </text>
<text top="117" left="943" width="127" height="15" font="1">complexes in induced AF </text>
<text top="164" left="54" width="47" height="15" font="1">Hamer A </text>
<text top="180" left="54" width="28" height="15" font="1">1981 </text>
<text top="195" left="54" width="29" height="15" font="1">(148) </text>
<text top="211" left="54" width="43" height="15" font="8">7223599</text>
<text top="211" left="97" width="6" height="15" font="1">  </text>
<text top="164" left="156" width="97" height="15" font="1">Single center study </text>
<text top="180" left="156" width="106" height="15" font="1">of IV verapamil in pts </text>
<text top="195" left="156" width="47" height="15" font="1">w/ AVRT </text>
<text top="164" left="277" width="33" height="15" font="1">19 pts </text>
<text top="164" left="369" width="129" height="15" font="1">All pts had AVRT: 12 w/ a </text>
<text top="180" left="369" width="170" height="15" font="1">manifest and 7 w/ a concealed AP </text>
<text top="164" left="556" width="76" height="15" font="1">lV verapamil to </text>
<text top="180" left="556" width="100" height="15" font="1">assess EP changes </text>
<text top="195" left="556" width="105" height="15" font="1">and effects on AVRT </text>
<text top="164" left="675" width="250" height="15" font="1">IV verapamil prolonged refractoriness and delayed </text>
<text top="180" left="675" width="254" height="15" font="1">conduction in the AV node but no effect on the AP.  </text>
<text top="195" left="675" width="248" height="15" font="1">Sustained AVRT initiated in 15 pts and terminated </text>
<text top="211" left="675" width="114" height="15" font="1">by verapamil in 13 pts. </text>
<text top="165" left="943" width="143" height="15" font="1">IV verapamil was effective in </text>
<text top="180" left="943" width="90" height="15" font="1">terminating AVRT </text>
<text top="227" left="54" width="61" height="15" font="1">Hombach V </text>
<text top="243" left="54" width="28" height="15" font="1">1981 </text>
<text top="258" left="54" width="29" height="15" font="1">(149) </text>
<text top="274" left="54" width="43" height="15" font="8">7206601</text>
<text top="274" left="97" width="6" height="15" font="1">  </text>
<text top="227" left="156" width="105" height="15" font="1">Acute EP study of IV </text>
<text top="243" left="156" width="108" height="15" font="1">atenolol for treatment </text>
<text top="258" left="156" width="86" height="15" font="1">of induced PSVT </text>
<text top="227" left="277" width="33" height="15" font="1">18 pts </text>
<text top="227" left="369" width="149" height="15" font="1">Mixed group: 5 w/ AVRT, 2 w/ </text>
<text top="243" left="369" width="172" height="15" font="1">AVNRT, 6 w/ atrial flutter, 6 w/ AT, </text>
<text top="258" left="369" width="41" height="15" font="1">1 w/ VT </text>
<text top="227" left="556" width="101" height="15" font="1">IV atenolol given for </text>
<text top="243" left="556" width="104" height="15" font="1">treatment of induced </text>
<text top="258" left="556" width="32" height="15" font="1">PSVT </text>
<text top="227" left="675" width="254" height="15" font="1">Atenolol was effective in preventing pacing induced </text>
<text top="243" left="675" width="144" height="15" font="1">AVRT in 3 of 5 pts w/ WPW.  </text>
<text top="227" left="943" width="144" height="15" font="1">Small study published in Klin </text>
<text top="243" left="943" width="164" height="15" font="1">Wochenschr showing IV atenolol </text>
<text top="258" left="943" width="188" height="15" font="1">prevented reinduction of AVRT in 3 of </text>
<text top="274" left="943" width="30" height="15" font="1">5 pts. </text>
<text top="290" left="54" width="77" height="15" font="1">Scheinman BD </text>
<text top="305" left="54" width="28" height="15" font="1">1982 </text>
<text top="321" left="54" width="29" height="15" font="1">(150) </text>
<text top="336" left="54" width="43" height="15" font="8">6812745</text>
<text top="336" left="97" width="3" height="15" font="1"> </text>
<text top="290" left="156" width="61" height="15" font="1">Case report </text>
<text top="290" left="277" width="22" height="15" font="1">1 pt </text>
<text top="290" left="369" width="75" height="15" font="1">WPW pt w/ AF </text>
<text top="290" left="556" width="105" height="15" font="1">IV amiodarone given </text>
<text top="305" left="556" width="55" height="15" font="1">to treat AF </text>
<text top="290" left="675" width="247" height="15" font="1">The ventricular rate during AF increased from 170 </text>
<text top="305" left="675" width="59" height="15" font="1">to 230 bpm </text>
<text top="290" left="943" width="188" height="15" font="1">IV amiodarone accelerated the rate of </text>
<text top="305" left="943" width="96" height="15" font="1">AF in a pt w/ WPW </text>
<text top="353" left="54" width="83" height="15" font="1">Morady F, et al., </text>
<text top="368" left="54" width="28" height="15" font="1">1987 </text>
<text top="384" left="54" width="29" height="15" font="1">(151) </text>
<text top="399" left="54" width="43" height="15" font="8">2439997</text>
<text top="399" left="97" width="3" height="15" font="1"> </text>
<text top="353" left="156" width="101" height="15" font="1">Observational study </text>
<text top="368" left="156" width="84" height="15" font="1">of IV propranolol </text>
<text top="384" left="156" width="100" height="15" font="1">administered during </text>
<text top="399" left="156" width="17" height="15" font="1">AF </text>
<text top="353" left="277" width="33" height="15" font="1">10 pts </text>
<text top="353" left="369" width="122" height="15" font="1">All pts w/ preexcited AF. </text>
<text top="353" left="556" width="84" height="15" font="1">The effects of IV </text>
<text top="368" left="556" width="92" height="15" font="1">propranolol during </text>
<text top="384" left="556" width="98" height="15" font="1">preexcited AF were </text>
<text top="399" left="556" width="53" height="15" font="1">assessed. </text>
<text top="353" left="675" width="217" height="15" font="1">AF terminated in 3 of the 10 pts.  The mean </text>
<text top="368" left="675" width="242" height="15" font="1">ventricular rate during preexcited AF was slowed </text>
<text top="384" left="675" width="222" height="15" font="1">by 15-56 bpm in 6 pts; no effect in 3 pts; and </text>
<text top="399" left="675" width="196" height="15" font="1">increased from 203 to 267 bpm in 1 pt.  </text>
<text top="353" left="943" width="151" height="15" font="1">The authors concluded that IV </text>
<text top="368" left="943" width="185" height="15" font="1">propranolol should not be used in pts </text>
<text top="384" left="943" width="148" height="15" font="1">w/ preexcited AF if most QRS </text>
<text top="399" left="943" width="132" height="15" font="1">complexes are preexcited. </text>
<text top="415" left="54" width="81" height="15" font="1">Schutzenberger </text>
<text top="431" left="54" width="74" height="15" font="1">W, et al., 1987 </text>
<text top="446" left="54" width="29" height="15" font="1">(152) </text>
<text top="462" left="54" width="43" height="15" font="8">3610399</text>
<text top="462" left="97" width="3" height="15" font="1"> </text>
<text top="415" left="156" width="61" height="15" font="1">Case report </text>
<text top="415" left="277" width="22" height="15" font="1">1 pt </text>
<text top="415" left="369" width="75" height="15" font="1">WPW pt w/ AF </text>
<text top="415" left="556" width="105" height="15" font="1">IV amiodarone given </text>
<text top="431" left="556" width="55" height="15" font="1">to treat AF </text>
<text top="415" left="675" width="242" height="15" font="1">IV amiodarone accelerated the rate of preexcited </text>
<text top="431" left="675" width="17" height="15" font="1">AF </text>
<text top="415" left="943" width="188" height="15" font="1">IV amiodarone accelerated the rate of </text>
<text top="431" left="943" width="96" height="15" font="1">AF in a pt w/ WPW </text>
<text top="478" left="54" width="58" height="15" font="1">Huycke EC </text>
<text top="494" left="54" width="28" height="15" font="1">1989 </text>
<text top="509" left="54" width="29" height="15" font="1">(153) </text>
<text top="524" left="54" width="46" height="15" font="8">2918157 </text>
<text top="540" left="54" width="3" height="15" font="1"> </text>
<text top="478" left="156" width="79" height="15" font="1">IV Diltiazem vs. </text>
<text top="494" left="156" width="76" height="15" font="1">placebo for the </text>
<text top="509" left="156" width="102" height="15" font="1">termination of PSVT </text>
<text top="478" left="277" width="33" height="15" font="1">54 pts </text>
<text top="478" left="369" width="74" height="15" font="1">20 pts AVNRT </text>
<text top="494" left="369" width="162" height="15" font="1">34 pts AVRT (19 pts w/ manifest </text>
<text top="509" left="369" width="132" height="15" font="1">and 15 w/ concealed APs) </text>
<text top="478" left="556" width="97" height="15" font="1">Safety and efficacy </text>
<text top="494" left="556" width="86" height="15" font="1">for termination of </text>
<text top="509" left="556" width="95" height="15" font="1">AVNRT and AVRT </text>
<text top="478" left="675" width="237" height="15" font="1">PSVT terminated in 90% of pts w/ diltiazem and </text>
<text top="494" left="675" width="241" height="15" font="1">19% w/ placebo.  100% of AVNRT pts converted </text>
<text top="509" left="675" width="161" height="15" font="1">and 81% of AVRT pts converted.</text>
<text top="509" left="836" width="6" height="15" font="9">  </text>
<text top="524" left="675" width="179" height="15" font="1">Side effects: adverse effects in 6%.  </text>
<text top="478" left="943" width="177" height="15" font="1">IV diltiazem is safe and effective for </text>
<text top="494" left="943" width="95" height="15" font="1">treatment of AVRT </text>
<text top="556" left="54" width="60" height="15" font="1">DiMarco JP </text>
<text top="572" left="54" width="28" height="15" font="1">1990 </text>
<text top="587" left="54" width="29" height="15" font="1">(114) </text>
<text top="603" left="54" width="43" height="15" font="8">2193560</text>
<text top="603" left="97" width="3" height="15" font="1"> </text>
<text top="556" left="156" width="94" height="15" font="1">Placebo controlled </text>
<text top="572" left="156" width="90" height="15" font="1">study of the acute </text>
<text top="587" left="156" width="94" height="15" font="1">treatment of PSVT </text>
<text top="603" left="156" width="103" height="15" font="1">w/ adenosine and IV </text>
<text top="618" left="156" width="51" height="15" font="1">verapamil </text>
<text top="556" left="277" width="40" height="15" font="1">359 pts </text>
<text top="556" left="369" width="137" height="15" font="1">PSVT pts given adenosine, </text>
<text top="572" left="369" width="125" height="15" font="1">placebo, or verapamil for </text>
<text top="587" left="369" width="173" height="15" font="1">termination.  36% had AVNRT and </text>
<text top="603" left="369" width="159" height="15" font="1">64% had AVRT. 22% of pts had </text>
<text top="618" left="369" width="71" height="15" font="1">manifest APs. </text>
<text top="556" left="556" width="97" height="15" font="1">Safety and efficacy </text>
<text top="572" left="556" width="82" height="15" font="1">of adenosine for </text>
<text top="587" left="556" width="32" height="15" font="1">PSVT </text>
<text top="556" left="675" width="242" height="15" font="1">Dose ranging study.  IV adenosine doses of 6, 9, </text>
<text top="572" left="675" width="229" height="15" font="1">12 mg converted 62.3%, 80.2%, and 91.4% of </text>
<text top="587" left="675" width="229" height="15" font="1">PSVT.  Placebo converted 10.7%, 14.3%, and </text>
<text top="603" left="675" width="146" height="15" font="1">16.1% w/ 4-dose sequence.   </text>
<text top="618" left="675" width="3" height="15" font="1"> </text>
<text top="634" left="675" width="241" height="15" font="1">In trial 2, adenosine 6 mg followed by 12 mg had </text>
<text top="649" left="675" width="229" height="15" font="1">success of 57.4% and 93.4% (average time to </text>
<text top="665" left="675" width="231" height="15" font="1">termination 30 sec). AVNRT success 92% and </text>
<text top="680" left="675" width="206" height="15" font="1">AVRT success 97%. 61 total pts received </text>
<text top="696" left="675" width="57" height="15" font="1">adenosine. </text>
<text top="711" left="675" width="3" height="15" font="1"> </text>
<text top="727" left="675" width="250" height="15" font="1">IV verapamil 5 mg followed by 7.5 mg if necessary </text>
<text top="742" left="675" width="243" height="15" font="1">was successful in 81.3% and 91.4%.  95% pts w/ </text>
<text top="758" left="675" width="242" height="15" font="1">AVNRT and 96% pts w/ AVRT were successfully </text>
<text top="773" left="675" width="222" height="15" font="1">converted w/ verapamil. 64 total pts received </text>
<text top="789" left="675" width="186" height="15" font="1">verapamil; manifest pts not excluded. </text>
<text top="556" left="943" width="180" height="15" font="1">Both IV adenosine and IV verapamil </text>
<text top="572" left="943" width="193" height="15" font="1">effective for acute treatment of AVNRT </text>
<text top="587" left="943" width="57" height="15" font="1">and AVRT. </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">68 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="675" width="3" height="15" font="1"> </text>
<text top="70" left="675" width="232" height="15" font="1">Side effects: 36% w/ adverse effects lasting &lt;1 </text>
<text top="86" left="675" width="252" height="15" font="1">min. Severe side effects in 2.3% including flushing, </text>
<text top="101" left="675" width="126" height="15" font="1">chest pain, and dyspnea. </text>
<text top="117" left="54" width="52" height="15" font="1">Furlong R </text>
<text top="133" left="54" width="28" height="15" font="1">1995 </text>
<text top="148" left="54" width="29" height="15" font="1">(154) </text>
<text top="164" left="54" width="43" height="15" font="8">7605518</text>
<text top="164" left="97" width="6" height="15" font="1">  </text>
<text top="117" left="156" width="91" height="15" font="1">Acute prospective </text>
<text top="133" left="156" width="101" height="15" font="1">case series study of </text>
<text top="148" left="156" width="70" height="15" font="1">adenosine for </text>
<text top="164" left="156" width="102" height="15" font="1">termination of PSVT </text>
<text top="117" left="277" width="33" height="15" font="1">31 pts </text>
<text top="117" left="369" width="121" height="15" font="1">PSVT of undocumented </text>
<text top="133" left="369" width="60" height="15" font="1">mechanism </text>
<text top="117" left="556" width="85" height="15" font="1">Adenosine given </text>
<text top="133" left="556" width="73" height="15" font="1">prehospital for </text>
<text top="148" left="556" width="80" height="15" font="1">management of </text>
<text top="164" left="556" width="32" height="15" font="1">PSVT </text>
<text top="117" left="675" width="249" height="15" font="1">31 pts w/ PSVT, 28 (90%) converted to sinus after </text>
<text top="133" left="675" width="222" height="15" font="1">the first (16) or second or third (13) dose. No </text>
<text top="148" left="675" width="167" height="15" font="1">significant complications reported </text>
<text top="117" left="943" width="178" height="15" font="1">Adenosine was effective for treating </text>
<text top="133" left="943" width="168" height="15" font="1">PSVT (unclear how many pts had </text>
<text top="148" left="943" width="36" height="15" font="1">AVRT) </text>
<text top="180" left="54" width="49" height="15" font="1">Boriani G </text>
<text top="195" left="54" width="28" height="15" font="1">1996 </text>
<text top="211" left="54" width="29" height="15" font="1">(155) </text>
<text top="226" left="54" width="43" height="15" font="8">8644602</text>
<text top="226" left="97" width="3" height="15" font="1"> </text>
<text top="180" left="156" width="64" height="15" font="1">Case report  </text>
<text top="180" left="277" width="22" height="15" font="1">1 pt </text>
<text top="180" left="369" width="75" height="15" font="1">WPW pt w/ AF </text>
<text top="180" left="556" width="105" height="15" font="1">IV amiodarone given </text>
<text top="195" left="556" width="55" height="15" font="1">to treat AF </text>
<text top="180" left="675" width="242" height="15" font="1">IV amiodarone given to treat WPW w/ preexcited </text>
<text top="195" left="675" width="89" height="15" font="1">AF resulted in VF </text>
<text top="180" left="943" width="186" height="15" font="1">IV amiodarone resulted in ventricular  </text>
<text top="195" left="943" width="50" height="15" font="1">fibrillation </text>
<text top="243" left="54" width="44" height="15" font="1">Wen ZC </text>
<text top="258" left="54" width="28" height="15" font="1">1998 </text>
<text top="274" left="54" width="23" height="15" font="1">(41) </text>
<text top="289" left="54" width="43" height="15" font="8">9851958</text>
<text top="289" left="97" width="6" height="15" font="1">  </text>
<text top="243" left="156" width="103" height="15" font="1">Acute study of vagal </text>
<text top="258" left="156" width="74" height="15" font="1">maneuvers for </text>
<text top="274" left="156" width="102" height="15" font="1">termination of PSVT </text>
<text top="243" left="277" width="39" height="15" font="1">133 pts </text>
<text top="243" left="369" width="143" height="15" font="1">Mixed group w/ PSVT: 85 w/ </text>
<text top="258" left="369" width="33" height="15" font="1">AVRT </text>
<text top="243" left="556" width="79" height="15" font="1">Effects of vagal </text>
<text top="258" left="556" width="105" height="15" font="1">maneuvers on PSVT </text>
<text top="274" left="556" width="58" height="15" font="1">termination </text>
<text top="243" left="675" width="241" height="15" font="1">Of 85 pts w/ AVRT, vagal maneuvers terminated </text>
<text top="258" left="675" width="25" height="15" font="1">53% </text>
<text top="243" left="943" width="194" height="15" font="1">Vagal maneuvers terminate 53% of pts </text>
<text top="258" left="943" width="47" height="15" font="1">w/ AVRT </text>
<text top="305" left="54" width="54" height="15" font="1">Glatter KA </text>
<text top="321" left="54" width="28" height="15" font="1">2001 </text>
<text top="336" left="54" width="29" height="15" font="1">(156) </text>
<text top="352" left="54" width="52" height="15" font="8">11602497 </text>
<text top="352" left="106" width="3" height="15" font="1"> </text>
<text top="305" left="156" width="87" height="15" font="1">Acute study of IV </text>
<text top="321" left="156" width="84" height="15" font="1">ibutilide in pts w/ </text>
<text top="336" left="156" width="58" height="15" font="1">WPW + AF </text>
<text top="305" left="277" width="33" height="15" font="1">22 pts </text>
<text top="305" left="369" width="147" height="15" font="1">WPW pts w/ AF at time of EP </text>
<text top="321" left="369" width="30" height="15" font="1">study </text>
<text top="305" left="556" width="73" height="15" font="1">EP properties, </text>
<text top="321" left="556" width="71" height="15" font="1">safety and AF </text>
<text top="336" left="556" width="58" height="15" font="1">termination </text>
<text top="305" left="675" width="250" height="15" font="1">Ibutilide terminated AF in 95%. In 18 additional pts </text>
<text top="321" left="675" width="234" height="15" font="1">ibutilide prolonged the AP ERP from 275±40 to </text>
<text top="336" left="675" width="202" height="15" font="1">320±60 msec p&lt;0.01. No placebo arm.   </text>
<text top="305" left="943" width="157" height="15" font="1">Ibutilide sass safe and effective </text>
<text top="321" left="943" width="121" height="15" font="1">terminating AF is WPW. </text>
<text top="368" left="54" width="57" height="15" font="1">Shiraishi H </text>
<text top="384" left="54" width="28" height="15" font="1">2002 </text>
<text top="399" left="54" width="29" height="15" font="1">(157) </text>
<text top="415" left="54" width="49" height="15" font="8">12135176</text>
<text top="415" left="103" width="3" height="15" font="1"> </text>
<text top="368" left="156" width="64" height="15" font="1">Case report  </text>
<text top="368" left="277" width="22" height="15" font="1">1 pt </text>
<text top="368" left="369" width="156" height="15" font="1">Pt w/ a concealed pathway and </text>
<text top="384" left="369" width="33" height="15" font="1">AVRT </text>
<text top="368" left="556" width="94" height="15" font="1">IV verapamil given </text>
<text top="384" left="556" width="70" height="15" font="1">to treat AVRT </text>
<text top="368" left="675" width="237" height="15" font="1">IV verapamil terminated AVRT the pt developed </text>
<text top="384" left="675" width="233" height="15" font="1">non-sustained polymorphic VT. Authers did EP </text>
<text top="399" left="675" width="161" height="15" font="1">study and mechanism unknown. </text>
<text top="368" left="943" width="191" height="15" font="1">IV verapamil terminated AVRT in pt w/ </text>
<text top="384" left="943" width="189" height="15" font="1">concealed pathway but non-sustained </text>
<text top="399" left="943" width="159" height="15" font="1">polymorphic VT then developed </text>
<text top="431" left="54" width="79" height="15" font="1">Neumar RW, et </text>
<text top="446" left="54" width="46" height="15" font="1">al., 2010 </text>
<text top="462" left="54" width="29" height="15" font="1">(158) </text>
<text top="477" left="54" width="49" height="15" font="8">20956224</text>
<text top="477" left="103" width="3" height="15" font="1"> </text>
<text top="431" left="156" width="58" height="15" font="1">AHA ACLS </text>
<text top="446" left="156" width="55" height="15" font="1">Guidelines </text>
<text top="431" left="277" width="22" height="15" font="1">N/A </text>
<text top="431" left="369" width="125" height="15" font="1">Acute treatment of pts w/ </text>
<text top="446" left="369" width="142" height="15" font="1">bradycardia and tachycardia </text>
<text top="431" left="556" width="89" height="15" font="1">Expert developed </text>
<text top="446" left="556" width="53" height="15" font="1">guidelines </text>
<text top="431" left="675" width="193" height="15" font="1">Reviews role of direct current electrical </text>
<text top="446" left="675" width="253" height="15" font="1">cardioversion, vagal maneuvers and antiarrhythmic </text>
<text top="462" left="675" width="244" height="15" font="1">drug therapy for the treatment of supraventridular </text>
<text top="477" left="675" width="253" height="15" font="1">tachycardia in the emergency department including </text>
<text top="493" left="675" width="109" height="15" font="1">WPW w/ AF and SVT </text>
<text top="431" left="943" width="191" height="15" font="1">Electrical cardioversion recommended </text>
<text top="446" left="943" width="172" height="15" font="1">for the treatment of WPW w/ AF or </text>
<text top="462" left="943" width="167" height="15" font="1">SVT and hemodynamic instability </text>
<text top="509" left="54" width="54" height="15" font="1">Delaney B </text>
<text top="524" left="54" width="28" height="15" font="1">2011 </text>
<text top="540" left="54" width="29" height="15" font="1">(159) </text>
<text top="555" left="54" width="49" height="15" font="8">20926952</text>
<text top="555" left="103" width="6" height="15" font="1">  </text>
<text top="509" left="156" width="102" height="15" font="1">Meta-analysis of the </text>
<text top="524" left="156" width="107" height="15" font="1">efficacy of adenosine </text>
<text top="540" left="156" width="84" height="15" font="1">vs. verapamil for </text>
<text top="555" left="156" width="95" height="15" font="1">treatment of stable </text>
<text top="571" left="156" width="32" height="15" font="1">PSVT </text>
<text top="509" left="277" width="75" height="15" font="1">692 pts/events </text>
<text top="509" left="369" width="121" height="15" font="1">PSVT of undocumented </text>
<text top="524" left="369" width="60" height="15" font="1">mechanism </text>
<text top="509" left="556" width="102" height="15" font="1">8 trials included that </text>
<text top="524" left="556" width="103" height="15" font="1">compared verapamil </text>
<text top="540" left="556" width="76" height="15" font="1">and adenosine </text>
<text top="509" left="675" width="252" height="15" font="1">Adenosine converted 90.8% and verapamil 89.9%. </text>
<text top="524" left="675" width="218" height="15" font="1">More minor side effects w/ adenosine. More </text>
<text top="540" left="675" width="212" height="15" font="1">hypotension w/ verapamil (3.7% vs. 0.6%). </text>
<text top="509" left="943" width="180" height="15" font="1">Both adenosine and verapamil were </text>
<text top="524" left="943" width="168" height="15" font="1">effective for termination of PSVT.  </text>
<text top="540" left="943" width="159" height="15" font="1">Verapamil had more associated </text>
<text top="555" left="943" width="66" height="15" font="1">hypotension. </text>
<text top="587" left="54" width="84" height="15" font="1">Smith GD, et al., </text>
<text top="603" left="54" width="28" height="15" font="1">2013 </text>
<text top="618" left="54" width="23" height="15" font="1">(39) </text>
<text top="634" left="54" width="49" height="15" font="8">23543578</text>
<text top="634" left="103" width="3" height="15" font="1"> </text>
<text top="587" left="156" width="102" height="15" font="1">Cochrane Database </text>
<text top="603" left="156" width="47" height="15" font="1">review of </text>
<text top="618" left="156" width="100" height="15" font="1">randomized trials of </text>
<text top="634" left="156" width="45" height="15" font="1">Valsalva </text>
<text top="587" left="277" width="48" height="15" font="1">316 pts  i </text>
<text top="587" left="369" width="162" height="15" font="1">All pts w/ SVT. Number of pts w/ </text>
<text top="603" left="369" width="124" height="15" font="1">AVRT was not specified. </text>
<text top="587" left="556" width="97" height="15" font="1">Valsalva compared </text>
<text top="603" left="556" width="78" height="15" font="1">to “other” vagal </text>
<text top="618" left="556" width="58" height="15" font="1">maneuvers </text>
<text top="587" left="675" width="232" height="15" font="1">The reversion of SVT to sinus rhythm following </text>
<text top="603" left="675" width="242" height="15" font="1">Valsalva in the 3 studies was 19.4%, 45.9%, and </text>
<text top="618" left="675" width="34" height="15" font="1">54.3% </text>
<text top="587" left="943" width="178" height="15" font="1">Valsalva was effective in converting </text>
<text top="603" left="943" width="106" height="15" font="1">SVT to sinus rhythm. </text>
<text top="650" left="54" width="196" height="15" font="1">Long-Term Pharmacological Treatment </text>
<text top="666" left="54" width="55" height="15" font="1">Sellers TD </text>
<text top="682" left="54" width="28" height="15" font="1">1977 </text>
<text top="697" left="54" width="29" height="15" font="1">(146) </text>
<text top="713" left="54" width="40" height="15" font="8">872319 </text>
<text top="713" left="94" width="3" height="15" font="1"> </text>
<text top="666" left="156" width="105" height="15" font="1">Acute EP study of IV </text>
<text top="682" left="156" width="91" height="15" font="1">digitalis effects on </text>
<text top="697" left="156" width="60" height="15" font="1">AF in WPW </text>
<text top="666" left="277" width="33" height="15" font="1">21 pts </text>
<text top="666" left="369" width="156" height="15" font="1">WPW pts w/ AF induced during </text>
<text top="682" left="369" width="152" height="15" font="1">EP study and given IV digitalis </text>
<text top="666" left="556" width="79" height="15" font="1">Safety for AF in </text>
<text top="682" left="556" width="31" height="15" font="1">WPW </text>
<text top="666" left="675" width="203" height="15" font="1">Digitalis shortened the CL of the shortest </text>
<text top="682" left="675" width="250" height="15" font="1">preexcited RR in 6/21 pts increased the CL in 7/21 </text>
<text top="697" left="675" width="229" height="15" font="1">pts and had no effect in 5/21.  Digitalis directly </text>
<text top="713" left="675" width="242" height="15" font="1">related to onset of AF degenerating to VF in 9/21 </text>
<text top="728" left="675" width="251" height="15" font="1">pts. Each of these 9 had a shortest RR &lt;230 msec </text>
<text top="744" left="675" width="98" height="15" font="1">during AF baseline. </text>
<text top="666" left="943" width="190" height="15" font="1">This study is old but highlights the risk </text>
<text top="682" left="943" width="145" height="15" font="1">of digitalis in WPW pts w/ AF </text>
<text top="760" left="54" width="84" height="15" font="1">Bauernfeind RA, </text>
<text top="775" left="54" width="58" height="15" font="1">et al., 1980 </text>
<text top="791" left="54" width="29" height="15" font="1">(160) </text>
<text top="760" left="156" width="100" height="15" font="1">Single center study  </text>
<text top="775" left="156" width="84" height="15" font="1">of multiple drugs </text>
<text top="791" left="156" width="89" height="15" font="1">given IV and then </text>
<text top="760" left="277" width="72" height="15" font="1">21 pts studied </text>
<text top="775" left="277" width="75" height="15" font="1">acutely; 18 pts </text>
<text top="791" left="277" width="69" height="15" font="1">followed 6-50 </text>
<text top="760" left="369" width="130" height="15" font="1">All pts w/ AV node reentry </text>
<text top="760" left="556" width="80" height="15" font="1">Drug efficacy at </text>
<text top="775" left="556" width="97" height="15" font="1">minimal f/u of 6 mo </text>
<text top="760" left="675" width="249" height="15" font="1">Pts were tested w/ IV drug to determine if the drug </text>
<text top="775" left="675" width="233" height="15" font="1">prevented induction of AVNRT.  Successful pts </text>
<text top="791" left="675" width="244" height="15" font="1">were then treated long term w/ oral drugs.  18 pts </text>
<text top="760" left="943" width="144" height="15" font="1">Small number of pts on each </text>
<text top="775" left="943" width="150" height="15" font="1">medication showing moderate </text>
<text top="791" left="943" width="46" height="15" font="1">success. </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">69 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="43" height="15" font="8">7438370</text>
<text top="55" left="97" width="3" height="15" font="1"> </text>
<text top="70" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="156" width="83" height="15" font="1">long term for AV </text>
<text top="70" left="156" width="65" height="15" font="1">node reentry </text>
<text top="55" left="277" width="19" height="15" font="1">mo </text>
<text top="55" left="675" width="249" height="15" font="1">followed at least 6 mo, 72% w/o recurrence: 3 of 5 </text>
<text top="70" left="675" width="223" height="15" font="1">pts on digoxin only; 2 of 3 pts on digoxin plus </text>
<text top="86" left="675" width="241" height="15" font="1">propranolol; 4 of 4 pts on propranolol only; 1 of 3 </text>
<text top="101" left="675" width="239" height="15" font="1">pts on procainamide; and 3 of 3 pts on quinidine </text>
<text top="117" left="675" width="26" height="15" font="1">only. </text>
<text top="133" left="54" width="53" height="15" font="1">Sakurai M </text>
<text top="148" left="54" width="28" height="15" font="1">1983 </text>
<text top="164" left="54" width="29" height="15" font="1">(161) </text>
<text top="179" left="54" width="43" height="15" font="8">6837416</text>
<text top="179" left="97" width="3" height="15" font="1"> </text>
<text top="195" left="54" width="3" height="15" font="1"> </text>
<text top="133" left="156" width="97" height="15" font="1">Single center study </text>
<text top="148" left="156" width="69" height="15" font="1">of IV and oral </text>
<text top="164" left="156" width="99" height="15" font="1">verapamil for PSVT </text>
<text top="133" left="277" width="72" height="15" font="1">15 pts studied </text>
<text top="148" left="277" width="60" height="15" font="1">acutely and </text>
<text top="164" left="277" width="65" height="15" font="1">followed 3 to </text>
<text top="179" left="277" width="68" height="15" font="1">31 mo (mean </text>
<text top="195" left="277" width="38" height="15" font="1">15 mo) </text>
<text top="133" left="369" width="160" height="15" font="1">AVNRT in 4 and AVRT in 11 (all </text>
<text top="148" left="369" width="98" height="15" font="1">w/ a concealed AP) </text>
<text top="133" left="556" width="80" height="15" font="1">Drug efficacy at </text>
<text top="148" left="556" width="97" height="15" font="1">minimal f/u of 3 mo </text>
<text top="133" left="675" width="248" height="15" font="1">13 pts followed 3-31 (mean 15) mo w/ 8 having no </text>
<text top="148" left="675" width="252" height="15" font="1">recurrent PSVT and 5 having decreased frequency </text>
<text top="164" left="675" width="180" height="15" font="1">and duration.  Mild constipation in 4. </text>
<text top="133" left="943" width="161" height="15" font="1">Small, uncontrolled study of oral </text>
<text top="148" left="943" width="194" height="15" font="1">verapamil for PSVT including some pts </text>
<text top="164" left="943" width="47" height="15" font="1">w/ AVRT </text>
<text top="211" left="54" width="44" height="15" font="1">Feld GK </text>
<text top="226" left="54" width="31" height="15" font="1">1984  </text>
<text top="242" left="54" width="29" height="15" font="1">(162) </text>
<text top="257" left="54" width="43" height="15" font="8">6707383</text>
<text top="257" left="97" width="3" height="15" font="1"> </text>
<text top="273" left="54" width="3" height="15" font="1"> </text>
<text top="211" left="156" width="79" height="15" font="1">EP testing after </text>
<text top="226" left="156" width="100" height="15" font="1">amiodarone loading </text>
<text top="242" left="156" width="95" height="15" font="1">and then long term </text>
<text top="257" left="156" width="15" height="15" font="1">f/u </text>
<text top="211" left="277" width="33" height="15" font="1">10 pts </text>
<text top="226" left="277" width="68" height="15" font="1">EP test at ≥4 </text>
<text top="242" left="277" width="17" height="15" font="1">wk </text>
<text top="211" left="369" width="119" height="15" font="1">All pts w/ AP and AVRT </text>
<text top="211" left="556" width="93" height="15" font="1">Assessment of EP </text>
<text top="226" left="556" width="52" height="15" font="1">properties </text>
<text top="211" left="675" width="223" height="15" font="1">9 pts no longer had inducible AVRT. 1 pt had </text>
<text top="226" left="675" width="242" height="15" font="1">nonsustained AVRT.  AP ERP increased by 20% </text>
<text top="242" left="675" width="241" height="15" font="1">anterograde p&lt;0.05 and 40% retrograde p&lt;0.02  </text>
<text top="257" left="675" width="249" height="15" font="1">symptomatic control of arrhythmia during 20 mo. 1 </text>
<text top="273" left="675" width="148" height="15" font="1">pt stopped due to side effects </text>
<text top="211" left="943" width="184" height="15" font="1">Amiodarone had favorable effects on </text>
<text top="226" left="943" width="168" height="15" font="1">AP and long-term rhythm control.  </text>
<text top="242" left="943" width="102" height="15" font="1">Small number of pts </text>
<text top="257" left="943" width="3" height="15" font="1"> </text>
<text top="289" left="54" width="47" height="15" font="1">Feld GK  </text>
<text top="305" left="54" width="28" height="15" font="1">1988 </text>
<text top="320" left="54" width="29" height="15" font="1">(163) </text>
<text top="336" left="54" width="43" height="15" font="8">3336964</text>
<text top="336" left="97" width="3" height="15" font="1"> </text>
<text top="351" left="54" width="3" height="15" font="1"> </text>
<text top="289" left="156" width="99" height="15" font="1">EP testing and long </text>
<text top="305" left="156" width="100" height="15" font="1">term assessment of </text>
<text top="320" left="156" width="62" height="15" font="1">amiodarone </text>
<text top="289" left="277" width="33" height="15" font="1">10 pts </text>
<text top="305" left="277" width="49" height="15" font="1">Acute EP </text>
<text top="320" left="277" width="51" height="15" font="1">study and </text>
<text top="336" left="277" width="64" height="15" font="1">mean 30 mo </text>
<text top="351" left="277" width="15" height="15" font="1">f/u </text>
<text top="289" left="369" width="168" height="15" font="1">All pts w/ WPW and AF w/ a rapid </text>
<text top="305" left="369" width="103" height="15" font="1">ventricular response </text>
<text top="289" left="556" width="101" height="15" font="1">EP measurement of </text>
<text top="305" left="556" width="101" height="15" font="1">drug effect and long </text>
<text top="320" left="556" width="90" height="15" font="1">term f/u of rhythm </text>
<text top="336" left="556" width="36" height="15" font="1">control </text>
<text top="289" left="675" width="231" height="15" font="1">EP study—amiodarone prolonged the AP ERP </text>
<text top="305" left="675" width="217" height="15" font="1">38% (p&lt;0.01) and atrial ERP 34% (p&lt;0.01). </text>
<text top="320" left="675" width="230" height="15" font="1">Amiodarone prolonged the mean RR 90% and </text>
<text top="336" left="675" width="197" height="15" font="1">minimum RR 104% (p&lt;0.01) during AF. </text>
<text top="351" left="675" width="250" height="15" font="1">Long-term f/u—no AF or VF. SVT in 1 who went to </text>
<text top="367" left="675" width="43" height="15" font="1">surgery. </text>
<text top="382" left="675" width="3" height="15" font="1"> </text>
<text top="398" left="675" width="169" height="15" font="1">1 serious and 5 minor side effects </text>
<text top="289" left="943" width="175" height="15" font="1">Amiodarone was safe and effective </text>
<text top="305" left="943" width="193" height="15" font="1">preventing AF in a small number of pts </text>
<text top="320" left="943" width="182" height="15" font="1">although side effect were significant. </text>
<text top="414" left="54" width="61" height="15" font="1">Chimienti M </text>
<text top="429" left="54" width="28" height="15" font="1">1995 </text>
<text top="445" left="54" width="23" height="15" font="1">(30) </text>
<text top="460" left="54" width="46" height="15" font="8">8682031 </text>
<text top="460" left="100" width="3" height="15" font="1"> </text>
<text top="414" left="156" width="75" height="15" font="1">Open label, no </text>
<text top="429" left="156" width="102" height="15" font="1">placebo comparison </text>
<text top="445" left="156" width="79" height="15" font="1">of flecainide vs. </text>
<text top="460" left="156" width="65" height="15" font="1">propafenone </text>
<text top="414" left="277" width="40" height="15" font="1">335 pts </text>
<text top="429" left="277" width="65" height="15" font="1">12 mo mean </text>
<text top="445" left="277" width="15" height="15" font="1">f/u </text>
<text top="414" left="369" width="54" height="15" font="1">PSVT 135 </text>
<text top="429" left="369" width="46" height="15" font="1">PAF 200 </text>
<text top="445" left="369" width="171" height="15" font="1">Unclear number of AVRT or WPW </text>
<text top="414" left="556" width="57" height="15" font="1">Arrhythmia </text>
<text top="429" left="556" width="56" height="15" font="1">recurrence </text>
<text top="414" left="675" width="241" height="15" font="1">Probability of 12 mo safe and effective treatment </text>
<text top="429" left="675" width="225" height="15" font="1">for PSVT was 93% for flecainide and 86% for </text>
<text top="445" left="675" width="218" height="15" font="1">propafenone p=0.24.  For AF it was 77% for </text>
<text top="460" left="675" width="224" height="15" font="1">flecainide and 75% for propafenone p=0.72.   </text>
<text top="476" left="675" width="209" height="15" font="1">One VT on propafenone, Two rapid AF on </text>
<text top="491" left="675" width="50" height="15" font="1">flecainide </text>
<text top="414" left="943" width="159" height="15" font="1">Propafenone and flecainide had </text>
<text top="429" left="943" width="169" height="15" font="1">similar efficacy for PSVT and AF   </text>
<text top="507" left="54" width="61" height="15" font="1">Hopson JR  </text>
<text top="523" left="54" width="28" height="15" font="1">1996 </text>
<text top="539" left="54" width="29" height="15" font="1">(164) </text>
<text top="554" left="54" width="43" height="15" font="8">8607395</text>
<text top="554" left="97" width="3" height="15" font="1"> </text>
<text top="569" left="54" width="3" height="15" font="1"> </text>
<text top="507" left="156" width="57" height="15" font="1">Open-label </text>
<text top="523" left="156" width="90" height="15" font="1">multicenter trial of </text>
<text top="539" left="156" width="50" height="15" font="1">flecainide </text>
<text top="507" left="277" width="40" height="15" font="1">151 pts </text>
<text top="523" left="277" width="18" height="15" font="1">1 y </text>
<text top="507" left="369" width="47" height="15" font="1">PSVT 67 </text>
<text top="523" left="369" width="40" height="15" font="1">PAF 67 </text>
<text top="539" left="369" width="168" height="15" font="1">CAF 17, unclear number of AVRT </text>
<text top="554" left="369" width="44" height="15" font="1">or WPW </text>
<text top="507" left="556" width="57" height="15" font="1">Arrhythmia </text>
<text top="523" left="556" width="56" height="15" font="1">recurrence </text>
<text top="507" left="675" width="234" height="15" font="1">At 1 y of treatment, 87% of PSVT, 73% of PAF, </text>
<text top="523" left="675" width="242" height="15" font="1">and 56% of CAF had improved symptomatically.  </text>
<text top="539" left="675" width="247" height="15" font="1">Proarrhythmia is 3, CHF in 7.  65% w/ visual sx or </text>
<text top="554" left="675" width="52" height="15" font="1">headache </text>
<text top="507" left="943" width="189" height="15" font="1">Poor study design, flecainide effective </text>
<text top="523" left="943" width="180" height="15" font="1">but important cardiac events.  Study </text>
<text top="539" left="943" width="181" height="15" font="1">done before results of CAST known. </text>
<text top="586" left="54" width="218" height="15" font="1">Catheter Ablation: Ablation of Standard APs </text>
<text top="602" left="54" width="70" height="15" font="1">Jackman WM </text>
<text top="617" left="54" width="28" height="15" font="1">1991 </text>
<text top="633" left="54" width="29" height="15" font="1">(165) </text>
<text top="648" left="54" width="43" height="15" font="8">2030716</text>
<text top="648" left="97" width="3" height="15" font="1"> </text>
<text top="664" left="54" width="3" height="15" font="1"> </text>
<text top="602" left="156" width="101" height="15" font="1">Observational study </text>
<text top="617" left="156" width="93" height="15" font="1">of RF ablation and </text>
<text top="633" left="156" width="84" height="15" font="1">short term f/u for </text>
<text top="648" left="156" width="31" height="15" font="1">WPW </text>
<text top="602" left="277" width="22" height="15" font="1">166 </text>
<text top="602" left="369" width="156" height="15" font="1">166 WPW pts w/ 177 pathways </text>
<text top="602" left="556" width="73" height="15" font="1">Acute ablation </text>
<text top="617" left="556" width="105" height="15" font="1">success and at 8 mo </text>
<text top="602" left="675" width="246" height="15" font="1">AP conduction eliminated in 164 of 166 pts (99%) </text>
<text top="617" left="675" width="249" height="15" font="1">by a median of 3 RF applications. F/u at 8±5.4 mo </text>
<text top="633" left="675" width="242" height="15" font="1">showed preexcitation or AVRT returned in 15 pts </text>
<text top="648" left="675" width="94" height="15" font="1">who underwent a 2</text>
<text top="649" left="768" width="8" height="10" font="10">nd</text>
<text top="648" left="777" width="150" height="15" font="1"> RF. EP study at 3±9 mo after </text>
<text top="664" left="675" width="242" height="15" font="1">RF in 75 pts verified absence of AP. 3 pts (1.8%) </text>
<text top="679" left="675" width="244" height="15" font="1">w/ complications – AV block, cardiac tamponade, </text>
<text top="695" left="675" width="60" height="15" font="1">pericarditis. </text>
<text top="602" left="943" width="175" height="15" font="1">Large series reporting success and </text>
<text top="617" left="943" width="183" height="15" font="1">safety of RF for treating AP in WPW. </text>
<text top="711" left="54" width="50" height="15" font="1">Calkins H </text>
<text top="727" left="54" width="28" height="15" font="1">1992 </text>
<text top="742" left="54" width="29" height="15" font="1">(166) </text>
<text top="758" left="54" width="49" height="15" font="8">1555278  </text>
<text top="711" left="156" width="101" height="15" font="1">Observational study </text>
<text top="727" left="156" width="73" height="15" font="1">of RF in WPW </text>
<text top="711" left="277" width="22" height="15" font="1">250 </text>
<text top="711" left="369" width="153" height="15" font="1">183 pts w/ manifest AP and 84 </text>
<text top="727" left="369" width="168" height="15" font="1">concealed. Failed 2.0+/-1.6 AADs </text>
<text top="711" left="556" width="80" height="15" font="1">Acute, 3 mo EP </text>
<text top="727" left="556" width="105" height="15" font="1">study,  and 10±4 mo </text>
<text top="742" left="556" width="43" height="15" font="1">success </text>
<text top="711" left="675" width="242" height="15" font="1">250 pts w/ 267 APs.  94% w/ both acute success </text>
<text top="727" left="675" width="198" height="15" font="1">and free of tachycardia at 10 mo. 4% w/ </text>
<text top="742" left="675" width="246" height="15" font="1">complications: MI-1, AV block-3, valve damage-1, </text>
<text top="758" left="675" width="87" height="15" font="1">TIA-1, vascular-2 </text>
<text top="711" left="943" width="175" height="15" font="1">Large series reporting success and </text>
<text top="727" left="943" width="130" height="15" font="1">safety of RF in pts w/ APs </text>
<text top="774" left="54" width="44" height="15" font="1">Kugler J </text>
<text top="789" left="54" width="28" height="15" font="1">1994 </text>
<text top="774" left="156" width="71" height="15" font="1">Observational </text>
<text top="789" left="156" width="99" height="15" font="1">multicenter study of </text>
<text top="774" left="277" width="184" height="15" font="1">652 615 </text>
<text top="774" left="390" width="23" height="15" font="1">APs </text>
<text top="774" left="556" width="81" height="15" font="1">Acute and short-</text>
<text top="789" left="556" width="84" height="15" font="1">term f/u 13.5 mo </text>
<text top="774" left="675" width="240" height="15" font="1">Success highest in left free wall APs (89%), high </text>
<text top="789" left="675" width="222" height="15" font="1">volume centers; lowest in right free wall AP’s </text>
<text top="774" left="943" width="142" height="15" font="1">Large multicenter series, RF </text>
<text top="789" left="943" width="154" height="15" font="1">acceptable treatment for AP w/ </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">70 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="29" height="15" font="1">(167) </text>
<text top="70" left="54" width="43" height="15" font="8">8164700</text>
<text top="70" left="97" width="3" height="15" font="1"> </text>
<text top="86" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="156" width="77" height="15" font="1">RF ablations in </text>
<text top="70" left="156" width="76" height="15" font="1">young pts SVT </text>
<text top="55" left="675" width="227" height="15" font="1">(69%), pt weight &gt;80 kg, or presence of CHD. </text>
<text top="70" left="675" width="248" height="15" font="1">Recurrence in 12-40%, higher in right free wall AP </text>
<text top="86" left="675" width="246" height="15" font="1">or presence of CHD. 3.7%; one procedural death; </text>
<text top="101" left="675" width="251" height="15" font="1">AV block, pericardial eff/usion; higher if weight &lt;15 </text>
<text top="117" left="675" width="252" height="15" font="1">kg; One post procedural death in 5 wk old infant w/ </text>
<text top="132" left="675" width="84" height="15" font="1">torn mitral valve. </text>
<text top="55" left="943" width="175" height="15" font="1">attention to pt age and body weight </text>
<text top="70" left="943" width="119" height="15" font="1">and center experience.  </text>
<text top="148" left="54" width="50" height="15" font="1">Calkins H </text>
<text top="164" left="54" width="28" height="15" font="1">1999 </text>
<text top="179" left="54" width="23" height="15" font="1">(59) </text>
<text top="195" left="54" width="46" height="15" font="8">9892593 </text>
<text top="195" left="100" width="3" height="15" font="1"> </text>
<text top="148" left="156" width="57" height="15" font="1">Multicenter </text>
<text top="164" left="156" width="98" height="15" font="1">observational study </text>
<text top="179" left="156" width="105" height="15" font="1">of RF using Atakr for </text>
<text top="195" left="156" width="32" height="15" font="1">PSVT </text>
<text top="148" left="277" width="28" height="15" font="1">1050 </text>
<text top="148" left="369" width="154" height="15" font="1">500 pts w/ AP; 373 w/ AVNRT; </text>
<text top="164" left="369" width="93" height="15" font="1">121 of AV junction </text>
<text top="148" left="556" width="102" height="15" font="1">Acute and long term </text>
<text top="164" left="556" width="76" height="15" font="1">safety and f/u.; </text>
<text top="179" left="556" width="92" height="15" font="1">median f/u 6.3 mo </text>
<text top="148" left="675" width="252" height="15" font="1">Acute AP success 93% for single APs and 86% for </text>
<text top="164" left="675" width="248" height="15" font="1">multiple APs. 7.8% of pts w/ AP had a recurrence. </text>
<text top="179" left="675" width="245" height="15" font="1">3% w/ major complication and 8.2% minor. Death-</text>
<text top="195" left="675" width="225" height="15" font="1">3, stroke-2, AV block-10, tamponade-6, valve </text>
<text top="210" left="675" width="81" height="15" font="1">damage-1, MI-1 </text>
<text top="148" left="943" width="165" height="15" font="1">Large series showing good acute </text>
<text top="164" left="943" width="176" height="15" font="1">success, 8% recurrence, and major </text>
<text top="179" left="943" width="185" height="15" font="1">complications in 3%. This is the most </text>
<text top="195" left="943" width="180" height="15" font="1">accurate study listing complications. </text>
<text top="226" left="54" width="50" height="15" font="1">Dagres N </text>
<text top="242" left="54" width="28" height="15" font="1">1999 </text>
<text top="257" left="54" width="29" height="15" font="1">(168) </text>
<text top="273" left="54" width="52" height="15" font="8">10581141 </text>
<text top="226" left="156" width="101" height="15" font="1">Observational study </text>
<text top="242" left="156" width="69" height="15" font="1">of RF for APs </text>
<text top="226" left="277" width="22" height="15" font="1">519 </text>
<text top="226" left="369" width="71" height="15" font="1">All pts w/ APs </text>
<text top="226" left="556" width="102" height="15" font="1">Acute and long term </text>
<text top="242" left="556" width="100" height="15" font="1">f/u at 22.6±12.4 mo </text>
<text top="226" left="675" width="229" height="15" font="1">398 pts responded to f/u questionnaire. 85.4% </text>
<text top="242" left="675" width="250" height="15" font="1">asymptomatic and 10.6% taking AADs. 41% of pts </text>
<text top="257" left="675" width="193" height="15" font="1">w/ failed ablations were asymptomatic. </text>
<text top="226" left="943" width="188" height="15" font="1">Large series reporting good long term </text>
<text top="242" left="943" width="114" height="15" font="1">success w/ RF for APs </text>
<text top="289" left="54" width="58" height="15" font="1">Schlapfer J </text>
<text top="305" left="54" width="28" height="15" font="1">2001 </text>
<text top="320" left="54" width="29" height="15" font="1">(169) </text>
<text top="336" left="54" width="52" height="15" font="8">11259148 </text>
<text top="289" left="156" width="101" height="15" font="1">Observational study </text>
<text top="305" left="156" width="69" height="15" font="1">of RF for APs </text>
<text top="320" left="156" width="93" height="15" font="1">followed long term </text>
<text top="289" left="277" width="22" height="15" font="1">180 </text>
<text top="289" left="369" width="168" height="15" font="1">Pts. w/ APs undergoing RF failing </text>
<text top="305" left="369" width="94" height="15" font="1">1.75+/- 1.25 AADs </text>
<text top="289" left="556" width="90" height="15" font="1">Long-term f/u at a </text>
<text top="305" left="556" width="95" height="15" font="1">median of 48.1 mo </text>
<text top="289" left="675" width="228" height="15" font="1">All pts has successful procedure. Pts followed </text>
<text top="305" left="675" width="255" height="15" font="1">median of 48.1 mo—79% remained asymptomatic.  </text>
<text top="320" left="675" width="204" height="15" font="1">10% required further RF’ or meds. 4% w/ </text>
<text top="336" left="675" width="212" height="15" font="1">procedure complications: vascular-5, valve </text>
<text top="351" left="675" width="99" height="15" font="1">perforation-1, TIA-2 </text>
<text top="289" left="943" width="178" height="15" font="1">Large study of acute RF success w/ </text>
<text top="305" left="943" width="180" height="15" font="1">21% having sxs by 4 y but only 10% </text>
<text top="320" left="943" width="140" height="15" font="1">requiring additional therapy. </text>
<text top="367" left="54" width="65" height="15" font="1">Belhassen B </text>
<text top="383" left="54" width="28" height="15" font="1">2007 </text>
<text top="398" left="54" width="29" height="15" font="1">(170) </text>
<text top="414" left="54" width="49" height="15" font="8">17491219</text>
<text top="414" left="103" width="3" height="15" font="1"> </text>
<text top="367" left="156" width="101" height="15" font="1">Observational study </text>
<text top="383" left="156" width="69" height="15" font="1">of RF for APs </text>
<text top="367" left="277" width="22" height="15" font="1">508 </text>
<text top="367" left="369" width="102" height="15" font="1">508 pts w/ 535 APs. </text>
<text top="367" left="556" width="102" height="15" font="1">Acute and long term </text>
<text top="383" left="556" width="89" height="15" font="1">RF results 85±43 </text>
<text top="398" left="556" width="34" height="15" font="1">mo f/u </text>
<text top="367" left="675" width="213" height="15" font="1">46.8% manifest and 44.4% concealed. 572 </text>
<text top="383" left="675" width="224" height="15" font="1">procedures in the 508 pts. Acute RF success </text>
<text top="398" left="675" width="237" height="15" font="1">93.1% and multiple RF 95.3%. 9.9% recurrence </text>
<text top="414" left="675" width="31" height="15" font="1">after 1</text>
<text top="414" left="706" width="6" height="10" font="10">st</text>
<text top="414" left="712" width="192" height="15" font="1"> RF. At 85 mo f/u, 94.9% cure. 2 major </text>
<text top="429" left="675" width="193" height="15" font="1">complications—pericardial effusion, MI </text>
<text top="367" left="943" width="157" height="15" font="1">Large series showing long-term </text>
<text top="383" left="943" width="173" height="15" font="1">success and safety of RF for APs.  </text>
<text top="446" left="54" width="74" height="15" font="1">Pappone C, et </text>
<text top="461" left="54" width="46" height="15" font="1">al., 2014 </text>
<text top="477" left="54" width="32" height="15" font="1"> (145) </text>
<text top="492" left="54" width="49" height="15" font="8">25052405</text>
<text top="492" left="103" width="3" height="15" font="1"> </text>
<text top="446" left="156" width="93" height="15" font="1">Prospective single </text>
<text top="461" left="156" width="85" height="15" font="1">center registry of </text>
<text top="477" left="156" width="52" height="15" font="1">WPW pts  </text>
<text top="446" left="277" width="46" height="15" font="1">2169 pts </text>
<text top="446" left="369" width="119" height="15" font="1">All pts w/ a manifest AP </text>
<text top="463" left="369" width="69" height="15" font="1">underwent EP</text>
<text top="461" left="438" width="8" height="17" font="0">±</text>
<text top="463" left="447" width="89" height="15" font="1">RF.  Followed 8 y </text>
<text top="446" left="556" width="97" height="15" font="1">Both asymptomatic </text>
<text top="461" left="556" width="105" height="15" font="1">and symptomatic pts </text>
<text top="477" left="556" width="81" height="15" font="1">studied at EP to </text>
<text top="492" left="556" width="95" height="15" font="1">identify risk factors </text>
<text top="507" left="556" width="33" height="15" font="1">for VF </text>
<text top="446" left="675" width="244" height="15" font="1">1001 pts (550 asymptomatic) did not undergo RF </text>
<text top="461" left="675" width="247" height="15" font="1">and 1168 (550 asymptomatic) underwent RF.  F/u </text>
<text top="477" left="675" width="236" height="15" font="1">of 8 y.  VF occurred in 1.5% of the no-RF group </text>
<text top="492" left="675" width="232" height="15" font="1">(mean age 11 y) and no VF occurred in the RF </text>
<text top="507" left="675" width="245" height="15" font="1">treated group (p&lt;0.001).  VF was associated w/ a </text>
<text top="523" left="675" width="238" height="15" font="1">short ERP of the AP w/ an optimal cut-off of 240 </text>
<text top="539" left="675" width="249" height="15" font="1">msec (p&lt;0.001) and AVRT initiating AF (p&lt;0.001). </text>
<text top="446" left="943" width="180" height="15" font="1">Large single center registry showing </text>
<text top="461" left="943" width="169" height="15" font="1">that EP findings identified pts w/ a </text>
<text top="477" left="943" width="193" height="15" font="1">manifest AP at high risk for VF and the </text>
<text top="492" left="943" width="156" height="15" font="1">risk was eliminated w/ ablation. </text>
<text top="555" left="54" width="1056" height="15" font="1">AAD indicates antiarrhythmic drugs; ACLS, Advanced Cardiovascular Life Support; AF, atrial fibrillation; AHA, American Heart Association; AP, accessory pathway; AT, atrial tachycardia; AV, atrioventricular; AVNRT, </text>
<text top="570" left="54" width="1073" height="15" font="1">atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; bpm, beats per min; CAF, chronic atrial fibrillation; CHF, congestive heart failure; CL, cycle length; EP, electrophysiological; ERP, </text>
<text top="586" left="54" width="1053" height="15" font="1">effective refractory period; f/u, follow up; h/o, history of; IV, intravenous; MI, myocardial infarction; N/A, not applicable; NPV, negative predictive value; PAF, paroxysmal atrial fibrillation; PPV, positive predictive value; </text>
<text top="601" left="54" width="1076" height="15" font="1">PSVT, paroxysmal supraventricular tachycardia; pt, patient; FR, radiofrequency; RVR, rapid ventricular response; SVT, supraventricular tachycardia; sx, symptom; TIA, transient ischemic attack; VF, ventricular fibrillation; </text>
<text top="617" left="54" width="340" height="15" font="1">w/, with; w/o, without; and WPW, Wolff–Parkinson-White syndrome.   </text>
<text top="632" left="54" width="3" height="15" font="1"> </text>
<text top="658" left="54" width="151" height="18" font="3"><b>Data Supplement 13. </b></text>
<text top="658" left="205" width="406" height="18" font="7"><b>Summary of Included Studies – ERC Report (Section 6.2)</b></text>
<text top="658" left="611" width="4" height="18" font="3"><b> </b></text>
<text top="676" left="67" width="34" height="15" font="16"><b>Study </b></text>
<text top="692" left="61" width="46" height="15" font="16"><b>(Author, </b></text>
<text top="707" left="69" width="31" height="15" font="16"><b>Year) </b></text>
<text top="676" left="204" width="74" height="15" font="16"><b>Study Design </b></text>
<text top="676" left="401" width="86" height="15" font="16"><b>Sample Size (N) </b></text>
<text top="676" left="564" width="143" height="15" font="16"><b>Participant Characteristics </b></text>
<text top="676" left="799" width="94" height="15" font="16"><b>Inclusion Criteria </b></text>
<text top="676" left="997" width="97" height="15" font="16"><b>Exclusion Criteria </b></text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">71 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="51" height="15" font="1">Milstein S </text>
<text top="70" left="54" width="28" height="15" font="1">1986 </text>
<text top="86" left="54" width="29" height="15" font="1">(171) </text>
<text top="101" left="54" width="43" height="15" font="8">3706161</text>
<text top="101" left="97" width="3" height="15" font="1"> </text>
<text top="55" left="127" width="225" height="15" font="1">Uncontrolled prospective cohort study. All pts </text>
<text top="70" left="127" width="121" height="15" font="1">underwent an EP study. </text>
<text top="55" left="368" width="15" height="15" font="1">42 </text>
<text top="54" left="537" width="186" height="17" font="1">  Mean age (±SD) 36 y (±12 y); age </text>
<text top="71" left="550" width="65" height="15" font="1">range 7-77 y </text>
<text top="86" left="537" width="199" height="17" font="1">  Gender: 21 (50%) men and 21 (50%) </text>
<text top="103" left="550" width="42" height="15" font="1">women  </text>
<text top="118" left="537" width="60" height="17" font="1">  SHD: ---  </text>
<text top="54" left="752" width="175" height="17" font="1">  WPW pattern seen on a routine </text>
<text top="71" left="770" width="166" height="15" font="1">ECG. These pts were considered </text>
<text top="86" left="770" width="162" height="15" font="1">asymptomatic because they had </text>
<text top="102" left="770" width="162" height="15" font="1">neither documented arrhythmias </text>
<text top="117" left="770" width="159" height="15" font="1">nor a h/o sustained palpitations  </text>
<text top="55" left="953" width="14" height="15" font="1">--- </text>
<text top="205" left="54" width="44" height="15" font="1">Satoh M </text>
<text top="221" left="54" width="28" height="15" font="1">1989 </text>
<text top="236" left="54" width="29" height="15" font="1">(172) </text>
<text top="252" left="54" width="43" height="15" font="8">2466266</text>
<text top="252" left="97" width="3" height="15" font="1"> </text>
<text top="205" left="127" width="216" height="15" font="1">Uncontrolled observational cohort study. All </text>
<text top="221" left="127" width="139" height="15" font="1">pts underwent an EP study. </text>
<text top="205" left="368" width="143" height="15" font="1">95 (34 asymptomatic and 61 </text>
<text top="221" left="368" width="87" height="15" font="1">symptomatic pts) </text>
<text top="205" left="537" width="168" height="17" font="1">  Mean age (± SD) 32 y (± 19 y) </text>
<text top="221" left="537" width="66" height="17" font="1">  Male 73% </text>
<text top="238" left="537" width="65" height="17" font="1">  SHD 13% </text>
<text top="254" left="537" width="166" height="17" font="1">  Intermittent preexcitation  23% </text>
<text top="205" left="752" width="87" height="17" font="1">  WPW pattern </text>
<text top="221" left="752" width="131" height="17" font="1">  Asymptomatic (neither </text>
<text top="238" left="770" width="155" height="15" font="1">documented tachycardia, nor a </text>
<text top="253" left="770" width="146" height="15" font="1">h/o palpitations suggestive of </text>
<text top="269" left="770" width="126" height="15" font="1">paroxysmal tachycardia.) </text>
<text top="205" left="953" width="14" height="15" font="1">--- </text>
<text top="308" left="54" width="45" height="15" font="1">Klein GJ </text>
<text top="324" left="54" width="28" height="15" font="1">1989 </text>
<text top="339" left="54" width="29" height="15" font="1">(173) </text>
<text top="355" left="54" width="43" height="15" font="8">2710202</text>
<text top="355" left="97" width="3" height="15" font="1"> </text>
<text top="308" left="127" width="226" height="15" font="1">Uncontrolled prospective observational study. </text>
<text top="324" left="127" width="154" height="15" font="1">All pts underwent an EP study. </text>
<text top="308" left="368" width="15" height="15" font="1">29 </text>
<text top="308" left="537" width="165" height="17" font="1">  Age (±SD): 50 y (±18 y) in the </text>
<text top="325" left="550" width="135" height="15" font="1">preexcitation lost subgroup </text>
<text top="340" left="550" width="159" height="15" font="1">39 y (±11 y) in the preexcitation </text>
<text top="356" left="550" width="100" height="15" font="1">persistent subgroup </text>
<text top="371" left="537" width="188" height="17" font="1">  Gender: 17/29 (58.6%) men, 12/29 </text>
<text top="388" left="550" width="84" height="15" font="1">(41.4%)  women </text>
<text top="403" left="537" width="57" height="17" font="1">  SHD: --- </text>
<text top="308" left="752" width="187" height="17" font="1">  Asymptomatic WPW ECG pattern </text>
<text top="325" left="752" width="180" height="17" font="1">  No documented tachycardia and </text>
<text top="341" left="770" width="153" height="15" font="1">no h/o sustained tachycardia.   </text>
<text top="308" left="953" width="14" height="15" font="1">--- </text>
<text top="420" left="54" width="52" height="15" font="1">Leitch JW </text>
<text top="436" left="54" width="28" height="15" font="1">1990 </text>
<text top="451" left="54" width="29" height="15" font="1">(174) </text>
<text top="467" left="54" width="43" height="15" font="8">2225373</text>
<text top="467" left="97" width="3" height="15" font="1"> </text>
<text top="420" left="127" width="226" height="15" font="1">Uncontrolled prospective observational study. </text>
<text top="436" left="127" width="154" height="15" font="1">All pts underwent an EP study. </text>
<text top="420" left="368" width="15" height="15" font="1">75 </text>
<text top="420" left="537" width="193" height="17" font="1">  Mean age (± SD) 34 y (± 13 y), age </text>
<text top="437" left="550" width="65" height="15" font="1">range 7-77 y </text>
<text top="452" left="537" width="89" height="17" font="1">  Male 44 (59%) </text>
<text top="469" left="537" width="174" height="17" font="1">  SHD 5/75 (7%): (1 w/ CAD, 2 w/ </text>
<text top="485" left="550" width="160" height="15" font="1">cardiomyopathy, 1 w/ VHD, 1 w/ </text>
<text top="501" left="550" width="100" height="15" font="1">Ebstein’s anomaly)  </text>
<text top="420" left="752" width="163" height="17" font="1">  Asymptomatic w/ WPW ECG </text>
<text top="437" left="770" width="38" height="15" font="1">pattern </text>
<text top="420" left="955" width="158" height="17" font="1">  All pts underwent sx-limited </text>
<text top="437" left="976" width="159" height="15" font="1">exercise stress testing and 24-h </text>
<text top="452" left="976" width="136" height="15" font="1">Holter monitoring and were </text>
<text top="468" left="976" width="154" height="15" font="1">excluded from the study if SVT </text>
<text top="483" left="976" width="150" height="15" font="1">was documented at any time.  </text>
<text top="499" left="955" width="173" height="17" font="1">  Other specific exclusions were </text>
<text top="515" left="976" width="154" height="15" font="1">intermittent preexcitation either </text>
<text top="531" left="976" width="161" height="15" font="1">at rest or during exercise testing </text>
<text top="546" left="976" width="75" height="15" font="1">and EP study.  </text>
<text top="575" left="54" width="50" height="15" font="1">Brembilla-</text>
<text top="590" left="54" width="44" height="15" font="1">Perrot B </text>
<text top="606" left="54" width="28" height="15" font="1">2001 </text>
<text top="621" left="54" width="29" height="15" font="1">(175) </text>
<text top="637" left="54" width="49" height="15" font="8">11707045</text>
<text top="637" left="103" width="3" height="15" font="1"> </text>
<text top="575" left="127" width="226" height="15" font="1">Uncontrolled prospective observational study. </text>
<text top="590" left="127" width="223" height="15" font="1">All pts underwent testing w/ transesophageal </text>
<text top="606" left="127" width="59" height="15" font="1">stimulation. </text>
<text top="575" left="368" width="15" height="15" font="1">92 </text>
<text top="575" left="537" width="189" height="17" font="1">  Mean age (±SD): 34 y (±15 y), age </text>
<text top="591" left="550" width="71" height="15" font="1">range 11-69 y </text>
<text top="607" left="537" width="111" height="17" font="1">  68 men, 24 women </text>
<text top="623" left="537" width="57" height="17" font="1">  No SHD </text>
<text top="575" left="752" width="187" height="17" font="1">  Asymptomatic WPW ECG pattern </text>
<text top="591" left="752" width="180" height="17" font="1">  No documented tachycardia and </text>
<text top="608" left="770" width="150" height="15" font="1">no h/o sustained tachycardia   </text>
<text top="575" left="955" width="168" height="17" font="1">  Documentation of SVT at any </text>
<text top="591" left="976" width="24" height="15" font="1">time </text>
<text top="658" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="673" left="54" width="28" height="15" font="1">2003 </text>
<text top="689" left="54" width="29" height="15" font="1">(176) </text>
<text top="704" left="54" width="49" height="15" font="8">12535816</text>
<text top="704" left="103" width="3" height="15" font="1"> </text>
<text top="658" left="127" width="226" height="15" font="1">Uncontrolled prospective observational study. </text>
<text top="673" left="127" width="154" height="15" font="1">All pts underwent an EP study. </text>
<text top="658" left="368" width="22" height="15" font="1">212 </text>
<text top="658" left="537" width="182" height="17" font="1">  Mean age of overall population (± </text>
<text top="674" left="550" width="175" height="15" font="1">SD): 35.8 y (± 20.5 y), age range 7-</text>
<text top="690" left="550" width="172" height="15" font="1">63 y. Gender in overall population: </text>
<text top="705" left="550" width="175" height="15" font="1">N/A. SHD in overall population was </text>
<text top="721" left="550" width="182" height="15" font="1">present in 10/212 (5%) (5 w/ MVP, 2 </text>
<text top="736" left="550" width="139" height="15" font="1">w/ HCM, 3 w/ hypertension) </text>
<text top="752" left="537" width="183" height="17" font="1">  Mean age (±SD) of the 162 pts w/ </text>
<text top="768" left="550" width="169" height="15" font="1">complete f/u 33.6 y (±14.3 y), age </text>
<text top="784" left="550" width="174" height="15" font="1">range 7-63 y. Male 105/162 (65%). </text>
<text top="658" left="752" width="182" height="17" font="1">  Asymptomatic WPW pattern was </text>
<text top="674" left="770" width="168" height="15" font="1">found either incidentally at routine </text>
<text top="690" left="770" width="160" height="15" font="1">examination or during a medical </text>
<text top="705" left="770" width="157" height="15" font="1">check-up before admission to a </text>
<text top="721" left="770" width="154" height="15" font="1">competitive sport or a high-risk </text>
<text top="736" left="770" width="57" height="15" font="1">occupation </text>
<text top="658" left="953" width="14" height="15" font="1">--- </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">72 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="550" width="159" height="15" font="1">SHD was present in 4/162 (3 w/ </text>
<text top="70" left="550" width="89" height="15" font="1">MVP, 1 w/ HCM)  </text>
<text top="149" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="164" left="54" width="28" height="15" font="1">2003 </text>
<text top="180" left="54" width="29" height="15" font="1">(177) </text>
<text top="196" left="54" width="49" height="15" font="8">14602878</text>
<text top="196" left="103" width="3" height="15" font="1"> </text>
<text top="149" left="127" width="160" height="15" font="1">Combined RCT and prospective </text>
<text top="164" left="127" width="223" height="15" font="1">observational cohort study. All pts underwent </text>
<text top="180" left="127" width="219" height="15" font="1">EP study. Pts w/ inducible arrhythmia on EP </text>
<text top="196" left="127" width="212" height="15" font="1">study who were ≤35 y were randomized to </text>
<text top="211" left="127" width="211" height="15" font="1">ablation vs. no ablation. The remaining pts </text>
<text top="227" left="127" width="207" height="15" font="1">were followed as an observational cohort. </text>
<text top="149" left="368" width="135" height="15" font="1">224 (EP study identified 76 </text>
<text top="164" left="368" width="138" height="15" font="1">high-risk pts who were then </text>
<text top="180" left="368" width="132" height="15" font="1">enrolled in a RCT and 148 </text>
<text top="196" left="368" width="122" height="15" font="1">low-risk pts enrolled in a </text>
<text top="211" left="368" width="129" height="15" font="1">prospective observational </text>
<text top="227" left="368" width="67" height="15" font="1">cohort study) </text>
<text top="149" left="537" width="192" height="17" font="1">  Median (IQR) age 23 y (15-30 y) for </text>
<text top="165" left="550" width="182" height="15" font="1">ablation group and 22 y (15-30 y) for </text>
<text top="181" left="550" width="176" height="15" font="1">no ablation group. Male sex 53% in </text>
<text top="196" left="550" width="180" height="15" font="1">ablation arm and 47% in no ablation </text>
<text top="212" left="550" width="158" height="15" font="1">group. No SHD in either group.  </text>
<text top="227" left="537" width="189" height="17" font="1">  Median (IQR) age for observational </text>
<text top="244" left="550" width="181" height="15" font="1">cohort 36 y (27-48 y). Male sex 59% </text>
<text top="259" left="550" width="118" height="15" font="1">in this cohort. SHD 7%. </text>
<text top="149" left="752" width="140" height="17" font="1">  Ventricular preexcitation </text>
<text top="165" left="770" width="146" height="15" font="1">documented by 12-lead ECG </text>
<text top="181" left="752" width="169" height="17" font="1">  Absence of arrhythmia-related </text>
<text top="197" left="770" width="20" height="15" font="1">sxs </text>
<text top="149" left="955" width="124" height="17" font="1">  Participation in other </text>
<text top="165" left="976" width="121" height="15" font="1">investigational protocols </text>
<text top="181" left="955" width="73" height="17" font="1">  Age &lt;13 y </text>
<text top="197" left="955" width="76" height="17" font="1">  Pregnancy </text>
<text top="214" left="955" width="180" height="17" font="1">  Concomitant medical conditions </text>
<text top="276" left="54" width="58" height="15" font="1">Santinelli V </text>
<text top="291" left="54" width="28" height="15" font="1">2009 </text>
<text top="307" left="54" width="29" height="15" font="1">(178) </text>
<text top="322" left="54" width="49" height="15" font="8">19808453</text>
<text top="322" left="103" width="3" height="15" font="1"> </text>
<text top="276" left="127" width="226" height="15" font="1">Uncontrolled prospective observational study. </text>
<text top="291" left="127" width="151" height="15" font="1">All pts underwent an EP study </text>
<text top="276" left="368" width="25" height="15" font="1">293  </text>
<text top="276" left="537" width="176" height="17" font="1">  Median age (IQR) 36 y (28-48 y) </text>
<text top="292" left="537" width="66" height="17" font="1">  Male 61% </text>
<text top="308" left="537" width="3" height="15" font="1"> </text>
<text top="276" left="752" width="180" height="17" font="1">  Incidental WPW pattern on ECG </text>
<text top="292" left="752" width="154" height="17" font="1">  Asymptomatic based on an </text>
<text top="308" left="770" width="81" height="15" font="1">accurate history </text>
<text top="276" left="955" width="170" height="17" font="1">  Participation in other research </text>
<text top="292" left="976" width="38" height="15" font="1">studies </text>
<text top="338" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="354" left="54" width="28" height="15" font="1">2014 </text>
<text top="369" left="54" width="29" height="15" font="1">(145) </text>
<text top="385" left="54" width="49" height="15" font="8">25052405</text>
<text top="385" left="103" width="3" height="15" font="1"> </text>
<text top="338" left="127" width="226" height="15" font="1">Uncontrolled prospective observational study. </text>
<text top="354" left="127" width="226" height="15" font="1">All pts underwent an EP study. They reported </text>
<text top="369" left="127" width="191" height="15" font="1">data by treatment w/ catheter ablation. </text>
<text top="338" left="368" width="146" height="15" font="1">2169 (756 asymptomatic and </text>
<text top="354" left="368" width="144" height="15" font="1">550 asymptomatic and w/ no </text>
<text top="369" left="368" width="91" height="15" font="1">ablation and 1413 </text>
<text top="385" left="368" width="87" height="15" font="1">symptomatic pts) </text>
<text top="338" left="537" width="129" height="17" font="1">  Median age 19 y, male </text>
<text top="355" left="550" width="186" height="15" font="1">preponderance among asymptomatic </text>
<text top="370" left="550" width="54" height="15" font="1">pts (63%). </text>
<text top="386" left="537" width="156" height="17" font="1">  SHDs were found in 1.5% of </text>
<text top="402" left="550" width="89" height="15" font="1">asymptomatic pts </text>
<text top="338" left="752" width="177" height="17" font="1">  Asymptomatic and symptomatic </text>
<text top="355" left="770" width="118" height="15" font="1">pts w/o prior ablation or </text>
<text top="370" left="770" width="140" height="15" font="1">documented life-threatening </text>
<text top="386" left="770" width="151" height="15" font="1">arrhythmias who consented to </text>
<text top="401" left="770" width="145" height="15" font="1">undergo a baseline EP study </text>
<text top="338" left="953" width="14" height="15" font="1">--- </text>
<text top="418" left="47" width="1061" height="15" font="1">CAD indicates coronary artery disease; ECG, electrocardiogram; EP, electophysiological; HCM, hypertrophic cardiomyopathy; IQR, interquartile range; MVP, mitral valve prolapse; N/A, not applicable; pt, patient; RCT, </text>
<text top="434" left="47" width="1044" height="15" font="1">randomized controlled trial; SD, standard deviation; SHD, structural heart disease; SVT, supraventricular tachycardia; sx, symptom; VHD, valvular heart disease; w/, with; w/o, without; WPW, Wolff-Parkinson-White </text>
<text top="449" left="47" width="165" height="15" font="1">syndrome; and ---, not available.  </text>
<text top="466" left="54" width="4" height="18" font="4"> </text>
<text top="494" left="54" width="151" height="18" font="3"><b>Data Supplement 14. </b></text>
<text top="494" left="205" width="396" height="18" font="7"><b>Comparators and Outcomes – ERC Report (Section 6.2)</b></text>
<text top="494" left="601" width="4" height="18" font="3"><b> </b></text>
<text top="513" left="65" width="34" height="15" font="16"><b>Study </b></text>
<text top="528" left="59" width="46" height="15" font="16"><b>(Author, </b></text>
<text top="543" left="67" width="31" height="15" font="16"><b>Year) </b></text>
<text top="513" left="155" width="76" height="15" font="16"><b>Study Groups </b></text>
<text top="513" left="304" width="57" height="15" font="16"><b>Results of </b></text>
<text top="528" left="277" width="111" height="15" font="16"><b>Noninvasive Testing </b></text>
<text top="513" left="452" width="60" height="15" font="16"><b>Results of  </b></text>
<text top="528" left="457" width="47" height="15" font="16"><b>Invasive </b></text>
<text top="543" left="453" width="55" height="15" font="16"><b> EP Study </b></text>
<text top="513" left="576" width="146" height="15" font="16"><b>Acute Outcome of Catheter </b></text>
<text top="528" left="625" width="47" height="15" font="16"><b>Ablation </b></text>
<text top="513" left="763" width="156" height="15" font="16"><b>Clinical Outcomes of Interest </b></text>
<text top="513" left="966" width="62" height="15" font="16"><b>Duration of </b></text>
<text top="528" left="987" width="20" height="15" font="16"><b>F/u </b></text>
<text top="513" left="1061" width="62" height="15" font="16"><b>Loss to F/u </b></text>
<text top="560" left="54" width="51" height="15" font="1">Milstein S </text>
<text top="575" left="54" width="28" height="15" font="1">1986 </text>
<text top="591" left="54" width="29" height="15" font="1">(171) </text>
<text top="606" left="54" width="43" height="15" font="8">3706161</text>
<text top="606" left="97" width="3" height="15" font="1"> </text>
<text top="560" left="123" width="119" height="15" font="1">Group 1: Asymptomatic </text>
<text top="575" left="123" width="69" height="15" font="1">WPW pattern </text>
<text top="591" left="123" width="3" height="15" font="1"> </text>
<text top="560" left="276" width="22" height="15" font="1">N/A </text>
<text top="560" left="400" width="158" height="15" font="1">43 APs in 42 asymptomatic pts. </text>
<text top="575" left="400" width="157" height="15" font="1">Mean ERP of AP was 333±106 </text>
<text top="591" left="400" width="148" height="15" font="1">msec in asymptomatic pts vs. </text>
<text top="606" left="400" width="157" height="15" font="1">298± 42 msec in asymptomatic </text>
<text top="622" left="400" width="145" height="15" font="1">pts (p&lt;0.025). Mean shortest </text>
<text top="637" left="400" width="150" height="15" font="1">RR interval during AF 277±48 </text>
<text top="653" left="400" width="131" height="15" font="1">msec in the asymptomatic </text>
<text top="668" left="400" width="155" height="15" font="1">groups vs. 247±51 msec in the </text>
<text top="684" left="400" width="150" height="15" font="1">symptomatic group (p&lt;0.025). </text>
<text top="699" left="400" width="130" height="15" font="1">Sustained AVRT could be </text>
<text top="715" left="400" width="105" height="15" font="1">induced in only 1 pt.  </text>
<text top="560" left="573" width="59" height="15" font="1">No ablation </text>
<text top="560" left="737" width="206" height="15" font="1">1 pt died of metastatic carcinoma after 43 </text>
<text top="575" left="737" width="177" height="15" font="1">mo, 1 pt died suddenly after he had </text>
<text top="591" left="737" width="182" height="15" font="1">agreed to participate in the study but </text>
<text top="606" left="737" width="193" height="15" font="1">before EP study could be performed. 4 </text>
<text top="622" left="737" width="179" height="15" font="1">pts received propranolol because of </text>
<text top="637" left="737" width="202" height="15" font="1">undocumented &#34;skipped beats.&#34; All other </text>
<text top="653" left="737" width="142" height="15" font="1">pts remained asymptomatic. </text>
<text top="560" left="959" width="54" height="15" font="1">29±18 mo </text>
<text top="560" left="1048" width="30" height="15" font="1">None </text>
<text top="731" left="54" width="45" height="15" font="1">Klein GJ </text>
<text top="746" left="54" width="28" height="15" font="1">1989 </text>
<text top="762" left="54" width="29" height="15" font="1">(173) </text>
<text top="777" left="54" width="43" height="15" font="8">2710202</text>
<text top="777" left="97" width="3" height="15" font="1"> </text>
<text top="731" left="123" width="137" height="15" font="1">Group 1: Invasive EP study </text>
<text top="746" left="123" width="105" height="15" font="1">w/o catheter ablation </text>
<text top="731" left="276" width="22" height="15" font="1">N/A </text>
<text top="731" left="400" width="153" height="15" font="1">28/29 (97%) pts had only 1 AP </text>
<text top="746" left="400" width="140" height="15" font="1">and 1/29 (3%) pts had more </text>
<text top="762" left="400" width="144" height="15" font="1">than 1 AP. The mean (± SD) </text>
<text top="777" left="400" width="152" height="15" font="1">ERP of pathway(s) at baseline </text>
<text top="793" left="400" width="151" height="15" font="1">334 msec (±105 msec) on the </text>
<text top="731" left="573" width="59" height="15" font="1">No ablation </text>
<text top="731" left="737" width="204" height="15" font="1">Sustained PSVT 2/29 (7%) (during 36-79 </text>
<text top="746" left="737" width="138" height="15" font="1">mo); 27/29 (93%) remained </text>
<text top="762" left="737" width="74" height="15" font="1">asymptomatic; </text>
<text top="777" left="737" width="192" height="15" font="1">9/29 (31%) lost WPW pattern on ECG. </text>
<text top="731" left="959" width="53" height="15" font="1">36-79 mo  </text>
<text top="731" left="1048" width="30" height="15" font="1">None </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">73 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="400" width="157" height="15" font="1">initial study and 301 msec (±78 </text>
<text top="70" left="400" width="118" height="15" font="1">msec) on the f/u study.  </text>
<text top="86" left="400" width="156" height="15" font="1">The shortest RR interval (±SD) </text>
<text top="101" left="400" width="137" height="15" font="1">during induced AF was 266 </text>
<text top="117" left="400" width="145" height="15" font="1">msec (±39 msec). Sustained </text>
<text top="132" left="400" width="145" height="15" font="1">AF was induced in 2/29 (7%) </text>
<text top="147" left="400" width="131" height="15" font="1">pts on the initial study and </text>
<text top="163" left="400" width="130" height="15" font="1">11/29 (38%) pts on the f/u </text>
<text top="178" left="400" width="36" height="15" font="1">study.  </text>
<text top="195" left="54" width="44" height="15" font="1">Satoh M </text>
<text top="210" left="54" width="28" height="15" font="1">1989 </text>
<text top="226" left="54" width="29" height="15" font="1">(172) </text>
<text top="241" left="54" width="43" height="15" font="8">2466266</text>
<text top="241" left="97" width="3" height="15" font="1"> </text>
<text top="195" left="123" width="137" height="15" font="1">Group 1: Asymptomatic pts </text>
<text top="210" left="123" width="83" height="15" font="1">w/ WPW pattern </text>
<text top="226" left="123" width="3" height="15" font="1"> </text>
<text top="195" left="276" width="58" height="15" font="1">Intermittent </text>
<text top="210" left="276" width="108" height="15" font="1">preexcitation on ECG </text>
<text top="226" left="276" width="78" height="15" font="1">recording  23% </text>
<text top="241" left="276" width="3" height="15" font="1"> </text>
<text top="195" left="400" width="151" height="15" font="1">Number of pts w/ multiple APs </text>
<text top="210" left="400" width="142" height="15" font="1">not reported. Baseline mean </text>
<text top="226" left="400" width="149" height="15" font="1">ERP of AP was 288±29 msec </text>
<text top="241" left="400" width="148" height="15" font="1">in asymptomatic pts. Shortest </text>
<text top="257" left="400" width="146" height="15" font="1">RR in AF not reported. AVRT </text>
<text top="272" left="400" width="159" height="15" font="1">induced in 6/34 (18%) pts in the </text>
<text top="288" left="400" width="156" height="15" font="1">asymptomatic group, sustained </text>
<text top="303" left="400" width="157" height="15" font="1">AF was induced in 2/34 (6%) of </text>
<text top="319" left="400" width="98" height="15" font="1">asymptomatic pts.   </text>
<text top="195" left="573" width="59" height="15" font="1">No ablation </text>
<text top="195" left="737" width="97" height="15" font="1">Group 1: no events </text>
<text top="210" left="737" width="184" height="15" font="1">Group 2: 2 pts w/ symptomatic WPW </text>
<text top="226" left="737" width="202" height="15" font="1">syndrome had VF and were resuscitated </text>
<text top="241" left="737" width="66" height="15" font="1">successfully  </text>
<text top="195" left="959" width="65" height="15" font="1">Mean 15 mo </text>
<text top="210" left="959" width="72" height="15" font="1">(range 2 to 47 </text>
<text top="226" left="959" width="22" height="15" font="1">mo) </text>
<text top="195" left="1048" width="14" height="15" font="1">--- </text>
<text top="335" left="54" width="52" height="15" font="1">Leitch JW </text>
<text top="350" left="54" width="28" height="15" font="1">1990 </text>
<text top="366" left="54" width="29" height="15" font="1">(174) </text>
<text top="381" left="54" width="43" height="15" font="8">2225373</text>
<text top="381" left="97" width="3" height="15" font="1"> </text>
<text top="335" left="123" width="137" height="15" font="1">Group 1: Invasive EP study </text>
<text top="350" left="123" width="105" height="15" font="1">w/o catheter ablation </text>
<text top="335" left="276" width="22" height="15" font="1">N/A </text>
<text top="335" left="400" width="157" height="15" font="1">At baseline, the median ERP of </text>
<text top="350" left="400" width="137" height="15" font="1">the AP was 293 msec (IQR </text>
<text top="366" left="400" width="159" height="15" font="1">280-310 msec), and the median </text>
<text top="381" left="400" width="151" height="15" font="1">retrograde ERP of the AP was </text>
<text top="397" left="400" width="157" height="15" font="1">288 msec (IQR 240-320 msec). </text>
<text top="412" left="400" width="123" height="15" font="1">The median shortest RR </text>
<text top="428" left="400" width="144" height="15" font="1">interval during preexcited AF </text>
<text top="443" left="400" width="144" height="15" font="1">was 274 msec (IQR 240-325 </text>
<text top="459" left="400" width="133" height="15" font="1">msec) in 72 pts, was ≤250 </text>
<text top="474" left="400" width="148" height="15" font="1">msec in 23 pts and was ≤200 </text>
<text top="490" left="400" width="71" height="15" font="1">msec in 8 pts. </text>
<text top="505" left="400" width="140" height="15" font="1">AVRT was induced in 12/75 </text>
<text top="521" left="400" width="145" height="15" font="1">(16%) and sustained AF was </text>
<text top="536" left="400" width="123" height="15" font="1">induced in 23/75 (31%).  </text>
<text top="335" left="573" width="59" height="15" font="1">No ablation </text>
<text top="335" left="737" width="186" height="15" font="1">3/75 (4%) died of noncardiac causes, </text>
<text top="350" left="737" width="188" height="15" font="1">1/75 (1%) pt died suddenly after initial </text>
<text top="366" left="737" width="185" height="15" font="1">consultation but before EP study was </text>
<text top="381" left="737" width="201" height="15" font="1">done. 5/75 (7%) developed symptomatic </text>
<text top="397" left="737" width="206" height="15" font="1">AVRT. 1/75 (1%) developed symptomatic </text>
<text top="412" left="737" width="199" height="15" font="1">AF. The presence of sustained AVRT at </text>
<text top="428" left="737" width="186" height="15" font="1">EP study did not differentiate pts who </text>
<text top="443" left="737" width="187" height="15" font="1">remained asymptomatic from pts who </text>
<text top="459" left="737" width="185" height="15" font="1">became symptomatic. Only 1 (4%) pt </text>
<text top="474" left="737" width="183" height="15" font="1">developed clinical AF of the 23 pts in </text>
<text top="490" left="737" width="180" height="15" font="1">whom AF was induced at EP study.  </text>
<text top="335" left="959" width="66" height="15" font="1">Median 4.3 y </text>
<text top="350" left="959" width="66" height="15" font="1">(range 1-9 y) </text>
<text top="335" left="1048" width="30" height="15" font="1">None </text>
<text top="552" left="54" width="50" height="15" font="1">Brembilla-</text>
<text top="568" left="54" width="44" height="15" font="1">Perrot B </text>
<text top="583" left="54" width="28" height="15" font="1">2001 </text>
<text top="599" left="54" width="29" height="15" font="1">(175) </text>
<text top="614" left="54" width="49" height="15" font="8">11707045</text>
<text top="614" left="103" width="3" height="15" font="1"> </text>
<text top="552" left="123" width="135" height="15" font="1">Group 1: Transesophageal </text>
<text top="568" left="123" width="145" height="15" font="1">stimulation                              </text>
<text top="552" left="276" width="80" height="15" font="1">All pts had 24-h </text>
<text top="568" left="276" width="108" height="15" font="1">Holter and stress test </text>
<text top="583" left="276" width="91" height="15" font="1">performed prior to </text>
<text top="599" left="276" width="102" height="15" font="1">study entry and only </text>
<text top="614" left="276" width="50" height="15" font="1">those w/o </text>
<text top="630" left="276" width="82" height="15" font="1">supraventricular </text>
<text top="645" left="276" width="82" height="15" font="1">arrhythmia were </text>
<text top="661" left="276" width="44" height="15" font="1">included </text>
<text top="552" left="400" width="152" height="15" font="1">The number of APs found was </text>
<text top="568" left="400" width="126" height="15" font="1">not reported. The ERP of </text>
<text top="583" left="400" width="135" height="15" font="1">pathway(s) at baseline and </text>
<text top="599" left="400" width="142" height="15" font="1">during isoproterenol infusion </text>
<text top="615" left="400" width="156" height="15" font="1">were not reported. Shortest RR </text>
<text top="630" left="400" width="137" height="15" font="1">interval (&lt;250 msec) during </text>
<text top="645" left="400" width="133" height="15" font="1">induced AF was present in </text>
<text top="661" left="400" width="113" height="15" font="1">20/92 (22%) pts. Atrial </text>
<text top="676" left="400" width="158" height="15" font="1">tachyarrhythmia was induced in </text>
<text top="692" left="400" width="59" height="15" font="1">27% of pts. </text>
<text top="552" left="573" width="59" height="15" font="1">No ablation </text>
<text top="552" left="737" width="205" height="15" font="1">3/92 (3%) pts developed symptomatic AF </text>
<text top="568" left="737" width="159" height="15" font="1">several y later. Of these 3 pts, 1 </text>
<text top="583" left="737" width="206" height="15" font="1">presented w/ AF and then VF 1 d after an </text>
<text top="599" left="737" width="192" height="15" font="1">aortic aneursymectomy. Among the 42 </text>
<text top="614" left="737" width="197" height="15" font="1">pts considered to have a benign form of </text>
<text top="630" left="737" width="189" height="15" font="1">WPW syndrome, there was no clinical </text>
<text top="645" left="737" width="173" height="15" font="1">event, except a death related to an </text>
<text top="661" left="737" width="47" height="15" font="1">accident. </text>
<text top="552" left="959" width="17" height="15" font="1">---  </text>
<text top="552" left="1048" width="14" height="15" font="1">--- </text>
<text top="708" left="54" width="47" height="15" font="1">Pappone </text>
<text top="724" left="54" width="11" height="15" font="1">C </text>
<text top="739" left="54" width="28" height="15" font="1">2003 </text>
<text top="755" left="54" width="29" height="15" font="1">(176) </text>
<text top="770" left="54" width="49" height="15" font="8">12535816</text>
<text top="770" left="103" width="3" height="15" font="1"> </text>
<text top="708" left="123" width="137" height="15" font="1">Group 1: Invasive EP study </text>
<text top="724" left="123" width="105" height="15" font="1">w/o catheter ablation </text>
<text top="708" left="276" width="22" height="15" font="1">N/A </text>
<text top="708" left="400" width="159" height="15" font="1">17/162 (10%) had multiple APs. </text>
<text top="724" left="400" width="138" height="15" font="1">Baseline mean (± SD) ERP </text>
<text top="739" left="400" width="135" height="15" font="1">275.2 msec (± 33.8 msec). </text>
<text top="755" left="400" width="135" height="15" font="1">Isoproterenol mean (± SD) </text>
<text top="770" left="400" width="125" height="15" font="1">ERP 246.1 msec (± 30.5 </text>
<text top="786" left="400" width="147" height="15" font="1">msec). Shortest RR in AF not </text>
<text top="708" left="573" width="59" height="15" font="1">No ablation </text>
<text top="708" left="737" width="196" height="15" font="1">129/209 (62%) remained asymptomatic </text>
<text top="724" left="737" width="179" height="15" font="1">at the end of follow- up, whereas 33 </text>
<text top="739" left="737" width="205" height="15" font="1">(16%) developed arrhythmic events: SVT </text>
<text top="755" left="737" width="195" height="15" font="1">in 25, AF in 8, documented VF in 3/209 </text>
<text top="770" left="737" width="185" height="15" font="1">(aborted sudden death in 2 (both had </text>
<text top="786" left="737" width="189" height="15" font="1">developed sxs due to AF) and sudden </text>
<text top="708" left="959" width="75" height="15" font="1">37.7±16.1 mo; </text>
<text top="724" left="959" width="74" height="15" font="1">range 14 to 60 </text>
<text top="739" left="959" width="22" height="15" font="1">mo  </text>
<text top="708" left="1048" width="66" height="15" font="1">3/212 (1.4%) </text>
<text top="724" left="1048" width="60" height="15" font="1">47/212 who </text>
<text top="739" left="1048" width="80" height="15" font="1">ref/used the 5-y </text>
<text top="755" left="1048" width="74" height="15" font="1">EP study were </text>
<text top="770" left="1048" width="73" height="15" font="1">excluded from </text>
<text top="786" left="1048" width="62" height="15" font="1">the analysis </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">74 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="400" width="44" height="15" font="1">reported </text>
<text top="70" left="400" width="138" height="15" font="1">47/162 (29%) had inducible </text>
<text top="86" left="400" width="156" height="15" font="1">arrhythmia: nonsustained AF in </text>
<text top="101" left="400" width="116" height="15" font="1">17, sustained AF in 19, </text>
<text top="117" left="400" width="101" height="15" font="1">inducible AVRT that </text>
<text top="132" left="400" width="118" height="15" font="1">degenerated into totally </text>
<text top="147" left="400" width="152" height="15" font="1">preexcited sustained AF in 11. </text>
<text top="55" left="737" width="83" height="15" font="1">death in 1/209)   </text>
<text top="164" left="54" width="47" height="15" font="1">Pappone </text>
<text top="179" left="54" width="11" height="15" font="1">C </text>
<text top="195" left="54" width="28" height="15" font="1">2003 </text>
<text top="210" left="54" width="29" height="15" font="1">(177) </text>
<text top="226" left="54" width="49" height="15" font="8">14602878</text>
<text top="226" left="103" width="3" height="15" font="1"> </text>
<text top="164" left="123" width="89" height="15" font="1">Group 1: Ablation </text>
<text top="179" left="123" width="105" height="15" font="1">Group 2: No ablation </text>
<text top="195" left="123" width="122" height="15" font="1">Group 3: Low-risk group </text>
<text top="210" left="123" width="74" height="15" font="1">followed as an </text>
<text top="226" left="123" width="103" height="15" font="1">observational cohort </text>
<text top="164" left="276" width="22" height="15" font="1">N/A </text>
<text top="164" left="400" width="153" height="15" font="1">15/37 (41%) pts in the ablation </text>
<text top="179" left="400" width="151" height="15" font="1">group had inducible AVRT.  In </text>
<text top="195" left="400" width="113" height="15" font="1">8 additional pts, AVRT </text>
<text top="210" left="400" width="157" height="15" font="1">degenerated into sustained AF. </text>
<text top="226" left="400" width="132" height="15" font="1">The median number of RF </text>
<text top="241" left="400" width="153" height="15" font="1">applications was 9 (range, 5 to </text>
<text top="257" left="400" width="25" height="15" font="1">22).  </text>
<text top="164" left="573" width="104" height="15" font="1">Ablation was acutely </text>
<text top="179" left="573" width="101" height="15" font="1">successful in all pts. </text>
<text top="195" left="573" width="140" height="15" font="1">Complications related to EP </text>
<text top="210" left="573" width="149" height="15" font="1">study (2 pneumothoraxes and </text>
<text top="226" left="573" width="136" height="15" font="1">1 large femoral hematoma) </text>
<text top="241" left="573" width="139" height="15" font="1">developed in 3 (1%) pts. An </text>
<text top="257" left="573" width="144" height="15" font="1">ablation-related complication </text>
<text top="272" left="573" width="121" height="15" font="1">(permanent right bundle-</text>
<text top="288" left="573" width="135" height="15" font="1">branch block) developed in </text>
<text top="303" left="573" width="93" height="15" font="1">1/37 (3%) pt w/ an </text>
<text top="319" left="573" width="85" height="15" font="1">anteroseptal AP. </text>
<text top="164" left="737" width="194" height="15" font="1">2/37 (5%) pts in the ablation group had </text>
<text top="179" left="737" width="206" height="15" font="1">an arrhythmic event found on EP study to </text>
<text top="195" left="737" width="181" height="15" font="1">be due to AVNRT in both pts. W/in a </text>
<text top="210" left="737" width="207" height="15" font="1">mean of 15 mo, 21/35 (60%) pts in the no </text>
<text top="226" left="737" width="195" height="15" font="1">ablation group had an arrhythmic event </text>
<text top="241" left="737" width="207" height="15" font="1">which was SVT in 15 pts, AF in 5 pts, and </text>
<text top="257" left="737" width="201" height="15" font="1">VF (not preceded by sxs) in 1 pt. Among </text>
<text top="272" left="737" width="193" height="15" font="1">the high-risk controls (group 2), the 5-y </text>
<text top="288" left="737" width="190" height="15" font="1">rate of arrhythmic events was 77% vs. </text>
<text top="303" left="737" width="156" height="15" font="1">7% in the ablation group. In the </text>
<text top="319" left="737" width="162" height="15" font="1">observational cohort, sxs of SVT </text>
<text top="334" left="737" width="168" height="15" font="1">developed in 6 pts and 20 pts lost </text>
<text top="350" left="737" width="129" height="15" font="1">ventricular preexcitation.   </text>
<text top="164" left="959" width="74" height="15" font="1">Ablation group </text>
<text top="179" left="959" width="70" height="15" font="1">median f/u 27 </text>
<text top="195" left="959" width="63" height="15" font="1">mo, range 9-</text>
<text top="210" left="959" width="76" height="15" font="1">60 mo. Control </text>
<text top="226" left="959" width="71" height="15" font="1">group median </text>
<text top="241" left="959" width="52" height="15" font="1">f/u 21 mo, </text>
<text top="257" left="959" width="57" height="15" font="1">range 8-60 </text>
<text top="272" left="959" width="22" height="15" font="1">mo. </text>
<text top="164" left="1048" width="30" height="15" font="1">None </text>
<text top="366" left="54" width="48" height="15" font="1">Santinelli </text>
<text top="381" left="54" width="10" height="15" font="1">V </text>
<text top="397" left="54" width="28" height="15" font="1">2009 </text>
<text top="412" left="54" width="29" height="15" font="1">(178) </text>
<text top="428" left="54" width="49" height="15" font="8">19808453</text>
<text top="428" left="103" width="3" height="15" font="1"> </text>
<text top="366" left="123" width="137" height="15" font="1">Group 1: Invasive EP study </text>
<text top="381" left="123" width="105" height="15" font="1">w/o catheter ablation </text>
<text top="366" left="276" width="22" height="15" font="1">N/A </text>
<text top="366" left="400" width="152" height="15" font="1">Anterograde ERP of AP  ≤250 </text>
<text top="381" left="400" width="141" height="15" font="1">msec was present in 39/293 </text>
<text top="397" left="400" width="54" height="15" font="1">(13%) pts. </text>
<text top="412" left="400" width="150" height="15" font="1">Multiple APs were found in 13 </text>
<text top="428" left="400" width="47" height="15" font="1">(4%) pts. </text>
<text top="443" left="400" width="156" height="15" font="1">Inducible arrhythmia was found </text>
<text top="459" left="400" width="81" height="15" font="1">in 47 (16%) pts. </text>
<text top="366" left="573" width="59" height="15" font="1">No ablation </text>
<text top="366" left="737" width="187" height="15" font="1">262/293 (89%) pts did not experience </text>
<text top="381" left="737" width="177" height="15" font="1">arrhythmic events, remaining totally </text>
<text top="397" left="737" width="207" height="15" font="1">asymptomatic, whereas 31/293 (11%) pts </text>
<text top="412" left="737" width="179" height="15" font="1">had an arrhythmic event, which was </text>
<text top="428" left="737" width="199" height="15" font="1">potentially life-threatening in 17 of them. </text>
<text top="443" left="737" width="130" height="15" font="1">Potentially life-threatening </text>
<text top="459" left="737" width="204" height="15" font="1">tachyarrhythmias resulted in resuscitated </text>
<text top="474" left="737" width="200" height="15" font="1">cardiac arrest (1 pt), presyncope (7 pts), </text>
<text top="490" left="737" width="181" height="15" font="1">syncope (4 pts), or dizziness (5 pts). </text>
<text top="366" left="959" width="39" height="15" font="1">Median </text>
<text top="381" left="959" width="71" height="15" font="1">duration of f/u </text>
<text top="397" left="959" width="73" height="15" font="1">after EP study </text>
<text top="412" left="959" width="57" height="15" font="1">was 67 mo </text>
<text top="428" left="959" width="76" height="15" font="1">(range 8 to 90) </text>
<text top="366" left="1048" width="14" height="15" font="1">--- </text>
<text top="506" left="54" width="47" height="15" font="1">Pappone </text>
<text top="522" left="54" width="11" height="15" font="1">C </text>
<text top="537" left="54" width="28" height="15" font="1">2014 </text>
<text top="552" left="54" width="29" height="15" font="1">(145) </text>
<text top="568" left="54" width="49" height="15" font="8">25052405</text>
<text top="568" left="103" width="3" height="15" font="1"> </text>
<text top="506" left="123" width="137" height="15" font="1">Group 1: Asymptomatic pts </text>
<text top="522" left="123" width="111" height="15" font="1">w/ WPW pattern (they </text>
<text top="537" left="123" width="92" height="15" font="1">presented data on </text>
<text top="552" left="123" width="119" height="15" font="1">symptomatic pts and by </text>
<text top="568" left="123" width="117" height="15" font="1">whether or not catheter </text>
<text top="583" left="123" width="113" height="15" font="1">ablation of the AP was </text>
<text top="599" left="123" width="135" height="15" font="1">done), but the groups were </text>
<text top="614" left="123" width="132" height="15" font="1">not matched and selection </text>
<text top="630" left="123" width="129" height="15" font="1">bias was not adjusted for) </text>
<text top="506" left="276" width="14" height="15" font="1">--- </text>
<text top="506" left="400" width="154" height="15" font="1">No ablation: Multiple APs in 59 </text>
<text top="522" left="400" width="155" height="15" font="1">(6%), median (IQR) ERP of AP </text>
<text top="537" left="400" width="135" height="15" font="1">280 msec (250-300 msec). </text>
<text top="552" left="400" width="146" height="15" font="1">Inducible AVRT triggering AF </text>
<text top="568" left="400" width="143" height="15" font="1">on EP study was found in 47 </text>
<text top="583" left="400" width="63" height="15" font="1">(5%) of pts.  </text>
<text top="599" left="400" width="3" height="15" font="1"> </text>
<text top="615" left="400" width="63" height="15" font="1">W/ Ablation: </text>
<text top="630" left="400" width="121" height="15" font="1">Multiple APs in 80 (7%), </text>
<text top="645" left="400" width="147" height="15" font="1">median ERP (IQR) of AP 280 </text>
<text top="661" left="400" width="113" height="15" font="1">msec (250-300 msec). </text>
<text top="676" left="400" width="146" height="15" font="1">Inducible AVRT triggering AF </text>
<text top="692" left="400" width="143" height="15" font="1">on EP study was found in 73 </text>
<text top="707" left="400" width="60" height="15" font="1">(6%) of pts. </text>
<text top="506" left="573" width="132" height="15" font="1">206/756 asymptomatic pts </text>
<text top="522" left="573" width="124" height="15" font="1">were treated w/ ablation; </text>
<text top="537" left="573" width="131" height="15" font="1">ablation was successful in </text>
<text top="552" left="573" width="38" height="15" font="1">98.5%. </text>
<text top="506" left="737" width="206" height="15" font="1">No ablation: during a median f/u of 22 mo </text>
<text top="522" left="737" width="138" height="15" font="1">VF occurred in 13/550 (2%) </text>
<text top="537" left="737" width="197" height="15" font="1">asymptomatic pts (almost exclusively in </text>
<text top="552" left="737" width="207" height="15" font="1">children). During a median f/u of 46.5 mo, </text>
<text top="568" left="737" width="203" height="15" font="1">48/550 (9%) additional asymptomatic pts </text>
<text top="583" left="737" width="175" height="15" font="1">experienced malignant arrhythmias </text>
<text top="599" left="737" width="190" height="15" font="1">86/756 (11%) of the asymptomatic pts </text>
<text top="614" left="737" width="188" height="15" font="1">developed benign arrhythmias (AVRT </text>
<text top="630" left="737" width="46" height="15" font="1">and AF). </text>
<text top="645" left="737" width="3" height="15" font="1"> </text>
<text top="661" left="737" width="194" height="15" font="1">W/ ablation: no pt developed malignant </text>
<text top="676" left="737" width="183" height="15" font="1">arrhythmias or VF over the 8 y of f/u. </text>
<text top="506" left="959" width="73" height="15" font="1">Median 96 mo </text>
<text top="506" left="1048" width="62" height="15" font="1">No ablation: </text>
<text top="522" left="1048" width="84" height="15" font="1">completeness of </text>
<text top="537" left="1048" width="85" height="15" font="1">f/u was 99.8% at </text>
<text top="552" left="1048" width="86" height="15" font="1">1 y and 92.3% at </text>
<text top="568" left="1048" width="71" height="15" font="1">the end of the </text>
<text top="583" left="1048" width="30" height="15" font="1">study </text>
<text top="599" left="1048" width="3" height="15" font="1"> </text>
<text top="614" left="1048" width="61" height="15" font="1">W/ ablation: </text>
<text top="630" left="1048" width="84" height="15" font="1">completeness of </text>
<text top="645" left="1048" width="85" height="15" font="1">f/u was 95.5% at </text>
<text top="661" left="1048" width="86" height="15" font="1">1 y and 90.2% at </text>
<text top="676" left="1048" width="71" height="15" font="1">the end of the </text>
<text top="692" left="1048" width="30" height="15" font="1">study </text>
<text top="724" left="47" width="1093" height="15" font="1">AF indicates atrial fibrillation; AP, accessory pathway; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventrial reentrant tachycardia; ECG, echocardiogram; EP, electrophysiological; ERP, effective refractory </text>
<text top="739" left="47" width="1066" height="15" font="1">period; f/u, follow up; IQR, interquartile range; N/A, not applicable; pt, patient; RF, radiofrequency; SD, standard deviation; SVT, supraventricular tachycardia; VF, ventricular fibrillation; w/, with; w/o, without; WPW, Wolf-</text>
<text top="755" left="47" width="249" height="15" font="1">Parkinson-White syndrome; and ---, not available.  </text>
<text top="770" left="47" width="3" height="15" font="1"> </text>
<text top="795" left="54" width="4" height="18" font="3"><b> </b></text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="20" size="9" family="Times" color="#000000"/>
<text top="814" left="1120" width="17" height="17" font="0">75 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="151" height="18" font="3"><b>Data Supplement 15. </b></text>
<text top="55" left="205" width="468" height="18" font="7"><b>Quality Assesment of Included Studies – ERC Report (Section 6.2)</b></text>
<text top="55" left="673" width="4" height="18" font="3"><b> </b></text>
<text top="74" left="55" width="80" height="15" font="16"><b>Study (Author, </b></text>
<text top="89" left="79" width="31" height="15" font="16"><b>Year) </b></text>
<text top="74" left="149" width="108" height="15" font="16"><b>Representativeness </b></text>
<text top="89" left="166" width="73" height="15" font="16"><b>of the Cohort </b></text>
<text top="74" left="285" width="55" height="15" font="16"><b>Selection  </b></text>
<text top="89" left="299" width="23" height="15" font="16"><b>of a </b></text>
<text top="104" left="276" width="69" height="15" font="16"><b>Nonexposed </b></text>
<text top="120" left="291" width="39" height="15" font="16"><b>Cohort </b></text>
<text top="74" left="370" width="80" height="15" font="16"><b>Ascertainment </b></text>
<text top="89" left="376" width="67" height="15" font="16"><b>of Exposure </b></text>
<text top="74" left="492" width="105" height="15" font="16"><b>Demonstration that </b></text>
<text top="89" left="468" width="152" height="15" font="16"><b>Outcome of Interest was not </b></text>
<text top="104" left="485" width="118" height="15" font="16"><b>Present at Enrollment </b></text>
<text top="74" left="656" width="100" height="15" font="16"><b>Independent Blind </b></text>
<text top="89" left="636" width="139" height="15" font="16"><b>Assessment of Outcomes </b></text>
<text top="74" left="795" width="82" height="15" font="16"><b>Was Follow Up </b></text>
<text top="89" left="799" width="74" height="15" font="16"><b>Long Enough </b></text>
<text top="104" left="792" width="88" height="15" font="16"><b>for Outcomes to </b></text>
<text top="120" left="815" width="42" height="15" font="16"><b>Occur? </b></text>
<text top="74" left="912" width="69" height="15" font="16"><b>Adequacy of </b></text>
<text top="89" left="912" width="69" height="15" font="16"><b>Follow Up of </b></text>
<text top="104" left="899" width="95" height="15" font="16"><b>Cohort (Including </b></text>
<text top="120" left="896" width="102" height="15" font="16"><b>Loss to Follow Up) </b></text>
<text top="74" left="1017" width="116" height="15" font="16"><b>Precision of Findings </b></text>
<text top="145" left="54" width="51" height="15" font="1">Milstein S </text>
<text top="161" left="54" width="28" height="15" font="1">1986 </text>
<text top="176" left="54" width="29" height="15" font="1">(171) </text>
<text top="192" left="54" width="43" height="15" font="8">3706161</text>
<text top="192" left="97" width="3" height="15" font="1"> </text>
<text top="145" left="149" width="241" height="15" font="1">Yes N/A </text>
<text top="145" left="291" width="116" height="15" font="1">(all </text>
<text top="145" left="309" width="116" height="15" font="1">pts </text>
<text top="161" left="269" width="73" height="15" font="1">underwent EP </text>
<text top="176" left="269" width="33" height="15" font="1">study) </text>
<text top="145" left="365" width="88" height="15" font="1">All pts underwent </text>
<text top="161" left="365" width="47" height="15" font="1">EP study </text>
<text top="145" left="468" width="22" height="15" font="1">Yes </text>
<text top="145" left="633" width="14" height="15" font="1">--- </text>
<text top="145" left="791" width="22" height="15" font="1">Yes </text>
<text top="145" left="894" width="22" height="15" font="1">Yes </text>
<text top="145" left="1013" width="114" height="15" font="1">Imprecise due to small </text>
<text top="161" left="1013" width="61" height="15" font="1">sample size </text>
<text top="215" left="54" width="45" height="15" font="1">Klein GJ </text>
<text top="231" left="54" width="28" height="15" font="1">1989 </text>
<text top="246" left="54" width="29" height="15" font="1">(173) </text>
<text top="262" left="54" width="43" height="15" font="8">2710202</text>
<text top="262" left="97" width="3" height="15" font="1"> </text>
<text top="215" left="149" width="241" height="15" font="1">Yes N/A </text>
<text top="215" left="291" width="118" height="15" font="1">(no </text>
<text top="231" left="269" width="59" height="15" font="1">comparator </text>
<text top="246" left="269" width="35" height="15" font="1">group) </text>
<text top="215" left="365" width="88" height="15" font="1">All pts underwent </text>
<text top="231" left="365" width="47" height="15" font="1">EP study </text>
<text top="215" left="468" width="116" height="15" font="1">2/29 had SVT between </text>
<text top="231" left="468" width="125" height="15" font="1">scheduling EP study and </text>
<text top="246" left="468" width="100" height="15" font="1">when EP study was </text>
<text top="262" left="468" width="54" height="15" font="1">performed </text>
<text top="215" left="633" width="14" height="15" font="1">--- </text>
<text top="215" left="791" width="22" height="15" font="1">Yes </text>
<text top="215" left="894" width="22" height="15" font="1">Yes </text>
<text top="215" left="1013" width="100" height="15" font="1">N/A (no comparator </text>
<text top="231" left="1013" width="35" height="15" font="1">group) </text>
<text top="313" left="54" width="44" height="15" font="1">Satoh M </text>
<text top="328" left="54" width="28" height="15" font="1">1989 </text>
<text top="344" left="54" width="29" height="15" font="1">(172) </text>
<text top="359" left="54" width="43" height="15" font="8">2466266</text>
<text top="359" left="97" width="3" height="15" font="1"> </text>
<text top="313" left="149" width="241" height="15" font="1">Yes N/A </text>
<text top="313" left="291" width="116" height="15" font="1">(all </text>
<text top="313" left="309" width="116" height="15" font="1">pts </text>
<text top="328" left="269" width="73" height="15" font="1">underwent EP </text>
<text top="344" left="269" width="33" height="15" font="1">study) </text>
<text top="313" left="365" width="88" height="15" font="1">All pts underwent </text>
<text top="328" left="365" width="47" height="15" font="1">EP study </text>
<text top="313" left="468" width="22" height="15" font="1">Yes </text>
<text top="313" left="633" width="14" height="15" font="1">--- </text>
<text top="313" left="791" width="22" height="15" font="1">Yes </text>
<text top="313" left="894" width="14" height="15" font="1">--- </text>
<text top="313" left="1013" width="110" height="15" font="1">Imprecise (no events) </text>
<text top="375" left="54" width="52" height="15" font="1">Leitch JW </text>
<text top="391" left="54" width="28" height="15" font="1">1990 </text>
<text top="406" left="54" width="29" height="15" font="1">(174) </text>
<text top="422" left="54" width="43" height="15" font="8">2225373</text>
<text top="422" left="97" width="3" height="15" font="1"> </text>
<text top="375" left="149" width="195" height="15" font="1">Questionable N/A </text>
<text top="375" left="291" width="71" height="15" font="1">(no </text>
<text top="391" left="269" width="59" height="15" font="1">comparator </text>
<text top="406" left="269" width="35" height="15" font="1">group) </text>
<text top="375" left="365" width="88" height="15" font="1">All pts underwent </text>
<text top="391" left="365" width="47" height="15" font="1">EP study </text>
<text top="375" left="468" width="22" height="15" font="1">Yes </text>
<text top="375" left="633" width="14" height="15" font="1">--- </text>
<text top="375" left="791" width="22" height="15" font="1">Yes </text>
<text top="375" left="894" width="22" height="15" font="1">Yes </text>
<text top="375" left="1013" width="100" height="15" font="1">N/A (no comparator </text>
<text top="391" left="1013" width="35" height="15" font="1">group) </text>
<text top="438" left="54" width="50" height="15" font="1">Brembilla-</text>
<text top="453" left="54" width="44" height="15" font="1">Perrot B </text>
<text top="469" left="54" width="28" height="15" font="1">2001 </text>
<text top="484" left="54" width="29" height="15" font="1">(175) </text>
<text top="500" left="54" width="49" height="15" font="8">11707045</text>
<text top="500" left="103" width="3" height="15" font="1"> </text>
<text top="438" left="149" width="241" height="15" font="1">Yes N/A </text>
<text top="438" left="291" width="118" height="15" font="1">(no </text>
<text top="453" left="269" width="59" height="15" font="1">comparator </text>
<text top="469" left="269" width="35" height="15" font="1">group) </text>
<text top="438" left="365" width="88" height="15" font="1">All pts underwent </text>
<text top="453" left="365" width="47" height="15" font="1">EP study </text>
<text top="438" left="468" width="129" height="15" font="1">Reasonable based on the </text>
<text top="453" left="468" width="133" height="15" font="1">absence of sxs. Pts had to </text>
<text top="469" left="468" width="148" height="15" font="1">have a normal ECG, exercise </text>
<text top="484" left="468" width="133" height="15" font="1">stress test and 24-h Holter </text>
<text top="500" left="468" width="40" height="15" font="1">monitor </text>
<text top="438" left="633" width="14" height="15" font="1">--- </text>
<text top="438" left="791" width="65" height="15" font="1">Uncertain as </text>
<text top="453" left="791" width="71" height="15" font="1">duration of f/u </text>
<text top="469" left="791" width="86" height="15" font="1">was not reported </text>
<text top="438" left="894" width="91" height="15" font="1">F/u and loss to f/u </text>
<text top="453" left="894" width="90" height="15" font="1">were not reported </text>
<text top="438" left="1013" width="100" height="15" font="1">N/A (no comparator </text>
<text top="453" left="1013" width="35" height="15" font="1">group) </text>
<text top="516" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="532" left="54" width="28" height="15" font="1">2003 </text>
<text top="547" left="54" width="29" height="15" font="1">(176) </text>
<text top="563" left="54" width="49" height="15" font="8">12535816</text>
<text top="563" left="103" width="3" height="15" font="1"> </text>
<text top="516" left="149" width="195" height="15" font="1">Questionable N/A </text>
<text top="516" left="291" width="71" height="15" font="1">(no </text>
<text top="532" left="269" width="59" height="15" font="1">comparator </text>
<text top="547" left="269" width="35" height="15" font="1">group) </text>
<text top="516" left="365" width="88" height="15" font="1">All pts underwent </text>
<text top="532" left="365" width="47" height="15" font="1">EP study </text>
<text top="516" left="468" width="22" height="15" font="1">Yes </text>
<text top="516" left="633" width="14" height="15" font="1">--- </text>
<text top="516" left="791" width="22" height="15" font="1">Yes </text>
<text top="516" left="894" width="68" height="15" font="1">Questionable </text>
<text top="516" left="1013" width="100" height="15" font="1">N/A (no comparator </text>
<text top="532" left="1013" width="35" height="15" font="1">group) </text>
<text top="579" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="594" left="54" width="28" height="15" font="1">2003 </text>
<text top="610" left="54" width="29" height="15" font="1">(177) </text>
<text top="625" left="54" width="49" height="15" font="8">14602878</text>
<text top="625" left="103" width="3" height="15" font="1"> </text>
<text top="579" left="149" width="195" height="15" font="1">Questionable Yes </text>
<text top="579" left="291" width="56" height="15" font="1"> </text>
<text top="579" left="365" width="22" height="15" font="1">Yes </text>
<text top="579" left="468" width="129" height="15" font="1">Reasonable based on the </text>
<text top="594" left="468" width="77" height="15" font="1">absence of sxs </text>
<text top="579" left="633" width="132" height="15" font="1">The events were reviewed </text>
<text top="594" left="633" width="94" height="15" font="1">by an independent </text>
<text top="610" left="633" width="138" height="15" font="1">committee whose members </text>
<text top="625" left="633" width="123" height="15" font="1">were unaware of the pts' </text>
<text top="641" left="633" width="115" height="15" font="1">treatment assignments </text>
<text top="579" left="791" width="22" height="15" font="1">Yes </text>
<text top="579" left="894" width="22" height="15" font="1">Yes </text>
<text top="579" left="1013" width="108" height="15" font="1">Fairly precise w/ 95% </text>
<text top="594" left="1013" width="83" height="15" font="1">CI: 0.02-0.33 for </text>
<text top="610" left="1013" width="112" height="15" font="1">arrhythmic events and </text>
<text top="625" left="1013" width="121" height="15" font="1">95% CI: 0.002-0.104 for </text>
<text top="641" left="1013" width="94" height="15" font="1">event-free survival </text>
<text top="657" left="54" width="58" height="15" font="1">Santinelli V </text>
<text top="673" left="54" width="28" height="15" font="1">2009 </text>
<text top="688" left="54" width="29" height="15" font="1">(178) </text>
<text top="704" left="54" width="49" height="15" font="8">19808453</text>
<text top="704" left="103" width="3" height="15" font="1"> </text>
<text top="657" left="149" width="195" height="15" font="1">Questionable N/A </text>
<text top="657" left="291" width="71" height="15" font="1">(no </text>
<text top="673" left="269" width="59" height="15" font="1">comparator </text>
<text top="688" left="269" width="35" height="15" font="1">group) </text>
<text top="657" left="365" width="88" height="15" font="1">All pts underwent </text>
<text top="673" left="365" width="47" height="15" font="1">EP study </text>
<text top="657" left="468" width="22" height="15" font="1">Yes </text>
<text top="657" left="633" width="14" height="15" font="1">--- </text>
<text top="657" left="791" width="22" height="15" font="1">Yes </text>
<text top="657" left="894" width="14" height="15" font="1">--- </text>
<text top="657" left="1013" width="100" height="15" font="1">N/A (no comparator </text>
<text top="673" left="1013" width="35" height="15" font="1">group) </text>
<text top="720" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="735" left="54" width="28" height="15" font="1">2014 </text>
<text top="751" left="54" width="29" height="15" font="1">(145) </text>
<text top="766" left="54" width="49" height="15" font="8">25052405</text>
<text top="766" left="103" width="3" height="15" font="1"> </text>
<text top="720" left="149" width="195" height="15" font="1">Questionable N/A </text>
<text top="720" left="291" width="71" height="15" font="1">(no </text>
<text top="735" left="269" width="59" height="15" font="1">comparator </text>
<text top="751" left="269" width="35" height="15" font="1">group) </text>
<text top="720" left="365" width="88" height="15" font="1">All pts underwent </text>
<text top="735" left="365" width="47" height="15" font="1">EP study </text>
<text top="720" left="468" width="22" height="15" font="1">Yes </text>
<text top="720" left="633" width="14" height="15" font="1">--- </text>
<text top="720" left="791" width="22" height="15" font="1">Yes </text>
<text top="720" left="894" width="14" height="15" font="1">--- </text>
<text top="720" left="1013" width="100" height="15" font="1">N/A (no comparator </text>
<text top="735" left="1013" width="35" height="15" font="1">group) </text>
<text top="783" left="54" width="983" height="15" font="1">CI indicates confidence intervals; ECG, echocardiogram; EP, electrophysiological; f/u, f/u; N/A, not applicable; pt, patient; SVT, supraventricular tachycardia; sx, symptom; w/, with; and ---, not available.</text>
<text top="784" left="1037" width="3" height="14" font="20"> </text>
<text top="798" left="54" width="3" height="15" font="1"> </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">76 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="151" height="18" font="3"><b>Data Supplement 16. </b></text>
<text top="55" left="205" width="404" height="18" font="7"><b>Randomized Trials Comparing Atrial Flutter – Section 7 </b></text>
<text top="55" left="609" width="4" height="18" font="3"><b> </b></text>
<text top="74" left="60" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="58" width="40" height="17" font="5"><b>Name, </b></text>
<text top="108" left="55" width="47" height="17" font="5"><b>Author, </b></text>
<text top="125" left="64" width="30" height="17" font="5"><b>Year </b></text>
<text top="74" left="119" width="42" height="17" font="5"><b>Aim of </b></text>
<text top="91" left="121" width="38" height="17" font="5"><b>Study </b></text>
<text top="74" left="182" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="185" width="32" height="17" font="5"><b>Type </b></text>
<text top="108" left="183" width="36" height="17" font="5"><b>(Size, </b></text>
<text top="125" left="193" width="16" height="17" font="5"><b>N) </b></text>
<text top="74" left="256" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="238" width="74" height="17" font="5"><b>Intervention </b></text>
<text top="108" left="245" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="74" left="344" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="326" width="73" height="17" font="5"><b>Comparator </b></text>
<text top="108" left="333" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="74" left="490" width="83" height="17" font="5"><b>Pt Population </b></text>
<text top="74" left="756" width="64" height="17" font="5"><b>Endpoints </b></text>
<text top="74" left="933" width="109" height="17" font="5"><b>P Values, OR: HR: </b></text>
<text top="91" left="945" width="85" height="17" font="5"><b>RR: &amp; 95% CI: </b></text>
<text top="74" left="1081" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="1066" width="69" height="17" font="5"><b>Limitations </b></text>
<text top="108" left="1068" width="64" height="17" font="5"><b>&amp; Adverse </b></text>
<text top="125" left="1078" width="44" height="17" font="5"><b>Events </b></text>
<text top="143" left="67" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="138" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="199" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="273" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="361" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="419" width="104" height="17" font="13"><i><b>Inclusion Criteria </b></i></text>
<text top="143" left="542" width="108" height="17" font="13"><i><b>Exclusion Criteria </b></i></text>
<text top="143" left="676" width="49" height="17" font="13"><i><b>Primary </b></i></text>
<text top="161" left="672" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="178" left="672" width="58" height="17" font="13"><i><b>(efficacy) </b></i></text>
<text top="195" left="664" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="143" left="771" width="40" height="17" font="13"><i><b>Safety </b></i></text>
<text top="161" left="763" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="178" left="755" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="143" left="846" width="70" height="17" font="13"><i><b>Secondary  </b></i></text>
<text top="161" left="851" width="67" height="17" font="13"><i><b>Endpoint    </b></i></text>
<text top="178" left="867" width="25" height="17" font="13"><i><b>and </b></i></text>
<text top="195" left="855" width="48" height="17" font="13"><i><b>Results </b></i></text>
<text top="143" left="986" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="1098" width="3" height="17" font="5"><b> </b></text>
<text top="213" left="54" width="49" height="15" font="1">Platia EV </text>
<text top="228" left="54" width="28" height="15" font="1">1989 </text>
<text top="244" left="54" width="29" height="15" font="1">(179) </text>
<text top="259" left="54" width="43" height="15" font="8">2564725</text>
<text top="259" left="97" width="3" height="15" font="1"> </text>
<text top="213" left="116" width="22" height="15" font="1">The </text>
<text top="228" left="116" width="36" height="15" font="1">effects </text>
<text top="244" left="116" width="12" height="15" font="1">of </text>
<text top="259" left="116" width="44" height="15" font="1">esmolol, </text>
<text top="275" left="116" width="15" height="15" font="1">an </text>
<text top="290" left="116" width="43" height="15" font="1">ultrashor</text>
<text top="306" left="116" width="39" height="15" font="1">t-acting </text>
<text top="321" left="116" width="25" height="15" font="1">beta </text>
<text top="337" left="116" width="42" height="15" font="1">blocker, </text>
<text top="352" left="116" width="21" height="15" font="1">and </text>
<text top="368" left="116" width="43" height="15" font="1">verapam</text>
<text top="383" left="116" width="35" height="15" font="1">il were </text>
<text top="399" left="116" width="43" height="15" font="1">compare</text>
<text top="414" left="116" width="21" height="15" font="1">d in </text>
<text top="430" left="116" width="44" height="15" font="1">controllin</text>
<text top="445" left="116" width="9" height="15" font="1">g </text>
<text top="461" left="116" width="41" height="15" font="1">ventricul</text>
<text top="476" left="116" width="13" height="15" font="1">ar </text>
<text top="492" left="116" width="39" height="15" font="1">respons</text>
<text top="507" left="116" width="36" height="15" font="1">e in 45 </text>
<text top="523" left="116" width="32" height="15" font="1">pts w/ </text>
<text top="538" left="116" width="30" height="15" font="1">AF or </text>
<text top="553" left="116" width="27" height="15" font="1">atrial </text>
<text top="569" left="116" width="31" height="15" font="1">flutter </text>
<text top="213" left="177" width="44" height="15" font="1">Randomi</text>
<text top="228" left="177" width="24" height="15" font="1">zed, </text>
<text top="244" left="177" width="42" height="15" font="1">parallel, </text>
<text top="259" left="177" width="28" height="15" font="1">open-</text>
<text top="275" left="177" width="26" height="15" font="1">label </text>
<text top="290" left="177" width="33" height="15" font="1">study. </text>
<text top="306" left="177" width="33" height="15" font="1">45 pts </text>
<text top="213" left="238" width="65" height="15" font="1">Esmolol (n = </text>
<text top="228" left="238" width="22" height="15" font="1">21)  </text>
<text top="213" left="325" width="66" height="15" font="1">Verapamil (n </text>
<text top="228" left="325" width="29" height="15" font="1">= 24) </text>
<text top="213" left="413" width="87" height="15" font="1">Pts w/ either new </text>
<text top="228" left="413" width="109" height="15" font="1">onset (less than 48 h, </text>
<text top="244" left="413" width="99" height="15" font="1">n = 31) or old onset </text>
<text top="259" left="413" width="113" height="15" font="1">(greater than 48 h, n = </text>
<text top="275" left="413" width="106" height="15" font="1">14) of AF or flutter w/ </text>
<text top="290" left="413" width="104" height="15" font="1">rapid ventricular rate </text>
<text top="213" left="541" width="94" height="15" font="1">Uncontrolled CHF, </text>
<text top="228" left="541" width="106" height="15" font="1">SSS w/o pacemaker, </text>
<text top="244" left="541" width="88" height="15" font="1">h/o intolerance to </text>
<text top="259" left="541" width="97" height="15" font="1">beta blockers or ca-</text>
<text top="275" left="541" width="89" height="15" font="1">channel blockers, </text>
<text top="290" left="541" width="96" height="15" font="1">AMI &lt;3 d, impaired </text>
<text top="306" left="541" width="88" height="15" font="1">renal and hepatic </text>
<text top="321" left="541" width="98" height="15" font="1">function, SVT other </text>
<text top="337" left="541" width="79" height="15" font="1">that AF or atrial </text>
<text top="352" left="541" width="74" height="15" font="1">flutter, digitalis </text>
<text top="368" left="541" width="93" height="15" font="1">toxicity, SBP &lt;100 </text>
<text top="383" left="541" width="105" height="15" font="1">mm Hg unless it was </text>
<text top="399" left="541" width="30" height="15" font="1">usual </text>
<text top="213" left="663" width="68" height="15" font="1">Drug efficacy </text>
<text top="228" left="663" width="23" height="15" font="1">was </text>
<text top="244" left="663" width="67" height="15" font="1">measured by </text>
<text top="259" left="663" width="54" height="15" font="1">ventricular </text>
<text top="275" left="663" width="71" height="15" font="1">rate reduction </text>
<text top="290" left="663" width="21" height="15" font="1">and </text>
<text top="306" left="663" width="69" height="15" font="1">conversion to </text>
<text top="321" left="663" width="69" height="15" font="1">sinus rhythm. </text>
<text top="337" left="663" width="63" height="15" font="1">HR declined </text>
<text top="352" left="663" width="55" height="15" font="1">w/ esmolol </text>
<text top="368" left="663" width="59" height="15" font="1">from 139 to </text>
<text top="383" left="663" width="68" height="15" font="1">100 bpm and </text>
<text top="399" left="663" width="65" height="15" font="1">w/ verapamil </text>
<text top="414" left="663" width="74" height="15" font="1">from 142 to 97 </text>
<text top="430" left="663" width="65" height="15" font="1">bpm. 50% of </text>
<text top="445" left="663" width="42" height="15" font="1">esmolol-</text>
<text top="461" left="663" width="70" height="15" font="1">treated pts w/ </text>
<text top="476" left="663" width="66" height="15" font="1">new onset of </text>
<text top="492" left="663" width="61" height="15" font="1">arrhythmias </text>
<text top="507" left="663" width="64" height="15" font="1">converted to </text>
<text top="523" left="663" width="69" height="15" font="1">NSR vs. 12% </text>
<text top="538" left="663" width="68" height="15" font="1">w/ verapamil. </text>
<text top="213" left="751" width="22" height="15" font="1">N/A </text>
<text top="213" left="845" width="22" height="15" font="1">N/A </text>
<text top="213" left="926" width="112" height="15" font="1">HR decline w/ esmolol </text>
<text top="228" left="926" width="111" height="15" font="1">(p&lt;0.001); HR decline </text>
<text top="244" left="926" width="119" height="15" font="1">w/ verapamil (p&lt;0.001). </text>
<text top="259" left="926" width="114" height="15" font="1">Conversion w/ esmolol </text>
<text top="275" left="926" width="110" height="15" font="1">vs. verapamil (&lt;0.03). </text>
<text top="213" left="1063" width="23" height="15" font="1">Mild </text>
<text top="228" left="1063" width="63" height="15" font="1">hypotension </text>
<text top="244" left="1063" width="62" height="15" font="1">both groups </text>
<text top="585" left="54" width="41" height="15" font="1">Salerno </text>
<text top="601" left="54" width="20" height="15" font="1">DM </text>
<text top="616" left="54" width="28" height="15" font="1">1989 </text>
<text top="632" left="54" width="29" height="15" font="1">(180) </text>
<text top="647" left="54" width="43" height="15" font="8">2650517</text>
<text top="647" left="97" width="3" height="15" font="1"> </text>
<text top="663" left="54" width="3" height="15" font="1"> </text>
<text top="585" left="116" width="30" height="15" font="1">study </text>
<text top="601" left="116" width="42" height="15" font="1">evaluate</text>
<text top="616" left="116" width="27" height="15" font="1">s the </text>
<text top="632" left="116" width="41" height="15" font="1">effective</text>
<text top="647" left="116" width="26" height="15" font="1">ness </text>
<text top="663" left="116" width="21" height="15" font="1">and </text>
<text top="678" left="116" width="45" height="15" font="1">safety of </text>
<text top="694" left="116" width="14" height="15" font="1">IV </text>
<text top="709" left="116" width="47" height="15" font="1">diltiazem </text>
<text top="725" left="116" width="34" height="15" font="1">for the </text>
<text top="740" left="116" width="44" height="15" font="1">treatmen</text>
<text top="756" left="116" width="36" height="15" font="1">t of AF </text>
<text top="771" left="116" width="21" height="15" font="1">and </text>
<text top="787" left="116" width="27" height="15" font="1">atrial </text>
<text top="585" left="177" width="39" height="15" font="1">Double-</text>
<text top="601" left="177" width="29" height="15" font="1">blind, </text>
<text top="616" left="177" width="42" height="15" font="1">parallel, </text>
<text top="632" left="177" width="40" height="15" font="1">randomi</text>
<text top="647" left="177" width="24" height="15" font="1">zed, </text>
<text top="663" left="177" width="42" height="15" font="1">placebo-</text>
<text top="678" left="177" width="42" height="15" font="1">controlle</text>
<text top="694" left="177" width="12" height="15" font="1">d. </text>
<text top="709" left="177" width="39" height="15" font="1">113 pts </text>
<text top="725" left="177" width="44" height="15" font="1">w/ AF or </text>
<text top="740" left="177" width="21" height="15" font="1">flutt </text>
<text top="585" left="238" width="60" height="15" font="1">IV diltiazem </text>
<text top="601" left="238" width="67" height="15" font="1">0.25 mg/kg/2 </text>
<text top="616" left="238" width="65" height="15" font="1">min followed </text>
<text top="632" left="238" width="61" height="15" font="1">15 min later </text>
<text top="647" left="238" width="39" height="15" font="1">by 0.35 </text>
<text top="663" left="238" width="72" height="15" font="1">mg/kg/2 min if </text>
<text top="678" left="238" width="66" height="15" font="1">the first dose </text>
<text top="694" left="238" width="69" height="15" font="1">was tolerated </text>
<text top="709" left="238" width="78" height="15" font="1">but ineffective.  </text>
<text top="725" left="238" width="67" height="15" font="1">If a pt did not </text>
<text top="740" left="238" width="65" height="15" font="1">respond, the </text>
<text top="756" left="238" width="50" height="15" font="1">code was </text>
<text top="771" left="238" width="59" height="15" font="1">broken and </text>
<text top="787" left="238" width="54" height="15" font="1">the pt was </text>
<text top="585" left="325" width="44" height="15" font="1">Identical </text>
<text top="601" left="325" width="42" height="15" font="1">placebo </text>
<text top="585" left="413" width="84" height="15" font="1">113 pts w/ AF or </text>
<text top="601" left="413" width="97" height="15" font="1">flutter, a ventricular </text>
<text top="616" left="413" width="98" height="15" font="1">rate greater than or </text>
<text top="632" left="413" width="110" height="15" font="1">equal to 120 bpm and </text>
<text top="647" left="413" width="95" height="15" font="1">systolic BP greater </text>
<text top="663" left="413" width="95" height="15" font="1">than or equal to 90 </text>
<text top="678" left="413" width="42" height="15" font="1">mm Hg. </text>
<text top="585" left="541" width="56" height="15" font="1">Severe HF </text>
<text top="585" left="663" width="66" height="15" font="1">Of 56 pts, 42 </text>
<text top="601" left="663" width="33" height="15" font="1">(75%) </text>
<text top="616" left="663" width="73" height="15" font="1">randomized to </text>
<text top="632" left="663" width="39" height="15" font="1">receive </text>
<text top="647" left="663" width="47" height="15" font="1">diltiazem </text>
<text top="663" left="663" width="68" height="15" font="1">responded to </text>
<text top="678" left="663" width="58" height="15" font="1">0.25 mg/kg </text>
<text top="694" left="663" width="65" height="15" font="1">and 10 of 14 </text>
<text top="709" left="663" width="68" height="15" font="1">responded to </text>
<text top="725" left="663" width="61" height="15" font="1">0.35 mg/kg, </text>
<text top="740" left="663" width="49" height="15" font="1">for a total </text>
<text top="756" left="663" width="71" height="15" font="1">response rate </text>
<text top="771" left="663" width="73" height="15" font="1">of 52 of 56 pts </text>
<text top="787" left="663" width="36" height="15" font="1">(93%), </text>
<text top="585" left="751" width="23" height="15" font="1">Mild </text>
<text top="601" left="751" width="63" height="15" font="1">hypotension </text>
<text top="585" left="845" width="22" height="15" font="1">N/A </text>
<text top="585" left="926" width="112" height="15" font="1">Response to diltiazem </text>
<text top="601" left="926" width="110" height="15" font="1">vs. placebo (p&lt;0.001) </text>
<text top="585" left="1063" width="60" height="15" font="1">IV diltiazem </text>
<text top="601" left="1063" width="58" height="15" font="1">was rapidly </text>
<text top="616" left="1063" width="60" height="15" font="1">effective for </text>
<text top="632" left="1063" width="59" height="15" font="1">slowing the </text>
<text top="647" left="1063" width="54" height="15" font="1">ventricular </text>
<text top="663" left="1063" width="60" height="15" font="1">response in </text>
<text top="678" left="1063" width="59" height="15" font="1">most pts w/ </text>
<text top="694" left="1063" width="57" height="15" font="1">AF or atrial </text>
<text top="709" left="1063" width="52" height="15" font="1">flutter. BP </text>
<text top="725" left="1063" width="55" height="15" font="1">decreased </text>
<text top="740" left="1063" width="65" height="15" font="1">slightly. Side </text>
<text top="756" left="1063" width="63" height="15" font="1">effects were </text>
<text top="771" left="1063" width="26" height="15" font="1">mild. </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">77 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="250" height="15" font="1">flutter. allowed </text>
<text top="55" left="278" width="100" height="15" font="1">to </text>
<text top="70" left="238" width="67" height="15" font="1">receive open-</text>
<text top="86" left="238" width="73" height="15" font="1">label diltiazem </text>
<text top="101" left="238" width="72" height="15" font="1">if placebo had </text>
<text top="117" left="238" width="60" height="15" font="1">been given. </text>
<text top="55" left="663" width="66" height="15" font="1">whereas 7 of </text>
<text top="70" left="663" width="66" height="15" font="1">57 pts (12%) </text>
<text top="86" left="663" width="68" height="15" font="1">responded to </text>
<text top="101" left="663" width="45" height="15" font="1">placebo. </text>
<text top="133" left="54" width="23" height="15" font="1">Van </text>
<text top="148" left="54" width="36" height="15" font="1">Gelder </text>
<text top="164" left="54" width="14" height="15" font="1">IC </text>
<text top="179" left="54" width="28" height="15" font="1">1989 </text>
<text top="195" left="54" width="29" height="15" font="1">(181) </text>
<text top="210" left="54" width="43" height="15" font="8">2511744</text>
<text top="210" left="97" width="3" height="15" font="1"> </text>
<text top="226" left="54" width="3" height="15" font="1"> </text>
<text top="133" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="148" left="116" width="21" height="15" font="1">and </text>
<text top="164" left="116" width="45" height="15" font="1">safety of </text>
<text top="179" left="116" width="41" height="15" font="1">flecainid</text>
<text top="195" left="116" width="9" height="15" font="1">e </text>
<text top="210" left="116" width="39" height="15" font="1">acetate </text>
<text top="226" left="116" width="30" height="15" font="1">in the </text>
<text top="241" left="116" width="39" height="15" font="1">mainten</text>
<text top="257" left="116" width="39" height="15" font="1">ance of </text>
<text top="272" left="116" width="29" height="15" font="1">sinus </text>
<text top="288" left="116" width="37" height="15" font="1">rhythm </text>
<text top="303" left="116" width="25" height="15" font="1">after </text>
<text top="319" left="116" width="47" height="15" font="1">electrical </text>
<text top="334" left="116" width="42" height="15" font="1">cardiove</text>
<text top="350" left="116" width="39" height="15" font="1">rsion of </text>
<text top="365" left="116" width="39" height="15" font="1">chronic </text>
<text top="381" left="116" width="30" height="15" font="1">AF or </text>
<text top="396" left="116" width="27" height="15" font="1">atrial </text>
<text top="412" left="116" width="34" height="15" font="1">flutter. </text>
<text top="133" left="177" width="33" height="15" font="1">81 pts </text>
<text top="133" left="238" width="109" height="15" font="1">N/A N/A </text>
<text top="133" left="413" width="102" height="15" font="1">Chronic AF or flutter </text>
<text top="133" left="541" width="91" height="15" font="1">Age &lt;16 or &gt;80 y; </text>
<text top="148" left="541" width="75" height="15" font="1">CHF or angina </text>
<text top="164" left="541" width="108" height="15" font="1">pectoris &gt; III (NYHA); </text>
<text top="179" left="541" width="93" height="15" font="1">MI &lt;2 y, flecainide </text>
<text top="195" left="541" width="89" height="15" font="1">intolerance, BBB, </text>
<text top="210" left="541" width="106" height="15" font="1">SSS w/o pacemaker, </text>
<text top="226" left="541" width="81" height="15" font="1">antiarrhythmics, </text>
<text top="241" left="541" width="82" height="15" font="1">severe systemic </text>
<text top="257" left="541" width="41" height="15" font="1">disease </text>
<text top="133" left="663" width="41" height="15" font="1">Multiple </text>
<text top="148" left="663" width="55" height="15" font="1">regression </text>
<text top="164" left="663" width="43" height="15" font="1">analysis </text>
<text top="179" left="663" width="66" height="15" font="1">showed New </text>
<text top="195" left="663" width="56" height="15" font="1">York Heart </text>
<text top="210" left="663" width="60" height="15" font="1">Association </text>
<text top="226" left="663" width="50" height="15" font="1">class I for </text>
<text top="241" left="663" width="44" height="15" font="1">exercise </text>
<text top="257" left="663" width="49" height="15" font="1">tolerance </text>
<text top="272" left="663" width="57" height="15" font="1">(p=0.0004) </text>
<text top="288" left="663" width="71" height="15" font="1">and flecainide </text>
<text top="303" left="663" width="50" height="15" font="1">treatment </text>
<text top="319" left="663" width="72" height="15" font="1">(p=0.01) to be </text>
<text top="334" left="663" width="46" height="15" font="1">the main </text>
<text top="350" left="663" width="36" height="15" font="1">factors </text>
<text top="365" left="663" width="72" height="15" font="1">increasing the </text>
<text top="381" left="663" width="56" height="15" font="1">arrhythmia-</text>
<text top="396" left="663" width="67" height="15" font="1">free episode. </text>
<text top="412" left="663" width="50" height="15" font="1">However, </text>
<text top="427" left="663" width="60" height="15" font="1">Mantel-Cox </text>
<text top="443" left="663" width="41" height="15" font="1">lifetable </text>
<text top="458" left="663" width="61" height="15" font="1">analysis did </text>
<text top="474" left="663" width="52" height="15" font="1">not reveal </text>
<text top="489" left="663" width="52" height="15" font="1">significant </text>
<text top="505" left="663" width="57" height="15" font="1">differences </text>
<text top="520" left="663" width="45" height="15" font="1">between </text>
<text top="535" left="663" width="56" height="15" font="1">arrhythmia-</text>
<text top="551" left="663" width="63" height="15" font="1">free survival </text>
<text top="567" left="663" width="73" height="15" font="1">curves of both </text>
<text top="582" left="663" width="50" height="15" font="1">treatment </text>
<text top="598" left="663" width="71" height="15" font="1">groups. In the </text>
<text top="613" left="663" width="50" height="15" font="1">flecainide-</text>
<text top="628" left="663" width="72" height="15" font="1">treated group, </text>
<text top="644" left="663" width="49" height="15" font="1">9% of pts </text>
<text top="659" left="663" width="63" height="15" font="1">experienced </text>
<text top="675" left="663" width="62" height="15" font="1">side effects, </text>
<text top="690" left="663" width="72" height="15" font="1">mostly related </text>
<text top="706" left="663" width="57" height="15" font="1">to negative </text>
<text top="721" left="663" width="61" height="15" font="1">dromotropic </text>
<text top="737" left="663" width="61" height="15" font="1">effects. The </text>
<text top="752" left="663" width="62" height="15" font="1">incidence of </text>
<text top="768" left="663" width="54" height="15" font="1">ventricular </text>
<text top="783" left="663" width="71" height="15" font="1">proarrhythmia </text>
<text top="133" left="751" width="22" height="15" font="1">N/A </text>
<text top="133" left="845" width="22" height="15" font="1">N/A </text>
<text top="133" left="926" width="22" height="15" font="1">N/A </text>
<text top="133" left="1063" width="49" height="15" font="1">9% of pts </text>
<text top="148" left="1063" width="52" height="15" font="1">treated w/ </text>
<text top="164" left="1063" width="71" height="15" font="1">flecainide had </text>
<text top="179" left="1063" width="42" height="15" font="1">adverse </text>
<text top="195" left="1063" width="36" height="15" font="1">events </text>
<text top="210" left="1063" width="51" height="15" font="1">(e.g,sinus </text>
<text top="226" left="1063" width="52" height="15" font="1">arrest, AV </text>
<text top="241" left="1063" width="57" height="15" font="1">block,  rate </text>
<text top="257" left="1063" width="37" height="15" font="1">related </text>
<text top="272" left="1063" width="38" height="15" font="1">LBBB). </text>
<text top="288" left="1063" width="50" height="15" font="1">Moderate </text>
<text top="303" left="1063" width="45" height="15" font="1">doses of </text>
<text top="319" left="1063" width="72" height="15" font="1">flecainide (not </text>
<text top="334" left="1063" width="50" height="15" font="1">&gt;300 mg) </text>
<text top="350" left="1063" width="74" height="15" font="1">recommended </text>
<text top="365" left="1063" width="25" height="15" font="1">after </text>
<text top="381" left="1063" width="69" height="15" font="1">cardioversion </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">78 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="63" height="15" font="1">in this group </text>
<text top="70" left="663" width="53" height="15" font="1">of pts was </text>
<text top="86" left="663" width="23" height="15" font="1">low. </text>
<text top="102" left="54" width="39" height="15" font="1">Suttrop </text>
<text top="117" left="54" width="18" height="15" font="1">MJ </text>
<text top="133" left="54" width="28" height="15" font="1">1990 </text>
<text top="148" left="54" width="29" height="15" font="1">(182) </text>
<text top="164" left="54" width="43" height="15" font="8">2123909</text>
<text top="164" left="97" width="3" height="15" font="1"> </text>
<text top="179" left="54" width="3" height="15" font="1"> </text>
<text top="102" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="117" left="116" width="38" height="15" font="1">rsion w </text>
<text top="133" left="116" width="33" height="15" font="1">meds: </text>
<text top="148" left="116" width="34" height="15" font="1">Single </text>
<text top="164" left="116" width="26" height="15" font="1">blind </text>
<text top="179" left="116" width="40" height="15" font="1">randomi</text>
<text top="195" left="116" width="21" height="15" font="1">zed </text>
<text top="210" left="116" width="42" height="15" font="1">study of </text>
<text top="226" left="116" width="14" height="15" font="1">IV </text>
<text top="241" left="116" width="44" height="15" font="1">propafen</text>
<text top="257" left="116" width="34" height="15" font="1">one (2 </text>
<text top="272" left="116" width="33" height="15" font="1">mg/kg </text>
<text top="288" left="116" width="34" height="15" font="1">per 10 </text>
<text top="303" left="116" width="42" height="15" font="1">min) vs. </text>
<text top="319" left="116" width="41" height="15" font="1">flecainid</text>
<text top="334" left="116" width="22" height="15" font="1">e (2 </text>
<text top="350" left="116" width="33" height="15" font="1">mg/kg </text>
<text top="365" left="116" width="34" height="15" font="1">per 10 </text>
<text top="381" left="116" width="25" height="15" font="1">min)<i> </i></text>
<text top="102" left="177" width="47" height="15" font="1">50 pts w/ </text>
<text top="117" left="177" width="30" height="15" font="1">AF or </text>
<text top="133" left="177" width="27" height="15" font="1">atrial </text>
<text top="148" left="177" width="31" height="15" font="1">flutter </text>
<text top="102" left="238" width="61" height="15" font="1">AF or flutter </text>
<text top="117" left="238" width="63" height="15" font="1">Group A- 20 </text>
<text top="133" left="238" width="49" height="15" font="1">pts w/ AF </text>
<text top="148" left="238" width="52" height="15" font="1">treated w/ </text>
<text top="164" left="238" width="65" height="15" font="1">propafenone </text>
<text top="179" left="238" width="58" height="15" font="1">Group C- 5 </text>
<text top="195" left="238" width="59" height="15" font="1">pts w/ atrial </text>
<text top="210" left="238" width="68" height="15" font="1">flutter treated </text>
<text top="226" left="238" width="14" height="15" font="1">w/ </text>
<text top="241" left="238" width="71" height="15" font="1">proopafenone </text>
<text top="257" left="238" width="3" height="15" font="1"> </text>
<text top="102" left="325" width="61" height="15" font="1">AF or flutter </text>
<text top="117" left="325" width="60" height="15" font="1">Group B-20 </text>
<text top="133" left="325" width="49" height="15" font="1">pts w/ AF </text>
<text top="148" left="325" width="55" height="15" font="1">treated w/  </text>
<text top="164" left="325" width="50" height="15" font="1">flecainide </text>
<text top="179" left="325" width="58" height="15" font="1">Group D- 5 </text>
<text top="195" left="325" width="59" height="15" font="1">pts w/ atrial </text>
<text top="210" left="325" width="68" height="15" font="1">flutter treated </text>
<text top="226" left="325" width="64" height="15" font="1">w/ flecainide </text>
<text top="241" left="325" width="3" height="15" font="1"> </text>
<text top="257" left="325" width="3" height="15" font="1"> </text>
<text top="102" left="413" width="104" height="15" font="1">AF or atrial flutter &lt;6 </text>
<text top="117" left="413" width="109" height="15" font="1">mo w/ ventricular rate </text>
<text top="133" left="413" width="101" height="15" font="1">&gt;100 bpm at rest w/ </text>
<text top="148" left="413" width="62" height="15" font="1">no HF signs </text>
<text top="102" left="541" width="59" height="15" font="1">Conduction </text>
<text top="117" left="541" width="94" height="15" font="1">disturbances more </text>
<text top="133" left="541" width="28" height="15" font="1">that 1</text>
<text top="133" left="569" width="6" height="10" font="10">st</text>
<text top="133" left="575" width="58" height="15" font="1"> degree AV </text>
<text top="148" left="541" width="82" height="15" font="1">block, on class I </text>
<text top="164" left="541" width="106" height="15" font="1">antiarrythmics, WPW </text>
<text top="179" left="541" width="83" height="15" font="1">syndrome, SSS, </text>
<text top="195" left="541" width="26" height="15" font="1">AMI, </text>
<text top="210" left="541" width="86" height="15" font="1">Hyperthyroidism, </text>
<text top="226" left="541" width="94" height="15" font="1">cardiac surgery &lt;2 </text>
<text top="241" left="541" width="52" height="15" font="1">wks, atrial </text>
<text top="257" left="541" width="102" height="15" font="1">enlargement,  w/ AF </text>
<text top="272" left="541" width="91" height="15" font="1">or atrial flutter w/o </text>
<text top="288" left="541" width="59" height="15" font="1">appropriate </text>
<text top="303" left="541" width="105" height="15" font="1">anticoagulants, body </text>
<text top="319" left="541" width="78" height="15" font="1">weight &gt;100 kg </text>
<text top="102" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="117" left="663" width="69" height="15" font="1">NSR w/in 1 H </text>
<text top="133" left="663" width="31" height="15" font="1">11/20 </text>
<text top="148" left="663" width="61" height="15" font="1">(55%)pts w/ </text>
<text top="164" left="663" width="69" height="15" font="1">AF treated w/ </text>
<text top="179" left="663" width="68" height="15" font="1">propafenone  </text>
<text top="195" left="663" width="31" height="15" font="1">18/20 </text>
<text top="210" left="663" width="61" height="15" font="1">(90%)pts w/ </text>
<text top="226" left="663" width="72" height="15" font="1">AF treated w/  </text>
<text top="241" left="663" width="50" height="15" font="1">flecainide </text>
<text top="257" left="663" width="45" height="15" font="1">(p&lt;0.02) </text>
<text top="272" left="663" width="69" height="15" font="1">2/5 (40%) pts </text>
<text top="288" left="663" width="72" height="15" font="1">w/ atrial flutter </text>
<text top="303" left="663" width="52" height="15" font="1">treated w/ </text>
<text top="319" left="663" width="65" height="15" font="1">propafenone </text>
<text top="334" left="663" width="69" height="15" font="1">1/5 (20%) pts </text>
<text top="350" left="663" width="72" height="15" font="1">w/ atrial flutter </text>
<text top="365" left="663" width="52" height="15" font="1">treated w/ </text>
<text top="381" left="663" width="53" height="15" font="1">flecainide. </text>
<text top="396" left="663" width="32" height="15" font="1">P=NS </text>
<text top="102" left="751" width="27" height="15" font="1">QRS </text>
<text top="117" left="751" width="60" height="15" font="1">lengthening </text>
<text top="133" left="751" width="79" height="15" font="1">(83±15 to <b>9920</b> </text>
<text top="148" left="751" width="56" height="15" font="1">msec) was </text>
<text top="164" left="751" width="72" height="15" font="1">observed only </text>
<text top="179" left="751" width="48" height="15" font="1">in the pts </text>
<text top="195" left="751" width="52" height="15" font="1">treated w/ </text>
<text top="210" left="751" width="50" height="15" font="1">flecainide </text>
<text top="226" left="751" width="54" height="15" font="1">(p&lt;0.001). </text>
<text top="102" left="845" width="22" height="15" font="1">N/A </text>
<text top="102" left="926" width="116" height="15" font="1">Conversion from AF w/ </text>
<text top="117" left="926" width="67" height="15" font="1">flecainide vs. </text>
<text top="133" left="926" width="113" height="15" font="1">propafenone (p&lt;0.02). </text>
<text top="148" left="926" width="111" height="15" font="1">Conversion from atrial </text>
<text top="164" left="926" width="112" height="15" font="1">flutter w/ fleainidec vs. </text>
<text top="179" left="926" width="107" height="15" font="1">propafenone (p=NS). </text>
<text top="195" left="926" width="117" height="15" font="1">Transient AE flecainide </text>
<text top="210" left="926" width="111" height="15" font="1">vs. propafenone more </text>
<text top="226" left="926" width="96" height="15" font="1">common (p&lt;0.001) </text>
<text top="102" left="1063" width="63" height="15" font="1">Flecainide 2 </text>
<text top="117" left="1063" width="60" height="15" font="1">mg/kg in 10 </text>
<text top="133" left="1063" width="60" height="15" font="1">min is more </text>
<text top="148" left="1063" width="69" height="15" font="1">effective than </text>
<text top="164" left="1063" width="65" height="15" font="1">propafenone </text>
<text top="179" left="1063" width="73" height="15" font="1">for conversion </text>
<text top="195" left="1063" width="68" height="15" font="1">of AF to NSR </text>
<text top="210" left="1063" width="53" height="15" font="1">but not for </text>
<text top="226" left="1063" width="69" height="15" font="1">conversion of </text>
<text top="241" left="1063" width="61" height="15" font="1">flutter.  Few </text>
<text top="257" left="1063" width="32" height="15" font="1">AE w/ </text>
<text top="272" left="1063" width="69" height="15" font="1">propafenone- </text>
<text top="288" left="1063" width="39" height="15" font="1">may be </text>
<text top="303" left="1063" width="69" height="15" font="1">related to low </text>
<text top="319" left="1063" width="36" height="15" font="1">dose.   </text>
<text top="412" left="54" width="43" height="15" font="1">Ellenbog</text>
<text top="428" left="54" width="33" height="15" font="1">en KA </text>
<text top="443" left="54" width="34" height="15" font="1">1991   </text>
<text top="459" left="54" width="29" height="15" font="1">(183) </text>
<text top="474" left="54" width="43" height="15" font="8">1894861</text>
<text top="474" left="97" width="3" height="15" font="1"> </text>
<text top="412" left="116" width="16" height="15" font="1">To </text>
<text top="428" left="116" width="42" height="15" font="1">demonst</text>
<text top="443" left="116" width="41" height="15" font="1">rate the </text>
<text top="459" left="116" width="33" height="15" font="1">safety </text>
<text top="474" left="116" width="21" height="15" font="1">and </text>
<text top="490" left="116" width="41" height="15" font="1">efficacy </text>
<text top="505" left="116" width="21" height="15" font="1">of a </text>
<text top="521" left="116" width="42" height="15" font="1">continuo</text>
<text top="536" left="116" width="28" height="15" font="1">us IV </text>
<text top="552" left="116" width="47" height="15" font="1">diltiazem </text>
<text top="567" left="116" width="41" height="15" font="1">infusion </text>
<text top="583" left="116" width="41" height="15" font="1">for 24 h </text>
<text top="598" left="116" width="28" height="15" font="1">heart </text>
<text top="614" left="116" width="22" height="15" font="1">rate </text>
<text top="629" left="116" width="39" height="15" font="1">control  </text>
<text top="645" left="116" width="3" height="15" font="1"> </text>
<text top="412" left="177" width="44" height="15" font="1">Randomi</text>
<text top="428" left="177" width="24" height="15" font="1">zed, </text>
<text top="443" left="177" width="37" height="15" font="1">double-</text>
<text top="459" left="177" width="29" height="15" font="1">blind, </text>
<text top="474" left="177" width="42" height="15" font="1">parallel, </text>
<text top="490" left="177" width="42" height="15" font="1">placebo-</text>
<text top="505" left="177" width="42" height="15" font="1">controlle</text>
<text top="521" left="177" width="12" height="15" font="1">d  </text>
<text top="536" left="177" width="3" height="15" font="1"> </text>
<text top="412" left="238" width="60" height="15" font="1">IV diltiazem </text>
<text top="428" left="238" width="59" height="15" font="1">vs. placebo </text>
<text top="443" left="238" width="3" height="15" font="1"> </text>
<text top="412" left="325" width="43" height="15" font="1">Placebo </text>
<text top="412" left="413" width="94" height="15" font="1">Pts &gt;18 y w/ AF or </text>
<text top="428" left="413" width="115" height="15" font="1">atrial flutter w/ duration </text>
<text top="443" left="413" width="100" height="15" font="1">&gt;24 h and HR &gt;120 </text>
<text top="459" left="413" width="28" height="15" font="1">bpm  </text>
<text top="474" left="413" width="3" height="15" font="1"> </text>
<text top="412" left="541" width="96" height="15" font="1">Severe CHF, sinus </text>
<text top="428" left="541" width="90" height="15" font="1">node dysfunction, </text>
<text top="443" left="541" width="91" height="15" font="1">2nd or 3rd degree </text>
<text top="459" left="541" width="81" height="15" font="1">AV block, WPW </text>
<text top="474" left="541" width="65" height="15" font="1">syndrome or </text>
<text top="490" left="541" width="66" height="15" font="1">hypotension  </text>
<text top="505" left="541" width="3" height="15" font="1"> </text>
<text top="412" left="663" width="62" height="15" font="1">Therapeutic </text>
<text top="428" left="663" width="49" height="15" font="1">response </text>
<text top="443" left="663" width="58" height="15" font="1">(ventricular </text>
<text top="459" left="663" width="49" height="15" font="1">response </text>
<text top="474" left="663" width="56" height="15" font="1">&lt;100 bpm, </text>
<text top="490" left="663" width="33" height="15" font="1">≥20% </text>
<text top="505" left="663" width="60" height="15" font="1">decrease in </text>
<text top="521" left="663" width="50" height="15" font="1">heart rate </text>
<text top="536" left="663" width="70" height="15" font="1">from baseline </text>
<text top="552" left="663" width="69" height="15" font="1">or conversion </text>
<text top="567" left="663" width="42" height="15" font="1">to NSR  </text>
<text top="583" left="663" width="65" height="15" font="1">74% vs. 0%  </text>
<text top="412" left="751" width="22" height="15" font="1">N/A </text>
<text top="412" left="845" width="22" height="15" font="1">N/A </text>
<text top="412" left="926" width="43" height="15" font="1">p&lt;0.001 </text>
<text top="412" left="1063" width="71" height="15" font="1">IV diltiazem is </text>
<text top="428" left="1063" width="45" height="15" font="1">safe and </text>
<text top="443" left="1063" width="57" height="15" font="1">effective at </text>
<text top="459" left="1063" width="68" height="15" font="1">slowing heart </text>
<text top="474" left="1063" width="64" height="15" font="1">rate in AF or </text>
<text top="490" left="1063" width="21" height="15" font="1">flutt </text>
<text top="661" left="54" width="23" height="15" font="1">Van </text>
<text top="676" left="54" width="36" height="15" font="1">Gelder </text>
<text top="692" left="54" width="14" height="15" font="1">IC </text>
<text top="707" left="54" width="28" height="15" font="1">1991 </text>
<text top="723" left="54" width="29" height="15" font="1">(184) </text>
<text top="738" left="54" width="43" height="15" font="8">2058558</text>
<text top="738" left="97" width="3" height="15" font="1"> </text>
<text top="754" left="54" width="3" height="15" font="1"> </text>
<text top="661" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="676" left="116" width="30" height="15" font="1">rsion: </text>
<text top="692" left="116" width="47" height="15" font="1">reassess </text>
<text top="707" left="116" width="42" height="15" font="1">prospect</text>
<text top="723" left="116" width="44" height="15" font="1">ively the </text>
<text top="738" left="116" width="42" height="15" font="1">immedia</text>
<text top="754" left="116" width="34" height="15" font="1">te and </text>
<text top="769" left="116" width="25" height="15" font="1">long-</text>
<text top="785" left="116" width="25" height="15" font="1">term </text>
<text top="661" left="177" width="40" height="15" font="1">246 pts </text>
<text top="661" left="238" width="60" height="15" font="1">Multivariate </text>
<text top="676" left="238" width="55" height="15" font="1">analysis to </text>
<text top="692" left="238" width="74" height="15" font="1">identify factors </text>
<text top="707" left="238" width="51" height="15" font="1">predicting </text>
<text top="723" left="238" width="53" height="15" font="1">short- and </text>
<text top="738" left="238" width="50" height="15" font="1">long-term </text>
<text top="754" left="238" width="55" height="15" font="1">arrhythmia </text>
<text top="769" left="238" width="45" height="15" font="1">outcome </text>
<text top="785" left="238" width="65" height="15" font="1">following DC </text>
<text top="661" left="325" width="22" height="15" font="1">N/A </text>
<text top="661" left="413" width="88" height="15" font="1">AF or atrial flutter </text>
<text top="661" left="541" width="71" height="15" font="1">Sinus rhythm, </text>
<text top="676" left="541" width="66" height="15" font="1">unstable HF, </text>
<text top="692" left="541" width="95" height="15" font="1">cardiogenic shock, </text>
<text top="707" left="541" width="82" height="15" font="1">severs systemic </text>
<text top="723" left="541" width="98" height="15" font="1">disease, SSS, AMI, </text>
<text top="738" left="541" width="93" height="15" font="1">contraindication to </text>
<text top="754" left="541" width="74" height="15" font="1">anticoagulants </text>
<text top="661" left="663" width="71" height="15" font="1">Cardioversion </text>
<text top="676" left="663" width="66" height="15" font="1">successful in </text>
<text top="692" left="663" width="70" height="15" font="1">70% of pts w/ </text>
<text top="707" left="663" width="50" height="15" font="1">AF and in </text>
<text top="723" left="663" width="70" height="15" font="1">96% of pts w/ </text>
<text top="738" left="663" width="34" height="15" font="1">flutter. </text>
<text top="754" left="663" width="48" height="15" font="1">Stepwise </text>
<text top="769" left="663" width="37" height="15" font="1">logistic </text>
<text top="785" left="663" width="55" height="15" font="1">regression </text>
<text top="661" left="751" width="22" height="15" font="1">N/A </text>
<text top="661" left="845" width="22" height="15" font="1">N/A </text>
<text top="661" left="926" width="100" height="15" font="1">Arrhythmia duration </text>
<text top="676" left="926" width="115" height="15" font="1">(p&lt;0.001); AF vs. atrial </text>
<text top="692" left="926" width="118" height="15" font="1">flutter (p&lt;0.02) and age </text>
<text top="707" left="926" width="98" height="15" font="1">(p&lt;0.05) influenced </text>
<text top="723" left="926" width="117" height="15" font="1">DCV rates. MVanalysis </text>
<text top="738" left="926" width="121" height="15" font="1">showed arrhythmia type </text>
<text top="754" left="926" width="110" height="15" font="1">(p=0.0008), functional </text>
<text top="769" left="926" width="100" height="15" font="1">class (p=0.002) and </text>
<text top="785" left="926" width="61" height="15" font="1">presence of </text>
<text top="661" left="1063" width="69" height="15" font="1">Predictors for </text>
<text top="676" left="1063" width="55" height="15" font="1">successful </text>
<text top="692" left="1063" width="69" height="15" font="1">cardioversion </text>
<text top="707" left="1063" width="69" height="15" font="1">include flutter </text>
<text top="723" left="1063" width="58" height="15" font="1">vs. AF. FC, </text>
<text top="738" left="1063" width="43" height="15" font="1">age and </text>
<text top="754" left="1063" width="52" height="15" font="1">rheumatic </text>
<text top="769" left="1063" width="69" height="15" font="1">heart disease </text>
<text top="785" left="1063" width="30" height="15" font="1">affect </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">79 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="36" height="15" font="1">results </text>
<text top="70" left="116" width="43" height="15" font="1">of direct-</text>
<text top="86" left="116" width="37" height="15" font="1">current </text>
<text top="101" left="116" width="47" height="15" font="1">electrical </text>
<text top="117" left="116" width="42" height="15" font="1">cardiove</text>
<text top="132" left="116" width="39" height="15" font="1">rsion in </text>
<text top="147" left="116" width="39" height="15" font="1">chronic </text>
<text top="163" left="116" width="30" height="15" font="1">AF or </text>
<text top="178" left="116" width="27" height="15" font="1">atrial </text>
<text top="194" left="116" width="34" height="15" font="1">flutter, </text>
<text top="210" left="116" width="34" height="15" font="1">and to </text>
<text top="225" left="116" width="43" height="15" font="1">determin</text>
<text top="240" left="116" width="45" height="15" font="1">e factors </text>
<text top="256" left="116" width="42" height="15" font="1">predictin</text>
<text top="271" left="116" width="45" height="15" font="1">g clinical </text>
<text top="287" left="116" width="45" height="15" font="1">outcome </text>
<text top="302" left="116" width="31" height="15" font="1">of the </text>
<text top="318" left="116" width="44" height="15" font="1">arrhythm</text>
<text top="333" left="116" width="37" height="15" font="1">ia after </text>
<text top="349" left="116" width="31" height="15" font="1">direct-</text>
<text top="364" left="116" width="37" height="15" font="1">current </text>
<text top="380" left="116" width="42" height="15" font="1">cardiove</text>
<text top="395" left="116" width="27" height="15" font="1">rsion </text>
<text top="55" left="238" width="825" height="15" font="1">cardioversion analysis </text>
<text top="70" left="663" width="67" height="15" font="1">revealed that </text>
<text top="86" left="663" width="55" height="15" font="1">arrhythmia </text>
<text top="101" left="663" width="70" height="15" font="1">duration, type </text>
<text top="117" left="663" width="68" height="15" font="1">of arrhythmia </text>
<text top="132" left="663" width="43" height="15" font="1">and age </text>
<text top="147" left="663" width="72" height="15" font="1">independently </text>
<text top="163" left="663" width="53" height="15" font="1">influenced </text>
<text top="178" left="663" width="57" height="15" font="1">conversion </text>
<text top="194" left="663" width="28" height="15" font="1">rate.  </text>
<text top="210" left="663" width="74" height="15" font="1">42 and 36% of </text>
<text top="225" left="663" width="67" height="15" font="1">pts remained </text>
<text top="240" left="663" width="41" height="15" font="1">in sinus </text>
<text top="256" left="663" width="71" height="15" font="1">rhythm during </text>
<text top="271" left="663" width="52" height="15" font="1">1 and 2 y, </text>
<text top="287" left="663" width="68" height="15" font="1">respectively.  </text>
<text top="302" left="663" width="60" height="15" font="1">Multivariate </text>
<text top="318" left="663" width="55" height="15" font="1">regression </text>
<text top="333" left="663" width="43" height="15" font="1">analysis </text>
<text top="349" left="663" width="67" height="15" font="1">revealed that </text>
<text top="364" left="663" width="55" height="15" font="1">the type of </text>
<text top="380" left="663" width="62" height="15" font="1">arrhythmia), </text>
<text top="395" left="663" width="20" height="15" font="1">low </text>
<text top="411" left="663" width="69" height="15" font="1">precardioversi</text>
<text top="426" left="663" width="66" height="15" font="1">on functional </text>
<text top="442" left="663" width="68" height="15" font="1">class and the </text>
<text top="457" left="663" width="61" height="15" font="1">presence of </text>
<text top="473" left="663" width="70" height="15" font="1">nonrheumatic </text>
<text top="488" left="663" width="59" height="15" font="1">mitral valve </text>
<text top="504" left="663" width="41" height="15" font="1">disease </text>
<text top="519" left="663" width="72" height="15" font="1">independently </text>
<text top="535" left="663" width="70" height="15" font="1">increased the </text>
<text top="550" left="663" width="64" height="15" font="1">length of the </text>
<text top="566" left="663" width="56" height="15" font="1">arrhythmia-</text>
<text top="581" left="663" width="67" height="15" font="1">free episode. </text>
<text top="597" left="663" width="56" height="15" font="1">Rheumatic </text>
<text top="612" left="663" width="69" height="15" font="1">heart disease </text>
<text top="628" left="663" width="73" height="15" font="1">shortened this </text>
<text top="643" left="663" width="37" height="15" font="1">period. </text>
<text top="55" left="926" width="111" height="15" font="1">nonrheumatic disease </text>
<text top="70" left="926" width="96" height="15" font="1">(p=0.03) increased </text>
<text top="86" left="926" width="114" height="15" font="1">arrhythmia free period. </text>
<text top="101" left="926" width="84" height="15" font="1">Rheumatic heart </text>
<text top="117" left="926" width="96" height="15" font="1">disease decreased </text>
<text top="132" left="926" width="111" height="15" font="1">arrhythmia free period </text>
<text top="148" left="926" width="45" height="15" font="1">(p=0.03) </text>
<text top="55" left="1063" width="72" height="15" font="1">cardioversion. </text>
<text top="659" left="54" width="41" height="15" font="1">Kingma </text>
<text top="675" left="54" width="17" height="15" font="1">JH </text>
<text top="690" left="54" width="28" height="15" font="1">1992 </text>
<text top="706" left="54" width="29" height="15" font="1">(185) </text>
<text top="721" left="54" width="43" height="15" font="8">1510000</text>
<text top="721" left="97" width="3" height="15" font="1"> </text>
<text top="737" left="54" width="3" height="15" font="1"> </text>
<text top="659" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="675" left="116" width="38" height="15" font="1">rsion w </text>
<text top="690" left="116" width="33" height="15" font="1">meds: </text>
<text top="706" left="116" width="34" height="15" font="1">Single-</text>
<text top="721" left="116" width="26" height="15" font="1">blind </text>
<text top="737" left="116" width="40" height="15" font="1">randomi</text>
<text top="752" left="116" width="21" height="15" font="1">zed </text>
<text top="768" left="116" width="30" height="15" font="1">study </text>
<text top="783" left="116" width="39" height="15" font="1">design. </text>
<text top="659" left="177" width="19" height="15" font="1">90  </text>
<text top="659" left="238" width="71" height="15" font="1">Conversion to </text>
<text top="675" left="238" width="71" height="15" font="1">NSR w/in 1 hr </text>
<text top="690" left="238" width="49" height="15" font="1">of start of </text>
<text top="706" left="238" width="44" height="15" font="1">infusion: </text>
<text top="721" left="238" width="46" height="15" font="1"> First 40: </text>
<text top="737" left="238" width="71" height="15" font="1">flecainide and </text>
<text top="752" left="238" width="51" height="15" font="1">verapamil </text>
<text top="768" left="238" width="50" height="15" font="1">assessed </text>
<text top="783" left="238" width="3" height="15" font="1"> </text>
<text top="659" left="325" width="71" height="15" font="1">Conversion to </text>
<text top="675" left="325" width="71" height="15" font="1">NSR w/in 1 hr </text>
<text top="690" left="325" width="49" height="15" font="1">of start of </text>
<text top="706" left="325" width="44" height="15" font="1">infusion: </text>
<text top="721" left="325" width="59" height="15" font="1">Second 50: </text>
<text top="737" left="325" width="71" height="15" font="1">flecainide and </text>
<text top="752" left="325" width="65" height="15" font="1">propafenone </text>
<text top="768" left="325" width="52" height="15" font="1">compared </text>
<text top="659" left="413" width="113" height="15" font="1">Consecutive pts w/ AF </text>
<text top="675" left="413" width="44" height="15" font="1">or flutter </text>
<text top="659" left="541" width="59" height="15" font="1">More than 1</text>
<text top="660" left="600" width="6" height="10" font="10">st</text>
<text top="659" left="606" width="41" height="15" font="1"> degree </text>
<text top="675" left="541" width="84" height="15" font="1">AV block, class I </text>
<text top="690" left="541" width="81" height="15" font="1">antiarrhtyhmics, </text>
<text top="706" left="541" width="86" height="15" font="1">WPW syndrome, </text>
<text top="721" left="541" width="54" height="15" font="1">SSS, AMI, </text>
<text top="737" left="541" width="84" height="15" font="1">hyperthyroidism, </text>
<text top="752" left="541" width="94" height="15" font="1">cardiac surgery &lt;2 </text>
<text top="768" left="541" width="65" height="15" font="1">wk, left atrial </text>
<text top="783" left="541" width="105" height="15" font="1">enlargement with AF </text>
<text top="659" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="675" left="663" width="44" height="15" font="1">NSR in:  </text>
<text top="690" left="663" width="63" height="15" font="1">32/37 (86%) </text>
<text top="706" left="663" width="31" height="15" font="1">AF w/ </text>
<text top="721" left="663" width="50" height="15" font="1">flecainide </text>
<text top="737" left="663" width="63" height="15" font="1">11/20 (55%) </text>
<text top="752" left="663" width="56" height="15" font="1">AF w/ PPF </text>
<text top="768" left="663" width="46" height="15" font="1">In recent </text>
<text top="783" left="663" width="50" height="15" font="1">onset AF, </text>
<text top="659" left="751" width="74" height="15" font="1">QRS widening </text>
<text top="675" left="751" width="58" height="15" font="1">occurred in </text>
<text top="690" left="751" width="50" height="15" font="1">flecainide-</text>
<text top="706" left="751" width="55" height="15" font="1">treated pts </text>
<text top="721" left="751" width="51" height="15" font="1">(83±15 to </text>
<text top="737" left="751" width="68" height="15" font="1">99±20 msec; </text>
<text top="752" left="751" width="69" height="15" font="1">p&lt;0.001), but </text>
<text top="768" left="751" width="44" height="15" font="1">not after </text>
<text top="783" left="751" width="65" height="15" font="1">propafenone </text>
<text top="659" left="845" width="22" height="15" font="1">N/A </text>
<text top="659" left="926" width="85" height="15" font="1">Recent onset AF </text>
<text top="675" left="926" width="122" height="15" font="1">flecainide more effective </text>
<text top="690" left="926" width="102" height="15" font="1">than propafenone at </text>
<text top="706" left="926" width="105" height="15" font="1">conversion ((p&lt;0.05) </text>
<text top="721" left="926" width="106" height="15" font="1">Flutter conversion no </text>
<text top="737" left="926" width="120" height="15" font="1">difference in conversion </text>
<text top="752" left="926" width="81" height="15" font="1">w/ flecainide vs. </text>
<text top="768" left="926" width="104" height="15" font="1">propafenone (p=NS) </text>
<text top="783" left="926" width="109" height="15" font="1">Verapamil ineffective. </text>
<text top="659" left="1063" width="65" height="15" font="1">Flecainide is </text>
<text top="675" left="1063" width="73" height="15" font="1">more effective </text>
<text top="690" left="1063" width="25" height="15" font="1">than </text>
<text top="706" left="1063" width="65" height="15" font="1">propafenone </text>
<text top="721" left="1063" width="66" height="15" font="1">at converting </text>
<text top="737" left="1063" width="64" height="15" font="1">recent onset </text>
<text top="752" left="1063" width="57" height="15" font="1">AF, but not </text>
<text top="768" left="1063" width="37" height="15" font="1">flutter.  </text>
<text top="783" left="1063" width="53" height="15" font="1">Verapamil </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">80 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="70" left="116" width="21" height="15" font="1">and </text>
<text top="86" left="116" width="45" height="15" font="1">safety of </text>
<text top="101" left="116" width="14" height="15" font="1">IV </text>
<text top="117" left="116" width="44" height="15" font="1">propafen</text>
<text top="132" left="116" width="34" height="15" font="1">one (2 </text>
<text top="147" left="116" width="33" height="15" font="1">mg/kg </text>
<text top="163" left="116" width="34" height="15" font="1">per 10 </text>
<text top="178" left="116" width="42" height="15" font="1">min) vs. </text>
<text top="194" left="116" width="41" height="15" font="1">flecainid</text>
<text top="210" left="116" width="22" height="15" font="1">e (2 </text>
<text top="225" left="116" width="33" height="15" font="1">mg/kg </text>
<text top="240" left="116" width="34" height="15" font="1">per 10 </text>
<text top="256" left="116" width="42" height="15" font="1">min) vs. </text>
<text top="271" left="116" width="43" height="15" font="1">verapam</text>
<text top="287" left="116" width="42" height="15" font="1">il 10 mg </text>
<text top="302" left="116" width="21" height="15" font="1">in 1 </text>
<text top="318" left="116" width="32" height="15" font="1">min.in </text>
<text top="333" left="116" width="32" height="15" font="1">pts w/ </text>
<text top="349" left="116" width="30" height="15" font="1">AF or </text>
<text top="364" left="116" width="21" height="15" font="1">flutt </text>
<text top="55" left="541" width="96" height="15" font="1">or atrial flutter &gt;2 d </text>
<text top="70" left="541" width="79" height="15" font="1">w/o appropriate </text>
<text top="86" left="541" width="105" height="15" font="1">anticoagulants, body </text>
<text top="101" left="541" width="78" height="15" font="1">weight &gt;100 kg </text>
<text top="55" left="663" width="50" height="15" font="1">flecainide </text>
<text top="70" left="663" width="57" height="15" font="1">conversion </text>
<text top="86" left="663" width="63" height="15" font="1">24/25 (96%) </text>
<text top="101" left="663" width="74" height="15" font="1">vs. 8/14 (57%) </text>
<text top="117" left="663" width="68" height="15" font="1">propafenone, </text>
<text top="132" left="663" width="40" height="15" font="1">p&lt;0.05. </text>
<text top="147" left="663" width="51" height="15" font="1">1/8 (13%) </text>
<text top="163" left="663" width="72" height="15" font="1">atrial flutter w/ </text>
<text top="178" left="663" width="50" height="15" font="1">flecainide </text>
<text top="194" left="663" width="51" height="15" font="1">2/5 (40%) </text>
<text top="210" left="663" width="58" height="15" font="1">atrial flutter </text>
<text top="225" left="663" width="68" height="15" font="1">propafenone, </text>
<text top="240" left="663" width="31" height="15" font="1">p=NS </text>
<text top="256" left="663" width="38" height="15" font="1">Overall </text>
<text top="271" left="663" width="51" height="15" font="1">verapamil </text>
<text top="287" left="663" width="51" height="15" font="1">1/20 (5%) </text>
<text top="302" left="663" width="3" height="15" font="1"> </text>
<text top="55" left="751" width="51" height="15" font="1">(83±11 to </text>
<text top="70" left="751" width="71" height="15" font="1">86±12 msec). </text>
<text top="55" left="926" width="102" height="15" font="1">QRS widening more </text>
<text top="70" left="926" width="109" height="15" font="1">common w/ flecainide </text>
<text top="86" left="926" width="90" height="15" font="1">than propafenone </text>
<text top="101" left="926" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="117" left="926" width="3" height="15" font="1"> </text>
<text top="55" left="1063" width="41" height="15" font="1">was not </text>
<text top="70" left="1063" width="57" height="15" font="1">effective at </text>
<text top="86" left="1063" width="71" height="15" font="1">converting AF </text>
<text top="101" left="1063" width="71" height="15" font="1">or atrial flutter </text>
<text top="117" left="1063" width="45" height="15" font="1">w/in 1 hr </text>
<text top="381" left="54" width="42" height="15" font="1">Roberts </text>
<text top="396" left="54" width="18" height="15" font="1">SA </text>
<text top="412" left="54" width="28" height="15" font="1">1993 </text>
<text top="427" left="54" width="29" height="15" font="1">(186) </text>
<text top="443" left="54" width="43" height="15" font="8">8362772</text>
<text top="443" left="97" width="3" height="15" font="1"> </text>
<text top="458" left="54" width="3" height="15" font="1"> </text>
<text top="381" left="116" width="39" height="15" font="1">Clinical </text>
<text top="396" left="116" width="41" height="15" font="1">effective</text>
<text top="412" left="116" width="26" height="15" font="1">ness </text>
<text top="427" left="116" width="45" height="15" font="1">and cost </text>
<text top="443" left="116" width="12" height="15" font="1">of </text>
<text top="458" left="116" width="38" height="15" font="1">digoxin </text>
<text top="474" left="116" width="12" height="15" font="1">at </text>
<text top="489" left="116" width="44" height="15" font="1">controllin</text>
<text top="505" left="116" width="40" height="15" font="1">g HR in </text>
<text top="520" left="116" width="39" height="15" font="1">AF and </text>
<text top="535" left="116" width="27" height="15" font="1">atrial </text>
<text top="551" left="116" width="42" height="15" font="1">flutter in </text>
<text top="567" left="116" width="42" height="15" font="1">prospect</text>
<text top="582" left="116" width="23" height="15" font="1">ive , </text>
<text top="597" left="116" width="42" height="15" font="1">observat</text>
<text top="613" left="116" width="26" height="15" font="1">ional </text>
<text top="628" left="116" width="42" height="15" font="1">study at </text>
<text top="644" left="116" width="15" height="15" font="1">18 </text>
<text top="659" left="116" width="42" height="15" font="1">academi</text>
<text top="675" left="116" width="9" height="15" font="1">c </text>
<text top="690" left="116" width="39" height="15" font="1">centers </text>
<text top="381" left="177" width="43" height="15" font="1">115 pts  </text>
<text top="381" left="238" width="51" height="15" font="1">Assessed </text>
<text top="396" left="238" width="55" height="15" font="1">time to HR </text>
<text top="412" left="238" width="50" height="15" font="1">control w/ </text>
<text top="427" left="238" width="41" height="15" font="1">digoxin  </text>
<text top="381" left="325" width="169" height="15" font="1">N/A 18 </text>
<text top="381" left="428" width="9" height="15" font="1">y </text>
<text top="396" left="413" width="102" height="15" font="1">AF or atrial flutter w/ </text>
<text top="412" left="413" width="114" height="15" font="1">ventricular rates ≥ 120 </text>
<text top="427" left="413" width="27" height="15" font="1">BPM </text>
<text top="381" left="541" width="94" height="15" font="1">NYHA class III, IV, </text>
<text top="396" left="541" width="87" height="15" font="1">HF, surgery, AMI </text>
<text top="381" left="663" width="62" height="15" font="1">The median </text>
<text top="396" left="663" width="36" height="15" font="1">time to </text>
<text top="412" left="663" width="54" height="15" font="1">ventricular </text>
<text top="427" left="663" width="58" height="15" font="1">rate control </text>
<text top="443" left="663" width="61" height="15" font="1">(i.e., resting </text>
<text top="458" left="663" width="54" height="15" font="1">ventricular </text>
<text top="474" left="663" width="50" height="15" font="1">rate &lt;100 </text>
<text top="489" left="663" width="28" height="15" font="1">bpm, </text>
<text top="505" left="663" width="60" height="15" font="1">decrease in </text>
<text top="520" left="663" width="54" height="15" font="1">ventricular </text>
<text top="535" left="663" width="69" height="15" font="1">rate of &gt;20%, </text>
<text top="551" left="663" width="42" height="15" font="1">or sinus </text>
<text top="567" left="663" width="63" height="15" font="1">rhythm) was </text>
<text top="582" left="663" width="59" height="15" font="1">11.6 h from </text>
<text top="597" left="663" width="66" height="15" font="1">the first dose </text>
<text top="613" left="663" width="66" height="15" font="1">of digoxin for </text>
<text top="628" left="663" width="65" height="15" font="1">all evaluable </text>
<text top="644" left="663" width="65" height="15" font="1">pts (n = 105) </text>
<text top="659" left="663" width="65" height="15" font="1">and 9.5 h for </text>
<text top="675" left="663" width="54" height="15" font="1">those only </text>
<text top="690" left="663" width="47" height="15" font="1">receiving </text>
<text top="706" left="663" width="61" height="15" font="1">digoxin (n = </text>
<text top="721" left="663" width="58" height="15" font="1">64). Before </text>
<text top="737" left="663" width="54" height="15" font="1">ventricular </text>
<text top="752" left="663" width="61" height="15" font="1">rate control, </text>
<text top="768" left="663" width="49" height="15" font="1">the mean </text>
<text top="783" left="663" width="65" height="15" font="1">±SD dose of </text>
<text top="381" left="751" width="22" height="15" font="1">N/A </text>
<text top="381" left="845" width="22" height="15" font="1">N/A </text>
<text top="381" left="926" width="22" height="15" font="1">N/A </text>
<text top="381" left="1063" width="71" height="15" font="1">Observational </text>
<text top="396" left="1063" width="30" height="15" font="1">study </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">81 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="38" height="15" font="1">digoxin </text>
<text top="70" left="663" width="66" height="15" font="1">administered </text>
<text top="86" left="663" width="23" height="15" font="1">was </text>
<text top="101" left="663" width="53" height="15" font="1">0.80±0.74 </text>
<text top="117" left="663" width="52" height="15" font="1">mg, and a </text>
<text top="132" left="663" width="43" height="15" font="1">mean of </text>
<text top="147" left="663" width="41" height="15" font="1">1.4±1.8 </text>
<text top="163" left="663" width="72" height="15" font="1">serum digoxin </text>
<text top="178" left="663" width="66" height="15" font="1">concentration</text>
<text top="194" left="663" width="36" height="15" font="1">s were </text>
<text top="210" left="663" width="60" height="15" font="1">ordered per </text>
<text top="225" left="663" width="15" height="15" font="1">pt. </text>
<text top="241" left="54" width="37" height="15" font="1">Tucker </text>
<text top="257" left="54" width="16" height="15" font="1">KJ </text>
<text top="272" left="54" width="28" height="15" font="1">1993 </text>
<text top="288" left="54" width="29" height="15" font="1">(187) </text>
<text top="303" left="54" width="43" height="15" font="8">8343321</text>
<text top="303" left="97" width="3" height="15" font="1"> </text>
<text top="319" left="54" width="28" height="15" font="17"><i>Pace </i></text>
<text top="334" left="54" width="42" height="15" font="17"><i>terminati</i></text>
<text top="350" left="54" width="15" height="15" font="17"><i>on </i></text>
<text top="365" left="54" width="3" height="15" font="1"> </text>
<text top="241" left="116" width="44" height="15" font="1">Prospect</text>
<text top="257" left="116" width="17" height="15" font="1">ive </text>
<text top="272" left="116" width="40" height="15" font="1">randomi</text>
<text top="288" left="116" width="21" height="15" font="1">zed </text>
<text top="303" left="116" width="36" height="15" font="1">clinical </text>
<text top="319" left="116" width="24" height="15" font="1">trial: </text>
<text top="334" left="116" width="42" height="15" font="1">Compari</text>
<text top="350" left="116" width="33" height="15" font="1">son of </text>
<text top="365" left="116" width="33" height="15" font="1">safety </text>
<text top="381" left="116" width="21" height="15" font="1">and </text>
<text top="396" left="116" width="41" height="15" font="1">efficacy </text>
<text top="412" left="116" width="12" height="15" font="1">of </text>
<text top="427" left="116" width="42" height="15" font="1">transeso</text>
<text top="443" left="116" width="42" height="15" font="1">phageal </text>
<text top="458" left="116" width="27" height="15" font="1">atrial </text>
<text top="474" left="116" width="36" height="15" font="1">pacing </text>
<text top="489" left="116" width="36" height="15" font="1">vs. DC </text>
<text top="505" left="116" width="42" height="15" font="1">cardiove</text>
<text top="520" left="116" width="39" height="15" font="1">rsion in </text>
<text top="535" left="116" width="33" height="15" font="1">pts on </text>
<text top="551" left="116" width="41" height="15" font="1">medical </text>
<text top="567" left="116" width="43" height="15" font="1">therapy. </text>
<text top="582" left="116" width="3" height="15" font="1"> </text>
<text top="241" left="177" width="15" height="15" font="1">21 </text>
<text top="257" left="177" width="38" height="15" font="1">consec </text>
<text top="272" left="177" width="18" height="15" font="1">pts </text>
<text top="241" left="238" width="63" height="15" font="1">Group A- 11 </text>
<text top="257" left="238" width="69" height="15" font="1">pts treated w/ </text>
<text top="272" left="238" width="25" height="15" font="1">TAP </text>
<text top="288" left="238" width="3" height="15" font="1"> </text>
<text top="241" left="325" width="63" height="15" font="1">Group B- 10 </text>
<text top="257" left="325" width="69" height="15" font="1">pts treated w/ </text>
<text top="272" left="325" width="19" height="15" font="1">DC </text>
<text top="288" left="325" width="69" height="15" font="1">cardioversion </text>
<text top="241" left="413" width="96" height="15" font="1">Consecutive pts w/ </text>
<text top="257" left="413" width="31" height="15" font="1">flutter </text>
<text top="272" left="413" width="68" height="15" font="1">- HD stable.   </text>
<text top="288" left="413" width="106" height="15" font="1">- Had failed 1A or 1C </text>
<text top="303" left="413" width="113" height="15" font="1">antiarrhythmic therapy </text>
<text top="319" left="413" width="82" height="15" font="1">-All pts received </text>
<text top="334" left="413" width="106" height="15" font="1">digoxin to control HR </text>
<text top="350" left="413" width="67" height="15" font="1">to &lt;100 BPM </text>
<text top="365" left="413" width="3" height="15" font="1"> </text>
<text top="241" left="541" width="22" height="15" font="1">N/A </text>
<text top="241" left="663" width="74" height="15" font="1">NSR achieved </text>
<text top="257" left="663" width="74" height="15" font="1">w/ intervention </text>
<text top="272" left="663" width="73" height="15" font="1">Group A- 8/11 </text>
<text top="288" left="663" width="42" height="15" font="1">TAP pts </text>
<text top="303" left="663" width="73" height="15" font="1">Group B- 9/10 </text>
<text top="319" left="663" width="19" height="15" font="1">DC </text>
<text top="334" left="663" width="69" height="15" font="1">cardioversion </text>
<text top="350" left="663" width="18" height="15" font="1">pts </text>
<text top="365" left="663" width="41" height="15" font="1">P= 0.31 </text>
<text top="381" left="663" width="3" height="15" font="1"> </text>
<text top="241" left="751" width="71" height="15" font="1">Nonsustained </text>
<text top="257" left="751" width="68" height="15" font="1">VT was more </text>
<text top="272" left="751" width="74" height="15" font="1">frequent in DC </text>
<text top="288" left="751" width="72" height="15" font="1">cardioversion  </text>
<text top="303" left="751" width="73" height="15" font="1">Group A- 0/11 </text>
<text top="319" left="751" width="25" height="15" font="1">TAP </text>
<text top="334" left="751" width="69" height="15" font="1">Group B 6/10 </text>
<text top="350" left="751" width="19" height="15" font="1">DC </text>
<text top="365" left="751" width="69" height="15" font="1">cardioversion </text>
<text top="381" left="751" width="42" height="15" font="1">P=0.02  </text>
<text top="396" left="751" width="3" height="15" font="17"><i> </i></text>
<text top="241" left="845" width="22" height="15" font="1">N/A </text>
<text top="241" left="926" width="118" height="15" font="1">P=0.31 NSR in TAP vs. </text>
<text top="257" left="926" width="88" height="15" font="1">DC cardioversion </text>
<text top="272" left="926" width="117" height="15" font="1">NSVT p= 0.02 Group A </text>
<text top="288" left="926" width="28" height="15" font="1">vs. B </text>
<text top="241" left="1063" width="60" height="15" font="1">TAP is safe </text>
<text top="257" left="1063" width="66" height="15" font="1">and effective </text>
<text top="272" left="1063" width="66" height="15" font="1">and was well </text>
<text top="288" left="1063" width="68" height="15" font="1">tolerated and </text>
<text top="303" left="1063" width="26" height="15" font="1">is as </text>
<text top="319" left="1063" width="70" height="15" font="1">efficacious as </text>
<text top="334" left="1063" width="19" height="15" font="1">DC </text>
<text top="350" left="1063" width="69" height="15" font="1">cardioversion </text>
<text top="598" left="54" width="43" height="15" font="1">Ellenbog</text>
<text top="614" left="54" width="33" height="15" font="1">en KA </text>
<text top="629" left="54" width="34" height="15" font="1">1995   </text>
<text top="645" left="54" width="29" height="15" font="1">(188) </text>
<text top="660" left="54" width="43" height="15" font="8">7801862</text>
<text top="660" left="97" width="3" height="15" font="1"> </text>
<text top="598" left="116" width="16" height="15" font="1">To </text>
<text top="614" left="116" width="42" height="15" font="1">demonst</text>
<text top="629" left="116" width="44" height="15" font="1">rate the  </text>
<text top="645" left="116" width="41" height="15" font="1">efficacy </text>
<text top="660" left="116" width="12" height="15" font="1">of </text>
<text top="676" left="116" width="39" height="15" font="1">various </text>
<text top="691" left="116" width="45" height="15" font="1">doses of </text>
<text top="707" left="116" width="14" height="15" font="1">IV </text>
<text top="722" left="116" width="47" height="15" font="1">diltiazem </text>
<text top="738" left="116" width="44" height="15" font="1">for heart </text>
<text top="753" left="116" width="22" height="15" font="1">rate </text>
<text top="769" left="116" width="36" height="15" font="1">control </text>
<text top="598" left="177" width="30" height="15" font="1">Open </text>
<text top="614" left="177" width="29" height="15" font="1">label, </text>
<text top="629" left="177" width="27" height="15" font="1">dose </text>
<text top="645" left="177" width="39" height="15" font="1">titration </text>
<text top="660" left="177" width="33" height="15" font="1">study. </text>
<text top="676" left="177" width="47" height="15" font="1">84 pts w/ </text>
<text top="691" left="177" width="47" height="15" font="1">AF, atrial </text>
<text top="707" left="177" width="47" height="15" font="1">flutter, or </text>
<text top="722" left="177" width="25" height="15" font="1">both </text>
<text top="598" left="238" width="70" height="15" font="1">Bolus dose of </text>
<text top="614" left="238" width="47" height="15" font="1">diltiazem </text>
<text top="629" left="238" width="59" height="15" font="1">followed by </text>
<text top="645" left="238" width="57" height="15" font="1">continuous </text>
<text top="660" left="238" width="55" height="15" font="1">infusion w/ </text>
<text top="676" left="238" width="67" height="15" font="1">monitoring of </text>
<text top="691" left="238" width="72" height="15" font="1">heart rate and </text>
<text top="707" left="238" width="18" height="15" font="1">BP </text>
<text top="598" left="325" width="22" height="15" font="1">N/A </text>
<text top="598" left="413" width="109" height="15" font="1">84 consecutive pts w/ </text>
<text top="614" left="413" width="104" height="15" font="1">AF or flutter, or both, </text>
<text top="629" left="413" width="103" height="15" font="1">received an IV bolus </text>
<text top="645" left="413" width="86" height="15" font="1">dose of diltiazem </text>
<text top="660" left="413" width="68" height="15" font="1">followed by a </text>
<text top="676" left="413" width="110" height="15" font="1">continuous infusion of </text>
<text top="691" left="413" width="111" height="15" font="1">diltiazem at 5, 10, and </text>
<text top="707" left="413" width="46" height="15" font="1">15 mg/h. </text>
<text top="598" left="541" width="85" height="15" font="1">&gt;18 y, women of </text>
<text top="614" left="541" width="91" height="15" font="1">child-bearing age, </text>
<text top="629" left="541" width="34" height="15" font="1">SSS, 3</text>
<text top="630" left="576" width="7" height="10" font="10">rd</text>
<text top="629" left="582" width="59" height="15" font="1"> degree AV </text>
<text top="645" left="541" width="66" height="15" font="1">block, WPW, </text>
<text top="660" left="541" width="87" height="15" font="1">hypotensive SBP </text>
<text top="676" left="541" width="102" height="15" font="1">&lt;90 mm Hg, allergic </text>
<text top="691" left="541" width="65" height="15" font="1">to diltiazem.  </text>
<text top="598" left="663" width="74" height="15" font="1">94% of pts (79 </text>
<text top="614" left="663" width="31" height="15" font="1">of 84) </text>
<text top="629" left="663" width="68" height="15" font="1">responded to </text>
<text top="645" left="663" width="48" height="15" font="1">the bolus </text>
<text top="660" left="663" width="50" height="15" font="1">dose w/ a </text>
<text top="676" left="663" width="32" height="15" font="1">&gt;20% </text>
<text top="691" left="663" width="60" height="15" font="1">reduction in </text>
<text top="707" left="663" width="44" height="15" font="1">HR from </text>
<text top="722" left="663" width="57" height="15" font="1">baseline, a </text>
<text top="738" left="663" width="69" height="15" font="1">conversion to </text>
<text top="753" left="663" width="69" height="15" font="1">sinus rhythm, </text>
<text top="769" left="663" width="73" height="15" font="1">or a heart rate </text>
<text top="784" left="663" width="71" height="15" font="1">&lt;100 bpm. 78 </text>
<text top="598" left="751" width="58" height="15" font="1">Statistically </text>
<text top="614" left="751" width="52" height="15" font="1">significant </text>
<text top="629" left="751" width="69" height="15" font="1">change in BP </text>
<text top="645" left="751" width="81" height="15" font="1">before and after </text>
<text top="660" left="751" width="63" height="15" font="1">20 mg bolus </text>
<text top="676" left="751" width="78" height="15" font="1">during infusion. </text>
<text top="691" left="751" width="70" height="15" font="1">NS difference </text>
<text top="707" left="751" width="58" height="15" font="1">in BP, after </text>
<text top="722" left="751" width="78" height="15" font="1">infustion at h 0, </text>
<text top="738" left="751" width="71" height="15" font="1">1, 2, 4, 8, and </text>
<text top="753" left="751" width="22" height="15" font="1">10.  </text>
<text top="598" left="845" width="22" height="15" font="1">N/A </text>
<text top="598" left="926" width="116" height="15" font="1">Continuous infusion 10 </text>
<text top="614" left="926" width="107" height="15" font="1">h response at 5 mg/h </text>
<text top="629" left="926" width="115" height="15" font="1">(95% CI for 5 mg/h: 36-</text>
<text top="645" left="926" width="89" height="15" font="1">59; 95% CI for 10 </text>
<text top="660" left="926" width="79" height="15" font="1">mg/hr: 57-79%) </text>
<text top="598" left="1063" width="71" height="15" font="1">IV diltiazem is </text>
<text top="614" left="1063" width="45" height="15" font="1">safe and </text>
<text top="629" left="1063" width="57" height="15" font="1">effective at </text>
<text top="645" left="1063" width="68" height="15" font="1">slowing heart </text>
<text top="660" left="1063" width="64" height="15" font="1">rate in AF or </text>
<text top="676" left="1063" width="37" height="15" font="1">flutter.  </text>
<text top="691" left="1063" width="3" height="15" font="1"> </text>
<text top="707" left="1063" width="53" height="15" font="1">Treatment </text>
<text top="722" left="1063" width="37" height="15" font="1">related </text>
<text top="738" left="1063" width="65" height="15" font="1">symptomatic </text>
<text top="753" left="1063" width="63" height="15" font="1">hypotension </text>
<text top="769" left="1063" width="62" height="15" font="1">(3.5-13% w/ </text>
<text top="784" left="1063" width="66" height="15" font="1">hypotension) </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">82 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="63" height="15" font="1">pts received </text>
<text top="70" left="663" width="18" height="15" font="1">the </text>
<text top="86" left="663" width="57" height="15" font="1">continuous </text>
<text top="101" left="663" width="71" height="15" font="1">infusion. After </text>
<text top="117" left="663" width="37" height="15" font="1">10 h of </text>
<text top="132" left="663" width="70" height="15" font="1">infusion, 47% </text>
<text top="147" left="663" width="52" height="15" font="1">of pts had </text>
<text top="163" left="663" width="57" height="15" font="1">maintained </text>
<text top="178" left="663" width="63" height="15" font="1">response w/ </text>
<text top="194" left="663" width="55" height="15" font="1">the 5 mg/h </text>
<text top="210" left="663" width="70" height="15" font="1">infusion, 68% </text>
<text top="225" left="663" width="57" height="15" font="1">maintained </text>
<text top="240" left="663" width="74" height="15" font="1">response after </text>
<text top="256" left="663" width="60" height="15" font="1">the infusion </text>
<text top="271" left="663" width="72" height="15" font="1">was titrated to </text>
<text top="287" left="663" width="68" height="15" font="1">10 mg/h, and </text>
<text top="302" left="663" width="51" height="15" font="1">76% after </text>
<text top="318" left="663" width="65" height="15" font="1">titration from </text>
<text top="333" left="663" width="65" height="15" font="1">the 5 and 10 </text>
<text top="349" left="663" width="69" height="15" font="1">mg/h infusion </text>
<text top="364" left="663" width="74" height="15" font="1">to the 15 mg/h </text>
<text top="380" left="663" width="68" height="15" font="1">dose. For the </text>
<text top="395" left="663" width="56" height="15" font="1">3 diltiazem </text>
<text top="411" left="663" width="47" height="15" font="1">infusions </text>
<text top="426" left="663" width="73" height="15" font="1">studied, mean </text>
<text top="442" left="663" width="61" height="15" font="1">(±SD) heart </text>
<text top="457" left="663" width="45" height="15" font="1">rate was </text>
<text top="473" left="663" width="68" height="15" font="1">reduced from </text>
<text top="488" left="663" width="53" height="15" font="1">a baseline </text>
<text top="504" left="663" width="42" height="15" font="1">value of </text>
<text top="519" left="663" width="66" height="15" font="1">144±14 bpm </text>
<text top="535" left="663" width="50" height="15" font="1">to 98±19, </text>
<text top="550" left="663" width="44" height="15" font="1">107±25, </text>
<text top="566" left="663" width="44" height="15" font="1">107±22, </text>
<text top="581" left="663" width="44" height="15" font="1">101±22, </text>
<text top="597" left="663" width="60" height="15" font="1">91±17, and </text>
<text top="612" left="663" width="72" height="15" font="1">88±18 bpm at </text>
<text top="628" left="663" width="71" height="15" font="1">infusion times </text>
<text top="643" left="663" width="61" height="15" font="1">0, 1, 2, 4, 8, </text>
<text top="659" left="663" width="49" height="15" font="1">and 10 h, </text>
<text top="674" left="663" width="65" height="15" font="1">respectively. </text>
<text top="690" left="663" width="68" height="15" font="1">By the end of </text>
<text top="705" left="663" width="63" height="15" font="1">the infusion, </text>
<text top="721" left="663" width="74" height="15" font="1">18% of pts (14 </text>
<text top="736" left="663" width="53" height="15" font="1">of 78) had </text>
<text top="752" left="663" width="69" height="15" font="1">conversion to </text>
<text top="767" left="663" width="66" height="15" font="1">sinus rhythm </text>
<text top="55" left="1063" width="50" height="15" font="1">was most </text>
<text top="70" left="1063" width="52" height="15" font="1">common.  </text>
<text top="783" left="54" width="41" height="15" font="1">Hou ZY </text>
<text top="783" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="783" left="177" width="15" height="15" font="1">51 </text>
<text top="783" left="238" width="53" height="15" font="1">Randomly </text>
<text top="783" left="325" width="63" height="15" font="1">Amiodarone </text>
<text top="783" left="413" width="112" height="15" font="1">Potentially useful for a </text>
<text top="783" left="541" width="72" height="15" font="1">Recent-onset, </text>
<text top="783" left="663" width="52" height="15" font="1">Heart rate </text>
<text top="783" left="751" width="62" height="15" font="1">amiodarone </text>
<text top="783" left="845" width="22" height="15" font="1">N/A </text>
<text top="783" left="926" width="106" height="15" font="1">Amiodarone reduced </text>
<text top="783" left="1063" width="73" height="15" font="1">Demonstrated </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">83 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="28" height="15" font="1">1995 </text>
<text top="70" left="54" width="29" height="15" font="1">(189) </text>
<text top="86" left="54" width="43" height="15" font="8">7671898</text>
<text top="86" left="97" width="3" height="15" font="1"> </text>
<text top="55" left="116" width="38" height="15" font="1">rsion w </text>
<text top="70" left="116" width="33" height="15" font="1">meds: </text>
<text top="86" left="116" width="44" height="15" font="1">Randomi</text>
<text top="101" left="116" width="24" height="15" font="1">zed, </text>
<text top="117" left="116" width="28" height="15" font="1">open </text>
<text top="132" left="116" width="29" height="15" font="1">label, </text>
<text top="147" left="116" width="39" height="15" font="1">digoxin-</text>
<text top="163" left="116" width="42" height="15" font="1">controlle</text>
<text top="178" left="116" width="39" height="15" font="1">d study </text>
<text top="194" left="116" width="12" height="15" font="1">to </text>
<text top="210" left="116" width="42" height="15" font="1">observe </text>
<text top="225" left="116" width="41" height="15" font="1">efficacy </text>
<text top="240" left="116" width="21" height="15" font="1">and </text>
<text top="256" left="116" width="45" height="15" font="1">safety of </text>
<text top="271" left="116" width="36" height="15" font="1">dosing </text>
<text top="287" left="116" width="43" height="15" font="1">regimen </text>
<text top="302" left="116" width="12" height="15" font="1">of </text>
<text top="318" left="116" width="40" height="15" font="1">amiodar</text>
<text top="333" left="116" width="33" height="15" font="1">one in </text>
<text top="349" left="116" width="34" height="15" font="1">recent-</text>
<text top="364" left="116" width="33" height="15" font="1">onset, </text>
<text top="380" left="116" width="39" height="15" font="1">persiste</text>
<text top="395" left="116" width="29" height="15" font="1">nt AF </text>
<text top="411" left="116" width="21" height="15" font="1">and </text>
<text top="426" left="116" width="27" height="15" font="1">atrial </text>
<text top="442" left="116" width="45" height="15" font="1">flutter w/ </text>
<text top="457" left="116" width="41" height="15" font="1">ventircul</text>
<text top="473" left="116" width="41" height="15" font="1">ar rates </text>
<text top="488" left="116" width="28" height="15" font="1">&gt;130 </text>
<text top="504" left="116" width="30" height="15" font="1">BPM. </text>
<text top="55" left="238" width="60" height="15" font="1">assigned to </text>
<text top="70" left="238" width="44" height="15" font="1">either IV </text>
<text top="86" left="238" width="61" height="15" font="1">amiodarone </text>
<text top="101" left="238" width="48" height="15" font="1">(n=26) or </text>
<text top="117" left="238" width="74" height="15" font="1">digoxin (n=24) </text>
<text top="132" left="238" width="63" height="15" font="1">Amiodarone </text>
<text top="147" left="238" width="63" height="15" font="1">infused over </text>
<text top="163" left="238" width="25" height="15" font="1">24 h </text>
<text top="178" left="238" width="61" height="15" font="1">(decreasing </text>
<text top="194" left="238" width="46" height="15" font="1">doses/h) </text>
<text top="210" left="238" width="40" height="15" font="1">Digoxin </text>
<text top="225" left="238" width="45" height="15" font="1">inf/used- </text>
<text top="240" left="238" width="64" height="15" font="1">0.013 mg/kg </text>
<text top="256" left="238" width="59" height="15" font="1">in 3 divided </text>
<text top="271" left="238" width="33" height="15" font="1">doses </text>
<text top="55" left="325" width="55" height="15" font="1">vs. digoxin </text>
<text top="55" left="413" width="86" height="15" font="1">recommendation </text>
<text top="55" left="541" width="93" height="15" font="1">persistent, AF and </text>
<text top="70" left="541" width="99" height="15" font="1">flutter w/ ventricular </text>
<text top="86" left="541" width="82" height="15" font="1">rates above 130 </text>
<text top="101" left="541" width="33" height="15" font="1">beats.<i> </i></text>
<text top="55" left="663" width="70" height="15" font="1">control: Mean </text>
<text top="70" left="663" width="31" height="15" font="1">HR in </text>
<text top="86" left="663" width="61" height="15" font="1">amiodarone </text>
<text top="101" left="663" width="31" height="15" font="1">group </text>
<text top="117" left="663" width="55" height="15" font="1">decreased </text>
<text top="132" left="663" width="72" height="15" font="1">from 157 + 20 </text>
<text top="147" left="663" width="56" height="15" font="1">to 122+ 25 </text>
<text top="163" left="663" width="61" height="15" font="1">BPM in 1 hr </text>
<text top="178" left="663" width="66" height="15" font="1">(p&lt;0.05) and </text>
<text top="194" left="663" width="35" height="15" font="1">further </text>
<text top="209" left="663" width="61" height="15" font="1">stabilized to </text>
<text top="225" left="663" width="62" height="15" font="1">96±25 BPM </text>
<text top="240" left="663" width="44" height="15" font="1">after 6 h </text>
<text top="256" left="663" width="48" height="15" font="1">(p&lt;0.05). </text>
<text top="271" left="663" width="53" height="15" font="1">Fewer HR </text>
<text top="287" left="663" width="66" height="15" font="1">reductions in </text>
<text top="302" left="663" width="70" height="15" font="1">digoxin group </text>
<text top="318" left="663" width="45" height="15" font="1">(p&lt;0.05) </text>
<text top="333" left="663" width="3" height="15" font="1"> </text>
<text top="55" left="751" width="64" height="15" font="1">infusion was </text>
<text top="70" left="751" width="61" height="15" font="1">prematurely </text>
<text top="86" left="751" width="73" height="15" font="1">aborted in two </text>
<text top="101" left="751" width="52" height="15" font="1">pts due to </text>
<text top="117" left="751" width="36" height="15" font="1">severe </text>
<text top="132" left="751" width="61" height="15" font="1">bradycardia </text>
<text top="147" left="751" width="78" height="15" font="1">and death after </text>
<text top="163" left="751" width="68" height="15" font="1">conversion in </text>
<text top="178" left="751" width="55" height="15" font="1">one pt and </text>
<text top="194" left="751" width="73" height="15" font="1">aggravation of </text>
<text top="210" left="751" width="76" height="15" font="1">HF in the other </text>
<text top="55" left="926" width="108" height="15" font="1">HR significantly more </text>
<text top="70" left="926" width="115" height="15" font="1">than digoxin at 1 and 6 </text>
<text top="86" left="926" width="99" height="15" font="1">h (p&lt;0.05 both time </text>
<text top="101" left="926" width="41" height="15" font="1">frames) </text>
<text top="55" left="1063" width="69" height="15" font="1">HR control w/ </text>
<text top="70" left="1063" width="65" height="15" font="1">amiodarone. </text>
<text top="520" left="54" width="46" height="15" font="1">Sung RJ </text>
<text top="535" left="54" width="28" height="15" font="1">1995 </text>
<text top="551" left="54" width="29" height="15" font="1">(190) </text>
<text top="567" left="54" width="43" height="15" font="8">7900626</text>
<text top="567" left="97" width="3" height="15" font="1"> </text>
<text top="582" left="54" width="3" height="15" font="1"> </text>
<text top="520" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="535" left="116" width="38" height="15" font="1">rsion w </text>
<text top="551" left="116" width="30" height="15" font="1">meds </text>
<text top="567" left="116" width="44" height="15" font="1">Multicent</text>
<text top="582" left="116" width="16" height="15" font="1">er, </text>
<text top="597" left="116" width="40" height="15" font="1">randomi</text>
<text top="613" left="116" width="24" height="15" font="1">zed, </text>
<text top="628" left="116" width="37" height="15" font="1">double-</text>
<text top="644" left="116" width="29" height="15" font="1">blind, </text>
<text top="659" left="116" width="42" height="15" font="1">placebo </text>
<text top="675" left="116" width="42" height="15" font="1">controlle</text>
<text top="690" left="116" width="45" height="15" font="1">d study:  </text>
<text top="706" left="116" width="43" height="15" font="1">Placebo </text>
<text top="721" left="116" width="17" height="15" font="1">vs. </text>
<text top="737" left="116" width="35" height="15" font="1">sotalol<i> </i></text>
<text top="520" left="177" width="130" height="15" font="1">93 Two </text>
<text top="520" left="261" width="85" height="15" font="1">phased </text>
<text top="535" left="238" width="33" height="15" font="1">study: </text>
<text top="551" left="238" width="47" height="15" font="1">Phase 1: </text>
<text top="567" left="238" width="61" height="15" font="1">randomized </text>
<text top="582" left="238" width="42" height="15" font="1">placebo </text>
<text top="597" left="238" width="58" height="15" font="1">infusion vs. </text>
<text top="613" left="238" width="50" height="15" font="1">1.0 or 1.5 </text>
<text top="628" left="238" width="47" height="15" font="1">mg/kg IV </text>
<text top="644" left="238" width="57" height="15" font="1">sotalol. (30 </text>
<text top="659" left="238" width="21" height="15" font="1">min </text>
<text top="675" left="238" width="64" height="15" font="1">observation) </text>
<text top="690" left="238" width="74" height="15" font="1">Phase 2: if not </text>
<text top="706" left="238" width="73" height="15" font="1">converted or if </text>
<text top="721" left="238" width="67" height="15" font="1">HR not fall to </text>
<text top="737" left="238" width="50" height="15" font="1">&lt;100, 1.5 </text>
<text top="752" left="238" width="68" height="15" font="1">mg/kg sotalol </text>
<text top="768" left="238" width="30" height="15" font="1">given </text>
<text top="520" left="325" width="44" height="15" font="1">Phase 1 </text>
<text top="535" left="325" width="52" height="15" font="1">sotalol vs. </text>
<text top="551" left="325" width="42" height="15" font="1">placebo </text>
<text top="567" left="325" width="3" height="15" font="1"> </text>
<text top="582" left="325" width="59" height="15" font="1">Phase 2 no </text>
<text top="597" left="325" width="59" height="15" font="1">comparetor </text>
<text top="520" left="413" width="81" height="15" font="1">Spontaneous or </text>
<text top="535" left="413" width="115" height="15" font="1">induced SVT (n=45) or </text>
<text top="551" left="413" width="108" height="15" font="1">atrial flutter/fibrillation </text>
<text top="567" left="413" width="35" height="15" font="1">(n=48) </text>
<text top="520" left="541" width="22" height="15" font="1">N/A </text>
<text top="520" left="663" width="67" height="15" font="1">SVT phase 1 </text>
<text top="535" left="663" width="69" height="15" font="1">conversion to </text>
<text top="551" left="663" width="51" height="15" font="1">NSR 2/14 </text>
<text top="567" left="663" width="47" height="15" font="1">(14%) w/ </text>
<text top="582" left="663" width="42" height="15" font="1">placebo </text>
<text top="597" left="663" width="67" height="15" font="1">SVT phase 1 </text>
<text top="613" left="663" width="69" height="15" font="1">conversion to </text>
<text top="628" left="663" width="57" height="15" font="1">NSR 10/15 </text>
<text top="644" left="663" width="68" height="15" font="1">(67%) sotalol </text>
<text top="659" left="663" width="52" height="15" font="1">1.0 mh/kg </text>
<text top="675" left="663" width="58" height="15" font="1">(p&lt;0.05 vs. </text>
<text top="690" left="663" width="46" height="15" font="1">placebo) </text>
<text top="706" left="663" width="67" height="15" font="1">SVT phase 1 </text>
<text top="721" left="663" width="69" height="15" font="1">conversion to </text>
<text top="737" left="663" width="57" height="15" font="1">NSR 10/15 </text>
<text top="752" left="663" width="68" height="15" font="1">(67%) sotalol </text>
<text top="768" left="663" width="52" height="15" font="1">1.5 mg/kg </text>
<text top="783" left="663" width="58" height="15" font="1">(p&lt;0.05 vs. </text>
<text top="520" left="751" width="22" height="15" font="1">N/A </text>
<text top="520" left="845" width="22" height="15" font="1">N/A </text>
<text top="520" left="926" width="106" height="15" font="1">Phase 1 SVT sotalol  </text>
<text top="535" left="926" width="92" height="15" font="1">1.0 mg/kg and 1.5 </text>
<text top="551" left="926" width="95" height="15" font="1">mg/kg vs. placebo, </text>
<text top="567" left="926" width="119" height="15" font="1">sotalol superior (p&lt;0.05 </text>
<text top="582" left="926" width="74" height="15" font="1">for each dose) </text>
<text top="597" left="926" width="96" height="15" font="1">Phase 1 sotalol vs. </text>
<text top="613" left="926" width="111" height="15" font="1">placebo conversion of </text>
<text top="628" left="926" width="109" height="15" font="1">AF 1.0 mg/kg and 1.5 </text>
<text top="644" left="926" width="95" height="15" font="1">mg kg not different </text>
<text top="659" left="926" width="112" height="15" font="1">(p=NS for both doses) </text>
<text top="675" left="926" width="3" height="15" font="17"><i> </i></text>
<text top="520" left="1063" width="60" height="15" font="1">Sotalol was </text>
<text top="535" left="1063" width="57" height="15" font="1">effective at </text>
<text top="551" left="1063" width="58" height="15" font="1">terminating </text>
<text top="567" left="1063" width="61" height="15" font="1">SVT but not </text>
<text top="582" left="1063" width="17" height="15" font="1">AF </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">84 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="46" height="15" font="1">placebo) </text>
<text top="70" left="663" width="52" height="15" font="1">SVT open </text>
<text top="86" left="663" width="51" height="15" font="1">label 7/17 </text>
<text top="101" left="663" width="33" height="15" font="1">(41%) </text>
<text top="117" left="663" width="69" height="15" font="1">conversion to </text>
<text top="132" left="663" width="59" height="15" font="1">NSR w/ 1.5 </text>
<text top="147" left="663" width="68" height="15" font="1">mg/kg sotalol </text>
<text top="163" left="663" width="60" height="15" font="1">AF phase 1 </text>
<text top="178" left="663" width="69" height="15" font="1">conversion to </text>
<text top="194" left="663" width="51" height="15" font="1">NSR 2/14 </text>
<text top="210" left="663" width="47" height="15" font="1">(14%) w/ </text>
<text top="225" left="663" width="42" height="15" font="1">placebo </text>
<text top="240" left="663" width="63" height="15" font="1">AF phase 1- </text>
<text top="256" left="663" width="57" height="15" font="1">2/11 (11%) </text>
<text top="271" left="663" width="69" height="15" font="1">conversion to </text>
<text top="287" left="663" width="59" height="15" font="1">NSR w/ 1.0 </text>
<text top="302" left="663" width="68" height="15" font="1">mg/kg sotalol </text>
<text top="318" left="663" width="52" height="15" font="1">(p=NS vs. </text>
<text top="333" left="663" width="46" height="15" font="1">placebo) </text>
<text top="349" left="663" width="63" height="15" font="1">AF phase 1- </text>
<text top="364" left="663" width="69" height="15" font="1">2/16 (13%) to </text>
<text top="380" left="663" width="45" height="15" font="1">NSR 1.5 </text>
<text top="395" left="663" width="68" height="15" font="1">mg/kg sotalol </text>
<text top="411" left="663" width="52" height="15" font="1">(p=NS vs. </text>
<text top="426" left="663" width="46" height="15" font="1">placebo) </text>
<text top="443" left="54" width="36" height="15" font="1">Doni F </text>
<text top="458" left="54" width="28" height="15" font="1">1996 </text>
<text top="474" left="54" width="29" height="15" font="1">(191) </text>
<text top="489" left="54" width="43" height="15" font="8">8945077</text>
<text top="489" left="97" width="3" height="15" font="1"> </text>
<text top="505" left="54" width="3" height="15" font="1"> </text>
<text top="443" left="116" width="28" height="15" font="1">Pace </text>
<text top="458" left="116" width="42" height="15" font="1">terminati</text>
<text top="474" left="116" width="15" height="15" font="1">on </text>
<text top="489" left="116" width="44" height="15" font="1">(randomi</text>
<text top="505" left="116" width="28" height="15" font="1">zed): </text>
<text top="520" left="116" width="42" height="15" font="1">Compari</text>
<text top="535" left="116" width="33" height="15" font="1">son of </text>
<text top="551" left="116" width="36" height="15" font="1">TAP in </text>
<text top="567" left="116" width="37" height="15" font="1">Type 2 </text>
<text top="582" left="116" width="27" height="15" font="1">atrial </text>
<text top="597" left="116" width="45" height="15" font="1">flutter w/ </text>
<text top="613" left="116" width="33" height="15" font="1">or w/o </text>
<text top="628" left="116" width="44" height="15" font="1">propafen</text>
<text top="644" left="116" width="22" height="15" font="1">one </text>
<text top="659" left="116" width="3" height="15" font="1"> </text>
<text top="443" left="177" width="47" height="15" font="1">12 pts w/ </text>
<text top="458" left="177" width="33" height="15" font="1">type 2 </text>
<text top="474" left="177" width="27" height="15" font="1">atrial </text>
<text top="489" left="177" width="31" height="15" font="1">flutter </text>
<text top="443" left="238" width="71" height="15" font="1">12 pts w/ type </text>
<text top="458" left="238" width="40" height="15" font="1">2 flutter </text>
<text top="474" left="238" width="73" height="15" font="1">randomized to </text>
<text top="489" left="238" width="49" height="15" font="1">2 groups: </text>
<text top="505" left="238" width="73" height="15" font="1">Group A- TAP </text>
<text top="520" left="238" width="61" height="15" font="1">on no meds </text>
<text top="535" left="238" width="3" height="15" font="1"> </text>
<text top="443" left="325" width="73" height="15" font="1">Group B- TAP </text>
<text top="458" left="325" width="44" height="15" font="1">2 h after </text>
<text top="474" left="325" width="65" height="15" font="1">propafenone </text>
<text top="489" left="325" width="40" height="15" font="1">600 mg </text>
<text top="443" left="413" width="89" height="15" font="1">Mean age = 59 y. </text>
<text top="458" left="413" width="94" height="15" font="1">Symptomatic atrial </text>
<text top="474" left="413" width="87" height="15" font="1">flutter, all pts had </text>
<text top="489" left="413" width="101" height="15" font="1">negative P waves in </text>
<text top="505" left="413" width="108" height="15" font="1">leads II, III, and aVF.  </text>
<text top="443" left="541" width="22" height="15" font="1">N/A </text>
<text top="443" left="663" width="74" height="15" font="1">NSR achieved </text>
<text top="458" left="663" width="15" height="15" font="1">in  </text>
<text top="474" left="663" width="63" height="15" font="1">Group A-0/6 </text>
<text top="489" left="663" width="53" height="15" font="1">(no meds) </text>
<text top="505" left="663" width="66" height="15" font="1">Group B- 4/6 </text>
<text top="520" left="663" width="40" height="15" font="1">on PPF </text>
<text top="535" left="663" width="3" height="15" font="1"> </text>
<text top="443" left="751" width="55" height="15" font="1">Flutter CL: </text>
<text top="458" left="751" width="65" height="15" font="1">propafenone </text>
<text top="474" left="751" width="68" height="15" font="1">slowed flutter </text>
<text top="489" left="751" width="73" height="15" font="1">cycle: 219±33 </text>
<text top="505" left="751" width="52" height="15" font="1">vs. 168±8 </text>
<text top="520" left="751" width="70" height="15" font="1">msec, p&lt;0.05 </text>
<text top="443" left="845" width="22" height="15" font="1">N/A </text>
<text top="443" left="926" width="100" height="15" font="1">NSR in Group A vs. </text>
<text top="458" left="926" width="93" height="15" font="1">Group B (P&lt;0.05). </text>
<text top="474" left="926" width="90" height="15" font="1">Flutter cycle legth </text>
<text top="489" left="926" width="98" height="15" font="1">propafenone vs. no </text>
<text top="505" left="926" width="71" height="15" font="1">meds, p&lt;0.05 </text>
<text top="443" left="1063" width="66" height="15" font="1">Propafenone </text>
<text top="458" left="1063" width="50" height="15" font="1">facilitated </text>
<text top="474" left="1063" width="27" height="15" font="1">pace </text>
<text top="489" left="1063" width="69" height="15" font="1">termination in </text>
<text top="505" left="1063" width="60" height="15" font="1">those pts in </text>
<text top="520" left="1063" width="42" height="15" font="1">whom a </text>
<text top="535" left="1063" width="52" height="15" font="1">slowing of </text>
<text top="551" left="1063" width="48" height="15" font="1">flutter CL </text>
<text top="567" left="1063" width="65" height="15" font="1">occurred but </text>
<text top="582" left="1063" width="60" height="15" font="1">not in those </text>
<text top="597" left="1063" width="72" height="15" font="1">w/ unchanged </text>
<text top="613" left="1063" width="58" height="15" font="1">atrial flutter </text>
<text top="628" left="1063" width="17" height="15" font="1">CL </text>
<text top="676" left="54" width="43" height="15" font="1">Ellenbog</text>
<text top="691" left="54" width="33" height="15" font="1">en KA </text>
<text top="707" left="54" width="28" height="15" font="1">1996 </text>
<text top="722" left="54" width="29" height="15" font="1">(192) </text>
<text top="738" left="54" width="43" height="15" font="8">8752805</text>
<text top="738" left="97" width="3" height="15" font="1"> </text>
<text top="753" left="54" width="3" height="15" font="1"> </text>
<text top="676" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="691" left="116" width="38" height="15" font="1">rsion w </text>
<text top="707" left="116" width="33" height="15" font="1">meds: </text>
<text top="722" left="116" width="44" height="15" font="1">Randomi</text>
<text top="738" left="116" width="33" height="15" font="1">zed to </text>
<text top="753" left="116" width="45" height="15" font="1">single IV </text>
<text top="769" left="116" width="27" height="15" font="1">dose </text>
<text top="784" left="116" width="42" height="15" font="1">Efficacy </text>
<text top="676" left="177" width="39" height="15" font="1">200 pts </text>
<text top="691" left="177" width="30" height="15" font="1">AF or </text>
<text top="707" left="177" width="27" height="15" font="1">atrial </text>
<text top="722" left="177" width="31" height="15" font="1">flutter </text>
<text top="738" left="177" width="43" height="15" font="1">3H-90 d </text>
<text top="676" left="238" width="19" height="15" font="1">Pts </text>
<text top="691" left="238" width="73" height="15" font="1">randomized to </text>
<text top="707" left="238" width="72" height="15" font="1">single IV dose </text>
<text top="722" left="238" width="59" height="15" font="1">vs. placebo </text>
<text top="738" left="238" width="21" height="15" font="1">159 </text>
<text top="753" left="238" width="76" height="15" font="1">randomized to  </text>
<text top="769" left="238" width="41" height="15" font="1">ibutilde: </text>
<text top="784" left="238" width="58" height="15" font="1">41 at 0.005 </text>
<text top="676" left="325" width="15" height="15" font="1">41 </text>
<text top="691" left="325" width="73" height="15" font="1">randomized to </text>
<text top="707" left="325" width="42" height="15" font="1">placebo </text>
<text top="676" left="413" width="109" height="15" font="1">AF or A flutter 3 h- 90 </text>
<text top="691" left="413" width="9" height="15" font="1">d </text>
<text top="676" left="541" width="105" height="15" font="1">Childbearing age, MI </text>
<text top="691" left="541" width="99" height="15" font="1">&lt;3 m, class I and III </text>
<text top="707" left="541" width="78" height="15" font="1">antiarrhythmics </text>
<text top="722" left="541" width="90" height="15" font="1">discontinued for 5 </text>
<text top="738" left="541" width="94" height="15" font="1">half lives, AF &gt;3 d, </text>
<text top="753" left="541" width="83" height="15" font="1">anticoags &gt;2 wk </text>
<text top="769" left="541" width="75" height="15" font="1">before ibutilide </text>
<text top="676" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="691" left="663" width="73" height="15" font="1">NSR during or </text>
<text top="707" left="663" width="71" height="15" font="1">w/in 60 min of </text>
<text top="722" left="663" width="44" height="15" font="1">infusion: </text>
<text top="738" left="663" width="25" height="15" font="1">24% </text>
<text top="753" left="663" width="69" height="15" font="1">conversion to </text>
<text top="769" left="663" width="63" height="15" font="1">NSR in drug </text>
<text top="784" left="663" width="69" height="15" font="1">treated group </text>
<text top="676" left="751" width="81" height="15" font="1">Polymorphic VT </text>
<text top="691" left="751" width="58" height="15" font="1">occurred in </text>
<text top="707" left="751" width="28" height="15" font="1">3.6% </text>
<text top="676" left="845" width="22" height="15" font="1">N/A </text>
<text top="676" left="926" width="95" height="15" font="1">Placebo and 0.005 </text>
<text top="691" left="926" width="105" height="15" font="1">mg/kg ibutilide vs. all </text>
<text top="707" left="926" width="95" height="15" font="1">other groups lower </text>
<text top="722" left="926" width="91" height="15" font="1">success (p&lt;0.05). </text>
<text top="738" left="926" width="86" height="15" font="1">No other statistic </text>
<text top="676" left="1063" width="62" height="15" font="1">Ibutilide can </text>
<text top="691" left="1063" width="36" height="15" font="1">rapidly </text>
<text top="707" left="1063" width="66" height="15" font="1">terminate AF </text>
<text top="722" left="1063" width="52" height="15" font="1">and flutter </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">85 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="26" height="15" font="1">of IV </text>
<text top="70" left="116" width="41" height="15" font="1">ibutilide </text>
<text top="86" left="116" width="17" height="15" font="1">vs. </text>
<text top="101" left="116" width="42" height="15" font="1">placebo </text>
<text top="117" left="116" width="46" height="15" font="1">for AF or </text>
<text top="132" left="116" width="37" height="15" font="1">flutter –</text>
<text top="147" left="116" width="27" height="15" font="1">dose </text>
<text top="163" left="116" width="39" height="15" font="1">respons</text>
<text top="178" left="116" width="45" height="15" font="1">e study.  </text>
<text top="55" left="238" width="33" height="15" font="1">mg/kg </text>
<text top="70" left="238" width="52" height="15" font="1">40 at 0.10 </text>
<text top="86" left="238" width="33" height="15" font="1">mg/kg </text>
<text top="101" left="238" width="58" height="15" font="1">38 at 0.015 </text>
<text top="117" left="238" width="33" height="15" font="1">mg/kg </text>
<text top="132" left="238" width="58" height="15" font="1">40 at 0.025 </text>
<text top="147" left="238" width="33" height="15" font="1">mg/kg </text>
<text top="55" left="663" width="48" height="15" font="1">vs. 3% in </text>
<text top="70" left="663" width="48" height="15" font="1">placebo.  </text>
<text top="86" left="663" width="59" height="15" font="1">Conversion </text>
<text top="101" left="663" width="40" height="15" font="1">rates at </text>
<text top="117" left="663" width="57" height="15" font="1">successive </text>
<text top="132" left="663" width="64" height="15" font="1">doses: 12%, </text>
<text top="147" left="663" width="57" height="15" font="1">33%, 45%, </text>
<text top="163" left="663" width="32" height="15" font="1">46%.  </text>
<text top="178" left="663" width="3" height="15" font="1"> </text>
<text top="195" left="54" width="47" height="15" font="1">Stambler </text>
<text top="210" left="54" width="18" height="15" font="1">BS </text>
<text top="226" left="54" width="28" height="15" font="1">1996 </text>
<text top="241" left="54" width="29" height="15" font="1">(193) </text>
<text top="257" left="54" width="43" height="15" font="8">8840852</text>
<text top="257" left="97" width="3" height="15" font="1"> </text>
<text top="272" left="54" width="3" height="15" font="1"> </text>
<text top="195" left="116" width="44" height="15" font="1">Multicent</text>
<text top="210" left="116" width="42" height="15" font="1">er study </text>
<text top="226" left="116" width="41" height="15" font="1">. Safety </text>
<text top="241" left="116" width="21" height="15" font="1">and </text>
<text top="257" left="116" width="41" height="15" font="1">efficacy </text>
<text top="272" left="116" width="30" height="15" font="1">study </text>
<text top="288" left="116" width="41" height="15" font="1">Varying </text>
<text top="303" left="116" width="45" height="15" font="1">doses of </text>
<text top="319" left="116" width="41" height="15" font="1">ibutilide </text>
<text top="195" left="177" width="22" height="15" font="1">226 </text>
<text top="210" left="177" width="39" height="15" font="1">133 AF </text>
<text top="226" left="177" width="21" height="15" font="1">133 </text>
<text top="241" left="177" width="27" height="15" font="1">atrial </text>
<text top="257" left="177" width="31" height="15" font="1">flutter </text>
<text top="195" left="238" width="65" height="15" font="1">Randomized </text>
<text top="210" left="238" width="65" height="15" font="1">to up to 2 10-</text>
<text top="226" left="238" width="54" height="15" font="1">min doses </text>
<text top="241" left="238" width="41" height="15" font="1">Ibutilide </text>
<text top="257" left="238" width="67" height="15" font="1">separated by </text>
<text top="272" left="238" width="39" height="15" font="1">10 min. </text>
<text top="288" left="238" width="41" height="15" font="1">Ibutilide </text>
<text top="303" left="238" width="58" height="15" font="1">doses= 1.0 </text>
<text top="319" left="238" width="71" height="15" font="1">and 0.5 mg or </text>
<text top="334" left="238" width="59" height="15" font="1">1.0 and 1.0 </text>
<text top="350" left="238" width="28" height="15" font="1">mg.   </text>
<text top="195" left="325" width="47" height="15" font="1">This was </text>
<text top="210" left="325" width="65" height="15" font="1">compared to </text>
<text top="226" left="325" width="45" height="15" font="1">placebo. </text>
<text top="195" left="413" width="100" height="15" font="1">AF and atrial flutter. </text>
<text top="210" left="413" width="115" height="15" font="1">Arrhythmia of 3 h to 45 </text>
<text top="226" left="413" width="52" height="15" font="1">d duration </text>
<text top="195" left="541" width="99" height="15" font="1">Pt could not be &lt;18 </text>
<text top="210" left="541" width="92" height="15" font="1">y, weight &gt;300lbs, </text>
<text top="226" left="541" width="89" height="15" font="1">h/o of torsade, on </text>
<text top="241" left="541" width="97" height="15" font="1">ibutilide previously, </text>
<text top="257" left="541" width="97" height="15" font="1">MI, cardiac surgery </text>
<text top="272" left="541" width="99" height="15" font="1">&lt;30 d, have digoxin </text>
<text top="288" left="541" width="40" height="15" font="1">toxicity, </text>
<text top="303" left="541" width="103" height="15" font="1">hyperthyroidism, not </text>
<text top="319" left="541" width="50" height="15" font="1">on class I </text>
<text top="195" left="663" width="59" height="15" font="1">Conversion </text>
<text top="210" left="663" width="58" height="15" font="1">rates were: </text>
<text top="226" left="663" width="39" height="15" font="1">47% w/ </text>
<text top="241" left="663" width="58" height="15" font="1">ibutilide vs. </text>
<text top="257" left="663" width="33" height="15" font="1">2% w/ </text>
<text top="272" left="663" width="42" height="15" font="1">placebo </text>
<text top="288" left="663" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="303" left="663" width="53" height="15" font="1">Efficacy in </text>
<text top="319" left="663" width="57" height="15" font="1">flutter &gt;AF: </text>
<text top="334" left="663" width="71" height="15" font="1">63% vs. 31%, </text>
<text top="350" left="663" width="43" height="15" font="1">p&lt;0.001 </text>
<text top="365" left="663" width="70" height="15" font="1">In AF (but not </text>
<text top="381" left="663" width="34" height="15" font="1">flutter) </text>
<text top="396" left="663" width="57" height="15" font="1">conversion </text>
<text top="412" left="663" width="73" height="15" font="1">rates higher in </text>
<text top="427" left="663" width="44" height="15" font="1">those w/ </text>
<text top="443" left="663" width="37" height="15" font="1">shorter </text>
<text top="458" left="663" width="43" height="15" font="1">duration </text>
<text top="474" left="663" width="55" height="15" font="1">arrhythmia </text>
<text top="489" left="663" width="72" height="15" font="1">The 2 ibutilide </text>
<text top="505" left="663" width="36" height="15" font="1">dosing </text>
<text top="520" left="663" width="66" height="15" font="1">regimens did </text>
<text top="535" left="663" width="58" height="15" font="1">not differ in </text>
<text top="551" left="663" width="57" height="15" font="1">conversion </text>
<text top="567" left="663" width="69" height="15" font="1">efficacy (44% </text>
<text top="582" left="663" width="49" height="15" font="1">vs. 49%). </text>
<text top="195" left="751" width="81" height="15" font="1">Polymorphic VT </text>
<text top="210" left="751" width="81" height="15" font="1">in 8.3% (15 pts) </text>
<text top="226" left="751" width="57" height="15" font="1">(3 required </text>
<text top="241" left="751" width="72" height="15" font="1">cardioversion, </text>
<text top="257" left="751" width="55" height="15" font="1">12 did not) </text>
<text top="195" left="845" width="22" height="15" font="1">N/A </text>
<text top="195" left="926" width="100" height="15" font="1">Ibutilide vs. placebo </text>
<text top="210" left="926" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="226" left="926" width="122" height="15" font="1">Efficacy in flutter vs. AF: </text>
<text top="241" left="926" width="51" height="15" font="1">(p&lt;0.001) </text>
<text top="257" left="926" width="81" height="15" font="1">No difference in </text>
<text top="272" left="926" width="112" height="15" font="1">conversion at different </text>
<text top="288" left="926" width="71" height="15" font="1">doses (p=NS) </text>
<text top="303" left="926" width="3" height="15" font="1"> </text>
<text top="195" left="1063" width="53" height="15" font="1">Ibutilide in </text>
<text top="210" left="1063" width="47" height="15" font="1">repeated </text>
<text top="226" left="1063" width="44" height="15" font="1">doses is </text>
<text top="241" left="1063" width="56" height="15" font="1">effective in </text>
<text top="257" left="1063" width="58" height="15" font="1">terminating </text>
<text top="272" left="1063" width="69" height="15" font="1">AF and flutter </text>
<text top="598" left="54" width="47" height="15" font="1">Volgman </text>
<text top="614" left="54" width="18" height="15" font="1">AS </text>
<text top="629" left="54" width="28" height="15" font="1">1998 </text>
<text top="645" left="54" width="29" height="15" font="1">(194) </text>
<text top="660" left="54" width="43" height="15" font="8">9581743</text>
<text top="660" left="97" width="3" height="15" font="1"> </text>
<text top="676" left="54" width="3" height="15" font="1"> </text>
<text top="598" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="614" left="116" width="38" height="15" font="1">rsion w </text>
<text top="629" left="116" width="33" height="15" font="1">meds: </text>
<text top="645" left="116" width="44" height="15" font="1">Multicent</text>
<text top="660" left="116" width="46" height="15" font="1">er study- </text>
<text top="676" left="116" width="46" height="15" font="1">compare </text>
<text top="691" left="116" width="41" height="15" font="1">efficacy </text>
<text top="707" left="116" width="21" height="15" font="1">and </text>
<text top="722" left="116" width="45" height="15" font="1">safety of </text>
<text top="738" left="116" width="41" height="15" font="1">ibutilide </text>
<text top="753" left="116" width="17" height="15" font="1">vs. </text>
<text top="769" left="116" width="42" height="15" font="1">procaina</text>
<text top="784" left="116" width="43" height="15" font="1">mide for </text>
<text top="598" left="177" width="159" height="15" font="1">127 Conversion </text>
<text top="598" left="297" width="52" height="15" font="1">to </text>
<text top="614" left="238" width="30" height="15" font="1">NSR: </text>
<text top="629" left="238" width="73" height="15" font="1">randomized to </text>
<text top="645" left="238" width="55" height="15" font="1">either 2 10 </text>
<text top="660" left="238" width="68" height="15" font="1">min infusions </text>
<text top="676" left="238" width="40" height="15" font="1">of 1 mg </text>
<text top="691" left="238" width="41" height="15" font="1">ibutilide </text>
<text top="707" left="238" width="67" height="15" font="1">separated by </text>
<text top="722" left="238" width="63" height="15" font="1">10 min vs. 3 </text>
<text top="738" left="238" width="72" height="15" font="1">successive 10 </text>
<text top="753" left="238" width="39" height="15" font="1">mg- /IV </text>
<text top="769" left="238" width="59" height="15" font="1">infusions of </text>
<text top="784" left="238" width="40" height="15" font="1">400 mg </text>
<text top="598" left="325" width="62" height="15" font="1">(Ibutilide vs. </text>
<text top="614" left="325" width="73" height="15" font="1">procainamide) </text>
<text top="598" left="413" width="85" height="15" font="1">2 h to 90 d AF or </text>
<text top="614" left="413" width="31" height="15" font="1">flutter </text>
<text top="598" left="541" width="22" height="15" font="1">N/A </text>
<text top="598" left="663" width="73" height="15" font="1">120 evaluated </text>
<text top="614" left="663" width="69" height="15" font="1">for efficacy of </text>
<text top="629" left="663" width="68" height="15" font="1">conversion in </text>
<text top="645" left="663" width="31" height="15" font="1">1.5 h: </text>
<text top="660" left="663" width="63" height="15" font="1">35/60 (58%) </text>
<text top="676" left="663" width="53" height="15" font="1">ibutilide to </text>
<text top="691" left="663" width="26" height="15" font="1">NSR </text>
<text top="707" left="663" width="73" height="15" font="1">11/60 (18.3%) </text>
<text top="722" left="663" width="39" height="15" font="1">procain </text>
<text top="738" left="663" width="64" height="15" font="1">converted to </text>
<text top="753" left="663" width="26" height="15" font="1">NSR </text>
<text top="769" left="663" width="57" height="15" font="1">(p=0.0001) </text>
<text top="784" left="663" width="38" height="15" font="1">Flutter- </text>
<text top="598" left="751" width="71" height="15" font="1">PMVT- 1 pt in </text>
<text top="614" left="751" width="72" height="15" font="1">ibutilide group </text>
<text top="629" left="751" width="78" height="15" font="1">Hypotension- 7 </text>
<text top="645" left="751" width="24" height="15" font="1">pt in </text>
<text top="660" left="751" width="69" height="15" font="1">procainamide </text>
<text top="676" left="751" width="31" height="15" font="1">group </text>
<text top="598" left="845" width="22" height="15" font="1">N/A </text>
<text top="598" left="926" width="70" height="15" font="1">Ibutilide more </text>
<text top="614" left="926" width="67" height="15" font="1">successful at </text>
<text top="629" left="926" width="111" height="15" font="1">conversion n 1.5 h vs. </text>
<text top="645" left="926" width="69" height="15" font="1">procainamide </text>
<text top="660" left="926" width="57" height="15" font="1">(p&lt;0.0001) </text>
<text top="676" left="926" width="119" height="15" font="1">Flutter: ibutlide superior </text>
<text top="691" left="926" width="102" height="15" font="1">to procain (p=0.001) </text>
<text top="707" left="926" width="117" height="15" font="1">AF- ibutilide superior to </text>
<text top="722" left="926" width="86" height="15" font="1">procain (p=0.005 </text>
<text top="598" left="1063" width="64" height="15" font="1">Ibutilide was </text>
<text top="614" left="1063" width="55" height="15" font="1">superior to </text>
<text top="629" left="1063" width="69" height="15" font="1">procainamide </text>
<text top="645" left="1063" width="66" height="15" font="1">at converting </text>
<text top="660" left="1063" width="61" height="15" font="1">either AF or </text>
<text top="676" left="1063" width="27" height="15" font="1">flutt.  </text>
<text top="691" left="1063" width="65" height="15" font="1">Hypotension </text>
<text top="707" left="1063" width="71" height="15" font="1">was major AE </text>
<text top="722" left="1063" width="16" height="15" font="1">for </text>
<text top="738" left="1063" width="76" height="15" font="1">procainamide.  </text>
<text top="753" left="1063" width="73" height="15" font="1">Low incidence </text>
<text top="769" left="1063" width="51" height="15" font="1">of serious </text>
<text top="784" left="1063" width="71" height="15" font="1">proarrhythmia </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">86 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="41" height="15" font="1">conversi</text>
<text top="70" left="116" width="28" height="15" font="1">on of </text>
<text top="86" left="116" width="34" height="15" font="1">recent </text>
<text top="101" left="116" width="47" height="15" font="1">onset AF </text>
<text top="117" left="116" width="34" height="15" font="1">or flutt<i> </i></text>
<text top="55" left="238" width="69" height="15" font="1">procainamide </text>
<text top="70" left="238" width="63" height="15" font="1">120 pts eval </text>
<text top="86" left="238" width="60" height="15" font="1">for efficacy: </text>
<text top="101" left="238" width="60" height="15" font="1">60 received </text>
<text top="117" left="238" width="41" height="15" font="1">ibutilide </text>
<text top="132" left="238" width="60" height="15" font="1">60 received </text>
<text top="147" left="238" width="25" height="15" font="1">proc </text>
<text top="55" left="663" width="41" height="15" font="1">ibutilide </text>
<text top="70" left="663" width="60" height="15" font="1">significantly </text>
<text top="86" left="663" width="73" height="15" font="1">more effective </text>
<text top="101" left="663" width="64" height="15" font="1">than procain </text>
<text top="117" left="663" width="60" height="15" font="1">(76% 13/17 </text>
<text top="132" left="663" width="64" height="15" font="1">vs. 4% 3/22; </text>
<text top="147" left="663" width="46" height="15" font="1">p=0.001. </text>
<text top="163" left="663" width="61" height="15" font="1">AF- ibutilide </text>
<text top="178" left="663" width="60" height="15" font="1">significantly </text>
<text top="194" left="663" width="73" height="15" font="1">more effective </text>
<text top="210" left="663" width="64" height="15" font="1">than procain </text>
<text top="225" left="663" width="60" height="15" font="1">(51% 22/43 </text>
<text top="240" left="663" width="70" height="15" font="1">vs. 21% 8/38; </text>
<text top="256" left="663" width="46" height="15" font="1">p=0.005. </text>
<text top="55" left="1063" width="64" height="15" font="1">wth ibutilide. </text>
<text top="272" left="54" width="42" height="15" font="1">Vos MA </text>
<text top="288" left="54" width="28" height="15" font="1">1998 </text>
<text top="303" left="54" width="29" height="15" font="1">(195) </text>
<text top="319" left="54" width="43" height="15" font="8">1007808</text>
<text top="334" left="54" width="6" height="15" font="8">3</text>
<text top="334" left="60" width="3" height="15" font="1"> </text>
<text top="350" left="54" width="3" height="15" font="1"> </text>
<text top="272" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="288" left="116" width="38" height="15" font="1">rsion w </text>
<text top="303" left="116" width="33" height="15" font="1">meds: </text>
<text top="319" left="116" width="44" height="15" font="1">Randomi</text>
<text top="334" left="116" width="33" height="15" font="1">zed to </text>
<text top="350" left="116" width="39" height="15" font="1">receive </text>
<text top="365" left="116" width="43" height="15" font="1">one of 2 </text>
<text top="381" left="116" width="45" height="15" font="1">doses of </text>
<text top="396" left="116" width="38" height="15" font="1">ibutilde </text>
<text top="412" left="116" width="30" height="15" font="1">or DL </text>
<text top="427" left="116" width="38" height="15" font="1">sotalol. </text>
<text top="443" left="116" width="16" height="15" font="1">To </text>
<text top="458" left="116" width="46" height="15" font="1">compare </text>
<text top="474" left="116" width="33" height="15" font="1">safety </text>
<text top="489" left="116" width="21" height="15" font="1">and </text>
<text top="505" left="116" width="41" height="15" font="1">efficacy<i> </i></text>
<text top="272" left="177" width="43" height="15" font="1">308 pts: </text>
<text top="288" left="177" width="42" height="15" font="1">251 AF, </text>
<text top="303" left="177" width="42" height="15" font="1">57 atrial </text>
<text top="319" left="177" width="37" height="15" font="1">flutter.  </text>
<text top="272" left="238" width="32" height="15" font="1">Three </text>
<text top="288" left="238" width="50" height="15" font="1">treatment </text>
<text top="303" left="238" width="40" height="15" font="1">groups: </text>
<text top="319" left="238" width="69" height="15" font="1">99 received 1 </text>
<text top="334" left="238" width="59" height="15" font="1">mg ibutilide </text>
<text top="350" left="238" width="66" height="15" font="1">106 received </text>
<text top="365" left="238" width="68" height="15" font="1">2 mg ibutilide </text>
<text top="381" left="238" width="66" height="15" font="1">103 received </text>
<text top="396" left="238" width="69" height="15" font="1">1.5 mg/kg DL-</text>
<text top="412" left="238" width="37" height="15" font="1">Sotalol </text>
<text top="272" left="325" width="22" height="15" font="1">N/A </text>
<text top="272" left="413" width="109" height="15" font="1">AF or flutter: Duration </text>
<text top="288" left="413" width="50" height="15" font="1">3 h - 45 d </text>
<text top="272" left="541" width="108" height="15" font="1">Hyperthyroidism, UA, </text>
<text top="288" left="541" width="107" height="15" font="1">bronchospasm, MI or </text>
<text top="303" left="541" width="100" height="15" font="1">cardiac surgery &lt;30 </text>
<text top="319" left="541" width="55" height="15" font="1">ds, 2 and 3</text>
<text top="319" left="596" width="7" height="10" font="10">rd</text>
<text top="319" left="603" width="41" height="15" font="1"> degree </text>
<text top="334" left="541" width="78" height="15" font="1">AV block, BBB, </text>
<text top="350" left="541" width="90" height="15" font="1">WPW, torsade de </text>
<text top="365" left="541" width="39" height="15" font="1">pointes </text>
<text top="272" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="288" left="663" width="71" height="15" font="1">NSR w/in 1 hr </text>
<text top="303" left="663" width="65" height="15" font="1">of treatment. </text>
<text top="319" left="663" width="57" height="15" font="1">Both drugs </text>
<text top="334" left="663" width="55" height="15" font="1">were more </text>
<text top="350" left="663" width="58" height="15" font="1">effective w/ </text>
<text top="365" left="663" width="58" height="15" font="1">atrial flutter </text>
<text top="381" left="663" width="45" height="15" font="1">than fib.  </text>
<text top="396" left="663" width="64" height="15" font="1">Ibutilide was </text>
<text top="412" left="663" width="73" height="15" font="1">more effective </text>
<text top="427" left="663" width="42" height="15" font="1">than DL-</text>
<text top="443" left="663" width="35" height="15" font="1">sotalol </text>
<text top="458" left="663" width="50" height="15" font="1">achieving </text>
<text top="474" left="663" width="65" height="15" font="1">SNR in atrial </text>
<text top="489" left="663" width="71" height="15" font="1">flutter in: 70% </text>
<text top="505" left="663" width="64" height="15" font="1">and 56% vs. </text>
<text top="520" left="663" width="28" height="15" font="1">19%. </text>
<text top="535" left="663" width="53" height="15" font="1">High dose </text>
<text top="551" left="663" width="63" height="15" font="1">ibutilide was </text>
<text top="567" left="663" width="73" height="15" font="1">more effective </text>
<text top="582" left="663" width="74" height="15" font="1">than DL-Sot in </text>
<text top="597" left="663" width="63" height="15" font="1">AF (44% vs. </text>
<text top="613" left="663" width="51" height="15" font="1">11%) and </text>
<text top="628" left="663" width="71" height="15" font="1">than low dose </text>
<text top="644" left="663" width="69" height="15" font="1">ibutilide (44% </text>
<text top="659" left="663" width="45" height="15" font="1">vs. 20%, </text>
<text top="675" left="663" width="41" height="15" font="1">p&lt;0.01) </text>
<text top="272" left="751" width="62" height="15" font="1">Bradycardia </text>
<text top="288" left="751" width="57" height="15" font="1">(6.5%) and </text>
<text top="303" left="751" width="63" height="15" font="1">hypotension </text>
<text top="319" left="751" width="63" height="15" font="1">(3.7%) were </text>
<text top="334" left="751" width="74" height="15" font="1">more common </text>
<text top="350" left="751" width="73" height="15" font="1">side effects w/ </text>
<text top="365" left="751" width="71" height="15" font="1">DL-sotalol. Of </text>
<text top="381" left="751" width="69" height="15" font="1">211 pts given </text>
<text top="396" left="751" width="64" height="15" font="1">ibutilide, two </text>
<text top="412" left="751" width="59" height="15" font="1">(0.9%) who </text>
<text top="427" left="751" width="63" height="15" font="1">received the </text>
<text top="443" left="751" width="61" height="15" font="1">higher dose </text>
<text top="458" left="751" width="54" height="15" font="1">developed </text>
<text top="474" left="751" width="63" height="15" font="1">polymorphic </text>
<text top="489" left="751" width="54" height="15" font="1">VT, one of </text>
<text top="505" left="751" width="76" height="15" font="1">whom required </text>
<text top="520" left="751" width="68" height="15" font="1">direct current </text>
<text top="535" left="751" width="69" height="15" font="1">cardioversion </text>
<text top="272" left="845" width="22" height="15" font="1">N/A </text>
<text top="272" left="926" width="87" height="15" font="1">High dose I more </text>
<text top="288" left="926" width="89" height="15" font="1">effective than. DL </text>
<text top="303" left="926" width="103" height="15" font="1">Sotalol and than low </text>
<text top="319" left="926" width="107" height="15" font="1">dose I in AF (p&lt;0.01) </text>
<text top="272" left="1063" width="64" height="15" font="1">Ibutilide was </text>
<text top="288" left="1063" width="73" height="15" font="1">more effective </text>
<text top="303" left="1063" width="42" height="15" font="1">than DL </text>
<text top="319" left="1063" width="41" height="15" font="1">sotalol.  </text>
<text top="334" left="1063" width="57" height="15" font="1">Duration of </text>
<text top="350" left="1063" width="71" height="15" font="1">atrial flutter or </text>
<text top="365" left="1063" width="40" height="15" font="1">AF was </text>
<text top="381" left="1063" width="58" height="15" font="1">predictor of </text>
<text top="396" left="1063" width="46" height="15" font="1">success. </text>
<text top="691" left="54" width="37" height="15" font="1">Benditt </text>
<text top="707" left="54" width="20" height="15" font="1">DG </text>
<text top="722" left="54" width="31" height="15" font="1">1999  </text>
<text top="738" left="54" width="29" height="15" font="1">(196) </text>
<text top="753" left="54" width="43" height="15" font="8">1049643</text>
<text top="769" left="54" width="6" height="15" font="8">4</text>
<text top="769" left="60" width="3" height="15" font="1"> </text>
<text top="784" left="54" width="3" height="15" font="1"> </text>
<text top="691" left="116" width="44" height="15" font="1">Prospect</text>
<text top="707" left="116" width="44" height="15" font="1">ive dose </text>
<text top="722" left="116" width="36" height="15" font="1">finding </text>
<text top="738" left="116" width="30" height="15" font="1">study </text>
<text top="691" left="177" width="44" height="15" font="1">Randomi</text>
<text top="707" left="177" width="21" height="15" font="1">zed </text>
<text top="691" left="238" width="74" height="15" font="1">Sotalol 80 BID </text>
<text top="707" left="238" width="26" height="15" font="1">(59)  </text>
<text top="722" left="238" width="59" height="15" font="1">Sotalol 120 </text>
<text top="738" left="238" width="47" height="15" font="1">BID (63)  </text>
<text top="753" left="238" width="59" height="15" font="1">Sotalol 160 </text>
<text top="769" left="238" width="47" height="15" font="1">BID (62)  </text>
<text top="784" left="238" width="69" height="15" font="1">Placebo (69)  </text>
<text top="691" left="325" width="22" height="15" font="1">N/A </text>
<text top="691" left="413" width="92" height="15" font="1">50 pts - outpatient </text>
<text top="707" left="413" width="91" height="15" font="1">134 pts - inpatient </text>
<text top="722" left="413" width="52" height="15" font="1">SHD 57% </text>
<text top="691" left="541" width="76" height="15" font="1">H/o torsade de </text>
<text top="707" left="541" width="85" height="15" font="1">pointes, CHF, QI </text>
<text top="722" left="541" width="61" height="15" font="1">&gt;450 msec, </text>
<text top="738" left="541" width="68" height="15" font="1">hypokalemia, </text>
<text top="753" left="541" width="100" height="15" font="1">hypomagenesemia, </text>
<text top="769" left="541" width="67" height="15" font="1">bradycardia.  </text>
<text top="691" left="663" width="61" height="15" font="1">Time to first </text>
<text top="707" left="663" width="47" height="15" font="1">recurrent </text>
<text top="722" left="663" width="65" height="15" font="1">symptomatic </text>
<text top="738" left="663" width="52" height="15" font="1">AF and/or </text>
<text top="753" left="663" width="58" height="15" font="1">atrial flutter </text>
<text top="769" left="663" width="71" height="15" font="1">after reaching </text>
<text top="784" left="663" width="61" height="15" font="1">drug steady </text>
<text top="691" left="751" width="61" height="15" font="1">No cases of </text>
<text top="707" left="751" width="74" height="15" font="1">VT/VF/torsade </text>
<text top="722" left="751" width="73" height="15" font="1">QT&gt;520 ms in </text>
<text top="738" left="751" width="73" height="15" font="1">7 pts (4 in 120 </text>
<text top="753" left="751" width="71" height="15" font="1">mg BID and 3 </text>
<text top="769" left="751" width="77" height="15" font="1">in 160 mg BID) </text>
<text top="784" left="751" width="55" height="15" font="1">Premature </text>
<text top="691" left="845" width="22" height="15" font="1">N/A </text>
<text top="707" left="845" width="3" height="15" font="1"> </text>
<text top="722" left="845" width="3" height="15" font="1"> </text>
<text top="691" left="926" width="22" height="15" font="1">N/A </text>
<text top="691" left="1063" width="73" height="15" font="1">It is unrealistic </text>
<text top="707" left="1063" width="45" height="15" font="1">to define </text>
<text top="722" left="1063" width="64" height="15" font="1">efficacy in tx </text>
<text top="738" left="1063" width="51" height="15" font="1">of AF and </text>
<text top="753" left="1063" width="61" height="15" font="1">atrial flutter. </text>
<text top="769" left="1063" width="3" height="15" font="1"> </text>
<text top="784" left="1063" width="69" height="15" font="1">HF pts for AF </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="21" size="11" family="Times" color="#231f20"/>
<text top="814" left="1120" width="17" height="17" font="0">87 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="27" height="15" font="1">state </text>
<text top="70" left="663" width="50" height="15" font="1">(p=0.004, </text>
<text top="86" left="663" width="52" height="15" font="1">significant </text>
<text top="101" left="663" width="70" height="15" font="1">longer time to </text>
<text top="117" left="663" width="62" height="15" font="1">recurreance </text>
<text top="132" left="663" width="73" height="15" font="1">for sotalol 120 </text>
<text top="147" left="663" width="57" height="15" font="1">mg BID vs. </text>
<text top="163" left="663" width="46" height="15" font="1">placebo) </text>
<text top="55" left="751" width="77" height="15" font="1">discontinuation </text>
<text top="70" left="751" width="57" height="15" font="1">due to AEs </text>
<text top="86" left="751" width="79" height="15" font="1">25% inpatients, </text>
<text top="101" left="751" width="50" height="15" font="1">but 6% of </text>
<text top="117" left="751" width="57" height="15" font="1">outpatients </text>
<text top="132" left="751" width="65" height="15" font="1">(bradycardia </text>
<text top="147" left="751" width="76" height="15" font="1">predominantly) </text>
<text top="55" left="1063" width="49" height="15" font="1">and atrial </text>
<text top="70" left="1063" width="49" height="15" font="1">flutter not </text>
<text top="86" left="1063" width="54" height="15" font="1">evaluated. </text>
<text top="179" left="54" width="36" height="15" font="1">Doni F </text>
<text top="195" left="54" width="28" height="15" font="1">2000 </text>
<text top="210" left="54" width="29" height="15" font="1">(197) </text>
<text top="226" left="54" width="43" height="15" font="8">1703345</text>
<text top="241" left="54" width="12" height="15" font="8">95</text>
<text top="241" left="66" width="3" height="15" font="1"> </text>
<text top="257" left="54" width="3" height="15" font="1"> </text>
<text top="179" left="116" width="28" height="15" font="1">Pace </text>
<text top="195" left="116" width="42" height="15" font="1">terminati</text>
<text top="210" left="116" width="28" height="15" font="1">on of </text>
<text top="226" left="116" width="27" height="15" font="1">atrial </text>
<text top="241" left="116" width="31" height="15" font="1">flutter </text>
<text top="257" left="116" width="45" height="15" font="1">via trans </text>
<text top="272" left="116" width="42" height="15" font="1">esophag</text>
<text top="288" left="116" width="18" height="15" font="1">eal </text>
<text top="303" left="116" width="39" height="15" font="1">pacing. </text>
<text top="319" left="116" width="44" height="15" font="1">Randomi</text>
<text top="334" left="116" width="42" height="15" font="1">zed to 4 </text>
<text top="350" left="116" width="40" height="15" font="1">groups  </text>
<text top="179" left="177" width="18" height="15" font="1"> 80 </text>
<text top="179" left="238" width="65" height="15" font="1">Randomized </text>
<text top="195" left="238" width="62" height="15" font="1">to 4 groups: </text>
<text top="210" left="238" width="44" height="15" font="1">A) Short </text>
<text top="226" left="238" width="70" height="15" font="1">bursts (5 sec) </text>
<text top="241" left="238" width="63" height="15" font="1">atrial pacing </text>
<text top="257" left="238" width="46" height="15" font="1">w/o drug </text>
<text top="272" left="238" width="44" height="15" font="1">B) Short </text>
<text top="288" left="238" width="70" height="15" font="1">bursts (5 sec) </text>
<text top="303" left="238" width="63" height="15" font="1">atrial pacing </text>
<text top="319" left="238" width="25" height="15" font="1">after </text>
<text top="334" left="238" width="65" height="15" font="1">propafenone </text>
<text top="350" left="238" width="40" height="15" font="1">600 mg </text>
<text top="365" left="238" width="70" height="15" font="1">C) Long burst </text>
<text top="381" left="238" width="70" height="15" font="1">(30 sec) atrial </text>
<text top="396" left="238" width="56" height="15" font="1">pacing w/o </text>
<text top="412" left="238" width="25" height="15" font="1">drug </text>
<text top="427" left="238" width="70" height="15" font="1">D) Long burst </text>
<text top="443" left="238" width="70" height="15" font="1">(30 sec) atrial </text>
<text top="458" left="238" width="61" height="15" font="1">pacing after </text>
<text top="474" left="238" width="65" height="15" font="1">propafenone </text>
<text top="489" left="238" width="40" height="15" font="1">600 mg </text>
<text top="179" left="325" width="22" height="15" font="1">N/A </text>
<text top="179" left="413" width="86" height="15" font="1">Atrial flutter- new </text>
<text top="195" left="413" width="30" height="15" font="1">onset </text>
<text top="210" left="413" width="3" height="15" font="1"> </text>
<text top="179" left="541" width="22" height="15" font="1">N/A </text>
<text top="179" left="663" width="57" height="15" font="1">Successful </text>
<text top="195" left="663" width="58" height="15" font="1">flutter pace </text>
<text top="210" left="663" width="76" height="15" font="1">termination in:  </text>
<text top="226" left="663" width="28" height="15" font="1">20%  </text>
<text top="241" left="663" width="25" height="15" font="1">55% </text>
<text top="257" left="663" width="25" height="15" font="1">50% </text>
<text top="272" left="663" width="28" height="15" font="1">85%  </text>
<text top="288" left="663" width="3" height="15" font="1"> </text>
<text top="179" left="751" width="22" height="15" font="1">N/A </text>
<text top="179" left="845" width="22" height="15" font="1">N/A </text>
<text top="179" left="926" width="90" height="15" font="1">(p&lt;0.05: C vs. A)  </text>
<text top="195" left="926" width="90" height="15" font="1">(p&lt;0.05: D vs. B). </text>
<text top="210" left="926" width="115" height="15" font="1">(p&lt;0.05: B vs. A and D </text>
<text top="226" left="926" width="32" height="15" font="1">vs. C) </text>
<text top="241" left="926" width="118" height="15" font="1">No other stats provided </text>
<text top="179" left="1063" width="66" height="15" font="1">Propafenone </text>
<text top="195" left="1063" width="67" height="15" font="1">+ long bursts </text>
<text top="210" left="1063" width="39" height="15" font="1">of atrial </text>
<text top="226" left="1063" width="58" height="15" font="1">pacing was </text>
<text top="241" left="1063" width="36" height="15" font="1">best at </text>
<text top="257" left="1063" width="58" height="15" font="1">terminating </text>
<text top="272" left="1063" width="61" height="15" font="1">atrial flutter  </text>
<text top="505" left="54" width="46" height="15" font="1">Natale A </text>
<text top="521" left="54" width="28" height="15" font="1">2000 </text>
<text top="536" left="54" width="29" height="15" font="1">(198) </text>
<text top="552" left="54" width="43" height="15" font="8">1084124</text>
<text top="567" left="54" width="6" height="15" font="8">1</text>
<text top="567" left="60" width="3" height="15" font="1"> </text>
<text top="583" left="54" width="3" height="15" font="1"> </text>
<text top="505" left="116" width="44" height="15" font="21">Multicent</text>
<text top="521" left="116" width="13" height="15" font="21">er </text>
<text top="536" left="116" width="42" height="15" font="21">prospect</text>
<text top="552" left="116" width="17" height="15" font="21">ive </text>
<text top="567" left="116" width="40" height="15" font="21">randomi</text>
<text top="583" left="116" width="21" height="15" font="21">zed </text>
<text top="598" left="116" width="39" height="15" font="21">compari</text>
<text top="614" left="116" width="33" height="15" font="21">son of </text>
<text top="629" left="116" width="43" height="15" font="21">antiarrhy</text>
<text top="645" left="116" width="29" height="15" font="21">thmic </text>
<text top="660" left="116" width="40" height="15" font="21">therapy </text>
<text top="676" left="116" width="39" height="15" font="21">vs. first-</text>
<text top="691" left="116" width="38" height="15" font="21">line RF </text>
<text top="707" left="116" width="42" height="15" font="21">ablation </text>
<text top="722" left="116" width="44" height="15" font="21">in pts w/ </text>
<text top="738" left="116" width="27" height="15" font="21">atrial </text>
<text top="753" left="116" width="34" height="15" font="21">flutter. </text>
<text top="505" left="177" width="15" height="15" font="1">61 </text>
<text top="505" left="238" width="46" height="15" font="21">Group 1: </text>
<text top="505" left="284" width="18" height="15" font="1">30  </text>
<text top="521" left="238" width="73" height="15" font="1">randomized to </text>
<text top="536" left="238" width="65" height="15" font="1">drug therapy </text>
<text top="536" left="303" width="3" height="15" font="21"> </text>
<text top="505" left="325" width="61" height="15" font="1">Group 2: 31 </text>
<text top="521" left="325" width="73" height="15" font="1">randomized to </text>
<text top="536" left="325" width="25" height="15" font="1">RFA </text>
<text top="505" left="413" width="110" height="15" font="21">Inclusion: At least two </text>
<text top="521" left="413" width="113" height="15" font="21">symptomatic episodes </text>
<text top="536" left="413" width="100" height="15" font="21">of atrial flutter in the </text>
<text top="552" left="413" width="67" height="15" font="21">last four mo.  </text>
<text top="567" left="413" width="6" height="15" font="21">. </text>
<text top="505" left="541" width="89" height="15" font="21">Exclusion:1) prior </text>
<text top="521" left="541" width="105" height="15" font="21">evidence of AF (AF); </text>
<text top="536" left="541" width="92" height="15" font="21">2) the presence of </text>
<text top="552" left="541" width="97" height="15" font="21">significant left atrial </text>
<text top="567" left="541" width="94" height="15" font="21">enlargement (≥4.5 </text>
<text top="583" left="541" width="104" height="15" font="21">cm); and 3) previous </text>
<text top="598" left="541" width="64" height="15" font="21">treatment w/ </text>
<text top="614" left="541" width="73" height="15" font="21">antiarrhythmic </text>
<text top="629" left="541" width="62" height="15" font="21">medications </text>
<text top="505" left="663" width="13" height="15" font="21">1) </text>
<text top="521" left="663" width="69" height="15" font="21">Rehospitalizat</text>
<text top="536" left="663" width="21" height="15" font="21">ion: </text>
<text top="552" left="663" width="57" height="15" font="21">medication </text>
<text top="567" left="663" width="60" height="15" font="21">group- 63% </text>
<text top="583" left="663" width="65" height="15" font="21">required one </text>
<text top="598" left="663" width="41" height="15" font="21">or more </text>
<text top="614" left="663" width="68" height="15" font="21">rehospitalizati</text>
<text top="629" left="663" width="66" height="15" font="21">ons, vs. post-</text>
<text top="645" left="663" width="63" height="15" font="21">RF ablation, </text>
<text top="660" left="663" width="55" height="15" font="21">22% of pts </text>
<text top="676" left="663" width="27" height="15" font="21">were </text>
<text top="691" left="663" width="71" height="15" font="21">rehospitalized </text>
<text top="707" left="663" width="51" height="15" font="21">(p&lt;0.01).  </text>
<text top="722" left="663" width="56" height="15" font="21">2) Post RF </text>
<text top="738" left="663" width="70" height="15" font="21">ablation, 29% </text>
<text top="753" left="663" width="71" height="15" font="21">developed AF </text>
<text top="769" left="663" width="73" height="15" font="21">vs. 53% of pts </text>
<text top="784" left="663" width="47" height="15" font="21">receiving </text>
<text top="505" left="751" width="22" height="15" font="1">N/A </text>
<text top="505" left="845" width="22" height="15" font="21">N/A </text>
<text top="505" left="926" width="100" height="15" font="1">1) Rehospitalization </text>
<text top="521" left="926" width="118" height="15" font="1">more common w/ meds </text>
<text top="536" left="926" width="45" height="15" font="1">(p&lt;0.01) </text>
<text top="552" left="926" width="104" height="15" font="1">2) AF more common </text>
<text top="567" left="926" width="104" height="15" font="1">post RFA than meds </text>
<text top="583" left="926" width="45" height="15" font="1">(p&lt;0.05) </text>
<text top="598" left="926" width="115" height="15" font="1">3) Sense on well being </text>
<text top="614" left="926" width="106" height="15" font="1">improved w/ RFA but </text>
<text top="629" left="926" width="103" height="15" font="1">not meds (change in </text>
<text top="645" left="926" width="67" height="15" font="1">scoe p&lt;0.01) </text>
<text top="505" left="1063" width="60" height="15" font="1">RF ablation </text>
<text top="521" left="1063" width="45" height="15" font="1">could be </text>
<text top="536" left="1063" width="66" height="15" font="1">considered a </text>
<text top="552" left="1063" width="42" height="15" font="1">first-line </text>
<text top="567" left="1063" width="74" height="15" font="1">therapy due to </text>
<text top="583" left="1063" width="50" height="15" font="1">the better </text>
<text top="598" left="1063" width="65" height="15" font="1">success rate </text>
<text top="614" left="1063" width="73" height="15" font="1">and impact on </text>
<text top="629" left="1063" width="48" height="15" font="1">QOL, the </text>
<text top="645" left="1063" width="29" height="15" font="1">lower </text>
<text top="660" left="1063" width="70" height="15" font="1">occurrence of </text>
<text top="676" left="1063" width="57" height="15" font="1">AF and the </text>
<text top="691" left="1063" width="73" height="15" font="1">lower need for </text>
<text top="707" left="1063" width="68" height="15" font="1">rehospitalizati</text>
<text top="722" left="1063" width="46" height="15" font="1">on at f/u. </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">88 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="62" height="15" font="21">medications </text>
<text top="70" left="663" width="51" height="15" font="21">(p&lt;0.05).  </text>
<text top="86" left="663" width="60" height="15" font="21">3) Sense of </text>
<text top="101" left="663" width="52" height="15" font="21">well being </text>
<text top="117" left="663" width="41" height="15" font="21">(pre-RF </text>
<text top="132" left="663" width="59" height="15" font="21">2.0±0.3 vs. </text>
<text top="147" left="663" width="42" height="15" font="21">post-RF </text>
<text top="163" left="663" width="44" height="15" font="21">3.8±0.5, </text>
<text top="178" left="663" width="62" height="15" font="21">p&lt;0.01) and </text>
<text top="194" left="663" width="53" height="15" font="21">function in </text>
<text top="210" left="663" width="66" height="15" font="21">daily life (pre-</text>
<text top="225" left="663" width="59" height="15" font="21">RF 2.3±0.4 </text>
<text top="240" left="663" width="60" height="15" font="21">vs. post-RF </text>
<text top="256" left="663" width="44" height="15" font="21">3.6±0.6, </text>
<text top="271" left="663" width="41" height="15" font="21">p&lt;0.01) </text>
<text top="287" left="663" width="74" height="15" font="21">improved after </text>
<text top="302" left="663" width="63" height="15" font="21">ablation, but </text>
<text top="318" left="663" width="36" height="15" font="21">did not </text>
<text top="333" left="663" width="39" height="15" font="21">change </text>
<text top="349" left="663" width="72" height="15" font="21">significantly in </text>
<text top="364" left="663" width="69" height="15" font="21">pts treated w/ </text>
<text top="380" left="663" width="34" height="15" font="21">drugs. </text>
<text top="396" left="54" width="41" height="15" font="1">Delacret</text>
<text top="412" left="54" width="25" height="15" font="1">az E </text>
<text top="427" left="54" width="28" height="15" font="1">2001 </text>
<text top="443" left="54" width="29" height="15" font="1">(199) </text>
<text top="458" left="54" width="43" height="15" font="8">1134538</text>
<text top="474" left="54" width="6" height="15" font="8">2</text>
<text top="474" left="60" width="3" height="15" font="1"> </text>
<text top="489" left="54" width="3" height="15" font="1"> </text>
<text top="396" left="116" width="46" height="15" font="1">Ablation: </text>
<text top="412" left="116" width="34" height="15" font="1">Single </text>
<text top="427" left="116" width="37" height="15" font="1">center, </text>
<text top="443" left="116" width="22" height="15" font="1">non-</text>
<text top="458" left="116" width="40" height="15" font="1">randomi</text>
<text top="474" left="116" width="42" height="15" font="1">zed trial </text>
<text top="489" left="116" width="39" height="15" font="1">compari</text>
<text top="505" left="116" width="15" height="15" font="1">ng </text>
<text top="520" left="116" width="42" height="15" font="1">ablation </text>
<text top="535" left="116" width="39" height="15" font="1">of multi </text>
<text top="551" left="116" width="28" height="15" font="1">IART </text>
<text top="567" left="116" width="38" height="15" font="1">circuits </text>
<text top="582" left="116" width="44" height="15" font="1">in adults </text>
<text top="597" left="116" width="41" height="15" font="1">w/ CHD </text>
<text top="613" left="116" width="36" height="15" font="1">guided </text>
<text top="628" left="116" width="15" height="15" font="1">by </text>
<text top="644" left="116" width="43" height="15" font="1">entrainm</text>
<text top="659" left="116" width="18" height="15" font="1">ent </text>
<text top="675" left="116" width="45" height="15" font="1">mapping </text>
<text top="690" left="116" width="36" height="15" font="1">w/ and </text>
<text top="706" left="116" width="37" height="15" font="1">w/o 3D </text>
<text top="721" left="116" width="39" height="15" font="1">electroa</text>
<text top="737" left="116" width="43" height="15" font="1">nanatom</text>
<text top="752" left="116" width="11" height="15" font="1">ic </text>
<text top="768" left="116" width="46" height="15" font="1">mapping </text>
<text top="396" left="177" width="33" height="15" font="1">20 pts </text>
<text top="412" left="177" width="19" height="15" font="1">(47 </text>
<text top="427" left="177" width="41" height="15" font="1">circuits) </text>
<text top="396" left="238" width="65" height="15" font="1">To define an </text>
<text top="412" left="238" width="65" height="15" font="1">approach for </text>
<text top="427" left="238" width="67" height="15" font="1">mapping and </text>
<text top="443" left="238" width="45" height="15" font="1">ablation, </text>
<text top="458" left="238" width="53" height="15" font="1">combining </text>
<text top="474" left="238" width="49" height="15" font="1">anatomy, </text>
<text top="489" left="238" width="50" height="15" font="1">activation </text>
<text top="505" left="238" width="51" height="15" font="1">sequence </text>
<text top="520" left="238" width="46" height="15" font="1">data and </text>
<text top="535" left="238" width="62" height="15" font="1">entrainment </text>
<text top="551" left="238" width="52" height="15" font="1">mapping.  </text>
<text top="567" left="238" width="54" height="15" font="1">a) 7 pts w/ </text>
<text top="582" left="238" width="42" height="15" font="1">ablation </text>
<text top="597" left="238" width="51" height="15" font="1">guided by </text>
<text top="613" left="238" width="62" height="15" font="1">entrainment </text>
<text top="628" left="238" width="69" height="15" font="1">mapping only </text>
<text top="644" left="238" width="3" height="15" font="1"> </text>
<text top="396" left="325" width="57" height="15" font="1">b)13 pts w/ </text>
<text top="412" left="325" width="42" height="15" font="1">ablation </text>
<text top="427" left="325" width="51" height="15" font="1">guided by </text>
<text top="443" left="325" width="62" height="15" font="1">entrainment </text>
<text top="458" left="325" width="39" height="15" font="1">and 3D </text>
<text top="474" left="325" width="70" height="15" font="1">electroanatom</text>
<text top="489" left="325" width="57" height="15" font="1">ic mapping </text>
<text top="396" left="413" width="22" height="15" font="1">N/A </text>
<text top="396" left="541" width="80" height="15" font="1">Recurrent IART </text>
<text top="412" left="541" width="95" height="15" font="1">refractory to meds. </text>
<text top="427" left="541" width="92" height="15" font="1">Late post repair of </text>
<text top="443" left="541" width="27" height="15" font="1">CHD </text>
<text top="396" left="663" width="53" height="15" font="1">Overall 38 </text>
<text top="412" left="663" width="60" height="15" font="1">(81%) of 47 </text>
<text top="427" left="663" width="34" height="15" font="1">IARTs </text>
<text top="443" left="663" width="63" height="15" font="1">successfully </text>
<text top="458" left="663" width="70" height="15" font="1">ablated. In f/u </text>
<text top="474" left="663" width="65" height="15" font="1">ranging from </text>
<text top="489" left="663" width="47" height="15" font="1">3-46 mo: </text>
<text top="505" left="663" width="70" height="15" font="1">a)16 (80%) of </text>
<text top="520" left="663" width="33" height="15" font="1">20 pts </text>
<text top="535" left="663" width="65" height="15" font="1">remains free </text>
<text top="551" left="663" width="68" height="15" font="1">of recurrence </text>
<text top="567" left="663" width="55" height="15" font="1">b)Success </text>
<text top="582" left="663" width="71" height="15" font="1">similar in both </text>
<text top="597" left="663" width="55" height="15" font="1">groups but </text>
<text top="613" left="663" width="60" height="15" font="1">fluoroscopy </text>
<text top="628" left="663" width="24" height="15" font="1">time </text>
<text top="644" left="663" width="55" height="15" font="1">decreased </text>
<text top="659" left="663" width="72" height="15" font="1">from 60 +/- 30 </text>
<text top="675" left="663" width="53" height="15" font="1">to 24 +/- 9 </text>
<text top="690" left="663" width="74" height="15" font="1">min/procedure </text>
<text top="706" left="663" width="68" height="15" font="1">w/ addition of </text>
<text top="721" left="663" width="17" height="15" font="1">3D </text>
<text top="737" left="663" width="70" height="15" font="1">electroanatom</text>
<text top="752" left="663" width="57" height="15" font="1">ic mapping </text>
<text top="396" left="751" width="22" height="15" font="1">N/A </text>
<text top="396" left="845" width="22" height="15" font="1">N/A </text>
<text top="396" left="926" width="109" height="15" font="1">No statistical analysis </text>
<text top="396" left="1063" width="63" height="15" font="1">Entrainment </text>
<text top="412" left="1063" width="45" height="15" font="1">mapping </text>
<text top="427" left="1063" width="65" height="15" font="1">combined w/ </text>
<text top="443" left="1063" width="17" height="15" font="1">3D </text>
<text top="458" left="1063" width="70" height="15" font="1">electroanatom</text>
<text top="474" left="1063" width="57" height="15" font="1">ic mapping </text>
<text top="489" left="1063" width="34" height="15" font="1">allows </text>
<text top="505" left="1063" width="69" height="15" font="1">delineation of </text>
<text top="520" left="1063" width="58" height="15" font="1">complex re-</text>
<text top="535" left="1063" width="65" height="15" font="1">entry circuits </text>
<text top="551" left="1063" width="56" height="15" font="1">and critical </text>
<text top="567" left="1063" width="68" height="15" font="1">isthmuses as </text>
<text top="582" left="1063" width="53" height="15" font="1">targets for </text>
<text top="597" left="1063" width="49" height="15" font="1">RFA as a </text>
<text top="613" left="1063" width="59" height="15" font="1">satisfactory </text>
<text top="628" left="1063" width="50" height="15" font="1">treatment </text>
<text top="644" left="1063" width="60" height="15" font="1">modality for </text>
<text top="659" left="1063" width="71" height="15" font="1">IARTs related </text>
<text top="675" left="1063" width="42" height="15" font="1">to CHD. </text>
<text top="784" left="54" width="167" height="15" font="1">Delle To  Randomi</text>
<text top="784" left="238" width="47" height="15" font="1">IV </text>
<text top="784" left="251" width="96" height="15" font="1">diltiazem N/A </text>
<text top="784" left="413" width="87" height="15" font="1">Critically ill pts w/ </text>
<text top="784" left="541" width="22" height="15" font="1">N/A </text>
<text top="784" left="663" width="52" height="15" font="1">Sustained </text>
<text top="784" left="751" width="75" height="15" font="1">Bradycardia or </text>
<text top="784" left="845" width="65" height="15" font="1">Uncontrolled </text>
<text top="784" left="926" width="85" height="15" font="1">1° endpoint: NS  </text>
<text top="784" left="1063" width="52" height="15" font="1">The study </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">89 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="41" height="15" font="1">Karth G </text>
<text top="70" left="54" width="31" height="15" font="1">2001  </text>
<text top="86" left="54" width="29" height="15" font="1">(200) </text>
<text top="101" left="54" width="43" height="15" font="8">1139559</text>
<text top="117" left="54" width="6" height="15" font="8">1</text>
<text top="117" left="60" width="3" height="15" font="1"> </text>
<text top="55" left="116" width="46" height="15" font="1">compare </text>
<text top="70" left="116" width="18" height="15" font="1">the </text>
<text top="86" left="116" width="41" height="15" font="1">efficacy </text>
<text top="101" left="116" width="26" height="15" font="1">of IV </text>
<text top="117" left="116" width="47" height="15" font="1">diltiazem </text>
<text top="132" left="116" width="41" height="15" font="1">bolus/inf</text>
<text top="147" left="116" width="47" height="15" font="1">usion vs. </text>
<text top="163" left="116" width="14" height="15" font="1">IV </text>
<text top="178" left="116" width="40" height="15" font="1">amiodar</text>
<text top="194" left="116" width="21" height="15" font="1">one </text>
<text top="210" left="116" width="47" height="15" font="1">bolus vs. </text>
<text top="225" left="116" width="14" height="15" font="1">IV </text>
<text top="240" left="116" width="40" height="15" font="1">amiodar</text>
<text top="256" left="116" width="21" height="15" font="1">one </text>
<text top="271" left="116" width="41" height="15" font="1">bolus/inf</text>
<text top="287" left="116" width="45" height="15" font="1">usion for </text>
<text top="302" left="116" width="42" height="15" font="1">immedia</text>
<text top="318" left="116" width="38" height="15" font="1">te (4 h) </text>
<text top="333" left="116" width="47" height="15" font="1">and 24-h </text>
<text top="349" left="116" width="22" height="15" font="1">rate </text>
<text top="364" left="116" width="36" height="15" font="1">control </text>
<text top="380" left="116" width="34" height="15" font="1">during </text>
<text top="395" left="116" width="20" height="15" font="1">AF  </text>
<text top="55" left="177" width="21" height="15" font="1">zed </text>
<text top="70" left="177" width="42" height="15" font="1">prospect</text>
<text top="86" left="177" width="20" height="15" font="1">ive, </text>
<text top="101" left="177" width="42" height="15" font="1">controlle</text>
<text top="117" left="177" width="9" height="15" font="1">d </text>
<text top="55" left="238" width="71" height="15" font="1">bolus/infusion </text>
<text top="70" left="238" width="31" height="15" font="1">vs. IV </text>
<text top="86" left="238" width="61" height="15" font="1">amiodarone </text>
<text top="101" left="238" width="60" height="15" font="1">bolus vs. IV </text>
<text top="117" left="238" width="61" height="15" font="1">amiodarone </text>
<text top="132" left="238" width="74" height="15" font="1">bolus/infusion  </text>
<text top="147" left="238" width="3" height="15" font="1"> </text>
<text top="55" left="413" width="96" height="15" font="1">recent-onset AF w/ </text>
<text top="70" left="413" width="104" height="15" font="1">ventricular rate &gt;120 </text>
<text top="86" left="413" width="28" height="15" font="1">bpm  </text>
<text top="101" left="413" width="3" height="15" font="1"> </text>
<text top="55" left="663" width="50" height="15" font="1">heart rate </text>
<text top="70" left="663" width="49" height="15" font="1">reduction </text>
<text top="86" left="663" width="77" height="15" font="1">≥30% w/in 4 h  </text>
<text top="101" left="663" width="68" height="15" font="1">70% vs. 55% </text>
<text top="117" left="663" width="45" height="15" font="1">vs. 75%  </text>
<text top="55" left="751" width="66" height="15" font="1">hypotension  </text>
<text top="70" left="751" width="79" height="15" font="1">35% vs. 0% vs. </text>
<text top="86" left="751" width="22" height="15" font="1">5%  </text>
<text top="55" left="845" width="63" height="15" font="1">tachycardia  </text>
<text top="70" left="845" width="61" height="15" font="1">0% vs. 45% </text>
<text top="86" left="845" width="39" height="15" font="1">vs. 5% <i> </i></text>
<text top="55" left="926" width="63" height="15" font="1">2° endpoint  </text>
<text top="70" left="926" width="59" height="15" font="1">p&lt;0.00016  </text>
<text top="86" left="926" width="83" height="15" font="1">Safety endpoint  </text>
<text top="101" left="926" width="40" height="15" font="1">p=0.01  </text>
<text top="55" left="1063" width="69" height="15" font="1">speaks about </text>
<text top="70" left="1063" width="58" height="15" font="1">rate control </text>
<text top="86" left="1063" width="68" height="15" font="1">during recent </text>
<text top="101" left="1063" width="57" height="15" font="1">AF or atrial </text>
<text top="117" left="1063" width="72" height="15" font="1">flutter in really </text>
<text top="132" left="1063" width="43" height="15" font="1">sick pts. </text>
<text top="412" left="54" width="44" height="15" font="1">DIAMON</text>
<text top="427" left="54" width="11" height="15" font="1">D </text>
<text top="443" left="54" width="31" height="15" font="1">2001  </text>
<text top="458" left="54" width="29" height="15" font="1">(201) </text>
<text top="474" left="54" width="43" height="15" font="8">1145774</text>
<text top="489" left="54" width="9" height="15" font="8">7 </text>
<text top="489" left="63" width="6" height="15" font="1">  </text>
<text top="505" left="54" width="3" height="15" font="1"> </text>
<text top="412" left="116" width="29" height="15" font="1">RCT, </text>
<text top="427" left="116" width="37" height="15" font="1">double-</text>
<text top="443" left="116" width="30" height="15" font="1">blind  </text>
<text top="458" left="116" width="16" height="15" font="1">To </text>
<text top="474" left="116" width="45" height="15" font="1">evaluate </text>
<text top="489" left="116" width="18" height="15" font="1">the </text>
<text top="505" left="116" width="41" height="15" font="1">efficacy </text>
<text top="520" left="116" width="12" height="15" font="1">of </text>
<text top="535" left="116" width="47" height="15" font="1">dofetilide </text>
<text top="551" left="116" width="12" height="15" font="1">to </text>
<text top="567" left="116" width="45" height="15" font="1">maintain </text>
<text top="582" left="116" width="42" height="15" font="1">SR in pt </text>
<text top="597" left="116" width="31" height="15" font="1">w/ LV </text>
<text top="613" left="116" width="44" height="15" font="1">dysfuncti</text>
<text top="628" left="116" width="19" height="15" font="1">on  </text>
<text top="644" left="116" width="3" height="15" font="1"> </text>
<text top="412" left="177" width="40" height="15" font="1">506 pts </text>
<text top="412" left="238" width="71" height="15" font="1">Dofetilide 500 </text>
<text top="427" left="238" width="62" height="15" font="1">mcg/d (249) </text>
<text top="443" left="238" width="3" height="15" font="1"> </text>
<text top="412" left="325" width="72" height="15" font="1">Placebo (257) </text>
<text top="412" left="413" width="102" height="15" font="1">Inclusion: Persistent </text>
<text top="427" left="413" width="87" height="15" font="1">AF associated w/ </text>
<text top="443" left="413" width="95" height="15" font="1">either HF or recent </text>
<text top="458" left="413" width="49" height="15" font="1">acute MI  </text>
<text top="474" left="413" width="94" height="15" font="1">Dose reduction for </text>
<text top="489" left="413" width="94" height="15" font="1">renal insufficiency  </text>
<text top="505" left="413" width="108" height="15" font="1">BBB), K &lt;3.6 or &gt;5.5, </text>
<text top="520" left="413" width="89" height="15" font="1">CrCl &lt;20 mL/min  </text>
<text top="412" left="541" width="97" height="15" font="1">Exclusion: HR: &lt;50 </text>
<text top="427" left="541" width="80" height="15" font="1">bpm, QTc &gt;460 </text>
<text top="443" left="541" width="99" height="15" font="1">msec (500 msec w/ </text>
<text top="412" left="663" width="67" height="15" font="1">Probability of </text>
<text top="427" left="663" width="60" height="15" font="1">maintaining </text>
<text top="443" left="663" width="52" height="15" font="1">SR at 1 y  </text>
<text top="458" left="663" width="76" height="15" font="1">79% dofetilide  </text>
<text top="474" left="663" width="39" height="15" font="1">42% w/ </text>
<text top="489" left="663" width="45" height="15" font="1">placebo  </text>
<text top="505" left="663" width="54" height="15" font="1">(p&lt;0.001)  </text>
<text top="412" left="751" width="77" height="15" font="1">No effect on all-</text>
<text top="427" left="751" width="81" height="15" font="1">cause mortality  </text>
<text top="443" left="751" width="49" height="15" font="1">Dofetilide </text>
<text top="458" left="751" width="70" height="15" font="1">associated w/ </text>
<text top="474" left="751" width="78" height="15" font="1">reduced rate of </text>
<text top="489" left="751" width="74" height="15" font="1">rehospitalizatio</text>
<text top="505" left="751" width="12" height="15" font="1">n  </text>
<text top="412" left="845" width="22" height="15" font="1">N/A </text>
<text top="412" left="926" width="98" height="15" font="1">Torsade de pointes </text>
<text top="427" left="926" width="114" height="15" font="1">occurred in 4 dofetilide </text>
<text top="443" left="926" width="57" height="15" font="1">pts (1.6%)  </text>
<text top="458" left="926" width="3" height="15" font="1"> </text>
<text top="412" left="1063" width="64" height="15" font="1">Subjects not </text>
<text top="427" left="1063" width="60" height="15" font="1">stratified by </text>
<text top="443" left="1063" width="40" height="15" font="1">rhythm. </text>
<text top="458" left="1063" width="71" height="15" font="1">Differences in </text>
<text top="474" left="1063" width="73" height="15" font="1">population, Lft </text>
<text top="489" left="1063" width="69" height="15" font="1">atrial size, LV </text>
<text top="505" left="1063" width="43" height="15" font="1">diastolic </text>
<text top="520" left="1063" width="62" height="15" font="1">dysfunction, </text>
<text top="535" left="1063" width="71" height="15" font="1">and MR could </text>
<text top="551" left="1063" width="27" height="15" font="1">have </text>
<text top="567" left="1063" width="53" height="15" font="1">influenced </text>
<text top="582" left="1063" width="39" height="15" font="1">results. </text>
<text top="660" left="54" width="44" height="15" font="1">Gallaghe</text>
<text top="676" left="54" width="28" height="15" font="1">r MM </text>
<text top="691" left="54" width="28" height="15" font="1">2001 </text>
<text top="707" left="54" width="29" height="15" font="1">(202) </text>
<text top="722" left="54" width="43" height="15" font="8">1169153</text>
<text top="738" left="54" width="6" height="15" font="8">0</text>
<text top="738" left="60" width="3" height="15" font="1"> </text>
<text top="753" left="54" width="3" height="15" font="1"> </text>
<text top="660" left="116" width="44" height="15" font="1">Cardiove</text>
<text top="676" left="116" width="30" height="15" font="1">rsion: </text>
<text top="691" left="116" width="45" height="15" font="1">design a </text>
<text top="707" left="116" width="28" height="15" font="1">more </text>
<text top="722" left="116" width="41" height="15" font="1">efficient </text>
<text top="738" left="116" width="42" height="15" font="1">protocol </text>
<text top="753" left="116" width="34" height="15" font="1">for the </text>
<text top="769" left="116" width="47" height="15" font="1">electrical </text>
<text top="784" left="116" width="42" height="15" font="1">cardiove</text>
<text top="660" left="177" width="28" height="15" font="1">1838 </text>
<text top="676" left="177" width="45" height="15" font="1">attempts </text>
<text top="691" left="177" width="12" height="15" font="1">at </text>
<text top="707" left="177" width="42" height="15" font="1">cardiove</text>
<text top="722" left="177" width="39" height="15" font="1">rsion of </text>
<text top="738" left="177" width="39" height="15" font="1">AF and </text>
<text top="753" left="177" width="21" height="15" font="1">678 </text>
<text top="769" left="177" width="45" height="15" font="1">attempts </text>
<text top="784" left="177" width="12" height="15" font="1">at </text>
<text top="660" left="238" width="67" height="15" font="1">Analyzed the </text>
<text top="676" left="238" width="48" height="15" font="1">effects of </text>
<text top="691" left="238" width="43" height="15" font="1">different </text>
<text top="707" left="238" width="37" height="15" font="1">energy </text>
<text top="722" left="238" width="62" height="15" font="1">deliveries at </text>
<text top="738" left="238" width="58" height="15" font="1">terminating </text>
<text top="753" left="238" width="61" height="15" font="1">either AF or </text>
<text top="769" left="238" width="70" height="15" font="1">atrial flutter in </text>
<text top="784" left="238" width="32" height="15" font="1">pts w/ </text>
<text top="660" left="325" width="22" height="15" font="1">N/A </text>
<text top="660" left="413" width="88" height="15" font="1">AF or atrial flutter </text>
<text top="676" left="413" width="77" height="15" font="1">undergoing DC </text>
<text top="691" left="413" width="69" height="15" font="1">cardioversion </text>
<text top="660" left="541" width="22" height="15" font="1">N/A </text>
<text top="660" left="663" width="59" height="15" font="1">Conversion </text>
<text top="676" left="663" width="58" height="15" font="1">rates were: </text>
<text top="691" left="663" width="73" height="15" font="1">a) AF of &gt;30 d </text>
<text top="707" left="663" width="53" height="15" font="1">duration = </text>
<text top="722" left="663" width="69" height="15" font="1">5.5% at &lt;200 </text>
<text top="738" left="663" width="71" height="15" font="1">J; 35% at 200 </text>
<text top="753" left="663" width="68" height="15" font="1">J and 56% at </text>
<text top="769" left="663" width="36" height="15" font="1">360 J.  </text>
<text top="784" left="663" width="40" height="15" font="1">b) atrial </text>
<text top="660" left="751" width="22" height="15" font="1">N/A </text>
<text top="660" left="845" width="22" height="15" font="1">N/A </text>
<text top="660" left="926" width="105" height="15" font="1">For AF &gt;180 d, initial </text>
<text top="676" left="926" width="105" height="15" font="1">use of a 360 J shock </text>
<text top="691" left="926" width="111" height="15" font="1">was associated w/ the </text>
<text top="707" left="926" width="101" height="15" font="1">eventual use of less </text>
<text top="722" left="926" width="122" height="15" font="1">electrical energy than w/ </text>
<text top="738" left="926" width="117" height="15" font="1">an initial shock of ≤100 </text>
<text top="753" left="926" width="86" height="15" font="1">J (581±316 J vs. </text>
<text top="769" left="926" width="99" height="15" font="1">758±433 J, p&lt;0.01, </text>
<text top="784" left="926" width="113" height="15" font="1">Mann-Whitney U test). </text>
<text top="660" left="1063" width="45" height="15" font="1">An initial </text>
<text top="676" left="1063" width="73" height="15" font="1">energy setting </text>
<text top="691" left="1063" width="71" height="15" font="1">of ≥360 J can </text>
<text top="707" left="1063" width="41" height="15" font="1">achieve </text>
<text top="722" left="1063" width="69" height="15" font="1">cardioversion </text>
<text top="738" left="1063" width="58" height="15" font="1">of AF more </text>
<text top="753" left="1063" width="61" height="15" font="1">efficiently in </text>
<text top="769" left="1063" width="42" height="15" font="1">pts than </text>
<text top="784" left="1063" width="51" height="15" font="1">traditional </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">90 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="39" height="15" font="1">rsion of </text>
<text top="70" left="116" width="27" height="15" font="1">atrial </text>
<text top="86" left="116" width="44" height="15" font="1">arrhythm</text>
<text top="101" left="116" width="17" height="15" font="1">ias </text>
<text top="55" left="177" width="42" height="15" font="1">cardiove</text>
<text top="70" left="177" width="42" height="15" font="1">rsion of  </text>
<text top="86" left="177" width="31" height="15" font="1">flutter </text>
<text top="55" left="238" width="73" height="15" font="1">arrhythmias of </text>
<text top="70" left="238" width="39" height="15" font="1">varying </text>
<text top="86" left="238" width="46" height="15" font="1">duration. </text>
<text top="55" left="663" width="62" height="15" font="1">flutter= 68% </text>
<text top="70" left="663" width="46" height="15" font="1">at 100 J  </text>
<text top="86" left="663" width="73" height="15" font="1">c) AF of &gt;30 d </text>
<text top="101" left="663" width="46" height="15" font="1">duration, </text>
<text top="117" left="663" width="50" height="15" font="1">shocks of </text>
<text top="132" left="663" width="78" height="15" font="1">&lt;200 J = 6.1%  </text>
<text top="147" left="663" width="74" height="15" font="1">d) AF &gt;180 d= </text>
<text top="163" left="663" width="71" height="15" font="1">2.2% at 200 J </text>
<text top="55" left="1063" width="51" height="15" font="1">protocols, </text>
<text top="70" left="1063" width="71" height="15" font="1">particularly w/ </text>
<text top="86" left="1063" width="63" height="15" font="1">AF of longer </text>
<text top="101" left="1063" width="46" height="15" font="1">duration. </text>
<text top="179" left="54" width="46" height="15" font="1">Wazni O </text>
<text top="195" left="54" width="28" height="15" font="1">2003 </text>
<text top="210" left="54" width="29" height="15" font="1">(203) </text>
<text top="226" left="54" width="43" height="15" font="8">1461001</text>
<text top="241" left="54" width="6" height="15" font="8">2</text>
<text top="241" left="60" width="3" height="15" font="1"> </text>
<text top="257" left="54" width="3" height="15" font="1"> </text>
<text top="179" left="116" width="44" height="15" font="1">Randomi</text>
<text top="195" left="116" width="21" height="15" font="1">zed </text>
<text top="210" left="116" width="30" height="15" font="1">study </text>
<text top="226" left="116" width="39" height="15" font="1">compari</text>
<text top="241" left="116" width="15" height="15" font="1">ng </text>
<text top="257" left="116" width="42" height="15" font="1">combine</text>
<text top="272" left="116" width="9" height="15" font="1">d </text>
<text top="288" left="116" width="42" height="15" font="1">pulmona</text>
<text top="303" left="116" width="36" height="15" font="1">ry vein-</text>
<text top="319" left="116" width="45" height="15" font="1">left atrial </text>
<text top="334" left="116" width="41" height="15" font="1">junction </text>
<text top="350" left="116" width="44" height="15" font="1">disconne</text>
<text top="365" left="116" width="26" height="15" font="1">ction </text>
<text top="381" left="116" width="21" height="15" font="1">and </text>
<text top="396" left="116" width="44" height="15" font="1">cavotricu</text>
<text top="412" left="116" width="23" height="15" font="1">spid </text>
<text top="427" left="116" width="41" height="15" font="1">isthmus </text>
<text top="443" left="116" width="42" height="15" font="1">ablation </text>
<text top="458" left="116" width="17" height="15" font="1">vs. </text>
<text top="474" left="116" width="42" height="15" font="1">pulmona</text>
<text top="489" left="116" width="36" height="15" font="1">ry vein-</text>
<text top="505" left="116" width="45" height="15" font="1">left atrial </text>
<text top="520" left="116" width="41" height="15" font="1">junction </text>
<text top="535" left="116" width="44" height="15" font="1">disconne</text>
<text top="551" left="116" width="26" height="15" font="1">ction </text>
<text top="567" left="116" width="42" height="15" font="1">alone in </text>
<text top="582" left="116" width="18" height="15" font="1">pts </text>
<text top="597" left="116" width="39" height="15" font="1">presenti</text>
<text top="613" left="116" width="29" height="15" font="1">ng w/ </text>
<text top="628" left="116" width="34" height="15" font="1">typical </text>
<text top="644" left="116" width="27" height="15" font="1">atrial </text>
<text top="659" left="116" width="31" height="15" font="1">flutter </text>
<text top="675" left="116" width="42" height="15" font="1">and AF. </text>
<text top="179" left="177" width="164" height="15" font="1">108 Consecutive </text>
<text top="195" left="238" width="32" height="15" font="1">pts w/ </text>
<text top="210" left="238" width="64" height="15" font="1">documented </text>
<text top="226" left="238" width="65" height="15" font="1">symptomatic </text>
<text top="241" left="238" width="73" height="15" font="1">AF and typical </text>
<text top="257" left="238" width="58" height="15" font="1">atrial flutter </text>
<text top="272" left="238" width="27" height="15" font="1">were </text>
<text top="288" left="238" width="49" height="15" font="1">randomly </text>
<text top="303" left="238" width="60" height="15" font="1">assigned to </text>
<text top="319" left="238" width="68" height="15" font="1">have PV-LAJ </text>
<text top="334" left="238" width="71" height="15" font="1">disconnection </text>
<text top="350" left="238" width="65" height="15" font="1">combined w/ </text>
<text top="365" left="238" width="63" height="15" font="1">CTI ablation </text>
<text top="381" left="238" width="47" height="15" font="1">(group 1, </text>
<text top="396" left="238" width="63" height="15" font="1">n=49) or PV-</text>
<text top="412" left="238" width="22" height="15" font="1">LAJ </text>
<text top="427" left="238" width="71" height="15" font="1">disconnection </text>
<text top="443" left="238" width="65" height="15" font="1">alone (group </text>
<text top="458" left="238" width="47" height="15" font="1">2, n=59). </text>
<text top="179" left="325" width="41" height="15" font="1">PV-LAJ </text>
<text top="195" left="325" width="71" height="15" font="1">disconnection </text>
<text top="210" left="325" width="65" height="15" font="1">combined w/ </text>
<text top="226" left="325" width="63" height="15" font="1">CTI ablation </text>
<text top="241" left="325" width="47" height="15" font="1">(group 1, </text>
<text top="257" left="325" width="63" height="15" font="1">n=49) or PV-</text>
<text top="272" left="325" width="22" height="15" font="1">LAJ </text>
<text top="288" left="325" width="71" height="15" font="1">disconnection </text>
<text top="303" left="325" width="30" height="15" font="1">alone </text>
<text top="179" left="413" width="103" height="15" font="1">Preablation  proof of </text>
<text top="195" left="413" width="104" height="15" font="1">both atrial flutter and </text>
<text top="210" left="413" width="75" height="15" font="1">AF on  ECG, 1 </text>
<text top="226" left="413" width="106" height="15" font="1">documented episode </text>
<text top="241" left="413" width="105" height="15" font="1">of typical atrial flutter </text>
<text top="257" left="413" width="62" height="15" font="1">while not on </text>
<text top="272" left="413" width="78" height="15" font="1">antiarrhythmics </text>
<text top="179" left="541" width="22" height="15" font="1">N/A </text>
<text top="179" left="663" width="74" height="15" font="1">W/in the first 8 </text>
<text top="195" left="663" width="42" height="15" font="1">wk after </text>
<text top="210" left="663" width="73" height="15" font="1">ablation, 32 of </text>
<text top="226" left="663" width="59" height="15" font="1">the group 2 </text>
<text top="241" left="663" width="74" height="15" font="1">pts had typical </text>
<text top="257" left="663" width="58" height="15" font="1">atrial flutter </text>
<text top="272" left="663" width="67" height="15" font="1">documented, </text>
<text top="288" left="663" width="73" height="15" font="1">whereas none </text>
<text top="303" left="663" width="61" height="15" font="1">was seen in </text>
<text top="319" left="663" width="44" height="15" font="1">group 1. </text>
<text top="334" left="663" width="51" height="15" font="1">Twenty of </text>
<text top="350" left="663" width="46" height="15" font="1">these 32 </text>
<text top="365" left="663" width="64" height="15" font="1">converted to </text>
<text top="381" left="663" width="66" height="15" font="1">sinus rhythm </text>
<text top="396" left="663" width="69" height="15" font="1">after initiating </text>
<text top="412" left="663" width="73" height="15" font="1">AADs. Twelve </text>
<text top="427" left="663" width="27" height="15" font="1">were </text>
<text top="443" left="663" width="67" height="15" font="1">cardioverted, </text>
<text top="458" left="663" width="53" height="15" font="1">and AADs </text>
<text top="474" left="663" width="67" height="15" font="1">were started. </text>
<text top="489" left="663" width="69" height="15" font="1">After 8 wk, all </text>
<text top="505" left="663" width="58" height="15" font="1">AADs were </text>
<text top="520" left="663" width="67" height="15" font="1">stopped, and </text>
<text top="535" left="663" width="50" height="15" font="1">only 3 pts </text>
<text top="551" left="663" width="63" height="15" font="1">continued to </text>
<text top="567" left="663" width="74" height="15" font="1">have recurrent </text>
<text top="582" left="663" width="50" height="15" font="1">sustained </text>
<text top="597" left="663" width="61" height="15" font="1">typical atrial </text>
<text top="613" left="663" width="52" height="15" font="1">flutter that </text>
<text top="628" left="663" width="23" height="15" font="1">was </text>
<text top="644" left="663" width="68" height="15" font="1">eliminated by </text>
<text top="659" left="663" width="66" height="15" font="1">CTI ablation. </text>
<text top="675" left="663" width="67" height="15" font="1">Beyond 8 wk </text>
<text top="690" left="663" width="70" height="15" font="1">of f/u, 7 pts in </text>
<text top="706" left="663" width="71" height="15" font="1">group 1 and 6 </text>
<text top="721" left="663" width="70" height="15" font="1">pts in group 2 </text>
<text top="737" left="663" width="51" height="15" font="1">(14% and </text>
<text top="752" left="663" width="28" height="15" font="1">11%, </text>
<text top="768" left="663" width="65" height="15" font="1">respectively) </text>
<text top="783" left="663" width="63" height="15" font="1">continued to </text>
<text top="179" left="751" width="22" height="15" font="1">N/A </text>
<text top="179" left="845" width="22" height="15" font="1">N/A </text>
<text top="179" left="926" width="22" height="15" font="1">N/A </text>
<text top="179" left="1063" width="71" height="15" font="1">Isolating of all </text>
<text top="195" left="1063" width="64" height="15" font="1">4 pulmonary </text>
<text top="210" left="1063" width="28" height="15" font="1">vs. is </text>
<text top="226" left="1063" width="65" height="15" font="1">challenging.  </text>
<text top="241" left="1063" width="3" height="15" font="1"> </text>
<text top="257" left="1063" width="72" height="15" font="1">No f/u beyond </text>
<text top="272" left="1063" width="24" height="15" font="1">1 y.  </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="22" size="7" family="Times" color="#231f20"/>
	<fontspec id="23" size="11" family="Times" color="#231f20"/>
<text top="814" left="1120" width="17" height="17" font="0">91 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="663" width="69" height="15" font="1">have AF. Ten </text>
<text top="70" left="663" width="58" height="15" font="1">of these 13 </text>
<text top="86" left="663" width="73" height="15" font="1">pts underwent </text>
<text top="101" left="663" width="62" height="15" font="1">a repeat PV-</text>
<text top="117" left="663" width="22" height="15" font="1">LAJ </text>
<text top="132" left="663" width="71" height="15" font="1">disconnection </text>
<text top="147" left="663" width="74" height="15" font="1">procedure and </text>
<text top="163" left="663" width="61" height="15" font="1">were cured. </text>
<text top="178" left="663" width="74" height="15" font="1">The remaining </text>
<text top="194" left="663" width="70" height="15" font="1">3 remained in </text>
<text top="210" left="663" width="66" height="15" font="1">normal sinus </text>
<text top="225" left="663" width="65" height="15" font="1">rhythm while </text>
<text top="240" left="663" width="67" height="15" font="1">taking AADs. </text>
<text top="257" left="54" width="35" height="15" font="1">LADIP </text>
<text top="272" left="54" width="25" height="15" font="1">Trial </text>
<text top="288" left="54" width="28" height="15" font="1">2006 </text>
<text top="303" left="54" width="29" height="15" font="1">(204) </text>
<text top="319" left="54" width="43" height="15" font="8">1703068</text>
<text top="334" left="54" width="9" height="15" font="8">0 </text>
<text top="350" left="54" width="3" height="15" font="1"> </text>
<text top="257" left="116" width="44" height="15" font="21">Randomi</text>
<text top="272" left="116" width="21" height="15" font="21">zed </text>
<text top="288" left="116" width="30" height="15" font="21">study </text>
<text top="303" left="116" width="39" height="15" font="21">compari</text>
<text top="319" left="116" width="15" height="15" font="21">ng </text>
<text top="334" left="116" width="40" height="15" font="21">amiodar</text>
<text top="350" left="116" width="43" height="15" font="21">one and </text>
<text top="365" left="116" width="18" height="15" font="21">RF </text>
<text top="381" left="116" width="42" height="15" font="21">ablation </text>
<text top="396" left="116" width="44" height="15" font="21">after the </text>
<text top="412" left="116" width="21" height="15" font="21">first </text>
<text top="427" left="116" width="42" height="15" font="21">episode </text>
<text top="443" left="116" width="12" height="15" font="21">of </text>
<text top="458" left="116" width="36" height="15" font="21">sympto</text>
<text top="474" left="116" width="29" height="15" font="21">matic </text>
<text top="489" left="116" width="27" height="15" font="21">atrial </text>
<text top="505" left="116" width="31" height="15" font="21">flutter </text>
<text top="257" left="177" width="39" height="15" font="1">104 pts </text>
<text top="272" left="177" width="41" height="15" font="1">w/ atrial </text>
<text top="288" left="177" width="34" height="15" font="1">flutter: </text>
<text top="303" left="177" width="3" height="15" font="1"> </text>
<text top="257" left="238" width="59" height="15" font="21">group I= 52 </text>
<text top="272" left="238" width="69" height="15" font="21">pts treated w/ </text>
<text top="288" left="238" width="46" height="15" font="21">RFA as 1</text>
<text top="288" left="284" width="6" height="10" font="22">st</text>
<text top="288" left="289" width="3" height="15" font="21"> </text>
<text top="303" left="238" width="20" height="15" font="21">line </text>
<text top="319" left="238" width="3" height="15" font="21"> </text>
<text top="257" left="325" width="40" height="15" font="1">Group2 </text>
<text top="272" left="325" width="52" height="15" font="1">treated w/ </text>
<text top="288" left="325" width="69" height="15" font="1">cardioversion </text>
<text top="303" left="325" width="21" height="15" font="1">and </text>
<text top="319" left="325" width="61" height="15" font="1">amiodarone </text>
<text top="334" left="325" width="21" height="15" font="1">as 1</text>
<text top="335" left="346" width="6" height="10" font="10">st</text>
<text top="334" left="352" width="23" height="15" font="1"> line </text>
<text top="257" left="413" width="63" height="15" font="1">1 episode of </text>
<text top="272" left="413" width="100" height="15" font="1">symptomatic typical </text>
<text top="288" left="413" width="58" height="15" font="1">atrial flutter </text>
<text top="257" left="541" width="22" height="15" font="1">N/A </text>
<text top="257" left="663" width="73" height="15" font="1">Recurrence of </text>
<text top="272" left="663" width="62" height="15" font="1">flutter: 3.8% </text>
<text top="288" left="663" width="68" height="15" font="1">after RFA vs. </text>
<text top="303" left="663" width="49" height="15" font="1">29.5% w/ </text>
<text top="319" left="663" width="61" height="15" font="1">amiodarone </text>
<text top="334" left="663" width="21" height="15" font="1">and </text>
<text top="350" left="663" width="72" height="15" font="1">cardioversion; </text>
<text top="365" left="663" width="50" height="15" font="1">p&lt;0.0001 </text>
<text top="257" left="751" width="73" height="15" font="1">Complications </text>
<text top="272" left="751" width="65" height="15" font="1">of treatment: </text>
<text top="288" left="751" width="24" height="15" font="1">Five </text>
<text top="303" left="751" width="70" height="15" font="1">complications </text>
<text top="319" left="751" width="60" height="15" font="1">(10%) were </text>
<text top="334" left="751" width="74" height="15" font="1">noted in group </text>
<text top="350" left="751" width="62" height="15" font="1">II (SSS in 2, </text>
<text top="365" left="751" width="81" height="15" font="1">hyperthyroidism </text>
<text top="381" left="751" width="45" height="15" font="1">in 1, and </text>
<text top="396" left="751" width="77" height="15" font="1">hypothyroidism </text>
<text top="412" left="751" width="74" height="15" font="1">in 2) and none </text>
<text top="427" left="751" width="76" height="15" font="1">in group I (0%) </text>
<text top="443" left="751" width="49" height="15" font="1">(P=0.03). </text>
<text top="257" left="845" width="50" height="15" font="21">long-term </text>
<text top="272" left="845" width="33" height="15" font="21">risk of </text>
<text top="288" left="845" width="60" height="15" font="21">subsequent </text>
<text top="303" left="845" width="45" height="15" font="21">AF (AF): </text>
<text top="319" left="845" width="51" height="15" font="21">25% after </text>
<text top="334" left="845" width="68" height="15" font="21">RFA vs. 18% </text>
<text top="350" left="845" width="25" height="15" font="21">after </text>
<text top="365" left="845" width="61" height="15" font="21">amiodarone </text>
<text top="381" left="845" width="21" height="15" font="21">and </text>
<text top="396" left="845" width="60" height="15" font="21">cardioversio</text>
<text top="412" left="845" width="45" height="15" font="21">n (p=NS)</text>
<text top="412" left="890" width="3" height="15" font="1"> </text>
<text top="257" left="926" width="68" height="15" font="1">RFA reduced </text>
<text top="272" left="926" width="122" height="15" font="1">recurrences of flutter vs. </text>
<text top="288" left="926" width="83" height="15" font="1">amiodarone and </text>
<text top="303" left="926" width="69" height="15" font="1">caridoversion </text>
<text top="319" left="926" width="57" height="15" font="1">(p&lt;0.0001) </text>
<text top="334" left="926" width="111" height="15" font="1">RFA not different than </text>
<text top="350" left="926" width="83" height="15" font="1">amiodarone and </text>
<text top="365" left="926" width="81" height="15" font="1">cardioversion at </text>
<text top="381" left="926" width="87" height="15" font="1">occurrence of AF </text>
<text top="396" left="926" width="75" height="15" font="1">(p=NS). Fewer </text>
<text top="412" left="926" width="110" height="15" font="1">complications w/ RFA </text>
<text top="427" left="926" width="96" height="15" font="1">than amiodarone + </text>
<text top="443" left="926" width="113" height="15" font="1">cardioversion (p=0.03) </text>
<text top="257" left="1063" width="61" height="15" font="1">RFA should </text>
<text top="272" left="1063" width="73" height="15" font="1">be considered </text>
<text top="288" left="1063" width="41" height="15" font="1">first line </text>
<text top="303" left="1063" width="67" height="15" font="1">therapy even </text>
<text top="319" left="1063" width="35" height="15" font="1">after 1 </text>
<text top="334" left="1063" width="68" height="15" font="1">recurrence of </text>
<text top="350" left="1063" width="58" height="15" font="1">atrial flutter </text>
<text top="521" left="54" width="49" height="15" font="1">Kuniss M </text>
<text top="536" left="54" width="28" height="15" font="1">2009 </text>
<text top="552" left="54" width="29" height="15" font="1">(205) </text>
<text top="567" left="54" width="43" height="15" font="8">1995911</text>
<text top="583" left="54" width="6" height="15" font="8">5</text>
<text top="583" left="60" width="3" height="15" font="1"> </text>
<text top="598" left="54" width="3" height="15" font="1"> </text>
<text top="521" left="116" width="44" height="15" font="21">Prospect</text>
<text top="536" left="116" width="17" height="15" font="21">ive </text>
<text top="552" left="116" width="40" height="15" font="21">randomi</text>
<text top="567" left="116" width="21" height="15" font="21">zed </text>
<text top="583" left="116" width="39" height="15" font="21">compari</text>
<text top="598" left="116" width="33" height="15" font="21">son of </text>
<text top="614" left="116" width="47" height="15" font="21">durability </text>
<text top="629" left="116" width="12" height="15" font="21">of </text>
<text top="645" left="116" width="44" height="15" font="21">bidirectio</text>
<text top="660" left="116" width="18" height="15" font="21">nal </text>
<text top="676" left="116" width="41" height="15" font="21">conducti</text>
<text top="691" left="116" width="44" height="15" font="21">on block </text>
<text top="707" left="116" width="30" height="15" font="21">in the </text>
<text top="722" left="116" width="44" height="15" font="21">cavotricu</text>
<text top="738" left="116" width="23" height="15" font="21">spid </text>
<text top="753" left="116" width="41" height="15" font="21">isthmus </text>
<text top="769" left="116" width="12" height="15" font="21">in </text>
<text top="784" left="116" width="43" height="15" font="21">pts after </text>
<text top="521" left="177" width="22" height="15" font="1">191 </text>
<text top="521" left="238" width="68" height="15" font="21">Cryoablation  </text>
<text top="536" left="238" width="3" height="15" font="21"> </text>
<text top="552" left="238" width="74" height="15" font="21">Do people use </text>
<text top="567" left="238" width="63" height="15" font="21">this for atrial </text>
<text top="583" left="238" width="31" height="15" font="21">flutter </text>
<text top="598" left="238" width="48" height="15" font="21">ablation? </text>
<text top="521" left="325" width="65" height="15" font="1">Vs. standard </text>
<text top="536" left="325" width="25" height="15" font="1">RFA </text>
<text top="521" left="413" width="86" height="15" font="21">Inclusion: 1. One </text>
<text top="536" left="413" width="82" height="15" font="21">episode of ECG-</text>
<text top="552" left="413" width="98" height="15" font="21">documented typical </text>
<text top="567" left="413" width="58" height="15" font="21">atrial flutter </text>
<text top="583" left="413" width="68" height="15" font="21">symptomatic  </text>
<text top="598" left="413" width="75" height="15" font="21">w/ eligibility for </text>
<text top="614" left="413" width="92" height="15" font="21">ablation treatment </text>
<text top="629" left="413" width="95" height="15" font="21">2. Age between 18 </text>
<text top="645" left="413" width="46" height="15" font="21">and 80 y </text>
<text top="660" left="413" width="97" height="15" font="21">3. Written informed </text>
<text top="676" left="413" width="76" height="15" font="21">consent for the </text>
<text top="691" left="413" width="95" height="15" font="21">ablation procedure </text>
<text top="707" left="413" width="22" height="15" font="21">and </text>
<text top="722" left="413" width="77" height="15" font="21">the invasive f/u </text>
<text top="738" left="413" width="109" height="15" font="21">procedure after 3 mo. </text>
<text top="753" left="413" width="3" height="15" font="1"> </text>
<text top="521" left="541" width="94" height="15" font="21">Exclusion: atypical </text>
<text top="536" left="541" width="28" height="15" font="21">flutter</text>
<text top="536" left="569" width="3" height="15" font="1"> </text>
<text top="521" left="663" width="74" height="15" font="21">Acute success </text>
<text top="536" left="663" width="56" height="15" font="21">rates: 91% </text>
<text top="552" left="663" width="68" height="15" font="21">(83/91) in the </text>
<text top="567" left="663" width="66" height="15" font="21">RF group vs. </text>
<text top="583" left="663" width="63" height="15" font="21">89% (80/90) </text>
<text top="598" left="663" width="30" height="15" font="21">in the </text>
<text top="614" left="663" width="63" height="15" font="21">cryoablation </text>
<text top="629" left="663" width="74" height="15" font="21">group (P=NS). </text>
<text top="645" left="663" width="44" height="15" font="21">Invasive </text>
<text top="660" left="663" width="74" height="15" font="21">2) f/u 3 mo EP </text>
<text top="676" left="663" width="30" height="15" font="21">study </text>
<text top="691" left="663" width="63" height="15" font="21">available for </text>
<text top="707" left="663" width="63" height="15" font="21">60 pts in the </text>
<text top="722" left="663" width="71" height="15" font="21">RF group and </text>
<text top="738" left="663" width="45" height="15" font="21">64 pts in </text>
<text top="753" left="663" width="63" height="15" font="21">cryoablation </text>
<text top="769" left="663" width="38" height="15" font="21">group.  </text>
<text top="784" left="663" width="65" height="15" font="21">3) Persistent </text>
<text top="521" left="751" width="22" height="15" font="1">N/A </text>
<text top="521" left="845" width="56" height="15" font="21">Secondary </text>
<text top="536" left="845" width="50" height="15" font="21">end-point-</text>
<text top="552" left="845" width="24" height="15" font="21">pain </text>
<text top="567" left="845" width="55" height="15" font="21">perception </text>
<text top="583" left="845" width="34" height="15" font="21">during </text>
<text top="598" left="845" width="65" height="15" font="21">ablation was </text>
<text top="614" left="845" width="52" height="15" font="21">significant </text>
<text top="629" left="845" width="60" height="15" font="21">lower in the </text>
<text top="645" left="845" width="63" height="15" font="21">cryoablation </text>
<text top="660" left="845" width="31" height="15" font="21">group </text>
<text top="676" left="845" width="52" height="15" font="21">(<i>P</i>&lt;0.001) </text>
<text top="691" left="845" width="3" height="15" font="21"> </text>
<text top="521" left="926" width="117" height="15" font="1">Acute success RFA vs. </text>
<text top="536" left="926" width="101" height="15" font="1">cryoablation (p=NS) </text>
<text top="552" left="926" width="82" height="15" font="1">Pesristent BCB- </text>
<text top="567" left="926" width="112" height="15" font="1">cryoablation inferior to </text>
<text top="583" left="926" width="76" height="15" font="1">RFA (p&lt;0.014) </text>
<text top="521" left="1063" width="73" height="15" font="1">Persistence of </text>
<text top="536" left="1063" width="55" height="15" font="1">BCB in pts </text>
<text top="552" left="1063" width="52" height="15" font="1">treated w/ </text>
<text top="567" left="1063" width="63" height="15" font="1">cryoablation </text>
<text top="583" left="1063" width="72" height="15" font="1">reinvestigated </text>
<text top="598" left="1063" width="64" height="15" font="1">after 3 mo is </text>
<text top="614" left="1063" width="71" height="15" font="1">inferior to that </text>
<text top="629" left="1063" width="18" height="15" font="1">pts </text>
<text top="645" left="1063" width="69" height="15" font="1">treated w/ RF </text>
<text top="660" left="1063" width="60" height="15" font="1">ablation, as </text>
<text top="676" left="1063" width="68" height="15" font="1">evidenced by </text>
<text top="691" left="1063" width="52" height="15" font="1">the higher </text>
<text top="707" left="1063" width="56" height="15" font="1">recurrence </text>
<text top="722" left="1063" width="35" height="15" font="1">rate of </text>
<text top="738" left="1063" width="73" height="15" font="1">common atrial </text>
<text top="753" left="1063" width="69" height="15" font="1">flutter seen in </text>
<text top="769" left="1063" width="53" height="15" font="1">this study. </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">92 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="42" height="15" font="21">ablation </text>
<text top="70" left="116" width="12" height="15" font="21">of </text>
<text top="86" left="116" width="45" height="15" font="21">common </text>
<text top="101" left="116" width="27" height="15" font="21">atrial </text>
<text top="117" left="116" width="31" height="15" font="21">flutter </text>
<text top="132" left="116" width="30" height="15" font="21">using </text>
<text top="147" left="116" width="40" height="15" font="21">cryother</text>
<text top="163" left="116" width="39" height="15" font="21">my and </text>
<text top="178" left="116" width="18" height="15" font="21">RF </text>
<text top="194" left="116" width="40" height="15" font="21">energy: </text>
<text top="210" left="116" width="22" height="15" font="21">The </text>
<text top="225" left="116" width="42" height="15" font="21">CRYOTI</text>
<text top="240" left="116" width="40" height="15" font="21">P study </text>
<text top="55" left="663" width="26" height="15" font="21">BCB </text>
<text top="70" left="663" width="63" height="15" font="21">confirmed in </text>
<text top="86" left="663" width="74" height="15" font="21">85% of the RF </text>
<text top="101" left="663" width="49" height="15" font="21">group vs. </text>
<text top="117" left="663" width="65" height="15" font="21">65.6% of the </text>
<text top="132" left="663" width="63" height="15" font="21">cryoablation </text>
<text top="147" left="663" width="38" height="15" font="21">group.  </text>
<text top="163" left="663" width="72" height="15" font="21">4)The primary </text>
<text top="178" left="663" width="56" height="15" font="21">end-point= </text>
<text top="194" left="663" width="69" height="15" font="21">nonpersistenc</text>
<text top="210" left="663" width="47" height="15" font="21">e of BCB </text>
<text top="225" left="663" width="55" height="15" font="21">block  was </text>
<text top="240" left="663" width="64" height="15" font="21">seen in 15% </text>
<text top="256" left="663" width="49" height="15" font="21">of the RF </text>
<text top="271" left="663" width="49" height="15" font="21">group vs. </text>
<text top="287" left="663" width="65" height="15" font="21">34.4% of the </text>
<text top="302" left="663" width="63" height="15" font="21">cryoablation </text>
<text top="318" left="663" width="31" height="15" font="21">group </text>
<text top="333" left="663" width="55" height="15" font="21">(P&lt;0.014). </text>
<text top="333" left="718" width="3" height="15" font="1"> </text>
<text top="350" left="54" width="45" height="15" font="1">Steinwen</text>
<text top="365" left="54" width="30" height="15" font="1">der C </text>
<text top="381" left="54" width="28" height="15" font="1">2009 </text>
<text top="396" left="54" width="29" height="15" font="1">(206) </text>
<text top="412" left="54" width="43" height="15" font="8">1913616</text>
<text top="427" left="54" width="6" height="15" font="8">4</text>
<text top="427" left="60" width="3" height="15" font="1"> </text>
<text top="443" left="54" width="3" height="15" font="1"> </text>
<text top="350" left="116" width="44" height="15" font="21">Randomi</text>
<text top="365" left="116" width="21" height="15" font="21">zed </text>
<text top="381" left="116" width="42" height="15" font="21">placebo </text>
<text top="396" left="116" width="42" height="15" font="21">controlle</text>
<text top="412" left="116" width="37" height="15" font="21">d Trial: </text>
<text top="427" left="116" width="39" height="15" font="21">Assess </text>
<text top="443" left="116" width="38" height="15" font="21">pretreat</text>
<text top="458" left="116" width="42" height="15" font="21">ment w/ </text>
<text top="474" left="116" width="42" height="15" font="21">magnesi</text>
<text top="489" left="116" width="34" height="15" font="21">um for </text>
<text top="505" left="116" width="41" height="15" font="21">conversi</text>
<text top="520" left="116" width="29" height="15" font="21">on w/ </text>
<text top="535" left="116" width="44" height="15" font="21">Ibutilide: </text>
<text top="551" left="116" width="44" height="15" font="21">Randomi</text>
<text top="567" left="116" width="42" height="15" font="21">zed 117 </text>
<text top="582" left="116" width="37" height="15" font="21">pts (58 </text>
<text top="597" left="116" width="36" height="15" font="21">w/ and </text>
<text top="613" left="116" width="36" height="15" font="21">59 w/o </text>
<text top="628" left="116" width="20" height="15" font="21">pre-</text>
<text top="644" left="116" width="44" height="15" font="21">injection </text>
<text top="659" left="116" width="12" height="15" font="21">of </text>
<text top="675" left="116" width="42" height="15" font="21">magnesi</text>
<text top="690" left="116" width="37" height="15" font="21">um; 65 </text>
<text top="706" left="116" width="14" height="15" font="21">w/ </text>
<text top="721" left="116" width="34" height="15" font="21">typical </text>
<text top="737" left="116" width="27" height="15" font="21">atrial </text>
<text top="752" left="116" width="31" height="15" font="21">flutter </text>
<text top="768" left="116" width="37" height="15" font="21">and 52 </text>
<text top="783" left="116" width="14" height="15" font="21">w/ </text>
<text top="350" left="177" width="41" height="15" font="1">117- 65 </text>
<text top="365" left="177" width="34" height="15" font="1">typical </text>
<text top="381" left="177" width="34" height="15" font="1">flutter; </text>
<text top="396" left="177" width="15" height="15" font="1">52 </text>
<text top="412" left="177" width="41" height="15" font="1">atypical </text>
<text top="427" left="177" width="31" height="15" font="1">flutter </text>
<text top="350" left="238" width="70" height="15" font="21">2 randomized </text>
<text top="365" left="238" width="40" height="15" font="21">groups: </text>
<text top="381" left="238" width="65" height="15" font="21">Group 1) 4 g </text>
<text top="396" left="238" width="26" height="15" font="21">of IV </text>
<text top="412" left="238" width="60" height="15" font="21">magnesium </text>
<text top="427" left="238" width="39" height="15" font="21">sulfate  </text>
<text top="443" left="238" width="3" height="15" font="1"> </text>
<text top="350" left="325" width="53" height="15" font="1">Vs. Group </text>
<text top="350" left="378" width="13" height="15" font="21">2) </text>
<text top="365" left="325" width="42" height="15" font="21">placebo </text>
<text top="381" left="325" width="62" height="15" font="21">immediately </text>
<text top="396" left="325" width="34" height="15" font="21">before </text>
<text top="412" left="325" width="72" height="15" font="21">administration </text>
<text top="427" left="325" width="73" height="15" font="21">of a maximum </text>
<text top="443" left="325" width="67" height="15" font="21">dose of 2 mg </text>
<text top="458" left="325" width="53" height="15" font="21">of ibutilide </text>
<text top="474" left="325" width="44" height="15" font="21">fumarate</text>
<text top="474" left="369" width="3" height="15" font="1"> </text>
<text top="350" left="413" width="100" height="15" font="1">Typical and atypical </text>
<text top="365" left="413" width="58" height="15" font="1">atrial flutter </text>
<text top="350" left="541" width="22" height="15" font="1">N/A </text>
<text top="350" left="663" width="60" height="15" font="1">1) TAF: pre-</text>
<text top="365" left="663" width="57" height="15" font="1">injection IV </text>
<text top="381" left="663" width="60" height="15" font="1">magnesium </text>
<text top="396" left="663" width="49" height="15" font="1">improved </text>
<text top="412" left="663" width="53" height="15" font="1">efficacy of </text>
<text top="427" left="663" width="57" height="15" font="1">ibutilide for </text>
<text top="443" left="663" width="57" height="15" font="1">conversion </text>
<text top="458" left="663" width="43" height="15" font="1">(85% w/ </text>
<text top="474" left="663" width="60" height="15" font="1">magnesium </text>
<text top="489" left="663" width="56" height="15" font="1">vs. 59% w/ </text>
<text top="505" left="663" width="45" height="15" font="1">placebo, </text>
<text top="520" left="663" width="50" height="15" font="1">p=0.017). </text>
<text top="535" left="663" width="69" height="15" font="1">Atypical atrial </text>
<text top="551" left="663" width="49" height="15" font="1">flutter: no </text>
<text top="567" left="663" width="52" height="15" font="1">significant </text>
<text top="582" left="663" width="63" height="15" font="1">difference in </text>
<text top="597" left="663" width="57" height="15" font="1">conversion </text>
<text top="613" left="663" width="73" height="15" font="1">rates between </text>
<text top="628" left="663" width="65" height="15" font="1">pts receiving </text>
<text top="644" left="663" width="60" height="15" font="1">magnesium </text>
<text top="659" left="663" width="59" height="15" font="1">vs. placebo </text>
<text top="675" left="663" width="46" height="15" font="1">(48% vs. </text>
<text top="690" left="663" width="72" height="15" font="1">56%,p=0.189) </text>
<text top="350" left="751" width="60" height="15" font="1">No effect of </text>
<text top="365" left="751" width="76" height="15" font="1">magnesium on </text>
<text top="381" left="751" width="66" height="15" font="1">QTc interval. </text>
<text top="396" left="751" width="3" height="15" font="1"> </text>
<text top="412" left="751" width="81" height="15" font="1">QTc intervals at </text>
<text top="427" left="751" width="61" height="15" font="1">30 min after </text>
<text top="443" left="751" width="80" height="15" font="1">ibutilitde did not </text>
<text top="458" left="751" width="73" height="15" font="1">differ between </text>
<text top="474" left="751" width="77" height="15" font="1">patients w/ and </text>
<text top="489" left="751" width="74" height="15" font="1">w/o ventricular </text>
<text top="505" left="751" width="36" height="15" font="1">ectopy </text>
<text top="350" left="845" width="22" height="15" font="1">N/A </text>
<text top="350" left="926" width="100" height="15" font="1">Preinjcention w/ Mg </text>
<text top="365" left="926" width="116" height="15" font="1">superior for conversion </text>
<text top="381" left="926" width="105" height="15" font="1">w/ ibutilide in trypical </text>
<text top="396" left="926" width="112" height="15" font="1">atrial flutter  (p=0.017) </text>
<text top="412" left="926" width="109" height="15" font="1">Preinjection w/ Mg for </text>
<text top="427" left="926" width="111" height="15" font="1">conversion w/ ibutilide </text>
<text top="443" left="926" width="97" height="15" font="1">no different (p=NS) </text>
<text top="458" left="926" width="117" height="15" font="1">Preinjection wih Mg did </text>
<text top="474" left="926" width="86" height="15" font="1">not affect QT (no </text>
<text top="489" left="926" width="81" height="15" font="1">statistic offered) </text>
<text top="350" left="1063" width="65" height="15" font="1">Pre-injection </text>
<text top="365" left="1063" width="73" height="15" font="1">of magnesium </text>
<text top="381" left="1063" width="60" height="15" font="1">significantly </text>
<text top="396" left="1063" width="70" height="15" font="1">enhances the </text>
<text top="412" left="1063" width="53" height="15" font="1">efficacy of </text>
<text top="427" left="1063" width="57" height="15" font="1">ibutilide for </text>
<text top="443" left="1063" width="18" height="15" font="1">the </text>
<text top="458" left="1063" width="69" height="15" font="1">conversion of </text>
<text top="474" left="1063" width="61" height="15" font="1">typical atrial </text>
<text top="489" left="1063" width="68" height="15" font="1">flutter but not </text>
<text top="505" left="1063" width="53" height="15" font="1">of atypical </text>
<text top="520" left="1063" width="61" height="15" font="1">atrial flutter. </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">93 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="44" height="15" font="21">atrypical </text>
<text top="70" left="116" width="27" height="15" font="21">atrial </text>
<text top="86" left="116" width="37" height="15" font="21">flutter.  </text>
<text top="86" left="153" width="3" height="15" font="17"><i> </i></text>
<text top="102" left="54" width="40" height="15" font="1">Bastani </text>
<text top="117" left="54" width="11" height="15" font="1">H </text>
<text top="133" left="54" width="28" height="15" font="1">2012 </text>
<text top="148" left="54" width="29" height="15" font="1">(207) </text>
<text top="164" left="54" width="43" height="15" font="8">2292766</text>
<text top="179" left="54" width="6" height="15" font="8">2</text>
<text top="179" left="60" width="6" height="15" font="1">  </text>
<text top="195" left="54" width="3" height="15" font="1"> </text>
<text top="102" left="116" width="44" height="15" font="21">Randomi</text>
<text top="117" left="116" width="21" height="15" font="21">zed </text>
<text top="133" left="116" width="39" height="15" font="21">compari</text>
<text top="148" left="116" width="33" height="15" font="21">son in </text>
<text top="164" left="116" width="32" height="15" font="21">pts w/ </text>
<text top="179" left="116" width="34" height="15" font="21">typical </text>
<text top="195" left="116" width="27" height="15" font="21">atrial </text>
<text top="210" left="116" width="34" height="15" font="21">flutter. </text>
<text top="226" left="116" width="47" height="15" font="21">RFA- 3.5 </text>
<text top="241" left="116" width="21" height="15" font="21">mm </text>
<text top="257" left="116" width="28" height="15" font="21">open-</text>
<text top="272" left="116" width="44" height="15" font="21">irrigated-</text>
<text top="288" left="116" width="15" height="15" font="21">tip </text>
<text top="303" left="116" width="43" height="15" font="21">catheter </text>
<text top="319" left="116" width="21" height="15" font="21">and </text>
<text top="334" left="116" width="44" height="15" font="21">Cryoabla</text>
<text top="350" left="116" width="39" height="15" font="21">tion a 9 </text>
<text top="365" left="116" width="44" height="15" font="21">F, 8 mm </text>
<text top="381" left="116" width="15" height="15" font="21">tip </text>
<text top="396" left="116" width="46" height="15" font="21">catheter. </text>
<text top="412" left="116" width="43" height="15" font="21">Ablation </text>
<text top="427" left="116" width="45" height="15" font="21">endpoint </text>
<text top="443" left="116" width="23" height="15" font="21">was </text>
<text top="458" left="116" width="44" height="15" font="21">bidirectio</text>
<text top="474" left="116" width="18" height="15" font="21">nal </text>
<text top="489" left="116" width="21" height="15" font="21">CTI </text>
<text top="505" left="116" width="32" height="15" font="21">block. </text>
<text top="102" left="177" width="22" height="15" font="1">153 </text>
<text top="102" left="238" width="72" height="15" font="21">Ablation RFA- </text>
<text top="117" left="238" width="68" height="15" font="21">3.5 mm open-</text>
<text top="133" left="238" width="58" height="15" font="21">irrigated-tip </text>
<text top="148" left="238" width="64" height="15" font="21">catheter (N= </text>
<text top="164" left="238" width="19" height="15" font="21">75) </text>
<text top="102" left="325" width="74" height="15" font="21">Cryoablation a </text>
<text top="117" left="325" width="68" height="15" font="21">9 F, 8 mm tip </text>
<text top="133" left="325" width="43" height="15" font="21">catheter </text>
<text top="148" left="325" width="34" height="15" font="21">(N=78)</text>
<text top="148" left="359" width="3" height="15" font="1"> </text>
<text top="102" left="413" width="111" height="15" font="21">Inclusion: Pts w/ a h/o </text>
<text top="117" left="413" width="94" height="15" font="21">AF included if they </text>
<text top="133" left="413" width="113" height="15" font="21">had predominant atrial </text>
<text top="148" left="413" width="101" height="15" font="21">flutter under chronic </text>
<text top="164" left="413" width="111" height="15" font="21">treatment w/ class I or </text>
<text top="179" left="413" width="85" height="15" font="21">III antiarrhythmic </text>
<text top="195" left="413" width="39" height="15" font="21">agents. </text>
<text top="210" left="413" width="3" height="15" font="21"> </text>
<text top="102" left="541" width="92" height="15" font="21">Exculsion: (i) prior </text>
<text top="117" left="541" width="85" height="15" font="21">ablation for atrial </text>
<text top="133" left="541" width="107" height="15" font="21">flutter; (ii) atrial flutter </text>
<text top="148" left="541" width="91" height="15" font="21">related to recently </text>
<text top="164" left="541" width="99" height="15" font="21">undergone surgery, </text>
<text top="179" left="541" width="94" height="15" font="21">hyperthyroidism or </text>
<text top="195" left="541" width="65" height="15" font="21">other severe </text>
<text top="210" left="541" width="102" height="15" font="21">disease; (iii) inability </text>
<text top="226" left="541" width="82" height="15" font="21">to adhere w/ the </text>
<text top="241" left="541" width="94" height="15" font="21">study protocol; (iv) </text>
<text top="257" left="541" width="74" height="15" font="21">pregnancy; (v) </text>
<text top="272" left="541" width="106" height="15" font="21">predominant AF; and </text>
<text top="288" left="541" width="99" height="15" font="21">(vi) contraindication </text>
<text top="303" left="541" width="58" height="15" font="21">to warfarin. </text>
<text top="102" left="663" width="41" height="15" font="1">Primary </text>
<text top="117" left="663" width="49" height="15" font="1">endpoint: </text>
<text top="133" left="663" width="73" height="15" font="1">demonstration </text>
<text top="148" left="663" width="62" height="15" font="1">of long-term </text>
<text top="164" left="663" width="41" height="15" font="1">efficacy </text>
<text top="179" left="663" width="70" height="15" font="1">defined as no </text>
<text top="195" left="663" width="65" height="15" font="1">symptomatic </text>
<text top="210" left="663" width="68" height="15" font="1">recurrence of </text>
<text top="226" left="663" width="70" height="15" font="1">atrial flutter at </text>
<text top="241" left="663" width="65" height="15" font="1">the 6-mo f/u. </text>
<text top="257" left="663" width="3" height="15" font="1"> </text>
<text top="272" left="663" width="67" height="15" font="1">Success rate </text>
<text top="288" left="663" width="56" height="15" font="1">at 6-mo f/u </text>
<text top="303" left="663" width="67" height="15" font="1">was 93% (73 </text>
<text top="319" left="663" width="47" height="15" font="1">of 78) for </text>
<text top="334" left="663" width="65" height="15" font="1">Cryoablation </text>
<text top="350" left="663" width="74" height="15" font="1">vs. 97% (73 of </text>
<text top="365" left="663" width="72" height="15" font="1">75) for RF (p= </text>
<text top="381" left="663" width="31" height="15" font="1">0.86). </text>
<text top="396" left="663" width="3" height="15" font="21"> </text>
<text top="102" left="751" width="33" height="15" font="1">safety </text>
<text top="117" left="751" width="65" height="15" font="1">assessed by </text>
<text top="133" left="751" width="53" height="15" font="1">the rate of </text>
<text top="148" left="751" width="74" height="15" font="1">periprocedural </text>
<text top="164" left="751" width="73" height="15" font="1">complications, </text>
<text top="179" left="751" width="74" height="15" font="1">procedure and </text>
<text top="195" left="751" width="60" height="15" font="1">fluoroscopy </text>
<text top="210" left="751" width="73" height="15" font="1">times, and the </text>
<text top="226" left="751" width="62" height="15" font="1">level of pain </text>
<text top="241" left="751" width="78" height="15" font="1">experienced by </text>
<text top="257" left="751" width="65" height="15" font="1">the pt during </text>
<text top="272" left="751" width="60" height="15" font="1">the ablation </text>
<text top="288" left="751" width="53" height="15" font="1">procedure </text>
<text top="303" left="751" width="3" height="15" font="1"> </text>
<text top="319" left="751" width="81" height="15" font="1">Procedural time </text>
<text top="334" left="751" width="68" height="15" font="1">was longer in </text>
<text top="350" left="751" width="81" height="15" font="1">the cryoablation </text>
<text top="365" left="751" width="76" height="15" font="1">group (152±54 </text>
<text top="381" left="751" width="68" height="15" font="1">min) than the </text>
<text top="396" left="751" width="49" height="15" font="1">RF group </text>
<text top="412" left="751" width="70" height="15" font="1">(116±41 min) </text>
<text top="427" left="751" width="58" height="15" font="1">(P&lt;0.001).  </text>
<text top="443" left="751" width="3" height="15" font="1"> </text>
<text top="458" left="751" width="65" height="15" font="1">Cryoablation </text>
<text top="474" left="751" width="81" height="15" font="1">was less painful </text>
<text top="489" left="751" width="66" height="15" font="1">compared w/ </text>
<text top="505" left="751" width="78" height="15" font="1">RF (mean VAS-</text>
<text top="520" left="751" width="65" height="15" font="1">Cryoablation </text>
<text top="536" left="751" width="59" height="15" font="1">0.7±1.2 vs. </text>
<text top="551" left="751" width="44" height="15" font="1">VAS-RF </text>
<text top="567" left="751" width="44" height="15" font="1">4.6±2.0; </text>
<text top="582" left="751" width="55" height="15" font="1">P&lt;0.001).  </text>
<text top="598" left="751" width="3" height="15" font="1"> </text>
<text top="613" left="751" width="3" height="15" font="1"> </text>
<text top="102" left="845" width="56" height="15" font="21">Secondary </text>
<text top="117" left="845" width="58" height="15" font="21">end-points: </text>
<text top="133" left="845" width="30" height="15" font="21">acute </text>
<text top="148" left="845" width="42" height="15" font="21">ablation </text>
<text top="164" left="845" width="43" height="15" font="21">success </text>
<text top="179" left="845" width="54" height="15" font="21">defined as </text>
<text top="195" left="845" width="62" height="15" font="21">bidirectional </text>
<text top="210" left="845" width="53" height="15" font="21">CTI-block; </text>
<text top="226" left="845" width="31" height="15" font="1">Acute </text>
<text top="241" left="845" width="65" height="15" font="1">success rate </text>
<text top="257" left="845" width="41" height="15" font="1">92% for </text>
<text top="272" left="845" width="63" height="15" font="1">cryoablation </text>
<text top="288" left="845" width="58" height="15" font="1">vs. 95% for </text>
<text top="303" left="845" width="66" height="15" font="1">RF (p=0.58). </text>
<text top="319" left="845" width="3" height="15" font="21"> </text>
<text top="102" left="926" width="112" height="15" font="1">1) Acute success rate  </text>
<text top="117" left="926" width="116" height="15" font="1">for Cryoablation vs. RF </text>
<text top="133" left="926" width="48" height="15" font="1">(p=0.58). </text>
<text top="148" left="926" width="116" height="15" font="1">2) Procedural time was </text>
<text top="164" left="926" width="64" height="15" font="1">longer in the </text>
<text top="179" left="926" width="114" height="15" font="1">Cryoablation group vs. </text>
<text top="195" left="926" width="106" height="15" font="1">RF group (p&lt;0.001).  </text>
<text top="210" left="926" width="101" height="15" font="1">3) Cryoablation was </text>
<text top="226" left="926" width="111" height="15" font="1">less painful compared </text>
<text top="241" left="926" width="92" height="15" font="1">vs. RF (p&lt;0.001).  </text>
<text top="257" left="926" width="120" height="15" font="1">4) Success rate at 6-mo </text>
<text top="272" left="926" width="113" height="15" font="1">f/u was no different for </text>
<text top="288" left="926" width="121" height="15" font="1">Cryoablation vs. RF (P= </text>
<text top="303" left="926" width="35" height="15" font="1">0.86).  </text>
<text top="319" left="926" width="3" height="15" font="1"> </text>
<text top="334" left="926" width="90" height="15" font="1">No major adverse </text>
<text top="350" left="926" width="114" height="15" font="1">events occurred in any </text>
<text top="365" left="926" width="34" height="15" font="1">group. </text>
<text top="102" left="1063" width="65" height="15" font="1">Cryoablation </text>
<text top="117" left="1063" width="66" height="15" font="1">is not inferior </text>
<text top="133" left="1063" width="53" height="15" font="1">to RFA for </text>
<text top="148" left="1063" width="65" height="15" font="1">typical flutter </text>
<text top="629" left="54" width="45" height="15" font="1">Mohanty </text>
<text top="645" left="54" width="9" height="15" font="1">s </text>
<text top="660" left="54" width="28" height="15" font="1">2013 </text>
<text top="676" left="54" width="29" height="15" font="1">(208) </text>
<text top="691" left="54" width="43" height="15" font="8">2357249</text>
<text top="707" left="54" width="6" height="15" font="8">9</text>
<text top="707" left="60" width="3" height="15" font="1"> </text>
<text top="722" left="54" width="3" height="15" font="1"> </text>
<text top="629" left="116" width="34" height="15" font="1">Single-</text>
<text top="645" left="116" width="29" height="15" font="1">blind, </text>
<text top="660" left="116" width="40" height="15" font="1">randomi</text>
<text top="676" left="116" width="21" height="15" font="1">zed </text>
<text top="691" left="116" width="33" height="15" font="1">study- </text>
<text top="707" left="116" width="43" height="15" font="1">Examine</text>
<text top="722" left="116" width="28" height="15" font="1">d the </text>
<text top="738" left="116" width="36" height="15" font="1">impact </text>
<text top="753" left="116" width="12" height="15" font="1">of </text>
<text top="769" left="116" width="43" height="15" font="1">different </text>
<text top="784" left="116" width="42" height="15" font="1">ablation </text>
<text top="629" left="177" width="39" height="15" font="1">360 pts </text>
<text top="645" left="177" width="14" height="15" font="1">w/ </text>
<text top="660" left="177" width="39" height="15" font="1">docume</text>
<text top="676" left="177" width="42" height="15" font="1">nted AF </text>
<text top="691" left="177" width="21" height="15" font="1">and </text>
<text top="707" left="177" width="27" height="15" font="1">atrial </text>
<text top="722" left="177" width="31" height="15" font="1">flutter </text>
<text top="629" left="238" width="62" height="15" font="1">Blinded and </text>
<text top="645" left="238" width="73" height="15" font="1">randomized to </text>
<text top="660" left="238" width="44" height="15" font="1">group 1, </text>
<text top="676" left="238" width="49" height="15" font="1">AF±atrial </text>
<text top="691" left="238" width="73" height="15" font="1">flutter ablation </text>
<text top="707" left="238" width="57" height="15" font="1">(n=182), or </text>
<text top="722" left="238" width="71" height="15" font="1">group 2, atrial </text>
<text top="738" left="238" width="73" height="15" font="1">flutter ablation </text>
<text top="753" left="238" width="68" height="15" font="1">only (n=178). </text>
<text top="769" left="238" width="73" height="15" font="1">AF recurrence </text>
<text top="784" left="238" width="74" height="15" font="1">was evaluated </text>
<text top="629" left="325" width="55" height="15" font="1">AF ± atrial </text>
<text top="645" left="325" width="73" height="15" font="1">flutter ablation </text>
<text top="660" left="325" width="44" height="15" font="1">vs. atrial </text>
<text top="676" left="325" width="73" height="15" font="1">flutter ablation </text>
<text top="691" left="325" width="23" height="15" font="1">only </text>
<text top="629" left="413" width="103" height="15" font="1">1 antiarrhythmic and </text>
<text top="645" left="413" width="105" height="15" font="1">preablation evidence </text>
<text top="660" left="413" width="105" height="15" font="1">of typical atrial flutter </text>
<text top="676" left="413" width="94" height="15" font="1">by 12-lead surface </text>
<text top="691" left="413" width="30" height="15" font="1">ECG. </text>
<text top="629" left="541" width="86" height="15" font="1">&lt;18 or &gt;85 y old, </text>
<text top="645" left="541" width="108" height="15" font="1">previous ablation, left </text>
<text top="660" left="541" width="107" height="15" font="1">atrium size ≥5 cm, or </text>
<text top="676" left="541" width="93" height="15" font="1">contraindication to </text>
<text top="691" left="541" width="99" height="15" font="1">oral anticoagulation </text>
<text top="629" left="663" width="73" height="15" font="1">At 21±9 mo of </text>
<text top="645" left="663" width="52" height="15" font="1">f/u, 117 in </text>
<text top="660" left="663" width="73" height="15" font="1">group 1 (64%) </text>
<text top="676" left="663" width="49" height="15" font="1">and 34 in </text>
<text top="691" left="663" width="73" height="15" font="1">group 2 (19%) </text>
<text top="707" left="663" width="27" height="15" font="1">were </text>
<text top="722" left="663" width="55" height="15" font="1">arrhythmia </text>
<text top="738" left="663" width="22" height="15" font="1">free </text>
<text top="753" left="663" width="67" height="15" font="1">(P&lt;0.001). In </text>
<text top="769" left="663" width="44" height="15" font="1">group 1, </text>
<text top="784" left="663" width="51" height="15" font="1">scores on </text>
<text top="629" left="751" width="22" height="15" font="1">N/A </text>
<text top="629" left="845" width="22" height="15" font="1">N/A </text>
<text top="629" left="926" width="103" height="15" font="1">Group 1 vs. Group 2 </text>
<text top="645" left="926" width="43" height="15" font="1">p&lt;0.001 </text>
<text top="629" left="1063" width="69" height="15" font="1">Questionnaire</text>
<text top="645" left="1063" width="38" height="15" font="1">s didn’t </text>
<text top="660" left="1063" width="42" height="15" font="1">address </text>
<text top="676" left="1063" width="71" height="15" font="1">comorbidities, </text>
<text top="691" left="1063" width="39" height="15" font="1">smaller </text>
<text top="707" left="1063" width="61" height="15" font="1">sample size </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">94 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="116" width="42" height="15" font="1">strategie</text>
<text top="70" left="116" width="41" height="15" font="1">s on AF </text>
<text top="86" left="116" width="41" height="15" font="1">recurren</text>
<text top="101" left="116" width="36" height="15" font="1">ce and </text>
<text top="117" left="116" width="38" height="15" font="1">QOL in </text>
<text top="132" left="116" width="41" height="15" font="1">coexiste</text>
<text top="147" left="116" width="29" height="15" font="1">nt AF </text>
<text top="163" left="116" width="21" height="15" font="1">and </text>
<text top="178" left="116" width="27" height="15" font="1">atrial </text>
<text top="194" left="116" width="34" height="15" font="1">flutter. </text>
<text top="55" left="238" width="44" height="15" font="1">w/ event </text>
<text top="70" left="238" width="71" height="15" font="1">recording and </text>
<text top="86" left="238" width="64" height="15" font="1">7-d Holter at </text>
<text top="101" left="238" width="58" height="15" font="1">3, 6, 9, and </text>
<text top="117" left="238" width="58" height="15" font="1">12-mo f/us. </text>
<text top="132" left="238" width="49" height="15" font="1">QOL was </text>
<text top="147" left="238" width="62" height="15" font="1">assessed at </text>
<text top="163" left="238" width="66" height="15" font="1">baseline and </text>
<text top="178" left="238" width="65" height="15" font="1">at the 12-mo </text>
<text top="194" left="238" width="39" height="15" font="1">f/u w/ 4 </text>
<text top="210" left="238" width="66" height="15" font="1">questionnaire</text>
<text top="225" left="238" width="12" height="15" font="1">s. </text>
<text top="55" left="663" width="63" height="15" font="1">most quality-</text>
<text top="70" left="663" width="30" height="15" font="1">of-life </text>
<text top="86" left="663" width="52" height="15" font="1">subscales </text>
<text top="101" left="663" width="41" height="15" font="1">showed </text>
<text top="117" left="663" width="52" height="15" font="1">significant </text>
<text top="132" left="663" width="67" height="15" font="1">improvement </text>
<text top="147" left="663" width="31" height="15" font="1">at f/u, </text>
<text top="163" left="663" width="45" height="15" font="1">whereas </text>
<text top="178" left="663" width="58" height="15" font="1">group 2 pts </text>
<text top="194" left="663" width="39" height="15" font="1">derived </text>
<text top="210" left="663" width="47" height="15" font="1">relatively </text>
<text top="225" left="663" width="70" height="15" font="1">minor benefit. </text>
<text top="241" left="54" width="1074" height="15" font="1">AAD, antiarrhythmic drug; AE, adverse events; AF, atrial fibrillation; AMI, acute myocardial infarction; AV, atrioventricular; BBB, bundle branch block; BCB, bidirectional conduction block; bid, two times per day; BP, blood </text>
<text top="257" left="54" width="1049" height="15" font="1">pressure; bpm, beats per min; CHD, congenital heart disease; CHF, congestive heart failure; CI, confidence interval; CL, cycle length; CrCl, creatinine clearance; CTI, cavotricuspid isthmus; DC, direct current; ECG, </text>
<text top="272" left="54" width="1061" height="15" font="1">electrocardiogram; EP, electrophysiological; f/u, follow up; HF, heart failure; h/o, history of; HR, heart rate; IART, intraatrial reentrant tachycardia; IV, intravenous; LBBB, left bundle branch block; LV, left ventricular; MI, </text>
<text top="288" left="54" width="1072" height="15" font="1">myocardial infarction; MR, mitral regurgitation; N/A, not applicable; NS, non-significant; NSR, normal sinus rhythm; NSVT, non-sustatined supraventricular tachycardia; NYHA, New York Heart Association; pt, patient; PV-</text>
<text top="303" left="54" width="1039" height="15" font="1">LAJ, pulmonary vein-left atrial junction; QTc, corrected QT interval; RCT, randomized controlled trial; RF, radiofrequency; RFA, radiofrequency ablation; SBP, systolic blood pressure; SD, standard deviation; SHD, </text>
<text top="319" left="54" width="1042" height="15" font="1">structural heart disease; SR, sinus rhythm; SSS, sick sinus syndrome; SVT, supraventricular tachycardia; TAP, transesophageal atrial pacing; tx, transplant; VAS, visual analog scale; VF, ventricular fibrillation; VT, </text>
<text top="334" left="54" width="458" height="15" font="1">ventricular tachycardia; w/, with; w/o, without; and WPW, Wolff-Parkinson-White syndrome.    </text>
<text top="350" left="54" width="3" height="15" font="1"> </text>
<text top="375" left="54" width="151" height="18" font="3"><b>Data Supplement 17. </b></text>
<text top="375" left="205" width="655" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Atrial Flutter – Section 7 </b></text>
<text top="394" left="66" width="38" height="17" font="5"><b>Study </b></text>
<text top="411" left="65" width="40" height="17" font="5"><b>Name, </b></text>
<text top="428" left="61" width="47" height="17" font="5"><b>Author, </b></text>
<text top="446" left="70" width="30" height="17" font="5"><b>Year </b></text>
<text top="394" left="138" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="411" left="152" width="44" height="17" font="5"><b>Design </b></text>
<text top="394" left="252" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="394" left="369" width="165" height="17" font="5"><b>Inclusion/Exclusion Criteria </b></text>
<text top="394" left="569" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="394" left="742" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="394" left="955" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="463" left="54" width="59" height="15" font="1">Van Gelder </text>
<text top="479" left="54" width="14" height="15" font="1">IC </text>
<text top="494" left="54" width="28" height="15" font="1">1989 </text>
<text top="510" left="54" width="29" height="15" font="1">(181) </text>
<text top="525" left="54" width="43" height="15" font="8">2511744</text>
<text top="525" left="97" width="6" height="15" font="1">  </text>
<text top="541" left="54" width="3" height="15" font="1"> </text>
<text top="463" left="129" width="91" height="15" font="1">Persistent AF and </text>
<text top="479" left="129" width="83" height="15" font="1">atrial flutter after </text>
<text top="494" left="129" width="69" height="15" font="1">cardioversion </text>
<text top="510" left="129" width="73" height="15" font="1">randomized to </text>
<text top="525" left="129" width="78" height="15" font="1">flecainide or no </text>
<text top="541" left="129" width="89" height="15" font="1">therapy to reduce </text>
<text top="556" left="129" width="56" height="15" font="1">recurrence </text>
<text top="463" left="233" width="93" height="15" font="1">81 pts (16 pts with </text>
<text top="479" left="233" width="88" height="15" font="1">atrial flutter – 6 in </text>
<text top="494" left="233" width="103" height="15" font="1">flecainide group and </text>
<text top="510" left="233" width="98" height="15" font="1">10 in control group) </text>
<text top="463" left="349" width="199" height="15" font="1">Inclusion: Persistent AF and atrial flutter </text>
<text top="479" left="349" width="204" height="15" font="1">referred for cardioversion. All pts w/ atrial </text>
<text top="494" left="349" width="205" height="15" font="1">flutter received verapamil 240 mg daily to </text>
<text top="510" left="349" width="133" height="15" font="1">reduce 1:1 AV conduction. </text>
<text top="525" left="349" width="3" height="15" font="1"> </text>
<text top="541" left="349" width="199" height="15" font="1">Exclusion: &lt;16 y or &gt;80 y, CHF, angina, </text>
<text top="556" left="349" width="177" height="15" font="1">MI &lt;2 y before, bifascicular block or </text>
<text top="572" left="349" width="156" height="15" font="1">bundle branch block, sick sinus </text>
<text top="587" left="349" width="187" height="15" font="1">syndrome without pacemaker, severe </text>
<text top="603" left="349" width="87" height="15" font="1">systemic disease </text>
<text top="463" left="567" width="79" height="15" font="1">Arrhythmia-free </text>
<text top="479" left="567" width="66" height="15" font="1">survival after </text>
<text top="494" left="567" width="69" height="15" font="1">cardioversion </text>
<text top="463" left="689" width="188" height="15" font="1">No significant difference in arrhythmia </text>
<text top="479" left="689" width="203" height="15" font="1">free survival. However, it postponed time </text>
<text top="494" left="689" width="127" height="15" font="1">to arrhythmia recurrence. </text>
<text top="510" left="689" width="3" height="15" font="1"> </text>
<text top="525" left="689" width="183" height="15" font="1">Adverse effects: 9% flecainide group </text>
<text top="541" left="689" width="158" height="15" font="1">experience side effects. 3 pts in </text>
<text top="556" left="689" width="196" height="15" font="1">flecainide group required pacemaker (2 </text>
<text top="572" left="689" width="193" height="15" font="1">w/ symptomatic sinus arrest and 1 with </text>
<text top="587" left="689" width="196" height="15" font="1">AV block). 1 pt had increase ventricular </text>
<text top="603" left="689" width="199" height="15" font="1">ectopy burden requiring discontinuation. </text>
<text top="463" left="909" width="210" height="15" font="1">No significant difference in arrhythmia free </text>
<text top="479" left="909" width="229" height="15" font="1">survival in pts w/ persistent AF or atrial flutter.  </text>
<text top="494" left="909" width="205" height="15" font="1">However, it postponed time to arrhythmia </text>
<text top="510" left="909" width="153" height="15" font="1">recurrence after cardioversion. </text>
<text top="525" left="909" width="3" height="15" font="1"> </text>
<text top="619" left="54" width="50" height="15" font="1">Pietersen </text>
<text top="635" left="54" width="28" height="15" font="1">1991 </text>
<text top="650" left="54" width="29" height="15" font="1">(209) </text>
<text top="666" left="54" width="43" height="15" font="8">1900978</text>
<text top="666" left="97" width="3" height="15" font="1"> </text>
<text top="619" left="129" width="68" height="15" font="1">Randomized, </text>
<text top="635" left="129" width="42" height="15" font="1">placebo </text>
<text top="650" left="129" width="81" height="15" font="1">controlled cross </text>
<text top="666" left="129" width="81" height="15" font="1">over design trial </text>
<text top="681" left="129" width="90" height="15" font="1">flecainide 150 mg </text>
<text top="697" left="129" width="80" height="15" font="1">bid vs. placebo. </text>
<text top="712" left="129" width="73" height="15" font="1">Pts received 3 </text>
<text top="728" left="129" width="85" height="15" font="1">mo of therapy w/ </text>
<text top="743" left="129" width="81" height="15" font="1">another 3 mo of </text>
<text top="759" left="129" width="51" height="15" font="1">crossover </text>
<text top="774" left="129" width="43" height="15" font="1">therapy. </text>
<text top="619" left="233" width="33" height="15" font="1">43 pts </text>
<text top="619" left="349" width="199" height="15" font="1">Inclusion: Paroxysmal AF or atrial flutter </text>
<text top="635" left="349" width="190" height="15" font="1">&gt;3 episodes &lt;3 mo prior to enrollment </text>
<text top="650" left="349" width="190" height="15" font="1">Exclusion: CHF, reduced LV fractional </text>
<text top="666" left="349" width="176" height="15" font="1">shortening, WPW, syncope, thyroid </text>
<text top="681" left="349" width="180" height="15" font="1">disease, sinus node dysfunction w/o </text>
<text top="697" left="349" width="162" height="15" font="1">pacer, more than isolated PVC’s </text>
<text top="619" left="567" width="55" height="15" font="1">Number of </text>
<text top="635" left="567" width="65" height="15" font="1">symptomatic </text>
<text top="650" left="567" width="61" height="15" font="1">recurrences </text>
<text top="619" left="689" width="169" height="15" font="1">Outcome:  Significant reduction in </text>
<text top="635" left="689" width="173" height="15" font="1">number of episodes with flecainide </text>
<text top="650" left="689" width="104" height="15" font="1">treatment (p&lt;0.002). </text>
<text top="666" left="689" width="3" height="15" font="1"> </text>
<text top="681" left="689" width="177" height="15" font="1">Adverse events: 1 pt developed 1:1 </text>
<text top="697" left="689" width="178" height="15" font="1">conduction of atrial flutter. 1 sudden </text>
<text top="712" left="689" width="197" height="15" font="1">death in flecainide group (bathing in the </text>
<text top="728" left="689" width="200" height="15" font="1">cold Norway sea after drinking alcohol).  </text>
<text top="743" left="689" width="197" height="15" font="1">Other minor adverse events occurred in </text>
<text top="759" left="689" width="195" height="15" font="1">74% (mostly visual changes, dizziness, </text>
<text top="774" left="689" width="165" height="15" font="1">and GI side effects) resulting in 2 </text>
<text top="789" left="689" width="64" height="15" font="1">withdrawals. </text>
<text top="619" left="909" width="221" height="15" font="1">Flecainide significantly redcuced the number </text>
<text top="635" left="909" width="190" height="15" font="1">of recurrent episodes of AF or flutter.   </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">95 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="35" height="15" font="1">Aliot E </text>
<text top="70" left="54" width="28" height="15" font="1">1996 </text>
<text top="86" left="54" width="29" height="15" font="1">(210) </text>
<text top="101" left="54" width="43" height="15" font="8">8607394</text>
<text top="101" left="97" width="6" height="15" font="1">  </text>
<text top="55" left="129" width="68" height="15" font="1">Randomized, </text>
<text top="70" left="129" width="82" height="15" font="1">open-label, long-</text>
<text top="86" left="129" width="70" height="15" font="1">term, parallel, </text>
<text top="101" left="129" width="63" height="15" font="1">comparative </text>
<text top="117" left="129" width="87" height="15" font="1">multicenter study </text>
<text top="132" left="129" width="55" height="15" font="1">comparing </text>
<text top="147" left="129" width="77" height="15" font="1">propafenone to </text>
<text top="163" left="129" width="50" height="15" font="1">flecainide </text>
<text top="55" left="233" width="96" height="15" font="1">97 pts (5 with atrial </text>
<text top="70" left="233" width="35" height="15" font="1">flutter) </text>
<text top="55" left="349" width="195" height="15" font="1">Inclusion: adults with paroxysmal AF or </text>
<text top="70" left="349" width="146" height="15" font="1">atrial flutter on ECG or Holter </text>
<text top="86" left="349" width="197" height="15" font="1">Exclusion: MI, recent heart surgery, VT, </text>
<text top="101" left="349" width="201" height="15" font="1">CHF, PR &gt;280 ms, QRS &gt;150 ms, sinus </text>
<text top="117" left="349" width="168" height="15" font="1">node dysfunction or heart block in </text>
<text top="132" left="349" width="115" height="15" font="1">absence of pacemaker </text>
<text top="55" left="567" width="84" height="15" font="1">Proportion of pts </text>
<text top="70" left="567" width="107" height="15" font="1">remaining on therapy </text>
<text top="86" left="567" width="30" height="15" font="1">at 1 y </text>
<text top="55" left="689" width="163" height="15" font="1">0.619 remained on flecainide 1 y </text>
<text top="70" left="689" width="99" height="15" font="1">0.469 propafenone  </text>
<text top="86" left="689" width="3" height="15" font="1"> </text>
<text top="101" left="689" width="199" height="15" font="1">Adverse events: 1 death in propafenone </text>
<text top="117" left="689" width="176" height="15" font="1">group. 8.5% flecainide experienced </text>
<text top="132" left="689" width="150" height="15" font="1">neurological side effects, 16% </text>
<text top="147" left="689" width="170" height="15" font="1">propafenone group GI side effects </text>
<text top="55" left="909" width="197" height="15" font="1">In paroxysmal AF and paroxysmal atrial </text>
<text top="70" left="909" width="189" height="15" font="1">flutter, flecainide and propafenone not </text>
<text top="86" left="909" width="216" height="15" font="1">significantly different. Too few pts with atrial </text>
<text top="101" left="909" width="196" height="15" font="1">flutter to draw conclusions. Rate of side </text>
<text top="117" left="909" width="188" height="15" font="1">effects was greater with propafenone. </text>
<text top="179" left="54" width="32" height="15" font="1">Baker </text>
<text top="195" left="54" width="28" height="15" font="1">1996 </text>
<text top="210" left="54" width="29" height="15" font="1">(211) </text>
<text top="226" left="54" width="43" height="15" font="8">8800118</text>
<text top="226" left="97" width="3" height="15" font="1"> </text>
<text top="241" left="54" width="3" height="15" font="1"> </text>
<text top="257" left="54" width="3" height="15" font="1"> </text>
<text top="179" left="129" width="89" height="15" font="1">Single center trial </text>
<text top="195" left="129" width="53" height="15" font="1">evaluating </text>
<text top="210" left="129" width="53" height="15" font="1">efficacy of </text>
<text top="226" left="129" width="65" height="15" font="1">anatomically </text>
<text top="241" left="129" width="58" height="15" font="1">based RFA </text>
<text top="257" left="129" width="76" height="15" font="1">ablation for the </text>
<text top="272" left="129" width="90" height="15" font="1">treatment of IART </text>
<text top="288" left="129" width="89" height="15" font="1">in pts w/ previous </text>
<text top="303" left="129" width="67" height="15" font="1">atrial surgery </text>
<text top="179" left="233" width="33" height="15" font="1">14 pts </text>
<text top="179" left="349" width="194" height="15" font="1">H/o atrial surgery and clinical intraatrial </text>
<text top="195" left="349" width="107" height="15" font="1">reentrant tachycardia </text>
<text top="179" left="567" width="73" height="15" font="1">Freedom from </text>
<text top="195" left="567" width="97" height="15" font="1">recurrence of IART </text>
<text top="179" left="689" width="203" height="15" font="1">Successfully terminated in 13 pts (93%).  </text>
<text top="195" left="689" width="172" height="15" font="1">Six pts required repeat ablation for </text>
<text top="210" left="689" width="204" height="15" font="1">recurrence.  Twelve (86%) remained free </text>
<text top="226" left="689" width="93" height="15" font="1">of IART at 7.5 mo. </text>
<text top="179" left="909" width="219" height="15" font="1">RFA is effective technique for IART in pts w/ </text>
<text top="195" left="909" width="112" height="15" font="1">previous atrial surgery </text>
<text top="319" left="54" width="58" height="15" font="1">Kalman JM </text>
<text top="335" left="54" width="28" height="15" font="1">1996 </text>
<text top="350" left="54" width="29" height="15" font="1">(212) </text>
<text top="366" left="54" width="43" height="15" font="8">8565168</text>
<text top="366" left="97" width="3" height="15" font="1"> </text>
<text top="381" left="54" width="3" height="15" font="1"> </text>
<text top="319" left="129" width="68" height="15" font="1">Single center </text>
<text top="335" left="129" width="60" height="15" font="1">observation </text>
<text top="350" left="129" width="76" height="15" font="1">cohort study to </text>
<text top="366" left="129" width="63" height="15" font="1">evaluate the </text>
<text top="381" left="129" width="80" height="15" font="1">success of RFA </text>
<text top="397" left="129" width="83" height="15" font="1">for IART in CHD </text>
<text top="412" left="129" width="73" height="15" font="1">using targeted </text>
<text top="428" left="129" width="89" height="15" font="1">ablation of critical </text>
<text top="443" left="129" width="41" height="15" font="1">isthmus </text>
<text top="319" left="233" width="33" height="15" font="1">18 pts </text>
<text top="319" left="349" width="121" height="15" font="1">IART and repaired CHD </text>
<text top="319" left="567" width="74" height="15" font="1">Acute success </text>
<text top="319" left="689" width="178" height="15" font="1">Successful termination in 15 pts (21 </text>
<text top="335" left="689" width="197" height="15" font="1">arrhythmias).  During f/u (mean 17 mo), </text>
<text top="350" left="689" width="205" height="15" font="1">11 pts (61%) remained free of recurrence </text>
<text top="366" left="689" width="179" height="15" font="1">(2 remained on antiarrhythmic drug) </text>
<text top="319" left="909" width="225" height="15" font="1">Describes early experience w/ targeted RF to </text>
<text top="335" left="909" width="196" height="15" font="1">critical isthmus in pts w/ repaired CHD.  </text>
<text top="350" left="909" width="224" height="15" font="1">Successful ablation IART can be achieved w/ </text>
<text top="366" left="909" width="202" height="15" font="1">ablation to critical isthmus of conduction. </text>
<text top="460" left="54" width="50" height="15" font="1">Triedman </text>
<text top="475" left="54" width="28" height="15" font="1">1997 </text>
<text top="491" left="54" width="29" height="15" font="1">(213) </text>
<text top="506" left="54" width="43" height="15" font="8">9316535</text>
<text top="506" left="97" width="3" height="15" font="1"> </text>
<text top="522" left="54" width="3" height="15" font="1"> </text>
<text top="460" left="129" width="68" height="15" font="1">Single center </text>
<text top="475" left="129" width="87" height="15" font="1">retrospective trial </text>
<text top="491" left="129" width="72" height="15" font="1">evaluating the </text>
<text top="506" left="129" width="70" height="15" font="1">short and mid </text>
<text top="522" left="129" width="78" height="15" font="1">term efficacy of </text>
<text top="537" left="129" width="81" height="15" font="1">RFA for IART in </text>
<text top="552" left="129" width="27" height="15" font="1">CHD </text>
<text top="460" left="233" width="33" height="15" font="1">45 pts </text>
<text top="460" left="349" width="186" height="15" font="1">Pts w/ CHD w/ IART undergoing RFA </text>
<text top="475" left="349" width="202" height="15" font="1">Non-isthmus dependent flutter instead of </text>
<text top="491" left="349" width="28" height="15" font="1">IART </text>
<text top="460" left="567" width="73" height="15" font="1">Freedom from </text>
<text top="475" left="567" width="97" height="15" font="1">recurrence of IART </text>
<text top="460" left="689" width="184" height="15" font="1">73% acutely successful.  Recurrence </text>
<text top="475" left="689" width="201" height="15" font="1">53% during mean f/u of 17.4 mo.  Seven </text>
<text top="491" left="689" width="134" height="15" font="1">underwent repeat ablation. </text>
<text top="460" left="909" width="208" height="15" font="1">Early experience w/ RFA for IART in CHD </text>
<text top="475" left="909" width="181" height="15" font="1">reduced events in population of pts.  </text>
<text top="491" left="909" width="214" height="15" font="1">However, recurrence was frequent often w/ </text>
<text top="506" left="909" width="92" height="15" font="1">new IART circuits. </text>
<text top="569" left="54" width="54" height="15" font="1">Huang DT </text>
<text top="584" left="54" width="28" height="15" font="1">1998 </text>
<text top="600" left="54" width="29" height="15" font="1">(214) </text>
<text top="615" left="54" width="43" height="15" font="8">9607453</text>
<text top="615" left="97" width="3" height="15" font="1"> </text>
<text top="631" left="54" width="3" height="15" font="1"> </text>
<text top="569" left="129" width="89" height="15" font="1">Single center trial </text>
<text top="584" left="129" width="52" height="15" font="1">assessing </text>
<text top="600" left="129" width="53" height="15" font="1">efficacy of </text>
<text top="615" left="129" width="53" height="15" font="1">combining </text>
<text top="631" left="129" width="75" height="15" font="1">pharmacologic </text>
<text top="646" left="129" width="57" height="15" font="1">and simple </text>
<text top="662" left="129" width="90" height="15" font="1">ablative therapies </text>
<text top="677" left="129" width="81" height="15" font="1">in treating AF in </text>
<text top="693" left="129" width="73" height="15" font="1">small targeted </text>
<text top="708" left="129" width="66" height="15" font="1">subset of pts </text>
<text top="569" left="233" width="88" height="15" font="1">13 pts w/ AF who </text>
<text top="584" left="233" width="64" height="15" font="1">converted to </text>
<text top="600" left="233" width="103" height="15" font="1">electrocardiographic </text>
<text top="615" left="233" width="92" height="15" font="1">atrial flutter during </text>
<text top="631" left="233" width="76" height="15" font="1">anti-arrhythmic </text>
<text top="646" left="233" width="50" height="15" font="1">treatment </text>
<text top="569" left="349" width="170" height="15" font="1">“Typical” atrial flutter in 11 pts and </text>
<text top="584" left="349" width="196" height="15" font="1">“atypical” atrial flutter in 2 suggested by </text>
<text top="600" left="349" width="69" height="15" font="1">surface ECG. </text>
<text top="615" left="349" width="3" height="15" font="1"> </text>
<text top="631" left="349" width="189" height="15" font="1">Intracardiac mapping and entrainment </text>
<text top="646" left="349" width="181" height="15" font="1">studies found 9 pts w/ CCW isthmus </text>
<text top="662" left="349" width="196" height="15" font="1">dependent atrial flutter and remaining 4 </text>
<text top="677" left="349" width="162" height="15" font="1">had complex activation patterns. </text>
<text top="693" left="349" width="3" height="15" font="1"> </text>
<text top="708" left="349" width="3" height="15" font="1"> </text>
<text top="569" left="567" width="98" height="15" font="1">Successful ablation </text>
<text top="584" left="567" width="88" height="15" font="1">w/o recurrence at </text>
<text top="600" left="567" width="94" height="15" font="1">mean f/u 14.3±6.9 </text>
<text top="615" left="567" width="18" height="15" font="1">mo </text>
<text top="569" left="689" width="170" height="15" font="1">All 9 pts w/ typical atrial flutter had </text>
<text top="584" left="689" width="153" height="15" font="1">successful ablation and 88.9% </text>
<text top="600" left="689" width="184" height="15" font="1">maintained sinus rhythm in f/u period </text>
<text top="615" left="689" width="205" height="15" font="1">(while continued on antiarrhythmic drugs) </text>
<text top="631" left="689" width="177" height="15" font="1">None of 4 pts w/ complex activation </text>
<text top="646" left="689" width="161" height="15" font="1">patterns had successful ablation </text>
<text top="569" left="909" width="209" height="15" font="1">In pts who experience conversion of AF to </text>
<text top="584" left="909" width="217" height="15" font="1">typical isthmus dependent flutter during anti-</text>
<text top="600" left="909" width="186" height="15" font="1">arrhythmic drug therapy, ablation and </text>
<text top="615" left="909" width="201" height="15" font="1">continuation of pharmacologic therapy is </text>
<text top="631" left="909" width="185" height="15" font="1">effective in maintaining sinus rhythm. </text>
<text top="724" left="54" width="48" height="15" font="1">Chan DP </text>
<text top="740" left="54" width="28" height="15" font="1">2000 </text>
<text top="755" left="54" width="29" height="15" font="1">(215) </text>
<text top="771" left="54" width="49" height="15" font="8">10982544</text>
<text top="771" left="103" width="3" height="15" font="1"> </text>
<text top="786" left="54" width="3" height="15" font="1"> </text>
<text top="724" left="129" width="68" height="15" font="1">Single center </text>
<text top="740" left="129" width="82" height="15" font="1">study assessing </text>
<text top="755" left="129" width="89" height="15" font="1">the importance of </text>
<text top="771" left="129" width="58" height="15" font="1">atrial flutter </text>
<text top="786" left="129" width="77" height="15" font="1">isthmus in post-</text>
<text top="724" left="233" width="85" height="15" font="1">19 postoperative </text>
<text top="740" left="233" width="87" height="15" font="1">CHD pts w/ IART </text>
<text top="724" left="349" width="179" height="15" font="1">All study pts underwent EP study w/ </text>
<text top="740" left="349" width="177" height="15" font="1">entrainment mapping of atrial flutter </text>
<text top="755" left="349" width="172" height="15" font="1">isthmuses to determine PPIs. RFA </text>
<text top="771" left="349" width="201" height="15" font="1">performed at identified isthmus to create </text>
<text top="786" left="349" width="65" height="15" font="1">line of block. </text>
<text top="724" left="567" width="102" height="15" font="1">Successful ablation  </text>
<text top="724" left="689" width="143" height="15" font="1">21 IARTS identified in 19 pts </text>
<text top="740" left="689" width="206" height="15" font="1">Atrial flutter isthmus part of circuit in 15 of </text>
<text top="755" left="689" width="57" height="15" font="1">21 (71.4%) </text>
<text top="771" left="689" width="198" height="15" font="1">Sites near atrial incisions or suture lines </text>
<text top="786" left="689" width="103" height="15" font="1">in remaining 6 of 21  </text>
<text top="724" left="909" width="216" height="15" font="1">When IART occurs late after repair of CHD, </text>
<text top="740" left="909" width="220" height="15" font="1">atrial flutter isthmus may be part of reentrant </text>
<text top="755" left="909" width="227" height="15" font="1">circuit and should be evaluated as a target for </text>
<text top="771" left="909" width="48" height="15" font="1">ablation.  </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">96 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="129" width="77" height="15" font="1">operative IART </text>
<text top="55" left="689" width="207" height="15" font="1">Ablation successful in 19 of 21 (90.4%) of </text>
<text top="70" left="689" width="185" height="15" font="1">IARTs and in 14 of 15 cases of at the </text>
<text top="86" left="689" width="141" height="15" font="1">atrial flutter isthmus (93.3%) </text>
<text top="102" left="54" width="23" height="15" font="1">Jais </text>
<text top="117" left="54" width="28" height="15" font="1">2000 </text>
<text top="133" left="54" width="29" height="15" font="1">(216) </text>
<text top="148" left="54" width="49" height="15" font="8">10869265</text>
<text top="148" left="103" width="3" height="15" font="1"> </text>
<text top="164" left="54" width="3" height="15" font="1"> </text>
<text top="102" left="129" width="68" height="15" font="1">Single center </text>
<text top="117" left="129" width="66" height="15" font="1">retrospective </text>
<text top="133" left="129" width="90" height="15" font="1">observational trial </text>
<text top="148" left="129" width="90" height="15" font="1">to assess efficacy </text>
<text top="164" left="129" width="58" height="15" font="1">of mapping </text>
<text top="179" left="129" width="61" height="15" font="1">guided RFA </text>
<text top="102" left="233" width="33" height="15" font="1">22 pts </text>
<text top="102" left="349" width="160" height="15" font="1">Pts w/ persistent left atrial flutter </text>
<text top="117" left="349" width="197" height="15" font="1">predominantly in pts w/ SHD.  18 (81%) </text>
<text top="133" left="349" width="94" height="15" font="1">failed amiodarone. </text>
<text top="102" left="567" width="96" height="15" font="1">Acute success and </text>
<text top="117" left="567" width="62" height="15" font="1">mid-term f/u </text>
<text top="102" left="689" width="184" height="15" font="1">Complete activation map achieved in </text>
<text top="117" left="689" width="198" height="15" font="1">17/22 pts.  20 pts (90%) in sinus rhythm </text>
<text top="133" left="689" width="121" height="15" font="1">at the end of procedure. </text>
<text top="148" left="689" width="3" height="15" font="1"> </text>
<text top="164" left="689" width="181" height="15" font="1">7 pts required 2 procedures and 1 pt </text>
<text top="179" left="689" width="121" height="15" font="1">required 3 procedures.   </text>
<text top="195" left="689" width="3" height="15" font="1"> </text>
<text top="210" left="689" width="185" height="15" font="1">During mean 15 mo f/u, 16 pts (73%) </text>
<text top="226" left="689" width="202" height="15" font="1">remained free of recurrence (2 remained </text>
<text top="241" left="689" width="95" height="15" font="1">on antiarrhythmic). </text>
<text top="102" left="909" width="221" height="15" font="1">Describes various left atrial reentrant circuits </text>
<text top="117" left="909" width="199" height="15" font="1">and demonstrated feasibility of mapping </text>
<text top="133" left="909" width="61" height="15" font="1">guided RFA </text>
<text top="257" left="54" width="57" height="15" font="1">Reithmann </text>
<text top="273" left="54" width="11" height="15" font="1">C </text>
<text top="288" left="54" width="28" height="15" font="1">2000 </text>
<text top="304" left="54" width="29" height="15" font="1">(217) </text>
<text top="319" left="54" width="49" height="15" font="8">10775011</text>
<text top="319" left="103" width="3" height="15" font="1"> </text>
<text top="335" left="54" width="3" height="15" font="1"> </text>
<text top="257" left="129" width="89" height="15" font="1">Single center trial </text>
<text top="273" left="129" width="52" height="15" font="1">assessing </text>
<text top="288" left="129" width="85" height="15" font="1">catheter ablation </text>
<text top="304" left="129" width="49" height="15" font="1">of CTI on </text>
<text top="319" left="129" width="62" height="15" font="1">amiodarone-</text>
<text top="335" left="129" width="69" height="15" font="1">induced atrial </text>
<text top="350" left="129" width="52" height="15" font="1">flutter and </text>
<text top="366" left="129" width="60" height="15" font="1">subsequent </text>
<text top="381" left="129" width="91" height="15" font="1">incidence of AF in </text>
<text top="397" left="129" width="73" height="15" font="1">comparison to </text>
<text top="412" left="129" width="75" height="15" font="1">CTI ablation of </text>
<text top="428" left="129" width="72" height="15" font="1">regular typical </text>
<text top="443" left="129" width="58" height="15" font="1">atrial flutter </text>
<text top="257" left="233" width="95" height="15" font="1">92 consecutive pts </text>
<text top="273" left="233" width="76" height="15" font="1">w/ typical atrial </text>
<text top="288" left="233" width="54" height="15" font="1">flutter who </text>
<text top="304" left="233" width="76" height="15" font="1">underwent CTI </text>
<text top="319" left="233" width="42" height="15" font="1">ablation </text>
<text top="257" left="349" width="46" height="15" font="1">3 groups </text>
<text top="273" left="349" width="89" height="15" font="1">28 pts w/o h/o AF </text>
<text top="288" left="349" width="151" height="15" font="1">10 pts w/ atrial flutter following </text>
<text top="304" left="349" width="152" height="15" font="1">amiodarone treatment for PAF </text>
<text top="319" left="349" width="138" height="15" font="1">54 pt w/ AF and atrial flutter </text>
<text top="257" left="567" width="77" height="15" font="1">Successful CTI </text>
<text top="273" left="567" width="56" height="15" font="1">ablation w/ </text>
<text top="288" left="567" width="91" height="15" font="1">bidirectional block </text>
<text top="304" left="567" width="83" height="15" font="1">eliminating atrial </text>
<text top="319" left="567" width="108" height="15" font="1">flutter and recurrence </text>
<text top="335" left="567" width="94" height="15" font="1">of AF during mean </text>
<text top="350" left="567" width="57" height="15" font="1">f/u 8±3 mo </text>
<text top="257" left="689" width="195" height="15" font="1">Successful ablation achieved in 90% of </text>
<text top="273" left="689" width="197" height="15" font="1">amiodarone-treated pt’s and 93% of pts </text>
<text top="288" left="689" width="122" height="15" font="1">w/o amiodarone therapy </text>
<text top="304" left="689" width="173" height="15" font="1">Recurrence of AF occurred in 20% </text>
<text top="319" left="689" width="206" height="15" font="1">amiodarone treated pts which was similar </text>
<text top="335" left="689" width="178" height="15" font="1">to pts w/o preexisting AF (25%) and </text>
<text top="350" left="689" width="192" height="15" font="1">markedly lower than pts w/ atrial flutter </text>
<text top="366" left="689" width="137" height="15" font="1">plus preexisting PAF (76%) </text>
<text top="257" left="909" width="190" height="15" font="1">CTI ablation w/ bidirectional block and </text>
<text top="273" left="909" width="188" height="15" font="1">continuation of amiodarone therapy is </text>
<text top="288" left="909" width="214" height="15" font="1">effective for treatment of atrial flutter due to </text>
<text top="304" left="909" width="145" height="15" font="1">amiodarone therapy for PAF. </text>
<text top="319" left="909" width="3" height="15" font="1"> </text>
<text top="335" left="909" width="228" height="15" font="1">Hybrid therapy belongs in this guideline? Yes. </text>
<text top="350" left="909" width="90" height="15" font="1">Merit a rec? Yes.  </text>
<text top="460" left="54" width="43" height="15" font="1">Akar JG </text>
<text top="475" left="54" width="28" height="15" font="1">2001 </text>
<text top="491" left="54" width="29" height="15" font="1">(218) </text>
<text top="506" left="54" width="49" height="15" font="8">11499727</text>
<text top="506" left="103" width="3" height="15" font="1"> </text>
<text top="522" left="54" width="3" height="15" font="1"> </text>
<text top="460" left="129" width="68" height="15" font="1">Single center </text>
<text top="475" left="129" width="82" height="15" font="1">study assessing </text>
<text top="491" left="129" width="80" height="15" font="1">the coexistence </text>
<text top="506" left="129" width="90" height="15" font="1">of IART and IDAF </text>
<text top="522" left="129" width="74" height="15" font="1">in pts w/ SVTs </text>
<text top="537" left="129" width="66" height="15" font="1">after surgical </text>
<text top="552" left="129" width="91" height="15" font="1">correction of CHD </text>
<text top="460" left="233" width="95" height="15" font="1">16 consecutive pts </text>
<text top="475" left="233" width="93" height="15" font="1">diagnosed w/ both </text>
<text top="491" left="233" width="81" height="15" font="1">IART and IDAF  </text>
<text top="460" left="349" width="193" height="15" font="1">IART and IDAF diagnosed by standard </text>
<text top="475" left="349" width="195" height="15" font="1">criteria and entrainment mapping. 7 pts </text>
<text top="491" left="349" width="192" height="15" font="1">had classic atrial flutter morphology on </text>
<text top="506" left="349" width="186" height="15" font="1">surface ECG, whereas 9 had atypical </text>
<text top="522" left="349" width="61" height="15" font="1">morphology </text>
<text top="460" left="567" width="98" height="15" font="1">Successful ablation </text>
<text top="475" left="567" width="76" height="15" font="1">w/o procedural </text>
<text top="491" left="567" width="77" height="15" font="1">complication or </text>
<text top="506" left="567" width="99" height="15" font="1">recurrence at mean </text>
<text top="522" left="567" width="62" height="15" font="1">f/u of 24 mo </text>
<text top="460" left="689" width="207" height="15" font="1">Successful ablation performed in 13 of 14 </text>
<text top="475" left="689" width="180" height="15" font="1">(93%) IART and 9 of 10 (90%) IDAF </text>
<text top="491" left="689" width="41" height="15" font="1">circuits. </text>
<text top="506" left="689" width="172" height="15" font="1">1 IART recurrence otherwise none </text>
<text top="522" left="689" width="91" height="15" font="1">reported at 24 mo </text>
<text top="537" left="689" width="200" height="15" font="1">Slow conduction zone involved region of </text>
<text top="552" left="689" width="185" height="15" font="1">right atriotomy scar in 12 of 14 (86%) </text>
<text top="568" left="689" width="66" height="15" font="1">IART circuits </text>
<text top="583" left="689" width="143" height="15" font="1">No procedural complications </text>
<text top="460" left="909" width="210" height="15" font="1">IDAF and IART are the most common and </text>
<text top="475" left="909" width="225" height="15" font="1">commonly coexistant mechanisms of atrial re-</text>
<text top="491" left="909" width="218" height="15" font="1">entrant tachyarrhythmias in pts w/ surgically </text>
<text top="506" left="909" width="199" height="15" font="1">corrected CHD. Majority of IART circuits </text>
<text top="522" left="909" width="213" height="15" font="1">involve lateral RA and may be successfully </text>
<text top="537" left="909" width="174" height="15" font="1">ablated by lesion extending to IVC. </text>
<text top="600" left="54" width="55" height="15" font="1">Nakagawa </text>
<text top="615" left="54" width="28" height="15" font="1">2001 </text>
<text top="631" left="54" width="29" height="15" font="1">(219) </text>
<text top="646" left="54" width="49" height="15" font="8">11156882</text>
<text top="646" left="103" width="3" height="15" font="1"> </text>
<text top="662" left="54" width="3" height="15" font="1"> </text>
<text top="600" left="129" width="84" height="15" font="1">Characterize the </text>
<text top="615" left="129" width="84" height="15" font="1">circuit of IART in </text>
<text top="631" left="129" width="76" height="15" font="1">pts w/ repaired </text>
<text top="646" left="129" width="49" height="15" font="1">CHD and </text>
<text top="662" left="129" width="88" height="15" font="1">evaluate success </text>
<text top="677" left="129" width="73" height="15" font="1">of RFA of w/in </text>
<text top="693" left="129" width="87" height="15" font="1">channels defined </text>
<text top="708" left="129" width="15" height="15" font="1">by </text>
<text top="724" left="129" width="81" height="15" font="1">electroanatomic </text>
<text top="739" left="129" width="46" height="15" font="1">mapping </text>
<text top="600" left="233" width="97" height="15" font="1">13 pts w/ 15 IARTs </text>
<text top="600" left="349" width="154" height="15" font="1">Pts w/ repaired CHD and IART </text>
<text top="600" left="567" width="95" height="15" font="1">Acute and medium </text>
<text top="615" left="567" width="68" height="15" font="1">term success </text>
<text top="600" left="689" width="201" height="15" font="1">Ablation acutely eliminated inducibility of </text>
<text top="615" left="689" width="194" height="15" font="1">all 15 IARTs. During f/u of median 13.5 </text>
<text top="631" left="689" width="171" height="15" font="1">mo, 13 pts (81%) remained free of </text>
<text top="646" left="689" width="189" height="15" font="1">recurrence.  Large area of low voltage </text>
<text top="662" left="689" width="129" height="15" font="1">scar identified in all pts w/ </text>
<text top="677" left="689" width="146" height="15" font="1">macroreentrant tachycardias. </text>
<text top="600" left="909" width="210" height="15" font="1">RFA of IART in pts w/ repaired CHD using </text>
<text top="615" left="909" width="194" height="15" font="1">electroanatomic mapping and targeting </text>
<text top="631" left="909" width="210" height="15" font="1">channels has a reasonable success rate.   </text>
<text top="755" left="54" width="42" height="15" font="1">Deal BJ </text>
<text top="771" left="54" width="28" height="15" font="1">2002 </text>
<text top="786" left="54" width="29" height="15" font="1">(220) </text>
<text top="755" left="129" width="71" height="15" font="1">Retrospective </text>
<text top="771" left="129" width="83" height="15" font="1">non-randomized </text>
<text top="786" left="129" width="72" height="15" font="1">comparison of </text>
<text top="755" left="233" width="33" height="15" font="1">23 pts </text>
<text top="755" left="349" width="188" height="15" font="1">Pts undergoing Fontan revision w/ AT </text>
<text top="771" left="349" width="3" height="15" font="1"> </text>
<text top="786" left="349" width="168" height="15" font="1">Maybe shouldn’t  be in here since </text>
<text top="755" left="567" width="100" height="15" font="1">Inducibility at f/u EP </text>
<text top="771" left="567" width="71" height="15" font="1">and long-term </text>
<text top="786" left="567" width="69" height="15" font="1">freedom from </text>
<text top="755" left="689" width="90" height="15" font="1">Inducibility of AT:  </text>
<text top="771" left="689" width="149" height="15" font="1">62% inferomedial RA ablation </text>
<text top="786" left="689" width="116" height="15" font="1">7% modified RA MAZE </text>
<text top="755" left="909" width="213" height="15" font="1">Modified RA maze procedure is superior to </text>
<text top="771" left="909" width="217" height="15" font="1">anatomic isthmus block in treating reentrant </text>
<text top="786" left="909" width="154" height="15" font="1">AT in postoperative Fontan pts </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">97 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="49" height="15" font="8">12147539</text>
<text top="55" left="103" width="3" height="15" font="1"> </text>
<text top="70" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="129" width="75" height="15" font="1">cryoablation of </text>
<text top="70" left="129" width="82" height="15" font="1">inferomedial RA </text>
<text top="86" left="129" width="67" height="15" font="1">vs. extensive </text>
<text top="101" left="129" width="63" height="15" font="1">modified RA </text>
<text top="117" left="129" width="60" height="15" font="1">maze in pts </text>
<text top="132" left="129" width="58" height="15" font="1">undergoing </text>
<text top="147" left="129" width="79" height="15" font="1">Fontan revision </text>
<text top="163" left="129" width="31" height="15" font="1">w/ AT </text>
<text top="55" left="349" width="183" height="15" font="1">surgical; may be more recent papers </text>
<text top="70" left="349" width="195" height="15" font="1">breaking down the differences by types </text>
<text top="86" left="349" width="39" height="15" font="1">of CHD </text>
<text top="55" left="567" width="86" height="15" font="1">recurrence of AT </text>
<text top="55" left="689" width="38" height="15" font="1">P&lt;0.02 </text>
<text top="70" left="689" width="3" height="15" font="1"> </text>
<text top="86" left="689" width="3" height="15" font="1"> </text>
<text top="101" left="689" width="180" height="15" font="1">Freedom from AT (mean 43 mo f/u): </text>
<text top="117" left="689" width="149" height="15" font="1">62% inferomedial RA ablation </text>
<text top="132" left="689" width="116" height="15" font="1">0% modified RA MAZE </text>
<text top="147" left="689" width="45" height="15" font="1">P&lt;0.001 </text>
<text top="163" left="689" width="3" height="15" font="1"> </text>
<text top="179" left="54" width="52" height="15" font="1">Spector P </text>
<text top="195" left="54" width="28" height="15" font="1">2010 </text>
<text top="210" left="54" width="23" height="15" font="1">(55)<i> </i></text>
<text top="226" left="54" width="49" height="15" font="8">19699343</text>
<text top="226" left="103" width="3" height="15" font="1"> </text>
<text top="241" left="54" width="3" height="15" font="1"> </text>
<text top="179" left="129" width="84" height="15" font="1">Meta-analysis of </text>
<text top="195" left="129" width="81" height="15" font="1">ablation of atrial </text>
<text top="210" left="129" width="80" height="15" font="1">flutter and SVT. </text>
<text top="179" left="233" width="94" height="15" font="1">A meta-analysis of </text>
<text top="195" left="233" width="90" height="15" font="1">21 studies RFA in </text>
<text top="210" left="233" width="73" height="15" font="1">atrial flutter:18 </text>
<text top="226" left="233" width="92" height="15" font="1">primary studies w/ </text>
<text top="241" left="233" width="93" height="15" font="1">22 treatment arms </text>
<text top="257" left="233" width="74" height="15" font="1">and 1,323 pts) </text>
<text top="179" left="349" width="22" height="15" font="1">N/A </text>
<text top="179" left="567" width="97" height="15" font="1">Evaluate the safety </text>
<text top="195" left="567" width="100" height="15" font="1">and efficacy of RFA </text>
<text top="210" left="567" width="105" height="15" font="1">of typical atrial flutter </text>
<text top="226" left="567" width="68" height="15" font="1">and AV node-</text>
<text top="241" left="567" width="92" height="15" font="1">dependent SVT in </text>
<text top="257" left="567" width="45" height="15" font="1">adult pts </text>
<text top="179" left="689" width="204" height="15" font="1">Single-procedure success for atrial flutter </text>
<text top="195" left="689" width="183" height="15" font="1">was 91.7% (95% CI: 88.4%-94.9%).  </text>
<text top="210" left="689" width="195" height="15" font="1">Multiple-procedure success was 97.0% </text>
<text top="226" left="689" width="186" height="15" font="1">(95% CI: 94.7%-99.4%). Postablation </text>
<text top="241" left="689" width="185" height="15" font="1">arrhythmia was noted in 13.2% of pts </text>
<text top="257" left="689" width="179" height="15" font="1">(95% CI: 7.5%-18.9%), while repeat </text>
<text top="272" left="689" width="186" height="15" font="1">ablation was reported in 8% (95% CI: </text>
<text top="288" left="689" width="70" height="15" font="1">4.5%-11.4%). </text>
<text top="179" left="909" width="212" height="15" font="1">RFA for the treatment of pts w/ atrial flutter </text>
<text top="195" left="909" width="212" height="15" font="1">and SVT report high efficacy rates and low </text>
<text top="210" left="909" width="113" height="15" font="1">rates of complications. </text>
<text top="226" left="909" width="3" height="15" font="1"> </text>
<text top="241" left="909" width="208" height="15" font="1">70% of pts who got ablation didn’t need it; </text>
<text top="257" left="909" width="197" height="15" font="1">interrelationship for AF and atrial flutter. </text>
<text top="272" left="909" width="217" height="15" font="1">When to ablate?  discussion. AF ablation </text>
<text top="288" left="909" width="208" height="15" font="1">covered in consensus document. Drive by </text>
<text top="303" left="909" width="225" height="15" font="1">protein disulfide isomerase vs. drive by flutter </text>
<text top="319" left="909" width="105" height="15" font="1">ablation. Both ways.  </text>
<text top="335" left="54" width="52" height="15" font="1">Coffey JO </text>
<text top="350" left="54" width="28" height="15" font="1">2013 </text>
<text top="366" left="54" width="29" height="15" font="1">(221) </text>
<text top="381" left="54" width="49" height="15" font="8">23385050</text>
<text top="381" left="103" width="3" height="15" font="1"> </text>
<text top="397" left="54" width="3" height="15" font="1"> </text>
<text top="335" left="129" width="71" height="15" font="1">Retrospective </text>
<text top="350" left="129" width="91" height="15" font="1">multicenter cohort </text>
<text top="366" left="129" width="79" height="15" font="1">study to assess </text>
<text top="381" left="129" width="71" height="15" font="1">the efficacy of </text>
<text top="397" left="129" width="81" height="15" font="1">RFA on atypical </text>
<text top="412" left="129" width="75" height="15" font="1">atrial flutter/AT </text>
<text top="335" left="233" width="92" height="15" font="1">91 pts w/ 171 ATs </text>
<text top="350" left="233" width="44" height="15" font="1">(1.9 / pt) </text>
<text top="335" left="349" width="192" height="15" font="1">Pts w/ atypical atrial flutter/AT in pts w/ </text>
<text top="350" left="349" width="193" height="15" font="1">prior catheter ablation for AF, MAZE or </text>
<text top="366" left="349" width="203" height="15" font="1">other cardiac surgery, or idiopathic scar.  </text>
<text top="381" left="349" width="183" height="15" font="1">Pts w/ on CTI-dependent flutter were </text>
<text top="397" left="349" width="50" height="15" font="1">excluded. </text>
<text top="335" left="567" width="103" height="15" font="1">Acute and long-term </text>
<text top="350" left="567" width="43" height="15" font="1">success </text>
<text top="335" left="689" width="193" height="15" font="1">Acute success was 97% for non-septal </text>
<text top="350" left="689" width="186" height="15" font="1">AT and 77% for septal AT. Long-term </text>
<text top="366" left="689" width="205" height="15" font="1">success rates 82% in pts w/ no septal AT </text>
<text top="381" left="689" width="197" height="15" font="1">and 67% in pts w/ 1 or more septal AT.  </text>
<text top="397" left="689" width="180" height="15" font="1">Long-term success rates were 75%, </text>
<text top="412" left="689" width="202" height="15" font="1">88%, and 57% for pts w/ ATs associated </text>
<text top="428" left="689" width="166" height="15" font="1">w/ prior catheter ablation, cardiac </text>
<text top="443" left="689" width="160" height="15" font="1">sugery/MAZE or idiopathic scar, </text>
<text top="459" left="689" width="65" height="15" font="1">respectively. </text>
<text top="335" left="909" width="225" height="15" font="1">High-density activation mapping combined w/ </text>
<text top="350" left="909" width="203" height="15" font="1">selective entrainment mapping allows for </text>
<text top="366" left="909" width="193" height="15" font="1">reasonable successful RFA of non-CTI </text>
<text top="381" left="909" width="214" height="15" font="1">dependent ATs occurring after AF ablation, </text>
<text top="397" left="909" width="223" height="15" font="1">cardiac surgery, or in the setting of idiopathic </text>
<text top="412" left="909" width="27" height="15" font="1">scar. </text>
<text top="475" left="54" width="50" height="15" font="1">Ghali WA </text>
<text top="491" left="54" width="28" height="15" font="1">2005 </text>
<text top="506" left="54" width="29" height="15" font="1">(222) </text>
<text top="522" left="54" width="3" height="15" font="1"> </text>
<text top="537" left="54" width="3" height="15" font="1"> </text>
<text top="475" left="129" width="57" height="15" font="1">Systematic </text>
<text top="491" left="129" width="85" height="15" font="1">review and meta-</text>
<text top="506" left="129" width="55" height="15" font="1">analysis of </text>
<text top="522" left="129" width="69" height="15" font="1">observational </text>
<text top="537" left="129" width="60" height="15" font="1">studies that </text>
<text top="552" left="129" width="82" height="15" font="1">investigated risk </text>
<text top="568" left="129" width="12" height="15" font="1">of </text>
<text top="583" left="129" width="91" height="15" font="1">thromboembolism </text>
<text top="599" left="129" width="79" height="15" font="1">associated with </text>
<text top="615" left="129" width="61" height="15" font="1">atrial flutter. </text>
<text top="475" left="233" width="93" height="15" font="1">The meta analysis </text>
<text top="491" left="233" width="98" height="15" font="1">included 13 studies </text>
<text top="506" left="233" width="77" height="15" font="1">on embolic risk </text>
<text top="522" left="233" width="74" height="15" font="1">around time of </text>
<text top="537" left="233" width="90" height="15" font="1">cardioversion that </text>
<text top="552" left="233" width="72" height="15" font="1">included 1546 </text>
<text top="568" left="233" width="65" height="15" font="1">patients. For </text>
<text top="583" left="233" width="90" height="15" font="1">chronic risk, there </text>
<text top="599" left="233" width="80" height="15" font="1">were 14 studies </text>
<text top="615" left="233" width="83" height="15" font="1">involving 17,691 </text>
<text top="630" left="233" width="45" height="15" font="1">patients. </text>
<text top="475" left="349" width="204" height="15" font="15">MEDLINE, EMBASE, bibliographies, and </text>
<text top="491" left="349" width="188" height="15" font="15">consultation with clinical experts were </text>
<text top="506" left="349" width="188" height="15" font="15">used to identify studies that report the </text>
<text top="522" left="349" width="202" height="15" font="15">risk of thromboembolism associated with </text>
<text top="537" left="349" width="202" height="15" font="15">attempted cardioversion and longer-term </text>
<text top="552" left="349" width="154" height="15" font="15">risk in patients with atrial flutter.</text>
<text top="552" left="503" width="3" height="15" font="1"> </text>
<text top="475" left="567" width="37" height="15" font="1">Risk of </text>
<text top="491" left="567" width="91" height="15" font="1">thromboembolism </text>
<text top="506" left="567" width="106" height="15" font="1">associated with atrial </text>
<text top="522" left="567" width="105" height="15" font="1">flutter around time of </text>
<text top="537" left="567" width="106" height="15" font="1">cardioversion or over </text>
<text top="553" left="567" width="79" height="15" font="1">the long term in </text>
<text top="568" left="567" width="100" height="15" font="1">chronic atrial flutter. </text>
<text top="475" left="689" width="204" height="15" font="1">Around the time of cardioversion, the risk </text>
<text top="491" left="689" width="193" height="15" font="1">of thromboembolic events ranged from </text>
<text top="506" left="689" width="202" height="15" font="15">0% to 7.3% depending of clinical factors. </text>
<text top="522" left="689" width="178" height="15" font="15">Lower event rates were observed in </text>
<text top="537" left="689" width="149" height="15" font="15">patients taking anticoagulants.</text>
<text top="537" left="838" width="3" height="15" font="1"> </text>
<text top="552" left="689" width="126" height="15" font="15">The long term risk rate of </text>
<text top="568" left="689" width="205" height="15" font="15">thromboembolism was approximately 3% </text>
<text top="583" left="689" width="131" height="15" font="15">with sustained atrial flutter.</text>
<text top="583" left="820" width="3" height="15" font="1"> </text>
<text top="475" left="909" width="186" height="15" font="15">The findings of this systematic review </text>
<text top="491" left="909" width="226" height="15" font="15">strongly suggest that atrial flutter does indeed </text>
<text top="506" left="909" width="170" height="15" font="15">impart a risk of thromboembolism. </text>
<text top="506" left="1079" width="3" height="15" font="1"> </text>
<text top="646" left="54" width="1040" height="15" font="1">AF indicates atrial fibrillation; AT, atrial tachycardia; AV, atrioventricular; bid, two times per day; CCW, counter-clockwise; CHD, congenital heart disease; CHF, congestive heart failure; CI, confidence interval; CTI, </text>
<text top="662" left="54" width="1068" height="15" font="1">cavotricuspid isthmus; ECG, electrocardiogram; EP, electrophysiological; f/u, follow up; GI, gastrointestinal; h/o, history of; IART, intraatrial reentrant tachycardia; IDAF, isthmus-dependent atrial flutter; IVC, inferior vena </text>
<text top="677" left="54" width="1068" height="15" font="1">cava; LV, left ventricular; MI, myocardial infarction; N/A, not applicable; PAF, paroxysmal atrial fibrillation; PPI, postpacing interval; pt, patient; PVC, premature ventricular contraction; RA, right atrial; RF, radiofrequency; </text>
<text top="693" left="54" width="813" height="15" font="1">RFA, radiofrequency ablation; SHD, structural heart disease; SVT, supraventricular tachycardia; w/, with; w/o, without; and WPW, Wolff-Parkinson-White syndrome.    </text>
<text top="708" left="54" width="3" height="14" font="20"> </text>
<text top="732" left="54" width="4" height="18" font="3"><b> </b></text>
<text top="760" left="54" width="4" height="18" font="3"><b> </b></text>
<text top="788" left="54" width="4" height="18" font="3"><b> </b></text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">98 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="151" height="18" font="3"><b>Data Supplement 18. </b></text>
<text top="55" left="205" width="412" height="18" font="7"><b>Randomized Trials for Junctional Tachycardia – Section 8</b></text>
<text top="55" left="617" width="4" height="18" font="3"><b> </b></text>
<text top="74" left="60" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="58" width="40" height="17" font="5"><b>Name, </b></text>
<text top="108" left="55" width="47" height="17" font="5"><b>Author, </b></text>
<text top="125" left="64" width="30" height="17" font="5"><b>Year </b></text>
<text top="74" left="119" width="42" height="17" font="5"><b>Aim of </b></text>
<text top="91" left="121" width="38" height="17" font="5"><b>Study </b></text>
<text top="74" left="182" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="185" width="32" height="17" font="5"><b>Type </b></text>
<text top="108" left="183" width="36" height="17" font="5"><b>(Size, </b></text>
<text top="125" left="193" width="16" height="17" font="5"><b>N) </b></text>
<text top="74" left="256" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="238" width="74" height="17" font="5"><b>Intervention </b></text>
<text top="108" left="245" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="74" left="344" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="326" width="73" height="17" font="5"><b>Comparator </b></text>
<text top="108" left="333" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="74" left="490" width="83" height="17" font="5"><b>Pt Population </b></text>
<text top="74" left="756" width="64" height="17" font="5"><b>Endpoints </b></text>
<text top="74" left="933" width="109" height="17" font="5"><b>P Values, OR: HR: </b></text>
<text top="91" left="945" width="85" height="17" font="5"><b>RR: &amp; 95% CI: </b></text>
<text top="74" left="1081" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="1066" width="69" height="17" font="5"><b>Limitations </b></text>
<text top="108" left="1068" width="64" height="17" font="5"><b>&amp; Adverse </b></text>
<text top="125" left="1078" width="44" height="17" font="5"><b>Events </b></text>
<text top="143" left="67" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="138" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="199" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="273" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="361" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="419" width="104" height="17" font="13"><i><b>Inclusion Criteria </b></i></text>
<text top="143" left="542" width="108" height="17" font="13"><i><b>Exclusion Criteria </b></i></text>
<text top="143" left="676" width="49" height="17" font="13"><i><b>Primary </b></i></text>
<text top="161" left="672" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="178" left="672" width="58" height="17" font="13"><i><b>(efficacy) </b></i></text>
<text top="195" left="664" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="143" left="771" width="40" height="17" font="13"><i><b>Safety </b></i></text>
<text top="161" left="763" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="178" left="755" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="143" left="846" width="70" height="17" font="13"><i><b>Secondary  </b></i></text>
<text top="161" left="851" width="67" height="17" font="13"><i><b>Endpoint    </b></i></text>
<text top="178" left="867" width="25" height="17" font="13"><i><b>and </b></i></text>
<text top="195" left="855" width="48" height="17" font="13"><i><b>Results </b></i></text>
<text top="143" left="986" width="3" height="17" font="5"><b> </b></text>
<text top="143" left="1098" width="3" height="17" font="5"><b> </b></text>
<text top="213" left="54" width="42" height="15" font="1">Mamchu</text>
<text top="228" left="54" width="25" height="15" font="1">r SE </text>
<text top="244" left="54" width="28" height="15" font="1">2012 </text>
<text top="259" left="54" width="29" height="15" font="1">(223) </text>
<text top="275" left="54" width="43" height="15" font="8">2297872</text>
<text top="290" left="54" width="9" height="15" font="8">3 </text>
<text top="290" left="63" width="3" height="15" font="1"> </text>
<text top="213" left="116" width="39" height="15" font="1">Assess </text>
<text top="228" left="116" width="39" height="15" font="1">the risk </text>
<text top="244" left="116" width="30" height="15" font="1">of AV </text>
<text top="259" left="116" width="29" height="15" font="1">block </text>
<text top="275" left="116" width="34" height="15" font="1">during </text>
<text top="290" left="116" width="42" height="15" font="1">ablation </text>
<text top="306" left="116" width="12" height="15" font="1">of </text>
<text top="321" left="116" width="39" height="15" font="1">parahisi</text>
<text top="337" left="116" width="15" height="15" font="1">an </text>
<text top="352" left="116" width="38" height="15" font="1">ectopic </text>
<text top="368" left="116" width="45" height="15" font="1">foci prior </text>
<text top="383" left="116" width="12" height="15" font="1">to </text>
<text top="399" left="116" width="42" height="15" font="1">ablation </text>
<text top="414" left="116" width="39" height="15" font="1">by high-</text>
<text top="430" left="116" width="42" height="15" font="1">amplitud</text>
<text top="445" left="116" width="36" height="15" font="1">e pace </text>
<text top="461" left="116" width="42" height="15" font="1">mapping</text>
<text top="476" left="116" width="9" height="15" font="1">.  </text>
<text top="213" left="177" width="26" height="15" font="1">RCT </text>
<text top="228" left="177" width="37" height="15" font="1">(N=20) </text>
<text top="244" left="177" width="3" height="15" font="1"> </text>
<text top="213" left="238" width="55" height="15" font="1">Ablation at </text>
<text top="228" left="238" width="53" height="15" font="1">site where </text>
<text top="244" left="238" width="25" height="15" font="1">high-</text>
<text top="259" left="238" width="71" height="15" font="1">amplitude (15-</text>
<text top="275" left="238" width="74" height="15" font="1">30 mA) pacing </text>
<text top="290" left="238" width="45" height="15" font="1">revealed </text>
<text top="306" left="238" width="57" height="15" font="1">absence of </text>
<text top="321" left="238" width="59" height="15" font="1">His capture </text>
<text top="337" left="238" width="57" height="15" font="1">(wide QRS </text>
<text top="352" left="238" width="60" height="15" font="1">complexes) </text>
<text top="368" left="238" width="35" height="15" font="1">(n=11) </text>
<text top="213" left="325" width="43" height="15" font="1">Ablation </text>
<text top="228" left="325" width="65" height="15" font="1">performed in </text>
<text top="244" left="325" width="65" height="15" font="1">conventional </text>
<text top="259" left="325" width="70" height="15" font="1">manner (n=9) </text>
<text top="213" left="413" width="87" height="15" font="1">Pts w/ parahisian </text>
<text top="228" left="413" width="115" height="15" font="1">ectopic foci (i.e., pts w/ </text>
<text top="244" left="413" width="49" height="15" font="1">focal JT)  </text>
<text top="259" left="413" width="3" height="15" font="1"> </text>
<text top="213" left="541" width="63" height="15" font="1">Pts w/ SHD  </text>
<text top="213" left="663" width="46" height="15" font="1">Group 1: </text>
<text top="228" left="663" width="43" height="15" font="1">Ablation </text>
<text top="244" left="663" width="50" height="15" font="1">(standard </text>
<text top="259" left="663" width="53" height="15" font="1">approach) </text>
<text top="275" left="663" width="56" height="15" font="1">effective in </text>
<text top="290" left="663" width="60" height="15" font="1">6/11 (55%); </text>
<text top="306" left="663" width="46" height="15" font="1">Group 2: </text>
<text top="321" left="663" width="43" height="15" font="1">Ablation </text>
<text top="337" left="663" width="58" height="15" font="1">effective w/ </text>
<text top="352" left="663" width="24" height="15" font="1">high </text>
<text top="368" left="663" width="51" height="15" font="1">amplitude </text>
<text top="383" left="663" width="66" height="15" font="1">pacing in 9/9 </text>
<text top="399" left="663" width="42" height="15" font="1">(100%), </text>
<text top="414" left="663" width="37" height="15" font="1">p=0.02 </text>
<text top="213" left="751" width="71" height="15" font="1">Group 1: 27% </text>
<text top="228" left="751" width="50" height="15" font="1">AV block; </text>
<text top="244" left="751" width="61" height="15" font="1">Group 2: no </text>
<text top="259" left="751" width="73" height="15" font="1">complications, </text>
<text top="275" left="751" width="37" height="15" font="1">p=0.09 </text>
<text top="213" left="845" width="25" height="15" font="1">Late </text>
<text top="228" left="845" width="56" height="15" font="1">recurrence </text>
<text top="244" left="845" width="50" height="15" font="1">of ectopic </text>
<text top="259" left="845" width="37" height="15" font="1">activity </text>
<text top="275" left="845" width="47" height="15" font="1">similar in </text>
<text top="290" left="845" width="65" height="15" font="1">both groups, </text>
<text top="306" left="845" width="31" height="15" font="1">p=NS </text>
<text top="213" left="926" width="89" height="15" font="1">Group 1: Ablation </text>
<text top="228" left="926" width="116" height="15" font="1">effective in 6/11 (55%); </text>
<text top="244" left="926" width="89" height="15" font="1">Group 2: Ablation </text>
<text top="259" left="926" width="116" height="15" font="1">effective in 9/9 (100%), </text>
<text top="275" left="926" width="112" height="15" font="1">p=0.02. Group 1: 27% </text>
<text top="290" left="926" width="111" height="15" font="1">AV block; Group 2: no </text>
<text top="306" left="926" width="73" height="15" font="1">complications, </text>
<text top="321" left="926" width="121" height="15" font="1">p=0.09. Late recurrence </text>
<text top="337" left="926" width="122" height="15" font="1">of ectopic activity similar </text>
<text top="352" left="926" width="113" height="15" font="1">in both groups, p=NS.  </text>
<text top="213" left="1063" width="73" height="15" font="1">Small sample, </text>
<text top="228" left="1063" width="68" height="15" font="1">generalizabilit</text>
<text top="244" left="1063" width="51" height="15" font="1">y unclear. </text>
<text top="259" left="1063" width="60" height="15" font="1">Cannot use </text>
<text top="275" left="1063" width="56" height="15" font="1">method for </text>
<text top="290" left="1063" width="68" height="15" font="1">ectopic focus </text>
<text top="306" left="1063" width="36" height="15" font="1">in right </text>
<text top="321" left="1063" width="46" height="15" font="1">coronary </text>
<text top="337" left="1063" width="60" height="15" font="1">sinus or the </text>
<text top="352" left="1063" width="31" height="15" font="1">aorta. </text>
<text top="492" left="54" width="677" height="15" font="1">AV indicates atrioventricular; NS, non-significant; pt, patient; RCT, randomized controlled trial; SHD, structural heart disease; and w/, with. </text>
<text top="508" left="54" width="3" height="15" font="1"> </text>
<text top="533" left="54" width="151" height="18" font="3"><b>Data Supplement 19. </b></text>
<text top="533" left="205" width="726" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Junctional Tachycardia – Section 8 </b></text>
<text top="552" left="67" width="38" height="17" font="5"><b>Study </b></text>
<text top="569" left="65" width="40" height="17" font="5"><b>Name, </b></text>
<text top="587" left="62" width="47" height="17" font="5"><b>Author, </b></text>
<text top="604" left="71" width="30" height="17" font="5"><b>Year </b></text>
<text top="552" left="135" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="569" left="149" width="44" height="17" font="5"><b>Design </b></text>
<text top="552" left="231" width="38" height="17" font="5"><b>Study </b></text>
<text top="569" left="236" width="28" height="17" font="5"><b>Size </b></text>
<text top="552" left="307" width="119" height="17" font="5"><b>Inclusion/Exclusion </b></text>
<text top="569" left="344" width="46" height="17" font="5"><b>Criteria </b></text>
<text top="552" left="513" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="552" left="729" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="552" left="944" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="622" left="54" width="129" height="15" font="1">Pharmacological Therapy </text>
<text top="638" left="54" width="33" height="15" font="1">Ruder </text>
<text top="653" left="54" width="28" height="15" font="1">1986 </text>
<text top="669" left="54" width="29" height="15" font="1">(224) </text>
<text top="684" left="54" width="43" height="15" font="8">3698238</text>
<text top="684" left="97" width="3" height="15" font="1"> </text>
<text top="638" left="130" width="61" height="15" font="1">Case report </text>
<text top="638" left="226" width="22" height="15" font="1">n=5 </text>
<text top="638" left="287" width="121" height="15" font="1">5 adult pts w/ JT (one pt </text>
<text top="653" left="287" width="109" height="15" font="1">refused drug therapy) </text>
<text top="638" left="459" width="177" height="15" font="1">Control or eradication of arrhythmia </text>
<text top="638" left="686" width="170" height="15" font="1">All pts responded to beta-blockers </text>
<text top="653" left="686" width="156" height="15" font="1">(nadolol, propranolol), and best </text>
<text top="669" left="686" width="146" height="15" font="1">response w/ beta-blockers w/ </text>
<text top="684" left="686" width="73" height="15" font="1">procainamide. </text>
<text top="638" left="887" width="223" height="15" font="1">First report of JT in adults. Good response to </text>
<text top="653" left="887" width="249" height="15" font="1">beta-blockers. Only 4/5 pts underwent EP study to </text>
<text top="669" left="887" width="179" height="15" font="1">definitively identify junctional origin.  </text>
<text top="701" left="54" width="29" height="15" font="1">Cook </text>
<text top="716" left="54" width="28" height="15" font="1">1988 </text>
<text top="731" left="54" width="29" height="15" font="1">(225) </text>
<text top="747" left="54" width="43" height="15" font="8">1951023</text>
<text top="747" left="97" width="3" height="15" font="1"> </text>
<text top="701" left="130" width="61" height="15" font="1">Case report </text>
<text top="701" left="226" width="22" height="15" font="1">n=1 </text>
<text top="701" left="287" width="103" height="15" font="1">19 y w/ refractory JT </text>
<text top="701" left="459" width="205" height="15" font="1">Flecainide therapy for JT refractory to AV </text>
<text top="716" left="459" width="199" height="15" font="1">nodal blockers, burst atrial or ventricular </text>
<text top="731" left="459" width="36" height="15" font="1">pacing </text>
<text top="701" left="686" width="178" height="15" font="1">Flecainide 150 mg bid successful in </text>
<text top="716" left="686" width="65" height="15" font="1">restoring SR </text>
<text top="701" left="887" width="243" height="15" font="1">First report of successful treatment of “incessant” </text>
<text top="716" left="887" width="106" height="15" font="1">JT w/ class Ic agent.  </text>
<text top="763" left="54" width="28" height="15" font="1">Kuck </text>
<text top="779" left="54" width="28" height="15" font="1">1988 </text>
<text top="794" left="54" width="29" height="15" font="1">(226) </text>
<text top="763" left="130" width="61" height="15" font="1">Case series </text>
<text top="763" left="226" width="22" height="15" font="1">n=3 </text>
<text top="763" left="287" width="137" height="15" font="1">16 total pts w/ ectopic atrial </text>
<text top="779" left="287" width="135" height="15" font="1">tachyarrhythmia in study, 2 </text>
<text top="794" left="287" width="158" height="15" font="1">spontaneous JT (not inducible), </text>
<text top="763" left="459" width="197" height="15" font="1">Flecainide and encainide therapy for JT </text>
<text top="763" left="686" width="151" height="15" font="1">Flecainide effective in 2 pts w/ </text>
<text top="779" left="686" width="185" height="15" font="1">spontaneous JT (200 and 300 mg/d). </text>
<text top="794" left="686" width="178" height="15" font="1">Pt w/ incessant JT had prolongation </text>
<text top="763" left="887" width="209" height="15" font="1">Encainide arm not valid for guidelines, but </text>
<text top="779" left="887" width="189" height="15" font="1">flecainide results valid for treatment of </text>
<text top="794" left="887" width="232" height="15" font="1">spontaneous JT. Builds on Cook’s data above. </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1120" width="17" height="17" font="0">99 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="43" height="15" font="8">3144166</text>
<text top="55" left="97" width="3" height="15" font="1"> </text>
<text top="55" left="287" width="75" height="15" font="1">1 incessant JT </text>
<text top="55" left="686" width="161" height="15" font="1">of H-V interval and hypotension. </text>
<text top="71" left="54" width="33" height="15" font="1">Villain </text>
<text top="86" left="54" width="28" height="15" font="1">1990 </text>
<text top="102" left="54" width="29" height="15" font="1">(227) </text>
<text top="117" left="54" width="43" height="15" font="8">2184944</text>
<text top="117" left="97" width="3" height="15" font="1"> </text>
<text top="71" left="130" width="57" height="15" font="1">Multicenter </text>
<text top="86" left="130" width="77" height="15" font="1">study; pediatric </text>
<text top="102" left="130" width="57" height="15" font="1">population  </text>
<text top="71" left="226" width="28" height="15" font="1">n=26 </text>
<text top="71" left="287" width="66" height="15" font="1">Infants w/ JT </text>
<text top="71" left="459" width="207" height="15" font="1">AAD therapy in congenital JT, w/ success </text>
<text top="86" left="459" width="205" height="15" font="1">defined as HR &lt;150 bpm, partial success </text>
<text top="102" left="459" width="142" height="15" font="1">as HR &gt;150 bpm w/ sx relief </text>
<text top="71" left="686" width="186" height="15" font="1">Combinations of digoxin, propranolol, </text>
<text top="86" left="686" width="168" height="15" font="1">amiodarone, quinidine, flecainide, </text>
<text top="102" left="686" width="169" height="15" font="1">chlorpromazine, phenytoin. 10 pts </text>
<text top="117" left="686" width="181" height="15" font="1">treated w/ amiodarone monotherapy </text>
<text top="133" left="686" width="188" height="15" font="1">—6 successes, 2 partial successes, 2 </text>
<text top="148" left="686" width="127" height="15" font="1">failures. One death in f/u. </text>
<text top="164" left="686" width="188" height="15" font="1">Amiodarone combination therapy less </text>
<text top="179" left="686" width="47" height="15" font="1">effective. </text>
<text top="71" left="887" width="202" height="15" font="1">Amiodarone monotherapy is effective for </text>
<text top="86" left="887" width="239" height="15" font="1">congenital JT, but associated w/ some mortality. </text>
<text top="102" left="887" width="204" height="15" font="1">Authors comment that ablation should be </text>
<text top="117" left="887" width="249" height="15" font="1">reserved for drug-refractory JT. Digoxin ineffective </text>
<text top="133" left="887" width="238" height="15" font="1">in rate control, and may be harmful--specifically, </text>
<text top="148" left="887" width="249" height="15" font="1">incriminated in producing VF in 4 wk old child; and </text>
<text top="164" left="887" width="245" height="15" font="1">atrial tachycardia and then atrial flutter in 10 d old </text>
<text top="179" left="887" width="33" height="15" font="1">infant. </text>
<text top="195" left="54" width="25" height="15" font="1">Paul </text>
<text top="211" left="54" width="28" height="15" font="1">1992 </text>
<text top="226" left="54" width="29" height="15" font="1">(228) </text>
<text top="242" left="54" width="43" height="15" font="8">1527301</text>
<text top="242" left="97" width="3" height="15" font="1"> </text>
<text top="195" left="130" width="64" height="15" font="1">Case series; </text>
<text top="211" left="130" width="45" height="15" font="1">pediatric </text>
<text top="226" left="130" width="54" height="15" font="1">population </text>
<text top="195" left="226" width="22" height="15" font="1">n=4 </text>
<text top="195" left="287" width="119" height="15" font="1">Infants w/ congenital JT </text>
<text top="195" left="459" width="191" height="15" font="1">Propafenone therapy for congenital JT </text>
<text top="195" left="686" width="181" height="15" font="1">Effective at restoring SR w/ doses of </text>
<text top="211" left="686" width="49" height="15" font="1">300 mg/m</text>
<text top="211" left="735" width="4" height="10" font="10">2</text>
<text top="211" left="739" width="116" height="15" font="1"> w/ f/u ranging 1-36 mo </text>
<text top="195" left="887" width="230" height="15" font="1">Efficacy of propafenone in pediatric population </text>
<text top="211" left="887" width="238" height="15" font="1">can avoid need for ablation in young population, </text>
<text top="226" left="887" width="162" height="15" font="1">and early toxicity of amiodarone. </text>
<text top="258" left="54" width="44" height="15" font="1">Heusch  </text>
<text top="274" left="54" width="28" height="15" font="1">1994 </text>
<text top="289" left="54" width="23" height="15" font="1">(91) </text>
<text top="305" left="54" width="43" height="15" font="8">7527342</text>
<text top="305" left="97" width="3" height="15" font="1"> </text>
<text top="258" left="130" width="71" height="15" font="1">Retrospective </text>
<text top="274" left="130" width="66" height="15" font="1">cohort study; </text>
<text top="289" left="130" width="45" height="15" font="1">pediatric </text>
<text top="305" left="130" width="54" height="15" font="1">population </text>
<text top="258" left="226" width="22" height="15" font="1">n=3 </text>
<text top="258" left="287" width="92" height="15" font="1">72 pediatric pts w/ </text>
<text top="274" left="287" width="143" height="15" font="1">supraventricular arrhythmias </text>
<text top="289" left="287" width="153" height="15" font="1">treated w/ propafenone, only 3 </text>
<text top="305" left="287" width="55" height="15" font="1">pts had JT </text>
<text top="258" left="459" width="197" height="15" font="1">Efficacy of propafenone in suppressing  </text>
<text top="274" left="459" width="137" height="15" font="1">supraventricular arrhythmia </text>
<text top="258" left="686" width="134" height="15" font="1">Successful in 2/3 pts w/ JT </text>
<text top="258" left="887" width="194" height="15" font="1">Supports results of Paul et al for use of </text>
<text top="274" left="887" width="235" height="15" font="1">propafenone, despite small subset of pts w/ JT. </text>
<text top="321" left="54" width="36" height="15" font="1">Raja P </text>
<text top="336" left="54" width="28" height="15" font="1">1994 </text>
<text top="352" left="54" width="29" height="15" font="1">(229) </text>
<text top="367" left="54" width="46" height="15" font="8">7946778 </text>
<text top="367" left="100" width="3" height="15" font="1"> </text>
<text top="321" left="130" width="71" height="15" font="1">Retrospective </text>
<text top="336" left="130" width="66" height="15" font="1">cohort study; </text>
<text top="352" left="130" width="45" height="15" font="1">pediatric </text>
<text top="367" left="130" width="54" height="15" font="1">population </text>
<text top="321" left="226" width="28" height="15" font="1">n=16 </text>
<text top="321" left="287" width="128" height="15" font="1">Postoperative (CHD) JET </text>
<text top="321" left="459" width="190" height="15" font="1">Efficacy of amiodarone for rate control </text>
<text top="321" left="686" width="167" height="15" font="1">Mean HR of 200 bpm, reduced to </text>
<text top="336" left="686" width="127" height="15" font="1">mean 153-170 in 24-h f/u </text>
<text top="321" left="887" width="231" height="15" font="1">Amiodarone effective in HR and hemodynamic </text>
<text top="336" left="887" width="140" height="15" font="1">control for postoperative JT. </text>
<text top="384" left="54" width="22" height="15" font="1">Lee </text>
<text top="399" left="54" width="28" height="15" font="1">1999 </text>
<text top="415" left="54" width="29" height="15" font="1">(230) </text>
<text top="430" left="54" width="49" height="15" font="8">10392383</text>
<text top="430" left="103" width="3" height="15" font="1"> </text>
<text top="384" left="130" width="61" height="15" font="1">Prospective </text>
<text top="399" left="130" width="63" height="15" font="1">cohort study </text>
<text top="384" left="226" width="28" height="15" font="1">n=17 </text>
<text top="399" left="226" width="41" height="15" font="1">(age 12-</text>
<text top="415" left="226" width="19" height="15" font="1">83) </text>
<text top="384" left="287" width="140" height="15" font="1">Pts developed JT during EP </text>
<text top="399" left="287" width="129" height="15" font="1">study, and all inducible w/ </text>
<text top="415" left="287" width="67" height="15" font="1">isoproterenol </text>
<text top="384" left="459" width="182" height="15" font="1">Effect of adenosine and verapamil in </text>
<text top="399" left="459" width="137" height="15" font="1">catecholamine-inducible JT </text>
<text top="384" left="686" width="173" height="15" font="1">Adenosine terminated rhythm in all </text>
<text top="399" left="686" width="159" height="15" font="1">pts, 11 w/ transient AV block. IV </text>
<text top="415" left="686" width="185" height="15" font="1">verapamil terminated rhythm in all 10 </text>
<text top="430" left="686" width="91" height="15" font="1">pts given the drug </text>
<text top="384" left="887" width="210" height="15" font="1">Supports treatment of JT due to enhanced </text>
<text top="399" left="887" width="206" height="15" font="1">automaticity w/ adenosine and verapamil. </text>
<text top="415" left="887" width="225" height="15" font="1">Presence of AV block w/ adenosine suggests </text>
<text top="430" left="887" width="201" height="15" font="1">differential effect on automaticity and AV </text>
<text top="446" left="887" width="246" height="15" font="1">conduction. Age range spans pediatric and adult.  </text>
<text top="462" left="54" width="44" height="15" font="1">Sarubbi  </text>
<text top="477" left="54" width="28" height="15" font="1">2002 </text>
<text top="493" left="54" width="29" height="15" font="1">(231) </text>
<text top="508" left="54" width="49" height="15" font="8">12117855</text>
<text top="508" left="103" width="3" height="15" font="1"> </text>
<text top="524" left="54" width="3" height="15" font="1"> </text>
<text top="462" left="130" width="71" height="15" font="1">Retrospective </text>
<text top="477" left="130" width="63" height="15" font="1">cohort study </text>
<text top="462" left="226" width="31" height="15" font="1">n = 9, </text>
<text top="477" left="226" width="41" height="15" font="1">age 2-6 </text>
<text top="493" left="226" width="18" height="15" font="1">mo </text>
<text top="462" left="287" width="123" height="15" font="1">5/9 pts w/ family h/o JT;  </text>
<text top="477" left="287" width="142" height="15" font="1">6/9 w/ decreased ventricular </text>
<text top="493" left="287" width="42" height="15" font="1">function </text>
<text top="462" left="459" width="159" height="15" font="1">Effects of digoxin, propafenone, </text>
<text top="477" left="459" width="62" height="15" font="1">amiodarone </text>
<text top="462" left="686" width="126" height="15" font="1">Digoxin alone ineffective; </text>
<text top="477" left="686" width="170" height="15" font="1">propafenone alone effective in 2/9 </text>
<text top="493" left="686" width="171" height="15" font="1">pts; amiodarone in combination w/ </text>
<text top="508" left="686" width="184" height="15" font="1">propafenone or flecainide effective in </text>
<text top="524" left="686" width="27" height="15" font="1">6 pts </text>
<text top="462" left="887" width="204" height="15" font="1">Digoxin or propafenone alone ineffective; </text>
<text top="477" left="887" width="219" height="15" font="1">Amiodarone effective as part of combination </text>
<text top="493" left="887" width="227" height="15" font="1">therapy w/ propafenone; or flecainide; genetic </text>
<text top="508" left="887" width="100" height="15" font="1">contribution noted.   </text>
<text top="540" left="54" width="87" height="15" font="1">Ablation Therapy </text>
<text top="556" left="54" width="58" height="15" font="1">Scheinman </text>
<text top="572" left="54" width="22" height="15" font="1">MM </text>
<text top="587" left="54" width="31" height="15" font="1">1994  </text>
<text top="603" left="54" width="29" height="15" font="1">(232) </text>
<text top="618" left="54" width="43" height="15" font="8">8074039</text>
<text top="618" left="97" width="3" height="15" font="1"> </text>
<text top="556" left="130" width="61" height="15" font="1">Case series </text>
<text top="556" left="226" width="22" height="15" font="1">n=8 </text>
<text top="556" left="287" width="76" height="15" font="1">Adult pts w/ JT </text>
<text top="556" left="459" width="53" height="15" font="1">RFA of JT </text>
<text top="556" left="686" width="157" height="15" font="1">6/8 w/ JT underwent ablation, 2 </text>
<text top="572" left="686" width="172" height="15" font="1">underwent AVJ ablation. Only 2 w/ </text>
<text top="587" left="686" width="130" height="15" font="1">preserved AV conduction. </text>
<text top="556" left="887" width="242" height="15" font="1">Early report establishing that RF ablation may be </text>
<text top="572" left="887" width="129" height="15" font="1">successful therapy for JT. </text>
<text top="634" left="54" width="57" height="15" font="1">Hamdan M </text>
<text top="650" left="54" width="28" height="15" font="1">1996 </text>
<text top="665" left="54" width="29" height="15" font="1">(233) </text>
<text top="681" left="54" width="46" height="15" font="8">8960595 </text>
<text top="681" left="100" width="3" height="15" font="1"> </text>
<text top="634" left="130" width="61" height="15" font="1">Case series </text>
<text top="634" left="226" width="28" height="15" font="1">n=11 </text>
<text top="634" left="287" width="103" height="15" font="1">Pts w/ JT (age 1-66) </text>
<text top="634" left="459" width="53" height="15" font="1">RFA of JT </text>
<text top="634" left="686" width="182" height="15" font="1">RFA successful w/o complications in </text>
<text top="650" left="686" width="165" height="15" font="1">9/11 pts (82%). 7/9 successful w/ </text>
<text top="665" left="686" width="153" height="15" font="1">ablation at site of earliest atrial </text>
<text top="681" left="686" width="181" height="15" font="1">activation and 2 pts required empiric </text>
<text top="696" left="686" width="178" height="15" font="1">lesions in posteroseptal area due to </text>
<text top="712" left="686" width="139" height="15" font="1">lack of VA conduction. CHB </text>
<text top="727" left="686" width="188" height="15" font="1">developed in 1 pt, and RFA failed in 1 </text>
<text top="743" left="686" width="81" height="15" font="1">pt. F/u 1-20 mo. </text>
<text top="634" left="887" width="246" height="15" font="1">RF ablation a largely successful strategy in series </text>
<text top="650" left="887" width="164" height="15" font="1">of pts, half of which were adults.  </text>
<text top="759" left="54" width="38" height="15" font="1">Law IH </text>
<text top="775" left="54" width="31" height="15" font="1">2006  </text>
<text top="790" left="54" width="29" height="15" font="1">(234) </text>
<text top="759" left="130" width="71" height="15" font="1">Retrospective </text>
<text top="775" left="130" width="66" height="15" font="1">cohort study; </text>
<text top="790" left="130" width="45" height="15" font="1">pediatric </text>
<text top="759" left="226" width="22" height="15" font="1">n=6 </text>
<text top="775" left="226" width="45" height="15" font="1">(range 7-</text>
<text top="790" left="226" width="27" height="15" font="1">36 y, </text>
<text top="759" left="287" width="111" height="15" font="1">All pts who underwent </text>
<text top="775" left="287" width="147" height="15" font="1">cryoablation for symptomatic, </text>
<text top="790" left="287" width="110" height="15" font="1">non-postoperative JT, </text>
<text top="759" left="459" width="202" height="15" font="1">Efficacy and safety of cryoablation for JT </text>
<text top="759" left="686" width="182" height="15" font="1">4 pts had no JT at end of procedure. </text>
<text top="775" left="686" width="173" height="15" font="1">All 5 pts who underwent procedure </text>
<text top="790" left="686" width="169" height="15" font="1">were free of JT on up to 2 y of f/u. </text>
<text top="759" left="887" width="212" height="15" font="1">Early report of cryoablation of JT, safe and </text>
<text top="775" left="887" width="220" height="15" font="1">effective (except w/ proximity to His-Purkinje </text>
<text top="790" left="887" width="216" height="15" font="1">system), and may confer long term benefit.  </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">100 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="49" height="15" font="8">16876738</text>
<text top="55" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="130" width="57" height="15" font="1">population  </text>
<text top="55" left="226" width="39" height="15" font="1">median </text>
<text top="70" left="226" width="22" height="15" font="1">8 y) </text>
<text top="55" left="287" width="142" height="15" font="1">refractory to AADs (primarily </text>
<text top="70" left="287" width="145" height="15" font="1">beta-blockers), at 2 hospitals.</text>
<text top="70" left="432" width="2" height="10" font="10"> </text>
<text top="55" left="887" width="3" height="15" font="1"> </text>
<text top="70" left="887" width="228" height="15" font="1">This study studied a small number of primarily </text>
<text top="86" left="887" width="230" height="15" font="1">pediatric pts at two institutions. Pharmacologic </text>
<text top="101" left="887" width="231" height="15" font="1">therapy not attempted in all pts. One pt had an </text>
<text top="117" left="887" width="212" height="15" font="1">ectopic focus proximal to His-Purkinje, and </text>
<text top="132" left="887" width="210" height="15" font="1">cryomapping resulted in transient CHB, so </text>
<text top="147" left="887" width="138" height="15" font="1">cryoablation not performed. </text>
<text top="164" left="54" width="101" height="15" font="1">EP Study Diagnosis </text>
<text top="180" left="54" width="42" height="15" font="1">Meiltz A </text>
<text top="195" left="54" width="31" height="15" font="1">2006  </text>
<text top="211" left="54" width="29" height="15" font="1">(235) </text>
<text top="226" left="54" width="52" height="15" font="8">16627404 </text>
<text top="226" left="106" width="3" height="15" font="1"> </text>
<text top="180" left="130" width="71" height="15" font="1">Retrospective </text>
<text top="195" left="130" width="37" height="15" font="1">cohort, </text>
<text top="211" left="130" width="57" height="15" font="1">multicenter </text>
<text top="180" left="226" width="28" height="15" font="1">n=49 </text>
<text top="180" left="287" width="143" height="15" font="1">Adults w/ PJRT confirmed at </text>
<text top="195" left="287" width="135" height="15" font="1">EP study, both paroxysmal </text>
<text top="211" left="287" width="104" height="15" font="1">(53%) and incessant </text>
<text top="180" left="459" width="209" height="15" font="1">Describe results of RFA in adults w/ PJRT </text>
<text top="180" left="686" width="137" height="15" font="1">RFA successful in 94% w/o </text>
<text top="195" left="686" width="187" height="15" font="1">complications, and long term success </text>
<text top="211" left="686" width="186" height="15" font="1">100% w/o AADs, w/ 49 mo mean f/u.  </text>
<text top="180" left="887" width="223" height="15" font="1">Rare report of PJRT in adults only, so results </text>
<text top="195" left="887" width="236" height="15" font="1">pertinent to guidelines, and support RF ablation </text>
<text top="211" left="887" width="102" height="15" font="1">as first line therapy.  </text>
<text top="243" left="54" width="55" height="15" font="1">Padanilam </text>
<text top="258" left="54" width="16" height="15" font="1">BJ </text>
<text top="274" left="54" width="31" height="15" font="1">2006  </text>
<text top="289" left="54" width="29" height="15" font="1">(236) </text>
<text top="305" left="54" width="49" height="15" font="8">19007691</text>
<text top="305" left="103" width="3" height="15" font="1"> </text>
<text top="243" left="130" width="61" height="15" font="1">Prospective </text>
<text top="258" left="130" width="63" height="15" font="1">cohort study </text>
<text top="243" left="226" width="28" height="15" font="1">n=39 </text>
<text top="243" left="287" width="123" height="15" font="1">Adults w/ AVNRT, JT, or </text>
<text top="258" left="287" width="128" height="15" font="1">“clinically indeterminate.”  </text>
<text top="243" left="459" width="189" height="15" font="1">To distinguish JT or AVNRT based on </text>
<text top="258" left="459" width="198" height="15" font="1">specific responses to PACs delivered at </text>
<text top="274" left="459" width="200" height="15" font="1">different phases of the tachycardia cycle </text>
<text top="243" left="686" width="139" height="15" font="1">PACs introduced during His </text>
<text top="258" left="686" width="137" height="15" font="1">refractoriness did not affect </text>
<text top="274" left="686" width="177" height="15" font="1">tachycardia. Earlier PACs preexcite </text>
<text top="289" left="686" width="181" height="15" font="1">the immediate His and ventricle, w/o </text>
<text top="305" left="686" width="175" height="15" font="1">terminating tachycardia, confirming </text>
<text top="320" left="686" width="161" height="15" font="1">JT. For AVNRT, 61% sensitivity, </text>
<text top="336" left="686" width="151" height="15" font="1">100% specificity; for JT, 100% </text>
<text top="351" left="686" width="127" height="15" font="1">sensitivity and specificity. </text>
<text top="243" left="887" width="229" height="15" font="1">The response to PACs during tachycardia can </text>
<text top="258" left="887" width="233" height="15" font="1">distinguish JT from AVNRT w/ 100% specificity </text>
<text top="274" left="887" width="103" height="15" font="1">and high sensitivity.  </text>
<text top="289" left="887" width="3" height="15" font="1"> </text>
<text top="305" left="887" width="189" height="15" font="1">However, PACs introduced during His </text>
<text top="320" left="887" width="237" height="15" font="1">refractoriness can lead to misdiagnosis of JT as </text>
<text top="336" left="887" width="231" height="15" font="1">AVNRT if dual AV nodal physiology is present. </text>
<text top="351" left="887" width="239" height="15" font="1">Furthermore, if double ventricular responses are </text>
<text top="367" left="887" width="237" height="15" font="1">present, a PAC during AVNRT can advance the </text>
<text top="382" left="887" width="189" height="15" font="1">His w/ continuation of the tachycardia, </text>
<text top="398" left="887" width="105" height="15" font="1">misdiagnosed as JT. </text>
<text top="414" left="54" width="55" height="15" font="1">Srivathsan </text>
<text top="429" left="54" width="10" height="15" font="1">K </text>
<text top="445" left="54" width="31" height="15" font="1">2007  </text>
<text top="460" left="54" width="29" height="15" font="1">(237) </text>
<text top="476" left="54" width="49" height="15" font="8">17916156</text>
<text top="476" left="103" width="3" height="15" font="1"> </text>
<text top="414" left="130" width="71" height="15" font="1">Retrospective </text>
<text top="429" left="130" width="63" height="15" font="1">cohort study </text>
<text top="414" left="226" width="28" height="15" font="1">n=35 </text>
<text top="414" left="287" width="148" height="15" font="1">Typical AVNRT and evidence </text>
<text top="429" left="287" width="143" height="15" font="1">of JT during EP study and/or </text>
<text top="445" left="287" width="42" height="15" font="1">ablation </text>
<text top="414" left="459" width="201" height="15" font="1">To assess the utility of delta H-A interval </text>
<text top="429" left="459" width="201" height="15" font="1">(difference in the H-A intervals observed </text>
<text top="445" left="459" width="211" height="15" font="1">during tachycardia and basal RV pacing to </text>
<text top="460" left="459" width="202" height="15" font="1">differentiate AVNRT and JT—delta HA = </text>
<text top="476" left="459" width="173" height="15" font="1">HA during pacing minus HA during </text>
<text top="491" left="459" width="208" height="15" font="1">tachycardia. (Helps to distinguish whether </text>
<text top="507" left="459" width="212" height="15" font="1">H-A interval represents true his conduction </text>
<text top="522" left="459" width="179" height="15" font="1">to the atria, or whether atria and His </text>
<text top="538" left="459" width="194" height="15" font="1">activated simultaneously from common </text>
<text top="553" left="459" width="69" height="15" font="1">focal source.) </text>
<text top="414" left="686" width="177" height="15" font="1">Average H-A interval was -10 msec </text>
<text top="429" left="686" width="184" height="15" font="1">during AVNRT and 9 msec during JT </text>
<text top="445" left="686" width="151" height="15" font="1">(p&lt;0.00001). Delta HA ≥0 has </text>
<text top="460" left="686" width="168" height="15" font="1">sensitivity/specificity of 89%/83%, </text>
<text top="476" left="686" width="180" height="15" font="1">PPV/NPV 84%/88% for diagnosis of </text>
<text top="491" left="686" width="18" height="15" font="1">JT. </text>
<text top="414" left="887" width="194" height="15" font="1">Delta HA is a useful metric that can aid </text>
<text top="429" left="887" width="244" height="15" font="1">differentiation of AVNRT and JT during EP study. </text>
<text top="445" left="887" width="234" height="15" font="1">Utility in that JT ablation confers high risk of AV </text>
<text top="460" left="887" width="225" height="15" font="1">block. Limited in that spontaneous JT may be </text>
<text top="476" left="887" width="228" height="15" font="1">mechanistically different from JT seen w/ slow </text>
<text top="491" left="887" width="93" height="15" font="1">path modification.  </text>
<text top="569" left="54" width="33" height="15" font="1">Fan R </text>
<text top="585" left="54" width="31" height="15" font="1">2011  </text>
<text top="600" left="54" width="29" height="15" font="1">(238) </text>
<text top="616" left="54" width="52" height="15" font="8">21220046 </text>
<text top="616" left="106" width="3" height="15" font="1"> </text>
<text top="569" left="130" width="61" height="15" font="1">Prospective </text>
<text top="585" left="130" width="63" height="15" font="1">cohort study </text>
<text top="569" left="226" width="28" height="15" font="1">n=21 </text>
<text top="585" left="226" width="3" height="15" font="1"> </text>
<text top="569" left="287" width="141" height="15" font="1">Adult pts referred to a single </text>
<text top="585" left="287" width="119" height="15" font="1">center for EP study and </text>
<text top="600" left="287" width="146" height="15" font="1">subsequent AVNRT ablation. </text>
<text top="569" left="459" width="193" height="15" font="1">To investigate whether the tachycardia </text>
<text top="585" left="459" width="211" height="15" font="1">response to atrial overdrive pacing at a CL </text>
<text top="600" left="459" width="178" height="15" font="1">shorter than the tachycardia CL can </text>
<text top="616" left="459" width="207" height="15" font="1">elucidate whether the tachycardia is JT or </text>
<text top="631" left="459" width="47" height="15" font="1">AVNRT.  </text>
<text top="570" left="686" width="173" height="15" font="1">The paced AH interval was shorter </text>
<text top="585" left="686" width="177" height="15" font="1">for JT compared w/ AVNRT (86±19 </text>
<text top="600" left="686" width="177" height="15" font="1">msec vs. 338±59 msec, p&lt;0.0001). </text>
<text top="616" left="686" width="3" height="15" font="1"> </text>
<text top="631" left="686" width="184" height="15" font="1">The mean CL of JT longer compared </text>
<text top="647" left="686" width="152" height="15" font="1">w/ AVNRT (614±118 msec vs. </text>
<text top="662" left="686" width="127" height="15" font="1">373±65 msec, p&lt;0.0001) </text>
<text top="569" left="887" width="227" height="15" font="1">Atrial overdrive pacing during tachycardia can </text>
<text top="585" left="887" width="214" height="15" font="1">help to rapidly differentiate JT from AVNRT </text>
<text top="600" left="887" width="228" height="15" font="1">(transiently suppresses JT, entrains AVNRT).  </text>
<text top="616" left="887" width="3" height="15" font="1"> </text>
<text top="631" left="887" width="208" height="15" font="1">Diagnosis of JT made on clinical grounds, </text>
<text top="647" left="887" width="249" height="15" font="1">although JT only observed post-ablation. Potential </text>
<text top="662" left="887" width="237" height="15" font="1">for misdiagnosis of AVNRT as JT. Included only </text>
<text top="678" left="887" width="240" height="15" font="1">spontaneous JT after AVNRT ablation (excluded </text>
<text top="693" left="887" width="221" height="15" font="1">“clinical” JT, i.e. not due to AVNRT ablation). </text>
<text top="710" left="54" width="1062" height="15" font="1">AAD indicates antiarrhythmic drug; AV, atrioventricular; AVJ, atrioventricular junction; AVNRT, atrioventricular nodal reentrant tachycardia; bid, two times per day; bpm, beats per min; CHB, complete heart block; CHD, </text>
<text top="725" left="54" width="1063" height="15" font="1">congenital heart disease; CL, cycle length; EP, electrophysiological; f/u, follow up; h/o, history of; HR, heart rate; IV, intravenous; JET, junctional ectopic tachycardia; JT, junctional tachycardia; NPV, negative predictive </text>
<text top="741" left="54" width="1013" height="15" font="1">value; PAC, premature atrial contractions; PJRT, permanent junctional reciprocating tachycardia; PPV, positive predictive value; pt, patient; RFA, radiofrequency ablation; SR, sinus rhythm; sx, symptom; VA, </text>
<text top="756" left="54" width="337" height="15" font="1">ventriculoatrial; VF, ventricular fibrillation; w/, with; and w/o, without.  </text>
<text top="772" left="54" width="3" height="15" font="1"> </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="24" size="11" family="Times" color="#4f82bd"/>
<text top="814" left="1113" width="24" height="17" font="0">101 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="151" height="18" font="3"><b>Data Supplement 20. </b></text>
<text top="55" left="205" width="697" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Special Populations – Section 9 </b></text>
<text top="74" left="70" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="69" width="40" height="17" font="5"><b>Name, </b></text>
<text top="108" left="66" width="47" height="17" font="5"><b>Author, </b></text>
<text top="125" left="74" width="30" height="17" font="5"><b>Year </b></text>
<text top="74" left="158" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="91" left="172" width="44" height="17" font="5"><b>Design </b></text>
<text top="74" left="282" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="74" left="381" width="165" height="17" font="5"><b>Inclusion/Exclusion Criteria </b></text>
<text top="74" left="569" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="74" left="752" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="74" left="961" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="143" left="54" width="127" height="15" font="1">Pediatrics: Epidemiology  </text>
<text top="159" left="54" width="60" height="15" font="1">Lundberg A </text>
<text top="175" left="54" width="28" height="15" font="1">1982 </text>
<text top="190" left="54" width="29" height="15" font="1">(239) </text>
<text top="206" left="54" width="43" height="15" font="8">7122164</text>
<text top="206" left="97" width="3" height="15" font="1"> </text>
<text top="159" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="175" left="137" width="34" height="15" font="1">center </text>
<text top="159" left="264" width="15" height="15" font="1">49 </text>
<text top="159" left="378" width="144" height="15" font="1">49 babies SVT in infancy, 40 </text>
<text top="175" left="378" width="170" height="15" font="1">SVT, 9 atrial flutter/AF 86% males </text>
<text top="190" left="378" width="74" height="15" font="1">F/u mean 24 y </text>
<text top="159" left="561" width="106" height="15" font="1">SVT recurrence after </text>
<text top="175" left="561" width="38" height="15" font="1">infancy </text>
<text top="159" left="696" width="168" height="15" font="1">Males w/ WPW: 60% recurrence.  </text>
<text top="175" left="696" width="155" height="15" font="1">Pts w/o WPW: 30% recurrence </text>
<text top="159" left="922" width="201" height="15" font="1">Recurrent SVT after infant SVT: 30-60% </text>
<text top="222" left="54" width="42" height="15" font="1">Deal BJ </text>
<text top="238" left="54" width="28" height="15" font="1">1985 </text>
<text top="253" left="54" width="29" height="15" font="1">(240) </text>
<text top="269" left="54" width="43" height="15" font="8">3964800</text>
<text top="269" left="97" width="3" height="15" font="24"> </text>
<text top="222" left="137" width="71" height="15" font="1">Retrospective </text>
<text top="238" left="137" width="57" height="15" font="1">multicenter </text>
<text top="222" left="264" width="15" height="15" font="1">90 </text>
<text top="222" left="378" width="164" height="15" font="1">90 babies WPW and SVT ≤4 mo </text>
<text top="238" left="378" width="149" height="15" font="1">of age. SHD 20%. AVRT, one </text>
<text top="253" left="378" width="100" height="15" font="1">atrial flutter, no AF.  </text>
<text top="269" left="378" width="79" height="15" font="1">Mean f/u 6.5 y.  </text>
<text top="222" left="561" width="118" height="15" font="1">WPW outcomes infants </text>
<text top="238" left="561" width="39" height="15" font="1">w/ SVT </text>
<text top="222" left="696" width="181" height="15" font="1">Cardioversion success 87%, chronic </text>
<text top="238" left="696" width="206" height="15" font="1">digoxin 85 pts. Deaths: 4.4%, 2 w/o SHD: </text>
<text top="253" left="696" width="169" height="15" font="1">all receiving digoxin. One no SHD </text>
<text top="269" left="696" width="209" height="15" font="1">developed cardiomyopathy thought due to </text>
<text top="284" left="696" width="179" height="15" font="1">recurrent high dose cardioversions.  </text>
<text top="222" left="922" width="199" height="15" font="1">Mortality 4.4%, (2 no SHD), all receiving </text>
<text top="238" left="922" width="44" height="15" font="1">digoxin.  </text>
<text top="253" left="922" width="206" height="15" font="1">1/3 pts developing wide QRS tachycardia </text>
<text top="269" left="922" width="30" height="15" font="1">died.  </text>
<text top="300" left="54" width="46" height="15" font="1">Perry JC </text>
<text top="316" left="54" width="28" height="15" font="1">1990 </text>
<text top="331" left="54" width="29" height="15" font="1">(241) </text>
<text top="347" left="54" width="43" height="15" font="8">2229769</text>
<text top="347" left="97" width="3" height="15" font="24"> </text>
<text top="300" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="316" left="137" width="34" height="15" font="1">center </text>
<text top="300" left="264" width="22" height="15" font="1">140 </text>
<text top="300" left="378" width="164" height="15" font="1">140 pts WPW w/ SVT &lt;18 y old.  </text>
<text top="316" left="378" width="131" height="15" font="1">CHD 37%--23% of CHD = </text>
<text top="331" left="378" width="145" height="15" font="1">Ebstein’s. Multiple AC: 12%.  </text>
<text top="300" left="561" width="103" height="15" font="1">SVT recurrences vs. </text>
<text top="316" left="561" width="64" height="15" font="1">age w WPW </text>
<text top="300" left="696" width="185" height="15" font="1">SVT age ≤2 mo: 31% recurrent SVT, </text>
<text top="316" left="696" width="89" height="15" font="1">average age 8 y.  </text>
<text top="331" left="696" width="211" height="15" font="1">SVT &gt; age 5 y: 78% recurrent SVT during  </text>
<text top="347" left="696" width="70" height="15" font="1">mean f/u 7 y.  </text>
<text top="300" left="922" width="203" height="15" font="1">SVT recurs more frequently in pts w/ first </text>
<text top="316" left="922" width="98" height="15" font="1">episode ≥ age 5 y.  </text>
<text top="363" left="54" width="40" height="15" font="1">Wu MH </text>
<text top="379" left="54" width="28" height="15" font="1">1994 </text>
<text top="394" left="54" width="29" height="15" font="1">(242) </text>
<text top="409" left="54" width="43" height="15" font="8">7850817</text>
<text top="409" left="97" width="3" height="15" font="1"> </text>
<text top="363" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="379" left="137" width="34" height="15" font="1">center </text>
<text top="363" left="264" width="15" height="15" font="1">90 </text>
<text top="363" left="378" width="163" height="15" font="1">90 pts w/ SVT &lt;15 y old, median </text>
<text top="379" left="378" width="62" height="15" font="1">f/u 215 mo.  </text>
<text top="394" left="378" width="114" height="15" font="1">CHF 16%. Stroke 1 pt. </text>
<text top="409" left="378" width="3" height="15" font="1"> </text>
<text top="363" left="561" width="115" height="15" font="1">Recurrent SVT vs. age </text>
<text top="379" left="561" width="55" height="15" font="1">onset SVT </text>
<text top="363" left="696" width="174" height="15" font="1">SVT age 1-5 y: 40% recurrent SVT </text>
<text top="379" left="696" width="197" height="15" font="1">prenatal SVT lowest risk recurrent SVT, </text>
<text top="394" left="696" width="209" height="15" font="1">followed by age &lt;1 y, then 1-5 y; onset &gt;5 </text>
<text top="409" left="696" width="74" height="15" font="1">y highest risk.  </text>
<text top="363" left="922" width="200" height="15" font="1">First SVT ≥5 y: highest risk for recurrent </text>
<text top="379" left="922" width="156" height="15" font="1">SVT vs. age 1-5 y, or age &lt;1 y  </text>
<text top="426" left="54" width="52" height="15" font="1">Riggs TW </text>
<text top="441" left="54" width="28" height="15" font="1">1999 </text>
<text top="457" left="54" width="29" height="15" font="1">(243) </text>
<text top="472" left="54" width="49" height="15" font="8">10393395</text>
<text top="472" left="103" width="3" height="15" font="24"> </text>
<text top="426" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="441" left="137" width="34" height="15" font="1">center </text>
<text top="426" left="264" width="229" height="15" font="1">70 70 </text>
<text top="426" left="393" width="153" height="15" font="1">pediatric pts w/ SVT, vs. WPW </text>
<text top="441" left="378" width="46" height="15" font="1">and age. </text>
<text top="457" left="378" width="159" height="15" font="1">Recurrent SVT: 29% w/ SVT &lt;1 </text>
<text top="472" left="378" width="154" height="15" font="1">y, vs. 94% w/ SVT onset &gt;1 y.  </text>
<text top="426" left="561" width="108" height="15" font="1">Risk recurrent SVT in </text>
<text top="441" left="561" width="51" height="15" font="1">young pts </text>
<text top="426" left="696" width="196" height="15" font="1">Only sig predictor of recurrent SVT was </text>
<text top="441" left="696" width="98" height="15" font="1">age at presentation </text>
<text top="457" left="696" width="180" height="15" font="1">WPW not significant multivariate. 11 </text>
<text top="426" left="922" width="190" height="15" font="1">First SVT after age 1 y: high likelihood </text>
<text top="441" left="922" width="195" height="15" font="1">recurrent SVT vs. onset SVT &lt;1 y (OR: </text>
<text top="457" left="922" width="35" height="15" font="1">34.6).  </text>
<text top="488" left="54" width="69" height="15" font="1">Tortoriello TA </text>
<text top="504" left="54" width="28" height="15" font="1">2003 </text>
<text top="519" left="54" width="29" height="15" font="1">(244) </text>
<text top="535" left="54" width="49" height="15" font="8">14583354</text>
<text top="535" left="103" width="3" height="15" font="24"> </text>
<text top="488" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="504" left="137" width="34" height="15" font="1">center </text>
<text top="488" left="264" width="22" height="15" font="1">150 </text>
<text top="488" left="378" width="157" height="15" font="1">All pts SVT &lt;1 y 1/1984-12/00.  </text>
<text top="488" left="561" width="108" height="15" font="1">Risk recurrent SVT in </text>
<text top="504" left="561" width="68" height="15" font="1">young pts vs. </text>
<text top="519" left="561" width="66" height="15" font="1">preexcitation </text>
<text top="488" left="696" width="202" height="15" font="1">Pts w/ preexcitation: 88% recurrent SVT, </text>
<text top="504" left="696" width="202" height="15" font="1">vs. 17% w/o WPW. WPW pts more likely </text>
<text top="519" left="696" width="125" height="15" font="1">to require multiple drugs. </text>
<text top="488" left="922" width="167" height="15" font="1">Presence of  WPW associated w/ </text>
<text top="504" left="922" width="143" height="15" font="1">increased risk recurrent SVT </text>
<text top="551" left="54" width="47" height="15" font="1">Gilljam T </text>
<text top="567" left="54" width="28" height="15" font="1">2008 </text>
<text top="582" left="54" width="29" height="15" font="1">(245) </text>
<text top="598" left="54" width="49" height="15" font="8">18489621</text>
<text top="598" left="103" width="6" height="15" font="24">  </text>
<text top="551" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="567" left="137" width="34" height="15" font="1">center </text>
<text top="551" left="264" width="22" height="15" font="1">109 </text>
<text top="551" left="378" width="160" height="15" font="1">109 pts SVT &lt;30 d, 1971-1997.  </text>
<text top="567" left="378" width="120" height="15" font="1">SVT = AVRT or AVNRT </text>
<text top="551" left="561" width="99" height="15" font="1">Outcomes neonatal </text>
<text top="567" left="561" width="25" height="15" font="1">SVT </text>
<text top="551" left="696" width="212" height="15" font="1">Freedom from arrhythmia: 52% 1 y, 82% 5 </text>
<text top="567" left="696" width="198" height="15" font="1">y, 83% 10 y. Recurrence 31% WPW vs. </text>
<text top="582" left="696" width="100" height="15" font="1">6% no overt WPW.  </text>
<text top="551" left="922" width="210" height="15" font="1">Mortality 2.7% related to arrhythmia/CHF.  </text>
<text top="567" left="922" width="203" height="15" font="1">Recurrences higher overt WPW, multiple </text>
<text top="582" left="922" width="200" height="15" font="1">meds, or &gt;6 d to obtain initial arrhythmia </text>
<text top="598" left="922" width="43" height="15" font="1">control.  </text>
<text top="614" left="54" width="58" height="15" font="1">Santinelli V </text>
<text top="629" left="54" width="28" height="15" font="1">2009 </text>
<text top="645" left="54" width="29" height="15" font="1">(246) </text>
<text top="660" left="54" width="49" height="15" font="8">19147045</text>
<text top="660" left="103" width="3" height="15" font="24"> </text>
<text top="614" left="137" width="96" height="15" font="1">Prospective, single </text>
<text top="629" left="137" width="34" height="15" font="1">center </text>
<text top="614" left="264" width="22" height="15" font="1">184 </text>
<text top="614" left="378" width="130" height="15" font="1">1995-2005, 184 pts ≤12 y </text>
<text top="629" left="378" width="122" height="15" font="1">(median 10 y, 8-12 y) w/ </text>
<text top="645" left="378" width="154" height="15" font="1">asymptomatic WPW evaluated </text>
<text top="660" left="378" width="151" height="15" font="1">and followed, median 57 mo.   </text>
<text top="614" left="561" width="57" height="15" font="1">Natural h/o </text>
<text top="629" left="561" width="114" height="15" font="1">asymptomatic WPW in </text>
<text top="645" left="561" width="45" height="15" font="1">children  </text>
<text top="614" left="696" width="152" height="15" font="1">72% remained asymptomatic.  </text>
<text top="629" left="696" width="185" height="15" font="1">28% sxs: 10% considered “POTS life-</text>
<text top="645" left="696" width="170" height="15" font="1">threatening”: cardiac arrest 1.6%;  </text>
<text top="660" left="696" width="74" height="15" font="1">Syncope 1.6% </text>
<text top="614" left="922" width="101" height="15" font="1">Cardiac arrest 1.6% </text>
<text top="629" left="922" width="182" height="15" font="1">Multivariate risk: APERP ≤240 msec </text>
<text top="645" left="922" width="45" height="15" font="1">(p=.001) </text>
<text top="660" left="922" width="130" height="15" font="1">And multiple AC (p= .001) </text>
<text top="677" left="54" width="58" height="15" font="1">Salerno JC </text>
<text top="692" left="54" width="28" height="15" font="1">2011 </text>
<text top="708" left="54" width="29" height="15" font="1">(247) </text>
<text top="723" left="54" width="52" height="15" font="8">21418251 </text>
<text top="739" left="54" width="3" height="15" font="1"> </text>
<text top="677" left="137" width="98" height="15" font="1">Retrospective multi-</text>
<text top="692" left="137" width="69" height="15" font="1">center review </text>
<text top="677" left="264" width="28" height="15" font="1">1755 </text>
<text top="677" left="378" width="162" height="15" font="1">Reviewed hospital databases 41 </text>
<text top="692" left="378" width="167" height="15" font="1">children’s hospitals between 1/03-</text>
<text top="708" left="378" width="25" height="15" font="1">9/08 </text>
<text top="723" left="378" width="150" height="15" font="1">Discharge dx SVT, age &lt;25 y  </text>
<text top="677" left="561" width="64" height="15" font="1">Case fatality </text>
<text top="677" left="696" width="116" height="15" font="1">Overall 68 deaths (4%) </text>
<text top="692" left="696" width="197" height="15" font="1">6% w/ SHD died vs. 1% of pts w/o SHD </text>
<text top="708" left="696" width="130" height="15" font="1">Case fatality increased in: </text>
<text top="723" left="696" width="207" height="15" font="1">Age &lt;1 mo, OR: 2.41 (95% CI: 1.35-4.32) </text>
<text top="739" left="696" width="177" height="15" font="1">SHD, OR: 2.67 (95% CI: 1.22-5.80) </text>
<text top="754" left="696" width="205" height="15" font="1">Cardiomyopathy, OR: 6.72 (95% CI: 1.79-</text>
<text top="769" left="696" width="128" height="15" font="1">25.28) regardless of SHD </text>
<text top="677" left="922" width="193" height="15" font="1">Case fatality in absence of SHD is low, </text>
<text top="692" left="922" width="25" height="15" font="1">1%,  </text>
<text top="708" left="922" width="137" height="15" font="1">Vs. 6% in presence of SHD </text>
<text top="723" left="922" width="3" height="15" font="1"> </text>
<text top="739" left="922" width="196" height="15" font="1">Case fatality highest in cardiomyopathy </text>
<text top="754" left="922" width="154" height="15" font="1">regardless of presence of SHD </text>
<text top="786" left="54" width="37" height="15" font="1">Cain N </text>
<text top="786" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="786" left="264" width="22" height="15" font="1">446 </text>
<text top="786" left="378" width="159" height="15" font="1">446 pts WPW; median age dx 7 </text>
<text top="786" left="561" width="89" height="15" font="1">Natural h/o WPW </text>
<text top="786" left="696" width="204" height="15" font="1">During f/u: additional 20% developed sx.  </text>
<text top="786" left="922" width="103" height="15" font="1">Sudden death: 1.3% </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">102 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="28" height="15" font="1">2013 </text>
<text top="70" left="54" width="23" height="15" font="1">(21) </text>
<text top="86" left="54" width="49" height="15" font="8">23827401</text>
<text top="86" left="103" width="3" height="15" font="24"> </text>
<text top="101" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="137" width="34" height="15" font="1">center </text>
<text top="55" left="378" width="116" height="15" font="1">y, 61% male, 9% SHD. </text>
<text top="70" left="378" width="156" height="15" font="1">Presentation: 64% w/ sxs--SVT </text>
<text top="86" left="378" width="153" height="15" font="1">38%; chest pain or palps 27%; </text>
<text top="101" left="378" width="154" height="15" font="1">syncope 4%, AF 0.4%; cardiac </text>
<text top="117" left="378" width="66" height="15" font="1">arrest 0.2%.  </text>
<text top="55" left="696" width="108" height="15" font="1"> 54% SVT, AF 1.6%.  </text>
<text top="70" left="696" width="194" height="15" font="1">Pts dx ≤3 mo, 35% WPW resolved, vs. </text>
<text top="86" left="696" width="83" height="15" font="1">5.8% dx &gt;3 mo.  </text>
<text top="101" left="696" width="177" height="15" font="1">Sudden death 1.3%, 2.8/1000 pt y.  </text>
<text top="117" left="696" width="3" height="15" font="1"> </text>
<text top="55" left="922" width="157" height="15" font="1">No heart disease: 1.1/1000 pt y </text>
<text top="70" left="922" width="97" height="15" font="1">SHD: 27/1000 pt y. </text>
<text top="133" left="54" width="157" height="15" font="1">Pediatrics: Mechanisms of SVT </text>
<text top="149" left="54" width="50" height="15" font="1">Garson A </text>
<text top="164" left="54" width="28" height="15" font="1">1981 </text>
<text top="180" left="54" width="29" height="15" font="1">(248) </text>
<text top="195" left="54" width="46" height="15" font="8">7258098 </text>
<text top="149" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="164" left="137" width="34" height="15" font="1">center </text>
<text top="149" left="264" width="268" height="15" font="1">103 Intracardiac </text>
<text top="149" left="439" width="96" height="15" font="1">EP study in pts 2 d-</text>
<text top="164" left="378" width="91" height="15" font="1">17 y, mean 4.2 y.  </text>
<text top="180" left="378" width="3" height="15" font="1"> </text>
<text top="149" left="561" width="119" height="15" font="1">Determine mechanisms </text>
<text top="164" left="561" width="114" height="15" font="1">of SVT in young pts w/ </text>
<text top="180" left="561" width="61" height="15" font="1">clinical SVT </text>
<text top="149" left="696" width="172" height="15" font="1">AVRT 50%, AVNRT 24%, AT 21% </text>
<text top="164" left="696" width="3" height="15" font="1"> </text>
<text top="180" left="696" width="205" height="15" font="1">55% of AP tachycardia w/ manifest WPW </text>
<text top="149" left="922" width="213" height="15" font="1">Predominance of AP mediated tachycardia </text>
<text top="164" left="922" width="66" height="15" font="1">in young pts  </text>
<text top="212" left="54" width="33" height="15" font="1">Ko JK </text>
<text top="227" left="54" width="28" height="15" font="1">1992 </text>
<text top="243" left="54" width="29" height="15" font="1">(249) </text>
<text top="258" left="54" width="46" height="15" font="8">1561973 </text>
<text top="212" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="227" left="137" width="34" height="15" font="1">center </text>
<text top="212" left="264" width="22" height="15" font="1">137 </text>
<text top="212" left="378" width="160" height="15" font="1">EP study (TEP 110, intracardiac </text>
<text top="227" left="378" width="167" height="15" font="1">14, both 13) performed in pts &lt;18 </text>
<text top="243" left="378" width="148" height="15" font="1">y of age, excluding significant </text>
<text top="258" left="378" width="159" height="15" font="1">heart disease or neuromuscular </text>
<text top="274" left="378" width="49" height="15" font="1">disorders </text>
<text top="212" left="561" width="114" height="15" font="1">Determine mechanism </text>
<text top="227" left="561" width="114" height="15" font="1">of SVT in young pts w/ </text>
<text top="243" left="561" width="61" height="15" font="1">clinical SVT </text>
<text top="212" left="696" width="175" height="15" font="1">AVRT 73%, AT 14%, AVNRT 13%. </text>
<text top="212" left="922" width="176" height="15" font="1">AVNRT rarely present &lt;2 y of age;  </text>
<text top="227" left="922" width="173" height="15" font="1">AVRT and AT occurred throughout </text>
<text top="243" left="922" width="50" height="15" font="1">childhood </text>
<text top="290" left="54" width="52" height="15" font="1">Weindling </text>
<text top="305" left="54" width="18" height="15" font="1">SN </text>
<text top="321" left="54" width="28" height="15" font="1">1996 </text>
<text top="336" left="54" width="29" height="15" font="1">(250) </text>
<text top="352" left="54" width="43" height="15" font="8">8554021</text>
<text top="352" left="97" width="3" height="15" font="24"> </text>
<text top="290" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="305" left="137" width="34" height="15" font="1">center </text>
<text top="290" left="264" width="22" height="15" font="1">112 </text>
<text top="290" left="378" width="131" height="15" font="1">SVT in infants, 7/85-3/93.  </text>
<text top="290" left="561" width="108" height="15" font="1">Mechanism of SVT in </text>
<text top="305" left="561" width="74" height="15" font="1">infants w/ SVT </text>
<text top="290" left="696" width="189" height="15" font="1">AVRT 77%, AVNRT 9%, Atrial reentry </text>
<text top="305" left="696" width="196" height="15" font="1">10%, ectopic atrial 4%. 106 pts treated: </text>
<text top="321" left="696" width="206" height="15" font="1">70% digoxin, propranolol, or both, Class I </text>
<text top="336" left="696" width="210" height="15" font="1">or III used in 12% each. 8% ablation failed </text>
<text top="352" left="696" width="194" height="15" font="1">med rx: 1/9 died related to ablation (VF </text>
<text top="367" left="696" width="198" height="15" font="1">after discharge). Overall mortality 4.4%, </text>
<text top="383" left="696" width="65" height="15" font="1">4/5 w/ SHD.  </text>
<text top="290" left="922" width="189" height="15" font="1">Ablation for medically refractory SVT.  </text>
<text top="305" left="922" width="165" height="15" font="1">Neonate w/o SHD died related to </text>
<text top="321" left="922" width="127" height="15" font="1">complications of ablation. </text>
<text top="336" left="922" width="208" height="15" font="1">Recommends ablation for rare infants: fail </text>
<text top="352" left="922" width="208" height="15" font="1">aggressive med rx, rx comp by ventricular </text>
<text top="367" left="922" width="196" height="15" font="1">dysfunction, severe sx, complex SHD.   </text>
<text top="399" left="54" width="50" height="15" font="1">Gross GJ </text>
<text top="415" left="54" width="28" height="15" font="1">1998 </text>
<text top="430" left="54" width="29" height="15" font="1">(251) </text>
<text top="446" left="54" width="43" height="15" font="8">9794351</text>
<text top="446" left="97" width="3" height="15" font="1"> </text>
<text top="399" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="415" left="137" width="34" height="15" font="1">center </text>
<text top="399" left="264" width="15" height="15" font="1">15 </text>
<text top="399" left="378" width="169" height="15" font="1">Infants AVNRT &lt;1 y mean age 58 </text>
<text top="415" left="378" width="139" height="15" font="1">d, 5/15 after CHD palliation. </text>
<text top="430" left="378" width="159" height="15" font="1">Typical AVNRT 14/15. Mean f/u </text>
<text top="446" left="378" width="40" height="15" font="1">45 mo.  </text>
<text top="399" left="561" width="113" height="15" font="1">Outcome of AVNRT in </text>
<text top="415" left="561" width="59" height="15" font="1">first y of life </text>
<text top="399" left="696" width="158" height="15" font="1">Digoxin: 87%, successful 38%.  </text>
<text top="415" left="696" width="211" height="15" font="1">40% digoxin + propranolol, successful 4/6. </text>
<text top="430" left="696" width="199" height="15" font="1">Class III in 3 pts: 2/3 RFA: ages 4.1 and </text>
<text top="446" left="696" width="33" height="15" font="1">6.7 y.  </text>
<text top="399" left="922" width="207" height="15" font="1">All pts alive and well, minority syx beyond </text>
<text top="415" left="922" width="189" height="15" font="1">infancy. Digoxin questionalble benefit. </text>
<text top="430" left="922" width="148" height="15" font="1">AVNRT remained inducible in </text>
<text top="446" left="922" width="95" height="15" font="1">asymptomatic pts.  </text>
<text top="462" left="54" width="55" height="15" font="1">Anand RG </text>
<text top="477" left="54" width="28" height="15" font="1">2009 </text>
<text top="493" left="54" width="29" height="15" font="1">(252) </text>
<text top="508" left="54" width="49" height="15" font="8">19925541</text>
<text top="508" left="103" width="3" height="15" font="1"> </text>
<text top="462" left="137" width="74" height="15" font="1">Retrospective, </text>
<text top="477" left="137" width="57" height="15" font="1">multicenter </text>
<text top="462" left="264" width="245" height="15" font="1">3556 Registry </text>
<text top="462" left="422" width="99" height="15" font="1">of </text>
<text top="462" left="434" width="110" height="15" font="1">pediatric EP reviewed </text>
<text top="477" left="378" width="150" height="15" font="1">for pts undergoing ablation for </text>
<text top="493" left="378" width="129" height="15" font="1">SVT between 1999-2004. </text>
<text top="508" left="378" width="165" height="15" font="1">Ages &lt;7 y: 378; 7-12: 964; 12-21 </text>
<text top="524" left="378" width="158" height="15" font="1">y: 2214; males 55%; white 82% </text>
<text top="462" left="561" width="98" height="15" font="1">Assess influence of </text>
<text top="477" left="561" width="109" height="15" font="1">age, gender, ethnicity </text>
<text top="493" left="561" width="40" height="15" font="1">on SVT </text>
<text top="462" left="696" width="196" height="15" font="1">AP: 68%;  decreased w/ increasing age </text>
<text top="477" left="696" width="66" height="15" font="1">AVNRT 32% </text>
<text top="493" left="696" width="187" height="15" font="1">In age 12-21 y, females more likely to </text>
<text top="508" left="696" width="110" height="15" font="1">have AVNRT than AP </text>
<text top="524" left="696" width="209" height="15" font="1">Black and Hispanic pts had less SVT than </text>
<text top="539" left="696" width="205" height="15" font="1">representation in population; whites more </text>
<text top="555" left="696" width="110" height="15" font="1">SVT than population.  </text>
<text top="462" left="922" width="211" height="15" font="1">Proportion of SVT due to AP decreases w/ </text>
<text top="477" left="922" width="78" height="15" font="1">increasing age. </text>
<text top="493" left="922" width="212" height="15" font="1">After age 12 y, females more likely to have </text>
<text top="508" left="922" width="104" height="15" font="1">AVNRT than males.  </text>
<text top="524" left="922" width="186" height="15" font="1">More whites in registry than expected </text>
<text top="539" left="922" width="109" height="15" font="1">based on population.  </text>
<text top="571" left="54" width="49" height="15" font="1">Brembilla </text>
<text top="587" left="54" width="33" height="15" font="1">Perrot </text>
<text top="602" left="54" width="28" height="15" font="1">2013 </text>
<text top="617" left="54" width="29" height="15" font="1">(253) </text>
<text top="633" left="54" width="49" height="15" font="8">23609066</text>
<text top="633" left="103" width="3" height="15" font="1"> </text>
<text top="571" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="587" left="137" width="34" height="15" font="1">center </text>
<text top="571" left="264" width="22" height="15" font="1">140 </text>
<text top="571" left="378" width="168" height="15" font="1">Sxs of palpitations/SVT w/ normal </text>
<text top="587" left="378" width="170" height="15" font="1">ECG, underwent transesophageal </text>
<text top="602" left="378" width="42" height="15" font="1">pacing.  </text>
<text top="617" left="378" width="90" height="15" font="1">Mean age 15±3 y </text>
<text top="571" left="561" width="118" height="15" font="1">Utility of TEP to identify </text>
<text top="587" left="561" width="74" height="15" font="1">SVT in pts w/o </text>
<text top="602" left="561" width="66" height="15" font="1">preexcitation </text>
<text top="571" left="696" width="196" height="15" font="1">59% AVNRT, AVRT 37%, AT 0.7%, VT </text>
<text top="587" left="696" width="25" height="15" font="1">3%.  </text>
<text top="602" left="696" width="3" height="15" font="1"> </text>
<text top="617" left="696" width="198" height="15" font="1">High risk antegrade conduction over AP </text>
<text top="633" left="696" width="162" height="15" font="1">&gt;240 bpm baseline or &gt;290 bpm </text>
<text top="648" left="696" width="141" height="15" font="1">isoproterenol found in 1.4%. </text>
<text top="571" left="922" width="185" height="15" font="1">Preexcitation found in 13.5% w/ atrial </text>
<text top="587" left="922" width="42" height="15" font="1">pacing.  </text>
<text top="665" left="54" width="208" height="15" font="1">Pediatrics: SVT Pharmacological Therapy </text>
<text top="681" left="54" width="60" height="15" font="1">Pfammatter </text>
<text top="696" left="54" width="16" height="15" font="1">JP </text>
<text top="712" left="54" width="28" height="15" font="1">1998 </text>
<text top="727" left="54" width="29" height="15" font="1">(254) </text>
<text top="743" left="54" width="43" height="15" font="8">9504781</text>
<text top="743" left="97" width="3" height="15" font="24"> </text>
<text top="681" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="696" left="137" width="34" height="15" font="1">center </text>
<text top="681" left="264" width="15" height="15" font="1">26 </text>
<text top="681" left="378" width="140" height="15" font="1">SVT in infants &lt;4 mo of age </text>
<text top="696" left="378" width="135" height="15" font="1">Mean age presentation 7 d </text>
<text top="712" left="378" width="111" height="15" font="1">SHD 31%; WPW 35% </text>
<text top="727" left="378" width="45" height="15" font="1">All AVRT</text>
<text top="727" left="423" width="3" height="15" font="9"> </text>
<text top="681" left="561" width="102" height="15" font="1">Digoxin for neonatal </text>
<text top="696" left="561" width="25" height="15" font="1">SVT </text>
<text top="681" left="696" width="123" height="15" font="1">Digoxin successful: 65% </text>
<text top="696" left="696" width="62" height="15" font="1">Failure 27% </text>
<text top="712" left="696" width="169" height="15" font="1">Mean f/u 54 mo, 73% no meds no </text>
<text top="727" left="696" width="156" height="15" font="1">recurrences; 8% recurrent SVT </text>
<text top="681" left="922" width="108" height="15" font="1">Digoxin success 65% </text>
<text top="696" left="922" width="129" height="15" font="1">73% no early recurrences </text>
<text top="712" left="922" width="146" height="15" font="1">8% symptomatic recurrences </text>
<text top="759" left="54" width="46" height="15" font="1">Villain E  </text>
<text top="775" left="54" width="28" height="15" font="1">1998 </text>
<text top="790" left="54" width="29" height="15" font="1">(255) </text>
<text top="759" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="775" left="137" width="34" height="15" font="1">center </text>
<text top="759" left="264" width="22" height="15" font="1">141 </text>
<text top="759" left="378" width="151" height="15" font="1">SVT &lt;1 y of age, 77% &lt;1 mo.  </text>
<text top="775" left="378" width="143" height="15" font="1">Digoxin first med in 114 pts,  </text>
<text top="790" left="378" width="143" height="15" font="1">81%; Amiodarone used after </text>
<text top="759" left="561" width="118" height="15" font="1">Infant SVT: digoxin and </text>
<text top="775" left="561" width="113" height="15" font="1">amiodarone outcomes </text>
<text top="759" left="696" width="202" height="15" font="1">Digoxin effective 65%; amiodarone 97%. </text>
<text top="775" left="696" width="199" height="15" font="1">Total amiodarone used in 58 pts, no pro-</text>
<text top="790" left="696" width="166" height="15" font="1">arrhythmia, increase TSH 10%. .  </text>
<text top="759" left="922" width="171" height="15" font="1">Digoxin: VF in 3 pts, (2/3 WPW) in </text>
<text top="775" left="922" width="211" height="15" font="1">hospital; one additional baby died at 3 mo, </text>
<text top="790" left="922" width="201" height="15" font="1">digoxin, no SHD.  Total 4 CA on digoxin: </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="25" size="11" family="Times" color="#c0504d"/>
<text top="814" left="1113" width="24" height="17" font="0">103 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="49" height="15" font="8">10223132</text>
<text top="55" left="103" width="3" height="15" font="24"> </text>
<text top="55" left="378" width="168" height="15" font="1">failure of digoxin (combo: 26%) or </text>
<text top="70" left="378" width="111" height="15" font="1">first: 19%. (solo 16%). </text>
<text top="70" left="490" width="3" height="15" font="9"> </text>
<text top="55" left="696" width="200" height="15" font="1">Adverse events 6 pts w/ digoxin: VF in 3 </text>
<text top="70" left="696" width="18" height="15" font="1">pts </text>
<text top="55" left="922" width="34" height="15" font="1">3.5%.  </text>
<text top="70" left="922" width="191" height="15" font="1">Amiodarone safer, more effective than </text>
<text top="86" left="922" width="44" height="15" font="1">digoxin.  </text>
<text top="102" left="54" width="49" height="15" font="1">Losek JD </text>
<text top="117" left="54" width="31" height="15" font="1">1999  </text>
<text top="133" left="54" width="29" height="15" font="1">(256) </text>
<text top="148" left="54" width="43" height="15" font="8">9922414</text>
<text top="148" left="97" width="3" height="15" font="24"> </text>
<text top="102" left="137" width="57" height="15" font="1">Multicenter </text>
<text top="117" left="137" width="81" height="15" font="1">prospective and </text>
<text top="133" left="137" width="70" height="15" font="1">retrospective  </text>
<text top="102" left="264" width="15" height="15" font="1">82 </text>
<text top="102" left="378" width="169" height="15" font="1">82 pts w/ 95 episodes SVT ≤18 y, </text>
<text top="117" left="378" width="165" height="15" font="1">in pediatric ED. 25 episodes &lt;1 y </text>
<text top="133" left="378" width="147" height="15" font="1">of age. 10% SHD. Adenosine </text>
<text top="148" left="378" width="152" height="15" font="1">doses: low 0.1 mg/kg, medium </text>
<text top="164" left="378" width="163" height="15" font="1">0.1-0.2 mg/kg, high ≥0.3 mg/kg.  </text>
<text top="102" left="561" width="116" height="15" font="1">Adenosine for pediatric </text>
<text top="117" left="561" width="25" height="15" font="1">SVT </text>
<text top="102" left="696" width="173" height="15" font="1">Adenosine success 72%; AV node-</text>
<text top="117" left="696" width="154" height="15" font="1">dependent SVT success 79%.  </text>
<text top="133" left="696" width="202" height="15" font="1">Successful dose:  low 6%, medium 62%, </text>
<text top="148" left="696" width="55" height="15" font="1">high 32%.  </text>
<text top="102" left="922" width="199" height="15" font="1">Adenosine cardioversion 72%; low dose </text>
<text top="117" left="922" width="81" height="15" font="1">rarely effective.  </text>
<text top="180" left="54" width="40" height="15" font="1">Dixon J </text>
<text top="195" left="54" width="28" height="15" font="1">2005 </text>
<text top="211" left="54" width="26" height="15" font="1">(257)</text>
<text top="211" left="80" width="3" height="15" font="24"> </text>
<text top="226" left="54" width="49" height="15" font="8">16243875</text>
<text top="226" left="103" width="3" height="15" font="24"> </text>
<text top="180" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="195" left="137" width="34" height="15" font="1">center </text>
<text top="180" left="264" width="15" height="15" font="1">35 </text>
<text top="180" left="378" width="158" height="15" font="1">SVT rx w/ adenosine 1/98-5/03. </text>
<text top="195" left="378" width="135" height="15" font="1">53 episodes. 23 infants, 12 </text>
<text top="211" left="378" width="75" height="15" font="1">children &lt;16 y. </text>
<text top="211" left="454" width="3" height="15" font="25"> </text>
<text top="226" left="378" width="3" height="15" font="25"> </text>
<text top="180" left="561" width="116" height="15" font="1">Dosing of adenosine to </text>
<text top="195" left="561" width="74" height="15" font="1">terminate SVT </text>
<text top="180" left="696" width="146" height="15" font="1">Adenosine efficacy vs. dose:  </text>
<text top="195" left="696" width="210" height="15" font="1">Infants: 50 mcg/kg, 9%, 150 mcg/kg, 35%; </text>
<text top="211" left="696" width="150" height="15" font="1">median effective 200 mcg/kg.  </text>
<text top="226" left="696" width="187" height="15" font="1">Children: 50 mcg/kg: 9%,100 mcg/kg: </text>
<text top="242" left="696" width="209" height="15" font="1">&lt;50%.  median effective dose 150 mcg/kg </text>
<text top="180" left="922" width="209" height="15" font="1">Adenosine in recommended dose has low </text>
<text top="195" left="922" width="82" height="15" font="1">efficacy, &lt;10%.  </text>
<text top="211" left="922" width="201" height="15" font="1">Recommend minimum dose 100 mcg/kg </text>
<text top="226" left="922" width="169" height="15" font="1">children, 150-200 mcg/kg infants.  </text>
<text top="258" left="54" width="55" height="15" font="1">Chang PM </text>
<text top="274" left="54" width="28" height="15" font="1">2010 </text>
<text top="289" left="54" width="29" height="15" font="1">(258) </text>
<text top="305" left="54" width="49" height="15" font="8">20194798</text>
<text top="305" left="103" width="3" height="15" font="24"> </text>
<text top="258" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="274" left="137" width="34" height="15" font="1">center </text>
<text top="258" left="264" width="15" height="15" font="1">37 </text>
<text top="258" left="378" width="163" height="15" font="1">Refractory SVT: 40 episodes, 37 </text>
<text top="274" left="378" width="166" height="15" font="1">pts. 7/04-8/06. Median 34 d, 0-19 </text>
<text top="289" left="378" width="161" height="15" font="1">y. 65 SHD. IV procainamide: 50, </text>
<text top="305" left="378" width="108" height="15" font="1">Amiodarone 158 pts.  </text>
<text top="320" left="378" width="141" height="15" font="1">AVRT 11, IART 18, EAT 11. </text>
<text top="336" left="378" width="146" height="15" font="1">Median dose amiodarone 2.5 </text>
<text top="351" left="378" width="158" height="15" font="1">mg/kg; procainamide 10 mg/kg. </text>
<text top="258" left="561" width="100" height="15" font="1">IV procainamide vs. </text>
<text top="274" left="561" width="78" height="15" font="1">amiodarone for </text>
<text top="289" left="561" width="88" height="15" font="1">terminating SV12 </text>
<text top="258" left="696" width="210" height="15" font="1">Success: full + partial: Procainamide 71%, </text>
<text top="274" left="696" width="93" height="15" font="1">amiodarone 34%.  </text>
<text top="289" left="696" width="166" height="15" font="1">Full success, Procainamide 50%, </text>
<text top="305" left="696" width="93" height="15" font="1">amiodarone 15%.  </text>
<text top="258" left="922" width="205" height="15" font="1">IV procainamide more efficacious than IV </text>
<text top="274" left="922" width="202" height="15" font="1">amiodarone for acute termination of SVT </text>
<text top="367" left="54" width="66" height="15" font="1">Diza-Parra S </text>
<text top="383" left="54" width="28" height="15" font="1">2014 </text>
<text top="398" left="54" width="29" height="15" font="1">(259) </text>
<text top="414" left="54" width="49" height="15" font="8">24849273</text>
<text top="414" left="103" width="3" height="15" font="1"> </text>
<text top="367" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="383" left="137" width="34" height="15" font="1">center </text>
<text top="367" left="264" width="15" height="15" font="1">26 </text>
<text top="367" left="378" width="159" height="15" font="1">Ped ED: 44 episodes SVT in 26 </text>
<text top="383" left="378" width="162" height="15" font="1">pts, mean age 3.1 y. 1/07-12/11. </text>
<text top="398" left="378" width="125" height="15" font="1">Adenosine given to 89%, </text>
<text top="414" left="378" width="102" height="15" font="1">increasing dosages. </text>
<text top="414" left="480" width="3" height="15" font="9"> </text>
<text top="367" left="561" width="108" height="15" font="1">Efficacy of adenosine </text>
<text top="383" left="561" width="69" height="15" font="1">pediatric SVT </text>
<text top="367" left="696" width="127" height="15" font="1">Adenosine efficacy 75%.  </text>
<text top="383" left="696" width="207" height="15" font="1">30% responded to single dose, mean 112 </text>
<text top="398" left="696" width="191" height="15" font="1">mcg/kg; 41% 2 doses, mean response </text>
<text top="414" left="696" width="191" height="15" font="1">dose 188 mcg/kg; 24% 3 doses, mean </text>
<text top="429" left="696" width="164" height="15" font="1">response dose 249 mcg/kg. 66% </text>
<text top="445" left="696" width="94" height="15" font="1">discharged home.  </text>
<text top="367" left="922" width="190" height="15" font="1">Mean effective dose of adenosine 173 </text>
<text top="383" left="922" width="213" height="15" font="1">mcg/kgm, higher than usual recommended </text>
<text top="398" left="922" width="33" height="15" font="1">dose.  </text>
<text top="414" left="922" width="129" height="15" font="1">Mean number doses 1.7.  </text>
<text top="461" left="54" width="145" height="15" font="1">Pediatrics:  JET Risk Factors </text>
<text top="477" left="54" width="47" height="15" font="1">Batra AS </text>
<text top="493" left="54" width="28" height="15" font="1">2006 </text>
<text top="508" left="54" width="29" height="15" font="1">(260) </text>
<text top="524" left="54" width="49" height="15" font="8">16391972</text>
<text top="524" left="103" width="3" height="15" font="24"> </text>
<text top="477" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="493" left="137" width="34" height="15" font="1">center </text>
<text top="477" left="264" width="22" height="15" font="1">336 </text>
<text top="477" left="378" width="141" height="15" font="1">336 consecutive pts surg for </text>
<text top="493" left="378" width="48" height="15" font="1">CHD/1 y. </text>
<text top="508" left="378" width="100" height="15" font="1">JET 8%, 27/336 pts </text>
<text top="477" left="561" width="111" height="15" font="1">Identify risk factors for </text>
<text top="493" left="561" width="59" height="15" font="1">postop JET </text>
<text top="477" left="696" width="192" height="15" font="1">Highest risk: TGA arterial switch, 23%; </text>
<text top="493" left="696" width="140" height="15" font="1">AVSD 21%; Norwood, 20%. </text>
<text top="508" left="696" width="210" height="15" font="1">JET pts younger, longer CPB times, hgher </text>
<text top="524" left="696" width="189" height="15" font="1">iinotrope schore, longer ischemic time </text>
<text top="477" left="922" width="95" height="15" font="1">JET incidence 8%. </text>
<text top="540" left="54" width="57" height="15" font="1">Andreasen </text>
<text top="555" left="54" width="16" height="15" font="1">JB </text>
<text top="571" left="54" width="28" height="15" font="1">2008 </text>
<text top="587" left="54" width="29" height="15" font="1">(261) </text>
<text top="602" left="54" width="49" height="15" font="8">18196218</text>
<text top="602" left="103" width="3" height="15" font="24"> </text>
<text top="540" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="555" left="137" width="100" height="15" font="1">center, case-control </text>
<text top="540" left="264" width="22" height="15" font="1">874 </text>
<text top="540" left="378" width="165" height="15" font="1">874 pts &lt;16 y, CHD surgery 1/98-</text>
<text top="555" left="378" width="31" height="15" font="1">12/05 </text>
<text top="571" left="378" width="154" height="15" font="1">Among JET pts: 26% had VSD </text>
<text top="587" left="378" width="165" height="15" font="1">closure; more often in pts w/ high </text>
<text top="602" left="378" width="162" height="15" font="1">RACHS score; 25% had surgery </text>
<text top="617" left="378" width="99" height="15" font="1">NOT near the AVN. </text>
<text top="540" left="561" width="111" height="15" font="1">Identify risk factors for </text>
<text top="555" left="561" width="59" height="15" font="1">postop JET </text>
<text top="540" left="696" width="91" height="15" font="1">Incidence 10.2%,  </text>
<text top="555" left="696" width="193" height="15" font="1">CPB &gt;90 min (OR: 2.6); high inotropes </text>
<text top="571" left="696" width="205" height="15" font="1">(OR: 2.6); high postop CK-MB (OR: 3.1).  </text>
<text top="587" left="696" width="197" height="15" font="1">Mortality increased: 13.5% vs. 1.7%; 12 </text>
<text top="602" left="696" width="121" height="15" font="1">deaths. Prolonged LOS. </text>
<text top="540" left="922" width="212" height="15" font="1">Rx protocol: sedation/electrolytes; reduced </text>
<text top="555" left="922" width="214" height="15" font="1">inotropes; reduced core temp to 34-35 d C; </text>
<text top="571" left="922" width="170" height="15" font="1">muscle relaxation, IV amiodarone. </text>
<text top="634" left="54" width="66" height="15" font="1">Borgman KY </text>
<text top="649" left="54" width="28" height="15" font="1">2012 </text>
<text top="665" left="54" width="29" height="15" font="1">(262) </text>
<text top="680" left="54" width="49" height="15" font="8">21740877</text>
<text top="680" left="103" width="3" height="15" font="24"> </text>
<text top="634" left="137" width="104" height="15" font="1">Retrospective Single </text>
<text top="649" left="137" width="37" height="15" font="1">center, </text>
<text top="634" left="264" width="15" height="15" font="1">36 </text>
<text top="634" left="378" width="160" height="15" font="1">CHD pts developing JET postop </text>
<text top="649" left="378" width="154" height="15" font="1">compared w/ CHD pts w/o JET </text>
<text top="634" left="561" width="78" height="15" font="1">Assess genetic </text>
<text top="649" left="561" width="114" height="15" font="1">polymorphism in CHD  </text>
<text top="665" left="561" width="119" height="15" font="1">pts who develop postop </text>
<text top="680" left="561" width="23" height="15" font="1">JET </text>
<text top="634" left="696" width="177" height="15" font="1">Risks for JET postop included, age, </text>
<text top="649" left="696" width="200" height="15" font="1">inotrope score, bypass time, crossclamp </text>
<text top="665" left="696" width="199" height="15" font="1">time. ACE I/D genotype associated w/ 2-</text>
<text top="680" left="696" width="139" height="15" font="1">fold increase in risk for JET. </text>
<text top="634" left="922" width="205" height="15" font="1">ACE I/D polymorphism may be risk factor </text>
<text top="649" left="922" width="39" height="15" font="1">for JET </text>
<text top="696" left="54" width="57" height="15" font="1">Makhoul M </text>
<text top="712" left="54" width="28" height="15" font="1">2013 </text>
<text top="727" left="54" width="29" height="15" font="1">(263) </text>
<text top="743" left="54" width="49" height="15" font="8">22987106</text>
<text top="743" left="103" width="3" height="15" font="24"> </text>
<text top="696" left="137" width="71" height="15" font="1">Single center, </text>
<text top="712" left="137" width="69" height="15" font="1">retrospective, </text>
<text top="727" left="137" width="85" height="15" font="1">matched cohorts </text>
<text top="696" left="264" width="15" height="15" font="1">54 </text>
<text top="696" left="378" width="169" height="15" font="1">Pts &lt;21 y, CHD surgery 1/06-6/10 </text>
<text top="712" left="378" width="156" height="15" font="1">Emory. Narrow QRS tach &gt;150 </text>
<text top="727" left="378" width="28" height="15" font="1">bpm. </text>
<text top="743" left="378" width="151" height="15" font="1">Identified JET in 54, incidence </text>
<text top="758" left="378" width="163" height="15" font="1">1.4%out of  2450 pts undergoing </text>
<text top="774" left="378" width="29" height="15" font="1">CPB. </text>
<text top="789" left="378" width="159" height="15" font="1">One death in each group, 1.8%. </text>
<text top="696" left="561" width="79" height="15" font="1">JET risk factors </text>
<text top="696" left="696" width="213" height="15" font="1">↑risk: weight &lt;4 kg, CPB &gt;100 min; postop </text>
<text top="712" left="696" width="114" height="15" font="1">lactic acid &gt;20 mg/dL.  </text>
<text top="727" left="696" width="198" height="15" font="1">Rx: ↓ surface cooling core temp 35 d C, </text>
<text top="743" left="696" width="195" height="15" font="1">↓exogenous catech; optimize sedation: </text>
<text top="758" left="696" width="207" height="15" font="1">used in 96%. Atrial overdrive pacing used </text>
<text top="774" left="696" width="32" height="15" font="1">74%.  </text>
<text top="789" left="696" width="184" height="15" font="1">Amiodarone 78%, Procainamide 9%; </text>
<text top="696" left="922" width="197" height="15" font="1">Lower mortality and incidence JET than </text>
<text top="712" left="922" width="70" height="15" font="1">prior studies.  </text>
<text top="727" left="922" width="3" height="15" font="1"> </text>
<text top="743" left="922" width="173" height="15" font="1">Study not designed to assess drug </text>
<text top="758" left="922" width="44" height="15" font="1">efficacy. </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">104 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="696" width="63" height="15" font="1">esmolol 6%. </text>
<text top="71" left="54" width="124" height="15" font="1">Pediatrics: JET Therapy  </text>
<text top="87" left="54" width="60" height="15" font="1">Pfammatter </text>
<text top="102" left="54" width="16" height="15" font="1">JP </text>
<text top="118" left="54" width="28" height="15" font="1">1995 </text>
<text top="134" left="54" width="29" height="15" font="1">(264) </text>
<text top="149" left="54" width="43" height="15" font="8">7677480</text>
<text top="149" left="97" width="3" height="15" font="24"> </text>
<text top="87" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="102" left="137" width="34" height="15" font="1">center </text>
<text top="87" left="264" width="9" height="15" font="1">6 </text>
<text top="87" left="378" width="112" height="15" font="1">Postop JET treated w/ </text>
<text top="102" left="378" width="70" height="15" font="1">hypothermia.  </text>
<text top="118" left="378" width="169" height="15" font="1">6 consecutive pts, surface cooling </text>
<text top="134" left="378" width="160" height="15" font="1">to rectal temperature 32-34 d C; </text>
<text top="149" left="378" width="113" height="15" font="1">sedated, vent. Cooling </text>
<text top="164" left="378" width="104" height="15" font="1">maintained 24-88 h.  </text>
<text top="87" left="561" width="110" height="15" font="1">Assess rx postop JET </text>
<text top="102" left="561" width="78" height="15" font="1">w/ hypothermia </text>
<text top="87" left="696" width="155" height="15" font="1">Mean interval Dx JET and start </text>
<text top="102" left="696" width="89" height="15" font="1">hypothermia 4 h.  </text>
<text top="118" left="696" width="191" height="15" font="1">JET rate ↓from 219 to 165 bpm mean. </text>
<text top="87" left="922" width="192" height="15" font="1">Early institution moderate hypothermia </text>
<text top="102" left="922" width="119" height="15" font="1">effective in lowering HR </text>
<text top="181" left="54" width="55" height="15" font="1">Walsh EP  </text>
<text top="196" left="54" width="28" height="15" font="1">1997 </text>
<text top="212" left="54" width="29" height="15" font="1">(265) </text>
<text top="227" left="54" width="43" height="15" font="8">9120158</text>
<text top="227" left="97" width="3" height="15" font="1"> </text>
<text top="181" left="137" width="96" height="15" font="1">Prospective, single </text>
<text top="196" left="137" width="34" height="15" font="1">center </text>
<text top="181" left="264" width="15" height="15" font="1">71 </text>
<text top="181" left="378" width="151" height="15" font="1">Staged rx for JET 1986-1994.  </text>
<text top="196" left="378" width="152" height="15" font="1">71 pts, HR &gt;170 bpm. Stages: </text>
<text top="212" left="378" width="154" height="15" font="1">↓catecholamines; correct feve; </text>
<text top="227" left="378" width="164" height="15" font="1">atrial pacing; digoxin; phenytoine </text>
<text top="243" left="378" width="164" height="15" font="1">or propranolol or verap; procaine </text>
<text top="258" left="378" width="125" height="15" font="1">or hypothermia; combine </text>
<text top="274" left="378" width="143" height="15" font="1">procainamide + hypothermia </text>
<text top="181" left="561" width="110" height="15" font="1">Assess rx JET postop </text>
<text top="181" left="696" width="176" height="15" font="1">Success: reduce HR &lt;170 w/in 2 h. </text>
<text top="196" left="696" width="151" height="15" font="1">Treatment success 70/71 pts.  </text>
<text top="212" left="696" width="196" height="15" font="1">JET associated w/ young age, transient </text>
<text top="227" left="696" width="123" height="15" font="1">AV block, VSD closures  </text>
<text top="181" left="922" width="190" height="15" font="1">Only correction of fever and combined </text>
<text top="196" left="922" width="205" height="15" font="1">procainamide + hypothermia efficacious.  </text>
<text top="290" left="54" width="49" height="15" font="1">Laird WP </text>
<text top="305" left="54" width="28" height="15" font="1">2003 </text>
<text top="321" left="54" width="26" height="15" font="1">(266)</text>
<text top="321" left="80" width="3" height="15" font="24"> </text>
<text top="336" left="54" width="49" height="15" font="8">12370794</text>
<text top="336" left="103" width="3" height="15" font="24"> </text>
<text top="290" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="305" left="137" width="34" height="15" font="1">center </text>
<text top="290" left="264" width="229" height="15" font="1">11 11 </text>
<text top="290" left="393" width="140" height="15" font="1">pediatric postop CHD pts w/ </text>
<text top="305" left="378" width="138" height="15" font="1">JET, mean HR 203 bpm. IV </text>
<text top="321" left="378" width="151" height="15" font="1">amiodarone 5 mg/kg x2 given, </text>
<text top="336" left="378" width="131" height="15" font="1">followed by infusion 10-15 </text>
<text top="352" left="378" width="105" height="15" font="1">mg/kg/d for 48-72 h.  </text>
<text top="290" left="561" width="119" height="15" font="1">Amiodarone efficacy for </text>
<text top="305" left="561" width="59" height="15" font="1">postop JET </text>
<text top="290" left="696" width="205" height="15" font="1">Amiodarone in higher dose (10 mg/kg vs. </text>
<text top="305" left="696" width="197" height="15" font="1">5 mg/kg) achieved control more rapids.  </text>
<text top="321" left="696" width="159" height="15" font="1">Hypotension/bradycardia 2 pts.  </text>
<text top="290" left="922" width="213" height="15" font="1">Amiodarone 10 mg/kg IV effective for rapid </text>
<text top="305" left="922" width="209" height="15" font="1">control of postop JET; continuous infusion </text>
<text top="321" left="922" width="57" height="15" font="1">necessary. </text>
<text top="368" left="54" width="60" height="15" font="1">Plumpton K </text>
<text top="384" left="54" width="28" height="15" font="1">2005 </text>
<text top="399" left="54" width="29" height="15" font="1">(267) </text>
<text top="415" left="54" width="49" height="15" font="8">15831155</text>
<text top="415" left="103" width="3" height="15" font="1"> </text>
<text top="368" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="384" left="137" width="34" height="15" font="1">center </text>
<text top="368" left="264" width="15" height="15" font="1">15 </text>
<text top="368" left="378" width="145" height="15" font="1">15 postop pediatric CHD pts, </text>
<text top="384" left="378" width="156" height="15" font="1">JET, median 2.6 mo. JET rates </text>
<text top="399" left="378" width="160" height="15" font="1">182-229 bpm, median 192 bpm. </text>
<text top="415" left="378" width="75" height="15" font="1">IV amiodarone </text>
<text top="368" left="561" width="119" height="15" font="1">Amiodarone efficacy for </text>
<text top="384" left="561" width="59" height="15" font="1">postop JET </text>
<text top="368" left="696" width="177" height="15" font="1">Amiodarone controlled tachycardia, </text>
<text top="384" left="696" width="179" height="15" font="1">median time 4.5 h, median dose 5.9 </text>
<text top="399" left="696" width="196" height="15" font="1">mg/kg. Hypotension or bradycardia in 2 </text>
<text top="415" left="696" width="24" height="15" font="1">pts.  </text>
<text top="368" left="922" width="177" height="15" font="1">Amiodarone controlled post-op JET </text>
<text top="384" left="922" width="42" height="15" font="1">rapidly.  </text>
<text top="431" left="54" width="47" height="15" font="1">Haas NA </text>
<text top="446" left="54" width="28" height="15" font="1">2008 </text>
<text top="446" left="82" width="3" height="15" font="24"> </text>
<text top="462" left="54" width="29" height="15" font="1">(268) </text>
<text top="477" left="54" width="49" height="15" font="8">19026806</text>
<text top="477" left="103" width="3" height="15" font="1"> </text>
<text top="431" left="137" width="61" height="15" font="1">Prospective </text>
<text top="446" left="137" width="72" height="15" font="1">observational  </text>
<text top="431" left="264" width="15" height="15" font="1">71 </text>
<text top="431" left="378" width="157" height="15" font="1">71 of 2106 CPB pts repair CHD </text>
<text top="446" left="378" width="159" height="15" font="1">received amiodarone for postop </text>
<text top="462" left="378" width="133" height="15" font="1">atrial (70) or ventricular (7) </text>
<text top="477" left="378" width="158" height="15" font="1">tachycardia. Median age 3 mo.  </text>
<text top="493" left="378" width="142" height="15" font="1">JET 37, ectopic AT 10, atrial </text>
<text top="508" left="378" width="116" height="15" font="1">flutter 8, AF 1, IART 1.  </text>
<text top="524" left="378" width="115" height="15" font="1">Early rx: w/in 60 min of </text>
<text top="539" left="378" width="166" height="15" font="1">arrhythmia detection vs. &gt;60 min. </text>
<text top="555" left="378" width="135" height="15" font="1">Protocol: reduce inotropes, </text>
<text top="570" left="378" width="144" height="15" font="1">correct lytes; IV amiodarone. </text>
<text top="586" left="378" width="168" height="15" font="1">Dose 5 mg/kg over 1-4 h, infusion </text>
<text top="601" left="378" width="127" height="15" font="1">5-15 mcg/kg/min. Repeat </text>
<text top="617" left="378" width="162" height="15" font="1">boluses; infusion 5-10 mg/kg/d.   </text>
<text top="431" left="561" width="100" height="15" font="1">Assess response of </text>
<text top="446" left="561" width="108" height="15" font="1">postop tachycardia to </text>
<text top="462" left="561" width="75" height="15" font="1">IV amiodarone </text>
<text top="431" left="696" width="202" height="15" font="1">Early rx postop tachycardia reduced rate </text>
<text top="446" left="696" width="208" height="15" font="1">(156 vs. 300 bpm, p&lt;0.01); time to control </text>
<text top="462" left="696" width="187" height="15" font="1">(400 vs. 1038 min, p&lt;0.001), reduced </text>
<text top="477" left="696" width="194" height="15" font="1">dose (28 vs. 67 mg, p&lt;0.025), and ICU </text>
<text top="493" left="696" width="142" height="15" font="1">LOS (3.3 vs. 5.3 d, p&lt;0.01).  </text>
<text top="431" left="922" width="166" height="15" font="1">Early RX w/ amiodarone (60 min) </text>
<text top="446" left="922" width="158" height="15" font="1">significant improved outcomes.  </text>
<text top="633" left="54" width="54" height="15" font="1">Collins KK </text>
<text top="648" left="54" width="28" height="15" font="1">2009 </text>
<text top="664" left="54" width="29" height="15" font="1">(269) </text>
<text top="679" left="54" width="49" height="15" font="8">19232902</text>
<text top="679" left="103" width="3" height="15" font="1"> </text>
<text top="633" left="137" width="57" height="15" font="1">Multicenter </text>
<text top="648" left="137" width="70" height="15" font="1">retrospective  </text>
<text top="633" left="264" width="15" height="15" font="1">94 </text>
<text top="633" left="378" width="158" height="15" font="1">Non postoperative JET, median </text>
<text top="648" left="378" width="159" height="15" font="1">age 0.8 y, range fetus – 16 y). .  </text>
<text top="664" left="378" width="121" height="15" font="1">Time frame 1969-2008.  </text>
<text top="679" left="378" width="159" height="15" font="1">CHF 16%. <i>VA dissociated 56%,</i> </text>
<text top="695" left="378" width="164" height="15" font="1">1:1 VA 32%; both 3%, NOS 9%.  </text>
<text top="710" left="378" width="88" height="15" font="1">Median f/u 4.5 y.  </text>
<text top="633" left="561" width="114" height="15" font="1">Assess outcomes of rx </text>
<text top="648" left="561" width="108" height="15" font="1">for non postop JET in </text>
<text top="664" left="561" width="63" height="15" font="1">pediatric pts </text>
<text top="633" left="696" width="171" height="15" font="1">Medications used in 89%; 62% ≥2 </text>
<text top="648" left="696" width="65" height="15" font="1">medications. </text>
<text top="664" left="696" width="188" height="15" font="1">Amiodarone used 60%, alone in 20%, </text>
<text top="679" left="696" width="149" height="15" font="1">combo w/ beta blocker (15%), </text>
<text top="695" left="696" width="215" height="15" font="1">procainamide, dif, flecainide, propafenone.  </text>
<text top="710" left="696" width="197" height="15" font="1">Ablation: indication CHF or refractory to </text>
<text top="726" left="696" width="170" height="15" font="1">medications; elective 15%. RF 17, </text>
<text top="741" left="696" width="183" height="15" font="1">cryoablation 27, efficacy 82 vs. 85%, </text>
<text top="757" left="696" width="192" height="15" font="1">p=NS; recurrence 13-14%; inadvertent </text>
<text top="772" left="696" width="212" height="15" font="1">CHB 18% of RF pts. AV node ablation 3%, </text>
<text top="788" left="696" width="62" height="15" font="1">pacer 14%.  </text>
<text top="633" left="922" width="150" height="15" font="1">Amiodarone effective in 60%;  </text>
<text top="648" left="922" width="159" height="15" font="1">Ablation: 47%: efficacy 82-85%, </text>
<text top="664" left="922" width="210" height="15" font="1">recurrence 13-14%, 18% inadvertent CHB </text>
<text top="679" left="922" width="178" height="15" font="1">in RF pts; 3% underwent intentional </text>
<text top="695" left="922" width="71" height="15" font="1">ablation AVN. </text>
<text top="710" left="922" width="141" height="15" font="1">Pacers 14% of ablation pts.  </text>
<text top="726" left="922" width="3" height="15" font="1"> </text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">105 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="696" width="175" height="15" font="1">Deaths 4%, all age ≤6 mo. 70% no </text>
<text top="70" left="696" width="137" height="15" font="1">chronic medical rx for JET.  </text>
<text top="86" left="54" width="72" height="15" font="1">Kovacikova L  </text>
<text top="102" left="54" width="28" height="15" font="1">2009 </text>
<text top="117" left="54" width="29" height="15" font="1">(270) </text>
<text top="133" left="54" width="49" height="15" font="8">19632422</text>
<text top="133" left="103" width="3" height="15" font="24"> </text>
<text top="86" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="102" left="137" width="34" height="15" font="1">center </text>
<text top="86" left="264" width="15" height="15" font="1">40 </text>
<text top="86" left="378" width="82" height="15" font="1">Postop CHD pts </text>
<text top="102" left="378" width="162" height="15" font="1">IV amiodarone 2 mg/kg boluses, </text>
<text top="117" left="378" width="132" height="15" font="1">continuous infusion 10=15 </text>
<text top="133" left="378" width="60" height="15" font="1">mcg/kg/min </text>
<text top="86" left="561" width="114" height="15" font="1">Assess IV amiodarone </text>
<text top="102" left="561" width="102" height="15" font="1">as rx for postop JET </text>
<text top="86" left="696" width="178" height="15" font="1">Amiodarone effective 45%; SR in 7, </text>
<text top="102" left="696" width="204" height="15" font="1">decreased HR 11; allowed effective atrial </text>
<text top="117" left="696" width="127" height="15" font="1">pacing w/ AV synchrony.  </text>
<text top="133" left="696" width="181" height="15" font="1">Failure of amiodarone associated w/ </text>
<text top="148" left="696" width="197" height="15" font="1">higher AV oxygen saturation difference, </text>
<text top="164" left="696" width="90" height="15" font="1">lower body temp.  </text>
<text top="86" left="922" width="201" height="15" font="1">Amiodarone achieved SR in 45% as first </text>
<text top="102" left="922" width="217" height="15" font="1">line; recommend in combo w/ hypothermia.  </text>
<text top="180" left="54" width="129" height="15" font="1">Pediatrics: EP Study/Risk </text>
<text top="196" left="54" width="45" height="15" font="1">Klein GJ </text>
<text top="212" left="54" width="28" height="15" font="1">1979 </text>
<text top="227" left="54" width="37" height="15" font="8">492252</text>
<text top="227" left="91" width="3" height="15" font="1"> </text>
<text top="243" left="54" width="29" height="15" font="1">(137) </text>
<text top="196" left="137" width="103" height="15" font="1">To assess risk of VF </text>
<text top="212" left="137" width="64" height="15" font="1">in WPW pts. </text>
<text top="196" left="264" width="277" height="15" font="1">73 WPW + h/o VF vs. preexcitation, </text>
<text top="212" left="378" width="114" height="15" font="1">WPW pts w/ no h/o VF </text>
<text top="196" left="561" width="17" height="15" font="1">VF </text>
<text top="196" left="696" width="190" height="15" font="1">These pts also had high prevelance of </text>
<text top="212" left="696" width="212" height="15" font="1">reciprocating tachycardia and AF (14 of 25 </text>
<text top="227" left="696" width="201" height="15" font="1">vs. 18 of 73 [P=0.004]) and multiple APs </text>
<text top="243" left="696" width="206" height="15" font="1">(5 of 25 vs. four of 73 [P=0.012]). WPW + </text>
<text top="258" left="696" width="209" height="15" font="1">h/o AF and tachycardia demonstrate rapid </text>
<text top="274" left="696" width="153" height="15" font="1">conduction over AP during AF. </text>
<text top="196" left="922" width="196" height="15" font="1">VF was  initial manifestation of WPW in </text>
<text top="212" left="922" width="137" height="15" font="1">10% of pts: ages 8,9, 16 y.  </text>
<text top="290" left="54" width="68" height="15" font="1">Timmermans </text>
<text top="305" left="54" width="11" height="15" font="1">C </text>
<text top="321" left="54" width="28" height="15" font="1">1995 </text>
<text top="336" left="54" width="29" height="15" font="1">(271) </text>
<text top="352" left="54" width="43" height="15" font="8">7653450</text>
<text top="352" left="97" width="3" height="15" font="1"> </text>
<text top="290" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="305" left="137" width="34" height="15" font="1">center </text>
<text top="290" left="264" width="15" height="15" font="1">15 </text>
<text top="290" left="378" width="142" height="15" font="1">15/690 pts w/ WPW referred </text>
<text top="305" left="378" width="155" height="15" font="1">1/79-2/95 presented w/ cardiac </text>
<text top="321" left="378" width="38" height="15" font="1">arrest.  </text>
<text top="336" left="378" width="153" height="15" font="1">53% not known to have WPW. </text>
<text top="352" left="378" width="143" height="15" font="1">EP study done to assess AP </text>
<text top="367" left="378" width="83" height="15" font="1">characteristics.   </text>
<text top="290" left="561" width="115" height="15" font="1">Characterize WPW pts </text>
<text top="305" left="561" width="46" height="15" font="1">w/ arrest </text>
<text top="290" left="696" width="159" height="15" font="1">VF initial manifestation in 8 pts.  </text>
<text top="305" left="696" width="196" height="15" font="1">10/15 exercising. 7 pts known ORT/AF. </text>
<text top="321" left="696" width="177" height="15" font="1">9/11 EP study: AP ERP≤250 msec. </text>
<text top="336" left="696" width="113" height="15" font="1">Multiple AP not a risk.  </text>
<text top="290" left="922" width="209" height="15" font="1">VF 2.2% of series; all under age 45 y, half </text>
<text top="305" left="922" width="80" height="15" font="1">under age 30y.  </text>
<text top="384" left="54" width="69" height="15" font="1">Ceresnak SR </text>
<text top="399" left="54" width="31" height="15" font="1">2012  </text>
<text top="415" left="54" width="32" height="15" font="1">(272)  </text>
<text top="430" left="54" width="49" height="15" font="8">22324823</text>
<text top="430" left="103" width="3" height="15" font="1"> </text>
<text top="384" left="137" width="101" height="15" font="1">Retrospective, multi-</text>
<text top="399" left="137" width="34" height="15" font="1">center </text>
<text top="384" left="264" width="18" height="15" font="1"> 30 </text>
<text top="384" left="378" width="164" height="15" font="1">1147 pts w/ WPW underwent EP </text>
<text top="399" left="378" width="147" height="15" font="1">study; 30 pts (2.6%) w/ ADT.  </text>
<text top="415" left="378" width="96" height="15" font="1">Mean age 16±3 y.  </text>
<text top="384" left="561" width="57" height="15" font="1">Assess EP </text>
<text top="399" left="561" width="118" height="15" font="1">characteristics of pts w/ </text>
<text top="415" left="561" width="25" height="15" font="1">ADT </text>
<text top="384" left="696" width="60" height="15" font="1">7% w/ CHD </text>
<text top="399" left="696" width="118" height="15" font="1">13% more than one AP </text>
<text top="415" left="696" width="207" height="15" font="1">Left sided AP 53%; right 47% often septal </text>
<text top="430" left="696" width="124" height="15" font="1">High risk in 17 pts (57%) </text>
<text top="384" left="922" width="205" height="15" font="1">ADT rare in children w/ WPW undergoing </text>
<text top="399" left="922" width="73" height="15" font="1">ablation, 2.6% </text>
<text top="415" left="922" width="3" height="15" font="1"> </text>
<text top="430" left="922" width="204" height="15" font="1">57% w/ ADT had high risk characteristics </text>
<text top="446" left="54" width="49" height="15" font="1">Brembilla </text>
<text top="462" left="54" width="40" height="15" font="1">Perot B </text>
<text top="477" left="54" width="28" height="15" font="1">2013 </text>
<text top="493" left="54" width="29" height="15" font="1">(273) </text>
<text top="508" left="54" width="49" height="15" font="8">23148120</text>
<text top="508" left="103" width="3" height="15" font="1"> </text>
<text top="446" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="462" left="137" width="34" height="15" font="1">center </text>
<text top="446" left="264" width="15" height="15" font="1">63 </text>
<text top="446" left="378" width="157" height="15" font="1">807 pts w/ WPW underwent EP </text>
<text top="462" left="378" width="145" height="15" font="1">study; ADT induced in 63 pts </text>
<text top="477" left="378" width="26" height="15" font="1">(8%) </text>
<text top="493" left="378" width="32" height="15" font="1">Ages  </text>
<text top="446" left="561" width="57" height="15" font="1">Assess EP </text>
<text top="462" left="561" width="118" height="15" font="1">characteristics of pts w/ </text>
<text top="477" left="561" width="78" height="15" font="1">WPW and ADT </text>
<text top="446" left="696" width="171" height="15" font="1">Pts w/ ADT more likely to have AF </text>
<text top="462" left="696" width="201" height="15" font="1">induction (41 vs. 24%, p&lt;.002), and high </text>
<text top="477" left="696" width="193" height="15" font="1">risk characteristics (22 vs. 12%, p&lt;.02) </text>
<text top="493" left="696" width="3" height="15" font="1"> </text>
<text top="508" left="696" width="182" height="15" font="1">No difference in age, gender, clinical </text>
<text top="524" left="696" width="93" height="15" font="1">presentation, ORT </text>
<text top="446" left="922" width="192" height="15" font="1">Clinical outcome did not differ in pts w/ </text>
<text top="462" left="922" width="208" height="15" font="1">ADT; older pts less likely to have high risk </text>
<text top="477" left="922" width="74" height="15" font="1">characteristics </text>
<text top="540" left="54" width="58" height="15" font="1">Pappone C </text>
<text top="555" left="54" width="28" height="15" font="1">2014 </text>
<text top="571" left="54" width="29" height="15" font="1">(145) </text>
<text top="587" left="54" width="49" height="15" font="8">25052405</text>
<text top="587" left="103" width="3" height="15" font="24"> </text>
<text top="602" left="54" width="3" height="15" font="1"> </text>
<text top="540" left="137" width="96" height="15" font="1">Prospective  single </text>
<text top="555" left="137" width="34" height="15" font="1">center </text>
<text top="540" left="264" width="28" height="15" font="1">2169 </text>
<text top="540" left="378" width="112" height="15" font="1">2169 pts w/ WPW, 8 y </text>
<text top="555" left="378" width="167" height="15" font="1">prospective study. 1001: no RFA; </text>
<text top="571" left="378" width="135" height="15" font="1">1168: RFA. EP study in all. </text>
<text top="587" left="378" width="139" height="15" font="1">Median f/u 96 mo. 92% f/u.  </text>
<text top="540" left="561" width="120" height="15" font="1">Assess VF or malignant </text>
<text top="555" left="561" width="104" height="15" font="1">arrhythmias in WPW </text>
<text top="540" left="696" width="199" height="15" font="1">In no RFA group, 1.5% experienced VF, </text>
<text top="555" left="696" width="210" height="15" font="1">vs. 0.4% in no RFA group. VF: 13/15 were </text>
<text top="571" left="696" width="204" height="15" font="1">children, median age 11 y. Associated w/ </text>
<text top="587" left="696" width="191" height="15" font="1">short AP ERP (APERP &lt;240 msec) (P </text>
<text top="602" left="696" width="193" height="15" font="1">&lt;0.001) and AVRT initiating AF, but no </text>
<text top="617" left="696" width="185" height="15" font="1">sxs. Posteroseptal AP more common </text>
<text top="633" left="696" width="207" height="15" font="1">among VF pts. VF w/ exertion in 4, at rest </text>
<text top="648" left="696" width="33" height="15" font="1">in 11.  </text>
<text top="540" left="922" width="209" height="15" font="1">1.5% VF, almost all in children; risk higher </text>
<text top="555" left="922" width="101" height="15" font="1">in asymptomatic pts </text>
<text top="571" left="922" width="3" height="15" font="1"> </text>
<text top="587" left="922" width="174" height="15" font="1">13/15 pts w/ VF &lt;15 y; 2 age 32 y.  </text>
<text top="665" left="54" width="98" height="15" font="1">Pediatrics: Ablation </text>
<text top="681" left="54" width="52" height="15" font="1">Kugler JD </text>
<text top="696" left="54" width="28" height="15" font="1">1994 </text>
<text top="712" left="54" width="29" height="15" font="1">(167) </text>
<text top="727" left="54" width="46" height="15" font="8">8164700 </text>
<text top="743" left="54" width="3" height="15" font="1"> </text>
<text top="681" left="137" width="101" height="15" font="1">Retrospective, multi-</text>
<text top="696" left="137" width="34" height="15" font="1">center </text>
<text top="681" left="264" width="25" height="15" font="1"> 652 </text>
<text top="681" left="378" width="158" height="15" font="1">652 pts underwent 725 ablation </text>
<text top="696" left="378" width="156" height="15" font="1">procedures between 1/91-9/92, </text>
<text top="712" left="378" width="164" height="15" font="1">Median age 13.5 y, 84% no SHD </text>
<text top="681" left="561" width="111" height="15" font="1">Assess outcomes and </text>
<text top="696" left="561" width="82" height="15" font="1">complications of </text>
<text top="712" left="561" width="105" height="15" font="1">ablation in young pts </text>
<text top="681" left="696" width="199" height="15" font="1">Success rates: AVRT and AVNRT 83%; </text>
<text top="696" left="696" width="181" height="15" font="1">highest in LFW AP and ↑institutional </text>
<text top="712" left="696" width="199" height="15" font="1">experience; lower in RFW AP, structural </text>
<text top="727" left="696" width="174" height="15" font="1">heart disease, body weight &gt;80 kg. </text>
<text top="743" left="696" width="193" height="15" font="1">Complications 4.8%, higher in very low </text>
<text top="758" left="696" width="174" height="15" font="1">weight &lt;15 kg and less institutional </text>
<text top="774" left="696" width="57" height="15" font="1">experience </text>
<text top="681" left="922" width="156" height="15" font="1">Uncontrolled, voluntary registry </text>
<text top="790" left="54" width="47" height="15" font="1">Kugler J  </text>
<text top="790" left="137" width="101" height="15" font="1">Retrospective, multi-</text>
<text top="790" left="264" width="31" height="15" font="1"> 4135 </text>
<text top="790" left="378" width="128" height="15" font="1">46 centers, pts 0.1-20.9 y </text>
<text top="790" left="561" width="108" height="15" font="1">Determine safety and </text>
<text top="790" left="696" width="188" height="15" font="1">Success rates: AVRT 90%, higher left </text>
<text top="790" left="922" width="205" height="15" font="1">Ablation evolving into treatment of choice </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="26" size="11" family="Times" color="#548ed4"/>
<text top="814" left="1113" width="24" height="17" font="0">106 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="28" height="15" font="1">1997 </text>
<text top="70" left="54" width="29" height="15" font="1">(274) </text>
<text top="86" left="54" width="46" height="15" font="8">9399718 </text>
<text top="101" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="137" width="34" height="15" font="1">center </text>
<text top="55" left="378" width="166" height="15" font="1">undergoing ablation 1/91-9/15/96 </text>
<text top="70" left="378" width="67" height="15" font="1">88% no SHD </text>
<text top="86" left="378" width="157" height="15" font="1">58% performed due to family/pt </text>
<text top="101" left="378" width="35" height="15" font="1">choice </text>
<text top="55" left="561" width="106" height="15" font="1">efficacy of ablation in </text>
<text top="70" left="561" width="50" height="15" font="1">childhood </text>
<text top="55" left="696" width="98" height="15" font="1">&gt;right, 95 vs. 86%;  </text>
<text top="70" left="696" width="72" height="15" font="1">AVNRT 96%;  </text>
<text top="86" left="696" width="183" height="15" font="1">Mean fluoroscopy time 47.6±40 min; </text>
<text top="101" left="696" width="129" height="15" font="1">Major complications 3.2% </text>
<text top="117" left="696" width="208" height="15" font="1">Deaths 4 pts, 1 immediate, 3 late (2 infant </text>
<text top="132" left="696" width="40" height="15" font="1">deaths) </text>
<text top="147" left="696" width="208" height="15" font="1">Freedom from recurrence at 3 y: AP 77%, </text>
<text top="163" left="696" width="66" height="15" font="1">AVNRT 71%.</text>
<text top="163" left="762" width="3" height="15" font="9"> </text>
<text top="55" left="922" width="98" height="15" font="1">for SVT in older pts </text>
<text top="70" left="922" width="3" height="15" font="1"> </text>
<text top="86" left="922" width="129" height="15" font="1">Deaths in 2 infants noted  </text>
<text top="101" left="922" width="3" height="15" font="1"> </text>
<text top="117" left="922" width="183" height="15" font="1">Higher recurrence than adult pts, but </text>
<text top="132" left="922" width="129" height="15" font="1">possibly due to higher f/u. </text>
<text top="179" left="54" width="44" height="15" font="1">Schaffer </text>
<text top="195" left="54" width="30" height="15" font="1">msec </text>
<text top="210" left="54" width="28" height="15" font="1">2000 </text>
<text top="226" left="54" width="29" height="15" font="1">(275) </text>
<text top="241" left="54" width="49" height="15" font="8">10980215</text>
<text top="241" left="103" width="3" height="15" font="1"> </text>
<text top="179" left="137" width="71" height="15" font="1">Retrospective </text>
<text top="195" left="137" width="57" height="15" font="1">multicenter </text>
<text top="179" left="264" width="15" height="15" font="1">10 </text>
<text top="179" left="378" width="163" height="15" font="1">Rviewed 4651 cases in Pediatric </text>
<text top="195" left="378" width="151" height="15" font="1">RFCA Registry; deaths 0.22% </text>
<text top="210" left="378" width="156" height="15" font="1">5/4092 w/ normal hearts 0.12% </text>
<text top="179" left="561" width="39" height="15" font="1">Assess </text>
<text top="195" left="561" width="100" height="15" font="1">incidence/causes of </text>
<text top="210" left="561" width="31" height="15" font="1">death </text>
<text top="179" left="696" width="202" height="15" font="1">Deaths: all in left sided AP; mural injury,  </text>
<text top="195" left="696" width="177" height="15" font="1">perforation, thromboembolism, vent </text>
<text top="210" left="696" width="55" height="15" font="1">arrhythmia </text>
<text top="226" left="696" width="178" height="15" font="1">Weight 32.7 kg vs. 55.6 kg (p=.023) </text>
<text top="241" left="696" width="200" height="15" font="1">Number of lesions 26.3 vs. 8.7, (p=.019) </text>
<text top="179" left="922" width="181" height="15" font="1">Mortality 0.12-0.22% in left sided AP </text>
<text top="195" left="922" width="209" height="15" font="1">ablations; lower weight, greater number of </text>
<text top="210" left="922" width="38" height="15" font="1">lesions </text>
<text top="257" left="54" width="58" height="15" font="1">Blaufox AD </text>
<text top="273" left="54" width="28" height="15" font="1">2001 </text>
<text top="288" left="54" width="32" height="15" font="1">(276)  </text>
<text top="304" left="54" width="49" height="15" font="8">11733398</text>
<text top="304" left="103" width="3" height="15" font="1"> </text>
<text top="257" left="137" width="71" height="15" font="1">Retrospective </text>
<text top="273" left="137" width="57" height="15" font="1">multicenter </text>
<text top="257" left="264" width="22" height="15" font="1">137 </text>
<text top="257" left="378" width="131" height="15" font="1">Reviewed Pediatric RFCA </text>
<text top="273" left="378" width="150" height="15" font="1">Registry, 1989-1999, age ≤18 </text>
<text top="288" left="378" width="165" height="15" font="1">mo, median 0.7 y, weight median </text>
<text top="304" left="378" width="36" height="15" font="1">10 kg.  </text>
<text top="319" left="378" width="141" height="15" font="1">152 procedures, CHD 36%.  </text>
<text top="257" left="561" width="107" height="15" font="1">Outcomes ablation in </text>
<text top="273" left="561" width="66" height="15" font="1">age ≤18  mo </text>
<text top="257" left="696" width="156" height="15" font="1">Success 87.6%, vs. 90.6%, NS </text>
<text top="273" left="696" width="174" height="15" font="1">Major comps 4.6% vs. 2.9%, p=.17 </text>
<text top="257" left="922" width="207" height="15" font="1">No difference in success or complications </text>
<text top="273" left="922" width="41" height="15" font="1">≤18 mo </text>
<text top="336" left="54" width="58" height="15" font="1">Blaufox AD </text>
<text top="351" left="54" width="28" height="15" font="1">2004 </text>
<text top="367" left="54" width="29" height="15" font="1">(277) </text>
<text top="382" left="54" width="49" height="15" font="8">14764175</text>
<text top="382" left="103" width="3" height="15" font="24"> </text>
<text top="398" left="54" width="3" height="15" font="1"> </text>
<text top="336" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="351" left="137" width="34" height="15" font="1">center </text>
<text top="336" left="264" width="15" height="15" font="1">18 </text>
<text top="336" left="378" width="160" height="15" font="1">18 RFA in pts &lt;15 kg 1/88-8/01; </text>
<text top="351" left="378" width="151" height="15" font="1">median weight 5.7 kg, age 5.8 </text>
<text top="367" left="378" width="96" height="15" font="1">mo; 4 CHD, 4 CHF </text>
<text top="336" left="561" width="117" height="15" font="1">Outcomes ablation &lt;15 </text>
<text top="351" left="561" width="15" height="15" font="1">kg </text>
<text top="336" left="696" width="200" height="15" font="1">ORT 9, MAT 1, VT 4; success all AP; no </text>
<text top="351" left="696" width="31" height="15" font="1">recur. </text>
<text top="367" left="696" width="196" height="15" font="1">Complications 3/18 myocardial infarct 1 </text>
<text top="382" left="696" width="179" height="15" font="1">occluding left circ, CHF, mitral valve </text>
<text top="398" left="696" width="161" height="15" font="1">replacement; torn mitral leaflet 1 </text>
<text top="336" left="922" width="213" height="15" font="1">Complications 16% associated w/ RF dose </text>
<text top="351" left="922" width="176" height="15" font="1">indexed for body size (duration and </text>
<text top="367" left="922" width="44" height="15" font="1">number) </text>
<text top="382" left="922" width="3" height="15" font="1"> </text>
<text top="398" left="922" width="123" height="15" font="1">Mitral valve replacement </text>
<text top="414" left="54" width="61" height="15" font="1">Van Hare G </text>
<text top="429" left="54" width="28" height="15" font="1">2004 </text>
<text top="445" left="54" width="29" height="15" font="1">(278) </text>
<text top="460" left="54" width="49" height="15" font="8">15250858</text>
<text top="460" left="103" width="3" height="15" font="26"> </text>
<text top="460" left="106" width="3" height="15" font="1"> </text>
<text top="414" left="137" width="91" height="15" font="1">Prospective, multi-</text>
<text top="429" left="137" width="34" height="15" font="1">center </text>
<text top="414" left="264" width="226" height="15" font="1">481 Pts </text>
<text top="414" left="397" width="135" height="15" font="1">≤16 y, w/o significant heart </text>
<text top="429" left="378" width="148" height="15" font="1">disease, w/ AVRT or AVNRT; </text>
<text top="445" left="378" width="138" height="15" font="1">compared w/ cohort-eligible </text>
<text top="460" left="378" width="99" height="15" font="1">registry pts, N =504 </text>
<text top="414" left="561" width="109" height="15" font="1">Assess success rates </text>
<text top="429" left="561" width="103" height="15" font="1">and complications in </text>
<text top="445" left="561" width="52" height="15" font="1">age &lt;16 y </text>
<text top="414" left="696" width="204" height="15" font="1">Acute success: 96%, highest in left sided </text>
<text top="429" left="696" width="131" height="15" font="1">AP; left 98% vs. right 91% </text>
<text top="445" left="696" width="162" height="15" font="1">Complications 4.2%; no deaths;  </text>
<text top="460" left="696" width="191" height="15" font="1">AV block 1.2% in AVNRT or septal AC </text>
<text top="414" left="922" width="199" height="15" font="1">High success rates for AVNRT or AVRT </text>
<text top="429" left="922" width="47" height="15" font="1">w/o CHD </text>
<text top="477" left="54" width="61" height="15" font="1">Van Hare G </text>
<text top="492" left="54" width="28" height="15" font="1">2004 </text>
<text top="507" left="54" width="29" height="15" font="1">(279) </text>
<text top="523" left="54" width="49" height="15" font="8">15851152</text>
<text top="523" left="103" width="3" height="15" font="1"> </text>
<text top="477" left="137" width="91" height="15" font="1">Prospective, multi-</text>
<text top="492" left="137" width="34" height="15" font="1">center </text>
<text top="477" left="264" width="25" height="15" font="1">481  </text>
<text top="477" left="378" width="143" height="15" font="1">481 pts w/ AVRT or AVNRT, </text>
<text top="492" left="378" width="162" height="15" font="1">excluding pts w/ significant heart </text>
<text top="507" left="378" width="41" height="15" font="1">disease </text>
<text top="523" left="378" width="71" height="15" font="1">Ages 0.1-16 y </text>
<text top="539" left="378" width="158" height="15" font="1">Followed at 2,6,12 mo following </text>
<text top="554" left="378" width="42" height="15" font="1">ablation </text>
<text top="477" left="561" width="95" height="15" font="1">Assess recurrence </text>
<text top="492" left="561" width="101" height="15" font="1">following successful </text>
<text top="507" left="561" width="45" height="15" font="1">ablation  </text>
<text top="477" left="696" width="206" height="15" font="1">Recurrence at 2,6, 12 mo was 7, 9.2, and </text>
<text top="492" left="696" width="34" height="15" font="1">10.7% </text>
<text top="507" left="696" width="212" height="15" font="1">Recurrence highest right septal AP 24.6%, </text>
<text top="523" left="696" width="209" height="15" font="1">RFW 15.8%, LFW 9.3%, left septal 4.8%;  </text>
<text top="539" left="696" width="201" height="15" font="1">AVNRT 4.8% vs. 12.9% for AP at 12 mo </text>
<text top="477" left="922" width="177" height="15" font="1">Recurrence after initially successful </text>
<text top="492" left="922" width="188" height="15" font="1">ablation occurs commonly in children, </text>
<text top="507" left="922" width="34" height="15" font="1">10.7% </text>
<text top="523" left="922" width="3" height="15" font="1"> </text>
<text top="539" left="922" width="185" height="15" font="1">Recurrence less common for AVNRT </text>
<text top="554" left="922" width="192" height="15" font="1">4.8%, most common for right sided AP </text>
<text top="570" left="922" width="74" height="15" font="1">&gt;25% at one y </text>
<text top="586" left="54" width="54" height="15" font="1">Aiyagari R </text>
<text top="601" left="54" width="28" height="15" font="1">2005 </text>
<text top="617" left="54" width="29" height="15" font="1">(280) </text>
<text top="632" left="54" width="49" height="15" font="8">16132307</text>
<text top="632" left="103" width="3" height="15" font="1"> </text>
<text top="586" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="601" left="137" width="34" height="15" font="1">center </text>
<text top="586" left="264" width="15" height="15" font="1">69 </text>
<text top="586" left="378" width="129" height="15" font="1">All pts ≤20 kg undergoing </text>
<text top="601" left="378" width="137" height="15" font="1">ablation between 1/94-1/03 </text>
<text top="617" left="378" width="119" height="15" font="1">Group 1, &lt;15 kg, 25 pts </text>
<text top="632" left="378" width="138" height="15" font="1">Group 2, 15.1-20 kg, 44 pts </text>
<text top="586" left="561" width="103" height="15" font="1">Compare safety and </text>
<text top="601" left="561" width="106" height="15" font="1">efficacy of ablation in </text>
<text top="617" left="561" width="112" height="15" font="1">pts &lt;15 kg vs. 15.1-20 </text>
<text top="632" left="561" width="15" height="15" font="1">kg </text>
<text top="586" left="696" width="209" height="15" font="1">SHD more common in pts &lt;15 kg 28% vs. </text>
<text top="601" left="696" width="63" height="15" font="1">7%, p&lt;0.01. </text>
<text top="617" left="696" width="208" height="15" font="1">No difference in mechanism SVT, number </text>
<text top="632" left="696" width="186" height="15" font="1">lesions, temperature, procedure time, </text>
<text top="648" left="696" width="141" height="15" font="1">success rates 91% vs. 89%. </text>
<text top="663" left="696" width="3" height="15" font="1"> </text>
<text top="679" left="696" width="206" height="15" font="1">Major complications 8% in Group 1, 2.3% </text>
<text top="694" left="696" width="90" height="15" font="1">Group 2, p=0.39.  </text>
<text top="586" left="922" width="170" height="15" font="1">Outcomes similar between groups </text>
<text top="601" left="922" width="3" height="15" font="1"> </text>
<text top="617" left="922" width="187" height="15" font="1">Complications 8% in smaller children, </text>
<text top="632" left="922" width="173" height="15" font="1">although not statistically significant </text>
<text top="710" left="54" width="40" height="15" font="1">Lee PC </text>
<text top="726" left="54" width="28" height="15" font="1">2007 </text>
<text top="741" left="54" width="29" height="15" font="1">(281) </text>
<text top="757" left="54" width="49" height="15" font="8">17461876</text>
<text top="757" left="103" width="3" height="15" font="1"> </text>
<text top="710" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="726" left="137" width="34" height="15" font="1">center </text>
<text top="710" left="264" width="22" height="15" font="1">228 </text>
<text top="710" left="378" width="153" height="15" font="1">228  pts 5-18 y old undergoing </text>
<text top="726" left="378" width="110" height="15" font="1">ablation 12/89 to 8/05 </text>
<text top="741" left="378" width="168" height="15" font="1">Mean age 9±7 y; mean f/u 86±38 </text>
<text top="757" left="378" width="18" height="15" font="1">mo </text>
<text top="710" left="561" width="87" height="15" font="1">Assess results of </text>
<text top="726" left="561" width="116" height="15" font="1">ablation in pediatric pts </text>
<text top="741" left="561" width="34" height="15" font="1">5-18 y </text>
<text top="710" left="696" width="196" height="15" font="1">AVRT 61%, AVNRT 29%, AT 5%, atrial </text>
<text top="726" left="696" width="56" height="15" font="1">flutter 5%.  </text>
<text top="741" left="696" width="202" height="15" font="1">Success rates 92% AVRT, 97% AVNRT, </text>
<text top="757" left="696" width="135" height="15" font="1">82% AT, 91% atrial flutter.  </text>
<text top="772" left="696" width="216" height="15" font="1">Complications 8.7%, major 0.9% AV block;  </text>
<text top="788" left="696" width="92" height="15" font="1">Recurrence 4.7%  </text>
<text top="710" left="922" width="191" height="15" font="1">AVRT incidence higher than in adults;  </text>
<text top="726" left="922" width="197" height="15" font="1">Success rates lowest for AT 82%; other </text>
<text top="741" left="922" width="113" height="15" font="1">mechanisms 91-97%.  </text>
<text top="757" left="922" width="188" height="15" font="1">Complications 8.7%, recurrence 4.7% </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">107 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="44" height="15" font="1">Chiu SN </text>
<text top="70" left="54" width="28" height="15" font="1">2009 </text>
<text top="86" left="54" width="29" height="15" font="1">(282) </text>
<text top="101" left="54" width="49" height="15" font="8">19609044</text>
<text top="101" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="70" left="137" width="34" height="15" font="1">center </text>
<text top="55" left="264" width="16" height="15" font="1">27 </text>
<text top="55" left="378" width="161" height="15" font="1">27/210 pts underwent RF at age </text>
<text top="70" left="378" width="30" height="15" font="1">&lt;6 y.  </text>
<text top="86" left="378" width="157" height="15" font="1">Median age 4.4 y (8 mo-5.9 y).  </text>
<text top="101" left="378" width="167" height="15" font="1">Median weight 15 kg (6.6-30 kg).  </text>
<text top="117" left="378" width="147" height="15" font="1">AVRT 55%, atrial flutter 19%, </text>
<text top="132" left="378" width="72" height="15" font="1">AVNRT 15%.  </text>
<text top="147" left="378" width="55" height="15" font="1">SHD 33%. </text>
<text top="147" left="433" width="3" height="15" font="9"> </text>
<text top="55" left="561" width="111" height="15" font="1">Outcomes ablation &lt;6 </text>
<text top="70" left="561" width="15" height="15" font="1">y.  </text>
<text top="55" left="696" width="199" height="15" font="1">Indications: drug refractory SVT, or tach-</text>
<text top="70" left="696" width="129" height="15" font="1">induced cardiomyopathy.  </text>
<text top="86" left="696" width="193" height="15" font="1">Acute success 93%, recurrence 7.4%.  </text>
<text top="55" left="922" width="190" height="15" font="1">Acute success 93%, recurrence 7.4%. </text>
<text top="70" left="922" width="111" height="15" font="1">CHB 3.7% in 5 y old.   </text>
<text top="164" left="54" width="53" height="15" font="1">Schneider </text>
<text top="179" left="54" width="18" height="15" font="1">HE </text>
<text top="195" left="54" width="28" height="15" font="1">2009 </text>
<text top="210" left="54" width="32" height="15" font="1">(283)  </text>
<text top="226" left="54" width="49" height="15" font="8">19324303</text>
<text top="226" left="103" width="3" height="15" font="1"> </text>
<text top="164" left="137" width="96" height="15" font="1">Prospective, single </text>
<text top="179" left="137" width="34" height="15" font="1">center </text>
<text top="164" left="264" width="25" height="15" font="1"> 212 </text>
<text top="164" left="378" width="155" height="15" font="1">212 pts ages &lt;21 y undergoing </text>
<text top="179" left="378" width="137" height="15" font="1">ablation for SVT underwent </text>
<text top="195" left="378" width="156" height="15" font="1">selective coronary angiography </text>
<text top="210" left="378" width="156" height="15" font="1">before and 30 min after RFA or </text>
<text top="226" left="378" width="170" height="15" font="1">cryoablation; CHD present in 15% </text>
<text top="241" left="378" width="145" height="15" font="1">Median age 12 y (0.3-20.4 y) </text>
<text top="257" left="378" width="170" height="15" font="1">Median weight 47 kg (5.5–130 kg) </text>
<text top="164" left="561" width="101" height="15" font="1">Assess incidence of </text>
<text top="179" left="561" width="76" height="15" font="1">coronary injury </text>
<text top="195" left="561" width="88" height="15" font="1">following ablation </text>
<text top="164" left="696" width="162" height="15" font="1">AP 53%; AVNRT  40%, both 7% </text>
<text top="179" left="696" width="3" height="15" font="1"> </text>
<text top="195" left="696" width="191" height="15" font="1">Coronary artery narrowing identified in </text>
<text top="210" left="696" width="156" height="15" font="1">2/117 pts (1.7%) w/ AP, both in </text>
<text top="226" left="696" width="110" height="15" font="1">posteroseptal region.  </text>
<text top="241" left="696" width="3" height="15" font="1"> </text>
<text top="164" left="922" width="202" height="15" font="1">Coronary artery injury present in 1.7% of </text>
<text top="179" left="922" width="208" height="15" font="1">AP ablations: both in posteroseptal region </text>
<text top="195" left="922" width="3" height="15" font="1"> </text>
<text top="210" left="922" width="213" height="15" font="1">Consider coronary angiography w/ ablation </text>
<text top="226" left="922" width="115" height="15" font="1">in posteroseptal region </text>
<text top="273" left="54" width="61" height="15" font="1">Kantoch MJ </text>
<text top="288" left="54" width="28" height="15" font="1">2011 </text>
<text top="304" left="54" width="29" height="15" font="1">(284) </text>
<text top="319" left="54" width="49" height="15" font="8">21621374</text>
<text top="319" left="103" width="3" height="15" font="1"> </text>
<text top="273" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="288" left="137" width="34" height="15" font="1">center </text>
<text top="273" left="264" width="15" height="15" font="1">34 </text>
<text top="273" left="378" width="150" height="15" font="1">1995-2009, 34 pts &lt;2y of age, </text>
<text top="288" left="378" width="147" height="15" font="1">RFA 42 procedures in 31 pts, </text>
<text top="304" left="378" width="168" height="15" font="1">mean wt 7.4 kg; 17/34 CHF; 3 pts </text>
<text top="319" left="378" width="36" height="15" font="1">ECMO </text>
<text top="273" left="561" width="328" height="15" font="1">Outcomes ablation &lt;2 y  AVRT 19, Focal 6, atrial flutter 1, VT 3, </text>
<text top="288" left="696" width="32" height="15" font="1">JET 2 </text>
<text top="304" left="696" width="163" height="15" font="1">Acute success 74% vs. 91% &gt;2y </text>
<text top="319" left="696" width="131" height="15" font="1">No recurrence mean 7.3 y </text>
<text top="335" left="696" width="200" height="15" font="1">Major complications 4/34 children; CHB, </text>
<text top="350" left="696" width="212" height="15" font="1">pacer in 6 wk old infant; RFA occusion x 2, </text>
<text top="273" left="922" width="208" height="15" font="1">Major complications 11.8% vs. 0.7% in &gt;2 </text>
<text top="288" left="922" width="46" height="15" font="1">y of age  </text>
<text top="367" left="54" width="52" height="15" font="1">Buddhe S </text>
<text top="382" left="54" width="28" height="15" font="1">2012 </text>
<text top="398" left="54" width="29" height="15" font="1">(282) </text>
<text top="413" left="54" width="49" height="15" font="8">22452328</text>
<text top="413" left="103" width="3" height="15" font="1"> </text>
<text top="367" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="382" left="137" width="34" height="15" font="1">center </text>
<text top="367" left="264" width="22" height="15" font="1">155 </text>
<text top="367" left="378" width="156" height="15" font="1">1/05-12/09, 155 pts ablation for </text>
<text top="382" left="378" width="164" height="15" font="1">SVT. Mean age 13.4±3.7 y. 22% </text>
<text top="398" left="378" width="133" height="15" font="1">African American. RF 107, </text>
<text top="413" left="378" width="131" height="15" font="1">Cryoablation 11, Both 97.  </text>
<text top="429" left="378" width="163" height="15" font="1">AVRT 74%, AVNRT 17%; SNRT </text>
<text top="444" left="378" width="146" height="15" font="1">5%, His bundle reentry 4%. .  </text>
<text top="460" left="378" width="95" height="15" font="1">Median f/u 41 mo.  </text>
<text top="367" left="561" width="95" height="15" font="1">Outcomes ablation </text>
<text top="382" left="561" width="83" height="15" font="1">during longer f/u </text>
<text top="367" left="696" width="210" height="15" font="1">Acute success 98%; 5 y f/u 83% success.  </text>
<text top="382" left="696" width="180" height="15" font="1">Recurrences higher w/ right anterior-</text>
<text top="398" left="696" width="208" height="15" font="1">anteroseptal AC (33%), multiple (27%), or </text>
<text top="413" left="696" width="170" height="15" font="1">broad distribution. Recurrence not </text>
<text top="429" left="696" width="159" height="15" font="1">statistical different RF (14%) vs. </text>
<text top="444" left="696" width="168" height="15" font="1">Cryoablation (22%) or both (20%) </text>
<text top="367" left="922" width="215" height="15" font="1">17% recurrence WPW or SVT during mean </text>
<text top="382" left="922" width="55" height="15" font="1">f/u 38 mo.  </text>
<text top="398" left="922" width="192" height="15" font="1">Recurrences higher vs. age, 11.7 y vs. </text>
<text top="413" left="922" width="81" height="15" font="1">13.6 y (p&lt;0.05). </text>
<text top="476" left="54" width="186" height="15" font="1">Pediatrics: QOL &amp; Cost Effectiveness </text>
<text top="492" left="54" width="50" height="15" font="1">Garson A </text>
<text top="507" left="54" width="28" height="15" font="1">1997 </text>
<text top="523" left="54" width="29" height="15" font="1">(285) </text>
<text top="539" left="54" width="43" height="15" font="8">9395176</text>
<text top="539" left="97" width="3" height="15" font="26"> </text>
<text top="554" left="54" width="3" height="15" font="1"> </text>
<text top="492" left="137" width="74" height="15" font="1">Cost modeling </text>
<text top="492" left="264" width="21" height="15" font="1">N/A </text>
<text top="492" left="378" width="158" height="15" font="1">Cost-effectiveness modeling for </text>
<text top="507" left="378" width="134" height="15" font="1">ablation vs. medications or </text>
<text top="523" left="378" width="167" height="15" font="1">surgery for WPW treatment in pts </text>
<text top="539" left="378" width="55" height="15" font="1">age 5-21 y </text>
<text top="492" left="561" width="111" height="15" font="1">Identify long term cost </text>
<text top="507" left="561" width="80" height="15" font="1">effectiveness of </text>
<text top="523" left="561" width="101" height="15" font="1">treatment strategies </text>
<text top="492" left="696" width="207" height="15" font="1">Ablation cost 39% of surgical rx, and 57% </text>
<text top="507" left="696" width="127" height="15" font="1">of medical management.  </text>
<text top="523" left="696" width="208" height="15" font="1">Estimated mortality ablation 0.15% = 10% </text>
<text top="539" left="696" width="182" height="15" font="1">of medical rx, and 28% of surgical rx </text>
<text top="554" left="696" width="202" height="15" font="1">Morbidity ablation = 32% of medications, </text>
<text top="569" left="696" width="99" height="15" font="1">and 36% of surgery </text>
<text top="492" left="922" width="209" height="15" font="1">Catheter ablation has lower cost, mortality </text>
<text top="507" left="922" width="191" height="15" font="1">and morbidity than either medical rx or </text>
<text top="523" left="922" width="207" height="15" font="1">surgery, and is treatment of choice for the </text>
<text top="539" left="922" width="216" height="15" font="1">child 5 y of age or older w/ WPW and SVT.  </text>
<text top="586" left="54" width="60" height="15" font="1">Pfammatter </text>
<text top="601" left="54" width="16" height="15" font="1">JP </text>
<text top="617" left="54" width="28" height="15" font="1">2004 </text>
<text top="632" left="54" width="29" height="15" font="1">(286) </text>
<text top="648" left="54" width="49" height="15" font="8">15093993</text>
<text top="648" left="103" width="3" height="15" font="1"> </text>
<text top="586" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="601" left="137" width="34" height="15" font="1">center </text>
<text top="586" left="264" width="18" height="15" font="1"> 88 </text>
<text top="586" left="378" width="131" height="15" font="1">Compare drug therapy vs. </text>
<text top="601" left="378" width="143" height="15" font="1">ablation as first line in 2 time </text>
<text top="617" left="378" width="150" height="15" font="1">periods: 1989-94, N = 40, and </text>
<text top="632" left="378" width="101" height="15" font="1">1995-2000, N = 48.  </text>
<text top="648" left="378" width="151" height="15" font="1">Early time period: medications </text>
<text top="663" left="378" width="23" height="15" font="1">only </text>
<text top="679" left="378" width="169" height="15" font="1">Later ablation as first line in 16/48 </text>
<text top="694" left="378" width="24" height="15" font="1">pts.  </text>
<text top="586" left="561" width="87" height="15" font="1">Assess impact of </text>
<text top="601" left="561" width="98" height="15" font="1">ablation as first line </text>
<text top="617" left="561" width="110" height="15" font="1">therapy for SVT in pts </text>
<text top="632" left="561" width="58" height="15" font="1">&gt;5 y of age </text>
<text top="586" left="696" width="201" height="15" font="1">Over time, number of SVT episodes (3.7 </text>
<text top="601" left="696" width="207" height="15" font="1">to 2), duration of meds  (15 mo to 4.6 mo, </text>
<text top="617" left="696" width="198" height="15" font="1">p&lt;0.05)  and numbers of cardioversions </text>
<text top="632" left="696" width="154" height="15" font="1">declined (1.1/pt to 0.2, p&lt;0.05) </text>
<text top="586" left="922" width="212" height="15" font="1">Use of ablation as first line treatment in pts </text>
<text top="601" left="922" width="201" height="15" font="1">over age 5 y results in fewer episodes of </text>
<text top="617" left="922" width="121" height="15" font="1">SVT and cardioversions </text>
<text top="710" left="54" width="54" height="15" font="1">Strieper M </text>
<text top="726" left="54" width="28" height="15" font="1">2010 </text>
<text top="741" left="54" width="29" height="15" font="1">(287) </text>
<text top="757" left="54" width="49" height="15" font="8">21106019</text>
<text top="757" left="103" width="3" height="15" font="1"> </text>
<text top="710" left="137" width="96" height="15" font="1">Prospective, single </text>
<text top="726" left="137" width="76" height="15" font="1">group, pre-test-</text>
<text top="741" left="137" width="78" height="15" font="1">posttest design </text>
<text top="710" left="264" width="15" height="15" font="1">27 </text>
<text top="710" left="378" width="162" height="15" font="1">Consecutive pts w/ SVT referred </text>
<text top="726" left="378" width="146" height="15" font="1">for catheter ablation between </text>
<text top="741" left="378" width="71" height="15" font="1">10/04 – 6/06.  </text>
<text top="757" left="378" width="141" height="15" font="1">Pre and 6 mo post ablation.  </text>
<text top="772" left="378" width="68" height="15" font="1">Ages 5-18 y.  </text>
<text top="788" left="378" width="3" height="15" font="1"> </text>
<text top="710" left="561" width="87" height="15" font="1">Assess impact of </text>
<text top="726" left="561" width="119" height="15" font="1">ablation on QOL scores </text>
<text top="741" left="561" width="3" height="15" font="1"> </text>
<text top="710" left="696" width="176" height="15" font="1">Pre test lowest scores in social and </text>
<text top="726" left="696" width="191" height="15" font="1">physical functioning; post test greatest </text>
<text top="741" left="696" width="185" height="15" font="1">improvement in physical functioning.  </text>
<text top="757" left="696" width="3" height="15" font="1"> </text>
<text top="772" left="696" width="209" height="15" font="1">Significant improvement in all QOL scores </text>
<text top="788" left="696" width="194" height="15" font="1">following successful elimination of SVT </text>
<text top="710" left="922" width="209" height="15" font="1">Significant improvement in all QOL scores </text>
<text top="726" left="922" width="194" height="15" font="1">following successful elimination of SVT </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">108 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="50" height="15" font="1">Wood KA </text>
<text top="70" left="54" width="28" height="15" font="1">2010 </text>
<text top="86" left="54" width="29" height="15" font="1">(288) </text>
<text top="101" left="54" width="49" height="15" font="8">20109982</text>
<text top="101" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="137" width="96" height="15" font="1">Prospective, single </text>
<text top="70" left="137" width="76" height="15" font="1">group, pre-test-</text>
<text top="86" left="137" width="78" height="15" font="1">posttest design </text>
<text top="55" left="264" width="15" height="15" font="1">52 </text>
<text top="55" left="378" width="162" height="15" font="1">Consecutive pts w/ SVT referred </text>
<text top="70" left="378" width="138" height="15" font="1">for catheter ablation ≥13 y,  </text>
<text top="86" left="378" width="162" height="15" font="1">Mean age 41±17 y, range 13-85 </text>
<text top="101" left="378" width="9" height="15" font="1">y </text>
<text top="117" left="378" width="65" height="15" font="1">Female 65% </text>
<text top="132" left="378" width="147" height="15" font="1">AVNRT 57%, AVRT 31%, AT </text>
<text top="147" left="378" width="25" height="15" font="1">12% </text>
<text top="55" left="561" width="105" height="15" font="1">Comparison of QOL, </text>
<text top="70" left="561" width="101" height="15" font="1">sxs before and after </text>
<text top="86" left="561" width="111" height="15" font="1">ablation procedure for </text>
<text top="101" left="561" width="25" height="15" font="1">SVT </text>
<text top="55" left="696" width="183" height="15" font="1">All sxs decreased but not completely </text>
<text top="70" left="696" width="109" height="15" font="1">eliminated at 1 mo f/u </text>
<text top="86" left="696" width="3" height="15" font="1"> </text>
<text top="101" left="696" width="197" height="15" font="1">Improvements in palpitations, p=0.001,  </text>
<text top="117" left="696" width="93" height="15" font="1">Fatigue, p=0.001,  </text>
<text top="132" left="696" width="207" height="15" font="1">Dizziness, p&lt;0.01, resp or chest pressure </text>
<text top="147" left="696" width="43" height="15" font="1">p&lt;0.001 </text>
<text top="163" left="696" width="3" height="15" font="1"> </text>
<text top="178" left="696" width="196" height="15" font="1">QOL improvements in number, severity </text>
<text top="194" left="696" width="136" height="15" font="1">and impact of sxs, p&lt;0.001 </text>
<text top="55" left="922" width="192" height="15" font="1">All sxs improved after ablation, women </text>
<text top="70" left="922" width="200" height="15" font="1">reported larger changes in sxs and QOL </text>
<text top="86" left="922" width="49" height="15" font="1">than men </text>
<text top="210" left="54" width="117" height="15" font="1">CHD: Incidence of SVT </text>
<text top="226" left="54" width="60" height="15" font="1">Engelfriet P </text>
<text top="242" left="54" width="28" height="15" font="1">2005 </text>
<text top="257" left="54" width="29" height="15" font="1">(289) </text>
<text top="273" left="54" width="49" height="15" font="8">15996978</text>
<text top="273" left="103" width="3" height="15" font="1"> </text>
<text top="226" left="137" width="74" height="15" font="1">Retrospective, </text>
<text top="242" left="137" width="57" height="15" font="1">multicenter </text>
<text top="226" left="264" width="28" height="15" font="1">4110 </text>
<text top="226" left="378" width="168" height="15" font="1">CONCOR national registry &gt;8600 </text>
<text top="242" left="378" width="156" height="15" font="1">pts ACHD  &gt;17y of age:  Pts w/ </text>
<text top="257" left="378" width="155" height="15" font="1">ACHD of 8 major types seen in </text>
<text top="273" left="378" width="151" height="15" font="1">1998, w/ complete f/u to 2003: </text>
<text top="288" left="378" width="151" height="15" font="1">(ASD, VSD, TGA, TOF, single </text>
<text top="304" left="378" width="156" height="15" font="1">ventricle, coarctation, Marfan’s, </text>
<text top="319" left="378" width="164" height="15" font="1">cyanotic heart disease); followed </text>
<text top="335" left="378" width="66" height="15" font="1">until 12/2003 </text>
<text top="226" left="561" width="103" height="15" font="1">assess endocarditis, </text>
<text top="242" left="561" width="108" height="15" font="1">arrhythmias, vascular </text>
<text top="257" left="561" width="36" height="15" font="1">events </text>
<text top="226" left="696" width="166" height="15" font="1">Median age 27.9 y, (21.7-38.6y),  </text>
<text top="242" left="696" width="74" height="15" font="1">79% &lt;50 y old </text>
<text top="257" left="696" width="142" height="15" font="1">median f/u 5.1 y (3.6-5.7 y);  </text>
<text top="273" left="696" width="194" height="15" font="1">SVA  occurred in TOF 20%, TGA 26%; </text>
<text top="288" left="696" width="117" height="15" font="1">ASD 28%, Fontan 45% </text>
<text top="226" left="922" width="202" height="15" font="1">Young population w/ ACHD, overall 18% </text>
<text top="242" left="922" width="79" height="15" font="1">developed SVA </text>
<text top="351" left="54" width="59" height="15" font="1">Verheugt C </text>
<text top="367" left="54" width="28" height="15" font="1">2008 </text>
<text top="382" left="54" width="29" height="15" font="1">(290) </text>
<text top="398" left="54" width="49" height="15" font="8">18559697</text>
<text top="398" left="103" width="3" height="15" font="1"> </text>
<text top="351" left="137" width="74" height="15" font="1">Retrospective, </text>
<text top="367" left="137" width="57" height="15" font="1">multicenter </text>
<text top="351" left="264" width="28" height="15" font="1">7414 </text>
<text top="351" left="378" width="161" height="15" font="1">CONCOR registry, Netherlands, </text>
<text top="367" left="378" width="160" height="15" font="1">&gt;8600 pts ACHD &gt;17 y old 1/02-</text>
<text top="382" left="378" width="119" height="15" font="1">1/08;  assess outcomes </text>
<text top="398" left="378" width="63" height="15" font="1">frequencies  </text>
<text top="351" left="561" width="119" height="15" font="1">Is gender associated w/ </text>
<text top="367" left="561" width="97" height="15" font="1">outcomes in ACHD </text>
<text top="351" left="696" width="197" height="15" font="1">Median age 35 y (17-91); males 50.2%; </text>
<text top="367" left="696" width="158" height="15" font="1">median f/u 2.7 y; frequencies of </text>
<text top="382" left="696" width="205" height="15" font="1">arrhythmias 22-44%;  females 12% lower </text>
<text top="398" left="696" width="212" height="15" font="1">risk arrhythmia, NS; females higher risk for </text>
<text top="413" left="696" width="81" height="15" font="1">pulmonary HTN </text>
<text top="351" left="922" width="181" height="15" font="1">15% developed SVA during f/u 2.7 y </text>
<text top="429" left="54" width="56" height="15" font="1">Bouchardy </text>
<text top="445" left="54" width="31" height="15" font="1">2009  </text>
<text top="460" left="54" width="29" height="15" font="1">(291) </text>
<text top="476" left="54" width="49" height="15" font="8">19822808</text>
<text top="476" left="103" width="3" height="15" font="1"> </text>
<text top="429" left="137" width="71" height="15" font="1">Retrospective </text>
<text top="445" left="137" width="57" height="15" font="1">multicenter </text>
<text top="429" left="264" width="40" height="15" font="1">38,428  </text>
<text top="429" left="378" width="147" height="15" font="1">Adult registry Canada; ACHD </text>
<text top="445" left="378" width="147" height="15" font="1">median age 42 y; 1983-2005; </text>
<text top="460" left="378" width="63" height="15" font="1">5812 pts AT </text>
<text top="429" left="561" width="71" height="15" font="1">Assess risk of </text>
<text top="445" left="561" width="84" height="15" font="1">developing atrial </text>
<text top="460" left="561" width="103" height="15" font="1">arrhythmias as adult </text>
<text top="429" left="696" width="212" height="15" font="1">Prevalence 15.1% AT; impact: 20 y risk for </text>
<text top="445" left="696" width="207" height="15" font="1">20 y old 7%, 50 y old 38%; adverse event </text>
<text top="460" left="696" width="203" height="15" font="1">HR 2.5; mortality 1.47; stroke, CHF 2.21  </text>
<text top="429" left="922" width="203" height="15" font="1">&gt;50% severe CHD developed AT by age </text>
<text top="445" left="922" width="152" height="15" font="1">65 y;  2-3↑ death, stroke, CHF </text>
<text top="492" left="54" width="67" height="15" font="1">Trojnarska O </text>
<text top="507" left="54" width="28" height="15" font="1">2009 </text>
<text top="523" left="54" width="29" height="15" font="1">(292) </text>
<text top="539" left="54" width="49" height="15" font="8">19437395</text>
<text top="539" left="103" width="3" height="15" font="1"> </text>
<text top="492" left="137" width="74" height="15" font="1">Retrospective, </text>
<text top="507" left="137" width="57" height="15" font="1">multicenter </text>
<text top="492" left="264" width="245" height="15" font="1">1304 National </text>
<text top="492" left="422" width="110" height="15" font="1">Polish registry, ACHD </text>
<text top="507" left="378" width="151" height="15" font="1">pts followed 1995-2004; mean </text>
<text top="523" left="378" width="133" height="15" font="1">age 29.4±10.6 y, mean f/u </text>
<text top="539" left="378" width="50" height="15" font="1">3.5±1.8 y </text>
<text top="492" left="561" width="102" height="15" font="1">Assess outcomes of </text>
<text top="507" left="561" width="25" height="15" font="1">SVA </text>
<text top="492" left="696" width="159" height="15" font="1">SVA developed in 10.3% of pts; </text>
<text top="507" left="696" width="199" height="15" font="1">multivariable predictors; presence of HF </text>
<text top="523" left="696" width="194" height="15" font="1">(HR: 4.66) CHD complexity (HR: 2.31), </text>
<text top="539" left="696" width="135" height="15" font="1">age (HR: 1.32)  gender NS </text>
<text top="492" left="922" width="114" height="15" font="1">10.3% developed SVA </text>
<text top="507" left="922" width="169" height="15" font="1">Increased w/ CHF, complex CHD, </text>
<text top="523" left="922" width="75" height="15" font="1">increasing age </text>
<text top="555" left="54" width="51" height="15" font="1">Bernier M </text>
<text top="570" left="54" width="28" height="15" font="1">2010 </text>
<text top="586" left="54" width="29" height="15" font="1">(293) </text>
<text top="601" left="54" width="49" height="15" font="8">20691314</text>
<text top="601" left="103" width="3" height="15" font="1"> </text>
<text top="555" left="137" width="71" height="15" font="1">Retrospective </text>
<text top="570" left="137" width="60" height="15" font="1">multicenter  </text>
<text top="555" left="264" width="37" height="15" font="1">71,467 </text>
<text top="555" left="378" width="162" height="15" font="1">Quebec database; ACHD ≥18 y; </text>
<text top="570" left="378" width="159" height="15" font="1">study period 1/88–12/05; ACHD </text>
<text top="586" left="378" width="167" height="15" font="1">pts <i>arrhythmia free </i>by age 18 y in </text>
<text top="601" left="378" width="37" height="15" font="1">1/1988 </text>
<text top="555" left="561" width="70" height="15" font="1">assess risk of </text>
<text top="570" left="561" width="115" height="15" font="1">developing AT vs. type </text>
<text top="586" left="561" width="27" height="15" font="1">CHD </text>
<text top="555" left="696" width="213" height="15" font="1">11% developed SVA; 30 y risk for 18 y old: </text>
<text top="570" left="696" width="184" height="15" font="1">18% for right sided CHD, 11% for left </text>
<text top="586" left="696" width="99" height="15" font="1">sided herat disease </text>
<text top="555" left="922" width="213" height="15" font="1">ACHD pts arrhythmia free by age 18 y: risk </text>
<text top="570" left="922" width="195" height="15" font="1">greater in pts w/ right-sided disease vs. </text>
<text top="586" left="922" width="48" height="15" font="1">left-sided </text>
<text top="617" left="54" width="45" height="15" font="1">Khairy P </text>
<text top="633" left="54" width="28" height="15" font="1">2010 </text>
<text top="648" left="54" width="29" height="15" font="1">(294) </text>
<text top="664" left="54" width="49" height="15" font="8">20713900</text>
<text top="664" left="103" width="3" height="15" font="1"> </text>
<text top="617" left="137" width="74" height="15" font="1">Retrospective, </text>
<text top="633" left="137" width="57" height="15" font="1">multicenter </text>
<text top="617" left="264" width="22" height="15" font="1">566 </text>
<text top="617" left="378" width="132" height="15" font="1">AARCC (Alliance for Adult </text>
<text top="633" left="378" width="141" height="15" font="1">Research in Cong Card); 11 </text>
<text top="648" left="378" width="168" height="15" font="1">centers; ACHD ages ≥18 y; study </text>
<text top="664" left="378" width="90" height="15" font="1">period 9/07-10/08 </text>
<text top="617" left="561" width="94" height="15" font="1">Assess arrhythmia </text>
<text top="633" left="561" width="94" height="15" font="1">prevalence in TOF </text>
<text top="648" left="561" width="33" height="15" font="1">adults </text>
<text top="617" left="696" width="130" height="15" font="1">Mean age 36.8±12 y; f/u;  </text>
<text top="633" left="696" width="178" height="15" font="1">Prevalence SVA 20.1%; risk factors </text>
<text top="648" left="696" width="210" height="15" font="1">reentrant AT: right atrial enlargement (OR: </text>
<text top="664" left="696" width="194" height="15" font="1">6.2); HTN (OR: 2.3), number of cardiac </text>
<text top="679" left="696" width="154" height="15" font="1">surgeries (OR: 1.4); ventricular </text>
<text top="695" left="696" width="95" height="15" font="1">arrhythmias 14.6% </text>
<text top="617" left="922" width="111" height="15" font="1">20.1% of TOF w/ SVA </text>
<text top="711" left="54" width="60" height="15" font="1">Cuypers JA </text>
<text top="727" left="54" width="28" height="15" font="1">2013 </text>
<text top="742" left="54" width="32" height="15" font="1">(295)  </text>
<text top="758" left="54" width="49" height="15" font="8">23886606</text>
<text top="758" left="103" width="3" height="15" font="1"> </text>
<text top="711" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="727" left="137" width="34" height="15" font="1">center </text>
<text top="711" left="264" width="15" height="15" font="1">85 </text>
<text top="711" left="378" width="149" height="15" font="1">135 pts, Netherlands; surgical </text>
<text top="727" left="378" width="166" height="15" font="1">ASD closure &lt;15 y of age, (mean </text>
<text top="742" left="378" width="161" height="15" font="1">7.5± 3.5 y) between 1968-1980; </text>
<text top="758" left="378" width="70" height="15" font="1">f/u on 131 pts </text>
<text top="711" left="561" width="64" height="15" font="1">Assess SVA </text>
<text top="727" left="561" width="113" height="15" font="1">development late after </text>
<text top="742" left="561" width="65" height="15" font="1">ASD closure </text>
<text top="711" left="696" width="200" height="15" font="1">Mean f/u 35 y (30-41 y), 16% developed </text>
<text top="727" left="696" width="125" height="15" font="1">SVA; 12% developed AF </text>
<text top="711" left="922" width="95" height="15" font="1">16% AT in f/u ASD </text>
<text top="774" left="54" width="60" height="15" font="1">Valente AM </text>
<text top="789" left="54" width="31" height="15" font="1">2014  </text>
<text top="774" left="137" width="60" height="15" font="1">Multicenter, </text>
<text top="789" left="137" width="63" height="15" font="1">prospective  </text>
<text top="774" left="264" width="22" height="15" font="1">873 </text>
<text top="774" left="378" width="159" height="15" font="1">Repaired TOF Median age 24.4 </text>
<text top="789" left="378" width="170" height="15" font="1">y, undergoing standard eval ECG, </text>
<text top="774" left="561" width="107" height="15" font="1">Assess TOF  primary </text>
<text top="789" left="561" width="119" height="15" font="1">outcome of VT or death </text>
<text top="774" left="696" width="200" height="15" font="1">SVA developed in 11% (7% atrial flutter, </text>
<text top="789" left="696" width="203" height="15" font="1">4% AF);  total 3.7% death or VT; Risk for </text>
<text top="774" left="922" width="153" height="15" font="1">TOF pts develop SVA in 11%;  </text>
<text top="789" left="922" width="214" height="15" font="1">SVA significant risk factor for VT or sudden </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">109 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="29" height="15" font="1">(296) </text>
<text top="70" left="54" width="49" height="15" font="8">24179163</text>
<text top="70" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="378" width="72" height="15" font="1">Exercise, MRI </text>
<text top="55" left="696" width="199" height="15" font="1">VT or sudden death included ↑RV mass </text>
<text top="70" left="696" width="207" height="15" font="1">(HR: 5.04), ↓LVEF (HR: 3.34) or h/o atrial </text>
<text top="86" left="696" width="110" height="15" font="1">arrhythmia (HR: 3.65) </text>
<text top="55" left="922" width="81" height="15" font="1">death, HR: 3.65 </text>
<text top="102" left="54" width="132" height="15" font="1">CHD: Mechanisms of SVT </text>
<text top="118" left="54" width="54" height="15" font="1">Collins KK </text>
<text top="134" left="54" width="28" height="15" font="1">2000 </text>
<text top="149" left="54" width="29" height="15" font="1">(297) </text>
<text top="164" left="54" width="49" height="15" font="8">11053709</text>
<text top="164" left="103" width="3" height="15" font="1"> </text>
<text top="118" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="134" left="137" width="34" height="15" font="1">center </text>
<text top="118" left="264" width="15" height="15" font="1">88 </text>
<text top="118" left="378" width="148" height="15" font="1">ACHD, 110 AT macro-reentry </text>
<text top="134" left="378" width="138" height="15" font="1">circuits, median age 23.4 y, </text>
<text top="149" left="378" width="161" height="15" font="1">repaired CHD: TGA/atrial repair, </text>
<text top="164" left="378" width="149" height="15" font="1">17%,; biventricular CHD 27%; </text>
<text top="180" left="378" width="103" height="15" font="1">Fontan 49%, other 7 </text>
<text top="118" left="561" width="95" height="15" font="1">Sites of successful </text>
<text top="134" left="561" width="75" height="15" font="1">ablation for AT </text>
<text top="118" left="696" width="204" height="15" font="1">Non-Fontan: CTI 57-67%, lateral RA wall </text>
<text top="134" left="696" width="190" height="15" font="1">22-43%, anterior RA 11%. Fontan pts: </text>
<text top="149" left="696" width="190" height="15" font="1">isthmus 15%, lateral RA 53%, anterior </text>
<text top="164" left="696" width="87" height="15" font="1">25%, septum 7% </text>
<text top="118" left="922" width="187" height="15" font="1">CTI involved in right AT in ~60%  non-</text>
<text top="134" left="922" width="58" height="15" font="1">Fontan AT; </text>
<text top="149" left="922" width="210" height="15" font="1"> Fontan multiple RA circuits esp lateral RA </text>
<text top="164" left="922" width="22" height="15" font="1">wall </text>
<text top="196" left="54" width="46" height="15" font="1">Akar  JG </text>
<text top="212" left="54" width="28" height="15" font="1">2001 </text>
<text top="227" left="54" width="29" height="15" font="1">(218) </text>
<text top="243" left="54" width="49" height="15" font="8">11499727</text>
<text top="243" left="103" width="3" height="15" font="1"> </text>
<text top="196" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="212" left="137" width="34" height="15" font="1">center </text>
<text top="196" left="264" width="277" height="15" font="1">16 Consecutive </text>
<text top="196" left="442" width="99" height="15" font="1">repaired ACHD pts, </text>
<text top="212" left="378" width="161" height="15" font="1">EP study &amp; ablation, mean ages </text>
<text top="227" left="378" width="164" height="15" font="1">32±18 y; 24 circuits. Mean f/u 24 </text>
<text top="243" left="378" width="18" height="15" font="1">mo </text>
<text top="258" left="378" width="146" height="15" font="1"> ASD/VSD 9; TOF 3, UVH 4.  </text>
<text top="274" left="378" width="151" height="15" font="1">ECG: 44% typical atrial flutter; </text>
<text top="289" left="378" width="72" height="15" font="1">56% atypical.  </text>
<text top="196" left="561" width="102" height="15" font="1">Frequency of typical </text>
<text top="212" left="561" width="115" height="15" font="1">atrial flutter vs. IART in </text>
<text top="227" left="561" width="27" height="15" font="1">CHD </text>
<text top="196" left="696" width="197" height="15" font="1">19% typical atrial flutter only; 37% IART </text>
<text top="212" left="696" width="172" height="15" font="1">alone; 44% both atrial flutter/IART; </text>
<text top="227" left="696" width="154" height="15" font="1">Isthmus dependent 86% IART; </text>
<text top="243" left="696" width="148" height="15" font="1">92% successful ablation; only </text>
<text top="258" left="696" width="74" height="15" font="1">failure=Fontan </text>
<text top="196" left="922" width="164" height="15" font="1">44% both atrial flutter and IART:  </text>
<text top="212" left="922" width="201" height="15" font="1">Surface ECG did not predict mechanism </text>
<text top="227" left="922" width="99" height="15" font="1">7% recurrence 2 y.  </text>
<text top="305" left="54" width="66" height="15" font="1">Delacretaz E </text>
<text top="321" left="54" width="28" height="15" font="1">2001 </text>
<text top="336" left="54" width="32" height="15" font="1">(199)  </text>
<text top="352" left="54" width="49" height="15" font="8">11345382</text>
<text top="352" left="103" width="3" height="15" font="1"> </text>
<text top="305" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="321" left="137" width="34" height="15" font="1">center </text>
<text top="305" left="264" width="15" height="15" font="1">20 </text>
<text top="305" left="378" width="162" height="15" font="1">47 Atrial reentry circuits mapped </text>
<text top="321" left="378" width="166" height="15" font="1">in 20 pts, repaired CHD, ASD 10, </text>
<text top="336" left="378" width="137" height="15" font="1">TOF 6; mean age 43 ±15 y </text>
<text top="305" left="561" width="114" height="15" font="1">Assess sites of reentry </text>
<text top="321" left="561" width="38" height="15" font="1">circuits </text>
<text top="305" left="696" width="211" height="15" font="1">Lateral RA wall 40%, CTI 38%; ASD patch </text>
<text top="321" left="696" width="32" height="15" font="1">17%.  </text>
<text top="336" left="696" width="204" height="15" font="1">Acute success 80% pts; mean f/u 19 mo, </text>
<text top="352" left="696" width="87" height="15" font="1">20% recurrence.  </text>
<text top="305" left="922" width="191" height="15" font="1">ALL RA macro-reentry, largely ASD or </text>
<text top="321" left="922" width="210" height="15" font="1">TOF pts; Circuits in 3 sites: lateral RA wall </text>
<text top="336" left="922" width="34" height="16" font="1">≅ CTI </text>
<text top="368" left="54" width="68" height="15" font="1">De Groot NM </text>
<text top="384" left="54" width="28" height="15" font="1">2006 </text>
<text top="399" left="54" width="29" height="15" font="1">(298) </text>
<text top="415" left="54" width="49" height="15" font="8">16648056</text>
<text top="415" left="103" width="3" height="15" font="1"> </text>
<text top="368" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="384" left="137" width="37" height="15" font="1">center  </text>
<text top="368" left="264" width="15" height="15" font="1">43 </text>
<text top="368" left="378" width="138" height="15" font="1">43 consecutive pts repaired </text>
<text top="384" left="378" width="111" height="15" font="1">ACHD undergoing EP </text>
<text top="399" left="378" width="167" height="15" font="1">study/ablation for SVT, mean age </text>
<text top="415" left="378" width="30" height="15" font="1">37 y,  </text>
<text top="368" left="561" width="111" height="15" font="1">Assess mechanism of </text>
<text top="384" left="561" width="101" height="15" font="1">SVT and success of </text>
<text top="399" left="561" width="47" height="15" font="1">ablations </text>
<text top="368" left="696" width="211" height="15" font="1">IART 77% including scar-related 43%, CTI </text>
<text top="384" left="696" width="129" height="15" font="1">34%; Focal 16%; AF 3%.  </text>
<text top="399" left="696" width="170" height="15" font="1">Ablation success 70% IART, atrial </text>
<text top="415" left="696" width="89" height="15" font="1">flutter,focal 100% </text>
<text top="368" left="922" width="119" height="15" font="1">RA macro-reentry: 77% </text>
<text top="384" left="922" width="55" height="15" font="1">Focal 16% </text>
<text top="399" left="922" width="36" height="15" font="1">AF 3% </text>
<text top="431" left="54" width="46" height="15" font="1">Mah DY  </text>
<text top="446" left="54" width="28" height="15" font="1">2011 </text>
<text top="462" left="54" width="29" height="15" font="1">(299) </text>
<text top="477" left="54" width="49" height="15" font="8">21539636</text>
<text top="477" left="103" width="3" height="15" font="1"> </text>
<text top="431" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="446" left="137" width="37" height="15" font="1">center  </text>
<text top="431" left="264" width="15" height="15" font="1">58 </text>
<text top="431" left="378" width="167" height="15" font="1">Repaired TOF or DORV pts, 1/97 </text>
<text top="446" left="378" width="167" height="15" font="1">to 3/10; 58 pts w/ 127 AT circuits, </text>
<text top="462" left="378" width="76" height="15" font="1">mean age 35 y </text>
<text top="431" left="561" width="103" height="15" font="1">Assess atrial reentry </text>
<text top="446" left="561" width="74" height="15" font="1">circuits in TOF </text>
<text top="431" left="696" width="194" height="15" font="1">RA reentry 75%; focal/ectopic 13%; AF </text>
<text top="446" left="696" width="212" height="15" font="1">12%; CTI 53% of IART; CTI and lateral RA </text>
<text top="462" left="696" width="190" height="15" font="1">wall = 85% of IART; AT ablation acute </text>
<text top="477" left="696" width="193" height="15" font="1">success 90%; 34% recurrence w/in 3 y </text>
<text top="431" left="922" width="160" height="15" font="1">13% focal;  AF 12%; IART 75%: </text>
<text top="446" left="922" width="183" height="15" font="1">Of IART 53%  involve isthmus; acute </text>
<text top="462" left="922" width="210" height="15" font="1">success high, recurrence moderate; target </text>
<text top="477" left="922" width="161" height="15" font="1">both isthmus and lateral RA wall </text>
<text top="494" left="54" width="47" height="15" font="1">Koyak Z  </text>
<text top="509" left="54" width="28" height="15" font="1">2013 </text>
<text top="524" left="54" width="29" height="15" font="1">(300) </text>
<text top="540" left="54" width="49" height="15" font="8">23993125</text>
<text top="540" left="103" width="3" height="15" font="1"> </text>
<text top="494" left="137" width="74" height="15" font="1">Retrospective  </text>
<text top="509" left="137" width="57" height="15" font="1">multicenter </text>
<text top="494" left="264" width="15" height="15" font="1">92 </text>
<text top="494" left="378" width="140" height="15" font="1">ACHD pts, CONCOR Dutch </text>
<text top="509" left="378" width="159" height="15" font="1">database;  First onset SVT 1/08-</text>
<text top="524" left="378" width="168" height="15" font="1">1/11 mean age 51±16 y; AF/atrial </text>
<text top="540" left="378" width="165" height="15" font="1">flutter &gt;80%; septal defects 50%, </text>
<text top="555" left="378" width="103" height="15" font="1">left sided CHD 21%. </text>
<text top="494" left="561" width="113" height="15" font="1">Mech of SVT in ACHD </text>
<text top="494" left="696" width="208" height="15" font="1">Mechanism of SVT described as AF 68%, </text>
<text top="509" left="696" width="195" height="15" font="1">atrial flutter 14%, AVNRT 8%, “AT” 7%, </text>
<text top="524" left="696" width="78" height="15" font="1">unspecified 3% </text>
<text top="494" left="922" width="129" height="15" font="1">AF 68%, atrial flutter 14% </text>
<text top="509" left="922" width="60" height="15" font="1">AVNRT 8% </text>
<text top="524" left="922" width="72" height="15" font="1">AT ? focal 7% </text>
<text top="572" left="54" width="55" height="15" font="1">Wasmer K </text>
<text top="587" left="54" width="28" height="15" font="1">2013 </text>
<text top="603" left="54" width="29" height="15" font="1">(301) </text>
<text top="618" left="54" width="49" height="15" font="8">23540398</text>
<text top="618" left="103" width="3" height="15" font="24"> </text>
<text top="572" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="587" left="137" width="37" height="15" font="1">center  </text>
<text top="572" left="264" width="15" height="15" font="1">54 </text>
<text top="572" left="378" width="158" height="15" font="1">54 pts repaired ASD, mean age </text>
<text top="587" left="378" width="153" height="15" font="1">47.3 y at study, 11/95-12/01, 2 </text>
<text top="603" left="378" width="165" height="15" font="1">pts w/ AF, 10 no inducible AT: 42 </text>
<text top="618" left="378" width="102" height="15" font="1">pts studied; f/u 7.7 y </text>
<text top="572" left="561" width="95" height="15" font="1">Assess RA reentry </text>
<text top="587" left="561" width="75" height="15" font="1">circuits in ASD </text>
<text top="572" left="696" width="201" height="15" font="1">CTI dependent 69%, of which 40% were </text>
<text top="587" left="696" width="196" height="15" font="1">clockwise; scar related 17%, both 12%; </text>
<text top="603" left="696" width="150" height="15" font="1">CTI ablation performed in non-</text>
<text top="618" left="696" width="200" height="15" font="1">inducible/AF; acute success ~90%; 60% </text>
<text top="634" left="696" width="117" height="15" font="1">arrhythmia free at 7.7 y </text>
<text top="572" left="922" width="167" height="15" font="1">ASD Ablation aimed at CTI highly </text>
<text top="587" left="922" width="154" height="15" font="1">successful; 11% developed AF </text>
<text top="650" left="54" width="159" height="15" font="1">CHD: Pharmacological Therapy </text>
<text top="666" left="54" width="44" height="15" font="1">Fish FA  </text>
<text top="682" left="54" width="28" height="15" font="1">1991 </text>
<text top="697" left="54" width="29" height="15" font="1">(302) </text>
<text top="713" left="54" width="43" height="15" font="8">1906902</text>
<text top="713" left="97" width="3" height="15" font="1"> </text>
<text top="666" left="137" width="98" height="15" font="1">Retrospective multi-</text>
<text top="682" left="137" width="37" height="15" font="1">center  </text>
<text top="666" left="264" width="22" height="15" font="1">455 </text>
<text top="666" left="378" width="132" height="15" font="1">455/579 rx for SVT (79%); </text>
<text top="682" left="378" width="140" height="15" font="1">369 pts rx flecainide (81%) . </text>
<text top="697" left="378" width="79" height="15" font="1">encainide 19%, </text>
<text top="713" left="378" width="3" height="15" font="1"> </text>
<text top="728" left="378" width="158" height="15" font="1">Mean age of flecainide death or </text>
<text top="744" left="378" width="123" height="15" font="1">CA: 9.9 y, range 4d-26 y </text>
<text top="759" left="378" width="3" height="15" font="1"> </text>
<text top="666" left="561" width="118" height="15" font="1">Pro-arrhythmia, cardiac </text>
<text top="682" left="561" width="89" height="15" font="1">arrest or death w/ </text>
<text top="697" left="561" width="112" height="15" font="1">flecainide/encainide in </text>
<text top="713" left="561" width="51" height="15" font="1">young pts </text>
<text top="666" left="696" width="202" height="15" font="1">Overall death/CA; 25 pts; 18/25 w/ CHD; </text>
<text top="682" left="696" width="3" height="15" font="1"> </text>
<text top="697" left="696" width="169" height="15" font="1">Flecainide for SVT: efficacy 7.1%, </text>
<text top="713" left="696" width="204" height="15" font="1">proarrhythmia 7.4%; cardiac arrest 2.3%; </text>
<text top="728" left="696" width="164" height="15" font="1">12 pts cardiac arrest; 8/12 CHD:  </text>
<text top="744" left="696" width="193" height="15" font="1">7/8 mild-mod ventricular dysfunction or </text>
<text top="759" left="696" width="137" height="15" font="1">single vent or systemic RV  </text>
<text top="775" left="696" width="3" height="15" font="1"> </text>
<text top="790" left="696" width="170" height="15" font="1"> Flecainide efficacy SVT 70%; pro-</text>
<text top="666" left="922" width="202" height="15" font="1">Flecainide rx SVT + CHD: 8.3% death or </text>
<text top="682" left="922" width="117" height="15" font="1">CA. vs. 0.3% w/o CHD. </text>
<text top="697" left="922" width="204" height="15" font="1">Deaths flecainide + CHD, average 16.1 y </text>
<text top="713" left="922" width="6" height="15" font="1">  </text>
<text top="728" left="922" width="3" height="15" font="1"> </text>
<text top="744" left="922" width="200" height="15" font="1">4 flecainide deaths in structurally normal </text>
<text top="759" left="922" width="153" height="15" font="1">hearts, 3 of 4 normal function.  </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">110 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="696" width="90" height="15" font="1">arrhythmia 7.4%;  </text>
<text top="71" left="54" width="56" height="15" font="1">Thorne SA </text>
<text top="86" left="54" width="28" height="15" font="1">1999 </text>
<text top="102" left="54" width="32" height="15" font="1">(303)  </text>
<text top="117" left="54" width="49" height="15" font="8">10402444</text>
<text top="117" left="103" width="3" height="15" font="1"> </text>
<text top="71" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="86" left="137" width="34" height="15" font="1">center </text>
<text top="71" left="264" width="15" height="15" font="1">92 </text>
<text top="71" left="378" width="126" height="15" font="1">ACHD, mean age 34.9 y, </text>
<text top="86" left="378" width="163" height="15" font="1">receiving amiodarone for ≥6 mo; </text>
<text top="102" left="378" width="129" height="15" font="1">case-control group. Mean </text>
<text top="117" left="378" width="162" height="15" font="1">duration 3 y, mean dose 191 mg </text>
<text top="71" left="561" width="111" height="15" font="1">Review side effects of </text>
<text top="86" left="561" width="87" height="15" font="1">chronic oral amio </text>
<text top="71" left="696" width="193" height="15" font="1">36% developed thyroid dysfunction: 19 </text>
<text top="86" left="696" width="191" height="15" font="1">hyper, 14 hypothyroid. Sig risk factors: </text>
<text top="102" left="696" width="192" height="15" font="1">Female gender (OR: 3.0)  cyanotic HD </text>
<text top="117" left="696" width="208" height="15" font="1">(OR: 7.0); Fontan (OR :4.0); dosage &gt;200 </text>
<text top="133" left="696" width="76" height="15" font="1">mg/d (OR: 4.0) </text>
<text top="71" left="922" width="204" height="15" font="1">Pts w/ CHD at higher risk for amiodarone </text>
<text top="86" left="922" width="175" height="15" font="1">adverse effects, especially women, </text>
<text top="102" left="922" width="176" height="15" font="1">cyanosis, Fontan, or dose &gt;200 mg </text>
<text top="149" left="54" width="47" height="15" font="1">Pass RH </text>
<text top="164" left="54" width="28" height="15" font="1">2000 </text>
<text top="180" left="54" width="29" height="15" font="1">(304) </text>
<text top="195" left="54" width="49" height="15" font="8">11009280</text>
<text top="195" left="103" width="3" height="15" font="1"> </text>
<text top="149" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="164" left="137" width="34" height="15" font="1">center </text>
<text top="149" left="264" width="15" height="15" font="1">10 </text>
<text top="149" left="378" width="135" height="15" font="1">IV diltiazem for AT w/ rapid </text>
<text top="164" left="378" width="169" height="15" font="1">response. Includes 3 adults w/ AT </text>
<text top="180" left="378" width="168" height="15" font="1">and repaired CHD, ages 18-21 y.  </text>
<text top="149" left="561" width="105" height="15" font="1">Efficacy diltiazem for </text>
<text top="164" left="561" width="20" height="15" font="1">AT  </text>
<text top="149" left="696" width="212" height="15" font="1">Diltiazem 0.25 mg/kg over 5 min + infusion </text>
<text top="164" left="696" width="170" height="15" font="1">0.11 mg/kg/h. HR median 166 pre-</text>
<text top="180" left="696" width="202" height="15" font="1">treatment, fell to 23 bpm w/in 10 min. No </text>
<text top="195" left="696" width="32" height="15" font="1">HTN.  </text>
<text top="149" left="922" width="210" height="15" font="1">Diltiazem effectively decreased ventricular </text>
<text top="164" left="922" width="84" height="15" font="1">rate w/in 10 min. </text>
<text top="212" left="54" width="53" height="15" font="1">Hoyer AW </text>
<text top="227" left="54" width="28" height="15" font="1">2007 </text>
<text top="243" left="54" width="29" height="15" font="1">(305) </text>
<text top="258" left="54" width="49" height="15" font="8">17669084</text>
<text top="258" left="103" width="3" height="15" font="1"> </text>
<text top="212" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="227" left="137" width="34" height="15" font="1">center </text>
<text top="212" left="264" width="15" height="15" font="1">19 </text>
<text top="212" left="378" width="157" height="15" font="1">15 w/ CHD, 4 w/ normal hearts. </text>
<text top="227" left="378" width="162" height="15" font="1">74 episodes of atrial flutter 4 AF. </text>
<text top="243" left="378" width="91" height="15" font="1">Median age 16 y.  </text>
<text top="212" left="561" width="99" height="15" font="1">Evaluate efficacy of </text>
<text top="227" left="561" width="41" height="15" font="1">ibutilide </text>
<text top="212" left="696" width="152" height="15" font="1">71% successful cardioversion; </text>
<text top="227" left="696" width="149" height="15" font="1">No symptomatic bradycardia.  </text>
<text top="243" left="696" width="77" height="15" font="1">1 TdP, 1 NSVT </text>
<text top="212" left="922" width="203" height="15" font="1">W/ careful monitoring, ibutilide can be an </text>
<text top="227" left="922" width="196" height="15" font="1">effective tool for cardioversion of flutter. </text>
<text top="274" left="54" width="45" height="15" font="1">Khairy P </text>
<text top="290" left="54" width="28" height="15" font="1">2008 </text>
<text top="305" left="54" width="29" height="15" font="1">(306) </text>
<text top="321" left="54" width="49" height="15" font="8">19808416</text>
<text top="321" left="103" width="3" height="15" font="1"> </text>
<text top="274" left="137" width="74" height="15" font="1">Retrospective  </text>
<text top="290" left="137" width="57" height="15" font="1">multicenter </text>
<text top="274" left="264" width="15" height="15" font="1">37 </text>
<text top="274" left="378" width="161" height="15" font="1">37 pts w/ intra-atrial baffle repair </text>
<text top="290" left="378" width="156" height="15" font="1">of TGA, 7 sites, ages 28±7.6 y, </text>
<text top="305" left="378" width="170" height="15" font="1">w/ AICD: primary prevention 62%, </text>
<text top="321" left="378" width="86" height="15" font="1">secondary 38%.  </text>
<text top="274" left="561" width="335" height="15" font="1">ICD and outcomes TGA  Annual rates approximately shock: 0.5% </text>
<text top="290" left="696" width="210" height="15" font="1">primary, 6% secondary. SVT preceded VT </text>
<text top="305" left="696" width="43" height="15" font="1">in 50%.  </text>
<text top="274" left="922" width="207" height="15" font="1">Lack of beta-blockers use: HR: 16.7; beta-</text>
<text top="290" left="922" width="210" height="15" font="1">blockers seem protective for SVT initiating </text>
<text top="305" left="922" width="17" height="15" font="1">VT </text>
<text top="337" left="54" width="57" height="15" font="1">Miyazaki A </text>
<text top="353" left="54" width="28" height="15" font="1">2008 </text>
<text top="368" left="54" width="29" height="15" font="1">(307) </text>
<text top="384" left="54" width="49" height="15" font="8">18931451</text>
<text top="384" left="103" width="3" height="15" font="1"> </text>
<text top="337" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="353" left="137" width="34" height="15" font="1">center </text>
<text top="337" left="264" width="19" height="15" font="1">27  </text>
<text top="337" left="378" width="167" height="15" font="1">44 ACHD, mean age 23±12 y, f/u </text>
<text top="353" left="378" width="141" height="15" font="1">13±12 mo; oral sotalol 2002-</text>
<text top="368" left="378" width="89" height="15" font="1">2007; 27 pts SVT </text>
<text top="337" left="561" width="120" height="15" font="1">Efficacy &amp; safety sotalol </text>
<text top="353" left="561" width="46" height="15" font="1">in ACHD </text>
<text top="337" left="696" width="106" height="15" font="1">Overall 41% control;  </text>
<text top="353" left="696" width="156" height="15" font="1">for SVT 52% complete control;  </text>
<text top="368" left="696" width="98" height="15" font="1">Not effective for AF </text>
<text top="337" left="922" width="212" height="15" font="1">AT w/ AF risk factor for rx failure, OR: 18.3 </text>
<text top="353" left="922" width="144" height="15" font="1">One death 34 y old, AT + AF </text>
<text top="400" left="54" width="42" height="15" font="1">Rao SO </text>
<text top="415" left="54" width="31" height="15" font="1">2009  </text>
<text top="431" left="54" width="29" height="15" font="1">(308) </text>
<text top="446" left="54" width="49" height="15" font="8">18653253</text>
<text top="446" left="103" width="3" height="15" font="1"> </text>
<text top="400" left="137" width="86" height="15" font="1">Prospective, non-</text>
<text top="415" left="137" width="61" height="15" font="1">randomized </text>
<text top="400" left="264" width="15" height="15" font="1">19 </text>
<text top="400" left="378" width="150" height="15" font="1">19 pts ACHD, mean age 20 y; </text>
<text top="415" left="378" width="167" height="15" font="1">present in AT, given oral sotalol 2 </text>
<text top="431" left="378" width="99" height="15" font="1">mg/kg as inpatients </text>
<text top="400" left="561" width="110" height="15" font="1">Sotalol for conversion </text>
<text top="400" left="696" width="132" height="15" font="1">Focal AT 21%, IART 79%; </text>
<text top="415" left="696" width="204" height="15" font="1">84% conversion w/in 98-145 min; 75% of </text>
<text top="431" left="696" width="210" height="15" font="1">focal and 87% IART. One fatality after 2 d: </text>
<text top="446" left="696" width="97" height="15" font="1">thromboembolism.  </text>
<text top="400" left="922" width="210" height="15" font="1">High efficacy 84% for oral sotalol in ACHD </text>
<text top="415" left="922" width="116" height="15" font="1">acute conversion of AT </text>
<text top="463" left="54" width="41" height="15" font="1">Wells R </text>
<text top="478" left="54" width="28" height="15" font="1">2009 </text>
<text top="494" left="54" width="29" height="15" font="1">(309) </text>
<text top="509" left="54" width="49" height="15" font="8">19691680</text>
<text top="509" left="103" width="3" height="15" font="1"> </text>
<text top="463" left="137" width="74" height="15" font="1">Retrospective  </text>
<text top="478" left="137" width="57" height="15" font="1">multicenter </text>
<text top="463" left="264" width="15" height="15" font="1">20 </text>
<text top="463" left="378" width="156" height="15" font="1">ACHD pts, 4 institutions, 7 y, rx </text>
<text top="478" left="378" width="153" height="15" font="1">w/ dofetilide, median age 30 y, </text>
<text top="494" left="378" width="126" height="15" font="1">19-53 y.11/20 pts Fontan </text>
<text top="509" left="378" width="55" height="15" font="1">surgeries.  </text>
<text top="524" left="378" width="147" height="15" font="1">AF 4, IART 13, AF + IART 3.  </text>
<text top="540" left="378" width="130" height="15" font="1">Dosage 125-500 mcg bid. </text>
<text top="555" left="378" width="107" height="15" font="1"> Median f/u ~ 12 mo.  </text>
<text top="463" left="561" width="119" height="15" font="1">Dofetilide efficacy AT in </text>
<text top="478" left="561" width="34" height="15" font="1">ACHD </text>
<text top="463" left="696" width="124" height="15" font="1">Conversion to SR: 85%.  </text>
<text top="478" left="696" width="195" height="15" font="1">Torsades de pointes: 10%, immediate.  </text>
<text top="494" left="696" width="103" height="15" font="1">Recurrent AT: 65%.  </text>
<text top="509" left="696" width="141" height="15" font="1">55% taking dofetilide at 1 y.  </text>
<text top="463" left="922" width="211" height="15" font="1">Dofetilide effective acute termination of AT </text>
<text top="478" left="922" width="182" height="15" font="1">(85%) w/ 10% Torsades de pointes.  </text>
<text top="494" left="922" width="138" height="15" font="1">65% recurrent AT in 12 mo. </text>
<text top="509" left="922" width="123" height="15" font="1">ie 35% control AT x 1 y.  </text>
<text top="572" left="54" width="46" height="15" font="1">Garnock-</text>
<text top="587" left="54" width="50" height="15" font="1">Jones KP </text>
<text top="603" left="54" width="28" height="15" font="1">2012 </text>
<text top="618" left="54" width="29" height="15" font="1">(310) </text>
<text top="634" left="54" width="49" height="15" font="8">22191799</text>
<text top="634" left="103" width="3" height="15" font="1"> </text>
<text top="572" left="137" width="84" height="15" font="1">Meta-analysis of </text>
<text top="587" left="137" width="54" height="15" font="1">databases </text>
<text top="572" left="264" width="3" height="15" font="1"> </text>
<text top="572" left="378" width="129" height="15" font="1">MEDLINE, EMBASE, and </text>
<text top="587" left="378" width="158" height="15" font="1">AdisBases databases searched </text>
<text top="603" left="378" width="163" height="15" font="1">for esmolol and tachycardia, and </text>
<text top="618" left="378" width="161" height="15" font="1">heart surgery, through 11/2011.  </text>
<text top="572" left="561" width="106" height="15" font="1">Review of databases </text>
<text top="587" left="561" width="71" height="15" font="1">using esmolol </text>
<text top="572" left="696" width="207" height="15" font="1">Includes comparison trials w/ other meds: </text>
<text top="587" left="696" width="200" height="15" font="1">placebo, propranolol, diltiazem, ibutilide, </text>
<text top="603" left="696" width="199" height="15" font="1">for treatment of SVT and for prophylaxis </text>
<text top="618" left="696" width="102" height="15" font="1">during heart surgery </text>
<text top="572" left="922" width="169" height="15" font="1">Hypotension in 2-40% of SVT pts. </text>
<text top="587" left="922" width="182" height="15" font="1">Resulted in discontinuation in 3-23% </text>
<text top="650" left="54" width="44" height="15" font="1">Koyak Z </text>
<text top="665" left="54" width="28" height="15" font="1">2013 </text>
<text top="681" left="54" width="29" height="15" font="1">(300) </text>
<text top="696" left="54" width="49" height="15" font="8">23993125</text>
<text top="696" left="103" width="3" height="15" font="1"> </text>
<text top="650" left="137" width="74" height="15" font="1">Retrospective  </text>
<text top="665" left="137" width="57" height="15" font="1">multicenter </text>
<text top="650" left="264" width="15" height="15" font="1">92 </text>
<text top="650" left="378" width="156" height="15" font="1">ACHD pts, CONCOR databse;  </text>
<text top="665" left="378" width="132" height="15" font="1">First onset SVT 1/08-1/11  </text>
<text top="681" left="378" width="99" height="15" font="1">mean age 51±16 y; </text>
<text top="696" left="378" width="146" height="15" font="1"> AF/atrial flutter &gt;80%; septal </text>
<text top="712" left="378" width="170" height="15" font="1">defects 50%, left sided CHD 21%. </text>
<text top="727" left="378" width="166" height="15" font="1">Sotalol used in 34%, (mean dose </text>
<text top="743" left="378" width="165" height="15" font="1">156 mg) ) and amiodarone 15%,( </text>
<text top="758" left="378" width="101" height="15" font="1">mean dose 350 mg) </text>
<text top="650" left="561" width="106" height="15" font="1">Long term efficacy of </text>
<text top="665" left="561" width="48" height="15" font="1">AA meds </text>
<text top="650" left="696" width="193" height="15" font="1">90% achieved sinus rhythm. 84% rx w/ </text>
<text top="665" left="696" width="193" height="15" font="1">chronic oral agents; f/u 2.5±1.4 y; 45% </text>
<text top="681" left="696" width="78" height="15" font="1">free from SVT.  </text>
<text top="696" left="696" width="206" height="15" font="1">Sotalol or Amiodarone: significantly fewer </text>
<text top="712" left="696" width="183" height="15" font="1">recurrences, (HR: 0.5); 22% adverse </text>
<text top="727" left="696" width="42" height="15" font="1">events;  </text>
<text top="743" left="696" width="206" height="15" font="1">all amiodarone pts w/ side effects, thyroid </text>
<text top="758" left="696" width="85" height="15" font="1">80%, AVB 20%.  </text>
<text top="650" left="922" width="198" height="15" font="1">Class III agents sotalol and amiodarone </text>
<text top="665" left="922" width="212" height="15" font="1">more efficacious in maintaining SR; sotalol </text>
<text top="681" left="922" width="153" height="15" font="1">considered as first choice med </text>
<text top="696" left="922" width="3" height="15" font="1"> </text>
<text top="712" left="922" width="164" height="15" font="1">Relatively high dose amiodarone </text>
<text top="727" left="922" width="201" height="15" font="1">associated w/ significant adverse events </text>
<text top="775" left="54" width="56" height="15" font="1">Banchs JE </text>
<text top="790" left="54" width="28" height="15" font="1">2014 </text>
<text top="775" left="137" width="82" height="15" font="1">Prospective non </text>
<text top="790" left="137" width="61" height="15" font="1">randomized </text>
<text top="775" left="264" width="15" height="15" font="1">13 </text>
<text top="775" left="378" width="139" height="15" font="1">ACHD, 4 TOF, 1 pulmonary </text>
<text top="790" left="378" width="162" height="15" font="1">atresia, 2 ASD, 1 dextro-TGA ; 2 </text>
<text top="775" left="561" width="111" height="15" font="1">Dofetilide efficacy and </text>
<text top="790" left="561" width="115" height="15" font="1">safety for AT in ACHD  </text>
<text top="775" left="696" width="210" height="15" font="1">Mechanism of SVT described as AF, atrial </text>
<text top="790" left="696" width="61" height="15" font="1">flutter or AT </text>
<text top="775" left="922" width="124" height="15" font="1">Dofetilide well tolerated,  </text>
<text top="790" left="922" width="155" height="15" font="1">Effective for conversion in 70% </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">111 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="29" height="15" font="1">(311) </text>
<text top="70" left="54" width="49" height="15" font="8">23947935</text>
<text top="70" left="103" width="3" height="15" font="1"> </text>
<text top="55" left="378" width="162" height="15" font="1">L-TGA, 2 tricuspid atresia, 1 asd </text>
<text top="70" left="378" width="169" height="15" font="1">and vsd, 1 vsd pulmonary atresia, </text>
<text top="86" left="378" width="143" height="15" font="1">1 noncompaction; mean age </text>
<text top="101" left="378" width="127" height="15" font="1">40±11; median f/u 16 mo </text>
<text top="55" left="696" width="82" height="15" font="1">70% conversion </text>
<text top="70" left="696" width="135" height="15" font="1">15% control of recurrences </text>
<text top="86" left="696" width="174" height="15" font="1">Average time to recurrence 5.5 mo </text>
<text top="101" left="696" width="173" height="15" font="1">39% ddischarge medication due to </text>
<text top="117" left="696" width="56" height="15" font="1">recurrence </text>
<text top="55" left="922" width="126" height="15" font="1">Recurrence still frequent. </text>
<text top="133" left="54" width="46" height="15" font="1">Stan MN </text>
<text top="148" left="54" width="28" height="15" font="1">2014 </text>
<text top="164" left="54" width="29" height="15" font="1">(312) </text>
<text top="179" left="54" width="49" height="15" font="8">22518347</text>
<text top="179" left="103" width="3" height="15" font="1"> </text>
<text top="133" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="148" left="137" width="34" height="15" font="1">center </text>
<text top="133" left="264" width="15" height="15" font="1">23 </text>
<text top="133" left="378" width="109" height="15" font="1">ACHD pts developing </text>
<text top="148" left="378" width="104" height="15" font="1">amiodarone-induced </text>
<text top="164" left="378" width="131" height="15" font="1">thyrotoxicosis after ≥3 mo </text>
<text top="179" left="378" width="153" height="15" font="1">amiodarone, Mayo Clinic 1987-</text>
<text top="195" left="378" width="119" height="15" font="1">2009; median f/u 3.1 y.  </text>
<text top="133" left="561" width="110" height="15" font="1">Identify incidence and </text>
<text top="148" left="561" width="118" height="15" font="1">risk factors amiodarone </text>
<text top="164" left="561" width="70" height="15" font="1">thyrotoxicosis </text>
<text top="133" left="696" width="185" height="15" font="1">13.6% (23/169) ACHD pts developed </text>
<text top="148" left="696" width="138" height="15" font="1">amiodarone thryrotoxicosis. </text>
<text top="133" left="922" width="208" height="15" font="1">Highest Risk: low BMI &lt;21, cyanotic heart </text>
<text top="148" left="922" width="41" height="15" font="1">disease </text>
<text top="211" left="54" width="95" height="15" font="1">CHD: Atrial Pacing </text>
<text top="227" left="54" width="65" height="15" font="1">Olshansky B </text>
<text top="243" left="54" width="28" height="15" font="1">1988 </text>
<text top="258" left="54" width="29" height="15" font="1">(313) </text>
<text top="274" left="54" width="43" height="15" font="8">3339174</text>
<text top="274" left="97" width="3" height="15" font="1"> </text>
<text top="227" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="243" left="137" width="34" height="15" font="1">center </text>
<text top="227" left="264" width="245" height="15" font="1">12 Rapid </text>
<text top="227" left="410" width="126" height="15" font="1">atrial </text>
<text top="227" left="437" width="135" height="15" font="1">pacing </text>
<text top="227" left="473" width="55" height="15" font="1">≥15 sec at </text>
<text top="243" left="378" width="150" height="15" font="1">≥10 msec shorter than AT, 12 </text>
<text top="258" left="378" width="168" height="15" font="1">adult pts, mean 55 y, 2/12 ACHD: </text>
<text top="274" left="378" width="165" height="15" font="1">VSD, VSD +ASD; mean atrial CL </text>
<text top="289" left="378" width="51" height="15" font="1">233 msec </text>
<text top="227" left="561" width="99" height="15" font="1">Conversion rates of </text>
<text top="243" left="561" width="117" height="15" font="1">AT/atrial flutter w/ rapid </text>
<text top="258" left="561" width="63" height="15" font="1">atrial pacing </text>
<text top="227" left="696" width="181" height="15" font="1">2/12 converted w/ rapid atrial pacing </text>
<text top="243" left="696" width="210" height="15" font="1">10 pts received procaine then repeat rapid </text>
<text top="258" left="696" width="166" height="15" font="1">atrial pacing: successful in 10 pts </text>
<text top="227" left="922" width="213" height="15" font="1">Procaine needed to assist RAP conversion </text>
<text top="243" left="922" width="78" height="15" font="1">in pts w/ ACHD </text>
<text top="305" left="54" width="45" height="15" font="1">Silka MJ </text>
<text top="321" left="54" width="28" height="15" font="1">1990 </text>
<text top="336" left="54" width="29" height="15" font="1">(314) </text>
<text top="352" left="54" width="43" height="15" font="8">2305688</text>
<text top="352" left="97" width="3" height="15" font="1"> </text>
<text top="305" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="321" left="137" width="34" height="15" font="1">center </text>
<text top="305" left="264" width="15" height="15" font="1">21 </text>
<text top="305" left="378" width="157" height="15" font="1">21 pts, CHD, AT or VT and anti-</text>
<text top="321" left="378" width="103" height="15" font="1">bradycardia pacing.  </text>
<text top="336" left="378" width="117" height="15" font="1">Mean age 11 y (2-19 y) </text>
<text top="305" left="561" width="108" height="15" font="1">Assess impact of anti-</text>
<text top="321" left="561" width="82" height="15" font="1">brady pacing on </text>
<text top="336" left="561" width="81" height="15" font="1">frequency of AT </text>
<text top="305" left="696" width="212" height="15" font="1">14 pts w/ AT. Prevention of bradycardia by </text>
<text top="321" left="696" width="176" height="15" font="1">pacing: significant decrease in SVT </text>
<text top="336" left="696" width="90" height="15" font="1">(p=0.008) and VT </text>
<text top="305" left="922" width="166" height="15" font="1">SVT reduced, but not atrial flutter </text>
<text top="368" left="54" width="64" height="15" font="1">Ragonese P </text>
<text top="384" left="54" width="28" height="15" font="1">1997 </text>
<text top="399" left="54" width="29" height="15" font="1">(315) </text>
<text top="415" left="54" width="43" height="15" font="8">9455751</text>
<text top="415" left="97" width="3" height="15" font="1"> </text>
<text top="368" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="384" left="137" width="34" height="15" font="1">center </text>
<text top="368" left="264" width="15" height="15" font="1">18 </text>
<text top="368" left="378" width="139" height="15" font="1">18 ACHD pts, recurrent late </text>
<text top="384" left="378" width="109" height="15" font="1">IART, implanted atrial </text>
<text top="399" left="378" width="145" height="15" font="1">pacemakers programmed for </text>
<text top="415" left="378" width="137" height="15" font="1">atrial pacing &gt;80% of time.  </text>
<text top="368" left="561" width="116" height="15" font="1">Atrial anti-brady pacing </text>
<text top="384" left="561" width="74" height="15" font="1">effect on IART </text>
<text top="399" left="561" width="56" height="15" font="1">recurrence </text>
<text top="368" left="696" width="172" height="15" font="1">Recurrent AT in 29% in first 6 mo.  </text>
<text top="384" left="696" width="207" height="15" font="1">Late recurrences in 11%; 83% arrhythmia </text>
<text top="399" left="696" width="119" height="15" font="1">free, 2 pts on AA meds. </text>
<text top="368" left="922" width="175" height="15" font="1">Chronic atrial pacing reduced IART </text>
<text top="384" left="922" width="105" height="15" font="1">recurrences to 11%.  </text>
<text top="399" left="922" width="121" height="15" font="1">One late sudden death.  </text>
<text top="431" left="54" width="69" height="15" font="1">Brockmeier K </text>
<text top="446" left="54" width="28" height="15" font="1">2002 </text>
<text top="462" left="54" width="29" height="15" font="1">(316) </text>
<text top="477" left="54" width="49" height="15" font="8">12539114</text>
<text top="477" left="103" width="3" height="15" font="1"> </text>
<text top="431" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="446" left="137" width="34" height="15" font="1">center </text>
<text top="431" left="264" width="15" height="15" font="1">39 </text>
<text top="431" left="378" width="141" height="15" font="1">62 conversions in 39 pts, 31 </text>
<text top="446" left="378" width="161" height="15" font="1">postop CHD, median age 12.5 y </text>
<text top="462" left="378" width="150" height="15" font="1">(0.1-33 y); “typical atrial flutter </text>
<text top="477" left="378" width="133" height="15" font="1">21”, median CL 235 msec  </text>
<text top="431" left="561" width="111" height="15" font="1">TEP conversion of AT </text>
<text top="446" left="561" width="39" height="15" font="1">in CHD </text>
<text top="431" left="696" width="209" height="15" font="1">81% successful conversions w/ TEP; 19% </text>
<text top="446" left="696" width="89" height="15" font="1">underwent CDDV </text>
<text top="462" left="696" width="211" height="15" font="1">Used AEST 4-6 x (CL-20) to minimum 120 </text>
<text top="477" left="696" width="87" height="15" font="1">msec; mA 24-28  </text>
<text top="431" left="922" width="198" height="15" font="1">TEP converted 81% atrial flutter or ART </text>
<text top="494" left="54" width="62" height="15" font="1">Stephenson </text>
<text top="509" left="54" width="18" height="15" font="1">EA </text>
<text top="524" left="54" width="28" height="15" font="1">2003 </text>
<text top="540" left="54" width="29" height="15" font="1">(317) </text>
<text top="555" left="54" width="49" height="15" font="8">14516898</text>
<text top="555" left="103" width="3" height="15" font="1"> </text>
<text top="494" left="137" width="71" height="15" font="1">Retrospective </text>
<text top="509" left="137" width="57" height="15" font="1">multicenter </text>
<text top="494" left="264" width="15" height="15" font="1">28 </text>
<text top="494" left="378" width="167" height="15" font="1">ATP in 28 ACHD pts, age 30 ±18 </text>
<text top="509" left="378" width="12" height="15" font="1">y. </text>
<text top="524" left="378" width="141" height="15" font="1">Medtronic AT500 pacer.  ≥2 </text>
<text top="540" left="378" width="159" height="15" font="1">episodes AT in 12 mo. Mean f/u </text>
<text top="555" left="378" width="37" height="15" font="1">10 mo. </text>
<text top="494" left="561" width="94" height="15" font="1">ATP detection and </text>
<text top="509" left="561" width="87" height="15" font="1">termination of AT </text>
<text top="494" left="696" width="207" height="15" font="1">57% of pts had AT after implant, mean 54 </text>
<text top="509" left="696" width="50" height="15" font="1">episodes. </text>
<text top="494" left="922" width="174" height="15" font="1">ATP efficacy for termination: 54%.  </text>
<text top="572" left="54" width="121" height="15" font="1">CHD: DC Cardioversion </text>
<text top="588" left="54" width="67" height="15" font="1">Ammash NM </text>
<text top="604" left="54" width="28" height="15" font="1">2012 </text>
<text top="619" left="54" width="29" height="15" font="1">(318) </text>
<text top="634" left="54" width="49" height="15" font="8">20934227</text>
<text top="634" left="103" width="3" height="15" font="1"> </text>
<text top="588" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="604" left="137" width="34" height="15" font="1">center </text>
<text top="588" left="264" width="15" height="15" font="1">63 </text>
<text top="588" left="378" width="154" height="15" font="1">63 ACHD underwent 80 DCCV </text>
<text top="604" left="378" width="160" height="15" font="1">6/00-7/03. Flutter most common </text>
<text top="619" left="378" width="74" height="15" font="1">46%. f/u 387 d </text>
<text top="634" left="378" width="3" height="15" font="1"> </text>
<text top="588" left="561" width="98" height="15" font="1">Outcome of  DCCV </text>
<text top="588" left="696" width="129" height="15" font="1">DCCV successful in 94%. </text>
<text top="604" left="696" width="171" height="15" font="1">60% ACHD pts recurred during f/u </text>
<text top="619" left="696" width="204" height="15" font="1">all cause mortality was 11% during one y </text>
<text top="634" left="696" width="18" height="15" font="1">f/u. </text>
<text top="588" left="922" width="173" height="15" font="1">DCCV safe and effective in ACHD. </text>
<text top="604" left="922" width="205" height="15" font="1">Recurrence rate is 60%/1 y; AF predicted </text>
<text top="619" left="922" width="147" height="15" font="1">recurrence, and spontaneous </text>
<text top="634" left="922" width="162" height="15" font="1">echocardiography contrast in LA </text>
<text top="651" left="54" width="153" height="15" font="1">CHD: Catheter Ablation - NOS </text>
<text top="667" left="54" width="66" height="15" font="1">Triedman JK </text>
<text top="682" left="54" width="28" height="15" font="1">1995 </text>
<text top="698" left="54" width="29" height="15" font="1">(319) </text>
<text top="713" left="54" width="43" height="15" font="8">7828297</text>
<text top="713" left="97" width="3" height="15" font="1"> </text>
<text top="667" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="682" left="137" width="34" height="15" font="1">center </text>
<text top="667" left="264" width="229" height="15" font="1">10 10 </text>
<text top="667" left="393" width="117" height="15" font="1">consecutive ACHD pts, </text>
<text top="682" left="378" width="148" height="15" font="1">median age 18.4 y (12-43 y).  </text>
<text top="698" left="378" width="157" height="15" font="1">Fontan 6, TGA atrial 2, 2 biVS.  </text>
<text top="713" left="378" width="134" height="15" font="1">30 IART circuits. Ablate 22 </text>
<text top="729" left="378" width="129" height="15" font="1">circuits. Median f/u 4 mo.  </text>
<text top="667" left="561" width="76" height="15" font="1">ACHD ablation </text>
<text top="682" left="561" width="51" height="15" font="1">outcomes </text>
<text top="667" left="696" width="126" height="15" font="1">Circuits in 4 areas of RA. </text>
<text top="682" left="696" width="143" height="15" font="1">77% acute success (circuits) </text>
<text top="698" left="696" width="134" height="15" font="1">50% recurrence short term </text>
<text top="667" left="922" width="210" height="15" font="1">77% acute success, 50% recurrence short </text>
<text top="682" left="922" width="53" height="15" font="1">term 4 mo </text>
<text top="745" left="54" width="58" height="15" font="1">Kalman JM </text>
<text top="761" left="54" width="28" height="15" font="1">1996 </text>
<text top="776" left="54" width="29" height="15" font="1">(212) </text>
<text top="792" left="54" width="43" height="15" font="8">8565168</text>
<text top="792" left="97" width="3" height="15" font="24"> </text>
<text top="745" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="761" left="137" width="34" height="15" font="1">center </text>
<text top="745" left="264" width="229" height="15" font="1">18 18 </text>
<text top="745" left="393" width="132" height="15" font="1">consecutive ACHD pts, 26 </text>
<text top="761" left="378" width="168" height="15" font="1">IART circuits, mean age 26 ±15 y </text>
<text top="776" left="378" width="140" height="15" font="1">map &amp; Ablation 1992-1995.  </text>
<text top="792" left="378" width="146" height="15" font="1">ASD 50%, Fontan 22%, TGA </text>
<text top="745" left="561" width="76" height="15" font="1">ACHD ablation </text>
<text top="761" left="561" width="51" height="15" font="1">outcomes </text>
<text top="745" left="696" width="103" height="15" font="1">Acute success  83% </text>
<text top="761" left="696" width="106" height="15" font="1">Fontan 50% success </text>
<text top="745" left="922" width="109" height="15" font="1">Acute success  83%,  </text>
<text top="761" left="922" width="211" height="15" font="1">50% asymptomatic, no medications during </text>
<text top="776" left="922" width="18" height="15" font="1">f/u. </text>
<text top="792" left="922" width="144" height="15" font="1">33% recurrence, plus 7% AF </text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">112 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="3" height="15" font="25"> </text>
<text top="55" left="378" width="151" height="15" font="1">atrial switch 22%, Rastelli 5%; </text>
<text top="70" left="378" width="160" height="15" font="1">conventional mapping, f/u mean </text>
<text top="86" left="378" width="40" height="15" font="1">17 mo.  </text>
<text top="102" left="54" width="49" height="15" font="1">Tanner H </text>
<text top="117" left="54" width="28" height="15" font="1">2004 </text>
<text top="133" left="54" width="29" height="15" font="1">(320) </text>
<text top="148" left="54" width="49" height="15" font="8">15851168</text>
<text top="148" left="103" width="3" height="15" font="1"> </text>
<text top="102" left="137" width="57" height="15" font="1">Multicenter </text>
<text top="117" left="137" width="70" height="15" font="1">retrospective  </text>
<text top="102" left="264" width="229" height="15" font="1">36 36 </text>
<text top="102" left="393" width="117" height="15" font="1">consecutive ACHD pts, </text>
<text top="117" left="378" width="91" height="15" font="1">median age 46 y.  </text>
<text top="133" left="378" width="158" height="15" font="1">ASD 20, TOF 8, TGA 5, VSD 1, </text>
<text top="148" left="378" width="95" height="15" font="1">UVH 1, cc-TGA 1.  </text>
<text top="164" left="378" width="80" height="15" font="1">Mean f/u 17 mo </text>
<text top="102" left="561" width="76" height="15" font="1">ACHD ablation </text>
<text top="117" left="561" width="54" height="15" font="1">outcomes  </text>
<text top="102" left="696" width="153" height="15" font="1">52 IART circuits; 48 ablations.  </text>
<text top="117" left="696" width="201" height="15" font="1">65% CTI dependent. 27% incisional, 8% </text>
<text top="133" left="696" width="23" height="15" font="1">LA.  </text>
<text top="148" left="696" width="109" height="15" font="1">Acute success: 87%.  </text>
<text top="102" left="922" width="188" height="15" font="1">87% acute success ablation ACHD (2 </text>
<text top="117" left="922" width="126" height="15" font="1">ventricles predominantly) </text>
<text top="133" left="922" width="127" height="15" font="1">25% on chronic AA meds </text>
<text top="148" left="922" width="116" height="15" font="1">92% free of recurrence </text>
<text top="164" left="922" width="97" height="15" font="1">14% developed AF </text>
<text top="180" left="54" width="43" height="15" font="1">Lukac P </text>
<text top="195" left="54" width="28" height="15" font="1">2005 </text>
<text top="211" left="54" width="29" height="15" font="1">(321) </text>
<text top="226" left="54" width="49" height="15" font="8">15851267</text>
<text top="226" left="103" width="3" height="15" font="1"> </text>
<text top="180" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="195" left="137" width="34" height="15" font="1">center </text>
<text top="180" left="264" width="15" height="15" font="1">52 </text>
<text top="180" left="378" width="162" height="15" font="1">52/83 pts postop ACHD, median </text>
<text top="195" left="378" width="46" height="15" font="1">age 36 y </text>
<text top="211" left="378" width="165" height="15" font="1">ASD 21, TOF 11, TGA 9; UVH 4, </text>
<text top="226" left="378" width="35" height="15" font="1">VSD 2 </text>
<text top="242" left="378" width="89" height="15" font="1">Median f/u 27 mo </text>
<text top="180" left="561" width="76" height="15" font="1">ACHD ablation </text>
<text top="195" left="561" width="51" height="15" font="1">outcomes </text>
<text top="180" left="696" width="102" height="15" font="1">CTI dependent 71% </text>
<text top="195" left="696" width="208" height="15" font="1">Fontan pts multiple circuits;lateral RA wall </text>
<text top="180" left="922" width="213" height="15" font="1">CTI dependent 71%-most common, except </text>
<text top="195" left="922" width="67" height="15" font="1">in Fontan pts </text>
<text top="211" left="922" width="112" height="15" font="1">31% chronic AA meds </text>
<text top="226" left="922" width="81" height="15" font="1">24% recurrence </text>
<text top="242" left="922" width="89" height="15" font="1">13% died or OHT </text>
<text top="258" left="54" width="68" height="15" font="1">De Groot NM </text>
<text top="274" left="54" width="28" height="15" font="1">2010 </text>
<text top="289" left="54" width="29" height="15" font="1">(322) </text>
<text top="305" left="54" width="49" height="15" font="8">20194797</text>
<text top="305" left="103" width="3" height="15" font="1"> </text>
<text top="258" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="274" left="137" width="34" height="15" font="1">center </text>
<text top="258" left="264" width="15" height="15" font="1">53 </text>
<text top="258" left="378" width="147" height="15" font="1">Ablation in 53 ACHD pts, age </text>
<text top="274" left="378" width="50" height="15" font="1">38±15 y.  </text>
<text top="258" left="561" width="120" height="15" font="1">Examine characteristics </text>
<text top="274" left="561" width="99" height="15" font="1">of recurrences after </text>
<text top="289" left="561" width="76" height="15" font="1">ablation ACHD </text>
<text top="258" left="696" width="199" height="15" font="1">Atrial flutter 51%; IART 42%; Focal 9%.  </text>
<text top="274" left="696" width="207" height="15" font="1">Acute success 65%; recurrence 59% w/in </text>
<text top="289" left="696" width="36" height="15" font="1">one y.  </text>
<text top="305" left="696" width="206" height="15" font="1">Repeat ablation 15: 7 similar mechanism. </text>
<text top="320" left="696" width="188" height="15" font="1">f/u: 5± 3 y: death 9%; AA meds 57%;  </text>
<text top="336" left="696" width="93" height="15" font="1">31% recurrent AT  </text>
<text top="258" left="922" width="151" height="15" font="1">ACHD: High recurrence 59%;  </text>
<text top="274" left="922" width="111" height="15" font="1"> 57% meds; 9% death </text>
<text top="289" left="922" width="217" height="15" font="1">Recurrent AT may be different mechanism.  </text>
<text top="305" left="922" width="3" height="15" font="1"> </text>
<text top="352" left="54" width="41" height="15" font="1">Yap SC </text>
<text top="367" left="54" width="28" height="15" font="1">2010 </text>
<text top="383" left="54" width="32" height="15" font="1">(323)  </text>
<text top="398" left="54" width="49" height="15" font="8">21029876</text>
<text top="398" left="103" width="3" height="15" font="1"> </text>
<text top="352" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="367" left="137" width="34" height="15" font="1">center </text>
<text top="352" left="264" width="22" height="15" font="1">130 </text>
<text top="352" left="378" width="169" height="15" font="1">193 ablations performed in ACHD </text>
<text top="367" left="378" width="145" height="15" font="1">130 pts, mean age 40 ±13 y; </text>
<text top="383" left="378" width="152" height="15" font="1">median f/u 3.4 y. Type of CHD </text>
<text top="398" left="378" width="163" height="15" font="1">ASD 21%, TGA 18%; UVH 20%; </text>
<text top="414" left="378" width="108" height="15" font="1">TGA 18%, other 12% </text>
<text top="352" left="561" width="91" height="15" font="1">Acute &amp; long term </text>
<text top="367" left="561" width="105" height="15" font="1">outcomes ablation of </text>
<text top="383" left="561" width="74" height="15" font="1">IART in ACHD </text>
<text top="352" left="696" width="191" height="15" font="1">Acute success 69%; 5% major comps; </text>
<text top="367" left="696" width="210" height="15" font="1">pacers 3%;  62% discharged on AA meds; </text>
<text top="383" left="696" width="174" height="15" font="1">IART recurrence: 4 y =51%; repeat </text>
<text top="398" left="696" width="196" height="15" font="1">ablation 35%; death 4%. Older age and </text>
<text top="414" left="696" width="210" height="15" font="1">Fontan palliation predictors of recurrence.  </text>
<text top="352" left="922" width="210" height="15" font="1">Differential outcomes of ablation based on </text>
<text top="367" left="922" width="205" height="15" font="1">type of CHD: in Fontan pts, 4 y r freedom </text>
<text top="383" left="922" width="193" height="15" font="1">from recurrence 15% vs.~42% in ASD, </text>
<text top="398" left="922" width="71" height="15" font="1">TOF, Mustard </text>
<text top="430" left="54" width="40" height="15" font="1">Ueda A </text>
<text top="446" left="54" width="28" height="15" font="1">2013 </text>
<text top="461" left="54" width="32" height="15" font="1">(324)  </text>
<text top="477" left="54" width="49" height="15" font="8">23685536</text>
<text top="477" left="103" width="3" height="15" font="1"> </text>
<text top="430" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="446" left="137" width="34" height="15" font="1">center </text>
<text top="430" left="264" width="22" height="15" font="1">116 </text>
<text top="430" left="378" width="151" height="15" font="1">Ablation 116 ACHD pts, mean </text>
<text top="446" left="378" width="153" height="15" font="1">age 41 y; 154 procedures, 228 </text>
<text top="461" left="378" width="161" height="15" font="1">circuits using remote navigation, </text>
<text top="477" left="378" width="156" height="15" font="1">3D mapping.  F/u mean 20 mo, </text>
<text top="492" left="378" width="87" height="15" font="1">Group A: manual </text>
<text top="507" left="378" width="148" height="15" font="1">mappping/ablation; B: remote </text>
<text top="523" left="378" width="162" height="15" font="1">navigation; C: remote navigation </text>
<text top="539" left="378" width="88" height="15" font="1">+difficult access.  </text>
<text top="430" left="561" width="90" height="15" font="1">Assess outcomes </text>
<text top="446" left="561" width="76" height="15" font="1">ablation ACHD </text>
<text top="430" left="696" width="196" height="15" font="1">Compare simple vs. complex lesions or </text>
<text top="446" left="696" width="208" height="15" font="1">complex vascular access. AVNRT 5-13%; </text>
<text top="461" left="696" width="197" height="15" font="1">AVRT 4-7%; Focal 11-26%; atrial flutter </text>
<text top="477" left="696" width="175" height="15" font="1">11-39%; IART 23-45%; AF 6-18%.  </text>
<text top="492" left="696" width="189" height="15" font="1"> No difference acute success 82-91%, </text>
<text top="507" left="696" width="100" height="15" font="1">recurrence 20-24%. </text>
<text top="430" left="922" width="134" height="15" font="1">ACHD population: ablation </text>
<text top="446" left="922" width="206" height="15" font="1">Acute success &gt;80%; 20-25% recurrence </text>
<text top="461" left="922" width="57" height="15" font="1">w/in 20 mo </text>
<text top="555" left="54" width="154" height="15" font="1">CHD: Catheter Ablation – ASD </text>
<text top="571" left="54" width="46" height="15" font="1">Teh AW  </text>
<text top="587" left="54" width="31" height="15" font="1">2011  </text>
<text top="602" left="54" width="29" height="15" font="1">(325) </text>
<text top="617" left="54" width="49" height="15" font="8">21208243</text>
<text top="617" left="103" width="3" height="15" font="24"> </text>
<text top="633" left="54" width="3" height="15" font="1"> </text>
<text top="571" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="587" left="137" width="34" height="15" font="1">center </text>
<text top="571" left="264" width="15" height="15" font="1">20 </text>
<text top="571" left="378" width="146" height="15" font="1">Ablation AT after ASD repair; </text>
<text top="587" left="378" width="149" height="15" font="1">mean age 53±13 y; post ASD </text>
<text top="602" left="378" width="134" height="15" font="1">closure interval 29±15 y.    </text>
<text top="571" left="561" width="101" height="15" font="1">ASD Outcome atrial </text>
<text top="587" left="561" width="87" height="15" font="1">flutter ablation in  </text>
<text top="571" left="696" width="190" height="15" font="1">All CTI dependent atrial flutter; + other </text>
<text top="587" left="696" width="41" height="15" font="1">circuits. </text>
<text top="602" left="696" width="199" height="15" font="1">Acute success 100%; 25% repeat abl at </text>
<text top="617" left="696" width="198" height="15" font="1">13 mo. F/u 3.2±1.6 y, 30% documented </text>
<text top="633" left="696" width="178" height="15" font="1">AF; stroke 5%; 35% AF intervention </text>
<text top="571" left="922" width="195" height="15" font="1">Excellent acute ablation success  ASD: </text>
<text top="587" left="922" width="171" height="15" font="1">100%; 25% recur-repeat ablation,  </text>
<text top="602" left="922" width="100" height="15" font="1">30% AF in 3 y of f/u </text>
<text top="649" left="54" width="55" height="15" font="1">Wasmer K </text>
<text top="665" left="54" width="28" height="15" font="1">2013 </text>
<text top="680" left="54" width="29" height="15" font="1">(301) </text>
<text top="696" left="54" width="49" height="15" font="8">23540398</text>
<text top="696" left="103" width="3" height="15" font="1"> </text>
<text top="649" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="665" left="137" width="34" height="15" font="1">center </text>
<text top="649" left="264" width="15" height="15" font="1">54 </text>
<text top="649" left="378" width="156" height="15" font="1">Consecutive Repaired ASD pts </text>
<text top="665" left="378" width="158" height="15" font="1">underwent EP study &amp; ablation, </text>
<text top="680" left="378" width="134" height="15" font="1">mean age 47 y. Mean 22 y </text>
<text top="696" left="378" width="39" height="15" font="1">postop. </text>
<text top="711" left="378" width="151" height="15" font="1">f/u in 83%, 7.7 y. Mean AT CL </text>
<text top="727" left="378" width="57" height="15" font="1">270 msec.  </text>
<text top="649" left="561" width="78" height="15" font="1">ASD ablation &amp; </text>
<text top="665" left="561" width="95" height="15" font="1">mechanisms of AT </text>
<text top="649" left="696" width="204" height="15" font="1">AT at EP study in 78%: RA macroreentry </text>
<text top="665" left="696" width="212" height="15" font="1">in 100%; CTI dependent 69%; typical atrial </text>
<text top="680" left="696" width="62" height="15" font="1">flutter 41%.  </text>
<text top="696" left="696" width="198" height="15" font="1">10% not inducible. CTI ablation in AF or </text>
<text top="711" left="696" width="191" height="15" font="1">non-inducible. Ablation acute success: </text>
<text top="727" left="696" width="25" height="15" font="1">93% </text>
<text top="649" left="922" width="172" height="15" font="1">93% acute success ablation ASD.  </text>
<text top="665" left="922" width="183" height="15" font="1">4% recurred w/ different mechanism. </text>
<text top="680" left="922" width="152" height="15" font="1">60% arrhythmia free during f/u </text>
<text top="696" left="922" width="97" height="15" font="1">11% developed AF </text>
<text top="743" left="54" width="64" height="15" font="1">Scaglione M </text>
<text top="758" left="54" width="31" height="15" font="1">2014  </text>
<text top="774" left="54" width="29" height="15" font="1">(326) </text>
<text top="789" left="54" width="49" height="15" font="8">24843050</text>
<text top="789" left="103" width="3" height="15" font="1"> </text>
<text top="743" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="758" left="137" width="34" height="15" font="1">center </text>
<text top="743" left="264" width="15" height="15" font="1">46 </text>
<text top="743" left="378" width="158" height="15" font="1">46 repaired ASD pts, mean age </text>
<text top="758" left="378" width="138" height="15" font="1">49 y; 89% secundum ASD.  </text>
<text top="774" left="378" width="154" height="15" font="1">ECG atrial flutter 48%, atypical </text>
<text top="789" left="378" width="157" height="15" font="1">atrial flutter 35%, AT 17%. 41% </text>
<text top="743" left="561" width="105" height="15" font="1">ASD mechanisms  &amp; </text>
<text top="758" left="561" width="93" height="15" font="1">ablation outcomes </text>
<text top="743" left="696" width="201" height="15" font="1">Typical AF: 48%, atypical 35%, AT 17%. </text>
<text top="758" left="696" width="178" height="15" font="1">CTI dependent 26%, 74% atriotomy </text>
<text top="774" left="696" width="62" height="15" font="1">dependent;  </text>
<text top="789" left="696" width="204" height="15" font="1">Ablation acute success 100%; recur 24% </text>
<text top="743" left="922" width="161" height="15" font="1">ALL RA macro-reentry; no focal. </text>
<text top="758" left="922" width="156" height="15" font="1">High success ablation for ASD: </text>
<text top="774" left="922" width="116" height="15" font="1">100%, 24% recurrence </text>
<text top="789" left="922" width="107" height="15" font="1">20% repeat ablations </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">113 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="378" width="47" height="15" font="1">also AF.  </text>
<text top="70" left="378" width="136" height="15" font="1">Onset AT 19±12 y postop.  </text>
<text top="86" left="378" width="96" height="15" font="1">Complete f/u, 7.3 y </text>
<text top="55" left="696" width="170" height="15" font="1">Recur same mechanism w/ gaps.  </text>
<text top="70" left="696" width="172" height="15" font="1">70% atypical atrial flutter had ECG </text>
<text top="86" left="696" width="73" height="15" font="1">concordance.  </text>
<text top="102" left="54" width="176" height="15" font="1">CHD: Catheter Ablation – Ebstein’s </text>
<text top="118" left="54" width="56" height="15" font="1">Cappato R </text>
<text top="134" left="54" width="28" height="15" font="1">1996 </text>
<text top="149" left="54" width="29" height="15" font="1">(327) </text>
<text top="164" left="54" width="43" height="15" font="8">8759079</text>
<text top="164" left="97" width="3" height="15" font="1"> </text>
<text top="118" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="134" left="137" width="34" height="15" font="1">center </text>
<text top="118" left="264" width="15" height="15" font="1">21 </text>
<text top="118" left="378" width="165" height="15" font="1">Ebstein pts w/ AVRT: EP study + </text>
<text top="134" left="378" width="168" height="15" font="1">attempted RFA. 34 right sided AP </text>
<text top="149" left="378" width="150" height="15" font="1">in 21 pts. Mean age 28±14 y.  </text>
<text top="164" left="378" width="86" height="15" font="1">Mean f/u 22 mo.  </text>
<text top="118" left="561" width="90" height="15" font="1">Ebstein’s ablation </text>
<text top="134" left="561" width="51" height="15" font="1">outcomes </text>
<text top="118" left="696" width="164" height="15" font="1">76% acute success ablation AP.  </text>
<text top="134" left="696" width="210" height="15" font="1">24% recurrent SVT (5 pts, including 4/5 w/ </text>
<text top="149" left="696" width="164" height="15" font="1">acute success)—4/16 successful </text>
<text top="164" left="696" width="98" height="15" font="1">ablations-rec SVT= </text>
<text top="180" left="696" width="3" height="15" font="1"> </text>
<text top="118" left="922" width="143" height="15" font="1">Cath ablation success 76%;  </text>
<text top="134" left="922" width="209" height="15" font="1">25% recurrence in 22 mo in pts w/ acutely </text>
<text top="149" left="922" width="100" height="15" font="1">successful ablation. </text>
<text top="196" left="54" width="48" height="15" font="1">Reich JD </text>
<text top="212" left="54" width="28" height="15" font="1">1998 </text>
<text top="227" left="54" width="29" height="15" font="1">(328) </text>
<text top="243" left="54" width="43" height="15" font="8">9869537</text>
<text top="243" left="97" width="3" height="15" font="24"> </text>
<text top="258" left="54" width="3" height="15" font="25"> </text>
<text top="196" left="137" width="101" height="15" font="1">Retrospective  multi-</text>
<text top="212" left="137" width="34" height="15" font="1">center </text>
<text top="196" left="264" width="15" height="15" font="1">65 </text>
<text top="196" left="378" width="159" height="15" font="1">65 Ebstein’s pts, age 9.8±5.4 y, </text>
<text top="212" left="378" width="159" height="15" font="1">82 accessory connections: 62% </text>
<text top="227" left="378" width="152" height="15" font="1">right, 34% septal, 4% left; only </text>
<text top="243" left="378" width="153" height="15" font="1">52% w/ single AP; 9% AP plus </text>
<text top="258" left="378" width="149" height="15" font="1">atrial tachycardia; 9% non-AP </text>
<text top="274" left="378" width="63" height="15" font="1">tachycardia. </text>
<text top="196" left="561" width="90" height="15" font="1">Ebstein’s ablation </text>
<text top="212" left="561" width="54" height="15" font="1">outcomes  </text>
<text top="196" left="696" width="122" height="15" font="1">Acute success 75-89%.  </text>
<text top="212" left="696" width="204" height="15" font="1">Mild tricuspid regurgitation and BSA &lt;1.7 </text>
<text top="227" left="696" width="128" height="15" font="1">predicted acute success.  </text>
<text top="196" left="922" width="201" height="15" font="1">SVT related to AC 82%; 18% other atrial </text>
<text top="212" left="922" width="128" height="15" font="1">tachycardia mechanisms. </text>
<text top="290" left="54" width="154" height="15" font="1">CHD: Catheter Ablation – UVH </text>
<text top="306" left="54" width="68" height="15" font="1">De Groot NM </text>
<text top="322" left="54" width="28" height="15" font="1">2009 </text>
<text top="337" left="54" width="29" height="15" font="1">(329) </text>
<text top="353" left="54" width="49" height="15" font="8">19808474</text>
<text top="353" left="103" width="3" height="15" font="1"> </text>
<text top="306" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="322" left="137" width="34" height="15" font="1">center </text>
<text top="306" left="264" width="15" height="15" font="1">19 </text>
<text top="306" left="378" width="156" height="15" font="1">19 Pts w/ UVH, age 29±9 y; 41 </text>
<text top="322" left="378" width="71" height="15" font="1">SVT circuits;   </text>
<text top="306" left="561" width="120" height="15" font="1">Procedural outcomes of </text>
<text top="322" left="561" width="80" height="15" font="1">ablation in UVH </text>
<text top="306" left="696" width="190" height="15" font="1">Mechanisms: IART 73%; Typical atrial </text>
<text top="322" left="696" width="160" height="15" font="1">flutter 10%; Focal 15%; AF 2%.  </text>
<text top="337" left="696" width="201" height="15" font="1">Acute ablation success: 73% IART; 75% </text>
<text top="353" left="696" width="122" height="15" font="1">atrial flutter; 100% focal  </text>
<text top="368" left="696" width="201" height="15" font="1">f/u 53±34 mo: 16% died; 11% transplant </text>
<text top="306" left="922" width="154" height="15" font="1">UVH pts: Acute success ~78% </text>
<text top="322" left="922" width="103" height="15" font="1">Death or OHT : 27% </text>
<text top="337" left="922" width="137" height="15" font="1">Recurrence: 27% by 53 mo </text>
<text top="384" left="54" width="41" height="15" font="1">Yap SC </text>
<text top="400" left="54" width="28" height="15" font="1">2012 </text>
<text top="415" left="54" width="29" height="15" font="1">(330) </text>
<text top="431" left="54" width="49" height="15" font="8">22035149</text>
<text top="431" left="103" width="3" height="15" font="1"> </text>
<text top="384" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="400" left="137" width="34" height="15" font="1">center </text>
<text top="384" left="264" width="15" height="15" font="1">11 </text>
<text top="384" left="378" width="143" height="15" font="1">Ablation in Fontan pts vs. 30 </text>
<text top="400" left="378" width="160" height="15" font="1">other ACHD pts; atriopulmonary </text>
<text top="415" left="378" width="161" height="15" font="1">and AV Fontan, mean age 33±0 </text>
<text top="431" left="378" width="15" height="15" font="1">y.  </text>
<text top="384" left="561" width="104" height="15" font="1">Assess AT substrate </text>
<text top="400" left="561" width="103" height="15" font="1">after Fontan surgery </text>
<text top="384" left="696" width="204" height="15" font="1">Fontan pts larger RA (p&lt;.001), larger low-</text>
<text top="400" left="696" width="180" height="15" font="1">voltage area (p=.01). Acute success </text>
<text top="415" left="696" width="205" height="15" font="1">Fontan 54% vs. 83% other CHD (p=.04).  </text>
<text top="431" left="696" width="188" height="15" font="1">F/u 2.3±1.6 y, IART recurrence 47%.  </text>
<text top="384" left="922" width="204" height="15" font="1">Fontan pts lower acute success vs. other </text>
<text top="400" left="922" width="38" height="15" font="1">ACHD  </text>
<text top="415" left="922" width="183" height="15" font="1">high recurrence 47% at 2.3 y all pts;  </text>
<text top="431" left="922" width="214" height="15" font="1">Fontan 50 ±19%, vs. 32 ±10% non-Fontan </text>
<text top="446" left="922" width="48" height="15" font="1">pts at 2 y </text>
<text top="462" left="922" width="187" height="15" font="1">Larger RA size and low voltage areas </text>
<text top="477" left="922" width="133" height="15" font="1">predicted IART recurrence </text>
<text top="494" left="54" width="48" height="15" font="1">Correa R </text>
<text top="509" left="54" width="28" height="15" font="1">2015 </text>
<text top="524" left="54" width="29" height="15" font="1">(331) </text>
<text top="540" left="54" width="49" height="15" font="8">25583982</text>
<text top="540" left="103" width="3" height="15" font="1"> </text>
<text top="494" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="509" left="137" width="34" height="15" font="1">center </text>
<text top="494" left="264" width="15" height="15" font="1">32 </text>
<text top="494" left="378" width="168" height="15" font="1">52 consectutive pts underwent 57 </text>
<text top="509" left="378" width="167" height="15" font="1">EP studies 2006-2012. Mean age </text>
<text top="524" left="378" width="159" height="15" font="1">18.4±11.8 y, all with TCPC type </text>
<text top="540" left="378" width="143" height="15" font="1">Fontans. 32 ablations, 31 for </text>
<text top="555" left="378" width="141" height="15" font="1">SVT. VT induced in 5/52 pts </text>
<text top="571" left="378" width="164" height="15" font="1">studied. No f/u in 19%. In others, </text>
<text top="587" left="378" width="92" height="15" font="1">median f/u 18 mo. </text>
<text top="494" left="561" width="120" height="15" font="1">Procedural outcomes of </text>
<text top="509" left="561" width="83" height="15" font="1">ablation in UVH. </text>
<text top="494" left="696" width="167" height="15" font="1">47 procedures w/ 54 defined SVT </text>
<text top="509" left="696" width="194" height="15" font="1">mechanisms. IART 46%, AVNRT 24%, </text>
<text top="524" left="696" width="165" height="15" font="1">focal 15%, AP 7%, twin AVN 7%. </text>
<text top="540" left="696" width="198" height="15" font="1">Additional 21 undefined AT. Ablation for </text>
<text top="555" left="696" width="181" height="15" font="1">SVT acute success 80%. Two major </text>
<text top="571" left="696" width="189" height="15" font="1">adverse events 6%: death, pulmonary </text>
<text top="587" left="696" width="185" height="15" font="1">embolus. 50% recurrence short term, </text>
<text top="602" left="696" width="143" height="15" font="1">improved arrhythmia scores. </text>
<text top="494" left="922" width="167" height="15" font="1">78% acute success for SVT. 50% </text>
<text top="509" left="922" width="160" height="15" font="1">recurrence short term; improved </text>
<text top="525" left="922" width="186" height="15" font="1">arrhythmia scores. 6% major adverse </text>
<text top="540" left="922" width="84" height="15" font="1">cardiac events.   </text>
<text top="618" left="54" width="154" height="15" font="1">CHD: Catheter Ablation – TGA </text>
<text top="634" left="54" width="52" height="15" font="1">Jones DG </text>
<text top="650" left="54" width="28" height="15" font="1">2013 </text>
<text top="665" left="54" width="29" height="15" font="1">(332) </text>
<text top="681" left="54" width="49" height="15" font="8">23219079</text>
<text top="681" left="103" width="3" height="15" font="1"> </text>
<text top="634" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="650" left="137" width="34" height="15" font="1">center </text>
<text top="634" left="264" width="9" height="15" font="1">9 </text>
<text top="634" left="378" width="146" height="15" font="1">AT ablations TGA Mustard; 9 </text>
<text top="650" left="378" width="159" height="15" font="1">procedures, 12 circuits between </text>
<text top="665" left="378" width="164" height="15" font="1">2007-2012, median age 38 y (18-</text>
<text top="681" left="378" width="153" height="15" font="1">56 y), used Carto and irrigated </text>
<text top="696" left="378" width="118" height="15" font="1">tips. Median f/u 15 mo.  </text>
<text top="634" left="561" width="120" height="15" font="1">Ablation outcomes TGA </text>
<text top="650" left="561" width="79" height="15" font="1">atrial switch pts </text>
<text top="634" left="696" width="193" height="15" font="1">Transbaffle puncture in all. AT mechs:  </text>
<text top="650" left="696" width="184" height="15" font="1">CTI dep: 75%, focal 25% (pulmonary </text>
<text top="665" left="696" width="192" height="15" font="1">venous ¾). Acute success 100%; 25% </text>
<text top="681" left="696" width="202" height="15" font="1">recurrence w/in 16 mo. Death 11% (1/9); </text>
<text top="696" left="696" width="111" height="15" font="1">recurrent AT w/ CHF.  </text>
<text top="712" left="696" width="66" height="15" font="1">ICD’s in 3/9.  </text>
<text top="634" left="922" width="182" height="15" font="1">Ablation in pulmonary venous atrium </text>
<text top="650" left="922" width="90" height="15" font="1">needed in all pts.  </text>
<text top="665" left="922" width="190" height="15" font="1">Acute success 100%, recurrence 25% </text>
<text top="681" left="922" width="60" height="15" font="1">short-term.  </text>
<text top="728" left="54" width="28" height="15" font="1">Wu J </text>
<text top="744" left="54" width="28" height="15" font="1">2013 </text>
<text top="759" left="54" width="29" height="15" font="1">(333) </text>
<text top="775" left="54" width="49" height="15" font="8">23355133</text>
<text top="775" left="103" width="3" height="15" font="1"> </text>
<text top="728" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="744" left="137" width="34" height="15" font="1">center </text>
<text top="728" left="264" width="15" height="15" font="1">26 </text>
<text top="728" left="378" width="159" height="15" font="1">Ablation in 26 TGA pts s/p atrial </text>
<text top="744" left="378" width="126" height="15" font="1">switch repairs, mean age </text>
<text top="759" left="378" width="116" height="15" font="1">28.7±6.7 y; 34 ablation </text>
<text top="775" left="378" width="65" height="15" font="1">procedures.  </text>
<text top="728" left="561" width="90" height="15" font="1">Assess outcomes </text>
<text top="744" left="561" width="106" height="15" font="1">ablation in TGA atrial </text>
<text top="759" left="561" width="52" height="15" font="1">switch pts </text>
<text top="728" left="696" width="192" height="15" font="1">34 AT: IART 88%; AVNRT 12%. Acute </text>
<text top="744" left="696" width="124" height="15" font="1">success 85% of circuits.  </text>
<text top="759" left="696" width="184" height="15" font="1">Mean f/u 34±24 mo, 30% recurrence </text>
<text top="775" left="696" width="35" height="15" font="1">IART.  </text>
<text top="728" left="922" width="190" height="15" font="1">TGA atrial switch: high acute success, </text>
<text top="744" left="922" width="105" height="15" font="1">34% recurrence &lt;3 y </text>
<text top="791" left="54" width="113" height="15" font="1">CHD: Surgical therapy </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">114 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="62" height="15" font="1">Pressley JC </text>
<text top="70" left="54" width="28" height="15" font="1">1992 </text>
<text top="86" left="54" width="29" height="15" font="1">(334) </text>
<text top="101" left="54" width="43" height="15" font="8">1394922</text>
<text top="101" left="97" width="3" height="15" font="1"> </text>
<text top="55" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="70" left="137" width="34" height="15" font="1">center </text>
<text top="55" left="264" width="15" height="15" font="1">38 </text>
<text top="55" left="378" width="129" height="15" font="1">38 pts, WPW and Ebstein </text>
<text top="70" left="378" width="164" height="15" font="1">anomly, surgical AP ablation and </text>
<text top="86" left="378" width="155" height="15" font="1">repair. Mean age 26.3 ±12.3 y, </text>
<text top="101" left="378" width="153" height="15" font="1">1968-88. Compared to 384 pts </text>
<text top="117" left="378" width="137" height="15" font="1">undergoing AP surgery w/o </text>
<text top="132" left="378" width="46" height="15" font="1">Ebstein.  </text>
<text top="147" left="378" width="150" height="15" font="1">76% documented AVRT; 42% </text>
<text top="163" left="378" width="95" height="15" font="1">AF. F/u 6.2± 3.8 y. </text>
<text top="55" left="561" width="115" height="15" font="1">Assess surgical impact </text>
<text top="70" left="561" width="94" height="15" font="1">AP ablation during </text>
<text top="86" left="561" width="74" height="15" font="1">Ebstein repair. </text>
<text top="55" left="696" width="153" height="15" font="1">Mult AP 50%, right sided 79%, </text>
<text top="70" left="696" width="150" height="15" font="1">posteroseptal 58%, left 7.9%.  </text>
<text top="86" left="696" width="194" height="15" font="1">Surgery mortality 5.3%, both &lt;15 y old. </text>
<text top="101" left="696" width="178" height="15" font="1">28/38 surgery repair + AP ablation;  </text>
<text top="117" left="696" width="191" height="15" font="1">Successful AP ablation: 95%. 82% NS </text>
<text top="132" left="696" width="116" height="15" font="1">arrhythmias during f/u.  </text>
<text top="55" left="922" width="192" height="15" font="1">Pts w/ Ebstein anomaly improved after </text>
<text top="70" left="922" width="120" height="15" font="1">surgery w/ AP ablation.  </text>
<text top="86" left="922" width="210" height="15" font="1">Late AF reduced from 42% to 9%, p&lt;.001. </text>
<text top="179" left="54" width="44" height="15" font="1">Misaki T </text>
<text top="195" left="54" width="28" height="15" font="1">1995 </text>
<text top="210" left="54" width="29" height="15" font="1">(335) </text>
<text top="226" left="54" width="43" height="15" font="8">8523883</text>
<text top="226" left="97" width="3" height="15" font="1"> </text>
<text top="179" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="195" left="137" width="34" height="15" font="1">center </text>
<text top="179" left="264" width="15" height="15" font="1">42 </text>
<text top="179" left="378" width="157" height="15" font="1">42 pts WPW = Ebstein, surgery </text>
<text top="195" left="378" width="158" height="15" font="1">1973-1993. Mean age 35±14 y. </text>
<text top="210" left="378" width="167" height="15" font="1">52 APs, 48 right or posteroseptal. </text>
<text top="226" left="378" width="160" height="15" font="1">Division of AP at surgery; 35 TV </text>
<text top="241" left="378" width="55" height="15" font="1">operation.  </text>
<text top="179" left="561" width="116" height="15" font="1">Assess outcome WPW </text>
<text top="195" left="561" width="92" height="15" font="1">surgery in Ebstein </text>
<text top="179" left="696" width="167" height="15" font="1">All 52 AP successfully rx at surg.  </text>
<text top="195" left="696" width="176" height="15" font="1">2 reops due to SVT: additional AP.  </text>
<text top="210" left="696" width="207" height="15" font="1">Hospital mortality 7.1%. no late deaths f/u </text>
<text top="226" left="696" width="65" height="15" font="1">mean 94 mo </text>
<text top="179" left="922" width="22" height="15" font="1">N/A </text>
<text top="257" left="54" width="69" height="15" font="1">Theodoro DA </text>
<text top="273" left="54" width="28" height="15" font="1">1998 </text>
<text top="288" left="54" width="29" height="15" font="1">(336) </text>
<text top="304" left="54" width="43" height="15" font="8">9456109</text>
<text top="304" left="97" width="3" height="15" font="1"> </text>
<text top="257" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="273" left="137" width="34" height="15" font="1">center </text>
<text top="257" left="264" width="15" height="15" font="1">18 </text>
<text top="257" left="378" width="153" height="15" font="1">18 ACHD pts mean age 34.9 y </text>
<text top="273" left="378" width="163" height="15" font="1">underwent RA Maze for AT/atrial </text>
<text top="288" left="378" width="64" height="15" font="1">flutter or AF: </text>
<text top="304" left="378" width="167" height="15" font="1">Ebstein 15, tricuspid regurgitation </text>
<text top="319" left="378" width="127" height="15" font="1">2, ASD1. Mean f/u 8 mo.  </text>
<text top="257" left="561" width="103" height="15" font="1">Assess outcome RA </text>
<text top="273" left="561" width="76" height="15" font="1">maze in ACHD </text>
<text top="257" left="696" width="188" height="15" font="1">No early deaths. Early postop SVT 3.  </text>
<text top="273" left="696" width="199" height="15" font="1">RA maze performed, even in pts w/ AF.  </text>
<text top="257" left="922" width="186" height="15" font="1">Inclusion RA maze in ACHD pt w/ RA </text>
<text top="273" left="922" width="209" height="15" font="1">dilatation and AT is effective in eliminating </text>
<text top="288" left="922" width="82" height="15" font="1">or reducing AT.  </text>
<text top="336" left="54" width="52" height="15" font="1">Huang CJ </text>
<text top="351" left="54" width="31" height="15" font="1">2000  </text>
<text top="367" left="54" width="29" height="15" font="1">(337) </text>
<text top="382" left="54" width="49" height="15" font="8">11145402</text>
<text top="382" left="103" width="3" height="15" font="1"> </text>
<text top="336" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="351" left="137" width="34" height="15" font="1">center </text>
<text top="336" left="264" width="15" height="15" font="1">30 </text>
<text top="336" left="378" width="143" height="15" font="1">30 pts w/ Ebstein:surg repair </text>
<text top="351" left="378" width="139" height="15" font="1">1973-1997. Preop EP study </text>
<text top="367" left="378" width="161" height="15" font="1">performed in 11 after 1980: surg </text>
<text top="382" left="378" width="141" height="15" font="1">ablation performed in 10/11: </text>
<text top="398" left="378" width="124" height="15" font="1">WPW 4, AVNRT 2, atrial </text>
<text top="413" left="378" width="90" height="15" font="1">flutter/AF 3, VT1.  </text>
<text top="336" left="561" width="79" height="15" font="1">Assess survival </text>
<text top="351" left="561" width="81" height="15" font="1">difference w/ op </text>
<text top="367" left="561" width="88" height="15" font="1">ablation Ebstein.  </text>
<text top="336" left="696" width="118" height="15" font="1">No mort in ablated pts.  </text>
<text top="351" left="696" width="193" height="15" font="1">7/30 died: 1-infection, 6 died suddenly. </text>
<text top="367" left="696" width="213" height="15" font="1">None of 6 sudden deaths underwent preop </text>
<text top="382" left="696" width="54" height="15" font="1">EP study.  </text>
<text top="336" left="922" width="177" height="15" font="1">Detailed preop EP study in Ebstein: </text>
<text top="351" left="922" width="66" height="15" font="1">“mandatory”: </text>
<text top="367" left="922" width="214" height="15" font="1">Aggressive surg intervention for arrhythmia </text>
<text top="382" left="922" width="170" height="15" font="1">may reduce risk of sudden death.  </text>
<text top="429" left="54" width="65" height="15" font="1">Mavroudis C </text>
<text top="445" left="54" width="28" height="15" font="1">2001 </text>
<text top="460" left="54" width="32" height="15" font="1">(338)  </text>
<text top="476" left="54" width="49" height="15" font="8">11689789</text>
<text top="476" left="103" width="3" height="15" font="1"> </text>
<text top="429" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="445" left="137" width="34" height="15" font="1">center </text>
<text top="429" left="264" width="15" height="15" font="1">40 </text>
<text top="429" left="378" width="129" height="15" font="1">40 Fontan conversions w/ </text>
<text top="445" left="378" width="151" height="15" font="1">arrhythmia surgery; mean age </text>
<text top="460" left="378" width="165" height="15" font="1">18.7±9 y. All pts w/ AT; AF in 15. </text>
<text top="429" left="561" width="87" height="15" font="1">Assess impact of </text>
<text top="445" left="561" width="111" height="15" font="1">arrhythmia surgery on </text>
<text top="460" left="561" width="66" height="15" font="1">AT in Fontan </text>
<text top="429" left="696" width="187" height="15" font="1">Isthmus ablation 10 pts, RA Maze 16, </text>
<text top="445" left="696" width="197" height="15" font="1">Biatrial maze 14. No mortality. Mean f/u </text>
<text top="460" left="696" width="167" height="15" font="1">2.5±1.9 y, OHT 7.5%. Arrhythmia </text>
<text top="476" left="696" width="94" height="15" font="1">recurrence 12.5%  </text>
<text top="429" left="922" width="210" height="15" font="1">Largely AP Fontan population;  arrhythmia </text>
<text top="445" left="922" width="130" height="15" font="1">recurrence 12.5% at 2.5 y </text>
<text top="492" left="54" width="42" height="15" font="1">Deal BJ </text>
<text top="507" left="54" width="28" height="15" font="1">2002 </text>
<text top="523" left="54" width="32" height="15" font="1">(220)  </text>
<text top="539" left="54" width="49" height="15" font="8">12147539</text>
<text top="539" left="103" width="3" height="15" font="24"> </text>
<text top="554" left="54" width="3" height="15" font="1"> </text>
<text top="492" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="507" left="137" width="34" height="15" font="1">center </text>
<text top="492" left="264" width="15" height="15" font="1">23 </text>
<text top="492" left="378" width="162" height="15" font="1">Comparison isthmus ablation (8) </text>
<text top="507" left="378" width="156" height="15" font="1">w/ RA maze (15)  in AP Fontan </text>
<text top="523" left="378" width="163" height="15" font="1">pts w/ AT; median  age 10.9 y (2-</text>
<text top="539" left="378" width="28" height="15" font="1">33 y) </text>
<text top="492" left="561" width="92" height="15" font="1">Assess efficacy of </text>
<text top="507" left="561" width="90" height="15" font="1">operative ablation </text>
<text top="523" left="561" width="100" height="15" font="1">techniques Fontan.  </text>
<text top="492" left="696" width="195" height="15" font="1">Isthmus ablation: 62% recurrent AT; f/u </text>
<text top="507" left="696" width="27" height="15" font="1">5.6 y </text>
<text top="523" left="696" width="169" height="15" font="1">RA maze: no recurrence, f/u 2.8 y </text>
<text top="492" left="922" width="199" height="15" font="1">RA maze superior to isthmus ablation in </text>
<text top="507" left="922" width="55" height="15" font="1">Fontan pts </text>
<text top="570" left="54" width="65" height="15" font="1">Khositseth A </text>
<text top="586" left="54" width="28" height="15" font="1">2004 </text>
<text top="601" left="54" width="29" height="15" font="1">(339) </text>
<text top="617" left="54" width="49" height="15" font="8">15573066</text>
<text top="617" left="103" width="3" height="15" font="1"> </text>
<text top="570" left="137" width="103" height="15" font="1">Retrospective single </text>
<text top="586" left="137" width="34" height="15" font="1">center </text>
<text top="570" left="264" width="15" height="15" font="1">83 </text>
<text top="570" left="378" width="157" height="15" font="1">83129 adult Ebstein pts w/ SVT </text>
<text top="586" left="378" width="150" height="15" font="1">underwent arrhy procedure w/ </text>
<text top="601" left="378" width="169" height="15" font="1">surgery for Ebstein. 41: AP, mean </text>
<text top="617" left="378" width="162" height="15" font="1">age 18 y; 7 AVNRT, mean 18 y ; </text>
<text top="632" left="378" width="161" height="15" font="1">48 atrial flutter/AF (RA maze 38, </text>
<text top="648" left="378" width="124" height="15" font="1">isthmus 10), mean 33 y.  </text>
<text top="570" left="561" width="94" height="15" font="1">Assess arrhythmia </text>
<text top="586" left="561" width="92" height="15" font="1">surgery in Ebstein </text>
<text top="570" left="696" width="199" height="15" font="1">Incidence SVT: atrial flutter/AF 54%, AP </text>
<text top="586" left="696" width="191" height="15" font="1">32%, AVNRT 8%. Surgical outcomes:  </text>
<text top="601" left="696" width="180" height="15" font="1">AP or AVNRT: 0 recurrence 48 mo;  </text>
<text top="617" left="696" width="170" height="15" font="1">Atrial flutter/AF 75% freedom from </text>
<text top="632" left="696" width="108" height="15" font="1">recurrence at 34 mo.  </text>
<text top="648" left="696" width="3" height="15" font="1"> </text>
<text top="570" left="922" width="205" height="15" font="1">Arrhy surg interventions should be added </text>
<text top="586" left="922" width="196" height="15" font="1">to surgical repair Ebstein in pts w/ SVT: </text>
<text top="601" left="922" width="191" height="15" font="1">AP, AVNRT, or atrial flutter/AF. AS AT </text>
<text top="617" left="922" width="188" height="15" font="1">present in 54% and increases w/ age, </text>
<text top="632" left="922" width="188" height="15" font="1">recommend AT surgery as well as AP </text>
<text top="648" left="922" width="43" height="15" font="1">surgery. </text>
<text top="664" left="54" width="55" height="15" font="1">Bockeria L </text>
<text top="679" left="54" width="31" height="15" font="1">2005  </text>
<text top="695" left="54" width="29" height="15" font="1">(340) </text>
<text top="710" left="54" width="49" height="15" font="8">16179193</text>
<text top="710" left="103" width="3" height="15" font="1"> </text>
<text top="664" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="679" left="137" width="34" height="15" font="1">center </text>
<text top="664" left="264" width="15" height="15" font="1">53 </text>
<text top="664" left="378" width="166" height="15" font="1">53 pts, Ebstein + SVT, mean age </text>
<text top="679" left="378" width="165" height="15" font="1">21.6±10.7 y. Surgery + operative </text>
<text top="695" left="378" width="169" height="15" font="1">ablation: 32 pts; preop RFablation </text>
<text top="710" left="378" width="86" height="15" font="1">later surg: 21 pt.  </text>
<text top="726" left="378" width="145" height="15" font="1">WPW 26, AVNRT 3, focal 3.  </text>
<text top="664" left="561" width="90" height="15" font="1">Assess combined </text>
<text top="679" left="561" width="107" height="15" font="1">arrhythmia surgery in </text>
<text top="695" left="561" width="92" height="15" font="1">Ebstein vs. RFA + </text>
<text top="710" left="561" width="43" height="15" font="1">surgery. </text>
<text top="664" left="696" width="178" height="15" font="1">Mortality 3.1% in combined ablation </text>
<text top="679" left="696" width="194" height="15" font="1">operation vs. 0% in 2 staged. Efficacy:  </text>
<text top="695" left="696" width="213" height="15" font="1">Surgery ablation 94% op vs. 76% catheter. </text>
<text top="710" left="696" width="183" height="15" font="1">Surgery efficacy WPW 92%, AVNRT </text>
<text top="726" left="696" width="92" height="15" font="1">100%, focal 66%.  </text>
<text top="664" left="922" width="210" height="15" font="1">Combined operative ablation + surg repair </text>
<text top="679" left="922" width="180" height="15" font="1">showed improved AT elimination vs. </text>
<text top="695" left="922" width="193" height="15" font="1">catheter ablation approach followed by </text>
<text top="710" left="922" width="46" height="15" font="1">surgery.  </text>
<text top="742" left="54" width="62" height="15" font="1">Giamberti A </text>
<text top="758" left="54" width="28" height="15" font="1">2006 </text>
<text top="773" left="54" width="29" height="15" font="1">(341) </text>
<text top="789" left="54" width="49" height="15" font="8">16996928</text>
<text top="789" left="103" width="3" height="15" font="1"> </text>
<text top="742" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="758" left="137" width="34" height="15" font="1">center </text>
<text top="742" left="264" width="15" height="15" font="1">15 </text>
<text top="742" left="378" width="137" height="15" font="1">15 ASD pts, &gt;40 y, surgical </text>
<text top="758" left="378" width="133" height="15" font="1">closure ASD w/ intraop RF </text>
<text top="773" left="378" width="127" height="15" font="1">ablation. All SVT: 8 AF, 7 </text>
<text top="789" left="378" width="156" height="15" font="1">AT/atrial flutter. 2002-2004. RA </text>
<text top="742" left="561" width="113" height="15" font="1">Assess op ablation AT </text>
<text top="758" left="561" width="55" height="15" font="1">in ASD pts </text>
<text top="742" left="696" width="151" height="15" font="1">No mortality, one pacemaker.  </text>
<text top="758" left="696" width="202" height="15" font="1">AF recurrentce 6.5%, no AT recurrence.  </text>
<text top="742" left="922" width="194" height="15" font="1">Rec add intraop RF ablation to surgical </text>
<text top="758" left="922" width="153" height="15" font="1">ASD closure, safe &amp; effective.  </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">115 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="378" width="169" height="15" font="1">Maze 8, biatrial cox maze iii 7 pts. </text>
<text top="70" left="378" width="90" height="15" font="1">F/u mean 24 mo.  </text>
<text top="86" left="54" width="60" height="15" font="1">Karamlou T </text>
<text top="102" left="54" width="28" height="15" font="1">2006 </text>
<text top="117" left="54" width="29" height="15" font="1">(342) </text>
<text top="133" left="54" width="49" height="15" font="8">16631673</text>
<text top="133" left="103" width="3" height="15" font="1"> </text>
<text top="86" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="102" left="137" width="34" height="15" font="1">center </text>
<text top="86" left="264" width="22" height="15" font="1">249 </text>
<text top="86" left="378" width="150" height="15" font="1">1969-2005, TOF or DORV pts </text>
<text top="102" left="378" width="167" height="15" font="1">undergoing reop for PVR or TVR; </text>
<text top="117" left="378" width="153" height="15" font="1">AT in 41 pts. Median age 23 y. </text>
<text top="133" left="378" width="165" height="15" font="1">Assess RA maze vs. no maze on </text>
<text top="148" left="378" width="73" height="15" font="1">late outcome.  </text>
<text top="86" left="561" width="105" height="15" font="1">Assess impact of RA </text>
<text top="102" left="561" width="113" height="15" font="1">ablation on arrhythmia </text>
<text top="117" left="561" width="79" height="15" font="1">outcomes TOF. </text>
<text top="86" left="696" width="184" height="15" font="1">Atrial flutter: isthmus ablation; AF RA </text>
<text top="102" left="696" width="36" height="15" font="1">maze.  </text>
<text top="117" left="696" width="204" height="15" font="1">AT recurrence: ablation pts, 9%, vs. 78% </text>
<text top="133" left="696" width="183" height="15" font="1">AT occurence in non-ablation; 7.5 y.  </text>
<text top="148" left="696" width="170" height="15" font="1">AT pts older, longer QRS duration </text>
<text top="86" left="922" width="210" height="15" font="1">RA Maze at time of surgery improved long </text>
<text top="102" left="922" width="103" height="15" font="1">term AT free status.  </text>
<text top="117" left="922" width="209" height="15" font="1">QRS duration &gt;160 msec predicted risk of </text>
<text top="133" left="922" width="54" height="15" font="1">AT in TOF </text>
<text top="164" left="54" width="52" height="15" font="1">Stulak JM </text>
<text top="180" left="54" width="28" height="15" font="1">2006 </text>
<text top="195" left="54" width="29" height="15" font="1">(343) </text>
<text top="211" left="54" width="49" height="15" font="8">16631672</text>
<text top="211" left="103" width="3" height="15" font="1"> </text>
<text top="164" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="180" left="137" width="34" height="15" font="1">center </text>
<text top="164" left="264" width="15" height="15" font="1">99 </text>
<text top="164" left="378" width="155" height="15" font="1">1993-2003, 99 pts RA maze w/ </text>
<text top="180" left="378" width="157" height="15" font="1">ACHD repair. Median age 43 y. </text>
<text top="195" left="378" width="156" height="15" font="17"><i>Did not distinguish between AT </i></text>
<text top="211" left="378" width="145" height="15" font="17"><i>and AF.</i>  Ebsteins 47, TR 19, </text>
<text top="226" left="378" width="164" height="15" font="1">UVH 11, ASD 8, TOF 8, other 6.  </text>
<text top="164" left="561" width="92" height="15" font="1">Impact arrhythmia </text>
<text top="180" left="561" width="116" height="15" font="1">surgery on AT: ACHD.  </text>
<text top="164" left="696" width="164" height="15" font="1">6% early mortality. 28% early AT </text>
<text top="180" left="696" width="198" height="15" font="1">Arrhythmia recurrence 7%, f/u 2.7 y; AA </text>
<text top="195" left="696" width="90" height="15" font="1">medications 55%. </text>
<text top="164" left="922" width="129" height="15" font="1">ACHD: 55% on AA meds; </text>
<text top="180" left="922" width="118" height="15" font="1"> 93% not  in AT at 2.7 y </text>
<text top="243" left="54" width="65" height="15" font="1">Mavroudis C </text>
<text top="258" left="54" width="28" height="15" font="1">2007 </text>
<text top="274" left="54" width="29" height="15" font="1">(344) </text>
<text top="289" left="54" width="49" height="15" font="8">17954046</text>
<text top="289" left="103" width="3" height="15" font="1"> </text>
<text top="243" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="258" left="137" width="34" height="15" font="1">center </text>
<text top="243" left="264" width="22" height="15" font="1">111 </text>
<text top="243" left="378" width="118" height="15" font="1">1994-2007, 111 Fontan </text>
<text top="258" left="378" width="132" height="15" font="1">conversions w/ arrhythmia </text>
<text top="274" left="378" width="167" height="15" font="1">surgery; mean age 22.5 y. Mainly </text>
<text top="289" left="378" width="62" height="15" font="1">AP Fontan.  </text>
<text top="243" left="561" width="94" height="15" font="1">Assess arrhythmia </text>
<text top="258" left="561" width="100" height="15" font="1">recurrence, survival </text>
<text top="274" left="561" width="38" height="15" font="1">Fontan </text>
<text top="243" left="696" width="211" height="15" font="1">Early mortality 0.9%, late death/OHT 11%. </text>
<text top="258" left="696" width="122" height="15" font="1">Late AT 13.5%, f/u 7.9 y </text>
<text top="243" left="922" width="171" height="15" font="1">Late AT in Fontan  13.5% at ~ 8 y; </text>
<text top="305" left="54" width="62" height="15" font="1">Giamberti A </text>
<text top="321" left="54" width="28" height="15" font="1">2008 </text>
<text top="336" left="54" width="29" height="15" font="1">(345) </text>
<text top="352" left="54" width="49" height="15" font="8">17689722</text>
<text top="352" left="103" width="3" height="15" font="1"> </text>
<text top="305" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="321" left="137" width="34" height="15" font="1">center </text>
<text top="305" left="264" width="15" height="15" font="1">50 </text>
<text top="305" left="378" width="141" height="15" font="1">50 ACHD adults undergoing </text>
<text top="321" left="378" width="159" height="15" font="1">surgery; mean age 39 y.  31 RA </text>
<text top="336" left="378" width="36" height="15" font="1">Maze,  </text>
<text top="352" left="378" width="131" height="15" font="1">13 biatrial, 6 VT ablations. </text>
<text top="305" left="561" width="80" height="15" font="1">Assess surgical </text>
<text top="321" left="561" width="101" height="15" font="1">arrhythmia outcome </text>
<text top="336" left="561" width="38" height="15" font="1">ACHD. </text>
<text top="305" left="696" width="190" height="15" font="1">Mortality 4%; Mean f/u 28 mo: 4/48 on </text>
<text top="321" left="696" width="206" height="15" font="1">medications; 43 sinus rhythm, 4 recurrent </text>
<text top="336" left="696" width="17" height="15" font="1">AF </text>
<text top="305" left="922" width="209" height="15" font="1">ACHD: 86% sinus rhythm, no medications </text>
<text top="321" left="922" width="102" height="15" font="1">during short term f/u </text>
<text top="368" left="54" width="68" height="15" font="1">Mavroudis C  </text>
<text top="384" left="54" width="28" height="15" font="1">2008 </text>
<text top="399" left="54" width="29" height="15" font="1">(346) </text>
<text top="415" left="54" width="49" height="15" font="8">18721574</text>
<text top="415" left="103" width="3" height="15" font="1"> </text>
<text top="368" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="384" left="137" width="34" height="15" font="1">center </text>
<text top="368" left="264" width="22" height="15" font="1">100 </text>
<text top="368" left="378" width="167" height="15" font="1">Arrhythmia operations, 11 no HD; </text>
<text top="384" left="378" width="151" height="15" font="1">89 associated CHD (33 UVH); </text>
<text top="399" left="378" width="164" height="15" font="1">mean age 15.9 y. SVT 87, VT 13 </text>
<text top="368" left="561" width="80" height="15" font="1">Assess surgical </text>
<text top="384" left="561" width="101" height="15" font="1">arrhythmia outcome </text>
<text top="399" left="561" width="34" height="15" font="1">ACHD </text>
<text top="368" left="696" width="213" height="15" font="1">Mechs AT: ART 45, AF 11, AC 19, AVNRT </text>
<text top="384" left="696" width="170" height="15" font="1">6, Focal 6; early mortality 3%, late </text>
<text top="399" left="696" width="193" height="15" font="1">death/OHT 6%; 10 y Freedom from AT </text>
<text top="415" left="696" width="71" height="15" font="1">85%, 68% VT </text>
<text top="368" left="922" width="199" height="15" font="1">Freedom from AT at 10 y: 85% in mixed </text>
<text top="384" left="922" width="89" height="15" font="1">population ACHD </text>
<text top="431" left="54" width="64" height="15" font="1">Aboulhosn J </text>
<text top="446" left="54" width="28" height="15" font="1">2010 </text>
<text top="462" left="54" width="29" height="15" font="1">(347) </text>
<text top="477" left="54" width="49" height="15" font="8">21087427</text>
<text top="477" left="103" width="3" height="15" font="1"> </text>
<text top="431" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="446" left="137" width="34" height="15" font="1">center </text>
<text top="431" left="264" width="15" height="15" font="1">27 </text>
<text top="431" left="378" width="134" height="15" font="1">27 atriopulm Fontan adults </text>
<text top="446" left="378" width="125" height="15" font="1">converted to TCPC; 67% </text>
<text top="462" left="378" width="163" height="15" font="1">extracardiac.  89% w/ atrial tach. </text>
<text top="477" left="378" width="165" height="15" font="1">21/27 w/ arrhythmia surg: RA 12, </text>
<text top="493" left="378" width="60" height="15" font="1">RA + LA 9.  </text>
<text top="508" left="378" width="124" height="15" font="1">Mean age 30 y (18-52 y) </text>
<text top="524" left="378" width="79" height="15" font="1">Mean f/u 4.2 y.  </text>
<text top="431" left="561" width="94" height="15" font="1">Assess arrhythmia </text>
<text top="446" left="561" width="119" height="15" font="1">recurrence after Fontan </text>
<text top="462" left="561" width="101" height="15" font="1">arrhythmia surgery.  </text>
<text top="431" left="696" width="130" height="15" font="1">Operative mortality 7.4%.  </text>
<text top="446" left="696" width="170" height="15" font="1">Arrhythmia recurrence 14% (3/21) </text>
<text top="462" left="696" width="3" height="15" font="1"> </text>
<text top="477" left="696" width="3" height="15" font="1"> </text>
<text top="493" left="696" width="200" height="15" font="1">PLE 3; 1 died 27 mo postop, 2 resolved. </text>
<text top="508" left="696" width="3" height="15" font="1"> </text>
<text top="431" left="922" width="157" height="15" font="1">Recurrrent AT in 14% w/ 4 y f/u </text>
<text top="540" left="54" width="67" height="15" font="1">Gutierrez SD </text>
<text top="555" left="54" width="28" height="15" font="1">2013 </text>
<text top="571" left="54" width="29" height="15" font="1">(348) </text>
<text top="587" left="54" width="49" height="15" font="8">23280242</text>
<text top="587" left="103" width="3" height="15" font="1"> </text>
<text top="540" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="555" left="137" width="34" height="15" font="1">center </text>
<text top="540" left="264" width="15" height="15" font="1">24 </text>
<text top="540" left="378" width="158" height="15" font="1">24 ACHD pts w/ AA undergoing </text>
<text top="555" left="378" width="132" height="15" font="1">surgery, mean age 40.9 y; </text>
<text top="571" left="378" width="115" height="15" font="1">incorporated cox maze </text>
<text top="587" left="378" width="156" height="15" font="1">procedure.  2004-2010. TOF 8, </text>
<text top="602" left="378" width="146" height="15" font="1">AVSD 4; RVOT repair 10, TV </text>
<text top="617" left="378" width="165" height="15" font="1">repair 8, ASD 7.  Mean F/u 2.8 y, </text>
<text top="633" left="378" width="54" height="15" font="1">(.1-5.7 y).  </text>
<text top="540" left="561" width="117" height="15" font="1">Assess outcome of cox </text>
<text top="555" left="561" width="95" height="15" font="1">maze procedure in </text>
<text top="571" left="561" width="34" height="15" font="1">ACHD </text>
<text top="540" left="696" width="104" height="15" font="1">Preop AT: 19, AF 5.  </text>
<text top="555" left="696" width="188" height="15" font="1">Mortality: 16.5%, (12.5% early, 1 late) </text>
<text top="571" left="696" width="172" height="15" font="1">74% of survivors arrhythmia free.   </text>
<text top="540" left="922" width="215" height="15" font="1">Pts w/ CHD and atrial arrhythmias, majority </text>
<text top="555" left="922" width="159" height="15" font="1">free of arrhythmias w Cox Maze </text>
<text top="571" left="922" width="59" height="15" font="1">procedure.  </text>
<text top="649" left="54" width="52" height="15" font="1">Terrada T </text>
<text top="665" left="54" width="28" height="15" font="1">2013 </text>
<text top="680" left="54" width="29" height="15" font="1">(349) </text>
<text top="696" left="54" width="49" height="15" font="8">24887891</text>
<text top="696" left="103" width="3" height="15" font="1"> </text>
<text top="649" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="665" left="137" width="34" height="15" font="1">center </text>
<text top="649" left="264" width="229" height="15" font="1">25 25 </text>
<text top="649" left="393" width="138" height="15" font="1">consecutive pts undergoing </text>
<text top="665" left="378" width="147" height="15" font="1">Fontan conversion 1/04-3/12. </text>
<text top="680" left="378" width="101" height="15" font="1">Mean age 21 6.3 y.  </text>
<text top="696" left="378" width="169" height="15" font="1">24/25 underwent arrhyth surg: RA </text>
<text top="711" left="378" width="153" height="15" font="1">maze 15, isthmus 3, biatrial 6.  </text>
<text top="727" left="378" width="134" height="15" font="1">Mean f/u 21 mo(11-86 mo) </text>
<text top="649" left="561" width="84" height="15" font="1">Assess outcome </text>
<text top="665" left="561" width="93" height="15" font="1">Fontan arrhythmia </text>
<text top="680" left="561" width="43" height="15" font="1">surgery. </text>
<text top="649" left="696" width="132" height="15" font="1">Late AT recurrence 12.5% </text>
<text top="665" left="696" width="114" height="15" font="1">Operative mortality: 0.  </text>
<text top="680" left="696" width="161" height="15" font="1">16/25 no pacemaker implanted.  </text>
<text top="696" left="696" width="174" height="15" font="1">5 pts reoperation to implant pacer.  </text>
<text top="649" left="922" width="113" height="15" font="1">Recurrent AT 12. 5%,  </text>
<text top="743" left="54" width="45" height="15" font="1">Said SM </text>
<text top="758" left="54" width="28" height="15" font="1">2014 </text>
<text top="774" left="54" width="29" height="15" font="1">(350) </text>
<text top="789" left="54" width="49" height="15" font="8">24786860</text>
<text top="789" left="103" width="3" height="15" font="24"> </text>
<text top="743" left="137" width="106" height="15" font="1">Retrospective, single </text>
<text top="758" left="137" width="34" height="15" font="1">center </text>
<text top="743" left="264" width="15" height="15" font="1">70 </text>
<text top="743" left="378" width="163" height="15" font="1">70 Fontan pts underwent Fontan </text>
<text top="758" left="378" width="119" height="15" font="1">conversion 1994-2011.  </text>
<text top="774" left="378" width="126" height="15" font="1">Median age 23 y (4-46 y) </text>
<text top="789" left="378" width="82" height="15" font="1">AT present 89% </text>
<text top="743" left="561" width="84" height="15" font="1">Assess outcome </text>
<text top="758" left="561" width="93" height="15" font="1">Fontan arrhythmia </text>
<text top="774" left="561" width="43" height="15" font="1">surgery. </text>
<text top="743" left="696" width="175" height="15" font="1">Late Recurrent AT in 16% of pts w/ </text>
<text top="758" left="696" width="95" height="15" font="1">arrhythmia surgery </text>
<text top="774" left="696" width="127" height="15" font="1">Operative mortality 14%.  </text>
<text top="789" left="696" width="90" height="15" font="1">10 y survival 67% </text>
<text top="743" left="922" width="130" height="15" font="1">Late Recurrent AT in 16% </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">116 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="378" width="114" height="15" font="1">TCPC intra-atrial 59%; </text>
<text top="70" left="378" width="162" height="15" font="1">extracardiac 26%, Lateral tunnel </text>
<text top="86" left="378" width="32" height="15" font="1">16%.  </text>
<text top="101" left="378" width="132" height="15" font="1">49/70 arrhythmia surgery.  </text>
<text top="117" left="378" width="70" height="15" font="1">Mean f/u 5 y.  </text>
<text top="55" left="696" width="124" height="15" font="1">Periop death predictors:  </text>
<text top="70" left="696" width="206" height="15" font="1">Age &gt;27 y, AV valve regurgitation, males. </text>
<text top="86" left="696" width="127" height="15" font="1">PLE improved in 1/7 pts.  </text>
<text top="133" left="54" width="333" height="15" font="1">Pregnancy: Acute Conversion of AV Node-Dependent Tachycardia  </text>
<text top="149" left="54" width="47" height="15" font="1">Ghosh N </text>
<text top="164" left="54" width="28" height="15" font="1">2011 </text>
<text top="180" left="54" width="29" height="15" font="1">(351) </text>
<text top="195" left="54" width="52" height="15" font="8">21272431 </text>
<text top="211" left="54" width="3" height="15" font="1"> </text>
<text top="149" left="137" width="103" height="15" font="1">Review of all reports </text>
<text top="164" left="137" width="106" height="15" font="1">published 1950-2010 </text>
<text top="180" left="137" width="103" height="15" font="1">on acute termination </text>
<text top="195" left="137" width="37" height="15" font="1">of SVT </text>
<text top="149" left="264" width="39" height="15" font="1">138 pts </text>
<text top="149" left="378" width="156" height="15" font="1">Variety of drugs. Most common </text>
<text top="164" left="378" width="143" height="15" font="1">adenosine w/ 58 cases. Also </text>
<text top="180" left="378" width="132" height="15" font="1">electrical DCCV  18 cases </text>
<text top="149" left="561" width="114" height="15" font="1">Successful termination </text>
<text top="165" left="561" width="37" height="15" font="1">of SVT </text>
<text top="149" left="696" width="172" height="15" font="1">Adenosine was most successful at </text>
<text top="164" left="696" width="89" height="15" font="1">terminating SVT.  </text>
<text top="180" left="696" width="202" height="15" font="1">Beta blockers and verapamil second, led </text>
<text top="195" left="696" width="211" height="15" font="1">to more hypotension. Antiarrhythmic drugs </text>
<text top="211" left="696" width="90" height="15" font="1">not very effective. </text>
<text top="149" left="922" width="198" height="15" font="1">Variety of interventions was reported on </text>
<text top="164" left="922" width="201" height="15" font="1">acute termination of SVT. Most common </text>
<text top="180" left="922" width="190" height="15" font="1">adenosine w/ 58 cases. Also electrical </text>
<text top="195" left="922" width="205" height="15" font="1">DCCV 18 cases, verapamil 16 cases and </text>
<text top="211" left="922" width="177" height="15" font="1">beta blockers 13 cases. Diversity of </text>
<text top="226" left="922" width="215" height="15" font="1">antiarrhythmic drugs as well. Most effective </text>
<text top="242" left="922" width="206" height="15" font="1">was adenosine w/ 84% success, followed </text>
<text top="257" left="922" width="159" height="15" font="1">by beta blockers and verapamil. </text>
<text top="273" left="922" width="98" height="15" font="1">Cardioversion safe. </text>
<text top="289" left="54" width="148" height="15" font="1">Pregnancy: Catheter Ablation </text>
<text top="305" left="54" width="60" height="15" font="1">Damilakis J </text>
<text top="321" left="54" width="28" height="15" font="1">2001 </text>
<text top="336" left="54" width="29" height="15" font="1">(352) </text>
<text top="352" left="54" width="49" height="15" font="8">11514375</text>
<text top="352" left="103" width="3" height="15" font="1"> </text>
<text top="305" left="137" width="101" height="15" font="1">Conceptus radiation </text>
<text top="321" left="137" width="69" height="15" font="1">dose and risk </text>
<text top="336" left="137" width="86" height="15" font="1">determination for </text>
<text top="352" left="137" width="85" height="15" font="1">catheter ablation </text>
<text top="367" left="137" width="62" height="15" font="1">procedures. </text>
<text top="305" left="264" width="15" height="15" font="1">20 </text>
<text top="305" left="378" width="156" height="15" font="1">20 women of childbearing ages </text>
<text top="321" left="378" width="120" height="15" font="1">who underwent ablation </text>
<text top="336" left="378" width="58" height="15" font="1">procedures </text>
<text top="305" left="561" width="113" height="15" font="1">Estimation of radiation </text>
<text top="321" left="561" width="103" height="15" font="1">dose using phantom </text>
<text top="336" left="561" width="55" height="15" font="1">pregnancy </text>
<text top="305" left="696" width="196" height="15" font="1">Typical dose to conceptus was &lt;1 mGy </text>
<text top="305" left="922" width="211" height="15" font="1">A typical ablation procedure results in very </text>
<text top="321" left="922" width="206" height="15" font="1">small increase in risk of harmful effects to </text>
<text top="336" left="922" width="75" height="15" font="1">the conceptus. </text>
<text top="384" left="54" width="58" height="15" font="1">Berruezo A </text>
<text top="399" left="54" width="31" height="15" font="1">2007  </text>
<text top="415" left="54" width="29" height="15" font="1">(353) </text>
<text top="430" left="54" width="52" height="15" font="8">17897139 </text>
<text top="384" left="137" width="73" height="15" font="1">Case report of </text>
<text top="399" left="137" width="76" height="15" font="1">ablation w/ low </text>
<text top="415" left="137" width="94" height="15" font="1">radiation exposure </text>
<text top="384" left="264" width="27" height="15" font="1">2 pts </text>
<text top="384" left="378" width="130" height="15" font="1">Pt w/ drug refractory SVT; </text>
<text top="399" left="378" width="138" height="15" font="1">ablation of SVT w/ radiation </text>
<text top="415" left="378" width="52" height="15" font="1">dosimeter </text>
<text top="384" left="561" width="102" height="15" font="1">Successful ablation; </text>
<text top="399" left="561" width="78" height="15" font="1">adverse effects </text>
<text top="384" left="696" width="182" height="15" font="1">All pathways eliminated successfully </text>
<text top="384" left="922" width="208" height="15" font="1">Both pts treated, fetus dose was very low, </text>
<text top="399" left="922" width="113" height="15" font="1">below dangerous limit. </text>
<text top="446" left="54" width="59" height="15" font="1">Szumowski </text>
<text top="462" left="54" width="28" height="15" font="1">2010 </text>
<text top="477" left="54" width="29" height="15" font="1">(354) </text>
<text top="493" left="54" width="52" height="15" font="8">20158563 </text>
<text top="508" left="54" width="3" height="15" font="1"> </text>
<text top="446" left="137" width="74" height="15" font="1">Observational, </text>
<text top="462" left="137" width="89" height="15" font="1">multicenter report </text>
<text top="477" left="137" width="113" height="15" font="1">experience w/ ablation </text>
<text top="493" left="137" width="103" height="15" font="1">of SVT in pregnancy </text>
<text top="446" left="264" width="27" height="15" font="1">9 pts </text>
<text top="446" left="378" width="151" height="15" font="1">Pt w/ severe SVT refractory to </text>
<text top="462" left="378" width="160" height="15" font="1">medical therapy; ablation w/ low </text>
<text top="477" left="378" width="94" height="15" font="1">radiation exposure </text>
<text top="446" left="561" width="102" height="15" font="1">Successful ablation; </text>
<text top="462" left="561" width="78" height="15" font="1">adverse effects </text>
<text top="446" left="696" width="182" height="15" font="1">All pathways eliminated successfully </text>
<text top="446" left="922" width="197" height="15" font="1">All pts treated successfully, w/ either no </text>
<text top="462" left="922" width="158" height="15" font="1">radiation at all to very low dose. </text>
<text top="524" left="54" width="267" height="15" font="1">Pregnancy: Prophylactic Antiarrhythmic Drug Therapy </text>
<text top="541" left="54" width="36" height="15" font="1">Wen Z </text>
<text top="556" left="54" width="28" height="15" font="1">1998 </text>
<text top="572" left="54" width="23" height="15" font="1">(41) </text>
<text top="587" left="54" width="43" height="15" font="8">9851958</text>
<text top="587" left="97" width="3" height="15" font="1"> </text>
<text top="541" left="137" width="95" height="15" font="1">Prospective cohort </text>
<text top="556" left="137" width="30" height="15" font="1">study </text>
<text top="541" left="264" width="22" height="15" font="1">133 </text>
<text top="541" left="378" width="71" height="15" font="1">AVRT (n=85)  </text>
<text top="556" left="378" width="76" height="15" font="1">AVNRT (n=48) </text>
<text top="572" left="378" width="3" height="15" font="1"> </text>
<text top="587" left="378" width="167" height="15" font="1">EP study to induce PSVT by PES </text>
<text top="603" left="378" width="3" height="15" font="1"> </text>
<text top="618" left="378" width="49" height="15" font="1">Excluded </text>
<text top="618" left="427" width="117" height="15" font="19">atrial flutter, AF organic </text>
<text top="634" left="378" width="157" height="15" font="19">heart disease or other systemic </text>
<text top="649" left="378" width="165" height="15" font="19">diseases involving the autonomic </text>
<text top="665" left="378" width="152" height="15" font="19">function (e.g., diabetes), those </text>
<text top="680" left="378" width="133" height="15" font="19">who could not blow into an </text>
<text top="696" left="378" width="166" height="15" font="19">aneroid manometer to maintain a </text>
<text top="711" left="378" width="167" height="15" font="19">pressure of 35 mm Hg for 20 sec, </text>
<text top="727" left="378" width="111" height="15" font="19">and those w/ unstable </text>
<text top="742" left="378" width="111" height="15" font="19">hemodynamics during </text>
<text top="758" left="378" width="60" height="15" font="19">tachycardia.</text>
<text top="758" left="438" width="3" height="15" font="1"> </text>
<text top="541" left="561" width="106" height="15" font="1">Termination of PSVT </text>
<text top="541" left="696" width="173" height="15" font="1">Vagal maneuvers more effective in </text>
<text top="556" left="696" width="192" height="15" font="1">terminating AVRT than AVNRT (53 vs. </text>
<text top="572" left="696" width="75" height="15" font="1">33%, p&lt;0.05).  </text>
<text top="587" left="696" width="3" height="15" font="1"> </text>
<text top="603" left="696" width="186" height="15" font="1">AVNRT: vagal maneuvers terminated </text>
<text top="618" left="696" width="194" height="15" font="1">tachycardia in antegrade slow pathway </text>
<text top="634" left="696" width="215" height="15" font="1">(14%) or in retrograde fast pathway (19%).  </text>
<text top="649" left="696" width="3" height="15" font="1"> </text>
<text top="665" left="696" width="181" height="15" font="1">Baroreflex sensitivity was poorer but </text>
<text top="680" left="696" width="200" height="15" font="1">isoproterenol sensitivity test better in pts </text>
<text top="696" left="696" width="58" height="15" font="1">w/ AVNRT. </text>
<text top="541" left="922" width="196" height="15" font="1">Vagal maneuvers effective, more so for </text>
<text top="556" left="922" width="39" height="15" font="1">AVRT.  </text>
<text top="572" left="922" width="3" height="15" font="1"> </text>
<text top="587" left="922" width="207" height="15" font="1">Limited in that study conducted during EP </text>
<text top="603" left="922" width="33" height="15" font="1">study. </text>
<text top="774" left="54" width="52" height="15" font="1">Lydakis C </text>
<text top="789" left="54" width="31" height="15" font="1">1999  </text>
<text top="774" left="137" width="100" height="15" font="1">Retrospective study </text>
<text top="789" left="137" width="76" height="15" font="1">on the effect of </text>
<text top="774" left="264" width="15" height="15" font="1">78 </text>
<text top="774" left="378" width="147" height="15" font="1">Atenolol given to 78 pregnant </text>
<text top="789" left="378" width="153" height="15" font="1">women and compared to other </text>
<text top="774" left="561" width="118" height="15" font="1">Comparison of adverse </text>
<text top="789" left="561" width="108" height="15" font="1">effects to fetal growth </text>
<text top="774" left="696" width="201" height="15" font="1">Increased risk of fetal growth retardation </text>
<text top="774" left="922" width="189" height="15" font="1">Possible increased risk of fetal growth </text>
<text top="789" left="922" width="206" height="15" font="1">retardation on atenolol compared to other </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">117 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="29" height="15" font="1">(355) </text>
<text top="70" left="54" width="52" height="15" font="8">10371362 </text>
<text top="86" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="137" width="93" height="15" font="1">Atenolol and other </text>
<text top="70" left="137" width="106" height="15" font="1">drugs on fetal growth </text>
<text top="55" left="378" width="34" height="15" font="1">drugs. </text>
<text top="55" left="922" width="212" height="15" font="1">drugs, risk related to duration of treatment. </text>
<text top="102" left="54" width="23" height="15" font="1">Von </text>
<text top="117" left="54" width="66" height="15" font="1">Dadelszen P </text>
<text top="133" left="54" width="28" height="15" font="1">2000 </text>
<text top="148" left="54" width="29" height="15" font="1">(356) </text>
<text top="164" left="54" width="49" height="15" font="8">10675164</text>
<text top="164" left="103" width="3" height="15" font="1"> </text>
<text top="102" left="137" width="74" height="15" font="1">Metanalysis of </text>
<text top="117" left="137" width="112" height="15" font="1">different drugs, mainly </text>
<text top="133" left="137" width="72" height="15" font="1">beta blockers, </text>
<text top="148" left="137" width="63" height="15" font="1">inpregnancy </text>
<text top="102" left="264" width="28" height="15" font="1">3773 </text>
<text top="102" left="378" width="157" height="15" font="1">Meta analysis of different drugs </text>
<text top="117" left="378" width="166" height="15" font="1">for pregnancy induced HTN to try </text>
<text top="133" left="378" width="165" height="15" font="1">to determine if growth retardation </text>
<text top="148" left="378" width="133" height="15" font="1">is due to drugs or disease. </text>
<text top="102" left="561" width="93" height="15" font="1">The association of </text>
<text top="117" left="561" width="92" height="15" font="1">treatment-induced </text>
<text top="133" left="561" width="94" height="15" font="1">difference in mean </text>
<text top="148" left="561" width="106" height="15" font="1">arterial pressure with </text>
<text top="164" left="561" width="64" height="15" font="1">measures of </text>
<text top="179" left="561" width="102" height="15" font="1">fetoplacental growth </text>
<text top="102" left="696" width="209" height="15" font="1">Relationship was observed between fall in </text>
<text top="117" left="696" width="204" height="15" font="1">MAP and growth retardation, but was not </text>
<text top="133" left="696" width="83" height="15" font="1">related to drugs. </text>
<text top="102" left="922" width="163" height="15" font="1">Beta blockers mainly safe during </text>
<text top="117" left="922" width="212" height="15" font="1">pregnancy, growth retardation likely due to </text>
<text top="133" left="922" width="50" height="15" font="1">fall in BP. </text>
<text top="195" left="54" width="50" height="15" font="1">Bartalena </text>
<text top="211" left="54" width="28" height="15" font="1">2001 </text>
<text top="226" left="54" width="29" height="15" font="1">(357) </text>
<text top="242" left="54" width="49" height="15" font="8">11263469</text>
<text top="242" left="103" width="3" height="15" font="1"> </text>
<text top="195" left="137" width="78" height="15" font="1">Review of case </text>
<text top="211" left="137" width="67" height="15" font="1">reports when </text>
<text top="226" left="137" width="84" height="15" font="1">amiodarone was </text>
<text top="242" left="137" width="63" height="15" font="1">given during </text>
<text top="257" left="137" width="55" height="15" font="1">pregnancy </text>
<text top="195" left="264" width="15" height="15" font="1">64 </text>
<text top="195" left="378" width="145" height="15" font="1">Review of case reports when </text>
<text top="211" left="378" width="149" height="15" font="1">amiodarone was given. There </text>
<text top="226" left="378" width="157" height="15" font="1">were 64 identified and effect on </text>
<text top="242" left="378" width="106" height="15" font="1">babies was reported. </text>
<text top="195" left="561" width="79" height="15" font="1">Adverse effects </text>
<text top="211" left="561" width="79" height="15" font="1">documented on </text>
<text top="226" left="561" width="98" height="15" font="1">progeny of mothers </text>
<text top="242" left="561" width="68" height="15" font="1">who received </text>
<text top="257" left="561" width="65" height="15" font="1">amiodarone. </text>
<text top="195" left="696" width="195" height="15" font="1">Hypothyroidism reported in 17%, which </text>
<text top="211" left="696" width="185" height="15" font="1">most of the time was transient. Some </text>
<text top="226" left="696" width="195" height="15" font="1">developmental disabilities seen even in </text>
<text top="242" left="696" width="52" height="15" font="1">euthyroid. </text>
<text top="195" left="922" width="194" height="15" font="1">Maternal use of amiodarone can cause </text>
<text top="211" left="922" width="154" height="15" font="1">hypothyroidism in progeny and </text>
<text top="226" left="922" width="167" height="15" font="1">occasionally neurodevelopmental </text>
<text top="242" left="922" width="75" height="15" font="1">abnormalities.  </text>
<text top="274" left="54" width="59" height="15" font="1">Qasqas SA </text>
<text top="289" left="54" width="28" height="15" font="1">2004 </text>
<text top="305" left="54" width="29" height="15" font="1">(358) </text>
<text top="320" left="54" width="49" height="15" font="8">15191632</text>
<text top="320" left="103" width="3" height="15" font="1"> </text>
<text top="274" left="137" width="101" height="15" font="1">Review article on all </text>
<text top="289" left="137" width="105" height="15" font="1">cardiovascular drugs </text>
<text top="305" left="137" width="70" height="15" font="1">in pregnancy. </text>
<text top="274" left="264" width="22" height="15" font="1">N/A </text>
<text top="274" left="378" width="118" height="15" font="1">This is a review article.  </text>
<text top="274" left="561" width="22" height="15" font="1">N/A </text>
<text top="274" left="696" width="173" height="15" font="1">All drugs are describe in detail and </text>
<text top="289" left="696" width="180" height="15" font="1">references made to all case reports. </text>
<text top="274" left="922" width="201" height="15" font="1">This is a comprehensive compendium of </text>
<text top="289" left="922" width="180" height="15" font="1">all antiarrhythmic agents give during </text>
<text top="305" left="922" width="58" height="15" font="1">pregnancy. </text>
<text top="336" left="54" width="53" height="15" font="1">Jaeggi ET </text>
<text top="352" left="54" width="28" height="15" font="1">2011 </text>
<text top="367" left="54" width="32" height="15" font="1">(359)  </text>
<text top="383" left="54" width="49" height="15" font="8">21931080</text>
<text top="383" left="103" width="3" height="15" font="1"> </text>
<text top="398" left="54" width="6" height="15" font="1">  </text>
<text top="336" left="137" width="81" height="15" font="1">Nonrandomized </text>
<text top="352" left="137" width="57" height="15" font="1">multicenter </text>
<text top="367" left="137" width="72" height="15" font="1">comparison of </text>
<text top="383" left="137" width="74" height="15" font="1">different drugs </text>
<text top="398" left="137" width="82" height="15" font="1">administered for </text>
<text top="414" left="137" width="112" height="15" font="1">transplacental therapy </text>
<text top="429" left="137" width="61" height="15" font="1">of fetal SVT </text>
<text top="336" left="264" width="22" height="15" font="1">159 </text>
<text top="336" left="378" width="131" height="15" font="1">The authors reviewed 159 </text>
<text top="352" left="378" width="168" height="15" font="1">consecutive referrals w/ fetal SVT </text>
<text top="367" left="378" width="167" height="15" font="1">(n=114) and AF (n=45). Of these, </text>
<text top="383" left="378" width="161" height="15" font="1">75 fetuses w/ SVT and 36 w/ AF </text>
<text top="398" left="378" width="146" height="15" font="1">were treated nonrandomly w/ </text>
<text top="414" left="378" width="160" height="15" font="1">transplacental flecainide (n=35), </text>
<text top="429" left="378" width="160" height="15" font="1">sotalol (n=52), or digoxin (n=24) </text>
<text top="445" left="378" width="100" height="15" font="1">as a first-line agent. </text>
<text top="336" left="561" width="81" height="15" font="1">Effectiveness of </text>
<text top="352" left="561" width="121" height="15" font="1">different drugs reported. </text>
<text top="336" left="696" width="196" height="15" font="1">Flecainide and digoxin were superior to </text>
<text top="352" left="696" width="103" height="15" font="1">sotalol for fetal SVT. </text>
<text top="336" left="922" width="213" height="15" font="1">This was a study for fetal SVT, but showed </text>
<text top="352" left="922" width="207" height="15" font="1">that flecainide sotalol and digoxin are well </text>
<text top="367" left="922" width="146" height="15" font="1">tolerated in pregnant women. </text>
<text top="461" left="54" width="92" height="15" font="1">SVT in the Elderly </text>
<text top="477" left="54" width="50" height="15" font="1">Chen SA  </text>
<text top="493" left="54" width="28" height="15" font="1">1995 </text>
<text top="508" left="54" width="29" height="15" font="1">(360) </text>
<text top="524" left="54" width="43" height="15" font="8">7490388</text>
<text top="524" left="97" width="3" height="15" font="1"> </text>
<text top="477" left="137" width="71" height="15" font="1">Observational </text>
<text top="477" left="264" width="80" height="15" font="1">66 pts w/ AVRT </text>
<text top="493" left="264" width="79" height="15" font="1">and AVNRT  w/ </text>
<text top="508" left="264" width="98" height="15" font="1">initial sx onset after </text>
<text top="524" left="264" width="94" height="15" font="1">age 65 vs. 440 pts </text>
<text top="539" left="264" width="98" height="15" font="1">w/ sxs onset before </text>
<text top="555" left="264" width="37" height="15" font="1">age 30 </text>
<text top="477" left="378" width="157" height="15" font="1">All pts underwent EP study and </text>
<text top="493" left="378" width="28" height="15" font="1">RFA; </text>
<text top="508" left="378" width="144" height="15" font="1">4 mm tip temperature control </text>
<text top="524" left="378" width="100" height="15" font="1">deflectable catheter </text>
<text top="477" left="561" width="85" height="15" font="1">Compare clinical </text>
<text top="493" left="561" width="104" height="15" font="1">characteristics in the </text>
<text top="508" left="561" width="88" height="15" font="1">older vs. younger </text>
<text top="524" left="561" width="43" height="15" font="1">grooups </text>
<text top="477" left="696" width="205" height="15" font="1">Older group: 32/66 had AVRT, 34/66 had </text>
<text top="493" left="696" width="41" height="15" font="1">AVNRT </text>
<text top="508" left="696" width="201" height="15" font="1">Younger group: 283/440 AVRT, 157/444 </text>
<text top="524" left="696" width="41" height="15" font="1">AVNRT </text>
<text top="539" left="696" width="196" height="15" font="1">Sxs of syncope and cardioversion were </text>
<text top="555" left="696" width="207" height="15" font="1">similar between two age groups; older pts </text>
<text top="570" left="696" width="191" height="15" font="1">had more atrial and ventricular ectopic </text>
<text top="586" left="696" width="210" height="15" font="1">beats on Holter; dispersion of anterograde </text>
<text top="601" left="696" width="192" height="15" font="1">ERP was greater in older pts; Success </text>
<text top="617" left="696" width="212" height="15" font="1">rate was 97-98% in all groups; Recurrence </text>
<text top="632" left="696" width="193" height="15" font="1">was similar (6-7%; f/u duration was not </text>
<text top="648" left="696" width="199" height="15" font="1">stated in the paper); complications were </text>
<text top="663" left="696" width="196" height="15" font="1">significantly higher (13-14% in older pts </text>
<text top="679" left="696" width="177" height="15" font="1">than younger pts (1%) (for AVRT: 2 </text>
<text top="694" left="696" width="183" height="15" font="1">arterial thrombosis, 1 TIA, 1 DVT; for </text>
<text top="710" left="696" width="141" height="15" font="1">AVNRT: 1 DVT, 1 AV block) </text>
<text top="477" left="922" width="205" height="15" font="1">Greater dispersion of ERP and increased </text>
<text top="493" left="922" width="195" height="15" font="1">atrial and ventricular ectopic beats may </text>
<text top="508" left="922" width="203" height="15" font="1">explain the later onset of sxs in older pts. </text>
<text top="726" left="54" width="47" height="15" font="1">Chen SA </text>
<text top="741" left="54" width="28" height="15" font="1">1996 </text>
<text top="757" left="54" width="29" height="15" font="1">(361) </text>
<text top="772" left="54" width="43" height="15" font="8">8540455</text>
<text top="772" left="97" width="3" height="15" font="1"> </text>
<text top="726" left="137" width="210" height="15" font="1">Observational 3966 </text>
<text top="726" left="291" width="117" height="15" font="1">consecutive </text>
<text top="741" left="264" width="97" height="15" font="1">EP study and 2593 </text>
<text top="757" left="264" width="103" height="15" font="1">ablation procedures  </text>
<text top="726" left="378" width="166" height="15" font="1">Tertiary referral center in Taiwan, </text>
<text top="741" left="378" width="65" height="15" font="1">1987 – 1994 </text>
<text top="757" left="378" width="144" height="15" font="1">4 mm tip temperature control </text>
<text top="772" left="378" width="100" height="15" font="1">deflectable catheter </text>
<text top="726" left="561" width="117" height="15" font="1">Risk factors associated </text>
<text top="741" left="561" width="84" height="15" font="1">w/ complications </text>
<text top="726" left="696" width="204" height="15" font="1">Overall complications, RFA vs. EP study, </text>
<text top="741" left="696" width="206" height="15" font="1">3.1% vs. 1.1% (p 0.00002); Older (≥65 y) </text>
<text top="757" left="696" width="207" height="15" font="1">vs. younger, 2.2% vs. 0.5% (p 0.0002) for </text>
<text top="772" left="696" width="187" height="15" font="1">EP study and 6.1% vs. 2.0% for RFA. </text>
<text top="788" left="696" width="180" height="15" font="1">Older age and presence of systemic </text>
<text top="726" left="922" width="208" height="15" font="1">Data suggest older age is an independent </text>
<text top="741" left="922" width="211" height="15" font="1">risk for EP study and RFA. These data are </text>
<text top="757" left="922" width="204" height="15" font="1">somewhat out dated. Older pts had more </text>
<text top="772" left="922" width="213" height="15" font="1">co-morbidies and the presence of systemic </text>
<text top="788" left="922" width="153" height="15" font="1">diseases (co-morbidities) is an </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">118 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="696" width="192" height="15" font="1">disease are independent predictors for </text>
<text top="70" left="696" width="73" height="15" font="1">complications. </text>
<text top="86" left="696" width="171" height="15" font="1">Complications included pericardial </text>
<text top="101" left="696" width="182" height="15" font="1">eff/usion, tamponade, AVB, vascular </text>
<text top="117" left="696" width="118" height="15" font="1">injury, systemic emboli) </text>
<text top="55" left="922" width="153" height="15" font="1">independent predictor of acute </text>
<text top="70" left="922" width="73" height="15" font="1">complications. </text>
<text top="133" left="54" width="49" height="15" font="1">Boulos M </text>
<text top="148" left="54" width="28" height="15" font="1">1998 </text>
<text top="164" left="54" width="29" height="15" font="1">(362) </text>
<text top="179" left="54" width="43" height="15" font="8">9708674</text>
<text top="179" left="97" width="3" height="15" font="1"> </text>
<text top="133" left="137" width="74" height="15" font="1">Observational  </text>
<text top="133" left="264" width="255" height="15" font="1">271 consecutive pts  AVNRT from a single center </text>
<text top="148" left="378" width="154" height="15" font="1">undergoing RFA, 1991 – 1995. </text>
<text top="164" left="378" width="145" height="15" font="1">4 mm tip deflectable catheter </text>
<text top="179" left="378" width="146" height="15" font="1">were used to map and ablate </text>
<text top="133" left="561" width="113" height="15" font="1">Slow pathway ablation </text>
<text top="133" left="696" width="212" height="15" font="1">Acute success rate 98.1%, recurrence rate </text>
<text top="148" left="696" width="209" height="15" font="1">4.1%; CHB 2.2%, 2% for pts &lt;65 y of age, </text>
<text top="164" left="696" width="212" height="15" font="1">8% in older pts; Older age is associated w/ </text>
<text top="179" left="696" width="96" height="15" font="1">higher risk of CHB. </text>
<text top="133" left="922" width="95" height="15" font="1">Data are historical. </text>
<text top="148" left="922" width="205" height="15" font="1">The focus was on AVB complicating slow </text>
<text top="164" left="922" width="203" height="15" font="1">pathway ablation; no other complications </text>
<text top="179" left="922" width="74" height="15" font="1">were reported. </text>
<text top="195" left="54" width="49" height="15" font="1">Kalusche </text>
<text top="211" left="54" width="28" height="15" font="1">1998 </text>
<text top="226" left="54" width="17" height="15" font="1">(9) </text>
<text top="242" left="54" width="46" height="15" font="8">9812187 </text>
<text top="242" left="100" width="3" height="15" font="1"> </text>
<text top="195" left="137" width="105" height="15" font="1">Retrospective cohort </text>
<text top="211" left="137" width="30" height="15" font="1">study </text>
<text top="195" left="264" width="98" height="15" font="1">395 pts undergoing </text>
<text top="211" left="264" width="84" height="15" font="1">AVNRT RFA. 85 </text>
<text top="226" left="264" width="98" height="15" font="1">(22%) ≥65 y (mean </text>
<text top="242" left="264" width="34" height="15" font="1">70 y).  </text>
<text top="195" left="378" width="148" height="15" font="1">Consecutive pts from a single </text>
<text top="211" left="378" width="162" height="15" font="1">center in Germany, 1992 – 1997 </text>
<text top="226" left="378" width="164" height="15" font="1">9 pts were excluded due to more </text>
<text top="242" left="378" width="153" height="15" font="1">than one tachycardia inducible </text>
<text top="257" left="378" width="159" height="15" font="1">4 mm tip temperature controlled </text>
<text top="273" left="378" width="100" height="15" font="1">deflectable catheter </text>
<text top="195" left="561" width="103" height="15" font="1">Clinical presentation </text>
<text top="211" left="561" width="117" height="15" font="1">and outcomes in young </text>
<text top="226" left="561" width="87" height="15" font="1">vs. elderly during </text>
<text top="242" left="561" width="82" height="15" font="1">AVNRT ablation </text>
<text top="195" left="696" width="205" height="15" font="1">Similar to younger pts, elderly more often </text>
<text top="211" left="696" width="208" height="15" font="1">had organic heart disease (CAD w/ or w/o </text>
<text top="226" left="696" width="201" height="15" font="1">MI,19.3% vs. 2.6%; P&lt;0.02), syncope or </text>
<text top="242" left="696" width="208" height="15" font="1">presyncope w/ AVNRT (43.2% vs. 29.8%; </text>
<text top="257" left="696" width="210" height="15" font="1">P&lt;0.05). 17.5% vs. 6.5% (P&lt;0.05) the fast </text>
<text top="273" left="696" width="209" height="15" font="1">pathway approach was chosen as the first </text>
<text top="288" left="696" width="204" height="15" font="1">therapy. The overall success rate (96.8% </text>
<text top="304" left="696" width="204" height="15" font="1">vs. 95.3%) and recurrence rate (5.8% vs. </text>
<text top="319" left="696" width="183" height="15" font="1">4.9%) were similar in both pt groups. </text>
<text top="335" left="696" width="204" height="15" font="1">Details of complications not listed: “minor </text>
<text top="350" left="696" width="206" height="15" font="1">complications such as hematoma; severe </text>
<text top="366" left="696" width="209" height="15" font="1">complications such as need of a PM” (2 in </text>
<text top="381" left="696" width="205" height="15" font="1">older group, 1 in younger group); f/u 2-68 </text>
<text top="397" left="696" width="22" height="15" font="1">mo. </text>
<text top="195" left="922" width="188" height="15" font="1">Elderly pts have more severe sxs and </text>
<text top="211" left="922" width="199" height="15" font="1">more comorbid illnesses, but RFA safe.  </text>
<text top="413" left="54" width="28" height="15" font="1">Zado </text>
<text top="429" left="54" width="28" height="15" font="1">2000 </text>
<text top="444" left="54" width="29" height="15" font="1">(363) </text>
<text top="460" left="54" width="52" height="15" font="8">10676694 </text>
<text top="460" left="106" width="3" height="15" font="1"> </text>
<text top="413" left="137" width="95" height="15" font="1">Prospective cohort </text>
<text top="429" left="137" width="30" height="15" font="1">study </text>
<text top="413" left="264" width="66" height="15" font="1">695 pts were </text>
<text top="429" left="264" width="94" height="15" font="1">divided into: ≥80 y </text>
<text top="444" left="264" width="70" height="15" font="1">(n=37), 60-79 </text>
<text top="460" left="264" width="100" height="15" font="1">(n=275),  and &lt;60 y </text>
<text top="475" left="264" width="41" height="15" font="1">(n=383) </text>
<text top="413" left="378" width="150" height="15" font="1">Ablation for SVT, VT (only 8% </text>
<text top="429" left="378" width="110" height="15" font="1">VT, 43% His ablation) </text>
<text top="413" left="561" width="97" height="15" font="1">Determine whether </text>
<text top="429" left="561" width="120" height="15" font="1">catheter ablation is safe </text>
<text top="444" left="561" width="117" height="15" font="1">and effective in pts &gt;80 </text>
<text top="460" left="561" width="9" height="15" font="1">y.</text>
<text top="460" left="570" width="3" height="15" font="9"> </text>
<text top="413" left="696" width="207" height="15" font="1">Overall success rate 95% (e groups (97% </text>
<text top="429" left="696" width="190" height="15" font="1">≥80 y; 94% 60-79 y; 95%, &lt;60 y). The </text>
<text top="444" left="696" width="188" height="15" font="1">overall complication rate for the entire </text>
<text top="460" left="696" width="164" height="15" font="1">group was 2.6%; no difference in </text>
<text top="475" left="696" width="210" height="15" font="1">complication rates among the groups (0%, </text>
<text top="491" left="696" width="186" height="15" font="1">≥80 y; 2.2%, 60 to 79 y; 3.1%, &lt;60 y) </text>
<text top="413" left="922" width="206" height="15" font="1">RFA safe in elderly. However ,only 37 pts </text>
<text top="429" left="922" width="64" height="15" font="1">were &gt;80 y.  </text>
<text top="444" left="922" width="3" height="15" font="1"> </text>
<text top="507" left="54" width="31" height="15" font="1">Li YG </text>
<text top="522" left="54" width="28" height="15" font="1">2001 </text>
<text top="538" left="54" width="29" height="15" font="1">(364) </text>
<text top="553" left="54" width="49" height="15" font="8">11133214</text>
<text top="553" left="103" width="3" height="15" font="1"> </text>
<text top="507" left="137" width="71" height="15" font="1">Observational </text>
<text top="507" left="264" width="92" height="15" font="1">18 pts among 346 </text>
<text top="522" left="264" width="90" height="15" font="1">pts w/ prolong PR </text>
<text top="538" left="264" width="57" height="15" font="1">at baseline </text>
<text top="507" left="378" width="157" height="15" font="1">Slow pathway ablation in pts w/ </text>
<text top="522" left="378" width="41" height="15" font="1">AVNRT </text>
<text top="538" left="378" width="144" height="15" font="1">4 mm tip temperature control </text>
<text top="553" left="378" width="100" height="15" font="1">deflectable catheter </text>
<text top="507" left="561" width="120" height="15" font="1">Late occurrence of AVB </text>
<text top="522" left="561" width="101" height="15" font="1">after complete short </text>
<text top="538" left="561" width="98" height="15" font="1">pathway ablation in </text>
<text top="553" left="561" width="41" height="15" font="1">AVNRT </text>
<text top="507" left="696" width="212" height="15" font="1">18/346 pts w/ prolong PR before RFA, age </text>
<text top="522" left="696" width="211" height="15" font="1">62±7; Holters were obtained before, 1 d, 1 </text>
<text top="538" left="696" width="205" height="15" font="1">wk, 1, 3, 6 mo after ablation. Incidence of </text>
<text top="553" left="696" width="181" height="15" font="1">delayed AVB occurred in 6/18 pts w/ </text>
<text top="569" left="696" width="201" height="15" font="1">preexisting PR prolongation; antepgrade </text>
<text top="584" left="696" width="174" height="15" font="1">ERP was longer in the study group </text>
<text top="507" left="922" width="177" height="15" font="1">Risk of AVB is increased after short </text>
<text top="522" left="922" width="208" height="15" font="1">pathway ablation in pts w/ pre-existing PR </text>
<text top="538" left="922" width="199" height="15" font="1">prolongation. These data have not been </text>
<text top="553" left="922" width="175" height="15" font="1">confirmed in the contemporary era. </text>
<text top="600" left="54" width="51" height="15" font="1">Porter MJ </text>
<text top="616" left="54" width="28" height="15" font="1">2004 </text>
<text top="631" left="54" width="29" height="15" font="1">(365) </text>
<text top="647" left="54" width="49" height="15" font="8">15851189</text>
<text top="647" left="103" width="3" height="15" font="1"> </text>
<text top="600" left="137" width="74" height="15" font="1">Observational  </text>
<text top="600" left="264" width="89" height="15" font="1">1754 consecutive </text>
<text top="616" left="264" width="81" height="15" font="1">pts, 1856 PSVT </text>
<text top="631" left="264" width="100" height="15" font="1">from a single center </text>
<text top="647" left="264" width="56" height="15" font="1">1991-2003 </text>
<text top="600" left="378" width="160" height="15" font="1">PSVT undergoing RFA; exclude </text>
<text top="616" left="378" width="158" height="15" font="1">IAST, flutter and fibrillation, age </text>
<text top="631" left="378" width="16" height="15" font="1">&lt;5 </text>
<text top="647" left="378" width="166" height="15" font="1">Mapping and ablation techniques </text>
<text top="662" left="378" width="103" height="15" font="1">were not described.  </text>
<text top="600" left="561" width="82" height="15" font="1">Age and gender </text>
<text top="616" left="561" width="99" height="15" font="1">correlation to PSVT </text>
<text top="600" left="696" width="190" height="15" font="1">Mean age 49±19 (5-96), women 62%; </text>
<text top="616" left="696" width="211" height="15" font="1">AVNRT 1042 (56%), AVRT 500 (27%), AT </text>
<text top="631" left="696" width="191" height="15" font="1">315 (17%); AVRT decreases w/ age in </text>
<text top="647" left="696" width="201" height="15" font="1">both genders; AVNRT and AT increased </text>
<text top="662" left="696" width="195" height="15" font="1">w/ older age; majority (54.6%) of AVRT </text>
<text top="678" left="696" width="188" height="15" font="1">were men; majority of AVNRT and AT </text>
<text top="693" left="696" width="170" height="15" font="1">were women; In women, 63% had </text>
<text top="709" left="696" width="208" height="15" font="1">AVNRT, 20% AVRT and 17% AT; in men, </text>
<text top="724" left="696" width="172" height="15" font="1">45% AVNRT, 39% AVRT, 17% AT </text>
<text top="600" left="922" width="204" height="15" font="1">SVT is age and gender dependent in this </text>
<text top="616" left="922" width="208" height="15" font="1">single center study among pts referred for </text>
<text top="631" left="922" width="198" height="15" font="1">RFA. It is unknown whether this reflects </text>
<text top="647" left="922" width="211" height="15" font="1">the epidemiology in the general population </text>
<text top="662" left="922" width="207" height="15" font="1">due to the evolution of ablation from 1990 </text>
<text top="678" left="922" width="175" height="15" font="1">– current and whether referral bias, </text>
<text top="693" left="922" width="130" height="15" font="1">specifically related to age. </text>
<text top="709" left="922" width="186" height="15" font="1">This is an age and gender dependent </text>
<text top="724" left="922" width="201" height="15" font="1">mechanism study; not an outcome study </text>
<text top="741" left="54" width="43" height="15" font="1">Rostock </text>
<text top="756" left="54" width="28" height="15" font="1">2005 </text>
<text top="772" left="54" width="29" height="15" font="1">(366) </text>
<text top="787" left="54" width="52" height="15" font="8">15946358 </text>
<text top="787" left="106" width="3" height="15" font="1"> </text>
<text top="741" left="137" width="105" height="15" font="1">Retrospective cohort </text>
<text top="756" left="137" width="30" height="15" font="1">study </text>
<text top="741" left="264" width="94" height="15" font="1">&lt;75 y (n=508) and </text>
<text top="756" left="264" width="85" height="15" font="1">pts ≥75 y (n=70) </text>
<text top="741" left="378" width="153" height="15" font="1">All pts w/ symptomatic AVNRT </text>
<text top="756" left="378" width="173" height="15" font="1">referred for slow-pathway ablation  </text>
<text top="741" left="561" width="97" height="15" font="1">Determine whether </text>
<text top="756" left="561" width="120" height="15" font="1">catheter ablation is safe </text>
<text top="772" left="561" width="118" height="15" font="1">and effective in pts ≥75 </text>
<text top="787" left="561" width="9" height="15" font="1">y.</text>
<text top="787" left="570" width="3" height="15" font="9"> </text>
<text top="741" left="696" width="190" height="15" font="1">Preexisting prolonged PR interval was </text>
<text top="756" left="696" width="212" height="15" font="1">present in 3.3 vs. 37% in pts &lt;75 vs. older, </text>
<text top="772" left="696" width="187" height="15" font="1">p&lt;0.0001). Following successful slow-</text>
<text top="787" left="696" width="198" height="15" font="1">pathway ablation, no induction of an AV </text>
<text top="741" left="922" width="179" height="15" font="1">Slow-pathway ablation in elderly pts </text>
<text top="756" left="922" width="162" height="15" font="1">effective and safe and should be </text>
<text top="772" left="922" width="197" height="15" font="1">considered as first line therapy in this pt </text>
<text top="787" left="922" width="185" height="15" font="1">population. Challenges evidence that </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">119 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="696" width="194" height="15" font="1">block was observed in &gt;75 y group. No </text>
<text top="70" left="696" width="160" height="15" font="1">recurrences occurred pts ≥75 y.<i> </i></text>
<text top="55" left="922" width="197" height="15" font="1">preexisting PR prolongation found to be </text>
<text top="70" left="922" width="212" height="15" font="1">associated w/ a higher risk of developing a </text>
<text top="86" left="922" width="154" height="15" font="1">delayed high-degree AV block. </text>
<text top="102" left="54" width="36" height="15" font="1">Kihel J </text>
<text top="117" left="54" width="28" height="15" font="1">2006 </text>
<text top="133" left="54" width="29" height="15" font="1">(367) </text>
<text top="148" left="54" width="49" height="15" font="8">16687422</text>
<text top="148" left="103" width="3" height="15" font="1"> </text>
<text top="102" left="137" width="101" height="15" font="1">Observational, case </text>
<text top="117" left="137" width="36" height="15" font="1">control </text>
<text top="102" left="264" width="82" height="15" font="1">42 pts ≥75 y vs. </text>
<text top="117" left="264" width="70" height="15" font="1">234 pts &lt;75 y </text>
<text top="102" left="378" width="162" height="15" font="1">Consecutive pts w/ AVNRT from </text>
<text top="117" left="378" width="164" height="15" font="1">a single center in France, 1997 – </text>
<text top="133" left="378" width="34" height="15" font="1">2004.  </text>
<text top="148" left="378" width="151" height="15" font="1">4 mm tip deflectable catheters </text>
<text top="164" left="378" width="137" height="15" font="1">were used for mapping and </text>
<text top="179" left="378" width="42" height="15" font="1">ablation </text>
<text top="102" left="561" width="97" height="15" font="1">Determine whether </text>
<text top="117" left="561" width="120" height="15" font="1">catheter ablation is safe </text>
<text top="133" left="561" width="121" height="15" font="1">and effective comparing </text>
<text top="148" left="561" width="106" height="15" font="1">older vs. younger pts </text>
<text top="102" left="696" width="181" height="15" font="1">Success rate 100% in the elderly vs. </text>
<text top="117" left="696" width="169" height="15" font="1">99.6% in the younger pts; 1 minor </text>
<text top="133" left="696" width="206" height="15" font="1">complication of groin hematoma occurred </text>
<text top="148" left="696" width="196" height="15" font="1">in older pts (2.4%), 4 (1.7%) in younger </text>
<text top="164" left="696" width="183" height="15" font="1">pts including one PE, one pericardial </text>
<text top="179" left="696" width="208" height="15" font="1">effusion, 2 hematoma. Recurrent was 0 in </text>
<text top="195" left="696" width="203" height="15" font="1">older pts, 3.4% in the younger pts (p 0.5) </text>
<text top="210" left="696" width="186" height="15" font="1">F/u duration was 28 mo and 35 mo in </text>
<text top="226" left="696" width="197" height="15" font="1">older and younger groups, respectively. </text>
<text top="102" left="922" width="213" height="15" font="1">Catheter ablation for AVNRT is reasonable </text>
<text top="117" left="922" width="209" height="15" font="1">w/ high success rate and low complication </text>
<text top="133" left="922" width="193" height="15" font="1">rate. The data are more contemporary. </text>
<text top="148" left="922" width="206" height="15" font="1">No difference between older and younger </text>
<text top="164" left="922" width="40" height="15" font="1">groups. </text>
<text top="242" left="54" width="50" height="15" font="1">Dagres N </text>
<text top="257" left="54" width="28" height="15" font="1">2007 </text>
<text top="273" left="54" width="29" height="15" font="1">(368) </text>
<text top="288" left="54" width="49" height="15" font="8">17434888</text>
<text top="288" left="103" width="3" height="15" font="1"> </text>
<text top="304" left="54" width="3" height="15" font="1"> </text>
<text top="242" left="137" width="204" height="15" font="1">Observational 131 </text>
<text top="242" left="285" width="117" height="15" font="1">consecutive </text>
<text top="242" left="347" width="73" height="15" font="1">pts </text>
<text top="257" left="264" width="49" height="15" font="1">≥80 y old </text>
<text top="273" left="264" width="103" height="15" font="1">undergoing ablation  </text>
<text top="242" left="378" width="159" height="15" font="1">Consecutive pts from 3 centers: </text>
<text top="257" left="378" width="112" height="15" font="1">Greece, Germany and </text>
<text top="273" left="378" width="128" height="15" font="1">Switzerland, 1998 – 2004 </text>
<text top="288" left="378" width="163" height="15" font="1">“Temperature guided” approach  </text>
<text top="242" left="561" width="66" height="15" font="1">Determine pt </text>
<text top="257" left="561" width="95" height="15" font="1">characteristics and </text>
<text top="273" left="561" width="93" height="15" font="1">ablation outcomes </text>
<text top="242" left="696" width="211" height="15" font="1">Flutter most common (54%), AVNRT 22%, </text>
<text top="257" left="696" width="212" height="15" font="1">AF 18%. 52% had SHD. AVN ablation was </text>
<text top="273" left="696" width="199" height="15" font="1">performed in pts w/ AF. Overall success </text>
<text top="288" left="696" width="205" height="15" font="1">rate was 97% w/ one pts had a CVA after </text>
<text top="304" left="696" width="164" height="15" font="1">isthmus ablation for flutter. Minor </text>
<text top="319" left="696" width="213" height="15" font="1">complications such as hematoma occurred </text>
<text top="335" left="696" width="136" height="15" font="1">in 3.1% of study population </text>
<text top="242" left="922" width="198" height="15" font="1">In selected elderly pts, ablation is highly </text>
<text top="257" left="922" width="193" height="15" font="1">successful for flutter, AVNRT and AVN </text>
<text top="273" left="922" width="203" height="15" font="1">ablation. More than half of the elderly pts </text>
<text top="288" left="922" width="192" height="15" font="1">have SHD when undergoing RFA. The </text>
<text top="304" left="922" width="200" height="15" font="1">consistent theme w/ other contemporary </text>
<text top="319" left="922" width="214" height="15" font="1">studies is that elderly have more co-morbid </text>
<text top="335" left="922" width="167" height="15" font="1">conditions but the overall ablation </text>
<text top="350" left="922" width="171" height="15" font="1">outcomes are highly successful w/ </text>
<text top="366" left="922" width="191" height="15" font="1">acceptable low complications. None of </text>
<text top="381" left="922" width="190" height="15" font="1">these studies are randomized studies; </text>
<text top="397" left="922" width="172" height="15" font="1">selection bias cannot be excluded. </text>
<text top="413" left="54" width="57" height="15" font="1">Haghjoo M </text>
<text top="429" left="54" width="28" height="15" font="1">2007 </text>
<text top="444" left="54" width="29" height="15" font="1">(369) </text>
<text top="460" left="54" width="49" height="15" font="8">17069836</text>
<text top="460" left="103" width="3" height="15" font="1"> </text>
<text top="413" left="137" width="98" height="15" font="1">Observational case </text>
<text top="429" left="137" width="36" height="15" font="1">control </text>
<text top="413" left="264" width="101" height="15" font="1">268 consecutive pts </text>
<text top="429" left="264" width="96" height="15" font="1">underwent RFA for </text>
<text top="444" left="264" width="78" height="15" font="1">AVNRT; 2001 - </text>
<text top="460" left="264" width="28" height="15" font="1">2005 </text>
<text top="413" left="378" width="140" height="15" font="1">Dichotomized at 65 y of age </text>
<text top="413" left="561" width="94" height="15" font="1">Ablation outcomes </text>
<text top="413" left="696" width="186" height="15" font="1">156/112 : younger/older; CL longer in </text>
<text top="429" left="696" width="208" height="15" font="1">older pts; success rate, complications, the </text>
<text top="444" left="696" width="196" height="15" font="1">recurrences were similar between older </text>
<text top="460" left="696" width="82" height="15" font="1">and younger pts </text>
<text top="413" left="922" width="190" height="15" font="1">No significant differences in outcomes </text>
<text top="429" left="922" width="210" height="15" font="1">between the two age groups dichotomized </text>
<text top="444" left="922" width="70" height="15" font="1">at 65 y of age </text>
<text top="476" left="54" width="69" height="15" font="1">Pedrinazzi C  </text>
<text top="491" left="54" width="28" height="15" font="1">2007 </text>
<text top="507" left="54" width="29" height="15" font="1">(370) </text>
<text top="522" left="54" width="49" height="15" font="8">17823861</text>
<text top="522" left="103" width="3" height="15" font="1"> </text>
<text top="476" left="137" width="63" height="15" font="1">Observation </text>
<text top="476" left="264" width="79" height="15" font="1">Total of 605 pts </text>
<text top="476" left="378" width="165" height="15" font="1">Consecutive pts undergoing RFA </text>
<text top="491" left="378" width="144" height="15" font="1">for all arrhythmias in a single </text>
<text top="507" left="378" width="128" height="15" font="1">center in Italy, 2000-2005 </text>
<text top="522" left="378" width="144" height="15" font="1">4 mm tip temperature control </text>
<text top="538" left="378" width="100" height="15" font="1">deflectable catheter </text>
<text top="553" left="378" width="3" height="15" font="1"> </text>
<text top="476" left="561" width="76" height="15" font="1">RFA outcomes </text>
<text top="476" left="696" width="198" height="15" font="1">Older pts had more co-morbidities; 69% </text>
<text top="491" left="696" width="189" height="15" font="1">&lt;70 y of age, 24% 70-79 y, 7% ≥80 y; </text>
<text top="507" left="696" width="204" height="15" font="1">complications were similar 1.2 vs. 1.4 vs. </text>
<text top="522" left="696" width="139" height="15" font="1">2%; Complications included </text>
<text top="538" left="696" width="201" height="15" font="1">pneumothorax, pericardial eff/usion, and </text>
<text top="553" left="696" width="62" height="15" font="1">hematoma;  </text>
<text top="569" left="696" width="198" height="15" font="1">success rates were similar 92 vs. 88 vs. </text>
<text top="584" left="696" width="194" height="15" font="1">88%; recurrence was followed up to 12 </text>
<text top="600" left="696" width="202" height="15" font="1">mo; AT and flutter had higher recurrence </text>
<text top="615" left="696" width="133" height="15" font="1">rate than AVNRT or AVRT </text>
<text top="476" left="922" width="197" height="15" font="1">Outcomes of RFA for SVT and VT were </text>
<text top="491" left="922" width="191" height="15" font="1">similar in younger and older pt groups. </text>
<text top="507" left="922" width="118" height="15" font="1">No major complications </text>
<text top="631" left="54" width="68" height="15" font="1">Yangni N’Da’ </text>
<text top="647" left="54" width="12" height="15" font="1">O </text>
<text top="662" left="54" width="28" height="15" font="1">2008 </text>
<text top="678" left="54" width="29" height="15" font="1">(371) </text>
<text top="693" left="54" width="49" height="15" font="8">18477940</text>
<text top="693" left="103" width="3" height="15" font="1"> </text>
<text top="631" left="137" width="225" height="15" font="1">Observational 141/816 </text>
<text top="631" left="307" width="88" height="15" font="1">(17%) </text>
<text top="647" left="264" width="100" height="15" font="1">elderly &gt;70 y of age </text>
<text top="662" left="264" width="61" height="15" font="1">admitted for </text>
<text top="678" left="264" width="72" height="15" font="1">recurrent SVT </text>
<text top="631" left="378" width="111" height="15" font="1">Paroxysmal junctional </text>
<text top="647" left="378" width="145" height="15" font="1">tachycardia actually included </text>
<text top="662" left="378" width="95" height="15" font="1">AVNRT and AVRT </text>
<text top="678" left="378" width="161" height="15" font="1">Temperature controlled catheter </text>
<text top="631" left="561" width="115" height="15" font="1">Clinical outcomes after </text>
<text top="647" left="561" width="25" height="15" font="1">RFA </text>
<text top="631" left="696" width="141" height="15" font="1">In the acute setting: Cardiac </text>
<text top="647" left="696" width="213" height="15" font="1">decompenstation 10, syncope 26, ACS 14, </text>
<text top="662" left="696" width="190" height="15" font="1">vascular event 5; typical AVNRT 73%; </text>
<text top="678" left="696" width="212" height="15" font="1">atypical AVNRT more common in older pts </text>
<text top="693" left="696" width="211" height="15" font="1">than in younger pts (15% vs. 4%); ablation </text>
<text top="709" left="696" width="207" height="15" font="1">was performed in 79% of the older pts vs. </text>
<text top="724" left="696" width="190" height="15" font="1">57% in the younger pts; complications </text>
<text top="740" left="696" width="199" height="15" font="1">more common 7% vs. 2.5% in older pts; </text>
<text top="755" left="696" width="197" height="15" font="1">more AF induced during study (19% vs. </text>
<text top="771" left="696" width="23" height="15" font="1">5%) </text>
<text top="631" left="922" width="159" height="15" font="1">Older pts have more severe sxs </text>
<text top="647" left="922" width="196" height="15" font="1">associated w/ SVT at baseline; Atypical </text>
<text top="662" left="922" width="186" height="15" font="1">AVNRT is more common in older pts. </text>
<text top="678" left="922" width="186" height="15" font="1">Complications are higher in older pts. </text>
<text top="693" left="922" width="205" height="15" font="1">Very difficult paper to understand; did not </text>
<text top="709" left="922" width="198" height="15" font="1">specifically, or clearly, state the types of </text>
<text top="724" left="922" width="73" height="15" font="1">complications. </text>
<text top="787" left="54" width="63" height="15" font="1">Hoffman BA </text>
<text top="787" left="137" width="101" height="15" font="1">German registry; 48 </text>
<text top="787" left="264" width="89" height="15" font="1">3234 consecutive </text>
<text top="787" left="378" width="92" height="15" font="1">AVNRT pts: &gt;50 y </text>
<text top="787" left="561" width="102" height="15" font="1">Acute and long term </text>
<text top="787" left="696" width="205" height="15" font="1">No differences were observed among the </text>
<text top="787" left="922" width="187" height="15" font="1">Catheter ablation for AVNRT is highly </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">120 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="28" height="15" font="1">2011 </text>
<text top="70" left="54" width="29" height="15" font="1">(372) </text>
<text top="86" left="54" width="49" height="15" font="8">21315834</text>
<text top="86" left="103" width="3" height="15" font="1"> </text>
<text top="101" left="54" width="3" height="15" font="1"> </text>
<text top="55" left="137" width="72" height="15" font="1">trial centers in </text>
<text top="70" left="137" width="49" height="15" font="1">Germany </text>
<text top="55" left="264" width="76" height="15" font="1">pts undergoing </text>
<text top="70" left="264" width="82" height="15" font="1">AVNRT ablation </text>
<text top="86" left="264" width="74" height="15" font="1">from 3/2007 to </text>
<text top="101" left="264" width="37" height="15" font="1">5/2010 </text>
<text top="55" left="378" width="133" height="15" font="1">Group 1, n=1,268 [39.2%]; </text>
<text top="70" left="378" width="159" height="15" font="1">median age 40 y (95% CI: 30.0–</text>
<text top="86" left="378" width="119" height="15" font="1">45.0 y), 74.1% women,  </text>
<text top="101" left="378" width="3" height="15" font="1"> </text>
<text top="117" left="378" width="103" height="15" font="1">Group 2 50–75 y old </text>
<text top="132" left="378" width="169" height="15" font="1">(n=1,707 [52.8%]; 63.0 y [95% CI: </text>
<text top="147" left="378" width="102" height="15" font="1">58.0–69.0] y, 63.0% </text>
<text top="163" left="378" width="42" height="15" font="1">women) </text>
<text top="178" left="378" width="3" height="15" font="1"> </text>
<text top="194" left="378" width="170" height="15" font="1">Group 3 &gt;75 y old (n =259 [8.0%]; </text>
<text top="209" left="378" width="137" height="15" font="1">79.0 [95% CI: 77.0–82.0] y, </text>
<text top="225" left="378" width="80" height="15" font="1">50.6% women). </text>
<text top="55" left="561" width="68" height="15" font="1">success rate, </text>
<text top="70" left="561" width="92" height="15" font="1">complications and </text>
<text top="86" left="561" width="56" height="15" font="1">recurrence </text>
<text top="55" left="696" width="185" height="15" font="1">three groups w/ regard to primary CA </text>
<text top="70" left="696" width="210" height="15" font="1">success rate (98.7% vs. 98.8% vs. 98.5%; </text>
<text top="86" left="696" width="42" height="15" font="17"><i>P=0</i>.92) </text>
<text top="101" left="696" width="177" height="15" font="1">Hemodynamically stable pericardial </text>
<text top="117" left="696" width="199" height="15" font="1">eff/usion occurred in five group 2 (0.3%) </text>
<text top="132" left="696" width="136" height="15" font="1">and two group 3 (0.8%) pts </text>
<text top="147" left="696" width="193" height="15" font="1">but in none of the group 1 (<i>P=0</i>.05) pts </text>
<text top="163" left="696" width="207" height="15" font="1">AV block requiring permanent pacemaker </text>
<text top="178" left="696" width="109" height="15" font="1">implantation occurred </text>
<text top="194" left="696" width="205" height="15" font="1">in two pts in group 1 (0.2%) and six pts in </text>
<text top="210" left="696" width="41" height="15" font="1">group 2 </text>
<text top="225" left="696" width="183" height="15" font="1">(0.4%) but none in group 3 (<i>P=</i> 0.41) </text>
<text top="240" left="696" width="202" height="15" font="1">During a median f/u of 511 d, recurrence </text>
<text top="256" left="696" width="117" height="15" font="1">rate was 5.7% in all pts </text>
<text top="55" left="922" width="199" height="15" font="1">effective and safe and does not pose an </text>
<text top="70" left="922" width="212" height="15" font="1">increased risk for complete AV block in pts </text>
<text top="86" left="922" width="167" height="15" font="1">over 75 y of age, despite a higher </text>
<text top="101" left="922" width="146" height="15" font="1">prevalence of structural heart </text>
<text top="117" left="922" width="44" height="15" font="1">disease. </text>
<text top="272" left="54" width="50" height="15" font="1">Ghali WA </text>
<text top="288" left="54" width="28" height="15" font="1">2005 </text>
<text top="303" left="54" width="29" height="15" font="1">(222) </text>
<text top="319" left="54" width="3" height="15" font="1"> </text>
<text top="334" left="54" width="3" height="15" font="1"> </text>
<text top="272" left="137" width="92" height="15" font="1">Systematic review </text>
<text top="288" left="137" width="105" height="15" font="1">and meta-analysis of </text>
<text top="303" left="137" width="107" height="15" font="1">observational studies </text>
<text top="319" left="137" width="104" height="15" font="1">that investigated risk </text>
<text top="334" left="137" width="103" height="15" font="1">of thromboembolism </text>
<text top="350" left="137" width="106" height="15" font="1">associated with atrial </text>
<text top="365" left="137" width="34" height="15" font="1">flutter. </text>
<text top="272" left="264" width="93" height="15" font="1">The meta analysis </text>
<text top="288" left="264" width="98" height="15" font="1">included 13 studies </text>
<text top="303" left="264" width="77" height="15" font="1">on embolic risk </text>
<text top="319" left="264" width="74" height="15" font="1">around time of </text>
<text top="334" left="264" width="90" height="15" font="1">cardioversion that </text>
<text top="350" left="264" width="72" height="15" font="1">included 1546 </text>
<text top="365" left="264" width="65" height="15" font="1">patients. For </text>
<text top="381" left="264" width="90" height="15" font="1">chronic risk, there </text>
<text top="396" left="264" width="80" height="15" font="1">were 14 studies </text>
<text top="412" left="264" width="83" height="15" font="1">involving 17,691 </text>
<text top="427" left="264" width="45" height="15" font="1">patients. </text>
<text top="272" left="378" width="108" height="15" font="1">MEDLINE, EMBASE, </text>
<text top="288" left="378" width="158" height="15" font="1">bibliographies, and consultation </text>
<text top="303" left="378" width="165" height="15" font="1">with clinical experts were used to </text>
<text top="319" left="378" width="168" height="15" font="1">identify studies that report the risk </text>
<text top="334" left="378" width="159" height="15" font="1">of thromboembolism associated </text>
<text top="350" left="378" width="165" height="15" font="1">with attempted cardioversion and </text>
<text top="365" left="378" width="156" height="15" font="1">longer-term risk in patients with </text>
<text top="381" left="378" width="61" height="15" font="1">atrial flutter. </text>
<text top="272" left="561" width="37" height="15" font="1">Risk of </text>
<text top="288" left="561" width="91" height="15" font="1">thromboembolism </text>
<text top="303" left="561" width="106" height="15" font="1">associated with atrial </text>
<text top="319" left="561" width="105" height="15" font="1">flutter around time of </text>
<text top="334" left="561" width="106" height="15" font="1">cardioversion or over </text>
<text top="350" left="561" width="118" height="15" font="1">the long term in chronic </text>
<text top="365" left="561" width="61" height="15" font="1">atrial flutter. </text>
<text top="272" left="696" width="204" height="15" font="1">Around the time of cardioversion, the risk </text>
<text top="288" left="696" width="212" height="15" font="1">of thromboembolic events ranged from 0% </text>
<text top="303" left="696" width="183" height="15" font="1">to 7.3% depending of clinical factors. </text>
<text top="319" left="696" width="178" height="15" font="1">Lower event rates were observed in </text>
<text top="334" left="696" width="152" height="15" font="1">patients taking anticoagulants. </text>
<text top="350" left="696" width="126" height="15" font="1">The long term risk rate of </text>
<text top="365" left="696" width="205" height="15" font="1">thromboembolism was approximately 3% </text>
<text top="381" left="696" width="134" height="15" font="1">with sustained atrial flutter. </text>
<text top="272" left="922" width="186" height="15" font="1">The findings of this systematic review </text>
<text top="288" left="922" width="190" height="15" font="1">strongly suggest that atrial flutter does </text>
<text top="303" left="922" width="209" height="15" font="1">indeed impart a risk of thromboembolism.  </text>
<text top="443" left="54" width="1055" height="15" font="1">AA indicates antiarrhythmic; AARCC, Allicance for Adult Research in Congential Cardiology; AC, atrioventricular connections; ACE I/D, angiotensin converting enzyme insertion/deletion; ACHD, adult congenital heart </text>
<text top="459" left="54" width="1071" height="15" font="1">disease; ACS, acute coronary syndrome; ADT, antidromic tachycardia; AF, atrial fibrillation; AICD, automatic implantable cardioverter defibrillator; AP, accessory pathway; APERP, accessory pathway effective refractory </text>
<text top="474" left="54" width="1052" height="15" font="1">period; ART, atrioventricular tachycardia; ASD, atrioventricular septal defect; AT, atrial tachycardia; ATP, antitachycardia pacing; AVB, atrioventricular block; AVN, atrioventricular node; AVNRT, atrioventricular nodal </text>
<text top="490" left="54" width="1064" height="15" font="1">reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; AVSD, atrioventricular septal defects; BMI, body mass index; bpm, beats per min; BP, blood pressure; BSA, body surface area; CAD, coronary artery </text>
<text top="505" left="54" width="1042" height="15" font="1">disease; cc-TGA, congenitally corrected transposition of the great arteries; CHD, congenital heart disease; CHF, congestive heart failure; CK-MB, creatinine kinase myocardial enzyme; CL, cycle length; CONCOR, </text>
<text top="521" left="54" width="1018" height="15" font="1">Interuniversity Cardiology Institute of the Netherlands and the Netherlands Heart Foundation; CPB, cardiopulmonary bypass; CTI, cavotricuspid isthmus; CVA, cerebral vascular accident; DCCV, direct current </text>
<text top="536" left="54" width="1054" height="15" font="1">cardioversion; DOVR, double outlet right ventricle; DVT, deep vein thrombosis; dx, diagnosis; EAT, ectopic atrial tachycardia; ECG, electrocardiogram; ECMO, extracorporeal membrane oxygenation; ED, emergency </text>
<text top="552" left="54" width="1064" height="15" font="1">department; EP, electrophysiological; ERP, effective refractory period; f/u, follow up; HF, heart failure; h/o, history of; HR, heart rate; HTN, hypertension; IART, intraatrial reentrant tachycardia; IAST, inappropriate sinus </text>
<text top="567" left="54" width="1081" height="15" font="1">tachycardia; ICD, implantable cardioverter defibrillator; ICU, intensive care unit; intraop, intraoperative; IV, intravenous; JET, junctional ectopic tachycardia; LA, left atrium; LFW, left free wall; LOS, length of stay; LVEF, left </text>
<text top="583" left="54" width="1025" height="15" font="1">ventricular ejection fraction; MAP, mean arterial pressure; MAT, multifocal atrial tachycardia; MI, myocardial infarction; MRI, magnetic resonance imaging; NOS, nitric oxide synthase; NS, non-significant; NSVT, </text>
<text top="598" left="54" width="1055" height="15" font="1">nonsustained ventricular tachycardia; OHT, orthotopic herat transplant; OR, odds ratio; ORT, orthodromic tachycardia; PES, programmed electrical stimulation; PLE, protein-losing enteropathy; postop, postoperative; </text>
<text top="614" left="54" width="1054" height="15" font="1">POTS, postural tachycardia syndrome; preop, preoperative; PSVT, paroxysmal supraventricular tachycardia; pt, patient; QOL, quality of life; RA, right atrium; RACHS, risk adjustment for congenital heart surgery; RF, </text>
<text top="629" left="54" width="1080" height="15" font="1">radiofrequency; RFA, radiofrequency ablation; RFCA, radiofrequency catheter ablation; RFW, right free wall; RV, right ventricular; RVOT, right ventricular outflow tract; rx, therapy; SHD, structural heart disease; s/p, status </text>
<text top="645" left="54" width="1073" height="15" font="1">post; SR, sinus rhythm; SVA, supraventricular arrhythmia; SVT, supraventricular tachycardia; sx, symptom; TCPC, total cavopulmonary connection; TEP, transesophageal pacing; TGA, transposition of the great arteries; </text>
<text top="660" left="54" width="1044" height="15" font="1">TIA, transischemic attack; TOF, tetralogy of Fallot; TSH, thyroid stimulating hormone; TV, tricuspid valve; UVH, univentricular heart; VA, ventriculoatrial; VF, ventricular fibrillation; VSD, ventricular septal defect; VT, </text>
<text top="676" left="54" width="458" height="15" font="1">ventricular tachycardia; w/, with; w/o, without; and WPW, Wolff-Parkinson-White syndrome.    </text>
<text top="691" left="54" width="3" height="15" font="1"> </text>
<text top="716" left="54" width="4" height="19" font="3"><b></b></text>
<text top="744" left="54" width="4" height="19" font="3"><b></b></text>
<text top="772" left="54" width="4" height="19" font="3"><b></b></text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">121 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="54" left="54" width="161" height="19" font="3"><b>DataSupplement21. </b></text>
<text top="55" left="215" width="446" height="18" font="7"><b>Randomized Trials Comparing Special Populations – Section 9 </b></text>
<text top="55" left="662" width="4" height="18" font="3"><b> </b></text>
<text top="74" left="60" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="58" width="40" height="17" font="5"><b>Name, </b></text>
<text top="109" left="55" width="47" height="17" font="5"><b>Author, </b></text>
<text top="126" left="64" width="30" height="17" font="5"><b>Year </b></text>
<text top="74" left="119" width="42" height="17" font="5"><b>Aim of </b></text>
<text top="91" left="121" width="38" height="17" font="5"><b>Study </b></text>
<text top="74" left="182" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="185" width="32" height="17" font="5"><b>Type </b></text>
<text top="109" left="183" width="36" height="17" font="5"><b>(Size, </b></text>
<text top="126" left="193" width="16" height="17" font="5"><b>N) </b></text>
<text top="74" left="256" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="238" width="74" height="17" font="5"><b>Intervention </b></text>
<text top="109" left="245" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="74" left="344" width="38" height="17" font="5"><b>Study </b></text>
<text top="91" left="326" width="73" height="17" font="5"><b>Comparator </b></text>
<text top="109" left="333" width="59" height="17" font="5"><b>Group (n) </b></text>
<text top="74" left="490" width="83" height="17" font="5"><b>Pt Population </b></text>
<text top="74" left="756" width="64" height="17" font="5"><b>Endpoints </b></text>
<text top="74" left="933" width="109" height="17" font="5"><b>P Values, OR: HR: </b></text>
<text top="91" left="945" width="85" height="17" font="5"><b>RR: &amp; 95% CI: </b></text>
<text top="74" left="1064" width="68" height="17" font="5"><b>Summary/C</b></text>
<text top="91" left="1066" width="68" height="17" font="5"><b>onclusions </b></text>
<text top="144" left="67" width="3" height="17" font="5"><b> </b></text>
<text top="144" left="138" width="3" height="17" font="5"><b> </b></text>
<text top="144" left="199" width="3" height="17" font="5"><b> </b></text>
<text top="144" left="273" width="3" height="17" font="5"><b> </b></text>
<text top="144" left="361" width="3" height="17" font="5"><b> </b></text>
<text top="144" left="419" width="104" height="17" font="13"><i><b>Inclusion Criteria </b></i></text>
<text top="144" left="542" width="108" height="17" font="13"><i><b>Exclusion Criteria </b></i></text>
<text top="144" left="676" width="49" height="17" font="13"><i><b>Primary </b></i></text>
<text top="161" left="672" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="178" left="672" width="58" height="17" font="13"><i><b>(efficacy) </b></i></text>
<text top="195" left="664" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="144" left="771" width="40" height="17" font="13"><i><b>Safety </b></i></text>
<text top="161" left="763" width="57" height="17" font="13"><i><b>Endpoint </b></i></text>
<text top="178" left="755" width="73" height="17" font="13"><i><b>and Results </b></i></text>
<text top="144" left="846" width="70" height="17" font="13"><i><b>Secondary  </b></i></text>
<text top="161" left="851" width="67" height="17" font="13"><i><b>Endpoint    </b></i></text>
<text top="178" left="867" width="25" height="17" font="13"><i><b>and </b></i></text>
<text top="195" left="855" width="48" height="17" font="13"><i><b>Results </b></i></text>
<text top="144" left="986" width="3" height="17" font="5"><b> </b></text>
<text top="144" left="1098" width="3" height="17" font="5"><b> </b></text>
<text top="213" left="54" width="41" height="15" font="1">Saul JP </text>
<text top="229" left="54" width="28" height="15" font="1">2005 </text>
<text top="244" left="54" width="29" height="15" font="1">(373) </text>
<text top="260" left="54" width="43" height="15" font="8">1631696</text>
<text top="275" left="54" width="6" height="15" font="8">9</text>
<text top="275" left="60" width="3" height="15" font="1"> </text>
<text top="213" left="116" width="14" height="15" font="1">IV </text>
<text top="229" left="116" width="40" height="15" font="1">amiodar</text>
<text top="244" left="116" width="21" height="15" font="1">one </text>
<text top="260" left="116" width="41" height="15" font="1">efficacy/</text>
<text top="275" left="116" width="33" height="15" font="1">safety </text>
<text top="213" left="177" width="44" height="15" font="1">Multicent</text>
<text top="229" left="177" width="13" height="15" font="1">er </text>
<text top="244" left="177" width="40" height="15" font="1">randomi</text>
<text top="260" left="177" width="21" height="15" font="1">zed </text>
<text top="275" left="177" width="37" height="15" font="1">double-</text>
<text top="291" left="177" width="26" height="15" font="1">blind </text>
<text top="306" left="177" width="37" height="15" font="1">(N=61) </text>
<text top="213" left="238" width="62" height="15" font="1">Ages &lt;16 y, </text>
<text top="229" left="238" width="70" height="15" font="1">median 1.6 y. </text>
<text top="244" left="238" width="66" height="15" font="1">SVT 26, JET </text>
<text top="260" left="238" width="22" height="15" font="1">31.  </text>
<text top="275" left="238" width="55" height="15" font="1">71% SHD. </text>
<text top="275" left="292" width="3" height="15" font="9"> </text>
<text top="213" left="325" width="70" height="15" font="1">Dosages: low </text>
<text top="229" left="325" width="45" height="15" font="1">1 mg/kg, </text>
<text top="244" left="325" width="52" height="15" font="1">medium 5 </text>
<text top="260" left="325" width="60" height="15" font="1">mg/kg, high </text>
<text top="275" left="325" width="52" height="15" font="1">10 mg/kg, </text>
<text top="291" left="325" width="48" height="15" font="1">plus 47 h </text>
<text top="306" left="325" width="69" height="15" font="1">maintenance. </text>
<text top="322" left="325" width="40" height="15" font="1">30 d f/u.</text>
<text top="322" left="365" width="3" height="15" font="9"> </text>
<text top="213" left="413" width="18" height="15" font="1">N/A</text>
<text top="213" left="432" width="3" height="15" font="9"> </text>
<text top="213" left="541" width="101" height="15" font="1">Ages &lt;16 y, median </text>
<text top="229" left="541" width="96" height="15" font="1">1.6 y, SVT 26, JET </text>
<text top="244" left="541" width="22" height="15" font="1">31.  </text>
<text top="260" left="541" width="58" height="15" font="1">71% SHD.  </text>
<text top="213" left="663" width="57" height="15" font="1">Amidarone </text>
<text top="229" left="663" width="58" height="15" font="1">use &lt;3 mo, </text>
<text top="244" left="663" width="25" height="15" font="1">drug </text>
<text top="260" left="663" width="74" height="15" font="1">intereaction w/ </text>
<text top="275" left="663" width="65" height="15" font="1">amiodarone, </text>
<text top="290" left="663" width="48" height="15" font="1">imminent </text>
<text top="306" left="663" width="34" height="15" font="1">death, </text>
<text top="322" left="663" width="53" height="15" font="1">intentional </text>
<text top="337" left="663" width="64" height="15" font="1">hypothermia </text>
<text top="353" left="663" width="34" height="15" font="1">to &lt;35 </text>
<text top="368" left="663" width="54" height="15" font="1">degrees C </text>
<text top="213" left="751" width="74" height="15" font="1">Endpoint: time </text>
<text top="229" left="751" width="58" height="15" font="1">to success. </text>
<text top="244" left="751" width="65" height="15" font="1">Success low </text>
<text top="260" left="751" width="71" height="15" font="1">47%, medium </text>
<text top="275" left="751" width="81" height="15" font="1">80%, high 73%. </text>
<text top="291" left="751" width="3" height="15" font="1"> </text>
<text top="213" left="845" width="44" height="15" font="1">Adverse </text>
<text top="229" left="845" width="64" height="15" font="1">events 87%, </text>
<text top="244" left="845" width="58" height="15" font="1">5 deaths, 2 </text>
<text top="260" left="845" width="49" height="15" font="1">related to </text>
<text top="275" left="845" width="28" height="15" font="1">drug: </text>
<text top="290" left="845" width="47" height="15" font="1">profound </text>
<text top="306" left="845" width="63" height="15" font="1">hypotension </text>
<text top="322" left="845" width="64" height="15" font="1">medium and </text>
<text top="337" left="845" width="54" height="15" font="1">high dose. </text>
<text top="213" left="926" width="22" height="15" font="1">N/A </text>
<text top="213" left="1063" width="55" height="15" font="1">Medium or </text>
<text top="229" left="1063" width="51" height="15" font="1">high dose </text>
<text top="244" left="1063" width="63" height="15" font="1">effective 2.1-</text>
<text top="260" left="1063" width="31" height="15" font="1">2.6 h. </text>
<text top="275" left="1063" width="65" height="15" font="1">Efficacy JET </text>
<text top="290" left="1063" width="47" height="15" font="1">67-83%.  </text>
<text top="306" left="1063" width="3" height="15" font="1"> </text>
<text top="322" left="1063" width="69" height="15" font="1">SVT 33-89%. </text>
<text top="384" left="54" width="39" height="15" font="1">Lim SH </text>
<text top="400" left="54" width="28" height="15" font="1">2009 </text>
<text top="415" left="54" width="23" height="15" font="1">(38) </text>
<text top="431" left="54" width="43" height="15" font="8">1926136</text>
<text top="446" left="54" width="6" height="15" font="8">7</text>
<text top="446" left="60" width="3" height="15" font="1"> </text>
<text top="384" left="116" width="39" height="15" font="1">Compar</text>
<text top="400" left="116" width="9" height="15" font="1">e </text>
<text top="415" left="116" width="41" height="15" font="1">efficacy </text>
<text top="431" left="116" width="42" height="15" font="1">of bolus </text>
<text top="446" left="116" width="39" height="15" font="1">adenosi</text>
<text top="462" left="116" width="33" height="15" font="1">ne vs. </text>
<text top="477" left="116" width="25" height="15" font="1">slow </text>
<text top="493" left="116" width="41" height="15" font="1">calcium </text>
<text top="508" left="116" width="42" height="15" font="1">channel </text>
<text top="524" left="116" width="44" height="15" font="1">blockers </text>
<text top="539" left="116" width="42" height="15" font="1">in ED rx </text>
<text top="555" left="116" width="25" height="15" font="1">SVT </text>
<text top="384" left="177" width="44" height="15" font="1">Prospect</text>
<text top="400" left="177" width="17" height="15" font="1">ive </text>
<text top="415" left="177" width="40" height="15" font="1">randomi</text>
<text top="431" left="177" width="42" height="15" font="1">zed trial </text>
<text top="446" left="177" width="46" height="15" font="1">(N=206). </text>
<text top="462" left="177" width="31" height="15" font="1">Mean </text>
<text top="477" left="177" width="30" height="15" font="1">ages  </text>
<text top="493" left="177" width="44" height="15" font="1">48.3±18.</text>
<text top="508" left="177" width="21" height="15" font="1">6 y. </text>
<text top="384" left="238" width="43" height="15" font="1">104 pts; </text>
<text top="400" left="238" width="63" height="15" font="1">adenosine 6 </text>
<text top="415" left="238" width="62" height="15" font="1">mg followed </text>
<text top="431" left="238" width="49" height="15" font="1">by 12 mg </text>
<text top="446" left="238" width="44" height="15" font="1">given as </text>
<text top="462" left="238" width="43" height="15" font="1">needed. </text>
<text top="477" left="238" width="58" height="15" font="1">Stopped w/ </text>
<text top="493" left="238" width="25" height="15" font="1">SVT </text>
<text top="508" left="238" width="53" height="15" font="1">conversion</text>
<text top="508" left="291" width="3" height="15" font="9"> </text>
<text top="384" left="325" width="39" height="15" font="1">102 pts </text>
<text top="400" left="325" width="41" height="15" font="1">infusion </text>
<text top="415" left="325" width="60" height="15" font="1">verapamil 1 </text>
<text top="431" left="325" width="52" height="15" font="1">mg/min to </text>
<text top="446" left="325" width="74" height="15" font="1">max 20 mg, or </text>
<text top="462" left="325" width="65" height="15" font="1">dilitazem 2.5 </text>
<text top="477" left="325" width="52" height="15" font="1">mg/min to </text>
<text top="493" left="325" width="61" height="15" font="1">max 50 mg. </text>
<text top="508" left="325" width="58" height="15" font="1">Stopped w/ </text>
<text top="524" left="325" width="25" height="15" font="1">SVT </text>
<text top="539" left="325" width="57" height="15" font="1">conversion.</text>
<text top="539" left="382" width="3" height="15" font="9"> </text>
<text top="384" left="413" width="95" height="15" font="1">Pts ≥10 y in ED w/ </text>
<text top="400" left="413" width="64" height="15" font="1">narrow QRS </text>
<text top="415" left="413" width="105" height="15" font="1">tachycardia, ECG dx </text>
<text top="431" left="413" width="114" height="15" font="1">SVT, not converting w/ </text>
<text top="446" left="413" width="91" height="15" font="1">vagal maneuvers. </text>
<text top="384" left="541" width="22" height="15" font="1">N/A </text>
<text top="384" left="663" width="71" height="15" font="1">Conversion to </text>
<text top="400" left="663" width="62" height="15" font="1">SR: calcium </text>
<text top="415" left="663" width="42" height="15" font="1">channel </text>
<text top="431" left="663" width="69" height="15" font="1">blockers 98% </text>
<text top="446" left="663" width="71" height="15" font="1">vs. adenosine </text>
<text top="462" left="663" width="60" height="15" font="1">86.5% (RR: </text>
<text top="477" left="663" width="43" height="15" font="1">1/13; p= </text>
<text top="493" left="663" width="34" height="15" font="1">0.002) </text>
<text top="508" left="663" width="3" height="15" font="1"> </text>
<text top="384" left="751" width="22" height="15" font="1">N/A </text>
<text top="384" left="845" width="57" height="15" font="1">Drop in BP </text>
<text top="400" left="845" width="28" height="15" font="1">more </text>
<text top="415" left="845" width="57" height="15" font="1">common in </text>
<text top="431" left="845" width="41" height="15" font="1">calcium </text>
<text top="446" left="845" width="44" height="15" font="1">blockers </text>
<text top="462" left="845" width="65" height="15" font="1">group, mean </text>
<text top="477" left="845" width="57" height="15" font="1">SBP ↓13-7 </text>
<text top="493" left="845" width="56" height="15" font="1">mm Hg vs. </text>
<text top="508" left="845" width="55" height="15" font="1">no change </text>
<text top="524" left="845" width="14" height="15" font="1">w/ </text>
<text top="539" left="845" width="57" height="15" font="1">adenosine. </text>
<text top="384" left="926" width="22" height="15" font="1">N/A </text>
<text top="384" left="1063" width="43" height="15" font="1">Calcium </text>
<text top="400" left="1063" width="42" height="15" font="1">channel </text>
<text top="415" left="1063" width="44" height="15" font="1">blockers </text>
<text top="431" left="1063" width="66" height="15" font="1">effective and </text>
<text top="446" left="1063" width="24" height="15" font="1">safe </text>
<text top="462" left="1063" width="66" height="15" font="1">alternative to </text>
<text top="477" left="1063" width="70" height="15" font="1">adenosine for </text>
<text top="493" left="1063" width="57" height="15" font="1">conversion </text>
<text top="508" left="1063" width="28" height="15" font="1">SVT; </text>
<text top="524" left="1063" width="61" height="15" font="1">implications </text>
<text top="539" left="1063" width="46" height="15" font="1">for cost.  </text>
<text top="571" left="54" width="40" height="15" font="1">Manriqu</text>
<text top="586" left="54" width="29" height="15" font="1">e AM </text>
<text top="602" left="54" width="28" height="15" font="1">2010 </text>
<text top="617" left="54" width="29" height="15" font="1">(374) </text>
<text top="633" left="54" width="43" height="15" font="8">1981946</text>
<text top="648" left="54" width="6" height="15" font="8">9</text>
<text top="648" left="60" width="3" height="15" font="1"> </text>
<text top="571" left="116" width="39" height="15" font="1">Assess </text>
<text top="586" left="116" width="42" height="15" font="1">magnesi</text>
<text top="602" left="116" width="18" height="15" font="1">um </text>
<text top="617" left="116" width="36" height="15" font="1">sulfate </text>
<text top="633" left="116" width="42" height="15" font="1">supplem</text>
<text top="648" left="116" width="42" height="15" font="1">entation </text>
<text top="664" left="116" width="34" height="15" font="1">during </text>
<text top="679" left="116" width="41" height="15" font="1">CPB on </text>
<text top="695" left="116" width="33" height="15" font="1">risk of </text>
<text top="710" left="116" width="23" height="15" font="1">JET </text>
<text top="571" left="177" width="44" height="15" font="1">Randomi</text>
<text top="586" left="177" width="24" height="15" font="1">zed, </text>
<text top="602" left="177" width="37" height="15" font="1">double-</text>
<text top="617" left="177" width="29" height="15" font="1">blind, </text>
<text top="633" left="177" width="42" height="15" font="1">controlle</text>
<text top="648" left="177" width="30" height="15" font="1">d trial </text>
<text top="664" left="177" width="37" height="15" font="1">(N=99) </text>
<text top="571" left="238" width="71" height="15" font="1">2/05-8/06, pts </text>
<text top="586" left="238" width="30" height="15" font="1">&lt;17 y </text>
<text top="602" left="238" width="58" height="15" font="1">undergoing </text>
<text top="617" left="238" width="57" height="15" font="1">CPB repair </text>
<text top="633" left="238" width="27" height="15" font="1">CHD </text>
<text top="648" left="238" width="73" height="15" font="1">randomized to </text>
<text top="664" left="238" width="39" height="15" font="1">receive </text>
<text top="679" left="238" width="74" height="15" font="1">MgSO4 during </text>
<text top="695" left="238" width="55" height="15" font="1">rewarming </text>
<text top="571" left="325" width="55" height="15" font="1">Placebo: 3 </text>
<text top="586" left="325" width="74" height="15" font="1">groups: Mg 25 </text>
<text top="602" left="325" width="52" height="15" font="1">mg/kg, 50 </text>
<text top="617" left="325" width="46" height="15" font="1">mg/kg or </text>
<text top="633" left="325" width="45" height="15" font="1">placebo. </text>
<text top="571" left="413" width="108" height="15" font="1">Pts from birth-17 y w/ </text>
<text top="586" left="413" width="79" height="15" font="1">elective cardiac </text>
<text top="602" left="413" width="43" height="15" font="1">surgery. </text>
<text top="571" left="541" width="60" height="15" font="1">Pts with Mg </text>
<text top="586" left="541" width="82" height="15" font="1">supplements for </text>
<text top="602" left="541" width="101" height="15" font="1">malnutrition, sepsis, </text>
<text top="617" left="541" width="63" height="15" font="1">pancreatitis, </text>
<text top="633" left="541" width="52" height="15" font="1">neonates. </text>
<text top="571" left="663" width="28" height="15" font="1">Total </text>
<text top="586" left="663" width="73" height="15" font="1">incidence JET </text>
<text top="602" left="663" width="31" height="15" font="1">7.0%. </text>
<text top="617" left="663" width="3" height="15" font="1"> </text>
<text top="633" left="663" width="23" height="15" font="1">JET </text>
<text top="648" left="663" width="58" height="15" font="1">incidences: </text>
<text top="664" left="663" width="71" height="15" font="1">Placebo 31%, </text>
<text top="679" left="663" width="66" height="15" font="1">low Mg 10%; </text>
<text top="695" left="663" width="81" height="15" font="1">higher Mg 0%.   </text>
<text top="571" left="751" width="22" height="15" font="1">N/A </text>
<text top="571" left="845" width="22" height="15" font="1">N/A </text>
<text top="571" left="926" width="104" height="15" font="1">Younger age &lt;1 mo, </text>
<text top="586" left="926" width="114" height="15" font="1">complex CHD Aristotle </text>
<text top="602" left="926" width="101" height="15" font="1">score ≥4, prior CHF </text>
<text top="617" left="926" width="95" height="15" font="1">correlated w/ JET.  </text>
<text top="571" left="1063" width="41" height="15" font="1">MgSO4 </text>
<text top="586" left="1063" width="43" height="15" font="1">reduced </text>
<text top="602" left="1063" width="62" height="15" font="1">incidence of </text>
<text top="617" left="1063" width="59" height="15" font="1">postop JET </text>
<text top="727" left="54" width="47" height="15" font="1">Sanatani </text>
<text top="742" left="54" width="10" height="15" font="1">S </text>
<text top="758" left="54" width="28" height="15" font="1">2012 </text>
<text top="773" left="54" width="29" height="15" font="1">(375) </text>
<text top="788" left="54" width="43" height="15" font="8">2296243</text>
<text top="727" left="116" width="39" height="15" font="1">Compar</text>
<text top="742" left="116" width="47" height="15" font="1">e digoxin </text>
<text top="758" left="116" width="17" height="15" font="1">vs. </text>
<text top="773" left="116" width="44" height="15" font="1">proprano</text>
<text top="788" left="116" width="30" height="15" font="1">lol for </text>
<text top="727" left="177" width="44" height="15" font="1">Multicent</text>
<text top="742" left="177" width="13" height="15" font="1">er </text>
<text top="758" left="177" width="40" height="15" font="1">randomi</text>
<text top="773" left="177" width="21" height="15" font="1">zed </text>
<text top="788" left="177" width="37" height="15" font="1">double-</text>
<text top="727" left="238" width="60" height="15" font="1">Digoxin (27)</text>
<text top="727" left="297" width="3" height="15" font="9"> </text>
<text top="727" left="325" width="60" height="15" font="1">Propranolol </text>
<text top="742" left="325" width="23" height="15" font="1">(34) </text>
<text top="727" left="413" width="112" height="15" font="1">Infants &lt;4 mo w/ SVT, </text>
<text top="742" left="413" width="89" height="15" font="1">AVRT or AVNRT. </text>
<text top="727" left="541" width="96" height="15" font="1">Excluding manifest </text>
<text top="742" left="541" width="34" height="15" font="1">WPW. </text>
<text top="727" left="663" width="52" height="15" font="1">Recurrent </text>
<text top="742" left="663" width="43" height="15" font="1">SVT. 27 </text>
<text top="758" left="663" width="57" height="15" font="1">digoxin, 34 </text>
<text top="773" left="663" width="62" height="15" font="1">propranolol  </text>
<text top="788" left="663" width="69" height="15" font="1">SVT recurred </text>
<text top="727" left="751" width="72" height="15" font="1">No deaths, no </text>
<text top="742" left="751" width="81" height="15" font="1">serious adverse </text>
<text top="758" left="751" width="39" height="15" font="1">events. </text>
<text top="727" left="845" width="40" height="15" font="1">Time to </text>
<text top="742" left="845" width="59" height="15" font="1">recurrence, </text>
<text top="758" left="845" width="42" height="15" font="1">adverse </text>
<text top="773" left="845" width="56" height="15" font="1">events. No </text>
<text top="788" left="845" width="21" height="15" font="1">first </text>
<text top="727" left="926" width="22" height="15" font="1">N/A </text>
<text top="727" left="1063" width="69" height="15" font="1">No difference </text>
<text top="742" left="1063" width="45" height="15" font="1">between </text>
<text top="758" left="1063" width="60" height="15" font="1">digoxin and </text>
<text top="773" left="1063" width="70" height="15" font="1">propranolol in </text>
<text top="788" left="1063" width="55" height="15" font="1">preventing </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">122 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="6" height="15" font="8">1</text>
<text top="55" left="60" width="3" height="15" font="1"> </text>
<text top="55" left="116" width="36" height="15" font="1">control </text>
<text top="70" left="116" width="42" height="15" font="1">of infant </text>
<text top="86" left="116" width="25" height="15" font="1">SVT </text>
<text top="55" left="177" width="26" height="15" font="1">blind </text>
<text top="70" left="177" width="37" height="15" font="1">(N=61) </text>
<text top="55" left="663" width="67" height="15" font="1">19% digoxin, </text>
<text top="70" left="663" width="25" height="15" font="1">31% </text>
<text top="86" left="663" width="58" height="15" font="1">propranolol </text>
<text top="101" left="663" width="69" height="15" font="1">(p=0.25, NS). </text>
<text top="117" left="663" width="60" height="15" font="1">Recurrence </text>
<text top="132" left="663" width="55" height="15" font="1">free status </text>
<text top="147" left="663" width="67" height="15" font="1">79% digoxin, </text>
<text top="163" left="663" width="25" height="15" font="1">67% </text>
<text top="178" left="663" width="61" height="15" font="1">propranolol, </text>
<text top="194" left="663" width="22" height="15" font="1">NS. </text>
<text top="55" left="845" width="56" height="15" font="1">recurrence </text>
<text top="70" left="845" width="53" height="15" font="1">after 10 d. </text>
<text top="55" left="1063" width="47" height="15" font="1">recurrent </text>
<text top="70" left="1063" width="31" height="15" font="1">SVT.  </text>
<text top="86" left="1063" width="3" height="15" font="1"> </text>
<text top="101" left="1063" width="16" height="15" font="1">As </text>
<text top="117" left="1063" width="61" height="15" font="1">recurrences </text>
<text top="132" left="1063" width="67" height="15" font="1">did not occur </text>
<text top="147" left="1063" width="64" height="15" font="1">&gt;110 d, may </text>
<text top="163" left="1063" width="46" height="15" font="1">not need </text>
<text top="178" left="1063" width="71" height="15" font="1">prolonged rx.  </text>
<text top="210" left="54" width="1045" height="15" font="1">AVNRT indicates atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; BP, blood pressure; CHD, congenital heart disease; CHF, congestive heart failure; CPB, cardiopulmonary </text>
<text top="226" left="54" width="1035" height="15" font="1">bypass; dx, diagnosis; ECG, echocardiogram; ED, emergency department; IV, intravenous; JET, junctional ectopic tachycardia; N/A, not applicable; NS, non-significant; pt, patient; rx, therapy; SBP, systolic blood </text>
<text top="241" left="54" width="739" height="15" font="1">pressure; SHD, structural heart disease; SR, sinush rhythm; SVT, supraventricular tachycardia; w/, with; and WPW, Wolff-Parkinson-White syndrome.  </text>
<text top="257" left="54" width="3" height="15" font="1"> </text>
<text top="282" left="54" width="151" height="18" font="3"><b>Data Supplement 22. </b></text>
<text top="282" left="205" width="780" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Quality-of-Life Considerations – Section 10</b></text>
<text top="282" left="985" width="4" height="18" font="3"><b> </b></text>
<text top="301" left="68" width="38" height="17" font="5"><b>Study </b></text>
<text top="318" left="67" width="40" height="17" font="5"><b>Name, </b></text>
<text top="336" left="64" width="47" height="17" font="5"><b>Author, </b></text>
<text top="353" left="72" width="30" height="17" font="5"><b>Year </b></text>
<text top="301" left="154" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="318" left="168" width="44" height="17" font="5"><b>Design </b></text>
<text top="301" left="275" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="301" left="391" width="119" height="17" font="5"><b>Inclusion/Exclusion </b></text>
<text top="318" left="427" width="46" height="17" font="5"><b>Criteria </b></text>
<text top="301" left="589" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="301" left="780" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="301" left="962" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="371" left="54" width="40" height="15" font="1">Lau CP </text>
<text top="386" left="54" width="28" height="15" font="1">1995 </text>
<text top="401" left="54" width="29" height="15" font="1">(376) </text>
<text top="417" left="54" width="46" height="15" font="8">7770362 </text>
<text top="417" left="100" width="3" height="15" font="1"> </text>
<text top="371" left="133" width="92" height="15" font="1">QOL and exercise </text>
<text top="386" left="133" width="87" height="15" font="1">capacity in pts w/ </text>
<text top="401" left="133" width="84" height="15" font="1">PSVT due to AP </text>
<text top="417" left="133" width="104" height="15" font="1">treated medically vs. </text>
<text top="432" left="133" width="42" height="15" font="1">ablation </text>
<text top="371" left="261" width="30" height="15" font="1">N=55 </text>
<text top="386" left="261" width="3" height="15" font="1"> </text>
<text top="401" left="261" width="45" height="15" font="1">Random </text>
<text top="417" left="261" width="62" height="15" font="1">allocation to </text>
<text top="432" left="261" width="59" height="15" font="1">ablation vs. </text>
<text top="448" left="261" width="81" height="15" font="1">medical therapy </text>
<text top="371" left="368" width="151" height="15" font="1">Pts w/ PSVT (including WPW) </text>
<text top="386" left="368" width="154" height="15" font="1">on stable medications for 3 mo </text>
<text top="401" left="368" width="155" height="15" font="1">Randomly selected for ablation </text>
<text top="417" left="368" width="148" height="15" font="1">or continuing medical therapy </text>
<text top="371" left="545" width="141" height="15" font="1">QOL questionnaire and ETT </text>
<text top="386" left="545" width="189" height="15" font="1">performed at baseline and every 3 mo </text>
<text top="401" left="545" width="37" height="15" font="1">for 1 y  </text>
<text top="417" left="545" width="3" height="15" font="1"> </text>
<text top="432" left="545" width="190" height="15" font="1">Assessed PSVT frequency/duration of </text>
<text top="448" left="545" width="186" height="15" font="1">episodes; hemodynamic disturbance, </text>
<text top="463" left="545" width="132" height="15" font="1">presence of preexcited AF </text>
<text top="371" left="751" width="157" height="15" font="1">46 pts selected for ablation and </text>
<text top="386" left="751" width="107" height="15" font="1">9 for medical therapy </text>
<text top="401" left="751" width="3" height="15" font="1"> </text>
<text top="417" left="751" width="158" height="15" font="1">36/46 successfully ablated, and </text>
<text top="432" left="751" width="151" height="15" font="1">they improved in QOL at 3 mo </text>
<text top="448" left="751" width="145" height="15" font="1">post ablation (total scores on </text>
<text top="463" left="751" width="153" height="15" font="1">General Health Questionnaire, </text>
<text top="479" left="751" width="147" height="15" font="1">Somatic Symptoms Inventory </text>
<text top="494" left="751" width="143" height="15" font="1">and Sickness Impact Profile) </text>
<text top="510" left="751" width="75" height="15" font="1">P&lt;0.01for all 3 </text>
<text top="525" left="751" width="127" height="15" font="1">Improvements held at 1 y </text>
<text top="541" left="751" width="3" height="15" font="1"> </text>
<text top="556" left="751" width="140" height="15" font="1">Exercise capacity increased </text>
<text top="572" left="751" width="156" height="15" font="1">from 13.1±5.5 to 14.9 ±4.5 min </text>
<text top="587" left="751" width="120" height="15" font="1">at 3 mo after successful </text>
<text top="603" left="751" width="153" height="15" font="1">ablation (p&lt;0.002) (due mostly </text>
<text top="618" left="751" width="125" height="15" font="1">to suppressing exercised </text>
<text top="634" left="751" width="81" height="15" font="1">induced PSVT). </text>
<text top="649" left="751" width="3" height="15" font="1"> </text>
<text top="665" left="751" width="130" height="15" font="1">Medical group or those w/ </text>
<text top="680" left="751" width="149" height="15" font="1">unsuccessful ablation  had no </text>
<text top="696" left="751" width="135" height="15" font="1">change in QOL or exercise </text>
<text top="711" left="751" width="44" height="15" font="1">capacity </text>
<text top="371" left="923" width="199" height="15" font="1">While pts randomly assigned to ablation </text>
<text top="386" left="923" width="212" height="15" font="1">vs. medical therapy, only 9 pts allocated to </text>
<text top="401" left="923" width="81" height="15" font="1">medical therapy </text>
<text top="417" left="923" width="3" height="15" font="1"> </text>
<text top="432" left="923" width="189" height="15" font="1">Population – WPW, not other forms of </text>
<text top="448" left="923" width="32" height="15" font="1">PSVT </text>
<text top="728" left="54" width="56" height="15" font="1">Bubien RS </text>
<text top="743" left="54" width="28" height="15" font="1">1996 </text>
<text top="758" left="54" width="29" height="15" font="1">(377) </text>
<text top="774" left="54" width="46" height="15" font="8">8840848 </text>
<text top="774" left="100" width="3" height="15" font="1"> </text>
<text top="728" left="133" width="95" height="15" font="1">Prospective cohort </text>
<text top="743" left="133" width="103" height="15" font="1">study, QOL of PSVT </text>
<text top="728" left="261" width="22" height="15" font="1">188 </text>
<text top="728" left="368" width="76" height="15" font="1">AVNRT (n=59) </text>
<text top="743" left="368" width="68" height="15" font="1">AVRT (n=46) </text>
<text top="758" left="368" width="136" height="15" font="1">AF s/p AVJ ablation (n=22) </text>
<text top="774" left="368" width="112" height="15" font="1">Atrial flutter/AT (n=22) </text>
<text top="789" left="368" width="53" height="15" font="1">VT (n=10) </text>
<text top="728" left="545" width="148" height="15" font="19">RFA associated w/ significant </text>
<text top="743" left="545" width="79" height="15" font="19">improvement in </text>
<text top="743" left="624" width="27" height="15" font="1">QOL </text>
<text top="743" left="650" width="84" height="15" font="19">sustained over 6 </text>
<text top="758" left="545" width="72" height="15" font="19">mo (p&lt;0.005). </text>
<text top="774" left="545" width="3" height="15" font="19"> </text>
<text top="789" left="545" width="132" height="15" font="19">RFA followed by improved </text>
<text top="728" left="751" width="22" height="15" font="1">N/A </text>
<text top="728" left="923" width="197" height="15" font="1">Overall demonstrates benefit of RFA on </text>
<text top="743" left="923" width="115" height="15" font="1">variety of arrhythmias.  </text>
<text top="758" left="923" width="3" height="15" font="1"> </text>
<text top="774" left="923" width="173" height="15" font="1">Tried to minimize response bias w/ </text>
<text top="789" left="923" width="196" height="15" font="19">anonymous mail surveys, self-reporting </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">123 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="368" width="3" height="15" font="1"> </text>
<text top="70" left="368" width="161" height="15" font="1">QOL before, compared w/ 1 and </text>
<text top="86" left="368" width="162" height="15" font="1">6 mo after RFA using SF-36 and </text>
<text top="101" left="368" width="150" height="15" font="19">disease-specific sx checklist—</text>
<text top="117" left="368" width="148" height="15" font="19">Frequency and Severity Scale</text>
<text top="117" left="516" width="3" height="15" font="1"> </text>
<text top="132" left="368" width="3" height="15" font="1"> </text>
<text top="55" left="545" width="179" height="15" font="19">performance of ADLs and a marked </text>
<text top="70" left="545" width="153" height="15" font="19">decrease in number of visits to </text>
<text top="86" left="545" width="180" height="15" font="19">physicians and emergency rooms in </text>
<text top="101" left="545" width="191" height="15" font="19">the 6 mo after RFA compared w/ 6 mo </text>
<text top="117" left="545" width="38" height="15" font="19">before. </text>
<text top="132" left="545" width="3" height="15" font="19"> </text>
<text top="147" left="545" width="136" height="15" font="19">Pt's perception of impact of </text>
<text top="163" left="545" width="183" height="15" font="19">arrhythmias on health improved after </text>
<text top="178" left="545" width="187" height="15" font="19">ablation, maintained between 1 and 6 </text>
<text top="194" left="545" width="89" height="15" font="19">mo after ablation. </text>
<text top="210" left="545" width="3" height="15" font="19"> </text>
<text top="225" left="545" width="190" height="15" font="19">90% of pts indicated that heart rhythm </text>
<text top="240" left="545" width="190" height="15" font="19">problems influenced health perception </text>
<text top="256" left="545" width="188" height="15" font="19">at baseline, and  declined to 59% at 1 </text>
<text top="271" left="545" width="108" height="15" font="19">mo and 58% at 6 mo. </text>
<text top="55" left="923" width="193" height="15" font="19">methods may be confounded by under-</text>
<text top="70" left="923" width="193" height="15" font="19">reporting of undesirable characteristics </text>
<text top="86" left="923" width="193" height="15" font="19">and over-reporting of socially desirable </text>
<text top="101" left="923" width="51" height="15" font="19">behaviors.</text>
<text top="101" left="974" width="3" height="15" font="1"> </text>
<text top="288" left="54" width="65" height="15" font="1">*Bathina MN </text>
<text top="303" left="54" width="28" height="15" font="1">1998 </text>
<text top="319" left="54" width="29" height="15" font="1">(378) </text>
<text top="334" left="54" width="43" height="15" font="8">9732885</text>
<text top="334" left="97" width="3" height="15" font="1"> </text>
<text top="288" left="133" width="61" height="15" font="1">Prospective </text>
<text top="303" left="133" width="91" height="15" font="1">comparison of the </text>
<text top="319" left="133" width="114" height="15" font="1">impact of QOL and CE </text>
<text top="334" left="133" width="92" height="15" font="1">between RFA and </text>
<text top="350" left="133" width="75" height="15" font="1">pharmacologic </text>
<text top="365" left="133" width="88" height="15" font="1">therapy for PSVT </text>
<text top="288" left="261" width="61" height="15" font="1">79 w/ newly-</text>
<text top="303" left="261" width="64" height="15" font="1">documented </text>
<text top="319" left="261" width="35" height="15" font="1">PSVT  </text>
<text top="334" left="261" width="3" height="15" font="1"> </text>
<text top="350" left="261" width="85" height="15" font="1">Average number </text>
<text top="365" left="261" width="80" height="15" font="1">of drugs 1.35/pt </text>
<text top="381" left="261" width="81" height="15" font="1">(CCB, BB, most </text>
<text top="396" left="261" width="49" height="15" font="1">common) </text>
<text top="288" left="368" width="156" height="15" font="1">Exclusions: drug-refractory pts, </text>
<text top="303" left="368" width="159" height="15" font="1">prior treatment, AF, atrial flutter, </text>
<text top="319" left="368" width="66" height="15" font="1">preexcitation </text>
<text top="288" left="545" width="186" height="15" font="1">SF-36 used to measure QOL after 12-</text>
<text top="303" left="545" width="34" height="15" font="1">mo f/u </text>
<text top="288" left="751" width="99" height="15" font="1">RFA vs. medication </text>
<text top="303" left="751" width="3" height="15" font="1"> </text>
<text top="319" left="751" width="60" height="15" font="1">Bodily pain: </text>
<text top="334" left="751" width="88" height="15" font="1">63±24 vs. 81±20 </text>
<text top="350" left="751" width="43" height="15" font="1">p&lt;0.005 </text>
<text top="365" left="751" width="3" height="15" font="1"> </text>
<text top="381" left="751" width="79" height="15" font="1">General health: </text>
<text top="396" left="751" width="88" height="15" font="1">69±21 vs. 79±21 </text>
<text top="412" left="751" width="37" height="15" font="1">p&lt;0.05 </text>
<text top="427" left="751" width="3" height="15" font="1"> </text>
<text top="443" left="751" width="39" height="15" font="1">Vitality: </text>
<text top="458" left="751" width="88" height="15" font="1">55±21 vs. 66±22 </text>
<text top="474" left="751" width="37" height="15" font="1">p&lt;0.05 </text>
<text top="489" left="751" width="3" height="15" font="1"> </text>
<text top="505" left="751" width="71" height="15" font="1">Role emotion: </text>
<text top="520" left="751" width="88" height="15" font="1">78±36 vs. 94±17 </text>
<text top="535" left="751" width="37" height="15" font="1">p&lt;0.05 </text>
<text top="551" left="751" width="3" height="15" font="1"> </text>
<text top="567" left="751" width="145" height="15" font="1">Ablation resulted in complete </text>
<text top="582" left="751" width="149" height="15" font="1">amelioration of sxs in 33% vs. </text>
<text top="597" left="751" width="32" height="15" font="1">74%.  </text>
<text top="288" left="923" width="205" height="15" font="1">First study to prospectively evaluate QOL </text>
<text top="303" left="923" width="204" height="15" font="1">and resource utilization between RFA vs. </text>
<text top="319" left="923" width="84" height="15" font="1">medical therapy. </text>
<text top="334" left="923" width="3" height="15" font="1"> </text>
<text top="350" left="923" width="213" height="15" font="1">Both effective, but RFA improves QOL to a </text>
<text top="365" left="923" width="74" height="15" font="1">greater extent. </text>
<text top="381" left="923" width="3" height="15" font="1"> </text>
<text top="396" left="923" width="3" height="15" font="1"> </text>
<text top="614" left="54" width="37" height="15" font="1">Larson </text>
<text top="629" left="54" width="30" height="15" font="1">msec </text>
<text top="645" left="54" width="28" height="15" font="1">1999 </text>
<text top="660" left="54" width="29" height="15" font="1">(379) </text>
<text top="676" left="54" width="49" height="15" font="8">10468092</text>
<text top="676" left="103" width="3" height="15" font="1"> </text>
<text top="614" left="133" width="103" height="15" font="1">Retrospective single </text>
<text top="629" left="133" width="87" height="15" font="1">center evaluation </text>
<text top="614" left="261" width="79" height="15" font="1">161 pts w/ RFA </text>
<text top="629" left="261" width="92" height="15" font="1">for drug-refractory </text>
<text top="645" left="261" width="41" height="15" font="1">AVNRT </text>
<text top="614" left="368" width="67" height="15" font="1">Not specified </text>
<text top="614" left="545" width="175" height="15" font="1">Duke Activity Status Index used for </text>
<text top="629" left="545" width="88" height="15" font="1">physical function, </text>
<text top="629" left="633" width="53" height="15" font="19">Symptom  </text>
<text top="645" left="545" width="176" height="15" font="19">Checklist—Frequency and Severity </text>
<text top="660" left="545" width="28" height="15" font="19">Scale</text>
<text top="660" left="573" width="157" height="15" font="1">, both used in telephone survey </text>
<text top="614" left="751" width="147" height="15" font="1">Mean number of sxs declined </text>
<text top="629" left="751" width="123" height="15" font="1">from 5.83.1 (p&lt;0.001) </text>
<text top="645" left="751" width="3" height="15" font="1"> </text>
<text top="660" left="751" width="151" height="15" font="1">Moderate-severe sxs declined </text>
<text top="676" left="751" width="104" height="15" font="1">4.61.1 (p&lt;0.0001) </text>
<text top="691" left="751" width="3" height="15" font="1"> </text>
<text top="707" left="751" width="158" height="15" font="1">Urgent care visits declined from </text>
<text top="722" left="751" width="150" height="15" font="1">mean of 4.60.4/y (p&lt;0.001) </text>
<text top="738" left="751" width="3" height="15" font="1"> </text>
<text top="753" left="751" width="139" height="15" font="1">Heath score increased from </text>
<text top="769" left="751" width="102" height="15" font="1">mean of 56.677.3 </text>
<text top="784" left="751" width="57" height="15" font="1">(p&lt;0.0001) </text>
<text top="614" left="923" width="165" height="15" font="1">RFA effective in improving QOL.  </text>
<text top="629" left="923" width="3" height="15" font="1"> </text>
<text top="645" left="923" width="198" height="15" font="1">Although single center, Kaiser is a large </text>
<text top="660" left="923" width="99" height="15" font="1">health care system. </text>
<text top="676" left="923" width="3" height="15" font="1"> </text>
<text top="691" left="923" width="126" height="15" font="1">Susceptible to recall bias </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">124 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="751" width="3" height="15" font="1"> </text>
<text top="70" left="751" width="149" height="15" font="1">Pt utility increased from mean </text>
<text top="86" left="751" width="131" height="15" font="1">of 0.71 to 0.88 (p&lt;0.0001) </text>
<text top="102" left="54" width="53" height="15" font="1">*Goldberg </text>
<text top="117" left="54" width="18" height="15" font="1">AS </text>
<text top="133" left="54" width="28" height="15" font="1">2002 </text>
<text top="148" left="54" width="29" height="15" font="1">(380) </text>
<text top="164" left="54" width="52" height="15" font="8">11988206 </text>
<text top="164" left="106" width="3" height="15" font="1"> </text>
<text top="102" left="133" width="61" height="15" font="1">Prospective </text>
<text top="117" left="133" width="100" height="15" font="1">comparison on long-</text>
<text top="133" left="133" width="100" height="15" font="1">term effects of QOL </text>
<text top="148" left="133" width="92" height="15" font="1">between RFA and </text>
<text top="164" left="133" width="75" height="15" font="1">pharmacologic </text>
<text top="179" left="133" width="88" height="15" font="1">therapy for PSVT </text>
<text top="102" left="261" width="79" height="15" font="1">83 pts w/ newly-</text>
<text top="117" left="261" width="54" height="15" font="1">diagnosed </text>
<text top="133" left="261" width="65" height="15" font="1">symptomatic </text>
<text top="148" left="261" width="32" height="15" font="1">PSVT </text>
<text top="164" left="261" width="3" height="15" font="1"> </text>
<text top="179" left="261" width="85" height="15" font="1">Average number </text>
<text top="195" left="261" width="80" height="15" font="1">of drugs 1.49/pt </text>
<text top="210" left="261" width="49" height="15" font="1">(BB most </text>
<text top="226" left="261" width="49" height="15" font="1">common) </text>
<text top="241" left="261" width="3" height="15" font="1"> </text>
<text top="257" left="261" width="86" height="15" font="1">39 w/ initial RFA, </text>
<text top="272" left="261" width="58" height="15" font="1">44 w/ initial </text>
<text top="288" left="261" width="81" height="15" font="1">medical therapy </text>
<text top="303" left="261" width="78" height="15" font="1">(of which 22/44 </text>
<text top="319" left="261" width="84" height="15" font="1">underwent RFA) </text>
<text top="102" left="368" width="161" height="15" font="1">Referred specifically for ablation </text>
<text top="117" left="368" width="145" height="15" font="1">Excluded AF and atrial flutter </text>
<text top="133" left="368" width="3" height="15" font="1"> </text>
<text top="148" left="368" width="73" height="15" font="1">AVNRT (67%) </text>
<text top="164" left="368" width="97" height="15" font="1">AVRT w/ AP (28%) </text>
<text top="179" left="368" width="44" height="15" font="1">AT (5%) </text>
<text top="195" left="368" width="3" height="15" font="1"> </text>
<text top="102" left="545" width="189" height="15" font="1">SF-36 used to measure QOL after 1-y </text>
<text top="117" left="545" width="55" height="15" font="1">and 5-y f/u </text>
<text top="133" left="545" width="3" height="15" font="1"> </text>
<text top="148" left="545" width="122" height="15" font="1">At 5-y f/u, both RFA and </text>
<text top="164" left="545" width="178" height="15" font="1">pharmacologic therapy w/ improved </text>
<text top="179" left="545" width="154" height="15" font="1">scores (cumulative p&lt;0.05 and </text>
<text top="195" left="545" width="112" height="15" font="1">p&lt;0.001, respectively) </text>
<text top="210" left="545" width="3" height="15" font="1"> </text>
<text top="226" left="545" width="189" height="15" font="1">RFA significantly improved in physical </text>
<text top="241" left="545" width="188" height="15" font="1">function, physical role, emotional role, </text>
<text top="257" left="545" width="114" height="15" font="1">mental health (p&lt;0.05) </text>
<text top="272" left="545" width="3" height="15" font="1"> </text>
<text top="288" left="545" width="154" height="15" font="1">At 5-y f/u, there was greater sx </text>
<text top="303" left="545" width="162" height="15" font="1">reduction in RFA group (p&lt;0.01) </text>
<text top="319" left="545" width="146" height="15" font="1">compared to medical therapy </text>
<text top="334" left="545" width="3" height="15" font="1"> </text>
<text top="350" left="545" width="177" height="15" font="1">Improvement in sxs who underwent </text>
<text top="365" left="545" width="193" height="15" font="1">initial RFA or cross-over to RFA after 5 </text>
<text top="381" left="545" width="158" height="15" font="1">y, compared to medical therapy </text>
<text top="396" left="545" width="45" height="15" font="1">(p&lt;0.05) </text>
<text top="412" left="545" width="3" height="15" font="1"> </text>
<text top="427" left="545" width="189" height="15" font="15">Over 5 y, the average cumulative cost </text>
<text top="443" left="545" width="177" height="15" font="15">for pts in the ablation therapy group </text>
<text top="458" left="545" width="188" height="15" font="15">was $7,507± $1,098.  The cumulative </text>
<text top="474" left="545" width="181" height="15" font="15">cost for pts in medical therapy group </text>
<text top="489" left="545" width="167" height="15" font="15">was significantly lower than in pts </text>
<text top="505" left="545" width="173" height="15" font="15">initially treated w/ ablation therapy: </text>
<text top="520" left="545" width="118" height="15" font="15">$6,249±$1,421, p&lt;0.05.</text>
<text top="520" left="664" width="3" height="15" font="1"> </text>
<text top="102" left="751" width="22" height="15" font="1">N/A </text>
<text top="102" left="923" width="204" height="15" font="1">RFA was associated w/ higher QOL in all </text>
<text top="117" left="923" width="201" height="15" font="1">health concepts at 1 y; this improvement </text>
<text top="133" left="923" width="191" height="15" font="1">was sustained in the physical function, </text>
<text top="148" left="923" width="201" height="15" font="1">emotional role, physical role, and mental </text>
<text top="164" left="923" width="108" height="15" font="1">health subsets at 5 y. </text>
<text top="179" left="923" width="3" height="15" font="1"> </text>
<text top="195" left="923" width="210" height="15" font="1">Cost estimated to be higher in RFA group. </text>
<text top="210" left="923" width="3" height="15" font="1"> </text>
<text top="226" left="923" width="200" height="15" font="1">Offers 5 y f/u and includes pts who were </text>
<text top="241" left="923" width="97" height="15" font="1">not drug-refractory. </text>
<text top="257" left="923" width="3" height="15" font="9"> </text>
<text top="536" left="54" width="61" height="15" font="1">Walfridsson </text>
<text top="552" left="54" width="11" height="15" font="1">U </text>
<text top="567" left="54" width="28" height="15" font="1">2005 </text>
<text top="583" left="54" width="23" height="15" font="1">(15) </text>
<text top="598" left="54" width="49" height="15" font="8">15733177</text>
<text top="598" left="103" width="3" height="15" font="1"> </text>
<text top="614" left="54" width="3" height="15" font="1"> </text>
<text top="536" left="133" width="96" height="15" font="1">Impact of PSVT on </text>
<text top="552" left="133" width="95" height="15" font="1">perceived ability to </text>
<text top="567" left="133" width="30" height="15" font="1">drive  </text>
<text top="536" left="261" width="36" height="15" font="1">N=301 </text>
<text top="552" left="261" width="3" height="15" font="1"> </text>
<text top="567" left="261" width="62" height="15" font="1">Interview w/ </text>
<text top="583" left="261" width="52" height="15" font="1">structured </text>
<text top="598" left="261" width="51" height="15" font="1">questions </text>
<text top="536" left="368" width="134" height="15" font="1">Pts referred for ablation, of </text>
<text top="552" left="368" width="148" height="15" font="1">which 226 were active drivers </text>
<text top="567" left="368" width="3" height="15" font="1"> </text>
<text top="536" left="545" width="22" height="15" font="1">N/A </text>
<text top="536" left="751" width="158" height="15" font="1">Sxs among drivers (irrespective </text>
<text top="552" left="751" width="119" height="15" font="1">of driving): fatigue 77%, </text>
<text top="567" left="751" width="132" height="15" font="1">dizziness 47%, cold sweat </text>
<text top="583" left="751" width="141" height="15" font="1">(52%), near syncope (50%), </text>
<text top="598" left="751" width="149" height="15" font="1">syncope (14%). Women more </text>
<text top="614" left="751" width="114" height="15" font="1">symptomatic than men </text>
<text top="629" left="751" width="51" height="15" font="1">(p&lt;0.05).  </text>
<text top="645" left="751" width="3" height="15" font="1"> </text>
<text top="660" left="751" width="159" height="15" font="1">57% had sxs while driving, 42% </text>
<text top="676" left="751" width="137" height="15" font="1">of those pts needed to stop </text>
<text top="691" left="751" width="138" height="15" font="1">driving and 24 pts regarded </text>
<text top="707" left="751" width="114" height="15" font="1">their tachycardia as an </text>
<text top="722" left="751" width="110" height="15" font="1">obstacle to driving, w/ </text>
<text top="738" left="751" width="139" height="15" font="1">correlation (p&lt;0.001) if near </text>
<text top="753" left="751" width="90" height="15" font="1">syncope was a sx </text>
<text top="536" left="923" width="202" height="15" font="1">PSVT common while driving. Correlation </text>
<text top="552" left="923" width="191" height="15" font="1">of near syncope as sx w/ deciding that </text>
<text top="567" left="923" width="150" height="15" font="1">PSVT was obstacle to driving. </text>
<text top="769" left="54" width="58" height="15" font="1">Meissner A </text>
<text top="785" left="54" width="28" height="15" font="1">2009 </text>
<text top="769" left="133" width="182" height="15" font="1">QOL pre-post RFA 309 </text>
<text top="769" left="368" width="82" height="15" font="1">AVNRT (n=230) </text>
<text top="785" left="368" width="68" height="15" font="1">AVRT (n=66) </text>
<text top="769" left="545" width="184" height="15" font="1">QOL following ablation, measured w/ </text>
<text top="785" left="545" width="153" height="15" font="1">SF-36 and Symptom Checklist-</text>
<text top="769" left="751" width="69" height="15" font="1">F/u 4.5±1.3 y </text>
<text top="785" left="751" width="3" height="15" font="1"> </text>
<text top="769" left="923" width="146" height="15" font="1">Large series w/ long-term f/u. </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">125 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="29" height="15" font="1">(381) </text>
<text top="70" left="54" width="52" height="15" font="8">19158961 </text>
<text top="70" left="106" width="3" height="15" font="1"> </text>
<text top="55" left="368" width="53" height="15" font="1">AT (n=13) </text>
<text top="55" left="545" width="151" height="15" font="1">Frequency and Severity Scale </text>
<text top="55" left="751" width="147" height="15" font="1">QOL significantly improved in </text>
<text top="70" left="751" width="152" height="15" font="1">AVNRT (p&lt;0.0005) and AVRT </text>
<text top="86" left="751" width="96" height="15" font="1">(p&lt;0.04); AT p=NS </text>
<text top="101" left="751" width="3" height="15" font="1"> </text>
<text top="117" left="751" width="138" height="15" font="1">Pre-RFA sxs of tachycardia </text>
<text top="132" left="751" width="158" height="15" font="1">(91.5%), increased incidence of </text>
<text top="147" left="751" width="156" height="15" font="1">tachycardia episodes over time </text>
<text top="163" left="751" width="128" height="15" font="1">(78.1%), anxiety (55.5%), </text>
<text top="178" left="751" width="141" height="15" font="1">reduced physical capacity in </text>
<text top="194" left="751" width="136" height="15" font="1">daily life (52%) significantly </text>
<text top="210" left="751" width="155" height="15" font="1">improved post RFA (p&lt;0.0001) </text>
<text top="226" left="54" width="61" height="15" font="1">Walfridsson </text>
<text top="241" left="54" width="11" height="15" font="1">U </text>
<text top="257" left="54" width="28" height="15" font="1">2009 </text>
<text top="272" left="54" width="23" height="15" font="1">(19) </text>
<text top="288" left="54" width="49" height="15" font="8">19702600</text>
<text top="288" left="103" width="3" height="15" font="1"> </text>
<text top="226" left="133" width="64" height="15" font="1">QOL Survey </text>
<text top="226" left="261" width="87" height="15" font="1">Pts w/ AVRT and </text>
<text top="241" left="261" width="82" height="15" font="1">AVNRT referred </text>
<text top="257" left="261" width="41" height="15" font="1">for RFA </text>
<text top="226" left="368" width="76" height="15" font="1">AVNRT (n=97) </text>
<text top="241" left="368" width="68" height="15" font="1">AVRT (n=79) </text>
<text top="257" left="368" width="3" height="15" font="1"> </text>
<text top="226" left="545" width="184" height="15" font="1">QOL scores measured by SF-36 and </text>
<text top="241" left="545" width="150" height="15" font="1">EuroQol, and disease-specific </text>
<text top="257" left="545" width="170" height="15" font="1">questions, compared w/ reference </text>
<text top="272" left="545" width="31" height="15" font="1">group </text>
<text top="226" left="751" width="149" height="15" font="1">QOL scores were significantly </text>
<text top="241" left="751" width="118" height="15" font="1">lower for pts w/ AVNRT </text>
<text top="257" left="751" width="148" height="15" font="1">compared to AVRT in several </text>
<text top="272" left="751" width="132" height="15" font="1">SF-36 measures (physical </text>
<text top="288" left="751" width="158" height="15" font="1">functioning, general health, and </text>
<text top="303" left="751" width="135" height="15" font="1">bodily pain) as w/ EuroQol. </text>
<text top="319" left="751" width="3" height="15" font="1"> </text>
<text top="334" left="751" width="155" height="15" font="1">Scores significantly affected by </text>
<text top="350" left="751" width="122" height="15" font="1">occurrence &gt;once a mo, </text>
<text top="365" left="751" width="123" height="15" font="1">arrhythmia duration, and </text>
<text top="381" left="751" width="150" height="15" font="1">whether sxs occurred not only </text>
<text top="396" left="751" width="157" height="15" font="1">during exercise but also at rest  </text>
<text top="226" left="923" width="174" height="15" font="1">Arrhythmia recurrence important to </text>
<text top="241" left="923" width="171" height="15" font="1">consider when setting priorities for </text>
<text top="257" left="923" width="95" height="15" font="1">treatment w/ RFA.  </text>
<text top="412" left="54" width="50" height="15" font="1">Wood KA </text>
<text top="428" left="54" width="28" height="15" font="1">2010 </text>
<text top="443" left="54" width="29" height="15" font="1">(288) </text>
<text top="459" left="54" width="49" height="15" font="8">20109982</text>
<text top="459" left="103" width="3" height="15" font="1"> </text>
<text top="412" left="133" width="176" height="15" font="1">QOL pre-post RFA 52 </text>
<text top="412" left="368" width="76" height="15" font="1">AVNRT (n=30) </text>
<text top="428" left="368" width="68" height="15" font="1">AVRT (n=16) </text>
<text top="443" left="368" width="46" height="15" font="1">AT (n=6) </text>
<text top="412" left="545" width="184" height="15" font="1">QOL following ablation, measured w/ </text>
<text top="428" left="545" width="187" height="15" font="1">Patient Perception scale, 3 subscales </text>
<text top="443" left="545" width="177" height="15" font="1">of SF-36, 2 subscales from Medical </text>
<text top="459" left="545" width="170" height="15" font="1">Outcomes Study, disease-specific </text>
<text top="474" left="545" width="52" height="15" font="1">measures </text>
<text top="412" left="751" width="133" height="15" font="1">Significant improvement in </text>
<text top="428" left="751" width="158" height="15" font="1">most sxs post-ablation (p&lt;0.05) </text>
<text top="443" left="751" width="3" height="15" font="1"> </text>
<text top="459" left="751" width="159" height="15" font="1">No sxs completely eliminated at </text>
<text top="474" left="751" width="55" height="15" font="1">one mo f/u </text>
<text top="490" left="751" width="3" height="15" font="1"> </text>
<text top="505" left="751" width="120" height="15" font="1">Effect greater in women </text>
<text top="412" left="923" width="172" height="15" font="1">Ablation improves QOL on several </text>
<text top="428" left="923" width="213" height="15" font="1">measures, both generic and PSVT-specific </text>
<text top="443" left="923" width="55" height="15" font="1">measures. </text>
<text top="459" left="923" width="3" height="15" font="1"> </text>
<text top="474" left="923" width="48" height="15" font="1">Short f/u. </text>
<text top="522" left="54" width="49" height="15" font="1">Yildrim O </text>
<text top="537" left="54" width="28" height="15" font="1">2010 </text>
<text top="552" left="54" width="29" height="15" font="1">(382) </text>
<text top="568" left="54" width="49" height="15" font="8">23280027</text>
<text top="568" left="103" width="3" height="15" font="1"> </text>
<text top="522" left="133" width="176" height="15" font="1">QOL pre-post RFA 50 </text>
<text top="522" left="277" width="36" height="15" font="1"> </text>
<text top="522" left="368" width="76" height="15" font="1">AVNRT (n=28) </text>
<text top="537" left="368" width="68" height="15" font="1">AVRT (n=22) </text>
<text top="522" left="545" width="181" height="15" font="1">WHOQOL-BREF and STAI domains </text>
<text top="522" left="751" width="130" height="15" font="1">Prior to RFA, greater than </text>
<text top="537" left="751" width="156" height="15" font="1">average anxiety score (p&lt;0.05) </text>
<text top="552" left="751" width="3" height="15" font="1"> </text>
<text top="568" left="751" width="154" height="15" font="1">All items significantly improved </text>
<text top="583" left="751" width="150" height="15" font="1">post-RFA—anxiety, QOL, and </text>
<text top="599" left="751" width="127" height="15" font="1">health satisfaction scores </text>
<text top="522" left="923" width="162" height="15" font="1">RFA improves anxiety and QOL. </text>
<text top="537" left="923" width="3" height="15" font="1"> </text>
<text top="552" left="923" width="210" height="15" font="1">Limited by 3 mo f/u, but consistent w/ prior </text>
<text top="568" left="923" width="30" height="15" font="1">work. </text>
<text top="615" left="54" width="53" height="15" font="1">Farkowski </text>
<text top="631" left="54" width="22" height="15" font="1">MM </text>
<text top="646" left="54" width="28" height="15" font="1">2014 </text>
<text top="662" left="54" width="29" height="15" font="1">(383) </text>
<text top="677" left="54" width="49" height="15" font="8">24919538</text>
<text top="677" left="103" width="3" height="15" font="1"> </text>
<text top="615" left="133" width="98" height="15" font="1">Prospective cohort, </text>
<text top="631" left="133" width="75" height="15" font="1">gender-related </text>
<text top="646" left="133" width="69" height="15" font="1">differences in </text>
<text top="662" left="133" width="95" height="15" font="1">outcomes pre-post </text>
<text top="677" left="133" width="25" height="15" font="1">RFA </text>
<text top="615" left="261" width="15" height="15" font="1">64 </text>
<text top="615" left="368" width="142" height="15" font="1">AVNRT (n=40, 32 women, 8 </text>
<text top="631" left="368" width="28" height="15" font="1">men) </text>
<text top="646" left="368" width="140" height="15" font="1">AVRT (n=26, 11 women, 15 </text>
<text top="662" left="368" width="28" height="15" font="1">men) </text>
<text top="677" left="368" width="134" height="15" font="1">(2 pts did not complete f/u) </text>
<text top="615" left="545" width="180" height="15" font="1">QOL measured by PPAQ, EQ-5D-3L</text>
<text top="615" left="725" width="3" height="15" font="9"> </text>
<text top="615" left="751" width="147" height="15" font="1">41 women completed survey. </text>
<text top="631" left="751" width="3" height="15" font="1"> </text>
<text top="646" left="751" width="114" height="15" font="1">No significant baseline </text>
<text top="662" left="751" width="133" height="15" font="1">differences except AVNRT </text>
<text top="677" left="751" width="139" height="15" font="1">prevalence, and HRQOL by </text>
<text top="693" left="751" width="38" height="15" font="1">gender </text>
<text top="708" left="751" width="3" height="15" font="1"> </text>
<text top="724" left="751" width="119" height="15" font="1">Women reported higher </text>
<text top="739" left="751" width="147" height="15" font="1">severity of sxs on PPAQ than </text>
<text top="755" left="751" width="75" height="15" font="1">men (p&lt;0.001) </text>
<text top="770" left="751" width="3" height="15" font="1"> </text>
<text top="786" left="751" width="133" height="15" font="1">At 2 mo after RFA, women </text>
<text top="615" left="923" width="176" height="15" font="1">Small but significant gender-related </text>
<text top="631" left="923" width="190" height="15" font="1">difference in outcome of RFA in pts w/ </text>
<text top="646" left="923" width="203" height="15" font="1">AVNRT or AVRT measured w/ a disease-</text>
<text top="662" left="923" width="95" height="15" font="1">specific instrument </text>
<text top="677" left="923" width="3" height="15" font="1"> </text>
<text top="693" left="923" width="210" height="15" font="1">No significant difference in QOL or access </text>
<text top="708" left="923" width="202" height="15" font="1">to healthcare resources between women </text>
<text top="724" left="923" width="49" height="15" font="1">and men. </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">126 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="751" width="151" height="15" font="1">reported higher severity of sxs </text>
<text top="70" left="751" width="144" height="15" font="1">(p=0.02) on PPAQ and more </text>
<text top="86" left="751" width="121" height="15" font="1">heart skipping than men </text>
<text top="101" left="751" width="57" height="15" font="1">(p=0.0014) </text>
<text top="117" left="751" width="3" height="15" font="1"> </text>
<text top="132" left="751" width="133" height="15" font="1">No significant difference in </text>
<text top="147" left="751" width="150" height="15" font="1">healthcare resource utilization </text>
<text top="163" left="751" width="138" height="15" font="1">during the y preceding RFA </text>
<text top="178" left="751" width="3" height="15" font="1"> </text>
<text top="194" left="751" width="154" height="15" font="1">AADs more often prescribed to </text>
<text top="210" left="751" width="111" height="15" font="1">women pre-procedure </text>
<text top="225" left="751" width="51" height="15" font="1">(p=0.022) </text>
<text top="241" left="54" width="179" height="15" font="1">*Study addressed both CE and QoL </text>
<text top="257" left="54" width="1054" height="15" font="1">AAD indicates antiarrhythmic drug; ADL, activities of daily living; AF, atrial fibrillation; AP, accessory pathway; AT, atrial tachycardia; AVJ, atrioventricular junction; AVNRT, atrioventricular nodal reentrant tachycardia; </text>
<text top="272" left="54" width="1065" height="15" font="1">AVRT, atrioventricular reentrant tachycardia; BB, beta blocker; CCB, calcium channel blocker; CE, cost effectiveness; EQ-5D-3L, EuroQol Research Foundation questionnaire; ETT, exercisetreadmill test; f/u, follow up; </text>
<text top="288" left="54" width="1053" height="15" font="1">HRQOL, health-related quality of life; N/A, not applicable; PPAQ, Patient Perception of Arrhythmia Questionnaire; PSVT, paroxysmal supraventricular tachycardia; pt, patient; QOL, quality of life; RFA, radiofrequency </text>
<text top="303" left="54" width="1058" height="15" font="1">ablation; SF-36, Short Form (36) Health Survey; s/p, status post; STAI, State and Trait Anxiety Inventory; sx, symptom; VT, ventricular tachycardia; w/, with; WHOQOL-BREF, World Health Organization Quality of Life </text>
<text top="319" left="54" width="255" height="15" font="1">Scale; and WPW, Wolff-Parkison-White syndrome.  </text>
<text top="334" left="54" width="3" height="15" font="1"> </text>
<text top="359" left="54" width="151" height="18" font="3"><b>Data Supplement 23. </b></text>
<text top="359" left="205" width="695" height="18" font="7"><b>Nonrandomized Trials, Observational Studies, and/or Registries of Cost Effectiveness – Section 11 </b></text>
<text top="359" left="900" width="4" height="18" font="3"><b> </b></text>
<text top="379" left="67" width="38" height="17" font="5"><b>Study </b></text>
<text top="396" left="65" width="40" height="17" font="5"><b>Name, </b></text>
<text top="413" left="62" width="47" height="17" font="5"><b>Author, </b></text>
<text top="430" left="70" width="30" height="17" font="5"><b>Year </b></text>
<text top="379" left="152" width="73" height="17" font="5"><b>Study Type/ </b></text>
<text top="396" left="166" width="44" height="17" font="5"><b>Design </b></text>
<text top="379" left="280" width="66" height="17" font="5"><b>Study Size </b></text>
<text top="379" left="393" width="119" height="17" font="5"><b>Inclusion/Exclusion </b></text>
<text top="396" left="429" width="46" height="17" font="5"><b>Criteria </b></text>
<text top="379" left="566" width="106" height="17" font="5"><b>Primary Endpoint </b></text>
<text top="379" left="768" width="102" height="17" font="5"><b>Results/p Values </b></text>
<text top="379" left="970" width="137" height="17" font="5"><b>Summary/Conclusions </b></text>
<text top="448" left="54" width="54" height="15" font="1">De Buitlier </text>
<text top="463" left="54" width="12" height="15" font="1">M </text>
<text top="479" left="54" width="28" height="15" font="1">1990 </text>
<text top="494" left="54" width="29" height="15" font="1">(384) </text>
<text top="510" left="54" width="43" height="15" font="8">2371949</text>
<text top="510" left="97" width="3" height="15" font="1"> </text>
<text top="448" left="130" width="105" height="15" font="1">Retrospective cohort </text>
<text top="463" left="130" width="117" height="15" font="1">study to evaluate CE of </text>
<text top="479" left="130" width="104" height="15" font="1">AP RFA c/w surgical </text>
<text top="494" left="130" width="42" height="15" font="1">ablation </text>
<text top="448" left="260" width="15" height="15" font="1">22 </text>
<text top="448" left="378" width="135" height="15" font="1">Pts w/ APs who underwent </text>
<text top="463" left="378" width="121" height="15" font="1">RFA or surgical ablation </text>
<text top="479" left="378" width="61" height="15" font="1">(n=11 RFA) </text>
<text top="494" left="378" width="118" height="15" font="1">(n=11 surgical ablation) </text>
<text top="448" left="540" width="154" height="15" font="1">Health care cost, w/ secondary </text>
<text top="463" left="540" width="71" height="15" font="1">endpoint LOS </text>
<text top="448" left="712" width="198" height="15" font="1">RFA success: 73% (all w/ posteroseptal </text>
<text top="463" left="712" width="22" height="15" font="1">AP) </text>
<text top="479" left="712" width="206" height="15" font="1">Surgical success: 100% (right, left lateral, </text>
<text top="494" left="712" width="91" height="15" font="1">posteroseptal AP) </text>
<text top="510" left="712" width="3" height="15" font="1"> </text>
<text top="525" left="712" width="82" height="15" font="1">RFA LOS 6±2 d </text>
<text top="541" left="712" width="103" height="15" font="1">Surgical LOS 8±4  d </text>
<text top="556" left="712" width="3" height="15" font="1"> </text>
<text top="572" left="712" width="143" height="15" font="1">RFA cost: 14,116±4,493 c/w </text>
<text top="587" left="712" width="156" height="15" font="1">34,175±5,434 in surgical group </text>
<text top="603" left="712" width="60" height="15" font="1">(p&lt;0.0001). </text>
<text top="618" left="712" width="3" height="15" font="1"> </text>
<text top="634" left="712" width="197" height="15" font="1">Mean time lost from work or school was </text>
<text top="649" left="712" width="185" height="15" font="1">10± 5 d in RFA group c/w 60±16 d in </text>
<text top="665" left="712" width="120" height="15" font="1">surgical group (p&lt;0.01). </text>
<text top="448" left="939" width="63" height="15" font="1">1988 dollars </text>
<text top="463" left="939" width="3" height="15" font="1"> </text>
<text top="479" left="939" width="190" height="15" font="1">RFA of APs substantially lower in cost </text>
<text top="494" left="939" width="153" height="15" font="1">and LOS c/w surgical ablation. </text>
<text top="681" left="54" width="57" height="15" font="1">De Buitlier  </text>
<text top="697" left="54" width="12" height="15" font="1">M </text>
<text top="712" left="54" width="28" height="15" font="1">1991 </text>
<text top="728" left="54" width="29" height="15" font="1">(385) </text>
<text top="743" left="54" width="43" height="15" font="8">1746469</text>
<text top="743" left="97" width="3" height="15" font="1"> </text>
<text top="681" left="130" width="105" height="15" font="1">Retrospective cohort </text>
<text top="697" left="130" width="117" height="15" font="1">study to evaluate CE of </text>
<text top="712" left="130" width="104" height="15" font="1">AP RFA c/w surgical </text>
<text top="728" left="130" width="42" height="15" font="1">ablation </text>
<text top="681" left="260" width="15" height="15" font="1">50 </text>
<text top="697" left="260" width="3" height="15" font="1"> </text>
<text top="681" left="378" width="135" height="15" font="1">Pts w/ APs who underwent </text>
<text top="697" left="378" width="121" height="15" font="1">RFA or surgical ablation </text>
<text top="712" left="378" width="91" height="15" font="1">(n=25 RFA, 1990) </text>
<text top="728" left="378" width="118" height="15" font="1">(n=25 surgical ablation, </text>
<text top="743" left="378" width="31" height="15" font="1">1989) </text>
<text top="681" left="540" width="154" height="15" font="1">Health care cost, w/ secondary </text>
<text top="697" left="540" width="71" height="15" font="1">endpoint LOS </text>
<text top="681" left="712" width="199" height="15" font="1">Success rate was 96% for both groups.  </text>
<text top="697" left="712" width="3" height="15" font="1"> </text>
<text top="712" left="712" width="201" height="15" font="1">Mean LOS was 3±1 d in RFA group and </text>
<text top="728" left="712" width="179" height="15" font="1">9±4 d in surgical group (p&lt;0.0001).  </text>
<text top="743" left="712" width="3" height="15" font="1"> </text>
<text top="758" left="712" width="209" height="15" font="1">RFA total cost $14,919 c/w $53,265 in the </text>
<text top="774" left="712" width="136" height="15" font="1">surgical group (p&lt;0.0001).  </text>
<text top="681" left="939" width="91" height="15" font="1">1990/1991 dollars </text>
<text top="697" left="939" width="3" height="15" font="1"> </text>
<text top="712" left="939" width="190" height="15" font="1">RFA of APs substantially lower in cost </text>
<text top="728" left="939" width="153" height="15" font="1">and LOS c/w surgical ablation. </text>
<text top="790" left="54" width="57" height="15" font="1">Kalbfleisch </text>
<text top="790" left="130" width="106" height="15" font="1">Retrospective review </text>
<text top="790" left="260" width="15" height="15" font="1">15 </text>
<text top="790" left="378" width="131" height="15" font="1">Symptomatic AVNRT who </text>
<text top="790" left="540" width="151" height="15" font="1">RFA cost of $15,893 would be </text>
<text top="790" left="712" width="461" height="15" font="1">N/A 1991 </text>
<text top="790" left="967" width="36" height="15" font="1">dollars </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">127 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="54" width="16" height="15" font="1">SJ </text>
<text top="70" left="54" width="28" height="15" font="1">1992 </text>
<text top="86" left="54" width="29" height="15" font="1">(386) </text>
<text top="101" left="54" width="43" height="15" font="8">1593054</text>
<text top="101" left="97" width="3" height="15" font="1"> </text>
<text top="55" left="130" width="83" height="15" font="1">to establish cost-</text>
<text top="70" left="130" width="108" height="15" font="1">advantage of RFA for </text>
<text top="86" left="130" width="41" height="15" font="1">AVNRT </text>
<text top="55" left="378" width="80" height="15" font="1">underwent RFA </text>
<text top="55" left="540" width="151" height="15" font="1">advantageous after 10 y in pts </text>
<text top="70" left="540" width="134" height="15" font="1">who visit ED once per y (in </text>
<text top="86" left="540" width="139" height="15" font="1">study medical therapy more </text>
<text top="101" left="540" width="130" height="15" font="1">expensive after 2 y due to </text>
<text top="117" left="540" width="131" height="15" font="1">frequent ED visits in study </text>
<text top="132" left="540" width="64" height="15" font="1">population).  </text>
<text top="147" left="540" width="3" height="15" font="1"> </text>
<text top="163" left="540" width="76" height="15" font="1">Perspective: pt </text>
<text top="178" left="540" width="135" height="15" font="1">Outcomes: annual charges </text>
<text top="55" left="939" width="3" height="15" font="1"> </text>
<text top="70" left="939" width="173" height="15" font="1">Early report using hospital charges </text>
<text top="86" left="939" width="175" height="15" font="1">showing cost advantage of RFA for </text>
<text top="101" left="939" width="41" height="15" font="1">AVNRT </text>
<text top="117" left="939" width="3" height="15" font="1"> </text>
<text top="132" left="939" width="164" height="15" font="1">Medical therapy at the time more </text>
<text top="147" left="939" width="183" height="15" font="1">expensive given drugs may not have </text>
<text top="163" left="939" width="115" height="15" font="1">been at generic prices. </text>
<text top="178" left="939" width="3" height="15" font="1"> </text>
<text top="194" left="939" width="3" height="15" font="1"> </text>
<text top="210" left="54" width="56" height="15" font="1">Hogenhuis </text>
<text top="226" left="54" width="14" height="15" font="1">W </text>
<text top="241" left="54" width="28" height="15" font="1">1993 </text>
<text top="257" left="54" width="29" height="15" font="1">(387) </text>
<text top="272" left="54" width="46" height="15" font="8">8222191 </text>
<text top="272" left="100" width="3" height="15" font="1"> </text>
<text top="210" left="130" width="110" height="15" font="1">CE of management in </text>
<text top="226" left="130" width="31" height="15" font="1">WPW </text>
<text top="210" left="260" width="76" height="15" font="1">Markov model, </text>
<text top="226" left="260" width="97" height="15" font="1">none-specified, but </text>
<text top="241" left="260" width="80" height="15" font="1">costs estimated </text>
<text top="257" left="260" width="90" height="15" font="1">from convenience </text>
<text top="272" left="260" width="84" height="15" font="1">sample of 13 pts </text>
<text top="210" left="378" width="22" height="15" font="1">N/A </text>
<text top="210" left="540" width="119" height="15" font="1">Evaluation of 5 different </text>
<text top="226" left="540" width="54" height="15" font="1">strategies: </text>
<text top="241" left="540" width="64" height="15" font="1">-observation </text>
<text top="257" left="540" width="117" height="15" font="1">- observation until SCD </text>
<text top="272" left="540" width="156" height="15" font="1">-therapy guided by noninvasive </text>
<text top="288" left="540" width="61" height="15" font="1">monitoring,  </text>
<text top="303" left="540" width="60" height="15" font="1">-initial RFA  </text>
<text top="319" left="540" width="115" height="15" font="1">-initial surgical ablation </text>
<text top="334" left="540" width="3" height="15" font="1"> </text>
<text top="350" left="540" width="113" height="15" font="1">Perspective: largely pt-</text>
<text top="365" left="540" width="60" height="15" font="1">perspective </text>
<text top="381" left="540" width="159" height="15" font="1">Outcomes: QALY and mortality, </text>
<text top="396" left="540" width="102" height="15" font="1">using Markov Model </text>
<text top="210" left="712" width="209" height="15" font="1">RFA yields life expectancy greater than or </text>
<text top="226" left="712" width="122" height="15" font="1">equal to other strategies </text>
<text top="241" left="712" width="3" height="15" font="1"> </text>
<text top="257" left="712" width="58" height="15" font="1">40 y-old pt: </text>
<text top="272" left="712" width="100" height="15" font="1">Observation: $2360 </text>
<text top="288" left="712" width="97" height="15" font="1">RFA: $5,150-6,250 </text>
<text top="303" left="712" width="88" height="15" font="1">Surgery: $15,120 </text>
<text top="319" left="712" width="188" height="15" font="1">Observation w/ RFA at cardiac arrest: </text>
<text top="334" left="712" width="43" height="15" font="1">$16,860 </text>
<text top="350" left="712" width="113" height="15" font="1">Drug therapy: $20,250 </text>
<text top="365" left="712" width="3" height="15" font="1"> </text>
<text top="381" left="712" width="192" height="15" font="1">In cardiac arrest survivors and pts who </text>
<text top="396" left="712" width="184" height="15" font="1">have had PSVT/AF w/ hemodynamic </text>
<text top="412" left="712" width="192" height="15" font="1">compromise, RFA should both prolong </text>
<text top="427" left="712" width="140" height="15" font="1">survival and save resources </text>
<text top="443" left="712" width="3" height="15" font="1"> </text>
<text top="458" left="712" width="193" height="15" font="1">For pts w/ PSVT/AF w/o hemodynamic </text>
<text top="474" left="712" width="154" height="15" font="1">compromise, the marginal cost-</text>
<text top="489" left="712" width="194" height="15" font="1">effectiveness of attempted RFA ranges </text>
<text top="505" left="712" width="209" height="15" font="1">from $6,600 per QALY gained for 20-y old </text>
<text top="520" left="712" width="202" height="15" font="1">pts to $19,000 per QALY gained for 60-y </text>
<text top="535" left="712" width="42" height="15" font="1">old pts.  </text>
<text top="551" left="712" width="3" height="15" font="1"> </text>
<text top="567" left="712" width="191" height="15" font="1">For asymptomatic pts, RFA costs from </text>
<text top="582" left="712" width="213" height="15" font="1">$174,000 per QALY gained for 20-y old pts </text>
<text top="598" left="712" width="208" height="15" font="1">to $540,000 per QALY gained for 60-y old </text>
<text top="613" left="712" width="18" height="15" font="1">pts </text>
<text top="210" left="939" width="191" height="15" font="1">Supports RFA in WPW syndrome who </text>
<text top="226" left="939" width="144" height="15" font="1">survive cardiac arrest or who </text>
<text top="241" left="939" width="197" height="15" font="1">experience PSVT/AF. but also supports </text>
<text top="257" left="939" width="161" height="15" font="1">the current practice of observing </text>
<text top="272" left="939" width="89" height="15" font="1">asymptomatic pts </text>
<text top="629" left="54" width="57" height="15" font="1">Kalbfleisch </text>
<text top="645" left="54" width="16" height="15" font="1">SJ </text>
<text top="660" left="54" width="28" height="15" font="1">1993 </text>
<text top="676" left="54" width="29" height="15" font="1">(388) </text>
<text top="691" left="54" width="43" height="15" font="8">8436736</text>
<text top="691" left="97" width="3" height="15" font="1"> </text>
<text top="629" left="130" width="95" height="15" font="1">Prospective cohort </text>
<text top="645" left="130" width="87" height="15" font="1">study to evaluate </text>
<text top="660" left="130" width="109" height="15" font="1">safety, feasibility, and </text>
<text top="676" left="130" width="109" height="15" font="1">cost of AP RFA as an </text>
<text top="691" left="130" width="28" height="15" font="1">outpt </text>
<text top="629" left="260" width="22" height="15" font="1">137 </text>
<text top="629" left="378" width="122" height="15" font="1">Exclusion: &lt;13 or &gt;70 y, </text>
<text top="645" left="378" width="139" height="15" font="1">anteroseptal AP, obesity, or </text>
<text top="660" left="378" width="102" height="15" font="1">clinical indication for </text>
<text top="676" left="378" width="73" height="15" font="1">hospitalization </text>
<text top="629" left="540" width="121" height="15" font="1">RFA of AP cost as outpt </text>
<text top="645" left="540" width="53" height="15" font="1">procedure </text>
<text top="629" left="712" width="201" height="15" font="1">97% success rate, w/ 73% performed as </text>
<text top="645" left="712" width="63" height="15" font="1">outpatients.  </text>
<text top="660" left="712" width="3" height="15" font="1"> </text>
<text top="676" left="712" width="210" height="15" font="1">In 70 cases the pt was discharged the d of </text>
<text top="691" left="712" width="209" height="15" font="1">ablation, and in 30 cases the pt required a </text>
<text top="707" left="712" width="173" height="15" font="1">short (≤18 h) overnight stay due to </text>
<text top="722" left="712" width="94" height="15" font="1">scheduling issues. </text>
<text top="738" left="712" width="3" height="15" font="1"> </text>
<text top="753" left="712" width="210" height="15" font="1">Mean duration of observation was 4.8±1.5 </text>
<text top="769" left="712" width="185" height="15" font="1">h for outpts and 15±1.4 h for pts who </text>
<text top="784" left="712" width="183" height="15" font="1">underwent overnight hospitalization.  </text>
<text top="629" left="939" width="163" height="15" font="1">Outpt ablation of AP, w/ possible </text>
<text top="645" left="939" width="176" height="15" font="1">overnight observation, is feasible in </text>
<text top="660" left="939" width="58" height="15" font="1">low-risk pts </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">128 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="712" width="3" height="15" font="1"> </text>
<text top="70" left="712" width="161" height="15" font="1">Mean cost of the procedure was </text>
<text top="86" left="712" width="208" height="15" font="1">$10,183±$1,082 in 30 pts studied for cost </text>
<text top="101" left="712" width="49" height="15" font="1">analysis.  </text>
<text top="117" left="712" width="3" height="15" font="1"> </text>
<text top="132" left="712" width="148" height="15" font="1">22 outpts vs. 8 overnight pts : </text>
<text top="147" left="712" width="170" height="15" font="1">Total charges: $9,873 vs. $11,034 </text>
<text top="163" left="712" width="45" height="15" font="1">(p&lt;0.01) </text>
<text top="178" left="712" width="3" height="15" font="1"> </text>
<text top="194" left="712" width="182" height="15" font="1">Professional fees: $6,163 vs. $6,286 </text>
<text top="210" left="712" width="38" height="15" font="1">(p=NS) </text>
<text top="225" left="712" width="3" height="15" font="1"> </text>
<text top="240" left="712" width="180" height="15" font="1">Hospital charges: $3,710 vs. $4,748 </text>
<text top="256" left="712" width="45" height="15" font="1">(p&lt;0.01) </text>
<text top="271" left="712" width="3" height="15" font="1"> </text>
<text top="287" left="712" width="186" height="15" font="1">2 pts w/ complications: femoral artery </text>
<text top="302" left="712" width="179" height="15" font="1">pseudoaneurysm notes 3-4 wk after </text>
<text top="318" left="712" width="191" height="15" font="1">procedure, one in outpt, one after 13 h </text>
<text top="333" left="712" width="75" height="15" font="1">overnight stay. </text>
<text top="350" left="54" width="51" height="15" font="1">Kertes PJ </text>
<text top="365" left="54" width="28" height="15" font="1">1993 </text>
<text top="381" left="54" width="29" height="15" font="1">(389) </text>
<text top="396" left="54" width="43" height="15" font="8">8240167</text>
<text top="396" left="97" width="3" height="15" font="1"> </text>
<text top="350" left="130" width="108" height="15" font="1">CE of RFA compared </text>
<text top="365" left="130" width="102" height="15" font="1">to AADs in Australia </text>
<text top="350" left="260" width="15" height="15" font="1">26 </text>
<text top="350" left="378" width="76" height="15" font="1">AVNRT (n=16) </text>
<text top="365" left="378" width="67" height="15" font="1">WPW (n=10) </text>
<text top="350" left="540" width="151" height="15" font="1">Mean cost of RFA $4067, c/w  </text>
<text top="365" left="540" width="77" height="15" font="1">AAD of $700/ y </text>
<text top="381" left="540" width="3" height="15" font="1"> </text>
<text top="396" left="540" width="114" height="15" font="17"><i>NOTE: these are likely </i></text>
<text top="412" left="540" width="137" height="15" font="17"><i>Australian dollars, although </i></text>
<text top="427" left="540" width="111" height="15" font="17"><i>authors do not specify </i></text>
<text top="443" left="540" width="3" height="15" font="1"> </text>
<text top="458" left="540" width="138" height="15" font="1">Extrapolating over 20 y and </text>
<text top="474" left="540" width="130" height="15" font="1">allowing for an annual 5% </text>
<text top="489" left="540" width="148" height="15" font="1">inflation factor, RFA becomes </text>
<text top="505" left="540" width="100" height="15" font="1">cost saving in 5.5 y  </text>
<text top="520" left="540" width="3" height="15" font="1"> </text>
<text top="535" left="540" width="153" height="15" font="1">Over 20 y, AAD estimated at 4-</text>
<text top="551" left="540" width="145" height="15" font="1">5 times more expensive than </text>
<text top="567" left="540" width="18" height="15" font="1">RF </text>
<text top="582" left="540" width="3" height="15" font="1"> </text>
<text top="597" left="540" width="138" height="15" font="1">Perspective: pt and societal </text>
<text top="613" left="540" width="60" height="15" font="1">perspective </text>
<text top="628" left="540" width="137" height="15" font="1">Outcomes: cost analysis w/ </text>
<text top="644" left="540" width="148" height="15" font="1">“cost-saving” criterion used to </text>
<text top="659" left="540" width="138" height="15" font="1">define effectiveness, on the </text>
<text top="675" left="540" width="156" height="15" font="1">assumption that RFA is at least </text>
<text top="690" left="540" width="141" height="15" font="1">as effective as AADs in long-</text>
<text top="706" left="540" width="149" height="15" font="1">term control of PSVT; authors </text>
<text top="721" left="540" width="106" height="15" font="1">used annual charges </text>
<text top="350" left="712" width="408" height="15" font="1">N/A RFA more cost-effective than AADs. </text>
<text top="365" left="939" width="3" height="15" font="1"> </text>
<text top="381" left="939" width="179" height="15" font="1">Limited to Australian population, but </text>
<text top="396" left="939" width="167" height="15" font="1">results consistent w/ other series. </text>
<text top="412" left="939" width="3" height="15" font="1"> </text>
<text top="427" left="939" width="164" height="15" font="1">Used pt data in constructing cost-</text>
<text top="443" left="939" width="121" height="15" font="1">analysis, not simulation. </text>
<text top="738" left="54" width="40" height="15" font="1">Ikeda T </text>
<text top="753" left="54" width="28" height="15" font="1">1994 </text>
<text top="769" left="54" width="29" height="15" font="1">(390) </text>
<text top="784" left="54" width="43" height="15" font="8">7823285</text>
<text top="784" left="97" width="3" height="15" font="1"> </text>
<text top="738" left="130" width="116" height="15" font="1">Prospective cohort, CE </text>
<text top="753" left="130" width="97" height="15" font="1">evaluation of CE of </text>
<text top="769" left="130" width="73" height="15" font="1">RFA for PSVT </text>
<text top="738" left="260" width="15" height="15" font="1">20 </text>
<text top="738" left="378" width="118" height="15" font="1">Symptomatic PSVT, on </text>
<text top="753" left="378" width="143" height="15" font="1">AADs, all w/ successful RFA </text>
<text top="769" left="378" width="3" height="15" font="1"> </text>
<text top="784" left="378" width="70" height="15" font="1">AVNRT (n=5) </text>
<text top="738" left="540" width="149" height="15" font="1">Mean total charge for ablation </text>
<text top="753" left="540" width="152" height="15" font="1">982,806 yen and 5.7 times the </text>
<text top="769" left="540" width="154" height="15" font="1">outpt charges in the previous y </text>
<text top="784" left="540" width="3" height="15" font="1"> </text>
<text top="738" left="712" width="22" height="15" font="1">N/A </text>
<text top="738" left="939" width="165" height="15" font="1">Small study, limited to Japan, but </text>
<text top="753" left="939" width="181" height="15" font="1">suggests RFA effective and reduces </text>
<text top="769" left="939" width="73" height="15" font="1">medical costs. </text>
<text top="784" left="939" width="3" height="15" font="1"> </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">129 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="55" left="378" width="67" height="15" font="1">WPW (n=15) </text>
<text top="55" left="540" width="132" height="15" font="1">Mean total life-expectancy </text>
<text top="70" left="540" width="115" height="15" font="1">charges w/ AADs were </text>
<text top="86" left="540" width="140" height="15" font="1">estimated at 7,064,726 yen, </text>
<text top="101" left="540" width="143" height="15" font="1">41.0 times the outpt charges </text>
<text top="117" left="540" width="3" height="15" font="1"> </text>
<text top="132" left="540" width="151" height="15" font="1">Total RFA charge 14% of total </text>
<text top="147" left="540" width="157" height="15" font="1">estimated charges of estimated </text>
<text top="163" left="540" width="149" height="15" font="1">lifetime medical treatment w/o </text>
<text top="178" left="540" width="79" height="15" font="1">RFA (p&lt;0.001)  </text>
<text top="194" left="540" width="3" height="15" font="1"> </text>
<text top="210" left="540" width="140" height="15" font="1">Perspective: pt-perspective, </text>
<text top="225" left="540" width="98" height="15" font="1">societal component </text>
<text top="240" left="540" width="158" height="15" font="1">Outcomes: total life-expectancy </text>
<text top="256" left="540" width="154" height="15" font="1">charges, total ablation charges </text>
<text top="55" left="939" width="175" height="15" font="1">Utilizes hospital charges, and not a </text>
<text top="70" left="939" width="113" height="15" font="1">cost-simulation model. </text>
<text top="272" left="54" width="45" height="15" font="1">*Bathina </text>
<text top="288" left="54" width="20" height="15" font="1">MN </text>
<text top="303" left="54" width="28" height="15" font="1">1998 </text>
<text top="319" left="54" width="29" height="15" font="1">(378) </text>
<text top="334" left="54" width="43" height="15" font="8">9732885</text>
<text top="334" left="97" width="3" height="15" font="1"> </text>
<text top="272" left="130" width="61" height="15" font="1">Prospective </text>
<text top="288" left="130" width="91" height="15" font="1">comparison of the </text>
<text top="303" left="130" width="114" height="15" font="1">impact of QOL and CE </text>
<text top="319" left="130" width="92" height="15" font="1">between RFA and </text>
<text top="334" left="130" width="115" height="15" font="1">pharmacologic therapy </text>
<text top="350" left="130" width="48" height="15" font="1">for PSVT </text>
<text top="272" left="260" width="61" height="15" font="1">79 w/ newly-</text>
<text top="288" left="260" width="99" height="15" font="1">documented PSVT  </text>
<text top="303" left="260" width="3" height="15" font="1"> </text>
<text top="319" left="260" width="97" height="15" font="1">Average number of </text>
<text top="334" left="260" width="68" height="15" font="1">drugs 1.35/pt </text>
<text top="350" left="260" width="81" height="15" font="1">(CCB, BB, most </text>
<text top="365" left="260" width="49" height="15" font="1">common) </text>
<text top="272" left="378" width="135" height="15" font="1">Exclusions: drug-refractory </text>
<text top="288" left="378" width="146" height="15" font="1">pts, prior treatment, AF, atrial </text>
<text top="303" left="378" width="100" height="15" font="1">flutter, preexcitation </text>
<text top="272" left="540" width="114" height="15" font="1">SF-36 and direct costs </text>
<text top="288" left="540" width="3" height="15" font="1"> </text>
<text top="303" left="540" width="137" height="15" font="1">Perspective: pt-perspective </text>
<text top="319" left="540" width="128" height="15" font="1">Outcomes: direct hospital </text>
<text top="334" left="540" width="42" height="15" font="1">charges </text>
<text top="272" left="712" width="99" height="15" font="1">RFA vs. medication </text>
<text top="288" left="712" width="3" height="15" font="1"> </text>
<text top="303" left="712" width="196" height="15" font="1">Potential long-term costs similar, but w/ </text>
<text top="319" left="712" width="185" height="15" font="1">specific assumptions about ED visits, </text>
<text top="334" left="712" width="186" height="15" font="1">pharmacologic costs will exceed RFA </text>
<text top="272" left="939" width="179" height="15" font="1">First study to prospectively evaluate </text>
<text top="288" left="939" width="188" height="15" font="1">QOL and resource utilization between </text>
<text top="303" left="939" width="127" height="15" font="1">RFA vs. medical therapy. </text>
<text top="319" left="939" width="3" height="15" font="1"> </text>
<text top="334" left="939" width="175" height="15" font="1">Cumulative cost of medical therapy </text>
<text top="350" left="939" width="181" height="15" font="1">equal to, or less than RFA. This is in </text>
<text top="365" left="939" width="165" height="15" font="1">contrast to studies by Cheng and </text>
<text top="381" left="939" width="135" height="15" font="1">Ikeda, which have stronger </text>
<text top="396" left="939" width="73" height="15" font="1">methodology.  </text>
<text top="412" left="54" width="55" height="15" font="1">Cheng CH </text>
<text top="428" left="54" width="28" height="15" font="1">2000 </text>
<text top="443" left="54" width="23" height="15" font="1">(60) </text>
<text top="459" left="54" width="49" height="15" font="8">11103056</text>
<text top="459" left="103" width="3" height="15" font="1"> </text>
<text top="412" left="130" width="106" height="15" font="1">Comparison of CE of </text>
<text top="428" left="130" width="80" height="15" font="1">RFA w/ medical </text>
<text top="443" left="130" width="112" height="15" font="1">management of PSVT </text>
<text top="412" left="260" width="99" height="15" font="1">Symptomatic pts w/ </text>
<text top="428" left="260" width="84" height="15" font="1">4.6 unscheduled </text>
<text top="443" left="260" width="52" height="15" font="1">visits/y for </text>
<text top="459" left="260" width="99" height="15" font="1">arrhythmia while on </text>
<text top="474" left="260" width="75" height="15" font="1">long-term drug </text>
<text top="490" left="260" width="40" height="15" font="1">therapy </text>
<text top="412" left="378" width="28" height="15" font="1">RFA: </text>
<text top="428" left="378" width="110" height="15" font="1">Estimated population: </text>
<text top="443" left="378" width="69" height="15" font="1">AVNRT: 65% </text>
<text top="459" left="378" width="146" height="15" font="1">AVRT w/ concealed AP: 30% </text>
<text top="474" left="378" width="3" height="15" font="1"> </text>
<text top="490" left="378" width="95" height="15" font="1">Efficacy estimates: </text>
<text top="505" left="378" width="69" height="15" font="1">AVNRT: 97% </text>
<text top="521" left="378" width="146" height="15" font="1">AVRT w/ concealed AP: 93% </text>
<text top="536" left="378" width="3" height="15" font="1"> </text>
<text top="552" left="378" width="114" height="15" font="1">Recurrence estimates: </text>
<text top="567" left="378" width="63" height="15" font="1">AVNRT: 5% </text>
<text top="583" left="378" width="140" height="15" font="1">AVRT w/ concealed AP: 8% </text>
<text top="598" left="378" width="3" height="15" font="1"> </text>
<text top="614" left="378" width="96" height="15" font="1">Drug efficacy: 60% </text>
<text top="412" left="540" width="105" height="15" font="1">Perspective: societal </text>
<text top="428" left="540" width="3" height="15" font="1"> </text>
<text top="443" left="540" width="146" height="15" font="1">Outcomes: Costs (office visit, </text>
<text top="459" left="540" width="156" height="15" font="1">annual drug rx, EP study, RFA, </text>
<text top="474" left="540" width="125" height="15" font="1">PPM, PPM replacement) </text>
<text top="490" left="540" width="33" height="15" font="1">QALY </text>
<text top="505" left="540" width="36" height="15" font="1">Life-ys </text>
<text top="521" left="540" width="94" height="15" font="1">Marginal CE ratios </text>
<text top="536" left="540" width="3" height="15" font="9"> </text>
<text top="412" left="712" width="205" height="15" font="1">W/ monthly episodes of PSVT, RFA most </text>
<text top="428" left="712" width="178" height="15" font="1">effective and least expensive option </text>
<text top="443" left="712" width="3" height="15" font="1"> </text>
<text top="459" left="712" width="148" height="15" font="1">RFA reduced lifetime medical </text>
<text top="474" left="712" width="191" height="15" font="1">expenditures by $27,940 compared w/ </text>
<text top="490" left="712" width="165" height="15" font="1">long-term pharmacologic therapy </text>
<text top="505" left="712" width="3" height="15" font="1"> </text>
<text top="521" left="712" width="74" height="15" font="1">Lifetime costs: </text>
<text top="536" left="712" width="31" height="15" font="1">RFA:  </text>
<text top="552" left="712" width="43" height="15" font="1">$61,880 </text>
<text top="567" left="712" width="94" height="15" font="1">Long-term drug rx: </text>
<text top="583" left="712" width="43" height="15" font="1">$89,820 </text>
<text top="598" left="712" width="86" height="15" font="1">Episodic drug rx: </text>
<text top="614" left="712" width="49" height="15" font="1">$143,530 </text>
<text top="629" left="712" width="3" height="15" font="1"> </text>
<text top="645" left="712" width="172" height="15" font="1">RFA improved quality-adjusted life </text>
<text top="660" left="712" width="140" height="15" font="1">expectancy by 3.10 QALYs. </text>
<text top="412" left="939" width="193" height="15" font="1">RFA improves QOL and reduces costs </text>
<text top="428" left="939" width="188" height="15" font="1">when treating highly symptomatic pts. </text>
<text top="443" left="939" width="3" height="15" font="1"> </text>
<text top="459" left="939" width="193" height="15" font="1">Effects in less symptomatic not studies </text>
<text top="676" left="54" width="46" height="15" font="1">Dewland </text>
<text top="692" left="54" width="17" height="15" font="1">TA </text>
<text top="707" left="54" width="28" height="15" font="1">2013 </text>
<text top="723" left="54" width="29" height="15" font="1">(391) </text>
<text top="738" left="54" width="49" height="15" font="8">24983868</text>
<text top="738" left="103" width="3" height="15" font="1"> </text>
<text top="676" left="130" width="105" height="15" font="1">Observational cohort </text>
<text top="676" left="260" width="103" height="15" font="1">Pts w/ atrial flutter in </text>
<text top="692" left="260" width="103" height="15" font="1">the California HCUP </text>
<text top="707" left="260" width="80" height="15" font="1">database, 2005-</text>
<text top="723" left="260" width="88" height="15" font="1">2009 (n=33,004), </text>
<text top="738" left="260" width="82" height="15" font="1">median f/u 2/1 y </text>
<text top="676" left="378" width="127" height="15" font="1">Exclusion: Non-California </text>
<text top="692" left="378" width="137" height="15" font="1">residence, concomitant AF, </text>
<text top="707" left="378" width="143" height="15" font="1">missing admission date data </text>
<text top="676" left="540" width="142" height="15" font="1">Whether catheter ablation of </text>
<text top="692" left="540" width="128" height="15" font="1">atrial flutter associated w/ </text>
<text top="707" left="540" width="121" height="15" font="1">reductions in healthcare </text>
<text top="723" left="540" width="111" height="15" font="1">utilization, AF, or CVA </text>
<text top="676" left="712" width="209" height="15" font="1">2,733 (8.2%) underwent catheter ablation. </text>
<text top="692" left="712" width="178" height="15" font="1">Atrial flutter ablation (in 8.2% of pts) </text>
<text top="707" left="712" width="213" height="15" font="1">lowered adjusted risk of inpt hospitalization </text>
<text top="723" left="712" width="199" height="15" font="1">and ED visits (p&lt;0.001); overall hospital-</text>
<text top="738" left="712" width="193" height="15" font="1">based healthcare utilization (p = 0.001); </text>
<text top="754" left="712" width="211" height="15" font="1">and 11% reduction in AF( p = 0.01). Risk of </text>
<text top="769" left="712" width="204" height="15" font="1">CVA not reduced after ablation (p = 0.57). </text>
<text top="676" left="939" width="175" height="15" font="1">Robust registry data supports early </text>
<text top="692" left="939" width="172" height="15" font="1">atrial flutter ablation to significantly </text>
<text top="707" left="939" width="167" height="15" font="1">reduce hospital-based healthcare </text>
<text top="723" left="939" width="127" height="15" font="1">utilization and risk of AF.  </text>
<text top="786" left="54" width="179" height="15" font="1">*Study addressed both CE and QoL </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1188">
<text top="814" left="1113" width="24" height="17" font="0">130 </text>
<text top="831" left="54" width="496" height="15" font="1">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="847" left="54" width="3" height="17" font="0"> </text>
<text top="54" left="54" width="1070" height="15" font="1">AAD indicates antiarrhythmic drug; AF, atrial fibrillation; AP, accessory pathway; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular tachycardia; BB, beta blocker; CCB, calcium channel blocker; </text>
<text top="69" left="54" width="1073" height="15" font="1">CE, cost effectiveness; CVA, cerebrovascular accident; c/w, consistent with; ED, emergency department; EP, electrophysiological; HCUP, Healthcare Cost and Utilization Project; LOS, length of stay; N/A, not applicable; </text>
<text top="85" left="54" width="1064" height="15" font="1">NS, non-significant; PPM, permanent pacemaker; PSVT, paroxysmal supraventricular tachycardia; pt, patient; QALY, quality-adjusted life year; QOL, quality of life; RF, radiofrequency; RFA, radiofrequency ablation; rx, </text>
<text top="100" left="54" width="510" height="15" font="1">therapy; SCD, sudden cardiac death; SF-36, Short Form (36) Heatlh Survey; w/, with; and w/o, without.  </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="27" size="13" family="Times" color="#000000"/>
	<fontspec id="28" size="11" family="Times" color="#000000"/>
	<fontspec id="29" size="14" family="Times" color="#000000"/>
	<fontspec id="30" size="13" family="Times" color="#000000"/>
<text top="1084" left="843" width="24" height="17" font="27">131 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="194" width="536" height="19" font="29"><b>Appendix1.AcuteDrugTherapyforSVT,IntravenousAdministration*</b></text>
<text top="92" left="66" width="45" height="17" font="30"><b>Drug† </b></text>
<text top="92" left="161" width="77" height="17" font="30"><b>Initial Dose </b></text>
<text top="75" left="279" width="96" height="17" font="30"><b>Subsequent or </b></text>
<text top="92" left="284" width="87" height="17" font="30"><b>Maintenance </b></text>
<text top="109" left="310" width="35" height="17" font="30"><b>Dose </b></text>
<text top="83" left="406" width="118" height="17" font="30"><b>Potential Adverse </b></text>
<text top="101" left="441" width="48" height="17" font="30"><b>Effects </b></text>
<text top="83" left="565" width="221" height="17" font="30"><b>Precautions (Exclude or Use With </b></text>
<text top="101" left="591" width="170" height="17" font="30"><b>Caution) and Interactions </b></text>
<text top="127" left="49" width="77" height="17" font="30"><b>Nucleoside  </b></text>
<text top="145" left="49" width="150" height="17" font="27">Adenosine 6-mg </text>
<text top="145" left="175" width="58" height="17" font="27">rapid </text>
<text top="145" left="210" width="43" height="17" font="27">IV </text>
<text top="162" left="140" width="120" height="17" font="27">bolus (injected into </text>
<text top="179" left="140" width="110" height="17" font="27">IV as proximal or </text>
<text top="197" left="140" width="88" height="17" font="27">as close to the </text>
<text top="214" left="140" width="112" height="17" font="27">heart as possible), </text>
<text top="231" left="140" width="112" height="17" font="27">administered over </text>
<text top="248" left="140" width="115" height="17" font="27">1–2 s, followed by </text>
<text top="266" left="140" width="111" height="17" font="27">rapid saline flush  </text>
<text top="145" left="273" width="70" height="17" font="27">If no result </text>
<text top="162" left="273" width="99" height="17" font="27">within 1–2 min, </text>
<text top="179" left="273" width="97" height="17" font="27">12-mg rapid IV </text>
<text top="197" left="273" width="105" height="17" font="27">bolus; can repeat </text>
<text top="214" left="273" width="86" height="17" font="27">12-mg dose 1 </text>
<text top="231" left="273" width="89" height="17" font="27">time. The safe </text>
<text top="248" left="273" width="83" height="17" font="27">use of 18-mg </text>
<text top="266" left="273" width="97" height="17" font="27">bolus doses has </text>
<text top="283" left="273" width="86" height="17" font="27">been reported </text>
<text top="300" left="273" width="40" height="17" font="27">(392). </text>
<text top="145" left="393" width="127" height="17" font="27">Transient AV block, </text>
<text top="162" left="393" width="125" height="17" font="27">flushing, chest pain, </text>
<text top="179" left="393" width="97" height="17" font="27">hypotension, or </text>
<text top="197" left="393" width="122" height="17" font="27">dyspnea, AF can be </text>
<text top="214" left="393" width="106" height="17" font="27">initiated or cause </text>
<text top="231" left="393" width="139" height="17" font="27">decompensation in the </text>
<text top="248" left="393" width="97" height="17" font="27">presence of pre-</text>
<text top="266" left="393" width="67" height="17" font="27">excitation, </text>
<text top="283" left="393" width="115" height="17" font="27">PVCs / ventricular </text>
<text top="300" left="393" width="77" height="17" font="27">tachycardia, </text>
<text top="317" left="393" width="131" height="17" font="27">bronchospasm (rare), </text>
<text top="335" left="393" width="108" height="17" font="27">or coronary steal. </text>
<text top="352" left="393" width="135" height="17" font="27">Minor side effects are </text>
<text top="369" left="393" width="103" height="17" font="27">usually transient </text>
<text top="386" left="393" width="142" height="17" font="27">because of adenosine’s </text>
<text top="404" left="393" width="124" height="17" font="27">very short half-life.  </text>
<text top="144" left="553" width="240" height="18" font="27">  AV block greater than first degree or </text>
<text top="163" left="568" width="218" height="17" font="27">SA node dysfunction (in absence of </text>
<text top="181" left="568" width="74" height="17" font="27">pacemaker) </text>
<text top="197" left="553" width="163" height="18" font="27">  Reactive airway disease<b> </b></text>
<text top="215" left="553" width="216" height="18" font="27">  Concomitant use of verapamil or </text>
<text top="234" left="568" width="50" height="17" font="27">digoxin </text>
<text top="251" left="553" width="55" height="18" font="27">  WPW </text>
<text top="422" left="49" width="91" height="17" font="30"><b>Beta blockers </b></text>
<text top="440" left="49" width="58" height="17" font="27">Esmolol  </text>
<text top="440" left="140" width="96" height="17" font="27">500-mcg/kg IV </text>
<text top="457" left="140" width="105" height="17" font="27">bolus over 1 min </text>
<text top="440" left="273" width="91" height="17" font="27">Infusion at 50–</text>
<text top="457" left="273" width="106" height="17" font="27">300 mcg/kg/min, </text>
<text top="474" left="273" width="71" height="17" font="27">with repeat </text>
<text top="491" left="273" width="103" height="17" font="27">boluses between </text>
<text top="509" left="273" width="75" height="17" font="27">each dosing </text>
<text top="526" left="273" width="53" height="17" font="27">increase </text>
<text top="440" left="393" width="84" height="17" font="27">Hypotension, </text>
<text top="457" left="393" width="93" height="17" font="27">worsening HF, </text>
<text top="474" left="393" width="94" height="17" font="27">bronchospasm, </text>
<text top="491" left="393" width="75" height="17" font="27">bradycardia </text>
<text top="439" left="553" width="240" height="18" font="27">  AV block greater than first degree or </text>
<text top="458" left="568" width="218" height="17" font="27">SA node dysfunction (in absence of </text>
<text top="475" left="568" width="74" height="17" font="27">pacemaker) </text>
<text top="492" left="553" width="187" height="18" font="27">  Decompensated systolic HF </text>
<text top="510" left="553" width="95" height="18" font="27">  Hypotension </text>
<text top="528" left="553" width="131" height="18" font="27">  Cardiogenic shock </text>
<text top="547" left="553" width="163" height="18" font="27">  Reactive airway disease </text>
<text top="565" left="553" width="128" height="18" font="27">  Renal dysfunction<b> </b></text>
<text top="583" left="553" width="217" height="18" font="27">  Drugs with SA and/or AV nodal–</text>
<text top="602" left="568" width="120" height="17" font="27">blocking properties<b> </b></text>
<text top="620" left="49" width="71" height="17" font="27">Metoprolol </text>
<text top="638" left="49" width="50" height="17" font="27">tartrate  </text>
<text top="620" left="140" width="92" height="17" font="27">2.5–5.0-mg IV </text>
<text top="638" left="140" width="105" height="17" font="27">bolus over 2 min </text>
<text top="620" left="273" width="96" height="17" font="27">Can repeat 2.5- </text>
<text top="638" left="273" width="82" height="17" font="27">to 5.0-mg IV </text>
<text top="655" left="273" width="101" height="17" font="27">bolus in 10 min, </text>
<text top="672" left="273" width="82" height="17" font="27">up to 3 doses </text>
<text top="620" left="393" width="84" height="17" font="27">Hypotension, </text>
<text top="638" left="393" width="93" height="17" font="27">worsening HF, </text>
<text top="655" left="393" width="94" height="17" font="27">bronchospasm, </text>
<text top="672" left="393" width="75" height="17" font="27">bradycardia </text>
<text top="620" left="553" width="240" height="18" font="27">  AV block greater than first degree or </text>
<text top="639" left="568" width="218" height="17" font="27">SA node dysfunction (in absence of </text>
<text top="656" left="568" width="74" height="17" font="27">pacemaker) </text>
<text top="673" left="553" width="187" height="18" font="27">  Decompensated systolic HF </text>
<text top="691" left="553" width="95" height="18" font="27">  Hypotension </text>
<text top="709" left="553" width="163" height="18" font="27">  Reactive airway disease </text>
<text top="728" left="553" width="217" height="18" font="27">  Drugs with SA and/or AV nodal–</text>
<text top="747" left="568" width="120" height="17" font="27">blocking properties </text>
<text top="765" left="49" width="187" height="17" font="27">Propranolol  1 mg IV over 1 </text>
<text top="782" left="140" width="27" height="17" font="27">min </text>
<text top="765" left="273" width="103" height="17" font="27">Can repeat 1 mg </text>
<text top="782" left="273" width="74" height="17" font="27">IV at 2-min </text>
<text top="799" left="273" width="105" height="17" font="27">intervals, up to 3 </text>
<text top="816" left="273" width="37" height="17" font="27">doses </text>
<text top="765" left="393" width="84" height="17" font="27">Hypotension, </text>
<text top="782" left="393" width="93" height="17" font="27">worsening HF, </text>
<text top="799" left="393" width="94" height="17" font="27">bronchospasm, </text>
<text top="816" left="393" width="75" height="17" font="27">bradycardia </text>
<text top="764" left="553" width="240" height="18" font="27">  AV block greater than first degree or </text>
<text top="783" left="568" width="218" height="17" font="27">SA node dysfunction (in absence of </text>
<text top="800" left="568" width="74" height="17" font="27">pacemaker) </text>
<text top="817" left="553" width="131" height="18" font="27">  Cardiogenic shock </text>
<text top="835" left="553" width="163" height="18" font="27">  Reactive airway disease </text>
<text top="853" left="553" width="137" height="18" font="27">  Decompensated HF </text>
<text top="872" left="553" width="95" height="18" font="27">  Hypotension </text>
<text top="890" left="553" width="190" height="18" font="27">  Hepatic or renal dysfunction </text>
<text top="908" left="553" width="217" height="18" font="27">  Drugs with SA and/or AV nodal–</text>
<text top="927" left="568" width="120" height="17" font="27">blocking properties </text>
<text top="946" left="49" width="319" height="17" font="30"><b>Nondihydropyridine calcium channel antagonists </b></text>
<text top="963" left="49" width="193" height="17" font="27">Diltiazem 0.25-mg/kg </text>
<text top="963" left="213" width="48" height="17" font="27">IV </text>
<text top="981" left="140" width="105" height="17" font="27">bolus over 2 min </text>
<text top="963" left="273" width="102" height="17" font="27">Infusion at 5–10 </text>
<text top="981" left="273" width="91" height="17" font="27">mg/h, up to 15 </text>
<text top="998" left="273" width="35" height="17" font="27">mg/h </text>
<text top="963" left="393" width="84" height="17" font="27">Hypotension, </text>
<text top="981" left="393" width="105" height="17" font="27">worsening HF in </text>
<text top="998" left="393" width="105" height="17" font="27">patients with pre-</text>
<text top="1015" left="393" width="120" height="17" font="27">existing ventricular </text>
<text top="1032" left="393" width="78" height="17" font="27">dysfunction, </text>
<text top="1050" left="393" width="139" height="17" font="27">bradycardia, abnormal </text>
<text top="963" left="553" width="240" height="18" font="27">  AV block greater than first degree or </text>
<text top="982" left="568" width="218" height="17" font="27">SA node dysfunction (in absence of </text>
<text top="999" left="568" width="74" height="17" font="27">pacemaker) </text>
<text top="1016" left="553" width="197" height="18" font="27">  WPW with  AF / atrial flutter </text>
<text top="1034" left="553" width="103" height="18" font="27">  Hypotension<b>‡</b> </text>
<text top="1052" left="553" width="211" height="18" font="27">  Decompensated systolic HF/LV </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">132 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="55" left="393" width="134" height="17" font="27">liver function studies, </text>
<text top="72" left="393" width="122" height="17" font="27">acute hepatic injury </text>
<text top="90" left="393" width="37" height="17" font="27">(rare) </text>
<text top="55" left="568" width="75" height="17" font="27">dysfunction </text>
<text top="72" left="553" width="217" height="18" font="27">  Drugs with SA and/or AV nodal–</text>
<text top="91" left="568" width="124" height="17" font="27">blocking properties  </text>
<text top="107" left="553" width="190" height="18" font="27">  Hepatic or renal dysfunction </text>
<text top="126" left="553" width="234" height="18" font="27">  Diltiazem is a substrate of CYP3A4 </text>
<text top="145" left="568" width="203" height="17" font="27">(major) and a moderate CYP3A4 </text>
<text top="162" left="568" width="55" height="17" font="27">inhibitor </text>
<text top="178" left="553" width="225" height="18" font="27">  Apixaban, itraconazole, bosutinib, </text>
<text top="197" left="568" width="207" height="17" font="27">ceritinib, cilostazol, cyclosporine, </text>
<text top="215" left="568" width="196" height="17" font="27">everolimus, ibrutinib, idelalisib, </text>
<text top="232" left="568" width="199" height="17" font="27">ivabradine, lomitapide, olaparib, </text>
<text top="249" left="568" width="217" height="17" font="27">posaconazole, ranolazine, rifampin, </text>
<text top="266" left="568" width="153" height="17" font="27">simeprevir, voriconazole </text>
<text top="284" left="49" width="173" height="17" font="27">Verapamil 5–10-mg </text>
<text top="284" left="198" width="46" height="17" font="27">(0.075–</text>
<text top="302" left="140" width="98" height="17" font="27">0.15-mg/kg) IV </text>
<text top="319" left="140" width="109" height="17" font="27">bolus over 2 min  </text>
<text top="284" left="273" width="92" height="17" font="27">If no response, </text>
<text top="302" left="273" width="72" height="17" font="27">can give an </text>
<text top="319" left="273" width="105" height="17" font="27">additional 10 mg </text>
<text top="336" left="273" width="101" height="17" font="27">(0.15 mg/kg) 30 </text>
<text top="353" left="273" width="86" height="17" font="27">min after first </text>
<text top="371" left="273" width="65" height="17" font="27">dose; then </text>
<text top="388" left="273" width="105" height="17" font="27">infusion at 0.005 </text>
<text top="405" left="273" width="70" height="17" font="27">mg/kg/min </text>
<text top="284" left="393" width="84" height="17" font="27">Hypotension, </text>
<text top="302" left="393" width="105" height="17" font="27">worsening HF in </text>
<text top="319" left="393" width="105" height="17" font="27">patients with pre-</text>
<text top="336" left="393" width="120" height="17" font="27">existing ventricular </text>
<text top="353" left="393" width="78" height="17" font="27">dysfunction, </text>
<text top="371" left="393" width="127" height="17" font="27">pulmonary edema in </text>
<text top="388" left="393" width="81" height="17" font="27">patients with </text>
<text top="405" left="393" width="80" height="17" font="27">hypertrophic </text>
<text top="422" left="393" width="105" height="17" font="27">cardiomyopathy, </text>
<text top="440" left="393" width="75" height="17" font="27">bradycardia </text>
<text top="284" left="553" width="240" height="18" font="27">  AV block greater than first degree or </text>
<text top="303" left="568" width="218" height="17" font="27">SA node dysfunction (in absence of </text>
<text top="320" left="568" width="74" height="17" font="27">pacemaker) </text>
<text top="337" left="553" width="215" height="18" font="27">  Decompensated systolic HF/ LV </text>
<text top="356" left="568" width="75" height="17" font="27">dysfunction </text>
<text top="372" left="553" width="217" height="18" font="27">  Drugs with SA and/or AV nodal–</text>
<text top="391" left="568" width="124" height="17" font="27">blocking properties  </text>
<text top="408" left="553" width="103" height="18" font="27">  Hypotension‡ </text>
<text top="426" left="553" width="131" height="18" font="27">  Cardiogenic shock </text>
<text top="444" left="553" width="192" height="18" font="27">  WPW with AF / atrial flutter </text>
<text top="463" left="553" width="190" height="18" font="27">  Hepatic or renal dysfunction </text>
<text top="481" left="553" width="224" height="18" font="27">  Verapamil is a moderate CYP3A4 </text>
<text top="500" left="568" width="171" height="17" font="27">inhibitor and also inhibits P-</text>
<text top="517" left="568" width="80" height="17" font="27">glycoprotein </text>
<text top="534" left="553" width="210" height="18" font="27">  Contraindicated with dofetilide  </text>
<text top="552" left="553" width="217" height="18" font="27">  Itraconazole, bosutinib, ceritinib, </text>
<text top="571" left="568" width="219" height="17" font="27">cilostazol, colchicine, cyclosporine, </text>
<text top="588" left="568" width="210" height="17" font="27">everolimus, dabigatran, edoxaban, </text>
<text top="606" left="568" width="197" height="17" font="27">flecainide, ibrutinib, ivabradine, </text>
<text top="623" left="568" width="215" height="17" font="27">olaparib, posaconazole, ranolazine, </text>
<text top="640" left="568" width="200" height="17" font="27">rivaroxaban, rifampin, silodosin, </text>
<text top="657" left="568" width="210" height="17" font="27">simeprevir, rivaroxaban, rifampin, </text>
<text top="675" left="568" width="216" height="17" font="27">simvastatin, topotecan, trabectedin, </text>
<text top="692" left="568" width="219" height="17" font="27">vincristine, voriconazole, grapefruit </text>
<text top="709" left="568" width="33" height="17" font="27">juice </text>
<text top="727" left="49" width="123" height="17" font="30"><b>Cardiac glycosides </b></text>
<text top="745" left="49" width="210" height="17" font="27">Digoxin 0.25–0.5-mg </text>
<text top="745" left="220" width="58" height="17" font="27">IV </text>
<text top="762" left="140" width="40" height="17" font="27">bolus  </text>
<text top="745" left="273" width="100" height="17" font="27">Can repeat 0.25-</text>
<text top="762" left="273" width="101" height="17" font="27">mg IV bolus, up </text>
<text top="780" left="273" width="80" height="17" font="27">to maximum </text>
<text top="797" left="273" width="93" height="17" font="27">dose of 1.0 mg </text>
<text top="814" left="273" width="91" height="17" font="27">over 24 h (i.e., </text>
<text top="831" left="273" width="65" height="17" font="27">maximum </text>
<text top="849" left="273" width="95" height="17" font="27">loading dose 8–</text>
<text top="866" left="273" width="76" height="17" font="27">12 mcg/kg), </text>
<text top="883" left="273" width="90" height="17" font="27">given at 6–8-h </text>
<text top="900" left="273" width="60" height="17" font="27">intervals; </text>
<text top="918" left="273" width="80" height="17" font="27">maintenance </text>
<text top="935" left="273" width="88" height="17" font="27">dose based on </text>
<text top="952" left="273" width="84" height="17" font="27">patient’s age, </text>
<text top="969" left="273" width="63" height="17" font="27">lean body </text>
<text top="987" left="273" width="82" height="17" font="27">weight, renal </text>
<text top="1004" left="273" width="83" height="17" font="27">function, and </text>
<text top="1021" left="273" width="78" height="17" font="27">concomitant </text>
<text top="1038" left="273" width="88" height="17" font="27">drugs (IV 2.4–</text>
<text top="1056" left="273" width="88" height="17" font="27">3.6 mcg/kg/d) </text>
<text top="745" left="393" width="112" height="17" font="27">Anorexia, nausea, </text>
<text top="762" left="393" width="101" height="17" font="27">vomiting, visual </text>
<text top="780" left="393" width="125" height="17" font="27">changes and cardiac </text>
<text top="797" left="393" width="138" height="17" font="27">arrhythmias if digoxin </text>
<text top="814" left="393" width="120" height="17" font="27">toxicity (associated </text>
<text top="831" left="393" width="136" height="17" font="27">with levels &gt;2 ng/mL, </text>
<text top="849" left="393" width="122" height="17" font="27">although symptoms </text>
<text top="866" left="393" width="109" height="17" font="27">may also occur at </text>
<text top="883" left="393" width="82" height="17" font="27">lower levels) </text>
<text top="744" left="553" width="128" height="18" font="27">  Renal dysfunction </text>
<text top="763" left="553" width="192" height="18" font="27">  WPW with AF / atrial flutter </text>
<text top="781" left="553" width="240" height="18" font="27">  AV block greater than first degree or </text>
<text top="800" left="568" width="218" height="17" font="27">SA node dysfunction (in absence of </text>
<text top="817" left="568" width="74" height="17" font="27">pacemaker) </text>
<text top="834" left="553" width="206" height="18" font="27">  Drugs with AV nodal-blocking </text>
<text top="853" left="568" width="64" height="17" font="27">properties </text>
<text top="870" left="553" width="242" height="18" font="27">  Digoxin is a P-glycoprotein substrate </text>
<text top="888" left="553" width="241" height="18" font="27">  Dronedarone (reduce dose by at least </text>
<text top="907" left="568" width="213" height="17" font="27">50%), amiodarone (reduce dose by </text>
<text top="924" left="568" width="71" height="17" font="27">30%–50%) </text>
<text top="941" left="553" width="182" height="18" font="27">  Verapamil, clarithromycin, </text>
<text top="960" left="568" width="173" height="17" font="27">cyclosporine, erythromycin, </text>
<text top="977" left="568" width="148" height="17" font="27">flecainide, itraconazole, </text>
<text top="994" left="568" width="171" height="17" font="27">posaconazole, propafenone, </text>
<text top="1011" left="568" width="227" height="17" font="27">voriconazole: Monitor digoxin levels </text>
<text top="1028" left="553" width="243" height="18" font="27">  A large retrospective study suggested </text>
<text top="1047" left="567" width="194" height="17" font="27">an increased risk in mortality in </text>
<text top="1064" left="567" width="188" height="17" font="27">patients who were treated with </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="31" size="11" family="Times" color="#000000"/>
<text top="1084" left="843" width="24" height="17" font="27">133 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="55" left="567" width="215" height="17" font="27">digoxin for newly diagnosed AF or </text>
<text top="72" left="567" width="219" height="17" font="27">atrial flutter; although the data were </text>
<text top="90" left="567" width="223" height="17" font="27">collected from a population that was </text>
<text top="107" left="567" width="224" height="17" font="27">different from SVT patients, digoxin </text>
<text top="124" left="567" width="211" height="17" font="27">should be used with caution (393). </text>
<text top="142" left="49" width="206" height="17" font="30"><b>Class III antiarrhythmic agents </b></text>
<text top="160" left="49" width="209" height="17" font="27">Amiodarone  150 mg IV over 10 </text>
<text top="177" left="140" width="27" height="17" font="27">min </text>
<text top="160" left="273" width="80" height="17" font="27">Infusion at 1 </text>
<text top="177" left="273" width="82" height="17" font="27">mg/min (360 </text>
<text top="195" left="273" width="99" height="17" font="27">mg) over next 6 </text>
<text top="212" left="273" width="68" height="17" font="27">h; then 0.5 </text>
<text top="229" left="273" width="82" height="17" font="27">mg/min (540 </text>
<text top="246" left="273" width="58" height="17" font="27">mg) over </text>
<text top="264" left="273" width="95" height="17" font="27">remaining 18 h </text>
<text top="160" left="393" width="84" height="17" font="27">Hypotension, </text>
<text top="177" left="393" width="137" height="17" font="27">bradycardia, phlebitis, </text>
<text top="195" left="393" width="108" height="17" font="27">QT prolongation, </text>
<text top="212" left="393" width="118" height="17" font="27">torsades de pointes </text>
<text top="229" left="393" width="131" height="17" font="27">(rare), increased INR </text>
<text top="246" left="393" width="4" height="17" font="27"> </text>
<text top="159" left="553" width="232" height="18" font="27">  Sinus or AV conduction disease (in </text>
<text top="178" left="568" width="141" height="17" font="27">absence of pacemaker) </text>
<text top="195" left="553" width="224" height="18" font="27">  Inflammatory lung disease (acute) </text>
<text top="213" left="553" width="140" height="18" font="27">  Hepatic dysfunction </text>
<text top="232" left="553" width="217" height="18" font="27">  Drugs with SA and/or AV nodal–</text>
<text top="251" left="568" width="120" height="17" font="27">blocking properties </text>
<text top="267" left="553" width="217" height="18" font="27">  Amiodarone is a substrate of and </text>
<text top="286" left="568" width="224" height="17" font="27">inhibits p-glycoprotein and CYP2C9 </text>
<text top="304" left="568" width="231" height="17" font="27">(moderate), CYP2D6 (moderate), and </text>
<text top="321" left="568" width="207" height="17" font="27">CYP3A4 (weak); amiodarone is a </text>
<text top="338" left="568" width="211" height="17" font="27">substrate for CYP3A4 (major) and </text>
<text top="355" left="568" width="213" height="17" font="27">CYP2C8 (major);amiodarone is an </text>
<text top="373" left="568" width="113" height="17" font="27">inhibitor of OCT2 </text>
<text top="389" left="553" width="229" height="18" font="27">   Reduce warfarin dose by 50% and </text>
<text top="408" left="568" width="209" height="17" font="27">reduce digoxin dose by 30%–50% </text>
<text top="425" left="553" width="212" height="18" font="27">  Agalsidase alfa, agalsidase beta, </text>
<text top="444" left="568" width="208" height="17" font="27">azithromycin, bosutinib, ceritinib, </text>
<text top="461" left="568" width="209" height="17" font="27">colchicine,  dabigatran, edoxaban, </text>
<text top="478" left="568" width="138" height="17" font="27">flecainide, ivabradine, </text>
<text top="495" left="568" width="196" height="17" font="27">ledipasvir/sofosbuvir, lopinavir, </text>
<text top="513" left="568" width="183" height="17" font="27">lopinavir/ritonavir, lovastatin, </text>
<text top="530" left="568" width="217" height="17" font="27">nelfinavir, pazopanib, propafenone, </text>
<text top="547" left="568" width="214" height="17" font="27">simvastatin, ritonavir, rivaroxaban, </text>
<text top="564" left="568" width="207" height="17" font="27">saquinavir, sofosbuvir, topotecan, </text>
<text top="582" left="568" width="167" height="17" font="27">vincristine, grapefruit juice </text>
<text top="600" left="49" width="227" height="17" font="27">Ibutilide Contraindicated </text>
<text top="617" left="140" width="101" height="17" font="27">when QTc &gt;440 </text>
<text top="634" left="140" width="119" height="17" font="27">ms<b>║</b>; 1 mg over 10 </text>
<text top="651" left="140" width="113" height="17" font="27">min (if ≥60 kg); if </text>
<text top="669" left="140" width="109" height="17" font="27">&lt;60 kg, then 0.01 </text>
<text top="686" left="140" width="42" height="17" font="27">mg/kg </text>
<text top="600" left="273" width="103" height="17" font="27">Can repeat 1 mg </text>
<text top="617" left="273" width="71" height="17" font="27">once, if the </text>
<text top="634" left="273" width="101" height="17" font="27">arrhythmia does </text>
<text top="651" left="273" width="83" height="17" font="27">not terminate </text>
<text top="669" left="273" width="95" height="17" font="27">within 10 min§ </text>
<text top="600" left="393" width="108" height="17" font="27">QT prolongation, </text>
<text top="617" left="393" width="122" height="17" font="27">torsades de pointes, </text>
<text top="634" left="393" width="63" height="17" font="27">AV block </text>
<text top="599" left="553" width="154" height="18" font="27">  Prolonged QT interval </text>
<text top="617" left="553" width="198" height="18" font="27">  History of torsades de pointes </text>
<text top="636" left="553" width="237" height="18" font="27">  Avoid other QT interval–prolonging </text>
<text top="655" left="568" width="37" height="17" font="27">drugs </text>
<text top="671" left="553" width="224" height="18" font="27">  Concurrent administration of high-</text>
<text top="690" left="568" width="225" height="17" font="27">dose magnesium has been associated </text>
<text top="707" left="568" width="208" height="17" font="27">with enhanced efficacy and safety </text>
<text top="725" left="568" width="70" height="17" font="27">(206, 394)  </text>
<text top="743" left="41" width="717" height="17" font="27">Note: For this reference table, drugs are presented in alphabetical order within the drug classes, not by COR and LOE.  </text>
<text top="760" left="40" width="801" height="17" font="27">*When 1 drug is used in combination with other drugs, appropriate dosing adjustments should be made with consideration of at least </text>
<text top="777" left="40" width="820" height="17" font="27">additive effects during dosage titration. All potential drug–drug interactions are not included in this list. For a more detailed list of drug–</text>
<text top="794" left="40" width="396" height="17" font="27">drug interactions, clinicians should consult additional resources.   </text>
<text top="812" left="40" width="834" height="17" font="27">‡If hypotension is a consideration, a slow infusion of diltiazem (2.5 mg/min) or verapamil (1 mg/min) for up to 20 minutes may lessen the </text>
<text top="829" left="40" width="191" height="17" font="27">potential for hypotension (38). <b> </b></text>
<text top="846" left="40" width="770" height="17" font="27">§The infusion should be stopped as soon as the arrhythmia is terminated or in the event of sustained or nonsustained ventricular </text>
<text top="863" left="40" width="415" height="17" font="27">tachycardia or marked prolongation of QT or corrected QT interval.  </text>
<text top="882" left="41" width="10" height="15" font="31"><b>║</b></text>
<text top="881" left="50" width="817" height="17" font="27">QTc calculation used the Bazett’s Formula in most clinical studies. Patients should be observed with continuous ECG monitoring for at </text>
<text top="898" left="40" width="365" height="17" font="27">least 4 h after infusion or until QTc has returned to baseline. </text>
<text top="915" left="40" width="4" height="17" font="27"> </text>
<text top="932" left="40" width="625" height="17" font="27">AF indicates atrial fibrillation; AV, atrioventricular; BID, twice daily; CrCl, creatinine clearance; ECG, </text>
<text top="950" left="40" width="795" height="17" font="27">electrocardiogram/electrocardiographic; HF, heart failure; INR, international normalized ratio; LV, left ventricular; QD, once daily; </text>
<text top="967" left="40" width="806" height="17" font="27">QID, four times a day; QTc, corrected QT interval; SA, sinoatrial; SVT, supraventricular tachycardia; TID, 3-times a day; and WPW, </text>
<text top="984" left="40" width="154" height="17" font="27">Wolff-Parkinson-White.  </text>
<text top="1001" left="54" width="3" height="15" font="28"> </text>
<text top="1017" left="41" width="4" height="18" font="29"><b> </b></text>
<text top="1036" left="41" width="4" height="18" font="29"><b> </b></text>
<text top="1055" left="41" width="4" height="18" font="29"><b> </b></text>
</page>
<page number="134" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">134 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="214" width="497" height="19" font="29"><b>Appendix2.OngoingDrugTherapyforSVT,OralAdministration*</b></text>
<text top="75" left="66" width="45" height="17" font="30"><b>Drug† </b></text>
<text top="75" left="165" width="131" height="17" font="30"><b>Initial Daily Dose(s) </b></text>
<text top="75" left="364" width="146" height="17" font="30"><b>Maximum Total Daily </b></text>
<text top="92" left="377" width="122" height="17" font="30"><b>Maintenance Dose </b></text>
<text top="75" left="577" width="61" height="17" font="30"><b>Potential </b></text>
<text top="92" left="556" width="104" height="17" font="30"><b>Adverse Effects </b></text>
<text top="75" left="678" width="185" height="17" font="30"><b>Precautions (Exclude or Use </b></text>
<text top="92" left="708" width="125" height="17" font="30"><b>With Caution) and </b></text>
<text top="109" left="730" width="81" height="17" font="30"><b>Interactions </b></text>
<text top="127" left="49" width="91" height="17" font="30"><b>Beta blockers </b></text>
<text top="145" left="49" width="56" height="17" font="27">Atenolol </text>
<text top="145" left="141" width="90" height="17" font="27">25–50 mg QD </text>
<text top="145" left="333" width="75" height="17" font="27">100 mg QD </text>
<text top="162" left="333" width="196" height="17" font="27">(reduced dosing in patients with </text>
<text top="179" left="333" width="155" height="17" font="27">severe renal dysfunction) </text>
<text top="145" left="554" width="84" height="17" font="27">Hypotension, </text>
<text top="162" left="554" width="94" height="17" font="27">bronchospasm, </text>
<text top="179" left="554" width="75" height="17" font="27">bradycardia </text>
<text top="144" left="673" width="182" height="18" font="27">  AV block greater than first </text>
<text top="163" left="690" width="116" height="17" font="27">degree or SA node </text>
<text top="181" left="690" width="162" height="17" font="27">dysfunction (in absence of </text>
<text top="198" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="214" left="673" width="189" height="18" font="27">  Decompensated systolic HF </text>
<text top="233" left="673" width="97" height="18" font="27">  Hypotension </text>
<text top="251" left="673" width="168" height="18" font="27">  Reactive airway disease  </text>
<text top="269" left="673" width="170" height="18" font="27">  Severe renal dysfunction </text>
<text top="288" left="673" width="178" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="307" left="690" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="325" left="49" width="71" height="17" font="27">Metoprolol </text>
<text top="342" left="49" width="46" height="17" font="27">tartrate </text>
<text top="325" left="141" width="75" height="17" font="27">25 mg BID  </text>
<text top="325" left="333" width="79" height="17" font="27">200 mg BID </text>
<text top="325" left="554" width="84" height="17" font="27">Hypotension, </text>
<text top="342" left="554" width="94" height="17" font="27">bronchospasm, </text>
<text top="359" left="554" width="75" height="17" font="27">bradycardia </text>
<text top="324" left="673" width="182" height="18" font="27">  AV block greater than first </text>
<text top="343" left="690" width="116" height="17" font="27">degree or SA node </text>
<text top="360" left="690" width="162" height="17" font="27">dysfunction (in absence of </text>
<text top="377" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="394" left="673" width="189" height="18" font="27">  Decompensated systolic HF </text>
<text top="412" left="673" width="97" height="18" font="27">  Hypotension </text>
<text top="431" left="673" width="168" height="18" font="27">  Reactive airway disease  </text>
<text top="449" left="673" width="178" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="468" left="690" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="486" left="49" width="71" height="17" font="27">Metoprolol </text>
<text top="503" left="49" width="60" height="17" font="27">succinate </text>
<text top="520" left="49" width="37" height="17" font="27">(long-</text>
<text top="538" left="49" width="45" height="17" font="27">acting) </text>
<text top="486" left="141" width="67" height="17" font="27">50 mg QD </text>
<text top="486" left="333" width="75" height="17" font="27">400 mg QD </text>
<text top="486" left="554" width="84" height="17" font="27">Hypotension, </text>
<text top="503" left="554" width="94" height="17" font="27">bronchospasm, </text>
<text top="520" left="554" width="75" height="17" font="27">bradycardia </text>
<text top="485" left="673" width="182" height="18" font="27">  AV block greater than first </text>
<text top="504" left="690" width="116" height="17" font="27">degree or SA node </text>
<text top="522" left="690" width="162" height="17" font="27">dysfunction (in absence of </text>
<text top="539" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="555" left="673" width="189" height="18" font="27">  Decompensated systolic HF </text>
<text top="574" left="673" width="97" height="18" font="27">  Hypotension </text>
<text top="592" left="673" width="168" height="18" font="27">  Reactive airway disease  </text>
<text top="610" left="673" width="178" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="629" left="690" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="647" left="49" width="52" height="17" font="27">Nadolol </text>
<text top="647" left="141" width="67" height="17" font="27">40 mg QD </text>
<text top="647" left="333" width="75" height="17" font="27">320 mg QD </text>
<text top="665" left="333" width="166" height="17" font="27">(reduced dosage with renal </text>
<text top="682" left="333" width="78" height="17" font="27">impairment) </text>
<text top="647" left="554" width="84" height="17" font="27">Hypotension, </text>
<text top="665" left="554" width="94" height="17" font="27">bronchospasm, </text>
<text top="682" left="554" width="75" height="17" font="27">bradycardia </text>
<text top="647" left="673" width="182" height="18" font="27">  AV block greater than first </text>
<text top="666" left="690" width="116" height="17" font="27">degree or SA node </text>
<text top="683" left="690" width="162" height="17" font="27">dysfunction (in absence of </text>
<text top="700" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="717" left="673" width="164" height="18" font="27">  Reactive airway disease </text>
<text top="735" left="673" width="132" height="18" font="27">  Cardiogenic shock </text>
<text top="753" left="673" width="139" height="18" font="27">  Decompensated HF </text>
<text top="772" left="673" width="97" height="18" font="27">  Hypotension </text>
<text top="790" left="673" width="130" height="18" font="27">  Renal dysfunction </text>
<text top="808" left="673" width="178" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="827" left="690" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="845" left="49" width="75" height="17" font="27">Propranolol </text>
<text top="845" left="141" width="145" height="17" font="27">30–60 mg in divided or </text>
<text top="863" left="141" width="173" height="17" font="27">single dose with long-acting </text>
<text top="880" left="141" width="80" height="17" font="27">formulations </text>
<text top="845" left="333" width="192" height="17" font="27">40–160 mg in divided or single </text>
<text top="863" left="333" width="134" height="17" font="27">dose with long-acting </text>
<text top="880" left="333" width="80" height="17" font="27">formulations </text>
<text top="845" left="554" width="84" height="17" font="27">Hypotension, </text>
<text top="863" left="554" width="93" height="17" font="27">worsening HF, </text>
<text top="880" left="554" width="94" height="17" font="27">bronchospasm, </text>
<text top="897" left="554" width="75" height="17" font="27">bradycardia </text>
<text top="914" left="579" width="4" height="17" font="27"> </text>
<text top="932" left="579" width="4" height="17" font="27"> </text>
<text top="845" left="673" width="182" height="18" font="27">  AV block greater than first </text>
<text top="864" left="690" width="116" height="17" font="27">degree or SA node </text>
<text top="881" left="690" width="162" height="17" font="27">dysfunction (in absence of </text>
<text top="898" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="915" left="673" width="164" height="18" font="27">  Reactive airway disease </text>
<text top="933" left="673" width="189" height="18" font="27">  Decompensated systolic HF </text>
<text top="951" left="673" width="97" height="18" font="27">  Hypotension </text>
<text top="970" left="673" width="178" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="989" left="690" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="1007" left="49" width="319" height="17" font="30"><b>Nondihydropyridine calcium channel antagonists</b> </text>
<text top="1025" left="49" width="63" height="17" font="27">Diltiazem </text>
<text top="1025" left="141" width="163" height="17" font="27">120 mg daily in divided or </text>
<text top="1042" left="141" width="173" height="17" font="27">single dose with long-acting </text>
<text top="1059" left="141" width="80" height="17" font="27">formulations </text>
<text top="1025" left="333" width="203" height="17" font="27">360 mg daily in divided or single </text>
<text top="1042" left="333" width="134" height="17" font="27">dose with long-acting </text>
<text top="1059" left="333" width="80" height="17" font="27">formulations </text>
<text top="1025" left="554" width="84" height="17" font="27">Hypotension, </text>
<text top="1042" left="554" width="105" height="17" font="27">worsening HF in </text>
<text top="1059" left="554" width="81" height="17" font="27">patients with </text>
<text top="1024" left="673" width="182" height="18" font="27">  AV block greater than first </text>
<text top="1043" left="690" width="116" height="17" font="27">degree or SA node </text>
<text top="1060" left="690" width="162" height="17" font="27">dysfunction (in absence of </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="32" size="13" family="Times" color="#000000"/>
<text top="1084" left="843" width="24" height="17" font="27">135 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="55" left="554" width="76" height="17" font="27">pre-existing </text>
<text top="72" left="554" width="69" height="17" font="27">ventricular </text>
<text top="90" left="554" width="78" height="17" font="27">dysfunction, </text>
<text top="107" left="554" width="78" height="17" font="27">bradycardia, </text>
<text top="124" left="554" width="92" height="17" font="27">abnormal liver </text>
<text top="141" left="554" width="103" height="17" font="27">function studies, </text>
<text top="159" left="554" width="83" height="17" font="27">acute hepatic </text>
<text top="176" left="554" width="77" height="17" font="27">injury (rare) </text>
<text top="55" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="72" left="673" width="104" height="18" font="27">  Hypotension‡ </text>
<text top="90" left="673" width="166" height="18" font="27">  Decompensated systolic </text>
<text top="109" left="690" width="171" height="17" font="27">HF / severe LV dysfunction </text>
<text top="126" left="673" width="193" height="18" font="27">  WPW with AF / atrial flutter </text>
<text top="144" left="673" width="178" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="163" left="690" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="180" left="673" width="175" height="18" font="27">  Diltiazem is a substrate of </text>
<text top="198" left="688" width="143" height="17" font="27">CYP3A4 (major) and a </text>
<text top="216" left="688" width="174" height="17" font="27">moderate CYP3A4 inhibitor </text>
<text top="232" left="673" width="163" height="18" font="27">  Apixaban, itraconazole, </text>
<text top="251" left="690" width="121" height="17" font="27">bosutinib, ceritinib, </text>
<text top="269" left="690" width="149" height="17" font="27">cilostazol, cyclosporine, </text>
<text top="286" left="690" width="133" height="17" font="27">everolimus, ibrutinib, </text>
<text top="303" left="690" width="133" height="17" font="27">idelalisib, ivabradine, </text>
<text top="320" left="690" width="128" height="17" font="27">lomitapide, olaparib, </text>
<text top="338" left="690" width="129" height="17" font="27">ranolazine, rifampin, </text>
<text top="355" left="690" width="68" height="17" font="27">simeprevir </text>
<text top="373" left="49" width="67" height="17" font="27">Verapamil </text>
<text top="373" left="141" width="163" height="17" font="27">120 mg daily in divided or </text>
<text top="390" left="141" width="173" height="17" font="27">single dose with long-acting </text>
<text top="407" left="141" width="80" height="17" font="27">formulations </text>
<text top="373" left="333" width="203" height="17" font="27">480 mg daily in divided or single </text>
<text top="390" left="333" width="134" height="17" font="27">dose with long-acting </text>
<text top="407" left="333" width="80" height="17" font="27">formulations </text>
<text top="373" left="554" width="84" height="17" font="27">Hypotension, </text>
<text top="390" left="554" width="105" height="17" font="27">worsening HF in </text>
<text top="407" left="554" width="81" height="17" font="27">patients with </text>
<text top="425" left="554" width="76" height="17" font="27">pre-existing </text>
<text top="442" left="554" width="69" height="17" font="27">ventricular </text>
<text top="459" left="554" width="78" height="17" font="27">dysfunction, </text>
<text top="476" left="554" width="69" height="17" font="27">pulmonary </text>
<text top="494" left="554" width="58" height="17" font="27">edema in </text>
<text top="511" left="554" width="81" height="17" font="27">patients with </text>
<text top="528" left="554" width="80" height="17" font="27">hypertrophic </text>
<text top="545" left="554" width="105" height="17" font="27">cardiomyopathy, </text>
<text top="563" left="554" width="78" height="17" font="27">bradycardia, </text>
<text top="580" left="554" width="92" height="17" font="27">abnormal liver </text>
<text top="597" left="554" width="99" height="17" font="27">function studies </text>
<text top="372" left="673" width="182" height="18" font="27">  AV block greater than first </text>
<text top="391" left="690" width="116" height="17" font="27">degree or SA node </text>
<text top="408" left="690" width="162" height="17" font="27">dysfunction (in absence of </text>
<text top="426" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="442" left="673" width="166" height="18" font="27">  Decompensated systolic </text>
<text top="461" left="690" width="171" height="17" font="27">HF / severe LV dysfunction </text>
<text top="478" left="673" width="104" height="18" font="27">  Hypotension‡ </text>
<text top="496" left="673" width="193" height="18" font="27">  WPW with AF / atrial flutter </text>
<text top="514" left="673" width="166" height="18" font="27">  Verapamil is a moderate </text>
<text top="533" left="688" width="168" height="17" font="27">CYP3A4 inhibitor and also </text>
<text top="551" left="688" width="142" height="17" font="27">inhibits P-glycoprotein </text>
<text top="567" left="673" width="145" height="18" font="27">  Contraindicated with </text>
<text top="586" left="688" width="65" height="17" font="27">dofetilide  </text>
<text top="603" left="673" width="161" height="18" font="27">  Itraconazole, bosutinib, </text>
<text top="622" left="690" width="123" height="17" font="27">ceritinib, cilostazol, </text>
<text top="639" left="690" width="153" height="17" font="27">colchicine, cyclosporine, </text>
<text top="656" left="690" width="145" height="17" font="27">everolimus, dabigatran, </text>
<text top="674" left="690" width="132" height="17" font="27">edoxaban, flecainide, </text>
<text top="691" left="690" width="130" height="17" font="27">ibrutinib, ivabradine, </text>
<text top="708" left="690" width="127" height="17" font="27">olaparib, ranolazine, </text>
<text top="725" left="690" width="138" height="17" font="27">rivaroxaban, rifampin, </text>
<text top="743" left="690" width="133" height="17" font="27">silodosin, simeprevir, </text>
<text top="760" left="690" width="138" height="17" font="27">rivaroxaban, rifampin, </text>
<text top="777" left="690" width="142" height="17" font="27">simvastatin, topotecan, </text>
<text top="794" left="690" width="145" height="17" font="27">trabectedin, vincristine, </text>
<text top="812" left="690" width="96" height="17" font="27">grapefruit juice </text>
<text top="830" left="49" width="123" height="17" font="30"><b>Cardiac glycosides </b></text>
<text top="848" left="49" width="53" height="17" font="27">Digoxin </text>
<text top="851" left="141" width="138" height="14" font="32"><i>Loading</i>: 0.5 mg, with </text>
<text top="865" left="141" width="159" height="17" font="27">additional 0.125–0.25-mg </text>
<text top="882" left="141" width="172" height="17" font="27">doses administered at 6–8-h </text>
<text top="899" left="141" width="160" height="17" font="27">intervals until evidence of </text>
<text top="917" left="141" width="165" height="17" font="27">adequate effect (maximum </text>
<text top="934" left="141" width="179" height="17" font="27">dose 8–12 mcg/kg over 24 h) </text>
<text top="951" left="141" width="4" height="17" font="27"> </text>
<text top="968" left="141" width="4" height="17" font="27"> </text>
<text top="848" left="333" width="78" height="17" font="27">0.25 mg QD </text>
<text top="865" left="333" width="4" height="17" font="27"> </text>
<text top="885" left="333" width="180" height="14" font="32"><i>Maintenance</i>: 0.125–0.25 mg </text>
<text top="899" left="333" width="160" height="17" font="27">QD, with dosing based on </text>
<text top="917" left="333" width="195" height="17" font="27">patient’s age, lean body weight, </text>
<text top="934" left="333" width="170" height="17" font="27">and renal function and drug </text>
<text top="951" left="333" width="194" height="17" font="27">interactions; occasionally down </text>
<text top="968" left="333" width="184" height="17" font="27">to 0.0625 mg in cases of renal </text>
<text top="986" left="333" width="161" height="17" font="27">impairment (trough serum </text>
<text top="1003" left="333" width="180" height="17" font="27">digoxin level 0.5 to 1 ng/mL) </text>
<text top="848" left="554" width="81" height="17" font="27">Bradycardia, </text>
<text top="865" left="554" width="75" height="17" font="27">heart block, </text>
<text top="882" left="554" width="59" height="17" font="27">anorexia, </text>
<text top="899" left="554" width="48" height="17" font="27">nausea, </text>
<text top="917" left="554" width="101" height="17" font="27">vomiting, visual </text>
<text top="934" left="554" width="78" height="17" font="27">changes and </text>
<text top="951" left="554" width="47" height="17" font="27">cardiac </text>
<text top="968" left="554" width="91" height="17" font="27">arrhythmias in </text>
<text top="986" left="554" width="101" height="17" font="27">cases of digoxin </text>
<text top="1003" left="554" width="50" height="17" font="27">toxicity </text>
<text top="1020" left="554" width="101" height="17" font="27">(associated with </text>
<text top="1037" left="554" width="106" height="17" font="27">levels &gt;2 ng/mL, </text>
<text top="1055" left="554" width="56" height="17" font="27">although </text>
<text top="847" left="673" width="130" height="18" font="27">  Renal dysfunction </text>
<text top="865" left="673" width="157" height="18" font="27">  WPW with  AF / atrial </text>
<text top="884" left="690" width="40" height="17" font="27">flutter </text>
<text top="901" left="673" width="182" height="18" font="27">  AV block greater than first </text>
<text top="920" left="690" width="116" height="17" font="27">degree or SA node </text>
<text top="937" left="690" width="162" height="17" font="27">dysfunction (in absence of </text>
<text top="954" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="971" left="673" width="178" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="990" left="690" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="1006" left="673" width="182" height="18" font="27">  Reduce dose by 30%–50% </text>
<text top="1025" left="690" width="153" height="17" font="27">when administering with </text>
<text top="1043" left="690" width="150" height="17" font="27">amiodarone and by 50% </text>
<text top="1060" left="690" width="153" height="17" font="27">when administering with </text>
</page>
<page number="136" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">136 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="55" left="554" width="95" height="17" font="27">symptoms may </text>
<text top="72" left="554" width="80" height="17" font="27">also occur at </text>
<text top="90" left="554" width="82" height="17" font="27">lower levels) </text>
<text top="55" left="690" width="79" height="17" font="27">dronedarone </text>
<text top="72" left="673" width="119" height="18" font="27">  Monitor digoxin </text>
<text top="91" left="690" width="122" height="17" font="27">concentrations with </text>
<text top="108" left="690" width="163" height="17" font="27">verapamil, clarithromycin, </text>
<text top="125" left="690" width="169" height="17" font="27">erythromycin, itraconazole, </text>
<text top="142" left="690" width="167" height="17" font="27">cyclosporine, propafenone, </text>
<text top="160" left="690" width="63" height="17" font="27">flecainide </text>
<text top="178" left="49" width="201" height="17" font="30"><b>Class Ic antiarrhythmic agents</b> </text>
<text top="196" left="49" width="66" height="17" font="27">Flecainide </text>
<text top="196" left="141" width="109" height="17" font="27">50 mg every 12 h </text>
<text top="196" left="333" width="116" height="17" font="27">150 mg every 12 h </text>
<text top="213" left="333" width="203" height="17" font="27">(PR and QRS intervals should be </text>
<text top="230" left="333" width="155" height="17" font="27">monitored. May consider </text>
<text top="247" left="333" width="180" height="17" font="27">monitoring flecainide plasma </text>
<text top="265" left="333" width="183" height="17" font="27">levels, keeping trough plasma </text>
<text top="282" left="333" width="187" height="17" font="27">levels below 0.7–1.0 mcg/mL) </text>
<text top="196" left="554" width="79" height="17" font="27">Atrial flutter </text>
<text top="213" left="554" width="79" height="17" font="27">with 1:1 AV </text>
<text top="230" left="554" width="105" height="17" font="27">conduction§, QT </text>
<text top="247" left="554" width="84" height="17" font="27">prolongation, </text>
<text top="265" left="554" width="71" height="17" font="27">torsades de </text>
<text top="282" left="554" width="51" height="17" font="27">pointes, </text>
<text top="299" left="554" width="93" height="17" font="27">worsening HF, </text>
<text top="316" left="554" width="75" height="17" font="27">bradycardia </text>
<text top="195" left="673" width="166" height="18" font="27">  Sinus or AV conduction </text>
<text top="214" left="690" width="135" height="17" font="27">disease (in absence of </text>
<text top="231" left="690" width="74" height="17" font="27">pacemaker) </text>
<text top="248" left="673" width="132" height="18" font="27">  Cardiogenic shock </text>
<text top="266" left="673" width="167" height="18" font="27">  Avoid in structural heart </text>
<text top="285" left="690" width="169" height="17" font="27">disease (including ischemic </text>
<text top="302" left="690" width="86" height="17" font="27">heart disease) </text>
<text top="319" left="673" width="142" height="18" font="27">  Atrial flutter (unless </text>
<text top="338" left="690" width="140" height="17" font="27">concomitant AV nodal </text>
<text top="355" left="690" width="124" height="17" font="27">therapy to avoid 1:1 </text>
<text top="373" left="690" width="75" height="17" font="27">conduction) </text>
<text top="389" left="673" width="134" height="18" font="27">  Brugada syndrome </text>
<text top="407" left="673" width="130" height="18" font="27">  Renal dysfunction </text>
<text top="426" left="673" width="142" height="18" font="27">  Hepatic dysfunction </text>
<text top="444" left="673" width="148" height="18" font="27">  QT-prolonging drugs </text>
<text top="462" left="673" width="152" height="18" font="27">  Amiodarone, digoxin, </text>
<text top="481" left="690" width="129" height="17" font="27">ritonavir, saquinavir, </text>
<text top="499" left="690" width="62" height="17" font="27">tipranavir </text>
<text top="517" left="49" width="201" height="17" font="27">Propafenone  150 mg every 8 h </text>
<text top="534" left="141" width="127" height="17" font="27">(immediate release); </text>
<text top="551" left="141" width="179" height="17" font="27">225 mg every 12 h (extended </text>
<text top="568" left="141" width="50" height="17" font="27">release) </text>
<text top="517" left="333" width="181" height="17" font="27">300 mg every 8 h (immediate </text>
<text top="534" left="333" width="55" height="17" font="27">release); </text>
<text top="551" left="333" width="179" height="17" font="27">425 mg every 12 h (extended </text>
<text top="568" left="333" width="50" height="17" font="27">release) </text>
<text top="586" left="333" width="197" height="17" font="27">(PR and QRS interval should be </text>
<text top="603" left="333" width="173" height="17" font="27">monitored. Consider dosage </text>
<text top="620" left="333" width="138" height="17" font="27">reduction with hepatic </text>
<text top="637" left="333" width="78" height="17" font="27">impairment) </text>
<text top="517" left="554" width="79" height="17" font="27">Atrial flutter </text>
<text top="534" left="554" width="79" height="17" font="27">with 1:1 AV </text>
<text top="551" left="554" width="105" height="17" font="27">conduction§, QT </text>
<text top="568" left="554" width="84" height="17" font="27">prolongation, </text>
<text top="586" left="554" width="71" height="17" font="27">torsades de </text>
<text top="603" left="554" width="51" height="17" font="27">pointes, </text>
<text top="620" left="554" width="78" height="17" font="27">bradycardia, </text>
<text top="637" left="554" width="90" height="17" font="27">bronchospasm </text>
<text top="516" left="675" width="163" height="18" font="27">  Sinus or AV conduction </text>
<text top="535" left="689" width="135" height="17" font="27">disease (in absence of </text>
<text top="552" left="689" width="77" height="17" font="27">pacemaker)  </text>
<text top="569" left="675" width="129" height="18" font="27">  Cardiogenic shock </text>
<text top="587" left="675" width="94" height="18" font="27">  Hypotension </text>
<text top="605" left="675" width="161" height="18" font="27">  Reactive airway disease<b> </b></text>
<text top="624" left="689" width="151" height="17" font="27">Avoid in structural heart </text>
<text top="642" left="689" width="169" height="17" font="27">disease (including ischemic </text>
<text top="659" left="689" width="86" height="17" font="27">heart disease) </text>
<text top="676" left="675" width="139" height="18" font="27">  Atrial flutter (unless </text>
<text top="694" left="689" width="140" height="17" font="27">concomitant AV nodal </text>
<text top="712" left="689" width="124" height="17" font="27">therapy to avoid 1:1 </text>
<text top="729" left="689" width="75" height="17" font="27">conduction) </text>
<text top="746" left="675" width="131" height="18" font="27">  Brugada syndrome </text>
<text top="764" left="675" width="138" height="18" font="27">  Hepatic dysfunction </text>
<text top="782" left="675" width="145" height="18" font="27">  QT-prolonging drugs </text>
<text top="801" left="675" width="175" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="820" left="689" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="836" left="675" width="155" height="18" font="27">  Amiodarone, ritonavir, </text>
<text top="855" left="689" width="132" height="17" font="27">saquinavir, tipranavir </text>
<text top="873" left="49" width="206" height="17" font="30"><b>Class III antiarrhythmic agents</b> </text>
<text top="891" left="49" width="261" height="17" font="27">Amiodarone  400–600 mg QD in divided </text>
<text top="908" left="141" width="158" height="17" font="27">doses for 2-4 wk (loading </text>
<text top="926" left="141" width="173" height="17" font="27">dose); followed by 100–200 </text>
<text top="943" left="141" width="169" height="17" font="27">mg QD (maintenance dose) </text>
<text top="891" left="333" width="167" height="17" font="27">Up to 1200 mg QD may be </text>
<text top="908" left="333" width="158" height="17" font="27">considered in an inpatient </text>
<text top="926" left="333" width="208" height="17" font="27">monitoring setting (loading dose); </text>
<text top="943" left="333" width="188" height="17" font="27">up to 200 mg QD maintenance </text>
<text top="960" left="333" width="193" height="17" font="27">(to minimize long-term adverse </text>
<text top="977" left="333" width="49" height="17" font="27">effects) </text>
<text top="891" left="554" width="104" height="17" font="27">Bradycardia, QT </text>
<text top="908" left="554" width="84" height="17" font="27">prolongation, </text>
<text top="926" left="554" width="71" height="17" font="27">torsades de </text>
<text top="943" left="554" width="88" height="17" font="27">pointes (rare), </text>
<text top="960" left="554" width="95" height="17" font="27">gastrointestinal </text>
<text top="977" left="554" width="39" height="17" font="27">upset, </text>
<text top="995" left="554" width="81" height="17" font="27">constipation, </text>
<text top="1012" left="554" width="102" height="17" font="27">hypothyroidism, </text>
<text top="1029" left="554" width="107" height="17" font="27">hyperthyroidism, </text>
<text top="1046" left="554" width="69" height="17" font="27">pulmonary </text>
<text top="1064" left="554" width="100" height="17" font="27">fibrosis, hepatic </text>
<text top="890" left="673" width="165" height="18" font="27">  Sinus or AV conduction </text>
<text top="909" left="689" width="135" height="17" font="27">disease (in absence of </text>
<text top="927" left="689" width="77" height="17" font="27">pacemaker)  </text>
<text top="943" left="673" width="179" height="18" font="27">  Inflammatory lung disease </text>
<text top="962" left="673" width="140" height="18" font="27">  Hepatic dysfunction </text>
<text top="980" left="673" width="121" height="18" font="27">  Hypothyroidism, </text>
<text top="999" left="689" width="103" height="17" font="27">hyperthyroidism </text>
<text top="1015" left="673" width="152" height="18" font="27">  Peripheral neuropathy </text>
<text top="1034" left="673" width="154" height="18" font="27">  Abnormal gait / ataxia </text>
<text top="1052" left="673" width="101" height="18" font="27">  Optic neuritis </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">137 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="55" left="554" width="101" height="17" font="27">toxicity, corneal </text>
<text top="72" left="554" width="90" height="17" font="27">deposits, optic </text>
<text top="90" left="554" width="53" height="17" font="27">neuritis, </text>
<text top="107" left="554" width="65" height="17" font="27">peripheral </text>
<text top="124" left="554" width="75" height="17" font="27">neuropathy, </text>
<text top="141" left="554" width="103" height="17" font="27">photosensitivity, </text>
<text top="159" left="554" width="102" height="17" font="27">adult respiratory </text>
<text top="176" left="554" width="49" height="17" font="27">distress </text>
<text top="193" left="554" width="94" height="17" font="27">syndrome after </text>
<text top="210" left="554" width="63" height="17" font="27">cardiac or </text>
<text top="228" left="554" width="70" height="17" font="27">noncardiac </text>
<text top="245" left="554" width="86" height="17" font="27">surgery (rare) </text>
<text top="54" left="673" width="177" height="18" font="27">  Drugs with SA and/or AV </text>
<text top="73" left="689" width="161" height="17" font="27">nodal–blocking properties </text>
<text top="90" left="673" width="191" height="18" font="27">  Amiodarone is a substrate of </text>
<text top="109" left="688" width="166" height="17" font="27">and inhibits p-glycoprotein </text>
<text top="126" left="688" width="157" height="17" font="27">and CYP2C9 (moderate), </text>
<text top="144" left="688" width="158" height="17" font="27">CYP2D6 (moderate), and </text>
<text top="161" left="688" width="108" height="17" font="27">CYP3A4 (weak); </text>
<text top="178" left="688" width="177" height="17" font="27">amiodarone is a substrate for </text>
<text top="195" left="688" width="133" height="17" font="27">CYP3A4 (major) and </text>
<text top="213" left="688" width="111" height="17" font="27">CYP2C8 (major); </text>
<text top="230" left="688" width="178" height="17" font="27">amiodarone is an inhibitor of </text>
<text top="247" left="688" width="41" height="17" font="27">OCT2 </text>
<text top="264" left="673" width="168" height="18" font="27">  Reduce warfarin dose by </text>
<text top="283" left="688" width="154" height="17" font="27">50%, and reduce digoxin </text>
<text top="300" left="688" width="116" height="17" font="27">dose by 30%–50% </text>
<text top="316" left="675" width="179" height="18" font="27">  Agalsidase alfa, agalsidase </text>
<text top="335" left="689" width="119" height="17" font="27">beta, azithromycin, </text>
<text top="353" left="689" width="121" height="17" font="27">bosutinib, ceritinib, </text>
<text top="370" left="689" width="144" height="17" font="27">colchicine,  dabigatran, </text>
<text top="387" left="689" width="132" height="17" font="27">edoxaban, flecainide, </text>
<text top="404" left="689" width="71" height="17" font="27">ivabradine, </text>
<text top="422" left="689" width="134" height="17" font="27">ledipasvir/sofosbuvir, </text>
<text top="439" left="689" width="62" height="17" font="27">lopinavir, </text>
<text top="456" left="689" width="118" height="17" font="27">lopinavir/ritonavir, </text>
<text top="473" left="689" width="132" height="17" font="27">lovastatin, nelfinavir, </text>
<text top="491" left="689" width="152" height="17" font="27">pazopanib, propafenone, </text>
<text top="508" left="689" width="135" height="17" font="27">simvastatin, ritonavir, </text>
<text top="525" left="689" width="149" height="17" font="27">rivaroxaban, saquinavir, </text>
<text top="542" left="689" width="137" height="17" font="27">sofosbuvir, topotecan, </text>
<text top="560" left="689" width="167" height="17" font="27">vincristine, grapefruit juice </text>
<text top="578" left="49" width="65" height="17" font="27">Dofetilide </text>
<text top="577" left="141" width="152" height="18" font="27"> 500 mcg every 12 h (if </text>
<text top="596" left="152" width="117" height="17" font="27">CrCl &gt;60 mL/min) </text>
<text top="613" left="141" width="152" height="18" font="27"> 250 mcg every 12 h (if </text>
<text top="632" left="152" width="131" height="17" font="27">CrCl 40–60 mL/min) </text>
<text top="648" left="141" width="152" height="18" font="27"> 125 mcg every 12 h (if </text>
<text top="667" left="152" width="152" height="17" font="27">CrCl 20 to &lt;40 mL/min) </text>
<text top="684" left="141" width="173" height="18" font="27"> Not recommended if CrCl </text>
<text top="703" left="152" width="79" height="17" font="27">&lt;20 mL/min </text>
<text top="719" left="141" width="142" height="18" font="27"> Adjust dose for renal </text>
<text top="738" left="152" width="148" height="17" font="27">function, body size, and </text>
<text top="755" left="152" width="25" height="17" font="27">age </text>
<text top="772" left="141" width="180" height="18" font="27"> Initiate for minimum of 3 d </text>
<text top="791" left="152" width="123" height="17" font="27">in a facility that can </text>
<text top="808" left="152" width="123" height="17" font="27">provide continuous  </text>
<text top="826" left="152" width="126" height="17" font="27">ECGmonitoring and </text>
<text top="843" left="152" width="127" height="17" font="27">cardiac resuscitation </text>
<text top="859" left="141" width="146" height="18" font="27"> Contraindicated if the </text>
<text top="878" left="152" width="149" height="17" font="27">baseline QTc interval or </text>
<text top="896" left="152" width="83" height="17" font="27">QTc &gt;440 ms</text>
<text top="897" left="235" width="10" height="15" font="28">║</text>
<text top="896" left="244" width="68" height="17" font="27"> or 500 ms </text>
<text top="913" left="152" width="165" height="17" font="27">in patients with ventricular </text>
<text top="930" left="152" width="156" height="17" font="27">conduction abnormalities </text>
<text top="578" left="333" width="148" height="17" font="27">Repeat ECG 2–3 h after </text>
<text top="595" left="333" width="187" height="17" font="27">administering the first dose to  </text>
<text top="612" left="333" width="164" height="17" font="27">determine QTc; if the QTc </text>
<text top="629" left="333" width="182" height="17" font="27">increased by &gt;15% compared </text>
<text top="647" left="333" width="191" height="17" font="27">with baseline or if QTc is &gt;500 </text>
<text top="664" left="333" width="17" height="17" font="27">ms</text>
<text top="665" left="351" width="10" height="15" font="31"><b>║</b></text>
<text top="664" left="360" width="153" height="17" font="27"> (550 ms in patients with </text>
<text top="681" left="333" width="139" height="17" font="27">ventricular conduction </text>
<text top="698" left="333" width="208" height="17" font="27">abnormalities), subsequent dosing </text>
<text top="716" left="333" width="195" height="17" font="27">should be downtitrated by 50%; </text>
<text top="733" left="333" width="185" height="17" font="27">at 2–3 h after each subsequent </text>
<text top="750" left="333" width="172" height="17" font="27">dose, determine QTc (for in-</text>
<text top="767" left="333" width="207" height="17" font="27">hospital doses 2–5); if at any time </text>
<text top="785" left="333" width="196" height="17" font="27">after the second dose the QTc is </text>
<text top="802" left="333" width="52" height="17" font="27">&gt;500 ms</text>
<text top="803" left="385" width="10" height="15" font="31"><b>║</b></text>
<text top="802" left="395" width="122" height="17" font="27"> (550 ms in patients </text>
<text top="819" left="333" width="169" height="17" font="27">with ventricular conduction </text>
<text top="836" left="333" width="199" height="17" font="27">abnormalities), dofetilide should </text>
<text top="854" left="333" width="98" height="17" font="27">be discontinued<b> </b></text>
<text top="578" left="554" width="24" height="17" font="27">QT </text>
<text top="595" left="554" width="84" height="17" font="27">prolongation, </text>
<text top="612" left="554" width="71" height="17" font="27">torsades de </text>
<text top="629" left="554" width="47" height="17" font="27">pointes </text>
<text top="577" left="675" width="166" height="18" font="27">  Severe renal dysfunction </text>
<text top="596" left="688" width="174" height="17" font="27">(contraindicated if CrCl &lt;20 </text>
<text top="613" left="688" width="57" height="17" font="27">mL/min) </text>
<text top="630" left="675" width="106" height="18" font="27">  Prolonged QT  </text>
<text top="648" left="675" width="149" height="18" font="27">  History of torsades de </text>
<text top="667" left="688" width="47" height="17" font="27">pointes </text>
<text top="684" left="675" width="135" height="18" font="27">  Concomitant use of </text>
<text top="703" left="688" width="128" height="17" font="27">hydrochlorothiazide, </text>
<text top="720" left="688" width="152" height="17" font="27">cimetidine, dolutegravir, </text>
<text top="737" left="688" width="167" height="17" font="27">itraconazole, ketoconazole, </text>
<text top="754" left="688" width="153" height="17" font="27">megestrol, trimethoprim, </text>
<text top="772" left="688" width="106" height="17" font="27">prochlorperazine </text>
<text top="789" left="688" width="171" height="17" font="27">trimethoprim/sulfamethoxaz</text>
<text top="806" left="688" width="110" height="17" font="27">ole or verapamil,  </text>
<text top="823" left="688" width="96" height="17" font="27">contraindicated </text>
<text top="840" left="675" width="184" height="18" font="27">  Avoid other QT-prolonging </text>
<text top="859" left="688" width="37" height="17" font="27">drugs </text>
<text top="948" left="49" width="46" height="17" font="27">Sotalol </text>
<text top="948" left="141" width="135" height="17" font="27">40–80 mg every 12 h  </text>
<text top="965" left="141" width="125" height="17" font="27">(Patients initiated or </text>
<text top="983" left="141" width="171" height="17" font="27">reinitiated on sotalol should </text>
<text top="1000" left="141" width="159" height="17" font="27">be placed in a facility that </text>
<text top="1017" left="141" width="121" height="17" font="27">can provide cardiac </text>
<text top="1034" left="141" width="175" height="17" font="27">resuscitation and continuous </text>
<text top="1052" left="141" width="127" height="17" font="27">electrocardiographic </text>
<text top="948" left="333" width="116" height="17" font="27">160 mg every 12 h </text>
<text top="965" left="333" width="190" height="17" font="27">(During initiation and titration, </text>
<text top="983" left="333" width="157" height="17" font="27">the QT interval should be </text>
<text top="1000" left="333" width="200" height="17" font="27">monitored 2–4 h after each dose. </text>
<text top="1017" left="333" width="181" height="17" font="27">If the QT interval prolongs to </text>
<text top="1034" left="333" width="164" height="17" font="27">≥500 ms, the dose must be </text>
<text top="1052" left="333" width="121" height="17" font="27">reduced or the drug </text>
<text top="948" left="554" width="24" height="17" font="27">QT </text>
<text top="965" left="554" width="84" height="17" font="27">prolongation, </text>
<text top="983" left="554" width="71" height="17" font="27">torsades de </text>
<text top="1000" left="554" width="51" height="17" font="27">pointes, </text>
<text top="1017" left="554" width="78" height="17" font="27">bradycardia, </text>
<text top="1034" left="554" width="90" height="17" font="27">bronchospasm </text>
<text top="1052" left="554" width="4" height="17" font="27"> </text>
<text top="948" left="673" width="104" height="18" font="27">  Prolonged QT </text>
<text top="966" left="673" width="129" height="18" font="27">  Renal dysfunction </text>
<text top="984" left="673" width="100" height="18" font="27">  Hypokalemia </text>
<text top="1003" left="673" width="117" height="18" font="27">  Diuretic therapy </text>
<text top="1021" left="673" width="186" height="18" font="27">  Avoid other QT-prolonging </text>
<text top="1040" left="689" width="37" height="17" font="27">drugs </text>
<text top="1056" left="673" width="131" height="18" font="27">  Sinus or AV nodal </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">138 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="55" left="141" width="164" height="17" font="27">monitoring for a minimum </text>
<text top="72" left="141" width="46" height="17" font="27">of 3 d.  </text>
<text top="90" left="141" width="161" height="17" font="27">Contraindicated if the QTc</text>
<text top="91" left="302" width="10" height="15" font="28">║</text>
<text top="90" left="311" width="4" height="17" font="27"> </text>
<text top="107" left="141" width="127" height="17" font="27">interval is &gt;450 ms.  </text>
<text top="124" left="141" width="163" height="17" font="27"> CrCl should be calculated </text>
<text top="141" left="141" width="164" height="17" font="27">before dosing. If CrCl &gt;60 </text>
<text top="159" left="141" width="129" height="17" font="27">mL/min, then dosing </text>
<text top="176" left="141" width="165" height="17" font="27">frequency is twice daily. If </text>
<text top="193" left="141" width="171" height="17" font="27">CrCl 40-60 mL/min, dosing </text>
<text top="210" left="141" width="148" height="17" font="27">interval is every 24 h. If </text>
<text top="228" left="141" width="160" height="17" font="27">CrCl &lt;40 mL/min, should </text>
<text top="245" left="141" width="81" height="17" font="27">not be used.) </text>
<text top="55" left="333" width="357" height="17" font="27">discontinued.)  </text>
<text top="72" left="554" width="4" height="17" font="27"> </text>
<text top="90" left="554" width="4" height="17" font="27"> </text>
<text top="107" left="554" width="4" height="17" font="27"> </text>
<text top="124" left="554" width="4" height="17" font="27"> </text>
<text top="141" left="554" width="4" height="17" font="27"> </text>
<text top="159" left="554" width="4" height="17" font="27"> </text>
<text top="176" left="554" width="4" height="17" font="27"> </text>
<text top="193" left="554" width="4" height="17" font="27"> </text>
<text top="210" left="554" width="4" height="17" font="27"> </text>
<text top="228" left="554" width="4" height="17" font="27"> </text>
<text top="245" left="554" width="4" height="17" font="27"> </text>
<text top="262" left="554" width="4" height="17" font="27"> </text>
<text top="279" left="554" width="4" height="17" font="27"> </text>
<text top="55" left="689" width="162" height="17" font="27">dysfunction (in absence of </text>
<text top="72" left="689" width="74" height="17" font="27">pacemaker) </text>
<text top="89" left="673" width="187" height="18" font="27">  Decompensated systolic HF </text>
<text top="107" left="673" width="131" height="18" font="27">  Cardiogenic shock </text>
<text top="126" left="673" width="163" height="18" font="27">  Reactive airway disease </text>
<text top="144" left="673" width="180" height="18" font="27">  Drugs with SA and/or AV–</text>
<text top="163" left="689" width="157" height="17" font="27">nodal blocking properties<b> </b></text>
<text top="298" left="49" width="103" height="18" font="29"><b>Miscellaneous </b></text>
<text top="317" left="49" width="68" height="17" font="27">Ivabradine </text>
<text top="317" left="141" width="64" height="17" font="27">5 mg BID </text>
<text top="317" left="333" width="75" height="17" font="27">7.5 mg BID </text>
<text top="317" left="554" width="101" height="17" font="27">Phosphenes, AF </text>
<text top="316" left="673" width="186" height="18" font="27">  Concomitant drugs that can </text>
<text top="335" left="690" width="142" height="17" font="27">exacerbate bradycardia </text>
<text top="352" left="673" width="132" height="18" font="27">  Contraindicated in </text>
<text top="371" left="690" width="119" height="17" font="27">decompensated HF </text>
<text top="388" left="673" width="151" height="18" font="27">  Contraindicated if BP </text>
<text top="407" left="690" width="96" height="17" font="27">&lt;90/50 mm Hg </text>
<text top="423" left="673" width="174" height="18" font="27">  Contraindicated in severe </text>
<text top="442" left="690" width="120" height="17" font="27">hepatic impairment </text>
<text top="459" left="673" width="101" height="18" font="27">  Hypertension </text>
<text top="477" left="673" width="186" height="18" font="27">  Ivabradine is a substrate  of </text>
<text top="496" left="690" width="107" height="17" font="27">CYP3A4 (major) </text>
<text top="513" left="673" width="190" height="18" font="27">  Avoid use with concomitant </text>
<text top="532" left="690" width="161" height="17" font="27">strong CYP3A4 inhibitors </text>
<text top="549" left="690" width="173" height="17" font="27">(boceprevir, clarithromycin, </text>
<text top="566" left="690" width="143" height="17" font="27">indinavir, itraconazole, </text>
<text top="583" left="690" width="118" height="17" font="27">lopinavir/ritonavir, </text>
<text top="601" left="690" width="125" height="17" font="27">nelfinavir, ritonavir, </text>
<text top="618" left="690" width="135" height="17" font="27">saquinavir, telaprevir, </text>
<text top="635" left="690" width="174" height="17" font="27">posaconazole, voriconazole) </text>
<text top="652" left="673" width="153" height="18" font="27">  Avoid use with strong </text>
<text top="671" left="690" width="113" height="17" font="27">CYP3A4 inducers </text>
<text top="688" left="690" width="170" height="17" font="27">(carbamazepine, phenytoin, </text>
<text top="705" left="690" width="158" height="17" font="27">rifampin, St. John’s wort) </text>
<text top="722" left="673" width="175" height="18" font="27">  Avoid use with diltiazem, </text>
<text top="741" left="690" width="163" height="17" font="27">verapamil, grapefruit juice </text>
<text top="759" left="41" width="717" height="17" font="27">Note: For this reference table, drugs are presented in alphabetical order within the drug classes, not by COR and LOE.  </text>
<text top="776" left="40" width="801" height="17" font="27">*When 1 drug is used in combination with other drugs, appropriate dosing adjustments should be made with consideration of at least </text>
<text top="793" left="40" width="793" height="17" font="27">additive effects during dosage titration. All potential drug–drug interactions and adverse reactions are not included in this list. For a </text>
<text top="810" left="40" width="730" height="17" font="27">more detailed list of drug interactions and adverse responses, clinicians should consult additional resources; for example, </text>
<text top="828" left="40" width="529" height="17" font="27">www.crediblemeds.org may be consulted for potential prolongation of the QT interval. <b> </b></text>
<text top="845" left="40" width="660" height="17" font="27">§Recommended given in conjunction with a beta blocker or nondihydropyridine calcium channel antagonist.  </text>
<text top="863" left="41" width="10" height="15" font="28">║</text>
<text top="862" left="50" width="406" height="17" font="27">QTc calculation used the Bazett’s Formula in most clinical studies. </text>
<text top="879" left="41" width="4" height="17" font="27"> </text>
<text top="897" left="41" width="747" height="17" font="27">AF indicates atrial fibrillation; AV, atrioventricular; BID, twice daily; BP, blood pressure; CrCl, creatinine clearance; ECG, </text>
<text top="914" left="41" width="795" height="17" font="27">electrocardiogram/electrocardiographic; HF, heart failure; INR, international normalized ratio; LV, left ventricular; QD, once daily; </text>
<text top="931" left="41" width="787" height="17" font="27">QID, 4 times a day; QTc, corrected QT interval; SA, sinoatrial; SVT, supraventricular tachycardia; TID, 3 times a day; and WPW, </text>
<text top="948" left="41" width="150" height="17" font="27">Wolff-Parkinson-White. </text>
<text top="966" left="41" width="4" height="17" font="27"> </text>
<text top="984" left="54" width="3" height="17" font="27"> </text>
<text top="982" left="270" width="4" height="19" font="29"><b></b></text>
</page>
<page number="139" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="33" size="14" family="Times" color="#000000"/>
<text top="1084" left="843" width="24" height="17" font="27">139 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="217" width="495" height="19" font="29"><b>Appendix3.SuccessandComplicationRatesforAblationofSVT*</b></text>
<text top="75" left="85" width="81" height="17" font="30"><b>Arrhythmia </b></text>
<text top="75" left="216" width="93" height="17" font="30"><b>Acute Success </b></text>
<text top="75" left="375" width="112" height="17" font="30"><b>Recurrence Rate </b></text>
<text top="75" left="586" width="141" height="17" font="30"><b>Major Complications </b></text>
<text top="75" left="786" width="74" height="17" font="30"><b>References </b></text>
<text top="93" left="54" width="102" height="17" font="30"><b>Common SVTs </b></text>
<text top="110" left="54" width="324" height="17" font="27">AVNRT 96%–97% </text>
<text top="110" left="277" width="128" height="17" font="27">(55, </text>
<text top="128" left="210" width="27" height="17" font="27">59)  </text>
<text top="110" left="327" width="52" height="17" font="27">5% (59) </text>
<text top="110" left="547" width="115" height="18" font="27">  Overall 3% (55) </text>
<text top="137" left="547" width="111" height="18" font="27">  PPM 0.7% (55)<b> </b></text>
<text top="164" left="547" width="105" height="18" font="27">  Death 0% (55)<b> </b></text>
<text top="110" left="779" width="55" height="17" font="27">(55, 59)  </text>
<text top="192" left="54" width="115" height="17" font="27">AVRT / accessory </text>
<text top="209" left="54" width="55" height="17" font="27">pathway </text>
<text top="192" left="210" width="82" height="17" font="27">93% (55, 59) </text>
<text top="192" left="327" width="52" height="17" font="27">8% (59) </text>
<text top="191" left="547" width="126" height="18" font="27">  Overall 2.8% (55) </text>
<text top="218" left="547" width="111" height="18" font="27">  PPM 0.3% (55)<b> </b></text>
<text top="245" left="547" width="117" height="18" font="27">  Death 0.1% (55)<b> </b></text>
<text top="272" left="547" width="152" height="18" font="27">  Tamponade 0.4% (55)<b> </b></text>
<text top="192" left="779" width="51" height="17" font="27">(55, 59) </text>
<text top="301" left="54" width="129" height="17" font="27">CTI-dependent atrial </text>
<text top="318" left="54" width="40" height="17" font="27">flutter </text>
<text top="301" left="210" width="64" height="17" font="27">97% (55)  </text>
<text top="301" left="327" width="189" height="17" font="27">10.6% atrial flutter (395), 33% </text>
<text top="318" left="327" width="139" height="17" font="27">atrial fibrillation (395) </text>
<text top="300" left="547" width="126" height="18" font="27">  Overall 0.5% (55)<b> </b></text>
<text top="327" left="547" width="111" height="18" font="27">  PPM 0.2% (55)<b> </b></text>
<text top="354" left="547" width="199" height="18" font="27">  Pericardial effusion 0.3% (55)<b> </b></text>
<text top="301" left="779" width="81" height="17" font="27">(55, 59, 395) </text>
<text top="382" left="54" width="130" height="17" font="30"><b>Less common SVTs </b></text>
<text top="400" left="54" width="61" height="17" font="27">Focal AT </text>
<text top="400" left="211" width="74" height="17" font="27">80%–100% </text>
<text top="400" left="327" width="59" height="17" font="27">4%–27% </text>
<text top="400" left="547" width="63" height="17" font="27">&lt;1%–2%  </text>
<text top="400" left="779" width="72" height="17" font="27">(89, 93, 97, </text>
<text top="417" left="779" width="82" height="17" font="27">99, 105, 106, </text>
<text top="435" left="779" width="61" height="17" font="27">396, 397) </text>
<text top="453" left="54" width="19" height="17" font="27">JT </text>
<text top="453" left="210" width="66" height="17" font="27">82%–85% </text>
<text top="453" left="327" width="46" height="17" font="27">0–18% </text>
<text top="453" left="547" width="219" height="17" font="27">0–18% CHB (overall complications </text>
<text top="470" left="547" width="35" height="17" font="27">N/A) </text>
<text top="453" left="779" width="65" height="17" font="27">(233, 234, </text>
<text top="470" left="779" width="31" height="17" font="27">269) </text>
<text top="488" left="54" width="128" height="17" font="27">Non–CTI-dependent </text>
<text top="505" left="54" width="75" height="17" font="27">atrial flutter </text>
<text top="488" left="210" width="218" height="17" font="27">73%–100% 7%–53% </text>
<text top="488" left="547" width="81" height="17" font="27">0–7% </text>
<text top="488" left="779" width="78" height="17" font="27">(106, </text>
<text top="488" left="814" width="73" height="17" font="27">211, </text>
<text top="505" left="779" width="60" height="17" font="27">213, 215, </text>
<text top="522" left="779" width="60" height="17" font="27">216, 218, </text>
<text top="540" left="779" width="60" height="17" font="27">219, 221, </text>
<text top="557" left="779" width="31" height="17" font="27">398) </text>
<text top="575" left="47" width="803" height="17" font="27">*Data in this table are derived from multiple observational studies and registries, and as such may not always reflect current practice. </text>
<text top="592" left="47" width="798" height="17" font="27">AT indicates atrial tachycardia; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; </text>
<text top="609" left="47" width="802" height="17" font="27">CHB, complete heart block; CTI, cavotricuspid isthmus; JT, junctional tachycardia; N/A, not available; PPM, permanent pacemaker; </text>
<text top="627" left="47" width="235" height="17" font="27">and SVT, supraventricular tachycardia.</text>
<text top="625" left="283" width="4" height="18" font="33"> </text>
<text top="644" left="54" width="3" height="17" font="27"> </text>
<text top="661" left="460" width="4" height="19" font="29"><b></b></text>
<text top="680" left="460" width="4" height="19" font="29"><b></b></text>
<text top="709" left="54" width="4" height="18" font="29"><b> </b></text>
<text top="726" left="54" width="3" height="17" font="27"> </text>
<text top="727" left="270" width="3" height="15" font="28"> </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">140 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="418" width="88" height="19" font="29"><b>References</b></text>
<text top="74" left="459" width="4" height="17" font="27"> </text>
<text top="91" left="54" width="4" height="17" font="27"> </text>
<text top="91" left="83" width="769" height="17" font="27">1.   Sganzerla P, Fabbiocchi F, Grazi S, et al. Electrophysiologic and haemodynamic correlates in supraventricular tachycardia. </text>
<text top="108" left="108" width="164" height="17" font="27">Eur Heart J. 1989;10:32-9. </text>
<text top="125" left="54" width="4" height="17" font="27"> </text>
<text top="125" left="83" width="751" height="17" font="27">2.   Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symptoms with occurrence of paroxysmal supraventricular </text>
<text top="143" left="108" width="726" height="17" font="27">tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study </text>
<text top="160" left="108" width="226" height="17" font="27">Group. Am Heart J. 1992;124:381-6. </text>
<text top="177" left="54" width="4" height="17" font="27"> </text>
<text top="177" left="83" width="785" height="17" font="27">3.   Leitch JW, Klein GJ, Yee R, et al. Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or </text>
<text top="194" left="108" width="316" height="17" font="27">vasomotor response? Circulation. 1992;85:1064-71. </text>
<text top="212" left="54" width="4" height="17" font="27"> </text>
<text top="212" left="83" width="713" height="17" font="27">4.   Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular </text>
<text top="229" left="108" width="261" height="17" font="27">tachycardia. Am J Cardiol. 1995;76:675-8. </text>
<text top="246" left="54" width="4" height="17" font="27"> </text>
<text top="246" left="83" width="764" height="17" font="27">5.   Drago F, Turchetta A, Calzolari A, et al. Reciprocating supraventricular tachycardia in children: low rate at rest as a major </text>
<text top="263" left="108" width="514" height="17" font="27">factor related to propensity to syncope during exercise. Am Heart J. 1996;132:280-5. </text>
<text top="281" left="54" width="4" height="17" font="27"> </text>
<text top="281" left="83" width="781" height="17" font="27">6.   Goyal R, Zivin A, Souza J, et al. Comparison of the ages of tachycardia onset in patients with atrioventricular nodal reentrant </text>
<text top="298" left="108" width="531" height="17" font="27">tachycardia and accessory pathway-mediated tachycardia. Am Heart J. 1996;132:765-7. </text>
<text top="315" left="54" width="4" height="17" font="27"> </text>
<text top="315" left="83" width="763" height="17" font="27">7.   Abe H, Nagatomo T, Kobayashi H, et al. Neurohumoral and hemodynamic mechanisms of diuresis during atrioventricular </text>
<text top="332" left="108" width="443" height="17" font="27">nodal reentrant tachycardia. Pacing Clin Electrophysiol. 1997;20:2783-8. </text>
<text top="350" left="54" width="4" height="17" font="27"> </text>
<text top="350" left="83" width="777" height="17" font="27">8.   Lessmeier TJ, Gamperling D, Johnson-Liddon V, et al. Unrecognized paroxysmal supraventricular tachycardia. Potential for </text>
<text top="367" left="108" width="410" height="17" font="27">misdiagnosis as panic disorder. Arch Intern Med. 1997;157:537-43. </text>
<text top="384" left="54" width="4" height="17" font="27"> </text>
<text top="384" left="83" width="747" height="17" font="27">9.   Kalusche D, Ott P, Arentz T, et al. AV nodal re-entry tachycardia in elderly patients: clinical presentation and results of </text>
<text top="401" left="108" width="459" height="17" font="27">radiofrequency catheter ablation therapy. Coron Artery Dis. 1998;9:359-63. </text>
<text top="419" left="54" width="4" height="17" font="27"> </text>
<text top="419" left="76" width="777" height="17" font="27">10.   Orejarena LA, Vidaillet H, Jr., DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am </text>
<text top="436" left="108" width="178" height="17" font="27">Coll Cardiol. 1998;31:150-7. </text>
<text top="453" left="54" width="4" height="17" font="27"> </text>
<text top="453" left="76" width="780" height="17" font="27">11.   Erdogan A, Schulte B, Carlsson J, et al. [Clinical characteristics of patients with AV-nodal reentrant tachycardia (AVNRT): </text>
<text top="470" left="108" width="731" height="17" font="27">modification by high frequency catheter ablation. Study of 748 patients after high frequency catheter ablation]. Med Klin </text>
<text top="488" left="108" width="171" height="17" font="27">(Munich ). 2001;96:708-12. </text>
<text top="505" left="54" width="4" height="17" font="27"> </text>
<text top="505" left="76" width="789" height="17" font="27">12.   Fitzsimmons PJ, McWhirter PD, Peterson DW, et al. The natural history of Wolff-Parkinson-White syndrome in 228 military </text>
<text top="522" left="108" width="446" height="17" font="27">aviators: a long-term follow-up of 22 years. Am Heart J. 2001;142:530-6. </text>
<text top="539" left="54" width="4" height="17" font="27"> </text>
<text top="539" left="76" width="710" height="17" font="27">13.   Hamdan MH, Zagrodzky JD, Page RL, et al. Effect of P-wave timing during supraventricular tachycardia on the </text>
<text top="557" left="108" width="477" height="17" font="27">hemodynamic and sympathetic neural response. Circulation. 2001;103:96-101. </text>
<text top="574" left="54" width="4" height="17" font="27"> </text>
<text top="574" left="76" width="751" height="17" font="27">14.   Razavi M, Luria DM, Jahangir A, et al. Acute blood pressure changes after the onset of atrioventricular nodal reentrant </text>
<text top="591" left="108" width="505" height="17" font="27">tachycardia: a time-course analysis. J Cardiovasc Electrophysiol. 2005;16:1037-40. </text>
<text top="608" left="54" width="4" height="17" font="27"> </text>
<text top="608" left="76" width="737" height="17" font="27">15.   Walfridsson U, Walfridsson H. The impact of supraventricular tachycardias on driving ability in patients referred for </text>
<text top="626" left="108" width="467" height="17" font="27">radiofrequency catheter ablation. Pacing Clin Electrophysiol. 2005;28:191-5. </text>
<text top="643" left="54" width="4" height="17" font="27"> </text>
<text top="643" left="76" width="783" height="17" font="27">16.   Drago F, Grutter G, Silvetti MS, et al. Atrioventricular nodal reentrant tachycardia in children. Pediatr Cardiol. 2006;27:454-</text>
<text top="660" left="108" width="15" height="17" font="27">9. </text>
<text top="677" left="54" width="4" height="17" font="27"> </text>
<text top="677" left="76" width="702" height="17" font="27">17.   Gonzalez-Torrecilla E, Almendral J, Arenal A, et al. Combined evaluation of bedside clinical variables and the </text>
<text top="695" left="108" width="750" height="17" font="27">electrocardiogram for the differential diagnosis of paroxysmal atrioventricular reciprocating tachycardias in patients without </text>
<text top="712" left="108" width="312" height="17" font="27">pre-excitation. J Am Coll Cardiol. 2009;53:2353-8. </text>
<text top="729" left="54" width="4" height="17" font="27"> </text>
<text top="729" left="76" width="744" height="17" font="27">18.   Laurent G, Leong-Poi H, Mangat I, et al. Influence of ventriculoatrial timing on hemodynamics and symptoms during </text>
<text top="746" left="108" width="457" height="17" font="27">supraventricular tachycardia. J Cardiovasc Electrophysiol. 2009;20:176-81. </text>
<text top="764" left="54" width="4" height="17" font="27"> </text>
<text top="764" left="76" width="731" height="17" font="27">19.   Walfridsson U, Stromberg A, Janzon M, et al. Wolff-Parkinson-White syndrome and atrioventricular nodal re-entry </text>
<text top="781" left="108" width="675" height="17" font="27">tachycardia in a Swedish population: consequences on health-related quality of life. Pacing Clin Electrophysiol. </text>
<text top="798" left="108" width="118" height="17" font="27">2009;32:1299-306. </text>
<text top="815" left="54" width="4" height="17" font="27"> </text>
<text top="815" left="76" width="749" height="17" font="27">20.   Kesek M, Ronn F, Tollefsen T, et al. Symptomatic improvement after catheter ablation of supraventricular tachycardia </text>
<text top="833" left="108" width="532" height="17" font="27">measured by the arrhythmia-specific questionnaire U22. Ups J Med Sci. 2011;116:52-9. </text>
<text top="850" left="54" width="4" height="17" font="27"> </text>
<text top="850" left="76" width="744" height="17" font="27">21.   Cain N, Irving C, Webber S, et al. Natural history of Wolff-Parkinson-White syndrome diagnosed in childhood. Am J </text>
<text top="867" left="108" width="156" height="17" font="27">Cardiol. 2013;112:961-5. </text>
<text top="884" left="54" width="4" height="17" font="27"> </text>
<text top="884" left="76" width="787" height="17" font="27">22.   Maryniak A, Bielawska A, Bieganowska K, et al. Does atrioventricular reentry tachycardia (AVRT) or atrioventricular nodal </text>
<text top="902" left="108" width="753" height="17" font="27">reentry tachycardia (AVNRT) in children affect their cognitive and emotional development? Pediatr Cardiol. 2013;34:893-7. </text>
<text top="919" left="54" width="4" height="17" font="27"> </text>
<text top="919" left="76" width="779" height="17" font="27">23.   Mauritson DR, Winniford MD, Walker WS, et al. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, </text>
<text top="936" left="108" width="394" height="17" font="27">double-blind randomized trial. Ann Intern Med. 1982;96:409-12. </text>
<text top="953" left="54" width="4" height="17" font="27"> </text>
<text top="953" left="76" width="785" height="17" font="27">24.   Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-</text>
<text top="971" left="108" width="536" height="17" font="27">blind comparison of digoxin, propranolol and verapamil. Am J Cardiol. 1984;54:1138-9. </text>
<text top="988" left="54" width="4" height="17" font="27"> </text>
<text top="988" left="76" width="772" height="17" font="27">25.   Anderson S, Blanski L, Byrd RC, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with </text>
<text top="1005" left="108" width="748" height="17" font="27">placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group. Am Heart </text>
<text top="1022" left="108" width="109" height="17" font="27">J. 1986;111:42-8. </text>
<text top="1040" left="54" width="4" height="17" font="27"> </text>
<text top="1040" left="76" width="717" height="17" font="27">26.   Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal </text>
<text top="1057" left="108" width="715" height="17" font="27">supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation. 1991;83:119-25. </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">141 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="4" height="17" font="27"> </text>
<text top="54" left="76" width="750" height="17" font="27">27.   Pritchett EL, DaTorre SD, Platt ML, et al. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and </text>
<text top="72" left="108" width="743" height="17" font="27">paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll </text>
<text top="89" left="108" width="163" height="17" font="27">Cardiol. 1991;17:297-303. </text>
<text top="106" left="54" width="4" height="17" font="27"> </text>
<text top="106" left="76" width="714" height="17" font="27">28.   Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular </text>
<text top="123" left="108" width="692" height="17" font="27">arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. </text>
<text top="141" left="108" width="111" height="17" font="27">1991;114:539-44. </text>
<text top="158" left="54" width="4" height="17" font="27"> </text>
<text top="158" left="76" width="735" height="17" font="27">29.   Anderson JL, Platt ML, Guarnieri T, et al. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The </text>
<text top="175" left="108" width="524" height="17" font="27">Flecainide Supraventricular Tachycardia Study Group. Am J Cardiol. 1994;74:578-84. </text>
<text top="192" left="54" width="4" height="17" font="27"> </text>
<text top="192" left="76" width="727" height="17" font="27">30.   Chimienti M, Cullen MT, Jr., Casadei G. Safety of flecainide versus propafenone for the long-term management of </text>
<text top="210" left="108" width="719" height="17" font="27">symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study </text>
<text top="227" left="108" width="287" height="17" font="27">(FAPIS) Group. Eur Heart J. 1995;16:1943-51. </text>
<text top="244" left="54" width="4" height="17" font="27"> </text>
<text top="244" left="76" width="766" height="17" font="27">31.   A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and </text>
<text top="261" left="108" width="588" height="17" font="27">paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation. 1995;92:2550-7. </text>
<text top="279" left="54" width="4" height="17" font="27"> </text>
<text top="279" left="76" width="725" height="17" font="27">32.   Dorian P, Naccarelli GV, Coumel P, et al. A randomized comparison of flecainide versus verapamil in paroxysmal </text>
<text top="296" left="108" width="678" height="17" font="27">supraventricular tachycardia. The Flecainide Multicenter Investigators Group. Am J Cardiol. 1996;77:89A-95A. </text>
<text top="313" left="54" width="4" height="17" font="27"> </text>
<text top="313" left="76" width="791" height="17" font="27">33.   Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic </text>
<text top="330" left="108" width="624" height="17" font="27">treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133:441-6. </text>
<text top="348" left="54" width="4" height="17" font="27"> </text>
<text top="348" left="76" width="770" height="17" font="27">34.   Lim SH, Anantharaman V, Teo WS, et al. Comparison of treatment of supraventricular tachycardia by Valsalva maneuver </text>
<text top="365" left="108" width="360" height="17" font="27">and carotid sinus massage. Ann Emerg Med. 1998;31:30-5. </text>
<text top="382" left="54" width="4" height="17" font="27"> </text>
<text top="382" left="76" width="788" height="17" font="27">35.   Gupta A, Naik A, Vora A, et al. Comparison of efficacy of intravenous diltiazem and esmolol in terminating supraventricular </text>
<text top="399" left="108" width="336" height="17" font="27">tachycardia. J Assoc Physicians India. 1999;47:969-72. </text>
<text top="417" left="54" width="4" height="17" font="27"> </text>
<text top="417" left="76" width="733" height="17" font="27">36.   Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug </text>
<text top="434" left="108" width="721" height="17" font="27">treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. </text>
<text top="451" left="108" width="103" height="17" font="27">2001;37:548-53. </text>
<text top="468" left="54" width="4" height="17" font="27"> </text>
<text top="468" left="76" width="753" height="17" font="27">37.   Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety of dofetilide in the prevention of symptomatic </text>
<text top="486" left="108" width="758" height="17" font="27">episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am </text>
<text top="503" left="108" width="146" height="17" font="27">Heart J. 2001;142:93-8. </text>
<text top="520" left="54" width="4" height="17" font="27"> </text>
<text top="520" left="76" width="779" height="17" font="27">38.   Lim SH, Anantharaman V, Teo WS, et al. Slow infusion of calcium channel blockers compared with intravenous adenosine </text>
<text top="537" left="108" width="546" height="17" font="27">in the emergency treatment of supraventricular tachycardia. Resuscitation. 2009;80:523-8. </text>
<text top="555" left="54" width="4" height="17" font="27"> </text>
<text top="555" left="76" width="783" height="17" font="27">39.   Smith GD, Dyson K, Taylor D, et al. Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia. </text>
<text top="572" left="108" width="300" height="17" font="27">Cochrane Database Syst Rev. 2013;3:CD009502. </text>
<text top="589" left="54" width="4" height="17" font="27"> </text>
<text top="589" left="76" width="733" height="17" font="27">40.   Mehta D, Wafa S, Ward DE, et al. Relative efficacy of various physical manoeuvres in the termination of junctional </text>
<text top="606" left="108" width="221" height="17" font="27">tachycardia. Lancet. 1988;1:1181-5. </text>
<text top="624" left="54" width="4" height="17" font="27"> </text>
<text top="624" left="76" width="781" height="17" font="27">41.   Wen ZC, Chen SA, Tai CT, et al. Electrophysiological mechanisms and determinants of vagal maneuvers for termination of </text>
<text top="641" left="108" width="438" height="17" font="27">paroxysmal supraventricular tachycardia. Circulation. 1998;98:2716-23. </text>
<text top="658" left="54" width="4" height="17" font="27"> </text>
<text top="658" left="76" width="770" height="17" font="27">42.   Waxman MB, Wald RW, Sharma AD, et al. Vagal techniques for termination of paroxysmal supraventricular tachycardia. </text>
<text top="675" left="108" width="192" height="17" font="27">Am J Cardiol. 1980;46:655-64. </text>
<text top="693" left="54" width="4" height="17" font="27"> </text>
<text top="693" left="76" width="769" height="17" font="27">43.   Rankin AC, Oldroyd KG, Chong E, et al. Value and limitations of adenosine in the diagnosis and treatment of narrow and </text>
<text top="710" left="108" width="356" height="17" font="27">broad complex tachycardias. Br Heart J. 1989;62:195-203. </text>
<text top="727" left="54" width="4" height="17" font="27"> </text>
<text top="727" left="76" width="772" height="17" font="27">44.   Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular </text>
<text top="744" left="108" width="288" height="17" font="27">tachycardia. Ann Emerg Med. 1991;20:717-21. </text>
<text top="762" left="54" width="4" height="17" font="27"> </text>
<text top="762" left="76" width="697" height="17" font="27">45.   McCabe JL, Adhar GC, Menegazzi JJ, et al. Intravenous adenosine in the prehospital treatment of paroxysmal </text>
<text top="779" left="108" width="389" height="17" font="27">supraventricular tachycardia. Ann Emerg Med. 1992;21:358-61. </text>
<text top="796" left="54" width="4" height="17" font="27"> </text>
<text top="796" left="76" width="726" height="17" font="27">46.   Gausche M, Persse DE, Sugarman T, et al. Adenosine for the prehospital treatment of paroxysmal supraventricular </text>
<text top="813" left="108" width="281" height="17" font="27">tachycardia. Ann Emerg Med. 1994;24:183-9. </text>
<text top="831" left="54" width="4" height="17" font="27"> </text>
<text top="831" left="76" width="730" height="17" font="27">47.   Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and verapamil for the treatment of supraventricular </text>
<text top="848" left="108" width="440" height="17" font="27">tachycardia in the prehospital setting. Ann Emerg Med. 1995;25:649-55. </text>
<text top="865" left="54" width="4" height="17" font="27"> </text>
<text top="865" left="76" width="768" height="17" font="27">48.   Brady WJ, Jr., DeBehnke DJ, Wickman LL, et al. Treatment of out-of-hospital supraventricular tachycardia: adenosine vs </text>
<text top="882" left="108" width="277" height="17" font="27">verapamil. Acad Emerg Med. 1996;3:574-85. </text>
<text top="900" left="54" width="4" height="17" font="27"> </text>
<text top="900" left="76" width="753" height="17" font="27">49.   Luber S, Brady WJ, Joyce T, et al. Paroxysmal supraventricular tachycardia: outcome after ED care. Am J Emerg Med. </text>
<text top="917" left="108" width="88" height="17" font="27">2001;19:40-2. </text>
<text top="934" left="54" width="4" height="17" font="27"> </text>
<text top="934" left="76" width="792" height="17" font="27">50.   Roth A, Elkayam I, Shapira I, et al. Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular </text>
<text top="951" left="108" width="533" height="17" font="27">tachyarrhythmias causing unstable hemodynamic states. Am J Cardiol. 2003;91:489-91. </text>
<text top="969" left="54" width="4" height="17" font="27"> </text>
<text top="969" left="76" width="727" height="17" font="27">51.   Neuss H, Schlepper M. Long-term efficacy and safety of flecainide for supraventricular tachycardia. Am J Cardiol. </text>
<text top="986" left="108" width="117" height="17" font="27">1988;62:56D-61D. </text>
<text top="1003" left="54" width="4" height="17" font="27"> </text>
<text top="1003" left="76" width="783" height="17" font="27">52.   Cockrell JL, Scheinman MM, Titus C, et al. Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-</text>
<text top="1020" left="108" width="337" height="17" font="27">entrant tachycardia. Ann Intern Med. 1991;114:189-94. </text>
<text top="1038" left="54" width="4" height="17" font="27"> </text>
<text top="1038" left="76" width="770" height="17" font="27">53.   Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supraventricular tachycardia due to atrioventricular nodal </text>
<text top="1055" left="108" width="639" height="17" font="27">reentry, by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med. 1992;327:313-8. </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">142 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="4" height="17" font="27"> </text>
<text top="54" left="76" width="774" height="17" font="27">54.   Gambhir DS, Bhargava M, Nair M, et al. Comparison of electrophysiologic effects and efficacy of single-dose intravenous </text>
<text top="72" left="108" width="719" height="17" font="27">and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia. Indian Heart J. 1996;48:133-7. </text>
<text top="89" left="54" width="4" height="17" font="27"> </text>
<text top="89" left="76" width="776" height="17" font="27">55.   Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J </text>
<text top="106" left="108" width="156" height="17" font="27">Cardiol. 2009;104:671-7. </text>
<text top="123" left="54" width="4" height="17" font="27"> </text>
<text top="123" left="76" width="779" height="17" font="27">56.   Bohnen M, Stevenson WG, Tedrow UB, et al. Incidence and predictors of major complications from contemporary catheter </text>
<text top="141" left="108" width="413" height="17" font="27">ablation to treat cardiac arrhythmias. Heart Rhythm. 2011;8:1661-6. </text>
<text top="158" left="54" width="4" height="17" font="27"> </text>
<text top="158" left="76" width="791" height="17" font="27">57.   Hindricks G. The Multicentre European Radiofrequency Survey (MERFS): complications of radiofrequency catheter ablation </text>
<text top="175" left="108" width="703" height="17" font="27">of arrhythmias. The Multicentre European Radiofrequency Survey (MERFS) investigators of the Working Group on </text>
<text top="192" left="108" width="506" height="17" font="27">Arrhythmias of the European Society of Cardiology. Eur Heart J. 1993;14:1644-53. </text>
<text top="210" left="54" width="4" height="17" font="27"> </text>
<text top="210" left="76" width="773" height="17" font="27">58.   Hindricks G. Incidence of complete atrioventricular block following attempted radiofrequency catheter modification of the </text>
<text top="227" left="108" width="739" height="17" font="27">atrioventricular node in 880 patients. Results of the Multicenter European Radiofrequency Survey (MERFS) The Working </text>
<text top="244" left="108" width="544" height="17" font="27">Group on Arrhythmias of the European Society of Cardiology. Eur Heart J. 1996;17:82-8. </text>
<text top="261" left="54" width="4" height="17" font="27"> </text>
<text top="261" left="76" width="770" height="17" font="27">59.   Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, </text>
<text top="279" left="108" width="750" height="17" font="27">and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators </text>
<text top="296" left="108" width="224" height="17" font="27">Group. Circulation. 1999;99:262-70. </text>
<text top="313" left="54" width="4" height="17" font="27"> </text>
<text top="313" left="76" width="770" height="17" font="27">60.   Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. </text>
<text top="330" left="108" width="215" height="17" font="27">Ann Intern Med. 2000;133:864-76. </text>
<text top="348" left="54" width="4" height="17" font="27"> </text>
<text top="348" left="76" width="707" height="17" font="27">61.   Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol. </text>
<text top="365" left="108" width="103" height="17" font="27">2000;23:1020-8. </text>
<text top="382" left="54" width="4" height="17" font="27"> </text>
<text top="382" left="76" width="733" height="17" font="27">62.   Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic </text>
<text top="399" left="108" width="655" height="17" font="27">dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-16. </text>
<text top="417" left="54" width="4" height="17" font="27"> </text>
<text top="417" left="76" width="779" height="17" font="27">63.   Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-</text>
<text top="434" left="108" width="264" height="17" font="27">controlled study. Lancet. 2010;376:875-85. </text>
<text top="451" left="54" width="4" height="17" font="27"> </text>
<text top="451" left="76" width="782" height="17" font="27">64.   Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a </text>
<text top="468" left="108" width="712" height="17" font="27">prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323-9. </text>
<text top="486" left="54" width="4" height="17" font="27"> </text>
<text top="486" left="76" width="777" height="17" font="27">65.   Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter modification of the sinus node for &#34;inappropriate&#34; sinus </text>
<text top="503" left="108" width="263" height="17" font="27">tachycardia. Circulation. 1995;92:2919-28. </text>
<text top="520" left="54" width="4" height="17" font="27"> </text>
<text top="520" left="76" width="731" height="17" font="27">66.   Rakovec P. Treatment of inappropriate sinus tachycardia with ivabradine. Wien Klin Wochenschr. 2009;121:715-8. </text>
<text top="537" left="54" width="4" height="17" font="27"> </text>
<text top="537" left="76" width="730" height="17" font="27">67.   Calo L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus </text>
<text top="555" left="108" width="273" height="17" font="27">tachycardia. Heart Rhythm. 2010;7:1318-23. </text>
<text top="572" left="54" width="4" height="17" font="27"> </text>
<text top="572" left="76" width="760" height="17" font="27">68.   Kaplinsky E, Comes FP, Urondo LS, et al. Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a </text>
<text top="589" left="108" width="702" height="17" font="27">three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life </text>
<text top="606" left="108" width="245" height="17" font="27">assessments. Cardiol J. 2010;17:166-71. </text>
<text top="624" left="54" width="4" height="17" font="27"> </text>
<text top="624" left="76" width="706" height="17" font="27">69.   Zellerhoff S, Hinterseer M, Felix KB, et al. Ivabradine in patients with inappropriate sinus tachycardia. Naunyn </text>
<text top="641" left="108" width="304" height="17" font="27">Schmiedebergs Arch Pharmacol. 2010;382:483-6. </text>
<text top="658" left="54" width="4" height="17" font="27"> </text>
<text top="658" left="76" width="786" height="17" font="27">70.   Benezet-Mazuecos J, Rubio JM, Farre J, et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: </text>
<text top="675" left="108" width="543" height="17" font="27">appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol. 2013;36:830-6. </text>
<text top="693" left="54" width="4" height="17" font="27"> </text>
<text top="693" left="76" width="736" height="17" font="27">71.   Ptaszynski P, Kaczmarek K, Ruta J, et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus </text>
<text top="710" left="108" width="616" height="17" font="27">tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15:116-21. </text>
<text top="727" left="54" width="4" height="17" font="27"> </text>
<text top="727" left="76" width="755" height="17" font="27">72.   Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in the treatment of inappropriate sinus tachycardia in patients after </text>
<text top="744" left="108" width="756" height="17" font="27">successful radiofrequency catheter ablation of atrioventricular node slow pathway. Pacing Clin Electrophysiol. 2013;36:42-9. </text>
<text top="762" left="54" width="4" height="17" font="27"> </text>
<text top="762" left="76" width="721" height="17" font="27">73.   Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in combination with metoprolol succinate in the treatment of </text>
<text top="779" left="108" width="483" height="17" font="27">inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18:338-44. </text>
<text top="796" left="54" width="4" height="17" font="27"> </text>
<text top="796" left="76" width="739" height="17" font="27">74.   Kang KT, Etheridge SP, Kantoch MJ, et al. Current management of focal atrial tachycardia in children: a multicenter </text>
<text top="813" left="108" width="356" height="17" font="27">experience. Circ Arrhythm Electrophysiol. 2014;7:664-70. </text>
<text top="831" left="54" width="4" height="17" font="27"> </text>
<text top="831" left="76" width="781" height="17" font="27">75.   Callans DJ, Ren JF, Schwartzman D, et al. Narrowing of the superior vena cava-right atrium junction during radiofrequency </text>
<text top="848" left="108" width="710" height="17" font="27">catheter ablation for inappropriate sinus tachycardia: analysis with intracardiac echocardiography. J Am Coll Cardiol. </text>
<text top="865" left="108" width="111" height="17" font="27">1999;33:1667-70. </text>
<text top="882" left="54" width="4" height="17" font="27"> </text>
<text top="882" left="76" width="776" height="17" font="27">76.   Man KC, Knight B, Tse HF, et al. Radiofrequency catheter ablation of inappropriate sinus tachycardia guided by activation </text>
<text top="900" left="108" width="274" height="17" font="27">mapping. J Am Coll Cardiol. 2000;35:451-7. </text>
<text top="917" left="54" width="4" height="17" font="27"> </text>
<text top="917" left="76" width="768" height="17" font="27">77.   Marrouche NF, Beheiry S, Tomassoni G, et al. Three-dimensional nonfluoroscopic mapping and ablation of inappropriate </text>
<text top="934" left="108" width="617" height="17" font="27">sinus tachycardia. Procedural strategies and long-term outcome. J Am Coll Cardiol. 2002;39:1046-54. </text>
<text top="951" left="54" width="4" height="17" font="27"> </text>
<text top="951" left="76" width="791" height="17" font="27">78.   Lin D, Garcia F, Jacobson J, et al. Use of noncontact mapping and saline-cooled ablation catheter for sinus node modification </text>
<text top="969" left="108" width="609" height="17" font="27">in medically refractory inappropriate sinus tachycardia. Pacing Clin Electrophysiol. 2007;30:236-42. </text>
<text top="986" left="54" width="4" height="17" font="27"> </text>
<text top="986" left="76" width="782" height="17" font="27">79.   Frankel DS, Lin D, Anastasio N, et al. Frequent additional tachyarrhythmias in patients with inappropriate sinus tachycardia </text>
<text top="1003" left="108" width="759" height="17" font="27">undergoing sinus node modification: an important cause of symptom recurrence. J Cardiovasc Electrophysiol. 2012;23:835-9. </text>
<text top="1020" left="54" width="4" height="17" font="27"> </text>
<text top="1020" left="76" width="718" height="17" font="27">80.   Takemoto M, Mukai Y, Inoue S, et al. Usefulness of non-contact mapping for radiofrequency catheter ablation of </text>
<text top="1038" left="108" width="716" height="17" font="27">inappropriate sinus tachycardia: new procedural strategy and long-term clinical outcome. Intern Med. 2012;51:357-62. </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">143 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="4" height="17" font="27"> </text>
<text top="54" left="76" width="741" height="17" font="27">81.   Huang HD, Tamarisa R, Mathur N, et al. Stellate ganglion block: a therapeutic alternative for patients with medically </text>
<text top="72" left="108" width="459" height="17" font="27">refractory inappropriate sinus tachycardia? J Electrocardiol. 2013;46:693-6. </text>
<text top="89" left="54" width="4" height="17" font="27"> </text>
<text top="89" left="76" width="753" height="17" font="27">82.   Gillette PC, Garson A, Jr. Electrophysiologic and pharmacologic characteristics of automatic ectopic atrial tachycardia. </text>
<text top="106" left="108" width="171" height="17" font="27">Circulation. 1977;56:571-5. </text>
<text top="123" left="54" width="4" height="17" font="27"> </text>
<text top="123" left="76" width="727" height="17" font="27">83.   Creamer JE, Nathan AW, Camm AJ. Successful treatment of atrial tachycardias with flecainide acetate. Br Heart J. </text>
<text top="141" left="108" width="96" height="17" font="27">1985;53:164-6. </text>
<text top="158" left="54" width="4" height="17" font="27"> </text>
<text top="158" left="76" width="772" height="17" font="27">84.   Kunze KP, Kuck KH, Schluter M, et al. Effect of encainide and flecainide on chronic ectopic atrial tachycardia. J Am Coll </text>
<text top="175" left="108" width="148" height="17" font="27">Cardiol. 1986;7:1121-6. </text>
<text top="192" left="54" width="4" height="17" font="27"> </text>
<text top="192" left="76" width="753" height="17" font="27">85.   Lucet V, Do ND, Fidelle J, et al. [Anti-arrhythmia efficacy of propafenone in children. Apropos of 30 cases]. Arch Mal </text>
<text top="210" left="108" width="192" height="17" font="27">Coeur Vaiss. 1987;80:1385-93. </text>
<text top="227" left="54" width="4" height="17" font="27"> </text>
<text top="227" left="76" width="713" height="17" font="27">86.   Mehta AV, Sanchez GR, Sacks EJ, et al. Ectopic automatic atrial tachycardia in children: clinical characteristics, </text>
<text top="244" left="108" width="394" height="17" font="27">management and follow-up. J Am Coll Cardiol. 1988;11:379-85. </text>
<text top="261" left="54" width="4" height="17" font="27"> </text>
<text top="261" left="76" width="756" height="17" font="27">87.   Colloridi V, Perri C, Ventriglia F, et al. Oral sotalol in pediatric atrial ectopic tachycardia. Am Heart J. 1992;123:254-6. </text>
<text top="279" left="54" width="4" height="17" font="27"> </text>
<text top="279" left="76" width="739" height="17" font="27">88.   von Bernuth G, Engelhardt W, Kramer HH, et al. Atrial automatic tachycardia in infancy and childhood. Eur Heart J. </text>
<text top="296" left="108" width="103" height="17" font="27">1992;13:1410-5. </text>
<text top="313" left="54" width="4" height="17" font="27"> </text>
<text top="313" left="76" width="755" height="17" font="27">89.   Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, </text>
<text top="330" left="108" width="720" height="17" font="27">pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation. 1994;90:1262-78. </text>
<text top="348" left="54" width="4" height="17" font="27"> </text>
<text top="348" left="76" width="756" height="17" font="27">90.   Engelstein ED, Lippman N, Stein KM, et al. Mechanism-specific effects of adenosine on atrial tachycardia. Circulation. </text>
<text top="365" left="108" width="111" height="17" font="27">1994;89:2645-54. </text>
<text top="382" left="54" width="4" height="17" font="27"> </text>
<text top="382" left="76" width="789" height="17" font="27">91.   Heusch A, Kramer HH, Krogmann ON, et al. Clinical experience with propafenone for cardiac arrhythmias in the young. Eur </text>
<text top="399" left="108" width="154" height="17" font="27">Heart J. 1994;15:1050-6. </text>
<text top="417" left="54" width="4" height="17" font="27"> </text>
<text top="417" left="76" width="791" height="17" font="27">92.   Janousek J, Paul T. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective </text>
<text top="434" left="108" width="758" height="17" font="27">multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric </text>
<text top="451" left="108" width="279" height="17" font="27">Cardiologists. Am J Cardiol. 1998;81:1121-4. </text>
<text top="468" left="54" width="4" height="17" font="27"> </text>
<text top="468" left="76" width="770" height="17" font="27">93.   Kalman JM, Olgin JE, Karch MR, et al. &#34;Cristal tachycardias&#34;: origin of right atrial tachycardias from the crista terminalis </text>
<text top="486" left="108" width="483" height="17" font="27">identified by intracardiac echocardiography. J Am Coll Cardiol. 1998;31:451-9. </text>
<text top="503" left="54" width="4" height="17" font="27"> </text>
<text top="503" left="76" width="777" height="17" font="27">94.   Markowitz SM, Stein KM, Mittal S, et al. Differential effects of adenosine on focal and macroreentrant atrial tachycardia. J </text>
<text top="520" left="108" width="277" height="17" font="27">Cardiovasc Electrophysiol. 1999;10:489-502. </text>
<text top="537" left="54" width="4" height="17" font="27"> </text>
<text top="537" left="76" width="745" height="17" font="27">95.   Morton JB, Sanders P, Das A, et al. Focal atrial tachycardia arising from the tricuspid annulus: electrophysiologic and </text>
<text top="555" left="108" width="492" height="17" font="27">electrocardiographic characteristics. J Cardiovasc Electrophysiol. 2001;12:653-9. </text>
<text top="572" left="54" width="4" height="17" font="27"> </text>
<text top="572" left="76" width="760" height="17" font="27">96.   Kistler PM, Sanders P, Hussin A, et al. Focal atrial tachycardia arising from the mitral annulus: electrocardiographic and </text>
<text top="589" left="108" width="439" height="17" font="27">electrophysiologic characterization. J Am Coll Cardiol. 2003;41:2212-9. </text>
<text top="606" left="54" width="4" height="17" font="27"> </text>
<text top="606" left="76" width="792" height="17" font="27">97.   Kistler PM, Sanders P, Fynn SP, et al. Electrophysiological and electrocardiographic characteristics of focal atrial tachycardia </text>
<text top="624" left="108" width="755" height="17" font="27">originating from the pulmonary veins: acute and long-term outcomes of radiofrequency ablation. Circulation. 2003;108:1968-</text>
<text top="641" left="108" width="22" height="17" font="27">75. </text>
<text top="658" left="54" width="4" height="17" font="27"> </text>
<text top="658" left="76" width="781" height="17" font="27">98.   Gonzalez MD, Contreras LJ, Jongbloed MR, et al. Left atrial tachycardia originating from the mitral annulus-aorta junction. </text>
<text top="675" left="108" width="193" height="17" font="27">Circulation. 2004;110:3187-92. </text>
<text top="693" left="54" width="4" height="17" font="27"> </text>
<text top="693" left="76" width="776" height="17" font="27">99.   Kistler PM, Fynn SP, Haqqani H, et al. Focal atrial tachycardia from the ostium of the coronary sinus: electrocardiographic </text>
<text top="710" left="108" width="655" height="17" font="27">and electrophysiological characterization and radiofrequency ablation. J Am Coll Cardiol. 2005;45:1488-93. </text>
<text top="727" left="54" width="771" height="17" font="27">  100.   Eidher U, Freihoff F, Kaltenbrunner W, et al. Efficacy and safety of ibutilide for the conversion of monomorphic atrial </text>
<text top="744" left="108" width="349" height="17" font="27">tachycardia. Pacing Clin Electrophysiol. 2006;29:358-62. </text>
<text top="762" left="54" width="795" height="17" font="27">  101.   Ouyang F, Ma J, Ho SY, et al. Focal atrial tachycardia originating from the non-coronary aortic sinus: electrophysiological </text>
<text top="779" left="108" width="443" height="17" font="27">characteristics and catheter ablation. J Am Coll Cardiol. 2006;48:122-31. </text>
<text top="796" left="54" width="776" height="17" font="27">  102.   Roberts-Thomson KC, Kistler PM, Haqqani HM, et al. Focal atrial tachycardias arising from the right atrial appendage: </text>
<text top="813" left="108" width="708" height="17" font="27">electrocardiographic and electrophysiologic characteristics and radiofrequency ablation. J Cardiovasc Electrophysiol. </text>
<text top="831" left="108" width="103" height="17" font="27">2007;18:367-72. </text>
<text top="848" left="54" width="787" height="17" font="27">  103.   Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-</text>
<text top="865" left="108" width="446" height="17" font="27">term outcome after catheter ablation. J Am Coll Cardiol. 2009;53:1791-7. </text>
<text top="882" left="54" width="774" height="17" font="27">  104.   Liu X, Dong J, Ho SY, et al. Atrial tachycardia arising adjacent to noncoronary aortic sinus: distinctive atrial activation </text>
<text top="900" left="108" width="419" height="17" font="27">patterns and anatomic insights. J Am Coll Cardiol. 2010;56:796-804. </text>
<text top="917" left="54" width="774" height="17" font="27">  105.   Biviano AB, Bain W, Whang W, et al. Focal left atrial tachycardias not associated with prior catheter ablation for atrial </text>
<text top="934" left="108" width="629" height="17" font="27">fibrillation: clinical and electrophysiological characteristics. Pacing Clin Electrophysiol. 2012;35:17-27. </text>
<text top="951" left="54" width="813" height="17" font="27">  106.   de Loma-Osorio F, Diaz-Infante E, ., et al. Spanish Catheter Ablation Registry. 12th Official Report of the Spanish Society of </text>
<text top="969" left="108" width="728" height="17" font="27">Cardiology Working Group on Electrophysiology and Arrhythmias (2012). Rev Esp Cardiol (Engl Ed). 2013;66:983-92. </text>
<text top="986" left="54" width="804" height="17" font="27">  107.   Mano H, Okumura Y, Watanabe I, et al. Potential anatomic substrate of peri-atrioventricular nodal atrial tachycardia ablated </text>
<text top="1003" left="108" width="519" height="17" font="27">from the noncoronary sinus of Valsalva. J Interv Card Electrophysiol. 2013;38:27-34. </text>
<text top="1020" left="54" width="804" height="17" font="27">  108.   Arsura E, Lefkin AS, Scher DL, et al. A randomized, double-blind, placebo-controlled study of verapamil and metoprolol in </text>
<text top="1038" left="108" width="428" height="17" font="27">treatment of multifocal atrial tachycardia. Am J Med. 1988;85:519-24. </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">144 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="806" height="17" font="27">  109.   McCord JK, Borzak S, Davis T, et al. Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with </text>
<text top="72" left="108" width="415" height="17" font="27">chronic obstructive pulmonary disease. Am J Cardiol. 1998;81:91-3. </text>
<text top="89" left="54" width="807" height="17" font="27">  110.   Iseri LT, Fairshter RD, Hardemann JL, et al. Magnesium and potassium therapy in multifocal atrial tachycardia. Am Heart J. </text>
<text top="106" left="108" width="111" height="17" font="27">1985;110:789-94. </text>
<text top="123" left="54" width="744" height="17" font="27">  111.   Hazard PB, Burnett CR. Treatment of multifocal atrial tachycardia with metoprolol. Crit Care Med. 1987;15:20-5. </text>
<text top="141" left="54" width="754" height="17" font="27">  112.   Waxman HL, Myerburg RJ, Appel R, et al. Verapamil for control of ventricular rate in paroxysmal supraventricular </text>
<text top="158" left="108" width="718" height="17" font="27">tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med. 1981;94:1-6. </text>
<text top="175" left="54" width="809" height="17" font="27">  113.   Yeh SJ, Lin FC, Chou YY, et al. Termination of paroxysmal supraventricular tachycardia with a single oral dose of diltiazem </text>
<text top="192" left="108" width="274" height="17" font="27">and propranolol. Circulation. 1985;71:104-9. </text>
<text top="210" left="54" width="813" height="17" font="27">  114.   DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison </text>
<text top="227" left="108" width="728" height="17" font="27">with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern </text>
<text top="244" left="108" width="146" height="17" font="27">Med. 1990;113:104-10. </text>
<text top="261" left="54" width="773" height="17" font="27">  115.   Dougherty AH, Jackman WM, Naccarelli GV, et al. Acute conversion of paroxysmal supraventricular tachycardia with </text>
<text top="279" left="108" width="496" height="17" font="27">intravenous diltiazem. IV Diltiazem Study Group. Am J Cardiol. 1992;70:587-92. </text>
<text top="296" left="54" width="783" height="17" font="27">  116.   Langberg JJ, Leon A, Borganelli M, et al. A randomized, prospective comparison of anterior and posterior approaches to </text>
<text top="313" left="108" width="649" height="17" font="27">radiofrequency catheter ablation of atrioventricular nodal reentry tachycardia. Circulation. 1993;87:1551-6. </text>
<text top="330" left="54" width="763" height="17" font="27">  117.   Kalbfleisch SJ, Strickberger SA, Williamson B, et al. Randomized comparison of anatomic and electrogram mapping </text>
<text top="348" left="108" width="742" height="17" font="27">approaches to ablation of the slow pathway of atrioventricular node reentrant tachycardia. J Am Coll Cardiol. 1994;23:716-</text>
<text top="365" left="108" width="22" height="17" font="27">23. </text>
<text top="382" left="54" width="793" height="17" font="27">  118.   Kopelman HA, Prater SP, Tondato F, et al. Slow pathway catheter ablation of atrioventricular nodal re-entrant tachycardia </text>
<text top="399" left="108" width="727" height="17" font="27">guided by electroanatomical mapping: a randomized comparison to the conventional approach. Europace. 2003;5:171-4. </text>
<text top="417" left="54" width="813" height="17" font="27">  119.   Kimman GP, Theuns DA, Szili-Torok T, et al. CRAVT: a prospective, randomized study comparing transvenous cryothermal </text>
<text top="434" left="108" width="639" height="17" font="27">and radiofrequency ablation in atrioventricular nodal re-entrant tachycardia. Eur Heart J. 2004;25:2232-7. </text>
<text top="451" left="54" width="798" height="17" font="27">  120.   Zrenner B, Dong J, Schreieck J, et al. Transvenous cryoablation versus radiofrequency ablation of the slow pathway for the </text>
<text top="468" left="108" width="742" height="17" font="27">treatment of atrioventricular nodal re-entrant tachycardia: a prospective randomized pilot study. Eur Heart J. 2004;25:2226-</text>
<text top="486" left="108" width="22" height="17" font="27">31. </text>
<text top="503" left="54" width="813" height="17" font="27">  121.   Kardos A, Paprika D, Shalganov T, et al. Ice mapping during tachycardia in close proximity to the AV node is safe and offers </text>
<text top="520" left="108" width="485" height="17" font="27">advantages for transcatheter ablation procedures. Acta Cardiol. 2007;62:587-91. </text>
<text top="537" left="54" width="809" height="17" font="27">  122.   Deisenhofer I, Zrenner B, Yin YH, et al. Cryoablation versus radiofrequency energy for the ablation of atrioventricular nodal </text>
<text top="555" left="108" width="718" height="17" font="27">reentrant tachycardia (the CYRANO Study): results from a large multicenter prospective randomized trial. Circulation. </text>
<text top="572" left="108" width="118" height="17" font="27">2010;122:2239-45. </text>
<text top="589" left="54" width="804" height="17" font="27">  123.   Rodriguez-Entem FJ, Exposito V, Gonzalez-Enriquez S, et al. Cryoablation versus radiofrequency ablation for the treatment </text>
<text top="606" left="108" width="718" height="17" font="27">of atrioventricular nodal reentrant tachycardia: results of a prospective randomized study. J Interv Card Electrophysiol. </text>
<text top="624" left="108" width="88" height="17" font="27">2013;36:41-5. </text>
<text top="641" left="54" width="767" height="17" font="27">  124.   Rinkenberger RL, Prystowsky EN, Heger JJ, et al. Effects of intravenous and chronic oral verapamil administration in </text>
<text top="658" left="108" width="487" height="17" font="27">patients with supraventricular tachyarrhythmias. Circulation. 1980;62:996-1010. </text>
<text top="675" left="54" width="746" height="17" font="27">  125.   Das G, Tschida V, Gray R, et al. Efficacy of esmolol in the treatment and transfer of patients with supraventricular </text>
<text top="693" left="108" width="558" height="17" font="27">tachyarrhythmias to alternate oral antiarrhythmic agents. J Clin Pharmacol. 1988;28:746-50. </text>
<text top="710" left="54" width="758" height="17" font="27">  126.   Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic blockade with intravenously </text>
<text top="727" left="108" width="684" height="17" font="27">administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol. 1991;31:714-8. </text>
<text top="744" left="54" width="743" height="17" font="27">  127.   Musto B, Cavallaro C, Musto A, et al. Flecainide single oral dose for management of paroxysmal supraventricular </text>
<text top="762" left="108" width="431" height="17" font="27">tachycardia in children and young adults. Am Heart J. 1992;124:110-5. </text>
<text top="779" left="54" width="792" height="17" font="27">  128.   Gambhir DS, Bhargava M, Arora R, et al. Electrophysiologic effects and therapeutic efficacy of intravenous flecainide for </text>
<text top="796" left="108" width="537" height="17" font="27">termination of paroxysmal supraventricular tachycardia. Indian Heart J. 1995;47:237-43. </text>
<text top="813" left="54" width="812" height="17" font="27">  129.   Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. </text>
<text top="831" left="108" width="186" height="17" font="27">Circulation. 1999;99:1034-40. </text>
<text top="848" left="54" width="744" height="17" font="27">  130.   Kay GN, Epstein AE, Dailey SM, et al. Selective radiofrequency ablation of the slow pathway for the treatment of </text>
<text top="865" left="108" width="750" height="17" font="27">atrioventricular nodal reentrant tachycardia. Evidence for involvement of perinodal myocardium within the reentrant circuit. </text>
<text top="882" left="108" width="186" height="17" font="27">Circulation. 1992;85:1675-88. </text>
<text top="900" left="54" width="760" height="17" font="27">  131.   Bogun F, Knight B, Weiss R, et al. Slow pathway ablation in patients with documented but noninducible paroxysmal </text>
<text top="917" left="108" width="399" height="17" font="27">supraventricular tachycardia. J Am Coll Cardiol. 1996;28:1000-4. </text>
<text top="934" left="54" width="796" height="17" font="27">  132.   D'Este D, Zoppo F, Bertaglia E, et al. Long-term outcome of patients with atrioventricular node reentrant tachycardia. Int J </text>
<text top="951" left="108" width="156" height="17" font="27">Cardiol. 2007;115:350-3. </text>
<text top="969" left="54" width="788" height="17" font="27">  133.   Friedman PL, Dubuc M, Green MS, et al. Catheter cryoablation of supraventricular tachycardia: results of the multicenter </text>
<text top="986" left="108" width="344" height="17" font="27">prospective &#34;frosty&#34; trial. Heart Rhythm. 2004;1:129-38. </text>
<text top="1003" left="54" width="719" height="17" font="27">  134.   de Sisti A, Tonet J. Cryoablation of atrioventricular nodal reentrant tachycardia: a clinical review. Pacing Clin </text>
<text top="1020" left="108" width="198" height="17" font="27">Electrophysiol. 2012;35:233-40. </text>
<text top="1038" left="54" width="760" height="17" font="27">  135.   Hanninen M, Yeung-Lai-Wah N, Massel D, et al. Cryoablation versus RF ablation for AVNRT: A meta-analysis and </text>
<text top="1055" left="108" width="402" height="17" font="27">systematic review. J Cardiovasc Electrophysiol. 2013;24:1354-60. </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">145 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="758" height="17" font="27">  136.   Santangeli P, Proietti R, Di BL, et al. Cryoablation versus radiofrequency ablation of atrioventricular nodal reentrant </text>
<text top="72" left="108" width="349" height="17" font="27">tachycardia. J Interv Card Electrophysiol. 2014;39:111-9. </text>
<text top="89" left="54" width="785" height="17" font="27">  137.   Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. </text>
<text top="106" left="108" width="111" height="17" font="27">1979;301:1080-5. </text>
<text top="123" left="54" width="748" height="17" font="27">  138.   Rinne C, Klein GJ, Sharma AD, et al. Relation between clinical presentation and induced arrhythmias in the Wolff-</text>
<text top="141" left="108" width="356" height="17" font="27">Parkinson-White syndrome. Am J Cardiol. 1987;60:576-9. </text>
<text top="158" left="54" width="782" height="17" font="27">  139.   Sharma AD, Yee R, Guiraudon G, et al. Sensitivity and specificity of invasive and noninvasive testing for risk of sudden </text>
<text top="175" left="108" width="486" height="17" font="27">death in Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1987;10:373-81. </text>
<text top="192" left="54" width="799" height="17" font="27">  140.   Gaita F, Giustetto C, Riccardi R, et al. Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-</text>
<text top="210" left="108" width="438" height="17" font="27">White syndrome at risk of sudden death. Am J Cardiol. 1989;64:487-90. </text>
<text top="227" left="54" width="802" height="17" font="27">  141.   Beckman KJ, Gallastegui JL, Bauman JL, et al. The predictive value of electrophysiologic studies in untreated patients with </text>
<text top="244" left="108" width="427" height="17" font="27">Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1990;15:640-7. </text>
<text top="261" left="54" width="784" height="17" font="27">  142.   Pappone C, Vicedomini G, Manguso F, et al. Risk of malignant arrhythmias in initially symptomatic patients with Wolff-</text>
<text top="279" left="108" width="681" height="17" font="27">Parkinson-White syndrome: results of a prospective long-term electrophysiological follow-up study. Circulation. </text>
<text top="296" left="108" width="103" height="17" font="27">2012;125:661-8. </text>
<text top="313" left="54" width="796" height="17" font="27">  143.   Spar DS, Silver ES, Hordof AJ, et al. Relation of the utility of exercise testing for risk assessment in pediatric patients with </text>
<text top="330" left="108" width="476" height="17" font="27">ventricular preexcitation to pathway location. Am J Cardiol. 2012;109:1011-4. </text>
<text top="348" left="54" width="761" height="17" font="27">  144.   Wackel P, Irving C, Webber S, et al. Risk stratification in Wolff-Parkinson-White syndrome: the correlation between </text>
<text top="365" left="108" width="597" height="17" font="27">noninvasive and invasive testing in pediatric patients. Pacing Clin Electrophysiol. 2012;35:1451-7. </text>
<text top="382" left="54" width="811" height="17" font="27">  145.   Pappone C, Vicedomini G, Manguso F, et al. Wolff-Parkinson-white syndrome in the era of catheter ablation: insights from a </text>
<text top="399" left="108" width="368" height="17" font="27">registry study of 2169 patients. Circulation. 2014;130:811-9. </text>
<text top="417" left="54" width="765" height="17" font="27">  146.   Sellers TD, Jr., Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. </text>
<text top="434" left="108" width="171" height="17" font="27">Circulation. 1977;56:260-7. </text>
<text top="451" left="54" width="778" height="17" font="27">  147.   Sellers TD, Jr., Campbell RW, Bashore TM, et al. Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-</text>
<text top="468" left="108" width="278" height="17" font="27">White syndrome. Circulation. 1977;55:15-22. </text>
<text top="486" left="54" width="792" height="17" font="27">  148.   Hamer A, Peter T, Platt M, et al. Effects of verapamil on supraventricular tachycardia in patients with overt and concealed </text>
<text top="503" left="108" width="400" height="17" font="27">Wolff-Parkinson-White syndrome. Am Heart J. 1981;101:600-12. </text>
<text top="520" left="54" width="772" height="17" font="27">  149.   Hombach V, Braun V, Hopp HW, et al. Antiarrhythmic effects of acute betablockade with atenolol on supraventricular </text>
<text top="537" left="108" width="460" height="17" font="27">tachycardias at rest and during exercise. Klin Wochenschr. 1981;59:123-33. </text>
<text top="555" left="54" width="812" height="17" font="27">  150.   Sheinman BD, Evans T. Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome. </text>
<text top="572" left="108" width="276" height="17" font="27">Br Med J (Clin Res Ed). 1982;285:999-1000. </text>
<text top="589" left="54" width="808" height="17" font="27">  151.   Morady F, DiCarlo LA, Jr., Baerman JM, et al. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-</text>
<text top="606" left="108" width="437" height="17" font="27">Parkinson-White syndrome. Pacing Clin Electrophysiol. 1987;10:492-6. </text>
<text top="624" left="54" width="782" height="17" font="27">  152.   Schutzenberger W, Leisch F, Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in </text>
<text top="641" left="108" width="365" height="17" font="27">atrial fibrillation. A case report. Int J Cardiol. 1987;16:93-5. </text>
<text top="658" left="54" width="772" height="17" font="27">  153.   Huycke EC, Sung RJ, Dias VC, et al. Intravenous diltiazem for termination of reentrant supraventricular tachycardia: a </text>
<text top="675" left="108" width="616" height="17" font="27">placebo-controlled, randomized, double-blind, multicenter study. J Am Coll Cardiol. 1989;13:538-44. </text>
<text top="693" left="54" width="778" height="17" font="27">  154.   Furlong R, Gerhardt RT, Farber P, et al. Intravenous adenosine as first-line prehospital management of narrow-complex </text>
<text top="710" left="108" width="603" height="17" font="27">tachycardias by EMS personnel without direct physician control. Am J Emerg Med. 1995;13:383-8. </text>
<text top="727" left="54" width="755" height="17" font="27">  155.   Boriani G, Biffi M, Frabetti L, et al. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White </text>
<text top="744" left="108" width="387" height="17" font="27">syndrome with atrial fibrillation. Am Heart J. 1996;131:1214-6. </text>
<text top="762" left="54" width="770" height="17" font="27">  156.   Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. </text>
<text top="779" left="108" width="186" height="17" font="27">Circulation. 2001;104:1933-9. </text>
<text top="796" left="54" width="794" height="17" font="27">  157.   Shiraishi H, Ishibashi K, Urao N, et al. Two cases of polymorphic ventricular tachycardia induced by the administration of </text>
<text top="813" left="108" width="532" height="17" font="27">verapamil against paroxysmal supraventricular tachycardia. Intern Med. 2002;41:445-8. </text>
<text top="831" left="54" width="808" height="17" font="27">  158.   Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association </text>
<text top="848" left="108" width="722" height="17" font="27">Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122:S729-S767. </text>
<text top="865" left="54" width="781" height="17" font="27">  159.   Delaney B, Loy J, Kelly AM. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal </text>
<text top="882" left="108" width="551" height="17" font="27">supraventricular tachycardia in adults: a meta-analysis. Eur J Emerg Med. 2011;18:148-52. </text>
<text top="900" left="54" width="768" height="17" font="27">  160.   Bauernfeind RA, Wyndham CR, Dhingra RC, et al. Serial electrophysiologic testing of multiple drugs in patients with </text>
<text top="917" left="108" width="519" height="17" font="27">atrioventricular nodal reentrant paroxysmal tachycardia. Circulation. 1980;62:1341-9. </text>
<text top="934" left="54" width="784" height="17" font="27">  161.   Sakurai M, Yasuda H, Kato N, et al. Acute and chronic effects of verapamil in patients with paroxysmal supraventricular </text>
<text top="951" left="108" width="264" height="17" font="27">tachycardia. Am Heart J. 1983;105:619-28. </text>
<text top="969" left="54" width="749" height="17" font="27">  162.   Feld GK, Nademanee K, Weiss J, et al. Electrophysiologic basis for the suppression by amiodarone of orthodromic </text>
<text top="986" left="108" width="650" height="17" font="27">supraventricular tachycardias complicating pre-excitation syndromes. J Am Coll Cardiol. 1984;3:1298-307. </text>
<text top="1003" left="54" width="783" height="17" font="27">  163.   Feld GK, Nademanee K, Stevenson W, et al. Clinical and electrophysiologic effects of amiodarone in patients with atrial </text>
<text top="1020" left="108" width="565" height="17" font="27">fibrillation complicating the Wolff-Parkinson-White syndrome. Am Heart J. 1988;115:102-7. </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">146 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="789" height="17" font="27">  164.   Hopson JR, Buxton AE, Rinkenberger RL, et al. Safety and utility of flecainide acetate in the routine care of patients with </text>
<text top="72" left="108" width="746" height="17" font="27">supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. </text>
<text top="89" left="108" width="206" height="17" font="27">Am J Cardiol. 1996;77:72A-82A. </text>
<text top="106" left="54" width="805" height="17" font="27">  165.   Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White </text>
<text top="123" left="108" width="441" height="17" font="27">syndrome) by radiofrequency current. N Engl J Med. 1991;324:1605-11. </text>
<text top="141" left="54" width="777" height="17" font="27">  166.   Calkins H, Langberg J, Sousa J, et al. Radiofrequency catheter ablation of accessory atrioventricular connections in 250 </text>
<text top="158" left="108" width="675" height="17" font="27">patients. Abbreviated therapeutic approach to Wolff-Parkinson-White syndrome. Circulation. 1992;85:1337-46. </text>
<text top="175" left="54" width="797" height="17" font="27">  167.   Kugler JD, Danford DA, Deal BJ, et al. Radiofrequency catheter ablation for tachyarrhythmias in children and adolescents. </text>
<text top="192" left="108" width="452" height="17" font="27">The Pediatric Electrophysiology Society. N Engl J Med. 1994;330:1481-7. </text>
<text top="210" left="54" width="773" height="17" font="27">  168.   Dagres N, Clague JR, Kottkamp H, et al. Radiofrequency catheter ablation of accessory pathways. Outcome and use of </text>
<text top="227" left="108" width="425" height="17" font="27">antiarrhythmic drugs during follow-up. Eur Heart J. 1999;20:1826-32. </text>
<text top="244" left="54" width="793" height="17" font="27">  169.   Schlapfer J, Fromer M. Late clinical outcome after successful radiofrequency catheter ablation of accessory pathways. Eur </text>
<text top="261" left="108" width="146" height="17" font="27">Heart J. 2001;22:605-9. </text>
<text top="279" left="54" width="790" height="17" font="27">  170.   Belhassen B, Rogowski O, Glick A, et al. Radiofrequency ablation of accessory pathways: a 14 year experience at the Tel </text>
<text top="296" left="108" width="427" height="17" font="27">Aviv Medical Center in 508 patients. Isr Med Assoc J. 2007;9:265-70. </text>
<text top="313" left="54" width="812" height="17" font="27">  171.   Milstein S, Sharma AD, Klein GJ. Electrophysiologic profile of asymptomatic Wolff-Parkinson-White pattern. Am J Cardiol. </text>
<text top="330" left="108" width="118" height="17" font="27">1986;57:1097-100. </text>
<text top="348" left="54" width="785" height="17" font="27">  172.   Satoh M, Aizawa Y, Funazaki T, et al. Electrophysiologic evaluation of asymptomatic patients with the Wolff-Parkinson-</text>
<text top="365" left="108" width="362" height="17" font="27">White pattern. Pacing Clin Electrophysiol. 1989;12:413-20. </text>
<text top="382" left="54" width="754" height="17" font="27">  173.   Klein GJ, Yee R, Sharma AD. Longitudinal electrophysiologic assessment of asymptomatic patients with the Wolff-</text>
<text top="399" left="108" width="491" height="17" font="27">Parkinson-White electrocardiographic pattern. N Engl J Med. 1989;320:1229-33. </text>
<text top="417" left="54" width="764" height="17" font="27">  174.   Leitch JW, Klein GJ, Yee R, et al. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-</text>
<text top="434" left="108" width="340" height="17" font="27">Parkinson-White pattern. Circulation. 1990;82:1718-23. </text>
<text top="451" left="54" width="805" height="17" font="27">  175.   Brembilla-Perrot B, Holban I, Houriez P, et al. Influence of age on the potential risk of sudden death in asymptomatic Wolff-</text>
<text top="468" left="108" width="444" height="17" font="27">Parkinson-White syndrome. Pacing Clin Electrophysiol. 2001;24:1514-8. </text>
<text top="486" left="54" width="802" height="17" font="27">  176.   Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic </text>
<text top="503" left="108" width="741" height="17" font="27">events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up </text>
<text top="520" left="108" width="261" height="17" font="27">study. J Am Coll Cardiol. 2003;41:239-44. </text>
<text top="537" left="54" width="792" height="17" font="27">  177.   Pappone C, Santinelli V, Manguso F, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients </text>
<text top="555" left="108" width="475" height="17" font="27">with the Wolff-Parkinson-White syndrome. N Engl J Med. 2003;349:1803-11. </text>
<text top="572" left="54" width="782" height="17" font="27">  178.   Santinelli V, Radinovic A, Manguso F, et al. Asymptomatic ventricular preexcitation: a long-term prospective follow-up </text>
<text top="589" left="108" width="443" height="17" font="27">study of 293 adult patients. Circ Arrhythm Electrophysiol. 2009;2:102-7. </text>
<text top="606" left="54" width="800" height="17" font="27">  179.   Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial </text>
<text top="624" left="108" width="228" height="17" font="27">flutter. Am J Cardiol. 1989;63:925-9. </text>
<text top="641" left="54" width="798" height="17" font="27">  180.   Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and </text>
<text top="658" left="108" width="608" height="17" font="27">atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1989;63:1046-51. </text>
<text top="675" left="54" width="800" height="17" font="27">  181.   Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm </text>
<text top="693" left="108" width="637" height="17" font="27">after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol. 1989;64:1317-21. </text>
<text top="710" left="54" width="796" height="17" font="27">  182.   Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal </text>
<text top="727" left="108" width="481" height="17" font="27">atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722-7. </text>
<text top="744" left="54" width="787" height="17" font="27">  183.   Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-</text>
<text top="762" left="108" width="724" height="17" font="27">hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18:891-7. </text>
<text top="779" left="54" width="812" height="17" font="27">  184.   Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from </text>
<text top="796" left="108" width="643" height="17" font="27">direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 1991;68:41-6. </text>
<text top="813" left="54" width="810" height="17" font="27">  185.   Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, </text>
<text top="831" left="108" width="299" height="17" font="27">and verapamil. Am J Cardiol. 1992;70:56A-60A. </text>
<text top="848" left="54" width="778" height="17" font="27">  186.   Roberts SA, Diaz C, Nolan PE, et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J </text>
<text top="865" left="108" width="156" height="17" font="27">Cardiol. 1993;72:567-73. </text>
<text top="882" left="54" width="806" height="17" font="27">  187.   Tucker KJ, Wilson C. A comparison of transoesophageal atrial pacing and direct current cardioversion for the termination of </text>
<text top="900" left="108" width="484" height="17" font="27">atrial flutter: a prospective, randomised clinical trial. Br Heart J. 1993;69:530-5. </text>
<text top="917" left="54" width="809" height="17" font="27">  188.   Ellenbogen KA, Dias VC, Cardello FP, et al. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. </text>
<text top="934" left="108" width="177" height="17" font="27">Am J Cardiol. 1995;75:45-9. </text>
<text top="951" left="54" width="776" height="17" font="27">  189.   Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing </text>
<text top="969" left="108" width="641" height="17" font="27">regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16:521-8. </text>
<text top="986" left="54" width="774" height="17" font="27">  190.   Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial </text>
<text top="1003" left="108" width="748" height="17" font="27">fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. </text>
<text top="1020" left="108" width="187" height="17" font="27">Am Heart J. 1995;129:739-48. </text>
<text top="1038" left="54" width="809" height="17" font="27">  191.   Doni F, Staffiere E, Manfredi M, et al. Type II atrial flutter interruption with transesophageal pacing: use of propafenone and </text>
<text top="1055" left="108" width="479" height="17" font="27">possible change of the substrate. Pacing Clin Electrophysiol. 1996;19:1958-61. </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">147 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="790" height="17" font="27">  192.   Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation </text>
<text top="72" left="108" width="457" height="17" font="27">and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130-6. </text>
<text top="89" left="54" width="771" height="17" font="27">  193.   Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid </text>
<text top="106" left="108" width="693" height="17" font="27">conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613-21. </text>
<text top="123" left="54" width="759" height="17" font="27">  194.   Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with </text>
<text top="141" left="108" width="640" height="17" font="27">intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31:1414-9. </text>
<text top="158" left="54" width="783" height="17" font="27">  195.   Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial </text>
<text top="175" left="108" width="604" height="17" font="27">flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart. 1998;79:568-75. </text>
<text top="192" left="54" width="808" height="17" font="27">  196.   Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic </text>
<text top="210" left="108" width="713" height="17" font="27">atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84:270-7. </text>
<text top="227" left="54" width="803" height="17" font="27">  197.   Doni F, Manfredi M, Piemonti C, et al. New onset atrial flutter termination by overdrive transoesophageal pacing: effects of </text>
<text top="244" left="108" width="358" height="17" font="27">different protocols of stimulation. Europace. 2000;2:292-6. </text>
<text top="261" left="54" width="761" height="17" font="27">  198.   Natale A, Newby KH, Pisano E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line </text>
<text top="279" left="108" width="558" height="17" font="27">radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35:1898-904. </text>
<text top="296" left="54" width="798" height="17" font="27">  199.   Delacretaz E, Ganz LI, Soejima K, et al. Multi atrial maco-re-entry circuits in adults with repaired congenital heart disease: </text>
<text top="313" left="108" width="725" height="17" font="27">entrainment mapping combined with three-dimensional electroanatomic mapping. J Am Coll Cardiol. 2001;37:1665-76. </text>
<text top="330" left="54" width="808" height="17" font="27">  200.   Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial </text>
<text top="348" left="108" width="317" height="17" font="27">tachyarrhythmias. Crit Care Med. 2001;29:1149-53. </text>
<text top="365" left="54" width="786" height="17" font="27">  201.   Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with </text>
<text top="382" left="108" width="722" height="17" font="27">reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. </text>
<text top="399" left="108" width="178" height="17" font="27">Circulation. 2001;104:292-6. </text>
<text top="417" left="54" width="812" height="17" font="27">  202.   Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of </text>
<text top="434" left="108" width="408" height="17" font="27">atrial fibrillation and flutter. J Am Coll Cardiol. 2001;38:1498-504. </text>
<text top="451" left="54" width="776" height="17" font="27">  203.   Wazni O, Marrouche NF, Martin DO, et al. Randomized study comparing combined pulmonary vein-left atrial junction </text>
<text top="468" left="108" width="742" height="17" font="27">disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients </text>
<text top="486" left="108" width="541" height="17" font="27">presenting with typical atrial flutter and atrial fibrillation. Circulation. 2003;108:2479-83. </text>
<text top="503" left="54" width="800" height="17" font="27">  204.   Da Costa A, Thevenin J, Roche F, et al. Results from the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) trial on atrial </text>
<text top="520" left="108" width="760" height="17" font="27">flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode </text>
<text top="537" left="108" width="369" height="17" font="27">of symptomatic atrial flutter. Circulation. 2006;114:1676-81. </text>
<text top="555" left="54" width="810" height="17" font="27">  205.   Kuniss M, Vogtmann T, Ventura R, et al. Prospective randomized comparison of durability of bidirectional conduction block </text>
<text top="572" left="108" width="747" height="17" font="27">in the cavotricuspid isthmus in patients after ablation of common atrial flutter using cryothermy and radiofrequency energy: </text>
<text top="589" left="108" width="334" height="17" font="27">the CRYOTIP study. Heart Rhythm. 2009;6:1699-705. </text>
<text top="606" left="54" width="759" height="17" font="27">  206.   Steinwender C, Honig S, Kypta A, et al. Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the </text>
<text top="624" left="108" width="569" height="17" font="27">conversion of typical but not of atypical persistent atrial flutter. Int J Cardiol. 2010;141:260-5. </text>
<text top="641" left="54" width="764" height="17" font="27">  207.   Bastani H, Drca N, Insulander P, et al. Cryothermal vs. radiofrequency ablation as atrial flutter therapy: a randomized </text>
<text top="658" left="108" width="237" height="17" font="27">comparison. Europace. 2013;15:420-8. </text>
<text top="675" left="54" width="767" height="17" font="27">  208.   Mohanty S, Mohanty P, Di BL, et al. Results from a single-blind, randomized study comparing the impact of different </text>
<text top="693" left="108" width="744" height="17" font="27">ablation approaches on long-term procedure outcome in coexistent atrial fibrillation and flutter (APPROVAL). Circulation. </text>
<text top="710" left="108" width="118" height="17" font="27">2013;127:1853-60. </text>
<text top="727" left="54" width="777" height="17" font="27">  209.   Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-</text>
<text top="744" left="108" width="479" height="17" font="27">Norwegian Flecainide Multicenter Study Group. Am J Cardiol. 1991;67:713-7. </text>
<text top="762" left="54" width="770" height="17" font="27">  210.   Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with </text>
<text top="779" left="108" width="754" height="17" font="27">symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol. 1996;77:66A-71A. </text>
<text top="796" left="54" width="782" height="17" font="27">  211.   Baker BM, Lindsay BD, Bromberg BI, et al. Catheter ablation of clinical intraatrial reentrant tachycardias resulting from </text>
<text top="813" left="108" width="636" height="17" font="27">previous atrial surgery: localizing and transecting the critical isthmus. J Am Coll Cardiol. 1996;28:411-7. </text>
<text top="831" left="54" width="766" height="17" font="27">  212.   Kalman JM, VanHare GF, Olgin JE, et al. Ablation of 'incisional' reentrant atrial tachycardia complicating surgery for </text>
<text top="848" left="108" width="701" height="17" font="27">congenital heart disease. Use of entrainment to define a critical isthmus of conduction. Circulation. 1996;93:502-12. </text>
<text top="865" left="54" width="812" height="17" font="27">  213.   Triedman JK, Bergau DM, Saul JP, et al. Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in </text>
<text top="882" left="108" width="453" height="17" font="27">patients with congenital heart disease. J Am Coll Cardiol. 1997;30:1032-8. </text>
<text top="900" left="54" width="796" height="17" font="27">  214.   Huang DT, Monahan KM, Zimetbaum P, et al. Hybrid pharmacologic and ablative therapy: a novel and effective approach </text>
<text top="917" left="108" width="510" height="17" font="27">for the management of atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:462-9. </text>
<text top="934" left="54" width="752" height="17" font="27">  215.   Chan DP, Van Hare GF, Mackall JA, et al. Importance of atrial flutter isthmus in postoperative intra-atrial reentrant </text>
<text top="951" left="108" width="263" height="17" font="27">tachycardia. Circulation. 2000;102:1283-9. </text>
<text top="969" left="54" width="747" height="17" font="27">  216.   Jais P, Shah DC, Haissaguerre M, et al. Mapping and ablation of left atrial flutters. Circulation. 2000;101:2928-34. </text>
<text top="986" left="54" width="808" height="17" font="27">  217.   Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal </text>
<text top="1003" left="108" width="285" height="17" font="27">atrial fibrillation. Eur Heart J. 2000;21:565-72. </text>
<text top="1020" left="54" width="804" height="17" font="27">  218.   Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with </text>
<text top="1038" left="108" width="495" height="17" font="27">surgically corrected congenital heart disease. J Am Coll Cardiol. 2001;38:377-84. </text>
</page>
<page number="148" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">148 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="813" height="17" font="27">  219.   Nakagawa H, Shah N, Matsudaira K, et al. Characterization of reentrant circuit in macroreentrant right atrial tachycardia after </text>
<text top="72" left="108" width="754" height="17" font="27">surgical repair of congenital heart disease: isolated channels between scars allow &#34;focal&#34; ablation. Circulation. 2001;103:699-</text>
<text top="89" left="108" width="30" height="17" font="27">709. </text>
<text top="106" left="54" width="754" height="17" font="27">  220.   Deal BJ, Mavroudis C, Backer CL, et al. Comparison of anatomic isthmus block with the modified right atrial maze </text>
<text top="123" left="108" width="511" height="17" font="27">procedure for late atrial tachycardia in Fontan patients. Circulation. 2002;106:575-9. </text>
<text top="141" left="54" width="788" height="17" font="27">  221.   Coffey JO, d'Avila A, Dukkipati S, et al. Catheter ablation of scar-related atypical atrial flutter. Europace. 2013;15:414-9. </text>
<text top="158" left="54" width="797" height="17" font="27">  222.   Ghali WA, Wasil BI, Brant R, et al. Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. </text>
<text top="175" left="108" width="174" height="17" font="27">Am J Med. 2005;118:101-7. </text>
<text top="192" left="54" width="800" height="17" font="27">  223.   Mamchur SE, Kurilin MY. High-amplitude pace mapping increases safety of radiofrequency catheter ablation of parahisian </text>
<text top="210" left="108" width="358" height="17" font="27">ectopic foci. Pacing Clin Electrophysiol. 2012;35:1458-63. </text>
<text top="227" left="54" width="800" height="17" font="27">  224.   Ruder MA, Davis JC, Eldar M, et al. Clinical and electrophysiologic characterization of automatic junctional tachycardia in </text>
<text top="244" left="108" width="214" height="17" font="27">adults. Circulation. 1986;73:930-7. </text>
<text top="261" left="54" width="791" height="17" font="27">  225.   Cook JR, Steinberg JS. An incessant form of junctional ectopic tachycardia in an adult responsive to a class 1C agent. Am </text>
<text top="279" left="108" width="161" height="17" font="27">Heart J. 1991;122:1487-9. </text>
<text top="296" left="54" width="809" height="17" font="27">  226.   Kuck KH, Kunze KP, Schluter M, et al. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. Am </text>
<text top="313" left="108" width="176" height="17" font="27">J Cardiol. 1988;62:37L-44L. </text>
<text top="330" left="54" width="806" height="17" font="27">  227.   Villain E, Vetter VL, Garcia JM, et al. Evolving concepts in the management of congenital junctional ectopic tachycardia. A </text>
<text top="348" left="108" width="290" height="17" font="27">multicenter study. Circulation. 1990;81:1544-9. </text>
<text top="365" left="54" width="792" height="17" font="27">  228.   Paul T, Reimer A, Janousek J, et al. Efficacy and safety of propafenone in congenital junctional ectopic tachycardia. J Am </text>
<text top="382" left="108" width="178" height="17" font="27">Coll Cardiol. 1992;20:911-4. </text>
<text top="399" left="54" width="814" height="17" font="27">  229.   Raja P, Hawker RE, Chaikitpinyo A, et al. Amiodarone management of junctional ectopic tachycardia after cardiac surgery in </text>
<text top="417" left="108" width="222" height="17" font="27">children. Br Heart J. 1994;72:261-5. </text>
<text top="434" left="54" width="806" height="17" font="27">  230.   Lee KL, Chun HM, Liem LB, et al. Effect of adenosine and verapamil in catecholamine-induced accelerated atrioventricular </text>
<text top="451" left="108" width="632" height="17" font="27">junctional rhythm: insights into the underlying mechanism. Pacing Clin Electrophysiol. 1999;22:866-70. </text>
<text top="468" left="54" width="782" height="17" font="27">  231.   Sarubbi B, Musto B, Ducceschi V, et al. Congenital junctional ectopic tachycardia in children and adolescents: a 20 year </text>
<text top="486" left="108" width="291" height="17" font="27">experience based study. Heart. 2002;88:188-90. </text>
<text top="503" left="54" width="775" height="17" font="27">  232.   Scheinman MM, Gonzalez RP, Cooper MW, et al. Clinical and electrophysiologic features and role of catheter ablation </text>
<text top="520" left="108" width="689" height="17" font="27">techniques in adult patients with automatic atrioventricular junctional tachycardia. Am J Cardiol. 1994;74:565-72. </text>
<text top="537" left="54" width="799" height="17" font="27">  233.   Hamdan M, Van Hare GF, Fisher W, et al. Selective catheter ablation of the tachycardia focus in patients with nonreentrant </text>
<text top="555" left="108" width="332" height="17" font="27">junctional tachycardia. Am J Cardiol. 1996;78:1292-7. </text>
<text top="572" left="54" width="785" height="17" font="27">  234.   Law IH, Von Bergen NH, Gingerich JC, et al. Transcatheter cryothermal ablation of junctional ectopic tachycardia in the </text>
<text top="589" left="108" width="265" height="17" font="27">normal heart. Heart Rhythm. 2006;3:903-7. </text>
<text top="606" left="54" width="795" height="17" font="27">  235.   Meiltz A, Weber R, Halimi F, et al. Permanent form of junctional reciprocating tachycardia in adults: peculiar features and </text>
<text top="624" left="108" width="406" height="17" font="27">results of radiofrequency catheter ablation. Europace. 2006;8:21-8. </text>
<text top="641" left="54" width="785" height="17" font="27">  236.   Padanilam BJ, Manfredi JA, Steinberg LA, et al. Differentiating junctional tachycardia and atrioventricular node re-entry </text>
<text top="658" left="108" width="589" height="17" font="27">tachycardia based on response to atrial extrastimulus pacing. J Am Coll Cardiol. 2008;52:1711-7. </text>
<text top="675" left="54" width="752" height="17" font="27">  237.   Srivathsan K, Gami AS, Barrett R, et al. Differentiating atrioventricular nodal reentrant tachycardia from junctional </text>
<text top="693" left="108" width="596" height="17" font="27">tachycardia: novel application of the delta H-A interval. J Cardiovasc Electrophysiol. 2008;19:1-6. </text>
<text top="710" left="54" width="796" height="17" font="27">  238.   Fan R, Tardos JG, Almasry I, et al. Novel use of atrial overdrive pacing to rapidly differentiate junctional tachycardia from </text>
<text top="727" left="108" width="448" height="17" font="27">atrioventricular nodal reentrant tachycardia. Heart Rhythm. 2011;8:840-4. </text>
<text top="744" left="54" width="808" height="17" font="27">  239.   Lundberg A. Paroxysmal atrial tachycardia in infancy: long-term follow-up study of 49 subjects. Pediatrics. 1982;70:638-42. </text>
<text top="762" left="54" width="785" height="17" font="27">  240.   Deal BJ, Keane JF, Gillette PC, et al. Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: </text>
<text top="779" left="108" width="379" height="17" font="27">management and follow-up. J Am Coll Cardiol. 1985;5:130-5. </text>
<text top="796" left="54" width="730" height="17" font="27">  241.   Perry JC, Garson A, Jr. Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: early </text>
<text top="813" left="108" width="439" height="17" font="27">disappearance and late recurrence. J Am Coll Cardiol. 1990;16:1215-20. </text>
<text top="831" left="54" width="791" height="17" font="27">  242.   Wu MH, Chang YC, Lin JL, et al. Probability of supraventricular tachycardia recurrence in pediatric patients. Cardiology. </text>
<text top="848" left="108" width="96" height="17" font="27">1994;85:284-9. </text>
<text top="865" left="54" width="759" height="17" font="27">  243.   Riggs TW, Byrd JA, Weinhouse E. Recurrence risk of supraventricular tachycardia in pediatric patients. Cardiology. </text>
<text top="882" left="108" width="96" height="17" font="27">1999;91:25-30. </text>
<text top="900" left="54" width="792" height="17" font="27">  244.   Tortoriello TA, Snyder CS, Smith EO, et al. Frequency of recurrence among infants with supraventricular tachycardia and </text>
<text top="917" left="108" width="739" height="17" font="27">comparison of recurrence rates among those with and without preexcitation and among those with and without response to </text>
<text top="934" left="108" width="409" height="17" font="27">digoxin and/or propranolol therapy. Am J Cardiol. 2003;92:1045-9. </text>
<text top="951" left="54" width="806" height="17" font="27">  245.   Gilljam T, Jaeggi E, Gow RM. Neonatal supraventricular tachycardia: outcomes over a 27-year period at a single institution. </text>
<text top="969" left="108" width="192" height="17" font="27">Acta Paediatr. 2008;97:1035-9. </text>
<text top="986" left="54" width="777" height="17" font="27">  246.   Santinelli V, Radinovic A, Manguso F, et al. The natural history of asymptomatic ventricular pre-excitation a long-term </text>
<text top="1003" left="108" width="580" height="17" font="27">prospective follow-up study of 184 asymptomatic children. J Am Coll Cardiol. 2009;53:275-80. </text>
<text top="1020" left="54" width="795" height="17" font="27">  247.   Salerno JC, Garrison MM, Larison C, et al. Case fatality in children with supraventricular tachycardia in the United States. </text>
<text top="1038" left="108" width="265" height="17" font="27">Pacing Clin Electrophysiol. 2011;34:832-6. </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">149 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="706" height="17" font="27">  248.   Garson A, Jr., Gillette PC. Electrophysiologic studies of supraventricular tachycardia in children. I. Clinical-</text>
<text top="72" left="108" width="380" height="17" font="27">electrophysiologic correlations. Am Heart J. 1981;102:233-50. </text>
<text top="89" left="54" width="764" height="17" font="27">  249.   Ko JK, Deal BJ, Strasburger JF, et al. Supraventricular tachycardia mechanisms and their age distribution in pediatric </text>
<text top="106" left="108" width="253" height="17" font="27">patients. Am J Cardiol. 1992;69:1028-32. </text>
<text top="123" left="54" width="788" height="17" font="27">  250.   Weindling SN, Saul JP, Walsh EP. Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and </text>
<text top="141" left="108" width="228" height="17" font="27">infants. Am Heart J. 1996;131:66-72. </text>
<text top="158" left="54" width="799" height="17" font="27">  251.   Gross GJ, Epstein MR, Walsh EP, et al. Characteristics, management, and midterm outcome in infants with atrioventricular </text>
<text top="175" left="108" width="352" height="17" font="27">nodal reentry tachycardia. Am J Cardiol. 1998;82:956-60. </text>
<text top="192" left="54" width="801" height="17" font="27">  252.   Anand RG, Rosenthal GL, Van Hare GF, et al. Is the mechanism of supraventricular tachycardia in pediatrics influenced by </text>
<text top="210" left="108" width="365" height="17" font="27">age, gender or ethnicity? Congenit Heart Dis. 2009;4:464-8. </text>
<text top="227" left="54" width="794" height="17" font="27">  253.   Brembilla-Perrot B, Moulin-Zinsch A, Sellal JM, et al. Impact of transesophageal electrophysiologic study to elucidate the </text>
<text top="244" left="108" width="751" height="17" font="27">mechanism of arrhythmia on children with supraventricular tachycardia and no preexcitation. Pediatr Cardiol. 2013;34:1695-</text>
<text top="261" left="108" width="30" height="17" font="27">702. </text>
<text top="279" left="54" width="751" height="17" font="27">  254.   Pfammatter JP, Stocker FP. Re-entrant supraventricular tachycardia in infancy: current role of prophylactic digoxin </text>
<text top="296" left="108" width="252" height="17" font="27">treatment. Eur J Pediatr. 1998;157:101-6. </text>
<text top="313" left="54" width="804" height="17" font="27">  255.   Villain E, Bonnet D, Acar P, et al. [Recommendations for the treatment of recurrent supraventricular tachycardia in infants]. </text>
<text top="330" left="108" width="172" height="17" font="27">Arch Pediatr. 1998;5:133-8. </text>
<text top="348" left="54" width="793" height="17" font="27">  256.   Losek JD, Endom E, Dietrich A, et al. Adenosine and pediatric supraventricular tachycardia in the emergency department: </text>
<text top="365" left="108" width="394" height="17" font="27">multicenter study and review. Ann Emerg Med. 1999;33:185-91. </text>
<text top="382" left="54" width="753" height="17" font="27">  257.   Dixon J, Foster K, Wyllie J, et al. Guidelines and adenosine dosing in supraventricular tachycardia. Arch Dis Child. </text>
<text top="399" left="108" width="103" height="17" font="27">2005;90:1190-1. </text>
<text top="417" left="54" width="746" height="17" font="27">  258.   Chang PM, Silka MJ, Moromisato DY, et al. Amiodarone versus procainamide for the acute treatment of recurrent </text>
<text top="434" left="108" width="583" height="17" font="27">supraventricular tachycardia in pediatric patients. Circ Arrhythm Electrophysiol. 2010;3:134-40. </text>
<text top="451" left="54" width="800" height="17" font="27">  259.   Diaz-Parra S, Sanchez-Yanez P, Zabala-Arguelles I, et al. Use of adenosine in the treatment of supraventricular tachycardia </text>
<text top="468" left="108" width="456" height="17" font="27">in a pediatric emergency department. Pediatr Emerg Care. 2014;30:388-93. </text>
<text top="486" left="54" width="787" height="17" font="27">  260.   Batra AS, Chun DS, Johnson TR, et al. A prospective analysis of the incidence and risk factors associated with junctional </text>
<text top="503" left="108" width="590" height="17" font="27">ectopic tachycardia following surgery for congenital heart disease. Pediatr Cardiol. 2006;27:51-5. </text>
<text top="520" left="54" width="791" height="17" font="27">  261.   Andreasen JB, Johnsen SP, Ravn HB. Junctional ectopic tachycardia after surgery for congenital heart disease in children. </text>
<text top="537" left="108" width="237" height="17" font="27">Intensive Care Med. 2008;34:895-902. </text>
<text top="555" left="54" width="791" height="17" font="27">  262.   Borgman KY, Smith AH, Owen JP, et al. A genetic contribution to risk for postoperative junctional ectopic tachycardia in </text>
<text top="572" left="108" width="534" height="17" font="27">children undergoing surgery for congenital heart disease. Heart Rhythm. 2011;8:1900-4. </text>
<text top="589" left="54" width="803" height="17" font="27">  263.   Makhoul M, Oster M, Fischbach P, et al. Junctional ectopic tachycardia after congenital heart surgery in the current surgical </text>
<text top="606" left="108" width="220" height="17" font="27">era. Pediatr Cardiol. 2013;34:370-4. </text>
<text top="624" left="54" width="772" height="17" font="27">  264.   Pfammatter JP, Paul T, Ziemer G, et al. Successful management of junctional tachycardia by hypothermia after cardiac </text>
<text top="641" left="108" width="345" height="17" font="27">operations in infants. Ann Thorac Surg. 1995;60:556-60. </text>
<text top="658" left="54" width="787" height="17" font="27">  265.   Walsh EP, Saul JP, Sholler GF, et al. Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia </text>
<text top="675" left="108" width="492" height="17" font="27">after operation for congenital heart disease. J Am Coll Cardiol. 1997;29:1046-53. </text>
<text top="693" left="54" width="796" height="17" font="27">  266.   Laird WP, Snyder CS, Kertesz NJ, et al. Use of intravenous amiodarone for postoperative junctional ectopic tachycardia in </text>
<text top="710" left="108" width="251" height="17" font="27">children. Pediatr Cardiol. 2003;24:133-7. </text>
<text top="727" left="54" width="801" height="17" font="27">  267.   Plumpton K, Justo R, Haas N. Amiodarone for post-operative junctional ectopic tachycardia. Cardiol Young. 2005;15:13-8. </text>
<text top="744" left="54" width="811" height="17" font="27">  268.   Haas NA, Camphausen CK. Impact of early and standardized treatment with amiodarone on therapeutic success and outcome </text>
<text top="762" left="108" width="624" height="17" font="27">in pediatric patients with postoperative tachyarrhythmia. J Thorac Cardiovasc Surg. 2008;136:1215-22. </text>
<text top="779" left="54" width="810" height="17" font="27">  269.   Collins KK, Van Hare GF, Kertesz NJ, et al. Pediatric nonpost-operative junctional ectopic tachycardia medical management </text>
<text top="796" left="108" width="388" height="17" font="27">and interventional therapies. J Am Coll Cardiol. 2009;53:690-7. </text>
<text top="813" left="54" width="749" height="17" font="27">  270.   Kovacikova L, Hakacova N, Dobos D, et al. Amiodarone as a first-line therapy for postoperative junctional ectopic </text>
<text top="831" left="108" width="292" height="17" font="27">tachycardia. Ann Thorac Surg. 2009;88:616-22. </text>
<text top="848" left="54" width="775" height="17" font="27">  271.   Timmermans C, Smeets JL, Rodriguez LM, et al. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J </text>
<text top="865" left="108" width="148" height="17" font="27">Cardiol. 1995;76:492-4. </text>
<text top="882" left="54" width="803" height="17" font="27">  272.   Ceresnak SR, Tanel RE, Pass RH, et al. Clinical and electrophysiologic characteristics of antidromic tachycardia in children </text>
<text top="900" left="108" width="508" height="17" font="27">with Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol. 2012;35:480-8. </text>
<text top="917" left="54" width="755" height="17" font="27">  273.   Brembilla-Perrot B, Pauriah M, Sellal JM, et al. Incidence and prognostic significance of spontaneous and inducible </text>
<text top="934" left="108" width="305" height="17" font="27">antidromic tachycardia. Europace. 2013;15:871-6. </text>
<text top="951" left="54" width="800" height="17" font="27">  274.   Kugler JD, Danford DA, Houston K, et al. Radiofrequency catheter ablation for paroxysmal supraventricular tachycardia in </text>
<text top="969" left="108" width="745" height="17" font="27">children and adolescents without structural heart disease. Pediatric EP Society, Radiofrequency Catheter Ablation Registry. </text>
<text top="986" left="108" width="199" height="17" font="27">Am J Cardiol. 1997;80:1438-43. </text>
<text top="1003" left="54" width="732" height="17" font="27">  275.   Schaffer MS, Gow RM, Moak JP, et al. Mortality following radiofrequency catheter ablation (from the Pediatric </text>
<text top="1020" left="108" width="708" height="17" font="27">Radiofrequency Ablation Registry). Participating members of the Pediatric Electrophysiology Society. Am J Cardiol. </text>
<text top="1038" left="108" width="103" height="17" font="27">2000;86:639-43. </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">150 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="796" height="17" font="27">  276.   Blaufox AD, Felix GL, Saul JP. Radiofrequency catheter ablation in infants &lt;/=18 months old: when is it done and how do </text>
<text top="72" left="108" width="565" height="17" font="27">they fare?: short-term data from the pediatric ablation registry. Circulation. 2001;104:2803-8. </text>
<text top="89" left="54" width="811" height="17" font="27">  277.   Blaufox AD, Paul T, Saul JP. Radiofrequency catheter ablation in small children: relationship of complications to application </text>
<text top="106" left="108" width="300" height="17" font="27">dose. Pacing Clin Electrophysiol. 2004;27:224-9. </text>
<text top="123" left="54" width="785" height="17" font="27">  278.   Van Hare GF, Javitz H, Carmelli D, et al. Prospective assessment after pediatric cardiac ablation: demographics, medical </text>
<text top="141" left="108" width="462" height="17" font="27">profiles, and initial outcomes. J Cardiovasc Electrophysiol. 2004;15:759-70. </text>
<text top="158" left="54" width="795" height="17" font="27">  279.   Van Hare GF, Javitz H, Carmelli D, et al. Prospective assessment after pediatric cardiac ablation: recurrence at 1 year after </text>
<text top="175" left="108" width="551" height="17" font="27">initially successful ablation of supraventricular tachycardia. Heart Rhythm. 2004;1:188-96. </text>
<text top="192" left="54" width="805" height="17" font="27">  280.   Aiyagari R, Saarel EV, Etheridge SP, et al. Radiofrequency ablation for supraventricular tachycardia in children &lt; or =15 kg </text>
<text top="210" left="108" width="322" height="17" font="27">is safe and effective. Pediatr Cardiol. 2005;26:622-6. </text>
<text top="227" left="54" width="812" height="17" font="27">  281.   Lee PC, Hwang B, Chen SA, et al. The results of radiofrequency catheter ablation of supraventricular tachycardia in children. </text>
<text top="244" left="108" width="273" height="17" font="27">Pacing Clin Electrophysiol. 2007;30:655-61. </text>
<text top="261" left="54" width="796" height="17" font="27">  282.   Buddhe S, Singh H, Du W, et al. Radiofrequency and cryoablation therapies for supraventricular arrhythmias in the young: </text>
<text top="279" left="108" width="449" height="17" font="27">five-year review of efficacies. Pacing Clin Electrophysiol. 2012;35:711-7. </text>
<text top="296" left="54" width="799" height="17" font="27">  283.   Schneider HE, Kriebel T, Gravenhorst VD, et al. Incidence of coronary artery injury immediately after catheter ablation for </text>
<text top="313" left="108" width="503" height="17" font="27">supraventricular tachycardias in infants and children. Heart Rhythm. 2009;6:461-7. </text>
<text top="330" left="54" width="791" height="17" font="27">  284.   Kantoch MJ, Gulamhusein SS, Sanatani S. Short- and long-term outcomes in children undergoing radiofrequency catheter </text>
<text top="348" left="108" width="414" height="17" font="27">ablation before their second birthday. Can J Cardiol. 2011;27:523-9. </text>
<text top="365" left="54" width="807" height="17" font="27">  285.   Garson A, Jr., Kanter RJ. Management of the child with Wolff-Parkinson-White syndrome and supraventricular tachycardia: </text>
<text top="382" left="108" width="448" height="17" font="27">model for cost effectiveness. J Cardiovasc Electrophysiol. 1997;8:1320-6. </text>
<text top="399" left="54" width="770" height="17" font="27">  286.   Pfammatter JP, Pavlovic M, Bauersfeld U. Impact of curative ablation on pharmacologic management in children with </text>
<text top="417" left="108" width="427" height="17" font="27">reentrant supraventricular tachycardias. Int J Cardiol. 2004;94:279-82. </text>
<text top="434" left="54" width="808" height="17" font="27">  287.   Strieper M, Leong T, Bajaj T, et al. Does ablation of supraventricular tachycardia in children with a structurally normal heart </text>
<text top="451" left="108" width="366" height="17" font="27">improve quality of life? Congenit Heart Dis. 2010;5:587-93. </text>
<text top="468" left="54" width="809" height="17" font="27">  288.   Wood KA, Stewart AL, Drew BJ, et al. Patient perception of symptoms and quality of life following ablation in patients with </text>
<text top="486" left="108" width="350" height="17" font="27">supraventricular tachycardia. Heart Lung. 2010;39:12-20. </text>
<text top="503" left="54" width="810" height="17" font="27">  289.   Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality </text>
<text top="520" left="108" width="709" height="17" font="27">in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J. 2005;26:2325-33. </text>
<text top="537" left="54" width="779" height="17" font="27">  290.   Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Gender and outcome in adult congenital heart disease. Circulation. </text>
<text top="555" left="108" width="103" height="17" font="27">2008;118:26-32. </text>
<text top="572" left="54" width="719" height="17" font="27">  291.   Bouchardy J, Therrien J, Pilote L, et al. Atrial arrhythmias in adults with congenital heart disease. Circulation. </text>
<text top="589" left="108" width="118" height="17" font="27">2009;120:1679-86. </text>
<text top="606" left="54" width="800" height="17" font="27">  292.   Trojnarska O, Grajek S, Kramer L, et al. Risk factors of supraventricular arrhythmia in adults with congenital heart disease. </text>
<text top="624" left="108" width="165" height="17" font="27">Cardiol J. 2009;16:218-26. </text>
<text top="641" left="54" width="768" height="17" font="27">  293.   Bernier M, Marelli AJ, Pilote L, et al. Atrial arrhythmias in adult patients with right- versus left-sided congenital heart </text>
<text top="658" left="108" width="315" height="17" font="27">disease anomalies. Am J Cardiol. 2010;106:547-51. </text>
<text top="675" left="54" width="794" height="17" font="27">  294.   Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-</text>
<text top="693" left="108" width="301" height="17" font="27">institutional study. Circulation. 2010;122:868-75. </text>
<text top="710" left="54" width="801" height="17" font="27">  295.   Cuypers JA, Opic P, Menting ME, et al. The unnatural history of an atrial septal defect: longitudinal 35 year follow up after </text>
<text top="727" left="108" width="334" height="17" font="27">surgical closure at young age. Heart. 2013;99:1346-52. </text>
<text top="744" left="54" width="779" height="17" font="27">  296.   Valente AM, Gauvreau K, Assenza GE, et al. Contemporary predictors of death and sustained ventricular tachycardia in </text>
<text top="762" left="108" width="620" height="17" font="27">patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart. 2014;100:247-53. </text>
<text top="779" left="54" width="812" height="17" font="27">  297.   Collins KK, Love BA, Walsh EP, et al. Location of acutely successful radiofrequency catheter ablation of intraatrial reentrant </text>
<text top="796" left="108" width="512" height="17" font="27">tachycardia in patients with congenital heart disease. Am J Cardiol. 2000;86:969-74. </text>
<text top="813" left="54" width="802" height="17" font="27">  298.   de Groot NM, Zeppenfeld K, Wijffels MC, et al. Ablation of focal atrial arrhythmia in patients with congenital heart defects </text>
<text top="831" left="108" width="635" height="17" font="27">after surgery: role of circumscribed areas with heterogeneous conduction. Heart Rhythm. 2006;3:526-35. </text>
<text top="848" left="54" width="810" height="17" font="27">  299.   Mah DY, Alexander ME, Cecchin F, et al. The electroanatomic mechanisms of atrial tachycardia in patients with tetralogy of </text>
<text top="865" left="108" width="518" height="17" font="27">Fallot and double outlet right ventricle. J Cardiovasc Electrophysiol. 2011;22:1013-7. </text>
<text top="882" left="54" width="745" height="17" font="27">  300.   Koyak Z, Kroon B, de Groot JR, et al. Efficacy of antiarrhythmic drugs in adults with congenital heart disease and </text>
<text top="900" left="108" width="383" height="17" font="27">supraventricular tachycardias. Am J Cardiol. 2013;112:1461-7. </text>
<text top="917" left="54" width="813" height="17" font="27">  301.   Wasmer K, Kobe J, Dechering DG, et al. Isthmus-dependent right atrial flutter as the leading cause of atrial tachycardias after </text>
<text top="934" left="108" width="408" height="17" font="27">surgical atrial septal defect repair. Int J Cardiol. 2013;168:2447-52. </text>
<text top="951" left="54" width="778" height="17" font="27">  302.   Fish FA, Gillette PC, Benson DW, Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and </text>
<text top="969" left="108" width="532" height="17" font="27">flecainide. The Pediatric Electrophysiology Group. J Am Coll Cardiol. 1991;18:356-65. </text>
<text top="986" left="54" width="783" height="17" font="27">  303.   Thorne SA, Barnes I, Cullinan P, et al. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital </text>
<text top="1003" left="108" width="270" height="17" font="27">heart disease. Circulation. 1999;100:149-54. </text>
<text top="1020" left="54" width="809" height="17" font="27">  304.   Pass RH, Liberman L, Al-Fayaddh M, et al. Continuous intravenous diltiazem infusion for short-term ventricular rate control </text>
<text top="1038" left="108" width="290" height="17" font="27">in children. Am J Cardiol. 2000;86:559-62, A9. </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">151 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="812" height="17" font="27">  305.   Hoyer AW, Balaji S. The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin </text>
<text top="72" left="108" width="198" height="17" font="27">Electrophysiol. 2007;30:1003-8. </text>
<text top="89" left="54" width="806" height="17" font="27">  306.   Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in transposition of the great arteries with intra-atrial </text>
<text top="106" left="108" width="447" height="17" font="27">baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008;1:250-7. </text>
<text top="123" left="54" width="796" height="17" font="27">  307.   Miyazaki A, Ohuchi H, Kurosaki K, et al. Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart </text>
<text top="141" left="108" width="220" height="17" font="27">disease. Circ J. 2008;72:1998-2003. </text>
<text top="158" left="54" width="768" height="17" font="27">  308.   Rao SO, Boramanand NK, Burton DA, et al. Atrial tachycardias in young adults and adolescents with congenital heart </text>
<text top="175" left="108" width="488" height="17" font="27">disease: conversion using single dose oral sotalol. Int J Cardiol. 2009;136:253-7. </text>
<text top="192" left="54" width="792" height="17" font="27">  309.   Wells R, Khairy P, Harris L, et al. Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. Pacing </text>
<text top="210" left="108" width="228" height="17" font="27">Clin Electrophysiol. 2009;32:1313-8. </text>
<text top="227" left="54" width="810" height="17" font="27">  310.   Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of </text>
<text top="244" left="108" width="331" height="17" font="27">tachycardia and hypertension. Drugs. 2012;72:109-32. </text>
<text top="261" left="54" width="791" height="17" font="27">  311.   Banchs JE, Baquero GA, Nickolaus MJ, et al. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in </text>
<text top="279" left="108" width="433" height="17" font="27">adults with congenital heart disease. Congenit Heart Dis. 2014;9:221-7. </text>
<text top="296" left="54" width="799" height="17" font="27">  312.   Stan MN, Hess EP, Bahn RS, et al. A risk prediction index for amiodarone-induced thyrotoxicosis in adults with congenital </text>
<text top="313" left="108" width="297" height="17" font="27">heart disease. J Thyroid Res. 2012;2012:210529. </text>
<text top="330" left="54" width="789" height="17" font="27">  313.   Olshansky B, Okumura K, Hess PG, et al. Use of procainamide with rapid atrial pacing for successful conversion of atrial </text>
<text top="348" left="108" width="363" height="17" font="27">flutter to sinus rhythm. J Am Coll Cardiol. 1988;11:359-64. </text>
<text top="365" left="54" width="784" height="17" font="27">  314.   Silka MJ, Manwill JR, Kron J, et al. Bradycardia-mediated tachyarrhythmias in congenital heart disease and responses to </text>
<text top="382" left="108" width="408" height="17" font="27">chronic pacing at physiologic rates. Am J Cardiol. 1990;65:488-93. </text>
<text top="399" left="54" width="747" height="17" font="27">  315.   Ragonese P, Drago F, Guccione P, et al. Permanent overdrive atrial pacing in the chronic management of recurrent </text>
<text top="417" left="108" width="721" height="17" font="27">postoperative atrial reentrant tachycardia in patients with complex congenital heart disease. Pacing Clin Electrophysiol. </text>
<text top="434" left="108" width="111" height="17" font="27">1997;20:2917-23. </text>
<text top="451" left="54" width="802" height="17" font="27">  316.   Brockmeier K, Ulmer HE, Hessling G. Termination of atrial reentrant tachycardias by using transesophageal atrial pacing. J </text>
<text top="468" left="108" width="235" height="17" font="27">Electrocardiol. 2002;35 Suppl:159-63. </text>
<text top="486" left="54" width="808" height="17" font="27">  317.   Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in </text>
<text top="503" left="108" width="416" height="17" font="27">patients with congenital heart disease. Am J Cardiol. 2003;92:871-6. </text>
<text top="520" left="54" width="787" height="17" font="27">  318.   Ammash NM, Phillips SD, Hodge DO, et al. Outcome of direct current cardioversion for atrial arrhythmias in adults with </text>
<text top="537" left="108" width="337" height="17" font="27">congenital heart disease. Int J Cardiol. 2012;154:270-4. </text>
<text top="555" left="54" width="766" height="17" font="27">  319.   Triedman JK, Saul JP, Weindling SN, et al. Radiofrequency ablation of intra-atrial reentrant tachycardia after surgical </text>
<text top="572" left="108" width="406" height="17" font="27">palliation of congenital heart disease. Circulation. 1995;91:707-14. </text>
<text top="589" left="54" width="792" height="17" font="27">  320.   Tanner H, Lukac P, Schwick N, et al. Irrigated-tip catheter ablation of intraatrial reentrant tachycardia in patients late after </text>
<text top="606" left="108" width="405" height="17" font="27">surgery of congenital heart disease. Heart Rhythm. 2004;1:268-75. </text>
<text top="624" left="54" width="786" height="17" font="27">  321.   Lukac P, Pedersen AK, Mortensen PT, et al. Ablation of atrial tachycardia after surgery for congenital and acquired heart </text>
<text top="641" left="108" width="757" height="17" font="27">disease using an electroanatomic mapping system: Which circuits to expect in which substrate? Heart Rhythm. 2005;2:64-72. </text>
<text top="658" left="54" width="809" height="17" font="27">  322.   de Groot NM, Atary JZ, Blom NA, et al. Long-term outcome after ablative therapy of postoperative atrial tachyarrhythmia in </text>
<text top="675" left="108" width="760" height="17" font="27">patients with congenital heart disease and characteristics of atrial tachyarrhythmia recurrences. Circ Arrhythm Electrophysiol. </text>
<text top="693" left="108" width="96" height="17" font="27">2010;3:148-54. </text>
<text top="710" left="54" width="763" height="17" font="27">  323.   Yap SC, Harris L, Silversides CK, et al. Outcome of intra-atrial re-entrant tachycardia catheter ablation in adults with </text>
<text top="727" left="108" width="688" height="17" font="27">congenital heart disease: negative impact of age and complex atrial surgery. J Am Coll Cardiol. 2010;56:1589-96. </text>
<text top="744" left="54" width="810" height="17" font="27">  324.   Ueda A, Suman-Horduna I, Mantziari L, et al. Contemporary outcomes of supraventricular tachycardia ablation in congenital </text>
<text top="762" left="108" width="625" height="17" font="27">heart disease: a single-center experience in 116 patients. Circ Arrhythm Electrophysiol. 2013;6:606-13. </text>
<text top="779" left="54" width="804" height="17" font="27">  325.   Teh AW, Medi C, Lee G, et al. Long-term outcome following ablation of atrial flutter occurring late after atrial septal defect </text>
<text top="796" left="108" width="307" height="17" font="27">repair. Pacing Clin Electrophysiol. 2011;34:431-5. </text>
<text top="813" left="54" width="796" height="17" font="27">  326.   Scaglione M, Caponi D, Ebrille E, et al. Very long-term results of electroanatomic-guided radiofrequency ablation of atrial </text>
<text top="831" left="108" width="513" height="17" font="27">arrhythmias in patients with surgically corrected atrial septal defect. Europace. 2014. </text>
<text top="848" left="54" width="790" height="17" font="27">  327.   Cappato R, Schluter M, Weiss C, et al. Radiofrequency current catheter ablation of accessory atrioventricular pathways in </text>
<text top="865" left="108" width="295" height="17" font="27">Ebstein's anomaly. Circulation. 1996;94:376-83. </text>
<text top="882" left="54" width="776" height="17" font="27">  328.   Reich JD, Auld D, Hulse E, et al. The Pediatric Radiofrequency Ablation Registry's experience with Ebstein's anomaly. </text>
<text top="900" left="108" width="495" height="17" font="27">Pediatric Electrophysiology Society. J Cardiovasc Electrophysiol. 1998;9:1370-7. </text>
<text top="917" left="54" width="740" height="17" font="27">  329.   de Groot NM, Lukac P, Blom NA, et al. Long-term outcome of ablative therapy of postoperative supraventricular </text>
<text top="934" left="108" width="745" height="17" font="27">tachycardias in patients with univentricular heart: a European multicenter study. Circ Arrhythm Electrophysiol. 2009;2:242-</text>
<text top="951" left="108" width="15" height="17" font="27">8. </text>
<text top="969" left="54" width="808" height="17" font="27">  330.   Yap SC, Harris L, Downar E, et al. Evolving electroanatomic substrate and intra-atrial reentrant tachycardia late after Fontan </text>
<text top="986" left="108" width="332" height="17" font="27">surgery. J Cardiovasc Electrophysiol. 2012;23:339-45. </text>
<text top="1003" left="54" width="741" height="17" font="27">  331.   Correa R, Sherwin ED, Kovach J, et al. Mechanism and Ablation of Arrhythmia Following Total Cavopulmonary </text>
<text top="1020" left="108" width="302" height="17" font="27">Connection. Circ Arrhythm Electrophysiol. 2015. </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">152 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="787" height="17" font="27">  332.   Jones DG, Jarman JW, Lyne JC, et al. The safety and efficacy of trans-baffle puncture to enable catheter ablation of atrial </text>
<text top="72" left="108" width="753" height="17" font="27">tachycardias following the Mustard procedure: a single centre experience and literature review. Int J Cardiol. 2013;168:1115-</text>
<text top="89" left="108" width="22" height="17" font="27">20. </text>
<text top="106" left="54" width="804" height="17" font="27">  333.   Wu J, Deisenhofer I, Ammar S, et al. Acute and long-term outcome after catheter ablation of supraventricular tachycardia in </text>
<text top="123" left="108" width="696" height="17" font="27">patients after the Mustard or Senning operation for D-transposition of the great arteries. Europace. 2013;15:886-91. </text>
<text top="141" left="54" width="803" height="17" font="27">  334.   Pressley JC, Wharton JM, Tang AS, et al. Effect of Ebstein's anomaly on short- and long-term outcome of surgically treated </text>
<text top="158" left="108" width="479" height="17" font="27">patients with Wolff-Parkinson-White syndrome. Circulation. 1992;86:1147-55. </text>
<text top="175" left="54" width="785" height="17" font="27">  335.   Misaki T, Watanabe G, Iwa T, et al. Surgical treatment of patients with Wolff-Parkinson-White syndrome and associated </text>
<text top="192" left="108" width="390" height="17" font="27">Ebstein's anomaly. J Thorac Cardiovasc Surg. 1995;110:1702-7. </text>
<text top="210" left="54" width="787" height="17" font="27">  336.   Theodoro DA, Danielson GK, Porter CJ, et al. Right-sided maze procedure for right atrial arrhythmias in congenital heart </text>
<text top="227" left="108" width="266" height="17" font="27">disease. Ann Thorac Surg. 1998;65:149-53. </text>
<text top="244" left="54" width="780" height="17" font="27">  337.   Huang CJ, Chiu IS, Lin FY, et al. Role of electrophysiological studies and arrhythmia intervention in repairing Ebstein's </text>
<text top="261" left="108" width="316" height="17" font="27">anomaly. Thorac Cardiovasc Surg. 2000;48:347-50. </text>
<text top="279" left="54" width="811" height="17" font="27">  338.   Mavroudis C, Backer CL, Deal BJ, et al. Total cavopulmonary conversion and maze procedure for patients with failure of the </text>
<text top="296" left="108" width="383" height="17" font="27">Fontan operation. J Thorac Cardiovasc Surg. 2001;122:863-71. </text>
<text top="313" left="54" width="784" height="17" font="27">  339.   Khositseth A, Danielson GK, Dearani JA, et al. Supraventricular tachyarrhythmias in Ebstein anomaly: management and </text>
<text top="330" left="108" width="333" height="17" font="27">outcome. J Thorac Cardiovasc Surg. 2004;128:826-33. </text>
<text top="348" left="54" width="762" height="17" font="27">  340.   Bockeria L, Golukhova E, Dadasheva M, et al. Advantages and disadvantages of one-stage and two-stage surgery for </text>
<text top="365" left="108" width="474" height="17" font="27">arrhythmias and Ebstein's anomaly. Eur J Cardiothorac Surg. 2005;28:536-40. </text>
<text top="382" left="54" width="803" height="17" font="27">  341.   Giamberti A, Chessa M, Foresti S, et al. Combined atrial septal defect surgical closure and irrigated radiofrequency ablation </text>
<text top="399" left="108" width="326" height="17" font="27">in adult patients. Ann Thorac Surg. 2006;82:1327-31. </text>
<text top="417" left="54" width="805" height="17" font="27">  342.   Karamlou T, Silber I, Lao R, et al. Outcomes after late reoperation in patients with repaired tetralogy of Fallot: the impact of </text>
<text top="434" left="108" width="440" height="17" font="27">arrhythmia and arrhythmia surgery. Ann Thorac Surg. 2006;81:1786-93. </text>
<text top="451" left="54" width="791" height="17" font="27">  343.   Stulak JM, Dearani JA, Puga FJ, et al. Right-sided Maze procedure for atrial tachyarrhythmias in congenital heart disease. </text>
<text top="468" left="108" width="215" height="17" font="27">Ann Thorac Surg. 2006;81:1780-4. </text>
<text top="486" left="54" width="799" height="17" font="27">  344.   Mavroudis C, Deal BJ, Backer CL, et al. J. Maxwell Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan </text>
<text top="503" left="108" width="640" height="17" font="27">conversions with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac Surg. 2007;84:1457-65. </text>
<text top="520" left="54" width="769" height="17" font="27">  345.   Giamberti A, Chessa M, Abella R, et al. Surgical treatment of arrhythmias in adults with congenital heart defects. Int J </text>
<text top="537" left="108" width="156" height="17" font="27">Cardiol. 2008;129:37-41. </text>
<text top="555" left="54" width="775" height="17" font="27">  346.   Mavroudis C, Deal BJ, Backer CL, et al. Arrhythmia surgery in patients with and without congenital heart disease. Ann </text>
<text top="572" left="108" width="185" height="17" font="27">Thorac Surg. 2008;86:857-68. </text>
<text top="589" left="54" width="771" height="17" font="27">  347.   Aboulhosn J, Williams R, Shivkumar K, et al. Arrhythmia recurrence in adult patients with single ventricle physiology </text>
<text top="606" left="108" width="445" height="17" font="27">following surgical Fontan conversion. Congenit Heart Dis. 2010;5:430-4. </text>
<text top="624" left="54" width="807" height="17" font="27">  348.   Gutierrez SD, Earing MG, Singh AK, et al. Atrial tachyarrhythmias and the Cox-maze procedure in congenital heart disease. </text>
<text top="641" left="108" width="212" height="17" font="27">Congenit Heart Dis. 2013;8:434-9. </text>
<text top="658" left="54" width="793" height="17" font="27">  349.   Terada T, Sakurai H, Nonaka T, et al. Surgical outcome of Fontan conversion and arrhythmia surgery: Need a pacemaker? </text>
<text top="675" left="108" width="285" height="17" font="27">Asian Cardiovasc Thorac Ann. 2013;22:682-6. </text>
<text top="693" left="54" width="736" height="17" font="27">  350.   Said SM, Burkhart HM, Schaff HV, et al. Fontan conversion: identifying the high-risk patient. Ann Thorac Surg. </text>
<text top="710" left="108" width="111" height="17" font="27">2014;97:2115-21. </text>
<text top="727" left="54" width="803" height="17" font="27">  351.   Ghosh N, Luk A, Derzko C, et al. The acute treatment of maternal supraventricular tachycardias during pregnancy: a review </text>
<text top="744" left="108" width="341" height="17" font="27">of the literature. J Obstet Gynaecol Can. 2011;33:17-23. </text>
<text top="762" left="54" width="770" height="17" font="27">  352.   Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation </text>
<text top="779" left="108" width="252" height="17" font="27">procedures. Circulation. 2001;104:893-7. </text>
<text top="796" left="54" width="796" height="17" font="27">  353.   Berruezo A, Diez GR, Berne P, et al. Low exposure radiation with conventional guided radiofrequency catheter ablation in </text>
<text top="813" left="108" width="395" height="17" font="27">pregnant women. Pacing Clin Electrophysiol. 2007;30:1299-302. </text>
<text top="831" left="54" width="809" height="17" font="27">  354.   Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J </text>
<text top="848" left="108" width="270" height="17" font="27">Cardiovasc Electrophysiol. 2010;21:877-82. </text>
<text top="865" left="54" width="749" height="17" font="27">  355.   Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J </text>
<text top="882" left="108" width="165" height="17" font="27">Hypertens. 1999;12:541-7. </text>
<text top="900" left="54" width="762" height="17" font="27">  356.   von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy </text>
<text top="917" left="108" width="338" height="17" font="27">hypertension: a meta-analysis. Lancet. 2000;355:87-92. </text>
<text top="934" left="54" width="787" height="17" font="27">  357.   Bartalena L, Bogazzi F, Braverman LE, et al. Effects of amiodarone administration during pregnancy on neonatal thyroid </text>
<text top="951" left="108" width="496" height="17" font="27">function and subsequent neurodevelopment. J Endocrinol Invest. 2001;24:116-30. </text>
<text top="969" left="54" width="792" height="17" font="27">  358.   Qasqas SA, McPherson C, Frishman WH, et al. Cardiovascular pharmacotherapeutic considerations during pregnancy and </text>
<text top="986" left="108" width="243" height="17" font="27">lactation. Cardiol Rev. 2004;12:201-21. </text>
<text top="1003" left="54" width="811" height="17" font="27">  359.   Jaeggi ET, Carvalho JS, De GE, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with </text>
<text top="1020" left="108" width="665" height="17" font="27">digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011;124:1747-54. </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">153 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="802" height="17" font="27">  360.   Chen SA, Lee SH, Wu TJ, et al. Initial onset of accessory pathway-mediated and atrioventricular node reentrant tachycardia </text>
<text top="72" left="108" width="697" height="17" font="27">after age 65: clinical features, electrophysiologic characteristics, and possible facilitating factors. J Am Geriatr Soc. </text>
<text top="89" left="108" width="103" height="17" font="27">1995;43:1370-7. </text>
<text top="106" left="54" width="777" height="17" font="27">  361.   Chen SA, Chiang CE, Tai CT, et al. Complications of diagnostic electrophysiologic studies and radiofrequency catheter </text>
<text top="123" left="108" width="749" height="17" font="27">ablation in patients with tachyarrhythmias: an eight-year survey of 3,966 consecutive procedures in a tertiary referral center. </text>
<text top="141" left="108" width="177" height="17" font="27">Am J Cardiol. 1996;77:41-6. </text>
<text top="158" left="54" width="796" height="17" font="27">  362.   Boulos M, Hoch D, Schecter S, et al. Age dependence of complete heart block complicating radiofrequency ablation of the </text>
<text top="175" left="108" width="408" height="17" font="27">atrioventricular nodal slow pathway. Am J Cardiol. 1998;82:390-1. </text>
<text top="192" left="54" width="764" height="17" font="27">  363.   Zado ES, Callans DJ, Gottlieb CD, et al. Efficacy and safety of catheter ablation in octogenarians. J Am Coll Cardiol. </text>
<text top="210" left="108" width="103" height="17" font="27">2000;35:458-62. </text>
<text top="227" left="54" width="808" height="17" font="27">  364.   Li YG, Gronefeld G, Bender B, et al. Risk of development of delayed atrioventricular block after slow pathway modification </text>
<text top="244" left="108" width="687" height="17" font="27">in patients with atrioventricular nodal reentrant tachycardia and a pre-existing prolonged PR interval. Eur Heart J. </text>
<text top="261" left="108" width="96" height="17" font="27">2001;22:89-95. </text>
<text top="279" left="54" width="813" height="17" font="27">  365.   Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart </text>
<text top="296" left="108" width="144" height="17" font="27">Rhythm. 2004;1:393-6. </text>
<text top="313" left="54" width="767" height="17" font="27">  366.   Rostock T, Risius T, Ventura R, et al. Efficacy and safety of radiofrequency catheter ablation of atrioventricular nodal </text>
<text top="330" left="108" width="496" height="17" font="27">reentrant tachycardia in the elderly. J Cardiovasc Electrophysiol. 2005;16:608-10. </text>
<text top="348" left="54" width="732" height="17" font="27">  367.   Kihel J, Da CA, Kihel A, et al. Long-term efficacy and safety of radiofrequency ablation in elderly patients with </text>
<text top="365" left="108" width="432" height="17" font="27">atrioventricular nodal re-entrant tachycardia. Europace. 2006;8:416-20. </text>
<text top="382" left="54" width="777" height="17" font="27">  368.   Dagres N, Piorkowski C, Kottkamp H, et al. Contemporary catheter ablation of arrhythmias in geriatric patients: patient </text>
<text top="399" left="108" width="506" height="17" font="27">characteristics, distribution of arrhythmias, and outcome. Europace. 2007;9:477-80. </text>
<text top="417" left="54" width="787" height="17" font="27">  369.   Haghjoo M, Arya A, Heidari A, et al. Electrophysiologic characteristics and results of radiofrequency catheter ablation in </text>
<text top="434" left="108" width="599" height="17" font="27">elderly patients with atrioventricular nodal reentrant tachycardia. J Electrocardiol. 2007;40:208-13. </text>
<text top="451" left="54" width="803" height="17" font="27">  370.   Pedrinazzi C, Durin O, Agricola P, et al. Efficacy and safety of radiofrequency catheter ablation in the elderly. J Interv Card </text>
<text top="468" left="108" width="198" height="17" font="27">Electrophysiol. 2007;19:179-85. </text>
<text top="486" left="54" width="814" height="17" font="27">  371.   Yangni NO, Brembilla-Perrot B. Clinical characteristics and management of paroxysmal junctional tachycardia in the elderly. </text>
<text top="503" left="108" width="237" height="17" font="27">Arch Cardiovasc Dis. 2008;101:143-8. </text>
<text top="520" left="54" width="812" height="17" font="27">  372.   Hoffmann BA, Brachmann J, Andresen D, et al. Ablation of atrioventricular nodal reentrant tachycardia in the elderly: results </text>
<text top="537" left="108" width="403" height="17" font="27">from the German Ablation Registry. Heart Rhythm. 2011;8:981-7. </text>
<text top="555" left="54" width="765" height="17" font="27">  373.   Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, </text>
<text top="572" left="108" width="425" height="17" font="27">double-blind, antiarrhythmic drug trial. Circulation. 2005;112:3470-7. </text>
<text top="589" left="54" width="791" height="17" font="27">  374.   Manrique AM, Arroyo M, Lin Y, et al. Magnesium supplementation during cardiopulmonary bypass to prevent junctional </text>
<text top="606" left="108" width="748" height="17" font="27">ectopic tachycardia after pediatric cardiac surgery: a randomized controlled study. J Thorac Cardiovasc Surg. 2010;139:162-</text>
<text top="624" left="108" width="15" height="17" font="27">9. </text>
<text top="641" left="54" width="810" height="17" font="27">  375.   Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized </text>
<text top="658" left="108" width="694" height="17" font="27">controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular </text>
<text top="675" left="108" width="420" height="17" font="27">tachycardia in infants. Circ Arrhythm Electrophysiol. 2012;5:984-91. </text>
<text top="693" left="54" width="797" height="17" font="27">  376.   Lau CP, Tai YT, Lee PW. The effects of radiofrequency ablation versus medical therapy on the quality-of-life and exercise </text>
<text top="710" left="108" width="734" height="17" font="27">capacity in patients with accessory pathway-mediated supraventricular tachycardia: a treatment comparison study. Pacing </text>
<text top="727" left="108" width="228" height="17" font="27">Clin Electrophysiol. 1995;18:424-32. </text>
<text top="744" left="54" width="793" height="17" font="27">  377.   Bubien RS, Knotts-Dolson SM, Plumb VJ, et al. Effect of radiofrequency catheter ablation on health-related quality of life </text>
<text top="762" left="108" width="591" height="17" font="27">and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996;94:1585-91. </text>
<text top="779" left="54" width="797" height="17" font="27">  378.   Bathina MN, Mickelsen S, Brooks C, et al. Radiofrequency catheter ablation versus medical therapy for initial treatment of </text>
<text top="796" left="108" width="686" height="17" font="27">supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol. 1998;82:589-93. </text>
<text top="813" left="54" width="791" height="17" font="27">  379.   Larson MS, McDonald K, Young C, et al. Quality of life before and after radiofrequency catheter ablation in patients with </text>
<text top="831" left="108" width="571" height="17" font="27">drug refractory atrioventricular nodal reentrant tachycardia. Am J Cardiol. 1999;84:471-3, A9. </text>
<text top="848" left="54" width="798" height="17" font="27">  380.   Goldberg AS, Bathina MN, Mickelsen S, et al. Long-term outcomes on quality-of-life and health care costs in patients with </text>
<text top="865" left="108" width="719" height="17" font="27">supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol. 2002;89:1120-3. </text>
<text top="882" left="54" width="785" height="17" font="27">  381.   Meissner A, Stifoudi I, Weismuller P, et al. Sustained high quality of life in a 5-year long term follow-up after successful </text>
<text top="900" left="108" width="724" height="17" font="27">ablation for supra-ventricular tachycardia. results from a large retrospective patient cohort. Int J Med Sci. 2009;6:28-36. </text>
<text top="917" left="54" width="777" height="17" font="27">  382.   Yildirim O, Yontar OC, Semiz M, et al. The effect of radiofrequency ablation treatment on quality of life and anxiety in </text>
<text top="934" left="108" width="549" height="17" font="27">patients with supraventricular tachycardia. Eur Rev Med Pharmacol Sci. 2012;16:2108-12. </text>
<text top="951" left="54" width="794" height="17" font="27">  383.   Farkowski MM, Pytkowski M, Maciag A, et al. Gender-related differences in outcomes and resource utilization in patients </text>
<text top="969" left="108" width="734" height="17" font="27">undergoing radiofrequency ablation of supraventricular tachycardia: results from Patients' Perspective on Radiofrequency </text>
<text top="986" left="108" width="397" height="17" font="27">Catheter Ablation of AVRT and AVNRT Study. Europace. 2014. </text>
<text top="1003" left="54" width="806" height="17" font="27">  384.   de Buitleir M, Bove EL, Schmaltz S, et al. Cost of catheter versus surgical ablation in the Wolff-Parkinson-White syndrome. </text>
<text top="1020" left="108" width="192" height="17" font="27">Am J Cardiol. 1990;66:189-92. </text>
<text top="1038" left="54" width="800" height="17" font="27">  385.   de Buitleir M, Sousa J, Bolling SF, et al. Reduction in medical care cost associated with radiofrequency catheter ablation of </text>
<text top="1055" left="108" width="325" height="17" font="27">accessory pathways. Am J Cardiol. 1991;68:1656-61. </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1084" left="843" width="24" height="17" font="27">154 </text>
<text top="1101" left="54" width="496" height="15" font="28">© 2015 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1117" left="54" width="3" height="17" font="27"> </text>
<text top="54" left="54" width="754" height="17" font="27">  386.   Kalbfleisch SJ, Calkins H, Langberg JJ, et al. Comparison of the cost of radiofrequency catheter modification of the </text>
<text top="72" left="108" width="752" height="17" font="27">atrioventricular node and medical therapy for drug-refractory atrioventricular node reentrant tachycardia. J Am Coll Cardiol. </text>
<text top="89" left="108" width="103" height="17" font="27">1992;19:1583-7. </text>
<text top="106" left="54" width="791" height="17" font="27">  387.   Hogenhuis W, Stevens SK, Wang P, et al. Cost-effectiveness of radiofrequency ablation compared with other strategies in </text>
<text top="123" left="108" width="419" height="17" font="27">Wolff-Parkinson-White syndrome. Circulation. 1993;88:II437-II446. </text>
<text top="141" left="54" width="781" height="17" font="27">  388.   Kalbfleisch SJ, el-Atassi R, Calkins H, et al. Safety, feasibility and cost of outpatient radiofrequency catheter ablation of </text>
<text top="158" left="108" width="458" height="17" font="27">accessory atrioventricular connections. J Am Coll Cardiol. 1993;21:567-70. </text>
<text top="175" left="54" width="798" height="17" font="27">  389.   Kertes PJ, Kalman JM, Tonkin AM. Cost effectiveness of radiofrequency catheter ablation in the treatment of symptomatic </text>
<text top="192" left="108" width="413" height="17" font="27">supraventricular tachyarrhythmias. Aust N Z J Med. 1993;23:433-6. </text>
<text top="210" left="54" width="751" height="17" font="27">  390.   Ikeda T, Sugi K, Enjoji Y, et al. Cost effectiveness of radiofrequency catheter ablation versus medical treatment for </text>
<text top="227" left="108" width="463" height="17" font="27">paroxysmal supraventricular tachycardia in Japan. J Cardiol. 1994;24:461-8. </text>
<text top="244" left="54" width="798" height="17" font="27">  391.   Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clinical outcomes after catheter ablation of atrial flutter. </text>
<text top="261" left="108" width="175" height="17" font="27">PLoS One. 2014;9:e100509. </text>
<text top="279" left="54" width="785" height="17" font="27">  392.   Domanovits H, Laske H, Stark G, et al. Adenosine for the management of patients with tachycardias-a new protocol. Eur </text>
<text top="296" left="108" width="154" height="17" font="27">Heart J. 1994;15:589-93. </text>
<text top="313" left="54" width="792" height="17" font="27">  393.   Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients </text>
<text top="330" left="108" width="575" height="17" font="27">with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64:660-8. </text>
<text top="348" left="54" width="772" height="17" font="27">  394.   Tercius AJ, Kluger J, Coleman CI, et al. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to </text>
<text top="365" left="108" width="561" height="17" font="27">successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol. 2007;30:1331-5. </text>
<text top="382" left="54" width="781" height="17" font="27">  395.   Perez FJ, Schubert CM, Parvez B, et al. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent </text>
<text top="399" left="108" width="470" height="17" font="27">atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol. 2009;2:393-401. </text>
<text top="417" left="54" width="784" height="17" font="27">  396.   Natale A, Breeding L, Tomassoni G, et al. Ablation of right and left ectopic atrial tachycardias using a three-dimensional </text>
<text top="434" left="108" width="398" height="17" font="27">nonfluoroscopic mapping system. Am J Cardiol. 1998;82:989-92. </text>
<text top="451" left="54" width="805" height="17" font="27">  397.   Goldberger J, Kall J, Ehlert F, et al. Effectiveness of radiofrequency catheter ablation for treatment of atrial tachycardia. Am </text>
<text top="468" left="108" width="165" height="17" font="27">J Cardiol. 1993;72:787-93. </text>
<text top="486" left="54" width="811" height="17" font="27">  398.   Stevenson IH, Kistler PM, Spence SJ, et al. Scar-related right atrial macroreentrant tachycardia in patients without prior atrial </text>
<text top="503" left="108" width="585" height="17" font="27">surgery: electroanatomic characterization and ablation outcome. Heart Rhythm. 2005;2:594-601. </text>
<text top="520" left="54" width="4" height="19" font="29"><b></b></text>
<text top="539" left="54" width="4" height="17" font="27"> </text>
</page>
</pdf2xml>
